-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DJXVIzP7T9GicvXG9B2uPmEtqLiSn2GbtY81omvH5NoDTY/deBv7RChaky9EeIxl
 smwTytVUZ+dWUmSu3qJI/Q==

<SEC-DOCUMENT>0000950144-07-004069.txt : 20070501
<SEC-HEADER>0000950144-07-004069.hdr.sgml : 20070501
<ACCEPTANCE-DATETIME>20070501172914
ACCESSION NUMBER:		0000950144-07-004069
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		38
FILED AS OF DATE:		20070501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-142535
		FILM NUMBER:		07807332

	BUSINESS ADDRESS:	
		STREET 1:		209 TENTH AVENUE SOUTH
		STREET 2:		SUITE 332
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>g06286sv1.htm
<DESCRIPTION>CUMBERLAND PHARMACEUTICALS INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>Cumberland Pharmaceuticals Inc.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 91%; margin-left: 4%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>As filed with the Securities and Exchange Commission on
    May&#160;1, 2007</B>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Registration
    No.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt"><FONT style="white-space: nowrap">FORM&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">Cumberland Pharmaceuticals
    Inc.</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B><FONT style="font-size: 10pt">Tennessee</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B><FONT style="font-size: 10pt">2834</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B><FONT style="font-size: 10pt">62-1765329</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification No.) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">2525&#160;West End Avenue,
    Suite&#160;950</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Nashville, Tennessee
    37203</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">(615)&#160;255-0068</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number, including</FONT></I>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">area code, of registrant&#146;s
    principal executive offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">A.J. Kazimi</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Chairman and CEO</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">2525&#160;West End Avenue,
    Suite&#160;950</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Nashville, Tennessee
    37203</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">(615)&#160;255-0068</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number, including area code, of agent for
    service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B><FONT style="font-size: 9pt">&#160;&#160;Martin S.
    Brown,&#160;Esq.<BR>
    Virginia Boulet,&#160;Esq.<BR>
    Adams and Reese LLP<BR>
    424 Church Street, Suite&#160;2800<BR>
    Nashville, Tennessee 37219<BR>
    <FONT style="white-space: nowrap">(615)&#160;259-1450</FONT></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B><FONT style="font-size: 9pt">Donald J. Murray,&#160;Esq.<BR>
    Dewey Ballantine LLP<BR>
    1301 Avenue of the Americas<BR>
    New York, New York 10019-6092<BR>
    (212) 259-8000</FONT></B><FONT style="font-size: 9pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed offering to the
    public:</B>&#160;&#160;As soon as practicable after this
    registration statement becomes effective.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act of 1933 check the
    following box:&#160;&#160;<FONT face="wingdings">o
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT face="wingdings">o
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT face="wingdings">o
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT face="wingdings">o
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>CALCULATION OF REGISTRATION FEE</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Proposed Maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Title of Each Class of<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Aggregate Offering<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Securities to be Registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Price(1)</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Registration Fee</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="border-top: 1px solid #000000">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Common Stock, no par value per share
    </FONT>
</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <FONT style="font-size: 9pt">$115,000,000
    </FONT>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <FONT style="font-size: 9pt">$3,531
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Estimated solely for purpose of
    calculating the registration fee pursuant to Rule&#160;457(o)
    under the Securities Act.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The registrant hereby amends this registration statement on
    such date or dates as may be necessary to delay its effective
    date until the registrant shall file a further amendment which
    specifically states that this registration statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933 or until the registration
    statement shall become effective on such date as the Commission,
    acting pursuant to said Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 91%; margin-left: 4%"><!-- BEGIN LOGICAL PAGE -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD style=text-align:justify>
<FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #E8112D">The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is effective. This preliminary prospectus is not an
offer to sell these securities and it is not soliciting an offer
to buy these securities in any state where the offer or sale is
not permitted.<BR>
</FONT>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <FONT style="font-size: 8pt; font-family: Arial, Helvetica; color: #E8112D">PRELIMINARY
    PROSPECTUS
    </FONT></TD>
    <TD nowrap align="center">    <FONT style="font-size: 8pt; font-family: Arial, Helvetica; color: #E8112D">SUBJECT
    TO COMPLETION
    </FONT></TD>
    <TD nowrap align="right">    <FONT style="font-size: 8pt; font-family: Arial, Helvetica; color: #E8112D">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2007
    </FONT></TD>
</TR>

</TABLE>

<DIV style="font-size: 3pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt; font-family: Arial, Helvetica">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    Shares</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="g06286g0628602.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)" ><B><FONT style="font-size: 14pt; font-family: Arial, Helvetica">
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt; font-family: Arial, Helvetica">Common
    Stock</FONT></B>
</DIV>

<DIV style="font-size: 24pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This is the initial public offering of our common stock. No
    public market currently exists for our common stock. We are
    offering all of
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock offered by this prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have our common stock included for quotation
    on The Nasdaq Global Market under the symbol &#147;CPIX&#148;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Investing in our common stock involves a high degree of risk.
    Before buying any shares, you should carefully read the
    discussion of material risks of investing in our common stock in
    &#147;Risk factors&#148; beginning on page&#160;6 of this
    prospectus.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Neither the Securities and Exchange Commission nor any state
    securities commission has approved or disapproved of these
    securities or determined if this prospectus is truthful or
    complete. Any representation to the contrary is a criminal
    offense.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Per
    share</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Total</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="font-family: Arial, Helvetica">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Public offering price
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="9" valign="top" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="9" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="font-family: Arial, Helvetica">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Underwriting discounts and
    commissions
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="9" valign="top" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="9" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="font-family: Arial, Helvetica">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Proceeds, before expenses, to us
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
    $
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="9" valign="top" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="9" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters may also purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock at the public offering price, less the
    underwriting discounts and commissions payable by us, to cover
    over-allotments, if any, within 30&#160;days from the date of
    this prospectus. If the underwriters exercise this option in
    full, the total underwriting discounts and commissions will be
    $&#160;&#160;&#160;&#160;&#160; and our total proceeds, before
    expenses, will be $&#160;&#160;&#160;&#160;&#160;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are offering the common stock as set forth
    under &#147;Underwriting.&#148; Delivery of the shares will be
    made on or
    about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 16pt; font-family: Arial, Helvetica">UBS
    Investment Bank</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 26%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=120 -->


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<TR>
<TD width="1%%" align="center" nowrap>
    <B><FONT style="font-size: 16pt; font-family: Arial, Helvetica">Jefferies&#160;&#38;
    Company</FONT></B>
</TD>
<TD width="99%%">
&nbsp;
</TD>
</TR>
</TABLE>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<TR>
<TD width="37%">
&nbsp;
</TD>
<TD width="33%" align="center" nowrap>
    <B><FONT style="font-size: 16pt; font-family: Arial, Helvetica">Wachovia
    Securities</FONT></B>
</TD>
<TD width="30%">
&nbsp;
</TD>
</TR>
</TABLE>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<TR>
<TD width="99%%">
&nbsp;
</TD>
<TD width="1%%" align="center" nowrap>
    <B><FONT style="font-size: 16pt; font-family: Arial, Helvetica">Morgan
    Joseph</FONT></B>
</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inside front cover of prospectus to feature two product photos:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    [Artwork to be submitted]
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus. We have not, and the underwriters have not,
    authorized anyone to provide you with additional information or
    information different from that contained in this prospectus. We
    are offering to sell, and seeking offers to buy, shares of our
    common stock only in jurisdictions where offers and sales are
    permitted. The information contained in this prospectus is
    accurate only as of the date of this prospectus, regardless of
    the time of delivery of this prospectus or of any sale of shares
    of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">TABLE OF
    CONTENTS</FONT></B>
</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=128 iwidth=455 length=0 -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Page</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'><FONT style="font-size: 10pt">Prospectus
    summary</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">1</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'><FONT style="font-size: 10pt">Risk
    factors</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">6</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'><FONT style="font-size: 10pt">Special note
    regarding forward-looking statements</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">22</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'><FONT style="font-size: 10pt">Use of
    proceeds</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">23</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'><FONT style="font-size: 10pt">Dividend
    policy</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">23</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'><FONT style="font-size: 10pt">Capitalization</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">24</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'><FONT style="font-size: 10pt">Dilution</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">25</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'><FONT style="font-size: 10pt">Selected
    consolidated financial data</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">27</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'><FONT style="font-size: 10pt">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">28</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'><FONT style="font-size: 10pt">Business</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">39</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'><FONT style="font-size: 10pt">Management</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">60</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#123'><FONT style="font-size: 10pt">Compensation</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">67</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'><FONT style="font-size: 10pt">Certain
    relationships and related party transactions</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">77</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'><FONT style="font-size: 10pt">Principal
    shareholders</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">78</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'><FONT style="font-size: 10pt">Description of
    capital stock</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">80</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'><FONT style="font-size: 10pt">Shares eligible for
    future sale</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">85</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'><FONT style="font-size: 10pt">Material
    U.S.&#160;federal income and estate tax consequences to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT></FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">88</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'><FONT style="font-size: 10pt">Underwriting</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">91</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'><FONT style="font-size: 10pt">Notice to
    investors</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">94</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'><FONT style="font-size: 10pt">Legal
    matters</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">97</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'><FONT style="font-size: 10pt">Experts</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">97</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'><FONT style="font-size: 10pt">Where you can find
    additional information</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">97</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#122'><FONT style="font-size: 10pt">Index to
    consolidated financial statements</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">F-1</FONT></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv3w1.htm">EX-3.1 SECOND AMENDED AND RESTATED CHARTER OF CUMBERLAND PHARMACEUTICALS INC.</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv3w2.htm">EX-3.2 AMENDED AND RESTATED BYLAWS OF CUMBERLAND PHARMACEUTICALS INC.</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv4w2.htm">EX-4.2 WARRANT TO PURCHASE COMMON STOCK</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv4w4.htm">EX-4.4 WARRANT TO PURCHASE COMMON STOCK</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv4w5.htm">EX-4.5 FORM OF OPTION AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w1.htm">EX-10.1 MANUFACTURING AND SUPPLY AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w2.htm">EX-10.2 NOVATION AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w3.htm">EX-10.3 FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w4.htm">EX-10.4 CARDINAL HEALTH CONTRACT SALES AND SERVICE</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w5.htm">EX-10.5 FIRST AMENDMENT TO CONTRACT SALES AND SERVICE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w6.htm">EX-10.6 CONSENT TO ASSIGNMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w7.htm">EX-10.7 DISTRIBUTION SERVICES AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w8.htm">EX-10.8 STRATEGIC ALLIANCE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w9.htm">EX-10.9 KRISTALOSE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w10.htm">EX-10.10 LICENSE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w11.htm">EX-10.11 EMPLOYMENT AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w12.htm">EX-10.12 EMPLOYMENT AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w13.htm">EX-10.13 EMPLOYMENT AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w14.htm">EX-10.14 EMPLOYMENT AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w15.htm">EX-10.15 EMPLOYMENT AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w17.htm">EX-10.17 1999 STOCK OPTION PLAN</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w20.htm">EX-10.20 FORM OF INDEMNIFICATION AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w21.htm">EX-10.21 LEASE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w23.htm">EX-10.23 AMENDED AND RESTATED LEASE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv10w24.htm">EX-10.24 FIRST AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv21.htm">EX-21 SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS INC.</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g06286exv23w1.htm">Ex-23.1 Consent of KPMG LLP</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Through and
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2007 (the 25th&#160;day after the date of this prospectus),
    federal securities laws may require all dealers that effect
    transactions in our common stock, whether or not participating
    in this offering, to deliver a prospectus. This is in addition
    to the dealers&#146; obligation to deliver a prospectus when
    acting as underwriters and with respect to their unsold
    allotments or subscriptions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior<B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></B>,
    Acetadote<B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    </B>and the Cumberland Pharmaceuticals logo are trademarks or
    service marks of Cumberland Pharmaceuticals Inc. All other
    trademarks or service marks appearing in this prospectus are the
    property of their respective holders.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">.1</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='101'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Prospectus summary
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>This summary highlights select contents of this prospectus,
    and may not contain all of the information that you should
    consider before investing in our common stock. This summary
    should be read together with the more detailed information found
    elsewhere in this prospectus, including &#147;Risk factors&#148;
    and our consolidated financial statements and related notes
    beginning on
    <FONT style="white-space: nowrap">page&#160;F-1.</FONT>
    References in this prospectus to &#147;Cumberland,&#148;
    &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
    Cumberland Pharmaceuticals Inc. and our consolidated
    subsidiaries, unless the context indicates otherwise.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR
    COMPANY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a profitable and growing specialty pharmaceutical company
    focused on the acquisition, development and commercialization of
    branded prescription products. Our primary target markets are
    hospital acute care and gastroenterology, which are
    characterized by relatively concentrated physician prescriber
    bases. Unlike many emerging pharmaceutical and biotechnology
    companies, we have established a product development and
    commercial operating infrastructure that is scalable to
    accommodate our expected growth. Our management team consists of
    pharmaceutical industry veterans experienced in business
    development, clinical and regulatory affairs, and sales and
    marketing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception in 1999, we have successfully funded the
    acquisition and development of our product portfolio with
    limited external investment, while maintaining profitable
    operations over the past three years. Our portfolio consists of
    two products approved by the U.S. Food and Drug Administration,
    or FDA, one late-stage development product candidate nearing
    completion of Phase&#160;III clinical trials and several
    early-stage development projects. We were directly responsible
    for the clinical development and regulatory approval of
    Acetadote, one of our marketed products, and are currently
    completing development of Amelior, our lead product candidate.
    We promote&#160;Acetadote and our other FDA-approved product,
    Kristalose, through dedicated hospital and gastroenterology
    sales forces, which together are comprised of 42 sales
    representatives and managers. We believe that our target markets
    are highly concentrated, and consequently can be penetrated
    effectively by small, dedicated sales forces without large-scale
    promotional activity. For the years 2004, 2005 and 2006, our net
    revenue was $12.0&#160;million, $10.7&#160;million and
    $17.8&#160;million, respectively, and our net income was
    $558,000, $2.0&#160;million and $4.4&#160;million, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR
    PRODUCTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our key products and product candidates include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="20%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="36%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="18%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="18%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Product</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Indication</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Delivery</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Status</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Amelior<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt"> Pain and Fever
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Phase&#160;III
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Acetaminophen Poisoning
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Chronic and Acute Constipation
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Oral Solution
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="7" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="7" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Amelior, </B>our lead pipeline candidate, is an intravenous
    formulation of ibuprofen that we expect will be the first
    injectable product approved in the U.S.&#160;for the treatment
    of both pain and fever. Amelior is currently in Phase&#160;III
    clinical trials. We expect to complete clinical development by
    early 2008 and are preparing to submit our new drug application,
    or NDA, to the FDA for review. Amelior is designed to provide
    physicians with a safe, effective treatment alternative for
    patients who are unable to take oral medication for pain relief
    and fever reduction. If approved, we plan to market Amelior in
    the U.S.&#160;through our hospital sales force and in
    international markets through alliances with marketing partners.
    We believe Amelior currently represents our most significant
    product opportunity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to IMS Health, the U.S.&#160;market for injectable
    analgesics, or pain relievers, exceeded $302&#160;million, or
    491&#160;million units, in 2006. This market consists primarily
    of the non-steroidal anti-inflammatory drug ketorolac and
    generic opioids. Despite having a poor safety profile, usage of
</DIV>
</DIV><!-- End box 1 -->
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">1</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ketorolac has grown from approximately 38&#160;million units in
    2003, or 7% of the market, to approximately 43&#160;million
    units in 2006, or 9% of the market, according to IMS Health.
    Injectable opioids such as morphine and meperidine accounted for
    approximately 447&#160;million units sold in 2006. While opioids
    are widely used for acute pain management, they are associated
    with a variety of side effects including sedation, nausea,
    vomiting, headache, cognitive impairment and respiratory
    depression. Based on the results of clinical studies to date, we
    believe Amelior represents a potentially safer alternative to
    ketorolac, the only non-opioid injectable pain relief drug
    available in the U.S. Further, we believe Amelior is a safe and
    effective treatment for hospitalized patients with fever who are
    unable to take oral medication. There is currently no approved
    injectable treatment for fever in the U.S.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Acetadote </B>is the only intravenous formulation of
    N-acetylcysteine, or NAC, approved in the U.S.&#160;for the
    treatment of acetaminophen poisoning. Though safe at recommended
    doses, acetaminophen can cause liver damage with excessive use.
    Acetaminophen overdose is the most common cause of acute liver
    failure in adults in the U.S. According to the American
    Association of Poison Control Centers&#146; Toxic Exposure
    Surveillance System, acetaminophen was the leading cause of
    poisonings presenting to emergency departments in the
    U.S.&#160;in 2005, with approximately 77,000&#160;cases treated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    NAC is accepted worldwide as the standard of care for treating
    acetaminophen overdose. Until our 2004 launch of Acetadote, the
    only FDA-approved form of NAC available in the U.S.&#160;was an
    oral preparation. Medical literature suggests that, for a number
    of patients, IV treatment is the only reasonable route of
    administration due to nausea and vomiting associated with the
    administration of oral NAC for acetaminophen overdose. Sales of
    Acetadote have increased consistently since we launched the
    product in June 2004, with wholesaler sales to hospitals growing
    43% from $9&#160;million in 2005 to $13&#160;million in 2006. We
    believe that we can continue to expand market share, and that
    our Acetadote sales and marketing platform should help
    facilitate the anticipated launch of Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Kristalose</B>, a prescription laxative product, is a
    crystalline form of lactulose designed to enhance patient
    acceptance and compliance. Based on data from IMS Health, the
    U.S.&#160;prescription laxative market has grown rapidly over
    the past few years, increasing from approximately
    $206&#160;million in 2003 to $389&#160;million in 2006,
    representing a compound annual growth rate of 24%. Wholesaler
    sales of Kristalose to pharmacies were $10.5&#160;million in
    2006. During that year, we acquired exclusive
    U.S.&#160;commercialization rights to Kristalose, subsequently
    assembling a dedicated field sales force and re-launching the
    product in October 2006 under the Cumberland brand. We believe
    that we can increase market share for Kristalose given its many
    positive, competitive attributes including better taste,
    consistency, ease of use and cost relative to competing products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Early-stage product candidates.</B>&#160;&#160;Our
    early-stage product candidates are being developed by Cumberland
    Emerging Technologies, Inc., or CET, our 86%-owned subsidiary.
    CET collaborates with leading research institutions to identify
    and advance the development of promising pre-clinical product
    candidates within our target segments. Current CET projects
    include an improved treatment for fluid buildup in the lungs of
    cancer patients and an anti-infective for treating fungal
    infections in immuno-compromised patients.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR COMPETITIVE
    STRENGTHS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our key competitive strengths include the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    A significant late-stage product opportunity in Amelior;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Strong growth potential of our existing marketed products,
    Acetadote and Kristalose;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Our focus on underserved niche markets, including hospital acute
    care and gastroenterology;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    A profitable business with a history of fiscal discipline; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Extensive management expertise in business development, clinical
    and regulatory affairs, and sales and marketing.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">2</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR
    STRATEGY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our objective is to develop, acquire and commercialize branded
    pharmaceutical products for specialty physician market segments.
    Our strategy to achieve this objective includes the following
    key elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Successfully develop and commercialize Amelior, our lead product
    candidate in Phase III clinical trials;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Maximize sales of our marketed products, Acetadote and
    Kristalose;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Expand our dedicated hospital and gastroenterology sales forces;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Expand our product portfolio by acquiring rights to additional
    marketed products and late-stage product candidates; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Develop a pipeline of early-stage products through CET, our
    majority-owned subsidiary.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS AFFECTING
    US</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to numerous risks that could prevent us
    from successfully implementing our business strategy. These and
    other risks are discussed further in the section entitled
    &#147;Risk factors&#148; immediately following this prospectus
    summary, and include the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Our Amelior product candidate has not been approved for sale and
    may never be successfully commercialized;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We currently market two products, Acetadote and Kristalose. An
    adverse development regarding either of these products could
    have a material and adverse impact on us;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    If any manufacturer we rely upon fails to produce our products
    and product candidates in the amounts we require on a timely
    basis, or fails to comply with stringent regulations applicable
    to pharmaceutical drug manufacturers, we may face delays in the
    commercialization of Amelior, or may be unable to meet demand
    for the product supplied by the manufacturer and may lose
    potential revenues;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We are dependent on a variety of other third parties. If these
    third parties fail to perform as we expect, our operations could
    be disrupted and our financial results could suffer; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    If we are unable to maintain and build an effective sales and
    marketing infrastructure, we will not be able to successfully
    commercialize and grow our products and product candidates.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">CORPORATE
    INFORMATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in Tennessee in 1999. Our principal
    executive offices are located at 2525&#160;West End Avenue,
    Suite&#160;950, Nashville, Tennessee 37203, and our telephone
    number is
    <FONT style="white-space: nowrap">(615)&#160;255-0068.</FONT>
    Our website address is www.cumberlandpharma.com. The information
    on, or accessible through, our website is not part of this
    prospectus.
</DIV>
</DIV><!-- End box 1 -->
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">3</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">The offering
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Common stock we are offering</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common stock to be outstanding after this offering</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We estimate that the net proceeds from this offering will be
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million if
    the underwriters exercise their over-allotment option in full,
    assuming an initial public offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share. We expect to use
    the net proceeds from this offering primarily for potential
    acquisitions, product development and expansion, and general
    corporate purposes. We may use a portion of the net proceeds to
    acquire the rights to one or more marketed, FDA-approved
    products or one or more product candidates in late-stage
    development. We may use a portion of the net proceeds to expand
    our operations in order to prepare for the launch of one or more
    new products. We may also repay outstanding borrowings under our
    credit facilities.</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Proposed Nasdaq Global Market Symbol</TD>
    <TD></TD>
    <TD valign="bottom">
    CPIX</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of shares of common stock to be outstanding after
    this offering is based
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    outstanding as
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    and excludes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon exercise of options issued under
    our 1999 Stock Option Plan and options issued in connection with
    debt financings in 2001 and 2003, at a weighted average exercise
    price of $&#160;&#160;&#160;&#160;&#160;&#160;per share;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon exercise of outstanding warrants
    at a weighted average exercise price of
    $&#160;&#160;&#160;&#160;&#160; and
    $&#160;&#160;&#160;&#160;&#160;&#160;per share;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon conversion of outstanding
    preferred stock; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for future issuance under our current
    stock option plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, all information in this prospectus
    assumes the underwriters do not exercise their option to
    purchase up
    to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock to cover over-allotments.
</DIV>
</DIV><!-- End box 1 -->
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">4</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Summary consolidated
    financial data
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The tables below summarize our financial data as of the dates
    and for the periods indicated. You should read the following
    information together with the more detailed information
    contained in &#147;Selected consolidated financial data,&#148;
    &#147;Management&#146;s discussion and analysis of financial
    condition and results of operations&#148; and our consolidated
    financial statements and the accompanying notes included
    elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pro forma data below gives effect to the conversion
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares of our preferred stock
    into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares of common stock. Pro forma as adjusted data below gives
    effect to the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares of common stock that we are offering at an assumed
    initial public offering price of $&#160;&#160;&#160;&#160;&#160;
    per share, after deducting underwriting discounts and
    commissions and estimated offering expenses to be paid by us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Years Ended
    December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Statement of
    operations data:</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in thousands,
    except per share data)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net revenues
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Operating income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income before income taxes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income per share&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income per share&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,541
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,045
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">As of
    December&#160;31, 2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pro Forma<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Balance sheet
    data:</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pro
    Forma</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">as
    Adjusted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in
    thousands)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Cash and cash equivalents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Working capital
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,945
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,481
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total long-term debt and other
    long-term obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Preferred stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total shareholders&#146; equity
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
</DIV><!-- End box 1 -->
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">5</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='102'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Risk factors
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    You should carefully consider the following risks, together with
    all of the information included in this prospectus, before
    investing in our common stock. In addition to the risks outlined
    below, there may be other unforeseen risks which may not or
    cannot be identified at this time. If any of these risks were to
    occur, our business, financial condition and results of
    operations could be materially and adversely affected. In that
    case, the trading price of our common stock could decline, and
    you might lose all or part of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS RELATED TO
    OUR BUSINESS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our Amelior
    product candidate has not been approved for sale and may never
    be successfully commercialized.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We anticipate that a substantial portion of our future growth
    will come from sales of our Amelior product candidate. However,
    Amelior has neither been approved nor marketed by the U.S. Food
    and Drug Administration, or FDA, and it is still subject to
    risks associated with its clinical development.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior is undergoing Phase&#160;III clinical trials to test its
    efficacy and safety. Delays in the completion of these clinical
    trials, which can result from unforeseen issues, FDA
    interventions, problems with enrolling patients and other
    reasons, could significantly delay commercial launch and affect
    our product development costs. Moreover, results from these
    clinical studies may not be as favorable as the results we
    obtained in prior, completed studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the results of our clinical trials are favorable, we intend
    to submit to the FDA an application for marketing approval for
    Amelior. The FDA may decline to accept our application. If the
    FDA declines our application, it may require that we conduct
    additional studies and submit additional data prior to
    resubmitting the application. If the FDA accepts and reviews the
    application, it may still require that we conduct additional
    studies or submit other data. Conducting studies and collecting,
    analyzing and submitting necessary data can be time-consuming
    and expensive. The FDA may not act on our application during the
    timeframe that we expect. Moreover, the FDA might not approve
    our application, in which event we would not be able to sell
    Amelior in the U.S., or it might approve Amelior for only
    limited uses, in which event the market for this product could
    be significantly reduced, adversely affecting our commercial
    opportunity. In addition, new government regulations could
    prevent or delay regulatory approval of Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior, which is injectable ibuprofen, is a non-steroidal
    anti-inflammatory drug, or NSAID. The widespread use of NSAIDs
    has meant that the adverse effects of these relatively safe
    drugs have become increasingly prevalent. The two main adverse
    drug reactions associated with NSAIDs relate to the
    gastrointestinal tract and the kidneys. Recent studies suggest
    there may also be a risk of cardiovascular adverse effects
    associated with NSAIDs. While we are currently studying the
    safety of Amelior in our clinical trials, the FDA may require
    additional safety data be collected prior to or after any
    approval of the product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Even if Amelior is successfully developed and approved by the
    FDA, it may never gain significant acceptance in the marketplace
    and therefore never generate substantial revenue or profits for
    us. Physicians may determine that existing drugs are adequate to
    address patients&#146; needs. For example, oral non-narcotic
    pain and fever reducers, as well as narcotic&#160;IV pain
    relievers, are widely available and commonly prescribed. If
    physicians determine that Amelior is safe and effective, it will
    still compete, on a
    <FONT style="white-space: nowrap">patient-by-patient</FONT>
    and
    <FONT style="white-space: nowrap">physician-by-physician</FONT>
    basis, with other therapeutic alternatives. Additionally, we are
    aware of other companies developing products that would address
    the same market that we are targeting for Amelior. The extent to
    which Amelior will be reimbursed by the U.S. government or third-
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">6</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    party payors is also currently unknown, and reimbursement levels
    of Amelior compared to those of other competitive drugs will
    also affect the level of market acceptance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of the foregoing and other factors, we do not know
    the extent to which Amelior will contribute to our future growth.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We currently
    market two products, Acetadote and Kristalose. An adverse
    development regarding either of these products could have a
    material and adverse impact on us.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently market and sell two products, Acetadote and
    Kristalose. Changes impacting either product in areas such as
    competition, government regulation, intellectual property,
    reimbursement and manufacturing would profoundly affect us.
    Similarly, a product contamination or other safety issue in
    either of our product markets, whether or not directly involving
    our products, could negatively impact us.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If any
    manufacturer we rely upon fails to produce our products and
    product candidates in the amounts we require on a timely basis,
    or fails to comply with stringent regulations applicable to
    pharmaceutical drug manufacturers, we may face delays in the
    commercialization of Amelior, or may be unable to meet demand
    for the product supplied by the manufacturer and may lose
    potential revenues.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not manufacture any of our products or product candidates,
    and we do not currently plan to develop any capacity to do so.
    Our dependence upon third parties for the manufacture of
    products could adversely affect our profit margins or our
    ability to develop and deliver products on a timely and
    competitive basis. If for any reason we are unable to obtain or
    retain third-party manufacturers on commercially acceptable
    terms, we may not be able to sell our products as planned.
    Furthermore, if we encounter delays or difficulties with
    contract manufacturers in producing our products, the
    distribution, marketing and subsequent sales of these products
    could be adversely affected. In either event, we may choose to
    or need to seek an alternative source of supply for, or abandon,
    a product line or sell a product line on unsatisfactory terms.
    Our agreement with Bioniche Teoranta, or Bioniche, for the
    exclusive manufacture and supply of Acetadote requires that we
    obtain Acetadote only from Bioniche, even if we could obtain
    Acetadote from another supplier on terms more favorable than the
    terms of our agreement with Bioniche.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have minimum purchase obligations under our Acetadote supply
    agreement with Bioniche and our Kristalose supply agreement with
    Inalco S.p.A. and Inalco Biochemicals, Inc., or collectively
    Inalco. If our purchase obligations exceed demand for these
    products, we may be forced to either breach our contract with
    that manufacturer or purchase a supply of the product that we
    may be unable to sell. Our contract with Bioniche extends until
    2011, and our contract with Inalco extends until 2021.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On February&#160;2, 2007, Mayne Pharma Pty. Ltd., our exclusive
    manufacturer of Amelior, was acquired by Hospira, Inc. If
    Hospira encounters integration problems or if we have
    disagreements with Hospira, with whom we have not collaborated
    in the past, our supply of Amelior could be interrupted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior is manufactured at a single facility in Australia.
    Acetadote is manufactured at a single facility in Ireland and
    the active pharmaceutical ingredient for Kristalose is
    manufactured at a single facility in Italy. If any one of these
    facilities is damaged or destroyed, or if local conditions
    result in a work stoppage, we could suffer a delay or suspension
    of clinical trials, in the case of Amelior, or an inability to
    meet demand in the case of our marketed products. Kristalose is
    manufactured through a complex process involving trade secrets
    of the manufacturer. Accordingly, it would be particularly
    difficult to find a new manufacturer of Kristalose on an
    expedited basis.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">7</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, all manufacturers of our products and product
    candidates must comply with current good manufacturing
    practices, referred to as cGMP, enforced by the FDA through its
    facilities inspection program. These requirements include
    quality control, quality assurance and the maintenance of
    records and documentation. Manufacturers of our product
    candidates may be unable to comply with cGMP requirements and
    with other FDA, state and foreign regulatory requirements. We
    have no control over our manufacturers&#146; compliance with
    these regulations and standards. If our third-party
    manufacturers do not comply with these requirements, we could be
    subject to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    fines and civil penalties;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    suspension of production or distribution;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    suspension or delay in product approval;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    product seizure or recall; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    withdrawal of product approval.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We are dependent
    on a variety of other third parties. If these third parties fail
    to perform as we expect, our operations could be disrupted and
    our financial results could suffer.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a relatively small internal infrastructure. We rely on a
    variety of third parties, other than our third-party
    manufacturers, to help us operate our business. Other third
    parties on which we rely include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Cardinal Health Specialty Pharmaceutical Services, a logistics
    and fulfillment company and business unit of Cardinal, which
    warehouses and ships both Kristalose and Acetadote;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Advogent Group, Inc., a spin-off of Cardinal, which provides a
    field sales force that is the primary selling team for
    Kristalose; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Vanderbilt University and the Tennessee Technology Development
    Corporation, co-owners with us of Cumberland Emerging
    Technologies, Inc., or CET, and the universities that
    collaborate with us in connection with CET&#146;s research and
    development programs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If these third parties do not continue to provide services to
    us, or collaborate with us, we might not be able to obtain
    others who can serve these functions. This could disrupt our
    business operations, delay completion of clinical trials,
    regulatory approval and market launch of Amelior or any future
    product candidate, increase our operating expenses and otherwise
    adversely affect our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If we are unable
    to maintain and build an effective sales and marketing
    infrastructure, we will not be able to commercialize and grow
    our products and product candidates successfully.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, we have relied on Cardinal, to provide sales
    representatives to promote our products. Recently, we exercised
    an option under our agreement with Cardinal to convert the
    hospital sales force for our products to Cumberland employees.
    This conversion was completed in January 2007. Our ability to
    maintain and increase our revenues and profitability,
    particularly in the near term, will depend on our ability to
    address any issues or inefficiencies that arise from
    transitioning this sales force from Cardinal employees to our
    employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we grow, we may not be able to secure sales personnel or
    organizations that are adequate in number or expertise to
    successfully market and sell our products. This risk would be
    accentuated if we acquire products in areas outside of acute
    care/emergency medicine and gastroenterology, since our sales
    forces specialize in these areas. If we are unable to expand our
    sales and marketing capability or any other capabilities
    necessary to commercialize our products and product candidates,
    we will need to contract
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">8</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with third parties to market and sell our products. If we are
    unable to establish and maintain adequate sales and marketing
    capabilities:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    we may not be able to increase our product revenue;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    we may generate increased expenses; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    we may not continue to be profitable.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Competitive
    pressures could reduce our revenues and profits.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pharmaceutical industry is intensely competitive. Our
    strategy is to target differentiated products in specialized
    markets. However, this strategy does not relieve us from
    competitive pressures, and can entail distinct competitive
    risks. For example, a new entrant into a smaller market could
    have a disproportionately large impact on others in the market.
    In addition, certain of our competitors do not aggressively
    promote their products in our markets. A relatively modest
    increase in promotional activity in our markets could result in
    large shifts in market share, adversely affecting us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Kristalose competes in the U.S. with several other prescription
    laxative products, two of which are marketed by large,
    international pharmaceutical companies. Acetadote competes
    domestically with several orally administered prescription
    products for treating acetaminophen overdose. We are aware of
    products under development, including an intravenous
    acetaminophen product, which could compete with Amelior. We have
    limited patent protection against direct competition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with numerous pharmaceutical, specialty
    pharmaceutical and biotechnology companies. Our competitors may
    sell or develop drugs that are more effective and useful and
    less costly than ours, and they may be more successful in
    manufacturing and marketing their products. Many of our
    competitors have significantly greater financial and marketing
    resources than we do. Additional competitors may enter our
    markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pharmaceutical industry is characterized by constant and
    significant investment in new product development, which can
    result in rapid technological change. The introduction of new
    products could substantially reduce our market share or render
    our products obsolete. The selling prices of pharmaceutical
    products tend to decline as competition increases, through new
    product introduction or otherwise, which could reduce our
    revenues and profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Governmental and private health care payors have recently
    emphasized substitution of branded pharmaceuticals with less
    expensive generic equivalents. An increase in the sales of
    generic pharmaceutical products could result in a decrease in
    our revenues. While there are no generic equivalents competing
    with Amelior, Acetadote or Kristalose at this time, in the
    future we could face generic competition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our future growth
    depends on our ability to identify and acquire rights to
    products. If we do not successfully identify and acquire rights
    to products and successfully integrate them into our operations,
    our growth opportunities would be limited.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We acquired rights to Amelior, Acetadote and Kristalose. Our
    business strategy is to continue to acquire rights to
    FDA-approved products as well as pharmaceutical product
    candidates in the late stages of development. We do not plan to
    conduct basic research or early-stage product development,
    except to the extent of our investment in CET. We have limited
    resources to acquire third-party products, businesses and
    technologies and integrate them into our current infrastructure.
    Many acquisition opportunities involve competition among several
    potential purchasers including large multi-national
    pharmaceutical companies and other competitors that have access
    to greater financial resources than we do.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">9</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With future acquisitions, we may face financial and operational
    risks and uncertainties, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    not realizing the expected economic return or other benefits
    from an acquisition;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    incurring higher than expected acquisition and integration costs;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    assuming or otherwise being exposed to unknown liabilities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    developing or integrating new products that could disrupt our
    business and divert our management&#146;s time and attention;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    not being able to preserve key suppliers or distributors of any
    acquired products;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    incurring substantial debt or issue dilutive securities to pay
    for acquisitions; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    acquiring products that could substantially increase our
    amortization expenses.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not precluded from engaging in a large acquisition in the
    future, including an acquisition that entails the investment of
    substantially all of the proceeds from this offering. While
    large acquisitions potentially present large opportunities, they
    also could magnify the risks identified above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may not be able to engage in future product acquisitions, and
    those we do complete may not be beneficial to us in the long
    term.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Continued
    consolidation of distributor networks in the pharmaceutical
    industry as well as increases in retailer concentration may
    limit our ability to profitably sell our products.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We sell most of our products to large pharmaceutical
    wholesalers, who in turn sell to, thereby supplying, hospitals
    and retail pharmacies. The distribution network for
    pharmaceutical products has become increasingly consolidated in
    recent years. Today, three large wholesalers control most of the
    market. Further consolidation among, or any financial
    difficulties of, pharmaceutical wholesalers or retailers could
    result in the combination or elimination of warehouses, which
    could cause product returns to us. In addition, further
    consolidation or financial difficulties could also cause our
    customers to reduce the amounts of our products that they
    purchase, which would materially and adversely affect our
    business, financial condition and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If governmental
    or third-party payors do not provide adequate reimbursement for
    our products, our revenue and prospects for continued
    profitability will be limited.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our financial success depends, in part, on the availability of
    adequate reimbursement from third-party healthcare payors. Such
    third-party payors include governmental health programs such as
    Medicare and Medicaid, managed care providers and private health
    insurers. Third-party payors are increasingly challenging the
    pricing of medical products and services, while governments
    continue to propose and pass legislation designed to reduce the
    cost of healthcare. Adoption of such legislation could further
    limit reimbursement for pharmaceuticals. For example, in
    December 2003, Congress enacted a limited prescription drug
    benefit for Medicare beneficiaries in the Medicare Prescription
    Drug, Improvement, and Modernization Act of 2003. Under this
    program, drug prices for certain prescription drugs are
    negotiated by drug plans, with the goal to lower costs for
    Medicare beneficiaries. Future cost control initiatives could
    decrease the price that we would receive for any products, which
    would limit our revenue and profitability. In addition,
    legislation and regulations affecting the pricing of
    pharmaceuticals might change.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reimbursement practices of third-party payors might preclude us
    from achieving market acceptance for our products or maintaining
    price levels sufficient to realize an appropriate return on our
    investment in product acquisition and development. If we cannot
    obtain adequate reimbursement levels, our business, financial
    condition and results of operations would be materially and
    adversely affected.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">10</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">&#147;Formulary&#148;
    practices of third-party payors could adversely affect our
    competitive position.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Many managed health care organizations are now controlling the
    pharmaceutical products listed on their formulary lists. The
    benefit of having products listed on these formulary lists
    creates competition among pharmaceutical companies which, in
    turn, has created a trend of downward pricing pressure in our
    industry. In addition, many managed care organizations are
    pursuing various ways to reduce pharmaceutical costs and are
    considering formulary contracts primarily with those
    pharmaceutical companies that can offer a full line of products
    for a given therapy sector or disease state. Our products might
    not be included on the formulary lists of managed care
    organizations, and downward pricing pressure in our industry
    generally could negatively impact our operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our CET joint
    initiative may not result in our gaining access to commercially
    viable products.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our CET joint initiative with Vanderbilt University and
    Tennessee Technology Development Corporation is designed to help
    us investigate, in a cost-effective manner, early-stage products
    and technologies. However, we may never gain access to
    commercially viable products from CET for a variety of reasons,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    CET investigates early-stage products, which have the greatest
    risk of failure prior to FDA approval and commercialization;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    In some programs, we do not have pre-set rights to product
    candidates developed by CET. We would need to agree with CET and
    its collaborators on the terms of any product license to, or
    acquisition by, us;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We rely principally on government grants to fund&#160;CET&#146;s
    research and development programs. If these grants were no
    longer available, we or our co-owners might be unable or
    unwilling to fund&#160;CET operations at current levels or at
    all;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We may become involved in disputes with our co-owners regarding
    CET policy or operations, such as how best to deploy CET assets
    or which product opportunities to pursue. Disagreement could
    disrupt or halt product development; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    CET may disagree with one of the various universities with which
    CET is collaborating on research. A disagreement could disrupt
    or halt product development.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The size of our
    organization and our activities are growing, and we may
    experience difficulties in managing growth.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of April&#160;30, 2007, we had 33&#160;full-time employees.
    We may need to continue to expand our managerial, operational,
    financial and other resources in order to increase our marketing
    efforts with regard to our currently marketed products, continue
    our business development and product development activities and
    commercialize our product candidates. We have experienced, and
    may continue to experience, rapid growth in the scope of our
    operations in connection with the commercial launch of new
    products. Our financial performance will depend, in part, on our
    ability to manage any such growth effectively. Our management,
    personnel, systems and facilities currently in place may not be
    adequate to support this future growth.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We depend on our
    key personnel, the loss of whom would adversely affect our
    operations. If we fail to attract and retain the talent required
    for our business, our business will be materially
    harmed.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a relatively small company, and we depend to a great
    extent on principal members of our management and scientific
    staff. If we lose the services of any key personnel, in
    particular, A.J. Kazimi,
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">11</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    our Chief Executive Officer, it could have a material adverse
    effect on our business prospects. We currently have a key man
    life insurance policy covering the life of Mr.&#160;Kazimi. We
    have entered into agreements with each of our employees that
    contain restrictive covenants relating to non-competition and
    non-solicitation of our customers and suppliers for one year
    after termination of employment. Nevertheless, each of our
    officers and key employees may terminate his or her employment
    at any time without notice and without cause or good reason, and
    so as a practical matter these agreements do not guarantee the
    continued service of these employees. Our success depends on our
    ability to attract and retain highly qualified scientific,
    technical and managerial personnel and research partners.
    Competition among pharmaceutical companies for qualified
    employees is intense, and we may not be able to retain existing
    personnel or attract and retain qualified staff in the future.
    If we experience difficulties in hiring and retaining personnel
    in key positions, we could suffer from delays in product
    development, loss of customers and sales and diversion of
    management resources, which could adversely affect operating
    results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We face potential
    product liability exposure, and if successful claims are brought
    against us, we may incur substantial liability for a product or
    product candidate and may have to limit its
    commercialization.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We face an inherent risk of product liability lawsuits related
    to the testing of our product candidates and the commercial sale
    of our products. An individual may bring a liability claim
    against us if one of our product candidates or products causes,
    or appears to have caused, an injury. If we cannot successfully
    defend ourselves against the product liability claim, we may
    incur substantial liabilities. Liability claims may result in:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    decreased demand for our products;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    injury to our reputation;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    withdrawal of clinical trial participants;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    significant litigation costs;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    substantial monetary awards to or costly settlement with
    patients;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    product recalls;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    loss of revenue; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the inability to commercialize our product candidates.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are highly dependent upon medical and patient perceptions of
    us and the safety and quality of our products. We could be
    adversely affected if we or our products are subject to negative
    publicity. We could also be adversely affected if any of our
    products or any similar products sold by other companies prove
    to be, or are asserted to be, harmful to patients. Also, because
    of our dependence upon medical and patient perceptions, any
    adverse publicity associated with illness or other adverse
    effects resulting from the use or misuse of our products or any
    similar products sold by other companies could have a material
    adverse impact on our results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have product liability insurance that covers our clinical
    trials and the marketing and sale of our products up to a
    $10&#160;million annual aggregate limit, subject to specified
    deductibles. Our current or future insurance coverage may prove
    insufficient to cover any liability claims brought against us.
    Because of the increasing costs of insurance coverage, we may
    not be able to maintain insurance coverage at a reasonable cost
    or obtain insurance coverage that will be adequate to satisfy
    any liability that may arise.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">12</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We have never
    paid dividends on our capital stock, and we do not anticipate
    paying any cash dividends in the foreseeable future.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never paid cash dividends on our capital stock. We do
    not anticipate paying cash dividends to our shareholders in the
    foreseeable future. The availability of funds for distributions
    to shareholders will depend substantially on our earnings. Even
    if we become able to pay dividends in the future, we expect that
    we would retain such earnings to enhance capital
    <FONT style="white-space: nowrap">and/or</FONT>
    reduce long-term debt.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS RELATING TO
    GOVERNMENT REGULATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We are subject to
    stringent government regulation. All of our products face
    regulatory challenges.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Virtually all aspects of our business activities are regulated
    by government agencies. The manufacturing, processing,
    formulation, packaging, labeling, distribution, promotion and
    sampling, and advertising of our products, and disposal of waste
    products arising from such activities, are subject to
    governmental regulation. These activities are regulated by one
    or more of the FDA, the Federal Trade Commission, or the FTC,
    the Consumer Product Safety Commission, the U.S.&#160;Department
    of Agriculture and the U.S.&#160;Environmental Protection
    Agency, or the EPA, as well as by comparable agencies in foreign
    countries. These activities are also regulated by various
    agencies of the states and localities in which our products are
    sold. For more information, see &#147;Business&#151;Government
    Regulation.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Like all pharmaceutical manufacturers, we are subject to
    regulation by the FDA under the authority of the Federal Food,
    Drug and Cosmetic Act, or the FDC Act. All &#147;new drugs&#148;
    must be the subject of an FDA-approved new drug application, or
    NDA, before they may be marketed in the U.S. The FDA has the
    authority to withdraw existing NDA approvals and to review the
    regulatory status of products marketed under the enforcement
    policy. The FDA may require an approved NDA for any drug product
    marketed under the enforcement policy if new information reveals
    questions about the drug&#146;s safety and effectiveness. All
    drugs must be manufactured in conformity with cGMP, and drug
    products subject to an approved NDA must be manufactured,
    processed, packaged, held and labeled in accordance with
    information contained in the NDA. Since we rely on third parties
    to manufacture our products, cGMP requirements directly affect
    our third party manufacturers and indirectly affect us. The
    manufacturing facilities of our third-party manufacturers are
    continually subject to inspection by such governmental agencies,
    and manufacturing operations could be interrupted or halted in
    any such facilities if such inspections prove unsatisfactory.
    Our third-party manufacturers are subject to periodic inspection
    by the FDA to assure such compliance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pharmaceutical products must be distributed, sampled and
    promoted in accordance with FDA requirements. The FDA also
    regulates the advertising of prescription drugs. The FDA has the
    authority to request post-approval commitments that can be
    time-consuming and expensive to comply with.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the FDC Act, the federal government has extensive
    enforcement powers over the activities of pharmaceutical
    manufacturers to ensure compliance with FDA regulations. Those
    powers include, but are not limited to, the authority to
    initiate court action to seize unapproved or non-complying
    products, to enjoin non-complying activities, to halt
    manufacturing operations that are not in compliance with cGMP,
    and to seek civil monetary and criminal penalties. The
    initiation of any of these enforcement activities, including the
    restriction or prohibition on sales of our products, could
    materially adversely affect our business, financial condition
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any change in the FDA&#146;s enforcement policy could have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">13</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cannot determine what effect changes in regulations or
    statutes or legal interpretation, when and if promulgated or
    enacted, may have on our business in the future. Such changes
    could, among other things, require:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    changes to manufacturing methods;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    expanded or different labeling;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    recall, replacement or discontinuance of certain products;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    additional record keeping; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    expanded documentation of the properties of certain products and
    scientific substantiation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Such changes, or new legislation, could have a material adverse
    effect on our business, financial condition and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS RELATING TO
    INTELLECTUAL PROPERTY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our strategy to
    secure and extend marketing exclusivity or patent rights may
    provide only limited protection from competition.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to secure and extend marketing exclusivity for our
    products through a variety of means, including FDA exclusivity
    and patent rights. Acetadote has been designated as an
    &#147;orphan drug&#148; and is indicated to prevent or lessen
    hepatic (liver) injury when administered intravenously within
    eight to ten hours after ingesting quantities of acetaminophen
    that are potentially toxic to the liver. As such, Acetadote is
    protected until 2011 against competition from another drug using
    the same active ingredient to treat the same indication. Orphan
    drug marketing exclusivity does not, however, protect a drug
    from competition by a different drug marketed for the same
    indications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have &#147;composition of matter&#148; or
    &#147;use&#148; patents for our marketed products. We do have a
    U.S.&#160;patent, No.&#160;6,727,286, and some related
    international patents, which are directed to ibuprofen solution
    formulations, methods of making the same, and methods of using
    the same, and which are related to our formulation and
    manufacture of Amelior. We have applied for additional U.S. and
    international patent protection for our invention related to
    ibuprofen solution formulations, methods of making the same, and
    methods of using the same, but those applications may not result
    in issued patents. Additionally, the active ingredient in
    Amelior&#151;ibuprofen&#151;is in the public domain, and if a
    competitor were to develop a sufficiently distinct formulation,
    it could develop and seek FDA approval for an ibuprofen product
    that competes with Amelior. Following successful completion of
    our clinical studies, we also plan to seek three-year marketing
    exclusivity for Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inalco manufactures Kristalose and owns two U.S.&#160;patents,
    Nos. 5,003,061 and 5,480,491, related to the manufacture of
    Kristalose. These patents are not directed to the composition or
    use of Kristalose and do not prevent a competitor from
    developing a formulation and developing and seeking FDA approval
    for a product that competes with Kristalose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While we consider patent protection when evaluating product
    acquisition opportunities, any products we acquire in the future
    may not have significant patent protection. Neither the
    U.S.&#160;Patent and Trademark Office nor the courts have a
    consistent policy regarding the breadth of claims allowed or the
    degree of protection afforded under many pharmaceutical patents.
    Patent applications in the U.S. and many foreign jurisdictions
    are typically not published until 18&#160;months following their
    priority filing date, and in some cases not at all. In addition,
    publication of discoveries in scientific literature often lags
    significantly behind actual discoveries. Therefore, neither we
    nor our licensors can be certain that we or they were the first
    to make the inventions claimed in our issued patents or pending
    patent applications, or that we or they were the first to file
    for protection of the inventions set forth in these
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">14</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    patent applications. In addition, changes in either patent laws
    or in interpretations of patent laws in the U.S. and other
    countries may diminish the value of our intellectual property or
    narrow the scope of our patent protection. Furthermore, our
    competitors may independently develop similar technologies or
    duplicate technology developed by us in a manner that does not
    infringe our patents or other intellectual property. As a result
    of these factors, our patent rights may not provide any
    commercially valuable protection from competing products.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If we are unable
    to protect the confidentiality of our proprietary information
    and know-how, the value of our technology and products could be
    adversely affected.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to patents, we rely upon trade secrets, unpatented
    proprietary know-how and continuing technological innovation
    where we do not believe patent protection is appropriate or
    attainable. For example, the manufacturing process for
    Kristalose involves substantial trade secrets and proprietary
    know-how. We have entered into confidentiality agreements with
    certain key employees and consultants pursuant to which such
    employees and consultants must assign to us any inventions
    relating to our business if made by them while they are our
    employees, as well as certain confidentiality agreements
    relating to the acquisition of rights to products.
    Confidentiality agreements can be breached, though, and we might
    not have adequate remedies for any breach. Also, others could
    acquire or independently develop similar technology.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We depend on our
    licensors for the maintenance and enforcement of our
    intellectual property and have limited, if any, control over the
    amount or timing of resources that our licensors devote on our
    behalf.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When we license products, we often depend on our licensors to
    protect the proprietary rights covering those products. We have
    limited, if any, control over the amount or timing of resources
    that our licensors devote on our behalf or the priority they
    place on maintaining patent or other rights and prosecuting
    patent applications to our advantage. While any such licensor is
    expected to be under contractual obligations to us to diligently
    prosecute its patent applications and allow us the opportunity
    to consult, review and comment on patent office communications,
    we cannot be sure that it will perform as required. If a
    licensor does not perform and if we do not assume the
    maintenance of the licensed patents in sufficient time to make
    required payments or filings with the appropriate governmental
    agencies, we risk losing the benefit of all or some of those
    patent rights.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If the use of our
    technology conflicts with the intellectual property rights of
    third parties, we may incur substantial liabilities, and we may
    be unable to commercialize products based on this technology in
    a profitable manner or at all.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Third parties, including our competitors, could have or acquire
    patent rights that they could enforce against us. In addition,
    we may be subject to claims from others that we are
    misappropriating their trade secrets or confidential proprietary
    information. If our products conflict with the intellectual
    property rights of others, they could bring legal action against
    us or our licensors, licensees, manufacturers, customers or
    collaborators. If we were found to be infringing a patent or
    other intellectual property rights held by a third party, we
    could be forced to seek a license to use the patented or
    otherwise protected technology. We might not be able to obtain
    such a license on terms acceptable to us or at all. If an
    infringement or misappropriation legal action were to be brought
    against us or our licensors, we would incur substantial costs in
    defending the action. If such a dispute were to be resolved
    against us, we could be subject to significant damages, and the
    manufacturing or sale of one or more of our products could be
    enjoined.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">15</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We may be
    involved in lawsuits to protect or enforce our patents or the
    patents of our collaborators or licensors, which could be
    expensive and time consuming.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Competitors may infringe our patents or the patents of our
    collaborators or licensors. To counter infringement or
    unauthorized use, we may be required to file infringement
    claims, which can be expensive and time-consuming. In addition,
    in an infringement proceeding, a court may decide that a patent
    of ours is not valid or is unenforceable, or may refuse to stop
    the other party from using the technology at issue on the
    grounds that our patents do not cover the technology in
    question. An adverse result in any litigation or defense
    proceeding could put one or more of our patents at risk of being
    invalidated or interpreted narrowly and could put our patent
    applications at risk of not issuing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interference proceedings brought by the U.S.&#160;Patent and
    Trademark Office may be necessary to determine the priority of
    inventions with respect to our patent applications or those of
    our collaborators or licensors. Litigation or interference
    proceedings may fail and, even if successful, may result in
    substantial costs and distract our management. We may not be
    able, alone or with our collaborators and licensors, to prevent
    misappropriation of our proprietary rights, particularly in
    countries where the laws may not protect such rights as fully as
    in the U.S.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, because of the substantial amount of discovery
    required in connection with intellectual property litigation,
    some of our confidential information could be disclosed during
    this type of litigation. In addition, there could be public
    announcements of the results of hearings, motions or other
    interim proceedings or developments. If securities analysts or
    investors perceive these results to be negative, it could have a
    substantial adverse effect on the price of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">If we breach any
    of the agreements under which we license rights to our products
    and product candidates from others, we could lose the ability to
    continue commercialization of our products and development and
    commercialization of our product candidates.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have exclusive licenses for the marketing and sale of certain
    products and may acquire additional licenses. Such licenses may
    terminate prior to expiration if we breach our obligations under
    the license agreement related to these pharmaceutical products.
    For example, the licenses may terminate if we fail to meet
    specified quality control standards, including cGMP with respect
    to the products, or commit a material breach of other terms and
    conditions of the licenses. Such early termination could have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreement with Inalco appoints us as the exclusive marketer,
    seller and distributor of Kristalose in the U.S. Either we or
    Inalco may terminate this agreement upon the breach of any
    material provision of the agreement if the breach is not cured
    within 45&#160;days following written notice. If our agreement
    with Inalco were terminated, we would lose our right to continue
    commercialization of Kristalose in the U.S.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under an agreement between us and Vanderbilt University, we have
    received certain clinical data to support our planned NDA
    submission for Amelior. Either we or Vanderbilt may terminate
    this agreement upon the breach of any material provision of the
    agreement if the breach is not cured within 45&#160;days
    following written notice. If our agreement with Vanderbilt were
    terminated, we would lose our right to use the data to support
    our planned NDA submission, and this loss may hinder our ability
    to commercialize Amelior in accordance with our plans.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">16</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS RELATED TO
    OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We have
    identified material weaknesses and a significant deficiency in
    our internal controls that, if not properly corrected, could
    result in material misstatements in our financial
    statements.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with our fiscal year 2006 financial statement
    audit, we identified three material weaknesses, and an
    additional significant deficiency (not rising to the level of a
    material weakness), in our internal controls. A significant
    deficiency is a control deficiency, or a combination of control
    deficiencies, that adversely affects our ability to initiate,
    authorize, record, process, or report external financial data
    reliably in accordance with U.S. generally accepted accounting
    principles such that there is more than a remote likelihood that
    a misstatement of our annual or interim financial statements
    that is more that inconsequential will not be prevented or
    detected by our employees. A material weakness is a significant
    deficiency, or combination of significant deficiencies, that
    results in more than a remote likelihood that a material
    misstatement of our annual or interim financial statement will
    not be presented or detected by our employees. We have
    undertaken a remediation plan designed to correct these issues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We summarize below the nature of the material weaknesses
    referenced above as well as the related remediation steps that
    we are implementing or plan to implement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    <I>Non-Routine Transactions.&#160;&#160;</I>We did not maintain
    adequate policies and procedures related to our financial
    reporting in order to account for significant, non-routine
    transactions in accordance with U.S. generally accepted
    accounting principles. To remedy this material weakness, we are
    implementing a new policy requiring management to review
    quarterly the accounting treatment for all transactions and
    contracts entered into.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    <I>Financial Statement Review Process.</I>&#160;&#160;We lack
    adequate personnel resources possessing sufficient expertise in
    U.S. generally accepted accounting principles to effectively
    perform a review of the annual financial statements. To remedy
    this material weakness, we intend to establish a new internal
    position that will be primarily responsible for SEC and other
    external reporting requirements. This position will report to
    the Vice President of Finance and Accounting.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    <I>Taxes.&#160;&#160;</I>We do not have an adequate number of
    personnel with appropriate qualifications and training in
    accounting for income taxes to perform a sufficient review of
    the income tax provision. To remedy this material weakness, we
    are implementing new procedures that, among other things,
    require us to further review the work of our external tax
    provider and to increase communication and information-sharing
    between our external tax provider and us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The significant deficiency relates to our policies and
    procedures for the review of our master listing of stock options
    granted. To remedy this significant deficiency, we are reviewing
    each transaction on our master listing against the relevant
    source documents and implementing new policies requiring
    quarterly review of the master listing by departments including
    our finance and accounting departments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we are not able to timely remedy the material weaknesses and
    significant deficiency described above, we may be unable to
    provide to our shareholders the required financial information
    in a timely and reliable manner, and we may misreport financial
    information, either of which could subject us to stockholder
    litigation and regulatory enforcement actions. This could
    materially and adversely impact our financial condition and the
    market value of our securities.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">17</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our operating
    results are likely to fluctuate from period to period.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a relatively new company seeking to capture significant
    growth. While our revenues and operating income have increased
    over time, we anticipate that there may be fluctuations in our
    future operating results. Potential causes of future
    fluctuations in our operating results may include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    new product launches, which could increase revenues but also
    increase sales and marketing expenses;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    acquisition activity and other one-time charges (such as for
    inventory expiration);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    increases in research and development expenses resulting from
    the acquisition of a product candidate that requires significant
    additional development;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    changes in the competitive, regulatory or reimbursement
    environment, which could drive down revenues or drive up sales
    and marketing or compliance costs; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    unexpected product liability or intellectual property claims and
    lawsuits.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See also &#147;Management&#146;s discussion and analysis of
    financial condition and results of operations&#160;&#151;
    Liquidity and capital resources.&#148; Fluctuation in operating
    results, particularly if not anticipated by investors and other
    members of the financial community, could add to volatility in
    our stock price.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our focus on
    acquisitions as a growth strategy has created a large amount of
    intangible assets whose amortization could negatively affect our
    results of operations.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total assets include intangible assets related to our
    acquisitions. The value of these intangible assets represents
    the excess of the acquisition purchase price over the fair value
    of the separate assets we acquired. As of December&#160;31,
    2006, intangible assets relating to product and data
    acquisitions represented approximately 37.1% of our total
    assets. We may never realize the value of these assets.
    Generally accepted accounting principles require that we
    evaluate on a regular basis whether events and circumstances
    have occurred that indicate that all or a portion of the
    carrying amount of the asset may no longer be recoverable, in
    which case we would write down the value of the asset and take a
    corresponding charge to earnings. Any determination requiring
    the write-off of a significant portion of unamortized intangible
    assets would adversely affect our results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We may need
    additional funding and may be unable to raise capital when
    needed, which could force us to delay, reduce or eliminate our
    product development or commercialization and marketing
    efforts.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may need to raise additional funds in order to meet the
    capital requirements of running our business and acquiring and
    developing new pharmaceutical products. If we require additional
    funding, we may seek to sell common stock or other equity or
    equity-linked securities, which could result in dilution to
    purchasers of common stock in this offering. We may also seek to
    raise capital through a debt financing, which would result in
    ongoing debt-service payments and increased interest expense.
    Any financings would also likely involve operational and
    financial restrictions being imposed on us. We might also seek
    to sell assets or rights in one or more commercial products or
    product development programs. Additional capital might not be
    available to us when we need it on acceptable terms or at all.
    If we are unable to raise additional capital when needed, we
    could be forced to scale back our operations to conserve cash.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">18</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We have a
    relatively short history of profitability and may not be able to
    sustain or increase our net income levels.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in 1999 and incurred operating losses until
    2004. We recorded our first year of profitability in 2004 and
    have increased profitability in each of 2005 and 2006. As of
    December&#160;31, 2006, however, we still had an accumulated
    deficit of ($7.4)&#160;million, representing the amount by which
    our historical losses have exceeded our historical profits. We
    may not be able to maintain or improve our current levels of
    revenue or net income. In such event, investors are likely to
    lose confidence in our ability to grow, and our stock price
    would suffer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISKS RELATED TO
    THIS OFFERING AND AN INVESTMENT IN OUR STOCK</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">As a new
    investor, you will experience immediate and substantial dilution
    in the net tangible book value of your shares.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price of our common stock in this
    offering is considerably more than the net tangible book value
    per share of our outstanding common stock. Investors purchasing
    shares of common stock in this offering will pay a price that
    substantially exceeds the value of our tangible assets after
    subtracting liabilities. As a result, investors in this offering
    will:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    incur immediate dilution of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share, based on an
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    contribute&#160;&#160;&#160;&#160;&#160;% of the total amount
    invested to date to fund our company based on an assumed initial
    offering price to the public of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    but will own only&#160;&#160;&#160;&#160;&#160;% of the shares
    of common stock outstanding after the offering.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may conduct substantial additional equity offerings or issue
    equity as consideration in an acquisition or otherwise. These
    future equity issuances, together with the exercise of
    outstanding options or warrants, could result in future dilution
    to investors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The market price
    of our common stock may fluctuate substantially.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price for the shares of our common
    stock sold in this offering has been determined by negotiation
    between the representatives of the underwriters and us. This
    price may not reflect the market price of our common stock
    following this offering. The price of our common stock may
    decline. In addition, the market price of our common stock is
    likely to be highly volatile and may fluctuate substantially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The realization of any of the risks described in these
    &#147;Risk factors&#148; could have a dramatic and material
    adverse impact on the market price of our common stock. In
    addition, securities class action litigation has often been
    instituted against companies whose securities have experienced
    periods of volatility in market price. Any such securities
    litigation brought against us could result in substantial costs
    and a diversion of management&#146;s attention and resources,
    which could negatively impact our business, operating results
    and financial condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We will incur
    increased costs as a result of operating as a public company,
    and our management will be required to devote additional time to
    new compliance initiatives.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will incur increased costs as a result of operating as a
    public company, and our management will be required to devote
    additional time to new compliance initiatives. As a public
    company, we will incur legal, accounting and other expenses that
    we did not incur as a private company. In addition, the
    Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well
    as rules subsequently implemented by
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">19</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the SEC and Nasdaq, have imposed various new requirements on
    public companies, including requiring establishment and
    maintenance of effective disclosure and financial controls and
    changes in corporate governance practices. These rules and
    regulations will increase our legal and financial compliance
    costs and will render some activities more time-consuming and
    costly.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Sarbanes-Oxley Act will require, among other things, that we
    maintain effective internal controls for financial reporting and
    disclosure controls and procedures. In particular, we must
    perform system and process evaluation and testing of our
    internal controls over financial reporting to allow management
    and our independent registered public accounting firm to report
    on the effectiveness of our internal controls over financial
    reporting, beginning with our Annual Report on Form&#160;10-K
    for the fiscal year ending December&#160;31, 2008, as required
    by Section&#160;404 of the Sarbanes-Oxley Act. Our testing, or
    the subsequent testing by our independent registered public
    accounting firm, may reveal deficiencies in our internal
    controls over financial reporting that are deemed to be material
    weaknesses. As described in a previous risk factor, we have
    identified certain deficiencies in the past. Our compliance with
    Section&#160;404 will require that we incur substantial
    accounting expense and expend significant management efforts.
    Moreover, if we are not able to comply with the requirements of
    Section&#160;404 in a timely manner, or if we or our independent
    registered public accounting firm identifies deficiencies in our
    internal controls over financial reporting that are deemed to be
    material weaknesses, the market price of our stock could decline
    and we could be subject to sanctions or investigations by
    Nasdaq, the SEC or other regulatory authorities, which would
    require additional financial and management resources.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">There may not be
    a viable public market for our common stock.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for our
    common stock, and a regular trading market might not develop or
    continue after this offering. Moreover, the market price of our
    common stock might decline below the initial public offering
    price.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">We will have
    broad discretion in how we use the proceeds of this offering,
    and we may not use these proceeds effectively, which could
    affect our results of operations and cause our stock price to
    decline.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will have broad discretion over the use of proceeds from this
    offering. We expect that the net proceeds from this offering
    will be used to fund clinical trials for Amelior and other
    research, marketing and development activities, and to fund
    working capital, capital expenditures and other general
    corporate purposes. We may also use a portion of the net
    proceeds to acquire products. We have no present agreements with
    respect to any such product acquisitions. We will have
    considerable discretion in the application of the net proceeds,
    and you will not have the opportunity, as part of your
    investment decision, to assess whether the proceeds are being
    used appropriately. The net proceeds may be used for purposes
    that do not increase our operating results or market value.
    Until the net proceeds are used, they may be placed in
    investments that do not produce significant income or that lose
    value.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Future sales of
    our common stock may depress our stock price.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales of a substantial number of shares of our common stock in
    the public market after this offering or the perception that
    these sales may occur could cause the market price of our common
    stock to decline. In addition, the sale of these shares in the
    public market could impair our ability to raise capital through
    the sale of additional common or preferred stock. After this
    offering, we will
    have&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock outstanding. Of these shares, all shares sold in
    the offering, other than shares, if any, purchased by our
    affiliates, will be freely tradable.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">20</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Risk
    factors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Some provisions
    of our second amended and restated charter, bylaws and Tennessee
    law may inhibit potential acquisition bids that you may consider
    favorable.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our corporate documents contain provisions that may enable our
    board of directors to resist a change in control of our company
    even if a change in control were to be considered favorable by
    you and other shareholders. These provisions include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the authorization of undesignated preferred stock, the terms of
    which may be established and shares of which may be issued
    without shareholder approval;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    advance notice procedures required for shareholders to nominate
    candidates for election as directors or to bring matters before
    an annual meeting of shareholders;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    limitations on persons authorized to call a special meeting of
    shareholders;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a staggered board of directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a requirement that vacancies in directorships are to be filled
    by a majority of the directors then in office and the number of
    directors is to be fixed by the board of directors; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    no cumulative voting.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These and other provisions contained in our second amended and
    restated charter and bylaws could delay or discourage
    transactions involving an actual or potential change in control
    of us or our management, including transactions in which our
    shareholders might otherwise receive a premium for their shares
    over then current prices, and may limit the ability of
    shareholders to remove our current management or approve
    transactions that our shareholders may deem to be in their best
    interests and, therefore, could adversely affect the price of
    our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we are subject to control share acquisitions
    provisions and affiliated transaction provision of the Tennessee
    Business Corporation Act, the applications of which may have the
    effect of delaying or preventing a merger, takeover or other
    change of control of us and therefore could discourage attempts
    to acquire our company. For more information, see
    &#147;Description of capital stock&#151;Anti-takeover effects of
    Tennessee law and provisions of our charter and bylaws.&#148;
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">21</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='103'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Special note
    regarding forward-looking statements
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Statements in this prospectus that are not historical factual
    statements are &#147;forward-looking statements.&#148;
    Forward-looking statements include, among other things,
    statements regarding our intent, belief or expectations, and can
    be identified by the use of terminology such as &#147;may,&#148;
    &#147;will,&#148; &#147;expect,&#148; &#147;believe,&#148;
    &#147;intend,&#148; &#147;plan,&#148; &#147;estimate,&#148;
    &#147;should,&#148; &#147;seek,&#148; &#147;anticipate&#148; and
    other comparable terms or the negative thereof. In addition, we,
    through our senior management, from time to time make
    forward-looking oral and written public statements concerning
    our expected future operations and other developments. While
    forward-looking statements reflect our good-faith beliefs and
    best judgment based upon current information, they are not
    guarantees of future performance and are subject to known and
    unknown risks and uncertainties, including those mentioned in
    &#147;Risk factors,&#148; &#147;Management&#146;s discussion and
    analysis of financial condition and results of operations&#148;
    and elsewhere in this prospectus. Actual results may differ
    materially from the expectations contained in the
    forward-looking statements as a result of various factors. Such
    factors include, without limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    legislative, regulatory or other changes in the healthcare
    industry at the local, state or federal level which increase the
    costs of, or otherwise affect our operations;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    changes in reimbursement available to us by government or
    private payers, including changes in Medicare and Medicaid
    payment levels and availability of third-party insurance
    coverage;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    competition; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    changes in national or regional economic conditions, including
    changes in interest rates and availability and cost of capital
    to us.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">22</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='104'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Use of proceeds
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds to us from the sale of
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock offered hereby will be approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming an
    initial public offering price of $&#160;&#160;&#160;&#160;&#160;
    and after deducting underwriting discounts and commissions and
    estimated offering expenses. If the underwriters exercise their
    over-allotment option in full, we estimate that our net proceeds
    will be approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Each $1.00
    increase (decrease) in the assumed initial public offering price
    of $&#160;&#160;&#160;&#160;&#160;&#160;per share would increase
    (decrease) the net proceeds to us from this offering by
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million,
    assuming that the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same.
    Depending on market conditions at the time of pricing of this
    offering and other considerations, we may sell fewer or more
    shares than the number set forth on the cover page of this
    prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The principal purposes of this offering are to obtain additional
    capital and to create a public market for our common stock. We
    expect to use the net proceeds from this offering primarily for
    potential acquisitions, product development and expansion and
    general corporate purposes. We may use a portion of the net
    proceeds to acquire the rights to one or more marketed,
    FDA-approved products or one or more product candidates. We may
    also use a portion of the net proceeds to expand our operations
    in order to prepare for the launch of one or more new products,
    including expanding our sales forces. We may also use a portion
    of the net proceeds of this offering to repay all or a portion
    of our outstanding borrowings under our credit facility. Amounts
    loaned under our credit facility bear interest at BBA LIBOR
    Daily Floating Rate plus 2.50%&#160;per annum, and the facility
    expires in April 2008 with respect to the revolving line of
    credit and in April 2009 with respect to the term loan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The amounts we actually expend for the above-specified purposes
    may vary depending on a number of factors, including changes in
    our business strategy, the amount of our future revenues and
    expenses and our future cash flow. If our future revenues or
    cash flow are less than we currently anticipate, we may need to
    support our ongoing business operations with net proceeds from
    this offering that we would otherwise use to support
    acquisitions and other methods of growth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Until we use the net proceeds from this offering for the above
    purposes, we intend to invest the funds in short-term,
    investment-grade, interest-bearing securities as directed by our
    investment policy. Our goals with respect to the investment of
    these net proceeds are capital preservation and liquidity so
    that such funds are readily available.
</DIV>
<A name='105'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Dividend policy
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not declared or paid any dividends on our common stock
    and do not anticipate paying cash dividends on our common stock
    for the foreseeable future. We currently intend to retain any
    future earnings for use in the operation of our business and to
    fund future growth. The payment of any dividends by us on our
    common or preferred stock is limited by our loan agreement with
    Bank of America. Any future decision to declare and pay
    dividends will be at the sole discretion of our board of
    directors.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">23</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='106'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Capitalization
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    on an actual basis;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    on a pro forma basis to give effect to the conversion of all of
    our outstanding preferred stock
    into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    on a pro forma as adjusted basis to give further effect to the
    sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock that we are offering at an assumed initial
    public offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share, after deducting
    underwriting discounts and commissions and estimated offering
    expenses to be paid by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should read the following table in conjunction with our
    consolidated financial statements and related notes and
    &#147;Management&#146;s discussion and analysis of financial
    condition and results of operations&#148; appearing elsewhere in
    this prospectus.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">As of
    December&#160;31, 2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pro Forma<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pro
    Forma</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">as
    Adjusted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in
    thousands)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Cash and cash
    equivalents<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Long-term debt and long-term
    obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Shareholders&#146; equity:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Preferred stock, no par value;
    3,000,000&#160;shares authorized, 855,495&#160;shares issued and
    outstanding, actual;
    and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized, no shares issued or outstanding, pro forma and pro
    forma as
    adjusted<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Common Stock, no par value;
    10,000,000&#160;shares authorized; 4,922,075&#160;shares issued
    and outstanding,
    actual;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding, pro forma;
    and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding on a pro forma as adjusted
    basis<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accumulated deficit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,360
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total shareholders&#146;
    equity<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total
    capitalization<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,783
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Each $1.00 increase or decrease in
    the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share would increase or
    decrease, as applicable, the amount of cash and cash
    equivalents, additional paid-in capital, total
    shareholders&#146; equity and total capitalization by
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million,
    assuming the number of shares offered by us, as set forth on the
    cover of this prospectus, remains the same and after deducting
    the estimated underwriting discounts and commissions payable by
    us.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Upon the completion of this
    offering, the outstanding shares of preferred stock will convert
    into an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Excludes:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT>&#160;
    </FONT>
</TD>
    <TD align="left">
    <FONT style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon exercise of outstanding options at
    a weighted average exercise price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share;
    </FONT>
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT>&#160;
    </FONT>
</TD>
    <TD align="left">
    <FONT style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for future issuance under our 2007
    Long-Term Incentive Compensation Plan and our 2007
    Directors&#146; Plan; and
    </FONT>
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT>&#160;
    </FONT>
</TD>
    <TD align="left">
    <FONT style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon the exercise of outstanding
    warrants at a weighted average exercise price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share.
    </FONT>
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">24</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='107'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Dilution
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our net tangible book as of December&#160;31, 2006 was
    $1.3&#160;million, or $&#160;&#160;&#160;&#160;&#160; per share.
    Net tangible book value per share represents the amount of our
    total tangible assets less total liabilities, divided by the
    total number of shares of common stock outstanding. Our pro
    forma net tangible book value as of December&#160;31, 2006 was
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    million, or
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per share of common stock. Pro forma net tangible book value per
    share gives effect to the conversion of all of our preferred
    stock
    into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock, which will occur upon completion of this
    offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After giving further effect to the sale by us
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock in this offering at an assumed initial public
    offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share, after taking into account the automatic conversion of our
    preferred stock upon completion of this offering, and after
    deducting underwriting discounts and commissions and estimated
    offering expenses payable by us, our pro forma as adjusted net
    tangible book value as of December&#160;31, 2006 would have been
    approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    or approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share. This amount represents an immediate increase in pro forma
    net tangible book value of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share to our existing shareholders and an immediate dilution in
    pro forma net tangible book value of approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share to new investors purchasing shares of common stock in this
    offering. We determine dilution by subtracting the pro forma as
    adjusted net tangible book value per share after this offering
    from the amount of cash that a new investor paid for a share of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table illustrates this dilution on a per share
    basis:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Assumed initial public offering
    price per share
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net tangible book value per share
    as of December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Effect on net tangible book value
    per share on conversion of preferred stock into common stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Pro forma net tangible book value
    per share as of December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Increase per share attributable to
    this offering
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Pro forma as adjusted net tangible
    book value per share after this offering
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dilution per share to new investors
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A $1.00 increase (decrease) in the assumed initial public
    offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share would increase (decrease) our pro forma as adjusted net
    tangible book value as of December&#160;31, 2006 by
    approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    the pro forma as adjusted net tangible book value per share
    after this offering by
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    and the dilution in pro forma as adjusted net tangible book
    value to new investors in this offering by
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share, assuming the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same and after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">25</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Dilution</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes, as of December&#160;31, 2006,
    the differences between the number of shares purchased from us,
    the total consideration paid to us and the average price per
    share that existing shareholders and new investors paid. The
    table gives effect to the conversion of all of our outstanding
    preferred stock
    into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock, which will occur upon completion of this offering.
    The calculation below is based on an assumed initial public
    offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share and before deducting underwriting discounts and
    commissions and estimated offering expenses that we must pay.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Average<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Total
    Shares</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Total
    Consideration</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Price<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">per
    Share</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="18" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Existing shareholders
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">New investors
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Total
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A $1.00 increase (decrease) in the assumed initial public
    offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share would increase (decrease) total consideration paid to us
    by investors participating in this offering by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    assuming the number of shares offered by us, as set forth on the
    cover page of this prospectus, remains the same and after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The discussion and tables above assume no exercise of the
    underwriters&#146; over-allotment option. If the
    underwriters&#146; over-allotment option is exercised in full,
    the number of shares of common stock held by existing
    shareholders will be further reduced
    to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    or&#160;&#160;% of the total number of shares of common stock to
    be outstanding after this offering, and the number of shares of
    common stock held by investors participating in this offering
    will be further increased
    to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    or&#160;&#160;% of the total number of shares of common stock to
    be outstanding after this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the above discussion and table assume no exercise
    of stock options after December&#160;31, 2006. As of
    December&#160;31, 2006, we had outstanding options to purchase a
    total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock at a weighted average exercise price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share and we had
    reserved&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock issuable upon the exercise of outstanding
    warrants at a weighted average exercise price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share. If all such
    options and warrants had been exercised as of December&#160;31,
    2006, pro forma as adjusted net tangible book value per share
    would have been $&#160;&#160;&#160;&#160;&#160;&#160;per share,
    and dilution to new investors would have been
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    share.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">26</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='108'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Selected
    consolidated financial data
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following consolidated statement of operations data for the
    years ended December&#160;31, 2004, 2005 and 2006 and
    consolidated balance sheet data as of December&#160;31, 2005 and
    2006 have been derived from our audited consolidated financial
    statements and related notes, which are included elsewhere in
    this prospectus. The consolidated statements of operations data
    for the years ended December&#160;31, 2002 and 2003 and the
    consolidated balance sheet data as of December&#160;31, 2002,
    2003 and 2004 have been derived from our audited consolidated
    financial statements that do not appear in this prospectus. The
    following selected consolidated financial data should be read in
    conjunction with, and is qualified by reference to, our
    consolidated financial statements and related notes, which were
    examined and reported upon by KPMG LLP, and
    &#147;Management&#146;s discussion and analysis of financial
    condition and results of operations&#148; appearing elsewhere in
    this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Years Ended
    December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Statement of
    operations
    data<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>:</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2002</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2003</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in thousands,
    except per share data)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Net revenues
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,943
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Costs and expenses:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">Cost of products sold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">Selling and marketing
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,802
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,647
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">Research and development
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    934
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">General and administrative
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,279
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">Amortization of product license
    rights
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    <FONT style="font-size: 9pt">Other
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    <FONT style="font-size: 9pt">Total costs and expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,313
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,654
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,940
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Gain on insurance recovery
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Operating income (loss)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,710
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Interest income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Interest expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    722
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Other expense (income)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Net income before minority interest
    and income taxes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,289
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,469
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Minority interest in net loss of
    consolidated subsidiary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Income tax benefit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,184
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Net income (loss)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3,282
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4,469
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Net income (loss) per
    share&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.80
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.05
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Net income (loss) per
    share&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.80
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.05
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Weighted average shares
    outstanding&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,541
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Weighted average shares
    outstanding&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,045
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The sum of the individual amounts
    may not agree due to rounding.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">As of
    December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Balance sheet
    data:</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2002</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2003</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in
    thousands)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Cash and cash equivalents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,790
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    771
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    516
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Working capital
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (485
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,110
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,640
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,945
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Total assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,507
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,481
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Total long-term debt and other
    long-term obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Preferred stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Total shareholders&#146; equity
    (deficit)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,762
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,433
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">27</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='109'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following discussion and analysis of our financial
    position and results of operations should be read together with
    our audited consolidated financial statements and related notes
    appearing elsewhere in this prospectus. This discussion and
    analysis may contain forward-looking statements that involve
    risks and uncertainties. You should review the &#147;Risk
    factors&#148; section of this prospectus for a discussion of
    important factors that could cause actual results to differ
    materially from the results described in or implied by the
    forward-looking statements described in the following discussion
    and analysis.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OVERVIEW</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a specialty pharmaceutical company focused on the
    acquisition, development and commercialization of branded,
    prescription products. We are building our product portfolio
    primarily by acquiring rights to FDA-approved and late-stage
    development products and marketing them to specialty physician
    segments. Our primary target markets are hospital acute care and
    gastroenterology. Our current portfolio consists of two marketed
    products and one late-stage development product nearing
    completion of Phase&#160;III clinical trials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We pursued the development of Acetadote for the treatment of
    acetaminophen poisoning and acquired rights to clinical data to
    support its approval. Approval of the product was obtained in
    January 2004 and we began to market Acetadote in the second
    quarter of 2004 and launched the product with a dedicated
    hospital sales force. In March 2006, we received approval from
    the FDA for the use of Acetadote in pediatric patients.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We gained access to marketed gastroenterology products by
    negotiating co-promotion agreements with the original developers
    of these products. These agreements allowed us to enter the
    gastroenterology market with minimal up-front costs and limited
    ongoing operating risk. In 2005, we made a strategic decision to
    de-emphasize our reliance on co-promotion agreements as a
    primary growth driver. In April 2006, we acquired exclusive
    commercial rights in the U.S.&#160;to Kristalose, a
    gastroenterology product we had previously co-promoted under an
    arrangement with Bertek Pharmaceuticals Inc., a subsidiary of
    Mylan Laboratories Inc. In October 2006, we re-launched
    Kristalose under the Cumberland brand with a dedicated field
    sales force targeting gastroenterologists and other high
    prescribers of laxative products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development expenses have grown consistently
    because of our program to develop Amelior. We expect research
    and development expenses to increase in 2007 as we continue our
    clinical work related to Amelior. We plan to complete the
    Amelior clinical work in early 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have funded our operations with private equity capital of
    approximately $14&#160;million during the past six years. We
    have supplemented this equity funding by re-investing our
    profits and utilizing our credit facilities in order to support
    our operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to 2007, our sales forces were contracted to us by a third
    party. In January 2007, we brought the hospital sales force
    in-house via our
    <FONT style="white-space: nowrap">newly-formed,</FONT>
    <FONT style="white-space: nowrap">wholly-owned</FONT>
    subsidiary, Cumberland Pharma Sales Corp. We continue to
    outsource the dedicated gastroenterology sales force. All
    expenses associated with the sales forces are included in
    selling and marketing expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2000, we formed CET with Vanderbilt University and Tennessee
    Technology Development Corporation to identify early-stage drug
    development activities. CET partners with universities and other
    research organizations to advance promising, early-stage product
    candidates through the development process and on to
    commercialization.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">28</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operating results have fluctuated in the past and are likely
    to fluctuate in the future. These fluctuations can result from
    competitive factors, new product acquisitions or introduction,
    the nature, scope and result of our research and development
    programs, pursuit of our growth strategy and other factors. As a
    result of these fluctuations, our historical financial results
    are not necessarily indicative of future results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in 1999 and have been headquartered in
    Nashville, Tennessee since inception.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">CRITICAL
    ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND
    ESTIMATES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Accounting
    Estimates and Judgments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of the consolidated financial statements in
    conformity with U.S. generally accepted accounting principles
    requires management to make estimates, judgments and assumptions
    that affect the reported amounts of assets and liabilities and
    disclosure of contingent liabilities at the date of the
    financial statements and the reported amounts of revenues and
    expenses during the period. We base our estimates on past
    experience and on other factors we deem reasonable given the
    circumstances. Past results help form the basis of our judgments
    about the carrying value of assets and liabilities that are not
    determined from other sources. Actual results could differ from
    those estimates. These estimates, judgments and assumptions are
    most critical with respect to our accounting for revenue
    recognition, provision for income taxes, stock-based
    compensation, research and development accounting, and
    intangible assets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Revenue
    Recognition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our revenue is derived primarily from the product sales of
    Acetadote and Kristalose. Revenue is recognized when persuasive
    evidence of an arrangement exists, delivery has occurred, the
    fee is fixed and determinable and collectibility is probable.
    Delivery is considered to have occurred upon either shipment or
    arrival at destination on shipping terms. When these conditions
    are satisfied, we recognize gross revenue, which is the price we
    charge generally to our wholesalers for a particular product. We
    record allowances for estimated chargebacks, discounts and
    damaged goods, and accruals for rebates and fees for services.
    Allowances and accruals are established by management as its
    best estimate at the time of sale based on each product&#146;s
    historical experience adjusted to reflect known changes in the
    factors that impact such reserves. Allowances for chargebacks
    and discounts, and accruals for rebates and returns are
    established based on the contractual terms with customers;
    analysis of historical levels of discounts, returns, chargebacks
    and rebates; communications with customers and purchased
    information about the rate of prescriptions being written and
    the levels of inventory remaining in the distribution channel,
    if known, as well as expectations about the market for each
    product and anticipated introduction of competitive products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The allowances for chargebacks and accruals for rebates and
    returns are established by product, and are the most significant
    estimates used in the recognition of our revenue from product
    sales. If the actual amount of cash discounts taken,
    chargebacks, rebates and expired product returns differ from the
    amounts estimated by management, material differences may result
    from the amount of our revenue recognized from product sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From January 2006 through part of April 2006, we recorded
    contract sales revenue which was based on co-promotion
    agreements primarily with Bertek Pharmaceuticals Inc., for the
    sales of Kristalose. Co-promotion fees were calculated based on
    a percent of gross sales or similar calculation. Contract sales
    revenue is included in net revenues.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">29</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other income, which is included in net revenues, includes rental
    and grant income. Rental income and grant income were three
    percent of net revenues in 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Income
    Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We provide for deferred taxes using the asset and liability
    approach. Under this method, deferred tax assets and liabilities
    are recognized for the future tax consequences attributable to
    operating loss and tax credit carry-forwards and differences
    between the financial statement carrying amounts of existing
    assets and liabilities and their respective tax bases. Our
    principal differences are related to the timing of deductibility
    of certain items such as depreciation, amortization and expense
    for options issued to non-employees. Deferred tax assets and
    liabilities are measured using management&#146;s estimate of tax
    rates expected to apply to taxable income in the years in which
    management believes those temporary differences are expected to
    be recovered or settled. The effect on deferred tax assets and
    liabilities of a change in tax rates is recognized in income in
    the period that includes the enactment date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the realizability of deferred tax assets,
    management considers whether it is more likely than not that
    some portion or all of the deferred tax assets will not be
    realized. The ultimate realization of deferred tax assets is
    dependent upon the generation of future taxable income during
    the periods in which those temporary differences become
    deductible. Management considers the scheduled reversal of
    deferred tax liabilities, projected future taxable income, and
    tax planning strategies in making this assessment. In order to
    fully utilize the deferred tax asset of $4.0 million as of
    December&#160;31, 2006, we will need to generate future taxable
    income of approximately $11.8&#160;million prior to the
    expiration of the net operating loss carry-forwards in 2025.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Stock-Based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January 1, 2006 we applied the intrinsic-value-based
    method of accounting prescribed by Accounting Principles Board
    (APB) Opinion No.&#160;25, <I>Accounting for Stock issued to
    Employees, </I>and related interpretations including
    FIN&#160;No.&#160;44, <I>Accounting for Certain Transactions
    involving Stock Compensation an interpretation of APB Opinion
    No.&#160;25</I>, to account for our stock options issued under
    the 1999 Stock Option Plan. Under this method, compensation
    expense is recorded on the date of grant only if the current
    market price of the underlying stock exceeded the exercise
    price. Statement of Financial Accounting Standards, or
    SFAS,&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>and Financial Accounting Standards Boards, or
    FASB No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#151;Transition and Disclosure, an amendment of
    FASB Statement No.&#160;123</I>, established accounting and
    disclosure requirements using a fair-value-based method of
    accounting for stock-based employee compensation plans. As
    permitted by then-existing accounting standards, we elected to
    continue to apply the intrinsic-value-based method of accounting
    described above, and adopted only the disclosure requirements of
    SFAS&#160;No.&#160;123, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we adopted  SFAS,
    No.&#160;123(R), Share-Based Payment, which revises
    SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation</I> and supersedes Accounting Principles Board, or
    APB, Opinion No.&#160;25, <I>Accounting for Stock Issued to
    Employees</I>. SFAS&#160;123(R) requires that share-based
    payment transactions with employees be recognized in the
    financial statements based on their fair value and recognized as
    compensation expense over the vesting period. We adopted
    SFAS&#160;123(R) effective January&#160;1, 2006, prospectively
    for new equity awards issued subsequent to December&#160;31,
    2005.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">30</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Information on employee and non-employee stock options granted
    in 2006 is summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Weighted<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Weighted
    Average<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock Options<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Intrinsic
    Value<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Fair Value of<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Grants made
    during quarter ended</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Granted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Exercise
    Price</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">per
    Share</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option (per
    Share)</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="13" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">March&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $4.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $8.36
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">June&#160;30, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,300
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $18.74
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $3.26
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $9.90
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">September&#160;30, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,075
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $4.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $11.16
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,600
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $4.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $11.01
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under SFAS&#160;No.&#160;123(R), we calculate the fair value of
    stock option grants using the Black-Scholes option-pricing
    model. The assumptions used in the Black-Scholes model ranged
    from two months to ten years for the expected term, 37%-63% for
    the expected volatility, 4.34% to 5.08% for the risk free rate
    and zero percent for dividend yield for the year ended
    December&#160;31, 2006. Future option expense could be impacted
    by changes in our model assumptions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For employee stock option grants, the weighted average expected
    option terms for 2006 represent the application of the
    simplified method as defined in SEC Staff Accounting Bulletin
    (or SAB), No.&#160;107 issued in March of 2005. The simplified
    method defines the expected life as the average of the
    contractual term of the options and the weighted average vesting
    period for the option. For non-employee stock option grants, the
    expected option terms for 2006 represent the contractual term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Estimated volatility for 2006 was determined in accordance of
    SAB&#160;No.&#160;107 and was determined by reviewing historical
    volatility of similar public companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, we had approximately $322,000 of
    unrecognized share-based compensation expense related to
    unvested option awards. Additionally, as of December&#160;31,
    2006, we had outstanding vested options to purchase
    3,899,088&#160;shares of our common stock and unvested options
    to purchase 105,890&#160;shares of our common stock.
    Furthermore, as of December&#160;31, 2006, we had outstanding
    34,479 warrants to purchase shares of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Research and
    Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for research and development costs and accrue
    expenses, based on estimates of work performed, patient
    enrollment or fixed-fee-for-services. As work is performed
    <FONT style="white-space: nowrap">and/or</FONT>
    invoices are received, we adjust our estimates and accruals. To
    date, our accruals have been within our estimates. Total
    research and development costs are a function of studies being
    conducted and will increase or decrease depending on the level
    of activity in any particular year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Intangible
    Assets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Intangible assets include license agreements, product rights and
    other identifiable intangible assets. We assess the impairment
    of identifiable intangible assets whenever events or changes in
    circumstances indicate that the carrying value may not be
    recoverable. In determining the recoverability of our intangible
    assets, we must make assumptions regarding estimated future cash
    flows and other factors. If the estimated undiscounted future
    cash flows do not exceed the carrying value of the intangible
    assets, we must determine the fair value of the intangible
    assets. If the fair value of the intangible assets is less than
    the carrying value, an impairment loss will be recognized in an
    amount equal to the difference.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">31</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RESULTS OF
    OPERATIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth, for the periods indicated,
    certain items from our statement of operations expressed as a
    percentage of net revenues, as well as the
    <FONT style="white-space: nowrap">period-to-period</FONT>
    change in these items.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Years Ended<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">%
    Change</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004-2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005-2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" nowrap align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net revenues
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.2
</TD>
<TD nowrap align="left" valign="bottom">
    %)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Costs and expenses:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Cost of products sold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Selling and marketing
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Research and development
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">General and administrative
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Amortization of product license
    rights
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    614.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Total costs and expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gain on insurance recovery
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Operating income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Interest income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    133.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Interest expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (93.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net income before income taxes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Income tax benefit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net
    income<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    125.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Not meaningful.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The sum of the individual amounts
    do not agree to the total due to rounding.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Description of
    operating accounts</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net revenues </I>consist of net product revenue, revenue from
    co-promotion agreements and other revenue. Net product revenue
    consists primarily of gross revenue less discounts and
    allowances, such as cash discounts, rebates, chargebacks and
    returns. Revenue from co-promotion agreements includes product
    promotion fees. Other income includes rental and grant income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of products sold </I>consists primarily of the cost of
    each unit of product sold. Cost of products sold also includes
    expense for slow moving or expired product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Selling and marketing expense </I>consists primarily of
    expense relating to the promotion, distribution and sale of
    products, including salaries and related costs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Research and development expense </I>consists primarily of
    clinical trial expenses, salary and wages and related costs of
    materials and supplies, and certain activities of third-party
    providers participating in our clinical studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>General and administrative expense </I>includes finance and
    accounting expenses, executive expenses, office expenses and
    business development expenses, including salaries and related
    costs.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">32</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amortization of product license rights </I>resulted from our
    acquisition of the exclusive U.S. commercialization rights to
    Kristalose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest income </I>consists primarily of interest income
    earned on cash deposits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest expense </I>consists primarily of interest incurred
    on debt and other long-term obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income tax benefit </I>consists primarily of the realization
    of our deferred tax assets less taxes incurred on income.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Year ended
    December&#160;31, 2006 compared to year ended December&#160;31,
    2005</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net revenues.</I>&#160;&#160;Net revenues in 2006 totaled
    $17.8&#160;million, representing an increase of
    $7.1&#160;million, or 66.7%, over net revenues in 2005 of
    $10.7&#160;million. This increase was primarily due to
    additional product revenue from sales of Kristalose, as well as
    continued growth of Acetadote. In April 2006, we entered into an
    agreement to acquire the exclusive U.S.&#160;commercial rights
    to Kristalose and began recording revenue based on shipments of
    the product. Prior to April 2006, we co-promoted Kristalose and
    recorded a co-promotion fee based on a percentage of the
    product&#146;s sales. In 2005, revenue was reduced by
    $2.0&#160;million for promotional costs owed to a wholesaler.
    Additionally, unlike prior years, in 2006, we did not offer any
    special purchasing opportunities to our customers prior to
    product price increases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of products sold.</I>&#160;&#160;Cost of products sold
    in 2006 totaled $2.4&#160;million, representing an increase of
    $1.9&#160;million, or 349.9%, over cost of products sold in 2005
    of $533,000. Cost of products sold as a percentage of net
    revenues was 13.5% and 5.0% in 2006 and 2005, respectively. The
    majority of the increase was due to recording the cost of
    products sold associated with Kristalose beginning in April
    2006. Prior to that date, we recorded no Kristalose cost of
    products sold because of the co-promotion arrangement referred
    to above. Acetadote cost of products sold, as a percentage of
    Acetadote net revenue, was not materially different between 2006
    and 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Selling and marketing.</I>&#160;&#160;Selling and marketing
    expense in 2006 totaled $7.3&#160;million, representing an
    increase of $1.7 million, or 30.1%, over selling and marketing
    expense in 2005 of $5.6&#160;million. Selling and marketing
    expense as a percentage of net revenues was 41.2% and 52.8% in
    2006 and 2005, respectively. The increase was primarily due to
    the launch of our new dedicated gastroenterology field sales
    force as well as other sales and marketing costs associated with
    the re-launch of Kristalose. We anticipate selling and marketing
    expense will grow, as we expand both sales forces as well as our
    product lines.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Research and development.</I>&#160;&#160;Research and
    development expense in 2006 totaled $2.2&#160;million,
    representing an increase of $1.1&#160;million, or 92.9%, over
    research and development expense in 2005 of $1.2&#160;million.
    Research and development expense as a percentage of net revenues
    was 12.5% and 10.8% in 2006 and 2005, respectively. This
    increase was primarily due to increased clinical studies
    activities associated with the development of Amelior. Research
    and development expense is expected to continue to grow in 2007,
    as we work to complete our final studies of Amelior prior to
    submission for approval to the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>General and administrative.</I>&#160;&#160;General and
    administrative expense in 2006 totaled $3.0&#160;million,
    representing an increase of $412,000, or 15.9%, over general and
    administrative expense in 2005 of $2.6&#160;million. General and
    administrative expense as a percentage of net revenues was 16.8%
    and 24.2% in 2006 and 2005, respectively. The dollar increase in
    general and administrative expense was primarily due to an
    increase in salaries and related expenses from 2005, as a result
    of the addition of personnel to support our growth. We expect
    general and administrative expense to increase in future
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">33</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    periods as we continue to add staff, expand our infrastructure
    and support the requirements of a public company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amortization of product license
    rights.</I>&#160;&#160;Amortization of product license rights
    totaled $515,000 in 2006. This expense is a result of
    amortization associated with our acquisition of the exclusive
    U.S. commercialization rights to Kristalose. We expect to incur
    annual amortization expense relating to these product license
    rights through&#160;March 2021.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest income.</I>&#160;&#160;Interest income in 2006
    totaled $209,000 compared to interest income in 2005 of $89,000.
    The majority of the increase in interest income was due to
    larger cash balances in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest expense.</I>&#160;&#160;Interest expense in 2006
    totaled $722,000 compared to interest expense in 2005 of
    $63,000. The majority of the increase in interest expense was
    due to interest expense associated with debt incurred to finance
    the acquisition of Kristalose. In 2005, we had minimal debt and
    thus, minimal interest expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income tax benefit.</I>&#160;&#160;Net income tax benefit in
    2006 totaled $2.7&#160;million compared to net income tax
    benefit in 2005 of $1.2&#160;million. The increase was due to
    full recording of our deferred tax asset after determining that
    it was more likely than not that we would realize the benefits
    of the deferred tax asset.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Year ended
    December&#160;31, 2005 compared to year ended December&#160;31,
    2004</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net revenues.</I>&#160;&#160;Net revenues in 2005 totaled
    $10.7&#160;million, representing a decrease of $1.3 million, or
    11.2%, over net revenues in 2004 of $12.0&#160;million. This
    decrease was primarily due to promotional costs owed to a
    wholesaler. This was partially off-set by a full year of sales
    of Acetadote in 2005, versus nine months in 2004. In 2005, two
    products accounted for all product sales, and there were two
    additional products for which we received a portion of product
    revenue based on promotion agreements. In 2004 and 2005, we
    provided our key customers the opportunity to purchase
    additional product prior to implementing a price increase.
    Certain customers took advantage of this opportunity and
    purchased additional product. The last year we offered such an
    incentive to our customers was 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of products sold.</I>&#160;&#160;Cost of products sold
    in 2005 totaled $533,000, representing a decrease of $283,000,
    or 34.7%, over cost of products sold in 2004 of $816,000. Cost
    of products sold as a percentage of net revenues was 5.0% and
    6.8% in 2005 and 2004, respectively. The majority of the
    decrease was due to a change in the product mix, which in 2004
    included a higher ratio of gastroenterology products as compared
    to 2005. Gastroenterology products tend to have a higher
    manufacturing cost per unit than our other products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Selling and marketing.</I>&#160;&#160;Selling and marketing
    expense in 2005 totaled $5.6&#160;million representing a
    decrease of $1.2 million, or 17.0%, over selling and marketing
    expense in 2004 of $6.8&#160;million. Selling and marketing
    expense as a percentage of net revenues was 52.8% and 56.5% in
    2005 and 2004, respectively. The decrease was due to lower
    royalty costs, a reduction in marketing costs relative to 2004
    when we launched Acetadote, reduced distribution costs and
    reduced sales force expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Research and development.</I>&#160;&#160;Research and
    development expense in 2005 totaled $1.2&#160;million,
    representing an increase of $412,000 or 55.2%, over research and
    development expense in 2004 of $746,000. Research and
    development expense as a percentage of net revenues was 10.8%
    and 6.2% in 2005 and 2004, respectively. This increase was
    primarily due to increased expenses relating to clinical studies
    associated with the development of Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>General and administrative.</I>&#160;&#160;General and
    administrative expense in 2005 totaled $2.6&#160;million,
    representing an increase of $230,000, or 9.7%, over general and
    administrative expense in 2004 of
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">34</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    $2.4&#160;million. General and administrative expense as a
    percentage of net revenues was 24.2% and 19.6% in 2005 and 2004,
    respectively. This increase was primarily due to increased stock
    option expense for consulting services as well as increased
    salaries and related expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest income.</I>&#160;&#160;Interest income in 2005
    totaled $89,000 compared to interest income in 2004 of $1,000.
    The majority of the increase in interest income in 2005 resulted
    from higher levels of cash and cash equivalents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest expense.</I>&#160;&#160;Interest expense in 2005
    totaled $63,000 compared to interest expense in 2004 of
    $1.0&#160;million. The majority of the decrease in interest
    expense in 2005 resulted from lower levels of outstanding debt
    as 2004 had significant interest expense associated with
    convertible debt which was converted to equity in 2004.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income tax benefit.</I>&#160;&#160;Net income tax benefit in
    2005 totaled $1.2&#160;million. We had no income tax benefit in
    2004. The existence of the income tax benefit was due to
    initial, partial recording of our deferred tax asset after
    determining that it was more likely than not that we would
    realize at least a portion of benefits of the deferred tax asset.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">LIQUIDITY AND
    CAPITAL RESOURCES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, cash and cash equivalents was
    $6.3&#160;million, working capital was $3.9&#160;million and our
    current ratio (current assets to current liabilities) was 1.5 to
    1. Management expects funds for our operating and capital
    requirements will be provided by continuing revenue and existing
    cash balances, as well as from collaborative agreements and
    other financing arrangements. As of December&#160;31, 2006, we
    also had the ability to make additional draws of up to
    $3&#160;million on our line of credit and will have substantial
    proceeds from this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes our net increase (decrease) in
    cash and cash equivalents for the years ended December&#160;31,
    2004, 2005 and 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Years Ended
    December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in
    thousands)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net cash provided by (used in):
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Operating activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,439
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,416
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Investing activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (318
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Financing activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,236
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net increase (decrease) in cash
    and cash equivalents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (255
</TD>
<TD nowrap align="left" valign="bottom">
    )<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The sum of the individual amounts
    do not agree to the total due to rounding.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash provided by operating activities was $2.2&#160;million
    for the year ended December&#160;31, 2006. During this time, net
    income of $4.4&#160;million was partially offset by net changes
    in assets and liabilities of $713,000 and adjustments to
    reconcile net income to net cash for depreciation, amortization,
    stock-based compensation, and deferred tax benefit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities was $6.6&#160;million for
    the year ended December&#160;31, 2006. This use of cash was
    primarily due to a payment of $6.5&#160;million for the
    acquisition of exclusive U.S. rights to Kristalose.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">35</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash provided by financing activities was $5.1&#160;million
    for the year ended December&#160;31, 2006, including
    $5.5&#160;million of proceeds from the issuance of long-term
    debt to fund the acquisition of rights to Kristalose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2006, we entered into an agreement with Inalco to
    acquire exclusive U.S.&#160;commercial rights for Kristalose. In
    order to complete this transaction, we obtained funding from
    Bank of America in the form of a three-year term loan for
    $5.5&#160;million and a new two-year revolving line of credit
    agreement, both with an interest rate of LIBOR plus 2.5% (7.83%
    as of December&#160;31, 2006). The borrowings are collateralized
    by a first lien against all of our assets. We are paying off the
    term loan in quarterly installments, with the final payment due
    in 2009. This agreement contains various covenants, all of which
    we were in compliance with as of December&#160;31, 2006. In
    addition to the three-year term loan, we deferred
    $4.5&#160;million of the purchase price, with $1.5&#160;million
    due in 2007 and $3.0&#160;million due in 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In conjunction with this line of credit agreement and term loan
    agreement, we issued to the lender warrants to purchase up to
    1,979&#160;shares of common stock at $18.00&#160;per share. The
    warrants expire in April 2016. The estimated fair value of such
    warrants of $25,680, as determined using the Black-Scholes
    model, has been recorded in the accompanying financial
    statements as permanent equity in accordance with Emerging
    Issues Task Force, or EITF,
    <FONT style="white-space: nowrap">No.&#160;00-19,</FONT>
    <I>Accounting for Derivative Financial Instruments Indexed to,
    and Potentially Settled in, a Company&#146;s Own Stock.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In conjunction with the Kristalose agreement with Inalco, we are
    obligated to purchase a minimum amount of Kristalose inventory
    each year. We expect our normal inventory purchasing to be above
    the required minimum amount.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of our agreement with Bioniche, our supplier of
    Acetadote, we are obligated to purchase a minimum amount of
    Acetadote inventory each year beginning in 2007, through 2011.
    We expect that our normal inventory purchasing to be above the
    required minimum amount.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the second quarter of 2005, we received approximately
    $2.0&#160;million from various investors in exchange for
    convertible promissory notes with a maturity date six months
    from the date of issuance. The notes bore interest at a fixed
    annual rate of 3.5%. In the fourth quarter of 2005, and pursuant
    to the terms of the notes, the principal value plus all elected
    accrued interest was converted into shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2005, we conducted a private placement of our common
    stock in which we issued 100,000&#160;shares of common stock for
    total gross proceeds of $1.8&#160;million, with net proceeds of
    $1.7&#160;million. The purpose of this offering was to provide
    funding to advance product agreements, to complete product
    development and for general corporate purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2004, we issued 43,000&#160;shares of our common stock to
    S.C.O.U.T. Healthcare Fund, L.P., or S.C.O.U.T., for cash
    consideration of $516,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;21, 2003, we amended our $1.0&#160;million,
    one-year revolving line of credit. Under the terms of the
    amended agreement, we had borrowing capacity up to the lesser of
    $3.5&#160;million or 80% of our eligible receivables, plus 50%
    of our eligible inventory. The agreement was extended to March
    2006. The agreement contained various provisions and covenants
    with which we were in compliance at December&#160;31, 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On September&#160;5, 2003, we received $1.0&#160;million from
    S.C.O.U.T. in the form of a convertible promissory note with a
    maturity date of September&#160;5, 2004. The note bore interest
    at a fixed annual rate of 10%. Pursuant to the terms of the
    note, on its maturity date the principal value of the note plus
    all accrued interest automatically converted into
    91,667&#160;shares of our common stock.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">36</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2000, we signed an agreement with a third party to cover
    a variety of development efforts related to a specific
    pharmaceutical drug, including preparation of submissions to the
    FDA. Under the terms of the agreement, we deferred a portion of
    each bill from the third party. One-third of the deferred amount
    accrued interest at an annual rate of 12.5% and was due after
    eighteen months. The remaining two-thirds will be due upon
    specific milestone events. Upon meeting the first milestone, an
    amount equal to one-third of the original deferred amount, or
    approximately $205,000, will become due and payable. Upon
    completion of the final milestone event, an amount equal to five
    times one-third of the original deferred amount, or
    approximately $1&#160;million, will become due and payable to
    the third party. Since the application of these factors is
    contingent upon specific events which may or may not occur in
    the future and which have not occurred as of December&#160;31,
    2006, the expense for these factors has not been recorded.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of our contractual cash
    obligations as of December&#160;31, 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Payments Due by
    Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Contractual
    obligations</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2010</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2011+</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(in
    thousands)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I><FONT style="font-size: 10pt">Amounts reflected in the
    balance sheet:</FONT></I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Line of credit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Term loan
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other contractual obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="5" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I><FONT style="font-size: 10pt">Other cash obligations not
    reflected in the balance sheet</FONT></I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Operating leases
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Purchase
    obligations<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,984
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Represents minimum purchase
    obligations under Kristalose and Acetadote manufacturing
    agreements.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OFF-BALANCE SHEET
    ARRANGEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2004, 2005 and 2006, we did not engage in any off-balance
    sheet arrangements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RECENT ACCOUNTING
    PRONOUNCEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2005, the EITF issued EITF Issue
    <FONT style="white-space: nowrap">No.&#160;04-13,</FONT>
    <I>Accounting for Purchases and Sales of Inventory with the Same
    Counterparty.</I> EITF
    <FONT style="white-space: nowrap">No.&#160;04-13</FONT>
    provides guidance as to when purchases and sales of inventory
    with the same counterparty should be accounted for as a single
    exchange transaction. EITF
    <FONT style="white-space: nowrap">No.&#160;04-13</FONT>
    also provides guidance as to when a non-monetary exchange of
    inventory should be accounted for at fair value. EITF
    <FONT style="white-space: nowrap">No.&#160;04-13</FONT>
    will be applied to new arrangements entered into, and
    modifications or renewals to existing arrangements occurring
    after January&#160;1, 2007. The application of EITF
    <FONT style="white-space: nowrap">No.&#160;04-13</FONT>
    is not expected to have a significant impact on our financial
    statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued FASB Statement No.&#160;157,
    <I>Fair Value Measurement, </I>or Statement&#160;157.
    SFAS&#160;157 defines fair value, establishes a framework for
    the measurement of fair value, and enhances disclosures about
    fair value measurements. The Statement does not require any new
    fair value measures. The Statement is effective for fair value
    measures already required or permitted by other standards for
    fiscal years beginning after November&#160;15, 2007. We are
    required to adopt Statement&#160;157 beginning on
    January&#160;1, 2008. Statement&#160;157 is required to be
    applied prospectively, except for certain financial instruments.
    Any transition adjustment will be recognized as an adjustment to
    opening retained earnings in the year of adoption. We are
    currently evaluating the impact of adopting Statement&#160;157
    on our results of operations and financial position.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">37</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management&#146;s
    discussion and analysis of financial condition and results of
    operations</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2006, the FASB issued FASB Interpretation No.&#160;48,
    <I>Accounting for Uncertainty in Income Taxes</I>, an
    interpretation of FASB Statement&#160;109 (FIN&#160;48).
    FIN&#160;48 clarifies the accounting for uncertainty in income
    taxes recognized in an enterprise&#146;s financial statements
    and prescribes a threshold of more-likely-than-not for
    recognition of tax benefits of uncertain tax positions taken or
    expected to be taken in a tax return. FIN&#160;48 also provides
    related guidance on measurement, de-recognition, classification,
    interest and penalties, and disclosure. The provisions of
    FIN&#160;48 are effective for us as of January&#160;1, 2007,
    with any cumulative effect of the change in accounting principle
    recorded as an adjustment to opening retained earnings. We are
    in the process of assessing the impact of adopting FIN&#160;48
    on our results of operations and financial position.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RECENTLY ADOPTED
    ACCOUNTING STANDARDS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, the FASB issued Statement No.&#160;123R (which
    replaces Statement No.&#160;123 issued in 1995), <I>Share-Based
    Payments</I>, which addresses accounting for transactions in
    which an entity exchanges its equity instruments for goods or
    services, with a primary focus on transactions in which an
    entity obtains employee services in share-based payment
    transactions. This Statement is a revision of Statement
    No.&#160;123 and supersedes APB Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees, </I>and its related
    implementation guidance. For nonpublic companies, this Statement
    requires measurement of the cost of employee services received
    in exchange for stock compensation based on the grant-date fair
    value of the employee stock options. Incremental compensation
    costs arising from subsequent modifications of awards after the
    grant date must be recognized. This Statement was effective for
    us as of January&#160;1, 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">QUANTITATIVE AND
    QUALITATIVE DISCLOSURE OF MARKET RISKS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our exposure to market risk is related to interest rates on our
    cash on deposit in highly liquid money market accounts. The main
    objective of our cash investment activities is to preserve
    principal while maximizing interest income through low risk
    investments. Derivative instruments are not included in our
    investment portfolio. Our investment policy focuses on principal
    preservation and liquidity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While we operate primarily in the U.S., we do have foreign
    currency exposure considerations. Acetadote is manufactured by a
    supplier that denominates supply prices in Canadian dollars.
    Additionally, much of our research and development is performed
    abroad. Foreign currency transactions in U.S. dollars totaled
    approximately $1.4&#160;million in 2006.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">38</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='110'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Business
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OVERVIEW</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a profitable and growing specialty pharmaceutical company
    focused on the acquisition, development and commercialization of
    branded prescription products. Our primary target markets are
    hospital acute care and gastroenterology, which are
    characterized by relatively concentrated physician prescriber
    bases. Unlike many emerging pharmaceutical and biotechnology
    companies, we have established a product development and
    commercial operating infrastructure that is scalable to
    accommodate our expected growth. Our management team consists of
    pharmaceutical industry veterans with significant experience in
    business development, clinical and regulatory affairs, and sales
    and marketing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception in 1999, we have successfully funded the
    acquisition and development of our product portfolio with
    limited external investment and maintained profitable operations
    over the past three years. Our portfolio consists of two
    products approved by the U.S. Food and Drug Administration, or
    FDA, one late-stage development product candidate nearing
    completion of Phase&#160;III clinical trials and several
    early-stage development projects. We were directly responsible
    for the clinical development and regulatory approval of
    Acetadote, one of our marketed products, and are currently
    completing development of Amelior, our lead product candidate.
    We promote&#160;Acetadote and our other FDA-approved product,
    Kristalose, through dedicated hospital and gastroenterology
    sales forces, which are comprised of 42 sales representatives
    and managers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our key products and product candidates include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Product</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Indication</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Delivery</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Status</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Amelior<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Pain and Fever
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Phase&#160;III
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Acetaminophen Poisoning
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Chronic and Acute Constipation
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Oral Solution
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="7" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="7" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Amelior</B>, our lead pipeline candidate, is an intravenous
    formulation of ibuprofen that we expect will be the first
    injectable product approved in the U.S.&#160;for the treatment
    of both pain and fever. Amelior is currently in Phase&#160;III
    clinical trials. We expect to complete clinical development by
    early 2008 and are preparing to submit our new drug application,
    or NDA, to the FDA for review. Amelior is designed to provide
    physicians with a safe, effective treatment alternative for
    patients who are unable to take oral medication for pain relief
    or fever reduction. If approved, we plan to market Amelior in
    the U.S.&#160;through our hospital sales force and in
    international markets through alliances with marketing partners.
    We believe Amelior currently represents our most significant
    product opportunity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Injectable analgesics, or pain relievers, currently available in
    the U.S.&#160;include opioids, such as morphine and meperdine,
    and ketorolac, a non-steroidal anti-inflammatory drug, or NSAID.
    While opioids accounted for over 91% of market volume, with
    approximately 447&#160;million units sold in 2006, they are
    known to cause undesirable side effects including nausea,
    vomiting and cognitive impairment. Ketorolac is the only
    non-opioid injectable analgesic approved for sale in the U.S.
    and has also been known to cause unwanted side effects. Despite
    strong safety warnings from the FDA, use of ketorolac in the
    U.S.&#160;has grown from approximately 38&#160;million units
    sold in 2003 (7% of the market) to approximately 43&#160;million
    units sold in 2006 (9% of the market) according to IMS Health
    Inc., or IMS Health. Based on the results of clinical studies to
    date, we believe Amelior represents a potentially safer
    alternative therapy to ketorolac. Further, we believe Amelior is
    a safe and effective treatment for hospitalized patients with
    fever who are unable to take oral medication. There is currently
    no approved injectable treatment for fever in the U.S.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">39</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Acetadote</B> is an intravenous formulation of
    N-acetylcysteine, or NAC, indicated for the treatment of
    acetaminophen poisoning. According to the American Association
    of Poison Control Centers&#146; Toxic Exposure Surveillance
    System, acetaminophen was the leading cause of poisonings
    presenting to emergency departments in the U.S., with
    approximately 77,000 cases treated in 2005. In January 2004,
    Acetadote received FDA approval as an orphan drug, a designation
    which provides for seven years of marketing exclusivity from
    date of approval. Since its launch in June 2004, we have
    consistently grown product sales for Acetadote, with wholesaler
    sales to hospitals growing 43% to $13&#160;million in 2006. We
    believe that we can continue to expand market share, and that
    our Acetadote sales and marketing platform should help
    facilitate the commercial launch of Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Kristalose, </B>a prescription laxative product, is a
    crystalline form of lactulose designed to enhance patient
    acceptance and compliance. Based on data from IMS Health, the
    market for prescription laxatives in the U.S.&#160;grew from
    approximately $206&#160;million in 2003 to $389&#160;million in
    2006, driven largely by new product introductions and increased
    promotional activity by our competitors. Wholesaler sales of
    Kristalose to pharmacies were $10.5&#160;million in 2006. We
    acquired exclusive U.S.&#160;commercialization rights to
    Kristalose during that year, assembled a new dedicated field
    sales force and re-launched the product in October 2006 under
    the Cumberland brand. We believe that Kristalose has competitive
    advantages over competing prescription laxatives, and that the
    potential for growth of this product is significant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Early-stage product candidates.</B>&#160;&#160;Our
    early-stage product candidates are being developed through
    Cumberland Emerging Technologies, Inc., or CET, our 86%-owned
    subsidiary. CET collaborates with leading research institutions
    to identify and pursue promising pre-clinical programs within
    our target market segments. We have negotiated rights to develop
    and commercialize these product candidates. Current CET projects
    include an improved treatment for fluid buildup in the lungs of
    cancer patients and an anti-infective for treating fungal
    infections in immuno-compromised patients. In conjunction with
    these research institutions, we have obtained grant funding to
    support the development of these programs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR COMPETITIVE
    STRENGTHS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Significant
    late-stage product opportunity in Amelior</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe Amelior currently represents our most significant
    product opportunity based on the large potential markets for
    intravenous treatment of pain and fever, as well as clinical
    results for the product to date. We have conducted several
    clinical trials to support this product and expect to complete
    Phase&#160;III clinical studies by early 2008. Based on our
    clinical results to date, we believe Amelior represents a
    potentially safer alternative to ketorolac, which is the only
    injectable non-opioid analgesic currently on the
    U.S.&#160;market, with approximately 43&#160;million units sold
    in 2006. We have retained exclusive commercialization rights for
    Amelior in the U.S. and plan to market the product through our
    existing hospital sales force.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Strong growth
    potential of our existing marketed products, Acetadote and
    Kristalose</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that there is significant opportunity to increase
    sales of our two currently approved products, Acetadote and
    Kristalose. Since its launch in June 2004, we have consistently
    grown product sales for Acetadote. During 2006, hospital
    purchases of Acetadote from wholesalers grew 43% to
    $13&#160;million. Kristalose competes in the high growth
    U.S.&#160;prescription laxatives market which, based on data
    from IMS Health, grew from approximately $206&#160;million in
    2003 to $389&#160;million in 2006, or a compound annual growth
    rate of approximately 24%. After acquiring exclusive U.S. rights
    to Kristalose in April 2006, we assembled an experienced,
    dedicated sales force and designed a new marketing
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">40</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    program, re-launching the product in October 2006. We believe
    both Kristalose and Acetadote have favorable competitive
    profiles, and that we can increase market share for each.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Focus on
    underserved niche markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We focus our efforts on specialty physician segments where we
    believe we can leverage our industry expertise and sales
    capability to deliver products that address unmet medical needs.
    Currently, our primary target markets are hospital acute care
    and gastroenterology. We consider these markets attractive
    because of their relatively concentrated prescriber bases, which
    allow us to reach target prescribers with a small number of
    sales representatives. Moreover, we believe these markets are
    less prone to competition from larger pharmaceutical companies
    than other pharmaceutical sectors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Profitable
    business with a history of fiscal discipline</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have been profitable since 2004, during which time we have
    generated sufficient cash flows to fund our development and
    marketing programs without the need for significant external
    financing. As an emerging pharmaceutical company with limited
    resources, we have historically focused on product opportunities
    with relatively low acquisition, development, and
    commercialization costs. Further, we believe that our
    third-party manufacturing and distribution relationships allow
    us to outsource these functions efficiently while directing most
    of our resources to our core competencies of business
    development, clinical and regulatory affairs, and sales and
    marketing.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Integrated
    specialty pharmaceutical company with extensive management
    expertise</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executives have significant pharmaceutical industry
    experience in business development, clinical and regulatory
    affairs, and sales and marketing. This team is augmented by our
    Pharmaceutical and Medical Advisory Boards, which consist of
    highly experienced healthcare professionals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Our business development team is led by our CEO and our Director
    of Business Development and is comprised of a multi-disciplinary
    group of executives. This team sources product opportunities
    independently as well as through our international network of
    pharmaceutical and medical industry insiders. Their efforts have
    resulted in acquisition, license, co-promotion and strategic
    alliance agreements, and have provided us with rights to our
    current portfolio. This group is also responsible for acquiring
    rights to early-stage product candidates through CET.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Our clinical, regulatory affairs and product development team is
    led by three professionals with substantial experience advancing
    late-stage clinical candidates successfully through the FDA
    approval process. This team was directly responsible for
    obtaining FDA approval for Acetadote and is responsible for our
    development of Amelior. We have established internal
    capabilities to develop proprietary product formulations, design
    and manage our clinical trials, prepare all regulatory
    submissions and manage our medical call center.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Our sales and marketing team is managed by five executives who
    have broad experience marketing branded pharmaceuticals. They
    manage the dedicated hospital and gastroenterology sales forces
    that promote our products and that together are comprised of 42
    sales representatives and managers. Our executives also direct
    our national marketing campaigns and manage relationships with
    key accounts.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">41</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUR
    STRATEGY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our objective is to develop, acquire and commercialize branded
    pharmaceutical products for specialty physician market segments.
    Specifically, we plan to:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Successfully
    develop and commercialize Amelior, our Phase&#160;III product
    candidate</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior is in late-stage Phase&#160;III clinical development for
    the treatment of pain and fever. We have gathered positive data
    regarding the safety and efficacy of this product, and we expect
    to complete clinical trials in early 2008. We believe that there
    is significant market potential for Amelior in both pain and
    fever. We intend to penetrate the U.S.&#160;hospital market with
    our existing hospital sales force and to commercialize the
    product internationally through alliances with marketing
    partners.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Maximize sales of
    our marketed products</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Over the past three years, we have employed an effective
    marketing campaign resulting in consistent sales growth for our
    product Acetadote. We intend to expand our hospital sales force
    in anticipation of a potential launch of Amelior. We believe we
    can leverage this expanded sales force to increase Acetadote
    sales. We are also supporting several studies to explore other
    potential indications for Acetadote. In October 2006, we
    re-launched Kristalose under the Cumberland brand with a new
    marketing program and dedicated sales force, which we expect to
    expand significantly over time. This marketing program is
    designed to enhance brand awareness through increased
    promotional activity and highlights Kristalose&#146;s many
    positive, competitive attributes. In addition to our sales
    efforts, we may also pursue co-promotion arrangements with third
    parties to support growth of our products.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Expand sales
    force operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to continue building our sales and marketing
    infrastructure in order to drive prescription volume and product
    sales. We currently utilize two distinct sales teams:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We promote&#160;Acetadote, and plan to promote&#160;Amelior,
    through our dedicated hospital sales team consisting of 16
    representatives and managers covering approximately 1,400 major
    U.S.&#160;medical centers. We expect to significantly increase
    this sales force in order to fully capitalize on the market
    potential of Acetadote and Amelior.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We promote&#160;Kristalose through a dedicated field sales force
    of 26 sales representatives and managers to approximately 6,400
    gastroenterologists and other high prescribers of laxatives. We
    believe that we can increase the market for Kristalose
    significantly by investing in our marketing program and
    significantly expanding this sales force.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Expand our
    product portfolio by acquiring rights to additional products and
    late-stage product candidates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to build a portfolio of complementary, niche products
    largely through product acquisitions. We focus on
    under-promoted, FDA-approved drugs with existing brand
    recognition as well as late-stage development products which
    address unmet medical needs, a strategy which we believe helps
    minimize our exposure to the significant risk, cost and time
    associated with drug discovery and research. We plan to continue
    to target products that are competitively differentiated, have
    valuable trademarks or other intellectual property, and allow us
    to leverage our existing infrastructure. We also plan to explore
    opportunities to seek approval for new uses of existing
    pharmaceutical products.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">42</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Develop a
    pipeline of early-stage products through CET</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to build our product pipeline, we are supplementing our
    acquisition and late-stage development activities with the
    early-stage drug development activities of CET, our
    majority-owned subsidiary. CET partners with universities and
    other research organizations to cost-effectively develop
    promising, early-stage product candidates. Current pre-clinical
    projects nearing clinical-stage development include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a treatment for fluid buildup in the lungs of cancer patients,
    in collaboration with Vanderbilt University, and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a highly purified anti-infective for treating fungal infections
    in immuno-compromised patients, in collaboration with the
    University of Mississippi.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INDUSTRY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The hospital
    market</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to IMS Health, U.S.&#160;hospitals accounted for
    approximately $31&#160;billion, or 11%, of
    U.S.&#160;pharmaceutical sales in 2006. IMS Health also reports
    that in 2006, marketing and promotional efforts focused on
    hospital-use drugs represented only about $662&#160;million, or
    3%, of approximately $21&#160;billion total pharmaceutical
    industry spending on promotional activity. The majority of
    promotional spending is directed towards large outpatient
    markets promoting drugs intended for chronic use rather than
    short-term use in the hospital setting. We believe the lack of
    promotional emphasis on the hospital marketplace indicates that
    the hospital market is underserved. We also believe that the
    hospital market is highly concentrated, with a small number of
    large institutions responsible for a majority of pharmaceutical
    spending, and consequently that it can be penetrated effectively
    without large-scale promotional activity by a small, dedicated
    sales force.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Market for
    injectable analgesics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Therapeutic agents used to treat pain are collectively known as
    analgesics. Physicians prescribe injectable analgesics for
    hospitalized patients who have high levels of acute pain,
    require rapid pain relief or cannot take oral analgesics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to IMS Health, the U.S.&#160;market for injectable
    analgesics exceeded $302&#160;million, or 491&#160;million
    units, in 2006. This market is comprised principally of generic
    opioids and the NSAID ketorolac. Injectable opioids such as
    morphine, meperidine, hydromorphone and fentanyl accounted for
    approximately 447&#160;million units sold in 2006. While opioids
    are widely used for acute pain management, they are associated
    with a variety of unwanted side effects including sedation,
    nausea, vomiting, constipation, headache, cognitive impairment
    and respiratory depression. Respiratory depression, if not
    monitored closely, can be deadly. Opioid-related side effects
    can warrant dosing limitations, which may reduce overall
    effectiveness of pain relief. Side effects from opioids can
    cause a need for further medication or treatment, and can
    increase lengths of stay in post-anesthesia care units as well
    as overall hospital stay, which can lead to increased costs for
    hospitals and patients.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Despite having a poor safety profile, usage of ketorolac, the
    only non-opioid injectable analgesic available in the U.S., has
    grown from approximately 38&#160;million units in 2003, or 7% of
    the market, to approximately 43&#160;million units in 2006,
    representing 9% of the market, according to IMS Health. The FDA
    specifically warns that ketorolac should not be used in various
    patient populations that are at-risk for bleeding, as a
    prophylactic analgesic prior to major surgery or for
    intraoperative administration when stoppage of bleeding is
    critical.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">43</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Fever</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant fever is generally defined as a temperature of
    greater than 102 degrees Fahrenheit. High fevers can cause
    hallucinations, confusion, convulsions and death. Hospitalized
    patients are subject to increased risk for developing fever,
    especially from exposure to infectious agents. Patients with
    endotracheal intubation, sedation, reduced gastric motility,
    nausea or recent surgery are frequently unable to ingest,
    digest, absorb, or tolerate oral products to reduce fever.
    Treatment for these patients ranges from rectal delivery of
    medication to physical cooling measures such as tepid baths, ice
    packs and cooling blankets. In the U.S., there is currently no
    FDA-approved intravenous medication for the treatment of fever.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Acetaminophen
    poisoning</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetaminophen is one of the most widely used drugs for oral
    treatment of pain and fever in the U.S. and can be found in many
    common
    <FONT style="white-space: nowrap">over-the-counter,</FONT>
    or OTC products and prescription narcotics. Though safe at
    recommended doses, the drug can cause liver damage with
    excessive use. According to the American Association of Poison
    Control Centers&#146; Toxic Exposure Surveillance System,
    acetaminophen poisoning is the leading cause of toxic drug
    ingestions in the U.S.&#160;In 2005, approximately 77,000 people
    were treated and 333&#160;people died due to acetaminophen
    poisoning in the U.S.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In a study published in 2005 that examined acute liver failure,
    researchers concluded that acetaminophen poisoning was
    responsible for acute liver failure in over half the patients
    examined in 2003, up from 28% in 1998. While an estimated 48% of
    cases were due to the accidental use of acetaminophen over
    several days, causing chronic liver failure, an estimated 44% of
    the cases were intentional overdoses, causing acute liver
    failure.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to the FDA, four grams of acetaminophen is the daily
    maximum dosage recommended for adults. Ingesting eight grams of
    acetaminophen in a single day causes a significant number of
    people, whose livers have been previously stressed by a virus,
    medication or alcohol, to experience more serious complications.
    When used in conjunction with opiates, acetaminophen can be
    effective in relieving pain after surgery or injury; however,
    some patients who take acetaminophen/opiate combination drugs on
    a chronic basis eventually require increasing amounts to achieve
    the same level of pain relief, which can also lead to liver
    failure.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Market for the
    treatment of Acetaminophen overdose</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    NAC is widely accepted as the standard of care for acetaminophen
    overdose. Throughout Europe and much of the rest of the world,
    NAC has been available in an injectable formulation for over
    25&#160;years. Until the 2004 approval of Acetadote, however,
    the only FDA-approved form of NAC available in the U.S.&#160;was
    an oral preparation. Prior to the approval of Acetadote, many
    U.S.&#160;hospitals prepared an off-label, IV form of NAC from
    the oral solution to treat patients suffering from acetaminophen
    poisoning. For a number of these patients, an&#160;IV product is
    the only reasonable route of administration due to nausea and
    vomiting associated with the administration of oral NAC for the
    overdose. Moreover, IV&#160;treatment requires fewer doses and a
    shorter treatment protocol, reducing treatment from three days
    to one day.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetaminophen poisoning treatment is typically initiated in the
    emergency department and continued in the intensive care unit.
    NAC is marketed to emergency physicians and nurses, critical
    care physicians, clinical and medical toxicologists and poison
    control centers. According to <I>The Medical Letter on Drugs and
    Therapeutics,</I> NAC is virtually 100% effective in preventing
    severe liver damage, renal failure and death if administered
    within eight to ten&#160;hours of the overdose.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">44</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The
    gastrointestinal market</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to the National Institute of Diabetes, Digestive and
    Kidney Diseases, gastrointestinal diseases  result in
    approximately 50&#160;million physician visits and
    14&#160;million hospitalizations annually. Many of these
    physician visits are to one of the only 11,700
    gastroenterologists in the U.S.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are over 40 common, well-defined gastrointestinal
    conditions recognized in the U.S., including constipation,
    chronic liver disease and cirrhosis, gastroesophageal reflux
    disease, infectious diarrhea, irritable bowel syndrome, lactose
    intolerance, pancreatitis and peptic ulcers. Because the market
    for gastrointestinal diseases is broad in patient scope, yet
    relatively narrow in physician base, we believe that it is an
    attractive specialty focus which can provide a wide variety of
    product opportunities but can be penetrated with a modest sales
    force.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Market for
    treatment of constipation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Constipation is a common condition in the U.S., affecting
    approximately 20% of the population each year. While many
    occurrences are non-recurring, a significant number are chronic
    in nature and require some treatment to control or resolve.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Constipation treatments are sold in both the OTC, and
    prescription segments. We believe that the prescription laxative
    market in which Kristalose competes has historically consisted
    of a few highly promoted brands including
    MiraLax<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    (polyethylene glycol 3350), which is now being sold as an OTC
    product, Amitiza and
    Zelnorm<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    which is used for multiple indications including constipation,
    as well as several generic forms of liquid lactulose and
    polyethylene glycol 3350. Zelnorm was removed from the market in
    March 2007 due to adverse safety findings, and is pending
    further FDA review. According to data from IMS Health, this
    market grew from approximately $206&#160;million in 2003 to
    $389&#160;million in 2006, a compound annual growth rate of
    approximately 24%. This increase in sales resulted primarily
    from new product introductions and increased promotion of
    branded products.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PRODUCTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our key products and product candidates include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="30%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Product</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Indication</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Delivery</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Status</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Amelior<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Pain and Fever
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Phase&#160;III
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Acetaminophen Poisoning
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Injectable
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Chronic and Acute Constipation
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Oral Solution
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Marketed
    </FONT>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
<TD colspan="7" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD colspan="7" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Amelior</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amelior is an intravenous formulation of ibuprofen. We expect
    Amelior will be the first injectable non-opioid product
    available in the U.S.&#160;for the treatment of pain and fever.
    The product is currently in Phase&#160;III clinical trials, and
    we are preparing for our NDA submission to the FDA for
    regulatory approval. If approved, we believe Amelior will
    provide physicians with a safe, effective treatment alternative
    for acute care patients requiring an intravenous product for
    pain relief or fever reduction. We have retained the
    U.S.&#160;marketing rights for Amelior and, if approved, plan to
    market it in the U.S.&#160;through our hospital sales force. We
    plan to commercialize the product outside of the
    U.S.&#160;through alliances with international marketing
    partners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ibuprofen, an NSAID, is a widely-used product now taken orally
    for pain relief and fever reduction, but is currently
    unavailable in an injectable formulation for this use. In May
    1999, we acquired from Vanderbilt University an exclusive,
    worldwide license to data on the use of intravenous ibuprofen.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">45</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Published in the <I>New England Journal of Medicine </I>in March
    1997, this data indicated that intravenous ibuprofen was
    effective in reducing high fever in critically ill patients who
    were largely unable to receive oral medication. Following
    discussion with and recommendation by the FDA, we implemented a
    development program for Amelior designed to obtain approval for
    a dual indication for the product&#151;reduction of pain and
    treatment of fever.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect Amelior will be administered primarily to hospitalized
    patients who are unable to receive analgesics or antipyretics
    orally. We believe Amelior represents our most significant
    product opportunity to date.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Development
    history</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have actively managed the development of Amelior by
    implementing the following steps:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We obtained exclusive rights to an investigator IND which
    contains supportive safety and efficacy data in which
    hospitalized adult patients with sepsis received intravenous
    ibuprofen.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We developed a patented formulation for Amelior as well as a
    proprietary manufacturing process.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We completed a clinical study to establish the pharmacokinetic
    equivalence of oral and intravenous ibuprofen in February 2001,
    a study to establish safe administration of the optimized
    dilution of Amelior&#146;s IV preparation in March 2002, and a
    study to demonstrate that the product is effective in reducing
    fever in hospitalized adult malaria patients in July 2002.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We completed a dose-ranging study to determine the optimum dose
    to treat fever in hospitalized adult patients in August 2005.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We completed enrollment for a dose-ranging study to determine
    the product&#146;s effectiveness in controlling pain in
    post-surgical adult patients in October 2006.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    In January 2007, we initiated a pivotal study to demonstrate the
    product&#146;s effectiveness in controlling pain in
    post-surgical adult patients. In April 2007, a subsequent study
    was initiated to support the product&#146;s use in additional
    surgical populations.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Over four years of stability studies for Amelior have been
    successfully completed.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    A study to obtain data to support pediatric use is ongoing.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    An integrated safety database is being built, combining both
    published experience with data from these new studies.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to complete clinical development of Amelior by early
    2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Commercialization
    strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to expand our existing U.S.&#160;hospital sales force
    to promote&#160;Amelior to physicians, nurses and pharmacy
    directors, principally in the hospital setting. We believe that
    we can achieve our commercial goals by utilizing our experienced
    sales organization, and supporting them with an internal
    marketing infrastructure that targets high-use institutions. We
    have an international strategic alliance with Mayne Pharma Pty.
    Ltd., which will manufacture commercial supplies of Amelior. We
    intend to partner with third-parties to reach markets outside
    the U.S.&#160;or to expand our reach to physician groups outside
    the hospital where applicable.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Acetadote</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetadote is N-acetylcysteine, or NAC, for the intravenous
    treatment of acetaminophen overdose. Until we obtained FDA
    approval for Acetadote in 2004, the only FDA-approved form of
    NAC available in
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">46</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the U.S.&#160;was an oral preparation. Medical literature
    suggested that many hospitals prepared an off-label, IV form of
    NAC from the oral solution for easier administration and
    accuracy in dosing. Given this market dynamic, we concluded that
    a medical need existed for an FDA-approved, injectable
    formulation of NAC for the U.S.&#160;market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We actively managed the development and regulatory approval of
    Acetadote by implementing the following steps:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We held initial discussions with the FDA to design a development
    plan.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Acetadote was granted orphan drug status in October 2001, which
    provides for seven years of marketing exclusivity from date of
    marketing approval.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We submitted our NDA in July 2002.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We submitted a complete response to FDA initial review questions
    in July 2003.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    We received FDA marketing approval for Acetadote in January 2004
    for the treatment of acetaminophen overdose.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Acetadote was launched in June 2004.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Early in 2006, the FDA-approved revised labeling for the
    product, which included an expanded indication for dosing in
    pediatric patients.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the FDA&#146;s approval of Acetadote, we
    committed to certain post-marketing activities for the product.
    Our first phase&#160;IV commitment (pediatric) was completed and
    accepted by the FDA in December 2004. Our second phase&#160;IV
    commitment (clinical) was completed and accepted by the FDA in
    August 2006. We anticipate completing our third and final
    phase&#160;IV commitment (manufacturing) for Acetadote in 2007.
    We are also supporting a number of studies to explore other
    potential indications for the product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe Acetadote has clinical and financial benefits
    relative to oral NAC, including ease of administration,
    minimizing nausea and vomiting associated with oral NAC,
    accurate dosage control, shorter treatment protocol and
    reduction in overall cost of acetaminophen overdose management.
    Acetadote makes NAC administration easier to tolerate for
    patients and easier to administer for medical providers. We
    believe Acetadote also offers a significant cost benefit to both
    patient and hospital by reducing the treatment regimen, usually
    from three days to one day.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetadote is manufactured for us by Bioniche Teoranta at its
    FDA-approved manufacturing facility in Ireland.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Kristalose</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Kristalose is a prescription laxative administered orally for
    the treatment of constipation. In patients with a history of
    chronic constipation, lactulose therapy increases the number of
    bowel movements per day and the number of days on which they
    occur. Lactulose is a product with a long history of use as a
    laxative, and as a treatment for hepatic encephalopathy, which
    is a deterioration of the liver resulting in a
    <FONT style="white-space: nowrap">build-up</FONT> of
    ammonia. Kristalose is an innovative, dry powder crystalline
    formulation of lactulose which is designed to enhance patient
    compliance and acceptance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We co-promoted Kristalose from 2002 until April 2006 under an
    agreement with Bertek Pharmaceuticals, Inc., the branded
    division of Mylan Laboratories, Inc. Following Mylan&#146;s
    discontinuance of Bertek operations in 2006, we acquired
    exclusive U.S.&#160;commercialization rights to Kristalose. We
    re-launched Kristalose under the Cumberland brand in October
    2006 with a dedicated, contract sales force of 26 sales
    representatives and managers. We direct our sales efforts to
    physicians
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">47</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    who are the most prolific writers of prescription laxatives.
    These physicians include gastroenterologists, pediatricians,
    internists and colon and rectal surgeons.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe Kristalose offers competitive advantages over other
    laxative products. Packaged in single dose packets, Kristalose
    is very portable, is reconstituted in as little as four ounces
    of water, is clear, virtually tasteless, does not change the
    viscosity of the water and contains almost no calories, all of
    which we believe cause Kristalose to compare favorably to liquid
    lactulose products. Compared to polyethylene glycol 3350
    products, we believe Kristalose has a fast onset of action and a
    better pregnancy category rating. Compared with
    Zelnorm<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and
    Amitiza<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    Kristalose has fewer potential side effects or contraindications
    and is less expensive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Kristalose is manufactured for us by Inalco S.p.A. at an
    FDA-approved facility in Italy.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Early-stage
    product candidates</FONT></B>
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our early-stage product candidates are being developed by CET,
    which collaborates with leading research institutions to
    identify and pursue promising pre-clinical programs. Two of the
    more advanced CET development programs are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    In collaboration with Vanderbilt University, we are currently
    developing a new treatment for fluid buildup in the lungs of
    cancer patients. The product candidate is a protein therapeutic
    being designed to treat &#147;pleural effusion,&#148; a
    condition which occurs when cancer spreads to the surface of the
    lung and chest cavity, causing fluid to accumulate and patients
    to suffer shortness of breath and chest pain. An estimated
    100,000&#160;patients are affected by this condition each year.
    Currently, the substances used in treating this cause pain and
    have only a
    <FONT style="white-space: nowrap">60-90%</FONT>
    success rate. Vanderbilt University researchers believe they
    have found a method of treating this condition which may involve
    less pain, a higher success rate and faster healing time,
    resulting in significantly shorter hospital stays.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    In collaboration with the University of Mississippi, we are
    developing a highly purified, injectable anti-infective used to
    treat fungal infections in immuno-compromised patients. This
    product candidate&#146;s active ingredient is currently
    FDA-approved in a different formulation, and while it is the
    therapeutic of choice for infectious disease specialists in
    treating such fungal infections, it can produce serious side
    effects related to renal toxicity, often resulting in dosage
    limitations or discontinued use. University of Mississippi
    researchers have developed what they believe is a purer and
    safer form of the anti-infective.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">BUSINESS
    DEVELOPMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since inception, we have had an active business development
    program focused on acquiring rights to marketed products and
    product candidates that fit our strategy and target markets. We
    source our business development leads both through our senior
    executives and our international network of pharmaceutical and
    medical industry insiders. These opportunities are reviewed and
    considered on a regular basis by a multi-disciplinary team of
    our managers against a list of selection criteria. We have
    historically focused on product opportunities with relatively
    low acquisition, development and commercialization costs,
    employing a variety of deal structures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to continue to build a portfolio of complementary,
    niche products largely through product acquisitions. Our primary
    targets are under-promoted, FDA-approved drugs with existing
    brand recognition and late-stage development products that
    address unmet medical needs in the hospital acute care and
    gastroenterology markets. We also plan to explore opportunities
    to acquire rights to and seek approval for new uses of
    pharmaceutical products. We believe that by focusing mainly on
    approved or
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">48</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    late-stage products, we can minimize the significant risk, cost
    and time associated with drug development. We have completed
    three material acquisitions including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    exclusive, worldwide rights from Vanderbilt University to data
    for intravenous ibuprofen to support our FDA submission for
    Amelior;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    exclusive, worldwide rights to clinical data supporting the
    safety and efficacy of Acetadote, which served as a key
    component of our FDA submission and approval; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    exclusive U.S.&#160;commercial rights to Kristalose.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business development team is also responsible for
    identifying appropriate CET product candidates and negotiating
    with our university partners to secure rights to these
    candidates. Through CET, we are collaborating with a growing
    list of research institutions including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Vanderbilt University;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    University of Mississippi, School of Pharmacy; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    University of Tennessee Research Foundation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since 2004, these collaborations secured nearly $1&#160;million
    in National Institutes of Health grant funding for the
    development of promising new products and several additional
    proposals have been submitted or are awaiting review.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">CLINICAL AND
    REGULATORY AFFAIRS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have established in-house capabilities for the management of
    our clinical, professional and regulatory affairs. Our team
    develops and manages our clinical trials, prepares regulatory
    submissions, manages ongoing product-related regulatory
    responsibilities and manages our medical information call
    center. They were responsible for devising the regulatory and
    clinical strategy and obtaining FDA approval for Acetadote and
    are responsible for ongoing development of Amelior.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Clinical
    development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our in-house clinical development personnel are responsible for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    creating clinical development strategies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    designing and monitoring our clinical trials;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    creating case report forms and other study-related documents;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    overseeing clinical work contracted to third parties; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    overseeing CET grant funding proposals.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Regulatory and
    quality affairs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our internal regulatory and quality affairs team is responsible
    for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    preparing and submitting NDAs and fulfilling post-approval
    marketing commitments;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    maintaining investigational and marketing applications through
    the submission of appropriate reports;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    submitting supplemental applications for additional label
    indications, product line extensions and manufacturing
    improvements;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    evaluating regulatory risk profiles for product acquisition
    candidates, including compliance with manufacturing, labeling,
    distribution and marketing regulations;
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">49</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    monitoring applicable third-party service providers for quality
    and compliance with current Good Manufacturing Practices, Good
    Laboratory Practices, and Good Clinical Practices, and
    performing periodic audits of such vendors; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    maintaining systems for document control, product and process
    change control, customer complaint handling, product stability
    studies and annual drug product reviews.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Professional and
    medical affairs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our clinical and regulatory team provides in-house, medical
    information support for our marketed products. This includes
    interacting directly with healthcare professionals to address
    any product or medical inquiries through our medical information
    call center. Our call center was previously operated by the
    Rocky Mountain Poison and Drug Center, or RMPDC. In 2006, we
    expanded our clinical and regulatory capabilities and brought
    our call center in-house in an effort to ensure the highest
    level of quality and service. The RMPDC continues to supplement
    our efforts by providing
    <FONT style="white-space: nowrap">after-hours</FONT>
    support for our call center and assisting us with our adverse
    event collection/reporting and global pharmacovigilance
    activities. In addition to coordinating the call center, our
    clinical/regulatory group generates medical information letters,
    provides informational memos to our sales forces and assists
    with ongoing training for the sales forces.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SALES AND
    MARKETING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing team has broad industry experience in
    selling branded pharmaceuticals. They manage the dedicated
    hospital and gastroenterology sales forces, which are comprised
    of 42 sales representatives and managers, direct our national
    marketing campaigns and maintain key national account
    relationships. We promote our products to hospitals and
    office-based physicians across the U.S. and plan to
    commercialize our products internationally through marketing
    alliances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2007, we converted our hospital sales force, which
    had previously been contracted to us by Cardinal Health Inc., or
    Cardinal, to Cumberland employees through our newly-formed,
    wholly-owned subsidiary, Cumberland Pharma Sales Corp. The
    hospital sales team is comprised of 16 sales representatives and
    managers, covering approximately 1,400 major medical centers
    across the U.S.&#160;The gastroenterology-focused team, formed
    in September 2006 with our re-launch of Kristalose, is a field
    sales force comprised of 26 representatives and managers and
    covering approximately 6,400 high prescribers of laxatives. This
    gastroenterology sales force is contracted to us by Advogent
    Group, Inc., or Advogent. Under our agreement, we pay Advogent a
    monthly fee, a portion of which is used to compensate the sales
    force. We also reimburse Advogent for bonuses and expense
    reimbursement paid to the sales force. This agreement terminates
    in August 2008. We have the option, with Advogent&#146;s
    consent, to extend the contract for one additional year. We also
    have the option to bring this sales force in-house. We expect to
    expand both sales forces significantly over the next several
    years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing executives conduct ongoing market
    analyses to evaluate marketing campaigns and promotional
    programs. The evaluations include development of product
    profiles, testing of the profiles against the needs of the
    market, determining what additional product information or
    development work is needed to effectively market the products
    and preparing financial forecasts. We utilize professional
    branding and packaging as well as promotional items to support
    our products, including direct mail, sales brochures, journal
    advertising, educational and reminder leave-behinds, patient
    educational pieces and product sampling. We also attend regular
    trade shows to promote broad awareness of our products.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">50</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our National Accounts group is responsible for key large buyers
    and related marketing programs. This group supports sales and
    marketing efforts by maintaining relationships with our
    wholesaler customers as well as with third-party payors such as
    Group Purchasing Organizations, Pharmacy Benefit Managers,
    Hospital Buying Groups, state and federal government purchasers
    and influencers and health insurance companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">International
    Sales and Marketing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Consistent with our strategy to outsource non-core functions, we
    have licensed to third parties the right to distribute Amelior
    outside the U.S.&#160;We have granted Alveda Pharmaceuticals
    Inc., or Alveda, an exclusive license to distribute Amelior in
    Canada subject to receipt of regulatory approval. Alveda is
    obligated to make payments to us upon Amelior&#146;s achieving
    specified regulatory milestones in Canada and to pay us a
    royalty based on Canadian sales of Amelior. This license
    terminates five years after regulatory approval is obtained in
    Canada for the later of the fever or pain indications. We have
    granted Mayne Pharma (SEA) Pte Limited an exclusive license to
    market and distribute Amelior in Southeast Asia subject to the
    receipt of regulatory approval. Mayne Pharma (SEA) Pte Limited
    is obligated to make payments to us upon Amelior&#146;s
    achieving specified regulatory milestones in Southeast Asia as
    well royalty payments. The initial term of the agreement expires
    on the fifth anniversary of Amelior obtaining regulatory
    approval in Southeast Asia.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">MANUFACTURING AND
    DISTRIBUTION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We outsource certain non-core, capital-intensive functions,
    including manufacturing and distribution. Our executives have
    years of experience in these areas and manage these third-party
    relationships with a focus on quality assurance.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Manufacturing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our key manufacturing relationships include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    In July 2000, we established an international manufacturing
    alliance with Australia-based Mayne Pharma Pty. Ltd., or Mayne.
    Mayne sources active pharmaceutical ingredients, or APIs, and
    manufactures Amelior exclusively for us under an agreement that
    expires on the fifth anniversary of FDA approval of Amelior,
    subject to early termination upon 45&#160;days prior notice in
    the event of uncured material breach by us or Mayne. The
    agreement will automatically renew for successive three-year
    terms unless Mayne or we provide at least 12&#160;months prior
    written notice of non-renewal. Under the agreement, we pay Mayne
    a transfer price per unit of Amelior supplied. In addition, we
    reimburse Mayne for
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    development, regulatory and inspection and audit costs. We have
    also granted Mayne a right of first negotiation with respect to
    the manufacture of all future pharmaceutical products we intend
    to sell and the distribution of these products in Australia, New
    Zealand, Canada and mutually agreed Southeast Asian and Latin
    American countries.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Bioniche Teoranta, or Bioniche, sources APIs and manufactures
    Acetadote exclusively for us for sale in the U.S.&#160;at its
    FDA-approved manufacturing facility in Ireland. Our relationship
    with Bioniche began in January 2002. Bioniche manufactures and
    packages Acetadote for us, and we purchase Acetadote exclusively
    from Bioniche, pursuant to an agreement expiring in January
    2011. This agreement is subject to early termination upon prior
    written notice in the event of an uncured material default by us
    or Bioniche. We have an option to renew the agreement for a
    five-year term upon expiration. Under the agreement, we pay
    Bioniche a transfer price per unit of Acetadote supplied, which
    transfer price is subject to annual adjustment, and a royalty
    based on our net sales of the product. In addition, we are
    required to purchase minimum quantities of Acetadote.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">51</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;</TD>
    <TD align="left">
    Inalco S.p.A. and Inalco Biochemicals, Inc., or collectively
    Inalco, from which we licensed exclusive
    U.S.&#160;commercialization rights to Kristalose in April 2006,
    source APIs and provide us with a manufacturing supply for the
    product under an agreement that expires in 2021. The agreement
    renews automatically for successive three-year terms unless we
    or Inalco provide written notice of intent not to renew at least
    12&#160;months prior to expiration of a term. Either we or
    Inalco may terminate this agreement upon at least 45&#160;days
    prior written notice in the event of uncured material breach.
    Under the agreement, we are required to pay Inalco a transfer
    price per unit of Kristalose supplied and a royalty based on our
    net sales of Kristalose. In addition, we are required to
    purchase minimum quantities of Kristalose.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Distribution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Like many other pharmaceutical companies, we employ an outside
    contractor to facilitate our distribution efforts. Since August
    2002, Specialty Pharmaceutical Services, or SPS, (formerly CORD
    Logistics, Inc.) has exclusively handled all aspects of our
    product logistics efforts, including warehousing, shipping,
    customer billing and collections. A division of Cardinal, SPS is
    located just outside of Nashville, Tennessee, and has a
    well-established infrastructure. We maintain ownership of
    finished products until their sale to our customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INTELLECTUAL
    PROPERTY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to protect our products from competition through a
    combination of patents, trademarks, trade secrets, FDA
    exclusivity and contractual restrictions on disclosure.
    Proprietary rights, including patents, are an important element
    of our business. We seek to protect our proprietary information
    by requiring our employees, consultants, contractors and other
    advisors to execute agreements providing for protection of our
    confidential information on commencement of their employment or
    engagement, through which we seek to protect our intellectual
    property. We also require confidentiality agreements from
    entities that receive our confidential data or materials.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Amelior</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are the owner of U.S.&#160;Patent No.&#160;6,727,286, which
    is directed to ibuprofen solution formulations, methods of
    making the same, and methods of using the same, and which
    expires in 2021. This U.S.&#160;patent is associated with our
    completed international application
    <FONT style="white-space: nowrap">No.&#160;PCT/US01/42894.</FONT>
    We have filed for international patent protection in association
    with this PCT application in various countries, some of which
    have been allowed and some of which remain pending.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied for additional protection for our invention
    related to ibuprofen solution formulations, methods of making
    the same and methods of using the same through
    U.S.&#160;application
    <FONT style="white-space: nowrap">No.&#160;10/739,050</FONT>
    and international application
    <FONT style="white-space: nowrap">No.&#160;PCT/US04/39770,</FONT>
    both of which remain pending.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have an exclusive, worldwide license to clinical data for
    intravenous ibuprofen from Vanderbilt University, in
    consideration for royalty and other payment obligations that are
    conditioned upon approval by the FDA of Amelior.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If Amelior is approved by the FDA, we intend to seek three years
    marketing exclusivity from the FDA based on the clinical studies
    we have sponsored to pursue approval of the product.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Acetadote</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetadote was approved by the FDA in January 2004 as an orphan
    drug for the intravenous treatment of acetaminophen overdose. As
    an orphan drug, Acetadote is entitled to seven years of
    marketing
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">52</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    exclusivity for the treatment of this approved indication. We
    have applied for patent protection for a new formulation of
    Acetadote through U.S. patent application
    <FONT style="white-space: nowrap">No.&#160;11/209,804,</FONT>
    as well as through international application
    <FONT style="white-space: nowrap">No.&#160;PCT/US06/20691,</FONT>
    both of which are directed to acetylcysteine compositions,
    methods of making the same and methods of using the same. In
    addition, we have an exclusive, worldwide license to NAC
    clinical data from Newcastle Master Misercordiae Hospital in
    Australia. We have no expected outstanding payment obligations
    pursuant to this contract.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Kristalose</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are the exclusive licensee of two U.S.&#160;patents owned by
    Inalco relating to Kristalose. The first, U.S.&#160;Patent
    No.&#160;5,003,061, is directed to a method for preparing
    high-purity crystalline lactulose. The second, U.S.&#160;Patent
    No.&#160;5,480,491, is directed to a process for preparation of
    crystalline lactulose. Our license rights include an exclusive
    license to use related Inalco know-how and the Kristalose
    trademark to manufacture, market and distribute Kristalose in
    the U.S.&#160;Under our agreement with Inalco, Inalco is solely
    responsible for prosecuting and maintaining both the patents and
    know-how that we license from them. Our license expires in 2021
    and is subject to earlier termination for material breach. Our
    payment obligations under this agreement are described under
    &#147;Manufacturing and Distribution&#160;&#151;
    Manufacturing.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">COMPETITION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pharmaceutical industry is characterized by intense
    competition and rapid innovation. Our continued success in
    developing and commercializing pharmaceutical products will
    depend, in part, upon our ability to compete against existing
    and future products in our target markets. Competitive factors
    directly affecting our markets include but are not limited to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    product attributes such as efficacy, safety,
    <FONT style="white-space: nowrap">ease-of-use</FONT>
    and cost-effectiveness;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    brand awareness and recognition driven by sales and marketing
    and distribution capabilities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    intellectual property and other exclusivity rights;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    availability of resources to build and maintain developmental
    and commercial capabilities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    successful business development activities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    extent of third-party reimbursements; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    establishment of advantageous collaborations to conduct
    development, manufacturing or commercialization efforts.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A number of our competitors possess research and development and
    sales and marketing capabilities as well as financial resources
    greater than ours. These competitors, in addition to emerging
    companies and academic research institutions, may be developing,
    or in the future could develop, new technologies that could
    compete with our current and future products or render our
    products obsolete.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Amelior</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are developing Amelior for the treatment of pain and fever,
    primarily in a hospital setting. A variety of products already
    address the acute pain market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Morphine, the most commonly used product for the treatment of
    acute, post-operative pain, is manufactured and distributed by
    several generic pharmaceutical companies.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Depodur<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    is an extended release injectable formulation of morphine that
    is marketed by SkyePharma PLC.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">53</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Other generic injectable opioids, including fentanyl, meperidine
    and hydromorphone.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Ketorolac (brand name
    Toradol<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>),
    an injectable NSAID, is also manufactured and distributed by
    several generic pharmaceutical companies.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are aware of other product candidates in development to treat
    acute pain including injectable NSAIDs, novel opioids, new
    formulations of existing therapies and extended release
    anesthetics. We believe the companies developing injectable,
    non-narcotic analgesics for the treatment of post-surgical pain
    are the primary potential competitors to Amelior. Cadence
    Pharmaceuticals Inc. is developing an injectable formulation of
    acetaminophen for the treatment of pain and fever, and Javelin
    Pharmaceuticals Inc. is developing an injectable form of an
    NSAID, diclofenac.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the injectable analgesic products above, many
    companies are developing analgesics for specific indications
    such as migraine and neuropathic pain, oral extended-release
    forms of existing narcotic and non-narcotic products, and
    products with new methods of delivery such as transdermal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not aware of any approved injectable products indicated
    for the treatment of fever in the U.S. There are, however,
    numerous drugs available to physicians to reduce fevers in
    hospital settings via oral administration to the patient,
    including acetaminophen, ibuprofen and aspirin. These drugs are
    manufactured by numerous pharmaceutical companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Acetadote</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acetadote is our injectable formulation of NAC for the treatment
    of acetaminophen overdose. NAC is accepted worldwide as the
    standard of care for acetaminophen overdose. Despite the
    availability of injectable NAC outside the United States,
    Acetadote, to our knowledge, is the only injectable NAC product
    approved in the U.S. to treat acetaminophen overdose. Our
    competitors in the acetaminophen overdose market are those
    companies selling orally administered NAC including, but not
    limited to, Geneva Pharmaceuticals, Inc., Bedford Laboratories
    division of Ben Venue Laboratories, Inc., Roxane Laboratories,
    Inc. and Hospira Inc.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Kristalose</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Kristalose is a dry powder crystalline prescription formulation
    of lactulose indicated for the treatment of constipation. The
    U.S.&#160;constipation therapy market includes various
    prescription and OTC products. The prescription products which
    we believe are our primary competitors are
    Amitiza<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and liquid lactuloses:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Amitiza is indicated for the treatment of chronic idiopathic
    constipation in adults and is marketed by Sucampo
    Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited;
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    Liquid lactulose products are marketed by a number of
    pharmaceutical companies.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, Kristalose competed with the prescription product
    Zelnorm<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    until it was pulled from the market in March 2007 due to adverse
    safety findings. Indicated for treatment of chronic idiopathic
    constipation in persons under aged 65 and produced by Novartis
    Pharma AG, Zelnorm is under further review by the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are several hundred OTC products used to treat
    constipation marketed by numerous pharmaceutical and consumer
    health companies.
    MiraLax<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    (polyethylene glycol 3350), previously a prescription product,
    is indicated for the treatment of constipation and is
    manufactured and marketed by Braintree Laboratories, Inc. and
    other generic pharmaceutical firms. Under an agreement with
    Braintree, Schering-Plough introduced MiraLax as an OTC product
    in February 2007.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">54</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">EMPLOYEES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of April&#160;30, 2007, we had 33&#160;full-time employees,
    which included 16 hospital sales representatives and managers.
    We also have a dedicated gastroenterology field sales force
    under contract that is comprised of 26 dedicated sales
    representatives and managers. We believe that employing
    experienced, independent contractors and consultants is a
    cost-efficient and effective way to accomplish our goals. A
    number of additional individuals have provided or are currently
    providing services to us pursuant to agreements between the
    individuals or their employers and us. None of our employees are
    represented by a collective bargaining unit. We believe that we
    have positive relationships with our employees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">FACILITIES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently lease approximately 6,300&#160;square feet of
    office space in Nashville, Tennessee for our headquarters under
    an agreement expiring in December 2010. We have an option to
    renew this lease for a five-year term upon expiration. We also
    have entered into an occupancy agreement for approximately
    9,000&#160;square feet of additional office space adjoining our
    headquarters. This occupancy agreement will be replaced by a
    sublease for the same space, effective June&#160;1, 2007. The
    sublease expires in October 2010. We believe that these
    facilities are adequate to meet our current needs for office
    space. We currently do not plan to purchase or lease facilities
    for manufacturing, packaging or warehousing, as such services
    are provided to us by third-party contract groups.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under an agreement expiring in May 2011, CET leases
    approximately 6,900&#160;square feet of office and wet
    laboratory space in Nashville, Tennessee. CET uses this space to
    operate the CET Life Sciences Center for product development
    work to be carried out in collaboration with universities,
    research institutions and entrepreneurs. CET has an option to
    lease up to 20,000&#160;square feet at the Life Sciences Center
    should it need additional space. The CET Life Sciences Center
    provides laboratory and office space, equipment and
    infrastructure to early-stage life sciences companies and
    university spin-outs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GOVERNMENT
    REGULATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pharmaceutical companies are subject to extensive regulation by
    national, state, and local agencies in countries in which they
    do business. The manufacture, distribution, marketing and sale
    of pharmaceutical products is subject to government regulation
    in the U.S. and various foreign countries. Additionally, in the
    U.S., we must follow rules and regulations established by the
    FDA requiring the presentation of data indicating that our
    products are safe and efficacious and are manufactured in
    accordance with cGMP regulations. If we do not comply with
    applicable requirements, we may be fined, the government may
    refuse to approve our marketing applications or allow us to
    manufacture or market our products and we may be criminally
    prosecuted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and our manufacturers and clinical research organizations may
    also be subject to regulations under other federal, state and
    local laws, including the Occupational Safety and Health Act,
    the Resource Conservation and Recovery Act, the Clean Air Act
    and import, export and customs regulations as well as the laws
    and regulations of other countries.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">FDA Approval
    Process</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The steps required to be taken before a new prescription drug
    may be marketed in the U.S.&#160;include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    completion of pre-clinical laboratory and animal testing;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the submission to the FDA of an investigational new drug
    application, or IND, which must be evaluated and found
    acceptable by the FDA before human clinical trials may commence;
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">55</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    performance of adequate and well-controlled human clinical
    trials to establish the safety and efficacy of the proposed drug
    for its intended use; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    submission and approval of a NDA.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sponsor of the drug typically conducts human clinical trials
    in three sequential phases, but the phases may overlap. In
    Phase&#160;I clinical trials, the product is tested in a small
    number of patients or healthy volunteers, primarily for safety
    at one or more dosages. In Phase&#160;II clinical trials, in
    addition to safety, the sponsor evaluates the efficacy of the
    product on targeted indications, and identifies possible adverse
    effects and safety risks in a patient population. Phase&#160;III
    clinical trials typically involve testing for safety and
    clinical efficacy in an expanded population at
    geographically-dispersed test sites.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The FDA requires that clinical trials be conducted in accordance
    with the FDA&#146;s good clinical practices (GCP) requirements.
    The FDA may order the partial, temporary or permanent
    discontinuation of a clinical trial at any time or impose other
    sanctions if it believes that the clinical trial is not being
    conducted in accordance with FDA requirements or presents an
    unacceptable risk to the clinical trial patients. The
    institutional review board (IRB), or ethics committee (outside
    of the U.S.), of each clinical site generally must approve the
    clinical trial design and patient informed consent and may also
    require the clinical trial at that site to be halted, either
    temporarily or permanently, for failure to comply with the
    IRB&#146;s requirements, or may impose other conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The results of the pre-clinical and clinical trials, together
    with, among other things, detailed information on the
    manufacture and composition of the product and proposed
    labeling, are submitted to the FDA in the form of an NDA for
    marketing approval. The FDA reviews all NDAs submitted before it
    accepts them for filing and may request additional information
    rather than accepting an NDA for filing. Once the submission is
    accepted for filing, the FDA begins an in-depth review of the
    NDA. Under the policies agreed to by the FDA under the
    Prescription Drug User Fee Act, or PDUFA, the FDA has ten months
    in which to complete its initial review of a standard NDA and
    respond to the applicant. The review process and the PDUFA goal
    date may be extended by three months if the FDA requests or the
    NDA sponsor otherwise provides additional information or
    clarification regarding information already provided in the
    submission within the last three months of the PDUFA goal date.
    If the FDA&#146;s evaluations of the NDA and the clinical and
    manufacturing procedures and facilities are favorable, the FDA
    may issue an approval letter. The FDA may also issue an
    approvable letter setting forth further conditions that must be
    met in order to secure final approval of the NDA. If and when
    those conditions have been met to the FDA&#146;s satisfaction,
    the FDA will issue an approval letter. An approval letter
    authorizes commercial marketing of the drug for certain
    indications. According to the FDA, the median total approval
    time for NDAs approved during calendar year 2004 was
    approximately 13&#160;months for standard applications. If the
    FDA&#146;s evaluations of the NDA submission and the clinical
    and manufacturing procedures and facilities are not favorable,
    it may refuse to approve the NDA and issue a not-approvable
    letter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The time and cost of completing these steps and obtaining FDA
    approval can vary dramatically depending on the drug. However,
    to complete these steps for a novel drug can take many years and
    cost millions of dollars.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Section&#160;505(b)(2)
    New Drug Applications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As an alternate path for FDA approval of new indications or new
    formulations of previously-approved products, a company may file
    a Section&#160;505(b)(2) NDA, instead of a
    &#147;stand-alone&#148; or &#147;full&#148; NDA.
    Section&#160;505(b)(2) of the FDC Act was enacted as part of the
    Drug Price Competition and Patent Term Restoration Act of 1984,
    otherwise known as the Hatch-Waxman Amendments.
    Section&#160;505(b)(2) permits the submission of an NDA where at
    least some of the information required for approval comes
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">56</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    from studies not conducted by or for the applicant and for which
    the applicant has not obtained a right of reference. Some
    examples of products that may be allowed to follow a 505(b)(2)
    path to approval are drugs which have a new dosage form,
    strength, route of administration, formulation or indication.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We successfully secured FDA approval of a 505(b)(2) NDA for
    Acetadote in January 2004. We also plan to pursue marketing
    approval for Amelior pursuant to the 505(b)(2) pathway.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon approval of a &#147;full&#148; or 505(b)(2) NDA, a drug may
    be marketed only for the FDA-approved indications in the
    approved dosage forms. Further clinical trials are necessary to
    gain approval for the use of the product for any additional
    indications or dosage forms. The FDA may also require
    post-market reporting and may require surveillance programs to
    monitor the side effects of the drug, which may result in
    withdrawal of approval after marketing begins.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Special Protocol
    Assessment Process</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The special protocol assessment, or SPA, process generally
    involves FDA evaluation of a proposed Phase&#160;III clinical
    trial protocol and a commitment from the FDA that the design and
    analysis of the trial are adequate to support approval of an
    NDA, if the trial is performed according to the SPA and meets
    its endpoints. The FDA&#146;s guidance on the SPA process
    indicates that SPAs are designed to evaluate individual clinical
    trial protocols primarily in response to specific questions
    posed by the sponsors. In practice, the sponsor of a product
    candidate may request an SPA for proposed Phase&#160;III trial
    objectives, designs, clinical endpoints and analyses. A request
    for an SPA is submitted in the form of a separate amendment to
    an IND, and the FDA&#146;s evaluation generally will be
    completed within a
    <FONT style="white-space: nowrap">45-day</FONT>
    review period under applicable PDUFA goals, provided that the
    trials have been the subject of discussion at an
    <FONT style="white-space: nowrap">end-of-Phase&#160;II</FONT>
    and pre-Phase&#160;III meeting with the FDA, or in other limited
    cases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;14, 2004, we submitted a request for SPA of our
    Amelior Phase&#160;III clinical study. During a meeting with the
    FDA on September&#160;29, 2004, the FDA confirmed that the
    efficacy data from our study of post-operative pain with a
    positive outcome will be considered sufficient to support a
    505(b)(2) application for the pain indication. Final
    determinations by the FDA with respect to a product candidate,
    including as to the scope of its &#147;labeling&#148;, are made
    after a complete review of the applicable NDA and are based on
    the entire data in the application. Moreover, notwithstanding
    any SPA, FDA approval of an NDA is subject to future public
    health concerns unrecognized at the time of protocol assessment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Orphan Drug
    Designation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Orphan Drug Act of 1983, or Orphan Drug Act, encourages
    manufacturers to seek approval of products intended to treat
    &#147;rare diseases and conditions&#148; with a prevalence of
    fewer than 200,000&#160;patients in the U.S. or for which there
    is no reasonable expectation of recovering the development costs
    for the product. For products that receive orphan drug
    designation by the FDA, the Orphan Drug Act provides tax credits
    for clinical research, FDA assistance with protocol design,
    eligibility for FDA grants to fund clinical studies, waiver of
    the FDA application fee, and a period of seven years of
    marketing exclusivity for the product following FDA marketing
    approval. Acetadote received Orphan Drug designation in October
    2001 and was approved by the FDA for the intravenous treatment
    of moderate to severe acetaminophen overdose in January 2004. As
    an orphan drug, Acetadote is entitled to marketing exclusivity
    until January 2011 for the treatment of this approved
    indication. This exclusivity would not prevent a product with a
    different formulation from competing with Acetadote, however.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">57</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The Hatch-Waxman
    Act</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Hatch-Waxman Act provides three years of marketing
    exclusivity for the approval of new and supplemental NDAs,
    including Section&#160;505(b)(2) NDAs, for, among other things,
    new indications, dosages or strengths of an existing drug, if
    new clinical investigations that were conducted or sponsored by
    the applicant are essential to the approval of the application.
    It is under this provision that we expect to receive three years
    marketing exclusivity for Amelior.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Other regulatory
    requirements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Regulations continue to apply to pharmaceutical products after
    FDA approval occurs. Post-marketing safety surveillance is
    required in order to continue to market an approved product. The
    FDA also may, in its discretion, require post-marketing testing
    and surveillance to monitor the effects of approved products or
    place conditions on any approvals that could restrict the
    commercial applications of these products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we seek to make certain changes to an FDA-approved product,
    such as promoting or labeling a product for a new indication,
    making certain manufacturing changes or product enhancements or
    adding labeling claims, we will need FDA review and approval
    before the change can be implemented. While physicians may use
    products for indications that have not been approved by the FDA,
    we may not label or promote the product for an indication that
    has not been approved. Securing FDA approval for new indications
    or product enhancements and, in some cases, for manufacturing
    and labeling claims, is generally a time-consuming and expensive
    process that may require us to conduct clinical trials under the
    FDA&#146;s IND regulations. Even if such studies are conducted,
    the FDA may not approve any change in a timely fashion, or at
    all. In addition, adverse experiences associated with use of the
    products must be reported to the FDA, and FDA rules govern how
    we can label, advertise or otherwise commercialize our products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to FDA restrictions on marketing of pharmaceutical
    products, several other types of state and federal laws have
    been applied to restrict certain marketing practices in the
    pharmaceutical industry in recent years. These laws include
    anti-kickback statutes and false claims statutes. The federal
    health care program anti-kickback statute prohibits, among other
    things, knowingly and willfully offering, paying, soliciting or
    receiving remuneration to induce or in return for purchasing,
    leasing, ordering or arranging for the purchase, lease or order
    of any health care item or service reimbursable under Medicare,
    Medicaid or other federally financed health care programs. This
    statute has been interpreted to apply to arrangements between
    pharmaceutical manufacturers on the one hand and prescribers,
    purchasers and formulary managers on the other. Violations of
    the anti-kickback statute are punishable by imprisonment,
    criminal fines, civil monetary penalties and exclusion from
    participation in federal health care programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Federal false claims laws prohibit any person from knowingly
    presenting, or causing to be presented, a false claim for
    payment to the federal government, or knowingly making, or
    causing to be made, a false statement to have a false claim
    paid. Recently, several pharmaceutical and other health care
    companies have been prosecuted under these laws for allegedly
    inflating drug prices they report to pricing services, which in
    turn were used by the government to set Medicare and Medicaid
    reimbursement rates, and for allegedly providing free product to
    customers with the expectation that the customers would bill
    federal programs for the product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Outside of the U.S., our ability to market our products will
    also depend on receiving marketing authorizations from the
    appropriate regulatory authorities. The foreign regulatory
    approval process includes all of the risks associated with the
    FDA approval process described above. The requirements
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">58</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Business</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    governing the conduct of clinical trials and marketing
    authorization vary widely from country to country.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">LEGAL
    PROCEEDINGS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as described below, we are not a party to litigation or
    other legal proceedings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the second quarter of 2006, our Chief Executive, a Vice
    President of ours, and we were named as co-defendants in
    <U>Parniani&#160;v. Cardinal Health, Inc. et&#160;al.</U>, Case
    <FONT style="white-space: nowrap">No.&#160;0:06-cv-02514-PJS-JJG</FONT>
    in the U.S.&#160;District Court in the District of Minnesota for
    unspecified damages based on workers&#146; compensation and
    related claims. A former employee of a third-party service
    provider to us filed the complaint. The service provider, which
    is also named as a co-defendant, has agreed to assume control of
    our defense at its cost pursuant to a contract between it and
    us. The service provider is seeking dismissal of the lawsuit
    against us, our Chief Executive, and our Vice President, among
    other co-defendants. Based upon the information available to us
    to date, we believe that all asserted claims against us and the
    individual defendants are without merit. However, if any of the
    claims are deemed meritorious by judicial determination, we
    expect to be indemnified by the service provider so that
    resolution of this matter is not expected to have a material
    adverse effect on our future financial results or financial
    condition.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">59</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='111'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Management
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OFFICERS AND
    DIRECTORS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the names and ages of our
    directors, executive officers and key managers as of
    April&#160;30, 2007:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="45%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Age</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Position</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">A.J. Kazimi
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    49
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Chairman and Chief Executive
    Officer
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin E.
    Cearnal<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    62
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dr. Robert G. Edwards
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    79
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dr. Lawrence W.
    Greer<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    62
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Thomas R.
    Lawrence<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    67
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jean W. Marstiller
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    57
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Senior Vice President and
    Corporate Secretary
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dr. Gordon R. Bernard
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    55
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Senior Vice President and Medical
    Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Leo Pavliv
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    46
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President, Operations
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">J. William Hix
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    59
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President, Sales&#160;&#38;
    Marketing
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">David L. Lowrance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    39
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President and Chief Financial
    Officer
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">James L. Herman
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    52
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Senior Director, National Accounts
    and Corporate Compliance Officer
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Elizabeth C. Gerken
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    38
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director, Business Development
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Bruce J. Kent
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    44
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Senior Manager, District Sales
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Amy D. Rock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    36
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Senior Manager, Regulatory Affairs
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Member of Audit Committee
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Member of Compensation Committee
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>A.J. Kazimi, Chairman and Chief Executive
    Officer.</I>&#160;&#160;Mr.&#160;Kazimi founded our company in
    1999 and has served as our Chief Executive Officer and Chairman
    of our Board of Directors since inception. His career includes
    20&#160;years in the biopharmaceutical industry. Prior to
    joining our company, he spent eleven years from 1987 to 1998
    helping to build Therapeutic Antibodies Inc., a
    biopharmaceutical company, where as President and Chief
    Operating Officer he made key contributions to the
    company&#146;s growth from its
    <FONT style="white-space: nowrap">start-up</FONT>
    phase through its initial public offering and product launches.
    Mr.&#160;Kazimi oversaw operations in three countries and was
    personally involved with the company&#146;s product development
    strategies, licensing and distribution agreements, and the
    raising of more than $100&#160;million through equity and debt
    financings. From
    <FONT style="white-space: nowrap">1984-1987,</FONT>
    Mr.&#160;Kazimi worked at Brown-Forman Corporation, rising
    through a series of management positions and helping to launch
    several new products. Mr.&#160;Kazimi currently serves on the
    board of directors for Aegis Sciences Corporation, a federally
    certified forensic toxicology laboratory; the Tennessee
    Biotechnology Association; and Aetos Technologies Inc., a
    technology development company associated with Auburn
    University. He also serves as Chairman and Chief Executive
    Officer of Cumberland Emerging Technologies, Inc., or CET. He
    holds a B.S. from the University of Notre Dame and an M.B.A.
    from the Vanderbilt Owen Graduate School of Management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Martin E. Cearnal, Director.</I>&#160;&#160;Mr.&#160;Cearnal
    has served as a member of our board of directors since 2004. He
    is the former President and Chief Executive Officer of
    Physicians World, which became the largest provider of
    continuing medical education during his tenure from 1985 to
    2000. Physicians World was acquired by Thomson Healthcare in
    2000. Mr.&#160;Cearnal served as President of Thomson Physicians
    World from 2000 to 2003, and Executive Vice President-Chief
    Strategy Officer for Thomson Medical Education from 2003 through
    2005. Since 2006, he has been Executive Vice President-Chief
    Strategy Officer for Jobson Medical Information.
    Mr.&#160;Cearnal has 40&#160;years experience in the Healthcare
    industry
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">60</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and has been involved with the launches of such noteworthy
    pharmaceutical products as
    Lipitor<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    Actos<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    Intron-A<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    Straterra<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    Botox<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and
    Humira<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    Mr.&#160;Cearnal spent 17&#160;years at Revlon Healthcare in a
    variety of domestic and international pharmaceutical marketing
    roles culminating in his position as Vice President, Marketing
    for the International Operations. He serves the industry through
    leadership and participation in several organizations, including
    the Healthcare Marketing&#160;&#38; Communications Council and
    the Alliance for Continuing Medical Education. Mr.&#160;Cearnal
    also serves as a member of our Audit Committee and our
    Compensation Committee. He has a BS degree from Southeast
    Missouri State University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Robert G. Edwards,
    Director.</I>&#160;&#160;Dr.&#160;Edwards has served as a member
    of our board of directors since 1999. From 1991 to 1999, he was
    Chairman and Managing Director of the Australasian subsidiary of
    Therapeutic Antibodies Inc., overseeing operations in Australia,
    New Zealand and Southeast Asia. Dr.&#160;Edwards also served as
    Deputy Director of the Institute for Medical&#160;&#38;
    Veterinary Science in South Australia, President of the Royal
    College of Pathologists of Australasia, and member of the
    Australian National Health&#160;&#38; Medical Research Council.
    He currently serves as a director for CET, and is chairman of
    the CET Scientific Advisory Board. Dr.&#160;Edwards holds a
    Primary Degree from London University, Master of Human
    Physiology from London University and an M.D. from the
    University of Adelaide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Lawrence W. Greer,
    Director.</I>&#160;&#160;Dr.&#160;Greer has served as a member
    of our board of directors since 1999. Since 2002, he has been
    Senior Managing Partner of Greer Capital Advisors of Birmingham,
    Alabama. Dr.&#160;Greer serves as investment advisor to two
    private equity funds and general partner for two additional
    private equity funds, including the S.C.O.U.T. Healthcare Fund
    from which we have received equity financing. Dr.&#160;Greer and
    his firm are established leaders in private healthcare
    investments in the mid-south. Previously, he served as Vice
    President-Investments of Dunn Investment Company, where he was
    responsible for management of a marketable securities portfolio
    plus personal management of a portfolio of 15 private equity
    investments. He is the former Chairman of Southern BioSystems
    which was acquired by DURECT Corporation in 2001. Dr.&#160;Greer
    has also worked as an independent consultant in healthcare
    administration and finance. Dr.&#160;Greer serves as the
    chairman of the Audit Committee of our board of directors, as a
    member of our Compensation Committee, and is an Audit Committee
    financial expert. He also served as the chairman of the Audit
    Committee for the Southtrust (Bank) Funds Board of Trustees for
    several years. Dr.&#160;Greer holds a B.S. from Tulane
    University, D.D.S. from Emory University and an M.B.A. from
    Emory University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Thomas R. Lawrence,
    Director.</I>&#160;&#160;Mr.&#160;Lawrence has served as a
    member of our board of directors since 1999. Since 2003 he has
    been Chairman and Chief Executive Officer of Aetos Technologies
    Inc., a corporation formed in 2003 by Auburn University to
    market technological breakthroughs by its faculty. From 1998 to
    2003, Mr.&#160;Lawrence advised business clients on matters of
    marketing and corporate governance through his firm Capital
    Consultants. He previously served as Co-Founder and Managing
    Partner of Delta Capital Partners in Memphis from 1989 to 1998.
    The partnership made investments in ten early-stage companies
    which, by 1998, were valued at more than $30&#160;million. Prior
    to the formation of Delta, Mr.&#160;Lawrence founded several
    companies in the areas of commercial leasing and venture capital
    financing. He also worked for most of the 1980s as an
    Institutional Sales Representative and Commercial Leasing
    Specialist with the Investment Banking Group of Union Planters
    Bank in Memphis, where he was responsible for the structure and
    sale of over $1&#160;billion in securities. Mr.&#160;Lawrence
    serves as the chairman of our Compensation Committee, as a
    member of our Audit Committee and as a director for CET. He
    holds a B.S. from Mississippi State University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Jean W. Marstiller, Senior Vice President and Corporate
    Secretary.</I>&#160;&#160;Ms.&#160;Marstiller joined our Company
    in 1999. She oversees our administrative operations, human
    resources, site services and information systems, and became our
    Corporate Secretary in 2007. She has 17&#160;years
    biopharmaceutical industry
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">61</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    experience and was formerly Director of Administrative
    Operations at Therapeutic Antibodies Inc., where she worked from
    1989 until 1998. In that capacity, she oversaw administrative
    services, information systems, and human resources.
    Ms.&#160;Marstiller was employed by Brown-Forman Corporation
    from 1982 until 1987, where she held management level positions
    in the areas of finance and operations. She holds a B.E. from
    Vanderbilt University and attended the Vanderbilt Owen Graduate
    School of Management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Gordon R. Bernard, Senior Vice President and Medical
    Director.</I>&#160;&#160;Dr.&#160;Bernard has served as our
    medical director since 1999. Dr.&#160;Bernard is the Assistant
    Vice-Chancellor for Research at Vanderbilt University, and also
    the Melinda Owen Bass Professor of Medicine and former Chief of
    the Division of Allergy, Pulmonary and Critical Care Medicine at
    Vanderbilt. In addition, he is the Medical Director of the
    Vanderbilt Institutional Review Board and Chairman of
    Vanderbilt&#146;s Pharmacy and Therapeutics Committee, which is
    responsible for approving the Vanderbilt Medical Center
    Formulary of approved drugs and therapeutics. Dr.&#160;Bernard
    also chairs the National Institutes of Health, Acute Respiratory
    Distress Syndrome Clinical Trials Network. He holds a B.S. from
    the University of Southwestern Louisiana and an M.D. from
    Louisiana State University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Leo Pavliv, Vice President, Operations.</I>&#160;&#160;Mr.
    Pavliv has served as our Vice President, Operations since 2003,
    and is responsible for Cumberland&#146;s overall drug
    development, including manufacturing and quality operations. He
    has 23&#160;years of experience developing pharmaceutical and
    biological products. From 1997 to 2003 he worked at Cato
    Research, a contract research organization, most recently as
    Vice President of Pharmaceutical Development where he oversaw
    development of a wide variety of products throughout the
    development cycle. Prior to 1997, he held various scientific and
    management positions at both large pharmaceutical and smaller
    biopharmaceutical firms including Parke-Davis from 1984 to 1986,
    Agouron Pharmaceuticals from 1992 to 1997, ProCyte from 1989 to
    1992, and Interferon Sciences from 1986 to 1989. He is a
    registered pharmacist (R.Ph.) and is regulatory affairs
    certified (RAC). Mr.&#160;Pavliv holds a B.S., Pharmacy, and an
    M.B.A. from Rutgers University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>J.&#160;William Hix, Vice President, Sales and
    Marketing.</I>&#160;&#160;Mr.&#160;Hix is responsible for all
    our sales and marketing efforts. He joined us in 2004 to form
    and manage our national sales force promoting our acute care
    product line to hospitals, poison control centers and
    physicians. He was also instrumental in the design and
    implementation of our field sales force which is responsible for
    promoting our products in the gastroenterology market.
    Mr.&#160;Hix brings significant industry experience to our
    company having spent 30&#160;years at Novartis/CIBA-GEIGY
    Pharmaceutical Corporation from 1974 to 2004. There, his
    responsibilities ranged from field sales, sales management,
    sales operations, planning and promotion to marketing support
    and operations. He holds a B.S. from the University of Memphis
    and an M.B.A. from Our Lady of the Lake University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>David L. Lowrance, Vice President and Chief Financial
    Officer.</I>&#160;&#160;Mr.&#160;Lowrance is responsible for
    overseeing all our accounting and financial activities,
    including financial reporting and planning. He has been with us
    since 2003 and has 17&#160;years of accounting and financial
    experience in both international business and manufacturing.
    From 1994 to 2003, he spent eight years with two global
    conglomerates, including four years as Senior Vice President for
    Icore International, a division of Smiths Group, PLC. Prior to
    that, Mr.&#160;Lowrance worked as a senior accountant for
    Ernst&#160;&#38; Young, LLP from 1990 to 1994. He is a Certified
    Public Accountant, or CPA, and holds a B.B.A. from the
    University of Georgia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>James L. Herman, Senior Director, National Accounts and
    Corporate Compliance Officer.</I>&#160;&#160;Mr.&#160;Herman
    handles all national accounts sales, including wholesalers and
    retail chain buying offices, managed care home offices and
    federal government accounts. He is also charged with overseeing
    our corporate compliance efforts. He has been with us since 2003
    and has 17&#160;years pharmaceutical industry experience. From
    1998 to 2003, he was with Solvay Pharmaceuticals and served as
    Director of
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">62</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Managed Care as well as Director of Trade Affairs and Customer
    Service. From 1990 to 1998, Mr.&#160;Herman was with Schwarz
    Pharma, where he held national sales leadership positions in
    National Accounts and Managed Care. He holds a B.S. from Indiana
    University and an M.B.A. from Cardinal Stritch University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Elizabeth C. Gerken, Director, Business
    Development.</I>&#160;&#160;Ms.&#160;Gerken has served as our
    head of business development since 2001. She coordinates all
    business development activities and is actively engaged in the
    identification of product opportunities, the process of due
    diligence and the negotiation of deal terms for our agreements.
    Ms.&#160;Gerken has 15&#160;years pharmaceutical industry
    experience. She worked at Eli Lilly and Company from 1992 to
    2000 with management roles in strategic planning, brand
    management, sales management, and business development. She
    holds a B.E. from Vanderbilt University and an M.B.A. from the
    Vanderbilt Owen Graduate School of Management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Bruce J. Kent, Senior Manager, District
    Sales.</I>&#160;&#160;Mr.&#160;Kent joined us in July 2006 to
    form and launch our field sales force. He is responsible for
    managing that group of sales representatives which promotes our
    gastroenterology product line. Mr.&#160;Kent has 19&#160;years
    of pharmaceutical industry experience. Beginning his career with
    CIBA Pharmaceuticals in 1988, he spent 15&#160;years with the
    company now known as Novartis Pharmaceuticals, where he held
    positions of increasing responsibility in sales, sales
    management, managed healthcare, business analysis, and
    <I>e</I>business. Prior to joining our company, Mr.&#160;Kent
    was the Executive Director of Sales for Rx Sample Solutions and
    the head of the Northeast Regional Office from 2004 to 2006. He
    holds a B.S. from the Pennsylvania State University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amy Dix Rock,&#160;Ph.D., Senior Manager, Regulatory
    Affairs.</I>&#160;&#160;Dr.&#160;Rock joined our company in 2001
    and built our Regulatory Affairs Department and infrastructure.
    In addition to managing all interactions between our company and
    the FDA, Dr.&#160;Rock oversees the preparation of pre-approval
    and post-approval regulatory submissions. Her additional
    responsibilities include involvement in protocol development and
    clinical trials management, overseeing our medical call center
    and supporting our corporate compliance initiatives. She holds a
    B.A. from Washington University, a PhD in Immunology from the
    University of Kentucky, and an M.B.A. from the Vanderbilt Owen
    Graduate School of Management.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">ADVISORY
    BOARDS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to augment the efforts of our management and directors,
    we have established two key advisory boards to support our
    management and directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Pharmaceutical
    Advisory Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Pharmaceutical Advisors is comprised of eight
    individuals who have spent their careers in the pharmaceutical
    industry. This group includes former senior executives from a
    number of the major pharmaceutical firms including
    Warner-Lambert Co. and its Parke-Davis division, Pfizer, Inc.,
    Bristol-Myers Squibb Company, and CIBA Geigy Corp. These
    individuals each advise members of our company&#146;s management
    on a wide variety of issues based on their expertise. These
    industry advisors are helping to build our company by actively
    contributing to many areas of our business such as strategy,
    business development, human resources, marketing, international
    activities, accounting and logistics.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Medical Advisory
    Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also established a Board of Medical Advisors to support
    our product development efforts. This board includes six
    physicians with representatives from the U.S. and international
    medical communities who are leaders in the fields of emergency,
    critical care and infectious disease medicine as well as
    toxicology and cardiology. These individuals meet as a group
    with our management to help us identify
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">63</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    unmet medical needs and underserved patient populations in our
    target areas. They also help us identify and evaluate relevant
    product opportunities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">BOARD
    COMPOSITION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors currently consists of five directors who
    are divided into three classes serving staggered three-year
    terms. Dr.&#160;Robert&#160;G. Edwards is a Class&#160;I
    director who will serve until our 2008 annual meeting of
    shareholders. Dr.&#160;Lawrence&#160;W. Greer and Thomas&#160;R.
    Lawrence are Class&#160;II directors who will serve until our
    2009 annual meeting. A.J.&#160;Kazimi and Martin&#160;E. Cearnal
    are Class&#160;III directors who will serve until our 2010
    annual meeting. Upon expiration of the term of a class of
    directors, directors in that class will be eligible to be
    elected for a new three-year term at the annual meeting of
    shareholders in the year in which their term expires. Any
    additional directorships resulting from an increase in the
    number of directors will be distributed among the three classes
    so that, as nearly as possible, each class will consist of
    one-third of the directors. This classification of directors
    could have the effect of increasing the length of time necessary
    to change the composition of a majority of our board of
    directors. In general, at least two annual meetings of
    shareholders will be necessary for shareholders to effect a
    change in a majority of the members of our board of directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DIRECTOR
    INDEPENDENCE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2006 and in February 2007, our board of directors
    undertook reviews of the independence of the directors and
    considered whether any director had a material relationship with
    us that could compromise his ability to exercise independent
    judgment in carrying out his responsibilities. As a result of
    this review, our board of directors determined that
    Dr.&#160;Lawrence W. Greer and Martin E. Cearnal are
    &#147;independent&#148; as defined under applicable National
    Association of Securities Dealers Automated Quotation System, or
    NASDAQ, rules and SEC rules and regulations. We expect that a
    majority of our board will be independent within a year
    following this offering as required by the Sarbanes-Oxley Act of
    2002, SEC rules and regulations and NASDAQ rules.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">BOARD
    COMMITTEES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The standing committees of our board consist of an audit
    committee and a compensation committee. Both committees will
    have three members following this offering, two of whom will be
    independent. We expect that all directors on our audit and
    compensation committees will be independent within a year
    following this offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Audit
    committee</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our audit committee are Dr.&#160;Lawrence W.
    Greer, Martin E. Cearnal and Thomas R. Lawrence. The Chair of
    the audit committee is Dr.&#160;Greer, who has been
    affirmatively determined by our board of directors to be
    independent in accordance with applicable rules. In addition,
    the board of directors has determined that Dr.&#160;Greer is an
    &#147;audit committee financial expert,&#148; as such term is
    described in Item&#160;407 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary function of the audit committee is to assist our
    board of directors in fulfilling its oversight responsibilities
    by reviewing the financial reports and certain financial
    information provided by us to any governmental body or the
    public, reviewing our systems of internal controls regarding
    finance, accounting, legal compliance and ethics that we have
    established and overseeing our auditing, accounting and
    financial reporting processes generally. Consistent with this
    function, we expect the audit committee to encourage continuous
    improvement of, and to foster adherence to, our policies,
    procedures and practices at all levels, to be responsible for
    managing the relationship with our
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">64</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    independent registered public accountants, and to provide a
    forum for discussion with the independent registered public
    accountants and our board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some of the audit committee&#146;s responsibilities include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    appointing, determining the compensation for and overseeing our
    relationship with our independent registered public accountants;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    overseeing, reviewing and evaluating our financial statements,
    the audits of our financial statements, our accounting and
    financial reporting processes, the integrity of our financial
    statements, our disclosure controls and procedures and our
    internal audit functions;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    reviewing and approving the services provided by our independent
    registered public accountants, including the scope and results
    of their audits and pre-approving permissible non-audit services
    to be performed by them;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    resolving disagreements between management and our independent
    registered public accountants;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    overseeing our compliance with legal and regulatory requirements
    and compliance with ethical standards adopted by us;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    establishing and maintaining whistleblower procedures; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    evaluating periodically our Standards of Business Conduct and
    Ethics, Code of Ethics for Senior Financial Officers and
    Procedures for Complaints and Concerns Regarding Accounting,
    Internal Accounting Controls and Auditing Matters.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Compensation
    committee</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are Dr.&#160;Lawrence
    W. Greer, Martin E. Cearnal, and Thomas R. Lawrence. The Chair
    of the compensation committee is Thomas R. Lawrence. The
    responsibilities of the compensation committee include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    reviewing and recommending to the board of directors the
    compensation and benefits of all of our executive officers and
    directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    evaluating the performance of the principal executive officer;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    administering our equity incentive plans;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    establishing and reviewing general policies relating to
    compensation and benefits of our employees;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    reviewing and evaluating the compensation discussion and
    analysis prepared by management; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    preparing an executive compensation report for publication in
    our annual proxy statement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">COMPENSATION
    COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Thomas R. Lawrence, the Chair of our compensation committee, is
    the Chairman of Aetos Technologies, Inc., a corporation formed
    in 2003 by Auburn University to market technological
    breakthroughs by its faculty. Mr.&#160;Kazimi, our Chairman and
    Chief Executive Officer, serves on the board of directors of
    Aetos Technologies. Other than this relationship, none of our
    executive officers serves as a member of the board of directors
    or compensation committee of any other entity that has one or
    more executive officers who serve on our board of directors or
    compensation committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">CODES OF CONDUCT
    AND CORPORATE GOVERNANCE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently in the process of developing a Corporate
    Compliance Program. Within this program, we plan to maintain
    internal processes and review procedures that ensure our
    business activities are
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">65</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Management</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    conducted in compliance with applicable federal and state laws,
    statutes, regulations or program requirements, including
    guidance documents drafted specifically by governing entities
    for the healthcare and pharmaceutical industries, consistent
    with advancing, preserving and protecting public health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To help ensure compliance, we plan to conduct regular, periodic
    compliance audits by internal and external auditors and
    compliance staff, who have expertise in federal and state
    healthcare laws and regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our codes of conduct consist of a Standards of Business Conduct
    and Ethics, a Code of Ethics for Senior Financial Officers, an
    Insider Information, Trading or Dealing and Stock Tipping Policy
    and Procedures for Complaints and Concerns Regarding Accounting,
    Internal Accounting Controls, and Auditing Matters. As part of
    our corporate compliance program, in 2006 we established a
    compliance hotline to enable employees, directors and other
    representatives to report compliance violations, including
    violations of our codes of conduct.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Standards of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors has adopted a Standards of Business
    Conduct and Ethics which establish the standards of ethical
    conduct applicable to all of our directors, officers, employees,
    key advisors, consultants and contract organizations. The code
    of ethics addresses, among other things, compliance with laws
    and regulations, business practices, conflicts of interest,
    employment policies and reporting procedures. Suspected
    violations of this code may be reported on a confidential,
    anonymous basis through the compliance hotline. The audit
    committee oversees this process, tracks the complaints and
    resolutions and reports the significant results to the full
    board of directors. The code is distributed to all employees and
    directors. All employees and directors must sign, date and
    return a certification stating that they received, understand
    and will comply with the code.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Code of Ethics
    for Senior Financial Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2006, we adopted a Code of Ethics for Senior Financial
    Officers. The code is designed to deter wrongdoing and to
    promote honest and ethical conduct, full and accurate disclosure
    in periodic reports, and compliance with laws and regulations by
    our senior management who has financial responsibility. We
    expect that any suspected violations of this code will be
    reported to the audit committee. Any waiver of this code may
    only be authorized by our audit committee and will be disclosed
    as required by applicable law.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Insider
    Information, Trading or Dealing and Stock Tipping
    Policy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are committed to fair trading for publicly traded securities
    and have established standards of conduct for directors,
    employees and others who obtain material or price-sensitive,
    non-public information through their work with us. The policy is
    distributed to all employees. Non-compliance with the policy may
    be submitted on a confidential, anonymous basis through the
    compliance hotline.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Procedures for
    Complaints and Concerns Regarding Accounting, Internal<BR>
    Accounting Controls, and Auditing Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2006, we established Procedures for Complaints and Concerns
    Regarding Accounting, Internal Accounting Controls and Auditing
    Matters to encourage any person who has a reasonable basis for a
    complaint or concern regarding our financial statement
    disclosures, accounting matters, internal accounting controls or
    auditing matters to promptly submit a complaint or concern.
    Complaints may be submitted on a confidential, anonymous basis
    through the compliance hotline. The audit committee oversees
    this process, immediately reviews the complaints and oversees
    all necessary investigations. The audit committee tracks the
    complaints and resolutions and reports the significant results
    to the full board of directors.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">66</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='123'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Compensation
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">COMPENSATION
    DISCUSSION AND ANALYSIS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We provide what we believe is a competitive total compensation
    package to our executive management team through a combination
    of base salary, long-term equity incentive compensation plan and
    broad-based benefits programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We place significant emphasis on performance-based incentive
    compensation programs. This Compensation Discussion and Analysis
    explains our compensation philosophy, policies and practices
    with respect to our chief executive officer, chief financial
    officer, and the other three most highly-compensated executive
    officers or the named executive officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The objectives of
    our executive compensation program</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee is responsible for establishing and
    administering the policies governing the compensation for our
    executive officers. Our executive officers are appointed by our
    board of directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation programs are designed to achieve the
    following objectives:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    attract and retain talented and experienced executives;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    motivate and reward executives whose knowledge, skills and
    performance are critical to our success;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    align the interests of our executive officers and shareholders
    by motivating executive officers to increase shareholder value
    and rewarding executive officers when shareholder value
    increases;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    provide a competitive compensation package in which total
    compensation is primarily determined by company and individual
    results and the creation of shareholder value;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    ensure fairness among the executive management team by
    recognizing the contributions each executive makes to our
    success; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    compensate our executives to manage our business to meet our
    long-range objectives.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee meets outside the presence of all of
    our executive officers, including the named executive officers,
    to consider appropriate compensation for our CEO. For all other
    named executive officers, the committee meets outside the
    presence of all executive officers except our CEO.
    Mr.&#160;Kazimi annually reviews each other named executive
    officer&#146;s performance with the committee and makes
    recommendations to the compensation committee with respect to
    the appropriate base salary and the grants of long-term equity
    incentive awards for all executive officers. Based in part on
    these recommendations from our CEO, the compensation committee
    approves the annual compensation package of our executive
    officers other than our CEO. The compensation committee also
    annually analyzes Mr.&#160;Kazimi&#146;s performance and
    determines his base salary and grants of long-term equity
    incentive awards based on its assessment of his performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When making decisions on setting base salary and initial grants
    of long-term equity incentive awards for new executive officers,
    the compensation committee considers the importance of the
    position to us, the past salary history of the executive officer
    and the contributions to be made by the executive officer to us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We use the following principles to guide our decisions regarding
    executive compensation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    provide compensation opportunities targeted at market median
    levels;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    require performance goals to be achieved or common stock price
    to increase in order for the majority of the target pay levels
    to be earned;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    offer a comprehensive benefits package to all full-time
    employees; and
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">67</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;</TD>
    <TD align="left">
    provide fair and equitable compensation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our executive
    compensation programs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Overall, our executive compensation programs are designed to be
    consistent with the objectives and principles set forth above.
    The basic elements of our executive compensation programs are
    base salary, long-term equity incentive plan awards, retirement
    savings opportunities and health and welfare benefits. Each of
    these elements is summarized below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Base
    salary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Annually we review salary ranges and individual salaries for our
    executive officers. We establish the base salary for each
    executive officer based on consideration of median pay levels in
    the market and internal factors, such as the individual&#146;s
    performance and experience, and the pay of others on the
    executive team.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The base salaries paid to our named executive officers are set
    forth below in the Summary Compensation Table. For the fiscal
    year ended December&#160;31, 2006, base cash compensation to our
    named executive officers was approximately $1,079,090, with our
    CEO receiving approximately $293,130 of that amount. We believe
    that the base salary paid to our executive officers during 2006
    achieves our executive compensation objectives, compares
    favorably to market pay levels and is within our target of
    providing a base salary at the market median.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, adjustments to our executive officers&#146; total
    compensation were made based on an analysis of current market
    pay levels of peer companies and in published surveys. In
    addition to the market pay levels, factors taken into account in
    making any changes for 2007 included the contributions made by
    the executive officer, the performance of the executive officer,
    the role and responsibilities of the executive officer and the
    relationship of the executive officer&#146;s base pay to the
    base salary of our other executives.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Long-term equity
    incentive compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We award long-term equity incentive grants to executive
    officers, including the named executive officers, as part of our
    total compensation package. These awards are consistent with our
    pay for performance principles and align the interests of the
    executive officers to the interests of our shareholders. The
    compensation committee reviews and recommends to the board of
    directors the amount of each award to be granted to each named
    executive officer and the board of directors approves each
    award. Long-term equity incentive awards to our executives were
    made pursuant to our 1999 Stock Option Plan, or the 1999 Plan,
    until April&#160;2007, and thereafter, pursuant to our Long-Term
    Incentive Compensation Plan.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Plan provides for the grant of incentive stock options
    and nonqualified stock options. Grants can be made under the
    1999 Plan to any of our employees, directors and consultants.
    The 1999 Plan is administered by a committee designated by our
    board of directors. The committee, in its sole discretion,
    granted options under the 1999 Plan to certain persons rendering
    services to us. Except as otherwise determined by the committee
    and stated in the applicable option agreement, the exercise
    price per share of each option granted under the 1999 Plan will
    be the fair market value per share, as defined in the 1999 Plan.
    In general, the fair market value per share is determined by our
    board of directors.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">68</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An option may generally be exercised until the tenth anniversary
    of the date that we granted the option. Option holders who
    exercise their options may pay for their shares in cash, check
    or such other consideration as is deemed acceptable by us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    there were outstanding options to purchase a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock pursuant to the 1999 Plan. The exercise price
    per share under such options ranges from $&#160;&#160; to
    $&#160;&#160;&#160;&#160;&#160;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the 1999 Plan, all executive officers were granted
    incentive option agreements for common stock at exercise prices
    equal to fair market value at time of issuance, except
    Mr.&#160;Kazimi&#146;s, whose exercise price is 110% of fair
    market value at time of issuance. Each option agreement has a
    term of ten years, except for Mr.&#160;Kazimi&#146;s option
    agreements, which have five-year terms. All agreements have
    defined vesting schedules.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Incentive Compensation Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purposes of the Long-Term Incentive Compensation Plan are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to encourage our employees and consultants to acquire stock and
    other equity-based interests; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to replace the 1999 Plan without impairing the vesting or
    exercise of any option granted thereunder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Long-Term Incentive Compensation Plan authorizes the
    issuance of each of the following incentives:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    incentive stock options (options that meet Internal Revenue
    Service requirements for special tax treatment);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    non-statutory stock options (all stock options other than
    Incentive Stock Options);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    stock appreciation rights (right to receive any excess in fair
    market values of shares over a specified exercise price);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    restricted stock (shares subject to transfer and forfeiture
    limitations); and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    performance shares (contingent awards comprised of stock
    <FONT style="white-space: nowrap">and/or</FONT> cash
    and paid only if specified performance goals are met).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee administers the Long-Term Incentive
    Compensation Plan. The compensation committee is authorized to
    select participants, determine the type and number of awards to
    be granted, determine and later amend, subject to certain
    limitations, the terms of any award, interpret and specify the
    rules and regulations relating to the Long-Term Incentive
    Compensation Plan and make all other necessary determinations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Employees and consultants other than non-employee directors are
    eligible to participate. We may cancel unvested or unpaid
    incentives for terminated employees and consultants to the
    extent permitted by law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the occurrence of a change of control event, as defined in
    the Long-Term Incentive Compensation Plan, all outstanding
    options will automatically become exercisable in full, and
    restrictions and conditions for other issued incentives will
    generally be deemed terminated or satisfied. In addition, our
    board of directors may amend or terminate the Long-Term
    Incentive Compensation Plan, subject to shareholder approval, to
    comply with tax or regulatory requirements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Retirement
    savings opportunity</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we established a 401(k) plan
    covering all employees meeting certain minimum service and age
    requirements. The plan allows all qualifying employees to
    contribute the
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">69</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    maximum tax-deferred contribution allowed by the Internal
    Revenue Code. The non-Highly Compensated Employees, or non-HCEs,
    do not have a minimum or maximum percentage limit that they can
    defer. The HCEs, however, are limited to what they can defer
    based on prior year&#146;s testing. Hardship distributions are
    permitted under well-defined circumstances. We do not currently
    match employee contributions nor provide profit sharing at this
    time; however, the plan is designed so that matching or profit
    sharing can be arranged at any time.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Health and
    welfare benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All full-time employees, including our named executive officers,
    may participate in our health and welfare benefits programs,
    including medical, dental and vision care coverage, disability
    insurance and life insurance.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Employment
    agreements, severance benefits and change in control
    provisions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment agreements in 2007 with A.J.
    Kazimi, our Chairman and CEO; Jean W. Marstiller, our Senior
    Vice President, Administrative Services and Corporate Secretary;
    Leo Pavliv, our Vice President, Operations; J. William Hix, our
    Vice President, Sales and Marketing; and David L. Lowrance, our
    Vice President and CFO. The following is a summary of the
    material provisions of those employment agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment agreements provide for an annual base salary of
    $303,390 for Mr.&#160;Kazimi, $170,000 for Ms.&#160;Marstiller,
    $211,000 for Mr.&#160;Pavliv, $180,000 for Mr.&#160;Hix, and
    $158,400 for Mr.&#160;Lowrance. In addition, the employment
    agreements provide that the individuals may be eligible for any
    bonus program which has been approved by our board of directors.
    Any such bonus is discretionary and will be subject to the terms
    of the bonus program, the terms of which may be modified from
    <FONT style="white-space: nowrap">year-to-year</FONT>
    in the sole discretion of our board of directors. During the
    period of employment under these agreements, each of our
    executives will be entitled to additional benefits, including
    eligibility to participate in any company-wide employee benefits
    programs approved by our board of directors and reimbursement of
    reasonable expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each executive&#146;s employment is at-will and may be
    terminated by us at any time, with or without notice and with or
    without cause. Similarly, each executive may terminate his or
    her employment with us at any time, with or without notice. The
    employment agreements do not provide for any severance payments
    in the event the employment is terminated for cause nor any
    severance benefits in the event the employment is terminated as
    a result of his or her death or permanent disability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment agreements also include non-competition,
    non-solicitation and nondisclosure covenants on the part of the
    executives. During the term of each executive&#146;s employment
    with us and for one year after the executive ceases to be
    employed by us, the employment agreements provide that he or she
    may not compete with our business in any manner, unless the
    executive discloses all facts to our board of directors and
    receives a release allowing him or her to engage in a specific
    activity. Pursuant to the employment agreements, the executives
    also agree for a period of one year after the executive ceases
    to be employed by us, he or she will not solicit business
    related to the development or sales of pharmaceuticals products
    from any entity, organization or person which is contracted with
    us, which has been doing business with us, or a firm which the
    executive knew we were going to solicit business from at the
    time the executive ceased to be employed. Also, the executives
    may not solicit our employees. The employment agreements also
    impose obligations regarding confidential information and state
    that any discoveries or improvements that are conceived,
    developed or otherwise made by the executives, or with others,
    are deemed our sole property. The employment agreements do not
    contain any termination or change in control provisions.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">70</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SUMMARY
    COMPENSATION TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information, for the fiscal year
    ended December&#160;31, 2006, regarding the aggregate
    compensation we paid to our named executive officers:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Change in<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pension<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value and<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Nonqualified<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Deferred<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Compensation<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">All Other<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name and<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Salary<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Bonus<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Earnings<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Compensation<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Total<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Principal
    Position</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="25" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">A.J. Kazimi
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293,130
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96,255
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,825
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    410,210
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Chairman and CEO
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">James D. Aderhold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,940
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    251,940
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <I><FONT style="font-size: 8pt">former
    </FONT></I><FONT style="font-size: 8pt">V.P., Sales&#160;&#38;
    Marketing
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Leo Pavliv
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    192,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,500
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">V.P., Operations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">J. William Hix
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    137,800
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,800
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">V.P., Sales&#160;&#38; Marketing
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Jean W. Marstiller
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135,160
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,180
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,340
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Senior V.P. and Corporate Secretary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">David L. Lowrance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">V.P. and CFO
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GRANTS OF
    PLAN-BASED AWARDS TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding grants of
    compensatory awards we paid to our named executive officers
    during the fiscal year ended December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">All Other<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">All Other<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards:<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards:<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Exercise or<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Grant Date<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Securities<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Base Price<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Fair Value<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock or<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Underlying<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of Stock<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Units<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Options<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">and Option<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Grant
    Date</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($/Sh)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="16" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">A.J. Kazimi
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/30/06
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19.80
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.33
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">James D. Aderhold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/30/06
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.04
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Leo Pavliv
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">J. William Hix
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Jean W. Marstiller
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/30/06
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.04
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">David L. Lowrance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation policies and practices, pursuant to
    which the compensation set forth in the Summary Compensation
    Table and the Grants of Plan-Based Awards Table was paid or
    awarded, are described above under, &#147;Compensation
    Discussion and Analysis.&#148; A summary of certain material
    terms of our compensation plans and arrangements is set forth
    above under &#147;Compensation Discussion and
    Analysis&#151;Employment Agreements, Severance Benefits and
    Change in Control Provisions.&#148;
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">71</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUTSTANDING
    EQUITY AWARDS TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding unvested
    stock and unexercised option awards held by our named executive
    officers as of December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="30%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Stock
    Awards</FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Equity<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Incentive<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Equity<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Plan<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Incentive<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards:<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Plan<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Market or<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Option
    Awards</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards:<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Payout<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Equity<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value of<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Incentive<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Market<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unearned<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unearned<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Plan<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares,<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares,<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards:<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of Shares<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares or<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Units or<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Units or<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">or Units<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Units of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Other<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Other<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Securities<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Securities<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Securities<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of Stock<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Rights<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Rights<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Underlying<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Underlying<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Underlying<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">That<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">That<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">That<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">That<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unexercised<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unexercised<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unexercised<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Have<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Have<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Have<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Have<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Options(#)<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Options(#)<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unearned<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Exercise<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Expiration<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Not<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Not<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Not<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Not<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Exercisable</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Unexercisable</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Options(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Price($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Date</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Vested(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Vested($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Vested(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Vested($)</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="28" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">A.J.
    Kazimi<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    292,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.22
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/23/09
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,048,545
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.10
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">09/15/09</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,465
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">12/18/11</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,154
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.58
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/04/07</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.70
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/31/08</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,700
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.20
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">04/01/09</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,900
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,600
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.20
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/15/10</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19.80
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    06/30/11
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">James D.
    Aderhold<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/27/09
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186,300
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/08/11</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,505
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">12/18/11</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,650
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/04/12</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,400
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/31/13</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">04/01/14</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/15/15</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,625
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,875
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">06/30/16</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Leo
    Pavliv<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">12/27/09</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">05/15/10</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">09/30/11</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">04/14/13</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/15/15</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">J. William
    Hix<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">05/03/14</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Jean W.
    Marstiller<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,840
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.20
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/23/09</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">09/15/09</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,615
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/04/12</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/31/13</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">04/01/14</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/15/15</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,375
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,125
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">06/30/16</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">David L.
    Lowrance<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/30/13</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">04/01/14</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.00
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">01/15/15</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">72</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A.J. Kazimi:<BR>
    292,500 Options granted on January&#160;23, 1999; vested
    immediately.<BR>
    2,048,545 Option granted on September&#160;15, 1999; vested 20%
    equally each December&#160;31 over 5&#160;year period
    <FONT style="white-space: nowrap">1999-2003.</FONT><BR>
    3,465 Options granted on December&#160;18, 2001; vested
    immediately.<BR>
    6,154 Options granted on January&#160;4, 2002; vested
    immediately.<BR>
    3,000 Options granted on January&#160;31, 2003; vested
    December&#160;31, 2003.<BR>
    1,700 Options granted on April&#160;1, 2004; vested
    immediately.<BR>
    26,500 Options granted on January&#160;15, 2005; 5,300 options
    or 20% vested immediately; 20% more vested each
    December&#160;31, 2005 and 2006; the remaining options will vest
    equally each December&#160;31, 2007 and 2008.<BR>
    10,000 Options granted on June&#160;30, 2006; 25% vested on
    December&#160;31, 2006; the remainder of options vest 25%
    equally each December&#160;31, 2007, 2008, 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">James D. Aderhold:<BR>
    5,000 Options granted on December&#160;27, 1999; vested on
    December&#160;31, 2000.<BR>
    186,300 Options granted on January&#160;8, 2001; 36,300 vested
    immediately; 50,000 options vested each December&#160;31, 2001,
    2002, 2003.<BR>
    4,505 Options granted on December&#160;18, 2001; vested
    immediately.<BR>
    9,650 Options granted on January&#160;4, 2002; vested
    immediately.<BR>
    1,400 Options granted on January&#160;31, 2003; vested
    immediately.<BR>
    525 Options granted on April&#160;1, 2004; vested
    immediately.<BR>
    10,000 Options granted on January&#160;15, 2005; 2,000 options
    vested immediately; 2,000 options vested each December&#160;31,
    2005 and 2006; 2,000 options will vest each December&#160;31,
    2007 and 2008.<BR>
    6,500 Options granted on June&#160;30, 2006; 25% or 1,625
    options vested on December&#160;31, 2006. The remaining options
    vest 1,625 each December&#160;31, 2007, 2008 and 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Leo Pavliv:<BR>
    2,500 Options granted on December&#160;27, 1999; vested
    immediately.<BR>
    9,000 Options granted on May&#160;15, 2000; vested
    immediately.<BR>
    1,500 Options granted on September&#160;30, 2001; vested
    immediately.<BR>
    80,000 Options granted on April&#160;14, 2003; 25% vested each
    December&#160;31 over the 4&#160;year period
    <FONT style="white-space: nowrap">2003-2006.</FONT><BR>
    20,000 Options granted on January&#160;15, 2005; all options
    will vest on December&#160;31, 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">J. William Hix:<BR>
    29,000 Options granted on May&#160;3, 2004; 5,000 vested
    immediately; 8,000 options vested each December&#160;31 2004,
    2005, 2006.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Jean W. Marstiller:<BR>
    72,840 Options granted on January&#160;23, 1999; vested
    immediately.<BR>
    140,000 Options granted on September&#160;15, 1999; 25,000
    vested immediately; 23,000 vested each December&#160;31,
    <FONT style="white-space: nowrap">1999-2003.</FONT><BR>
    4,615 Options granted on January&#160;4, 2002; vested
    immediately.<BR>
    200 Options granted on January&#160;31, 2003; vested
    immediately.<BR>
    5,000 Options granted on April&#160;1, 2004; vested
    immediately.<BR>
    7,500 Options granted on January&#160;15, 2005; 1,500 vested
    immediately; 1,500 vested each December&#160;31, 2005 and 2006;
    1,500 will vest each December&#160;31, 2007 and 2008.<BR>
    5,500 Options granted on June&#160;30, 2006; 1,375 vested
    December&#160;31, 2006; 1,375 will vest each December&#160;31,
    2007, 2008, 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">David L. Lowrance:<BR>
    45,000 Options granted on January&#160;30, 2003; 5,000 vested
    immediately; 10,000 options vested each December&#160;31,
    <FONT style="white-space: nowrap">2003-2006.</FONT><BR>
    2,000 Options granted on April&#160;1, 2004; vested
    immediately.<BR>
    12,500 Options granted on January&#160;15, 2005; all options
    will vest on December&#160;31, 2009.
    </FONT></TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">73</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OPTION EXERCISES
    AND STOCK VESTED</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding the
    exercise and vesting of stock and option awards held by our
    named executive officers during the fiscal year ended
    December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Option
    Awards</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Stock
    Awards</FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares
    Acquired<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value Realized<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares
    Acquired<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value Realized<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">on
    Exercise(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">on
    Exercise($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">on
    Vesting(#)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">on
    Vesting($)</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="13" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">A.J. Kazimi
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,154
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113,357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">James D. Aderhold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Leo Pavliv
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">J. William Hix
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Jean W. Marstiller
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,830
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,374
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">David L. Lowrance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PENSION BENEFITS
    TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have any plan that provides for payments or other
    benefits at, following, or in connection with retirement.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">NONQUALIFIED
    DEFERRED COMPENSATION TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have any plan that provides for the deferral of
    compensation on a basis that is not tax qualified.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DIRECTOR
    COMPENSATION TABLE</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding the
    aggregate compensation we paid to the members of our board of
    directors during the fiscal year ended December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="38%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Change in<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Pension<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Fees<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Value and<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Earned<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Non-Equity<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Nonqualified<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">or Paid<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Stock<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Option<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Incentive Plan<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Deferred<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">All Other<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">in Cash<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Awards<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Compensation<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Compensation<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Compensation<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Total<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Name</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Earnings</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">($)</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="22" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Martin E.
    Cearnal<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,500
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Dr. Robert G.
    Edwards<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,420
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178,920
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Dr. Lawrence W.
    Greer<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,500
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <FONT style="font-size: 9pt">Thomas R.
    Lawrence<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,500
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97,000
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">For service as a director in 2006,
    Mr.&#160;Cearnal received fees equal to $26,500, paid as
    follows: $2,500 cash, and shares of our common stock valued at
    $24,000. These amounts exclude options to purchase
    2,000&#160;shares of our common stock that vested in 2006.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">For service as a director in 2006,
    Dr.&#160;Edwards received fees equal to $50,500, paid as
    follows: $26,500 cash, and shares of our common stock valued at
    $24,000. For consulting services provided in 2006 Dr. Edwards
    received other compensation of $128,420, paid as follows:
    $20,420 cash, and shares of our common stock valued at $108,000.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">For service as a director in 2006,
    Dr.&#160;Greer received fees equal to $50,500, paid as follows:
    $26,500 cash, and shares of our common stock valued at $24,000.
    In addition, for service as chairman of the Audit Committee of
    the board of directors, Dr.&#160;Greer received a fee equal to
    $45,000 paid in shares of our common stock valued at $45,000.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">For service as a director in 2006,
    Mr.&#160;Lawrence received fees equal to $50,500, paid as
    follows: $26,500 cash, and shares of our common stock valued at
    $24,000. In addition, for service as chairman of the
    Compensation Committee of the board of directors,
    Mr.&#160;Lawrence received a fee of $30,000 cash. For consulting
    services provided in 2006, Mr. Lawrence received other
    compensation of $16,500, paid entirely in cash.
    </FONT></TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">74</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Director
    compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Compensation to each outside director for service on the board
    of directors including board committee responsibilities for 2007
    will consist of a total fee in the amount of $75,500. All fees
    will be paid in a combination of cash and equity, as we and each
    director shall agree. Cash fees will include $2,500 paid in the
    first quarter of 2007 and the remainder accrued and paid on
    either a monthly or quarterly basis. Directors will not receive
    separate compensation for attendance at board meetings, board
    committee meetings or other company related activities. In
    addition, outside directors will be reimbursed for all
    reasonable and necessary business expenses incurred in the
    performance of their service on the board of directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of their director compensation for 2007, Martin E.
    Cearnal and Dr.&#160;Lawrence W. Greer have elected to take
    equity. Martin E. Cearnal will be granted 3,318&#160;shares of
    common stock and Dr.&#160;Lawrence W. Greer will be granted
    2,200&#160;shares of common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Long-term equity incentive awards to our directors were made
    pursuant to the 1999&#160;Plan until April&#160;2007, and
    thereafter, pursuant to the 2007 Directors&#146; Compensation
    Plan, or the Directors&#146; Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purposes of the Directors&#146; Plan are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to strengthen our ability to attract, motivate, and retain
    qualified independent directors; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to replace the 1999 Plan without impairing the vesting or
    exercise of any option granted to any director thereunder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Directors&#146; Plan authorizes the issuance to non-employee
    directors of each of the following types of awards:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    options (all options to be issued under the Directors&#146; Plan
    will not meet IRS requirements for special tax treatment and
    therefore are non-qualified options);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    restricted stock grants (shares subject to various restrictions
    and conditions as determined by our compensation committee); and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    stock grants (award of shares or our common stock with full and
    unrestricted ownership rights).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee of our board of directors will
    administer the Directors&#146; Plan, if it is adopted. In the
    event of a change of control of our company (as defined in the
    Directors&#146; Plan), all outstanding options would
    automatically become exercisable in full, and restrictions and
    conditions for other issued awards shall generally be deemed
    terminated or satisfied. Our board of directors may amend or
    terminate the Directors&#146; Plan, subject to shareholder
    approval if necessary, to comply with tax or regulatory
    requirements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INDEMNIFICATION
    OF DIRECTORS AND EXECUTIVE OFFICERS AND LIMITATION OF
    LIABILITY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our charter and bylaws provide for indemnification of our
    directors to the fullest extent permitted by the Tennessee
    Business Corporation Act, as amended from time to time. Our
    directors shall not be liable to us or our shareholders for
    monetary damages for breach of their fiduciary duty of care. The
    Tennessee Business Corporation Act provides that a Tennessee
    corporation may indemnify its directors and officers against
    expenses, judgments, fines and amounts paid in settlement
    actually and reasonably incurred by them in connection with any
    proceeding, whether criminal or civil, administrative or
    investigative if, in connection with the matter in issue, the
    individual&#146;s conduct was in good faith, and the individual
    reasonably believed: in the case of conduct in the
    individual&#146;s official capacity with the corporation, that
    the individual&#146;s conduct was in its best interest; and in
    all other cases, that the individual&#146;s behavior was at
    least not opposed to its best interest; and in the case of a
    criminal
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">75</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Compensation</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    proceeding, the individual had no reason to believe the
    individual&#146;s conduct was unlawful. In addition, we have
    entered into indemnification agreements with our directors.
    These provisions and agreements may have the practical effect in
    certain cases of eliminating the ability of our shareholders to
    collect monetary damages from directors. We believe that these
    contractual agreements and the provisions in our charter and
    bylaws are necessary to attract and retain qualified persons as
    directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DIRECTORS AND
    OFFICERS INSURANCE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain a directors&#146; and officers&#146; insurance
    policy that provides coverage to our directors and officers
    relating to certain potential liabilities. The directors&#146;
    and officers&#146; insurance policy, provided by The Hartford
    with a coverage amount of up to $3,000,000, covers
    &#147;wrongful act&#148; or &#147;securities&#148; claims.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">76</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='112'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Certain
    relationships and related party transactions
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other than compensation agreements and other arrangements which
    are described in &#147;Compensation&#148; and the transactions
    described below, since January&#160;1, 2004, there has not been,
    and there is not currently proposed, any transaction or series
    of similar transactions to which we were or will be a party in
    which the amount involved exceeded or will exceed $120,000 and
    in which any related party, including any director, executive
    officer, holder of five percent or more of any class of our
    capital stock or any member of their immediate families had or
    will have a direct or indirect material interest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of the transactions set forth below were approved by a
    majority of the board of directors, including a majority of any
    independent and disinterested members of the board of directors.
    We believe that all of the transactions set forth below had
    terms no less favorable to us than we could have obtained from
    unaffiliated third parties. In connection with this offering, we
    have adopted a written policy which requires all future
    transactions between us and any related persons (as defined in
    Item&#160;404 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K)</FONT>
    be approved in advance by our audit committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2003, we borrowed $1,000,000 from S.C.O.U.T. in the
    form of a convertible promissory note with a maturity date of
    September 2004. The President and majority shareholder of the
    general partner of S.C.O.U.T., Dr.&#160;Lawrence W. Greer,
    serves on our board of directors. Pursuant to the terms of the
    note, on its maturity date, S.C.O.U.T. converted the principal
    value of the note plus all interest accrued at a fixed rate of
    ten percent per annum into 91,667&#160;shares of our common
    stock at a price of $12.00&#160;per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2004, S.C.O.U.T. purchased 43,000&#160;shares of our
    common stock at a price of $12.00&#160;per share and a five-year
    warrant to purchase 20,000 of our common stock at an exercise
    price of $12.00&#160;per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Board members were granted a total of 12,409, 23,120 and
    15,600&#160;shares of common stock in 2006, 2005 and 2004,
    respectively, for services rendered as directors and
    consultants. The amounts recorded for such services were
    $249,000, $277,000, and $187,000 in 2006, 2005 and 2004,
    respectively. Additionally, two board members received a total
    of 11,000 options with an exercise price of $18.00&#160;per
    share in 2005 and 16,780 options with an exercise price of
    $12.00&#160;per share in 2004. No options were issued to board
    members in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with this offering, we have adopted a written
    policy, the Policy and Procedures with Respect to Related Person
    Transactions. Our board of directors has determined that our
    audit committee is best suited to review and approve all future
    related person transactions. The Policy and Procedures with
    Respect to Related Person Transactions covers a transaction,
    arrangement, or relationship in which we or any of our
    subsidiaries is or will be a participant and the amount involved
    exceeds $120,000&#160;per year, and in which any related person
    has or will have a direct or indirect interest. The Policy and
    Procedures with Respect to Related Person Transactions defines a
    related person as:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    any person who is, or at any time since the beginning of our
    last fiscal year was, a director or executive officer of ours or
    a nominee to become a director of ours;
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    any person who is known to be the beneficial owner of more than
    5% of any class of our voting securities;
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    any immediate family member of any of the foregoing
    persons;&#160;and
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    any firm, corporation or other entity in which any of the
    foregoing persons is employed or is a partner or principal or in
    a similar position or in which such person has a 5% or greater
    beneficial ownership interest.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No member of our audit committee shall review or approve a
    related person transaction in which he or an immediate family
    member of his is the related person. The audit committee shall
    approve only those related person transactions that are in, or
    are not inconsistent with, the best interests of us and our
    shareholders.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">77</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='113'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Principal
    shareholders
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information known to us with
    respect to beneficial ownership of shares of our common stock as
    of February&#160;28, 2007 by (i)&#160;each of our directors,
    (ii)&#160;each of our named executive officers; (iii)&#160;all
    of our directors and executive officers as a group; and
    (iv)&#160;each person or group of affiliated persons known to us
    to be the beneficial owner of 5% or more of our outstanding
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beneficial ownership and percentage ownership are determined in
    accordance with the rules of the SEC. This information does not
    necessarily indicate beneficial ownership for any other purpose.
    In computing the number of shares beneficially owned by a person
    and the percentage ownership of that person, shares of common
    stock underlying options or warrants held by that person that
    are currently exercisable or will become exercisable within
    60&#160;days of February&#160;28, 2007 are deemed outstanding
    and are included in the number of shares beneficially owned,
    while the shares are not deemed outstanding for purposes of
    computing percentage ownership of any other person. To our
    knowledge, except as indicated in the footnotes to this table
    and subject to community property laws where applicable, the
    persons named in the table have sole voting and investment power
    with respect to all shares of our common stock shown as
    beneficially owned by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of February&#160;28, 2007, there were 228&#160;holders of
    record of our common stock and 42 holders of record of preferred
    stock, which will automatically be converted into common stock
    at the completion of this offering. For purposes of calculating
    amounts beneficially owned by a shareholder before the offering,
    the number of shares deemed issued and outstanding was
    4,938,845&#160;shares of common stock as of February&#160;28,
    2007. The percentage of beneficial ownership after this offering
    is based
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock. For purposes of calculating the percentage
    beneficially owned after the offering, the number of shares
    deemed outstanding includes all shares deemed to be outstanding
    before the offering, all shares into which our outstanding
    shares of preferred stock will be converted as a result of the
    offering and all shares being sold in the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, the address for each person listed
    is c/o&#160;Cumberland Pharmaceuticals Inc., 2525&#160;West End
    Ave., Suite&#160;950, Nashville, Tennessee 37203.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">78</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Principal
    shareholders</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Percentage of
    Shares<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="right" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Beneficially
    Owned</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Beneficially<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Before<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">After<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Executive
    officers and directors</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Owned </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Offering</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Offering</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" nowrap align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">A.J.
    Kazimi<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,647,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49.92
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Thomas R.
    Lawrence<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Robert G.
    Edwards<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    220,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.37
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Lawrence W.
    Greer<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,090
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.15
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin E.
    Cearnal<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">James D. Aderhold,
    Jr.<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.34
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Leo
    Pavliv<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jean W.
    Marstiller<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    317,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.14
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gordon R.
    Bernard<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.15
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">David L.
    Lowrance<SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">J. William
    Hix<SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Directors and executive officers
    as a group (11 persons)
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,878,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">5%
    Shareholders</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Douglas J.
    Marchant<SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    350,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.09
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Mr. and Mrs.&#160;J. Kenneth
    Hazen<SUP style="font-size: 85%; vertical-align: text-top">(13)(14)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.07
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">S.C.O.U.T. Healthcare Fund,
    L.P.<SUP style="font-size: 85%; vertical-align: text-top">(15)(16)</SUP>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    348,184
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.05
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 2pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="center" valign="top">
    <FONT style="font-size: 9pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Less than 1.0% of the outstanding
    common stock.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 2,367,610&#160;shares that
    Mr.&#160;Kazimi has the right to acquire upon the exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 19,233&#160;shares
    Mr.&#160;Lawrence has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 107,904&#160;shares
    Dr.&#160;Edwards has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes
    (i)&#160;306,624&#160;shares owned of record by S.C.O.U.T., a
    limited partnership with respect to which Dr.&#160;Greer is the
    President and majority Shareholder of the general partner,
    (ii)&#160;21,560&#160;shares S.C.O.U.T. has the right to acquire
    upon exercise of outstanding stock options,
    (iii)&#160;20,000&#160;shares S.C.O.U.T. has the right to
    acquire immediately from us pursuant to a warrant, and
    (iv)&#160;26,000&#160;shares Dr.&#160;Greer has the right to
    acquire immediately upon exercise of outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes
    (i)&#160;11,700&#160;shares Mr.&#160;Cearnal has the right to
    acquire upon exercise of outstanding stock options and
    (ii)&#160;7,700&#160;shares Mr.&#160;Cearnal will receive upon
    conversion of his preferred stock.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 215,005&#160;shares
    Mr.&#160;Aderhold has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 93,000&#160;shares
    Mr.&#160;Pavliv has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 228,530&#160;shares
    Ms.&#160;Marstiller has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 2,308&#160;shares
    Dr.&#160;Bernard has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 47,000&#160;shares
    Mr.&#160;Lowrance has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes 29,000&#160;shares
    Mr.&#160;Hix has the right to acquire upon exercise of
    outstanding stock options.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The address for Mr.&#160;Marchant
    is 60 Germantown Court, Suite&#160;220, Cordova, Tennessee,
    38018.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The address for Mr.&#160;and
    Mrs.&#160;J. Kenneth Hazen is 260 St. Andrews Fairway, Memphis,
    Tennessee, 38111.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The number of shares reflected
    above as beneficially held by Mr.&#160;and Mrs.&#160;J. Kenneth
    Hazen are held jointly.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Includes
    (i)&#160;21,560&#160;shares S.C.O.U.T. has the right to acquire
    upon exercise of outstanding stock options, and
    (ii)&#160;20,000&#160;shares S.C.O.U.T. has the right to acquire
    immediately from us pursuant to a warrant.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 9pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">The address for S.C.O.U.T. is 2200
    Woodcrest Place, Suite&#160;309, Birmingham, Alabama, 35209.
    </FONT></TD>
</TR>

</TABLE>
<P>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">79</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='114'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Description of
    capital stock
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GENERAL</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our authorized capital stock consists of one hundred million
    shares of common stock, no par value, three million shares of
    Series&#160;A preferred stock, no par value, and twenty million
    shares of undesignated preferred stock, no par value.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">COMMON
    STOCK</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock were issued and outstanding (which does not
    include&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock issuable upon exercise of outstanding stock options
    issued pursuant to our 1999 Plan or other options or warrants to
    purchase common stock, and which does not
    include&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock issuable upon conversion of all outstanding shares
    of our preferred stock). We plan to issue additional stock
    options to our directors, employees and consultants, and we may
    issue shares of common stock to sellers of rights to certain
    pharmaceutical products. Giving effect to the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    offered hereby and the conversion of all outstanding shares of
    our preferred stock, there would
    be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock outstanding following this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of shares of common stock are entitled to one vote
    per share on any matter that comes before the shareholders.
    Cumulative voting is not authorized. Holders of shares of common
    stock do not have preemptive rights to purchase securities that
    we may subsequently issue. Subject to preferences that may be
    applicable to any outstanding preferred stock, the holders of
    common stock are entitled to receive such dividends as may be
    declared by our board of directors out of funds legally
    available for payment as dividends. However, we do not
    anticipate paying any dividends in the foreseeable future to
    holders of our common stock. In the event of a liquidation,
    dissolution, or winding up of our affairs, the holders of
    outstanding shares will be entitled to share pro rata according
    to their respective interests in our assets and funds remaining
    after payment of all of our debts and other liabilities and the
    liquidation preference of any outstanding preferred stock. All
    of the shares of common stock currently outstanding are fully
    paid and nonassessable.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PREFERRED
    STOCK</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors is authorized, without approval of our
    shareholders, to provide for the issuance of shares of preferred
    stock in one or more series, to establish the number of shares
    in each series, and to fix the designations, powers,
    preferences, and rights of each such series and the
    qualifications, limitations, or restrictions. Among the specific
    matters that may be determined by our board are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the designation of each series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the number of shares of each series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the rights in respect of dividends, if any;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    whether dividends, if any, shall be cumulative or non-cumulative;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the terms of redemption, repurchase obligation or sinking fund,
    if any;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the rights in the event of any voluntary or involuntary
    liquidation, dissolution or winding up of our affairs;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    rights and terms of conversion, if any;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    restrictions on the creation of indebtedness, if any;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    restrictions on the issuance of additional preferred stock or
    other capital stock, if any;
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">80</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Description of
    capital stock</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    restrictions on the payment of dividends on shares ranking
    junior to the preferred stock; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    voting rights, if any.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, no shares of preferred stock
    will be outstanding and we have no current plans to issue
    preferred stock. The issuance of shares of preferred stock, or
    the issuance of rights to purchase preferred stock, could be
    used to discourage an unsolicited acquisition proposal. For
    example, a business combination could be impeded by the issuance
    of a series of preferred stock containing class voting rights
    that would enable the holder or holders of such series to block
    any such transaction. Alternatively, a business combination
    could be facilitated by the issuance of a series of preferred
    stock having sufficient voting rights to provide a required
    percentage vote of our shareholders. In addition, under some
    circumstances, the issuance of preferred stock could adversely
    affect the voting power and other rights of the holders of
    common stock. Although prior to issuing any series of preferred
    stock our board is required to make a determination as to
    whether the issuance is in the best interests of our
    shareholders, our board could act in a manner that would
    discourage an acquisition attempt or other transaction that
    some, or a majority, of our shareholders might believe to be in
    their best interests or in which our shareholders might receive
    a premium for their stock over prevailing market prices of such
    stock. Our board of directors does not at present intend to seek
    shareholder approval prior to any issuance of currently
    authorized preferred stock, unless otherwise required by law or
    applicable stock exchange requirements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OUTSTANDING
    OPTIONS AND WARRANTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    in addition to outstanding options to
    acquire&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock issued pursuant to our 1999 Plan, we have issued
    options to
    purchase&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in connection with two debt financing rounds
    in 2001 and 2003. These options have ten-year terms with
    exercise prices of $&#160;&#160;&#160;&#160;&#160; and
    $&#160;&#160;&#160;&#160;&#160;&#160;per share, respectively.
    Total options outstanding as
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    have an average exercise price of
    $&#160;&#160;&#160;&#160;&#160;&#160;per share. We have also
    issued warrants to purchase 32,500&#160;shares of our common
    stock at a price of $12.00&#160;per share to Bank of America and
    to S.C.O.U.T., a consulting and investment company in which
    Dr.&#160;Lawrence W. Greer, one of our directors, is a
    principal, and warrants to purchase 1,979&#160;shares of our
    common stock at a price of $18.00&#160;per share to Bank of
    America.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">ANTI-TAKEOVER
    EFFECTS OF TENNESSEE LAW AND PROVISIONS OF OUR CHARTER AND
    BYLAWS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tennessee Business Combination Act, the Tennessee Investor
    Protection Act, the Tennessee Greenmail Act and the Tennessee
    Control Share Acquisition Act provide certain anti-takeover
    protections for Tennessee corporations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The Tennessee
    Business Combination Act</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tennessee Business Combination Act, or TBCA, governs all
    Tennessee corporations. It imposes a five-year standstill on
    transactions such as mergers, share exchanges, sales of assets,
    liquidations and other interested party transactions between
    Tennessee corporations and &#147;interested shareholders&#148;
    and their associates or affiliates, unless the business
    combination is approved by the board of directors before the
    interested shareholder goes above the 10% ownership threshold.
    Thereafter, the transaction either requires a two-thirds vote of
    the shareholders other than the interested shareholder or
    satisfaction of certain fair price standards.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The TBCA also provides for additional exculpatory protection for
    the board of directors in resisting mergers, exchanges and
    tender offers if a Tennessee corporation&#146;s charter
    specifically opts-in to such
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">81</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Description of
    capital stock</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    provisions. A Tennessee corporation&#146;s charter may
    specifically authorize the members of a board of directors, in
    the exercise of their judgment, to give due consideration to
    factors other than price and to consider whether a merger,
    exchange, tender offer or significant disposition of assets
    would adversely affect the corporation&#146;s employees,
    customers, suppliers, the communities in which the corporation
    operates, or any other relevant factor in the exercise of their
    fiduciary duty to the shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our charter expressly opts-in and provides for exculpation of
    the board of directors to the full extent permitted under the
    TBCA. The opt-in will have the effect of protecting us from
    unwanted takeover bids, because the board of directors is
    permitted by the charter to take into account all relevant
    factors in performing its duly authorized duties and acting in
    good faith and in our best interests.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The Tennessee
    Investor Protection Act</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tennessee Investor Protection Act, or TIPA, generally
    requires the registration, or an exemption from registration,
    before a person can make a tender offer for shares of a
    Tennessee corporation which, if successful, will result in the
    offeror beneficially owning more than 10% of any class of
    shares. Registration requires the filing with the Tennessee
    Commissioner of Commerce and Insurance of a registration
    statement, a copy of which must be sent to the target company,
    and the public disclosure of the material terms of the proposed
    offer. Additional requirements are imposed under that act if the
    offeror beneficially owns 5% or more of any class of equity
    securities of the target company, any of which was purchased
    within one year prior to the proposed takeover offer. TIPA also
    prohibits fraudulent and deceptive practices in connection with
    takeover offers, and provides remedies for violations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    TIPA does not apply to an offer involving a vote by holders of
    equity securities of the offeree company, pursuant to its
    charter, on a share exchange, consolidation or sale of corporate
    assets in consideration of the issuance of securities of another
    corporation, or on a sale of its securities in exchange for cash
    or securities of another corporation. Also exempt from TIPA are
    tender offers which are open on substantially equal terms to all
    shareholders, are recommended by the board of directors of the
    target company, and include full disclosure of all terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The Tennessee
    Greenmail Act</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tennessee Greenmail act, or TGA, prohibits us from
    purchasing or agreeing to purchase any of our securities, at a
    price higher than fair market value, from a holder of 3% or more
    of any class of its securities who has beneficially owned the
    securities for less than two years. We can, however, make this
    purchase if the majority of the outstanding shares of each class
    of voting stock issued by us approves the purchase or if we make
    an offer of at least equal value per share to all holders of
    shares of the same class of securities as those held by the
    prospective seller.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The Tennessee
    Control Share Acquisition Act</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">Sections&#160;48-103-301</FONT>
    through
    <FONT style="white-space: nowrap">48-103-312</FONT>
    of the Tennessee Control Share Acquisition Act, or TCSA, limit
    the voting rights of shares owned by a person above certain
    percentage thresholds, unless the non-interested shareholders of
    the corporation approve the acquisition above the designated
    threshold. However, the TCSA only applies to corporations whose
    charter or bylaws contain an express declaration that control
    share acquisitions are to be governed by the TCSA. In addition,
    the charter or bylaws must specifically provide for the
    redemption of control shares or appraisal rights for dissenting
    shareholders in a control share transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our charter makes all of the express declarations necessary to
    avail us of the full protection under the TCSA. The provisions
    described above will have the general effect of discouraging, or
    rendering more
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">82</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Description of
    capital stock</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    difficult, unfriendly takeover or acquisition attempts.
    Consequently, such provisions would be beneficial to current
    management in an unfriendly takeover attempt but could have an
    adverse effect on shareholders who might wish to participate in
    such a transaction. However, management believes that such
    provisions are advantageous to shareholders in that they will
    permit management and the shareholders to carefully consider and
    understand a proposed acquisition and may require a higher level
    of shareholder participation in the decision.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">Section&#160;48-103-308</FONT>
    of the TCSA, we, at our option, may redeem from an acquiring
    person all, but not less than all, control shares acquired in a
    control share acquisition, at any time during the period ending
    60&#160;days after the last acquisition of control shares by
    that person, for the fair value of those shares, if (1)&#160;no
    control acquisition statement has been filed, or (2)&#160;a
    control acquisition statement has been filed and the shares are
    not accorded voting rights by the shareholders of this
    corporation pursuant to
    <FONT style="white-space: nowrap">Section&#160;48-103-307.</FONT>
    For these purposes, fair value shall be determined as of the
    effective date of the vote of the shareholders denying voting
    rights to the acquiring person, if a control acquisition
    statement is filed, or if no control acquisition statement is
    filed, as of the date of the last acquisition of control shares
    by the acquiring person in a control share acquisition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">Section&#160;48-103-309</FONT>
    of the TCSA, if control shares acquired in a control share
    acquisition are accorded voting rights and the acquiring person
    has acquired control shares that confer upon that person a
    majority or more of all voting power entitled to vote generally
    with respect to the election of directors, all this
    corporation&#146;s shareholders of record, other than the
    acquiring person, who have not voted in favor of granting those
    voting rights to the acquiring person shall be entitled to an
    appraisal of the fair market value of their shares in accordance
    with Chapter&#160;23 of the Tennessee Business Corporation Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our corporate documents contain provisions that may enable our
    board of directors to resist a change in control of our company
    even if a change in control were to be considered favorable by
    you and other shareholders. These provisions include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the authorization of undesignated preferred stock, the terms of
    which may be established and shares of which may be issued
    without shareholder approval;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    advance notice procedures required for shareholders to nominate
    candidates for election as directors or to bring matters before
    an annual meeting of shareholders;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    limitations on persons authorized to call a special meeting of
    shareholders;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a staggered board of directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a requirement that vacancies in directorships are to be filled
    by a majority of the directors then in office and the number of
    directors is to be fixed by the board of directors; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    no cumulative voting.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These and other provisions contained in our second amended and
    restated charter and bylaws could delay or discourage
    transactions involving an actual or potential change in control
    of us or our management, including transactions in which our
    shareholders might otherwise receive a premium for their shares
    over then current prices, and may limit the ability of
    shareholders to remove our current management or approve
    transactions that our shareholders may deem to be in their best
    interests and, therefore, could adversely affect the price of
    our common stock.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">83</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Description of
    capital stock</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">TRANSFER AGENT
    AND REGISTRAR</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The transfer agent and registrar for our common stock is Mellon
    Investor Services.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">NASDAQ GLOBAL
    MARKET LISTING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied for our common stock to be quoted on The Nasdaq
    Global Market under the trading symbol &#147;CPIX&#148;.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">84</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='115'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Shares eligible for
    future sale
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately prior to this offering, there was no public market
    for our common stock. Future sales of substantial amounts of
    common stock in the public market, or the perception that such
    sales may occur, could adversely affect the market price of our
    common stock and could impair our ability to raise capital in
    the future through the sale of our securities. Although we have
    applied to have our common stock approved for quotation on The
    Nasdaq Global Market, we cannot assure you that there will be an
    active public market for our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will have outstanding an
    aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock, assuming the issuance
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock offered in our initial public offering,
    conversion of our outstanding shares of preferred stock and no
    exercise of options after December&#160;31, 2006. Of these
    shares, the shares sold in this offering will be freely tradable
    without restriction or further registration under the Securities
    Act, except for any shares purchased by our
    &#147;affiliates,&#148; as that term is defined in Rule&#160;144
    under the Securities Act, whose sales would be subject to
    certain limitations and restrictions described below. See
    <FONT style="white-space: nowrap">&#147;&#151;Lock-Up</FONT>
    Agreements.&#148; Persons who may be deemed affiliates generally
    include individuals or entities that control, are controlled by
    or are under common control with us and may include our
    officers, directors and significant shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The remaining&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock held by existing shareholders were issued and sold
    by us in reliance on exemptions from the registration
    requirements of the Securities Act. Of these shares,
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>&#160;shares
    will be subject to
    <FONT style="white-space: nowrap">&#147;lock-up&#148;</FONT>
    agreements described below on the effective date of this
    offering. Upon expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements 180&#160;days after the effective date of this
    offering, shares will become eligible for sale, subject in most
    cases to the limitations of Rule&#160;144. In addition, holders
    of stock options could exercise such options and sell certain of
    the shares issued upon exercise as described below. See
    <FONT style="white-space: nowrap">&#147;&#151;Lock-Up</FONT>
    Agreements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="25%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="23%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="47%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Days after date
    of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares
    eligible<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">this
    prospectus</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">for
    sale</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Comment</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="5" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Upon effectiveness
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Shares sold in the offering
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Upon effectiveness
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Freely tradable shares saleable
    under Rule&#160;144(k) that are not subject to the
    <FONT style="white-space: nowrap">lock-up</FONT>
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">90 Days
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Shares saleable under
    Rules&#160;144 and 701 that are not subject to a
    <FONT style="white-space: nowrap">lock-up</FONT>
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">180 Days
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt"><FONT style="white-space: nowrap">Lock-up</FONT>
    released; shares saleable under Rules&#160;144 and 701
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Thereafter
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Restricted securities held for one
    year or less
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">EMPLOYEE BENEFIT
    PLANS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, there were a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock subject to outstanding options under our 1999
    Option Plan,
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of
    which were vested and exercisable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately after the completion of this offering, we intend to
    file registration statements on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act to register all of the shares of common
    stock issued or reserved for future issuance under the 1999
    Option Plan and the 2007 Long-Term Incentive Compensation Plan.
    On the date which is 180&#160;days after the effective date of
    this offering, a total of
    approximately&#160;&#160;&#160;&#160;&#160;&#160;shares of
    common stock subject to outstanding options will be vested and
    exercisable. After the effective dates of the registration
    statements on
    <FONT style="white-space: nowrap">Form&#160;S-8,</FONT>
    shares purchased under the 1999 Option Plan and the 2007
    Long-Term Incentive Compensation Plan generally would be
    available for resale in the public market.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">85</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Shares eligible
    for future sale</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica"><FONT style="white-space: nowrap">LOCK-UP</FONT>
    AGREEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We, all of our directors and executive officers and their
    affiliates, and holders
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our outstanding stock have agreed that, without the prior
    written consent of UBS Securities LLC, we and they will not
    directly or indirectly, sell, offer, contract or grant any
    option to sell (including without limitation any short sale),
    pledge, transfer, establish an open &#147;put equivalent
    position&#148; or liquidate or decrease a &#147;call equivalent
    position&#148; or otherwise dispose of or transfer (or enter
    into any transaction which is designed to, or might reasonably
    be expected to, result in the disposition of), including the
    filing (or participation in the filing) of a registration
    statement with the SEC in respect of, any shares of common
    stock, options or warrants to acquire shares of common stock, or
    securities exchangeable or exercisable for or convertible into
    shares of common stock currently or hereafter owned either of
    record or beneficially by such persons (except for the
    <FONT style="white-space: nowrap">S-8</FONT> filings
    referred to in the previous paragraph), or publicly announce an
    intention to do any of the foregoing, for a period commencing on
    the date hereof and continuing through the close of trading on
    the date 180&#160;days after the date of this prospectus, other
    than permitted transfers described below. In addition, we and
    they agree that, without the prior written consent of UBS
    Securities LLC, we and they will not, during such period, make
    any demand for or exercise any right with respect to, the
    registration of any shares of common stock or any security
    convertible into or exercisable or exchangeable for common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The <FONT style="white-space: nowrap">180-day</FONT>
    restricted period described in the preceding two paragraphs will
    be extended if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    during the last 17&#160;days of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period we issue an earnings release or announce
    material news or a material event relating to us occurs; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    prior to the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">180-day</FONT>
    period,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which case the restrictions described in the preceding two
    paragraphs will continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release, the
    announcement of material news or the occurrence of a material
    event.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    UBS Securities LLC, in its sole discretion, may release the
    common stock and other securities subject to the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above in whole or in part at any time with
    or without notice. When determining whether or not to release
    common stock and other securities from
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements, UBS Securities LLC will consider, among other
    factors, the holder&#146;s reasons for requesting the release,
    the number of shares of common stock and other securities for
    which the release is being requested and market conditions at
    the time.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RULE&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect,
    beginning 90&#160;days after the date of this prospectus, a
    person who has beneficially owned shares of our common stock for
    at least one year, including an affiliate, would be entitled to
    sell in &#147;broker&#146;s transactions&#148; or to market
    makers, within any three-month period, a number of shares that
    does not exceed the greater of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    1% of the number of shares of our common stock then outstanding,
    which will equal
    approximately&#160;&#160;&#160;&#160;&#160;&#160;shares
    immediately after this offering; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the average weekly trading volume in our common stock on The
    Nasdaq Global Market during the four calendar weeks preceding
    the filing of a notice on Form&#160;144 with respect to such
    sale.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales under Rule&#160;144 are generally subject to the
    availability of current public information about us.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">86</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Shares eligible
    for future sale</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RULE&#160;144(K)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under Rule&#160;144(k), a person who is not deemed to have been
    an affiliate of ours at any time during the three months
    preceding a sale, and who has beneficially owned the shares
    proposed to be sold for at least two years, is entitled to sell
    such shares without having to comply with the manner of sale,
    public information, volume limitation or notice filing
    provisions of Rule&#160;144. Therefore, unless otherwise
    restricted, &#147;144(k) shares&#148; may be sold immediately
    upon the completion of this offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RULE&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;701, any of our employees,
    directors, officers, consultants or advisors who purchases
    shares from us in connection with a compensatory stock or option
    plan or other written agreement before the effective date of
    this offering is entitled to sell such shares 90&#160;days after
    the effective date of this offering in reliance on
    Rule&#160;144, without having to comply with the holding period
    and notice filing requirements of Rule&#160;144 and, in the case
    of non-affiliates, without having to comply with the public
    information, volume limitation or notice filing provisions of
    Rule&#160;144.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SEC has indicated that Rule&#160;701 will apply to typical
    stock options granted by an issuer before it becomes subject to
    the reporting requirements of the Securities Exchange Act of
    1934, as amended, along with the shares acquired upon exercise
    of such options, including exercises after the date of this
    prospectus.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">87</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='118'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Material
    U.S.&#160;federal income and estate tax consequences to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GENERAL</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a general summary of the material
    U.S.&#160;federal income and estate tax consequences of the
    ownership and disposition of our common stock that may be
    relevant to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (as defined below). The summary is based on provisions of the
    Internal Revenue Code of 1986, as amended, U.S.&#160;Treasury
    regulations promulgated thereunder, rulings and pronouncements
    of the Internal Revenue Service, or IRS, and judicial decisions,
    all as in effect on the date of this prospectus and all of which
    are subject to change (possibly on a retroactive basis) or to
    differing interpretations. We have not sought, and will not
    seek, any ruling from the IRS with respect to the tax
    consequences discussed in this prospectus, and there can be no
    assurance that the IRS will not take a position contrary to the
    tax discussion below or that any such position would not be
    sustained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This summary is limited to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    that purchase our common stock issued pursuant to this offering
    and that hold our common stock as a capital asset, which
    generally is property held for investment. This summary also
    does not address the tax considerations arising under the laws
    of any foreign, state or local jurisdiction, or under
    U.S.&#160;federal estate or gift tax laws except as specifically
    described below. In addition, this summary does not address tax
    considerations that may be applicable to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in light of its particular circumstances or to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    that may be subject to special tax rules, including, without
    limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    banks, insurance companies or other financial institutions;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    partnerships or other pass through entities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    U.S.&#160;expatriates;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    tax-exempt organizations;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    tax-qualified retirement plans;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    dealers in securities or currencies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    traders in securities that elect to use a
    <FONT style="white-space: nowrap">mark-to-market</FONT>
    method of accounting for their securities holdings; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    persons that will hold common stock as a position in a hedging
    transaction, &#147;straddle&#148; or &#147;conversion
    transaction&#148; for tax purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For purposes of this summary, the term
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    means a beneficial owner of our common stock that is not, for
    U.S.&#160;federal income tax purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    an individual citizen or resident of the U.S.;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a corporation, or other entity treated as a corporation for
    U.S.&#160;federal income tax purposes, that is created or
    organized under the laws of the United States or any political
    subdivision of the United States;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    an estate whose income, regardless of its source, is includible
    in gross income for U.S.&#160;federal income tax purposes;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a trust (1)&#160;if a U.S.&#160;court is able to exercise
    primary supervision over the administration of the trust and one
    or more U.S.&#160;persons have the authority to control all
    substantial decisions regarding the trust, or (2)&#160;that has
    in effect a valid election to be treated as a U.S.&#160;person;
    or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    a partnership, or other entity treated as a partnership for
    U.S.&#160;federal income tax purposes.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">88</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Material
    U.S.&#160;federal income and estate tax consequences to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT></FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership or other entity classified as such for
    U.S.&#160;federal income tax purposes holds shares of our common
    stock, the tax treatment of a partner or owner will generally
    depend on the status of the partner or owner and the activities
    of the partnership or other entity. It is advised that
    partnerships (and other entities classified as such for
    U.S.&#160;federal income tax purposes) owning shares of our
    common stock, and holders of interests in such entities, consult
    their tax advisors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Any
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of our common stock should consult their tax advisor regarding
    the tax consequences of purchasing, holding, and disposing of
    these shares of stock.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DIVIDENDS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As previously discussed, we do not anticipate paying dividends
    on our common stock in the foreseeable future. If we pay
    dividends on our common stock, however, those payments will
    constitute dividends for U.S.&#160;federal income tax purposes
    to the extent paid from our current or accumulated earnings and
    profits, as determined under U.S.&#160;federal income tax
    principles. To the extent those payments exceed our current and
    accumulated earnings and profits, the payments will constitute a
    return of capital and first reduce the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    adjusted tax basis, but not below zero, and then will be treated
    as gain from the sale of stock, as described below under the
    heading &#147;Gain on Disposition of Common Stock.&#148; Any
    amount treated as a dividend paid to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will ordinarily be subject to a 30% U.S.&#160;federal
    withholding tax, or a lower rate if an applicable income tax
    treaty so provides. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be required to satisfy certain certification and disclosure
    requirements in order to claim a reduced rate of withholding
    pursuant to an applicable income tax treaty.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dividends that are effectively connected with a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    conduct of trade or business within the United States (and,
    where an applicable tax treaty so requires, are attributable to
    a permanent establishment or fixed base in the U.S.) will not be
    subject to U.S.&#160;federal withholding tax, provided certain
    certification and disclosure requirements are met, but instead
    generally will be taxed in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a U.S.&#160;person. Additionally,
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    that are corporations receiving such dividends may be subject to
    an additional branch profits tax at a rate of 30%, or at a lower
    rate if provided by an applicable income tax treaty.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">Non-U.S.&#160;holders</FONT>
    are encouraged to consult their tax advisors regarding any claim
    to benefits under an applicable income tax treaty and the method
    of claiming the benefits of the treaty. A refund or credit for
    any
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that is subject to a reduced U.S.&#160;federal withholding
    income tax rate may be obtained by timely filing a claim for a
    refund with the IRS.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GAIN ON
    DISPOSITION OF COMMON STOCK</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of our common stock generally will not be taxed on gain
    recognized upon disposition unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is present in the U.S. for 183&#160;days or more during the
    taxable year of the disposition and has met certain other
    requirements.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the income or gain is effectively connected with the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    conduct of trade or business within the U.S. and, if an
    applicable income tax treaty so requires, is attributable to a
    permanent establishment or fixed base of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in the U.S.; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    we are or have been a &#147;United States real property holding
    corporation&#148; for U.S.&#160;federal income tax purposes at
    any time within the shorter of the five-year period preceding
    such disposition or your holding period for our common stock,
    and certain other requirements are met. We believe that we are
    not, and that we will not become, a United States real property
    holding corporation.
</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">89</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Material
    U.S.&#160;federal income and estate tax consequences to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT></FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are an individual described in the first bullet point
    immediately above you will be subject to a flat 30% tax on the
    amount by which gain resulting from the disposition of our
    common stock and any other
    <FONT style="white-space: nowrap">U.S.-source</FONT>
    capital gains realized in the same taxable year exceed the
    <FONT style="white-space: nowrap">U.S.-source</FONT>
    capital losses recognized in that taxable year, unless an
    applicable income tax treaty provides for an exemption or lower
    rate. If you are an individual described in the second bullet
    point immediately above you will be subject to tax on the net
    gain derived from the sale under regular graduated
    U.S.&#160;federal income tax rates. If you are a corporation
    described in the second bullet point immediately above, you will
    be subject to tax on the net gain generally in the same manner
    as if you were a U.S.&#160;corporation for U.S.&#160;federal
    income tax purposes, and may also be subject to the branch
    profits tax equal to 30%, or such lower rate as may be specified
    by an applicable income tax treaty, on your effectively
    connected earnings and profits.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">U.S.&#160;FEDERAL
    ESTATE TAX</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Common stock owned or treated as owned by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    who is an individual will be included in that
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    gross estate for U.S.&#160;federal estate tax purposes unless an
    applicable estate tax or other treaty provides otherwise and
    such
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    therefore may be subject to U.S.&#160;federal estate tax.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">U.S.&#160;INFORMATION
    REPORTING AND BACKUP WITHHOLDING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We must report to you and to the Internal Revenue Service on an
    annual basis the amount of dividends paid to you and any related
    taxes withheld from those dividends. Copies of the information
    returns reporting dividends and the related tax withheld may
    also be made available to the tax authorities in the country in
    which you reside under the provisions of an applicable income
    tax treaty.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding generally will not apply to payments of
    dividends made by us or our paying agents, in their capacities
    as such, to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of our common stock if the holder has provided the required
    certification that it is not a U.S.&#160;person or certain other
    requirements are met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, backup withholding and information reporting will
    not apply to proceeds from the disposition of our common stock
    paid to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    if the holder has provided the required certification that it is
    a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding is not an additional tax. Any amounts
    withheld may be refunded or credited against the holder&#146;s
    U.S.&#160;federal income tax liability, if any, provided that
    the required information is furnished to the IRS in a timely
    manner.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">Non-U.S.&#160;holders</FONT>
    should consult their tax advisors regarding the application of
    the information reporting and backup withholding rules to them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Prospective
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    of our common stock should consult their tax advisors with
    respect to the particular tax consequences to them of owning and
    disposing of our common stock, including the consequences under
    the laws of any state, local or foreign jurisdiction or under
    any applicable tax treaty.</B>
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">90</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='116'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Underwriting
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are offering the shares of our common stock described in this
    prospectus through the underwriters named below. UBS Securities
    LLC, Jefferies&#160;&#38; Company, Inc., Wachovia Capital
    Markets, LLC and Morgan Joseph&#160;&#38; Co. Inc. are the
    representatives of the underwriters. UBS Securities LLC is the
    sole book-running manager of this offering. We have entered into
    an underwriting agreement with the representatives. Subject to
    the terms and conditions of the underwriting agreement, each of
    the underwriters has severally agreed to purchase the number of
    shares of common stock listed next to its name in the following
    table.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Underwriters</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="4" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">UBS Securities LLC</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Jefferies &#38; Company,
    Inc.</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Wachovia Capital Markets,
    LLC</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Morgan Joseph&#160;&#38; Co.
    Inc.</FONT></B><FONT style="font-size: 10pt">&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B><FONT style="font-size: 10pt">Total</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriting agreement provides that the underwriters must
    buy all of the shares if they buy any of them. However, the
    underwriters are not required to take or pay for the shares
    covered by the underwriters&#146; over-allotment option
    described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our common stock is offered subject to a number of conditions,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    receipt and acceptance of our common stock by the underwriters,
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the underwriters&#146; right to reject orders in whole or in
    part.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have been advised by the representatives that the
    underwriters intend to make a market in our common stock, but
    that they are not obligated to do so and may discontinue making
    a market at any time without notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with this offering, certain of the underwriters or
    securities dealers may distribute prospectuses electronically.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">OVER-ALLOTMENT
    OPTION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted the underwriters an option to buy up to an
    aggregate of additional shares of our common stock. The
    underwriters may exercise this option solely for the purpose of
    covering over-allotments, if any, made in connection with this
    offering. The underwriters have 30&#160;days from the date of
    this prospectus to exercise this option. If the underwriters
    exercise this option, they will each purchase additional shares
    approximately in proportion to the amounts specified in the
    table above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">COMMISSIONS AND
    DISCOUNTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares sold by the underwriters to the public will initially be
    offered at the initial offering price set forth on the cover of
    this prospectus. Any shares sold by the underwriters to
    securities dealers may be sold at a discount of up to
    $&#160;&#160;&#160;&#160;&#160;&#160;per share from the initial
    public offering price. Any of these securities dealers may
    resell any shares purchased from the underwriters to other
    brokers or dealers at a discount of up to
    $&#160;&#160;&#160;&#160;&#160;&#160;per share from the initial
    public offering price. If all the shares are not sold at the
    initial public offering price, the representatives may change
    the offering price and the other selling terms. Upon execution
    of the underwriting agreement, the underwriters will be
    obligated to purchase the shares at
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">91</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Underwriting</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the prices and upon the terms stated therein and, as a result,
    will thereafter bear any risk associated with changing the
    offering price to the public or other selling terms. The
    representatives of the underwriters have informed us that they
    do not expect to sell more than an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock to accounts over which such representatives
    exercise discretionary authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows the per share and total underwriting
    discounts and commissions we will pay to the underwriters
    assuming both no exercise and full exercise of the
    underwriters&#146; option to purchase up to an additional shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No
    exercise</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Full
    exercise</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Per share</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B><FONT style="font-size: 10pt">Total</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the total expenses of this offering payable by
    us, not including the underwriting discounts and commissions,
    will be approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">NO SALES OF
    SIMILAR SECURITIES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We, our executive officers and directors and shareholders owning
    substantially all of our stock have entered into
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements with the underwriters. Under these agreements,
    subject to certain exceptions, we and each of these persons may
    not, without the prior written approval of UBS Securities LLC,
    offer, sell, contract to sell or otherwise dispose of, directly
    or indirectly, or hedge our common stock or securities
    convertible into or exchangeable or exercisable for our common
    stock. These restrictions will be in effect for a period of
    180&#160;days after the date of this prospectus. At any time and
    without public notice, UBS Securities LLC may, in its sole
    discretion, release some or all of the securities from these
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INDEMNIFICATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have agreed to indemnify the underwriters against certain
    liabilities, including certain liabilities under the Securities
    Act. If we are unable to provide this indemnification, we have
    agreed to contribute to payments the underwriters may be
    required to make in respect of those liabilities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">NASDAQ GLOBAL
    MARKET QUOTATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have our common stock approved for quotation
    on The Nasdaq Global Market under the trading symbol
    &#147;CPIX&#148;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PRICE
    STABILIZATION, SHORT POSITIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with this offering, the underwriters may engage in
    activities that stabilize, maintain or otherwise affect the
    price of our common stock, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    stabilizing transactions;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    short sales;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    purchases to cover positions created by short sales;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    imposition of penalty bids; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    syndicate covering transactions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stabilizing transactions consist of bids or purchases made for
    the purpose of preventing or retarding a decline in the market
    price of our common stock while this offering is in progress.
    These transactions
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">92</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Underwriting</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    may also include making short sales of our common stock, which
    involve the sale by the underwriters of a greater number of
    shares of common stock than they are required to purchase in
    this offering, and purchasing shares of common stock on the open
    market to cover positions created by short sales. Short sales
    may be &#147;covered short sales,&#148; which are short
    positions in an amount not greater than the underwriters&#146;
    over-allotment option referred to above, or may be &#147;naked
    short sales,&#148; which are short positions in excess of that
    amount.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters may close out any covered short position by
    either exercising their over-allotment option, in whole or in
    part, or by purchasing shares in the open market. In making this
    determination, the underwriters will consider, among other
    things, the price of shares available for purchase in the open
    market as compared to the price at which they may purchase
    shares through the over-allotment option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Naked short sales are in excess of the over-allotment option.
    The underwriters must close out any naked short position by
    purchasing shares in the open market. A naked short position is
    more likely to be created if the underwriters are concerned that
    there may be downward pressure on the price of the common stock
    in the open market that could adversely affect investors who
    purchased in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters also may impose a penalty bid. This occurs when
    a particular underwriter repays to the underwriters a portion of
    the underwriting discount received by it because the
    representatives have repurchased shares sold by or for the
    account of that underwriter in stabilizing or short covering
    transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of these activities, the price of our common stock
    may be higher that the price that otherwise might exist in the
    open market. If these activities are commenced, they may be
    discontinued by the underwriters at any time. The underwriters
    may carry out these transactions on The Nasdaq Global Market, in
    the
    <FONT style="white-space: nowrap">over-the-counter</FONT>
    market or otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DETERMINATION OF
    OFFERING PRICE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there was no public market for our
    common stock. The initial public offering price will be
    determined by negotiation by us and the representatives of the
    underwriters. The principal factors to be considered in
    determining the initial public offering price include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the information set forth in this prospectus and otherwise
    available to representatives;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    our history and prospects, and the history of and prospects for
    the industry in which we compete;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    our past and present financial performance and an assessment of
    our management;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    our prospects for future earnings and the present state of our
    development;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the general condition of the securities markets at the time of
    this offering;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    the recent market prices of, and demand for, publicly traded
    common stock of generally comparable companies; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    other factors deemed relevant by the underwriters and us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">AFFILIATIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain of the underwriters and their affiliates may from time
    to time provide certain commercial banking, financial advisory,
    investment banking and other services for us for which they were
    and will be entitled to receive separate fees. The underwriters
    and their affiliates may from time to time in the future engage
    in transactions with us and perform services for us in the
    ordinary course of their business.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">93</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='117'>
</DIV>

<DIV style="font-size: 7pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Notice to investors
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">EUROPEAN ECONOMIC
    AREA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area,
    or EEA, which has implemented the Prospectus Directive (each, a
    Relevant Member State), with effect from and including the date
    on which the Prospectus Directive is implemented in that
    Relevant Member State, or the Relevant Implementation Date, our
    common stock will not be offered to the public in that Relevant
    Member State prior to the publication of a prospectus in
    relation to our common stock that has been approved by the
    competent authority in that Relevant Member State or, where
    appropriate, approved in another Relevant Member State and
    notified to the competent authority in that Relevant Member
    State, all in accordance with the Prospectus Directive, except
    that, with effect from and including the Relevant Implementation
    Date, our common stock may be offered to the public in that
    Relevant Member State at any time:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to legal entities which are authorized or regulated to operate
    in the financial markets or, if not so authorized or regulated,
    whose corporate purpose is solely to invest in securities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    to any legal entity which has two or more of (1)&#160;an average
    of at least 250 employees during the last financial year;
    (2)&#160;a total balance sheet of more than &#128;43,000,000 and
    (3)&#160;an annual net turnover of more than &#128;50,000,000,
    as shown in its last annual or consolidated accounts; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-size: 8pt"><FONT face="wingdings">&#216;</FONT></FONT>&#160;
</TD>
    <TD align="left">    in any other circumstances which do not require the publication
    by us of a prospectus pursuant to Article&#160;3 of the
    Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As used above, the expression &#147;offered to the public&#148;
    in relation to any of our common stock in any Relevant Member
    State means the communication in any form and by any means of
    sufficient information on the terms of the offer and our common
    stock to be offered so as to enable an investor to decide to
    purchase or subscribe for our common stock, as the same may be
    varied in that Member State by any measure implementing the
    Prospectus Directive in that Member State and the expression
    &#147;Prospectus Directive&#148; means Directive
    <FONT style="white-space: nowrap">2003/71/</FONT> EC
    and includes any relevant implementing measure in each Relevant
    Member State.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EEA selling restriction is in addition to any other selling
    restrictions set out below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">UNITED
    KINGDOM</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our common stock may not be offered or sold and will not be
    offered or sold to any persons in the United Kingdom other than
    to persons whose ordinary activities involve them in acquiring,
    holding, managing or disposing of investments (as principal or
    as agent) for the purposes of their businesses and in compliance
    with all applicable provisions of the Financial Services and
    Markets Act 2000, or the FSMA, with respect to anything done in
    relation to our common stock in, from or otherwise involving the
    United Kingdom. In addition, each underwriter has only
    communicated or caused to be communicated and will only
    communicate or cause to be communicated any invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the FSMA) received by it in connection
    with the issue or sale of our common stock in circumstances in
    which Section&#160;21(1) of the FSMA does not apply to us.
    Without limitation to the other restrictions referred to herein,
    this prospectus is directed only at (1)&#160;persons outside the
    United Kingdom, (2)&#160;persons having professional experience
    in matters relating to investments who fall within the
    definition of &#147;investment professionals&#148; in
    Article&#160;19(5) of the Financial Services and Markets Act
    2000 (Financial Promotion) Order 2005; or (3)&#160;high net
    worth bodies corporate, unincorporated associations and
    partnerships and trustees of high value trusts as described in
    Article&#160;49(2) of the Financial Services and Markets Act
    2000 (Financial Promotion) Order 2005. Without limitation to the
    other restrictions referred to herein, investment or investment
    activity to which this prospectus relates is available only to,
    and will be engaged in only with, such persons, and persons
    within the United Kingdom who receive this
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">94</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notice to
    investors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    communication (other than persons who fall within (2)&#160;or
    (3)&#160;above) should not rely or act upon this communication.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">FRANCE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No prospectus (including any amendment, supplement or
    replacement thereto) has been prepared in connection with the
    offering of our common stock that has been approved by the
    Autorit&#233; des march&#233;s financiers or by the competent
    authority of another State that is a contracting party to the
    Agreement on the European Economic Area and notified to the
    Autorit&#233; des march&#233;s financiers; no common stock has
    been offered or sold and will be offered or sold, directly or
    indirectly, to the public in France except to permitted
    investors, consisting of persons licensed to provide the
    investment service of portfolio management for the account of
    third parties, qualified investors (investisseurs
    qualifi&#233;s) acting for their own account
    <FONT style="white-space: nowrap">and/or</FONT>
    corporate investors meeting one of the four criteria provided in
    Article&#160;1 of Decree N7
    <FONT style="white-space: nowrap">2004-1019</FONT> of
    September&#160;28, 2004 and belonging to a limited circle of
    investors (cercle restreint d&#146;investisseurs) acting for
    their own account, with &#147;qualified investors&#148; and
    &#147;limited circle of investors&#148; having the meaning
    ascribed to them in Article&#160;L.
    <FONT style="white-space: nowrap">411-2</FONT> of the
    French Code Mon&#233;taire et Financier and applicable
    regulations thereunder; none of this prospectus or any other
    materials related to the offer or information contained therein
    relating to our common stock has been released, issued or
    distributed to the public in France except to Permitted
    Investors; and the direct or indirect resale to the public in
    France of any common stock acquired by any Permitted Investors
    may be made only as provided by articles&#160;L.
    <FONT style="white-space: nowrap">412-1</FONT> and L.
    <FONT style="white-space: nowrap">621-8</FONT> of the
    French Code Mon&#233;taire et Financier and applicable
    regulations thereunder.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">ITALY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The offering of shares of our common stock has not been cleared
    by the Italian Securities Exchange Commission (Commissione
    Nazionale per le Societ&#224; e la Borsa, or the CONSOB)
    pursuant to Italian securities legislation and, accordingly,
    shares of our common stock may not and will not be offered, sold
    or delivered, nor may or will copies of this prospectus or any
    other documents relating to shares of our common stock or the
    offering be distributed in Italy other than to professional
    investors (operatori qualificati), as defined in
    Article&#160;31, paragraph&#160;2 of CONSOB
    Regulation&#160;No.&#160;11522 of July&#160;1, 1998, as amended,
    or Regulation&#160;No.&#160;11522.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any offer, sale or delivery of shares of our common stock or
    distribution of copies of this prospectus or any other document
    relating to shares of our common stock or the offering in Italy
    may and will be effected in accordance with all Italian
    securities, tax, exchange control and other applicable laws and
    regulations, and, in particular, will be: (i)&#160;made by an
    investment firm, bank or financial intermediary permitted to
    conduct such activities in Italy in accordance with the
    Legislative Decree No.&#160;385 of September&#160;1, 1993, as
    amended, or the Italian Banking Law, Legislative Decree
    No.&#160;58 of February&#160;24, 1998, as amended,
    Regulation&#160;No.&#160;11522, and any other applicable laws
    and regulations; (ii)&#160;in compliance with Article&#160;129
    of the Italian Banking Law and the implementing guidelines of
    the Bank of Italy; and (iii)&#160;in compliance with any other
    applicable notification requirement or limitation which may be
    imposed by CONSOB or the Bank of Italy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any investor purchasing shares of our common stock in the
    offering is solely responsible for ensuring that any offer or
    resale of shares of common stock it purchased in the offering
    occurs in compliance with applicable laws and regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus and the information contained herein are
    intended only for the use of its recipient and are not to be
    distributed to any third party resident or located in Italy for
    any reason. No person
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">95</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notice to
    investors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    resident or located in Italy other than the original recipients
    of this document may rely on it or its content.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the above (which shall continue to apply to the
    extent not inconsistent with the implementing measures of the
    Prospective Directive in Italy), after the implementation of the
    Prospectus Directive in Italy, the restrictions, warranties and
    representations set out under the heading &#147;European
    Economic Area&#148; above shall apply to Italy.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">GERMANY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares of our common stock may not be offered or sold or
    publicly promoted or advertised by any underwriter in the
    Federal Republic of Germany other than in compliance with the
    provisions of the German Securities Prospectus Act
    (Wertpapierprospektgestz&#151;WpPG) of June&#160;22, 2005, as
    amended, or of any other laws applicable in the Federal Republic
    of Germany governing the issue, offering and sale of securities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SPAIN</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Neither the common stock nor this prospectus have been approved
    or registered in the administrative registries of the Spanish
    National Securities Exchange Commission (Comisi&#243;n Nacional
    del Mercado de Valores). Accordingly, our common stock may not
    be offered in Spain except in circumstances which do not
    constitute a public offer of securities in Spain within the
    meaning of articles&#160;30bis of the Spanish Securities Markets
    Law of 28&#160;July 1988 (Ley
    <FONT style="white-space: nowrap">24/1988,</FONT> de
    28&#160;de Julio, del Mercado de Valores), as amended and
    restated, and supplemental rules enacted thereunder.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SWEDEN</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This is not a prospectus under, and has not been prepared in
    accordance with the prospectus requirements provided for in, the
    Swedish Financial Instruments Trading Act [lagen (1991:980) om
    handel med finasiella instrument] nor any other Swedish
    enactment. Neither the Swedish Financial Supervisory Authority
    nor any other Swedish public body has examined, approved, or
    registered this document.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SWITZERLAND</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The common stock may not and will not be publicly offered,
    distributed or re-distributed on a professional basis in or from
    Switzerland and neither this prospectus nor any other
    solicitation for investments in our common stock may be
    communicated or distributed in Switzerland in any way that could
    constitute a public offering within the meaning of
    Articles&#160;1156 or 652a of the Swiss Code of Obligations or
    of Article&#160;2 of the Federal Act on Investment Funds of
    March&#160;18, 1994. This prospectus may not be copied,
    reproduced, distributed or passed on to others without the
    underwriters&#146; prior written consent. This prospectus is not
    a prospectus within the meaning of Articles&#160;1156 and 652a
    of the Swiss Code of Obligations or a listing prospectus
    according to article&#160;32 of the Listing Rules of the Swiss
    Exchange and may not comply with the information standards
    required thereunder. We will not apply for a listing of our
    common stock on any Swiss stock exchange or other Swiss
    regulated market and this prospectus may not comply with the
    information required under the relevant listing rules. The
    common stock offered hereby has not and will not be registered
    with the Swiss Federal Banking Commission and has not and will
    not be authorized under the Federal Act on Investment Funds of
    March&#160;18, 1994. The investor protection afforded to
    acquirers of investment fund certificates by the Federal Act on
    Investment Funds of March&#160;18, 1994 does not extend to
    acquirers of our common stock.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">96</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notice to
    investors</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>
<A name='119'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Legal matters
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock issued in this
    offering will be passed upon for us by the law firm of Adams and
    Reese LLP, Nashville, Tennessee. Dewey Ballantine LLP, New York,
    New York is counsel to the underwriters in connection with this
    offering.
</DIV>
<A name='120'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Experts
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements and schedule of the
    Company as of December&#160;31, 2006 and 2005, and for each of
    the years in the three-year period ended December&#160;31, 2006,
    have been included herein and in the registration statement in
    reliance upon the report of KPMG&#160;LLP, independent
    registered public accounting firm, appearing elsewhere herein,
    and upon the authority of said firm as experts in accounting and
    auditing. The audit report covering the December 31, 2006
    financial statements refer to a change in accounting for
    stock-based compensation.
</DIV>
<A name='121'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Where you can find
    additional information
    </FONT>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We filed a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    with the Commission with respect to the registration of the
    common stock offered for sale with this prospectus. This
    prospectus, which constitutes part of the registration
    statement, does not contain all of the information set forth in
    the registration statement and the exhibits to the registration
    statement. For further information about us, the common stock we
    are offering by this prospectus and related matters, you should
    review the registration statement, including the exhibits filed
    as a part of the registration statement. Statements contained in
    this prospectus about the contents of any contract or any other
    document that is filed as an exhibit to the registration
    statement are not necessarily complete, and we refer you to the
    full text of the contract or other document filed as an exhibit
    to the registration statement. A copy of the registration
    statement and the exhibits that were filed with the registration
    statement may be inspected without charge at the public
    reference facilities maintained by the Securities and Exchange
    Commission Headquarters Office, 100 F Street, N.E.,
    Washington,&#160;D.C. 20549, and copies of all or any part of
    the registration statement may be obtained from the SEC upon
    payment of the prescribed fee. Information on the operation of
    the public reference facilities may be obtained by calling the
    SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330.</FONT>
    The SEC maintains a world wide web site that contains reports,
    proxy and information statements and other information regarding
    registrants that file electronically with the SEC. The address
    of the site is <I>http://www.sec.gov.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will become subject to the
    information and periodic reporting requirements of the Exchange
    Act, and, in accordance with such requirements, will file
    periodic reports, proxy statements and other information with
    the SEC. These periodic reports, proxy statements and other
    information will be available for inspection and copying at the
    regional offices, public reference facilities and web site of
    the SEC referred to above.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">97</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">CUMBERLAND
    PHARMACEUTICALS INC. AND SUBSIDIARIES</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<A name='122'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Page</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="4" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'><FONT style="font-size: 10pt">Report of KPMG LLP,
    Independent Registered Public Accounting Firm</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-2</B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'><FONT style="font-size: 10pt">Consolidated
    Balance Sheets as of December&#160;31, 2005 and
    December&#160;31, 2006</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-3</B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'><FONT style="font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Income for the three
    years ended December&#160;31, 2004, December&#160;31, 2005, and
    December&#160;31, 2006</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-4</B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'><FONT style="font-size: 10pt">Consolidated
    Statements of Shareholders&#146; Equity for the three years
    ended December&#160;31, 2004, December&#160;31, 2005, and
    December&#160;31, 2006</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-5</B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'><FONT style="font-size: 10pt">Consolidated
    Statements of Cash Flows for the three years ended
    December&#160;31, 2004, December&#160;31, 2005, and
    December&#160;31, 2006</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-6</B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#306'><FONT style="font-size: 10pt">Notes to the
    Consolidated Financial Statements</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom" style="font-family: Arial, Helvetica">
    <B>F-7 </B>
</TD>
<TD nowrap align="left" valign="bottom" style="font-family: Arial, Helvetica">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-1</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Report of
    Independent Registered Public Accounting Firm
    </FONT>
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cumberland Pharmaceuticals Inc.:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Cumberland Pharmaceuticals Inc. and subsidiaries (the Company)
    as of December&#160;31, 2005 and 2006, and the related
    consolidated statements of income, shareholders&#146; equity
    (deficit) and comprehensive income, and cash flows for each of
    the years in the three-year period ended December&#160;31, 2006.
    In connection with our audits of the consolidated financial
    statements, we have also audited the financial statement
    Schedule&#160;II&#151;Valuation and Qualifying Accounts for each
    of the years in the three-year period ended December&#160;31,
    2006. These consolidated financial statements and financial
    statement schedule are the responsibility of the Company&#146;s
    management. Our responsibility is to express an opinion on these
    consolidated financial statements and financial statement
    schedule based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. An audit includes examining, on a
    test basis, evidence supporting the amounts and disclosures in
    the financial statements. An audit also includes assessing the
    accounting principles used and significant estimates made by
    management, as well as evaluating the overall financial
    statement presentation. We believe that our audits provide a
    reasonable basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the consolidated financial statements referred
    to above present fairly, in all material respects, the financial
    position of Cumberland Pharmaceuticals Inc. and subsidiaries as
    of December&#160;31, 2005 and 2006, and the results of their
    operations and their cash flows for each of the years in the
    three-year period ended December&#160;31, 2006, in conformity
    with U.S.&#160;generally accepted accounting principles. Also,
    in our opinion, the related financial statement schedule, when
    considered in relation to the consolidated financial statements
    taken as a whole, present fairly, in all material respects, the
    information set forth herein.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in notes&#160;2 and 9 to the consolidated financial
    statements, effective January&#160;1, 2006, the Company adopted
    the fair value method of accounting for stock-based compensation
    as required by Statement of Financial Accounting Standards
    No.&#160;123(R), <I>Share-Based Payments.</I>
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="g06286g0628610.gif" alt="KPMG" >
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April&#160;23, 2007
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-2</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Cumberland
    Pharmaceuticals Inc. and Subsidiaries</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Consolidated balance
    sheets
    </FONT>
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">December&#160;31,
    2005 and 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">ASSETS</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Current assets:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Cash and cash equivalents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,535,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,255,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accounts receivable, net of
    allowances
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,414,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,120,462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Inventories
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    546,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    671,098
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Prepaid assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,040
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    142,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Deferred tax assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    405,443
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other current assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,352
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total current assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,590,897
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,643,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Property and equipment, net
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    373,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    365,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Intangible assets, net
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,834,270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Deferred tax assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,171,508
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,611,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,897
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,173,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,481,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">LIABILITIES AND
    SHAREHOLDERS&#146; EQUITY</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Current liabilities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Current portion of long-term debt
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    281,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,833,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Current portion of other long-term
    obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,127,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,052,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accounts payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    990,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,372,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accrued interest
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,205
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other accrued liabilities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    549,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,337,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    <FONT style="font-size: 10pt">Total current liabilities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,950,715
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,698,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Long-term debt, excluding current
    portion
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,575,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other long-term obligations,
    excluding current portion
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    988,961
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,081,359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    <FONT style="font-size: 10pt">Total liabilities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,939,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,355,464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Commitments and contingencies (see
    notes)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Shareholders&#146; equity:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Preferred stock&#151;no par value.
    Authorized 3,000,000&#160;shares; $2,780,359 or $3.25&#160;per
    share liquidation preference; issued and outstanding
    855,495&#160;shares at both December&#160;31, 2005 and 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Common stock&#151;no par value.
    Authorized 10,000,000&#160;shares; issued and outstanding
    4,890,149 and 4,922,075&#160;shares at December&#160;31, 2005
    and 2006, respectively
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,255,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,742,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accumulated deficit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,764,375
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,359,924
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    <FONT style="font-size: 10pt">Total shareholders&#146; equity
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,233,648
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,125,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    <FONT style="font-size: 10pt">Total liabilities and
    shareholders&#146; equity
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,173,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,481,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to consolidated financial statements.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-3</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">CUMBERLAND
    PHARMACEUTICALS INC. AND SUBSIDIARIES</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Consolidated
    Statements of Income
    </FONT>
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Years ended
    December&#160;31, 2004, 2005, and 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Revenues:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net product revenue
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,869,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,224,670
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,980,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Revenue from co-promotion
    agreements
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,874,544
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,812,242
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    286,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other revenue
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    288,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    652,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    547,958
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Net revenues
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,032,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,689,664
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,815,480
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Costs and expenses:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Cost of products sold
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    816,345
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,399,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Selling and marketing
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,802,482
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,647,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,348,540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Research and development
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    745,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,157,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,232,984
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">General and administrative
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,357,968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,587,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999,347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Amortization of product license
    rights
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    515,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,205
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total costs and expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,728,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,939,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,591,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gain on insurance recovery
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    265,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Operating income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    749,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,223,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Interest income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    969
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,239
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    208,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Interest expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,011,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    721,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Net income before income taxes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    770,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,707,935
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Income tax benefit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,184,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,696,516
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Net income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income per share&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net income per share&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,541,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,747,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,741,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,045,045
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,016,426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to consolidated financial statements.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-4</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Cumberland
    Pharmaceuticals Inc. and Subsidiaries</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Consolidated
    statements of shareholders&#146; equity (deficit) and
    comprehensive income
    </FONT>
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Years ended
    December&#160;31, 2004, 2005, and 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Total<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Preferred
    stock</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Common
    stock</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Accumulated<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">shareholders&#146;<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Shares</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">deficit</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">equity
    (deficit)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="24" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B><FONT style="font-size: 9pt">Balance, December&#160;31,
    2003</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,444,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,101,251
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (14,276,898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3,432,653
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock, net of
    proceeds allocated to common stock warrants issued with the
    common stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    373,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    373,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock warrants
    in consideration with issuance of common stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    142,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    142,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock upon
    conversion of note payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,337,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,337,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock for
    services received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Stock options granted for services
    received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Exercise of options and related tax
    benefit, net of mature shares redeemed for the exercise price
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,799
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Options granted to note holders
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    454,453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    454,453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock options
    upon extension of notes payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    151,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    151,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Change in fair value of embedded
    conversion feature
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Net and comprehensive income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B><FONT style="font-size: 9pt">Balance, December&#160;31,
    2004</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,643,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,953,312
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,718,694
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,789,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,789,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Offering costs settled with stock
    options
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock upon
    conversion of note payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,032,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,032,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock for
    services received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Stock options granted for services
    received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,709
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,709
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Exercise of options and related tax
    benefit, net of mature shares redeemed for the exercise price
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Net and comprehensive income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B><FONT style="font-size: 9pt">Balance, December&#160;31,
    2005</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,890,149
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,255,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,764,375
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,233,648
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock for
    services received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,759
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    273,298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    273,298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Stock options granted for services
    received
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Exercise of options and related tax
    benefit, net of mature shares redeemed for the exercise price
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Stock-based
    compensation&#151;employee stock options grants
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,085
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,085
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Issuance of common stock warrants
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 9pt">Net and comprehensive income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B><FONT style="font-size: 9pt">Balance, December&#160;31,
    2006</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,742,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,922,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,742,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (7,359,924
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,125,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to consolidated financial statements.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-5</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Cumberland
    Pharmaceuticals Inc. and Subsidiaries</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Consolidated
    statements of cash flows
    </FONT>
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Years ended
    December&#160;31, 2004, 2005, and 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="70%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Cash flows from operating
    activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Net income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Adjustments to reconcile net income
    to net cash (used in) provided by operating activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Depreciation and amortization
    expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    587,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Deferred tax benefit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,184,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,833,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Non-employee stock grant expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    273,298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Non-employee stock option grant
    expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,903
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Stock-based
    compensation&#160;&#151; employee stock options
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,085
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Excess tax benefit derived from
    exercise of stock options
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37,747
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Non-cash interest expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    785,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    339,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    <FONT style="font-size: 8pt">Net changes in assets and
    liabilities affecting operating activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Accounts receivable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,789,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    584,603
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,705,649
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Inventory
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,905
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (124,716
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Prepaid and other current assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36,743
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (71,844
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Accounts payable, accrued interest,
    and other accrued liabilities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    501,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (518,922
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,308,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Deferred revenue
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (699,718
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Other long-term obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (169,784
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    833,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,118,422
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Net cash provided by (used in)
    operating activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,439,380
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,416,007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,163,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Cash flows from investing
    activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Purchase of intangible
    assets-license
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,479,658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Additions to property and equipment
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,271
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (301,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (59,714
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Additions to trademarks and patents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (839
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,591
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,558
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Net cash used in investing
    activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51,110
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (318,499
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,552,930
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Cash flows from financing
    activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Proceeds from issuance of note
    payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Costs of financing for long-term
    debt and credit facility
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,733
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Principal payments on notes payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (278,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (916,668
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Net borrowings (repayments) on line
    of credit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    997,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (871,839
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    544,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Proceeds from issuance of
    convertible note
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Proceeds from exercise of stock
    options
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Excess tax benefit from stock
    compensation
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Proceeds from issuance of stock and
    warrants
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    516,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,789,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Net cash provided by financing
    activities
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,235,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,922,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,109,088
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 40pt">
    <FONT style="font-size: 8pt">Net (decrease) increase in cash and
    cash equivalents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (254,913
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,019,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    719,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Cash and cash equivalents,
    beginning of year
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    770,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    516,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Cash and cash equivalents, end of
    year
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    516,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,255,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Supplemental disclosure of cash
    flow information:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Cash paid during the year for:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    <FONT style="font-size: 8pt">Interest
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    123,482
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    377,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    <FONT style="font-size: 8pt">Income taxes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <FONT style="font-size: 8pt">Non-cash investing and financing
    activities:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    <FONT style="font-size: 8pt">Liability for license acquired
    (note&#160;6)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    <FONT style="font-size: 8pt">Deferred financing costs
    (note&#160;5)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    <FONT style="font-size: 8pt">Settlement of notes payable
    including accrued interest with issuance of common stock
    (notes&#160;5)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,337,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,032,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to consolidated financial statements.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-6</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">CUMBERLAND
    PHARMACEUTICALS INC. AND SUBSIDIARIES</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(1)&#160;&#160;ORGANIZATION
    AND BASIS OF PRESENTATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cumberland Pharmaceuticals Inc. and its subsidiaries (the
    Company or Cumberland) is a specialty pharmaceutical company,
    which was incorporated in Tennessee on January&#160;6, 1999. Its
    mission is to provide high quality products to address
    underserved medical needs. Cumberland is focused on acquiring
    rights to, developing, and commercializing branded prescription
    products for the acute care and gastroenterology markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s corporate operations and product acquisitions
    have been funded by a combination of equity and debt financings.
    The Company focuses its resources on maximizing the commercial
    potential of its products, as well as developing new product
    candidates, and has outsourced manufacturing and distribution to
    carefully selected entities with the appropriate expertise and
    infrastructure to support these activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to create access to a pipeline of early-stage product
    candidates, the Company formed a subsidiary, Cumberland Emerging
    Technologies (CET), which assists universities and other
    research organizations to help bring biomedical projects from
    the laboratory to the marketplace. The Company&#146;s ownership
    in CET is 86%. The remaining interest is owned by Vanderbilt
    University and the Tennessee Technology Development Corporation.
    During 2002, CET&#146;s losses reduced its equity to a deficit
    position. Accordingly, the Company reduced minority interest to
    zero and has recorded 100% of the losses associated with the
    joint venture since that time in accordance with Accounting
    Research Bulletin&#160;No.&#160;51, <I>Consolidated Financial
    Statements.</I>&#160;&#160;These losses amounted to
    approximately $92,000, $22,000, and $172,000 at
    December&#160;31, 2004, 2005, and 2006, respectively. The
    Company will recover the cumulative loss of $445,000 before any
    income is allocated to the minority interest holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2006, the Company created a new, wholly-owned
    subsidiary, Cumberland Pharma Sales Corp., that includes the
    Company&#146;s newly acquired hospital sales force who promote
    the Company&#146;s products,
    Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These consolidated financial statements are stated in
    U.S.&#160;dollars and are prepared under U.S. generally accepted
    accounting principles. The accompanying consolidated financial
    statements include the accounts of the Company and its majority
    owned subsidiaries. All significant inter-company balances and
    transfers have been eliminated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(2)&#160;&#160;SIGNIFICANT
    ACCOUNTING POLICIES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(a)&#160;&#160;Cash
    and Cash Equivalents</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purpose of the consolidated statements of cash flows,
    cash and cash equivalents include highly liquid investments with
    original maturities of three months or less when purchased.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(b)&#160;&#160;Accounts
    Receivable</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Trade accounts receivable are recorded at the invoiced amount
    and do not bear interest. The Company records allowances for
    uncollectible amounts, cash discounts, chargebacks, and credits
    to be taken by customers for product damaged in shipment based
    on historical experience. The Company reviews its customer
    balances on an individual account basis for collectibility. As
    of December&#160;31, 2005 and 2006, the allowance for
    uncollectible amounts, cash discounts, chargebacks, and credits
    for damaged product was $184,334 and $298,913, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cash discounts are reductions to invoiced amounts offered to
    customers for payment within a specified period of time from the
    date of the invoice. The majority of the Company&#146;s products
    are distributed
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-7</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    through independent pharmaceutical wholesalers. In conjunction
    with recognizing a sale to a wholesaler, &#147;Net Product
    revenue&#148; and &#147;Accounts Receivables&#148; take into
    account the sale of the product at the wholesale acquisition
    cost and an accrual to reflect the difference between the
    wholesale acquisition cost and the estimated average end-user
    contract price. This accrual is calculated on a product specific
    basis and is based on the estimated number of outstanding units
    sold to wholesalers that will ultimately be sold under end-user
    contracts. When the wholesaler sells the product to the end user
    at the agreed upon end-user contract price, the wholesaler
    charges the Company (&#147;chargeback&#148;) for the difference
    between the wholesale acquisition price and the end-user
    contract price and that chargeback is offset against the initial
    accrual balance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s estimate of the allowance for damaged product
    is based upon historical experience of claims made for damaged
    product. The Company recognizes revenue for its product when the
    shipment is received by the customer. At this time, the Company
    records a reduction in revenue for the estimate of product
    damaged in shipment as the damaged product may not always be
    discovered upon receipt of the product by the customer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accrued balances for discounts, chargebacks, and credits for
    damaged product are recorded as a reduction to &#147;Accounts
    Receivable.&#148; The majority of the 2006 allowance relates to
    anticipated chargebacks.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(c)&#160;&#160;Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company utilizes third parties to manufacturer and package
    finished goods for sale, takes title to the finished goods at
    the time of shipment from the manufacturer, and warehouses such
    goods until distribution and sale. The Company&#146;s inventory
    was comprised completely of finished goods at December&#160;31,
    2005 and 2006. Inventories are stated at the lower of cost or
    market. Cost is determined using the
    <FONT style="white-space: nowrap">first-in,</FONT>
    first-out method (FIFO).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2004, the Company recorded the net impact of an insurance
    recovery of $265,588 related to the settlement of an insurance
    claim for $73,815 of damaged inventory. The cost of the
    inventory included in cost of products sold has been offset by a
    portion of the insurance proceeds.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(d)&#160;&#160;Prepaid
    Assets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prepaid assets consist of the prepaid premium for
    directors&#146; and officers&#146; insurance, product liability
    insurance, prepaid consulting services, etc. The Company
    expenses or amortizes all prepaid amounts as used or over the
    period of benefit on a straight-line basis, as applicable.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(e)&#160;&#160;Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment, including leasehold improvements, are
    stated at cost. Depreciation is provided using the straight-line
    method over the estimated useful lives of the assets, ranging
    from three to 15&#160;years. Leasehold improvements are
    amortized over the shorter of the initial lease term plus its
    renewal options, if renewal is reasonably assured, or the
    remaining useful life of the related asset. Upon retirement or
    disposal of assets, the asset and accumulated depreciation
    accounts are adjusted accordingly and any gain or loss is
    reflected in operations. Repairs and maintenance costs are
    expensed as incurred. Improvements that extend an asset&#146;s
    useful life are capitalized.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(f)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Intangible
    Assets</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s intangible assets consist of costs incurred
    related to licenses, trademarks, and patents.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-8</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2006, the Company acquired the exclusive
    U.S.&#160;commercialization rights (licenses) to
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    The cost of acquiring the licenses of products that are approved
    for commercial use are capitalized and are amortized ratably
    over the estimated life of the products. At the time of
    acquisition, the product life is estimated based upon the term
    of the license agreement, patent life or market exclusivity of
    the products and our assessment of future sales and
    profitability of the product. We assess this estimate regularly
    during the amortization period and adjust the asset value or
    useful life when appropriate. The total purchase price, which
    includes the cost of the U.S.&#160;commercialization rights and
    other related costs of obtaining these licenses, is being
    amortized on a straight-line basis over 15&#160;years, which is
    management&#146;s estimate of the asset&#146;s useful life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Trademarks are amortized on a straight-line basis over
    10&#160;years, which is management&#146;s estimate of the
    asset&#146;s useful life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Patents consist of outside legal costs associated with obtaining
    patents for products that have already been approved for
    marketing by the Food and Drug Administration (FDA). Upon
    issuance of a patent, the finite useful economic life of the
    patent (or family of patents) is determined, and the patent is
    amortized over such useful life. If it becomes probable that a
    patent will not be issued, related costs associated with the
    patent application will be expensed at that time. All costs
    associated with obtaining patents for products that have not
    been approved for marketing by the FDA are expensed as incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When the Company acquires license agreements, product rights,
    and other identifiable intangible assets, it records the
    aggregate purchase price as an intangible asset. The Company
    allocates the purchase price to the fair value of the various
    intangible assets in order to amortize their cost as an expense
    in the consolidated statements of income, over the estimated
    useful life of the related asset.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(g)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Long-Lived
    Assets</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with Statement of Financial Accounting Standards
    (SFAS) No.&#160;144, <I>Accounting for the Impairment or
    Disposal of Long-Lived Assets</I>, long-lived assets, such as
    property, plant, and equipment, and purchased intangible assets
    subject to amortization, are reviewed for impairment whenever
    events or changes in circumstances indicate that the carrying
    amount of an asset may not be recoverable. If circumstances
    require a long-lived asset be tested for possible impairment,
    the Company first compares undiscounted cash flows expected to
    be generated by an asset to the carrying value of the asset. If
    the carrying value of the long-lived asset is not recoverable on
    an undiscounted cash flow basis, an impairment is recognized to
    the extent that the carrying value exceeds its fair value. Fair
    value is determined through various valuation techniques
    including discounted cash flow models, quoted market values and
    third-party independent appraisals, as considered necessary.
    Assets to be disposed of would be separately presented in the
    balance sheet and reported at the lower of the carrying amount
    or fair value less costs to sell, and no longer depreciated. The
    assets and liabilities of a disposed group classified as held
    for sale would be presented separately in the appropriate asset
    and liability sections of the balance sheet. The Company
    recorded no impairment charges during the three-year period
    ended December&#160;31, 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(h)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Revenue
    Recognition</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognizes revenue in accordance with the Security
    and Exchange Commission&#146;s (SEC) Staff Accounting
    Bulletin&#160;No.&#160;101, <I>Revenue Recognition in Financial
    Statements </I>as amended by Staff Accounting
    Bulletin&#160;No.&#160;104 (together, SAB&#160;101), and
    SFAS&#160;No.&#160;48, <I>Revenue Recognition When Right of
    Return Exists </I>(SFAS&#160;48). Revenue is realized or
    realizable and earned when all of the following criteria are
    met: (1)&#160;persuasive evidence of an arrangement exists;
    (2)&#160;delivery has occurred or services have been rendered;
    (3)&#160;the seller&#146;s price to the buyer is fixed and
    determinable; and (4)&#160;collectibility is
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-9</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reasonably assured. SFAS&#160;48&#160;states that revenue from
    sales transactions where the buyer has the right to return the
    product shall be recognized at the time of sale only if
    (1)&#160;the seller&#146;s price to the buyer is substantially
    fixed or determinable at the date of sale, (2)&#160;the buyer
    has paid the seller, or the buyer is obligated to pay the seller
    and the obligation is not contingent on resale of the product,
    (3)&#160;the buyer&#146;s obligation to the seller would not be
    changed in the event of theft or physical destruction or damage
    of the product, (4)&#160;the buyer acquiring the product for
    resale has economic substance apart from that provided by the
    seller, (5)&#160;the seller does not have significant
    obligations for future performance to directly bring about
    resale of the product by the buyer, and (6)&#160;the amount of
    future returns can be reasonably estimated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s net product revenue reflects reduction of
    gross product revenue at the time of initial sales recognition
    for estimated allowances for chargebacks, discounts, and damaged
    goods and accruals of rebates, product returns, and
    administrative fees for product promotion and fee for services.
    Allowances of $184,334 and $298,913 as of December&#160;31, 2005
    and 2006, respectively, for chargebacks, discounts and
    allowances for product damaged in shipment reduce accounts
    receivable, and accrued balances of $83,056 and $742,678 as of
    December&#160;31, 2005 and 2006, respectively, for rebates,
    product returns, and administrative fees increase other accrued
    expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in 2(b) above, the allowances for chargebacks,
    discounts, and damaged goods are determined on a
    <FONT style="white-space: nowrap">product-by-product</FONT>
    basis, and are established by management as the Company&#146;s
    best estimate at the time of sale based on each product&#146;s
    historical experience adjusted to reflect known changes in the
    factors that impact such allowances. These are established based
    on the contractual terms with direct and indirect customers and
    analysis of historical levels of chargebacks, discounts, and
    credits claimed for damaged product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other organizations, such as managed care providers, pharmacy
    benefit management companies, and government agencies, may
    receive rebates from the Company based on negotiated contracts
    to carry our product or reimbursements for filled prescriptions.
    These entities represent indirect customers of the Company. In
    addition, the Company may provide rebates to the end user. In
    conjunction with recognizing a sale to a wholesaler, sales
    revenues are reduced and accrued expenses are increased by our
    estimates of the rebates that will be owed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Consistent with industry practice, the Company maintains a
    return policy that allows customers to return product within a
    specified period prior to and subsequent to the expiration date.
    The Company&#146;s estimate of the provision for returns of
    expired product is based upon historical experience with actual
    returns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has also entered into agreements with key
    wholesalers, resulting in product promotion and fee service
    costs. In accordance with Emerging Issues Task Force (EITF)
    <FONT style="white-space: nowrap">No.&#160;01-9,</FONT>
    <I>Accounting for Consideration Given by a Vendor (Including a
    Reseller of the Vendor&#146;s Products) </I>(EITF
    <FONT style="white-space: nowrap">01-9),</FONT> these
    administrative costs have been netted against product revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the first quarter of 2006 and the years ended
    December&#160;31, 2004 and 2005, the Company had two products
    for which it received a co-promotion fee under the related
    co-promotion agreements. The Company recognized the promotional
    fees as revenue from co-promotion agreements during the period
    in which the sales of the respective product occurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other revenue is primarily comprised of revenue generated by CET
    through consulting services, development funding, either from
    private sector investment or through federal Small Business
    (SBIR/STTR) grant programs, and lease income generated by
    CET&#146;s Life Sciences Center, a research center that provides
    scientists with access to flexible lab space and other resources
    to develop their products. The Company has received two grants
    for medical research and a grant related to the product
    Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-10</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue related to grants is recognized when all conditions
    related to such grants have been met. Grant revenue totaled
    approximately $50,000, $253,000, and $375,000 for the years
    ended December&#160;31, 2004, 2005, and 2006, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(i)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Income
    Taxes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company provides for deferred taxes using the asset and
    liability approach. Under this method, deferred tax assets and
    liabilities are recognized for future tax consequences
    attributable to operating loss and tax credit carryforwards, as
    well as differences between the carrying amounts of existing
    assets and liabilities and their respective tax bases. The
    Company&#146;s principal differences are related to timing of
    deductibility of certain items, such as depreciation,
    amortization, and expense for options issued to nonemployees.
    Deferred tax assets and liabilities are measured using enacted
    tax rates, which are expected to apply to taxable income in the
    years such temporary differences are expected to be recovered or
    settled. The effect on deferred tax assets and liabilities of a
    change in tax rates is recognized in income in the period of
    enactment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(j)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Stock Option
    Plan</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, the Company applied the
    intrinsic-value-based method of accounting prescribed by
    Accounting Principles Board (APB) Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees</I>, and related
    interpretations and provided the required pro-forma disclosures
    of SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>(SFAS&#160;123)&#160;and
    SFAS&#160;No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#151;Transition and Disclosure-an Amendment of FASB
    Statement No.&#160;123.</I> Under this method, compensation
    expense is recorded only if the current market price of the
    underlying stock exceeded the exercise price on the date of
    grant. All options granted by the Company had an exercise price
    equal to or greater than the market price of the underlying
    stock on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company adopted the
    requirements of SFAS&#160;No.&#160;123 (revised), <I>Share-Based
    Payment </I>(SFAS&#160;123R), utilizing the prospective method
    of adoption. Under this approach, SFAS&#160;123R applies to new
    awards and the modification, repurchase, or cancellation of
    outstanding awards beginning on January&#160;1, 2006. Under the
    prospective method of adoption, compensation cost recognized in
    2006 includes only share-based compensation cost for all
    share-based payments granted subsequent to January&#160;1, 2006.
    The cost is based on the grant-date fair value estimated in
    accordance with the provisions of SFAS&#160;123R and is
    recognized as expense over the employee&#146;s requisite service
    period. The Company calculates the fair value of employee
    options using the Black-Scholes option pricing model. No
    compensation cost for share-based payments granted prior to, but
    not yet vested as of January&#160;1, 2006 has been recognized.
    Because the Company used the minimum value method for purposes
    of estimating fair value under SFAS&#160;No.&#160;123 prior to
    January&#160;1, 2006, no pro forma disclosures (as required by
    SFAS&#160;123 related to 2004 and 2005)&#160;are permitted under
    SFAS&#160;123R.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(k)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Research and
    Development</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development costs are expensed in the period
    incurred. Research and development costs are comprised mainly of
    clinical trial expenses, salary and wages, and other related
    costs such as materials and supplies. Development expense
    includes activities performed by third-party providers
    participating in the Company&#146;s clinical studies. The
    Company accounts for these costs based on estimates of work
    performed, patient enrollment, or fixed fee for services.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-11</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(l)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Advertising
    Costs</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Advertising costs, including samples and print materials, are
    expensed as incurred and amounted to $777,010, $479,361, and
    $738,647 in 2004, 2005, and 2006, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(m)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Distribution
    Costs</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses distribution costs as incurred.
    Distribution costs included in sales and marketing expenses
    amounted to $610,424, $365,331, and $436,115 in 2004, 2005, and
    2006, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(n)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Earnings per
    Share</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company accounts for net income per share in accordance with
    Statement of Financial Accounting Standards No.&#160;128,
    <I>Earnings per Share.</I> Basic net income per share is
    calculated by dividing net income by the weighted average number
    of shares outstanding. Except where the result would be
    antidilutive to income from continuing operations, diluted
    earnings per share is calculated by assuming the conversion of
    convertible instruments and the elimination of related interest
    expense, and the exercise of stock options, as well as their
    related income tax benefits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table reconciles the numerator and the denominator
    used to calculate diluted net income per share:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Year ended
    December&#160;31</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Numerator:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    558,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,954,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,404,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Denominator:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;basic
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,541,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,747,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Preferred stock shares
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    855,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Dilutive effect of stock options
    and warrants
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,344,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,441,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,262,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Weighted average shares
    outstanding&#151;diluted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,741,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,045,045
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,016,426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of outstanding stock options that are excluded from
    the above calculation, as their impact would be anti-dilutive,
    was 18,038 for the year ended December&#160;31, 2006. There were
    no anti-dilutive outstanding options as of December&#160;31,
    2004 and 2005. The convertible promissory notes were excluded
    from the diluted computation in 2004, as they were anti-dilutive.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(o)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Comprehensive
    Income</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Total comprehensive income was comprised solely of net income
    for all periods presented.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(p)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Accounting
    Estimates</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of the consolidated financial statements in
    conformity with U.S.&#160;generally accepted accounting
    principles requires management of the Company to make estimates
    and assumptions that affect the reported amounts of assets and
    liabilities and disclosure of contingent liabilities at the date
    of the financial statements and the reported amounts of revenues
    and expenses during the period. Significant items subject to
    estimates and assumptions include those related to chargebacks,
    rebates, discounts, credits for damaged product, and returns,
    the valuation and determination of useful lives of
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-12</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    intangible assets and the rate such assets are amortized, and
    the realization of deferred tax assets. Actual results could
    differ from those estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(q)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Recently Issued
    Accounting Standards</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2005, the Emerging Issues Task Force issued EITF
    No. <FONT style="white-space: nowrap">04-13,</FONT>
    <I>Accounting for Purchases and Sales of Inventory with the Same
    Counterparty </I>(EITF
    <FONT style="white-space: nowrap">01-14).</FONT> EITF
    <FONT style="white-space: nowrap">04-13</FONT>
    provides guidance as to when purchases and sales of inventory
    with the same counterparty should be accounted for as a single
    exchange transaction. EITF
    <FONT style="white-space: nowrap">04-13</FONT> also
    provides guidance as to when a nonmonetary exchange of inventory
    should be accounted for at fair value. EITF
    <FONT style="white-space: nowrap">04-13</FONT> will
    be applied to new arrangements entered into, and modifications
    or renewals to existing arrangements occurring after
    January&#160;1, 2007. The application of EITF
    <FONT style="white-space: nowrap">04-13</FONT> is not
    expected to have a material impact on the Company&#146;s
    consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2006, the Financial Accounting Standards Board (FASB)
    issued FIN&#160;No.&#160;48, <I>Accounting for Uncertainty in
    Income Taxes-an interpretation of FASB Statement&#160;109
    </I>(FIN&#160;48). FIN&#160;48 clarifies the accounting for
    uncertainty in income taxes recognized in an enterprise&#146;s
    financial statements and prescribes a threshold of
    more-likely-than-not for recognition of tax benefits of
    uncertain tax positions taken or expected to be taken in a tax
    return. FIN&#160;48 also provides related guidance on
    measurement, derecognition, classification, interest and
    penalties, and disclosure. The provisions of FIN&#160;48 will be
    effective for the Company on January&#160;1, 2007, with any
    cumulative effect of the change in accounting principle recorded
    as an adjustment to opening retained earnings. The Company is in
    the process of assessing the impact of adopting FIN&#160;48 on
    its results of operations and financial position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement</I> (SFAS&#160;157). SFAS&#160;157
    defines fair value, establishes a framework for the measurement
    of fair value, and enhances disclosures about fair value
    measurements. The Statement does not require any new fair value
    measures. The Statement is effective for fair value measures
    already required or permitted by other standards for fiscal
    years beginning after November&#160;15, 2007. The Company is
    required to adopt SFAS&#160;157 beginning on January&#160;1,
    2008. SFAS&#160;157 is required to be applied prospectively,
    except for certain financial instruments. Any transition
    adjustment will be recognized as an adjustment to opening
    retained earnings in the year of adoption. The Company is
    currently evaluating the impact of adopting SFAS&#160;157 on its
    results of operations and financial position.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(3)&#160;&#160;PROPERTY
    AND EQUIPMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment consist of the following at
    December&#160;31:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Range of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">useful
    lives</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Computer hardware and software
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3-5&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    97,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,143
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Office equipment
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3-15&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Furniture and fixtures
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5-10&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Leasehold improvements
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    273,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    513,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    573,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Less accumulated depreciation and
    amortization
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (139,783
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (207,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    373,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    365,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-13</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation and amortization expense during 2004, 2005, and
    2006 was $39,216, $48,862, and $67,884, respectively, and is
    included in the consolidated statements of income in general and
    administrative expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(4)&#160;&#160;INTANGIBLE
    ASSETS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Intangible assets consist of the following at December&#160;31:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Trademarks
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    46,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Less accumulated amortization
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total trademarks
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">License
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,303,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Less accumulated amortization
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (515,181
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total license
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,788,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Patents
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,312
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,834,270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amortization expense, excluding amortization of product license
    rights of $515,181 in 2006, for fiscal years 2004, 2005, and
    2006 was $4,790, $4,675, and $4,677, respectively, and is
    reflected in general and administrative expenses on the
    accompanying consolidated statements of income. Amortization
    expense, including the amortization of product licenses, is
    expected to be approximately $690,000 in each of the years 2007
    through 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2006, the Company completed a transaction to acquire
    exclusive U.S.&#160;commercial rights (product licenses) for
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    for fair value of $10,303,595. This amount includes cash paid on
    the effective date of the agreement of $6,500,000, installment
    payments discounted using an interest rate of 7.33% of
    $1,397,560 and $2,426,377 due April&#160;7, 2007 and
    April&#160;7, 2009, respectively, and acquisition costs of
    $13,775, and is net of the fair value of services received by
    the Company in 2006 of $34,117 under a transition agreement. The
    fair value of these services was included in selling and
    marketing expenses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(5)&#160;&#160;LONG-TERM
    DEBT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A summary of long-term debt is as follows at December&#160;31:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Revolving line of credit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    281,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    825,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Term note payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,583,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    281,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,409,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Less current portion
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    281,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,833,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,575,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August and September 2003, the Company issued nine unsecured
    promissory notes (the notes) with a combined face value of
    $500,000 to several investors with original maturity dates of
    130&#160;days. One of the notes in the amount of $100,000 was
    issued to a member of the Company&#146;s Board of Directors, and
    the transaction is considered to be a related party transaction.
    These notes bore interest at the
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-14</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    contractual rate of 12%&#160;per annum for the first
    30&#160;days and 15%&#160;per annum thereafter. In addition to
    the contractual interest rate, if the Company had not paid all
    amounts due under the notes, the Company agreed to grant stock
    options at the rate of 770&#160;shares of common stock per
    $50,000 face value of the notes on each of (i)&#160;the
    30&#160;day after the issuance of the notes and (ii)&#160;on a
    continuing basis, each successive
    <FONT style="white-space: nowrap">30-day</FONT>
    period thereafter, or portion thereof, as the notes remained
    outstanding. The holders of the notes had, at their option,
    until the maturity date of the notes, the right to convert all
    or a portion of unpaid principal and interest into shares of the
    Company&#146;s common stock at an exercise price of one share
    per $12. In accordance with the terms of the note agreements,
    the Company also agreed to issue stock options upon the issuance
    of the notes to purchase shares of the Company&#146;s common
    stock at an exercise price of $12&#160;per share and at the rate
    of 1,540&#160;shares of common stock per $50,000 face value of
    the notes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate fair value of the stock options granted upon the
    issuance of the notes was $153,538. In accordance with
    Accounting Principles Board Opinion No.&#160;14, <I>Accounting
    for Convertible Debt and Debt Issued with Stock Purchase
    Warrants, </I>the portion of the proceeds of the notes which is
    allocable to the options was recorded as paid-in capital. The
    allocation of value between the notes and the options of
    $346,462 and $153,538, respectively, was based on the fair value
    of the stock options at time of issuance, since the instruments
    qualified for equity classification under EITF
    <FONT style="white-space: nowrap">No.&#160;00-19,</FONT>
    <I>Accounting for Derivative Instruments Indexed to, and
    Potentially Settled in, a Company&#146;s Own
    Stock.</I>&#160;&#160;The discount on the instruments created by
    an allocation of value to the options resulted in an effective
    conversion price less than the fair market value of the
    Company&#146;s common stock on the day the debt was issued
    (commitment date). In accordance with EITF
    <FONT style="white-space: nowrap">No.&#160;98-5,</FONT>
    <I>Accounting for Convertible Securities with Beneficial
    Conversion Features or Contingently Adjustable Conversion
    Ratios</I>, and EITF
    <FONT style="white-space: nowrap">No.&#160;00-27,</FONT>
    <I>Application of Issue
    <FONT style="white-space: nowrap">No.&#160;98-5</FONT>
    to Certain Convertible Instruments, </I>this difference was the
    per share beneficial conversion feature and resulted in an
    additional discount on the notes of $153,538. The total of the
    discounts on the notes of $307,076 was accreted back to the
    notes redemption value based on the effective-interest method
    over the term of the notes. The Company amended the note
    agreements in January 2004 to extend the maturity date an
    additional 130&#160;days. The modification was not considered to
    be substantial under EITF
    <FONT style="white-space: nowrap">No.&#160;96-19,</FONT>
    <I>Debtors Accounting for a Modification or Exchange of Debt
    Instruments
    </I><FONT style="white-space: nowrap">(EITF&#160;96-19),</FONT>
    and was accounted for as a modification of the original debt. In
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-19,</FONT>
    since the modification of the terms did not result in a debt
    extinguishment, the change in the fair value of the embedded
    conversion feature at the modification date (difference between
    the fair value of the embedded conversion option immediately
    before and after the modifications) of $45,534 should be
    accounted for as an additional debt discount resulting in an
    effect on the subsequent recognition of interest expense for the
    associated debt. The amendments provided for an additional 1,540
    stock options per $50,000 face value of the notes upon extension
    of the notes. The fair value of the stock options, $151,074, was
    recognized as additional interest expense over the extension
    period. The modified notes had a 15% contractual interest rate
    and contained similar provisions for granting 770 stock options
    per $50,000 face value of the notes of each
    <FONT style="white-space: nowrap">30-day</FONT>
    anniversary of the notes being outstanding in the event of
    nonpayment on the
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    due dates. The following is a summary of the settlement of the
    notes in May 2004.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="70%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Accrued<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Principal</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">interest</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Total</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Settled in 19,822&#160;shares of
    common stock
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    222,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,864
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    237,864
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Settled in cash
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    315,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    552,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-15</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2004, interest expense of $1,011,631 included $710,794
    recorded by the Company as a result of the notes, which included
    interest based on the contractual interest rate of the notes of
    $29,167, the accretion of the discounts on the notes of $227,174
    resulting from the fair value of the options granted when the
    notes were issued and modified and the beneficial conversion
    feature, and the fair value of the options issued at each thirty
    day anniversary of $454,453.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At December&#160;31, 2003, the Company&#146;s revolving line of
    credit provided that the Company could borrow the lesser of
    $3.5&#160;million or 80% of eligible accounts receivable, plus
    50% of eligible inventory. The interest rate on the line was
    LIBOR, plus 4% and 2.5% at December&#160;31, 2003 and 2004,
    respectively (5.13% and 4.92% as of December&#160;31, 2003 and
    2004, respectively). In 2004, the remaining unamortized discount
    related to the value of stock warrants to purchase
    12,500&#160;shares of common stock at an exercise price of
    $12&#160;per share that were issued when the Company modified
    this line of credit in 2003 was $103,806 and was included in
    interest expense. The warrants, which were outstanding and
    exercisable as of December&#160;31, 2006 and expire October
    2013, were valued utilizing the Black-Scholes model, with a
    expected term of 10&#160;years, 0% dividend yield, expected
    volatility of 79%, and a risk-free interest rate of 4.26%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2006, the Company completed a transaction with Inalco
    Biochemicals, Inc. and Inalco S.p.A. (collectively Inalco) to
    acquire exclusive U.S.&#160;commercial rights for
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    In order to complete this transaction, funding was obtained from
    Bank of America in the form of a three-year term loan for
    $5,500,000 and a new two-year revolving line of credit
    agreement, both with an interest rate of LIBOR plus 2.5% (7.83%
    as of December&#160;31, 2006). The term loan is being paid off
    in quarterly installments of $458,334, with final payment due in
    2009. The Company can borrow under the revolving line of credit
    through April 2008 the lesser of $4.0&#160;million or 80% of
    eligible accounts receivable, plus 50% of eligible inventory.
    The Company must pay an annual commitment fee of
    <FONT style="vertical-align: top; font-size: 70&#37;">1</FONT>/<FONT style="font-size: 70&#37;">2</FONT>
    of 1% on the unused portion of the commitment. The credit
    agreement provides that borrowings are collateralized by a first
    priority lien on all of the Company&#146;s assets, except for
    the Company&#146;s equity interest in Cumberland Emerging
    Technologies, Inc. The credit agreement contains an adverse
    subjective acceleration clause and also requires that the
    Company maintain a lockbox. However, cash received in the
    lockbox is not required to be applied against amounts borrowed
    under the line of credit. This credit agreement contains various
    covenants and the Company was in compliance with all covenants
    at December&#160;31, 2006. As of December&#160;31, 2005 and
    2006, the Company has borrowed $281,209 and $825,951,
    respectively, under its revolving line of credit and had
    additional credit available under the revolving line of credit
    of approximately $2,982,000 at December&#160;31, 2006. In
    conjunction with these agreements, the Company issued warrants
    to purchase up to 1,979&#160;share of common stock at an
    exercise price of $18 per share, which expire in April 2016 and
    are outstanding and exercisable as of December&#160;31, 2006.
    The estimated fair value of these warrants of $25,680, as
    determined using the Black-Scholes model utilizing a expected
    term of 10&#160;years, risk-free interest rate of 4.89%,
    volatility of 60%, and 0% dividend yield, has been recorded in
    the accompanying consolidated financial statements as equity and
    deferred financing costs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On September&#160;4, 2003, the Company borrowed $1,000,000 from
    S.C.O.U.T. Healthcare Fund, L.P. (S.C.O.U.T.) in the form of an
    uncollateralized convertible promissory note with a maturity
    date of September&#160;3, 2004. This transaction is a related
    party transaction as the general partner of S.C.O.U.T. serves on
    the Board of Directors of the Company. The note bore interest at
    a fixed annual rate of 10%. Pursuant to the terms of the note,
    on its maturity date, the principal value of the note plus any
    accrued interest totaling $1,100,004 automatically converted
    into 91,667&#160;shares of common stock of the Company. Total
    interest expense under this note in 2004 was $67,670.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the second quarter of 2005, the Company received
    approximately $2,000,000 from various individuals and companies
    in exchange for uncollateralized convertible promissory notes
    with maturity
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-16</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    dates six months from the date of issuance. The notes bore
    interest at a fixed annual rate of 3.5%. In the fourth quarter
    of 2005, and pursuant to the terms of the note, the principal
    value of the note of $2,000,000, plus all accrued interest of
    $32,488, converted into 112,916&#160;shares of the
    Company&#146;s common stock. Accrued interest of $2,205 was paid
    in cash at the request of the noteholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future maturities of debt at December&#160;31, 2006, by year and
    in the aggregate, were as follow:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2007
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,833,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2008
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,659,281
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2009
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    916,670
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total debt payments
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,409,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest expense associated with the Company&#146;s long-term
    debt and other long-term obligations consist of the following
    components for the years ended December&#160;31.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Noncash interest expense:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Amortization of deferred financing
    costs&#151;revolving line of credit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Amortization of deferred financing
    costs&#151;term note payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Options grant
    expense&#151;unsecured promissory notes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    454,453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accretion of
    discount&#151;unsecured promissory notes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    227,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accretion of
    discount&#151;deferred purchase price
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    210,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Accretion of discount&#151;product
    promotion costs
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,709
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    785,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    339,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Contractual interest expense:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Revolving line of credit and term
    note payable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,967
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    351,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Uncollateralized convertible
    promissory notes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,670
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,693
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Unsecured promissory notes
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Other long-term obligations
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29,456
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    382,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total interest expense
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,011,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    721,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(6)&#160;&#160;OTHER
    LONG-TERM OBLIGATIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other long-term obligations consist of the following components
    at December&#160;31:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Deferred purchase price, net of
    discount of $465,843
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,034,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Third-party development costs
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    410,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    410,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Third-party sales force costs
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    329,169
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Product promotional costs
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376,401
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578,111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,116,416
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,133,860
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Less current portion
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,127,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,052,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    988,961
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,081,359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-17</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2006, the Company entered into an agreement with Inalco
    Biochemicals, Inc. and Inalco S.p.A. (collectively Inalco) to
    acquire exclusive U.S.&#160;commercialization rights (the
    rights) for
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    In order to complete this transaction, funding was obtained from
    Bank of America in the form of a term loan and a new revolving
    line of credit. Additionally, in accordance with the terms of
    the agreement, the Company has deferred a portion of this
    purchase price. The following is a summary of amounts deferred
    under the agreement as of December&#160;31, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">First installment paid upon the
    effective date of the agreement
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Second installment of $1,500,000
    due on April&#160;7, 2007, net of $25,610 discount using an
    effective interest rate of 7.33%, as of December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,474,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Third installment of $3,000,000
    due on April&#160;7, 2009, net of $440,233 discount using an
    effective interest rate of 7.33%, as of December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,559,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,534,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Less amounts previously paid
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Deferred purchase price, net of
    unaccreted discount
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,034,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2000, the Company signed an agreement with a third party
    to cover a variety of development efforts related to a specific
    pharmaceutical drug, including preparation of submissions to the
    FDA. In accordance with the agreement, the Company was billed,
    and the Company expensed, approximately $1,010,000 during the
    fiscal years 2001 through 2003. As of December&#160;31, 2006,
    the Company has paid approximately $600,000 of this balance and
    has accrued approximately $410,000 as a long-term obligation.
    The balance of approximately $410,000 is due in the following
    timeframe (a)&#160;approximately $205,000 due no later than
    submission of an application to the FDA, and
    (b)&#160;approximately $205,000 due no later than FDA approval.
    If neither the submission of the FDA application nor FDA
    approval occurs due to the Company terminating the project, the
    $410,000 will become due and payable and will accrue interest at
    12.5% until paid.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The agreement also calls for contingent payments upon certain
    milestones. Upon meeting the first milestone, New Drug
    Application (NDA) submission for the pharmaceutical drug and FDA
    acceptance of the submission for review, a contingent payment of
    approximately $205,000 will become due and payable. Upon meeting
    the second milestone, FDA approval, a contingent payment of
    approximately $1,005,000 will become due and payable as follows:
    approximately $800,000 immediately and approximately $205,000 in
    twelve monthly installments starting on the date the milestone
    is met. Since the payments are contingent on specific events
    which may or may not occur in the future, and which have not
    occurred or are deemed probable of occurring as of
    December&#160;31, 2006, the contingent liability for these
    amounts of approximately $1,200,000 has not been recorded.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the aforementioned agreement, the Company
    granted 50,000 stock options with contingent vesting clauses to
    purchase the Company&#146;s common stock at an exercise price of
    $3.25. Vesting for 20,000 of these options was contingent upon
    an NDA submission for the product candidate and FDA acceptance
    of the submission for review on or before a target date of
    July&#160;30, 2003. If the NDA submission were to occur three
    months after the target date, 12,000 options would vest. If the
    submission for the product occurred between three and six months
    after this target, 5,000 options would vest. None of the 20,000
    options vested since the milestone was not met within six months
    subsequent to the target date. The third party will have the
    ability to vest in 30,000 options if FDA approval occurs within
    13&#160;months after the NDA is accepted for review. If approval
    occurs within 14 and 15&#160;months after acceptance for review,
    the third party will vest in 15,000 options. If approval occurs
    between 15 and 18&#160;months after acceptance, the third party
    will vest in 7,500 options. No options will vest after
    18&#160;months. As of December&#160;31, 2006, the NDA submission
    for the product candidate has not been submitted to the FDA for
    review. Because vesting for these options is contingent
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-18</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    on events, which may or may not occur in the future, and which
    have not occurred as of December&#160;31, 2006, the expense for
    these options has not been accounted for in the accompanying
    consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company outsources certain sales force activities through an
    agreement with a third party. Under the terms of the original
    two-year agreement, the third party would bill the Company for
    services performed regardless of whether or not the services led
    to the generation and collection of co-promotion fees. However,
    the agreement provided for deferral of payment for certain
    amounts during the initial 12&#160;months of the program, which
    ended in November 2002. Beginning in the 13th&#160;month
    (December 2002), the cumulative deferred amounts became due no
    later than the 24th&#160;month of the program (November 2003),
    payable in monthly installments of principal and interest.
    However, the Company amended the agreement in April 2003 to
    extend the due date of such deferred amounts to January&#160;31,
    2004. In February 2004, the Company amended the agreement to
    extend the due date of such deferred amounts to June&#160;30,
    2004, at which time the full amount deferred was due. In 2005,
    the Company agreed to make equal monthly payments to pay off the
    balance owed. The amounts due under this agreement at
    December&#160;31, 2005 and 2006 were $329,169 and $0,
    respectively. Total fees billed by the third party under this
    and similar agreements, including various amendments, and
    expensed by the Company totaled approximately $2,960,000,
    $3,082,000, and $3,393,000 in 2004, 2005, and 2006, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2005, the Company entered into an agreement with a key
    wholesaler for settlement of amounts owed under a contract in
    the amount of $2,100,000 to be paid in installments over
    28&#160;months. The Company recorded this liability based on its
    net present value of the payments of $1,976,000 using an
    interest rate of 10%. At December&#160;31, 2005 and 2006, the
    Company had recorded liabilities of approximately $1,376,000 and
    $578,000, respectively, related to this arrangement. In 2006,
    interest expense includes accretion of the discount of $101,709
    related to this liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As stated above in note&#160;5, interest expense associated with
    the Company&#146;s other long-term obligations in 2004, 2005,
    and 2006 was $53,520, $(29,456), and $30,336, respectively. In
    2005, amounts owed to a vendor were forgiven and the accrued
    interest balance was reduced by that amount.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(7)&#160;&#160;Income
    Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income tax benefit includes the following components:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Current:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Federal
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (121,359
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">State
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,429
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (136,788
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Deferred:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Federal
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,146,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,861,859
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">State
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,184,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,833,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,184,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,696,516
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-19</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s effective income tax rate for 2004, 2005, and
    2006 reconciles with the federal statutory tax rate as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Federal tax expense at statutory
    rate
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">State income tax expense (net of
    federal income tax benefit)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Permanent differences
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Other
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Change in deferred tax asset
    valuation allowance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net income tax benefit
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    154
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    158
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Components of the net deferred tax assets are as follows at
    December&#160;31:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Net operating loss and tax credits
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,096,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,520,054
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,834,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Depreciation and amortization
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,412
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Allowance for accounts receivable
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Inventory write-off
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175,961
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Deferred charges
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    358,302
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Investment income
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,448
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,448
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Employee stock-based compensation
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Expense for options and stock
    grants to nonemployees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    488,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    505,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    517,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Total deferred tax assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,825,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,533,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,056,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Less deferred tax asset valuation
    allowance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,825,965
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,349,786
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,612
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Net deferred tax assets
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,184,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,017,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the realizability of deferred tax assets,
    management considers whether it is more likely than not that
    some portion or all of the deferred tax assets will not be
    realized. The ultimate realization of deferred tax assets is
    dependent upon the generation of future taxable income during
    the periods in which those temporary differences become
    deductible. Management considers the scheduled reversal of
    deferred tax liabilities, projected future taxable income, and
    tax planning strategies in making this assessment. In order to
    fully realize the deferred tax asset, the Company will need to
    generate future taxable income of approximately $11,816,000
    prior to the expiration of the net operating loss carryforwards
    in 2025. Taxable income for the years ended December&#160;31,
    2004, 2005, and 2006 was $1,616,571, $1,969,198, and $2,139,954,
    respectively. In the fiscal years 2004, 2005, and 2006, the
    valuation allowance was reduced by $490,198, $1,476,179, and
    $3,310,174, respectively, resulting in corresponding credits to
    deferred income tax expense. Based upon the level of taxable
    income over the last three years and projections for future
    taxable income over the periods in which the deferred tax assets
    are deductible, management believes it is more likely than not
    that the Company will realize the benefits of these deductible
    differences, net of the existing valuation allowances, at
    December&#160;31, 2006. The valuation allowance at
    December&#160;31, 2006 represents the deferred tax assets
    associated with CET that the Company believes are not more
    likely than not will be utilized. The amount of the deferred tax
    asset considered realizable, however, could be reduced in the
    near term if estimates of future taxable income during the
    carryforward period are reduced.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has federal net operating loss carryforwards of
    approximately $6,255,000 at December&#160;31, 2006 that expire
    between 2022 and 2025. The Company also has state net operating
    losses of approximately $9,615,000 that expire between 2016 and
    2025. The Company has federal credit carryforwards of
    approximately $323,000 that expire starting in 2021.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-20</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(8)&#160;&#160;SHAREHOLDERS&#146;
    EQUITY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(a)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Preferred
    Stock</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preferred stock shareholders are entitled to vote with the
    holders of common stock, as each preferred share is entitled to
    the number of votes the holder would be entitled to if converted
    to shares of common stock immediately prior to the vote. They
    are also entitled to receive dividends on an equal basis with
    holders of common stock on an if-converted equivalent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preferred stock shareholders are entitled to receive a
    $3.25&#160;per share liquidation preference in the event of the
    dissolution, liquidation, or winding up of the Company. If
    assets are insufficient to permit full payment, preferred
    holders are entitled to ratable distribution of the available
    assets. Preferred shares are convertible, at the option of the
    holder, at any time after issuance, at the rate of one share of
    common stock for each share of preferred stock. The preferred
    stock will automatically be converted into common stock in the
    event of an underwritten public offering of the Company&#146;s
    common stock or in the event of a consolidation, merger, or sale
    of substantially all of the assets of the Company. In addition,
    preferred shareholders are entitled to adjustment of the ratio
    of conversion of Series&#160;A Preferred Stock into common stock
    to reduce dilution in the event that the Company issued
    additional equity securities at a purchase price of less than
    $3.25&#160;per share.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">(b)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">Common Stock and
    Warrants</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2004, the Company issued 43,000&#160;shares of common
    stock to a related party at a purchase price of $12&#160;per
    share for total proceeds of $516,000. Simultaneously with the
    issuance of the shares of stock, the Company issued a stock
    purchase warrant with a fair value of $196,200 to purchase
    20,000&#160;shares of common stock at an exercise price of
    $12&#160;per share at any time within seven years of issuance.
    The warrants, all of which are outstanding as of
    December&#160;31, 2006, were valued using the Black-Scholes
    model using the following assumptions: 0% dividend yield, 77%
    volatility, and 3.90% risk-free interest rate. The shares of
    stock and the stock warrants were recorded at their relative
    fair value of $142,150 and $373,850, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, the Company initiated a private placement
    offering of its common stock. The purpose of this offering was
    for working capital and for other general corporate purposes,
    including, but not limited to, the acquisition and development
    of pharmaceutical products. The offering was a private, limited
    offering by the Company in reliance upon exemptions from the
    federal registration provisions of the Securities Act of 1933,
    as amended, promulgated by the SEC under Regulation&#160;D. This
    offering was completed in 2005, and the Company issued
    100,000&#160;shares of common stock at $18&#160;per share, for
    total net proceeds of $1,789,364 (gross proceeds of
    $1,800,000&#160;net of cash offering costs of $10,636). The
    Company issued 3,500 stock options with a fair value of $51,806
    to a non-employee as compensation for consulting services
    associated with the private placement. The fair value of these
    options has been recorded as additional offering costs and as
    stock options granted for services received.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2004 and 2005, the Company issued 111,489 and
    112,916&#160;shares of common stock, respectively, upon
    conversion of certain promissory notes into shares of the
    Company&#146;s common stock. See note&#160;5 for a more in-depth
    discussion of these transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2004, 2005, and 2006, the Company issued 25,267, 25,001,
    and 13,759&#160;shares of common stock, respectively, valued at
    $303,204, $300,012, and $273,298, respectively, to executives,
    related parties, and advisors as compensation for services, and
    is included in general and administrative expenses in the
    consolidated statements of income. Included in these amounts are
    shares of common stock granted to board members of 15,600,
    23,120, and 12,409 in 2004, 2005, and 2006, respectively, for
    consulting services rendered. The expense associated with these
    grants to board members was
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-21</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    $187,200, $277,400, and $248,998 in 2004, 2005, and 2006,
    respectively. In addition, the Company issued 18,799, 8,825, and
    18,167&#160;net shares of common stock to key executives and an
    advisor, who exercised options in 2004, 2005, and 2006,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As disclosed in notes&#160;5 and 8(b), at December&#160;31,
    2006, the Company had outstanding warrants to acquire
    34,479&#160;shares of its common stock. See notes&#160;5 and
    8(b) for further information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(9)&#160;&#160;STOCK
    OPTIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has adopted the Cumberland Pharmaceuticals Inc. 1999
    Stock Option Plan (the Plan) that includes both incentive stock
    options and nonqualified stock options to be granted to
    employees, officers, consultants, directors, and affiliates of
    the Company. The Company has reserved 4,050,000&#160;shares of
    no par value common stock for issuance under this Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Incentive stock options must be granted with an exercise price
    not less than the fair market value of the common stock on the
    grant date. The options granted to shareholders owning more than
    10% of the common stock on the grant date must be granted with
    an exercise price not less than 110% of the fair market value of
    the common stock on the grant date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The options are exercisable on the date(s) established by each
    grant; however, options granted to officers or directors are not
    exercisable until at least six months after grant date. The
    maximum exercise life of an option is ten years from grant date
    and is five years for stock options issued to 10% shareholders.
    Vesting is determined on a
    <FONT style="white-space: nowrap">grant-by-grant</FONT>
    basis, in accordance with the terms of the Plan and the related
    grant agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options granted in connection with financing arrangements
    discussed in note 5 were separately approved by the board of
    directors and do not reduce the amount of options available for
    issuance under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock option activity for the three-year period ended
    December&#160;31, 2006 was as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Weighted<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">exercise price<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">shares</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">per
    share</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options outstanding,
    December&#160;31, 2003
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,901,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options granted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.01
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options exercised
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,150
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options expired
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options outstanding,
    December&#160;31, 2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,032,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options granted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options exercised
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options outstanding,
    December&#160;31, 2005
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,154,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options granted
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options exercised
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,484
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.93
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options expired
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options forfeited
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (173,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Options outstanding,
    December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,004,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.74
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-22</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the options outstanding in 2004, 2005, and 2006, 2,361,518,
    2,388,018, and 2,391,864, respectively, were options issued to
    one key executive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes information concerning currently
    outstanding and exercisable options:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Number<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Weighted<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">outstanding<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Remaining<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Range of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">and expected<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">contractual<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">exercise<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Options<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Exercise
    Prices</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">to vest</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">life</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">price</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">exercisable</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="18" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">1999
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">$0.20-0.22
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    422,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.06&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    422,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">1999
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">1.00-1.10
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,355,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.70&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.09
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,355,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2000
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">1.85
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.55&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2001
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">3.25
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    401,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.22&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    401,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2002
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">3.25-3.58
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.03&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2002
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">6.25
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.48&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2003
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">6.25-12.00
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    227,923
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.32&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    227,923
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">12.00-13.20
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.36&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.01
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2005
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">12.00-18.00
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.15&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <FONT style="font-size: 10pt">18.00-19.80
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.48&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,004,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,899,088
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair value of employee options granted during 2006 were
    estimated using the Black-Scholes option pricing model and the
    following assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="85%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dividend yield
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Expected term (years)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3-7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Expected volatility (range)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47%-54%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Risk-free interest rate (range)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.68%-5.08%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company determined the expected life of share options based
    on the simplified method allowed by <I>SEC Staff Accounting
    Bulletin&#160;No.&#160;107.</I>&#160;&#160;Under this approach,
    the expected term is presumed to be the average between the
    weighted average vesting period and the contractual term. The
    expected volatility over the term of the respective option was
    based on the volatility of similar entities. In evaluating
    similarity, the Company considered factors such as industry,
    stage of life cycle, size, and financial leverage. The risk-free
    rate is based on a zero-coupon U.S.&#160;Treasury bond with a
    term substantially equal to the corresponding option&#146;s
    expected term. The Company has never declared or paid any cash
    dividends and does not presently plan to pay cash dividends in
    the foreseeable future. The Company has reviewed historical
    termination behavior and does not anticipate any further
    forfeitures on options granted during 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair value of non-employee options was estimated using the
    Black-Scholes option pricing model and the following assumptions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dividend yield
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Expected term (years)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .17-10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Expected volatility (range)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37%-63%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Risk-free interest rate (range)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.90%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.13%-4.39%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.34%-4.42%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-23</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company determined the above assumptions utilizing the same
    methodology as noted above for employees, except for the
    expected term, which was calculated to be the contractual terms
    of the options in accordance with SFAS&#160;123R.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As previously discussed in item (j)&#160;of note&#160;2, there
    was no expense recorded in 2006 and there will be no expense in
    future years associated with unvested employee stock option
    awards outstanding as of January&#160;1, 2006 due to the Company
    utilizing the prospective method upon adoption of SFAS&#160;123R.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The weighted average grant date fair value of share options
    granted during the year ended December&#160;31, 2004, 2005, and
    2006 was approximately $12.00, $12.73, and $18.00, respectively.
    The Company received cash from the exercise of stock options of
    $4,950 and $9,000 during 2005 and 2006, respectively. Upon
    exercise, the Company issues new shares of stock. During the
    years ended December&#160;31, 2004, 2005, and 2006, the
    aggregate intrinsic value of options exercised under the Plan
    was $225,587, $153,899, and $357,730, respectively, determined
    as of the date of option exercise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;31, 2006, the Company
    recognized $141,836 of compensation expense related to stock
    options and recognized a corresponding tax benefit of $37,747.
    This amount consists of non-employee stock option expense of
    $37,751 and employee stock option expense of $104,085. Such
    expense is presented as a component of general and
    administrative expenses. At December&#160;31, 2006, there was
    approximately $321,535 of unrecognized compensation cost related
    to share-based payments granted in 2006, which is expected to be
    recognized over a period of four years. This amount consists of
    non-employee unrecognized compensation cost of $55,077 and
    employee unrecognized compensation cost of $266,458.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company issued a total of 18,780, 23,800, and 12,000 stock
    options to non-employees for services rendered by these
    individuals in 2004, 2005, and 2006 as compensation for
    assisting the Company&#146;s management and supporting
    operations. The amount of compensation expense recorded for such
    services was $43,928, $226,709, and $37,751, in 2004, 2005, and
    2006, respectively. Such expense is presented as a component of
    general and administrative expenses. Included in these amounts
    are options to purchase 16,780&#160;shares of common stock at an
    exercise price of $12.00 in 2004 and options to purchase
    11,000&#160;shares of common stock at an exercise price of
    $18.00 in 2005 and that were granted to two board members.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(10)&#160;&#160;LEASES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is obligated under long-term real estate leases for
    office space expiring at various times through December 2011.
    The Company also subleases a portion of the space under these
    leases. Rent expense is recognized over the expected term of the
    lease, including renewal option periods, on a straight-line
    basis. Rent expense for 2004, 2005, and 2006 was $139,587,
    $151,479, and $286,037, respectively, and sublease income was
    $45,035, $49,131, and $71,173, respectively. Future minimum
    lease payments under non-cancelable operating leases (with
    initial or remaining lease terms in excess of one year) are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Year ending December&#160;31:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">2007
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">2008
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    487,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">2009
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">2010
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">2011
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,711
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    <FONT style="font-size: 10pt">Total minimum lease payments
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,861,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-24</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Minimum lease payments have not been reduced by minimum sublease
    rentals of $49,880 and $7,860 in 2007 and 2008, respectively,
    under non-cancelable subleases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During December of 2006, the Company signed a lease agreement
    for additional office space at its West End location. The lease
    agreement begins June&#160;1, 2007 and ends on October&#160;31,
    2010. The additional cost of this agreement is approximately
    $223,000&#160;per year and has been included in the table above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(11)&#160;&#160;MANUFACTURING
    AND SUPPLY AGREEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company utilizes one supplier to manufacture each of its
    products and product candidates. Although there are a limited
    number of manufacturers of pharmaceutical products, management
    believes that they could utilize other suppliers to manufacture
    their prescription products on comparable terms. A change in
    suppliers, any problems with such manufacturing operations or
    capacity, or contract disputes with the suppliers, however,
    could cause a delay in manufacturing and a possible loss of
    sales, which would affect operating results adversely.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s manufacturing and supply agreements with the
    manufacturers of its products contain minimum purchase
    obligations. For 2007, these obligations require the Company to
    purchase approximately $2.1&#160;million of product,
    $2.4&#160;million during 2008, $2.7&#160;million during 2009,
    $3.0&#160;million during 2010, and $800,000 during 2011.
    Beginning in April 2011 and continuing through the life of the
    agreement, one of the manufacturing and supply agreements
    requires minimum purchases of not less than 65% of the average
    purchases in each of the three immediately preceding annual
    periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s purchases under these agreements are
    reflected in the cost of products sold in the accompanying
    consolidated statements of income.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(12)&#160;&#160;CONTINGENCIES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is currently party to one legal proceeding brought
    about by an employee of a third-party contract sales
    organization that does business with the Company. The lawsuit
    asserts a multitude of claims arising out of the contract sales
    organization&#146;s decision to separate employment after the
    employee claimed to have suffered a workers&#146; compensation
    injury. The Company filed a Motion to Dismiss all of the claims
    against the Company and its representatives. The oral arguments
    were heard on the motion in November 2006. In December 2006, the
    Magistrate Judge recommended the Company&#146;s Motion to
    Dismiss be granted on all claims.
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(13)&#160;&#160;EMPLOYMENT
    AGREEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company entered into
    employment agreements with its full-time and part-time
    employees. Each employment agreement provides for a salary basis
    for services performed, a potential annual bonus, and, if
    applicable, a grant of incentive options to purchase the
    Company&#146;s common shares pursuant to an option agreement.
    Two of the employment agreements address expense reimbursements
    for relevant and applicable licenses and continuing education.
    Employment agreements are amended each successive one-year
    period, unless terminated.
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(14)&#160;&#160;MARKET
    CONCENTRATIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company currently focuses on acquiring, developing, and
    commercializing branded prescription products for the acute care
    and gastroenterology markets. The Company&#146;s principal
    financial instruments subject to potential concentration of
    credit risk are accounts receivable, which are unsecured, and
    cash equivalents. The Company&#146;s cash equivalents consist
    primarily of money market
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-25</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Notes to
    consolidated financial statements</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    funds. Certain bank deposits may at times be in excess of the
    Federal Deposit Insurance Corporation (FDIC) insurance limits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s primary customers are wholesale
    pharmaceutical distributors in the U.S.&#160;Total revenues from
    customers representing 10% or more of total revenues for the
    respective years are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2004</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2005</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="12" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Customer 1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Customer 2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Customer 3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, 92% and 67% of the Company&#146;s accounts
    receivable balances were due from these three customers at
    December&#160;31, 2005 and 2006, respectively.
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(15)&#160;&#160;EMPLOYEE
    BENEFIT PLAN</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sponsors an employee benefit plan that was
    established January&#160;1, 2006, the Cumberland Pharmaceuticals
    401(k) Plan (the Plan) under section&#160;401(k) of the Internal
    Revenue Code of 1986, as amended, for the benefit of all
    employees over the age of&#160;21, having been employed by the
    Company for at least six months. The Plan provides that
    participants may contribute up to the maximum amount of their
    compensation as set forth by the Internal Revenue Service each
    year. Employee contributions are invested in various investment
    funds based upon elections made by the employee. There were no
    contributions made by the Company to the Plan in 2006.
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">(16)&#160;&#160;SUBSEQUENT
    EVENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning January&#160;1, 2007, the Company&#146;s newly formed
    subsidiary, Cumberland Pharma Sales Corp., began full operations
    for the purpose of employing the newly acquired hospital sales
    force, which promotes the Company&#146;s products,
    Acetadote<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and
    Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    in the acute care market. Previously, this sales force was
    contracted through a third-party contract sales organization. In
    October 2006, the Company notified the contract sales
    organization that it was exercising its right to convert the
    sales force to the Company&#146;s employees and would,
    therefore, not renew the contract sales agreement which expired
    on December&#160;31, 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2007, the Company&#146;s board of directors approved
    the Long-Term Incentive Compensation Plan, which was
    subsequently approved by the shareholders in April 2007. The
    purposes of the Long-Term Incentive Compensation Plan are to
    encourage the Company&#146;s employees and consultants to
    acquire stock and other equity-based interests and is intended
    to replace the Cumberland Pharmaceuticals Inc. 1999 Stock Option
    Plan without impairing the vesting or exercise of any option
    granted thereunder.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-26</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Cumberland
    Pharmaceuticals Inc. and Subsidiaries</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Schedule&#160;II&#151;valuation
    and qualifying accounts
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Column
    B</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Column
    C</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Column
    E</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Balance at<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Charged to<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Charged to<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-family: Arial, Helvetica">Column
    D</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Balance<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-family: Arial, Helvetica">Column
    A</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">beginning<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">costs and<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">other accounts<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Deductions&#160;&#151;<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">at end<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of
    period</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">expenses</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">describe</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">describe(1)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">of
    period</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Allowance for uncollectible
    amounts, cash discounts, chargebacks, and credits issued for
    damaged products:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 17pt">
    <FONT style="font-size: 8pt">For the period ended:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,134,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (944,094
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    189,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2005
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    616,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (622,533
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,449,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,334,985
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <FONT style="font-size: 8pt">Valuation allowance for deferred
    tax assets:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 17pt">
    <FONT style="font-size: 8pt">For the period ended:
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,316,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (490,198
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,825,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2005
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,825,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,476,179
</TD>
<TD nowrap align="left" valign="bottom">
    )(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,349,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 25pt">
    <FONT style="font-size: 8pt">December&#160;31, 2006
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,349,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,310,174
</TD>
<TD nowrap align="left" valign="bottom">
    )(3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,612
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Write-off of uncollectible accounts, net of recoveries,
    discounts, chargebacks, and credits taken by customers.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes a $1,184,000 reduction in the valuation allowance
    reflecting the Company&#146;s belief that the future recognition
    of this amount of deferred tax assets is more likely than not.
    Remaining decrease is due to the utilization of deferred tax
    assets.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes a $2,833,303 reduction in the valuation allowance
    reflecting the Company&#146;s belief that the future recognition
    of this amount of deferred tax assets is more likely than not.
    Remaining decrease is due to the utilization of deferred tax
    assets.</TD>
</TR>

</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">F-27</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="g06286g0628603.gif" alt="CUMBERLAND LOGO" >
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Information not
    required in prospectus
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">OTHER EXPENSES OF
    ISSUANCE AND DISTRIBUTION.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The expenses relating to the registration of the shares of
    common stock being offered hereby, other than underwriting
    discounts and commissions, will be borne by us. Such expenses
    are estimated to be as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Item</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="4" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">SEC registration fee
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">NASD filing fee
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">NASDAQ listing fee
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Printing expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Legal fees and expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Accounting fees and expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Transfer agent and registrar
    expenses
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B><FONT style="font-size: 10pt">Total</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">INDEMNIFICATION
    OF DIRECTORS AND OFFICERS.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our charter and bylaws provide for indemnification of our
    directors to the fullest extent permitted by the Tennessee
    Business Corporation Act, as amended from time to time. Our
    directors shall not be liable to the corporation or its
    shareholders for monetary damages for breach of fiduciary duty
    as a director. The Tennessee Business Corporation Act provides
    that a Tennessee corporation may indemnify its directors and
    officers against expenses, judgments, fines and amounts paid in
    settlement actually and reasonably incurred by them in
    connection with any proceeding, whether criminal or civil,
    administrative or investigative if, in connection with the
    matter in issue, the individual&#146;s conduct was in good
    faith, and the individual reasonably believed: in the case of
    conduct in the individual&#146;s official capacity with the
    corporation, that the individual&#146;s conduct was in its best
    interest; and in all other cases, that the individual&#146;s
    behavior was at least not opposed to its best interest; and in
    the case of a criminal proceeding, the individual had no reason
    to believe the individual&#146;s conduct was unlawful. In
    addition, we have entered into indemnification agreements with
    our directors. These provisions and agreements may have the
    practical effect in certain cases of eliminating the ability of
    our shareholders to collect monetary damages from directors. We
    believe that these contractual agreements and the provisions in
    our charter and bylaws are necessary to attract and retain
    qualified persons as directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">RECENT SALES OF
    UNREGISTERED SECURITIES.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2003, we borrowed $500,000 from nine existing and
    accredited shareholders pursuant to uncollateralized secured
    notes payable with original maturity dates of 130&#160;days.
    These notes bore interest at 12% for the first 30&#160;days and
    15% thereafter. The holders of the notes had, at their option,
    until the maturity date of the notes payable, the right to
    convert all or a portion of the unpaid principal and interest
    into shares of our common stock at a rate of $12.00 per share.
    We also issued to these lenders options to purchase shares of
    our common stock, at an exercise price of $12.00&#160;per share,
    and at the rate of 1,540&#160;shares of common stock per $50,000
    face value of the notes. If we had not prepaid all amounts due
    and owing under the notes, we agreed to grant additional options
    at the rate of 770&#160;shares of common stock per $50,000 face
    value on each of (i)&#160;the 30th&#160;day after the date of
    the notes and (ii)&#160;on a continuing basis, each successive
    <FONT style="white-space: nowrap">30-day</FONT>
    period thereafter, or portion thereof, as the notes remained
    outstanding. At December&#160;31, 2003, the notes payable had
    not been prepaid, so we granted options to acquire an additional
    30,800&#160;shares. We amended the notes agreements in
    January&#160;2004 to extend the maturity date 130&#160;days. The
    amendments granted an additional option to
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-1</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    purchase 1,540&#160;shares per $50,000 face value upon extension
    of the notes and contained similar provisions for granting
    options in the event of nonpayment on the
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    due dates. Based on the extension of the maturity date, to
    purchase a total of 61,600&#160;shares were earned by the
    holders of the notes in 2004. We repaid these notes or settled
    these notes in shares in May 2004. The issuance of these
    securities was exempt from registration under the Securities Act
    in reliance on Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2003, we borrowed $1,000,000 from S.C.O.U.T.
    Healthcare Fund, L.P., or S.C.O.U.T., in the form of a
    convertible promissory note with a maturity date of September
    2004. The President and majority shareholder of the general
    partner of S.C.O.U.T., Dr.&#160;Lawrence W. Greer, serves on our
    board of directors. Pursuant to the terms of the note, on its
    maturity date, S.C.O.U.T. converted the principal value of the
    note plus all interest accrued at a fixed rate of ten percent
    per annum into 91,667&#160;shares of our common stock at a price
    of $12.00&#160;per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;15, 2004, we issued 43,000 common shares at
    $12.00&#160;per share, for an aggregate consideration of
    $516,000 and a five-year warrant to purchase 20,000 common
    shares at $12.00&#160;per share to S.C.O.U.T., which represented
    to us that it was an accredited investor. This issuance was
    exempt from registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By an offering memorandum dated April&#160;1, 2005, we offered
    100,000&#160;shares of our common stock at a purchase price of
    $18.00&#160;per share. Thirty investors subscribed for
    100,000&#160;shares in the aggregate, for an aggregate
    consideration of $1,800,000. This issuance was exempt from
    registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By an offering memorandum dated May&#160;5, 2005, we received
    approximately $2,000,000 from approximately 41 investors in
    exchange for uncollateralized convertible promissory notes with
    a maturity date six months from the date of issuance. Upon
    maturity, the principal and accrued interest payable on the
    notes converted into 112,916&#160;shares of common stock at a
    rate of $18.00&#160;per share. This issuance was exempt from
    registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since January&#160;1, 2004, we have granted options to purchase
    287,610&#160;shares of our common stock under the
    1999&#160;Option Plan to our employees, directors and
    consultants at exercise prices ranging from $12.00 to
    $22.00&#160;per share. Of these, an aggregate of 775&#160;shares
    of our common stock were issued upon the exercise of stock
    options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since January&#160;1, 2004, we also issued an aggregate of
    75,645&#160;shares of common stock as compensation for services
    pursuant to contracts. Restricted-stock legends were affixed to
    the securities issued in these transactions. Our board of
    directors determined that the fair value of the services
    received equaled the value of the stock granted with values
    ranging from $12.00 to $22.00&#160;per share. The issuances of
    common stock in connection with awards of restricted stock were
    exempt either pursuant to Rule&#160;701 or pursuant to
    Section&#160;4(2) of the Securities Act as transactions by an
    issuer not involving a public offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">EXHIBITS AND
    FINANCIAL STATEMENT SCHEDULES.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">1.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Underwriting Agreement.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">3.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Second Amended and Restated
    Charter of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">3.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Amended and Restated Bylaws of
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
</TABLE>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-2</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Specimen Common Stock Certificate
    of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Warrant to Purchase Common Stock
    of Cumberland Pharmaceuticals Inc., issued to Bank of America,
    N.A. on October&#160;21, 2003.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.3*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Stock Purchase Warrant, issued to
    S.C.O.U.T. Healthcare Fund L.P. on April&#160;15, 2004.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Warrant to Purchase Common Stock
    of Cumberland Pharmaceuticals Inc., issued to Bank of America,
    N.A. on April&#160;6, 2006.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.5#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Option Agreement under
    1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.6*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Option Agreement under
    2007 Long-Term Incentive Compensation Plan of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.7*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Agreement under
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">5.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Opinion of Adams and Reese LLP.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.1&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Manufacturing and Supply Agreement
    for N-Acetylcysteine, dated January&#160;15, 2002, by and
    between Bioniche Life Sciences, Inc. and Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Novation Agreement, dated
    January&#160;27, 2006, by and among Bioniche Life Sciences,
    Inc., Bioniche Pharma Group Ltd., and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.3&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Manufacturing
    and Supply Agreement for N-Acetylcysteine, dated
    November&#160;16, 2006, by and between Bioniche Teoranta and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.4&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Cardinal Health Contract Sales and
    Services for Cumberland Pharmaceuticals Inc. Dedicated Sales
    Force Agreement, dated May&#160;16, 2006, by and between
    Cardinal Health  PTS, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.5&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Contract Sales
    and Service Agreement, dated July&#160;19, 2006, by and between
    Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent to Assignment by Cardinal
    Health PTS, LLC to PG Holding Corporation of all of their
    rights, title, interests and obligations under that certain
    Cardinal Health Contract Sales and Services for Cumberland
    Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
    May&#160;16, 2006, by and between Cardinal Health  PTS, LLC and
    Cumberland Pharmaceuticals Inc., as amended by that certain
    First Amendment to Contract Sales and Service Agreement, dated
    July&#160;19, 2006, by and between Cardinal Health PTS, LLC and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.7&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Distribution Services Agreement,
    dated August&#160;3, 2000, by and between CORD Logistics, Inc.
    and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.8&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Strategic Alliance Agreement,
    dated July&#160;21, 2000, by and between F.H.
    Faulding&#160;&#38; Co. Limited and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.9&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Kristalose Agreement, dated
    April&#160;7, 2006, by and among Inalco Biochemicals, Inc.,
    Inalco S.p.A., and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.10&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">License Agreement, dated
    May&#160;28, 1999, by and between Vanderbilt University and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.11#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between A.J. Kazimi and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
</TABLE>
<P>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-3</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.12#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between Jean W. Marstiller and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.13#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between Leo Pavliv and Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.14#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between J. William Hix and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.15#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between David L. Lowrance and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.16*&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Second Amended and Restated Loan
    Agreement by and between Cumberland Pharmaceuticals Inc. and
    Bank of America, N.A., dated April&#160;6, 2006.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.17#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">1999 Stock Option Plan of
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.18*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">2007 Long-Term Incentive
    Compensation Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.19*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">2007&#160;Directors&#146;
    Compensation Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.20
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Indemnification Agreement
    between Cumberland Pharmaceuticals Inc. and all members of its
    Board of Directors.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.21&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Lease Agreement, dated
    September&#160;10, 2005, by and between Nashville Hines
    Development, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.22*&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Sublease Agreement, dated
    December&#160;14, 2006, by and between Robert W.
    Baird&#160;&#38; Co. Incorporated and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.23&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Amended and Restated Lease
    Agreement, dated November&#160;11, 2004, by and between The
    Gateway to Nashville LLC and Cumberland Emerging Technologies,
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.24
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Amended and
    Restated Lease Agreement, dated August&#160;23, 2005, by and
    between The Gateway to Nashville LLC and Cumberland Emerging
    Technologies, Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">21
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Subsidiaries of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">23.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent of KPMG LLP.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">23.2*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent of Adams and Reese, LLP
    (contained in Exhibit&#160;5).
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">24
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Powers of Attorney (contained on
    the signature page hereto).
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    *&#160;
</TD>
    <TD align="left">    To be filed by amendment.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    #&#160;
</TD>
    <TD align="left">    Indicates a management contract or compensatory plan.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#134;&#160;
</TD>
    <TD align="left">    Confidential treatment has been requested for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    (b)&#160;&#160;</TD>
    <TD align="left">
    See Schedule&#160;II&#151;Valuation and qualifying accounts
    included in our audited financial statements included elsewhere
    in this registration statement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All other schedules have been omitted because they are not
    applicable.
</DIV>
<P>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-4</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<P>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;17.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">UNDERTAKINGS.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933 may be permitted to directors, officers,
    and controlling persons of the registrant pursuant to the
    foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Securities Act of 1933 and is, therefore,
    unenforceable. In the event that a claim for indemnification
    against such liabilities (other than the payment by the
    registrant of expenses incurred or paid by a director, officer,
    or controlling person of the registrant in the successful
    defense of any action, suit, or proceeding) is asserted by such
    director, officer, or controlling person in connection with the
    securities being registered, the registrant will, unless in the
    opinion of its counsel the matter has been settled by
    controlling precedent, submit to a court of appropriate
    jurisdiction the question whether such indemnification by it is
    against public policy as expressed in the Securities Act of 1933
    and will be governed by the final adjudication of such issue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 7%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1)&#160;&#160;For purposes of determining any liability under
    the Securities Act of 1933, the information omitted from the
    form of prospectus filed as part of this Registration Statement
    in reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the Registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this Registration Statement as
    of the time it was declared effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 7%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2)&#160;&#160;For the purpose of determining any liability under
    the Securities Act of 1933, each post-effective amendment that
    contains a form of prospectus shall be deemed to be a new
    Registration Statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial <I>bona fide </I>offering thereof.
</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-5</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Signatures
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    registrant has duly caused this registration statement to be
    signed on its behalf by the undersigned, thereunto duly
    authorized in the City of Nashville, State of Tennessee, on the
    1st day of May, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CUMBERLAND PHARMACEUTICALS INC.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="50%"></TD>
    <TD width="3%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">a.j.
    kazimi</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 3pt; margin-left: 53%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.J. Kazimi<BR>
    Chairman and CEO<BR>
    (Principal Executive Officer)
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Signatures and Power
    of Attorney
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each person whose signature appears below constitutes and
    appoints A. J. Kazimi and David L. Lowrance, and each of them
    individually, his or her true and lawful
    <FONT style="white-space: nowrap">attorneys-in-fact</FONT>
    and agents, with full power of substitution and resubstitution,
    for him or her and in his or her name, place and stead, in any
    and all capacities, to sign any and all amendments (including
    post effective amendments) to this registration statement and
    any additional registration statements to be filed pursuant to
    Rule&#160;462(b) under the Securities Act of 1933, and to file
    the same, with all exhibits thereto and other documents in
    connection therewith, with the SEC, granting unto said
    <FONT style="white-space: nowrap">attorneys-in-fact</FONT>
    and agents, and each of them, full power and authority to do and
    perform each and every act and thing requisite and necessary to
    be done in connection therewith, as fully to all intents and
    purposes as he or she might or could do in person, hereby
    ratifying and confirming all that said
    <FONT style="white-space: nowrap">attorneys-in-fact</FONT>
    and agents or any of them, or their or his or her substitute or
    substitutes, may lawfully do or cause to be done by virtue
    hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    registration statement has been signed by the following persons
    in the capacities and on the dates indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="36%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Signature</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Title</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Date</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">a.j.
    kazimi</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->A.J.
    Kazimi
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Chairman and CEO (Principal
    Executive Officer)
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">david
    l. lowrance</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->David
    L. Lowrance
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Vice President and CFO (Principal
    Financial and Accounting Officer)
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">robert
    g. edwards</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->Robert
    G. Edwards
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">thomas
    r. lawrence</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->Thomas
    R. Lawrence
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">lawrence
    w. greer</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->Lawrence
    W. Greer
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-size: 10pt">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">martin
    e. cearnal</FONT></FONT></DIV><FONT style="font-size: 10pt"><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=191 length=0 -->Martin
    E. Cearnal
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">May&#160;1, 2007
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<P>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">S-1</FONT></B>
</DIV>
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Exhibit&#160;Index
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">1.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Underwriting Agreement.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">3.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Second Amended and Restated
    Charter of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">3.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Amended and Restated Bylaws of
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Specimen Common Stock Certificate
    of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Warrant to Purchase Common Stock
    of Cumberland Pharmaceuticals Inc., issued to Bank of America,
    N.A. on October&#160;21, 2003.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.3*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Stock Purchase Warrant, issued to
    S.C.O.U.T. Healthcare Fund L.P. on April&#160;15, 2004.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Warrant to Purchase Common Stock
    of Cumberland Pharmaceuticals Inc., issued to Bank of America,
    N.A. on April&#160;6, 2006.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.5#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Option Agreement under
    1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.6*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Option Agreement under
    2007 Long-Term Incentive Compensation Plan of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">4.7*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Agreement under
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">5.1*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Opinion of Adams and Reese LLP.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.1&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Manufacturing and Supply Agreement
    for N-Acetylcysteine, dated January&#160;15, 2002, by and
    between Bioniche Life Sciences, Inc. and Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Novation Agreement, dated
    January&#160;27, 2006, by and among Bioniche Life Sciences,
    Inc., Bioniche Pharma Group Ltd., and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.3&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Manufacturing
    and Supply Agreement for N-Acetylcysteine, dated
    November&#160;16, 2006, by and between Bioniche Teoranta and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.4&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Cardinal Health Contract Sales and
    Services for Cumberland Pharmaceuticals Inc. Dedicated Sales
    Force Agreement, dated May&#160;16, 2006, by and between
    Cardinal Health  PTS, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.5&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Contract Sales
    and Service Agreement, dated July&#160;19, 2006, by and between
    Cardinal Health PTS, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent to Assignment by Cardinal
    Health PTS, LLC to PG Holding Corporation of all of their
    rights, title, interests and obligations under that certain
    Cardinal Health Contract Sales and Services for Cumberland
    Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
    May&#160;16, 2006, by and between Cardinal Health  PTS, LLC and
    Cumberland Pharmaceuticals Inc., as amended by that certain
    First Amendment to Contract Sales and Service Agreement, dated
    July&#160;19, 2006, by and between Cardinal Health PTS, LLC and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.7&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Distribution Services Agreement,
    dated August&#160;3, 2000, by and between CORD Logistics, Inc.
    and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.8&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Strategic Alliance Agreement,
    dated July&#160;21, 2000, by and between F.H.
    Faulding&#160;&#38; Co. Limited and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.9&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Kristalose Agreement, dated
    April&#160;7, 2006, by and among Inalco Biochemicals, Inc.,
    Inalco S.p.A., and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.10&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">License Agreement, dated
    May&#160;28, 1999, by and between Vanderbilt University and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.11#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between A.J. Kazimi and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.12#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between Jean W. Marstiller and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.13#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between Leo Pavliv and Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.14#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between J. William Hix and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.15#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Employment Agreement effective as
    of January&#160;1, 2007 by and between David L. Lowrance and
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.16*&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Second Amended and Restated Loan
    Agreement by and between Cumberland Pharmaceuticals Inc. and
    Bank of America, N.A., dated April&#160;6, 2006.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.17#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">1999 Stock Option Plan of
    Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.18*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">2007 Long-Term Incentive
    Compensation Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.19*#
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">2007&#160;Directors&#146;
    Compensation Plan of Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.20
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Form of Indemnification Agreement
    between Cumberland Pharmaceuticals Inc. and all members of its
    Board of Directors.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.21&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Lease Agreement, dated
    September&#160;10, 2005, by and between Nashville Hines
    Development, LLC and Cumberland Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.22*&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Sublease Agreement, dated
    December&#160;14, 2006, by and between Robert W.
    Baird&#160;&#38; Co. Incorporated and Cumberland Pharmaceuticals
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.23&#134;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Amended and Restated Lease
    Agreement, dated November&#160;11, 2004, by and between The
    Gateway to Nashville LLC and Cumberland Emerging Technologies,
    Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">10.24
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">First Amendment to Amended and
    Restated Lease Agreement, dated August&#160;23, 2005, by and
    between The Gateway to Nashville LLC and Cumberland Emerging
    Technologies, Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">21
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Subsidiaries of Cumberland
    Pharmaceuticals Inc.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">23.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent of KPMG LLP.
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">23.2*
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Consent of Adams and Reese, LLP
    (contained in Exhibit&#160;5).
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">24
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Powers of Attorney (contained on
    the signature page hereto).
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    *&#160;
</TD>
    <TD align="left">    To be filed by amendment.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    #&#160;
</TD>
    <TD align="left">    Indicates a management contract or compensatory plan.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#134;&#160;
</TD>
    <TD align="left">    Confidential treatment has been requested for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>g06286exv3w1.htm
<DESCRIPTION>EX-3.1 SECOND AMENDED AND RESTATED CHARTER OF CUMBERLAND PHARMACEUTICALS INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 3.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED CHARTER</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;), a corporation organized and existing under
and by virtue of the Tennessee Business Corporation Act, as amended (the &#147;Act&#148;), does hereby
certify:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I.&nbsp;That the Company was incorporated upon the filing of its charter (the &#147;Original
Charter&#148;) with the Secretary of State of the State of Tennessee (the &#147;Tennessee Secretary of
State&#148;) on January&nbsp;7, 1999.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;II.&nbsp;That the Company filed an Amended and Restated Charter (the &#147;Restated Charter&#148;) with the
Tennessee Secretary of State on October&nbsp;12, 2000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;III. That the Company filed a Charter Amendment to the Restated Charter with the Tennessee
Secretary of State on June&nbsp;5, 2003 that changed the principal office address and registered office
address of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IV.&nbsp;That the Board of Directors of the Company (the &#147;Board of Directors&#148;) proposed and
recommended, on January&nbsp;16, 2007, the amendments (the &#147;Amendments&#148;) to the shareholders of the
Company (the &#147;Shareholders) included in the Second Amended and Restated Charter (the &#147;Second
Restated Charter&#148;) set forth below as the charter of the Company (the &#147;Charter&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;V.&nbsp;That the Shareholders adopted, on April&nbsp;18, 2007, the Amendments included in the Second
Restated Charter as the Company&#146;s Charter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VI.&nbsp;That the Charter has been duly adopted in accordance with Sections&nbsp;48-20-103 and 48-20-107
of the Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The adopted Restated Charter of Cumberland Pharmaceuticals Inc. is as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The name of the Company is Cumberland Pharmaceuticals Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Company is for profit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The duration of the Company is perpetual.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The street address of the Company&#146;s principal office is:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">2525 West End Avenue, Suite&nbsp;950<BR>
Nashville, Tennessee 37203<BR>
County of Davidson

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;(a)&nbsp;The name of the Company&#146;s initial registered agent is A.J. Kazimi.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The street address of the Company&#146;s initial
registered office in Tennessee is:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">2525 West End Avenue, Suite&nbsp;950<BR>
Nashville, Tennessee 37203<BR>
County of Davidson

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The name and address of the incorporator is:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">Martin S. Brown, Jr.<BR>
Adams and Reese LLP<BR>
424 Church Street, Suite&nbsp;2800<BR>
Nashville, Tennessee 37219

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;The purpose for which the Company is organized is to engage in any lawful act or activity
for which corporations may be organized under the Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;The maximum number of shares of stock the Company is authorized to issue is (i)&nbsp;One Hundred
Million (100,000,000) shares of common stock, no par value per share (&#147;Common Stock&#148;), (ii)&nbsp;Twenty
Million (20,000,000) shares of preferred stock, no par value per share (&#147;Preferred Stock&#148;) and
(iii)&nbsp;Three Million (3,000,000) shares of Series&nbsp;A Preferred Stock, no par value per share (&#147;Series
A Preferred Stock&#148; and collectively with Common Stock and Preferred Stock, the &#147;Capital Stock&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of each of the classes of stock of the Company and a statement
of the powers, preferences and rights of such stock, and the qualifications, limitations and
restrictions thereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;<U>Common Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Voting Rights</U>. Each holder of Common Stock shall be entitled to one vote per share
of Common Stock on all matters to be voted on by the shareholders of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Dividends and Rights Upon Liquidation</U>. Dividends shall be declared and paid on
Common Stock from funds lawfully available therefore as and when determined by the Board of
Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock.
In the event of a voluntary or involuntary dissolution or liquidation of the Company, after
distribution in full of the preferential amounts, if any, to be distributed to the holders of
Preferred Stock, the holders of Common Stock shall, subject to the additional rights, if any, of
the holders of Preferred Stock fixed in accordance with the provisions of this Charter, be entitled
to receive all of the remaining assets of the Company, tangible and intangible, of whatever kind
available for distribution to shareholders ratably in proportion to the number of shares of Common
Stock held by them respectively.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;<U>Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Authorization and Issuance</U>. Twenty million (20,000,000) shares of Preferred Stock,
no par value per share. Shares of Preferred Stock may be issued from time to time in one or more
classes or series, each such class or series to be so designated as to distinguish the shares
thereof from the shares of all other series and classes. The Board of Directors is hereby vested
with the authority to divide Preferred Stock into classes or series and to fix and determine the
relative rights, preferences, qualifications and limitations of the shares of any class or series
so established.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;<U>Series&nbsp;A Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Designation</U>. There shall be a series of Preferred Stock designated as
Series&nbsp;A Convertible Preferred Stock (the &#147;Series&nbsp;A Preferred Stock&#148;). The number of shares
initially constituting the Series&nbsp;A Preferred Stock shall be Three Million (3,000,000), which
number may be decreased by the Board of Directors without a vote of shareholders; <U>provided,
however</U>, that such number may not be decreased below the number of then-outstanding shares of
Series&nbsp;A Preferred Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Voting Rights</U>. Except as otherwise provided by law, each holder of issued and
outstanding Series&nbsp;A Preferred Stock shall be entitled to vote on each matter on which the
shareholders of the Company are entitled to vote. Each share of Series&nbsp;A Preferred Stock shall
have the number of votes equal to the number of shares of Common Stock into which such share is
convertible under Section&nbsp;5 hereof on the applicable record date for the meeting at which a vote is
taken or as of the date on which any written consent of shareholders is being solicited, and such
number of shares of Common Stock shall be included in determining the number of shares voting or
entitled to voted on any such matter. Except as otherwise required by law and except for any
matter on which holders of Series&nbsp;A Preferred Stock have the right to vote separately as a class
either hereunder or under applicable law, holders of Series&nbsp;A Preferred Stock shall vote together
as a single class with holders of Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Dividends</U>. No dividend may be declared or paid or set aside for payment to, or
other distribution made upon, the Common Stock or on any other stock of the Company ranking junior
to or on parity with the Series&nbsp;A Preferred Stock as to dividends unless the same dividends are
declared and paid (or declared and a sum sufficient for the payment thereof set apart for such
payment) with respect to the Series&nbsp;A Preferred Stock. The amount of such dividends payable to the
holders of the Series&nbsp;A Preferred Stock shall equal the amount that would be payable with respect
to such Series&nbsp;A Preferred Stock had it been converted into Common Stock in accordance with the
terms and provisions of Section&nbsp;5 hereof as of the date of such dividend.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Liquidation</U>. In the event of any liquidation, dissolution, or winding up of the
Company, whether voluntary or involuntary, holders of each share of Series&nbsp;A Preferred Stock shall
be entitled to be paid out of the assets of the Company available for distribution to holders of
the Company&#146;s capital stock an amount per share equal to Three Dollars and Twenty-Five Cents
($3.25) (the &#147;Preference Amount&#148;). The Preference Amount shall be paid to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">holders of the Series&nbsp;A Preferred Stock with respect to such liquidation, dissolution, or winding
up before any sums shall be paid or any assets distributed to the holders of shares of Common Stock
or to the holders of any other stock of the Company ranking junior to the Series&nbsp;A Preferred Stock
as to liquidation preferences, but after the payment of liquidation amounts to the holders of any
other stock of the Company ranking senior to the Series&nbsp;A Preferred Stock as to liquidation
preferences. If the assets of the Company shall be insufficient to permit the payment in full of
the Preference Amount to the holders of the Series&nbsp;A Preferred Stock, then the entire assets of the
Company available for such distribution shall be distributed ratably among the holders of the
Series&nbsp;A Preferred Stock and the holders of any other class of stock of the Company ranking on a
parity with the Senior A Preferred Stock as to liquidation preferences. After the Preference
Amount shall have been paid in full to the holders of the Series&nbsp;A Preferred Stock (or funds
necessary for such payment shall have been set aside by the Company in trust for the account of
holders of the Series&nbsp;A Preferred Stock so as to be available for such payment), the holders of the
Series&nbsp;A Preferred Stock shall not be entitled to participate in any further distributions by the
Company and shall have no further rights or claims to any of the assets of the Company. Whenever
the Preference Amount shall be paid in property other than cash, the value of such distribution
shall be the fair value thereof determined in good faith by the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In case the outstanding shares of Series&nbsp;A Preferred Stock shall be subdivided into a greater
number of shares of Series&nbsp;A Preferred Stock or, conversely, in case outstanding shares of Series&nbsp;A
Preferred Stock shall be combined into a smaller number of shares of Series&nbsp;A Preferred Stock, the
Preference Amount in effect immediately prior to each such subdivision or combination shall be
adjusted simultaneously with the effectiveness of such subdivision or combination in such a manner
so as to equate the amount to be paid to the holders of the subdivided or combined shares of Series
A Preferred Stock upon liquidation with the amount that would have been paid to the holders of
Series&nbsp;A Preferred Stock upon liquidation absent the subdivision or combination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Conversion of Series&nbsp;A Preferred Stock.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Right to Convert and Conversion Ratio; Anti-Dilution</U>. At any time and from
time to time, any holder of Series&nbsp;A Preferred Stock may convert all or any portion of the
Series&nbsp;A Preferred Stock held by such holder into fully paid and nonassessable shares of
Common Stock. The conversion of Series&nbsp;A Preferred Stock shall be automatic upon completion
of a Public Offering or the approval by the shareholders of the Company of a Qualified Sale
(as defined hereinafter). As used herein, a &#147;Public Offering&#148; shall be defined as an
underwritten public offering of the Company&#146;s equity securities pursuant to an effective
registration statement filed with the United States Securities and Exchange Commission. As
used herein, a &#147;Qualified Sale&#148; shall be defined as a sale (whether in the form of a merger,
consolidation or sale of substantially all assets) of the Company in
which the holders of shares of Series&nbsp;A Preferred Stock would receive at least Three Dollars and Twenty-Five
Cents ($3.25) for each share of Series&nbsp;A Preferred Stock or for that number of shares of
Common Stock into which each share of Series&nbsp;A Preferred Stock is convertible, as the case
may be. The conversion of any shares of Series&nbsp;A Preferred Stock shall be conditioned upon
the completion of the Public Offering or Qualified Sale, in which case such conversion shall
not be effective
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">until the consummation of the Public Offering or Qualified Sale. Each share of Series&nbsp;A
Preferred Stock shall be converted (the &#147;Conversion&#148;) into one (1)&nbsp;share of Common Stock
(the &#147;Conversion Ratio&#148;). Upon the happening of an Extraordinary Capital Stock Event (as
hereinafter defined), the Conversion Ratio, simultaneously with the happening of such
Extraordinary Capital Stock Event, shall be appropriately adjusted such that the
proportionate interest of the holders of the Series&nbsp;A Preferred Stock in the Common Stock
upon Conversion shall be maintained. The Conversion Ratio, as so adjusted, shall be
readjusted upon the happening of any successive Extraordinary Capital Stock Event(s).
&#147;Extraordinary Capital Stock Event&#148; shall mean (w)&nbsp;the issuance, other than through a Public
Offering or Qualified Sale of additional shares of Capital Stock, or other securities
convertible into shares of Capital Stock, without consideration or for a consideration per
share less than Three Dollars and Twenty-Five Cents ($3.25),
(x)&nbsp;the issuance of additional shares of Capital Stock as a dividend or other distribution on all outstanding shares of
Capital Stock, (y)&nbsp;a stock split or subdivision of outstanding shares of Capital Stock into
a greater number of shares of Capital Stock, or (z)&nbsp;a reverse stock split or combination of
outstanding shares of Capital Stock into a smaller number of shares of Capital Stock. If the
Conversion Ratio is adjusted, the Company shall file at its principal executive offices and
shall mail within thirty (30)&nbsp;days after the date upon which such adjustment shall be made,
by registered or certified mail to each registered holder of shares of Series&nbsp;A Preferred
Stock, a statement signed by a responsible financial officer of the Company specifying the
adjusted Conversion Ratio and setting forth in reasonable detail the method of calculation
of such adjustment and the facts requiring the adjustment and upon which the calculation is
based.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <U>Procedure for Conversion</U>. The certificate(s) for shares of Series&nbsp;A
Preferred Stock surrendered for Conversion shall be accompanied by proper assignment thereof
to the Company or in blank. As promptly as practicable after delivery of the shares to the
Company, the Company shall issue and deliver to the holder of the shares of Series&nbsp;A
Preferred Stock being converted, or on its written order, such certificate(s) as it may
request of the number of whole shares of Common Stock issuable upon
the Conversion of such shares of Series&nbsp;A Preferred Stock in accordance with the provisions of this Section&nbsp;5(ii),
and cash, as provided in Section&nbsp;5(iii) herein, in respect of any fraction of a share of
Common Stock issuable upon such Conversion. Such Conversion shall be deemed to have been
effected immediately prior to the close of business on the date of the Conversion (the
&#147;Conversion Date&#148;), and at such time the rights of the
holder as holder of the converted shares of Series&nbsp;A Preferred Stock shall cease and the person(s) in whose name(s) any
certificate(s) for shares of Common Stock shall be issuable upon such Conversion shall be
deemed to have become the holder(s) of record of the shares of Common Stock represented
thereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <U>Cash in Lieu of Fractional Shares</U>. No fractional shares of Common Stock
shall be issued upon the Conversion of shares of Series&nbsp;A Preferred Stock. Instead of any
fractional shares of Common Stock that otherwise would be issuable upon Conversion of Series
A Preferred Stock, the Company shall pay to the holder of the shares of Series&nbsp;A Preferred
Stock that were converted a cash adjustment in respect of such fractional shares in an
amount equal to the same fraction of the fair market value price per share of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Common Stock (as determined in a reasonable manner prescribed by the Board of Directors) at
the close of business on the Conversion Date. The determination as to whether any
fractional shares are issuable shall be based upon the total number of shares of Series&nbsp;A
Preferred Stock being converted at any one time by any holder thereof, not upon each share
of Series&nbsp;A Preferred Stock being converted.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <U>Reservation of Common Stock</U>. The Company shall at all times reserve and
keep available out of its authorized but unissued shares of Common Stock, solely for the
purpose of effecting the Conversion of the shares of the Series&nbsp;A Preferred Stock, such
number of its shares of Common Stock as from time to time shall be sufficient to effect the
Conversion of all outstanding shares of the Series&nbsp;A Preferred Stock, and if at any time the
number of authorized but unissued shares of Common Stock shall not be sufficient to effect
the Conversion of all then outstanding shares of the Series&nbsp;A Preferred Stock, the Company
shall take such corporate action as may be necessary to increase its
authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <U>No Charge for Conversion</U>. The issuance of certificates for shares of
Common Stock upon the Conversion of any shares of the Series&nbsp;A Preferred Stock shall be made
without charge to the converting holder for such certificates or for any tax in respect of
the issuance of such certificates, and such certificates shall be issued in the name of, or
in such names as may be directed by, the holder of the Series&nbsp;A Preferred Stock; provided,
however, that the Company shall not be required to pay any taxes or other governmental
charges which may be payable in respect of any transfer involved in the issuance and
delivery of any such certificate in a name other than that of the holder of the Series&nbsp;A
Preferred Stock, and the Company shall not be required to issue or deliver such certificates
unless or until the person or persons requesting the issuance thereof shall have paid to the
Company the amount of such tax or other governmental charge or shall have established to the
reasonable satisfaction of the Company that such tax or other governmental charge has been
paid or provided for. The Company may also require, as a condition to the issuance and
delivery of any such certificate, an opinion of counsel acceptable to the Company to the
effect that the proposed transfer does not require registration under federal or any state
securities law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <U>Notices of Record Date</U>. In the event of any:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. taking by the Company of a record of the holders of any class of securities
for the purpose of determining the holders thereof who are entitled to receive any
dividend or other distribution, or any right to subscribe for, purchase, or
otherwise acquire any shares of stock of any class or any other securities or
property, or to receive any other right;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. capital reorganization of the Company, any reclassification or
recapitalization of the capital stock of the Company, a merger, or a sale; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. voluntary or involuntary dissolution, liquidation, or winding up the
Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">then and in each such event the Company shall mail or cause to be mailed to each
holder of Series&nbsp;A Preferred Stock a notice specifying (i)&nbsp;the record date for such
dividend, distribution, or right and a description of such dividend, distribution,
or right, (ii)&nbsp;the date on which any such reorganization, reclassification,
recapitalization, merger, or sale is expected to become effective, and (iii)&nbsp;the
time, if any, that is to be fixed, as to when the holders of record of Common Stock
(or other securities) shall be entitled to exchange their shares of Common Stock (or
other securities) for securities or other property deliverable upon such
reorganization, reclassification, recapitalization, merger, sale, dissolution,
liquidation, or winding up. Such notice shall be mailed at least ten (10)&nbsp;days
prior to the date specified in such notice on which such action is to be taken.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <U>Dividend Payment Upon Conversion</U>. At the date of any Conversion, the
Company shall pay to the holder of record of any Series&nbsp;A Preferred Stock surrendered for or
subject to Conversion any cumulated but unpaid dividends on the shares so converted. This
payment shall be made by the Company in cash or in marketable securities of the Company or
another issuer having a fair market value on the date of payment in an amount equal to the
cumulated dividend so paid. For purposes hereof, &#147;marketable securities&#148; shall mean equity
securities of an issuer which have been registered under the Securities Exchange Act of
1934, as amended, and which are listed on a national securities exchange or included in an
interdealer quotation system which reports last sale information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) <U>No Reissuance of Series&nbsp;A Preferred Stock</U>. No share(s) of Series&nbsp;A
Preferred Stock acquired by the Company by reason of Conversion or otherwise shall be
reissued, and, upon Conversion, all such shares shall be canceled, retired, and eliminated
from the shares that the Company shall be authorized to issue. The Company from time to
time may take such appropriate corporate action as may be necessary to reduce the authorized
number of shares of the Series&nbsp;A Preferred Stock accordingly.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) <U>No Impairment</U>. The Company will not, by amendment of its Charter or
through any reorganization, transfer of assets, consolidation, merger, share exchange,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of the Series&nbsp;A Preferred Stock set
forth herein, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the holders of the Series&nbsp;A Preferred Stock against dilution or other
impairment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;The management of the business and the conduct of the affairs of the Company shall be
vested in its Board of Directors. The number of directors which shall constitute the whole Board of
Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the
Board of Directors.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II,
and Class&nbsp;III, respectively. Directors shall be assigned to each class in accordance with one or
more resolutions adopted by the Board of Directors. At the first annual meeting of shareholders
following the date of this Charter (the &#147;Effective Date&#148;), the term of office of the Class&nbsp;I
directors shall expire and the Class&nbsp;I directors shall be elected for a full term of three years.
At the second annual meeting of shareholders following the Effective Date, the term of office of
the Class&nbsp;II directors shall expire and the Class&nbsp;II directors shall be elected for a full term of
three years. At the third annual meeting of shareholders following the Effective Date, the term of
office of the Class&nbsp;III directors shall expire and the Class&nbsp;III directors shall be elected for a
full term of three years. At each succeeding annual meeting of shareholders, directors shall be
elected for a full term of three years to succeed the directors of the class whose terms expire at
such annual meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing provisions of this Paragraph&nbsp;9, each director shall serve until
his or her successor is duly elected and qualified or until his or her death, resignation or
removal. No decrease in the number of directors constituting the Board of Directors shall shorten
the term of any incumbent director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any vacancies on the Board of Directors resulting from death, resignation, disqualification,
removal or other causes shall be filled by the affirmative vote of a majority of the remaining
directors then in office, even though less than a quorum of the Board of Directors. Newly created
directorships resulting from any increase in the number of directors shall, unless the Board of
Directors determines by resolution that any such newly created directorship shall be filled by the
shareholders, be filled only by the affirmative vote of the directors then in office, even though
less than a quorum of the Board of Directors. Any director elected in accordance with the preceding
sentence shall hold office for the remainder of the full term of the class of directors in which
the new directorship was created or the vacancy occurred and until such director&#146;s successor shall
have been elected and qualified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in limitation of the powers conferred by the Act, the Board of
Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;The Company shall indemnify every person who is or was a party or is or was threatened to
be made a party to any action, suit, or proceeding, whether civil, criminal, administrative, or
investigative, by reason of the fact that he or she is or was a director or officer or is or was
serving at the request of the Company as a director or officer, against all expense, liability, and
loss (including counsel fees, judgments, fines, ERISA excise taxes, penalties, and amounts paid in
settlement) actually and reasonably incurred or suffered in connection with such action, suit, or
proceeding, to the fullest extent permitted by applicable law, as in effect on the date hereof and
as hereafter amended. Such indemnification may include advancement of expenses in advance of final
disposition of such action, suit, or proceeding, subject to the provision of any applicable
statute.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indemnification and advancement of expenses provisions of this Paragraph&nbsp;10 shall not be
exclusive of any other right that any person (and his or her heirs, executors, and administrators)
may have or hereafter acquire under any statute, this Charter, the Company&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bylaws, resolution adopted by the shareholders, resolution adopted by the Board of Directors,
agreement, or insurance, purchased by the Company or otherwise, both as to action in his or her
official capacity and as to action in another capacity. The Company is hereby authorized to
provide for indemnification and advancement of expenses through its Bylaws, resolution of
shareholders, resolution of the Board of Directors, or agreement, in addition to that provided by
this Charter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;To the fullest extent permitted by the Act as in effect on the date hereof and as
hereafter amended from time to time, a director of the Company shall not be liable to the Company
or its shareholders for monetary damages for breach of fiduciary duty as a director. If the Act or
any successor statute is amended after adoption of this provision to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a
director of the Company shall be eliminated or limited to the fullest extent permitted by the Act,
as so amended from time to time. Any repeal or modification of this Paragraph&nbsp;11 by the
shareholders of the Company shall not adversely affect any right or protection of a director of the
Company existing at the time of such repeal or modification with respect to events occurring prior
to such time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated this <U>23</U> day of <U>April</U>, 2007.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                     /s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">A.J. Kazimi, Chairman of the Board of</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Directors and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>g06286exv3w2.htm
<DESCRIPTION>EX-3.2 AMENDED AND RESTATED BYLAWS OF CUMBERLAND PHARMACEUTICALS INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 3.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED BYLAWS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE I</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">NAME
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affairs of the corporation shall be conducted using the name Cumberland Pharmaceuticals
Inc., or such other name or names as the board of directors may from time to time authorize.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE II</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MEETINGS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. <U>Annual Meetings</U>. An annual meeting of shareholders for the purposes of
electing directors and transacting such other business as may properly come before the meeting
shall be held at such date and time as shall be designated from time to time by the Board of
Directors, the Chairman of the Board, or the Chief Executive.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. <U>Special Meetings</U>. A special meeting of shareholders may be called for any
purpose or purposes by the Board of Directors, and shall be called by the Chairman of the Board or
the Chief Executive whenever shareholders owning at least thirty three (33)&nbsp;percent of the votes
entitled to be cast on any issue proposed to be considered at a proposed special meeting sign,
date, and deliver to the Secretary one (1)&nbsp;or more written demands for the meeting describing the
purpose or purposes for which the meeting is to be held, including all statements necessary to make
any statement of such purpose not incomplete, false or misleading, and include any other
information specified in the rules and regulations of the Securities and Exchange Commission and
which written request shall be accompanied by a certified check for fifty thousand dollars
($50,000) payable to the Company to help cover the Company&#146;s expenses in connection with such
meeting, including the preparation of proxy materials or information statements and the mailing of
notices and proxy materials to shareholders. Only business within the purpose or purposes
described in the meeting notice may be conducted at a special shareholders&#146; meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. <U>Place of Meetings</U>. Annual and special meetings of shareholders shall be
held at the principal office of the corporation or at such other place, either within or without
the State of Tennessee, as the Board of Directors, the Chairman of the Board, or the Chief
Executive shall designate.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4. <U>Notice of Meetings</U>. Notice stating the date, time, and place of the
meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is
being called, shall be provided to each shareholder entitled to vote at such meeting no fewer than
ten (10)&nbsp;days nor more than two (2)&nbsp;months before the date of such meeting. In the case of special
meetings of shareholders, the notice of meeting shall include the purpose or purposes for which the
meeting is being called. Notice may be in writing, or oral if reasonable in the circumstance, and
notice shall be deemed provided when received or, if mailed, when deposited in the United States
mail addressed to the shareholder at his or her address as it appears in the Corporation&#146;s current
record of shareholders, with first class postage affixed thereon. When a meeting is adjourned to
another date, time, or place, it shall not be necessary to provide any notice of the adjourned
meeting if the new date, time, or place to which the meeting is adjourned is announced at the
meeting at which the adjournment is taken, and at the adjourned meeting any business may be
transacted that might have been transacted at the original meeting. If after the adjournment,
however, the Board of Directors fixes a new record date for the adjourned meeting pursuant to
Section&nbsp;8 of this Article&nbsp;II, a new notice of the adjourned meeting shall be provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5. <U>Waiver of Notice</U>. A shareholder may waive in writing any notice required
by these Bylaws, provided that the waiver must be signed by the shareholder entitled to the notice
and must be delivered to the corporation for inclusion in the minutes or for filing with the
corporate records. A shareholder&#146;s attendance at a meeting (i)&nbsp;waives objection to lack of notice
or defective notice of the meeting unless the shareholder at the beginning of the meeting (or
promptly upon his or her arrival) objects to holding the meeting or transacting business at the
meeting and (ii)&nbsp;waives objection to consideration of a particular matter at the meeting that is
not within the purpose or purposes described in the meeting notice, unless the shareholder objects
to considering the matter when it is presented.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6. <U>Quorum and Voting</U>. The holders of a majority of shares entitled to vote,
whether present in person or represented by proxy, shall constitute a quorum. Once a share is
represented for any purpose at a meeting, the holder of such share is deemed present for quorum
purposes for the remainder of the meeting and for any adjournment of that meeting, unless a new
record date is or must be set for the adjourned meeting. A meeting may be adjourned despite the
absence of a quorum. If a quorum exists, action on a matter, other than the election of directors,
is approved by the shareholders if the votes cast favoring the action exceeds the votes cast
opposing the action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7. <U>Proxies</U>. A shareholder may vote his or her shares in person or by proxy
and may appoint a proxy to vote or otherwise act for him or her by signing a proxy or other
appointment form, either personally or by his or her attorney-in-fact. An appointment of a proxy
is effective when received by the Secretary or other officer or agent of the corporation authorized
to tabulate votes. An appointment is valid for eleven (11)&nbsp;months unless another period is
expressly provided in the proxy or other appointment form. An appointment of a proxy is revocable
by the shareholder unless the proxy or other appointment form conspicuously states that it is
irrevocable and the appointment is coupled with an interest, as provided in the Tennessee Business
Corporation Act.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8. <U>Action Without a Meeting</U>. Any action required or permitted to be taken at
a meeting of the shareholders may be taken without a meeting. If all shareholders entitled to vote
on the action consent to taking such action without a meeting, the affirmative vote of the number
of shares that would be necessary to authorize or take such action at a meeting is the act of the
shareholders. The action must be evidenced by one (1)&nbsp;or more written consents describing the
action taken, signed by each shareholder entitled to vote on the action in one (1)&nbsp;or more
counterparts, and indicating each shareholder&#146;s vote or abstention on the action, and such written
consent or consents must be delivered to the corporation for inclusion in the minutes or for filing
with the corporate records. A consent effected as provided in this section shall have the effect
of a meeting vote and may be described as such in any document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9. <U>Record Date</U>. For the purpose of determining the shareholders entitled to
notice of or entitled to vote at any meeting of shareholders, or for the purpose of determining the
shareholders entitled to receive payment of any dividend, or in order to make a determination of
shareholders for any other purpose, the Board of Directors may fix a future date as the record date
for such purpose, provided that such record date shall not be more than seventy (70)&nbsp;days before
the meeting or action requiring a determination of shareholders. If no record date is fixed by the
Board of Directors: (i)&nbsp;the record date shall be at the close of business on the day next
preceding the day on which notice of the meeting is given, or, if notice is waived, at the close of
business on the eleventh day next preceding the day on which such meeting is held; (ii)&nbsp;the record
date for the determination of shareholders entitled to consent to an action in writing without a
meeting shall be at the close of business on the eleventh day next preceding the date on which the
first shareholder, being entitled so to do, signs such a consent; and (iii)&nbsp;the record date for the
determination of shareholders for any other purpose shall be at the close of business on the date
on which the Board of Directors adopts the resolution or resolutions relating thereto. A
determination of shareholders entitled to notice of or to vote at a shareholders&#146; meeting is
effective for any adjournment of the meeting unless the Board of Directors fixes a new record date,
which it shall do if the meeting is adjourned to a date more than four (4)&nbsp;months after the date
fixed for the original meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10. <U>List of Shareholders</U>. After a record date has been fixed for a meeting,
the Secretary shall prepare or cause to be prepared a complete list of the shareholders entitled to
notice of the meeting, arranged in alphabetical order by class of stock and series, if any, and
showing the address of each shareholder and the number of shares registered in the name of the
shareholder. The shareholders&#146; list shall be available for inspection by any shareholder,
beginning two (2)&nbsp;business days after notice of the meeting is given for which the list was
prepared and continuing through the meeting, at the Corporation&#146;s principal office or at the place
identified in the meeting notice in the city where the meeting will be held. If the right to vote
at any meeting is challenged, the person presiding may rely on such list as evidence of the right
of the person challenged to vote at such meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11. <U>Presiding Officer and Secretary</U>. Meetings of the shareholders shall be
presided over by the Chairman, or if the Chairman is not present or if the Corporation shall not
have a Chairman, by the Chief Executive or the President, or if neither the Chairman, Chief
Executive, President is present, by a chairman chosen by the Board of Directors. The Secretary or,
in the Secretary&#146;s absence, an Assistant Secretary shall act as secretary of every meeting, but if
neither the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Secretary nor an Assistant Secretary is present, a majority of the shareholders entitled to
vote at such meeting shall choose any person present to act as secretary of the meeting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12. <U>Notice of Nominations</U>. Nominations for the election of directors may be
made by the Board of Directors or a committee appointed by the Board of Directors authorized to
make such nominations or by any shareholder entitled to vote in the election of directors
generally. Any such shareholder nomination may be made, however, only if written notice of such
nomination has been given, either by personal delivery or the United States mail, postage prepaid,
to the Secretary of the Corporation not later than (a)&nbsp;with respect to an election to be held at an
annual meeting of shareholders, one hundred twenty days (120)&nbsp;in advance of the anniversary date of
the proxy statement for the previous year&#146;s annual meeting, and (b)&nbsp;with respect to an election to
be held at a special meeting of shareholders for the election of directors called other than by
written request of a shareholder, the close of business on the tenth (10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day
following the date on which notice of such meeting is first given to shareholders, and (c)&nbsp;in the
case of a special meeting of shareholders duly called upon the written request of a shareholder to
fill a vacancy or vacancies (then existing or proposed to be created by removal at such meeting),
within ten business days of such written request. In the case of any nomination by the Board of
Directors or a committee appointed by the Board of Directors authorized to make such nominations,
compliance with the proxy rules of the Securities and Exchange Commission shall constitute
compliance with the notice provisions of the preceding sentence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the case of any nomination by a shareholder, each such notice shall set forth: (a)&nbsp;as to
each person whom the shareholder proposes to nominate for election or re-election as a director,
(i)&nbsp;the name, age, business address, and residence address of such person, (ii)&nbsp;the principal
occupation or employment of such person, (iii)&nbsp;the class and number of shares of the Corporation
which are beneficially owned by such person, and (iv)&nbsp;any other information relating to such person
that is required to be disclosed in solicitations of proxies with respect to nominees for election
as directors, pursuant to Regulation&nbsp;14A under the Securities Exchange Act of 1934, as amended
(including without limitation such person&#146;s written consent to being named in the proxy statement
as a nominee and to serving as a director, if elected); and (b)&nbsp;as to the shareholder giving the
notice (i)&nbsp;the name and address, as they appear on the Corporation&#146;s books, of such shareholder,
and (ii)&nbsp;the class and number of shares of the Corporation which are beneficially owned by such
shareholder; and (c)&nbsp;a description of all arrangements or understandings between the shareholder
and each nominee and any other person or persons (naming such person or persons) pursuant to which
the nomination or nominations are to be made by the shareholder. The presiding officer of the
meeting may refuse to acknowledge the nomination of any person not made in compliance with the
foregoing procedure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13. <U>Notice of New Business</U>. At an annual meeting of the shareholders only such
new business shall be conducted, and only such proposals shall be acted upon, as have been properly
brought before the meeting. To be properly brought before the annual meeting such new business must
be (a)&nbsp;specified in the notice of meeting (or any supplement thereto) given by or at the direction
of the Board of Directors, (b)&nbsp;otherwise properly brought before the meeting by or at the direction
of the Board of Directors, or (c)&nbsp;otherwise properly brought before the meeting by a shareholder.
For a proposal to be properly brought before an annual meeting by a shareholder, the shareholder
must have given timely notice thereof in writing to the Secretary of the Corporation, and the
proposal and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the shareholder must comply with Rule&nbsp;14a-8 under the Securities Exchange Act of 1934. To be
timely, a shareholder&#146;s notice must be delivered to or mailed and received at the principal
executive offices of the Corporation within the time limits specified by Rule&nbsp;14a-8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A shareholder&#146;s notice to the Secretary shall set forth as to each matter the shareholder
proposes to bring before the annual meeting (a)&nbsp;a brief description of the proposal desired to be
brought before the annual meeting and the reasons for conducting such business at the annual
meeting, (b)&nbsp;the name and address, as they appear on the Corporation&#146;s books, of the shareholder
proposing such business, (c)&nbsp;the class and number of shares of the Corporation which are
beneficially owned by the shareholder, and (d)&nbsp;any financial interest of the shareholder in such
proposal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at an
annual meeting except in accordance with the procedures set forth in this Section&nbsp;13. The presiding
officer of the meeting shall, if the facts warrant, determine and declare to the meeting that new
business or any shareholder proposal was not properly brought before the meeting in accordance with
the provisions of this Section&nbsp;13, and if he or she should so determine, he or she shall so declare
to the meeting and any such business or proposal not properly brought before the meeting shall not
be acted upon at the meeting. This provision shall not prevent the consideration and approval or
disapproval at the annual meeting of reports of officers, directors and committees, but in
connection with such reports, no new business shall be acted upon at such annual meeting unless
stated and filed as herein provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;14. <U>Conduct of Meetings</U>. Meetings of the shareholders generally shall follow
accepted rules of parliamentary procedure subject to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The presiding officer of the meeting shall have absolute authority over the matters of
procedure, and there shall be no appeal from the ruling of the presiding officer. If, in his or her
absolute discretion, the presiding officer deems it advisable to dispense with the rules of
parliamentary procedure as to any meeting of shareholders or part thereof, he or she shall so state
and shall state the rules under which the meeting or appropriate part thereof shall be conducted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If disorder should arise which prevents the continuation of the legitimate business of the
meeting, the presiding officer may quit the chair and announce the adjournment of the meeting, and
upon so doing, the meeting will immediately be adjourned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The presiding officer may ask or require that anyone not a bona fide shareholder or proxy
leave the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The resolution or motion shall be considered for vote only if proposed by a shareholder or
a duly authorized proxy and seconded by a shareholder or duly authorized proxy other than the
individual who proposed the resolution or motion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except as the President, Chief Executive, or Chairman may permit, no matter shall be
presented to the meeting which has not been submitted for inclusion in the agenda at least thirty
(30)&nbsp;days prior to the meeting.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE III</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">DIRECTORS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. <U>Management</U>. All corporate powers shall be exercised by or under the
authority of, and the business and affairs of the corporation managed under the direction of, the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. <U>Number</U>. The number of directors of the corporation shall be as fixed from
time to time by the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. <U>Election and Term of Office</U>. A plurality of all the votes cast at a
meeting of shareholders duly called and at which a quorum is present shall be sufficient to elect a
Director. Each share may be voted for as many individuals as there are Directors to be elected and
for whose election the share is entitled to be voted. Each director, including a director elected
to fill a vacancy, shall hold office until the next annual meeting of shareholders and until his or
her successor is elected and qualified, or until his or her earlier death, resignation, or removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as prohibited by law or by the Charter, any nominee for election as a Director at a
meeting of shareholders duly called and at which a quorum is present, in an uncontested election,
who receives a greater number of votes cast &#147;withheld&#148; for his or her election than &#147;for&#148; such
election (a &#147;Majority Withhold Vote&#148;) shall tender his or her resignation to the Board of
Directors, or an applicable committee of the Board, for consideration following certification of
such vote.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall promptly consider the resignation offer, and a range of possible
responses based on any facts or circumstances it considers relevant. The independent Directors who
did not receive a Majority Withhold Vote shall appoint a committee amongst themselves to consider
the resignation offers and will make a determination on how to proceed within 90&nbsp;days following
certification of the stockholder vote. The Company will publicly disclose each such resignation and
the related action taken by the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors expects that any Director whose resignation is under consideration to
abstain from participating in any decision regarding that resignation. However, if the only
Directors who did not receive a Majority Withhold Vote in the same election constitute three or
fewer Directors, all Directors may participate in the action regarding whether to accept the
resignation offers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An election will be deemed to be uncontested if no stockholder provides notice of an intention
to nominate one or more candidates to compete with the Board of Directors&#146; nominees in a Director
election in the manner required by these Bylaws, or if any such shareholders have withdrawn all
such nominations by the day before the mailing of notice of the meeting to shareholders.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A majority of the votes cast at a meeting of shareholders duly called and at which a quorum is
present shall be sufficient to approve any other matter which may properly come before the meeting,
unless more than a majority of the votes cast is required by statute or by the Charter.
Notwithstanding the foregoing, unless otherwise provided by statute or by the Charter, each
outstanding share, regardless of class, shall be entitled to one vote on each matter submitted to a
vote at a meeting of shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4. <U>Resignation</U>. Any director may resign at any time by delivering written
notice to the Board of Directors, the Chairman of the Board, the Chief Executive, or the
corporation. A resignation shall be effective when notice thereof is so delivered, unless the
notice specifies a later effective date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5. <U>Removal</U>. One or more directors may be removed with or without cause by a
vote of the shareholders or with cause by a vote of a majority of the number of directors then
prescribed. A director may be removed only at a meeting called for the purpose, and the notice of
the meeting must state that the purpose, or one (1)&nbsp;of the purposes, of the meeting is the removal
of a director or directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6. <U>Annual and Other Regular Meetings</U>. An annual meeting of the Board of
Directors shall be held on the date of the annual meeting of shareholders, at the place of such
annual meeting of shareholders. The Board of Directors may provide for the holding of other
regular meetings of the Board of Directors, and may fix the dates, times, and places thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7. <U>Special Meetings</U>. A special meeting of the Board of Directors shall be
held whenever called by the Chairman of the Board, the Chief Executive, or any three (3)&nbsp;directors,
at such date, time, and place as may be specified by the person or persons calling the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8. <U>Notice</U>. Notice of an annual or other regular meeting of the Board of
Directors need not be provided. Notice stating the date, time, and place of any special meeting of
the Board of Directors shall be provided to each director in writing, or it may be provided orally
if reasonable in the circumstances, no fewer than two (2)&nbsp;days before such meeting. Notice shall
be deemed provided when received or, if mailed, five (5)&nbsp;days after it is deposited in the United
States mail addressed to the director at his or her address as it appears in the corporation&#146;s
current record of directors, with first class postage affixed thereon. Notice of an adjourned
meeting need not be given if the time and place to which such meeting is adjourned are fixed at the
meeting at which the adjournment is taken and if the period of adjournment does not exceed one (1)
month in any one (1)&nbsp;adjournment. At the adjourned meeting, the Board of Directors may transact
any business that might have been transacted at the original meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9. <U>Waiver of Notice</U>. A director may waive in writing any notice required by
these Bylaws, provided that the waiver must be signed by the director entitled to the notice and
must be filed with the minutes or corporate records. A director&#146;s attendance at or participation
in a meeting waives any required notice to him of the meeting unless the director at the beginning
of the meeting (or promptly upon his or her arrival) objects to holding the meeting or transacting
business at the meeting and does not thereafter vote for or assent to action taken at the meeting.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10. <U>Quorum and Voting</U>. A majority of the number of directors then in office
shall constitute a quorum for the transaction of business, provided that at no time shall a quorum
consist of fewer than one-third (1/3) of the number of directors then prescribed. If a quorum is
present when a vote is taken, the affirmative vote of a majority of directors present is the act of
the Board of Directors. A director who is present at a meeting of the Board of Directors when
corporate action is taken is deemed to have assented to the action taken unless: (i)&nbsp;the director
objects at the beginning of the meeting (or promptly upon his or her arrival) to holding the
meeting or transacting business at the meeting; (ii)&nbsp;the director&#146;s dissent or abstention from the
action taken is entered in the minutes of the meeting; or (iii)&nbsp;the director delivers written
notice of his or her dissent or abstention to the presiding officer of the meeting before its
adjournment or to the corporation immediately after adjournment of the meeting. The right of
dissent or abstention is not available to a director who votes in favor of the action taken.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11. <U>Telephone Meetings</U>. Any or all directors may participate in a meeting of
the Board of Directors by use of conference telephone or similar communications equipment by means
of which all persons participating in the meeting may simultaneously hear each other during the
meeting, and participation in such a meeting shall constitute presence in person at such a meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12. <U>Action Without a Meeting</U>. Any action required or permitted to be taken
at a meeting of the Board of Directors may be taken without a meeting. If all directors consent to
taking such action without a meeting, the affirmative vote of the number of directors that would be
necessary to authorize or take such action at a meeting is the act of the Board of Directors. The
action must be evidenced by one (1)&nbsp;or more written consents describing the action taken, signed by
each director in one (1)&nbsp;or more counterparts, and indicating each director&#146;s vote or abstention on
the action, and such written consent or consents shall be included in the minutes or filed with the
corporate records reflecting the action taken. Any action taken under this section shall be
effective when the last director signs the consent, unless the consent specifies a different
effective date. A consent effected as provided in this section shall have the effect of a meeting
vote and may be described as such in any document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13. <U>Committees</U>. Unless the Charter otherwise provides, the Board of
Directors may create one (1)&nbsp;or more committees, each consisting of one (1)&nbsp;or more members. All
members of committees of the Board of Directors which exercise powers of the Board of Directors
must be members of the Board of Directors and serve at the pleasure of the Board of Directors.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The creation of a committee and appointment of a member or members to it must be approved by the
greater of (i)&nbsp;a majority of all directors in office when the action is taken or (ii)&nbsp;the number of
directors required by the Charter or these Bylaws to take action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Unless otherwise provided in the Act, to the extent specified by the Board of Directors or in the
Charter, each committee may exercise the authority of the Board of Directors. All such committees
and their members shall be governed by the same statutory requirements regarding meetings, action
without meetings, notice and waiver of notice, quorum and voting requirements as are applicable to
the Board of Directors and its members.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;14. <U>Reliance Upon Information, Opinions, Reports, or Statements</U>. To the full
extent allowed by law, a director shall be, in the performance of his or her duties, protected in
relying in good faith upon information, opinions, reports, or statements, including financial
statements and other financial data, if prepared or presented by (i)&nbsp;one or more officers or
employees of the corporation whom the director reasonably believes to be reliable and competent in
the matters presented; (ii)&nbsp;legal counsel, public accountants, or other persons as to matters the
director reasonably believes are within the person&#146;s professional or expert competence; or (iii)&nbsp;a
committee of the Board of Directors of which he or she is not a member if the director reasonably
believes the committee merits confidence.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE IV</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">OFFICERS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. <U>General</U>. The corporation shall have a President and a Secretary, and may
have a Chairman of the Board, a Chief Executive, one or more Vice Presidents, a Treasurer, and such
other officers as may from time to time be deemed advisable by the Board of Directors, the Chairman
of the Board, or the President. Any two (2)&nbsp;or more offices may be held by the same person, except
the offices of President and Secretary. The Chairman of the Board, the Chief Executive, the
President, any Vice President, the Secretary, and the Treasurer shall be appointed by the Board of
Directors. Each other officer may be appointed by the Board of Directors, the Chairman of the
Board, or the President. Each officer shall hold office until the meeting of the Board of
Directors following the next annual meeting of shareholders and until his or her successor has been
appointed and qualified, or until his or her earlier death, resignation, or removal. The Chairman
of the Board must be a director of the corporation. Any other officer may be, but is not required
to be, a director of the corporation. Each officer shall have the authority and perform the duties
set forth in these Bylaws or, to the extent consistent with these Bylaws, the duties prescribed by
the Board of Directors or prescribed by an officer authorized by the Board of Directors to
prescribe the duties of other officers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. <U>Resignation</U>. Any officer may resign at any time by delivering notice to
the corporation. A resignation shall be effective when notice thereof is so delivered, unless the
notice specifies a later effective date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. <U>Removal</U>. The Board of Directors may remove any officer at any time with
or without cause, and any officer appointed by another officer may be removed likewise by such
other officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4. <U>Vacancies</U>. Any vacancy occurring in any office for any reason may be
filled by the Board of Directors or by an officer having the power of appointment with respect to
the office in question.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5. <U>Reliance Upon Information, Opinions, Reports, or Statements</U>. To the full
extent allowed by law, an officer shall be, in the performance of his or her duties, protected in
relying in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">good faith upon information, opinions, reports, or statements, including financial statements
and other financial data, if prepared or presented by (i)&nbsp;one or more officers or employees of the
corporation whom the officer reasonably believes to be reliable and competent in the matters
presented; or (ii)&nbsp;legal counsel, public accountants, or other persons as to matters the officer
reasonably believes are within the person&#146;s professional or expert competence.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6. <U>Chairman of the Board</U>. The Chairman of the Board, when present, shall
preside at all meetings of the Board of Directors. The Chairman of the Board shall also perform
such other duties and have such other powers as the Board of Directors shall from time to time
prescribe.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7. <U>Chief Executive</U>. The Chief Executive shall exercise general supervision
over the management of the business and affairs of the corporation and shall perform such other
duties and have such other powers as the Board of Directors shall from time to time prescribe. In
the absence of the Chairman of the Board or in the event of his or her inability or refusal to act,
the Chief Executive may perform the duties of the Chairman of the Board, and when so acting shall
have all the powers of and be subject to all the restrictions upon the Chairman of the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8. <U>President and Vice Presidents</U>. The President shall perform such duties
and have such powers as the Board of Directors shall from time to time prescribe. In the absence of
the President or in the event of his or her inability or refusal to act, the Vice President, or in
the event there is more than one Vice President, the Vice Presidents in the order designated, or in
the absence of any designation, then in the order of their appointment, may perform the duties of
the President, and when so acting shall have all the powers of and be subject to all the
restrictions upon the President. Each Vice President shall also perform such other duties and have
such other powers as the Board of Directors or the President may from time to time prescribe.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9. <U>Secretary and Assistant Secretaries</U>. The Secretary shall, when possible,
attend all meetings of the shareholders and all meetings of the Board of Directors, shall prepare
or supervise the preparation of minutes of the proceedings of the shareholders, the Board of
Directors, and the Executive Committee and other committees, and shall keep such minutes, along
with all written consents to action without a meeting, in a book or books devoted to that purpose.
The Secretary shall be the officer primarily responsible for authenticating records of the
corporation. The Secretary shall keep a record of the shareholders of the corporation, arranged
alphabetically for class and series, if any, giving the names and addresses of all shareholders and
the number of shares held by each, and shall cause such a list as of the appropriate record date to
be open for inspection prior to and at any meeting of shareholders, as provided in Section&nbsp;10 of
Article&nbsp;II. The Secretary shall give, or cause to be given, notice of meetings of the shareholders
and special meetings of the Board of Directors. The Secretary shall also perform such other duties
as are generally performed by a secretary of a corporation and, in addition, shall perform such
other duties and have such other powers as the Board of Directors or the President, or the Chairman
of the Board if he or she is the Chief Executive, may from time to time prescribe. Any Assistant
Secretary may, in the absence of the Secretary or in the event of his or her inability or refusal
to act, perform the duties of the Secretary, and when so acting shall have all the powers of and be
subject to all the restrictions upon the Secretary. Each Assistant Secretary shall also perform
such other duties and have such other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">powers as the Board of Directors, the Chief Executive, the Secretary, or the Chairman of the
Board if he or she is the Chief Executive, may from time to time prescribe.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10. <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall have custody of
the corporation&#146;s funds and securities, shall keep or cause to be kept full and accurate accounts
of receipts and disbursements, and shall deposit all monies and other valuable effects in the name
and to the credit of the corporation in such depositories as may be designated by the Board of
Directors. The Treasurer shall disburse the funds of the corporation as ordered by the Board of
Directors or by an officer authorized by the Board of Directors so to order, taking proper vouchers
for such disbursements, and shall render to the Board of Directors, the Chairman of the Board, and
the Chief Executive an account of all his or her transactions as Treasurer and of the financial
condition of the corporation. The Treasurer shall also perform such other duties as are generally
performed by a treasurer of a corporation and, in addition, shall perform such other duties and
have such other powers as the Board of Directors or the Chief Executive, or the Chairman of the
Board if he or she is the chief executive officer, may from time to time prescribe. Any Assistant
Treasurer may, in the absence of the Treasurer or in the event of his or her inability or refusal
to act, perform the duties of the Treasurer, and when so acting shall have all the powers of and be
subject to all the restrictions upon the Treasurer. Each Assistant Treasurer shall also perform
such other duties and have such other powers as the Board of Directors, the Chief Executive, the
Treasurer, or the Chairman of the Board may from time to time prescribe.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><U>ARTICLE V</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">SHARES OF STOCK
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. <U>Certificates</U>. Unless the Board of Directors authorizes the issuance of
some or all of the shares of the corporation as uncertificated shares, the shares of the
corporation shall be represented by certificates signed on behalf of the corporation by the
Chairman of the Board, the Chief Executive, or the President and by the Treasurer, an Assistant
Treasurer, the Secretary, or an Assistant Secretary. The certificates shall be in such form as
shall be approved by the Board of Directors and shall be numbered and registered in the order
issued. Each certificate shall include, as a minimum, the name of the corporation and that the
corporation is organized under the laws of the State of Tennessee, the name of the person to whom
issued, and the number and class of shares and the designation of the series, if any, the
certificate represents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. <U>Lost, Destroyed, or Stolen Certificates</U>. The corporation may issue a new
certificate in the place of any certificate previously issued and alleged to have been lost,
destroyed, or stolen, on production of such evidence of loss, destruction, or theft as the Board of
Directors may require. The Board of Directors may require the owner of such lost, destroyed, or
stolen certificate, or his or her legal representative, to provide to the corporation a bond in
such sum as the Board of Directors may direct, and with such surety or sureties as may be
satisfactory to the Board of Directors, to indemnify the corporation against any claims, loss,
liability, or damage it may suffer on account of issuing a new certificate.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. <U>Transfers of Shares</U>. Transfers of shares of the corporation shall be made
on the stock transfer books of the corporation only as permitted in this section and only by the
holder of record thereof, or by his or her duly authorized attorney, upon surrender for
cancellation of the certificate or certificates representing such shares, with an assignment or
power of transfer endorsed thereon or delivered therewith, duly executed with such proof of the
authenticity of the signature and of authority to transfer as the corporation may require. The
corporation shall be entitled to treat the holder of record of any share or shares as the absolute
owner thereof for all purposes and, accordingly, shall not be bound to recognize any legal,
equitable, or other claim to, or interest in, such share or shares on the part of any other person,
whether or not it shall have express or other notice thereof, except as otherwise expressly
provided by law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE VI</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TRANSACTIONS IN WHICH A DIRECTOR OR OFFICER HAS AN INTEREST
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No transaction in which a director or officer has a direct or indirect interest shall be
voidable solely for this reason, provided that (i)&nbsp;the material facts of the transaction and of the
director&#146;s or officer&#146;s interest were disclosed or known to the Board of Directors or a committee
of the Board of Directors, and the Board of Directors or such committee authorized, approved, or
ratified the transaction by the affirmative vote of a majority of the directors on the Board of
Directors, or on such committee, who had no direct or indirect interest in the transaction, except
that such a transaction may not be authorized, approved, or ratified by a single director; (ii)&nbsp;the
material facts of the transaction and of the director&#146;s or officer&#146;s interest were disclosed or
known to the shareholders entitled to vote on the transaction, and the shareholders authorized,
approved, or ratified the transaction; or (iii)&nbsp;the transaction was fair to the corporation. If a
majority of the directors who have no direct or indirect interest in the transaction vote to
authorize, approve, or ratify the transaction, a quorum is present for the purpose of taking
action.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE VII</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">INDEMNIFICATION OF OFFICERS, DIRECTORS, EMPLOYEES, AND AGENTS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. <U>General</U>. The Board of Directors may indemnify any person authorized by
the Tennessee Business Corporation Act, as amended, in the manner and to the extent set forth
therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. <U>Insurance</U>. The corporation shall have the power to purchase and maintain
insurance on behalf of any person who is or was a director, officer, employee, or agent of the
corporation, or who, while a director, officer, employee, or agent of the corporation, is or was
serving at the request of the corporation as a director, officer, partner, trustee, employee, or
agent of another corporation, partnership, joint venture, trust, employee benefit plan, or other
enterprise, against any liability asserted against him or incurred by him in any such capacity or
arising from his status as such, whether or not the corporation would have the power to indemnify
him against such liability under the provisions of this Article&nbsp;VII.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE VIII</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FISCAL YEAR
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fiscal year of the corporation shall be fixed by the Board of Directors from time to time.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE IX</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CORPORATE SEAL
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporate seal, if any, shall be in such form as shall be approved from time to time by
the Board of Directors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>ARTICLE X</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AMENDMENTS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These Bylaws may be amended or repealed, and new Bylaws may be adopted, by the Board of
Directors or the shareholders, but no such action may be taken at any annual or special meeting of
shareholders unless notice of such action is contained in the notice of such meeting.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>g06286exv4w2.htm
<DESCRIPTION>EX-4.2 WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.2 WARRANT TO PURCHASE COMMON STOCK</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 4.2</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING
SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Warrant No.&nbsp;W &#151; 1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Number of Shares &#151; 25,000</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Issuance: October&nbsp;21, 2003
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(subject to adjustment)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WARRANT TO PURCHASE<BR>
COMMON STOCK OF<BR>
CUMBERLAND PHARMACEUTICALS, INC.<BR>
(Void after October&nbsp;21, 2013)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS WARRANT TO PURCHASE COMMON STOCK OF CUMBERLAND PHARMACEUTICALS, INC. (the &#147;Warrant&#148;) is
issued as of this 21st day of October, 2003, by CUMBERLAND PHARMACEUTICALS, INC., a Tennessee
corporation (the &#147;Company&#148;), having a place of business at 2525 West End Avenue, Suite&nbsp;950,
Nashville, Tennessee 37203, to BANK OF AMERICA, N.A., a national banking association (Bank of
America, N.A. and any subsequent assignee or transferee hereof are hereinafter referred to
collectively as the &#147;Holder&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For and in consideration of the Holder making available to the Company a revolving credit
facility in the maximum principal amount of Three Million Five Hundred Thousand and No/100ths
Dollars ($3,500,000.00) (the &#147;Loan&#148;) pursuant to the terms of an Amended and Restated Promissory
Note of even date herewith in the aforesaid amount (together with any and all extensions,
modifications, replacements and renewals thereof, the &#147;Note&#148;) and an Amended and Restated Loan
Agreement of even date herewith (as amended, supplemented or otherwise modified from time to time,
the &#147;Loan Agreement&#148;; any capitalized terms used but not otherwise defined herein shall have the
same meanings as in the Loan Agreement), and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company hereby grants to the Holder the right to
purchase from the Company at a per share price equal to $12.00 (the &#147;Exercise Price&#148;), 25,000
shares of the Company&#146;s common stock, $0 par value per share (the &#147;Common Stock&#148;), at any time or
from time to time, from October&nbsp;21, 2003 up to and including 5:00 p.m. (Central time) on October
21, 2013 (the &#147;Expiration Date&#148;), upon surrender to the Company at its principal office (or at such
other location as the Company may advise the Holder in writing) of this Warrant properly endorsed
with the Notice of Exercise attached hereto as <U>Exhibit&nbsp;A</U>, duly completed and signed and, if
applicable, upon payment in cash or by check acceptable to the Company of the aggregate Exercise
Price for the number of shares for which this Warrant is being exercised determined in accordance
with the provisions hereof. The Exercise Price and the number of shares purchasable hereunder are
subject to adjustment as provided in Section&nbsp;3 of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Warrant is subject to the following terms and conditions:<BR>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Exercise; Issuance of Certificates; Payment for Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 General. </B>Subject to the terms of Section&nbsp;1.3 below, this Warrant is exercisable at the
option of the Holder, at any time or from time to time, from the date of the issuance of this
Warrant up to the Expiration Date, for all or any part of the shares of Common Stock (but not for a
fraction of a share) that may be purchased hereunder. The Company agrees that the shares of Common
Stock purchased under this Warrant shall be and are deemed to be issued to the Holder as the record
owner of such shares as of the close of business on the date on which this Warrant shall have been
surrendered to the Company, properly endorsed, the completed, executed Form of Subscription shall
have been delivered and any required payment made for such shares. Certificates for the shares of
Common Stock so purchased, together with any other securities or property to which the Holder is
entitled upon such exercise, shall be delivered to the Holder by the Company at the Company&#146;s
expense within a reasonable time after the rights represented by this Warrant have been so
exercised. In case of a purchase of less than all of the shares that may be purchased under this
Warrant, the Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of
like tenor for the balance of the shares purchasable under the Warrant surrendered upon such
purchase to the Holder within a reasonable time. Each stock certificate so delivered shall be in
such denominations of Common Stock as may be requested by the Holder and shall be registered in the
name of such Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 Net Issue Exercise. </B>Notwithstanding any provisions herein to the contrary, if the Fair
Market Value of one share of the Company&#146;s Common Stock is greater than the Exercise Price (at the
date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder
may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with the properly endorsed Form of Subscription and notice of such election in which event
the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 10%; margin-top: 6pt">X = <U>Y (A-B)</U><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where X = the number of shares of Common Stock to be issued to the Holder
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Y = the number of shares of Common Stock purchasable under the Warrant or, if only
a portion of the Warrant is being exercised, the portion of the Warrant being canceled
(at the date of such calculation)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A = the Fair Market Value of one share of the Company&#146;s Common Stock (at the date
of such calculation)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B = Exercise Price (as adjusted to the date of such calculation)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The &#147;Fair Market Value&#148; of a share of Common Stock as of a particular date shall mean: (a)&nbsp;if
there is an active public market for the Company&#146;s Common Stock at the time of such exercise, the
fair market value per share shall be the average of the closing prices of the Common Stock of the
Company over the five (5)&nbsp;trading days ending immediately prior to the applicable date of valuation
if traded on a securities exchange or the Nasdaq National Market; or, if actively
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">traded over-the-counter, the average of the closing bid prices over the 30-day period ending
immediately prior to the applicable date of valuation, whichever is applicable; or (b)&nbsp;if there is
no active public market for the Company&#146;s Common Stock at the time of such exercise, the Fair
Market Value shall be the value thereof as determined in good faith by the board of directors of
the Company (the &#147;Determination&#148;). The board of directors shall provide to the Holder a written
notice of the Determination which notice shall set forth supporting data in respect of such
calculation (the &#147;Determination Notice&#148;). Holder shall have 10&nbsp;days following receipt of the
Determination Notice within which to deliver to the Company a written notice of an objection, if
any, to the Determination. The failure by Holder to deliver such notice within such 10-day period
shall constitute the Holder&#146;s acceptance of the Determination as conclusive. In the event of the
timely delivery by Holder of its objection notice, the Company and the Holder shall attempt in good
faith to arrive at an agreement with respect to the Fair Market Value of a share of Common Stock of
the Company, which agreement shall be set forth in writing within 15&nbsp;days following delivery of
such objection notice by Holder. If the Company and the Holder are unable to reach an agreement
within such 15-day period, the matter shall be promptly referred for determination to a regionally
or nationally recognized investment banking or valuation firm (the &#147;Valuer&#148;) reasonably acceptable
to the Company and the Holder. The Company and the Holder will cooperate with each other in good
faith to select such Valuer. The Valuer may select the Determination or may select any other number
or value. The Valuer&#146;s selection will be furnished to the Company and the Holder in writing and be
conclusive and binding upon the parties and shall not be subject to collateral attack. The fees and
expenses of the Valuer shall be borne by the Company unless the Valuer&#146;s determination of Fair
Market Value per share of the Company&#146;s Common Stock is within 10% of the Determination, in which
case the Valuer&#146;s fees and expenses shall be borne by the Holder.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding the foregoing, in the event the Warrant is exercised in connection with the
Company&#146;s initial public offering of Common Stock, the fair market value per share shall be the per
share offering price to the public of the Company&#146;s initial public offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.3 Vesting. </B>Notwithstanding anything to the contrary contained herein, the Holder may
exercise its right to purchase up to 12,500 shares of the Common Stock, or any portion thereof, at
any time or from time to time from the date of the issuance of this Warrant up to the Expiration
Date. With respect to the remaining 12,500 shares of Common Stock, the Holder&#146;s right to purchase
all or any portion of such shares shall be deemed to vest hereunder in the event that, and at such
time as, the Company fails to achieve a Successful CeraLyte<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Launch.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Shares to be Fully Paid; Reservation of Shares. </B>The Company covenants and agrees that all
shares of Common Stock that may be issued upon the exercise of the rights represented by this
Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and
free from all preemptive rights of any stockholder and free of all taxes, liens and charges with
respect to the issuance thereof. The Company further covenants and agrees that during the period
within which the rights represented by this Warrant may be exercised, the Company will at all times
have authorized and reserved, for the purpose of issue or transfer upon exercise of the
subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but
unissued Common Stock, or other securities and property, when and as required to provide for the
exercise of the rights represented by this Warrant. The Company will take all such action as may
be necessary to assure that such shares of Common Stock may
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be issued as provided herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange upon which the Common Stock may be listed;
provided, however, that the Company shall not be required to effect a registration under federal or
state securities laws with respect to such exercise. The Company will not take any action which
would result in any adjustment of the Exercise Price (as set forth in Section&nbsp;3 hereof) if the
total number of shares of Common Stock issuable after such action upon exercise of all outstanding
warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock
then issuable upon exercise of all options and upon the conversion of all convertible securities
then outstanding, would exceed the total number of shares of Common Stock then authorized by the
Company&#146;s charter, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Adjustment of Exercise Price and Number of Shares. </B>The Exercise Price and the number of
shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to
time upon the occurrence of certain events described in this Section&nbsp;3. Upon each adjustment to the
Exercise Price, the Holder shall thereafter be entitled to purchase, at the Exercise Price
resulting from such adjustment, the number of shares obtained by multiplying the Exercise Price in
effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto
immediately prior to such adjustment, and dividing the product thereof by the Exercise Price
resulting from such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Subdivision or Combination of Stock. </B>In case the Company shall at any time subdivide its
outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination shall be proportionately
increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Dividends in Common Stock, Other Stock, Property, Reclassification. </B>If at any time or
from time to time the holders of Common Stock shall have received or become entitled to receive,
without further payment therefor,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Common Stock or any shares of stock or other securities that are at any time directly or
indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe
for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>any cash paid or payable otherwise than as a cash dividend, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Common Stock or additional stock or other securities or property (including cash) by way
of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement
(other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section&nbsp;3.1 above), then and in each such case, the Holder shall, upon
the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common
Stock receivable thereupon, and without payment of any additional consideration therefor, the
amount of stock and other securities and property (including cash in the cases referred to in
clause (b)&nbsp;above and this clause (c)) that Holder would hold on the date of such exercise had
Holder been the holder of record of such Common Stock as of the date on which holders of Common
Stock received or became entitled to receive such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shares or all other additional stock and other securities and property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Reorganization, Reclassification, Consolidation, Merger or Sale. </B>If any recapitalization,
reclassification or reorganization of the capital stock of the Company, or any consolidation or
merger of the Company with another company, or the sale of all or substantially all of its assets
or other transaction shall be effected in such a way that holders of Common Stock shall be entitled
to receive stock, securities or other assets or property (an &#147;Organic Change&#148;), then, as a
condition of such Organic Change, lawful and adequate provisions shall be made by the Company
whereby the Holder thereafter shall have the right to purchase and receive (in lieu of the shares
of the Common Stock of the Company immediately theretofore purchasable and receivable upon the
exercise of the rights represented hereby) such shares of stock, securities or other assets as may
be issued or payable with respect to or in exchange for a number of outstanding shares of such
Common Stock equal to the number of shares of such stock immediately theretofore purchasable and
receivable upon the exercise of the rights represented hereby. In the event of any Organic Change,
appropriate provision shall be made by the Company with respect to the rights and interests of the
Holder to the end that the provisions hereof (including, without limitation, provisions for
adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the
exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock,
securities or assets thereafter deliverable upon the exercise hereof. The Company will not effect
any such Organic Change unless, prior to the consummation thereof, the successor company (if other
than the Company) resulting from such consolidation or the company purchasing such assets shall
assume by written instrument reasonably satisfactory in form and substance to the Holder, executed
and mailed or delivered to the registered Holder at the last address of such Holder appearing on
the books of the Company, the obligation to deliver to such Holder such shares of stock, securities
or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.4 Certain Events. </B>If any change in the outstanding Common Stock of the Company or any other
event occurs as to which the other provisions of this Section&nbsp;3 are not strictly applicable or if
strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in
accordance with such provisions, then the Board of Directors of this Company shall make an
adjustment in the number and class of shares available under the Warrant, the Exercise Price or the
application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment
shall be such as will give the Holder, upon exercise for the same aggregate Exercise Price, the
total number, class and kind of shares as the Holder would have owned had the Warrant been
exercised prior to the event and had the Holder continued to hold such Common Stock until after the
event requiring adjustment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Issue Tax. </B>The issuance of certificates for shares of Common Stock upon the exercise of
the Warrant shall be made without charge to the Holder for any issue tax (other than any applicable
income taxes) in respect thereof; provided, however, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Closing of Books. </B>The Company will at no time close its transfer books against the
transfer of any warrant or of any shares of Common Stock issued or issuable upon the exercise of
any warrant in any manner which interferes with the timely exercise of this Warrant.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;No Voting or Dividend Rights; Limitation of Liability. </B>Nothing contained in this Warrant
shall be construed as conferring upon the Holder the right to vote or to consent or to receive
notice as a stockholder of the Company or any other matters or any rights whatsoever as a
stockholder of the Company. Except as set forth in Section&nbsp;3.2 hereof, no dividends or interest
shall be payable or accrued in respect of this Warrant or the interest represented hereby or the
shares purchasable hereunder until, and only to the extent that, this Warrant shall have been
exercised. No provisions hereof, in the absence of affirmative action by the Holder to purchase
shares of Common Stock, and no mere enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of such Holder for the Exercise Price or as a stockholder of the
Company, whether such liability is asserted by the Company or by its creditors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Rights and Obligations Survive Exercise of Warrant. </B>The rights and obligations of the
Company, of the Holder and of the holder of shares of Common Stock (or other shares of stock,
securities or assets) issued upon exercise of this Warrant shall survive the exercise of this
Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Amendments.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Any term of this Warrant may be amended with the written consent of the Company and the
Holder. Any amendment effected in accordance with this Section&nbsp;8 shall be binding upon the existing
and each future holder and the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>No waivers of, or exceptions to, any term, condition or provision of this Warrant, in any
one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of
any such term, condition or provision.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Notices.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted
pursuant to Section&nbsp;3 hereof, the Company shall issue a certificate signed by its Chief Financial
Officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the
adjustment, the method by which such adjustment was calculated and the Exercise Price and number of
shares purchasable hereunder after giving effect to such adjustment, and shall cause a copy of such
certificate to be mailed (by first-class mail, postage prepaid) to the Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>In case:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>the Company shall take a record of the holders of its Common Stock
(or other stock or securities at the time receivable upon the exercise of this
Warrant) for the purpose of entitling them to receive any dividend or other
distribution, or any right to subscribe for or purchase any shares of stock of
any class or any other securities, or to receive any other right, or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>of any capital reorganization of the Company, any reclassification of the
capital stock of the Company, any consolidation or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">merger of the Company with or into another company, or any conveyance of all
or substantially all of the assets of the Company to another company, or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii) </B>of any voluntary dissolution, liquidation or winding-up of the
Company,
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, and in each such case, the Company will mail or cause to be mailed to the Holder or Holders a
notice specifying, as the case may be, (A)&nbsp;the date on which a record is to be taken for the
purpose of such dividend, distribution or right, and stating the amount and character of such
dividend, distribution or right, or (B)&nbsp;the date on which such reorganization, reclassification,
consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the
time, if any is to be fixed, as of which the holders of record of Common Stock (or such stock or
securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Common Stock (or such other stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. Such notice shall be mailed at least 15&nbsp;days prior to the
date therein specified.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>Any notice, request or other document required or permitted to be given or delivered to
the Holder or the Company shall be delivered or shall be sent by certified mail, postage prepaid,
to the Holder at its address as shown on the books of the Company or to the Company at the address
indicated therefor in the first paragraph of this Warrant or such other address as either may from
time to time provide to the other. Any notice, request or other document required or permitted to
be given or delivered pursuant to this Warrant shall be deemed effectively given: (i)&nbsp;upon personal
delivery to the party to be notified; (iii)&nbsp;five days after having been sent by registered or
certified mail, return receipt requested, postage prepaid; or (iv)&nbsp;one day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Binding Effect on Successors. </B>This Warrant shall be binding upon any company succeeding
the Company by merger, consolidation or acquisition of all or substantially all of the Company&#146;s
assets. All of the obligations of the Company relating to the Common Stock issuable upon the
exercise of this Warrant shall survive the exercise and termination of this Warrant. This Warrant
and all rights hereunder may be transferred or assigned, in whole or in part, to any person or
business entity upon surrender of this Warrant at the principal office of the Company, accompanied
by an Assignment Form attached hereto as <U>Exhibit&nbsp;B</U>, duly completed and signed. Upon
surrender of&#146; this Warrant and receipt of the Assignment Form, the Company, at its expense, shall
issue to or on the order of the new Holder a new warrant or warrants of like tenor in accordance
with the Assignment Form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Descriptive Headings. </B>The description headings of the several sections and paragraphs of
this Warrant are inserted for convenience only and do not constitute a part of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Governing Law. </B>This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of Tennessee.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Replacement Warrants. </B>The Company represents and warrants to the Holder that upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to the Company, or in the case of any such mutilation, upon surrender and
cancellation of such Warrant, the Company, at its expense, will execute and deliver a new Warrant,
of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Fractional Shares. </B>No fractional shares shall be issued upon exercise of this Warrant.
The Company shall, in lieu of issuing any fractional share, pay the Holder entitled to such
fraction a sum in cash equal to such fraction multiplied by the Fair Market Value of a share of
Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Equity Participation. </B>This Warrant and the rights of the Holder hereunder are intended to
constitute an &#147;equity participation&#148; for purposes of Title 47, Chapter&nbsp;24, Tennessee Code
Annotated, and the consideration or value received by the Holder in respect of this Warrant shall
not be deemed to be interest, loan charges, commitment fees or brokerage commissions for purposes
of Title 47, Chapter&nbsp;14, Tennessee Code Annotated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be duly executed by its officers,
thereunto duly authorized this 21<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> day of October, 2003.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CUMBERLAND PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>

    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Title:&nbsp;</TD>

    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">Chief Executive &#038; President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>NOTICE OF EXERCISE</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To: Cumberland Pharmaceuticals, Inc.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;? The undersigned hereby elects to exercise the attached Warrant and to purchase
thereunder
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Common Stock at a purchase price of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Dollars
($<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) per Share or an aggregate purchase price of &#95;&#95;&#95;Dollars ($&#95;&#95;&#95;).
Pursuant to the terms of the Warrant, the undersigned has delivered the purchase price herewith in
full.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;? The undersigned hereby elects to convert <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> percent (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%) of the
value of the Warrant pursuant to the provisions of Section&nbsp;1.2 of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue a new Warrant for the unexercised portion of the attached Warrant, if applicable,
in the name of the undersigned or in such other name as is specified below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Date)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Signature)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT B</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ASSIGNMENT FORM</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR VALUE RECEIVED, the undersigned registered owner of the attached Warrant hereby sells,
assigns and transfers all of the rights of the undersigned under the attached Warrant with respect
to the number of shares of the security covered thereby set forth below, unto:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><U><I>Name of Assignee</I></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><I>Address</I></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><I>No. of Shares</I></U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Date)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Signature)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>g06286exv4w4.htm
<DESCRIPTION>EX-4.4 WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.4 WARRANT TO PURCHASE COMMON STOCK</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 4.4</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING
SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Warrant No.&nbsp;W &#151; 3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Number of Shares &#151; 1,979</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Issuance: April&nbsp;6, 2006
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(subject to adjustment)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WARRANT TO PURCHASE<BR>
COMMON STOCK OF<BR>
CUMBERLAND PHARMACEUTICALS, INC.<BR>
(Void after April&nbsp;6, 2016)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS WARRANT TO PURCHASE COMMON STOCK OF CUMBERLAND PHARMACEUTICALS, INC. (the
&#147;<U>Warrant</U>&#148;) is issued as of this 6th day of April, 2006, by CUMBERLAND PHARMACEUTICALS,
INC., a Tennessee corporation, having a place of business at 2525 West End Avenue, Suite&nbsp;950,
Nashville, Tennessee 37203 (the &#147;<U>Company</U>&#148;), to BANK OF AMERICA, N.A., a national banking
association (Bank of America, N.A. and any subsequent assignee or transferee hereof are hereinafter
referred to collectively as the &#147;<U>Holder</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For and in consideration of the Holder making available to the Company (i)&nbsp;a revolving credit
facility in the maximum principal amount of Four Million and No/100ths Dollars ($4,000,000.00) (the
&#147;<U>Line of Credit</U>&#148;) and (ii)&nbsp;a term loan facility in the original principal amount of Five
Million Five Hundred Thousand and No/100ths Dollars ($5,500,000) (the &#147;<U>Term</U> <U>Loan</U>&#148;
and together with the &#147;<U>Line of Credit</U>&#148;, the &#147;<U>Loans</U>&#148;) pursuant to the terms of (i)&nbsp;a
Fourth Amended and Restated Promissory Note (Revolving) of even date herewith in the maximum
principal amount of Four Million and No/100ths Dollars ($4,000,000) (together with any and all
extensions, modifications, replacements and renewals thereof, the &#147;<U>Line of Credit Note</U>&#148;),
(ii)&nbsp;Secured Term Promissory Note of even date herewith in the original principal amount of Five
Million Five Hundred Thousand and No/100ths Dollars ($5,500,000) (together with any and all
extensions, modifications, replacements and renewals thereof, the &#147;<U>Term Note</U>&#148;; and together
with the Line of Credit Note, the &#147;<U>Notes</U>&#148;) and (iii)&nbsp;a Second Amended and Restated Loan
Agreement of even date herewith (as amended, supplemented or otherwise modified from time to time,
the &#147;<U>Loan Agreement</U>&#148;; any capitalized terms used but not otherwise defined herein shall
have the same meanings as in the Loan Agreement), and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company hereby grants to the Holder
the right to purchase from the Company at a per share price equal to $18.00 (the &#147;<U>Exercise
Price</U>&#148;), 1,979 shares of the Company&#146;s common stock, $0 par value per share (the &#147;<U>Common
Stock</U>&#148;), at any time or from time to time, from April&nbsp;6, 2006 up to and including 5:00
p.m. (Central time) on April&nbsp;6, 2016 (the &#147;<U>Expiration Date</U>&#148;), upon surrender to the
Company at its principal office (or at such other location as the Company may advise the Holder in
writing) of this Warrant properly endorsed with the Notice of Exercise attached hereto as
<U>Exhibit&nbsp;A</U>, duly
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">completed and signed and, if applicable, upon payment in cash or by check
acceptable to the Company of the aggregate Exercise Price for the number of shares for which this
Warrant is being exercised determined in accordance with the provisions hereof. The Exercise Price
and the number of shares purchasable hereunder are subject to adjustment as provided in <U>Section
3</U> of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Warrant is subject to the following terms and conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Exercise; Issuance of Certificates; Payment for Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 General. </B>This Warrant is exercisable at the option of the Holder, at any time or from
time to time, from the date of the issuance of this Warrant up to the Expiration Date, for all or
any part of the shares of Common Stock (but not for a fraction of a share) that maybe purchased
hereunder. The Company agrees that the shares of Common Stock purchased under this Warrant shall be
and are deemed to be issued to the Holder as the record owner of such shares as of the close of
business on the date on which this Warrant shall have been surrendered to the Company, properly
endorsed, the completed, executed Form of Subscription shall have been delivered and any required
payment made for such shares. Certificates for the shares of Common Stock so purchased, together
with any other securities or property to which the Holder is entitled upon such exercise, shall be
delivered to the Holder by the Company at the Company&#146;s expense within a reasonable time after the
rights represented by this Warrant have been so exercised. In case of a purchase of less than all
of the shares that may be purchased under this Warrant, the Company shall cancel this Warrant and
execute and deliver a new Warrant or Warrants of like tenor for the balance of the shares
purchasable under the Warrant surrendered upon such purchase to the Holder within a reasonable
time. Each stock certificate so delivered shall be in such denominations of Common Stock as may be
requested by the Holder and shall be registered in the name of such Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 Net Issue Exercise. </B>Notwithstanding any provisions herein to the contrary, if the Fair
Market Value of one share of the Company&#146;s Common Stock is greater than the Exercise Price (at the
date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder
may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with the properly endorsed Form of Subscription and notice of such election in which event
the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt"><U>X=Y(A-B)</U><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where X = the number of shares of Common Stock to be issued to the Holder
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Y = the number of shares of Common Stock purchasable under the Warrant or, if only a
portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the
date of such calculation)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A = the Fair Market Value of one share of the Company&#146;s Common Stock (at the date of
such calculation)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B = Exercise Price (as adjusted to the date of such calculation)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The &#147;Fair Market Value&#148; of a share of Common Stock as of a particular date shall mean: (a)&nbsp;if
there is an active public market for the Company&#146;s Common Stock at the time of such exercise, the
fair market value per share shall be the average of the closing prices of the Common Stock of the
Company over the five (5)&nbsp;trading days ending immediately prior to the applicable date of valuation
if traded on a securities exchange or the Nasdaq National Market; or, if actively traded
over-the-counter, the average of the closing bid prices over the 30-day period ending immediately
prior to the applicable date of valuation, whichever is applicable; or (b)&nbsp;if there is no active
public market for the Company&#146;s Common Stock at the time of such exercise, the Fair Market Value
shall be the value thereof as determined in good faith by the board of directors of the Company
(the &#147;<U>Determination</U>&#148;). The board of directors shall provide to the Holder a written notice
of the Determination which notice shall set forth supporting data in respect of such calculation
(the &#147;<U>Determination Notice</U>&#148;). Holder shall have 10&nbsp;days following receipt of the
Determination Notice within which to deliver to the Company a written notice of an objection, if
any, to the Determination. The failure by Holder to deliver such notice within such 10-day period
shall constitute the Holder&#146;s acceptance of the Determination as conclusive. In the event of the
timely delivery by Holder of its objection notice, the Company and the Holder shall attempt in good
faith to arrive at an agreement with respect to the Fair Market Value of a share of Common Stock of
the Company, which agreement shall be set forth in writing within 15&nbsp;days following delivery of
such objection notice by Holder. If the Company and the Holder are unable to reach an agreement
within such 15-day period, the matter shall be promptly referred for determination to a regionally
or nationally recognized investment banking or valuation firm (the &#147;<U>Valuer</U>&#148;) reasonably
acceptable to the Company and the Holder. The Company and the Holder will cooperate with each
other in good faith to select such Valuer. The Valuer may select the Determination or may select
any other number or value. The Valuer&#146;s selection will be furnished to the Company and the Holder
in writing and be conclusive and binding upon the parties and shall not be subject to collateral
attack. The fees and expenses of the Valuer shall be borne by the Company unless the Valuer&#146;s
determination of Fair Market Value per share of the Company&#146;s Common Stock is within 10% of the
Determination, in which case the Valuer&#146;s fees and expenses shall be borne by the Holder.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding the foregoing, in the event the Warrant is exercised in connection with the
Company&#146;s initial public offering of Common Stock, the fair market value per share shall be the per
share offering price to the public of the Company&#146;s initial public offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Shares to be Fully Paid; Reservation of Shares. </B>The Company covenants and
agrees that all shares of Common Stock that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and
nonassessable and free from all preemptive rights of any stockholder and free of all taxes, liens
and charges with respect to the issuance thereof. The Company further covenants and agrees that
during the period within which the rights represented by this Warrant may be exercised, the Company
will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise
of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized
but unissued Common Stock, or other securities and property, when and as required to provide for
the exercise of the rights represented by this Warrant. The Company will take all such action as
may be necessary to assure that such shares of Common Stock may be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">issued as provided herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange upon which the Common Stock may be listed;
provided, however, that the Company shall not be required to effect a registration under federal or
state securities laws with respect to such exercise. The Company will not take any action which
would result in any adjustment of the Exercise Price (as set forth in <U>Section&nbsp;3</U> hereof) if
the total number of shares of Common Stock issuable after such action upon exercise of all
outstanding warrants, together with all shares of Common Stock then outstanding and all shares of
Common Stock then issuable upon exercise of all options and upon the conversion of all convertible
securities then outstanding, would exceed the total number of shares of Common Stock then
authorized by the Company&#146;s charter, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Adjustment of Exercise Price and Number of Shares. </B>The Exercise Price and
the number of shares purchasable upon the exercise of this Warrant shall be subject to
adjustment from time to time upon the occurrence of certain events described in this <U>Section
3</U>. Upon each adjustment to the Exercise Price, the Holder shall thereafter be entitled to
purchase, at the Exercise Price resulting from such adjustment, the number of shares obtained by
multiplying the Exercise Price in effect immediately prior to such adjustment by the number of
shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product
thereof by the Exercise Price resulting from such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Subdivision or Combination of Stock. </B>In case the Company shall at any time subdivide its
outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a smaller number of
shares, the Exercise Price in effect immediately prior to such combination shall be proportionately
increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Dividends in Common Stock, Other Stock, Property, Reclassification. </B>If at any time or from
time to time. the holders of Common Stock shall have received or become entitled to receive,
without further payment therefor,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Common Stock or any shares of stock or other securities that are at any time directly or
indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe
for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>any cash paid or payable otherwise than as a cash dividend, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Common Stock or additional stock or other securities or property
(including cash) by way of spinoff, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or
adjustments in respect of which shall be covered by the terms of <U>Section&nbsp;3.1</U> above), then
and in
each such case, the Holder shall, upon the exercise of this Warrant, be entitled to receive,
in addition to the number of shares of Common Stock receivable thereupon, and without payment of
any additional consideration therefor, the amount of stock and other securities and property
(including cash in the cases referred to in clause (b)&nbsp;above and this clause (c)) that Holder would
hold on the date of such exercise had Holder been the holder of record of such Common Stock as of
the date on which holders of Common Stock received or became entitled to receive such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shares or all other additional stock and other securities and property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Reorganization, Reclassification, Consolidation, Merger or Sale. </B>If
any recapitalization, reclassification or reorganization of the capital stock of the Company,
or any consolidation or merger of the Company with another company, or the sale of all or
substantially all of its assets or other transaction shall be effected in such a way that holders
of Common Stock shall be entitled to receive stock, securities or other assets or property (an
&#147;<U>Organic Change</U>&#146;&#146;), then, as a condition of such Organic Change, lawful and adequate
provisions shall be made by the Company whereby the Holder thereafter shall have the right to
purchase and receive (in lieu of the shares of the Common Stock of the Company immediately
theretofore purchasable and receivable upon the exercise of the rights represented hereby) such
shares of stock, securities or other assets as may be issued or payable with respect to or in
exchange for a number of outstanding shares of such Common Stock equal to the number of shares of
such stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented hereby. In the event of any Organic Change, appropriate provision shall be made by the
Company with respect to the rights and interests of the Holder to the end that the provisions
hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the
number of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be
applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon
the exercise hereof. The Company will not effect any such Organic Change unless, prior to the
consummation thereof, the successor company (if other than the Company) resulting from such
consolidation or the company purchasing such assets shall assume by written instrument reasonably
satisfactory in form and substance to the Holder, executed and mailed or delivered to the
registered Holder at the last address of such Holder appearing on the books of the Company,
the obligation to deliver to such Holder such shares of stock, securities or assets as, in
accordance with the foregoing provisions, such Holder may be entitled to purchase.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.4 Certain Events. </B>If any change in the outstanding Common Stock of the
Company or any other event occurs as to which the other provisions of this <U>Section&nbsp;3</U>
are not strictly applicable or if strictly applicable would not fairly protect the purchase rights
of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of
this Company shall make an adjustment in the number and class of shares available under the
Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase
rights as aforesaid. The adjustment shall be such as will give the Holder, upon exercise for the
same aggregate Exercise Price, the total number, class and kind of shares as the Holder would have
owned had the Warrant been exercised prior to the event and had the Holder continued to hold such
Common Stock until after the event requiring adjustment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Issue Tax. </B>The issuance of certificates for shares of Common Stock upon the exercise of
the Warrant shall be made without charge to the Holder for any issue tax (other than any applicable
income taxes) in respect thereof; provided, however, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than that of the then Holder of the Warrant being exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Closing of Books. </B>The Company will at no time close its transfer books against the
transfer of any warrant or of any shares of Common Stock issued or issuable upon the exercise of
any warrant in any manner which interferes with the timely exercise of this Warrant.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;No Voting or Dividend Rights; Limitation of Liability. </B>Nothing contained in this Warrant
shall be construed as conferring upon the Holder the right to vote or to consent or to receive
notice as a stockholder of the Company or any other matters or any rights whatsoever as a
stockholder of the Company. Except as set forth in <U>Section&nbsp;3.2</U> hereof, no dividends or
interest shall be payable or accrued in respect of this Warrant or the interest represented hereby
or the shares purchasable hereunder until, and only to the extent that, this Warrant shall have
been exercised. No provisions hereof, in the absence of affirmative action by the Holder to
purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of the
Holder, shall give rise to any liability of such Holder for the Exercise Price or as a stockholder
of the Company, whether such liability is asserted by the Company or by its creditors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Rights and Obligations Survive Exercise of Warrant. </B>The rights and obligations of the
Company, of the Holder and of the holder of shares of Common Stock (or other shares of stock,
securities or assets) issued upon exercise of this Warrant shall survive the exercise of this
Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Amendments.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Notices.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted
pursuant to <U>Section&nbsp;3</U> hereof, the Company shall issue a certificate signed by its Chief
Financial Officer setting forth, in reasonable detail, the event requiring the adjustment, the
amount of the adjustment, the method by which such adjustment was calculated and the Exercise Price
and number of shares purchasable hereunder after giving effect to such adjustment, and shall cause
a copy of such certificate to be mailed (by first-class mail, postage prepaid) to the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>In case:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>the Company shall take a record of the holders of its Common Stock
(or other stock or securities at the time receivable upon the exercise of
this Warrant) for the purpose of entitling them to receive any dividend or
other distribution, or any right to subscribe for or purchase any shares of
stock of any class or any other securities, or to receive any other right,
or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>of any capital reorganization of the Company, any reclassification
of the capital stock of the Company, any consolidation or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">merger of the Company with or into another company, or any conveyance of all
or substantially all of the assets of the Company to another company, or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii) </B>of any voluntary dissolution, liquidation or winding-up of the
Company,
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, and in each such case, the Company will mail or cause to be mailed to the Holder or Holders a
notice specifying, as the case maybe, (A)&nbsp;the date on which a record is to be taken for the purpose
of such dividend, distribution or right, and stating the amount and character of such dividend,
distribution or right, or (B)&nbsp;the date on which such reorganization, reclassification,
consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the
time, if any is to be fixed, as of which the holders of record of Common Stock (or such stock or
securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Common Stock (or such other stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. Such notice shall be mailed at least 15&nbsp;days prior to the
date therein specified.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Any notice, request or other document required or permitted to be
given or delivered to the Holder or the Company shall be delivered or shall be sent by
certified mail, postage prepaid, to the Holder at its address as shown on the books of the Company
or to the Company at the address indicated therefor in the first paragraph of this Warrant or such
other address as either may from time to time provide to the other. Any notice, request or other
document required or permitted to be given or delivered pursuant to this Warrant shall be deemed
effectively given: (i)&nbsp;upon personal delivery to the party to be notified; (iii)&nbsp;five days after
having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv)&nbsp;one day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Binding Effect on Successors. </B>This Warrant shall be binding upon any company succeeding
the Company by merger, consolidation or acquisition of all or substantially all of the Company&#146;s
assets. All of the obligations of the Company relating to the Common Stock issuable upon the
exercise of this Warrant shall survive the exercise and termination of this Warrant. This Warrant
and all rights hereunder may be transferred or assigned, in whole or in part, to any person or
business entity upon surrender of this Warrant at the principal office of the Company, accompanied
by an Assignment Form attached hereto as <U>Exhibit&nbsp;B</U>, duly completed and signed. Upon
surrender of this Warrant and receipt of the Assignment Form, the Company, at its expense, shall
issue to or on the order of the new Holder a new warrant or warrants of like tenor in accordance
with the Assignment Form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Descriptive Headings. </B>The description headings of the several sections and paragraphs of
this Warrant are inserted for convenience only and do not constitute a part of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Governing Law. </B>This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of Tennessee.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Replacement Warrants. </B>The Company represents and warrants to the Holder that upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to the Company, or in the case of any such mutilation, upon surrender and
cancellation of such Warrant, the Company, at its expense, will execute and deliver a new Warrant,
of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Fractional Shares. </B>No fractional shares shall be issued upon exercise of this Warrant.
The Company shall, in lieu of issuing any fractional share, pay the Holder entitled to such
fraction a sum in cash equal to such fraction multiplied by the Fair Market Value of a share of
Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Equity Participation. </B>This Warrant and the rights of the Holder hereunder are intended to
constitute an &#147;equity participation&#148; for purposes of Title 47, Chapter&nbsp;24, Tennessee Code
Annotated, and the consideration or value received by the Holder in respect of this Warrant shall
not be deemed to be interest, loan charges, commitment fees or brokerage commissions for purposes
of Title 47,.Chapter&nbsp;14, Tennessee Code Annotated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;No Novation. </B>This Warrant does not constitute a discharge or novation of any warrant
existing prior to this Warrant, including, without limitation, that certain Warrant to Purchase
Common Stock of Cumberland Pharmaceuticals, Inc. (W-1) dated as of October&nbsp;21, 2003, and such
documents shall continue in full force and effect, shall be fully binding upon the Company, and all
rights hereunder shall be cumulative in effect with such documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT><B>, </B>the Company has caused this Warrant to be duly executed by its
officers, thereunto duly authorized this 6th day of April, 2006.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CUMBERLAND PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/  A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>NOTICE OF EXERCISE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">To: Cumberland Pharmaceuticals, Inc.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings">&#111;</FONT> The undersigned hereby elects to exercise the attached Warrant and to purchase
thereunder
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Common Stock at a purchase price of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Dollars
($<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) per Share or an aggregate purchase price of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Dollars ($<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>).
Pursuant to the terms of the Warrant, the undersigned has delivered the purchase price herewith
in full.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings">&#111;</FONT> The undersigned hereby elects to convert <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> percent (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> %) of the value
of the Warrant pursuant to the provisions of <U>Section&nbsp;1.2</U>, of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue a new Warrant for the unexercised portion of the attached Warrant, if applicable,
in the name of the undersigned or in such other name as is specified below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Date)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Signature)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ASSIGNMENT FORM</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR VALUE RECEIVED, the undersigned registered owner of the attached Warrant hereby sells,
assigns and transfers all of the rights of the undersigned under the attached Warrant with respect
to the number of shares of the security covered thereby set forth below, unto:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><U><I>Name of Assignee</I></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><I>Address</I></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><I>No. of Shares</I></U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Date)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Signature)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>6
<FILENAME>g06286exv4w5.htm
<DESCRIPTION>EX-4.5 FORM OF OPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.5 FORM OF OPTION AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 4.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>STOCK OPTION AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Option Agreement is entered into and effective on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, by
and between Cumberland Pharmaceuticals Inc., a Tennessee corporation (the &#147;Company&#148;), and
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(the &#147;Participant&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company has adopted the 1999 Stock Option Plan (the &#147;Plan&#148;); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as an increased incentive to contribute to the Company&#146;s future success and
prosperity, the Company will, subject to the Participant continuing to provide services to the
Company, or any of its current or future subsidiaries, provide the Participant an opportunity to
acquire shares of the Company&#146;s common stock, no par value (the &#147;Stock&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Grant of Option. Subject to the terms of the Plan and the terms of this Option Agreement,
the Company grants to the Participant an option (the &#147;Option&#148;) to purchase from the Company up to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) shares of Stock (the &#147;Shares&#148;), subject to adjustment as provided in the Plan. This Option is not
intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Exercise Price. If the Option is exercised, the purchase price per Share shall be <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
($<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> ).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Method of Exercise. The Option granted under this Agreement shall be fully vested and
exercisable after , in whole or in part, by written notice in the manner set forth in Section&nbsp;7 hereof, accompanied by payment of the purchase price in accordance with the terms of
the Plan for the Shares which the Participant elects to purchase. The Company shall make prompt
delivery of such Shares; provided that if any law or regulation which requires the Company to take
any action with respect to the Shares specified in such notice before issuance thereof, then the
date of delivery of such Shares shall be extended for the period necessary to take such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Termination of Option. Except as otherwise stated in this Agreement, this Option, to the
extent not previously exercised, shall expire on the tenth anniversary (the &#147;Expiration Date&#148;) of
the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Provisions of Plan. This Option is subject to the Plan. The terms and provisions of the
Plan as it may be amended from time to time are hereby incorporated herein by reference. In the
event of a conflict between any term or provision contained herein and a term or provision of the
Plan, the applicable terms and provisions of the Plan will govern and prevail.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Representations and Warranties of Participant. Recognizing that the Company will be relying
on the information and on the representations and warranties set forth herein, the Participant
hereby acknowledges, represents, and warrants to the Company that the Participant has been advised
that neither this Option nor the Shares will be registered under the Securities Act of 1933, as
amended (the &#147;Securities Act&#148;), or under the securities law of any state, unless the Company in its
sole discretion determines that registration under an applicable state securities law would not
subject it to unreasonable expense, and that the Shares will only be offered and sold in reliance
upon an exemption from the registration requirements of the Securities Act. The Participant further
understands and agrees that the Option and any exercise thereof must comply with all applicable
securities laws, including, but not limited to, the Securities Act and the securities laws of the
several states, as such laws exist on the date of this Agreement and on such future dates that the
Option may be exercised. By executing this Option, the Participant represents that this Option, and
the Shares issuable upon exercise of this Option, is being and will be purchased solely for the
Participant&#146;s own account as an investment, and not with a view to the resale or distribution, in
whole or in part, thereof. The Participant has such knowledge and experience in financial and
business matters that the Participant is capable of evaluating the merits and risks of the
acquisition of this Option and the Shares issuable upon the exercise of this Option. Further, the
Participant understands and agrees that all certificates representing Shares issued pursuant to an
exercise of this Option shall be inscribed with a legend in substantially the following form:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAW AND MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Notices. Any notice, request, instruction, or other document given under this Option
Agreement shall be in writing and shall be addressed and delivered, in the case of the Company, to
the Secretary of the Company at the principal office of the Company and, in the case of the
Participant, the Participant&#146;s address as set forth herein or to such other address as the
Participant may provide in a written notice to the Company, a copy of which shall be on file with
the Secretary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;Governing Law. This Option Agreement shall be construed in accordance with and governed by
the law of the State of Tennessee, without giving effect to the conflict of law provisions thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, each of the parties hereto has caused this Option Agreement to be executed
by its duly authorized representative.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left"><DIV style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</DIV>
</TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left"><DIV style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left"><DIV style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">PARTICIPANT:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>g06286exv10w1.htm
<DESCRIPTION>EX-10.1 MANUFACTURING AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.1 MANUFACTURING AND SUPPLY AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MANUFACTURING AND SUPPLY AGREEMENT<BR>
for<BR>
N-ACETYLCYSTEINE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>and</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BIONICHE LIFE SCIENCES, INC.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>January&nbsp;15, 2002</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MANUFACTURING AND SUPPLY<BR>
AGREEMENT FOR N-ACETYLCYSTEINE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS AGREEMENT is made and entered into as of the 15th day of January, 2002.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>BY AND BETWEEN:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CUMBERLAND PHARMACEUTICALS INC., a corporation organized and existing under the laws of Tennessee,
United States, with its principal offices located at 209 Tenth Avenue South, Suite&nbsp;332, Nashville,
Tennessee, 37203 (hereinafter referred to as &#147;<B>CUMBERLAND</B>&#148;)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>AND:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BIONICHE LIFE SCIENCES INC., a corporation organized and existing under the laws of Ontario,
Canada, with its principal place of business located at 231 Dundas Street, East Belleville,
Ontario, Canada K8N 1E2 (hereinafter referred to as &#147;<B>BIONICHE</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, CUMBERLAND is the owner of certain intellectual property rights with respect to a Drug
Product (as hereinafter defined);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, BIONICHE has the expertise and the manufacturing facility suitable for the pharmaceutical
preparation and production of the Drug Product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, CUMBERLAND wishes to have BIONICHE manufacture the Drug Product on an exclusive basis for
sale in the Territory (as hereinafter defined) and BIONICHE wishes to supply the Drug Product on an
exclusive basis to CUMBERLAND on and subject to the terms and conditions set out herein;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>NOW, THEREFORE</B>, in consideration of the premises and the undertakings, terms, conditions and
covenants set forth below, the parties hereto agree as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>1. DEFINITIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 AFFILIATE </B>shall mean, with respect to any Person, any other Person that controls, is
controlled by or is under common control with, such Person. A Person shall be regarded as in
control of another Person if such Person owns, or directly or indirectly controls, more than fifty
percent (50%) of the voting securities (or comparable equity interests) or other ownership
interests of the other Person, or if such Person directly or indirectly possesses the power to
direct or cause the d<SUP style="font-size: 85%; vertical-align: text-top">i</SUP>rection of the management or policies of the other Person, whether
through the ownership of voting securities, by contract or any other means whatsoever.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 BUFFER SOLUTION </B>shall mean the buffer solution used for the manufacture of the Drug
Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.3 BULK DRUG SUBSTANCE </B>shall mean the active ingredients in the Drug Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.4 cGMP or GMP </B>shall have the meaning set forth in Schedule&nbsp;I.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.5 CONFIDENTIAL INFORMATION </B>shall have the meaning set forth in Article&nbsp;9.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.6 DEVELOPMENT </B>shall mean all work necessary to develop a process to manufacture the Drug
Product in full accord with cGMP and to supply the Drug Product conforming to the Specifications.
Development activities shall include, but not be limited to, pilot batches, scale-up batches,
validation of the manufacturing process, and successful completion of the Drug Product manufacture
and delivery as defined in Schedule&nbsp;I attached hereto.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.7 DRUG PRODUCT </B>shall mean the N-Acetylcysteine pharmaceutical product developed by
CUMBERLAND and marketed under the trade name ACETADOTE or any other trade name selected by
CUMBERLAND.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.8 EXCIPIENT </B>shall mean any inert substance selected by CUMBERLAND and used to give the Drug
Product proper consistency.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.9 FACILITY </B>shall mean the manufacturing facility and the real property underlying such
manufacturing facility operated by Bioniche Teoranta, an Affiliate of BIONICHE, located at
Inverin, Co. Galway, Republic of Ireland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.10 FDA </B>shall mean the United States Food and Drug Administration (FDA)&nbsp;or any successor
entity thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.11 IN-PROCESS SOLUTION </B>shall mean all Buffer Solutions and Excipients needed to produce
Drug Product in the finished dosage form set forth in Schedule&nbsp;I.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.12 INVENTION </B>shall have the meaning set forth in Paragraph&nbsp;9.4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.13 LABELING </B>shall mean all labels and other written, printed, or graphic matter upon: (i)
the Drug Product or any container or wrapper utilized with the Drug Product and (ii)&nbsp;any written
material accompanying the Drug Product, including without limitation, package inserts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.14 MANUAL </B>shall mean the Manufacturing Project Manual attached as Schedule&nbsp;II to this
Agreement and reviewed and accepted by CUMBERLAND and BIONICHE, the terms and provisions of which
are incorporated by reference as though fully set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.15 MANUFACTURE </B>shall mean the act of compounding, component preparations, filling,
packaging, testing and any other pharmaceutical manufacturing procedures, or any part thereof,
involved in manufacturing the Drug Product from the Bulk Drug Substance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.16 PERSON </B>shall mean an individual, corporation, partnership, limited liability company, or
any other form of entity not specifically listed herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.17 SPECIFICATIONS </B>shall mean those specifications set forth in Attachment I to the Manual.<BR>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.18 TERRITORY </B>shall have the meaning set forth in Schedule&nbsp;III.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2. DEVELOPMENT AND MANUFACTURING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.1 Initiation: </B>Upon request by CUMBERLAND and subject to the provisions hereof, BIONICHE,
directly or through an Affiliate thereof, shall Manufacture and package at the Facility all of
CUMBERLAND&#146;s requirements for Drug Product in the Territory in the batch size set forth in
Schedule&nbsp;I in accordance with the terms hereof, including without limitation, Schedules I and II
hereof, the Specifications, and all applicable laws and regulations. Prior to distributing and
selling the Drug Product, CUMBERLAND shall prepare and file submissions to the FDA in order to
obtain and maintain during the term hereof regulatory approval of the Drug Product, BIONICHE shall
prepare and test the Drug Product in accordance with cGMP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.2 Documentation: </B>BIONICHE shall provide CUMBERLAND with required supporting documentation
for the manufacture of the Drug Product in a form suitable for CUMBERLAND&#146;s submission to the FDA
or applicable governmental authorities for any country into which the Drug Product will be
distributed. BIONICHE shall provide draft Chemistry, Manufacturing, and Controls sections for
CUMBERLAND&#146;s FDA submissions,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.3 Bulk Drug Substance Supply: </B>BIONICHE shall be responsible for the supply of all Bulk Drug
Substance in accordance with Schedules I and II hereto; provided that the supply of Bulk Drug
Substance shall be exclusively from such suppliers and in such grades as have been approved in
writing by CUMBERLAND as reflected on an approved list to be attached hereto as Schedule&nbsp;IV, and
provided further that such suppliers and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">grades may not be changed without CUMBERLAND&#146;s prior written consent, which consent shall not
be unreasonably withheld or delayed. BIONICHE shall maintain, at its expense, secure storage areas
for the Bulk Drug Substance at the Facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.4 Supply of Components: </B>BIONICHE shall be responsible for the supply of all Buffer Solution,
Excipients, and all other components of the finished Drug Product in accordance with Schedules I
and II hereto; provided that the supply of these components shall be exclusively from such
suppliers and in such grades as have been approved in writing by CUMBERLAND as reflected on an
approved list to be attached hereto as Schedule&nbsp;IV, and provided further that such suppliers and
grades may not be changed without CUMBERLAND&#146;s prior written consent which consent shall not be
unreasonably withheld or delayed. BIONICHE shall maintain, at its expense, secure storage areas for
the Buffer Solution, Excipients, and all other components at the Facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.5 Delivery Terms: </B>All deliveries of Drug Product under this Agreement shall be made by
BIONICHE to CUMBERLAND in the manner set forth in Schedule&nbsp;I. CUMBERLAND shall, within twenty (20)
working days after its receipt of any shipment, notify BIONICHE in writing, of any claim relating
to a Drug Product not conforming to GMP or to the Specifications, and, failing such notification,
notwithstanding Paragraph&nbsp;5.1 of this Agreement, CUMBERLAND shall be deemed to have accepted the
Drug Product. If BIONICHE disputes CUMBERLAND&#146;s claim that the Drug Product is non-conforming, then
such dispute shall be resolved by an independent testing organization of recognized repute within
the pharmaceutical industry mutually agreed upon by BIONICHE and CUMBERLAND, the appointment of
which shall not be unreasonably withheld or delayed by either party. In such event, CUMBERLAND
shall ship the testing organization representative samples of the Drug Product from the disputed
production lot, and the fees and costs of such testing organization and related shipping and supply
costs shall be borne by the party whose position is not sustained by the testing organization.
Should CUMBERLAND&#146;s claim of non-conformity be sustained by the testing organization, BIONICHE
shall, at CUMBERLAND&#146;S sole option, (a)&nbsp;credit towards future orders, or (b)&nbsp;refund within thirty
(30)&nbsp;days thereof; the payment for such non-conforming goods, plus the cost to CUMBERLAND of
Manufacturing and shipping the related Bulk Drug Substance and components.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.6 Forecasts: </B>In order to permit BIONICHE to regularly supply CUMBERLAND with Drug Product
hereunder, at least &#091;***&#093; prior to its first requested delivery date, CUMBERLAND shall provide
BIONICHE a non-binding twelve (12)&nbsp;month rolling forecast (the &#147;Forecast&#148;) of CUMBERLAND&#146;s
estimated requirements of Drug Product, itemized for use as commercial product or Regulatory
Samples (as defined below), for the term of this Agreement. The Forecast shall be reviewed and
updated by CUMBERLAND on a monthly basis, with copies delivered to BIONICHE. BIONICHE shall have an
opportunity to confirm its ability to deliver the quantities set out in the Forecast and each
update thereto, or to request amendments thereto to ensure its ability to supply. Once accepted by
BIONICHE, the first three (3)&nbsp;months of each Forecast shall constitue a firm order for Drug
Product. Each such Forecast shall reflect a good faith attempt by CUMBERLAND to estimate quantity
requirements of Drug Product, based on anticipated demand therefore.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.7 Periodic Orders: </B>A purchase order (the &#147;Purchase Order&#148;) shall be provided by CUMBERLAND
to BIONICHE with respect to Drug Product to be supplied at least &#091;***&#093; prior to the scheduled
delivery date of such Drug Product. Such Purchase Order shall specify the quantities ordered by
CUMBERLAND for delivery by BIONICHE hereunder and the requested delivery date therefore, and, once
delivered to BIONICHE, and shall be firm and binding on the parties (the &#147;Delivery Date&#148;). Each
such Purchase Order shall become firm and binding on the parties and, except as specifically
provided for herein, may not be increased or decreased by more than &#091;***&#093; from the quantities shown
in the Forecast accepted by BIONICHE pursuant to Section&nbsp;2.6 without the prior written approval of
the parties. If CUMBERLAND requires quantities of Drug Product exceeding <I>those </I>mentioned in the
Forecast, as updated, BIONICHE shall deliver the amount indicated in the Forecast on the scheduled
Delivery Date and shall use reasonable efforts to supply the additional amount exceeding such
Forecast on the scheduled Delivery Date, but shall have no liability for failure to deliver the
additional amount. Each Purchase Order shall constitute a separate agreement to purchase Drug
Product but where in conflict with the terms and conditions of this Agreement, this Agreement, and
not the standard terms and conditions set forth in the purchase orders, shall govern the
Manufacturing, purchase and sale of the Drug
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product under this Agreement. Any Purchase Order for Drug Product shall be placed in the minimum
amounts listed below or in integral multiples thereof.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">For the 10mL form of Drug Product&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;<BR>
For the 30mL form of Drug Product&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.8 Failure to Supply: </B>Subject to the provisions of Article&nbsp;7, BIONICHE shall supply all of
the Drug Product ordered by CUMBERLAND within &#091;***&#093; of receipt of a written order from CUMBERLAND.
If BIONICHE is unable to meet its supply obligations with respect to any Purchase Order,
CUMBERLAND shall be free to procure from third parties part or all of the quantities of the Drug
Product covered by the relevant Purchase Order. In the event that BIONICHE is unable to supply the
Drug Product to CUMBERLAND for any reason other than for Force Majeure or failure of CUMBERLAND to
fulfill its obligations hereunder, BIONICHE will reimburse CUMBERLAND for any increase in the
price of obtaining the Drug Product from an alternate supplier; provided that such replacement
Drug Product was purchased on reasonable commercial terms, and provided further that such failure
to supply was in respect of Drug Product that was the subject of a Purchase Order provided by
CUMBERLAND and accepted by BIONICHE under Paragraph&nbsp;2.7. Should BIONICHE reimburse CUMBERLAND as
set out in this paragraph, BIONICHE shall have no further liability to CUMBERLAND for said failure
to supply.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.9 Payment for the Drug Product: </B>At the time of each shipment, BIONICHE shall invoice
CUMBERLAND for BIONICHE&#146;s manufacturing services at the prices set forth in Schedule&nbsp;I. Payment
shall be made in Canadian dollars within &#091;***&#093; of each such shipment of conforming Product in
accordance with the terms hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.10 Price Variations:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Prices are as set on Schedule&nbsp;I for the term hereof unless changed pursuant to Paragraph
2.10(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Subject to Subparagraph 2.10(c), prices are subject to annual adjustment beginning two
(2)&nbsp;years after the date hereof. Price increases or decreases will be commensurate with documented
Manufacturing cost increases or decreases since the date that the then-current prices became
effective. For purposes hereof, &#147;Manufacturing cost&#148; shall mean, with respect to the Drug Product,
BIONICHE&#146;s actual and documented cost of raw materials, direct labor, Manufacturing, packaging,
and overhead amounts directly applicable to such Manufacturing costs (including appropriately
amortized capital equipment costs and excluding non-manufacturing overhead and allocations and
excluding costs representing Manufacturing changes for which CUMBERLAND does not provide prior
written consent pursuant to Article&nbsp;8), calculated in accordance with generally accepted
accounting principles consistently applied (the allocation of overhead to be consistent with
BIONICHE&#146;s allocation of overhead as of the date of this Agreement). CUMBERLAND reserves the right
to audit the records of BIONICHE in order to determine that such increases and/or decreases are
appropriate. Any increase in price shall not exceed the twelve (12)&nbsp;month percent increase in the
Producer Price Index as published by the U.S. government and shall be further subject to a maximum
increase of five percent (5%) per year over the life of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding any of the contrary herein contained, should CUMBERLAND: (i)&nbsp;request a
change in Specifications, or (ii)&nbsp;unreasonably withhold the consent requested under Paragraphs 2.3
or 2.4, which request or refusal results in an increase in Manufacturing Costs, BIONICHE shall be
entitled to pass on such costs to CUMBERLAND immediately in the form of a Drug Product price
increase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. TERM AND TERMINATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Term: </B>This Agreement shall commence on the date first above written and will continue
until the fifth anniversary of the date on which the FDA grants approval to market and sell the
Drug Product, unless sooner terminated pursuant to Paragraphs 3.2 or 3.3 hereof. Subject to
Paragraphs 3.2 and 3.3, the Agreement shall be automatically renewed for successive three-year
terms unless either party notifies the other party in writing at least twelve (12)&nbsp;months in
advance of the expiration of the then current term that the party is terminating the Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Termination: </B>This Agreement may be terminated at any time upon the occurrence of any of
the following events:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Default: Thirty (30)&nbsp;days following written notice, by either party to the other party, in
the event that the other party breaches any provision of this Agreement, and such party fails to
remedy the breach prior to the expiration of the thirty (30)&nbsp;day period; provided that, in the case
of nonpayment of sums due hereunder, the remedy period shall be decreased to ten (10)&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Insolvency: Written notice by either party to the other upon insolvency or bankruptcy of
the other party, and the failure of any such insolvency or bankruptcy to be dismissed within sixty
(60)&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Force majeure: If, as a result of causes described in Paragraph&nbsp;7.1, either party is
unable to fully perform its obligations hereunder for a period of one hundred fifty (150)
consecutive days, the other party shall have the right to terminate this Agreement upon at least
thirty (30)&nbsp;days prior written notice; provided that if the required performance is met during that
thirty-day period, this Agreement shall continue in full force and effect as if the notice had not
been given.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Costs: Immediately upon written notice by BIONICHE to CUMBERLAND if the Manufacturing cost
per unit of Drug Product calculated in the manner set forth in Paragraph&nbsp;2.10(a) hereof exceeds the
purchase price per unit of Drug Product set forth in Schedule&nbsp;I, as adjusted pursuant to Paragraphs
2.10(b) and/or (c)&nbsp;hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No FDA Approval: Immediately upon written notice by BIONICHE to CUMBERLAND if the FDA does
not grant CUMBERLAND approval to market and sell the Drug Product on or before the second
anniversary of the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;By mutual agreement of the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise specifically set forth in this Paragraph&nbsp;3.2, termination, expiration,
cancellation or abandonment of this Agreement, through any means and for any reason, shall not
relieve the parties of any obligation accruing prior thereto and shall be without prejudice to the
rights and remedies of either party with respect to any antecedent breach of any of the provisions
of this Agreement. Without limiting the generality of the foregoing, termination, expiration,
cancellation, or abandonment of this Agreement shall not relieve CUMBERLAND of its obligation to
pay the royalty provided for under Schedule&nbsp;I for Drug Product manufactured by BIONICHE hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Minimum Quantities Purchased: </B>If the parties fail to agree on minimum purchase quantities
as provided under Paragraph&nbsp;5.7, or if following such agreement, CUMBERLAND should fail to meet the
agreed upon minimum purchase requirements, BIONICHE shall have the right (but not the obligation)
to terminate this Agreement in its entirety or with respect to any one or more format of the Drug
Product upon ninety (90)&nbsp;days notice; provided, however, that CUMBERLAND shall have the right (but
not the obligation) within such ninety (90)&nbsp;day period to pay BIONICHE any short-fall and avoid
such termination. Such shortfall shall be calculated by subtracting the purchase price of the
amount of each format of Drug Product actually ordered from the amount calculated by multiplying
the minimum quantity of such format under Schedule&nbsp;V by the purchase price thereof. It is
understood and agreed between the parties that BIONICHE shall not be required to supply Drug
Product for such payment. Should BIONICHE exercise its right to terminate under this Paragraph&nbsp;3.3,
CUMBERLAND shall have no liability to BIONICHE for failing to purchase any minimum quantity of Drug
Product hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.4 Impact of Termination on Outstanding Purchase Orders: </B>Upon termination of the Agreement
for any reason whatsoever (except for termination by either party pursuant to Paragraphs 3.2(a),
(b), or (c), or upon expiration of this Agreement), BIONICHE will, at CUMBERLAND&#146;s written request
delivered after termination, continue to supply Drug Product to CUMBERLAND in satisfaction of
Purchase Orders already submitted to BIONICHE, subject to the same terms and conditions as applied
during the term of the Agreement, for a period of sixty (60)&nbsp;days from the date of termination or
expiration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.5 Survival: </B>Paragraphs 2.5, 2.8, 3.2, 3.3, and 3.5 and Articles 5, 6, 9, and 10 shall
survive the termination or cancellation of the Agreement for any reason.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4. CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.1 Certificates of Analysis: </B>BIONICHE shall perform, or cause to be performed, certain tests
requested by CUMBERLAND in writing and as indicated in the Specifications on each batch of the Drug
Product manufactured pursuant to this Agreement before delivery to CUMBERLAND. A certificate of
analysis for each batch delivered shall be delivered with each batch and shall set forth the items
tested, specifications, and test results. BIONICHE shall also indicate on the certificate of
analysis that all batch production and control records have been reviewed and approved by the
appropriate quality control unit. Subject to Paragraph&nbsp;2.5, CUMBERLAND shall test, or cause to be
tested, prior to final release, each batch of the Drug Product as meeting the Specifications. As
required by the FDA (see Paragraph&nbsp;5.2 below), CUMBERLAND shall assume full responsibility for
final release of each lot of the Drug Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.2 Manufacturing Compliance: </B>BIONICHE shall advise CUMBERLAND immediately if an authorized
agent of any regulatory body visits the Facility and makes an inquiry regarding BIONICHE&#146;s method
of manufacture of the Drug Product for CUMBERLAND. Upon receipt of any Form&nbsp;483 Notice of
Inspectional Observations issued by the FDA or notice of deficit from any other regulatory
inspection after a visit to the Facility, BIONICHE shall immediately send CUMBERLAND a copy
thereof; provided that it may redact any language that is subject to a written confidentiality
agreement between BIONICHE and a third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.3 Regulatory Agency Requirements: </B>BIONICHE shall prepare and test the Drug Product in
conformity with GMP. Subject to the allocation of responsibility for regulatory compliance as set
forth in Paragraph&nbsp;5.2, each party shall consult with the other party hereto before implementing
additional regulatory agency requirements concerning the control of Drug Product components,
manufacture of the Drug Product, or storage and handling of the Drug Product. The full text of
regulatory agency requests or comments will be provided by the party receiving such requests or
comments to the other party hereto. The parties will mutually agree on how to respond to such
requests and comments and on the allocation of the costs thereof; provided that BIONICHE shall be
entitled to reimbursement from CUMBERLAND for any out-of-pocket expenses or extraordinary costs
previously approved in writing by CUMBERLAND and required in connection with implementing such
regulatory requirements other than the ordinary costs of compliance with GMP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.4 Regulatory Documents: </B>Each party will advise the other party hereto of its intention to
change any Drug Product regulatory documents prior to submission of the document to any regulatory
body. If the change affects the rights and obligations of a party hereto under this Agreement, such
party may seek to review or alter any part of the document at any time within ten (10)&nbsp;business
days after receipt of notification thereof; provided that if no alterations are submitted to the
other party within such ten-day period, each party will be deemed to have consented to the
documents, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. REPRESENTATIONS AND WARRANTIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.1 Conformity with Specifications: </B>BIONICHE represents and warrants that, at the time of
Manufacture, the Drug Product is prepared and tested in accordance with cGMP and meets the
Specifications. In the event that any production lot of a Drug Product is not Manufactured in
accordance with the Specifications or other requirements hereunder, BIONICHE shall, at CUMBERLAND&#146;s
request, perform new Manufacturing as necessary to fulfill any then outstanding purchase order of
CUMBERLAND. BIONICHE shall be fully responsible for the costs of any Bulk Drug Substance or
components required for such new Manufacturing. Because BIONICHE has no control of the conditions
under which the Drug Product is used, the diagnosis of the patient before or after treatment with
the Drug Product, the method of use or administration of the Drug Product, and handling of the Drug
Product after delivery to CUMBERLAND, BIONICHE does not warrant either a good effect, or against an
ill effect, following the use of the Drug Product. The foregoing warranty is exclusive and in lieu
of all other warranties either written, oral, or implied. No representative of BIONICHE may change
any of the foregoing warranties and CUMBERLAND accepts the Drug Product subject to all terms
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXCEPT AS SPECIFICALLY PROVIDED FOR IN THIS ARTICLE 5 AND PARAGRAPH 11.4, BIOMCHE MAKES NO
REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED (i)&nbsp;OF COMMERCIAL UTILITY; (ii)&nbsp;OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii)&nbsp;THAT THE USE OF THE DRUG PRODUCTS BY
CUMBERLAND OR ANY THIRD PARTY WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR TRADEMARK OR OTHER
PROPRIETARY OR PROPERTY
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RIGHTS OF OTHERS. EXCEPT AS PROVIDED FOR HEREIN, BIONICHE WILL NOT BE LIABLE TO CUMBERLAND,
CUMBERLAND&#146;S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM ARISING FROM
CUMBERLAND&#146;S OR ANY THIRD PARTY&#146;S USE OF THE DRUG PRODUCTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CUMBERLAND ACCEPTS ALL RISK AND RESPONSIBILITY FOR DETERMINING THE MANNER IN WHICH CUMBERLAND
WILL USE THE DRUG PRODUCTS, AND BIONICHE MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING, AND
ASSUMES NO RESPONSIBILITY FOR, THE PERFORMANCE OF ANY OTHER PRODUCT(S) INTO WHICH THE DRUG
PRODUCTS MAY BE INCORPORATED.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.2 Compliance: </B>CUMBERLAND represents and warrants that CUMBERLAND assumes responsibility for
coordinating all contact with the FDA and other regulatory bodies, pertaining specifically to the
Drug Product. During the term of this Agreement, BIONICHE authorizes CUMBERLAND&#146;s representatives
to inspect the methods used in and facilities used for manufacturing, processing, packaging, and
handling of the Drug Product; provided that each such inspection shall be at CUMBERLAND&#146;S own
cost, on reasonable prior notice, and subject to the prior execution of reasonable confidentiality
agreement by each inspector who is not an employee of CUMBERLAND but has been selected by
CUMBERLAND to represent it; and provided further that CUMBERLAND shall have no such obligation
under this Agreement. Except as otherwise required by applicable regulations, CUMBERLAND&#146;s
inspections shall be conducted during normal business hours; provided that CUMBERLAND may inspect
such facilities immediately after any regulatory inspection thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.3 Debarring: </B>BIONICHE represents and warrants that it has not been debarred in the United
States within the meaning of 21 U.S.C. &#167; 335a(a) and 335a(b), nor will it use, knowingly after due
inquiry, in any capacity the services of any person debarred pursuant to subsections 3.06(a) or
3.06(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 335(a) and (b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.4 FDA Submission: </B>BIONICHE represents and warrants that it has submitted to the FDA
information about the Facility and the operating procedures, and personnel at such site in the
form required by the FDA. BIONICHE shall keep and maintain the equipment necessary for the
Manufacture of any Drug Product in a manufacture-ready state and in good repair. During the term
hereof and until the fifth anniversary of termination or expiration, BIONICHE shall maintain
written documentation of all use, repair, service, and maintenance of such equipment and shall
provide CUMBERLAND copies of such documentation; provided that in the event that a Person acquires
substantially all of the assets and business of BIONICHE, BIONICHE may send all such documentation
to CUMBERLAND promptly after such acquisition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.5 Reimbursement: </B>BIONICHE shall not incur any costs for which it intends to seek
reimbursement from CUMBERLAND unless BIONICHE has the prior written consent of CUMBERLAND.
CUMBERLAND shall reimburse BIONICHE at a rate equal to one hundred fifty percent (150%) of all
such costs actually incurred and documented and directly related to the production of materials or
data for submissions to the FDA (&#147;Pre-Approval Costs&#148;) hereunder, provided that reimbursement of
such Pre-Approval Costs shall be paid by means of twelve (12)&nbsp;equal installments thereof to be
made on the first day of each of the twelve (12)&nbsp;months following the date on which the FDA issues
final approval to CUMBERLAND to market and sell the Drug Product commercially in the United States
(the &#147;Approval Date&#148;); and provided further that if the Approval Date has not occurred on or
before one year from the date of signing of the Agreement then CUMBERLAND shall immediately
reimburse BIONICHE at a rate equal to one hundred percent (100%) of all Pre-Approval Costs
incurred prior to such date in complete satisfaction of its obligations to reimburse such
Pre-Approval Costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.6 Exclusivity:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Neither BIONICHE nor any Affiliate thereof will sell, give away, or deliver to any other
person, firm, or corporation any form of the Drug Product in the Territory for indications
currently approved as of the date of signing this Agreement (&#147;currently-approved indications&#148;),
while this Agreement is effective and for two years after the termination of this Agreement;
provided that such restrictions shall not apply in the event of termination by BIONICHE pursuant to
Subparagraphs 3.2 (a), (b), (e), or Paragraph&nbsp;3.3 and shall not apply to the sale by BIONICHE of a
product that contains the same active ingredients as the Drug Product for use as a chemoprotectant
(&#147;Excluded Products&#148;) or Other Products, as defined below, subject to the rights set out in
Subparagraph 5.6 (d).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If, during the term hereof, BIONICHE wishes to market or distribute Excluded Products <I>in</I>
the Territory in association with any third Person, BIONICHE shall give CUMBERLAND written notice
thereof, and CUMBERLAND shall have thirty (30)&nbsp;days to notify BIONICHE of its interest in entering
into an arrangement with BIONICHE, on terms to be negotiated by the parties in good faith during
the period of one hundred twenty (120)&nbsp;days immediately following the receipt by CUMBERLAND of
such notice (the &#147;Option Period&#148;). If the parties negotiate in good faith but do not conclude an
agreement within the Option Period, BIONICHE agrees not to enter into an agreement covering the
Excluded Products <I>in </I>the Territory with any third Person on terms that are more favorable than the
terms previously offered to CUMBERLAND without first offering to enter into an agreement with
CUMBERLAND, to be negotiated during an additional thirty day period, such offer to be made on
terms no less favorable than the terms being offered to the third Person. If CUMBERLAND does not
enter into negotiations with BIONICHE within thirty (30)&nbsp;days following receipt of such notice,
then BIONICHE shall be free to negotiate with third Persons with no further obligation to
CUMBERLAND.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding the provisions of Subparagraph 5.6 (b)&nbsp;above, BIONICHE shall have no
obligation to make any offer to CUMBERLAND with respect to any development, marketing or sale of
Excluded Products in the Territory if it chooses to so develop, market or sell directly, rather
than in association with any third Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;With respect to any product that contains the same active ingredient as the Drug Product
for indications other than Excluded Products that BIONICHE may seek to develop (&#147;Other Products&#148;),
BIONICHE shall provide notice to CUMBERLAND as set out in Subparagraph 5.6 (b)&nbsp;above, and the same
procedures shall apply. Likewise, with respect to any indications other than currently-approved
indications for the Drug Product that CUMBERLAND seeks to develop, CUMBERLAND shall provide notice
to BIONICHE regarding the possibility of supply of said Drug Product to CUMBERLAND and the
procedures described in Subparagraph 5.6 (b)&nbsp;above shall apply.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If CUMBERLAND does not acquire rights to Excluded Products or to Other Products as
described in Subparagraphs 5.6 (c)&nbsp;and (d)&nbsp;above, and CUMBERLAND establishes, through the dispute
resolution process set forth in Paragraph&nbsp;11.7, that sales by BIONICHE of said products have
detrimentally impacted sales of the Drug Product then BIONICHE shall pay CUMBERLAND an amount
equal to the lost profits so established by CUMBERLAND. CUMBERLAND shall bear the burden of
establishing lost sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except in the event that BIONICHE fails to supply all Drug Product ordered within ninety
(90)&nbsp;days of receipt of a Purchase Order in accordance with Paragraph&nbsp;2.7, or in the event of
Force Majeure, CUMBERLAND will order its entire requirement of the Drug Product for the Territory
from BIONICHE, If CUMBERLAND notifies BIONICHE that it intends. to distribute the Drug Product in
countries other than the United States and its territories, then the parties shall negotiate in
good faith, for a period not to exceed one hundred twenty (120)&nbsp;days after CUMBERLAND provides
such notice, to amend this agreement to expand the Territory hereunder; provided that if the
parties fail to agree upon the terms of supply for an expanded Territory within such 120-day
period, CUMBERLAND shall have no obligation to purchase requirements of Drug Products for such
other countries from BIONICHE, but its obligations hereunder with respect to the United States and
its territories shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;In the event of breach of this Paragraph&nbsp;5.6, the parties shall have the right, in
addition to other rights hereunder, to seek injunctive relief, notwithstanding any other provision
of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.7 Minimum Purchase Quantities: </B>CUMBERLAND shall have no minimum purchase requirements for
the first year following FDA approval of the Drug Product. The parties shall, no later than three
(3)&nbsp;months before the end of the first year following FDA approval, negotiate in good faith to set
on the minimum quantities applicable to the second to fifth years of commercial sale, which shall
be incorporated into Schedule&nbsp;V and shall form part of this Agreement. The parties shall negotiate
in good faith to set additional minimum purchase requirements for any extension of the Term of
this Agreement under Paragraph&nbsp;3.1. CUMBERLAND shall use its best efforts to achieve the minimum
purchase requirements set forth in Schedule&nbsp;V of this Agreement for each format of Drug Product
being sold in the Territory by CUMBERLAND. In the event CUMBERLAND is required to procure Drug
Product from other sources in accordance with Paragraph&nbsp;2.7, the minimum annual purchase
obligation set out in Schedule&nbsp;V shall be decreased by the quantity BIONICHE failed to deliver
hereunder.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6. DRUG PRODUCT RECALLS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.1 Drug Product Recalls: </B>In the event: (a)&nbsp;any government authority issues a request,
directive or order that the Drug Product be recalled, or (b)&nbsp;a court of competent jurisdiction
orders such a recall, (c)&nbsp;CUMBERLAND determines that the Drug Product should be recalled, or (d)
BIONICHE recommends to CUMBERLAND that a recall be initiated, the parties shall take all
appropriate corrective actions; provided that a recall pursuant to Subparagraph 6.1 (c)&nbsp;shall be
without prejudice to the parties&#146; rights under Paragraph&nbsp;2.5. In the event that BIONICHE
recommends a recall of Drug Product by CUMBERLAND, such recommendation must take the form of a
notice as per Paragraph&nbsp;11.1, and CUMBERLAND shall respond promptly indicating to BIONICHE whether
the Drug Product will be recalled. In no event, however, shall BIONICHE have responsibility for
regulatory compliance in connection with any recall, except to the extent and under the
circumstances set forth in the Manual or any other written agreement between the parties hereto or
as required by law. All costs and expenses incurred in connection with such recall shall be the
responsibility of CUMBERLAND unless caused by the negligence of BIONICHE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7. FORCE MAJEURE; FAILURE TO SUPPLY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.1 Force Majeure Events: </B>Failure of either party to perform under this Agreement (except the
obligation to make payments) shall not subject such party to any liability to the other if such
failure is caused by acts such as, but not limited to, acts of God, fire, explosion, flood, war,
riot, sabotage, embargo, or by any cause beyond the reasonable control of the parties, provided
that written notice of such event is promptly given to the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>8. MANUFACTURING CHANGES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BIONICHE may implement commercially reasonable changes in the equipment used for
Manufacturing of the Drug Product in the Facility, or the Manufacturing methods, labeling, or
packaging of the Drug Product only as expressly provided in the Specifications unless BIONICHE has
the prior written consent of CUMBERLAND, which consent shall not be unreasonably withheld or
delayed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>9. CONFIDENTIALITY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.1 Confidential Information: </B>&#147;Confidential Information&#148; means collectively Confidential
Information of CUMBERLAND (as defined herein) and Confidential Information of BIONICHE (as defined
herein).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.2 Confidential Information of CUMBERLAND: </B>Except as expressly set forth herein,
&#147;Confidential Information of CUMBERLAND&#148; means all information obtained or developed by BIONICHE
which relates to CUMBERLAND&#146;s business or the Drug Product, regardless of the form in which such
information is transmitted. The following shall not be considered Confidential Information of
CUMBERLAND for purposes hereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Information that is already in the possession of BIONICHE at the time it is received from
CUMBERLAND or developed by BIONICHE on CUMBERLAND&#146;s behalf, if BIONICHE notifies CUMBERLAND of its
belief that the information is excepted under the terms of this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Information received by BIONICHE from a person <I>which </I>has the right to disclose the same,
when BIONICHE notifies CUMBERLAND of its belief that the information is excepted under the terms
of this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of BIONICHE;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;An Invention as defined in Paragraph&nbsp;9.4; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Confidential Information of BIONICHE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of CUMBERLAND, BIONICHE shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of CUMBERLAND. BIONICHE shall not use or permit the use of the
Confidential Information of CUMBERLAND other than for the limited purposes expressly permitted by
or consistent with this Agreement. Recipients of Confidential Information of CUMBERLAND shall be
granted access thereto strictly on a &#147;need-to-know&#148; basis. BIONICHE shall take all reasonable steps
to ensure that recipients comply with the terms of this Agreement, including all restrictions on
use, disclosure and dissemination of Confidential Information of CUMBERLAND. BIONICHE shall notify
CUMBERLAND immediately upon becoming aware of any breach hereof and shall take all reasonable steps
to prevent any further disclosure or unauthorized use.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination or expiration of this Agreement, BIONICHE shall deliver to CUMBERLAND all
Confidential Information of CUMBERLAND, all copies thereof, and all documents or data storage media
containing such Confidential Information of CUMBERLAND, except that one copy of such information
may be retained by BIONICHE as required by regulation or law for future reference. The Confidential
Information of CUMBERLAND shall remain confidential and not be disclosed by BIONICHE for a period
of ten (10)&nbsp;years following the date of expiration or termination of this Agreement except as
expressly set forth herein or in any other written agreement between the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.3 Confidential Information of BIONICHE: </B>Except as expressly set forth herein, &#147;Confidential
Information of BIONICHE&#148; means all information obtained or developed by CUMBERLAND which relates to
the manufacture, sale, and distribution of pharmaceutical products by BIONICHE, regardless of the
form in which such information is transmitted. The following shall not be considered Confidential
Information of BIONICHE for purposes hereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Information that is already in the possession of CUMBERLAND at the time it is received
from BIONICHE or developed by CUMBERLAND on BIONICHE&#146;s behalf, if CUMBERLAND notifies BIONICHE of
its belief that the information is excepted under the terms of this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Information received by CUMBERLAND from a person which has the right to disclose the same,
when CUMBERLAND notifies BIONICHE of its belief that the information is excepted under the terms of
this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of CUMBERLAND; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Confidential Information of CUMBERLAND.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of BIONICHE, CUMBERLAND shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of BIONICHE. CUMBERLAND shall not use or permit the use of the
Confidential Information of BIONICHE other than for the limited purposes expressly permitted by or
consistent with this Agreement. Recipients of Confidential Information of BIONICHE shall be granted
access thereto strictly on a &#147;need-to-know&#148; basis. CUMBERLAND shall take all reasonable steps to
ensure that recipients comply with the terms of this Agreement, including all restrictions on use,
disclosure and dissemination of Confidential Information of BIONICHE. CUMBERLAND shall notify
BIONICHE immediately upon becoming aware of any breach hereof and shall take all reasonable steps
to prevent any further disclosure or unauthorized use.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination or expiration of this Agreement, CUMBERLAND shall deliver to BIONICHE all
Confidential Information of BIONICHE, all copies thereof, and all documents or data storage media
containing such Confidential Information of BIONICHE, except that one copy of such information may
be retained by CUMBERLAND as required by regulation or law for future reference. The Confidential
Information of BIONICHE shall remain confidential and not be disclosed by CUMBERLAND for a period
of ten (10)&nbsp;years following the date of expiration or termination of this Agreement except as
expressly set forth herein or in any other written agreement between the parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.4 Invention: </B>As between the parties, CUMBERLAND owns all intellectual property rights in any
improvement to the Drug Product and, subject to Paragraph&nbsp;5.6, any existing or further developments
or modifications of the Drug Product in the Territory (&#147;Invention&#148;). Subject to Article&nbsp;10,
BIONICHE shall, at CUMBERLAND&#146;s request and expense, take such actions and execute such documents
as necessary or desirable, in CUMBERLAND&#146;s sole judgment, to create, maintain, enforce or defend
CUMBERLAND&#146;s rights in any such Invention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.5 Press Release; Other Disclosure: </B>Except pursuant to a press release subject to the prior
written approval of both parties hereto, the parties agree that the contents of this Agreement
shall not be disclosed to any third party except (i)&nbsp;the controlling companies of the parties, (ii)
the companies controlled by the parties, (iii)&nbsp;individuals and entities providing paid services to
either of the parties who are bound by confidentiality obligations, and (iv)&nbsp;governmental
regulatory agencies, including, but not limited to, environmental protection authorities, without
prior written consent of the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.6 Production of Records: </B>BIONICHE shall prepare, maintain, and submit all documents or
reports required under applicable laws and regulations or as reasonably requested by CUMBERLAND
concerning the Manufacture of the Drug Products, including without limitation, batch production
records for each Drug Product. Notwithstanding the restrictions set forth in this Agreement,
BIONICHE shall retain production records for batches of Drug Product for a period of at least one
year after the respective expiration date for each batch. These records will be stored by
appropriate means, including without limitation, optical disk or microfilm in a secure manner in
compliance with current GMP with duplicate copies submitted to CUMBERLAND promptly after the
creation thereof and shall be made available on request of the FDA or any other authorized
regulatory body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>10. INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.1 Indemnification by CUMBERLAND: </B>Subject to Paragraph&nbsp;5.1, CUMBERLAND shall indemnify and
hold BIONICHE (and any Affiliate and their officers, directors, shareholders, agents, and the
employees and insurers of any of them and/or their successors and assigns thereto), free and
harmless from any and all claims, demands, liability, actions or causes of actions, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and reasonable attorney&#146;s fees), arising out of or in connection with, as a result of, or
otherwise related to any third party claims arising from: (i)&nbsp;any negligence or recklessness of
CUMBERLAND, its agents, or employees; (ii)&nbsp;the promotion, distribution, use, misuse or sale or
effects of the Drug Product except to the extent any alleged Drug Product defects were caused by
BIONICHE; (iii)&nbsp;CUMBERLAND&#146;s non-compliance with any applicable FDA or other applicable
regulations; or, (iv)&nbsp;any failure of CUMBERLAND to perform, in whole or in part, any of its
obligations hereunder in each case, unless caused by the acts or omissions of BIONICHE. Beginning
prior to delivery of the first order of Drug Products pursuant to this Agreement and continuing
until the third anniversary of termination of this Agreement, CUMBERLAND shall maintain products
liability insurance with limits of liability of not less than Five Million U.S. Dollars
($5,000,000) and shall name BIONICHE as additional insured under said policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.2 Indemnification by BIONICHE: </B>Subject to Paragraph&nbsp;5.1, BIONICHE will indemnify and hold
CUMBERLAND (and any Affiliate and their officers, directors, shareholders, agents, and the
employees and issuers of any of them and/or their successors and assigns thereto), free and
harmless from any and all claims, demands, liability, actions or causes of action, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and reasonable attorney&#146;s fees), arising out of or in connection with, as a result of, or
otherwise related to any third party claims arising from: (i)&nbsp;any negligence or recklessness of
BIONICHE, its agents or employees; (ii)&nbsp;personal injury (including death) or property damage
arising out of or in connection with BIONICHE&#146;s manufacture or handling of the Drug Product
otherwise than in accordance with the Specifications and CUMBERLAND&#146;S written directions; (iii)
BIONICHE&#146;s non-compliance with any applicable FDA or other applicable regulations; or (iv)&nbsp;any
failure of BIONICHE to perform any of its obligations hereunder, in each case, unless caused by the
acts or omissions of CUMBERLAND. Beginning prior to delivery of the first order for Drug Product
pursuant to this Agreement and continuing until the third anniversary of termination of this
Agreement, BIONICHE shall maintain products liability insurance with limits of liability of not
less than U.S. $5,000,000 and shall name CUMBERLAND as additional insured under said policy.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.3 Conditions of Indemnification: </B>If either party seeks indemnification from the other
under Paragraphs 10.1 or 10.2, it shall promptly give written notice to the other party of any
such claim or suit threatened, made or filed against it, which forms the basis for such claim of
indemnification and shall cooperate fully with the other party in the defense of all such claims
or suits. No settlement or compromise shall be binding on a party hereto without its prior written
consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.4 Limitation: </B>Except as expressly set forth herein, neither party will be liable to the
other for any claim for loss of profits, for loss or interruption of business or for indirect,
special or consequential damages of any kind under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>11. GENERAL PROVISIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.1 Notices: </B>Any notice permitted or required by this Agreement may be sent by facsimile with
the original document being sent by certified (or registered) mail, return receipt requested, or
overnight delivery and shall be effective when received (or refused) via facsimile or mail or
overnight if faxed and sent and addressed as follows (or to such other facsimile number or address
as may be designated by a party in writing):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>If to CUMBERLAND:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">209 Tenth Avenue South, Suite&nbsp;332</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;615-255-0068</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;615-255-0094</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to BIONICHE:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE LIFE SCIENCES, INC.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">231 Dundas Street East,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Belleville, Ontario, Canada K8N 1E2</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;800-265-5464</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;613-966-4177</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With a copy to:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE PHARMA (CANADA)&nbsp;LIMITED</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">151 Dundas Street, Suite&nbsp;507</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">London, Ontario, Canada N6A 5R7</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: President</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;519-453-0641</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;519-453-6169</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">And to:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE LIFE SCIENCES, INC.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Vice President, Corporate Counsel</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;800-265-5464</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;613-966-4177</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.2 Master Agreement; Amendment: </B>This Agreement is being entered into pursuant to the
Strategic Alliance Agreement dated January&nbsp;15, 2002, between CUMBERLAND and BIONICHE (the &#147;Master
Agreement&#148;), and this Agreement (including any and all exhibits hereto, whether entered into now or
hereafter) constitutes an Addendum (as defined in the Master Agreement). In the event of any
conflict or inconsistency between the terms of this Agreement and the Master Agreement, the terms
of this Agreement shall govern. No modification of any of the terms of this Agreement, or any
amendments thereto, shall be deemed to be valid unless in writing and signed by both parties
hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions
herein.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Without limiting the generality of the foregoing, no provisions of any CUMBERLAND purchase order
that are inconsistent with the terms of this Agreement shall apply.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.3 Waiver: </B>None of the provisions of the Agreement shall be considered waived by any party
hereto unless such waiver is agreed to, in writing, by both parties. The failure of a party to
insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any
party hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.4 Obligations to Third Parties: </B>Each party warrants and represents that this Agreement is
not inconsistent with any contractual obligations, expressed or implied, undertaken with any third
party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.5 Assignment: </B>This Agreement shall be binding upon and inure to the benefit of the
successors or permitted assigns of each of the parties and may not be assigned, transferred, or
subcontracted by either party without the prior written consent of&#146; the other, which consent will
not be unreasonably withheld or delayed, except that no consent shall be required in the case of a
transfer to an Affiliate of a party hereto or transaction involving the merger, consolidation or
sale of substantially all of&#146; the assets of the party seeking such assignment or transfer and such
transaction relates to the business covered by this Agreement and the resulting entity assumes all
the obligations of the assigning party under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.6 Independent Contractor: </B>BIONICHE shall act as an independent contractor for CUMBERLAND
in providing the services required hereunder and shall not be considered an agent of or joint
venturer with CUMBERLAND. Unless otherwise provided herein to the contrary, BIONICHE shall furnish
all expertise, labor, supervision, machining and equipment necessary for performance hereunder and
shall obtain and maintain all building and other permits and licenses required by public
authorities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.7 Governing Law and Dispute Resolution: </B>This Agreement is subject to and shall be governed
by the laws of the State of New York. Any dispute, controversy, or claim arising out of or
relating to this Agreement, any purchase orders between the parties hereto, or the breach,
termination, or invalidity thereof shall be settled under the Rules of the American Arbitration
Association by one or more arbitrators appointed in accordance with said Rules. The place of
arbitration shall be within the State of New York. The parties agree that the award of the
arbitrator(s) shall be the sole and exclusive remedy between them regarding any claims,
counterclaims, issues or accountings presented or pled to the arbitrator(s); that it shall be made
and shall promptly be payable in U.S. dollars free of any tax, deduction, or offset; that any
costs and attorney fees incurred by the prevailing party as determined by the arbitrator(s)
incident to the arbitration, shall be included as part of the arbitration award; and that any
costs. fees, or taxes incident to enforcing the award shall, to the maximum extent permitted by
law, be charged against the party resisting such enforcement. The award shall include interest
from the date of any damages incurred for breach or other violation of the Agreement, and from the
date of the award until paid in full, at a rate to be fixed by the arbitrator(s), but in no event
less than the prime interest rate for Bank of America in Nashville, Tennessee, U.S.A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.8 Severability: </B>In the event that any term or provision of this Agreement shall violate
any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or
otherwise be unenforceable, such provision shall be ineffective to the extent of such violation
without invalidating any other provision hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.9 Headings, Interpretation: </B>The headings used in this Agreement are for convenience only
and are not part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.10 Conflict: </B>In the event of conflict between the terms and provisions of this Agreement
and the terms and provisions of the Manual, the terms of this Agreement shall control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.11 Limitation: </B>The parties hereto acknowledge and agree that the International Sale of
Goods Act and the United Nations Convention on Contracts for the International Sale of Goods have
no application to this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly authorized representatives effective as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE LIFE SCIENCES, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A. J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Albert Beraldo</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Authorized Signature</TD>
    <TD></TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Authorized Signature</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Albert Beraldo</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Vice President, Business Development</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;remainder of the Schedule to be inserted as agreed to by the Parties&#093;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Shipping and Storage
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Finished Drug Product shall be stored by BIONICHE after completion, at &#95;&#95;&#95;degrees C
to &#95;&#95;&#95;degrees C.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Drug product will be delivered by BIONICHE to CUMBERLAND by air on the basis of FCA
(ex works) ex works BIONICHE&#146;s plant in Galway, Ireland with the carrier to be selected
by CUMBERLAND.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;FCA&#148; (&#147;ex works&#148;) and &#147;DDP&#148; and the Parties&#146; respective obligations
shall be determined in accordance with the INCOTERMS adopted by the International
Chamber of Commerce, effective July&nbsp;1, 1990, unless otherwise specifically provided in
this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Additional details regarding packaging shall be incorporated herein upon adoption
thereof by written agreement of BIONICHE and CUMBERLAND.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Pricing &#151;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The prices to be paid by CUMBERLAND to BIONICHE for the Drug Products arc as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">N-acetylcysteine 30 mL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;<BR>
N-acetylcysteine 10 mL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; currency conversions will be based upon the then current exchange rate listed in the Wall
Street Journal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The minimum size of any order of the Drug Product shall be one production lot of &#091;***&#093; for the 30
mL Drug Product and &#091;***&#093; for the 10 mL Drug Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;remainder of the Schedule to be inserted as agreed to by the Parties&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SCHEDULE II
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;to be inserted as agreed to by the Parties&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SCHEDULE III</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Territory </U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>The United States of America and all its possessions and territories</U>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SCHEDULE IV</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Approved Suppliers

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;to be inserted as agreed to by the Parties&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Schedule&nbsp;V</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Minimum Purchase Quantities</U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;to be inserted as agreed to by the Parties&#093;

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>g06286exv10w2.htm
<DESCRIPTION>EX-10.2 NOVATION AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.2 NOVATION AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.2</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXECUTION COPY
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOVATION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Novation Agreement (as amended, supplemented, restated or otherwise modified from time to
time, this &#147;Novation Agreement&#148;) is made as of January&nbsp;27, 2006 between:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 35%; margin-top: 6pt"><B>BIONICHE LIFE SCIENCES INC., </B>a corporation organized<BR>
under the laws of Canada<BR>
(&#147;<B>BLSI</B>&#148;),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 40%; margin-top: 6pt">and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 35%; margin-top: 6pt"><B>CUMBERLAND PHARMACEUTICALS INC., </B>a corporation<BR>
organized under the laws of the United States<BR>
(the <B>&#147;CPI&#148;</B>),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 40%; margin-top: 6pt">and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 35%; margin-top: 6pt"><B>BIONICHE PHARMA GROUP LIMITED, </B>a corporation<BR>
organized under the laws of Ireland<BR>
<B>(&#147;Pharma&#148;)</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 35%; margin-top: 6pt">(hereinafter collectively referred to as the &#147;Parties&#148;)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>RECITALS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A. BLSI and the CPI have entered into a Strategic Alliance Agreement dated January&nbsp;15, 2002 and a
Manufacturing and Supply Agreement for N-Acetylcysteine dated January&nbsp;15, 2002 copies of which are
annexed as Schedules &#147;A&#148; and &#147;B&#148; attached hereto (such agreements and contracts, together with all
notices, certificates, Agreement, instruments and other documents delivered or entered into in
connection therewith, as amended, supplemented, restated or otherwise modified from time to time,
are collectively referred to herein as the <B>&#147;Agreements"</B>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">B. BLSI desires to be released and discharged from its obligations to the CPI under the Agreements
and the CPI has agreed to release and discharge BLSI.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">C. The Parties have agreed that as and from the date of this Novation Agreement (the &#147;Effective
Date&#148;), the Agreements shall be novated to Pharma so that from the Effective Date Pharma shall be
bound by the terms of the Agreements in place of BLSI and agrees to acknowledge and expressly
assume in the name, place and stead of BLSI all liabilities and obligations of BLSI under the
Agreements.
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby
acknowledged by each party, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>SECTION
1 &#151; NOVATION AND RELEASE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.1 Novation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, Pharma agrees and undertakes to perform the obligations of BLSI
under the Agreements, whether arising prior to, on or subsequent to the Effective Date, and agrees
to be bound by the terms and conditions of the Agreements in every way as if Pharma were named as a
party to the Agreements in place of BLSI. Pharma agrees to perform any and all past, present and
future obligations of BLSI under the Agreements, including without limitation indemnification
obligations of BLSI arising out of any failure of BLSI to perform an obligation under the
Agreements prior to the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.2 Release of the Obligations of BLSI</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, the CPI and BLSI mutually release each other from the various
covenants, undertakings, warranties and other obligations contained in the Agreements and from all
claims and demands whatsoever in respect of the Agreements whether arising prior to, on or
subsequent to the Effective Date.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>SECTION 2 &#151; REPRESENTATIONS AND WARRANTIES OF BLSI AND PHARMA TO THE CPI</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BLSI and Pharma represent and warrant to the CPI as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.1 Status</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BLSI and Pharma are corporations duly constituted and validly existing and are in good
standing under the laws of their incorporating jurisdictions and are duly qualified to conduct
their business in each jurisdiction where the nature and extent of their business and property
require the same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.2 Authority</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BLSI and Pharma possess all requisite authority and power to execute, deliver and comply with
the terms of this Novation Agreement. This Novation Agreement has been duly authorized by all
necessary action, has been duly executed and delivered by BLSI and Pharma and constitutes a valid
and binding obligation of BLSI and Pharma enforceable in accordance with its terms, except as the
enforcement thereof may be limited by applicable bankruptcy, insolvency, moratorium, rearrangement,
reorganization or similar legislation affecting the rights of creditors generally.
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.3 Right to Novate</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BLSI has the right to novate its rights and benefits under the Agreements to Pharma, free and
clear of any charge, lien, pledge, security interest or direct or indirect participation interest
in favour of any other person, and as of the Effective Date, the Agreements are free and clear of
all charges, liens, pledges, security interests or direct or indirect participation interests in
favour of any other person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.4 Non-Conflict</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution nor the performance of this Novation Agreement requires the approval of
any governmental or regulatory agency having jurisdiction over BLSI or Pharma, nor is this
Novation Agreement in contravention of or in conflict with the articles, by-laws or resolutions of
the directors or shareholders of BLSI or Pharma, or, of the provisions of any agreement to which
BLSI or Pharma is a party, or by which any of the property of BLSI or Pharma may be bound, or of
any statute, regulation, by-law, ordinance or other law, or of any judgment, decree, award, ruling
or order to which BLSI or Pharma, or any of the property of BLSI or Pharma, may be subject.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2.5 Representations and Warranties Repeated</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma hereby makes the same representations and warranties with respect to itself that BLSI
made with respect to itself in the Agreements and Pharma represents and warrants to the CPI that
such representations and warranties are true and correct as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SECTION 3 &#151; REPRESENTATIONS AND WARRANTIES OF CPI TO PHARMA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The CPI represents and warrants to Pharma that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the representations and warranties of such CPI made in the Agreements are true
and correct as of the Effective Date,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>such CPI possesses all requisite power and authority to execute, deliver and
comply with the terms of this Novation Agreement, and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the novation hereunder has been duly authorized by all necessary action, has
been duly executed and delivered by such CPI and constitutes a valid and binding
obligation of such CPI enforceable in accordance with its terms, except as the
enforcement thereof may be limited by applicable bankruptcy, insolvency, moratorium,
rearrangement, reorganization or similar legislation affecting the rights of creditors
generally.</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SECTION 4 &#150; GENERAL</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.1 Severability</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any provision of this Novation Agreement is held to be illegal, invalid or unenforceable
under present or future laws effective during the term of this Novation Agreement, the legality,
validity and enforceability of the remaining provisions of this Novation Agreement shall not be
affected thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4.2 Multiple Counterparts</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Novation Agreement may be executed in a number of identical counterparts, each of which,
for all purposes, is to be deemed to be an original, and all of which constitute, collectively,
one agreement, but in making proof of this Novation Agreement, it shall not be necessary to
produce or account for more than one such counterpart.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4.3 Notices</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice given hereunder, under any of the Agreements or pursuant to the provisions hereof
or thereof shall be given in accordance with notice provisions of the Agreements, except that no
notice is required to be delivered to BLSI after the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of the notice provisions of the Agreements, address for notices or
communications to Pharma shall be as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bioniche Pharma Group Limited<BR>
Inverin County, Galway<BR>
Ireland<BR>
Telecopier: 011 353 91 593 228<BR>
Attention; Albert Beraldo, Chief Executive Officer

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4.4 Governing Law</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Novation Agreement shall be interpreted, construed and governed by and in accordance with
the laws of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4.5 Confirmation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereby confirm, in all other respects, that the Agreements are in full force and
effect, unchanged and unmodified, except in accordance with this Novation Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4.6 Further Assurances</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties shall, with reasonable diligence, do all such things and provide all such
reasonable assurances as may be required to consummate the transactions contemplated by this
Novation Agreement, and each party shall provide such further documents or instruments
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">required by any other party as may be reasonably necessary or desirable to effect the purpose
of this Novation Agreement and carry out is provisions,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties have executed this Novation Agreement and this Novation Agreement shall be
effective as of the Effective Date.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BIONICHE LIFE SCIENCES INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Graeme McRae
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD colspan="2" align="left">Graeme McRae&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD colspan="2" align="left">President &#038; CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CUMBERLAND PHARMACEUTICALS INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD colspan="2" align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD colspan="2" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BIONICHE PHARMA GROUP LIMITED</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John &#091;illegible&#093;
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD colspan="2" align="left">Dr. John &#091;illegible&#093;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD colspan="2" align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>g06286exv10w3.htm
<DESCRIPTION>EX-10.3 FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.3 FIRST AMENDMENT TO MANUFACTURING AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT<BR>
FOR N-ACETYLCYSTEINE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS FIRST AMENDMENT (the &#147;<U>First Amendment</U>&#148;) to that certain Manufacturing and Supply
Agreement for N-Acetylcysteine (the <SUP style="font-size: 85%; vertical-align: text-top">"</SUP><U>Agreement</U>&#148;), dated as of January&nbsp;15, 2002,
as modified by that certain Novation Agreement, dated as of January&nbsp;27, 2006 (to be attached
hereto), is entered into by and between CUMBERLAND PHARMACEUTICALS INC., a corporation organized
and existing under the laws of Tennessee, United States (&#147;<U>CUMBERLAND</U>&#148;), and BIONICHE
TEORANTA, a corporation organized and existing under the laws of Ireland (&#147;<U>BIONICHE</U>&#148;), and
is effective as of November&nbsp;16, 2006. Capitalized terms used but not defined in this First
Amendment shall have the meanings that are set forth in the Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WITNESSETH:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, BIONICHE is the assignee under the Agreement of BIONICHE PHARMA GROUP LIMITED, an
Affiliate thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, CUMBERLAND and BIONICHE agree that the exceptions to the exclusivity provisions set
forth in Paragraph&nbsp;5.6 of the Agreement which permit BIONICHE to (i)&nbsp;sell Excluded Products or
Other Products or (ii)&nbsp;market or distribute Excluded Products or Other Products in association with
any third Person other than CUMBERLAND in certain circumstances shall be deleted from the
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual covenants, agreements, representation and
warranties contained herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;1.7 is amended and restated in its entirety as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>DRUG PRODUCT </B>shall mean the N-acetylcysteine pharmaceutical product developed by
CUMBERLAND and marketed for any current or future approved indications under the
trade name ACETADOTE or any other trade name selected by CUMBERLAND.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;1.9 is hereby amended and restated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>FACILITY </B>shall mean the manufacturing facility and the real property underlying such
manufacturing facility operated by BIONICHE, located at Inverin, Co, Galway,
Republic of Ireland.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;1.18 defines <B>TERRITORY </B>as having the meaning set forth in Schedule
III. Schedule&nbsp;III of the Agreement, and therefore the TERRITORY, is hereby amended and
restated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The United States of America and all its possessions and territories, &#091;***&#093;.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;3.1 is amended and restated in its entirety as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall commence on the date first above written and will continue until
January&nbsp;23, 2011, unless sooner terminated pursuant to Paragraphs 3.2 or 3.3 hereof or
extended pursuant to this Paragraph&nbsp;3.1. CUMBERLAND shall have the option to extend the
duration of this Agreement for five (5)&nbsp;years upon prior written notice provided by
CUMBERLAND to BIONICHE at least 180&nbsp;days prior to January&nbsp;23, 2011; otherwise, the
Agreement shall expire on such date in accordance with its terms. If CUMBERLAND
exercises such option, then subject to Paragraphs 3.2 and 3.3, the Agreement shall be
automatically renewed for successive three-year terms after expiration of the initial
extended term, unless either party notifies the other party in writing at least twelve
(12)&nbsp;months in advance of the expiration of the then current term that the party is
terminating the Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subparagraphs 3.2(d) and (e)&nbsp;are deleted from the Agreement in their entirety and
Subparagraph 3.2(f) is re-lettered as 3.2(d).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;3.5 is amended by adding a reference to Paragraph&nbsp;3.4 thereto (such that
Paragraph&nbsp;3.4 is identified as a &#147;surviving&#148; provision.)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subparagraph 5.6(a) is amended and restated in its entirety as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither BIONICHE nor any Affiliate thereof will sell, give away, or deliver to any
other person, firm, or corporation any form of the Drug Product in the Territory for
any indications, while this Agreement is effective and for two years after the
termination of this Agreement; provided that such restrictions shall not apply in the
event of termination by BIONICHE pursuant to Subparagraphs 3.2(a) or (b), or Paragraph
3.3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subparagraphs 5.6(b), (c), (d), and (e)&nbsp;are deleted from the Agreement in their entirety;
Subparagraphs 5.6(f) and (g)&nbsp;are re-lettered as 5.6(b) and (c), respectively; and
Subparagraph 5.6(f) (re-lettered 5.6(b)) is amended and restated in its entirety as
follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except in the event that BIONICHE fails to supply all Drug Product ordered within
&#091;***&#093; of receipt of a Purchase Order in accordance with Paragraph&nbsp;2.7, or in the event
of Force Majeure, CUMBERLAND will order its entire requirement of the Drug Product for
the Territory from BIONICHE. If CUMBERLAND notifies BIONICHE that it intends to
distribute the Drug Product in countries not included in the Territory, then the
parties shall negotiate in good faith, for a period not to exceed &#091;***&#093; after
CUMBERLAND provides such notice, to amend this Agreement to expand the Territory
hereunder (and to add additional minimum purchase quantities for such expanded
Territory, as contemplated under Paragraph&nbsp;5.7); provided that, if the parties fail to
agree upon the terms of supply for an expanded Territory within such &#091;***&#093;, CUMBERLAND
shall have no obligation to purchase requirements of such Drug Products for such other
countries</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">from BIONICHE, but its obligations hereunder with respect to the Territory shall
remain in full force and effect.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;5.7 is amended and restated in its entirety as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CUMBERLAND shall use its best efforts to achieve the minimum purchase quantities set forth
in Schedule&nbsp;V to this Agreement for each format of Drug Product sold in the Territory by
CUMBERLAND. In the event CUMBERLAND is required to procure Drug Product from other sources
in accordance with Paragraph&nbsp;2.7, the minimum annual purchase obligation set out in Schedule
V shall be decreased by the quantity BIONICHE failed to deliver hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Schedule&nbsp;V of the Agreement is hereby stated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;11.1 is amended by replacing the address for notice (and relevant copies) for
CUMBERLAND and BIONICHE, as follows:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="72%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>If to CUMBERLAND:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue, Suite&nbsp;950</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;615-255-0068</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;615-255-0094</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to BIONICHE:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE TEORANTA</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inverin,<BR>
Co. Galway,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ireland</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Managing Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#043;353 91 593202</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#043;353 91 593228</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Miscellaneous.</TD>
</TR>


<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(a) <U>Authorization.</U> Each party to this First Amendment hereby represents and warrants
that the execution, delivery and performance of this First Amendment is within the powers of
such party and has been duly authorized by the party, is in accordance with all applicable
laws and regulations, and this First Amendment constitutes the valid and enforceable
obligation of each party in accordance with its terms.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(b)<U>Effect of First Amendment.</U> Each party acknowledges that this First Amendment
constitutes a written instrument as contemplated by Paragraph&nbsp;11.2 of the Agreement. Except
as specifically amended above, the Agreement shall remain in full force and effect, and is
hereby ratified and confirmed.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(c) <U>Counterparts.</U> This First Amendment may be executed in any number of
counterparts, each of which may be executed by only one of the parties hereto, and
each of which shall be enforceable against the party actually executing such
counterpart, and all of which shall together constitute one instrument.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(d) <U>Titles and Subtitles.</U> The titles and subtitles used in this First
Amendment are used for convenience only and are not to be considered in construing or
interpreting this First Amendment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(e) <U>Governing Law and Dispute Resolution.</U> This First Amendment shall be
construed in accordance with the laws of the State of New York without regard to
applicable conflicts of laws provisions and any dispute, controversy, or claim
arising out of or relating to this First Amendment shall be governed by the
provisions of Paragraph&nbsp;11.7 of the Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(f) <U>Severability.</U> Should any part of this First Amendment be invalid or
unenforceable, such invalidity or unenforceability shall not affect the validity and
enforceability of the remaining portion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, each of the undersigned has caused this First Amendment to be
executed as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>CUMBERLAND:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">December&nbsp;13, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>BIONICHE:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIONICHE TEORANTA</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ John Kavanagh</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">November&nbsp;16, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>g06286exv10w4.htm
<DESCRIPTION>EX-10.4 CARDINAL HEALTH CONTRACT SALES AND SERVICE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.4 CARDINAL HEALTH CONTRACT SALES AND SERVICE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.4</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B><U>Contract Sales and Services Agreement</U><BR>
</B>

</DIV>
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Between</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Cumberland Pharmaceuticals, Inc.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>&#038;</B></U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Cardinal Health Contract Sales &#038; Services</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>For</B></U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Cumberland Pharmaceuticals Dedicated Sales Force</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>May&nbsp;16, 2006</B></U>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="72%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;I</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Definitions and References to Cardinal Health</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 3</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Appointment of Cardinal Health; General Scope of Activities</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 5</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;III</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compensation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 8</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;IV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Representations, Warranties and Covenants</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 9</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;V</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Status of Cardinal Health and the Representatives</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 10</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;VI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Training</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 11</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;VII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Samples</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 11</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;VIII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trademarks and Intellectual Property Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 12</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;IX</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Communications; Monitoring the Program</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 12</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;X</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 13</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Adverse Reaction Reporting and Regulatory Matters</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 14</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Return/Recall</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 15</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XIV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term and Termination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 16</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recordkeeping; Audit Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 18</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XVI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 18</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XVII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 21</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Article&nbsp;XVIII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 21</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Schedule&nbsp;1.1(k)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">List of Products</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 25</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Schedule&nbsp;1.1(0)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Definition of Territory</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 26</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Schedule&nbsp;3.1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Service Fees and Payment Schedule</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Page 27</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT (&#147;Agreement&#148;) is dated as of May&nbsp;16, 2006 by and between Cardinal Health PTS, LLC
(&#147;Cardinal Health&#148;) with a place of business at 7000 Cardinal Place, Dublin, Ohio, and Cumberland
Pharmaceuticals, Inc. (&#147;Cumberland&#148;), having a principal place of business at 2525 West End,
Suite&nbsp;950, Nashville, Tennessee 37203.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Background Information</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland is a Tennessee-based company which focuses on the acquisition, marketing, and
distribution of a portfolio of niche pharmaceutical products. Cardinal Health provides medical
representatives who Detail (as hereinafter defined) pharmaceutical products for third parties.
Cumberland desires Cardinal Health to provide representatives to Detail certain products as
determined and directed by Cumberland in the geographical territory hereinafter specified,
pursuant to the terms and conditions of this Agreement, and Cardinal Health desires to provide
the Representatives and perform such services pursuant to the terms and conditions set forth in
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereby agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>DEFINITIONS AND REFERENCES TO CARDINAL HEALTH</B></U></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. <U>Definitions.</U> The following terms when used in this Agreement shall, except
where the context otherwise requires, have the following meanings:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;Act&#148; means the Federal Food, Drug and Cosmetic Act, as amended, and the regulations
promulgated thereunder from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&#147;Affiliate&#148; means any corporate or non-corporate business entity that controls, is
controlled by, or is under common control with a party to this Agreement. A corporation or
non-corporate business entity shall be regarded as in control of another corporation if it owns
or directly or indirectly controls at least forty percent (40%) of the voting stock of the other
corporation, or (i)&nbsp;in the absence of the ownership of at least forty percent (40%) of the voting
stock of a corporation or (ii)&nbsp;in the case of a non-corporate business entity, if it possesses
directly or indirectly, the power to direct or cause the direction of the management and policies
of such corporation or non-corporate business entity, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&#147;Agency&#148; means any governmental regulatory authority in the Territory responsible for
granting approvals for the sale or maintaining regulatory oversight of the Products, including,
without limitation, the FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&#147;Cardinal Health&#148; means Cardinal Health PTS, LLC and shall be deemed to include the
Representatives and Managers.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&#147;Detail&#148; means an interactive, face-to-face visit by a Representative
with a Target Customer or his or her legally empowered designee in the Territory, during
which the FDA-approved indicated uses, safety, effectiveness, contraindications, side
effects, warnings and other relevant characteristics of one or more of the Products (as
defined herein) are described by the Representative in a fair and balanced manner consistent
with the requirements of the Act, and using, as necessary or desirable, the Product Labeling
(as defined herein) and the Product Promotional Materials (as defined herein). &#147;Product
Detail&#148; means Detail of a Product between Target Customer and Representative. When used as a
verb, &#147;Detail&#148; or &#147;Detailing&#148; shall mean to engage in a Detail as defined in this Section
1.1(f).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&#147;FDA&#148; means the United States Food and Drug Administration and any successor agency
having substantially the same functions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&#147;Manager&#148; means an individual hired by and retained as an employee of Cardinal
Health to oversee activities of Representatives under this Agreement, including a project
manager.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&#147;PDMA&#148; means the Prescription Drug Marketing Act of 1987, as amended, and the
regulations promulgated thereunder from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&#147;Product Labeling&#148; means all labels and other written, printed, or graphic matter
provided by Cumberland including (i)&nbsp;any container or wrapper utilized with a Product, or
(ii)&nbsp;any written material accompanying a Product, including, without limitation, Product
package inserts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&#147;Product Promotional Materials&#148; means all written, printed or graphic material
provided by Cumberland, including Product Labeling, intended for use by Representatives
during a Detail, including visual aids, file cards, premium items, clinical studies,
reprints, drug information updates and any other promotional support items that Cumberland
deems necessary or appropriate to conduct the Program. Product Promotional Materials shall
include FDA approved indicated uses, safety, effectiveness, contraindications, side effects,
warnings and other relevant characteristics of each of the Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&#147;Products&#148; means the pharmaceutical products to be detailed by Representatives and
marketed by Cumberland as set forth on attached Schedule&nbsp;1.1(k) and such other products as
may be added by Cumberland from time to time to Schedule&nbsp;1.1(k) attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&#147;Program&#148; means the program of Detailing to be conducted by the Representatives
pursuant to this Agreement beginning as of September&nbsp;5, 2006 and continuing thorugh the
remainder of the Term, as defined in Section&nbsp;14.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&#147;Representative&#148; and &#147;Representatives&#148; mean an individual or individuals hired
by and retained as an employee of Cardinal Health to conduct Detailing of Cumberland
Products only in connection with the Program.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&#147;Target&#148; or &#147;Target Customer&#148; means a physician or other specialist identified by
Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&#147;Territory&#148; means the geographical area specified in the attached Schedule&nbsp;1.1(o).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B><BR>
<U><B>APPOINTMENT OF CARDINAL HEALTH; GENERAL SCOPE OF ACTIVITIES</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. <U>Detailing.</U> Cardinal Health shall provide twenty four (24)&nbsp;Representatives to
engage in Product Detail activities in the Territory. Cardinal Health shall assign
Representatives for such Target Customers, in such numbers, and in such Territories as
shall be designated by Cumberland during the term of this Agreement. Each Representative shall
make Product Details to his or her assigned Target Customers based on any reasonable
general direction given by Cumberland&#146;s designated management team. The duties of such
Representatives shall be exclusively to Detail the Products and perform other related
activities reasonably agreed upon by Cardinal Health as deemed necessary for the establishment
and maintenance of new and existing customers of the Products in the Territories. Cumberland
shall at all times retain the right to promote the Products by whomever, wherever, and to
whomever it chooses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Furnishing Managers</U>. Cardinal Health shall provide two Managers to oversee
the activities of Representatives and to perform this Agreement in such numbers and for such
Territories (when relevant) as mutually agreed upon by Cardinal Health and Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. <U>Scope of Activities.</U> The parties shall perform the following activities as
applicable to each in connection with the Program:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Cardinal Health shall have sole and exclusive authority to discipline or terminate the
employment of Representatives. Cumberland may reasonably request that a Representative or
Manager be terminated or reassigned if such Representative&#146;s or Manager&#146;s activities or conduct
are not adequately achieving the performance goals of the Product, or if the Representative or
Manager fails to comply with all applicable laws, regulations, and Cumberland requirements for
Detailing the Product. Cardinal Health shall use its best efforts to comply with such request;
provided that such action complies with applicable laws and is in accordance with Cardinal
Health&#146;s policies and procedures, as determined by Cardinal Health&#146;s human resources manager. In
the event Cardinal Health determines that its policies and procedures or applicable laws
prohibit the termination or reassignment of any Representative so requested by Cumberland, it
shall notify Cumberland of such determination and submit a corrective action plan for
Cumberland&#146;s approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Cardinal Health shall cause each Representative to attend and successfully complete the
Training Program (as defined in Section&nbsp;6.1) conducted by Cumberland for each of the Products
prior to participating in the Program. Any such Representative who shall not successfully
complete all such requirements shall be removed and replaced by another Representative who shall
comply with such requirements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Cumberland shall provide the Representatives without cost with sufficient
quantities of the Product Promotional Materials and Product Labeling for the performance of
Detailing. Cumberland shall be solely responsible for the preparation, content, and method
of distribution of the Product Promotional Materials and the Product Labeling. In
connection with the Detailing of the Products, the Representatives shall use only the
Product Labeling and the Product Promotional Materials provided by Cumberland; and under no
circumstances shall Cardinal Health or the Representatives develop, create, or use any
other promotional material or literature for the Detailing of the Products. Cumberland
shall advise Cardinal Health immediately of any inaccuracy or incompleteness of the Product
Promotional Materials or the Product Labeling, and upon such notice Cardinal Health and the
Representatives shall immediately cease the use of any portion or all of the Product
Promotional Materials or Product Labeling so identified by Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Cardinal Health shall instruct the Representatives to limit their verbal
statements and claims regarding the Products, including efficacy and safety, to those that
are consistent with the Product Labeling and the Product Promotional Materials. The
Representatives shall not add, delete, or modify claims of efficacy or safety in the
Detailing of the Products, nor make any changes (including underlining or otherwise
highlighting any language or adding any notes thereto) in the Product Promotional
Materials. Representatives shall not make any disparaging, untrue, or misleading statements
about Cumberland or its Affiliates, employees, competitors, or competing products.
Representatives shall Detail the Products in strict adherence to all applicable laws,
regulations, and professional requirements, including, but not limited to, the Act, the
Medicare and Medicaid Anti-Kickback Statute, and the American Medical Association Gifts to
Physicians from Industry Guidelines.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Representatives shall remain under the direct authority and control of
Cardinal Health, but shall cooperate with the members of Cumberland and shall receive
advice and direction related to Detail activities on the Products from Cumberland and
Cardinal Health mutually. Cumberland shall make all decisions with respect to the overall
strategy in connection with the Detailing of the Products. Any Cumberland personnel
interacting with Cardinal Health Representatives shall not discipline the Representatives
or implement terms or conditions of employment or personnel policies and/or practices with
respect to the Representatives. Cumberland shall provide Cardinal Health with copies of all
reports, memoranda, audits and other data it develops pertaining to (i)&nbsp;the
Representatives, Detailing, and the Program within 30&nbsp;days of the preparation of such
documents, and (ii)&nbsp;any negligent or wrongful acts or omissions of Representatives as
promptly as practicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;In the event Cardinal Health supplies Representatives and Managers with fleet
vehicles for their use in performing the Detailing as described in the Schedules of this
Agreement, Cumberland shall reimburse Cardinal Health for all of its out-of-pocket costs
related to using such vehicles for Detailing, including but not limited to costs related to
owning, leasing, maintaining, insuring, and/or operating such vehicles (including fuel
costs). Cumberland shall reimburse Cardinal Health for all reasonable out-of-pocket costs
and expenses (i.e., airline tickets and other travel expenses, hotel, rent-a-car,
business meals, travel meals) of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Representatives and Managers in connection with performing services pursuant to this
Agreement. Cumberland and Cardinal Health shall establish a mutually acceptable budget for
the costs and expenses referenced in this subparagraph for each Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Cumberland shall provide Cardinal Health with a list of Target Customers in the
Territory and with data on prescriptions and sales in the Territory for Cardinal Health&#146;s use
in performing this Agreement. Cumberland shall also provide Cardinal Health with other sales
and marketing information concerning the Products that Cumberland obtains or prepares during
the term of this Agreement and deems useful to Cardinal Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. <U>Orders for Products</U>. Cumberland shall be solely responsible for
establishing the terms and conditions of the sale of the Products, including without
limitation, the price at which the Products will be sold, whether sales of the Products will
be subject to any discounts, the method of distribution of the Products, and whether any
credit will be granted or refused in connection with the sale or return of any Product.
Cumberland shall be exclusively responsible for accepting and filling all purchase orders for
the Products, billing and returns for the Products, and all other activities in connection
with the sale and delivery of the Products, other than Detailing. If Cardinal Health or the
Representatives receive an order for the Products, they shall immediately transmit such order
to Cumberland for further handling and communications with the submitter of the order,
including acceptance or rejection, which shall be in Cumberland&#146;s sole discretion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5. <U>Representatives&#146; Activity</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to Cumberland&#146;s obligations and representations and warranties in this
Agreement, any negligent or wrongful act or omission on the part of the Representatives (both
individually and as a group) that occur during the term of this Agreement and that arise
during the course and within the scope of their employment with Cardinal Health pursuant to
this Agreement shall be deemed to be negligent or wrongful acts or omissions of Cardinal
Health. Notwithstanding the foregoing, any acts or omissions of the Representatives pursuant
to the exclusive direction, control or supervision of Cumberland or its employees or agents
shall not be deemed to be negligent or wrongful acts or omissions of Cardinal Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each party shall notify the other in writing as promptly as practicable of any such
material alleged negligent or wrongful acts or omissions on the part of the Representatives
of which it becomes aware along with a plan to remedy such acts or omissions, and Cumberland
shall provide Cardinal Health with a reasonable opportunity to remedy such acts or omissions,
and if indicated, to replace the involved Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Vacancies/Turnover</U>. In the event of a Representative vacancy due to
resignation, reassignment or termination of a Representative, Cardinal Health shall fill any
such vacancy within a six (6)&nbsp;week period. Cumberland shall be responsible for paying the
Service Fees (as defined in Section&nbsp;3.1 below) during such vacancy, unless such vacancy
exceeds the six (6)&nbsp;week period, in which event, the associated Service Fees for such vacancy
shall be suspended after the six (6)&nbsp;week period and shall resume once the vacancy is filled
by Cardinal Health. All recruiting and other related expenses for filling a vacancy shall
be borne by Cardinal Health;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provided, however, that Cumberland shall be responsible for all recruiting and other
related expenses for filling any vacancy occurring pursuant to Cumberland&#146;s request for
reassignment or termination other than a request pursuant to Section&nbsp;2.5(b) or resulting from
the Representative&#146;s failure to comply with any one or more of the provisions of Section&nbsp;2.3.
In addition, if Cumberland desires to interview any candidates, Cumberland shall bear its own
cost of attending any final interview conducted by Cardinal Health or the costs of any
separate interview arranged for by Cumberland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <U>Management Reports</U>. Cardinal Health or its third party designee shall provide
Cumberland with monthly reports in the form agreed between Cumberland and Cardinal Health
within fifteen (15)&nbsp;days after the end of each month. At the request of Cumberland, Cardinal
Health shall furnish Cumberland at reasonable times such documentation as Cumberland
reasonably requests for purposes of verifying the accuracy of any monthly report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <U>Project Manager</U>. Cardinal Health shall appoint a Project Manager to serve
as a liaison between Cardinal Health, Representatives and Cumberland regarding the performance
by Cardinal Health and Cumberland of their respective obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <U>Non-compete</U>. During the term hereof and until the first anniversary of the
expiration thereof, the Representatives shall not, directly or indirectly, solicit or
influence or attempt to solicit or influence any Target Customer to acquire pharmaceutical
products manufactured by a competitor of Cumberland for a laxative product, an oral
rehydration solution or other Products added to Schedule&nbsp;1.1(k) by Cumberland.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B><BR>
<U><B>COMPENSATION</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. <U>Amount and Time of Payment</U>. For services hereunder, Cumberland shall pay
to Cardinal Health the fees set forth in Schedule&nbsp;3.1 attached hereto and incorporated by
reference (the &#147;Service Fees&#148;), which shall be payable as set forth in the payment schedule
set forth therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Cumberland&#146;s Hiring of Representatives.</U> Cumberland shall not solicit,
directly or indirectly, any Representative or other employee of Cardinal Health to terminate
their employment with Cardinal Health and/or hire any such Representative or employee during
the Term of this Agreement without the prior written consent of Cardinal Health, which consent
shall not be unreasonably withheld or delayed. At the expiration or termination of this
Agreement, Cumberland shall have the right to hire as its own employee or as an independent
contractor or agent any one or more of the Representatives or Managers (collectively, the
&#147;Targeted Employees&#148;). Cumberland shall have the right to negotiate with any Targeted
Employee concerning the terms on which Cumberland might hire that Targeted Employee prior to
the end of the Term only upon the prior written consent of Cardinal Health, which shall not be
unreasonably withheld or delayed. Cardinal agrees not to interfere with or restrict in any
manner Cumberland&#146;s solicitation and hiring of the Targeted Employees and Cardinal Health will
assist Cumberland in the transition of Targeted Employees from Cardinal Health to Cumberland.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3. <U>Reimbursement of Expenses</U>. All expenses of Cardinal Health for which
Cumberland is obligated to reimburse Cardinal Health as expressly provided in this
Agreement, including but not limited to travel expenses and vehicle expenses under Section
2.3(e), shall be paid by Cumberland within &#091;***&#093; days after Cardinal Health has submitted a
statement itemizing such expenses. Cardinal Health shall submit such expense statements to
Cumberland monthly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Past Due Amounts</U>. All amounts owing by Cumberland to Cardinal Health
pursuant to this Agreement that are not timely paid by Cumberland will bear interest at the
rate of twelve (12%) per annum from the due date. An invoice will be considered late and
begin to accrue interest if unpaid 30&nbsp;days past its due date.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B><BR>
<U><B>REPRESENTATIONS, WARRANTIES AND COVENANTS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. <U>By Cardinal Health.</U> Cardinal Health represents, warrants, and covenants to
Cumberland, as of execution of this Agreement and during the term of this Agreement, as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;that Cardinal Health and the Representatives shall perform the Detailing in a
professional and timely manner;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;that Cardinal Health and the Representatives shall comply with all laws, rules and
regulations that apply to the performance of services under this Agreement, including but
not limited to the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. &#167;
1320a-7b(a)), the Civil False Claims Act (31 U.S.C. &#167; 3729(a)), Sections&nbsp;1128A, 1128B, and
1877 of the Social Security Act (42 U.S.C. &#167;&#167; 1320a-7a, -7b, and 1395nn), the Health Care
Fraud Act (18 U.S.C. &#167; 1347), and the Criminal False Claims Act (18 U.S.C. &#167; 287), as
amended from time to time, as well as similar applicable state laws; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;that Cardinal Health is under no obligation to any third party that would prevent
the execution of this Agreement or interfere with its performance under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. <U>By Cumberland</U>. Cumberland represents, warrants, and covenants to
Cardinal Health, as of execution of this Agreement and during the term of this Agreement,
as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;that Cumberland is under no obligation to any third party that would prevent the
execution of this Agreement or interfere with its performance under this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;that Cumberland shall comply with all laws, rules and regulations that apply to the
Products and their sale, the Program, and this Agreement, including but not limited to the
Act, the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. &#167; 1320a-7b(a)), the
Civil False Claims Act (31 U.S.C. &#167; 3729(a)), Sections&nbsp;1128A, 1128B, and 1877 of the Social
Security Act (42 U.S.C. &#167;&#167; 1320a-7a, -7b, and 1395nn), the Health Care Fraud Act (18
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">U.S.C. &#167; 1347), and the Criminal False Claims Act (18 U.S.C. &#167; 287), as amended from
time to time, as well as similar applicable state laws;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;that the Product Labeling and Product Promotional Materials are accurate,
complete, and in compliance with the Act and all applicable rules and regulations of the
FDA; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;that to the best knowledge of Cumberland, the manufacture, sale, and distribution
of the products do not and will not during the term of this Agreement, infringe any patent
or other proprietary rights of third parties, and the Products have all necessary
governmental approvals and may be lawfully Detailed and sold by Cumberland and the
Representatives.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B><BR>
<U><B>STATUS OF CARDINAL HEALTH AND THE REPRESENTATIVES</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. <U>Cardinal Health Independent Contractor.</U> Cardinal Health is being
retained and shall perform hereunder strictly as an independent contractor. Representatives
and Managers of Cardinal Health performing services hereunder shall not be, and shall not
be considered to be, employees of Cumberland for any purpose, and shall at all times remain
employees of Cardinal Health, subject to Section&nbsp;3.3. Neither party shall have any
responsibility for the hiring, termination, compensation, benefits or other conditions of
employment of the other party&#146;s employees, except as otherwise provided in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. <U>No Cumberland Benefits.</U> While employees of Cardinal Health, the
Managers and Representatives are not eligible to participate in any benefits programs or
sales bonuses offered by Cumberland to its employees, or in any pension plans, profit
sharing plans, insurance plans or any other employee benefit plans offered from time to
time by Cumberland to its employees, provided that the Representatives shall be eligible to
participate in Cumberland sales contests and bonus plans if so requested by Cumberland and
approved by Cardinal Health. Cardinal Health acknowledges and agrees that Cumberland does
not, and will not, maintain or procure any worker&#146;s compensation or unemployment
compensation insurance for or on behalf of the Managers or Representatives while they are
employees of Cardinal Health. Cardinal Health acknowledges and agrees that it shall be
solely responsible for paying all salaries, wages, benefits and other compensation which
its employees (including Representatives and Managers) may be entitled to receive in
connection with the performance of the services hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Sales, Use and Excise Taxes.</U> If any state or local government or other
taxing authority determines that sales, use or excise Taxes (&#147;Taxes&#148;) are applicable to
Cardinal Health&#146;s services performed hereunder, Cardinal Health shall promptly accrue and
Cumberland shall pay such Taxes on behalf of Cardinal Health to the appropriate taxing
authorities. In addition, Cumberland shall be responsible for the payment of any applicable
Taxes related to Cumberland&#146;s supply to Cardinal Health of Product Promotional Materials
and Product Samples.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4. <U>No Joint Venture.</U> Nothing contained in this Agreement shall be
construed as creating a joint venture or, except as otherwise provided herein, as granting
to either party the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">authority to bind or contract any obligations in the name of or on the account of the
other party or to make any guarantees or warranties on behalf of the other party.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B><BR>
<U><B>TRAINING</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. <U>Training Programs</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Cumberland shall conduct a training program for new Representatives and Managers
prior to participating in the Program, which shall include such medical and technical
information about the Products and such sales training as Cumberland, along with Cardinal
Health, deems necessary and appropriate (the &#147;Training Program&#148;). The Training Program
shall also include instruction on compliance with applicable laws, Company policies and
procedures, and computer training. Cardinal Health shall assist Cumberland with
the Training Program only to the extent requested by Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In order to qualify for assignment in a Territory, a Representative must
demonstrate thorough knowledge of the Products by passing Cumberland approved Product
tests at a level of proficiency agreed upon by Cumberland and Cardinal Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. <U>Training Materials</U>. Cumberland shall prepare written training
materials for the Training Program and an up-to-date programmed learning unit for the
Products, to be sent to each Representative for &#147;at home&#148; study a minimum of five (5)&nbsp;days
prior to the commencement of the Training Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. <U>Cumberland Assistance</U>. During the term of this Agreement,
Cumberland shall make available to Cardinal Health, free of charge, a reasonable number
of, and for a reasonable amount of time, at locations reasonably agreed by Cumberland and
Cardinal Health, Cumberland&#146;s sales training and marketing personnel to assist Cardinal
Health&#146;s Representatives and Managers with respect to the Training Program and additional
orientation and ongoing training for the Representatives.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B><BR>
<U><B>SAMPLES</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1. <U>Provision of Samples.</U> Cumberland shall provide samples of the Products
to the Representatives at Cumberland&#146;s option and at its expense. Cumberland shall
determine the quantity and types of samples to be provided to the Representatives and the
method of distribution of the samples. In the event Cumberland elects to have Cardinal
Health manage the storage and distribution of samples, Cardinal Health shall pass on to
Cumberland the actual invoice costs for storage, distribution and other related costs and
use prudent business sense in costs incurred. All samples shall be stored and handled by
Cumberland and Cardinal Health in compliance with the PDMA and applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Sample Accountability</U>. Cardinal Health shall prepare and provide to
Cumberland for approval a sample accountability program applicable to the samples
provided by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland. After the parties agree in writing to adopt a sample accountability
program Cardinal Health shall comply with such program.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3. <U>Return of Samples.</U> Within 30&nbsp;days following the termination or
expiration of this Agreement or within 30&nbsp;days from the termination or removal from the
Program of a Representative (unless such Representative has been hired or retained by
Cumberland), Cardinal Health shall cause the Representatives to return to Cumberland all
unused Product samples provided to Cardinal Health or the Representatives by Cumberland.
Cumberland shall pay or reimburse Cardinal Health for all out-of-pocket costs and expenses
in connection with the storage and shipment of returned samples.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B><BR>
<U><B>TRADEMARKS AND INTELLECTUAL PROPERTY RIGHTS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Products shall be Detailed by Cardinal Health&#146;s Representatives under trademarks
owned or licensed by Cumberland or an Affiliate of Cumberland. This Agreement does not
constitute a grant to Cardinal Health of any property right or interest in the Products or
any trademarks which Cumberland or an Affiliate of Cumberland uses with respect to the
Products or to the name or business style of Cumberland. Cardinal Health and the
Representatives shall use the Product Promotional Materials only for the purposes of this
Agreement, and all copyright and other intellectual property rights in the Product
Promotional Materials shall remain with Cumberland.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B><BR>
<U><B>COMMUNICATIONS; MONITORING THE PROGRAM</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1. <U>Communications from Third Parties.</U> Cardinal Health and its
Representatives shall advise Cumberland promptly of all comments, statements, requests and
inquiries of the medical profession or any other third parties relating to the Products
that are not addressed by either Product Labeling or the Product Promotional Materials, of
which Cardinal Health becomes aware. All responses to such communications to the medical
profession or such other third parties shall be handled solely by Cumberland. Cardinal
Health shall provide reasonable assistance to Cumberland to the extent requested by
Cumberland, and at Cumberland&#146;s cost and expense, to fully respond to such communications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2. <U>Government Agencies.</U> All communications with government agencies,
including the FDA, concerning the Products shall be the sole responsibility of Cumberland.
Cardinal Health shall assist Cumberland with respect to such communications with
government agencies to the extent requested by Cumberland, and at Cumberland&#146;s cost
and expense. Cardinal Health shall provide Cumberland with any documents or information
reasonably requested by Cumberland for purposes of responding to any communications with
government agencies within 72 hours of Cumberland&#146;s request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3. <U>Cumberland Communications.</U> In addition to Detailing, Cardinal Health shall assist
Cumberland with respect to customer communications (as reasonably requested by Cumberland and at
Cumberland&#146;s cost and expense) within the Territory and shall regularly
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">advise Cumberland of market, economic, regulatory and other developments of which Cardinal
Health may become aware which may affect the sale of the Products in the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4. <U>Review of Results.</U> The parties shall meet periodically, but at least once per
calendar quarter, to review and discuss the actual results compared to the marketing plans for
Detailing of the Products. Cumberland shall regularly and promptly share with Cardinal Health
all reports, audits and other data it develops relative to the Program.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X</B><BR>
<U><B>INSURANCE</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Cardinal Health Insurance</U>.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Term of this Agreement, Cardinal Health shall
obtain and maintain the following insurance with limits not less than those
specified below:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commercial General Liability Insurance with a
limit of One Million Dollars ($1,000,000) per occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">ii.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Worker&#146;s Compensation and Employers Liability
Insurance with statutory limits for Workers&#146; Compensation and
Employers&#146; Liability limits of One Million Dollars ($1,000,000) per
accident.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">iii.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Automobile Liability Insurance with a combined
single limit of $1,000,000.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">iv.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Products Liability Insurance with a limit of
Five Million Dollars ($5,000,000) per occurrence.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(b)&nbsp;Cardinal Health may self-insure any or a portion of the required insurance.
In the event that any of the required policies of insurance are written on a claims
made basis, then such policies shall be maintained during the entire term of this
Agreement and for a period of not less than five (5)&nbsp;years following the
termination or expiration of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(c)&nbsp;Cardinal Health shall waive subrogation rights against Cumberland for
workers&#146; compensation benefits and shall obtain a waiver from any insurance
carriers with which Cardinal Health carries workers&#146; compensation insurance
releasing their subrogation rights against Cumberland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(d)&nbsp;Each insurance policy which is required under this Section shall be
obtained from an insurance carrier with an A.M. Best rating of at least A- VII.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Cumberland Insurance</U>.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Term of this Agreement, Cumberland shall obtain and
maintain the following insurance with limits not less than those specified
below.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commercial General Liability Insurance with a limit of One
Million Dollars ($1,000,000) per occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">ii.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Products Liability Insurance with a
limit of Five Million Dollars ($5,000,000) per occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">iii.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Worker&#146;s Compensation and Employers
Liability Insurance with statutory limits for Workers&#146;
Compensation and Employers&#146; Liability limits of One Million
Dollars ($1,000,000) per accident.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(b)&nbsp;Cumberland may self-insure any or a portion of the required insurance. In
the event that any of the required policies of insurance are written on a
claims made basis, then such policy(ies) shall be maintained during the
entire period of this Agreement and for a period of not less than five (5)
years following the termination or expiration of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(c)&nbsp;Cumberland shall waive subrogation rights against Cardinal Health for
workers&#146; compensation benefits and shall obtain a waiver from any insurance
carriers with which Cumberland carries workers&#146; compensation insurance
releasing their subrogation rights against Cardinal Health.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(d)&nbsp;Each insurance policy which is required under this Section shall be
obtained from an insurance carrier with an A.M. Best rating of at least A-
VII.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XI</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>ADVERSE REACTION REPORTING AND REGULATORY MATTERS</B></U></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1. <U>Immediate Notification.</U> Cardinal Health and Cumberland agree to notify the
other party as soon as reasonably practicable of any information that each may obtain or
learn concerning any Product or package complaint or any serious unexpected side effect,
injury, toxicity, or sensitivity reaction or any unexpected incidence of severity thereof
associated with the clinical uses, studies, investigations, tests and marketing of the
Products, whether or not determined to be attributable to the Products. &#147;Serious&#148; as used in
this Section&nbsp;11.1 refers to an experience which results in death, permanent or substantial
disability, in-patient hospitalization, prolongation of existing in-patient hospitalization,
a congenital anomaly or cancer, or a result of an overdose or life threatening condition.
&#147;Unexpected&#148; as used in this Section&nbsp;11.1 refers to (i)&nbsp;conditions or developments not
previously submitted to governmental Agencies or encountered during clinical studies of the
Products and not reflected in the Product Promotional Materials or the Product Labeling, or
(ii)&nbsp;conditions or developments occurring with greater frequency, severity, or specificity
than shown by information previously submitted to governmental Agencies or encountered
during clinical studies of the Products and not reflected in the Product Promotional
Materials or the Product Labeling. Each party shall also notify the other in a timely manner
of any other adverse experience, i.e., any unfavorable and unintended change in the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">structure (signs), function (symptoms)&nbsp;or chemistry (laboratory data) of the body
temporally associated with the use of the Products, whether or not considered related
thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2. <U>Threatened Agency Action.</U> Cardinal Health and Cumberland shall each
immediately notify the other party of any information that each may obtain or learn
regarding any threatened or pending action by an Agency which may affect the Products.
Cardinal Health shall, at the request of Cumberland and at the cost and expense of
Cumberland, cooperate with Cumberland in formulating a procedure for taking appropriate
action in response to such information. Unless compelled by law, Cardinal Health shall not
respond to an Agency without the prior written consent of Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3. <U>Training</U>. Cardinal Health and Cumberland shall develop appropriate
instructions in the Training Program for Representatives as to handling of information
received or obtained subject to Sections&nbsp;11.1 and 11.2.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XII</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>RETURN/RECALL</B></U></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1. <U>Returned Products</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Cumberland shall be responsible for handling all returned Products, including
shipment and compensation or credit for the returned Products. Any Products inadvertently
returned to Cardinal Health shall be shipped to Cumberland or at its direction, in
compliance with Cumberland&#146;s returned goods policy, and Cardinal Health shall advise the
customer who made the return that the Products have been returned to Cumberland. Cumberland
shall reimburse Cardinal Health&#146;s out-of-pocket shipping costs arising from its handling of
such returned Products within 30&nbsp;days of delivery to Cumberland of Cardinal Health&#146;s
statement for such costs. Upon request Cardinal Health shall provide Cumberland with
documentation relating to such costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;At Cumberland&#146;s request, Cardinal Health shall assist Cumberland in obtaining and
receiving any Products that have been recalled, and any costs incurred by Cardinal Health,
agreed upon in advance by Cumberland, with respect to participating in any such recall shall
be reimbursed by Cumberland within 30&nbsp;days of delivery to Cumberland of Cardinal Health&#146;s
statement for such costs.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XIII</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>CONFIDENTIAL INFORMATION</B></U></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.1 <U>Mutual Obligation</U>. Cardinal Health and Cumberland agree that they will not
disclose the other party&#146;s Confidential Information (defined below) to any third party
without the prior written consent of the other party except as required by law, regulation or
court or administrative order; provided, however, that prior to making any such legally
required disclosure, the party making such disclosure shall give the other party as much
prior notice of the requirement for and contents of such disclosure as is practicable under
the circumstances. Notwithstanding the foregoing, each party may disclose the other party&#146;s
Confidential Information to any of its Affiliates that (A)&nbsp;need to know such
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential Information for the purpose of performing under this Agreement, (B)&nbsp;are
advised of the contents of this Article, and (C)&nbsp;agree to be bound by the terms of this
Article.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.2 <U>Definition</U>. As used in this Agreement, the term <B>&#147;Confidential Information&#148;</B>
includes all such information furnished by Cardinal Health or Cumberland, or any of their
respective representatives or Affiliates, to the other or its representatives or Affiliates,
whether furnished before, on or after the date of this Agreement and furnished in any form,
including but not limited to written, verbal, visual, electronic or in any other media or
manner. Confidential Information includes all proprietary technologies, know-how, trade
secrets, discoveries, inventions and any other Intellectual Property (whether or not
patented), analyses, compilations, business or technical information and other materials
prepared by either party, or any of their respective representatives, containing or based in
whole or in part on any such information furnished by the other party or its representatives.
Confidential Information also includes the existence of this Agreement and its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.3 <U>Exclusions</U>. Notwithstanding Section&nbsp;13.2, Confidential Information does not
include information that (A)&nbsp;is or becomes generally available to the public or within the
industry to which such information relates other than as a result of a breach of this
Agreement, or (B)&nbsp;is already known by the receiving party at the time of disclosure as
evidenced by the receiving party&#146;s written records, or (C)&nbsp;becomes available to the
receiving party on a non-confidential basis from a source that is entitled to disclose it on
a non-confidential basis, or (D)&nbsp;was or is independently developed by or for the receiving
party without reference to the Confidential Information, as evidenced by the receiving
party&#146;s written records.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.4 <U>No Implied License</U>. The receiving party will obtain no right of any kind or
license under any patent application or patent by reason of this Agreement. All Confidential
Information will remain the sole property of the party disclosing such information or data.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.5 <U>Return of Confidential Information</U>. Upon written request or termination of this
Agreement, the receiving party shall promptly return within thirty (30)&nbsp;days all such
information, including any copies thereof, and cease its use or, at the request of the
disclosing party, shall promptly destroy the same and certify such destruction to the
disclosing party; except for a single copy thereof, which may be retained for the sole
purpose of determining the scope of the obligations incurred under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.6 <U>Survival</U>. The obligations of this Article&nbsp;13 will terminate five (5)&nbsp;years from
the expiration of this Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XIV</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>TERM AND TERMINATION</B></U></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1. <U>Term</U>. This Agreement shall take effect as of September&nbsp;5, 2006 and shall
continue in effect until August&nbsp;30, 2008 (the &#147;Initial Term&#148;), unless terminated earlier
as set forth herein. Notwithstanding the foregoing, Cumberland may, at its option
upon written notice to Cardinal Health at least ninety (90)&nbsp;days prior to the expiration of
the Initial Term, and with the written consent of Cardinal Health, extend the Initial
Term for one additional year (the &#147;Renewal Term&#148;). If Cumberland desires to exercise the
Renewal Term, parties shall negotiate in good faith provisions of Section&nbsp;3.1 regarding
Service Fees. References in this Agreement to the term of this Agreement include both the
Initial Term and the Renewal Term, if applicable.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2. <U>Bankruptcy: Insolvency.</U> Either party may terminate this Agreement
upon notice to the other upon the occurrence of: (a)&nbsp;the entry of a decree or order for
relief by a court of proper jurisdiction in an involuntary case of the other party under the
Federal Bankruptcy Code, as now constituted or hereafter amended, or any other applicable
federal or state insolvency or other similar laws, and the continuance of any such decree or
order in effect for a period of sixty (60)&nbsp;consecutive days; or (b)&nbsp;the filing by the other
party of a petition for relief under the Federal Bankruptcy Code, as now constituted or
hereafter amended, or any other applicable federal or state insolvency or similar laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3 <U>Termination For Breach</U>. Subject to Section&nbsp;3.2 and other continuing
obligations, either party may terminate this Agreement (i)&nbsp;in the event of a material breach
of the other party&#146;s obligations under this Agreement, provided that such breach has not
been cured within thirty (30)&nbsp;days after written notice thereof from the non-breaching party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.4 <U>Termination Due To Regulatory And Other Problems</U>. If the Product is not
being marketed due to regulatory problems, court or administrative proceedings, product
liability claims, recalls, raw materials shortages, or similar factors beyond the control of
Cumberland, then, subject to Section&nbsp;3.2, either party may terminate this Agreement upon
thirty (30)&nbsp;days written notice to the other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.5 <U>Termination Due To Assignment or Change in Control</U>. In the event of a
Change of Control (defined herein), the party that has had a Change In Control (the
&#147;Affected Party&#148;) shall give written notice to the other party (the &#147;Non-Affected Party&#148;)
within thirty (30)&nbsp;days of the occurrence of such Change In Control. If the Change In
Control involves a material and direct competitor of the Non-Affected Party, the
Non-Affected Party may terminate this Agreement by written notice to the Affected Party
within 60&nbsp;days after receipt of the Notice of a Change In Control . If the Change In Control
does not involve a material and direct competitor of the Non-Affected Party, this
Agreement may not be terminated by the Non-Affected Party. For purposes of this Section,
&#147;Change In Control&#148; includes a purchase, assignment or transfer of a controlling interest
in the Affected Party or substantially all of its business and assets and any merger or
consolidation involving the Affected Party or any Affiliate of the Affected Party that
requires a vote of the stockholders of the Ultimate Parent of the Affected Party. &#147;Ultimate
Parent&#148; for Cardinal Health is Cardinal Health, Inc. and the Ultimate Parent for Cumberland
is its stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.6. <U>Termination: Phase Out.</U> In the event that this Agreement is terminated
pursuant to Sections&nbsp;14.2 through 14.5, and at Cumberland&#146;s request, the parties shall
discuss in good faith an appropriate phase-out of Cardinal Health&#146;s Detailing activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.7 <U>Termination: Written Notice</U>. Cumberland may terminate the Agreement, with
or without cause, upon 60&nbsp;days prior written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.8. <U>Termination: Continuing Rights.</U> The termination or expiration of this Agreement
shall not affect Cumberland&#146;s obligation to reimburse or pay Cardinal Health any amount then
due and owing under this Agreement. Further, the termination or expiration of this
Agreement
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall not affect any rights or obligations of any party under this Agreement which are
intended by the parties to survive such termination. The Service Fee paid by Cumberland
for the month in which this Agreement is terminated shall be prorated based on the number of
days in that month, and Cardinal Health shall refund any overpayment to Cumberland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.9 <U>Termination: Return of Materials.</U> Within sixty (60)&nbsp;days following the
termination or expiration of this Agreement, Cardinal Health shall return to Cumberland all
Confidential Information, Product Promotional Materials, marketing plans, forms, territory
lists, reports and any and all other tangible items provided to Cardinal Health by Cumberland.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XV</B><BR>
<U><B>RECORDKEEPING; AUDIT RIGHTS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1. <U>Cardinal Health Record Keeping: Inspection by Cumberland.</U> Cardinal Health
shall keep accurate records in sufficient detail as to costs and expenses for which Cumberland must reimburse Cardinal Health under this Agreement. Upon Cumberland&#146;s reasonable
request made during or within one (1)&nbsp;year after the term of this Agreement, and at
Cumberland&#146;s expense, Cardinal Health shall permit Cumberland&#146;s designated employees or
agents to have access during ordinary business hours to records of such costs and expenses in
order to verify the accuracy of amounts reimbursed by Cumberland to Cardinal Health. Cumberland
and its designated employees or agents shall maintain in confidence all such cost and expense
records of Cardinal Health.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XVI</B><BR>
<U><B>INDEMNIFICATION</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.1 <U>Definitions</U>. As used in this Article&nbsp;16 and this Agreement, &#147;Damages&#148; shall
mean all liabilities, damages, assessments, levies, losses, fines, penalties, costs,
and expenses, including, without limitation, reasonable attorneys&#146;, accountants&#146;,
investigators&#146;, and experts&#146; fees and expenses, sustained or incurred as a result of any
claims, suits, liabilities, or actions by any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.2. <U>Indemnification by Cardinal Health.</U> Except to the extent that any of the
following Damages arises from the negligence or willful misconduct of Cumberland or breach
of this Agreement by Cumberland, Cardinal Health shall indemnify and hold Cumberland, its
Affiliates, directors, officers, employees and agents harmless from and against any and all
Damages arising directly or indirectly from:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Cardinal Health&#146;s breach of or failure to comply with any of its obligations
under this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any inaccuracy in or breach or failure of any representation, warranty, or
covenant made by Cardinal Health in this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any negligent or wrongful act or omission on the part of Cardinal Health or
its employees or agents;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Cardinal Health&#146;s violation of or failure to comply with all applicable laws
relating to the promotion, distribution and sale of the Products, including but not limited
to the Act, the PDMA, the Medicare and Medicaid Anti-Kickback Act (42 U.S.C. &#167;
1320a-7b(a)), the Civil False Claims Act (31 U.S.C. &#167; 3729(a)), Sections&nbsp;1128A,
1128B, and 1877 of the Social Security Act (42 U.S.C. &#167;&#167; 1320a-7a, -7b, and 1395nn),
the Health Care Fraud Act (18 U.S.C. &#167; 1347), and the Criminal False Claims Act
(18 U.S.C. &#167; 287), as amended from time to time, as well as similar applicable
state laws;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Detailing of the Products, except to the extent such Damages arise from a negligent or
wrongful act or omission of Cumberland;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;any federal or state claim or assessment for nonpayment or late payment by
Cardinal Health of any tax or contribution based on the status of any Representatives
as employees of Cardinal Health:; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;except as limited by Section&nbsp;2.3(a) or by Cumberland&#146;s indemnification obligations, any
employment actions and/or employment related claims alleging violation of any state or federal
employment laws arising out of any action taken or omission made independently by Cardinal
Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.3. <U>Indemnification by Cumberland.</U> Except to the extent that any of the following
Damages arise from the negligence or willful misconduct of Cardinal Health or breach of this
Agreement by Cardinal Health, Cumberland shall indemnify and hold Cardinal Health and its
Affiliates, directors, officers, employees and agents harmless from and against any and all
Damages arising directly or indirectly from:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Cumberland&#146;s breach of or failure to comply with any of its obligations under this
Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any inaccuracy in or breach or failure of any representation, warranty, or covenant made
by Cumberland in this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;any negligent or wrongful act or omission on the part of Cumberland or its employees or
agents;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Cumberland&#146;s violation of or failure to comply with all applicable laws relating to the
manufacture, sale, distribution, possession and use of the Product, the Program and this
Agreement, including but not limited to the Act, the PDMA, the Medicare and Medicaid
Anti-Kickback Act (42 U.S.C. &#167; 1320a-7b(a)), the Civil.False Claims Act (31 U.S.C. &#167; 3729(a)),
Sections&nbsp;1128A, 1128B, and 1877 of the Social Security Act (42 U.S.C. &#167;&#167; 1320a-7a, -7b, and
1395nn), the Health Care Fraud Act (18 U.S.C. &#167; 1347), and the Criminal False Claims Act (18
U.S.C. &#167; 287), as amended from time to time, as well as similar applicable state laws;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Detailing of the Products, except to the extent such Damages arise from a
negligent or wrongful act or omission of Cardinal Health;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the accuracy or completeness of the Product Labels, Product Promotional
Materials, or the Training Program;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any claims or liabilities for injury to or death of persons, regardless of
when such claim or liability is asserted or incurred, resulting from or arising out
of the manufacture, use, sale, distribution, possession of the Products, or a
manufacturing design or defect of the Products, or any failure to warn or inadequacy
of warning regarding the Products;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Cumberland&#146;s failure to pay when due or to reimburse Cardinal Health for
any Taxes (as defined in Section&nbsp;5.3);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any negligent or wrongful acts or omissions on the part of Cumberland with
respect to Cardinal Health&#146;s employees or Representatives or those individuals who
have made application to be Representatives of Cardinal Health;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) any federal or state claim or assessment for nonpayment or late payment by
Cumberland of any tax or contribution based on the status of any former
Representatives as employees or agents of Cumberland; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) the use by Cardinal Health, in the performance of its duties hereunder and
as specified or directed by Cumberland, of any trademark, trade name, copyright,
patent or other rights which use actually or allegedly infringes on the rights of
any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.4. <U>Indemnification Procedures.</U> A party (the &#147;Indemnitee&#148;) which intends to
claim indemnification under this Article&nbsp;16 shall promptly notify the other party (the
&#147;lndemnitor&#148;) in writing of any action, claim or liability in respect of which the
lndemnitee or any of its employees or agents are entitled to indemnification. The
Indemnitee shall permit, and shall cause its employees and agents to permit, the Indemnitor
at its discretion, to settle any such action, claim or liability and agrees to the complete
control of such defense or settlement by the Indemnitor; provided, however, that such
settlement or defense does not adversely affect the lndemnitee&#146;s rights hereunder or impose
any obligations on the Indemnitee in addition to those set forth in this Agreement. The
Indemnitee, its employees, and agents, shall cooperate fully with the Indemnitor and its
legal representatives in the investigation and defense of any action, claim or liability
subject to indemnification. The Indemnitee shall have the right, but not the obligation, to
be represented by counsel of its own selection and at its own expense: in connection with
any indemnified claim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.5. <U>Limitation on Cardinal Health Liability.</U> In no event shall Cardinal
Health&#146;s total liability under this Agreement exceed an amount equal to the total fees paid
to Cardinal Health under this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.6 <U>No Consequential Damages</U>. Notwithstanding any provision of this
Agreement to the contrary, and except with regard to claims by third parties, neither party
shall be liable to the other for any special, indirect, incidental or consequential damages
(other than liability for personal injury as provided in this Article&nbsp;16), including lost
profits.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 17</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>NOTICE</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notices and other communications hereunder shall be in writing and shall be deemed
given: (A)&nbsp;when delivered personally; (B)&nbsp;when delivered by facsimile transmission (receipt
verified); (C)&nbsp;when received or refused, if mailed by registered or certified mail (return
receipt requested), postage prepaid; or (D)&nbsp;when delivered if sent by express courier
service,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the parties at the following addresses (or at such other address for a party as shall be
specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">To Cumberland:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi, CEO</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue, Suite&nbsp;950</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile (615)&nbsp;255-0094</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Adams and Reese / Stokes Bartholomew LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">424 Church Street, Suite&nbsp;2800</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37219</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn. Martin S. Brown, Jr.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile (615)&nbsp;259-1470</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">To Cardinal Health:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cardinal Health PTS, LLC</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7000 Cardinal Place</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dublin, Ohio 43017</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Thomas Dimke, SVP/GM</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cardinal Health Contract Sales and Services</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (614)&nbsp;757-6117</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cardinal Health, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7000 Cardinal Place</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dublin, Ohio 43017</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Associate General Counsel,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmaceutical Technologies and Services</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (614)&nbsp;757-5051</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 18<BR>
MISCELLANEOUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.1 <U>Entire Agreement; Amendments</U>. This Agreement, the attachments, and any
amendments thereto constitute the entire understanding between the parties and supersede
any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contracts, agreements or understanding (oral or written) of the parties with respect
to the subject matter hereof. No term of this Agreement may be amended except upon written
agreement of both parties, unless otherwise provided in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.2 <U>Captions</U>. The captions in this Agreement are for convenience only and
are not to be interpreted or construed as a substantive part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.3 <U>Further Assurances</U>. The parties agree to execute, acknowledge and
deliver such further instruments and to take all such other incidental acts as may be
reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.4 <U>No Waiver</U>. Failure by either party to insist upon strict compliance
with any term of this Agreement in any one or more instances will not be deemed to be a
waiver of its rights to insist upon such strict compliance with respect to any subsequent
failure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.5 <U>Severability</U>. If any term of this Agreement is declared invalid or
unenforceable by a court or other body of competent jurisdiction, the remaining terms of
this Agreement will continue in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.6 <U>Independent Contractors</U>. The relationship of the parties is that of
independent contractors, and neither party will incur any debts or make any commitments for
the other party except to the extent expressly provided in this Agreement. Nothing in this
Agreement is intended to create or will be construed as creating between the parties the
relationship of joint ventures, co-partners, employer/employee or principal and agent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.7 <U>Successors and Assigns</U>. This Agreement will be binding upon and inure
to the benefit of the parties, their successors and permitted assigns. Neither party may
assign this Agreement, in whole or in part, without the prior written consent of the other
party, except that either party may, without the other party&#146;s consent, assign this
Agreement to an Affiliate or to a successor to substantially all of the business or assets
of the assigning company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.8 <U>Governing Law</U>. This Agreement shall be governed by and construed under
the laws of the State of Tennessee, excluding its conflicts of law provisions. The United
Nations Convention on Contracts for the International Sale of Goods shall not apply to this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.9 <U>Alternative Dispute Resolution</U>. If any Dispute arises between the
parties, such Dispute shall be presented to the respective presidents or senior executives
of Cardinal Health and Cumberland for their consideration and resolution. If such parties
cannot reach a resolution of the Dispute, then such Dispute shall be resolved by binding
alternative dispute resolution in accordance with the then existing commercial arbitration
rules of CPR Institute for Dispute Resolution, 366 Madison Avenue, New York, NY 10017.
Arbitration shall be conducted in the jurisdiction of the defendant party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.10 <U>Prevailing Party</U>. In any dispute resolution proceeding between the
parties in connection with this Agreement, the prevailing party will be entitled to its
reasonable attorney&#146;s fees and costs in such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.11 <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each
of which will be deemed an original but all of which together will constitute one and the
same
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement
shall constitute an original.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.12 <U>Publicity</U>. Neither party will make any press release or other public
disclosure regarding this Agreement or the transactions contemplated hereby without the
other party&#146;s express prior written consent, except as required under applicable law or by
any governmental agency, in which case the party required to make the press release or
public disclosure shall use commercially reasonable efforts to obtain the approval of the
other party as to the form, nature and extent of the press release or public disclosure
prior to issuing the press release or making the public disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.13 <U>Setoff</U>. Without limiting Cardinal Health&#146;s rights under law or in
equity, Cardinal Health and its Affiliates, parent or related entities, collectively or
individually, may exercise a right of set-off against any and all amounts due to Cardinal
Health from Cumberland. For purposes of this Article, Cardinal Health, its Affiliates,
parent or related entities shall be deemed to be a single creditor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.14 <U>Survival</U>. The rights and obligations of the parties shall continue
under Articles 6 (Confidentiality), 7 (Intellectual Property), 9 (Indemnification), 10
(Limitations of Liability), 11 (Insurance), to the extent expressly stated therein, 13
(Notice), 14 (Miscellaneous) and Section&nbsp;12.3 (Effect of Termination), notwithstanding
expiration or termination of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.15 <U>Force Majeure</U>. Except as to payments required under this Agreement,
neither party shall be liable in damages for, nor shall this Agreement be terminable or
cancelable by reason of, any delay or default in such party&#146;s performance hereunder if such
default or delay is caused by events beyond such party&#146;s reasonable control including, but
not limited to, acts of God, regulation or law or other action or failure to act of any
government or agency thereof, war or insurrection, civil commotion, destruction of
production facilities or materials by earthquake, fire, flood or storm, labor disturbances,
epidemic, or failure of suppliers, public utilities or common carriers; provided however,
that the party seeking relief hereunder shall immediately notify the other party of such
cause(s) beyond such party&#146;s reasonable control. The party that may invoke this section
shall use all reasonable endeavors to reinstate its ongoing obligations to the other. If the
cause(s) shall continue unabated for one hundred eighty (180)&nbsp;days, then both parties shall
meet to discuss and negotiate in good faith what modifications to this Agreement should
result from this force majeure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized officers.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CARDINAL HEALTH PTS, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="white-space: nowrap">CUMBERLAND PHARMACEUTICALS INC.</FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas G. Dimke
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ AJ Kazimi</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas G. Dimke
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AJ Kazimi</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SVP/GM HCSS
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">C.E.O.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5-18-06
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5-17-06</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Schedule&nbsp;1.1(k)</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>List of Products</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CeraLyte<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP><BR>
Kristalose<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></sup>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Schedule&nbsp;1.1(o)</B></U><BR>
<BR>
<U><B>Definition of Territory</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The mutually agreed upon headquarter locations for the twenty four representatives are
as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Atlanta, GA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Birmingham, AL</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Boston, MA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Charlotte, NC</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chicago, IL</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dallas, TX</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dayton, OH</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Detroit, MI</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Hartford, CT</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Houston, TX</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Knoxville, TN</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lafayette, LA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Long Island, NY</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Manhattan, NY</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Miami, FL</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mobile, AL</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Newark, NJ</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Philadelphia N, PA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Philadelphia S, PA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cleveland, OH</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">San Antonio, TX</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tampa, FL</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Washington, DC</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Yonkers, NY</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Each Territory shall include the Target Customers identified by Cumberland and Cardinal
Health.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-25-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Schedule&nbsp;3.1</B></U>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Service Fees and Payment Schedule</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With respect to the Program defined herein, the following fees shall apply:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A. As compensation for the satisfactory performance by Cardinal Health of its obligations
under the Agreement, Cumberland agrees to pay Cardinal Health Service Fees at the annual rate of
&#091;***&#093;. The Service Fees shall be billed in monthly installments on the last day of each month
during the term hereof. Each such installment shall be in the amount of &#091;***&#093; or pro rata portion
thereof in the event of early termination. The payment schedule for the term is as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Invoice Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Payment</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">September&nbsp;30, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">October&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">November&nbsp;30, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;28, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">March&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April&nbsp;30, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">May&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June&nbsp;30, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">August&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">September&nbsp;30, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">October&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">November&nbsp;30, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;28, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">March&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April&nbsp;30, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">May&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June&nbsp;30, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">August&nbsp;31, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;In addition to the Service Fees, Cardinal Health will invoice Cumberland for
the following pass through costs:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-26-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>bonuses to Representatives in amounts as agreed in writing by Cardinal
Health and Cumberland before payment and based upon well-defined
performance criteria (typically &#091;***&#093; of salaries); and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>actual expenses associated with regular territory
business travel for Detailing, training meetings, and plan of action
meetings including airfare, hotels, meals, meeting rooms, A/V
equipment, materials, parking and tolls, each of which is subject to
the Territory Budget as set forth in the Agreement</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The expiration or termination of this Agreement shall not release Cumberland from
any obligation to pay Cardinal Health any amounts accrued under this Agreement in
connection with activities completed, expenses accrued prior to the effective date of
such expiration or termination; provided that the Service Fee paid by Cumberland for the
month in which this Agreement is terminated shall be prorated based on the number of days
in that month, and Cardinal Health shall refund any overpayment to Cumberland.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-27-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.&nbsp;<U>Performance Incentive.</U> Cardinal Health shall be eligible to receive a
Performance Incentive based upon Cardinal Health&#146;s performance resulting in Kristalose sales
during the term hereof in excess of a mutually agreed upon threshold which is based on sales
to targeted physicians, over which Cardinal Health will be paid a maximum of &#091;***&#093; in
Performance Incentives according to the scale below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-28-<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>g06286exv10w5.htm
<DESCRIPTION>EX-10.5 FIRST AMENDMENT TO CONTRACT SALES AND SERVICE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.5 FIRST AMENDMENT TO CONTRACT SALES AGRMT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for<BR>
confidential treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>FIRST AMENDMENT TO</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>CONTRACT SALES AND SERVICES AGREEMENT</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This First Amendment to Contract Sales and Services Agreement (the &#147;Amendment&#148;),
between Cardinal Health PTS, LLC (&#147;Cardinal Health&#148;) and Cumberland Pharmaceuticals, Inc.
(&#147;Cumberland&#148;) is entered into by and between Cardinal Health and Cumberland to modify
the terms of the Contract Sales and Services Agreement between the parties dated May&nbsp;16,
2006 (&#147;Agreement&#148;). All capitalized terms used in this Amendment shall have the meaning
ascribed to them in the Agreement.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>Amendments.</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;2.1 of the agreement is hereby amended to the add the following
to the end of Section&nbsp;2.1:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In addition to the twenty-four Representatives dedicated to Detailing Products
for Cumberland under this Section, Cardinal Health shall also provide Cumberland
with access to a syndicated sales force which will provide Details for
Cumberland products as well as products of other Cardinal Health customers
(&#147;Syndicated Sales Force&#148;). Upon agreement of the parties, the Syndicated Sales
Force shall provide Details in accordance with terms set forth in amendments to
Schedule&nbsp;3.1 of this Agreement. Such amendment shall set forth the details of
the Details, priority of Details, Products, services and fees to be provided by
Cardinal Health through the Syndicated Sales Force. The provisions of Sections
2.3(a) and 3.2 shall not apply with respect to the Syndicated Sales Force.
Cumberland agrees that it will not recruit, solicit or hire any Representative
which is a member of the Syndicated Sales Force during the Term of this
Agreement and for one year thereafter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;2.2 of the Agreement is hereby amended to add the following to
the end of Section&nbsp;2.2:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The two Managers shall be responsible for oversight of the dedicated sales force
and not the Syndicated Sales Force. The Syndicated Sales Force shall continue to
be managed by individuals appointed by Cardinal Health to manage the Syndicated
Sales Force.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Schedule&nbsp;3.1 is hereby amended to add the
following at the end:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>SYNDICATED SALES FORCE</B></U></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cardinal Health&#146;s Syndicated Sales Force will make Calls on Target Customers
identified by Cumberland within the territory currently served by the
Syndicated Sales Force. The Syndicated Sales Force will Detail up to 3
Cumberland products during calls that are dedicated exclusively to Cumberland.
For purposes of this Agreement, a &#147;Call&#148; means a visit by a Representative or
Manager to a Target Customer in which multiple Products shall be Detailed to
the Target Customer, with the understanding that a small number (less than
10%) of Calls may not involve the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Detailing of all required Products (i.e., where Target Customers will not listen
to all Details).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Call schedule shall begin on July&nbsp;1, 2006 and end on June&nbsp;30, 2007. Cardinal will
deliver &#091;***&#093; during this period. The service fee schedule will be as follows:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Month</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Invoice Amount</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">August</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">September</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">October</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">November</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">March</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">May</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cardinal Health will invoice Cumberland the amount set forth in the above table on the
last day of each month for service fees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cardinal Health will also have the ability to earn up to &#091;***&#093; in performance incentive
for mutually agreed upon sales achievement levels on the target audience.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>The following expenses shall be direct pass-through to Cumberland for the syndicated program:</B></U></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Actual travel expenses for all required participation in any subsequent POA meetings.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Actual promotional expenses and percentage of representative sample storage cost. The
parties will agree upon and manage to a budget based upon marketing programs and storage
requirements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>Effective Date.</B></U> This Amendment shall be effective upon full execution hereof
(&#147;Effective Date&#148;). Except as otherwise amended herein, the terms and conditions of the
Addendum shall remain in full force and effect.
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><B>CUMBERLAND PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>CARDINAL HEALTH PTS, LLC.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ James D. Aderhold, Jr
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas G. Dimke</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James D. Aderhold, Jr
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas G. Dimke</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">V-P
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SVP/GM</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7/13/06
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7/19/06</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>12
<FILENAME>g06286exv10w6.htm
<DESCRIPTION>EX-10.6 CONSENT TO ASSIGNMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.6 CONSENT TO ASSIGNMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.6</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 75%; margin-top: 6pt">Cardinal Health<BR>
Contract Sales &#038; Services<BR>
7000 Cardinal Place<BR>
Dublin, OH 43017<BR>
614.757.5900 main

</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 75%; margin-top: 6pt">www.cardinal.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g06286g0628601.gif" alt="(CARDINALHEALTH LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">November&nbsp;10, 2006
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr. A.J. Kazimi<BR>
Cumberland Pharmaceuticals, Inc.<BR>
2525 West End Avenue, Suite&nbsp;950<BR>
Nashville, Tennessee 37203
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Re:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Contract Sales and Services Agreement dated May&nbsp;16, 2006,
by and between Cardinal Health PTS, LLC (&#147;Cardinal
Health&#148;) and Cumberland Pharmaceuticals, Inc.
(&#147;Cumberland&#148;), as amended by First Amendment to Contract
Sales and Services Agreement dated July&nbsp;19, 2006
(collectively referred to as the &#147;Agreement&#148;)</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Mr.&nbsp;Kazimi:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As you may already know, Cardinal Health has signed a definitive agreement to sell its
Healthcare Marketing Services division to Platinum Equity. This transaction includes Cardinal
Health&#146;s Contract Sales Organization (&#147;CSO Business&#148;) that is providing detailing and sampling
services under the Agreement. Cardinal Health and Platinum Equity expect the transaction to close
before the end of 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale of the CSO Business, Cardinal Health will need to assign the
Agreement to Platinum Equity. As Section&nbsp;18.7 of the Agreement requires Cumberland to consent to
an assignment of the Agreement, we are requesting that Cumberland provide its consent by signing
the Consent to Assignment attached.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We look forward to continuing to provide you the same high level of service you expect and
deserve. Please feel free to contact me at Tel: (614)&nbsp;757-5117 with any questions you may have
about this transition. We would like to receive your consent as soon as possible, but no later
than November&nbsp;22, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thank you for your assistance in this matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Very Truly Yours,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">/s/ Thomas Dimke

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Thomas Dimke<BR>
Senior Vice President &#038; General Manager,<BR>
Cardinal Health Contract Sales and Service

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">cc:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Martin S. Brown, Jr.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Adams and Reese / Stokes Bartholomew LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">424 Church Street, Suite&nbsp;2800</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37219</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONSENT TO ASSIGNMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;Cumberland Pharmaceuticals, Inc. hereby consents to and approves the assignment by Cardinal
Health PTS, LLC of all of their rights, title, interests and obligations in and under the Contract
Sales and Services Agreement dated May&nbsp;16, 2006, by and between Cardinal Health PTS, LLC and
Cumberland Pharmaceuticals, Inc., as amended by First Amendment to the Contract Sales and Services
Agreement dated July&nbsp;19, 2006 (collectively referred to as the &#147;Agreement&#148;) to PG Holding
Corporation, a Delaware corporation. This consent and approval is given pursuant to Section&nbsp;18.7 of
the Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dated as of November <U>&nbsp;&nbsp;&nbsp; 21 &nbsp;&nbsp;&nbsp;</U> ,<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>2006
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ A. J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>13
<FILENAME>g06286exv10w7.htm
<DESCRIPTION>EX-10.7 DISTRIBUTION SERVICES AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.7 DISTRIBUTION SERVICES AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.7</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><U><B>DISTRIBUTION SERVICES AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This agreement is made as of August&nbsp;3, 2000, between Cumberland Pharmaceuticals Inc., a
Tennessee corporation (&#147;Cumberland&#148;), and CORD Logistics, Inc., an Ohio corporation
(&#147;CORD&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><U>Background Information</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Cumberland is a Tennessee-based company formed primarily to acquire and market a
portfolio of niche pharmaceutical products to specific physician segments in the United
States, the District of Columbia and Puerto Rico (the &#147;Territory&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;CORD is in the business of distributing pharmaceutical products to wholesalers,
specialty distributors, physicians, clinics, hospitals, retail pharmacies, and other health
care providers in the Territory, and of providing Information Systems and other services
that support its customers&#146; use of its distribution capabilities (collectively, the
&#147;Services&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;Cumberland desires to engage CORD as its exclusive distribution agent (described
below) for the pharmaceutical products described on the exhibits attached hereto (each, a
&#147;Product&#148;) and, with respect to each Product, to perform certain other services described in
this agreement, all upon the terms and conditions set forth in this agreement. This
agreement is being entered into pursuant to a letter of intent from CORD dated April&nbsp;5,
2000, which was accepted and executed by Cumberland as of April&nbsp;10, 2000.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Statement of Agreement</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland and CORD (the &#147;Parties&#148;) hereby acknowledge the accuracy of the above
Background Information and agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;1. <U>Appointment.</U> Upon the terms and conditions described in this agreement,
Cumberland hereby appoints CORD as its exclusive distribution agent in and for the Territory
for distribution of each Product (including samples) to Cumberland&#146;s direct customers
(&#147;Customers&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Services for each Product or group of Products identified on the same
Product-specific exhibit to this agreement shall be implemented pursuant to the
Implementation Schedule included in such exhibit (each, an &#147;Implementation Schedule&#148;), with
distribution of each Product to begin on the date specified in the Implementation Schedule
for such Product (the &#147;Commencement Date&#148;). In performing the Services, CORD will provide,
at its discretion, the services of either the Vice President and General Manager, Director
of Sales or other such representative as mutually agreed to by Cumberland and CORD. CORD&#146;s
designated representative will be the primary liaison with Cumberland, unless otherwise
agreed to by the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;2. <U>Product Supply. Warehousing and Storage.</U> Cumberland shall ship each Product
to CORD at CORD&#146;s distribution facility currently located at 15 Ingram Boulevard, Suite&nbsp;100,
La Vergne, TN 37086 or to such other distribution facility as may be designated by CORD
(individually or collectively, the &#147;CORD Facility&#148;) and agreed by Cumberland, in sufficient
quantities to meet Cumberland&#146;s anticipated Customer orders. CORD shall visually inspect
each shipment of each Product for external damage or loss in transit and, in the event of
any such damage or loss, shall, within a commercially reasonable period of time following
discovery of such damage or loss by CORD, notify Cumberland that such damage or loss has
occurred.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Product or group of Products identified on the same Product-specific
exhibit to this agreement: (a)&nbsp;Cumberland shall, during the Product Term set forth on such exhibit,
provide CORD with applicable regulatory storage and handling requirements and projections of such
Product&#146;s volume requirements not less often than quarterly, at least 30&nbsp;days in advance of the
quarter and written instructions setting forth the storage and handling requirements applicable to
such Product; and (b)&nbsp;CORD shall store such Product in the CORD Facility and comply with applicable
regulatory storage and handling requirements and the storage and handling requirements applicable
to such Product, as such requirements may be supplemented or amended from time to time in writing
by Cumberland with reasonable prior notice to CORD and its prior approval, which approval shall not
be unreasonably withheld or delayed. If CORD notifies Cumberland in good faith that any such
supplement or amendment will require any material modification to the CORD Facility or CORD&#146;s
procedures or requirements which are unique and specific to the Product or the Services resulting
in a material increase to CORD&#146;s anticipated costs and expenses, then Cumberland and CORD shall
consult regarding such reasonable costs and expenses (hereinafter, simply &#147;unique costs&#148;) and
Cumberland shall pay such unique costs resulting from that modification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland shall pay all costs and expenses of delivering each Product to the CORD Facility.
CORD will never take title to any Product, even when such Product is located at the CORD Facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;3. <U>Standard Product Distribution.</U> With respect to each Product or group of Products
identified on the same Product-specific exhibit to this agreement, and during the Product Term set
forth on such exhibit, all Customer orders shall be taken by CORD as described in the Operating
Guidelines (defined in &#167;6, below). CORD shall confirm the receipt of and process each order and, so
long as the ordered Product is then in stock at the CORD Facility and the orders are received no
later than 2:00 p.m. local time at the CORD Facility, routinely have that order available for
shipment within 24 hours of CORD&#146;s receipt of the order (exclusive of holidays and weekends) or
such longer period as may be designated or permitted by Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer orders will be delivered by a courier mutually chosen by Cumberland and CORD. CORD
will invoice Cumberland for such handling services and freight cost on a monthly basis. CORD will
use best efforts to manage any claims by Cumberland against the courier, provided, however, that
Cumberland shall be responsible for all lost or damaged shipments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, Cumberland shall reimburse CORD for all documented costs and expenses of
packaging material used for shipping the Product and all business forms unique to Cumberland (e.g.,
packing slips, invoices, etc.); provided that the use of such packaging material and business forms
is authorized in advance by Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Product shall be shipped on a &#147;first expiration date, first out&#148; basis or as otherwise
directed by Cumberland. In addition, CORD shall establish (and Cumberland shall approve) procedures
for the processing and shipment of emergency orders on weekends and holidays, provided that
Cumberland shall separately pay all increased costs resulting from such orders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;4. <U>Product Prices.</U> With respect to each Product or group of Products identified in
the same Product-specific exhibit to this agreement, Cumberland shall, upon execution of such
exhibit, deliver to CORD a price list for Customers who purchase such Product or Products (the
&#147;Customer Price List&#148;). Cumberland shall notify CORD of any change in the Customer Price List not
less than 10 business days prior to the effective date of any such change. The Parties hereby
acknowledge that Cumberland, and not CORD, is the seller of each Product to Customers.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;5. <U>Financial Support Services.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to Section&nbsp;5(b), during each Product Term set forth on the Product-specific
exhibits to this agreement, CORD shall perform the customer credit research, billing, cash
application, collections, and reporting services described in the Operating Guidelines in
accordance with the policies and procedures set forth in such Operating Guidelines, as such
policies and procedures may be supplemented or amended from time to time by Cumberland with
reasonable prior notice to CORD and with its prior approval (the &#147;Financial Support Services&#148;);
provided that if CORD notifies Cumberland in good faith that any such supplement or amendment will
require any material modification to CORD&#146;s procedures or requirements for providing the Services,
then Cumberland shall pay all unique costs resulting from that modification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;CORD shall have no obligation to pay for any Product or to reimburse Cumberland for any
losses incurred in connection with the failure of any Customer to pay Cumberland any amount due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Customers shall be directed to make payments for the Products in accordance with the
Operating Guidelines.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;6. <U>Operating Guidelines.</U> As soon as practicable after the date of this agreement,
CORD and Cumberland shall develop operating guidelines relating to the Products and the Services,
which guidelines (the &#147;Operating Guidelines&#148;) will be in writing, in a form satisfactory to CORD
and Cumberland, and will define and document the responsibilities of CORD and Cumberland in
support of the relationship described in this agreement. All Operating Guidelines shall be
developed and implemented in good faith and in a commercially reasonable manner, subject to the
qualifications set forth therein; provided that in the event of any inconsistency between the
Operating Guidelines and the other provisions of this agreement (including each Product-specific
exhibit to this agreement), the other provisions of this agreement shall control. The Operating
Guidelines may be amended from time to time upon the mutual agreement of CORD and Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;7. <U>Returns and Recalls.</U> Pursuant to this agreement and any applicable Operating
Guidelines, CORD shall assist in the processing of Product returns (excluding recall returns,
which will be dealt with as described below) in coordination with the third party returns company
chosen by Cumberland to facilitate return of Product. No such assistance will involve handling by
CORD of the Product being returned. The fees to be paid to CORD for these return services are
described in Section&nbsp;8.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CORD shall process Customer Product return authorizations and credits as set forth in the
Operating Guidelines. The fee for such Services by CORD will be included as a part of the Customer
Service Fees described in Section&nbsp;8.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If Cumberland is required to recall, or on its own initiative recalls, any Product, CORD will
assist Cumberland with that recall as reasonably requested by Cumberland; provided that Cumberland
shall pay to CORD an amount equal to all costs incurred by CORD in connection with any such
recall.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;8. <U>Fees.</U> As compensation for services being provided by CORD in connection with the
development and implementation of the infrastructure for the relationship contemplated by this
agreement, including CORD&#146;s information system development (separate from the Information System
Access Fees described below) and implementation for Cumberland&#146;s use, Cumberland shall pay CORD a
one-time implementation fee of &#091;***&#093; (the &#147;Implementation Fee&#148;), one-half of which shall be
payable on the first anniversary of the date of this agreement and one-half of which shall be
payable on the second anniversary of the date of this agreement. Cumberland&#146;s obligation to pay
the Implementation
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fee is not contingent upon the acquisition by Cumberland of any Product marketing and distribution
rights and shall survive the termination of this agreement. However, the Implementation Fee shall
not be due and payable if this Agreement is terminated early for any reason other than breach by
Cumberland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, with respect to each Product or group of Products identified on the same
Product-specific exhibit to this agreement, Cumberland shall pay CORD, as compensation for the
Services related to such Product or Products, the fees described in such exhibit (the &#147;Fees&#148;). CORD
will use commercially reasonable efforts to keep total fees in line with industry standards. The
Fees shall include:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Storage/Distribution Fees. </I>The Storage and Distribution Fees shall be in the
amounts set forth in each applicable Product Exhibit. This component of the Fees shall cover
storage of Product and distribution services, which fees (the &#147;Storage and Distribution Fees&#148;),
with respect to each Product or group of Products identified on the same Product-specific exhibit
to this agreement, shall be in the amount specified in such exhibit.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Storage Fees shall be based upon the average weekly number of pallets in storage. The
Distribution Fees, for each calendar month during the Term of this Agreement, shall be based upon
the aggregate number of units (or cases) shipped by CORD from the warehouse. Cumberland shall be
charged an initial price per unit or case (collectively referred to as &#147;pick&#148;) on the first pick of
each order placed by Cumberland each month, and then a recurring amount per pick for each
incremental pick shipped from the same order thereafter. For example, for the distribution of
Reglan and Donnatal, on a monthly basis, Cumberland shall be charged the sum of &#091;***&#093; per pick of
each order of product shipped that month and the sum of &#091;***&#093; per pick for each incremental pick
from the same order.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Information System Access Fees. </I>This component of the Fees shall cover
Cumberland&#146;s access to CORD&#146;s or an affiliate of CORD&#146;s standard Information Systems, consisting of
the computer hardware and software and other components described in the attached Schedule&nbsp;8(c)-1
(the &#147;System&#148;), and other services relating to Cumberland&#146;s access to the System as described in
Schedule&nbsp;8(c)-1, which fees (the &#147;System Access Fees&#148;), with respect to each Product or group of
Products identified on the same Product-specific exhibit to this agreement, shall be in the amount
specified in such exhibit. Access to the System shall be provided pursuant to a System Access
Agreement in the form of the attached Schedule&nbsp;8(c)-2, which agreement (the &#147;System Access
Agreement&#148;) shall be executed by the Parties concurrently with this agreement. Access to the System
shall be made available to Cumberland&#146;s facility for each Product at the prices set forth in the
exhibit for such Product, so long as Cumberland first has in place a local area network sufficient
to support all Cumberland terminals and personal computers which will have access to the System and
a centralized server sufficient for data storage related to Cumberland&#146;s access to the System. All
costs and expenses associated with establishing initial hook-up of all communication and electronic
information lines necessary for interface of the System with Cumberland&#146;s information systems
located at Cumberland&#146;s address set forth at the end of this agreement are included in the
Implementation Fee and are separate from the services and costs and expenses covered by the System
Access Fees. Cumberland shall have sole responsibility for payment of all costs and expenses of
maintaining all such communication and electronic information lines. CORD and Cumberland shall each
assign knowledgeable and qualified employees to facilitate the access to the System as contemplated
by this agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Financial Support Services Fees. </I>This component of the Fees shall be payment for cash
application, collections and chargeback processing services (including chargeback system access)
described in the Operating Guidelines, which fees (the &#147;Financial Support Services Fees&#148;), with
respect to each Product or group of Products identified on the same Product-specific exhibit to this
agreement, shall be in the amount specified in such exhibit.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 4 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<I>Customer Service Fees. </I>This component of the Fees shall be payment for the
customer services performed by CORD pursuant to the Operating Guidelines, which fees (the
&#147;Customer Support Fees&#148;), with respect to each Product or group of Products identified in the same
Product-specific exhibit to this agreement, shall be in the amount specified in such exhibit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<I>EDI Set-up, Maintenance, Access Fees. </I>This component of the Fees shall be
payment for services related to the set-up and maintenance of Electronic Data Interchange (&#147;EDI&#148;)
transaction capabilities between Cumberland and its Customers and access and use of a mutually
agreed upon EDI provider. These fees are included in the System Access Fees described in &#167;8(b)
above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Product or group of Products identified on the same Product-specific
exhibit to this agreement, following the end of each calendar month with respect to Product Term
set forth on such exhibit, CORD shall issue an invoice to Cumberland for the Fees payable with
respect to CORD&#146;s performance of the Services for the prior month. The Fees or other amounts owed
to CORD by Cumberland under this agreement shall be payable within 30&nbsp;days of the date of CORD&#146;s
invoice for such Fees or other amounts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fees shall be held firm for the first contract year. Thereafter, CORD shall adjust the
price not more often than once per contract year by not more than the increase in the Producer
Price Index &#151; All Commodities published by the United States Department of Labor, Bureau of
Statistics, as amended from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the above Price Increase, if CORD can demonstrate that the costs for
providing the Services have materially increased, or are likely to materially increase in the
coming year due to the adoption of any applicable law or regulation, or any material change in the
interpretation or administration thereof, then upon notice from CORD, the Parties agree to meet in
good faith and negotiate a mutually acceptable adjustment to the Fees, which compensates CORD for
the change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;9. <U>Term and Termination.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The initial term of this agreement shall begin upon the day Cumberland signs a letter of
intent to acquire its first Product and shall continue for a period of three (3)&nbsp;years (the
&#147;Initial Term&#148;), unless terminated earlier pursuant to this agreement. Thereafter, this agreement
shall automatically renew for additional terms of one (1)&nbsp;year each, unless written notice of
termination is given by either Party at least 90&nbsp;days prior to the end of the Initial Term, or
such other term, in which case this agreement shall terminate at the end of the relevant term. Any
reference in this agreement to the &#147;term of this agreement&#148; shall include the Initial Term and any
such renewal terms. Upon termination of this agreement or upon the written request of Client, all
Product shall be expeditiously returned to the Client or a designee of the Client.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Either Party shall have the right to terminate this agreement or any Product-specific exhibit
to this agreement upon the breach by the other Party of a material provision of this agreement or
such exhibit and that Party&#146;s failure to cure such breach within 60&nbsp;days following written notice
thereof from the non-breaching Party or, in the event such failure is not capable of being cured
within such 60-day period, the non-breaching Party&#146;s failure to continue to diligently prosecute
such cure thereafter; provided, that, with respect to any failure to make any payment when due under this agreement
or any Product-specific exhibit to this agreement, such period in which to cure shall be reduced
to 30&nbsp;days.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 5 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Either Party shall have the right to terminate this agreement or any Product-specific
exhibit to this agreement immediately upon notice to the other Party following the commencement of
any bankruptcy or insolvency proceeding (whether voluntary or involuntary) with respect to such
other Party or its assets, the general assignment for the benefit of creditors by such other
Party, or the appointment of a receiver, trustee or liquidator by or for such other Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Sections&nbsp;8 and Sections&nbsp;14 through 17, inclusive, of this agreement shall survive the
termination or expiration of this agreement and each Product-specific exhibit to this agreement,
and except as set forth herein, no termination of this agreement or any Product-specific exhibit
to this agreement shall affect any liabilities arising, or based upon acts or omissions occurring,
prior to the date of such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167; 10. <U>Audits.</U> In connection with any services being provided pursuant to this
Agreement, CORD agrees to maintain written records and data during and after the term of this
Agreement in compliance with all applicable legal and regulatory requirements, including without
limitation applicable requirements of the United States Food and Drug Administration. Further,
CORD shall furnish Cumberland within thirty (30)&nbsp;days following each March&nbsp;31, June&nbsp;30, September
30, and December&nbsp;31 of each calendar year a complete and accurate statement for the immediately
preceding calendar quarterly period of (a)&nbsp;the number of units of Products sold; (b)&nbsp;information
as to returns actually credited; (c)&nbsp;current inventory levels for Products; and (d)&nbsp;such other
information as Cumberland may reasonably request. In order to verify compliance, CORD shall
provide Cumberland with such records and agrees to permit representatives of Cumberland to visit
facilities of CORD at which Services are being performed during normal business hours (i.e., 8:00
a.m. to 5:00 p.m. local time), upon 15 business days prior notice, to: (a)&nbsp;review and audit CORD&#146;s
records relating directly to Product received at and shipped from the CORD Facility; and (b)
conduct, together with representatives of CORD, an inventory of the Product at the CORD Facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;11. <U>Compliance With Laws.</U> Each Party shall conduct its activities in connection with
this agreement in substantial compliance with all applicable laws, rules, regulations, and orders
of governmental entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167; 12. <U>Representations and Warranties.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Mutual Representations and Warranties. </I>Each Party represents and warrants to
the other that: (i)&nbsp;it has full power and authority to enter into this agreement and perform and
observe all obligations and conditions to be performed or observed by it under this agreement
without any restriction by any other agreement or otherwise; (ii)&nbsp;the execution, delivery and
performance of this agreement have been duly authorized by all necessary corporate action of that
Party; and (iii)&nbsp;this agreement constitutes the legal, valid and binding obligation of that Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Cumberland Representations and Warranties. </I>Cumberland further represents and
warrants to CORD that (i)&nbsp;each Product is and shall be manufactured in conformity with the Food,
Drug, and Cosmetic Act, as amended, and all other applicable laws, rules, regulations and orders
of governmental entities, and (ii)&nbsp;as of the effective date of any Product-specific exhibit
hereto, Cumberland will have (and will have provided CORD with written documentation in form
reasonably satisfactory to CORD that Cumberland has, as of such effective date) title to such
Product or Products and the right to market and distribute such Product or Products as
contemplated hereby.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 6 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>CORD Representations and Warranties. </I>CORD hereby represents and warrants that it
has the experience, capability and resources, including without limitation, sufficient personnel
and supervisors, to perform the Services offered hereunder in a commercially reasonable manner in
conformity with applicable regulations of any governmental authority, including the United States
Food and Drug Administration. CORD further represent that it will at all times devote the necessary
personnel and supervisors to perform the Services in such a manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CORD shall not make any representations, warranties, or guarantees to Customers with respect
to the Products that are inconsistent with information provided by Cumberland to CORD, including
without limitation, representations, warranties, and guarantees concerning specifications,
features, efficacy, prices, or availability of the Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;13. <U>Taxes.</U> Cumberland shall pay when due all sales, use, gross receipts, excise,
personal property taxes associated with each Product (excluding any personal property tax
associated with CORD&#146;s equipment used in connection with the Services), and other taxes or similar
charges now or hereafter imposed as a result of the transactions contemplated by this agreement,
none of which have been included in the fees payable to CORD under this agreement; provided that
the amounts payable by Cumberland under this section shall not include taxes based on the net
income of CORD.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167; 14. <U>Trademarks and Proprietary Rights.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 Neither party hereto shall have the right to use the trademarks, service marks, logos, or
other similar marks of the party hereto, or any of its affiliates, in any manner except with the
prior written approval of the party that has rights to such intellectual property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2 All materials, documents, information, inventions, improvements, data, programs and
suggestions of every kind and description, whether or not patentable, and all copyrightable works
supplied to CORD by Cumberland pursuant to this Agreement shall be the property of Cumberland
solely and exclusively (the &#147;Cumberland Property&#148;); provided that any and all information,
processes, documents, computer software or other proprietary information used, owned, licensed or
developed by CORD shall be the property of CORD.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;15. <U>Master Agreement.</U> This agreement is being entered into pursuant to the Strategic
Alliance Agreement dated June&nbsp;6, 2000, between Cardinal Health (as defined below) and Cumberland
(the &#147;Master Agreement&#148;), and this agreement (including any and all exhibits hereto, whether
entered into now or hereafter) constitutes an Addendum, as defined in the Master Agreement. In the
event of any conflict or inconsistency between the terms of this agreement (including any and all
exhibits hereto) and the terms of the Master Agreement, the terms of this agreement shall govern.
For purposes of this agreement, &#147;Cardinal Health&#148; means the following affiliated operating
companies: Cardinal MarketForce, a division of RedKey, Inc., an Ohio corporation (Dublin, OH); CORD
Logistics, Inc., an Ohio corporation (Dublin, OH); and any other subsidiary of Cardinal Health,
Inc., an Ohio corporation (&#147;CHI&#148;), as may be designated by CHI and agreed by client in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167; 16. <U>Indemnification.</U> Each Party shall indemnify and hold harmless the other and its
parent and affiliates, and each of their respective directors, officers, employees, agents, and
representatives from and against all claims, liabilities, losses, damages, costs, and expenses
(including without limitation reasonable attorneys&#146; fees) arising directly or indirectly out of any
failure of that Party to perform and observe fully all obligations and conditions to be performed
or observed by that Party pursuant to this agreement or any breach of any warranty made by that
Party in this agreement. Cumberland further agrees to indemnify and hold harmless CORD and its parent and affiliates and each of their
respective directors, officers, employees, agents and representatives from and against all claims,
liability, losses, damages, costs, and expenses (including without limitation reasonable attorney&#146;s
fees) arising directly or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 7 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">indirectly out of injury or death to person or property alleged to have
been caused by any defect in any
Product. <B>NOTWITHSTANDING THE FOREGOING, OR ANY OTHER PROVISION OF THIS AGREEMENT TO THE
CONTRARY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL,
INDIRECT, SPECIAL, OR OTHER SIMILAR DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT,
AND IN NO EVENT SHALL CORD&#146;S LIABILITY HEREUNDER EXCEED CORD&#146;S INSURANCE LIMITS SET FORTH BELOW IN
SECTION </B><B>17(b)(i)</B><B>.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#167;17. <U>Insurance.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Promptly after Cumberland acquires rights to distribute its first Product and for as long
thereafter as necessary to cover claims resulting from this agreement, Cumberland shall obtain and
maintain: (i)&nbsp;product liability and commercial general liability insurance having a limit of not
less than $10&nbsp;million; and (ii)&nbsp;property damage insurance at replacement value for each Product
located at the CORD Facility or in transit to or from the CORD Facility, pursuant to one or more
insurance policies with reputable insurance carriers. Cardinal Health, Inc. and its subsidiaries
shall be designated as &#147;additional insureds&#148; under the product liability and commercial general
liability insurance policy(ies), and as &#147;loss payees&#148; under the property damage insurance
policy(ies). Prior to CORD&#146;s receipt of Product, Cumberland shall deliver to CORD certificates
evidencing such insurance. Cumberland shall not cause or permit such insurance to be canceled or
modified to materially reduce its scope or limits of coverage during the term of this agreement or
thereafter as provided above. Except for any losses resulting from the negligence or intentional
misconduct of CORD, Cumberland shall bear all risk of loss or damage with respect to each Product,
whether located at the CORD Facility or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Promptly after Cumberland acquires rights to distribute its first Product and for as long
thereafter as necessary to cover claims resulting from this agreement, CORD shall obtain and
maintain: (i)&nbsp;product liability and commercial general liability insurance having a limit of not
less than $1&nbsp;million; and (ii)&nbsp;property damage insurance at replacement value for each Product
located at the CORD Facility or in transit to or from the CORD Facility, pursuant to one or more
insurance policies with reputable insurance carriers. Cumberland shall be designated as &#147;additional
insureds&#148; under the product liability and commercial general liability insurance policy(ies), and
as &#147;loss payees&#148; under the property damage insurance policy(ies). Prior to CORD&#146;S receipt of
Product, CORD shall deliver to Cumberland certificates evidencing such insurance. CORD shall not
cause or permit such insurance to be canceled or modified to materially reduce its scope or limits
of coverage during the term of this agreement or thereafter as provided above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;18. <U>Relationship of the Parties.</U> The relationship among the Parties is and shall be
that of independent contractors. This agreement does not establish or create a partnership or joint
venture among the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;19. <U>Notices.</U> Any notice or other communication required or desired to be given to any
Party under this agreement shall be delivered in writing to the address or facsimile number set
forth beneath the authorized signatures on this agreement and shall be deemed given: (a)&nbsp;three
business days after such notice is deposited in the United States mail, first-class postage
prepaid, and addressed to that Party at the address for such Party set forth at the end of this
agreement; (b)&nbsp;one business day after delivered to Federal Express, Airborne, or any other similar
express delivery service for delivery to that Party at that address; or (c)&nbsp;when sent by facsimile
transmission, with electronic confirmation, to that Party at its
facsimile number set forth at the end of this agreement. Any notice delivered by facsimile
transmission will be deemed delivered upon electronic confirmation provided the notice is also
deposited in the U.S. mail, first-class postage prepaid. Any Party may change its address or
facsimile number for notices under this agreement by giving the other Parties notice of such
change.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 8 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;20. <U>Alternative Dispute Resolution.</U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Parties agree to use good faith efforts to resolve all disputes within ninety (60)&nbsp;days of
written notice that such a dispute exists. If dispute under this Agreement cannot be resolved by
the Parties within such sixty (60)&nbsp;day period, the Parties agree to refer the matter to one
executive from each Party not directly involved in the dispute for review and resolution. A copy
of the terms of this Agreement, agreed upon facts and areas of disagreement, and a concise summary
of the basis for each side&#146;s contentions will be provided to both executives who shall review the
same, confer, and attempt to reach a mutual resolution of the issue within forty-five (45)&nbsp;days
after receipt of the materials referenced above. If the matter has not been resolved within such
forty-five (45)&nbsp;day period, either or both Parties may pursue resolution of the matter through
litigation or other process available under law or equity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;21. <U>Remedies.</U> Each Party acknowledges that in the event of any violation by that
Party of any of the provisions of Section&nbsp;14 of this agreement or Article&nbsp;III., Sections&nbsp;D or E of
the Master Agreement, the other Party would suffer irreparable harm and its remedies at law would
be inadequate. Accordingly, in the event of any violation or attempted violation of any such
provisions by either Party, the other Party shall be entitled to a temporary restraining order,
temporary and permanent injunctions, specific performance, and other equitable relief, without any
showing of irreparable harm or damage or the posting of any bond. The rights and remedies of each
Party under this agreement shall be cumulative and in addition to any other rights or remedies
available to such Party, whether under any other agreement, at law, or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;22. <U>Governing Law.</U> All questions concerning the validity or meaning of this
agreement or relating to the rights and obligations of the Parties with respect to performance
under this agreement shall be construed and resolved under the laws of the State of Tennessee ,
without regard to principles of conflicts of laws. The parties agree that any claims asserted in
any legal proceeding by one party against the other shall be commenced and maintained in any state
or federal court in Nashville, Tennessee or Columbus, Ohio and the parties submit to the
jurisdiction of these courts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;23. <U>Severability.</U> The intention of the Parties is to comply fully with all laws and
public policies, and this agreement shall be construed consistently with all laws and public
policies to the extent possible. If and to the extent that any court of competent jurisdiction
determines that it is impossible to construe any provision of this agreement consistently with any
law or public policy and consequently holds that provision to be invalid, such holding shall in no
way affect the validity of the other provisions of this agreement, which shall remain in full
force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;24. <U>Non-waiver.</U> No failure by either Party to insist upon strict compliance with any
term of this agreement, to exercise any option, to enforce any right, or to seek any remedy upon
any default of the other Party shall affect, or constitute a waiver of, the first Party&#146;s right to
insist upon strict compliance, to exercise that option, to enforce that right, or to seek that
remedy with respect to that default or any prior, contemporaneous, or subsequent default. No
custom or practice of the Parties at variance with any provision of this agreement shall affect,
or constitute a waiver of, that Party&#146;s right to demand strict compliance with all provisions of
this agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;25. <U>Force Majeure.</U> If the performance of any part of this agreement by either Party shall
be affected for any length of time by fire or other casualty, government restrictions, war, riots,
strikes or labor disputes, lock out, transportation delays, acts of God, or any other causes which
are beyond the control of the Parties, such Party shall not be responsible for delay or failure of
performance of this agreement for such length of time, provided, however, that the obligation of
one Party to pay amounts due to any other Party shall not be subject to the provisions of this
section
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 9 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;26. <U>Genders and Numbers.</U> Where permitted by the context, each pronoun in this
agreement includes the same pronoun in the other genders or numbers and each noun used in this
agreement includes the same noun in other genders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;27. <U>Complete Agreement.</U> This agreement (together with the Master Agreement, the
Product-specific exhibits hereto, and the other documents referred to herein, all of which are
hereby incorporated herein by reference) contains the entire agreement between the Parties and
supersedes all prior or contemporaneous discussions, negotiations, representations, warranties, or
agreements relating to the subject matter of this agreement. CORD and Cumberland agree to comply
with the obligations of confidentiality set forth in Article&nbsp;III, Section&nbsp;E of the Master
Agreement. No changes to this agreement shall be made or be binding on either Party unless made in
writing and signed by both Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#167;28. <U>Successors.</U> This Agreement may not be assigned or transferred by a party without
the prior written consent of the other party hereto, provided, however, that either party may
assign this Agreement to any subsidiary, affiliate or an entity which acquires substantially all of
it&#146;s assets and business that is not in direct competition with CORD. Any such assignment shall not
materially or adversely affect the rights or obligations of either party to this Agreement.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CUMBERLAND PHARMACEUTICALS, INC.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CORD LOGISTICS, INC.<BR></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ A.J. Kazimi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Frank C. Wegerson</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">A.J. Kazimi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Frank C. Wegerson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President and General Manager</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Initials: <U>/s/ AJK</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Initials: <U>/s/ FCW</U></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">209 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Avenue South
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15 Ingram Blvd, #100</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Nashville, TN 37203
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LaVergne, TN 37086</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile No. (615)&nbsp;255-0094
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile No. (615)&nbsp;793-4783</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 10 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Schedule&nbsp;8 (c) -1</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><U>OPERATING SYSTEM BASE PACKAGE</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A. <U>System Access</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Includes access to CORD&#146;s processor and operating system Monday through Friday, excluding
holidays, 12 hours per day (5:30 am to 5:30 p.m., Pacific local time).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">B. <U>Software Access and Maintenance</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Includes access to CORD&#146;s or an affiliate of CORD&#146;s standard software. CORD or an affiliate of CORD
shall perform at it&#146;s own expense any necessary modification to bring the systems in compliance
with the standard functionality described below.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Customer service</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reports necessary to perform Medicaid rebate calculations</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Billing (Customization of invoicing/packing slips)</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Inventory tracking and reporting</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Lot tracking</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Order entry</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Warehousing</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Returns processing</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Ability to download system data to Cumberland&#146;s processors for reporting writing</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>All standard reports</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Contracts/Pricing maintenance and chargeback processing</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Systems Development/Additional Services:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland bears financial responsibility for customization beyond the standard systems
functionality described above. Such customization performed by CORD or its representatives
(exclusive of the base package) in connection with this agreement shall be billed to Cumberland
as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Systems and software development&#151;$120 per hour per person, plus travel.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On-site training&#151;$120 per hour per person, plus travel.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Supplies, equipment and other, to be agreed upon by both parties.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 11 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U><B>Schedule&nbsp;8 (c) -2</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SYSTEM ACCESS AGREEMENT</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This agreement is made as of July &#95;&#95;&#95;, 2000, between CORD Logistics, Inc., an Ohio corporation
(&#147;Licensor&#148;), and Cumberland Pharmaceuticals Inc., a Tennessee corporation (&#147;Licensee&#148;), who hereby
agree as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>System Access; Maintenance Obligations</U>. On the terms and subject to the conditions
described in this agreement and the Distribution Services Agreement having the same date as this
agreement between Licensor and Licensee (the &#147;Distribution Agreement&#148;), Licensor hereby grants to
Licensee a nonexclusive license (the &#147;License&#148;) to utilize Licensor&#146;s Order Entry System,
consisting of the computer hardware, software and other components described in Schedule&nbsp;8(c)-1 to
the Distribution Agreement (collectively, the &#147;System&#148;), for the information processing needs of
Licensee in connection with the Services to be provided by Licensor under the Distribution
Agreement. Licensee shall maintain during the term of this agreement the network and local area
network (including without limitation centralized server) requirements for the System described in
the Distribution Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the term of this agreement, Licensee shall employ reasonable security measures and
policies designed to safeguard the integrity, accessibility, and confidentiality of all of
Licensee&#146;s data resident on the System and establish reasonable disaster and emergency recovery
plans designed to minimize disruption from System operation interruptions. Licensee shall have the
right to review the operation of the System from time to time upon reasonable prior notice from
Licensee to Licensor; provided that such reviews shall be conducted in a manner to avoid disruption
of Licensor&#146;s business operations to the extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Proprietary Rights.</U> Licensee shall have the right to use the System during the term
of this agreement as expressly provided in paragraph 1 of this agreement, but not otherwise.
Licensee shall not assign or otherwise transfer, disclose, copy, modify, or decompile the System or
any part thereof without prior written consent of the Licensor. The System and all parts thereof,
in all of their tangible and intangible manifestations, all existing or new enhancements,
developments, derivative works, and other adaptations or modifications to the System (or any part
thereof), and all related proprietary rights, are and shall remain the exclusive property of
Licensor. Except for the License, Licensee shall have no right, title, or interest in or to the
System or any part thereof. Upon termination of this agreement, Licensee shall promptly return to
Licensor all portions of the System then in Licensee&#146;s possession or under its control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Warranties.</U> Licensee acknowledges that it has had adequate opportunity to review
the System and its features and operation and Licensee accepts the System &#147;AS IS&#148; for its use as
contemplated in the Distribution Agreement. <B>EXCEPT AS EXPRESSLY SET FORTH HEREIN OR IN THE
DISTRIBUTION AGREEMENT, LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY EXPRESSLY
DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED RELATING DIRECTLY OR INDIRECTLY TO
THE SYSTEM OR ANY PART THEREOF, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF QUALITY,
PERFORMANCE, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Limitation On Liability.</U> <B>LICENSOR SHALL NOT BE LIABLE FOR ANY CONSEQUENTIAL,
INDIRECT, SPECIAL, OR OTHER SIMILAR DAMAGES ARISING DIRECTLY OR INDIRECTLY OUT OF THE USE OR
INABILITY TO USE THE SYSTEM OR ANY PART THEREOF, EVEN IF INFORMED OF THE POSSIBILITY OF SUCH
DAMAGES, WHETHER CLAIMED UNDER CONTRACT, TORT, OR ANY OTHER LEGAL THEORY.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IF ANY OF THE LIMITATIONS ON THE LIABILITY OF LICENSOR CONTAINED IN THIS AGREEMENT ARE FOUND
TO BE INVALID OR UNENFORCEABLE FOR ANY REASON THEN LICENSOR AND LICENSEE EXPRESSLY AGREE THAT THE
MAXIMUM AGGREGATE LIABILITY OF LICENSOR FOR ALL CLAIMS RELATING TO THE SYSTEM SHALL NOT EXCEED 100%
OF THE AGGREGATE BASE PACKAGE FEES PAID BY LICENSEE TO LICENSOR FOR LICENSEE&#146;S USE OF THE SYSTEM
UNDER THE DISTRIBUTION AGREEMENT.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Taxes.</U> Licensee shall pay when due all sales, use, gross receipts, excise,
property, and other taxes or similar charges (other than taxes based upon Licensor&#146;s net income)
now or hereafter imposed as a result of the transactions contemplated by this agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Term.</U> The term of this agreement shall begin upon Licensee&#146;s initial use of the
System as evidenced by the first entry of inventory into the System (which may be a date earlier
than the Commencement Date specified for the Distribution Agreement) and shall end: (a)
automatically upon the termination of the Distribution Agreement (for any reason), or (b)&nbsp;on any
earlier date specified by Licensee in notice to Licensor given not less than 180&nbsp;days prior to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 12 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the specified termination date; provided that: (i)&nbsp;paragraph 2 through 5 inclusive, and
paragraph 8<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>of this agreement shall survive the termination of this agreement, and (ii)
no termination of this agreement shall affect any liabilities arising, or based upon acts or
omissions occurring, prior to such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee shall continue to have access to the System for a reasonable period of time (not be
exceed 60&nbsp;days) following termination of this agreement solely for purposes of retrieving and
transferring to a separate system Licensee&#146;s data relating to its pre-termination operations, and
Licensor shall reasonably cooperate with Licensee to preserve the integrity and accessibility of
Licensee&#146;s data during such period; provided that, during such period, Licensee shall continue to
pay the full Base Package and other fees payable by Licensee under the Distribution Agreement and
comply with all other requirements imposed upon Licensee under this agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Notices.</U> Any notice or other communication required or desired to be given to
either party under this agreement shall be in writing and shall be deemed given: (a)&nbsp;three days
after mailing, if deposited in the United States mail, first-class postage prepaid,
and<SUP style="font-size: 85%; vertical-align: text-top">-</SUP>addressed to that party at its address set forth at the end of this agreement; (b)
when received if delivered to Federal Express or any other similar overnight<SUB style="font-size: 85%; vertical-align: text-bottom">,</SUB> delivery
service for delivery to that party at that address; or (c)&nbsp;when sent by facsimile transmission,
with electronic confirmation, to that party at its facsimile number set forth at the end of this
agreement. Either party may change its address or facsimile number for notices under this agreement
by giving the other party notice of such change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Remedies.</U> Licensee shall indemnify Licensor and its affiliates, directors,
officers, employees, agents, and representatives against all claims, liabilities, losses, damages,
costs and expenses (including without limitation reasonable attorneys&#146; fees) arising directly or
indirectly out of any failure of Licensee to perform and observe fully all obligations and
conditions to be performed or observed by Licensee pursuant to this agreement. Licensee
acknowledges that in the event of any violation by it of any of the provisions of paragraph 2 of
this agreement, Licensor would suffer irreparable harm and its remedies at law would be inadequate.
Accordingly, in the event of any violation or attempted violation of any such provisions by
Licensee, Licensor shall be entitled to a temporary restraining order, temporary and permanent
injunctions, specific performance, and other equitable relief, without any showing of irreparable
harm or damage or the posting of any bond, in addition to any other rights or remedies which may be
available to Licensor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Force Majeure.</U> Notwithstanding any other provisions of this agreement or the
Distribution Agreement to the contrary, each party&#146;s obligations under this agreement (exclusive of
payment obligations) shall be excused if and to the extent that any delay or failure to perform
such obligations is due to fire or other casualty, material shortages, strikes or labor disputes,
acts of God, or other causes beyond the reasonable control of that party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Successors.</U> Licensee shall not assign or otherwise transfer this agreement or any
of its rights or obligations under this agreement without the prior written consent of Licensor,
which consent shall not be unreasonably withheld. Subject to the preceding sentence, this agreement
shall be binding upon, inure to the benefit of, and be enforceable by and against the respective
successors and assigns of each party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Interpretation.</U> This agreement shall be governed by and construed in accordance
with the laws of the State of Tennessee. If and to the extent that any court of competent
jurisdiction determines that it is impossible to construe any provision of this agreement
consistently with any law or public policy and consequently holds that provision to be invalid,
such holding shall in no way affect the validity or the other provisions of this agreement, which
shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Complete Agreement.</U> This agreement (together with the Distribution Agreement,
which is hereby incorporated herein by reference) constitutes the entire agreement between the
parties with respect to the subject matter of this agreement and supersedes all prior or
contemporaneous discussions, negotiations, representations, warranties, or agreements relating to
the subject matter of this agreement. This agreement may not be amended or otherwise modified
except by a written instrument signed by each party.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CORD LOGISTICS, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Frank C. Wegerson</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Frank C. Wegerson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President and General Manager</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Initials: <U>/s/ AJK</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Initials: <U>/s/ FCW</U></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">209 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Avenue South, Suite&nbsp;332</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">15 Ingram Blvd., #100</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Nashville, TN 37203</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">LaVergne, TN 37086</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Facsimile No. (615)&nbsp;255-0094</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Facsimile No. (615)&nbsp;793-4783</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 13 of 14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U><B>Exhibit&nbsp;A</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 14 of 14<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>14
<FILENAME>g06286exv10w8.htm
<DESCRIPTION>EX-10.8 STRATEGIC ALLIANCE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.8 STRATEGIC ALLIANCE AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.8</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>STRATEGIC ALLIANCE AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS AGREEMENT is made and entered into as of the 21st day of July, 2000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY AND BETWEEN:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CUMBERLAND PHARMACEUTICALS INC., a corporation organized and existing under the laws of Tennessee,
with its principal offices located at 209 Tenth Avenue South, Suite&nbsp;332, Nashville, Tennessee,
37203 (hereinafter referred to as &#147;<B>CUMBERLAND</B>&#148;)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>AND:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">F.H. FAULDING &#038; CO. LIMITED (ABN 88 007 870 984), a corporation organized under the laws of South
Australia, with its principal place of business located at 115 Sheriff Street, Underdale, South
Australia 5032 (hereinafter referred to as &#147;<B>FAULDING</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, CUMBERLAND is the owner of intellectual property rights, formulations and know- how
related to intravenous formulations of a certain pharmaceutical product set forth in Schedule&nbsp;I;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, FAULDING has the expertise and the manufacturing facility suitable for the pharmaceutical
preparation and production of the Drug Product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, CUMBERLAND wishes to have FAULDING manufacture the Drug Product and FAULDING wishes to
supply the Drug Product to CUMBERLAND;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, CUMBERLAND will appoint FAULDING as its preferred manufacturer for CUMBERLAND&#146;s products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS</B>, FAULDING and CUMBERLAND will explore opportunities to collaborate on the manufacture and
distribution of other pharmaceutical products of CUMBERLAND;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>NOW, THEREFORE</B>, in consideration of the premises and the undertakings, terms, conditions and
covenants set forth below, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. DEFINITIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 BUFFER SOLUTION </B>shall mean the buffer solution selected by CUMBERLAND for the manufacture
of the Drug Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 BULK DRUG SUBSTANCE </B>shall mean the active ingredients in the Drug Product.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.3 cGMP </B>or <B>GMP </B>shall have the meaning set forth in Schedule&nbsp;I.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.4 CONFIDENTIAL INFORMATION </B>shall have the meaning set forth in Paragraph&nbsp;9.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.5 DEVELOPMENT </B>shall mean all work necessary to develop a process to manufacture the Drug
Product in full accord with cGMP and to supply the Drug Product conforming to the Specifications.
Development activities shall include, but not be limited to, pilot batches, scale- up batches,
validation of the manufacturing process, and successful completion of the Drug Product manufacture
and delivery as defined in Schedule&nbsp;I attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.6 DRUG PRODUCT </B>shall mean the Ibuprofen for injection pharmaceutical product developed by
Cumberland and marketed under the trade name AMELIOR&#153;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.7 EXCIPIENT </B>shall mean any inert substance selected by CUMBERLAND and used to give the Drug
Product proper consistency.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.8 FDA </B>shall mean the United States Food and Drug Administration (FDA).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.9 IN-PROCESS SOLUTION </B>shall mean all Buffer Solutions and Excipients needed to produce Drug
Product in the finished dosage form set forth in Schedule&nbsp;I.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.10 INVENTION </B>shall have the meaning set forth in Paragraph&nbsp;9.4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.11 LABELING </B>shall mean all labels and other written, printed, or graphic matter upon: (i)
the Drug Product or any container or wrapper utilized with the Drug Product or (ii)&nbsp;any written
material accompanying the Drug Product, including without limitation, package inserts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.12 MANUAL </B>shall mean the Manufacturing Project Manual attached as Schedule&nbsp;II to this
Agreement and reviewed and accepted by CUMBERLAND and FAULDING, the terms and provisions of which
are incorporated by reference as though fully set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.13 SPECIFICATIONS </B>shall mean those specifications set forth in Attachment I to the Manual.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2. DEVELOPMENT AND MANUFACTURING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.1 Initiation: </B>Upon request by CUMBERLAND, FAULDING shall proceed with the schedule for
completing Development of the Drug Product. Upon request by CUMBERLAND, FAULDING shall manufacture
the Drug Product in the batch size set forth in Schedule&nbsp;I in accordance with the terms hereof, the
Specifications, and all applicable laws and
regulations. Prior to distributing and selling the Drug Product, CUMBERLAND shall prepare and
file submissions to the FDA in order to obtain and maintain during the term hereof regulatory
approval of the Drug Product. FAULDING shall prepare and test the Drug Product in accordance with
cGMP.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.2 Processing and Manufacturing: </B>FAULDING shall manufacture and package the Drug Product in
accordance with Schedules I and II hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.3 Documentation: </B>Subject to CUMBERLAND&#146;s prior consent pursuant to Paragraph&nbsp;5.5 hereof to
reimburse FAULDING for all out-of-pocket expenses and reasonable internal costs, FAULDING shall
provide CUMBERLAND with required supporting documentation for the Development of the Drug Product
in a form suitable for CUMBERLAND&#146;s submission to the FDA or applicable governmental authorities
for any country into which the Drug Product will be distributed with the prior written consent of
FAULDING, which consent shall not be unreasonably withheld or delayed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.4 Bulk Drug Substance Supply: </B>FAULDING shall be responsible for the supply of all Bulk Drug
Substance in accordance with Schedules I and II hereto; provided that the supply of Bulk Drug
Substance shall be exclusively from such suppliers and in such grades as have been approved in
writing by CUMBERLAND as reflected on an approved list to be attached hereto as Schedule&nbsp;III, and
provided further that such suppliers and grades may not be changed without CUMBERLAND&#146;s prior
written consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.5 Supply of Components: </B>FAULDING shall be responsible for the supply of all components in
accordance with Schedules I and II hereto; provided that the supply of components shall be
exclusively from such suppliers and in such grades as have been approved in writing by CUMBERLAND
as reflected on an approved list to be attached hereto as Schedule&nbsp;III, and provided further that
such suppliers and grades may not be changed without CUMBERLAND&#146;s prior written consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.6 Delivery Terms: </B>All deliveries of Drug Product under this Agreement shall be made by
FAULDING to CUMBERLAND in the manner set forth in Schedule&nbsp;I. CUMBERLAND shall, within twenty (20)
working days after its receipt of any shipment, notify FAULDING in writing, of any claim relating
to a Drug Product not conforming to the Specifications, and, failing such notification,
notwithstanding Paragraph&nbsp;5.1 of this Agreement, CUMBERLAND shall be deemed to have accepted the
Drug Product. If FAULDING disputes CUMBERLAND&#146;s claim that the Drug Product is non-conforming, then
such dispute shall be resolved by an independent testing organization of recognized repute within
the pharmaceutical industry mutually agreed upon by FAULDING and CUMBERLAND, the appointment of
which shall not be unreasonably withheld by either party. In such event, CUMBERLAND shall ship the
testing organization representative samples of the Drug Product from the disputed production lot,
and the fees and costs of such testing organization and related shipping and supply costs shall be
borne by the party whose position is not sustained by the testing organization. CUMBERLAND&#146;s sole
remedy for non-conforming product (other than indemnification under Paragraph&nbsp;10.2) is to be
provided with replacement Drug Product free of charge, including compensation for all CUMBERLAND
inputs and all freight charges.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.7 Payment for the Drug Product: </B>At the time of each shipment, FAULDING shall invoice
CUMBERLAND for FAULDING&#146;s manufacturing services at the cost per batch as set forth in Schedule&nbsp;I.
Payment shall be made in &#091;***&#093; of the latter of the invoice date or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CUMBERLAND&#146;s acceptance of
shipment of conforming Product at its designated receiving facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.8 </B>&#091;***&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. TERM AND TERMINATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Term: </B>This Agreement shall commence on the date first above written and will continue
until the fifth anniversary of the date on which the FDA grants approval to market and sell the
Drug Product, unless sooner terminated pursuant to Paragraph&nbsp;3.2 herein. The Agreement shall be
automatically renewed for successive three-year terms unless either party notifies the other party
in writing at least twelve (12)&nbsp;months in advance of the expiration of the then current term that
the party is terminating the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Termination: </B>This Agreement may be terminated at any time upon the occurrence of any of
the following events:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Default: Forty-five (45)&nbsp;days following written notice, by either party to the other
party, in the event that the other party breaches any provision of this Agreement, and such party
fails to remedy the breach prior to the expiration of the forty-five (45)&nbsp;day period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Insolvency: Written notice by either party to the other upon insolvency or bankruptcy of
the other party, and the failure of any such insolvency or bankruptcy to be dismissed within sixty
(60)&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If, as a result of causes described in Paragraph&nbsp;7.1, either party is unable to fully
perform its obligations hereunder for a period of one hundred eighty (180)&nbsp;consecutive days, the
other party shall have the right to terminate this Agreement upon at least thirty (30)&nbsp;days prior
written notice; provided that if the required performance is met during that thirty-day period,
this Agreement shall continue in full force and effect as if the notice had not been given.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination, expiration, cancellation or abandonment of this Agreement, through any means and
for any reason, shall not relieve the parties of any obligation accruing prior thereto and shall be
without the prejudice to the rights and remedies of either party with respect to any antecedent
breach of any of the provisions of this Agreement or CUMBERLAND&#146;s purchase order issued hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Survival: </B>Paragraphs 5, 6, 9, and 10 shall survive the termination or cancellation of the
Agreement for any reason.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4. CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.1 Certificates of Analysis: </B>FAULDING shall perform, or cause to be performed, certain tests
requested by CUMBERLAND as indicated in the Specifications on each batch of the Drug Product
manufactured pursuant to this Agreement before delivery to CUMBERLAND.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A certificate of analysis
for each batch delivered shall be delivered with each batch and shall set forth the items tested,
specifications, and test results. FAULDING shall also indicate on the certificate of analysis that
all batch production and control records have been reviewed and approved by the appropriate quality
control unit. FAULDING shall send, or cause to be sent, such certificates to CUMBERLAND prior to
the shipment of the Drug Product. CUMBERLAND shall test, or cause to be tested, prior to final
release, each batch of the Drug Product as meeting the Specifications. As required by the FDA (see
Paragraph&nbsp;5.2 below), CUMBERLAND shall assume full responsibility for final release of each lot of
the Drug Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.2 Manufacturing Compliance: </B>FAULDING shall advise CUMBERLAND immediately if an authorized
agent of any regulatory body visits FAULDING&#146;s manufacturing facility and makes an inquiry
regarding FAULDING&#146;s method of manufacture of the Drug Product for CUMBERLAND. Upon receipt of any
Form&nbsp;483 Notice of Inspectional Observations issued by the FDA or notice of deficit from any other
regulatory inspection after a visit to FAULDING&#146;s manufacturing facility, FAULDING shall
immediately send CUMBERLAND a copy thereof; provided that it may redact any language that is
subject to a legally enforceable confidentiality agreement between FAULDING and a third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.3 Regulatory Agency Requirements: </B>FAULDING shall prepare and test the Drug Product in
conformity with GMP. Subject to the allocation of responsibility for regulatory compliance as set
forth in Paragraph&nbsp;5.2, each party shall consult with the other party hereto before implementing
additional regulatory agency requirements concerning the control of Drug Product components,
manufacture of the Drug Product, or storage and handling of the Drug Product. The full text of
regulatory agency requests or comments will be provided by the party receiving such requests or
comments to the other party hereto. The parties will mutually agree on how to respond to such
requests and comments and on the allocation of the costs thereof; provided that FAULDING shall be
liable only for its reasonable internal costs and not for any out-of-pocket expenses or
extraordinary costs required in connection with implementing such regulatory requirements other
than the ordinary costs of compliance with GMP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.4 Regulatory Documents: </B>Each party will advise the other party hereto of its intention to
change any Drug Product regulatory documents prior to submission of the document to any regulatory
body. If the change affects the rights and obligations of a party hereto under this Agreement, such
party may seek to review or alter any part of the document at any time within ten (10)&nbsp;business
days after receipt of notification thereof; provided that if no alterations are submitted to the
other party within such ten-day period, each party will be deemed to have consented to the
alteration. CUMBERLAND shall reimburse FAULDING for all out-of-pocket expenses and reasonable
internal costs of changes to Drug Product regulatory documents, subject to CUMBERLAND&#146;s prior
consent pursuant to Paragraph&nbsp;5.5.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. REPRESENTATIONS AND WARRANTIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.1 Conformity with Specifications: </B>FAULDING warrants that, at the time of manufacture, the
Drug Product is prepared and tested in accordance with cGMP and meets the Specifications. Because
FAULDING has no control of the conditions under which the Drug Product is used, the diagnosis of
the patient before or after treatment with the Drug Product, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">method of use or administration of
the Drug Product, and handling of the Drug Product after delivery to CUMBERLAND, FAULDING does not
warrant either a good effect, or against an ill effect, following the use of the Drug Product. The
foregoing warranty is exclusive and in lieu of all other warranties either written, oral, or
implied. THERE ARE NO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. No
representative of FAULDING may change any of the foregoing warranties and CUMBERLAND accepts the
Drug Product subject to all terms hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.2 Compliance: </B>CUMBERLAND assumes responsibility for coordinating all contact with the FDA
and other regulatory bodies, pertaining specifically to Drug Product. FAULDING authorizes
CUMBERLAND&#146;s representatives to supervise and inspect the methods used in and facilities used for
manufacturing, processing, packaging, and handling of the Drug Product, but CUMBERLAND shall have
no such obligation under this Agreement. Except as otherwise required by applicable regulations,
CUMBERLAND&#146;s inspections shall be limited to two per year, each to occur upon seven days notice and
to be conducted during normal business hours; provided that CUMBERLAND may also inspect such
facilities promptly after any regulatory inspection thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.3 Debarring: </B>FAULDING represents and warrants that it has not been debarred in the United
States within the meaning of 21 U.S.C. &#167; 335a(a) and 335a(b), nor will it use in any capacity the
services of any person debarred pursuant to subsections 3.06(a) or 3.06(b) of the Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. Section 335(a) and (b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.4 FDA Submission: </B>FAULDING represents and warrants that it has submitted to the FDA
information about the manufacturing site to be used for the Drug Product and the facilities,
operating procedures, and personnel at such site.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.5 Reimbursement: </B>FAULDING shall not incur any development costs for which it intends to seek
reimbursement from CUMBERLAND for the manufacturing facility, equipment, or manufacturing method
unless FAULDING has the prior written consent of CUMBERLAND.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.6 Exclusivity: </B>FAULDING will not sell, give away, or deliver to any other person, firm, or
corporation any Drug Product without CUMBERLAND&#146;s prior written consent while this Agreement is
effective and for two years after the termination of this Agreement. In the event of breach,
CUMBERLAND shall have the right, in addition to other rights, to seek injunctive relief.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6. DRUG PRODUCT RECALLS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.1 Drug Product Recalls: </B>In the event: (a)&nbsp;any government authority issues a request,
directive or order that the Drug Product be recalled, or (b)&nbsp;a court of competent jurisdiction
orders such a recall, (c)&nbsp;CUMBERLAND determines that the Drug Product should be recalled because
the Drug Product does not conform to Specifications, or (d)&nbsp;FAULDING
recommends to CUMBERLAND that a recall be initiated, the parties shall take all appropriate
corrective actions. In the event that FAULDING recommends a recall of Drug Product by CUMBERLAND,
such recommendation must take the form of a notice as per Paragraph&nbsp;14.1, and CUMBERLAND shall
respond promptly indicating to FAULDING whether the Drug
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Product will be recalled. In no event,
however, shall FAULDING have responsibility for regulatory compliance in connection with any
recall, except to the extent and under the circumstances set forth in the Manual or any other
written agreement between the parties hereto or as required by law. All costs and expenses incurred
in connection with such recall shall be the responsibility of CUMBERLAND unless caused by the
negligence of FAULDING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7. FORCE MAJEURE; FAILURE TO SUPPLY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.1 Force Majeure Events: </B>Failure of either party to perform under this Agreement (except the
obligation to make payments) shall not subject such party to any liability to the other if such
failure is caused by acts such as, but not limited to, acts of God, fire, explosion, flood,
drought, war, riot, sabotage, embargo, strikes or other labor trouble, compliance with any order or
regulation of any government entity, or by any cause beyond the reasonable control of the parties,
provided that written notice of such event is promptly given to the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.2 Failure to Supply; Delivery Dates; Forecasts: </B>FAULDING shall supply all of the Drug
Product ordered by CUMBERLAND within sixty (60)&nbsp;days of receipt of a written order from CUMBERLAND.
On the date that CUMBERLAND makes its first order, CUMBERLAND will supply FAULDING with a
non-binding forecast of its future orders of Drug Product for each of the eleven calendar months
following the month in which the initial order is made. CUMBERLAND will update the forecasts on the
first day of the calendar month and on a monthly basis thereafter throughout the term of this
Agreement. The quantity of any Drug Product ordered pursuant to this Agreement shall not be less
than seventy percent (70%) nor more than one hundred thirty percent (130%) of the quantity
indicated in the most recent monthly forecast provided hereunder for the month in which the order
is placed. If CUMBERLAND fails to provide orders, or forecasts by agreed dates, FAULDING shall not
be required to deliver the quantity ordered by CUMBERLAND within sixty (60)&nbsp;days. The provisions of
this Paragraph&nbsp;7.2 shall be without prejudice to CUMBERLAND&#146;s rights under Paragraph&nbsp;3.2 and
remedies provided for thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>8. IMPROVEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.1 Changes by CUMBERLAND:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When CUMBERLAND seeks to change the Drug Product Specifications, such change shall be
incorporated within the Specifications only with the prior written consent of FAULDING, such
consent not to be unreasonably withheld or delayed. The price of the Drug Product may be adjusted
for such change, and CUMBERLAND shall pay FAULDING the agreed costs associated with such change,
including any development work, if necessary, based upon FAULDING&#146;s then-prevailing development
rates. Such prices and costs shall be set forth in a written amendment to this Agreement. It is the
responsibility of CUMBERLAND to ensure that proper regulatory agencies approve the suggested
changes. CUMBERLAND will notify
FAULDING if it intends to change the process or test specifications related to the preparation
of the Bulk Drug Substance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.2 Changes by FAULDING:</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FAULDING shall inform CUMBERLAND in writing of all proposed changes in the manufacturing
facility, equipment, or manufacturing methods and labeling of the Drug Product, each as approved by
applicable regulatory authorities, including the FDA, in advance of the time such changes are
intended to be made to allow CUMBERLAND sufficient time to provide any notice required by FDA
regulations. FAULDING shall not implement any such changes without prior written authorization by
the FDA or other applicable regulatory authorities and the prior written consent of CUMBERLAND,
which consent shall not be unreasonably withheld or delayed. FAULDING shall be liable only for its
reasonable internal costs and not for extraordinary costs in connection with such manufacturing
changes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>9. CONFIDENTIALITY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.1 Confidential Information: </B>&#147;Confidential Information&#148; means collectively Confidential
Information of CUMBERLAND (as defined herein) and Confidential Information of FAULDING (as defined
herein).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.2 Confidential Information of CUMBERLAND: </B>&#147;Confidential Information of CUMBERLAND&#148; means all
information obtained or developed by FAULDING or any third party which related to CUMBERLAND&#146;s
business or the Drug Product, regardless of the form in which such information is transmitted. The
following shall not be considered Confidential Information of CUMBERLAND for purposes hereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Information that is already in the possession of FAULDING at the time it is received from
CUMBERLAND or developed on CUMBERLAND&#146;s behalf, if FAULDING notifies CUMBERLAND of its belief that
the information is excepted under the terms of this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Information received by FAULDING from a person which has the right to disclose the same,
when FAULDING notifies CUMBERLAND of its belief that the information is excepted under the terms of
this subsection;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of FAULDING; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;An Invention as defined in Paragraph&nbsp;9.4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of CUMBERLAND, FAULDING shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of CUMBERLAND. FAULDING shall not use or permit the use of the
Confidential Information of CUMBERLAND other than for the limited purposes
expressly permitted by or consistent with this Agreement. Recipients of Confidential
Information of CUMBERLAND shall be granted access thereto strictly on a &#147;need-to-know&#148; basis.
FAULDING shall take all reasonable steps to ensure that recipients comply with the terms of this
Agreement, including all restrictions on use, disclosure and dissemination of Confidential
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Information of CUMBERLAND. FAULDING shall notify CUMBERLAND immediately upon becoming aware of any
breach hereof and shall take all reasonable steps to prevent any further disclosure or unauthorized
use.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination or expiration of this Agreement, FAULDING shall deliver to CUMBERLAND all
Confidential Information of CUMBERLAND, all copies thereof, and all documents or data storage media
containing such Confidential Information of CUMBERLAND, except as expressly set forth herein or in
any other written agreement between the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.3 Confidential Information of FAULDING: </B>&#147;Confidential Information of FAULDING&#148; means all
information obtained by CUMBERLAND which relates to FAULDING&#146;s business, regardless of the form in
which such information is transmitted. The following shall not be considered Confidential
Information of FAULDING for purposes hereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Information that is already in the possession of CUMBERLAND at the time it is received
from FAULDING, if CUMBERLAND notifies FAULDING of its belief that the information is excepted under
the terms of this subsection; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Information received by CUMBERLAND from a person which has the right to disclose the same,
when CUMBERLAND notifies FAULDING of its belief that the information is excepted under the terms of
this subsection; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Information that is or becomes published, or is or becomes otherwise publicly available
without the fault of CUMBERLAND.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a dispute regarding the applicability of the above exceptions to the
definition of Confidential Information of FAULDING, CUMBERLAND shall have the burden of producing
clear and convincing proof that the information should be excepted from the definition of
Confidential Information of FAULDING. CUMBERLAND shall not use or permit the use of the
Confidential Information of FAULDING other than for the limited purposes expressly permitted by or
consistent with this Agreement. Recipients of Confidential Information of FAULDING shall be
granted access thereto strictly on a &#147;need-to-know&#148; basis. CUMBERLAND shall take all reasonable
steps to ensure that recipients comply with the terms of this Agreement, including all restrictions
on use, disclosure and dissemination of Confidential Information of FAULDING. CUMBERLAND shall
notify FAULDING immediately upon becoming aware of any breach hereof and shall take all reasonable
steps to prevent any further disclosure or unauthorized use.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination or expiration of this Agreement, CUMBERLAND shall deliver to FAULDING all
Confidential Information of FAULDING, all copies thereof, and all documents or data storage media
containing such Confidential Information of FAULDING, except as expressly set forth herein or in
any other written agreement between the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.4 Invention: </B>CUMBERLAND owns all intellectual property rights in any improvement to or
derived from the Drug Product and any existing or further developments or modifications of the Drug
Products (&#147;Invention&#148;), except to the extent that a manufacturing
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">process used therewith is
developed exclusively by FAULDING, in which case the intellectual property rights for such process
shall be retained by FAULDING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.5 Disclosure: </B>The parties agree that the existence of this Agreement may be disclosed to
third parties but that the contents of this Agreement shall not be disclosed to any third party
except (i)&nbsp;the controlling companies of the parties, (ii)&nbsp;the companies controlled by the parties,
(iii)&nbsp;individuals and entities providing paid services to either of the parties, and (iv)
governmental regulatory agencies, including, but not limited to, environmental protection
authorities, without prior written consent of the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.6 Retention of Records: </B>Notwithstanding the restrictions set forth in this Agreement,
FAULDING shall retain production records (a)&nbsp;for batches of Drug Products manufactured prior to
establishment by CUMBERLAND of an expiry date (CTM and validation batches) for three (3)&nbsp;years
after (i)&nbsp;issuance of regulatory approval of the Drug Product necessary for distribution thereof or
(ii)&nbsp;withdrawal of the IND (Notice of Claimed Investigational Exemption for a New Drug) and (b)&nbsp;for
batches of Drug Product manufactured after establishment by CUMBERLAND of an expiry date for a
period of at least one year after the respective expiry date for each batch. These records will be
stored by appropriate means, including without limitation, optical disk or microfilm in a secure
manner in compliance with current GMP with duplicate copies submitted to CUMBERLAND promptly after
the creation thereof and shall be made available on request of the FDA or any other authorized
regulatory body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.7 Confidential Information Upon Termination: </B>Upon termination of this Agreement for whatever
reason, FAULDING shall return to CUMBERLAND originals, copies, and derivative forms of disclosed or
developed information relating to the purpose of this Agreement; except that one copy of such
information may be retained as required by regulation or law for future reference. The Confidential
Information shall remain confidential and not be disclosed by either party for a period of ten (10)
years following the date of expiration or termination of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>10. INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.1 Indemnification by CUMBERLAND: </B>CUMBERLAND shall indemnify and hold FAULDING (and any
parent, subsidiary, or affiliate company or corporation, and their officers, directors,
shareholders, agents, and the employees and insurers of any of them and/or their successors and
assigns thereto), free and harmless from any and all claims, demands, liability, actions or causes
of actions, and any and all expenses associated therewith (including, without limiting the
generality of the foregoing, attorney&#146;s fees), arising out of or in connection with, as a result
of, or otherwise related to any third party claims arising from: (i)&nbsp;any negligence or recklessness
of CUMBERLAND, its agents, or employees; (ii)&nbsp;the promotion, distribution, use, misuse or sale or
effects of the Drug Product except to the extent the alleged Drug Product
defects were caused by FAULDING; (iii)&nbsp;CUMBERLAND&#146;s non-compliance with any applicable FDA or
other applicable regulations; or, (iv)&nbsp;any failure of CUMBERLAND to perform, in whole or in part,
any of its obligations hereunder in each case, unless caused by the acts or omissions of FAULDING.
Beginning prior to use of the Drug Product in humans and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">continuing until the third anniversary of
termination of this Agreement, CUMBERLAND shall maintain products liability insurance with limits
of liability of not less than [***] and shall name
FAULDING as additional insured under said policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.2 Indemnification by FAULDING: </B>FAULDING will indemnify and hold CUMBERLAND (and any parent,
subsidiary, or affiliate company or corporation, and their officers, directors, shareholders,
agents, and the employees and issuers of any of them and/or their successors and assigns thereto),
free and harmless against any and all claims, demands, actions or causes of action, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, defense
costs and attorney&#146;s fees), arising out of or in connection with, as a result of, or otherwise
related to any third party claims arising from (i)&nbsp;any negligence or recklessness of FAULDING, its
agents or employees; (ii)&nbsp;personal injury (including death) or property damage arising out of or in
connection with FAULDING&#146;s manufacture or handling of the Drug Product otherwise than in accordance
with the Specifications and CUMBERLAND&#146;S written directions; (iii)&nbsp;FAULDING&#146;s non-compliance with
any applicable FDA or other applicable regulations; provided that CUMBERLAND perform its
obligations under Paragraph&nbsp;2.1, or (iv)&nbsp;any failure of FAULDING to perform any of its obligations
hereunder, unless caused by the acts or omissions of CUMBERLAND. Beginning prior to delivery of the
first order for Drug Product pursuant to this Agreement and continuing until the third anniversary
of termination of this Agreement, FAULDING shall maintain products liability insurance with limits
of liability of not less than [***] and shall name CUMBERLAND as additional insured under
said policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.3 Patent Indemnity: </B>Subject to Paragraph&nbsp;5.1, CUMBERLAND further warrants that importation,
manufacture (excluding manufacturing not specific to the manufacture of the Drug Product to be
performed by FAULDING for CUMBERLAND), use, supply, and sale of the Drug Product and Bulk Drug
Substance will not infringe any patent rights or any other third-party intellectual property rights
and that CUMBERLAND will indemnify, defend, and hold FAULDING free and harmless from any damage,
judgment, liability, loss, cost or expense, including legal expenses, arising from claims that the
Drug Product and Bulk Drug Substance infringe patent rights of a third party or any third-party
intellectual property rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.4 Conditions of Indemnification: </B>If either party seeks indemnification from the other under
Paragraphs 10.1, 10.2, or 10.3, it shall promptly give written notice to the other party of any
such claim or suit threatened, made or filed against it, which forms the basis for such claim of
indemnification and shall cooperate fully with the other party in the defense of all such claims or
suits. No settlement or compromise shall be binding on a party hereto without its prior written
consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.5 Disclaimer of Warranties; Limited Liability: </B>Under no circumstances shall either party be
liable to the other on account of any claim (whether based upon principles of
contract, warranty, negligence, or other tort, breach of any statutory duty, principles of
indemnity, the failure of any expressly limited remedy to achieve its essential purpose) for any
special, consequential, incidental or exemplary damages, or including but not limited to lost
profits.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>11. APPOINTMENT AS PREFERRED MANUFACTURER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until the expiration or earlier termination of this Agreement, CUMBERLAND agrees to provide
FAULDING with the first opportunity to negotiate to manufacture each CUMBERLAND pharmaceutical
product to be sold anywhere in the world in addition to the Drug Product; provided that the
foregoing shall not apply to pharmaceutical products in respect of which CUMBERLAND is unable to
enter into a manufacturing arrangement with FAULDING, due to contractual obligations applicable to
CUMBERLAND or where to enter into such an arrangement with FAULDING would adversely affect any
existing regulatory approval or application for regulatory approval for the product, in either case
as reasonably determined by CUMBERLAND having regard to documented evidence which CUMBERLAND shall
provide to FAULDING or FAULDING&#146;s advisers for review at FAULDING&#146;s request. Except as set forth to
the contrary in the preceding sentence, CUMBERLAND agrees not to manufacture, or to have
manufactured, such a product anywhere in the world unless CUMBERLAND first notifies FAULDING of the
opportunity hereunder and unless CUMBERLAND negotiates in good faith with FAULDING for sixty (60)
days after providing such notice in an attempt to enter into a written agreement on substantially
the same terms as this Agreement with respect to such additional product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>12. LICENSING AND DISTRIBUTION OF CUMBERLAND PRODUCTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until the expiration or earlier termination of this Agreement, CUMBERLAND agrees to provide
FAULDING with the first opportunity to negotiate to license and distribute each pharmaceutical
product of CUMBERLAND in Australia, New Zealand, Canada, and mutually agreed Southeast Asian and
Latin American countries; provided that the foregoing shall not apply to pharmaceutical products in
respect of which CUMBERLAND is unable to enter into a license and distribution arrangement with
FAULDING, due to contractual obligations applicable to CUMBERLAND as reasonably determined by
CUMBERLAND having regard to documented evidence which CUMBERLAND shall provide to FAULDING or
FAULDING&#146;s advisers for review at FAULDING&#146;s request, and further provided that CUMBERLAND shall
use good faith efforts to initiate such negotiations with FAULDING as soon as such a product is
reasonably available for license and distribution in such territory. Except as set forth to the
contrary in the preceding sentence, CUMBERLAND agrees not to license or distribute such a product
in such territory unless CUMBERLAND first notifies FAULDING of the opportunity hereunder and unless
CUMBERLAND negotiates in good faith with FAULDING for sixty (60)&nbsp;days after providing such notice
in an attempt to enter into a written agreement with respect to the services that are being
negotiated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>13. REGULATORY SUPPORT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If requested by CUMBERLAND, and at CUMBERLAND&#146;S cost at reasonable fees to be agreed
by the parties, FAULDING shall provide CUMBERLAND with reasonable assistance in relation to the
Development of, and applications for regulatory approval for, pharmaceutical products other than
the Drug Product which are identified by CUMBERLAND, including but not limited to the preparation
of development reports, stability reports, manufacturing documentation and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">instructions for use
necessary to support applications for regulatory approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>14. GENERAL PROVISIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.1 Notices: </B>Any notice permitted or required by this Agreement may be sent by facsimile with
the original document being sent by certified (or registered) mail, return receipt requested, or
overnight delivery and shall be effective when received (or refused) via facsimile or mail or
overnight if faxed and sent and addressed as follows (or to such other facsimile number or address
as may be designated by a party in writing):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to CUMBERLAND:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">209 Tenth Avenue South, Suite&nbsp;332</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Attn: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">615-255-0068</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">615-255-0094</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to FAULDING:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">F.H. Faulding &#038; Co. Limited</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">115 Sherriff Street</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Underdale, South Australia 5032</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Attn: Company Secretary</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">61-8-8205-6500</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">61-8-8234-8380</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.2 Entire Agreement: </B>Amendment: The parties hereto acknowledge that this Agreement sets
forth the entire agreement and understanding of the parties and supersedes all prior written or
oral agreements or understandings with respect to the subject matter hereof; provided that the
Confidentiality Agreement dated August&nbsp;1, 1999, between FAULDING and CUMBERLAND shall remain in
effect and that the terms thereof shall supersede any conflicting term of Paragraph&nbsp;9 hereof. No
modification of any of the terms of this Agreement, or any amendments thereto, shall be deemed to
be valid unless in writing and signed by both parties hereto. No course of dealing or usage of
trade shall be used to modify the terms and conditions herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.3 Waiver: </B>None of the provisions of the Agreement shall be considered waived by any party
hereto unless such waiver is agreed to, in writing, by both parties. The failure of a party to
insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any
party hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.4 Obligations to Third Parties: </B>Each party warrants and represents that this Agreement is
not inconsistent with any contractual obligations, expressed or implied, undertaken
with any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.5 Assignment: </B>This Agreement shall be binding upon and inure to the benefit of the
successors or permitted assigns of each of the parties and may not be assigned, transferred, or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">subcontracted by either party without the prior written consent of the other, which consent will
not be unreasonably withheld or delayed, except that no consent shall be required in the case of a
transfer to a wholly-owned subsidiary or transaction involving the merger, consolidation or sale of
substantially all of the assets of the party seeking such assignment or transfer and such
transaction relates to the business covered by this Agreement and the resulting entity assumes all
the obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.6 Independent Contractor: </B>FAULDING shall act as an independent contractor for CUMBERLAND in
providing the services required hereunder and shall not be considered an agent of or joint venturer
with CUMBERLAND. Unless otherwise provided herein to the contrary, FAULDING shall furnish all
expertise, labor, supervision, machining and equipment necessary for performance hereunder and
shall obtain and maintain all building and other permits and licenses required by public
authorities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.7 Governing Law: </B>This Agreement is subject to and shall be governed by the laws of the
State of Tennessee. The parties hereby submit to the jurisdiction of the courts of the State of
Tennessee in respect to all disputes arising out of or in connection with this Agreement and waive
any and all objections to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.8 Severability: </B>In the event that any term or provision of this Agreement shall violate any
applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise
be unenforceable, such provision shall be ineffective to the extent of such violation without
invalidating any other provision hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.9 Headings, Interpretation: </B>The headings used in this Agreement are for convenience only
and are not part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.10 Conflict: </B>In the event of conflict between the terms and provisions of this Agreement
and the terms and provisions of the Manual, the terms of this Agreement shall control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the parties hereto have each caused this Agreement to be executed by their
duly authorized representatives effective as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CUMBERLAND PHARMACEUTICALS INC.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">F.H. FAULDING &#038; CO. LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ A.J. Kazimi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Alex Bell</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Authorized Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Authorized Signature
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Printed Name
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Printed Name</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">A.J. Kazimi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alex Bell</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Printed Name
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Printed Name</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CEO
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">V.P. Tech Ops.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>DEVELOPMENT ACTIVITIES AND PRICING</B></U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Development </B>of the Drug Product for use in Clinical Studies and for sale will consist of the
following:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Product -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amelior&#153;. Ibuprofen for intravenous injection.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Timing -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND shall provide FAULDING with non-binding
forecasts of its requirements in the manner set forth in
Paragraph&nbsp;7.2 of this Agreement. FAULDING shall
manufacture the number of batches of Drug Product
corresponding to each purchase order therefor within 60
days of receipt of any such order.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Special Issues -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">All product contact components must be dedicated or
disposed of after use. CUMBERLAND may be present for
manufacturing. The initial batches are for an FDA
submission, and may subsequently be used in clinical
studies or sold. FAULDING shall provide process
validation (scale-up and three validation batches) in
accordance with this Agreement and the Schedules thereto.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>cGMP or GMP -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GMP or cGMP shall mean the current good manufacturing
practices as defined from time in regulations promulgated
under the Federal Food, Drug and Cosmetic Act of the
United States or any successor laws or regulations
governing the manufacture of the Drug Product.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Storage -</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FAULDING shall store and handle Bulk Drug Substance and finished Drug Product at 20E to 25E
C.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Composition, Process &#038; Container</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Preparation </B>-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional details regarding preparation shall be
incorporated herein upon adoption thereof by written
agreement of FAULDING and
CUMBERLAND.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Disposal -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Method of disposal is incineration. Any disposal costs
incurred by FAULDING will be charged back to CUMBERLAND;
provided that CUMBERLAND shall not be required to reimburse
FAULDING for such costs if the Drug Product is disposed of
because of FAULDING&#146;s negligence or breach of this
Agreement. FAULDING shall prepare and provide CUMBERLAND
with complete documentation of disposal throughout the chain
of custody.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Documentation by FAULDING &#150;</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Master batch record for review and approval by FAULDING and CUMBERLAND.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Product specific validation summaries.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Executed batch records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Analytical records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Inventory records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disposal records.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Compensation -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The price to be paid by CUMBERLAND to FAULDING for the satisfactory performance of its obligations under this Agreement are as
follows:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Reimbursement of Development Costs -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND shall reimburse FAULDING
for development costs incurred and
approved as agreed by the parties.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Reimbursement of Regulatory Costs -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND shall reimburse FAULDING
for regulatory costs incurred and
approved as agreed by the parties.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Reimbursement of Inspection and Audit
<BR>
Costs -</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND shall reimburse FAULDING
for inspection and audit costs
incurred and approved as agreed by
the parties.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>MANUFACTURING PROJECT MANUAL</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>(To be expanded by mutual written consent of F.H. Faulding &#038; Co., Limited (&#147;FHF&#148;) and<BR>
Cumberland Pharmaceuticals, Inc. (&#147;CPI&#148;))</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Responsibility</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Documentation/Activity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">GMP certificate and other permits
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Active Pharmaceutical Ingredient
(&#147;API&#148;)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Supply of API
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CPI to identify source</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Provide specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of API specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Provide sampling and testing
methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing
methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documents
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Starting Materials (except API)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Supply of starting materials
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CPI to identify arginine source</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Provide specifications of starting
materials
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of starting materials
specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing
methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing
materials
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Manufacturing Formula</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Development of manufacturing
formula
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of manufacturing formula
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Processing Instructions</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Development of processing
instructions
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of processing instructions
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bulk Product</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Supply of Bulk Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Provide specifications of Bulk Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of Bulk Product specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Prepare stability data for Bulk Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Packaging</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Supply of packaging materials
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Provide packaging materials specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of specifications
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Batch Processing Records</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Preparation of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Review of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Product</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Prepare stability data for Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Supply of Materials</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Supplier (check one):</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Documentation/Activity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Starting Materials</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Active Pharmaceutical Ingredient</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CPI will identify source</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Other Starting Materials</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">(Auxiliaries, fluids, gases, etc.):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Excipients</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">WFI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">N2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Packaging Materials</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vials</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stoppers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Seals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Boxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shippers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Labeling</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Quality Control</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Distribution of responsibilities:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">F.H. Faulding &#038; Co. (FHF)&nbsp;shall ensure that all quality control measures follow the applicable cGMP
guidelines. The responsibilities shall be distributed between FAULDING and CPI as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Supplier (check one):</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Documentation/Activity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Active Pharmaceutical Ingredient</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Starting Materials (except API)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Supplier (check one):</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Documentation/Activity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bulk Product</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Prepare stability data for Bulk Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Packaging Materials</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">FHF</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">CPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Comments</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Batch Documentation</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Assignment of batch numbers
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Preparation of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Review of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of batch processing records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Product</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Providing sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Approval of sampling and testing methods
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sampling and testing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Release
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of samples</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Storage of documentation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Prepare stability data for Product
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ATTACHMENT I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>BULK DRUG SUBSTANCE</U><BR>
<U>AND DRUG PRODUCT SPECIFICATIONS</U><BR>
<U>AND PROCEDURES</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Bulk Drug Substance -</B><BR>
To be agreed.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Drug Product Specifications and Procedures -</B><BR>
To be decided.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 3</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Ibuprofen Injection 100mg/ml</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>15
<FILENAME>g06286exv10w9.htm
<DESCRIPTION>EX-10.9 KRISTALOSE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.9 KRISTALOSE AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.9</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>KRISTALOSE AGREEMENT</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Between</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>And</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INALCO BIOCHEMICALS, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>And</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INALCO S.P.A.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>APRIL 2006</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1. DEFINITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2. REGULATORY APPROVAL, MARKETING AND DISTRIBUTION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3. TERM AND TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4. PAYMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5. CONFIDENTIALITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6. PROTECTION AND OWNERSHIP OF INTELLECTUAL PROPERTY </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">7. REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">8. GENERAL </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">9. ARBITRATION </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT A &#151; Minimum Purchases </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT B &#151; Patents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT C &#151; Transition Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT D &#151; Specifications</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EXHIBIT E &#151; Adverse Event Reporting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;i
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS AGREEMENT, by and among CUMBERLAND PHARMACEUTICALS INC. (&#147;CUMBERLAND&#148;), a corporation
organized and existing under the laws of the State of Tennessee, U.S.A., with its principal place
of business located at 2525 West End Avenue, Suite&nbsp;950, Nashville, Tennessee, U.S.A., 37203, and
INALCO BIOCHEMICALS, INC., a corporation organized and existing under the laws of California, with
its principal place of business located at 3440 Empresa Drive, Suite&nbsp;A, San Luis Obispo,
California 93401 (&#147;INALCO U.S.&#148;), and INALCO S.p.A., a corporation organized and existing under
the laws of Italy, with its principal place of business located at Via Calabiana 18, 20139 Milan,
Italy (&#147;INALCO ITALY&#148;) (INALCO U.S. and INALCO ITALY are hereinafter collectively referred to as
&#147;INALCO&#148;) is entered into as of the day of April, 2006 (the &#147;Execution Date&#148;).
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, INALCO is negotiating the acquisition of the Kristalose Trademark from Mylan Laboratories
Inc. and this Agreement is conditional upon the successful acquisition of the Kristalose
Trademark;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, INALCO owns or has the right to use all Intellectual Property Rights related to the
Product (each as defined herein);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, CUMBERLAND is a pharmaceutical company with capabilities in the marketing, development,
registration and distribution of various pharmaceutical products in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, INALCO has obtained and is willing to seek all necessary regulatory approvals for the
marketing and distribution of the Product in the Territory (as defined herein);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, CUMBERLAND wishes to acquire the exclusive distribution and marketing rights to the
Product in the Territory, in accordance with and subject to the terms and conditions set forth in
this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, INALCO is willing to grant an exclusive license to CUMBERLAND to market and distribute
the Product in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, it is
agreed by the parties as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1. DEFINITIONS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Affiliate</U> shall mean, with respect to any Person, any other Person that controls, is
controlled by or is under common control with, such Person. A Person shall be regarded as in
control of another Person if such Person owns, or directly or indirectly controls, more than
fifty percent (50%) of the voting securities (or comparable equity interests) or other
ownership interests of the other Person, or if such Person directly or indirectly possesses
the power to direct or cause the direction of the management or policies of the other Person,
whether through the ownership of voting securities, by
contract or any other means whatsoever.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Agreement</U> shall mean this Agreement and all instruments supplemental hereto or in
amendment or confirmation hereof; &#147;herein&#148;, &#147;hereof&#148;, &#147;hereto&#148;, &#147;hereunder&#148; and similar
expressions mean and refer to this Agreement and not to any particular Article, Section,
Subsection or other subdivision; &#147;Article&#148;, &#147;Section&#148;, &#147;Subsection&#148; or other subdivision of
this Agreement means and refers to the specified Article, Section, Subsection or other
subdivision of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>ANDA</U> shall mean any Abbreviated New Drug Application covering the Product and filed
with the FDA pursuant to the U.S. Federal Food, Drug, and Cosmetic Act, as amended, or any
regulations thereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Calendar Quarter</U> shall mean each three (3)&nbsp;month period ending March&nbsp;31, June&nbsp;30,
September&nbsp;30, and December&nbsp;31.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Certificate of Analysis</U> means a document which is signed and dated by a duly
authorized representative of INALCO certifying that the Product conforms with the Product
Specifications.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Competent Authority</U> shall mean each and every Governmental Body from which approvals
are required for the manufacture, marketing, distribution or sale of the Product within the
Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Confidential Information</U> shall have the meaning set forth in Subsection 5.1(A) hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Delivery Date</U> is the date of delivery for Products agreed to by the parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Effective Date</U> shall mean the date on which an authorized representative of INALCO
certifies in a writing delivered to CUMBERLAND that INALCO has met all requirements in order
to transfer exclusive marketing and distribution rights to the Product in accordance with this
Agreement, including without limitation, obtaining all rights to the Trademarks from Mylan
Pharmaceuticals, Inc.; provided that such certificate must be in a form reasonably
satisfactory to CUMBERLAND.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>FDA</U> shall mean the U.S. Food and Drug Administration.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Governmental Body</U> shall mean (i)&nbsp;any domestic or foreign national, federal,
provincial, state, municipal or other government or body, (ii)&nbsp;any international or
multilateral body, (iii)&nbsp;any subdivision, ministry, department, secretariat, bureau, agency,
commission, board, instrumentality or authority of any of the foregoing governments or
bodies, (iv)&nbsp;any quasi-governmental or private body exercising any regulatory, expropriation
or taxing authority under or for the account of any of the foregoing governments or bodies,
or (v)&nbsp;any domestic, foreign, international, multilateral, or multinational judicial,
quasi-judicial, arbitration or administrative court, grand jury, tribunal, commission, board
or panel.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Independent Analyst</U> is an analyst which is acceptable to the parties for the purposes
of
Sections&nbsp;2.7(C) or 2.10.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Intellectual Property Rights</U> shall mean whether or not reduced to writing, all
discoveries, inventions, all rights to inventions, patents, patent applications and issued
patents, data, including patient records, proprietary formulation, non-clinical and clinical
data, FDA registrations, market information and plans, designs, design applications and design
registrations, trade marks, trade mark applications, trade mark registration, trade names,
trade dresses, service marks, logos (whether registered or unregistered), copyright, copyright
applications and registrations, and all other rights and intellectual property relating to the
Product now or hereafter owned, held or used by INALCO or any of its Affiliates or
Subsidiaries; without limiting the generality of the foregoing, Intellectual Property Rights
shall include the Patent Rights, the Trademarks, the Know-How (each as defined herein) and all
other rights and intellectual property now or hereafter owned, held or used by INALCO or any
of its Affiliates or Subsidiaries.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Know-How</U> shall mean all know-how, information, data, knowledge, discoveries, trade
secrets, works, data, analytical reference materials and confidential or proprietary processes
relating to the Product or to the manufacturing, distribution or sale of the Product in the
Territory, and other information relating to the Product, owned or developed by, in the
possession of, known to or used by INALCO or its Affiliates or Subsidiaries prior to the
Effective Date. Without limiting the generality of the foregoing, Know-How shall include all
techniques, technology, processes, and know-how related to production and purification of the
Product, including systems for fully processing and purifying the Product; types and
configuration of processing equipment; lists of suppliers, customers and prospective
customers; market research data and reports, customer segmentation reports, detail pieces and
any other marketing information relating to Product; development plans; methods of operation
and management; cost control methods of setting prices; reporting methods; quality assurance
programs; information systems; training manuals; databases; production solutions; financial
information; and all other trade secrets of INALCO.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Labels</U> shall mean all labels and packaging and other written, printed, or graphic
matter approved by the Competent Authority upon or containing: (i)&nbsp;the Product or any
packaging, container or wrapper utilized with the Product, and (ii)&nbsp;any written material
accompanying the Product, including without limitation, package inserts, produced by INALCO
with CUMBERLAND&#146;s prior written approval.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Laws shall mean:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all constitutions, treaties, laws, statutes, codes, ordinances, orders,
decrees, rules, regulations, and municipal by-laws, whether domestic, foreign or
international;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all judgments, orders, writs, injunctions, decisions, rulings, decrees, and
awards of any Governmental Body; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all policies, practices and guidelines of any Governmental Body;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in each case binding on or affecting the party or Person referred to in the context in</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>which such word is used; and &#147;Law&#148; shall mean any one of them.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Listing</U> means obtaining approval from the relevant pricing authority in the
Territory to qualify the Product for price reimbursement and/or (as appropriate) obtaining
formulary listing approval in the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.18</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Minimum Purchases</U> shall mean the minimum number of
commercial pouches of the Product that CUMBERLAND must purchase, as set forth in <U>Exhibit&nbsp;A</U>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.19</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Mylan</U> shall have the meaning set forth in Section&nbsp;2.5(A).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.20</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Net Sales</U> shall mean the aggregate amount billed by CUMBERLAND for the sale of the
Product, less returns, buying group chargebacks, group purchasing organization administrative
fees, managed care organization rebates, sales/purchasing discounts, prompt payment
discounts, federally mandated discounts or rebates, state medical assistance program rebates
and discounts, adjustments for quantities shipped, and other discounts and fees, all as
determined on an accrual basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.21</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Order</U> is defined in Section&nbsp;2.6(C).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.22</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Patent Rights</U> shall mean all issued patents and patent applications relating to the
Product in the Territory, whether owned by INALCO or its Affiliates or Subsidiaries and/or
made available in any other way to INALCO or its Affiliates or Subsidiaries, including those
listed in <U>Exhibit&nbsp;B</U> hereto, and every divisional, continuation, continuation-in-part,
substitution and confirmation application based thereon, and any reissue or extension based
on any of the foregoing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.23</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Person</U> shall mean an individual, corporation, company, co-operative, partnership,
organization or any similar entity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.24</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product</U> shall mean INALCO&#146;s pharmaceutical product lactulose crystals sold under the
Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> trademark or any other trademark agreed by the parties, containing the
Label and packaged for sale in 10-gram and 20-gram pouches and all other strengths and dosage
forms.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.25</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Drug Master File</U> shall mean all confidential reference files submitted to the
FDA or other applicable Competent Authorities in the Territory for use in the review of the
ANDA or in connection with obtaining or maintaining Regulatory Approval for the Product in the
Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.26</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Payments</U> shall have the meaning set forth in Section&nbsp;4.3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.27</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Specifications</U> means the specifications contained in <U>Exhibit&nbsp;D</U> or any
later approved specification of the Products by the Competent Authority in the Territory which
may also include specifications for packaging material, labeling and product information.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.28</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Regulatory Approval(s)</U> shall mean all approvals, licenses, registrations, or
authorizations</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>of any Competent Authority necessary for the manufacturing, marketing, distribution and/or
sale of the Product in the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.29</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Royalty Payment</U> shall have the meaning set forth in Section&nbsp;4.2.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.30</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Subcontractor</U> shall mean a Third Person to whom either party hereto has delegated
responsibilities under this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.31</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Subsidiaries</U> shall mean any and all existing and future subsidiaries of Inalco S.p.A.
and/or Inalco Biochemicals, Inc. and their Affiliates, or of Cumberland Pharmaceuticals Inc.
and its Affiliates.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.32</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Term</U> shall mean the term of this Agreement, as set forth in Section&nbsp;3.1.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.33</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Territory</U> shall mean the U.S., subject to potential modifications pursuant to Section
4.2, Exhibit&nbsp;A, and the following understandings:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As of the Effective Date of this Agreement, INALCO does not have Regulatory
Approval for the Product in Canada.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO cannot guarantee that Regulatory Approval will be granted for the
Product in Canada.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CUMBERLAND and INALCO agree to cooperate reasonably to determine the
feasibility of and develop a strategy for registering and commercializing the Product
in Canada. Upon mutual agreement between INALCO and CUMBERLAND that commercialization
of the Product in Canada is justified, INALCO will act in good faith in order to obtain
the Regulatory Approvals required to register the Product in Canada, and at such time
as the Regulatory Approvals are obtained, the Territory shall be deemed to include
Canada.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Regulatory Approval in Canada is granted and CUMBERLAND is
not actively marketing and distributing the Product in Canada (as evidenced by its
distribution of the Product in such country or by entering into an agreement with a
Subcontractor to market and distribute the Product) within two (2)&nbsp;years of the date of
issuance of Regulatory Approval for the Product in Canada, then INALCO has the right to
remove Canada from the defined Territory upon ninety (90)&nbsp;days written notice to
CUMBERLAND.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.34</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Third Person</U> shall mean any Person other than one of the parties hereto or an
Affiliate or Subsidiary of one of the parties hereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.35</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Trademarks</U> shall mean all trademarks, trademark applications and registrations, trade
names, trade dresses, service logos and other designations of origin owned by INALCO or its
Affiliates or Subsidiaries pursuant to Section&nbsp;6 and used on or in connection with the
Product, whether registered or not, including without limitation,
Kristalose<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.36</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>U.S.</U> shall mean the United States of America and each of its territories and
possessions.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.37</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Valid Claim</U> shall mean, with respect to the Patent Rights; (i)&nbsp;a claim of an issued
and unexpired patent that has not been revoked or held unenforceable or invalid by a decision
of a court or other Governmental Body of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal, and which has not been disclaimed, denied or admitted to
be invalid or unenforceable through reissue, disclaimer or otherwise; or (ii)&nbsp;a claim included
in a pending patent application that is actively prosecuted and which has not been cancelled,
withdrawn, finally determined to be unallowable by the applicable Governmental Body pursuant
to an unappealable decision and/or abandoned in accordance with the terms hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.38</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Year</U> shall mean the twelve (12)&nbsp;month period commencing on the first date that INALCO
delivers an order of Product to CUMBERLAND pursuant to this Agreement, and each twelve month
period beginning on the anniversary thereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2. REGULATORY APPROVAL, MARKETING AND DISTRIBUTION</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Regulatory Approval.</U> INALCO shall, at INALCO&#146;s expense, secure with the least
possible delay, and maintain Regulatory Approval for the Product from all relevant Competent
Authorities in the Territory, and fulfill any reasonable additional requirements for approval
from the Competent Authorities in the Territory. All registrations and approvals obtained
shall be the sole and exclusive property of INALCO. INALCO agrees to provide additional
information in its possession or control to support CUMBERLAND in answering or attending to
any queries or requests of the Competent Authorities in relation to the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Know-How.</U> INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts, an
exclusive license to use the Know-How to the extent reasonably required by CUMBERLAND in
order to market, distribute, advertise, promote and sell the Product in the Territory in
accordance with and subject to the terms and conditions set forth herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Trademarks.</U> INALCO is negotiating the acquisition of the Kristalose Trademark from
Mylan Laboratories Inc. and this Agreement is conditional upon the successful acquisition of
the Kristalose Trademark. INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts,
an exclusive license to use the Trademarks on the Product and in connection with the
marketing, advertisement, promotion, distribution and sale of the Product in the Territory
during the Term. In order to have authority to grant such license to CUMBERLAND, INALCO
agrees to obtain all rights to the Trademarks from Mylan Pharmaceuticals, Inc., prior to the
Effective Date hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Patent Rights.</U> INALCO hereby grants to CUMBERLAND, and CUMBERLAND hereby accepts, an
exclusive license to the Patent Rights for purposes of marketing, distribution, and sale of
the Product in the Territory during the Term.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Certain Responsibilities of INALCO.</U></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Transition Plan.</U> Prior to the Effective Date, INALCO will submit to
CUMBERLAND for consideration a transition plan for Mylan Pharmaceuticals Inc. (&#147;Mylan&#148;)
to transfer commercial responsibilities for the Product to CUMBERLAND, which plan will
include accurate and complete customer lists, customer data, customer contracts, and
market, financial and other information relating to the Product, as well as provisions
for transitioning Product inventory, Product returns and chargebacks processing,
government reporting, and regulatory reporting. The transition plan will also include
Mylan&#146;s commitment to processing and payment of rebates, returns and chargebacks for
Product sold by Mylan. The transition plan shall also include Mylan&#146;s commitment to
provide information necessary to comply with the CMS Medicaid Drug Rebate Program
Release Number 48, which requires that a termination date be supplied equal to the shelf
life of the last lot sold under the old NDC number, as well as pricing data extending
four (4)&nbsp;Calendar Quarters beyond the shelf life. The transition plan shall be finalized
after INALCO and CUMBERLAND agree to any amendments thereto, and in any event, the
parties hereto agree to finalize the transition plan on or before the thirtieth
(30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day after the Effective Date. The transition plan shall be attached
hereto as <U>Exhibit&nbsp;C</U> when it is completed and shall be a part of this Agreement
effective as of the date thereof. INALCO shall complete all of its responsibilities
under the transition plan. At all times until such transition plan has been completed,
INALCO shall make best efforts to resolve any outstanding items in the transition plan
as promptly as possible.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Exclusive Appointment.</U> INALCO hereby appoints CUMBERLAND as exclusive
(even as to INALCO) distributor, marketer, advertiser, promoter, and seller of the
Product in the Territory during the Term. INALCO will not without
CUMBERLAND<SUP style="font-size: 85%; vertical-align: text-top">&#145;</SUP>s prior written approval, itself promote, sell or distribute, nor
appoint nor allow any third party to promote, sell or distribute in the Territory any
presentation of the Product nor any product which competes with the Product; provided
that INALCO may make sales in the Territory of its liquid lactulose products in
existence as of the date hereof. INALCO will ensure that its Affiliates and licensees do
not supply the Products to any other party which it knows, or has reasonable grounds for
suspecting, will store, promote, sell or distribute the Products in or to the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Maintenance of Patent Rights and Trademark.</U> INALCO shall diligently
prosecute and maintain Patent Rights and the Trademarks at its own expense throughout
the Territory in accordance with Article&nbsp;6.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Supply of the Product.</U> INALCO shall manufacture, package or have
packaged, and supply the Product to CUMBERLAND for resale during the Term. Except as
otherwise set forth in the transition plan pursuant to Section&nbsp;2.5(A) for the first
one-hundred-twenty (120)&nbsp;days of the Term, INALCO shall manufacture, label, store, and
ship the Product with existing packaging from Mylan. At the end of one hundred twenty
(120)&nbsp;days or sooner pursuant to the written agreement of both parties hereto, INALCO
shall manufacture, label, store, and ship the Product with packaging designed by
CUMBERLAND. INALCO shall deliver the Product to CUMBERLAND in finished packages that
shall include the CUMBERLAND NDC number and logo.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">E.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Provide Promotional Pouches.</U> INALCO shall provide up to 1,000,000
promotional pouches of Product to CUMBERLAND per Year upon request at a price per pouch
as</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>set forth in Section&nbsp;4.3 for Promotional Unit Payments. In the event that CUMBERLAND
identifies the need for additional promotional pouches in any given Year, the parties
agree to negotiate in good faith regarding the price and delivery of such additional
pouches.</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">F.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Specifications.</U> INALCO shall manufacture all Product in
compliance with (i)&nbsp;the Product DMF as submitted to the FDA, (ii)&nbsp;the FDA&#146;s Good
Manufacturing Practices, as promulgated under the U.S. Food, Drug and Cosmetic Act, as
amended, (iii)&nbsp;the Abbreviated New Drug Application for the Product, (iv)&nbsp;the Patent
Rights, and (v)&nbsp;all other applicable Laws, requirements and regulations of the FDA or
other applicable Competent Authorities. In no event will INALCO implement any alteration
(that requires approval of the Competent Authority) to the materials or processes
described in the Drug Master File in relation to any of the Products supplied to
CUMBERLAND under this Agreement until INALCO has provided reasonable prior written
notice of such alteration to CUMBERLAND and the Competent Authority in the Territory has
approved all requisite amendments to the applicable Regulatory Approval. INALCO will not
change the Product Specifications during the Term without CUMBERLAND&#146;s prior written
consent. INALCO shall provide for or arrange on-site inspections of each of the
facilities related to manufacturing or packaging the Product at least one time per year
by authorized representatives of CUMBERLAND at any time during regular business hours
and shall provide all reasonably requested information to confirm that the Product is
manufactured and packaged in accordance with the Specifications.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">G.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Fulfillment of Regulatory Requirements.</U> INALCO shall maintain all
Regulatory Approvals for the Product required to enable the Product to be sold in the
Territory at its own expense. INALCO shall maintain and fulfill all applicable
regulatory requirements with respect to the Product, including reporting and
pharmacovigilance in the Territory, and shall fully cooperate with CUMBERLAND to fulfill
and meet all requirements imposed by applicable law. INALCO shall inform CUMBERLAND of
any governmental submissions relating to the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">H.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Adverse Events.</U> INALCO shall promptly notify CUMBERLAND of any event that
materially affects or could materially affect the marketing of the Product. With respect
to adverse events, the parties hereto shall report such events to Competent Authorities
per <U>Exhibit&nbsp;E</U>, Adverse Event Reporting.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">I.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Additional Markets.</U> At any time during the Term, CUMBERLAND may notify
INALCO of its interest in distributing the Product in a country outside of the Territory
for which INALCO does not, as of the date of such notice, already have a distribution
arrangement in effect or pending, as evidenced by a fully executed letter of intent. For
up to ninety (90)&nbsp;days after providing such notice, the parties hereto shall negotiate
in good faith toward developing an agreement for marketing and distribution rights for
the Product in the relevant country(ies).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">J.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Delivery of Product.</U> INALCO shall deliver Product to Cumberland in a
timely manner and in compliance with specifications for the Product and its packaging in
accordance with Section&nbsp;2.11, et seq.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Certain Responsibilities of CUMBERLAND.</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Marketing Plans.</U> Within sixty (60)&nbsp;days after the Effective Date,
CUMBERLAND shall provide INALCO with a summary of marketing plans for the Product in
the Territory, including five (5)&nbsp;year sales forecasts. CUMBERLAND shall provide
updated marketing plans thereafter on an annual basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Package Design.</U> Except as otherwise set forth in Section&nbsp;2.5(D),
CUMBERLAND, at its expense, shall design all labeling and exterior packaging to be
used on the Product. CUMBERLAND shall provide such package designs to INALCO within
thirty (30)&nbsp;days of the Effective Date. In the event of a change in the package design
for the Product, CUMBERLAND shall notify INALCO of the package design at least one
hundred fifty (150)&nbsp;days prior to its required use thereof. All labeling and packaging
designs for the Product must be in compliance with the rules and regulations of all
Competent Authorities. CUMBERLAND shall not implement any changes in labeling and
packaging for the Product unless CUMBERLAND has INALCO&#146;s prior written consent, not to
be unreasonably withheld or delayed. INALCO and CUMBERLAND agree to work together to
minimize cost increases related to packaging design changes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Purchase Orders.</U> CUMBERLAND shall submit to INALCO a purchase order
setting forth the quantity of Product ordered, Delivery Date, destination, and any
other delivery instructions at least ninety (90)&nbsp;days in advance of its requested
Delivery Date for such purchase order. INALCO will respond to CUMBERLAND promptly
after receipt of any purchase order, and each such response shall (i)&nbsp;accept the
Delivery Date or (ii)&nbsp;reject the Delivery Date and propose an alternative Delivery
Date. When such a purchase order for Product is accepted in writing or by facsimile,
it shall become binding upon INALCO and CUMBERLAND, and shall not be changed or
cancelled by CUMBERLAND without written approval of INALCO. Such approval shall not be
unreasonably withheld or delayed.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Rolling Forecasts.</U> Within thirty (30)&nbsp;days after the Effective Date,
and every thirty (30)&nbsp;days thereafter, CUMBERLAND shall complete and provide INALCO a
twelve (12)&nbsp;month rolling forecast of its projected monthly purchases of the Product
and shall adjust them thereafter on a monthly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">E.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Minimum Purchases.</U> CUMBERLAND agrees to meet Minimum Purchases
annually in accordance with <U>Exhibit&nbsp;A.</U></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">F.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Sales Reports.</U> Within thirty (30)&nbsp;days after each month in which
CUMBERLAND sells any Product to a third party, CUMBERLAND shall prepare and provide
INALCO with a monthly sales report for the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">G.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Compliance.</U> CUMBERLAND shall market, distribute, and sell the Product
in the Territory in accordance with applicable Laws.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">H.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Adverse Drug Experiences.</U> CUMBERLAND shall provide reasonable
cooperation and assistance to INALCO in the investigation of complaints and adverse
events with respect to the Product (see <U>Exhibit&nbsp;E</U>). Each party will bear its
own expenses associated with its duties set forth in Exhibit&nbsp;E.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">I.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Interaction with DDMAC.</U> CUMBERLAND shall be responsible for
interacting with the FDA Division of Drug Marketing, Advertising and Communication
regarding the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">J.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Formulary Listings.</U> CUMBERLAND shall be responsible for filing and
maintaining Listings to obtain formulary listing approval from states or localities in
the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">K.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Rebate and Managed Care Programs.</U> CUMBERLAND shall have administrative
responsibility for the Product in any rebate and managed care programs through which
the Product is made available in the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">L.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Returns.</U> CUMBERLAND shall be responsible for administering
returns, discounts, and chargebacks involving third-party purchasers of the Product
during the Term in the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">M.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Non-Compete Obligation.</U> CUMBERLAND will not without INALCO&#146;s prior
written approval, itself promote, sell or distribute in the Territory during the Term
hereof, any laxative product which competes with the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">N.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Inspections.</U> CUMBERLAND shall provide for or arrange on-site
inspections of all facilities related to the storage and distribution of the Product
at least one time per year by authorized representatives of INALCO at any time during
regular business hours and shall provide all reasonably requested information to
confirm that the Product is stored, handled, and distributed in accordance with all
applicable rules and regulations of Competent Authorities.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Certain Responsibilities of Both Parties.</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Insurance.</U> Beginning on the Effective Date, both CUMBERLAND and INALCO
shall have in place, and shall maintain during the Term and until the third
anniversary of the expiration or earlier termination of this Agreement, comprehensive
product liability insurance in amounts not less than $5,000,000 U.S. per incident and
$5,000,000 U.S. annual aggregate. The minimum amounts of insurance coverage required
shall not be construed to create or limit CUMBERLAND&#146;s or INALCO&#146;s liability with
respect to its indemnification under this Agreement. Both INALCO and CUMBERLAND shall
provide evidence of insurance to one another on or within thirty (30)&nbsp;days after the
Effective Date and each anniversary date thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Publicity.</U> Either party may issue a press release or other public
announcement relating to the existence or terms of this Agreement, subject to the
prior review and written approval of the other party, which approval shall not be
unreasonably withheld or delayed; except where required by Law, in which event the
parties</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>will use all reasonable efforts to consult with each other and cooperate with
respect to the wording of any such announcement. The parties shall cooperate in
issuing (an)&nbsp;initial public release(s) with respect to the signing of this
Agreement, either separately or as a joint release.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Recalls:</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If either party determines that any quantity of the Product
should be recalled for any reason, that party will give to the other party
written notice of its intention to recall that quantity and specify its
reasons.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If within three (3)&nbsp;days of the receipt of the notice the
parties are unable to agree upon the need to carry out the recall, the parties
agree to submit a sample of the Product to an Independent Analyst for a
report.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The costs of the report of the Independent Analyst and of the
recall will be paid by the party against which the report is unfavourable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding paragraphs (i)&nbsp;to (iii), CUMBERLAND will
administer any such recall in the Territory.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any Product recall initiated by a Competent Authority due to
the negligence or breach of warranty by a party hereto shall be the
responsibility of such party at its sole cost.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each of CUMBERLAND and INALCO agrees to comply with the
obligations set forth in <U>Exhibit&nbsp;E</U> with respect to any adverse drug
event (as defined therein) or any similar event described in <U>Exhibit&nbsp;E</U>
for the Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a recall results from a cause other than 2.7C (v), then
INALCO and CUMBERLAND will share equally all out-of-pocket costs to administer
the recall.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Subcontractors.</U> CUMBERLAND may make such arrangements with Subsidiaries, Affiliates
or Third Persons as it, in its reasonable judgment, believes is necessary to assure the
diligent and adequate registration, approval, release testing (if applicable), distribution
and sale of the Product in the Territory. Any such Third Persons or Affiliates or
Subsidiaries engaged by CUMBERLAND shall be referred to as &#147;Subcontractors.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Delivery:</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to shipping, INALCO will submit to CUMBERLAND appropriate shipment
notification documents for signature and approval to ship. These documents shall
include CUMBERLAND&#146;s Approval to Ship form, packing slip, Certificate of Analysis, and
any required FDA shipment notification.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Following receipt of CUMBERLAND approval to ship, INALCO will deliver the
Products to CUMBERLAND F.O.B. the facility of INALCO&#146;s packager, which facility shall
be located in the U.S. or Canada unless otherwise agreed in writing by INALCO and
CUMBERLAND, to such location in the Territory as is designated by CUMBERLAND in the
applicable purchase order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All risk of loss or of damage to, and title to the Product, will pass to
CUMBERLAND upon delivery of the Products to the, freight company specified by
CUMBERLAND in the purchase order in accordance with the terms of Article&nbsp;2 of this
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CUMBERLAND shall be responsible for all costs of transportation from the
facility of INALCO&#146;s packager to the location in the Territory as designated by
CUMBERLAND in the applicable purchase order, except that INALCO shall be responsible
for any costs associated with Customs Clearance at an international border (including
but not limited to brokers&#146; fees, import duties, taxes, permits, and licenses).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Acceptance of the Products:</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO will supply a Certificate of Analysis with each delivery of the
Products.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If CUMBERLAND does not notify INALCO in accordance with the following
paragraph, then CUMBERLAND will, for the purposes of this Section&nbsp;2.10 only, be deemed
to have accepted the Products upon the expiration of the thirty (30)&nbsp;day period
referred to in that paragraph.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If CUMBERLAND notifies INALCO within thirty (30)&nbsp;days of the receipt of any
shipment of the Product that CUMBERLAND believes any of the Product does not conform
to the warranty set out in Section&nbsp;2.11 (&#147;Defective Product&#148;) the parties agree to
consult with each other in order to resolve the issue (during which time INALCO may
conduct its own retention sample testing). If such consultation does not resolve the
discrepancy within a further thirty (30)&nbsp;days from receipt of the notice, the parties
agree to nominate an Independent Analyst within the Territory, acceptable to both
parties, that will carry out tests on representative samples taken from such shipment,
and the results of such tests will be binding on the parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Independent Analyst determines that the Defective Product does not
conform to the warranty set out in Section&nbsp;2.11:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO will, at its expense, replace any such Defective Product
and reimburse CUMBERLAND for the costs of the Independent Analyst; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all quantities of Defective Product will, at INALCO&#146;s election and
expense be either:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>returned to INALCO, and packed and shipped
according to</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>instructions provided by INALCO; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>destroyed by CUMBERLAND under INALCO&#146;s direction.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">E.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Independent Analyst determines that the Defective Product does conform
to the warranty set out in Section&nbsp;2.11, CUMBERLAND will for the purposes of Section
2:10 only, be deemed to have accepted the Product and will reimburse INALCO for the
costs of the Independent Analyst.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">F.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Replacement of Defective Product is in addition to any other obligations,
indemnities or warranties given by INALCO under this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Warranties:</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO represents and warrants that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any Product supplied under this Agreement will, upon delivery
to CUMBERLAND, have a shelf life of at least two (2)&nbsp;years nine (9)&nbsp;months;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any Product supplied under this Agreement will upon delivery:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conform in all respects to the Product
Specifications and to any applicable Regulatory Approval in the
Territory;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be manufactured, identically labelled and
identically packaged for the Territory and tested in accordance with
applicable laws and regulations in the Territory relating to the
manufacture, labelling, packaging and testing of the Product, subject
to any alterations required by law or applicable regulations; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>will not be adulterated or misbranded in
contravention of applicable Law;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>it will, at its expense, apply for, prosecute, maintain,
defend and enforce the Trademarks, the Patent Rights, and any Intellectual
Property Rights concerning the Product which are owned by or licensed to it to
the maximum extent commercially feasible and will also apply for any
appropriate extension of term for any patents covering the Product in
accordance with the laws and regulations in the Territory.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Product Defects:</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any quantities of the Product that do not conform with Section
2.11(A) or that contravene applicable Law, regulations, or Regulatory approvals
will, for the purposes of this Agreement, be deemed to have a defect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If either party becomes aware of any defect in the Product, it
will immediately notify the other party and provide it with a full disclosure
of
that defect.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Where any defect in the Product arises either partially or
wholly as a result of a defect in raw material supplied to INALCO by a third
party, INALCO will make best efforts to ensure that the third party conforms to
any demands of the Competent Authority concerning the defect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as otherwise set forth in this Agreement,
INALCO<SUP style="font-size: 85%; vertical-align: text-top">&#145;</SUP>s remedy for breach of warranty pertaining to the Product
provided hereunder shall be limited solely to replacement of such Product.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>UNLESS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY SHALL BE
LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, IRRESPECTIVE OF WHETHER
ATTRIBUTABLE TO CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>3. TERM AND TERMINATION</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Term.</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Condition for Commencement of Term.</U> Notwithstanding any other provision
hereof, the commencement of the Term is subject to the satisfaction as of the Effective
Date of the following conditions: (i)&nbsp;the termination of any letter agreements
currently in effect between Mylan Bertek Pharmaceuticals Inc. (f/k/a Bertek
Pharmaceuticals Inc.) (&#147;Mylan Bertek&#148;) and CUMBERLAND (the &#147;Letter Agreements&#148;), and
(ii)&nbsp;the full and final mutual release of Mylan Bertek and Mylan by CUMBERLAND and of
CUMBERLAND by Mylan Bertek and Mylan for any and all obligations and/or liabilities in
connection with the Co-Promotion Agreement between CUMBERLAND and Mylan Bertek dated
January&nbsp;4, 2002, as amended (the &#147;Co-Promotion Agreement&#148;), and the Letter Agreements;
provided that the sections listed as surviving provisions in Section&nbsp;11.6 of the
Co-Promotion Agreement survive the termination and release set forth hereinabove.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Duration.</U> This Agreement shall commence on the Effective Date and will
continue until the fifteenth (15<SUP style="font-size: 85%; vertical-align: text-top">&#145;h</SUP>) anniversary thereof. Thereafter, subject
to Section&nbsp;3.2 hereof, the Agreement will automatically renew for successive terms of
three (3)&nbsp;years unless either party gives written notice of its intention not to renew
this Agreement to the other party at least twelve (12)&nbsp;months prior to the expiration
of the period.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Termination.</U> This Agreement may be terminated prior to expiration of the Term under
the following circumstances:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Material Breach.</U> In the event that one party commits a material breach
of this Agreement, the non-breaching party may, at its option, terminate this Agreement
by giving the breaching party written notice pursuant to Section&nbsp;8.2 of its election</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to terminate as of a stated date, but not less than forty-five (45)&nbsp;days from the
date of the notice. Such notice shall state the nature of the breach claimed by the
non-breaching party. The breaching party, during said forty-five (45)&nbsp;day period or
such longer period as may be indicated by the other, may correct any breach stated
in said notice and if such breach is corrected, this Agreement shall continue in
full force and effect as if such notice had not been given. If the breaching party
does not cure the breach to the reasonable satisfaction of the notifying party
within said forty-five (45)&nbsp;day period, or such longer period indicated by the
non-breaching party, then the notifying party may terminate this Agreement. For
purposes hereof, &#147;material breach&#148; shall mean failure by CUMBERLAND to comply with
any of its obligations under Sections&nbsp;2.6(G), 2.6(M), 4.1, 4.2, or 4.3 hereunder or
failure by INALCO to comply with any of its obligations under Section&nbsp;2.5(B),(C),
(D), (F), and (G).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Anniversary.</U> If CUMBERLAND gives INALCO written notice at least ninety
(90)&nbsp;days prior to the fourth anniversary of the Effective Date or any subsequent such
anniversary during the Term, CUMBERLAND may terminate the Agreement on the day
immediately preceding such anniversary date without any further liability except as
expressly set forth herein. Notwithstanding the foregoing, in no event shall
termination under this Section&nbsp;3.2.B. terminate or modify CUMBERLAND&#146;s obligations to
make the payments set forth in Section&nbsp;4.1.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Effect of Expiration or Termination.</U> Upon expiration or termination of this
Agreement,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CUMBERLAND shall cease the sale of all Product for the Territory; provided,
however, that CUMBERLAND may continue to store, promote, sell and distribute its stock
on hand and fill all orders accepted by it prior to the expiration or termination of
the Agreement. INALCO will fill all orders accepted by INALCO hereunder prior to
expiration or termination of the Agreement. All applicable provisions of this
Agreement shall survive termination for such purpose; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all rights, title and interest in and to the Product and the Intellectual
Property Rights in the Product and the Know-How and the Patent Rights and the
Trademarks that INALCO owned prior to this Agreement shall revert to INALCO.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Remedies Not Limited.</U> Except as otherwise provided herein, the termination of this
Agreement by either party shall not limit remedies that may be otherwise available, including
without limitation, injunctive relief.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Survival.</U> Expiration or termination of this Agreement for any reason shall not
relieve either party of its obligations that have accrued prior to the expiration or
termination of this Agreement. Without limiting the generality of the foregoing, Sections
2.11, 5.1, 5.2, and 5.3 and Article&nbsp;3 of this Agreement shall survive expiration or
termination of this Agreement.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Expectation of Profits.</U> Except as otherwise provided herein, both parties
acknowledge and agree that they have no expectations and have received no assurances that any
investment by them in the development, marketing or distribution of the Product will be
recovered or recouped, or that they shall obtain any anticipated amount of profit by virtue
of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Option Regarding Transfer.</U> CUMBERLAND shall have the first opportunity to negotiate
to acquire all rights to the Product in the Territory. Each party hereto shall negotiate in
good faith if the parties undertake discussions regarding such option. INALCO agrees not to
transfer any rights to the Product in the Territory unless INALCO first notifies CUMBERLAND
of the opportunity hereunder and unless INALCO negotiates in good faith with CUMBERLAND for
sixty (60)&nbsp;days after providing such notice in an attempt to enter into a written agreement
with respect to the rights that are being negotiated.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4. PAYMENTS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Payments.</U> Subject to the terms and conditions contained in this Agreement, in
consideration for rights granted to CUMBERLAND hereunder, CUMBERLAND shall pay Eleven Million
Dollars to INALCO in the following installments:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>First Installment.</U> &#091;***&#093;, payable upon the Effective Date of this
Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Second Installment.</U> &#091;***&#093;, payable upon the first anniversary of the
Effective Date of this Agreement; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Third Installment.</U> &#091;***&#093;, payable upon the third anniversary of the
Effective Date of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Royalty Payment.</U> In further consideration of the rights granted to CUMBERLAND
hereunder, CUMBERLAND shall pay INALCO an amount equal to the following percentage of Net
Sales during the preceding &#091;***&#093; (each such payment shall hereinafter be referred to as a
&#147;Royalty Payment&#148;), within &#091;***&#093; of the end of each &#091;***&#093;:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093; during first Year of the Term;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093; during each of the second, third, and fourth Years of the Term; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093; for each Year thereafter during the Term;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provided that the accrual of any obligation to make Royalty Payments shall cease immediately
with respect to Net Sales in a country within the Territory if a generic equivalent to the
Product receives Regulatory Approval, and is commercially available in such country.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Payment for Product.</U> Subject to Section&nbsp;2.10, CUMBERLAND shall pay INALCO,</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>within &#091;***&#093; of receipt of Product under Section&nbsp;2.5(D) during the first year of the Term,
and within &#091;***&#093; of receipt of Product thereafter, (a)&nbsp;an amount equal to &#091;***&#093; 10-gram
pouch and &#091;***&#093; per 20-gram pouch for each unit of Product supplied pursuant to purchase
orders submitted in accordance with Section&nbsp;2.6(C) (&#147;Product Payments&#148;), and (b)&nbsp;an amount
equal to &#091;***&#093; per pouch for each 10-gram pouch and &#091;***&#093; per pouch for each 20-gram pouch
of Product pursuant to requests for promotional units submitted in accordance with Section
2.5(E) (&#147;Promotional Unit Payments&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Promotional Unit Prices are based upon a packaging configuration and cost that is
equivalent to the existing 30-count Commercial and/or 7-count Sample. If a new Sample
package configuration is required, then INALCO has the right to adjust the &#147;per pouch&#148;
price to reflect any increased direct costs incurred with such reconfiguration. Promotional
Units will be ordered under a unique Purchase Order Number, and such orders are subject to
the terms of Paragraph&nbsp;2.6C.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Payment Currency.</U> All payments under Article&nbsp;4 hereof shall be made in &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Records.</U> CUMBERLAND shall maintain complete and accurate records sufficient to
enable accurate calculation of Royalty Payments due to INALCO under this Agreement.
CUMBERLAND shall, at INALCO&#146;s request and expense, provide certified statements from
CUMBERLAND&#146;s auditors, concerning Royalty Payments due pursuant to this Agreement. Once a
calendar year, INALCO shall have the right to request that a certified public accountant, the
selection of whom shall be subject to CUMBERLAND&#146;s prior written consent, not to be
unreasonably withheld or delayed, inspect, on reasonable notice and during regular business
hours, the records of CUMBERLAND to verify INALCO&#146;s statements and payments of Royalty
Payments due pursuant to this Agreement. The entire cost for such inspection shall be borne
by INALCO, unless there is a discrepancy of greater than 5% in INALCO&#146;s favor, in which case
CUMBERLAND shall bear the entire cost of the inspection. Records shall be preserved by
CUMBERLAND for three (3)&nbsp;years after preparation thereof for inspection by INALCO.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Acquisition.</U> In the event that INALCO or CUMBERLAND is acquired by a Third Person or
in any other way transfers all of its assets, including this Agreement to a Third Person, all
obligations of this Agreement, including the foregoing Royalty Payment terms, shall be binding
upon the party acquiring this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Manner of Payment.</U> All payments hereunder shall be made by bank wire transfer of
immediately available funds to the account of INALCO or such other reasonable method as INALCO
may request. Each party hereto shall be responsible for and pay all fees and other charges
imposed by its own bank in connection with any such bank wire transfer. Where required to do
so by Law, CUMBERLAND shall withhold taxes required to be paid to a taxing authority on
account of such income to INALCO, and CUMBERLAND shall furnish INALCO with satisfactory
evidence of such withholding and payment in order to permit INALCO to obtain a tax credit or
other relief as may be available under the Law.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>5. CONFIDENTIALITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Protection of Confidential Information.</U> The parties recognize that during the Term,
it may be necessary that one party and/or its Affiliates or Subsidiaries hereto be given
access to certain Confidential Information (as defined herein) of the other party and/or its
Affiliates or Subsidiaries hereto. Each party must ensure that the following Subsections shall
be applicable to such Confidential Information and the words &#147;Recipient&#148; and &#147;Disclosing
Party&#148; shall be interchangeable as between each of the parties and/or their Affiliates or
Subsidiaries hereto as appropriate under the circumstances:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Title to Confidential Information and Related Documents.</U> Recipient
hereby acknowledges that the Confidential Information and all, including without
limitation, related documents, drawings, designs, products, or samples disclosed or
furnished hereunder by or on behalf of the Recipient are the sole and exclusive
property of Disclosing Party. Recipient hereby agrees to return all such documents,
drawings, designs, products, or samples furnished to it hereunder, together with all
reproductions and copies thereof and shall delete all references thereto stored
electronically promptly under the request of Disclosing Party or upon termination or
expiration of this Agreement, except that the Recipient&#146;s legal representative may
retain one copy of such of the Confidential Information as required solely for the
purpose of determining the scope of its obligations under this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Nondisclosure or Use of Confidential Information.</U> Recipient hereby
agrees that it shall hold all Confidential Information disclosed to it in strict
confidence and in a secure place, that it will use the same only for the purpose of
performing this Agreement and for no other purpose whatsoever, and that it will not
disclose the same to any Third Persons (except to its employees or consultants,
strictly on a &#147;need-to-know basis,&#148; to the extent such disclosure is permitted by or
consistent with this Agreement and the Third Persons are subject to written obligations
of confidentiality no less onerous than are contained in this Agreement) except to the
extent Disclosing Party agrees to it in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Definition of Confidential Information.</U> &#147;Confidential Information&#148; as
used herein shall include without limitation any and all oral, written, or tangible
proprietary or confidential ideas, inventions, information, data, plans, materials,
trade secrets and know-how and the like owned, controlled or developed by or on behalf
of one party hereto and disclosed to the other party for the purposes of this
Agreement; provided however, that Confidential Information shall not include any
information, discovery, invention, improvement, or innovation which:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>was in the public domain at the time of disclosure to the
Recipient, or which becomes generally available to the public after its
disclosure through no fault of the Recipient or breach of this Agreement;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is already known to, or in the possession of, the Recipient
prior to disclosure by the Disclosing Party as can be demonstrated by
documentary evidence;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is lawfully disclosed on a non-confidential basis from a
Third Person having the right to make such a disclosure; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is independently developed by the Recipient or its
Subsidiaries as can be demonstrated by documentary evidence.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Unauthorized Use.</U> In case either party becomes aware or has knowledge of any
unauthorized use or disclosure of Confidential Information, it shall promptly notify the
other party of such unauthorized use or disclosure and, thereafter, shall take all reasonable
steps to assist the other party in attempting to minimize any potential or actual damages or
losses resulting from such unauthorized use or disclosure.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Permitted Disclosure.</U> Each party may disclose Confidential Information of the other
party to the Competent Authorities or Listing authorities in the Territory where such
disclosure is reasonably necessary in the application, grant, variation, renewal or
maintenance of a Regulatory Approval or Listing. Each party may also disclose Confidential
Information where it is required to do so under any laws or regulations in the Territory,
provided that it gives the other party such notice as is reasonably practicable in the
circumstances and allows the other party, at the other party&#146;s cost, a reasonable opportunity
to resist such requirements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Term.</U> The provisions of this Article&nbsp;5 shall survive the expiration or termination
of the Agreement until all of the Confidential Information has fallen within one of the
exceptions set forth in Sections&nbsp;5.I(C) (i)&nbsp;through (iv), inclusive.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>6. PROTECTION AND OWNERSHIP OF INTELLECTUAL PROPERTY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Registration of Trademarks.</U> INALCO shall be responsible, at its expense, for the
preparation, filing, prosecution and maintenance of the Trademarks in the Territory and for
conducting any interferences, re-examinations, reissues, oppositions, or requests for
extension relating thereto. INALCO shall take all steps necessary to maintain the Trademarks
in the Territory in good standing. INALCO shall not use any alternative trademark in the
Territory on or in connection with the Product. Subject to Section&nbsp;3.3(A), upon the
termination or expiration of this Agreement or CUMBERLAND&#146;s right to use the Trademarks,
CUMBERLAND shall cease using the Trademarks.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Patent Filings: Maintenance; Prosecution.</U> INALCO shall be responsible, at its
expense, for the preparation, filing, prosecution and maintenance of the Patent Rights in the
Territory and for conducting any interferences, re-examinations, reissues, oppositions, or
requests for extension relating thereto. INALCO shall take all steps necessary to maintain
the Patent Rights in the Territory in good standing. CUMBERLAND agrees to cooperate
reasonably with INALCO, at INALCO&#146;s expense, when requested, on matters relating to the
preparation, filing, prosecution and maintenance of the Patent Rights.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Infringement by Third Persons.</U></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that either party determines that a Third Person is making,
using, or selling a product that may infringe the Patent Rights or Trademark, it will
promptly notify the other party in writing. INALCO will, at its own cost and to the
extent commercially feasible, take all legal action it deems necessary or advisable to
eliminate or minimize the consequences of the infringement, but will not without
CUMBERLAND&#146;s prior written consent enter into any settlement in relation to such
matters nor take any step in relation to the potential or alleged infringement which
will affect CUMBERLAND&#146;s storage, promotion, sale and distribution of the Product in
the Territory or other rights under this Agreement. CUMBERLAND shall take all
reasonable steps to assist INALCO at INALCO&#146;s expense.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon receiving any written request from CUMBERLAND to do so, INALCO will
forthwith disclose to CUMBERLAND all necessary information about the Products, their
formulation, use or process of manufacture, to enable CUMBERLAND to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ascertain whether the storage, promotion, sale or other
distribution of the Products in the Territory will infringe any existing
patent or other third party intellectual property rights; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>determine its conduct in relation to any proceedings alleging
infringement of a patent or other third party intellectual property rights in
the Territory.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO represents and warrants that any information disclosed to CUMBERLAND
under paragraph (B)&nbsp;above will be a full and accurate disclosure and that INALCO will
not withhold any information in its possession which might have a material adverse
impact on CUMBERLAND.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If INALCO does not take any action to eliminate or minimize the consequences
of any such infringement within ninety (90)&nbsp;days of becoming aware of that
infringement, CUMBERLAND may take any reasonable action to prosecute such
infringement; provided that CUMBERLAND shall not retain legal counsel to prosecute any
such infringement without INALCO&#146;s prior written consent, not to be unreasonably
withheld or delayed. In the event that legal counsel is so retained, INALCO shall
reimburse CUMBERLAND for such counsel&#146;s reasonable fees and expenses directly related
to the prosecution of such infringement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">E.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each party will cooperate fully and promptly with, and provide all reasonable
assistance to, the other party in respect of any action brought by the other party
under this Agreement in relation to alleged infringement of intellectual property
rights in connection with this Agreement and will be entitled to be promptly
reimbursed for all costs and expenses incurred in connection with such co-
operation and assistance.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>7. REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of CUMBERLAND.</U> CUMBERLAND represents and warrants
that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>it is a corporation duly organized and validly existing under the laws of
Tennessee;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the execution and delivery by CUMBERLAND of this Agreement, the performance by
CUMBERLAND of all the terms and conditions thereof to be performed by it and the
consummation of the transactions contemplated hereby have been duly authorized by all
necessary action, and no other act or approval of any person or entity is required to
authorize such execution, delivery, and performance;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Agreement constitutes a valid and binding obligation of CUMBERLAND,
enforceable in accordance with its terms; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Agreement and the execution and delivery thereof by CUMBERLAND, does not,
and the fulfillment and compliance with the terms and conditions hereof and the
consummation of the transactions contemplated hereby will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conflict with any of, or require the consent of any person or
entity under, the terms, conditions, or provisions of the organizational
documents of CUMBERLAND;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>violate any provision of, or require any consent,
authorization, or approval under, any Law applicable to CUMBERLAND; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conflict with, result in a breach of, or constitute a default
under, any material agreement or obligation to which CUMBERLAND is a party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of INALCO.</U> INALCO ITALY and INALCO U.S. jointly and
severally represent and warrant that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">A.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO U.S. is a corporation duly organized and validly existing under the
laws of California and INALCO ITALY is a corporation duly organized and validly
existing under the laws of Italy and;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">B.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the execution and delivery by INALCO of this Agreement, the performance by
INALCO of all the terms and conditions thereof to be performed by it and the
consummation of the transactions contemplated hereby have been duly authorized by all
necessary action, and no other act or approval of any person or entity is required to
authorize such execution, delivery, and performance;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">C.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Agreement constitutes a valid and binding obligation by each of INALCO
ITALY and INALCO U.S., enforceable in accordance with its terms; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">D.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Agreement and the execution and delivery thereof by INALCO, does not, and
the fulfillment and compliance with the terms and conditions hereof and the
consummation of the transactions contemplated hereby will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conflict with any of, or require the consent of any person or
entity under, the terms, conditions, or provisions of the organizational
documents of INALCO;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>violate any provision of, or require any consent,
authorization, or approval under, any Law applicable to INALCO; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conflict with, result in a breach of, or constitute a default
under, any material agreement or obligation to which INALCO is a party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">E.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the manufacture, storage, promotion, sale or other distribution of the Product
in the Territory will not infringe any patent (whether in relation to the Products,
their formulation, use or process of manufacture) or infringe upon any other rights of
a Third Person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">F.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as of the Effective Date, INALCO has not received any notice of opposition,
interference, or refusal to register in connection with the Patent Rights in the
Territory or elsewhere;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">G.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as of the Effective Date, INALCO holds, and shall continue to hold for the
duration of the Term, valid rights to the Patent Rights and all other Intellectual
Property Rights relating to the Product and has the full right, power and authority to
grant the rights granted to CUMBERLAND hereunder, free and clear of any mortgage, lien,
encumbrance or other Third Person interest of any kind;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">H.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO has licensed to CUMBERLAND all Intellectual Property Rights necessary
for CUMBERLAND to perform its obligations under this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">I.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO has not granted to any other Person in the Territory the rights it is
granting to CUMBERLAND hereunder in respect of the Product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">J.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INALCO has informed CUMBERLAND about all information in its possession or
control concerning the safety and efficacy of the Product, and any side effects,
injury, toxicity or sensitivity reactions and incidents associated with all uses,
studies, investigations or tests involving the Product (animal or human) throughout the
world;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">K.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as of the Effective Date of this Agreement, INALCO is not aware of any facts
that would reasonably lead it to conclude that the Product will be unable to maintain
Regulatory Approval in the Territory or that would indicate that future</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>marketing and sales of the Product in the Territory may be adversely affected in any
material respect; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">L.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no representations, warranties or covenants made by INALCO in this Agreement or
in any document, certificate, exhibit, or schedule furnished or to be furnished in
connection with the transactions contemplated hereby, contain or will contain, to the
best of INALCO&#146;s knowledge, any untrue statement of fact or omit or will omit to state
any material fact necessary to make the statement of facts contained therein not
misleading to the best of INALCO&#146;s knowledge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Indemnification by CUMBERLAND.</U> Without affecting any other remedies and recourses
available under this Agreement, under law and in equity, CUMBERLAND shall indemnify INALCO
and its Affiliates and Subsidiaries, and their respective directors, officers, and employees,
from and against claims, suits or demands for liability, damages, costs and expenses
(including reasonable attorney fees) arising from or relating to (i)&nbsp;the negligence or
willful misconduct of CUMBERLAND or its Affiliates or its Subsidiaries, or their respective
directors, shareholders, officers or employees in connection with this Agreement, or (ii)&nbsp;any
breach by CUMBERLAND of any of its representations and warranties provided for in Section
7.1; except to the extent that such claims, suits or demands are the result of the fault,
negligence or willful misconduct of INALCO and/or its Affiliates and/or its Subsidiaries, or
their respective directors, shareholders, officers or employees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Indemnification by INALCO.</U> Without affecting any other remedies and recourses
available under this Agreement, under law and in equity, INALCO shall indemnify CUMBERLAND
and its Affiliates and Subsidiaries, and their respective directors, officers, and employees
from and against claims, suits or demands for liability, damages, costs and expenses
(including reasonable attorney fees) arising from or relating to (i)&nbsp;the negligence or
willful misconduct of INALCO or its Affiliates or Subsidiaries, or their respective
directors, shareholders, officers or employees in connection with this Agreement; or (ii)&nbsp;any
breach by INALCO of any of its representations and warranties provided for in Sections
2.5(F), 2.11 and 7.2 hereof ; (iii)&nbsp;the export, storage, promotion, sale or other
distribution of the Product in the Territory (including the packaging of the Product and
associated promotional and like material provided by or on behalf of INALCO, if any) will not
infringe any patent (whether in relation to the Products, their formulation, use or process
of manufacture) or infringe upon any other rights of a Third Person; except to the extent
that such claims, suits or demands are the result of the fault, negligence or willful
misconduct of CUMBERLAND or its directors, shareholders, officers or employees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Indemnification Procedures.</U> A party (the &#147;Indemnitee&#148;) which intends to claim
indemnification under this Article&nbsp;7 shall promptly notify the other party (the &#147;Indemnitor&#148;)
in writing of the claim, suit or demand for liability with respect to which the claim of
indemnification relates. If the Indemnitor wishes to assume the defense it must notify the
Indemnitee within sixty (60)&nbsp;days of receipt of such notice. Legal counsel of the Indemnitor
must be reasonably satisfactory to the Indemnitee. The Indemnitee shall permit, and shall
cause its employees and agents to permit the Indemnitor, at its discretion, to settle any
such claim, suit or demand for liability, the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>defense and settlement of which shall be under the complete control of the Indemnitor;
provided, however, that such settlement shall not adversely affect the Indemnitee&#146;s rights
hereunder or impose any obligations on the Indemnitee in addition to those set forth herein
in order for it to exercise those rights. No such claim, suit or demand for liability shall
be settled without the prior written consent of the Indemnitee and the Indemnitee shall not
be responsible for any legal fees or other costs incurred other than as provided herein.
The Indemnitee, its employees and agents shall co-operate fully with the Indemnitor and its
legal representatives in the investigation and defense of any claim, suit or demand for
liability covered by this indemnification. The Indemnitee shall have the right, but not the
obligation, to be represented by counsel of its own selection and expense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>8. GENERAL</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Provisions Contrary to Law.</U> In performing this Agreement, the parties shall comply
with all applicable Laws. In particular, it is understood and acknowledged that the transfer
of certain commodities and technical data is subject to U.S. Laws controlling the export of
such commodities and technical data, including all Export Administration Regulations of the
United States Department of Commerce. These Laws among other things prohibit or require a
license for the export of certain types of technical data to certain specified countries.
CUMBERLAND hereby agrees to do all things reasonably requested of it by INALCO to comply with
all U.S. Laws controlling the export of commodities and technical data.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing in this Agreement shall be construed so as to require the violation of any Law, and
wherever there is any conflict between any provision of this Agreement and any Law, the Law
shall prevail, but in such event the affected provision of this Agreement shall be affected
only to the extent necessary to bring it within the applicable Law.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Notices.</U> Any notice permitted or required by this Agreement may be sent by facsimile
with the original document being sent by certified (or registered) mail, return receipt
requested, or overnight delivery and shall be effective when received (or refused) via
facsimile or mail or overnight if faxed and sent and addressed as follows (or to such other
facsimile number or address as may be designated by a party in writing):</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="56%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><u><B>If to CUMBERLAND:</B></u>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u><B>If to INALCO U.S.:</B></u></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cumberland Pharmaceuticals Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inalco Biochemicals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2525 West End Ave., Suite&nbsp;950
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3440 Empresa Drive, Suite&nbsp;A</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Nashville, Tennessee 37203
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Luis Obispo, CA 93401</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 615-255-0094
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 805-782-0719</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attn: Chief Executive Officer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Eric A. Lowe</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>With a copy to:</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Adams and Reese/Stokes Bartholomew LLP<BR>
424 Church Street, 28<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor<BR>
Nashville, Tennessee 37219<BR>
Fax: 615-259-1470<BR>
Attn: Martin S. Brown, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>If to INALCO ITALY:</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Inalco S.p.A.<BR>
Via Calabiana, 18<BR>
20139 Milan<BR>
ITALY<BR>
Fax: 011-39-02-55213277<BR>
Attn: Giovanni Cipolletti

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Such notice shall be effective upon the earlier of (i)&nbsp;actual receipt by the party to whom notice
is sent, (ii)&nbsp;seven (7)&nbsp;days after deposit into the mail, or (iii)&nbsp;receipt of fax-back confirmation
if notice is sent via facsimile.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Force Majeure.</U> Neither party to this Agreement shall be liable for delay or failure
in the performance of any of its obligations hereunder if such delay or failure is due to
causes beyond its reasonable control, including, without limitation, acts of God, fires,
earthquakes, strikes and labor disputes, acts of war, civil unrest, or intervention of any
governmental authority, but any such delay or failure shall be notified to the other party,
and remedied by such party, as soon as is reasonably possible.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Assignments.</U> Except as otherwise set forth herein or in connection with the sale of
all or substantially all of the assets or business of either party or as expressly set forth
in this Agreement, rights and obligations under this Agreement may not be assigned by either
party hereto without the prior written consent of the other party hereto, which consent shall
not be unreasonably withheld or delayed; provided, however, that nothing in this Agreement
shall limit CUMBERLAND&#146;s right to assign its rights or delegate its obligations under this
Agreement to a lender to CUMBERLAND in the event of a default in its agreement with such
lender.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Independent Contractors.</U> The parties hereto agree that each is acting as an
independent contractor and not as an agent of the other or as joint venturers.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Waivers and Modifications.</U> The failure of any party to insist on the performance of
any obligation hereunder shall not act as a waiver of such obligation. No waiver,
modification, release, or amendment of any obligation under this Agreement shall be valid or
effective unless in writing and signed by both parties hereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Successors in Interest.</U> This Agreement shall inure to the benefit of and be binding
on the parties&#146; permitted assigns or successors in interest.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Severability.</U> In the event that any term or provision of this Agreement shall violate
any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise be unenforceable, such provision shall be ineffective to the extent of such
violation without invalidating any other provision hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Exhibits; Headings.</U> All exhibits attached to and incorporated in this Agreement by
reference are deemed to be a part hereof. The headings used in this Agreement are for
convenience only and are not part of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Choice of Law.</U> This Agreement is subject to and shall be construed and enforced in
accordance with the laws of the State of Delaware, United States of America. The Parties
hereby submit to the jurisdiction of the courts of the State of Delaware in respect to all
disputes arising out of or in connection with this Agreement and waive any and all objections
to such venue.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Entire Agreement.</U> This Agreement, constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations, representations,
agreements and understandings are merged into, extinguished by and completely expressed by
this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>9. ARBITRATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any matter or disagreement arising under this Agreement shall be submitted for decision to a
panel of three neutral arbitrators with expertise in the subject matter to be arbitrated. One
arbitrator shall be selected by each party and the two arbitrators so selected shall select the
third arbitrator. The arbitration shall be conducted in accordance with the Rules of the American
Arbitration Association. The decision and award rendered by the arbitrators shall be final and
binding. Judgment upon the award may be entered in any court having jurisdiction thereof. Any
arbitration shall be held in Wilmington, Delaware, or such other place as may be mutually agreed
upon in writing by the parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
officers on the date first written above.
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">

<TD valign="top" colspan="3"><DIV style="margin-left:0px; text-indent:-0px"><B>CUMBERLAND PHARMACEUTICALS INC.</B></DIV>

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="3"><DIV style="margin-left:0px; text-indent:-0px"><B>INALCO BIOCHEMICALS, INC.</B></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ Eric A. Lowe
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Eric A. Lowe</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Chief Executive Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>INALCO S.p.A.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ Giovanni Cipolletti</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Giovanni Cipolletti</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Minimum Purchases</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>EXHIBIT B</B></U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Patents</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>United States Patent<BR>
Bimbi</B>

</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="18%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>US005480491A</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Patent Number:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;<B>5,480,491</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Date of Patent:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;<B>Jan. 2, 1996</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PROCESS FOR THE PREPARATION OF
CRYSTALLINE LACTULOS FROMCOMMERCIAL SYRUPS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Inventor:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Giuseppe Bimbi, Pontedera, Italy</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Assignee:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inalco S.p.A., Milan, Italy</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Appl. No.:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;229,559</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Filed:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">April&nbsp;18, 1994</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Foreign Application Priority Data
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Apr. 28, 1993 &#091;IT&#093; Italy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">MI93A0833</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Int. Cl<SUP style="font-size: 85%; vertical-align: text-top">6</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">C13F 1/00; C13F 1/02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Cl.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><FONT style="white-space: nowrap">127/61;127/46.2;127/55;</FONT></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127/56; 127/58</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Field of Search</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127/61; 58, 56,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127/55, 46.2</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">References Cited
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">U.S. PATENT DOCUMENTS

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4,555,271 11/1985 Carobbi et al </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127/46.2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4,978,397 12/1990 Carobbi et al </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127/46.2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>5,034,064 7/1991 Deya et al </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>127/46.2</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>5,304,251 4/1994 Tomita et al </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>127/42</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FOREIGN PATENT DOCUMENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="18%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="19%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>0132509</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>2/1985</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>European Pat. Off</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>C13K 13/00</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>0159521</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>10/1985</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>European Pat. Off</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>CO8F 8/42</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>0158148</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>6/1988</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>European Pat. Off</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>C13K 13/00</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>0284959</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>1/1992</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>European Pat. Off</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>CO8F 8/42</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>0284960</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>6/1992</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>European Pat. Off</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>C08F 8/42</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OTHER PUBLICATIONS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">J. Agric. Chem. 1984, 32, 288-292 Jul./Dec. 1983.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Primary
Examiner&#151;</I>Paul Lieberman <I>Assistant<BR>
Examiner&#151;</I>Patricia Halley<BR>
<I>Attorney, Agent, or Firm&#151;</I>Hedman, Gibson &#038; Costigan

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ABSTRACT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following description sets forth a new process for the preparation of .gtoreq.98.5% pure
crystalline lactulose from commercially available aqueous syrups having the following composition:
50-70% by weight of lactulose, 3-9% by weight of lactose, 3-14% by weight of galactose, 4-7% by
weight of other carbohydrates, the total content of carbohydrates different from lactulose being of
from 10% to 30%.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>8 Claims, No Drawings</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROCESS FOR THE PREPARATION OF<BR>
CRYSTALLINE LACTULOSE FROM<BR>
COMMERCIAL SYRUPS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FIELD OF THE INVENTION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The present invention relates to a process for the preparation of high-purity crystalline
lactulose by crystallization of commercially available aqueous syrups.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PRIOR ART</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lactulose,
or 4-0-<FONT face="Symbol">&#098;</FONT>-D-galactopyranosyl-D-fructofuranose, is a semisynthetic disaccharide, used
in the form of syrup or of crystalline product on account of its laxative action, efficacy in the
treatment of hepatic dysfunctions, in particular of portal systemic encephalopathy, and as a
sweetener.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lactulose syrups that are now available on the market are generally not pure, but contain more
or less large amounts of other carbohydrates, in particular galactose and lactose, and typically
50% by weight of lactulose; from 5 to 8% by weight of galactose; from 3 to 5% by weight of lactose;
from 5 to 10% by weight of other carbohydrates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As may be seen, the per cent amount of carbohydrates different from lactulose contained in the
syrups of commerce is relatively high. The use of products containing other carbohydrates in
addition to lactulose for the therapy of disorders requiring administration of lactulose alone,
would be prejudicial and raise problems, e.g. in patients suffering from diabetes or requiring a
diet without galactose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore, as lactulose becomes ever more important in pharmaceutical practice, there is a
need for an adequate purification of same from contaminating carbohydrates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As disclosed in U.S. Pat. No.&nbsp;4,536,221, various processes known for lactulose purification
are based on the crystallization from alcoholic solvents, usually ethanol.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;However, the lactulose crystals obtained from alcohols always contain a given amount of
solvent, probably due to the formation of hydrogen bonds between the OH groups of sugar and the OH
groups of the solvent, while the solvent residue cannot be completely removed even by prolonged
dryings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disadvantage of the crystallization from ethanol is not only that complex process are
required for solvent residue elimination, but also that high operating costs are generally
involved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some process for the direct recovery of lactulose from aqueous solutions based on the
concentration of same by drying under vacuum, lyophilization, and spray-drying are also known.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of them are mentioned below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;the process disclosed in JP No.&nbsp;61,104,800, which comprises concentrating an aqueous solution
containing at least 60% lactulose, adding the concentrate with crystal seeds at from 60&#176; to
110&#176; C., kneading and pulverizing, thus affording a powder containing lactulose crystals;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;the process disclosed in European patent application EP-A-333,295, for the preparation of solid
lactulose from an aqueous syrup by high-temperature evaporation to lower the water content to
10% max., followed by cooling, grinding, sieving or crumbling of the resulting solid, whose
purity is the same as that of the starting syrup;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;the process disclosed in European patent application EP-A-480,519, consisting of lactulose
solidification from aqueous solutions by evaporating the water contained therein and conversion of
the resulting product into a free-flowing powder. Lactulose solidification may be initiated by
addition of crystal seeds, preferably in amounts of from 1% to 5% by weight (on dry residue
basis);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;the process disclosed in patent application JP No.&nbsp;2,200,693, (&#147;Derwent&#148; abstract) consisting of
lactulose crystallization from a condensed syrup, followed by condensate drying at a reduced
pressure and pulverization of the dried product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aforementioned processes are essentially based on the evaporation and concentration of the
starting syrup and greatly differ from crystallizations in that they simply cause the solute
solidification without eliminating&#151;as crystallizations do&#151;the undesirable secondary components
present in mother liquors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore, since the processes based on concentration give lactulose of the same purity as
that of the starting syrup, they cannot be utilized for the production of high-purity lactulose
from commercial syrups that, as already mentioned, contain high amounts of other carbohydrates.
Furthermore, the aforementioned processes can give crystalline lactulose only if combined with
crystallization from alcohols.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The only known process which involves a real crystallization from water, with no need of
alcoholic solvents, is disclosed in EP-A-318,630 by the Applicant. It is also the only known
process that yields highly pure (<FONT face="Symbol">&#179;</FONT> 98%) and non-hygroscopic crystalline lactulose. However, this
process cannot be exploited if the lactulose aqueous syrup to be crystallized contains
carbohydrates different from lactulose in amounts exceeding 14% by weight of lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In case of lactulose syrups containing carbohydrates different from lactulose in amounts
exceeding said limit value, it was always deemed it necessary to lower the content of said
carbohydrates below said limit value and, to this purpose, before crystallization from water, the
aqueous syrup was always purified according to one of the other known methods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ever growing importance of lactulose in pharmaceutical practice is a spur to the
development of new processes to be applied to the industrial production of high-purity crystalline
lactulose, without causing the inconveniences of the processes already known.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUMMARY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Applicant has now found a new process for lactulose purification that may be exploited on
an industrial scale, yielding high-purity crystalline lactulose, in particular having a content of
carbohydrates different from lactulose lower than 1% and a purity higher than 98.5%. The present
process is based on the crystallization of a commercial lactulose aqueous syrup having a total
content of carbohydrates different from lactulose higher than 10% by weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In particular, the process of the present invention can be applied to commercial lactulose
aqueous syrups having the following composition: from 50% to 70% by weight of lactulose; from 3% to
9% by weight of lactose; from 3% to 14% by weight of galactose; from 4% to 7% by weight of other
carbohydrates; the total content of carbohydrate different from lactulose ranging between 10% and
30% by weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It has surprisingly been found&#151;and this finding constitutes a fundamental feature of the
present invention&#151;that by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">adding a commercial lactulose aqueous syrup with trihydrated crystalline lactulose in
amounts ranging from 5% to 30% of the total lactulose present, a high-purity lactulose
crystallizes in good yields.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As known, in crystallization processes, once the right solvent and the right crystallization
conditions in respect of concentration and temperature have been found, few seed crystals are
generally enough for initiating the progressive crystallization of the product in solution,
according to laws governed by:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">product concentration in the concentrated matrix;<BR>
crystallization temperature;<BR>
residence time.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As far as sugars are concerned, said conditions are generally reached in such long times that
a &#147;random self-initiation&#148; of the solutes having lower k<SUB style="font-size: 85%; vertical-align: text-bottom">ps</SUB> than the product to be
crystallized becomes highly probable: consequently, the crystalline cake recovered is still
contaminated by said solutes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is, therefore, surprising that the addition to a lactulose aqueous syrup of a large amount
of trihydrated lactulose in the crystal state&#151;and not of few seed crystals&#151;can initiate a
preferential crystallization of lactulose in respect of the other carbohydrates present in the
syrup, yielding a high-purity crystalline lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compared with the process disclosed in European patent application EP-A-318630, the process of
the present invention has the advantage of giving very-high-purity crystalline lactulose starting
from any syrup of commerce.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DETAILED DESCRIPTION OF THE<BR>
INVENTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lactulose crystallization according to the present invention is characterized by the following
process: the water content of the lactulose aqueous syrup is lowered to a sugar concentration of
from 70&#176; to 80&#176; Brix; the resulting syrup is added at from 5&#176; C. to 20&#176; C. with crystalline
trihydrated lactulose, acting as a crystallization initiator, in amounts ranging from 5% to 30% by
weight of the lactulose present in the starting syrup, which temperature is maintained for a period
of from 20 to 120 hrs. The crystalline solid obtained consisted of trihydrated lactulose having a
content of carbohydrates different from lactulose below 1% by weight and a lactulose content of at
least 98.5% (on anhydrous basis).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In particular, the process for the preparation of crystalline lactulose according to the
present invention comprises the following steps:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commercial lactulose aqueous syrup is evaporated under continuous stirring at a temperature
of from 50&#176; to 60&#176; C. and at a pressure of 2660 to 6650 Pa, up to a sugar concentration of
70&#176;-80&#176; Brix;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the resulting concentrated syrup is cooled to 5&#176; to 20&#176; C. and added with crystalline
trihydrated lactulose in an amount of from 5 to 30 parts by weight of the lactulose present in
the syrup;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the suspension obtained is stirred at said temperature for a period of from 20 to 120 hours
and the lactulose present in the syrup is crystallizes in the form of trihydrated lactulose;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the crystallized trihydrated lactulose obtained is separated by centrifuging or filtering
from mother liquors, washed with cold water, and dried at a pressure of from 6650 to 13300 Pa,
at a temperature of from 30&#176; to 60&#176; C., to yield crystalline lactulose having a water content
below 0.5%.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The process of the invention gives highly pure (98.5% minimum) crystalline lactulose in yields
per cycle greater than 40% of the lactulose present in the starting syrup.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The mother liquors resulting from the separation of crystalline trihydrated lactulose are
passed once or several times through columns containing anionic or cationic exchange resins, either
individually or in sequence, as illustrated in European patent applications EP-A-132,509,
EP-A-158,148, EP-A-159,521, EP-A-284,959, and EP-A-294,960 by the Applicant, so to lower the
content of carbohydrates different from lactulose below the aforesaid limits and, therefore, to
allow the mixing of same with the commercial starting syrup to be subjected to the process of the
present invention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This operation allows the recycling of the mother liquors and the almost complete recovery of
the lactulose present in the syrups of commerce.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In a preferred embodiment of the present invention, the concentrated syrup of step b) has a
content of 55% to 62% by weight of lactulose and the crystalline trihydrated lactulose is added in
an amount ranging between 5% and 15% by weight of the lactulose present in the commercial syrup
(the amount of trihydrated lactulose used as a crystallization initiator is expressed as % by
weight of anhydrous lactulose).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A single washing of the crystalline trihydrated lactulose obtained in d) with cold water
(3&#176;-5&#176; C.) is generally enough for a satisfactory removal of the residual mother liquors and for
obtaining a product of the desired purity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following examples illustrate some embodiments of the claimed process.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXAMPLES</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Crystallization of Lactulose Starting<BR>
From Commercially Available Syrups

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several crystallizations of commercially available lactulose syrups were carried out according
to the standard procedure described below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Syrups characteristics are shown in Table 1 and the results obtained in Table 2.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>STANDARD PROCEDURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A syrup (1000 kg) of composition as shown in Table 1 was concentrated under vacuum at a
pressure of from 2660 to 6650 Pa, under continuous stirring, at a temperature of from 50&#176; to 60&#176;
C., to a sugar concentration of 70&#176;-80&#176; Brix.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The resulting solution was fed to a crystallizer and cooled to 8&#176; C. under continuous
stirring. Once said conditions have been reached, crystalline trihydrated lactulose was fed in the
amounts shown in Table 2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obtained suspension was slowly stirred at 8&#176; C. for the period indicated in Table 2, then
the mother liquors were removed by centrifuging, the crystal cake was squeezed to remove most
mother liquors, washed with cold water, and squeezed again.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The resulting product was dried in an air oven at a temperature not exceeding 60&#176; C. and at a
pressure of from 6650 to 13300 Pa, until obtaining anhydrous lactulose crystals (i.e. having a
maximum water content of 0.5%) of &#062;98.8% purity (on dry basis) (Table 2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purity of lactulose crystals was determined on the dried product by HPLC analysis (J.
Agric. Food Chem., 32, 288-292, 1984), by means of comparison with standard lactulose produced and
sold by MERCK.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE 1
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Composition (%) of the aqueous solutions used</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><I>Item</I></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">LTL</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">LTS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">EPI</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">GLT</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">ND</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">H<SUB style="font-size: 85%; vertical-align: text-bottom">2</SUB>O</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">I</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34.0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33.7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">III</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31.8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">IV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32.0</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Remarks: all quantities are by weight percentages of the solution total weight.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Abbreviations<BR>
LTL lactulose;<BR>
LTS lactose;<BR>
EPI epilactose;<BR>
GLT galactose;<BR>
ND carbohydrates different from LTL, LTS, EPI, and GLT.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE </B>2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><U><B>Experimental results</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 6pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>LTL</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Cone. syr.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>LTL as initiator</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>LTL</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>LTL recovered</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000"><B>Ex.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Syr </B><SUP style="font-size: 85%; vertical-align: text-top"><B>a</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Brix</B><SUP style="font-size: 85%; vertical-align: text-top"><B>b</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>h</B><SUP style="font-size: 85%; vertical-align: text-top"><B>c</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>% w</B><SUP style="font-size: 85%; vertical-align: text-top"><B>d</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Xg</B><SUP style="font-size: 85%; vertical-align: text-top"><B>e</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>%</B><SUP style="font-size: 85%; vertical-align: text-top"><B>f</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Kg</B><SUP style="font-size: 85%; vertical-align: text-top"><B>g</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Kg</B><SUP style="font-size: 85%; vertical-align: text-top"><B>h</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Kg</B><SUP style="font-size: 85%; vertical-align: text-top"><B>i</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>% tit</B><SUP style="font-size: 85%; vertical-align: text-top"><B>l</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>% fil</B><SUP style="font-size: 85%; vertical-align: text-top"><B>m</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>yield</B><SUP style="font-size: 85%; vertical-align: text-top"><B>n</B></SUP></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="49" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">I</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">931</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18.7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>111.6</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">610</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42.2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">I</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">929</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">254</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38.5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>I</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">929</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>61.1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">565</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38.9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">II</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">888</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">531</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">212</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33.5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">II</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">544</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38.9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">II</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">933</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">558</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46.3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">7</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">II</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">954</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46.7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">558</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">255</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38.4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">8</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IV</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">924</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">587</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">238</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33.9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">9</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IV</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">919</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">548</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">248</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38.3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">IV</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">948</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">548</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">213</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32.9</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">a</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Commercial aqueous syrup used</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">b</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Brix degrees after syrup concentration</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">c</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Residence time in crystallizer at 8&#176; C</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">d</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>By weight %, amount of LTL after syrup concentration</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">e</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Amount of concentrated syrup (kg)</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">f</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>By weight % amount of trihydrated LTL used as a crystallization initiator</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">g</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Weight of trihydrated LTL used as a crystallization initiator</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">h</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>LTL total weight (LTL of the syrup &#043; LTL used as a crystallization initiator)</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">i</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Weight of trihydrated LTL recovered</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">l</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>titre of anhydrous LTL in trihydrated crystal before drying</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">m</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>titre of anhydrous LTL after drying</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">n</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>yield calculated by:<br>
<U>(anhydrous)&nbsp;crystalline LTL recovered (kg)</U><BR>
(anhydrous)&nbsp;total LTL In the system (kg)</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt">I claim:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. A process for the preparation of crystalline lactulose having a content of carbohydrates
which are different from lactulose that is lower than 1% and a lactulose content of more than
98.5%, said process comprising the following steps:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaporating a part of the water from an aqueous lactulose syrup under continuous stirring
at a temperature of from 50&#176; to 60&#176; C. and at a pressure of from 2660 to 6650 Pa to obtain
a concentrated lactulose syrup with a sugar concentration of 70&#176;-80&#176; Brix, said aqueous
lactulose syrup having a lactulose content of from 50% to about 62% by weight and a content
of carbohydrates which are different from lactulose and include lactose, galactose and
other carbohydrates, the lactose content being from 3% to 9% by weight; the galactose
content being from 3% to 14 % and the other carbohydrate content being from 4% to 7% by
weight;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cooling the concentrated syrup obtained in step (a)&nbsp;to a temperature of from 5&#176; to 20&#176; C.
prior to adding from 5% to 30% by weight of crystalline trihydrated lactulose based on the total weight of lactulose which is present in said aqueous lactulose syrup;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>stirring the product of step (c)&nbsp;for a period of from 20 to 120 hours to crystallize the
lactulose which is present as trihydrated lactulose;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>separating the crystallized trihydrated lactulose by centrifugation or filtration of the
product of Step (c)&nbsp;to obtain a mother liquor and separated crystallized trihydrated
lactulose; and thereafter washing said separated crystallized trihydrate of lactulose with
cold water prior to drying the separated crystallized trihydrate of lactulose at a temperature
of from 30&#176; to 60&#176; C., to obtain crystalline lactulose having a water content of less that
0.5%.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The process according to claim 1, wherein the crystalline trihydrated lactulose is
added in an amount of between 5% and 15% by weight of the lactulose present in said aqueous
lactulose syrup.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The process according to claim 1, wherein the mother liquors obtained in step (d)&nbsp;are
passed one or more times through columns containing ion exchange resins to reduce the content of
carbohydrates which are other than lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The process according to claim 3, wherein the mother liquors which are recovered after the
passage through the ion exchange columns are mixed with the aqueous lactulose syrup of step (a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;A process for the preparation of crystalline lactulose having a content of carbohydrates
which are different from lactulose that is lower than 1% and a lactulose content of more than
98.5%, said process consisting essentially of the following steps:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;evaporating a part of the water from an aqueous lactulose syrup under continuous stirring at a
temperature of from 50&#176; to 60&#176; C. and at a pressure of from 2660 to 6650 Pa to obtain a
concentrated lactulose
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>syrup with a sugar concentration of 70&#176;&#150;80&#176; Brix, said aqueous lactulose syrup having a
lactulose content of from 50% to about 62% by weight and a content of carbohydrates which are
different from lactulose and include lactose, galactose and other carbohydrates, the lactose
content being from 3% to 9% by weight; the galactose content being from 3% to 14 % and the other
carbohydrate content being from 4% to 7% by weight;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cooling the concentrated syrup obtained in step (a)&nbsp;to a temperature of from 5&#176; to 20&#176; C.
prior to adding from 5% to 30% by weight of crystalline trihydrated lactulose based on the
total weight of lactulose which is present in said aqueous lactulose syrup;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>stirring the product of step (c)&nbsp;for a period of from 20 to 120 hours to crystallize the
lactulose which is present as trihydrated lactulose;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>separating the crystallized trihydrated lactulose by centrifugation or filtration of the
product of step (c)&nbsp;to obtain a mother liquor and separated crystallized tri-
hydrated lactulose; and thereafter washing said separated crystallized trihydrate of
lactulose with cold water prior to drying the separated crystallized trihydrate of lactulose at
a temperature of from 30&#176; to 60&#176; C., to obtain crystalline lactulose having a water content of
less that 0.5%.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The process according to claim 5, wherein the crystal-line trihydrated lactulose is added
in an amount of between 5% and 15% by weight of the lactulose present in said aqueous lactulose
syrup.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;The process according to claim 5, wherein the mother liquors obtained in step (d)&nbsp;are
passed one or more times through columns containing ion exchange resins to reduce the content of
carbohydrates which are other than lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;The process according to claim 7, wherein the mother liquors which are recovered after the
passage through the ion exchange columns are mixed with the aqueous lactulose syrup of step (a).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * *
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>United States Patent</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Patent Number:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>5,003,061</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Carobbi et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Date of Patent:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top"><B>Mar. 26, 1991</B>
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>METHOD FOR PREPARING HIGH-PURITY CRYSTALLINE LACTULOSE</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Inventors:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Renato Carobbi, Pistoia; Franco
Innocenti, Bagno a Ripoli, both of
Italy</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Assignee:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>SIRAC Srl, Milan, Italy</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Appl. No.:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;<B>141,786</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Filed:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Jan. 11, 1988</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Foreign Application Priority Data</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dec. 1, 1987 &#091;IT&#093; Italy
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">22848 A/87</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Int. Cl.<SUP style="font-size: 85%; vertical-align: text-top">5</SUP>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">C07H 1/06; C13F 1/02</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">U.S. Cl
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">536/127; 536/1.1;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><FONT style="white-space: nowrap">536/4.1; 127/30; 127/46.1; 127/58</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Field of Search
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">536/1.1, 4.1, 127;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">127/30, 46.1, 58</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>References Cited<BR>
U.S. PATENT DOCUMENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>3,110,600</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>11/1963</B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bok</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>536/1.1</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>3,546,206</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>12/1970</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Guth et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>127/30</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>3,562,012</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>2/1971</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Reinicke et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>536/1.1</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>3,816,174</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>6/1974</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Nagasawa et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>127/30</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>3,816,394</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>6/1974</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Nagasawa et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>536/124</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,142,916</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>3/1979</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Ogasa et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>127/63</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,264,763</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>4/1981</B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Gasparotti</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>536/1.1</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,273,922</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>6/1981</B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Hicks</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>127/46.1</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4.536,221</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>8/1985</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Carobbi et al.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>536/127</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,555,271</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>11/1985</B>
</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Carobbi et al.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>127/46.2</B></TD>
</TR>


<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,605,646</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>8/1986</B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bernardi</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>514/53</B></TD>
</TR>


<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top"><B>4,812,444 </B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>3/1989</B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Mitsuhashi et al.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>514/53</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FOREIGN PATENT DOCUMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">57-102200 6/1982 Japan.<BR>
61<SUP style="font-size: 85%; vertical-align: text-top">-</SUP>104800 5/1986 Japan.<BR>
1232554 5/1971 United Kingdom.<BR>2031430 4/1980
United Kingdom.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OTHER PUBLICATIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Montgomery et al; J.A.C.S. 52:2101-2106, May&nbsp;1930.<BR>
Oosten; Chemical Abstracts 67:73799k (1967).<BR>
Nitsch et al; Chemical Abstracts 84:150910v (1976).<BR>
Krol et al; Chemical Abstracts 90:40510f (1979).<BR>
Takahashi; Chemical Abstracts 105:135841g (1986).

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Primary </I>Examiner&#151;Ronald W. Griffin<BR>
<I>Assistant Examiner</I>&#151;Nancy S. Carson<BR>
<I>Attorney, Agent, </I>or Firm&#151;Parkhurst, Wendel &#038; Rossi

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ABSTRACT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A method for preparing high-purity crystalline lactulose and the product obtained by the method,
which comprises crystallization from aqueous solutions at a temperature of 5&#146;-40&#146; C., the starting
aqueous solution having a lactulose concentration of 50-80% w/w, a lactose concentration of less
than 5% of the lactulose concentration by weight, a galactose concentration of less than 5% of the
lactulose concentration by weight, and a concentration of other sugars of less than 4% of the
lactulose concentration by weight.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4 Claims, No Drawings</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>METHOD FOR PREPARING HIGH-PURITY<BR>
CRYSTALLINE LACTULOSE</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FIELD OF THE INVENTION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This invention relates to a new method for preparing high-purity crystalline lactulose by
crystallizing aqueous solutions which contain it and eliminating the secondary components during
the crystallization stage, and to the crystalline lactulose obtained in this manner.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PRIOR ART</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lactulose, or 4-O-<FONT face="Symbol">&#098;</FONT>-D-galactopyranosyl-D-fructofuranose, is a semisynthetic disaccharide used
in the form of a syrup or crystalline product for its laxative effects, for its effectiveness in
hepatic disfunctions and particularly in portosystemic encephalopathy, or as a sweetener.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercially available lactulose syrup is generally impure, containing variable quantities of
other carbohydrates, particularly lactose and galactose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A typical composition of currently available syrup is the following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>lactulose</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>50%by weight</B></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>galactose</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>5-8%by weight</B></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>lactose</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>3-3%by weight</B></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>other carbohydrates</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>5-10%by weight</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in which relatively large percentages of carbohydrates other than lactulose are present. These
carbohydrates are also present, generally in lesser quantity, in currently commercially available
crystalline lactulose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Carbohydrates other than lactulose are undesirable in therapeutic applications for which
lactulose is intended, and in particular for patients requiring a galactose-free diet and diabetic
patients.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is therefore a requirement for crystalline lactulose of higher purity, in particular
with the greatest possible reduction in carbohydrates other than lactulose and with the absence of
undesirable residual alcoholic solvent concentrations, which are present when lactulose is
crystallized from alcoholic solutions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The main currently known lactulose purification methods involve the use of alcoholic solvents,
generally ethanol, together with complex procedures based on the extreme solubility of lactulose in
an aqueous environment, or on various concentration processes by drying.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Crystalline lactulose obtained from alcoholic solvents is known to always contain a
considerable percentage of solvent retained by the crystal, probably by the formation of hydrogen
bonds between the sugar OH groups and the solvent OH groups, and it is never possible to eliminate
the solvent residue even by prolonged drying.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One example of a process of purification by crystallization from ethanol is described in
Italian patent No.&nbsp;1,155,429.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The yield of such processes when calculated with respect to the lactulose contained in the
starting syrup is particularly low.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the present text the term &#147;yield&#148; indicates the amount of crystalline product obtained in a
single step, as a weight percentage of the starting lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thus, processes for obtaining crystalline lactulose from alcoholic solutions have the
drawbacks of greater complication, lower yields and consequent higher cost,
and a product from which the undesirable alcoholic solvent traces cannot be eliminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Again, processes involving concentration by direct drying of aqueous lactulose solutions, even
if of high purity and whatever drying method is used (vacuum, lyophilization, spray drying), are
known to lead to a very hygroscopic solid amorphous product or, as described in JP No.&nbsp;61104800, to
a solid containing crystalline lactulose which has to undergo further mixing and grinding before it
can be used.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thus none of the previously used methods has provided crystalline lactulose free both of
impurities in the form of other undesirable carbohydrates and of residual concentrations of
alcoholic solvent retained by the lactulose crystal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Up to the present time it has been impossible in practice to directly obtain from aqueous
solutions high-purity crystalline lactulose having the characteristics of the lactulose claimed in
the present patent.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUMMARY OF THE INVENTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the present invention we have now discovered a new industrially applicable
lactulose purification process which obviates all these drawbacks and enables crystalline lactulose
to be obtained in a particularly simple and economical manner with a degree of purity exceeding 98%
by weight and practically free of carbohydrates other than lactulose, in particular lactose and
galactose, from aqueous solutions which contain it in an impure state due to the presence of
carbohydrates other than lactulose, and/or alcohols. If the process of the present invention is
applied to lactulose crystallized from alcoholic solutions and then redissolved in water, the
crystalline lactulose finally obtained is practically free of any trace of the alcoholic solvent
used and thus has a degree of purity considerably higher than that obtainable by any process
previously used.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The final yield of the process according to the invention varies according to the
crystallization temperature, the crystallization time, the lactulose purity and the solution
purity, and lies between 10 and 70%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In its preferred embodiments, the yield varies from 55 to 70% as indicated hereinafter, and is
therefore considerably greater than in all previously used methods, so making this process usable
more economically on an industrial scale than previous processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The method of the present invention enables crystalline lactulose to be obtained from aqueous
solutions which are impure because of the presence of carbohydrates other than lactulose and/or
alcohols, and in particular from aqueous solutions having the following characteristics:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;lactulose concentration of 50-80% w/w and preferably 65-70% w/w in the aqueous solution;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;lactose concentration of less than 5% of the lactulose concentration by weight;
(c)&nbsp;galactose concentration of less than 5% of the lactulose concentration by weight;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;concentration of other carbohydrates of less than 4% of the lactulose concentration by
weight;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;total concentration of carbohydrates other than lactulose not exceeding 6% of the
lactulose concentration by weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The method according to the present invention is characterised by maintaining the
crystallization conditions within precise critical values, and more specifi-
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">cally by simultaneously maintaining all the indicated parameters within the following
defined critical values:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;Crystallization temperature between 5&#176; and 40&#176; C., and preferably
between 10&#176; and 15&#176; C.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;Crystallization time between 10 and 60 hours, and preferably between 24 and 36 hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside these values an extremely low final process yield is obtained such that the process
cannot be used industrially, it being sufficient for only one of these parameters to lie outside
the range of values defined by the present invention for the final yield to be such as to make the
process unusable industrially.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This process, which is described in detail in the examples, therefore not only enables
crystalline lactulose to be obtained directly from sufficiently pure aqueous solutions, but also
enables the residual solvent to be completely eliminated from crystalline lactulose obtained by
conventional crystallization from alcoholic solvents such as methanol, ethanol and propanol.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following examples are given as non-limiting illustration of the process according to the
invention for purifying and crystallizing lactulose from aqueous solutions.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXAMPLE 1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1000 kg of a lactulose solution having the following composition:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">lactulose
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">50%</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">lactose
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0.7%</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">galactose
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0.9%</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">other sugars
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0.3%</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">water
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">to make up to 100%</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are concentrated under vacuum to a lactulose concentration of 70%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The concentrated solution is then cooled to 13&#176; C. and 1 kg of crystalline lactulose
is added.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The mixture is left under agitation for 24 hours maintaining the temperature at 13&#176;
C., after which the solid obtained, consisting of crystalline lactulose, is filtered off.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The solid is dried in an air oven at a temperature not exceeding 35&#176; -40&#176;
C. to obtain 273 kg of crystalline lactulose with a purity exceeding 98% and a yield of 54.5%.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXAMPLE 2</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1000 kg of a lactulose solution having the following composition:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">lactulose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">50</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">lactose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.7</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">galactose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.9</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">other sugars</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.3</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">water to make up to</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">100</TD>
    <TD nowrap>%</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">are concentrated under vacuum to a lactulose concentration of 68%.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The concentrated solution is cooled to 35&#176; C. after which 1 kg of crystalline
lactulose is added.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Over a period of 20 hours the temperature is cooled to 15&#176; C. while maintaining slow
agitation, this temperature then being maintained for a further 16 hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By centrifuging, 373 kg of wet product (KF 17%) are obtained, equivalent to 309.5 kg of dry
product, with a yield of 61.7% and a purity of 98.3%.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXAMPLE 3</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;500 kg of crystalline lactulose (purity 98.7%) obtained by crystallization from ethanol, with
a residual ethanol concentration of 5000 ppm, are dissolved in 2000 l of water.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The solution obtained is concentrated under vacuum to 68% of lactulose and its temperature
allowed to reach 30&#176; -35&#176; C. spontaneously.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Crystallization is triggered by adding 800g of crystalline lactulose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The solution is then cooled to about 15&#176; C. and kept at this temperature for 30
hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By centrifuging, 430 kg of wet product (KF 18%) are obtained, equivalent to 342.5 kg of dry
product, with a yield of 68.5% and a purity exceeding 99%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The residual ethanol content is reduced to less than 5 ppm.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We claim:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;A method for preparing crystalline lactulose having less than 2% of carbohydrate other than
lactulose and a purity exceeding 98% comprising:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>adding a crystalline lactulose seed to an aqueous solution of lactulose having a
lactulose concentration of from 50% to 80% w/w, a lactose concentration of less than 5% of
the lactulose concentration by wt., a galactose concentration of less than 5% of the
lactulose concentration by wt. and concentration of other carbohydrates of less than 4% of
the lactulose concentration by wt.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>crystallizing said lactulose solution at a temperature between 5&#176; and
40&#176; C. and in a time between 10 and 60 hours; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>drying the obtained crystalline lactulose.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;A method as claimed in claim 1, wherein the lactulose concentration in the aqueous solution
is 65-70% w/w and the total concentration of carbohydrates other than lactulose does not exceed 6%
of the lactulose concentration by weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The method of claim 1 wherein said lactulose solution crystallizing temperature is between
10&#176; C. and 15&#176; C. and said time is between 24 and 36 hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The method of claim 1 wherein the aqueous solution of lactulose is obtained by dissolving
lactulose, which was previously crystallized from alcoholic solutions, in water.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>* * * * *</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>UNITED STATES PATENT AND TRADEMARK OFFICE<BR>
CERTIFICATE OF CORRECTION</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>PATENT NO.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;<B>5,003,061</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>DATED</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>March&nbsp;26, 1991</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap"><B>INVENTORS) :</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Renato CAROBBI et al.</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>It is certified that error appears in the above-identified parent and that said Letters Patent is
hereby corrected as shown below:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Title Page:<BR>
&#091;73&#093; Assignee: Please change &#147;SIRAC Srl, Milan, Italy&#148; to</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#151;INALCO S.p.A., Milano, Italy&#151;</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Signed and Sealed this<BR><br>
Fifth Day of January, 1993</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I><B>Attest:</B></I></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>DOUGLAS B. COMER</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap><B><I>Attesting Officer</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap><B><I>Acting Commissioner
of Patents and Trademarks</I></B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>REEXAMINATION CERTIFICATE<BR>
ISSUED UNDER 35 U.S.C. 307</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>THE PATENT IS HEREBY AMENDED AS<BR>
INDICATED BELOW.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Matter enclosed in heavy brackets &#091; &#093; appeared in the patent, but has been deleted and is no
longer a part of the patent; matter printed in italics indicates additions made to the patent.</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AS A RESULT OP REEXAMINATION, IT HAS BEEN DETERMINED THAT:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Claim 1 is determined to be patentable as amended.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims 2, 3 and 4, dependent on an amended claim, are determined to be patentable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;A method for preparing crystalline lactulose having less than 2% of carbohydrate
other than lactulose and a purity exceeding 98% comprising;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;adding a crystalline lactulose seed to an aqueous solution of lactulose having a
lactulose concentration of from 50% to 80% w/w, a lactose concentration of less than 5% of the
lactulose concentration by wt., a galactose concentration of less than 5% of the lactulose
concentration by wt. and concentration of other carbohydrates of less than 4% of the lactulose
concentration by wt., <I>said aqueous solution containing water as the only solvent;</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;crystallizing said lactulose solution at a temperature between 5&#176; and 40&#176; C. and in a
time between 10 and 60 hours; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;drying the obtained crystalline lactulose.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * *
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Transition Plan</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>16
<FILENAME>g06286exv10w10.htm
<DESCRIPTION>EX-10.10 LICENSE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.10 LICENSE AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.10</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">License Agreement
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">between

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Vanderbilt University
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">and

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Cumberland Pharmaceuticals Inc.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">May&nbsp;1999
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LICENSE AGREEMENT<BR>
between<BR>
VANDERBILT UNIVERSITY<BR>
and<BR>
CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS AGREEMENT, by and between VANDERBILT UNIVERSITY, a not-for-profit corporation, organized and
existing under the laws of the state of Tennessee (&#147;VANDERBILT&#148;), and Cumberland Pharmaceuticals
Inc., a Tennessee corporation, having a principal place of business at Nashville, Tennessee (the
&#147;LICENSEE&#148;) is effective as of the <U>28<SUP style="font-size: 85%; vertical-align: text-top">TH</SUP></U> day of <U> May </U>, 1999 (the
&#147;EFFECTIVE DATE&#148;).
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, VANDERBILT represents that it holds title, by assignment, to the data, including patient
records, created by Gordon R. Bernard, M.D., Professor of Medicine (&#147;the Data&#148;) relating to
intravenously administered ibuprofen for treatment of sepsis and that it has all rights to the Data
and VANDERBILT is willing to grant a license to the Data and any intellectual property rights
associated therewith; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, LICENSEE desires to acquire, and VANDERBILT desires to grant to LICENSEE, an exclusive,
worldwide license to use the Data in connection with the development and production of the
&#147;Product,&#148; as hereinafter defined, for which LICENSEE intends to seek necessary approvals from
regulatory governmental agencies in order to market and sell such products upon the terms and
conditions hereinafter set forth;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, it is
agreed by the parties as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1. DEFINITIONS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.1 <U>Product(s)</U> shall mean a pharmaceutical product, consisting, in whole or part, of
intravenously administered ibuprofen manufactured by or for LICENSEE based on the Data and approved
by a regulatory agency for sale or other distribution in the country in which the agency has
regulatory authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.2 <U>Net Sales</U>. The term &#147;Net Sales&#148; shall mean the receipts for Products sold by LICENSEE
or a sublicense during the term of this Agreement, computed quarter by quarter, less allowances
for:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;cash, trade, or quantity discounts and rebates,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;taxes, including sales taxes and duties,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;credits, returns and replacements, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;shipping and insurance charges.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Products shall be deemed sold when paid for.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.3 <U>The Inventor</U>. The term &#147;Inventor&#148; shall mean Gordon R. Bernard, M.D., Professor of
Medicine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.4 <U>Affiliate</U> means, when used with reference to LICENSEE, any entity directly or
indirectly controlling, controlled by or under common control with LICENSEE. For purposes of this
Agreement, &#147;control&#148; means the direct or indirect ownership of over fifty percent (50%) of the
outstanding voting securities of an entity, or the right to receive over fifty percent (50%) of the
profits or earnings of an entity, or the right to control the policy decisions of an entity.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2. GRANT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.0 <U>Exclusive License</U>. VANDERBILT hereby grants to LICENSEE and LICENSEE hereby accepts
from VANDERBILT, upon the terms and conditions herein specified, an exclusive, royalty bearing,
worldwide license, with the right to sublicense, to use Data for any purpose, including manufacture
and sale of the Product(s) as well as submission to regulatory governmental agencies for approval
to sell Product(s), except as otherwise expressly set forth herein. Upon execution of this
Agreement, VANDERBILT through Gordon Bernard will promptly deliver to LICENSEE all information and
data relating to intravenously administered ibuprofen to which VANDERBILT holds title.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.1 <U>Federal Government Rights Reserved</U>. Notwithstanding the exclusive license granted
herein, the Federal Government shall receive all the rights, if any, to the Data required by law or
regulation to be reserved to the government. All rights granted in this Agreement are expressly
granted subject to the rights of the Federal Government and such rights are specifically reserved
to the Government by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.2 <U>Reservation of Right</U>. VANDERBILT reserves the right to make, use and further develop
the Data for its own non-commercial, educational and research purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.3 Upon receipt of regulatory approval to sell the Product, LICENSEE shall use reasonable efforts
to effect introduction of the Products into the commercial market as soon as practicable,
consistent with sound and reasonable business practices and judgment; thereafter, until the
expiration of this Agreement, LICENSEE shall use commercially reasonable efforts to keep Products
reasonably available to the public.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.4 <U>Subsidiaries and Distributors</U>. License rights granted hereunder shall enable LICENSEE
to make, use, sell or otherwise distribute Product through any of its subsidiaries and to sell
Product through any of its normal channels including its subsidiaries, distributors, and agents.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>3. TERMS AND TERMINATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.0 <U>Term</U>. Unless previously terminated as herein provided, this Agreement shall become
effective as stated above and shall continue until LICENSEE ceases distribution of Product in all
countries in which it has obtained regulatory approval for manufacture and distribution of such
product based on use of the Data.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.1 <U>Termination</U>. This Agreement may be terminated by written notice to the other party:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Other than as stated in Article&nbsp;3.1(b), in the event that one party commits any
substantial breach of this Agreement, the non-breaching party at its option, may terminate this
Agreement by giving the breaching party written notice pursuant to Article&nbsp;10.2 of its election to
terminate as of a stated date, not less than forty-five (45)&nbsp;days from the date of the notice.
Such notice shall state the nature of the defaults claimed by the non-breaching party. The
breaching party during said forty-five (45)&nbsp;day period, or such longer period as may be indicated
by the other, may correct any default stated in said notice and if such default is corrected, this
Agreement shall continue in full force and effect as if such notice had not been given. Failure by
LICENSEE to pay earned royalties to VANDERBILT in a timely manner shall be deemed a substantial
breach of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event LICENSEE shall file a petition for voluntary bankruptcy, has a petition for
involuntary bankruptcy filed against it (which petition is not withdrawn within sixty (60)&nbsp;days of
such filing), is adjudicated to be bankrupt, or shall make an assignment for the benefit of
creditors, or shall apply for or consent to the appointment of a receiver or trustee of a
substantial part of its property, to the extent permitted by law, this Agreement shall
automatically terminate effective as of a date ten (10)&nbsp;days prior to LICENSEE&#146;s change of status
hereunder and shall be subject to Article&nbsp;3.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In the event a LICENSEE provides written notice to VANDERBILT and LICENSEE is terminating
pursuing regulatory approval for the Product.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.2 <U>Effect of Termination</U>. Upon termination of this Agreement, LICENSEE shall cease all
production and sale of Product except for the production and sale of Product on which production
had begun prior to notice of such termination. LICENSEE may continue to sell such Product for up
to one year after such notice upon payment of royalties accruing thereon, and shall render an
accounting to VANDERBILT of any royalties which may be due. Immediately upon termination all
rights of Licensee, except as expressly stated in this article, shall revert to VANDERBILT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.3 Sections&nbsp;3.2, 3.4, 5.1, Article&nbsp;6, Article&nbsp;7, Article&nbsp;8, Article&nbsp;9, and Section&nbsp;10.8 of the
agreement shall survive termination.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4. CONSULTING AGREEMENTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4.0 <U>Consulting Agreements</U>. In the event LICENSEE desires to have a Consulting Agreement
with Dr.&nbsp;Bernard, any such Consulting Agreement will be separate and apart from this Agreement, and
in accord with VANDERBILT policy and procedures.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>5. ROYALTIES AND &#091;***&#093;</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.0 &#091;***&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.1 <U>Royalties</U>. Commencing on the effective date of this Agreement, LICENSEE agrees to pay
VANDERBILT at the rate of &#091;***&#093; percent of Net Sales of Products sold to third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.2 <U>Schedule of Payment</U>. LICENSEE further agrees to pay royalties on a quarterly basis
based on LICENSEE&#146;s fiscal quarter and payments shall be due within forty-five (45)&nbsp;days after the
completion of the fiscal quarter. Each such payment shall be accompanied by a statement for the
period covered by such royalties showing total number or volume of Products sold, and total
royalties due, and identified as Net Sales within U.S. or non-U.S. This statement is to be
certified as accurate by a responsible officer of LICENSEE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.3 &#091;***&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.4 <U>Reports</U>. LICENSEE shall provide written annual reports within &#091;***&#093; after December&nbsp;31
of each calendar year which shall include but not be limited to: reports of progress on research
and development, regulatory approvals, manufacturing, marketing and sales during the preceding
twelve (12)&nbsp;months as well as plans for the coming year. LICENSEE shall promptly notify VANDERBILT
if any changes in the marketplace or in LICENSEE&#146;s financial condition or business aims suggest
commercialization will not occur within three (3)&nbsp;years from the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.5 <U>Records</U>. LICENSEE shall maintain complete and accurate records sufficient to enable
accurate calculation of royalties due VANDERBILT under this Agreement. LICENSEE shall, at
VANDERBILT&#146;s request and expense, provide certified statements from LICENSEE&#146;s auditors, concerning
royalties due pursuant to this Agreement. Once a calendar year, VANDERBILT shall have the right to
select a certified public accountant to inspect, on reasonable notice and during regular business
hours, the records of LICENSEE to verify LICENSEE&#146;s statements and royalty payments pursuant to
this Agreement. The entire cost for such inspection shall be borne by VANDERBILT, unless there is
a discrepancy greater than 5% in VANDERBILT&#146;s favor, in which case LICENSEE shall bear the entire
cost of the inspection. Records shall be preserved by LICENSEE for three (3)&nbsp;years for inspection
by VANDERBILT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.6 If this Agreement is not terminated in accordance with other provisions hereof, LICENSEE&#146;s
obligation to pay royalties hereunder shall continue as long as Product is being distributed by
LICENSEE.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.7 The royalty on sales in currencies other than U.S. Dollars shall be calculated using the
appropriate exchange rate for such transactions quoted by CITICORP BANK (NEW YORK) foreign exchange
desk on the last banking day of each calendar quarter. Royalty payments to VANDERBILT shall be in
U.S. Dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.8 In the event that LICENSEE is acquired by a third party or enters into a joint venture with a
third party, or in any other way transfers all of its assets, including this License to a third
party, all obligations of this License, including the foregoing royalty terms, shall be binding
upon the party acquiring this License.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>6. CONFIDENTIALITY</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.0 It may be necessary for one party to disclose to the other party certain confidential or
proprietary information, including business plans and marketing strategies. In such event, the
receiving party agrees to preserve such identified information as confidential. The obligation of
confidentiality shall not apply to information which:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;is now in the public domain or which becomes generally available to the public through no
fault of the receiving party; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;is already known to, or in the possession of, the receiving party prior to disclosure by
the disclosing party as can be demonstrated by documentary evidence; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;is disclosed on a non-confidential basis from a third party having the right to make such
a disclosure; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;is independently developed by the receiving party as can be demonstrated by documentary
evidence.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.1 <U>Term</U>. The confidentiality obligations of this Article shall continue for a period of
five (5)&nbsp;years beyond the termination of this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>7. INFRINGEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.0 <U>Products Infringing Third Parties</U>. Each party shall promptly notify the other if any
legal proceedings are commenced or threatened against either party or any purchaser of a Product
sold by LICENSEE on the ground that the manufacture, use, sale or possession of the Product is an
infringement of a third party&#146;s patent or other intellectual property rights. LICENSEE shall, at
its own expense, conduct all suits brought against it as a result of the exercise of the rights
granted hereunder, and VANDERBILT shall, at the request and expense of LICENSEE, give LICENSEE all
reasonable assistance in any such proceedings. Payment of any amounts which may be recovered by
such third party by way of judgment, award, decree, or settlement that resulted from infringement
of third party patent rights or other rights by a Product, including attorneys&#146; fees and other
costs shall be the sole responsibility of LICENSEE. LICENSEE agrees not to settle or compromise any
action, suit or proceeding without the consent of VANDERBILT.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>8. WARRANTIES AND INDEMNITIES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.0 Nothing in this Agreement shall be constructed as:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;a warranty or representation by VANDERBILT that anything made, used, sold, or otherwise
disposed of through the license granted herein is or will be free from infringement of patents
rights of third parties;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;an obligation by VANDERBILT to bring or prosecute actions or suits against third parties
for infringement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Granting by implication, estoppel, or otherwise any licenses under patents of VANDERBILT.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.1 To the best of its knowledge and belief, VANDERBILT hereby represents and warrants that it is
the sole owner of the Data and has the right to grant the license to the Data provided herein and
that to the best of its knowledge and belief after due inquiry, no rights of patients or other
persons are or will be infringed by the license granted to LICENSEE. VANDERBILT further represents
and warrants that the Data is both accurate and complete and includes all information and data
relating to intravenously administered ibuprofen to which VANDERBILT holds title. VANDERBILT also
represents and warrants that it has full right, title, and authority to enter into this Agreement
and that VANDERBILT is not under any obligation resulting from any contract or arrangement, to any
person, firm, or corporation, which is inconsistent or in conflict with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.2 (a)&nbsp;LICENSEE shall indemnify, defend and hold harmless VANDERBILT and its trustees, officers,
faculty, staff, employees, students, agents and representatives, and their respective successors,
heirs and assigns (the &#147;Indemnities&#148;), against any liability, damage, loss or expenses (including
reasonable attorneys&#146; fees and expense of litigation) incurred by or imposed upon the Indemnities
or any one of them in connection with any claims, suits, actions, demands, or judgments arising out
of any theory of law (including, but not limited
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to, actions in the form of tort, warranty, or strict liability) arising from LICENSEE&#146;s use of the
Data pursuant to any right or license granted under this Agreement. Such indemnity obligation
shall include claims and expenses related to infringement of a third party&#146;s rights by the Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;LICENSEE agrees, at its own expense, to provide attorneys reasonably acceptable to
VANDERBILT to defend against any actions brought or filed against any party indemnified hereunder
with respect to the subject of indemnity contained herein, whether or not such actions are
rightfully brought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;VANDERBILT shall indemnify, defend and hold harmless LICENSEE and its officers, directors,
employees, agents, and shareholders, notwithstanding termination of this Agreement, against any
liability, damage, loss, or expenses (including reasonable attorney&#146;s fees) incurred by or imposed
in connection with any claims, suits, actions, demands or judgments arising out of any theory of
law (including, but not limited to, actions in the form of tort, warranty, or strict liability)
arising from default under any provision of this Agreement by VANDERBILT.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.3 VANDERBILT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND EXPRESS OR IMPLIED,
OTHER THAN AS EXPRESSLY STATED HEREIN. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT USE OF A PRODUCT WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.4 Regarding the indemnity and hold harmless provisions, under Paragraph&nbsp;8.2, VANDERBILT shall
give prompt written notice to LICENSEE of the commencement of any action, suit, or proceeding for
which indemnification may be sought, and LICENSEE, through counsel reasonably satisfactory to
VANDERBILT shall assume the defense thereof; provided, however, that VANDERBILT shall be entitled
to participate in any such action, suit, or proceeding with counsel of its own choice, but at its
own expense. If LICENSEE fails to assume the defense within ninety (90)&nbsp;days of receipt of written
notice of the action, suit, or proceeding, VANDERBILT may assume such defense and the reasonable
fees and expenses of its attorneys will be covered by the indemnity provided for in Paragraph&nbsp;8.2.
No such action, suit, or proceeding shall be compromised or settled in any manner which might
adversely affect the interests of VANDERBILT without the prior written consent of VANDERBILT.
Notwithstanding anything in this Paragraph to the contrary, LICENSEE shall not, without the written
consent of VANDERBILT, which consent shall not be unreasonably withheld:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Settle or compromise any action, suit, or proceeding or consent to the entry of any
judgment which does not include as an unconditional term thereof the delivery by the claimant or
plaintiff to VANDERBILT of a written release from all liability in respect of such action, suit, or
proceeding; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Settle or compromise any action, suit, or proceeding in any manner which may adversely
affect VANDERBILT.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.5 <U>Insurance</U>. (a)&nbsp;Beginning at the time as any Product is being commercially distributed
or sold by LICENSEE or agent of LICENSEE, LICENSEE or such other, shall make commercially
reasonable efforts to procure and maintain comprehensive general product liability and tort
liability insurance in amounts not less than $5,000,000 per incident and $5,000,000 annual
aggregate and name the Indemnities as additional insureds. Such comprehensive general liability
insurance shall provide (i)&nbsp;product liability coverage and (ii)&nbsp;broad form contractual liability
coverage for LICENSEE&#146;s indemnification under this Agreement. If LICENSEE elects to self-insure or
otherwise finds it necessary to self-insure all or part of the limits described above, such
self-insurance program must be reasonably acceptable to VANDERBILT. LICENSEE agrees that no amount
greater than the sum of $250,000 shall be deductible under LICENSEE&#146;s primary coverage for
VANDERBILT and LICENSEE against any claims or suits arising from alleged defects in Products. The
minimum amounts of insurance coverage required shall not be construed to create or limit LICENSEE&#146;s
liability with respect to its indemnification under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;LICENSEE represents and warrants that it will make commercially reasonable efforts to
acquire its product liability and general tort liability is of the occurrence-based rather than
claims-made type. Within thirty (30)&nbsp;day after the date of the first commercial sale of a Product
hereunder, LICENSEE shall provide VANDERBILT with a certificate or certificates of insurance
evidencing that VANDERBILT has been named as an additional insured party and evidencing the
insurer(s) is required to notify VANDERBILT in writing at least thirty (30)&nbsp;days in advance of any
termination of the policy or certificate, or any modification that would cause LICENSEE no longer
to be in compliance with the provisions of this Article, or would cause the representation and
warranties set forth above in this Article no longer to be true, such written notification to
specify the reason for such termination, the nature of the proposed modification, as the case may
be. It is expressly agreed by the parties that the provisions of this Article regarding insurance
shall in no way limit LICENSEE&#146;s indemnity obligations, except to the extent that LICENSEE&#146;s
insurer(s) actually pays VANDERBILT amounts for which VANDERBILT is entitled to be indemnified
under this Agreement, nor shall VANDERBILT have any obligation to pursue any insurer as a
precondition to its rights to be indemnified by LICENSEE. As used in this Article, the term
&#147;VANDERBILT&#148; shall include VANDERBILT, and its officers, directors, agents and employees. If
LICENSEE does not make commercially reasonable efforts to obtain replacement insurance within such
thirty (30)&nbsp;day period specified above, VANDERBILT shall have the right to terminate this Agreement
effective at the end of such thirty (30)&nbsp;day period without notice or any additional waiting
periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;LICENSEE shall maintain such comprehensive general product liability and tort liability
insurance or self-insurance beyond the expiration or termination of this Agreement during (i)&nbsp;the
period that any product relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold by LICENSEE or agent of LICENSEE and (ii)&nbsp;a period not less than the statute of
limitations for product liability claims in the state in which the product is being used.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>9. USE OF VANDERBILT&#146;S NAME</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.0 LICENSEE agrees not to identify VANDERBILT or to use the name of VANDERBILT, its faculty,
employees, or students, or any trademark, service mark, trade name, or symbol of VANDERBILT, or
that is associated with any of them, in promotional advertising or other similar materials without
VANDERBILT&#146;s written consent, except as required by governmental authority. LICENSEE may, without
prior consent, refer to VANDERBILT as LICENSOR of the Data submitted in support of marketing
approval for Product in a business plan, fund raising material or the like. All other uses of
VANDERBILT&#146;s name shall be made only after prior approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.1 VANDERBILT agrees not to identify LICENSEE or to use the name of LICENSEE&#146;s officers,
employees, or any trademark, service mark, trade name or symbol of LICENSEE without the written
consent of LICENSEE, except as may be required by governmental authority or as necessary in the
normal course of VANDERBILT&#146;S business operations.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>10. TERMS AND CONDITIONS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10. <U>Manner of Payment</U>. All payments hereunder shall be made by check to VANDERBILT. Where
required to do so by applicable law or treaty, LICENSEE shall withhold taxes required to be paid
to a taxing authority on account of such income to VANDERBILT, and LICENSEE shall furnish
VANDERBILT with satisfactory evidence of such withholding and payment in order to permit
VANDERBILT to obtain a tax credit or other relief as may be available under the applicable law or
treaty.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.1 <U>Provisions Contrary to Law</U>. In performing this Agreement, the parties shall comply
with all applicable laws and regulations. In particular, it is understood and acknowledged that
the transfer of certain commodities and technical data is subject to United States laws and
regulations controlling the export of such commodities and technical data, including all Export
Administration Regulations of the United States Department of Commerce. These laws and regulations
among other things, prohibit or require a license for the export of certain types of technical
data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it
will comply with all United States laws and regulations controlling the export of commodities and
technical data, that it will be solely responsible for any violation of such by LICENSEE or its
Affiliates, and that it will defend and hold VANDERBILT harmless in the event of any legal action
of any nature occasioned by such violation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Nothing in this Agreement shall be construed so as to require the violation of any law, and
wherever there is any conflict between any provision of this Agreement and any law the law shall
prevail, but in such event the affected provision of this Agreement shall be affected only to the
extent necessary to bring it within the applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.2 <U>Notices</U>. Any notice may be initially given by facsimile with confirmation required or
permitted to be given by this License by postpaid, first class, registered or certified mail
addressed as set forth below unless changed by notice so given:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="53%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For LICENSEE:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">For VANDERBILT:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cumberland Pharmaceuticals Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Office of Technology Transfer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">209 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. South, Suite&nbsp;332
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VANDERBILT University</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Nashville, Tennessee 37203
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1207 17<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Avenue, S., Suite&nbsp;210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 615-259-9085
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, TN 37212</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 615-343-4419</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">With a copy to:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Stokes &#038; Bartholomew, P.A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">424 Church Street, 28<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Nashville, Tennessee 37214</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attn: Martin S. Brown, Esq.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 615-259-1470</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Such notice shall be effective upon receipt by the party to whom notice is sent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.3 <U>Dispute Resolution</U>. The parties acknowledge and agree that they have entered into this
agreement with the expectation of a long-term, mutually beneficial relationship. However, should
disagreement arise regarding obligations imposed on the parties be this Agreement, it is agreed
that the parties will, in good faith, promptly attempt to reach an amicable resolution of such
disagreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.4 <U>Force Majeure</U>. Neither party to this License Agreement shall be liable for delay or
failure in the performance of any of its obligations hereunder if such delay or failure is due to
causes beyond its reasonable control, including, without limitation, acts of God, fires,
earthquakes, strikes, and labor disputes, acts of was, civil unrest, or intervention of any
governmental authority, but any such delay or failure shall be remedied by such party as soon as is
reasonably possible. Failure to make timely royalty payments shall not be excused by Force
Majeure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.5 <U>Assignments</U>. Except in connection with the sale of all or substantially all of the
assets of either party, this Agreement may not be assigned by either party without the prior
written consent of the other party, which consent shall not be unreasonably withheld. The parties
hereto agree that each is acting as an independent contractor and not as an agent of the other or
as joint ventures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.6 <U>Waivers and Modifications</U>. The failure of any party to insist on the performance of
any obligation hereunder shall not act as a waiver of such obligation. No waiver, modification,
release, or amendment of any obligation under this Agreement shall be valid or effective unless in
writing and signed by both parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.7 <U>Successors in Interest</U>. This Agreement shall inure to the benefit of and be binding on
the parties&#146; permitted assigns, successors in interest, and subsidiaries.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.8 <U>Choice of Law and Jurisdiction</U>. This Agreement is subject to and shall be construed
and enforced in accordance with the laws of the U.S.A., and Tennessee. Any action on any dispute
arising out of this Agreement shall be tried in Davidson County, and the parties consent to the
jurisdiction of the state and federal courts there.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.9 <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties
as to the subject matter hereof, and all prior negotiations, representations, agreements and
understandings are merged into, extinguished by and completely expressed by this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties have duly executed this Agreement on the date(s) written below.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">LICENSEE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">VANDERBILT UNIVERSITY</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ Larry R. Steranka
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Larry R. Steranka, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Office of Technology Transfer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">May&nbsp;28, 1999
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">June&nbsp;4, 1999</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ACKNOWLEDGED AND AGREED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gordon R. Bernard, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Professor of Medicine</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6/2/99</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>17
<FILENAME>g06286exv10w11.htm
<DESCRIPTION>EX-10.11 EMPLOYMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.11 EMPLOYMENT AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.11</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628600.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;31, 2007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;A.J. Kazimi<BR>
712 Overton Park<BR>
Nashville, Tennessee 37215

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Re: Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear A.J.:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective January 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2007, this letter agreement (the &#147;Agreement&#148;) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
&#147;Company&#148;). In consideration of your appointment as Chief Executive Officer of the Company, and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.&nbsp;<U>Compensation.</U> The Company agrees to compensate you as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of three hundred three thousand three hundred ninety dollars ($303,390.00), payable in arrears in
equal monthly installments on the last day of each calendar month during the term of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Company&#146;s overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;You have elected <U>not</U> to receive this year, as part of your 2007 compensation, an option
award to purchase Cumberland common shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(e)&nbsp;Except as set forth in Section&nbsp;2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Company&#146;s prior written consent to reimburse you for such
expense.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CUMBERLAND PHARMACEUTICALS INC.<BR>
2525 West End Avenue, Suite&nbsp;950 <B>&#149;</B> Nashville, Tennessee 37203 <B>&#149;</B> Telephone: (615)&nbsp;255-0068 <B>&#149;</B> Facsimile: (615)&nbsp;255-0094
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>www.cumberlandpharma.com</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
A.J. Kazimi<BR>
Page 2.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.&nbsp;<U>Additional Payments</U>. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.&nbsp;<U>Employment at Will</U>. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections&nbsp;4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4.&nbsp;<U>Confidentiality</U>. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Company&#146;s business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Company&#146;s business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.&nbsp;<U>Discoveries and Improvements</U>. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you, alone or with others, that relate in any way to the Company&#146;s present or
planned business or products (collectively the &#147;Developments&#148;), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute &#147;Works for Hire&#148; (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.&nbsp;<U>Publication</U>. All documents and other writings produced by you during the period of
your employment, which relate to work you are doing or have done for the Company or to the business
of the Company or its affiliates, shall belong to the Company. You will not publish outside of the
Company any such writing without the prior written consent of the Board of Directors of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
A.J. Kazimi<BR>
Page 3.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.&nbsp;<U>Litigation</U>. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.&nbsp;<U>Competition</U>. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activity&#151;whether as owner,
stockholder, partner, officer, consultant, or otherwise&#151;involving a trademark, product, or process
that, in the opinion of the Company&#146;s President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Company&#146;s President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i)&nbsp;listed on a national securities
exchange, or (ii)&nbsp;having at least one hundred (100)&nbsp;stockholders shall not make you a &#147;stockholder&#148;
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term &#147;Affiliate&#148; shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.&nbsp;<U>Conflicting Contracts</U>. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
A.J. Kazimi<BR>
Page 4.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.&nbsp;<U>Solicitation</U>. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the
Company to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11.&nbsp;<U>Return of Documents</U>. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This
includes, but is not limited to, trade secrets, confidential information, knowledge, data or
know-how, and software containing such information, whether or not the documents are marked
&#147;Confidential.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12.&nbsp;<U>Remedies</U>. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Company&#146;s remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys&#146; fees, to enforce the provisions of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.&nbsp;<U>Debarment</U>. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14.&nbsp;<U>Notice</U>. Any notice required or permitted to be given under this Agreement shall
be sufficient if in writing and if sent by registered or certified mail to your residence or to
the Company&#146;s principal office in the case of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">15.&nbsp;<U>Waiver</U>. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
A.J. Kazimi<BR>
Page 5.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">16.&nbsp;<U>Entire Agreement</U>. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">17.&nbsp;<U>Governance</U>. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company&#146;s sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">18.&nbsp;<U>Enforceability</U>. In the event that any provision of this Agreement shall be held
by a court to be unenforceable, such provision will be enforced to the maximum extent permissible,
and the remaining portions of this Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">19.&nbsp;<U>Survival</U>. Notwithstanding any termination of your employment, this Agreement
shall survive and remain in effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter agreement may be signed in one or more counterparts, each of which shall be an
original and all of which will constitute one and the same instrument.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Sincerely yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">/s/ Jean W. Marstiller</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jean W. Marstiller</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Secretary</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Accepted as to all terms
and conditions as</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">of
the 7th of
February, 2007:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ A.J. Kazimi</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
A.J. Kazimi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>18
<FILENAME>g06286exv10w12.htm
<DESCRIPTION>EX-10.12 EMPLOYMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.12 EMPLOYMENT AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.12</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628600.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;31, 2007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mrs.&nbsp;Jean Marstiller<BR>
6251 Hillsboro Road<BR>
Nashville, TN 37215

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>Employment of Jean W. Marstiller as Senior Vice President, Administrative Services by
Cumberland Pharmaceuticals Inc.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Jeanie:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective January 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>,<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>2007, this letter agreement (the &#147;Agreement&#148;) will
evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals
Inc. (the &#147;Company&#148;). In consideration of your appointment as Senior Vice President,
Administrative Services of the Company, and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. <U>Compensation.</U> The Company agrees to compensate you as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred seventy thousand dollars ($170,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Company&#146;s overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;You will receive a grant of options, as set forth in <U>Exhibit&nbsp;A</U>, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(e)&nbsp;Except as set forth in Section&nbsp;2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Company&#146;s prior written consent to reimburse you for such
expense.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CUMBERLAND PHARMACEUTICALS INC.<BR>
2525 West End Avenue, Suite&nbsp;950 <B>&#149;</B> Nashville, Tennessee 37203 <B>&#149;</B> Telephone: (615)&nbsp;255-0068 <B>&#149;</B> Facsimile: (615)&nbsp;255-0094
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>www.cumberlandpharma.com</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Jean W. Marstiller<BR>
Page 2.

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. <U>Additional Payments</U>. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. <U>Employment at Will</U>. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections&nbsp;4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4. <U>Confidentiality</U>. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Company&#146;s business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Company&#146;s business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5. <U>Discoveries and Improvements</U>. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Company&#146;s present or
planned business or products (collectively the &#147;Developments&#148;), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute &#147;Works for Hire&#148; (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.
<U>Publication</U>.
All documents and
other writings
produced by you
during the period
of your employment,
which relate to
work you are doing
or have done for
the Company or to
the business of the
Company or its
affiliates, shall
belong to the
Company. You will
not publish outside
of the Company any
such writing
without the prior
written consent of
the Board of
Directors of
the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31,
2007<BR>
Jean W. Marstiller<BR>
Page 3.

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7. <U>Litigation</U>. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8. <U>Competition</U>. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activity&#151;whether as owner,
stockholder, partner, officer, consultant, or otherwise&#151;involving a trademark, product, or process
that, in the opinion of the Company&#146;s President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Company&#146;s President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i)&nbsp;listed on a national securities
exchange, or (ii)&nbsp;having at least one hundred (100)&nbsp;stockholders shall not make you a &#147;stockholder&#148;
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term &#147;Affiliate&#148; shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9. <U>Conflicting Contracts</U>. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Jean W. Marstiller<BR>
Page 4.

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10. <U>Solicitation</U>. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting
at the time of your termination, or a firm which you knew or had reason to know that the Company
was going to solicit business at the time you ceased to be employed by the Company. The
restriction set forth in the preceding sentence shall not apply if you have disclosed to the
Company in writing all the known facts relating to such solicitation and have received a release
in writing from the Board of Directors of the Company to engage in such solicitation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the
Company to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11. <U>Return of Documents</U>. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This
includes, but is not limited to, trade secrets, confidential information, knowledge, data or
know-how, and software containing such information, whether or not the documents are marked
&#147;Confidential.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12. <U>Remedies</U>. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Company&#146;s remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys&#146; fees, to enforce the provisions of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13. <U>Debarment</U>. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14. <U>Notice</U>. Any notice required or permitted to be given under this Agreement shall
be sufficient if in writing and if sent by registered or certified mail to your residence or to
the Company&#146;s principal office in the case of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">15. <U>Waiver</U>. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Jean W. Marstiller<BR>
Page 5.

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">16. <U>Entire Agreement</U>. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">17. <U>Governance</U>. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company&#146;s sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">18. <U>Enforceability</U>. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">19. <U>Survival</U>. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sincerely yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND PHARMACEUTICALS INC.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By: A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Accepted as to all terms and conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">as of the 7<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of February, 2007;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Jean W. Marstiller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Jean W. Marstiller
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Jean W. Marstiller<BR>
Page 6.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Option Agreement</U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s standard option agreement shall be forthcoming and shall incorporate the
following several terms:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to six thousand
(6,000) of its shares of common stock.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,500 options will vest on each 31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>
of December over the four-year period from 2007-2010.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share.</TD>
</TR>

</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have a term of ten years from grant date.</TD>
</TR>

</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon termination of employment, the employee will vest the number of options that
otherwise would have vested through the date of termination of employment including those
pro-rated to the actual percent of working time during the calendar year.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>19
<FILENAME>g06286exv10w13.htm
<DESCRIPTION>EX-10.13 EMPLOYMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.13 EMPLOYMENT AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.13</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628600.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;31, 2007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Leo Pavliv<BR>
707 Walcott Way<BR>
Cary, NC 27519

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Re: Employment of Leo Pavliv as Vice President, Operations by Cumberland Pharmaceuticals Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Leo:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective January 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2007, this letter agreement (the &#147;Agreement&#148;) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
&#147;Company&#148;). In consideration of your appointment as Vice President, Operations of the Company, and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.&nbsp;<U>Compensation.</U> The Company agrees to compensate you as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of two hundred eleven thousand dollars ($211,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Company&#146;s overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;You will receive a grant of options, as set forth in <U>Exhibit&nbsp;A</U>, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(e)&nbsp;Except as set forth in Section&nbsp;2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Company&#146;s prior written consent to reimburse you for such
expense.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CUMBERLAND PHARMACEUTICALS INC.<BR>
2525 West End Avenue, Suite&nbsp;950 <B>&#149;</B> Nashville, Tennessee 37203 <B>&#149;</B> Telephone: (615)&nbsp;255-0068 <B>&#149;</B> Facsimile: (615)&nbsp;255-0094
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>www.cumberlandpharma.com</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Leo Pavliv<BR>
Page 2.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.&nbsp;<U>Additional Payments</U>. During the term hereof, you shall be entitled to receive
prompt reimbursement for all reasonable and documented expenses incurred in the performance of
services in accordance with the expense reimbursement policy of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.&nbsp;<U>Employment at Will</U>. This Agreement is not intended to and shall not be understood in any
manner as affecting or modifying the at-will status of your employment with the Company. As an
at-will employee either you or the Company may terminated the employment relationship at any time
with or without cause or notice. The obligations of Sections&nbsp;4, 5, 6, 7, 8, 10, 11 and 12 herein
shall survive the termination of the employment relationship or of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4.&nbsp;<U>Confidentiality</U>. All knowledge and information, not already available to the public,
which you acquire, have acquired, or will acquire in the course of your employment with the Company
with respect to the Company&#146;s business, work methods, or pending regulatory matters, or other
Company matters that are treated by the Company as confidential, shall be regarded by you as trade
secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you
as strictly confidential. Such knowledge and information shall not either directly or indirectly be
used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course
of the Company&#146;s business under circumstances in which you are authorized to use or disclose such
information. No disclosures of such confidential information shall be made outside of those you are
authorized to make in the regular and ordinary course of your duties unless and until you receive
prior written permission of the Board of Directors of the Company to make such disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.&nbsp;<U>Discoveries and Improvements</U>. During the time that you are employed by the Company, all
confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Company&#146;s present or
planned business or products (collectively the &#147;Developments&#148;), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute &#147;Works for Hire&#148; (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.<BR>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.&nbsp;<U>Publication</U>.
All documents and
other writings
produced by you
during the period
of your employment,
which relate to
work you are doing
or have done for
the Company or to
the business of the
Company or its
affiliates, shall
belong to the
Company. You will
not publish outside
of the Company any
such writing
without the prior
written consent of
the Board of
Directors of
the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Leo Pavliv<BR>
Page 3.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.&nbsp;<U>Litigation</U>. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.&nbsp;<U>Competition</U>. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activity&#151;whether as owner,
stockholder, partner, officer, consultant, or otherwise&#151;involving a trademark, product, or process
that, in the opinion of the Company&#146;s President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Company&#146;s President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i)&nbsp;listed on a national securities
exchange, or (ii)&nbsp;having at least one hundred (100)&nbsp;stockholders shall not make you a &#147;stockholder&#148;
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term &#147;Affiliate&#148; shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.&nbsp;<U>Conflicting Contracts</U>. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Leo Pavliv<BR>
Page 4.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.&nbsp;<U>Solicitation</U>. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11.&nbsp;<U>Return of Documents</U>. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked &#147;Confidential.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12.&nbsp;<U>Remedies</U>. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Company&#146;s remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys&#146; fees, to enforce the provisions of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.&nbsp;<U>Debarment</U>. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14.&nbsp;<U>Notice</U>. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Company&#146;s principal office in the case of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">15.&nbsp;<U>Waiver</U>. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007
<BR>
Leo Pavliv
<BR>
Page 5.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">16.&nbsp;<U>Entire Agreement</U>. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">17.&nbsp;<U>Governance</U>. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company&#146;s sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">18.&nbsp;<U>Enforceability</U>. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">19.&nbsp;<U>Survival</U>. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Sincerely yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Accepted as to all terms and conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">as of the 14<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of February, 2007:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Leo Pavliv</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Leo Pavliv
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
Leo Pavliv<BR>
Page 6.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Option Agreement</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s standard option agreement shall be forthcoming and shall incorporate the
following several terms:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to six thousand
(6,000) of its shares of common stock.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,500 options will vest on each 31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>
of December over the four-year period from 2007-2010.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have a term of ten years from grant date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon termination of employment, the employee will vest the number of options that otherwise
would have vested through the date of termination of employment including those pro-rated to
the actual percent of working time during the calendar year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>20
<FILENAME>g06286exv10w14.htm
<DESCRIPTION>EX-10.14 EMPLOYMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.14 EMPLOYMENT AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.14</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628600.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;23, 2007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;James William Hix<BR>
127 Abigail Avenue<BR>
Murfreesboro, TN 37129

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Re: Employment of Bill Hix as VP, Sales and Marketing by Cumberland Pharmaceuticals Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Bill:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective February 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2007, this letter agreement (the &#147;Agreement&#148;) will evidence the
terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the
&#147;Company&#148;). In consideration of your appointment as Vice President, Sales and Marketing of the
Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.&nbsp;<U>Compensation.</U> The Company agrees to compensate you as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred eighty thousand dollars ($180,000.00), payable in arrears in equal monthly
installments on the last day of each calendar month during the term of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;You may be eligible for any Company bonus program, with a potential annual bonus of up to
$45,000.00, based upon performance in meeting your individual objectives and the Company&#146;s overall
performance, both as determined and approved by the Board of Directors of the Company. Any such
bonus will be discretionary and will be subject to the terms of the applicable bonus program, the
terms of which program may be modified from year to year in the sole discretion of the Company&#146;s
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;You
will receive a grant of options, as set forth in <U>Exhibit&nbsp;A</U>, to purchase Cumberland common
shares pursuant to an option agreement. Such options will be subject to the option agreement and
the terms set forth in the option plan under which they are awarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(e)&nbsp;Except as set forth in Section&nbsp;2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Company&#146;s prior written consent to reimburse you for such
expense.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CUMBERLAND PHARMACEUTICALS INC.<BR>
2525 West End Avenue, Suite&nbsp;950 <B>&#149;</B> Nashville, Tennessee 37203 <B>&#149;</B> Telephone: (615)&nbsp;255-0068 <B>&#149;</B> Facsimile: (615)&nbsp;255-0094
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>www.cumberlandpharma.com</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;23, 2007<BR>
James William Hix<BR>
Page 2.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.&nbsp;<U>Additional Payments</U>. During the term hereof, you shall be entitled to
receive prompt reimbursement for all reasonable and documented expenses incurred in the performance
of services in accordance with the expense reimbursement policy of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.&nbsp;<U>Employment at Will</U>. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections&nbsp;4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4.&nbsp;<U>Confidentiality</U>. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Company&#146;s business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Company&#146;s business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.&nbsp;<U>Discoveries and Improvements</U>. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Company&#146;s present or
planned business or products (collectively the &#147;Developments&#148;), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute &#147;Works for Hire&#148; (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.&nbsp;<U>Publication</U>. All documents and other writings produced by you during the period of
your employment, which relate to work you are doing or have done for the Company or to the business
of the Company or its affiliates, shall belong to the Company. You will not publish outside of the
Company any such writing without the prior written consent of the Board of Directors of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;23, 2007<BR>
James William Hix<BR>
Page 3.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.&nbsp;<U>Litigation</U>. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.&nbsp;<U>Competition</U>. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activity&#151;whether as owner,
stockholder, partner, officer, consultant, or otherwise&#151;involving a trademark, product, or process
that, in the opinion of the Company&#146;s President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Company&#146;s President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i)&nbsp;listed on a national securities
exchange, or (ii)&nbsp;having at least one hundred (100)&nbsp;stockholders shall not make you a &#147;stockholder&#148;
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term &#147;Affiliate&#148; shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.&nbsp;<U>Conflicting Contracts</U>. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;23, 2007<BR>
James William Hix<BR>
Page 4.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.&nbsp;<U>Solicitation</U>. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11.&nbsp;<U>Return of Documents</U>. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked &#147;Confidential.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12.&nbsp;<U>Remedies</U>. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Company&#146;s remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys&#146; fees, to enforce the provisions of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.&nbsp;<U>Debarment</U>. You represent and warrant that you have not been debarred and will
notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the
Federal Food, Drug, and Cosmetic Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14.&nbsp;<U>Notice</U>. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Company&#146;s principal office in the case of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">15.&nbsp;<U>Waiver</U>. The waiver by either party of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;23, 2007<BR>
James William Hix<BR>
Page 5.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">16.&nbsp;<U>Entire Agreement</U>. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">17.&nbsp;<U>Governance</U>. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company&#146;s sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">18.&nbsp;<U>Enforceability</U>. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">19.&nbsp;<U>Survival</U>. Notwithstanding any termination of your employment, this Agreement
shall survive and remain in effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Sincerely yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Accepted as to all terms and conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">as of the 23<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> of January, 2007:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ James William Hix</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
James William Hix
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;23, 2007<BR>
James William Hix<BR>
Page 6.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Option Agreement</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s standard option agreement shall be forthcoming and shall incorporate the
following several terms:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to five thousand
(5,000) of its shares of common stock.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,250 options will vest on each 31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>
of December over the four-year period from 2007-2010.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have a term of ten years from grant date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon termination of employment, the employee will vest the number of options that
otherwise would have vested through the date of termination of employment including those
pro-rated to the actual percent of working time during the calendar year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>21
<FILENAME>g06286exv10w15.htm
<DESCRIPTION>EX-10.15 EMPLOYMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.15 EMPLOYMENT AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.15</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628600.gif" alt="(CUMBERLAND PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;31, 2007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;David L. Lowrance<BR>
422 William Wallace Drive<BR>
Franklin, TN 37064

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>Employment of David L. Lowrance as Vice President, Finance and Accounting by
Cumberland Pharmaceuticals Inc.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Dave:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective January 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2007, this letter agreement (the &#147;Agreement&#148;) will evidence
the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc.
(the &#147;Company&#148;). In consideration of your appointment as Vice President, Finance and Accounting
of the Company, and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.&nbsp;<U>Compensation.</U> The Company agrees to compensate you as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;The Company agrees to pay you on a salary basis for services performed, based on an annual rate
of one hundred fifty-eight thousand four hundred dollars ($158,400.00), payable in arrears in equal
monthly installments on the last day of each calendar month during the term of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You will be eligible to participate in any Company-wide employee benefits as approved by the
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;You may be eligible for any Company bonus program, based upon performance in meeting your
individual objectives and the Company&#146;s overall performance, both as determined and approved by the
Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the
terms of the applicable bonus program, the terms of which program may be modified from year to year
in the sole discretion of the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;You will receive a grant of options, as set forth in <U>Exhibit&nbsp;A</U>, to purchase Cumberland
common shares pursuant to an option agreement. Such options will be subject to the option agreement
and the terms set forth in the option plan under which they are awarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(e)&nbsp;Except as set forth in Section&nbsp;2, the Company shall not be liable to you for any expense
incurred by you unless you receive the Company&#146;s prior written consent to reimburse you for such
expense.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CUMBERLAND PHARMACEUTICALS INC.<BR>
2525 West End Avenue, Suite&nbsp;950 <B>&#149;</B> Nashville, Tennessee 37203 <B>&#149;</B> Telephone: (615)&nbsp;255-0068 <B>&#149;</B> Facsimile: (615)&nbsp;255-0094
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>www.cumberlandpharma.com</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
David L. Lowrance<BR>
Page 2.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.&nbsp;<U>Additional Payments</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;During the term hereof, you shall be entitled to receive prompt reimbursement for all
reasonable and documented expenses incurred in the performance of Services in accordance with the
expense reimbursement policy of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Assuming you maintain an active license, the Company agrees to pay the following expenses
which are professional costs associated with your CPA: Tennessee Department of Revenue Professional
Privilege Tax, Continuing Professional Education (the Company will reimburse 32 hours of the 40
hours required per year), Tennessee Society of CPAs Annual Membership (excludes elective fees), and
the Tennessee State Board of Accounting License Fee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3.&nbsp;<U>Employment at Will</U>. This Agreement is not intended to and shall not be understood
in any manner as affecting or modifying the at-will status of your employment with the Company. As
an at-will employee either you or the Company may terminated the employment relationship at any
time with or without cause or notice. The obligations of Sections&nbsp;4, 5, 6, 7, 8, 10, 11 and 12
herein shall survive the termination of the employment relationship or of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4.&nbsp;<U>Confidentiality</U>. All knowledge and information, not already available to the
public, which you acquire, have acquired, or will acquire in the course of your employment with the
Company with respect to the Company&#146;s business, work methods, or pending regulatory matters, or
other Company matters that are treated by the Company as confidential, shall be regarded by you as
trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated
by you as strictly confidential. Such knowledge and information shall not either directly or
indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the
ordinary course of the Company&#146;s business under circumstances in which you are authorized to use or
disclose such information. No disclosures of such confidential information shall be made outside of
those you are authorized to make in the regular and ordinary course of your duties unless and until
you receive prior written permission of the Board of Directors of the Company to make such
disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.&nbsp;<U>Discoveries and Improvements</U>. During the time that you are employed by the Company,
all confidential information, trade secrets, or proprietary information and all other discoveries,
inventions, software programs, processes, methods and improvements that are conceived, developed,
or otherwise made by you , alone or with others, that relate in any way to the Company&#146;s present or
planned business or products (collectively the &#147;Developments&#148;), whether or not patentable or
subject to copyright protection and whether or not reduced to tangible form or reduced to practice,
shall be the sole property of the Company. You agree to disclose all Developments promptly, fully
and in writing to the Company. You agree to keep and maintain adequate and current dated and
witnessed written records of all such Developments, in the form of notes, sketches, drawings, or
reports, which records shall be promptly submitted to the Company and shall be and remain the
property of the Company at all times. You agree to assign, and hereby do assign, to, the Company
all your right, title and interest throughout the world in and to all Developments. You agree that
all Developments shall constitute &#147;Works for Hire&#148; (as such are defined under the U.S. Copyright
Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may
have in any Developments without any obligation on the part of the Company to pay royalties or any
other consideration to you for such Developments.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
David L. Lowrance<BR>
Page 3.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.&nbsp;<U>Publication</U>. All documents and other writings produced by you during the period
of your employment, which relate to work you are doing or have done for the Company or to the
business of the Company or its affiliates, shall belong to the Company. You will not publish
outside of the Company any such writing without the prior written consent of the Board of Directors
of the Company. You will, without further compensation, execute at any time (whether or not you are
still employed by the Company) all documents requested of you relating to the protection of such
rights, including the assignment of such rights to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.&nbsp;<U>Litigation</U>. You shall notify the Company within three business days if no longer
employed and immediately if still employed by the Company if you are contacted by any person
relating to any claim or litigation against the Company. You shall not communicate in any manner
with any person related to any claim or litigation against the Company without the prior consent of
the Board of Directors of the Company unless compelled to do so by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.&nbsp;<U>Competition</U>. For so long as you are employed by the Company or any Affiliate (as defined
below) and for a period of one year after you cease to be employed by the Company or any Affiliate,
you shall not, directly or indirectly, engage in any work or other activity&#151;whether as owner,
stockholder, partner, officer, consultant, or otherwise&#151;involving a trademark, product, or process
that, in the opinion of the Company&#146;s President, is similar to a trademark, product or process on
which you worked for the Company (or any Affiliate) or obtained knowledge about while working for
the Company at any time during the period of employment, if such work or other activity is then, or
reasonably expected to become, competitive with that of the Company (or any Affiliate). The
restriction in the preceding sentence shall not apply if you have disclosed to the Company in
writing all the known facts relating to such work or activity and have received a release in
writing from the Board of Directors of the Company allowing you to engage in such work or activity.
The Company&#146;s President shall have sole discretion to determine whether your work or activity for
another employer involves trademarks, products, or processes that are similar to trademarks,
products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or
less of the outstanding shares of stock of any company either (i)&nbsp;listed on a national securities
exchange, or (ii)&nbsp;having at least one hundred (100)&nbsp;stockholders shall not make you a &#147;stockholder&#148;
within the meaning of that term as used in this paragraph. For one year after you cease to work for
the Company, you will not engage in any work or activity that will cause you to inevitably disclose
to anyone not employed by the Company (or an Affiliate) any trade secret or confidential
information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall
limit the rights or remedies of the Company arising, directly or indirectly, from such competitive
employment, including, without limitation, claims based upon breach of fiduciary duty,
misappropriation, or theft of confidential information. The term &#147;Affiliate&#148; shall mean the Company
and any entity controlling, controlled by, or under common control with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.&nbsp;<U>Conflicting Contracts</U>. You represent and warrant that you are not now under any
obligation resulting from any contract or arrangement, to any person, firm, or corporation, which
is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are
not now under any obligation resulting from any contract or arrangement to any person, firm, or
corporation which would prevent, limit, or impair in any way the performance by you of your
obligations to the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
David L, Lowrance<BR>
Page 4.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.&nbsp;<U>Solicitation</U>. For a period of one year after you cease to be employed by
the Company (or a Company affiliate):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;You agree not to solicit, directly or indirectly, business related to the development or sales
of pharmaceutical products from any entity, organization, or person which is contracted with the
Company, which has been doing business with the Company or from which the Company was soliciting at
the time of your termination, or a firm which you knew or had reason to know that the Company was
going to solicit business at the time you ceased to be employed by the Company. The restriction set
forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all
the known facts relating to such solicitation and have received a release in writing from the Board
of Directors of the Company to engage in such solicitation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company
to work for you or another person, firm, corporation, or business in competition with, or
reasonably likely to become in competition with, the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11.&nbsp;<U>Return of Documents</U>. Upon termination of your employment for any reason, you shall
immediately return to the Company all documents and things belonging to the Company. This includes,
but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and
software containing such information, whether or not the documents are marked &#147;Confidential.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12.&nbsp;<U>Remedies</U>. You acknowledge that in the event of breach of this Agreement by you, actual
damages to the Company will be impossible to calculate, the Company&#146;s remedies at law will be
inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the
covenants contained in this Agreement may be specifically enforced through injunctive relief, but
such right to injunctive relief shall not preclude the Company from other remedies which may be
available to it. You further agree that should you fail to keep any of the promises made by you in
this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all
monies the Company is required to spend, including attorneys&#146; fees, to enforce the provisions of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">13.&nbsp;<U>Debarment</U>. You represent and warrant that you have not been debarred and will notify
the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal
Food, Drug, and Cosmetic Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14.&nbsp;<U>Notice</U>. Any notice required or permitted to be given under this Agreement shall be
sufficient if in writing and if sent by registered or certified mail to your residence or to the
Company&#146;s principal office in the case of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">15.&nbsp;<U>Waiver</U>. The waiver by either party of any provision of this Agreement shall not operate
or be construed as a waiver of any subsequent breach.<BR>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
David L. Lowrance<BR>
Page 5.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">16.&nbsp;<U>Entire Agreement</U>. This Agreement contains the entire agreement of the
parties and may not be changed orally, but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension, or discharge is sought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">17.&nbsp;<U>Governance</U>. This Agreement shall be governed by the laws of the State of
Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company&#146;s sole
option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">18.&nbsp;<U>Enforceability</U>. In the event that any provision of this Agreement shall be held by
a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and
the remaining portions of this Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">19.&nbsp;<U>Survival</U>. Notwithstanding any termination of your employment, this Agreement shall
survive and remain in effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter agreement may be signed in one or more counterparts, each of which shall be an original
and all of which will constitute one and the same instrument.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Sincerely yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Accepted as to all terms
and conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">as of the 20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of
February, 2007:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ David L. Lowrance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
David L. Lowrance
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;31, 2007<BR>
David L. Lowrance<BR>
Page 6.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Option Agreement</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s standard option agreement shall be forthcoming and shall incorporate the
following several terms:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms therein, the Company will provide a grant of options under its 1999
Stock Option Plan upon the Effective Date of the Agreement to purchase up to five thousand
(5,000) of its shares of common stock.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on your individual performance and the overall performance of the Company, and as
determined by the Board of Directors, up to 1,250 options will vest on each 31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>
of December over the four-year period from 2007-2010.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have an Exercise Price of twenty-two dollars ($22.00) per
share.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The options awarded will have a term of ten years from grant date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon termination of employment, the employee will vest the number of options that otherwise
would have vested through the date of termination of employment including those pro-rated to
the actual percent of working time during the calendar year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is important that, after you receive your option agreement and other related documents, you read
and understand the terms and conditions of the option agreement. The Company recommends that you
always seek guidance from your personal accountant or tax advisor prior to initiating any exercise
or action involving your option agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>22
<FILENAME>g06286exv10w17.htm
<DESCRIPTION>EX-10.17 1999 STOCK OPTION PLAN
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.17 1999 STOCK OPTION PLAN</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.17</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;) desires to establish a plan through
which the Company may award options to purchase the common stock of the Company, or the right to
receive compensation due to the increase in the value of the common stock of the Company, to
directors, officers, employees, and consultants of the Company and its affiliates;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company desires to grant options that qualify as &#147;incentive stock options&#148; within
the meaning of section 422 of the Internal Revenue Code of 1986, and options that are not so
qualified; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company intends that this stock option plan and the methods granted hereunder (i)
qualify as &#147;performance-based compensation&#148; described in section 162(m)(4)(C) of the Code, and (ii)
conform to the provisions of Rule&nbsp;16b-3 of the Securities Exchange Act of 1934, as amended;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the Company hereby establishes the Cumberland Pharmaceuticals Inc. 1999 Stock
Option Plan (the &#147;Plan&#148;), effective on the date of its adoption by the Board of Directors of the
Company:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I. DEFINITIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Affiliate</U>. A &#147;parent corporation,&#148; as defined in section 424(e) of the Code, or
&#147;subsidiary corporation,&#148; as defined in Section 424(f) of the Code, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Agreement</U>. A written agreement (including any amendment or supplement thereto)
between the Company or Affiliate and a Participant specifying the terms and conditions of an Option
granted to such Participant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Board</U>. The Board of Directors of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Code</U>. The Internal Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <U>Committee</U>. A committee composed of individuals who are designated by the Board as
the &#147;compensation committee&#148; or are otherwise designated to administer the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <U>Company</U>. Cumberland Pharmaceuticals Inc. and its successors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <U>Date of Exercise</U>. The date that the Company accepts tender of the Option exercise
price of an Incentive Option or Nonqualified Option, or accepts an election to exercise rights
under an SAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <U>Exchange Act</U>. The Securities Exchange Act of 1934, as amended.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <U>Fair Market Value</U>. On any given date, Fair Market Value shall be the mean between
the closing bid and the asked price of the Stock on the National Associations of Securities Dealers
Automated Quotations System (&#147;NASDAQ&#148;), or if no such quotation is listed on NASDAQ, the Fair
Market Value as determined and fixed by the Board; provided that in the case of Incentive Options,
Fair Market Value shall in no event be less than 100% of the fair market value of the stock on the
date of grant of such option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 <U>Incentive Option</U>. The right that is granted hereunder to a participant to
purchase from the Company a stated number of shares of Stock at the price set forth in an Agreement
and that is subject to certain provisions herein and to &#147;incentive stock options&#148; that are
described in Section&nbsp;422 of the Code. An Incentive Option, or a portion thereof, shall not be
invalid for failure to qualify under Section&nbsp;422 of the Code, but shall be treated as a
Nonqualified Option to the extent that it does not satisfy such conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <U>Nonqualified Option</U>. The right that is granted hereunder to a Participant to
purchase from the Company a stated number of shares of Stock at the price set forth in an
Agreement, but is not subject to the conditions of an Incentive Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 <U>Option</U>. The right that is granted hereunder to a Participant under the terms of
an Incentive Option, a Nonqualified Option or an SAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 <U>Participant</U>. A Board member, employee, consultant or advisor of the Company or of
an Affiliate who: either satisfies the requirements of Article&nbsp;IV and is selected by the Committee
to receive an Option, or receives an Option pursuant to a grant specified in this Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14 <U>Plan</U>. The Cumberland Pharmaceuticals Inc. 1999 Stock Option Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.15 <U>SAR</U>. A right to receive compensation hereunder calculated by reference to the
increase in the value of a certain number of shares of Stock from the date of an award, as
described in Section&nbsp;4.5. An SAR is an unfunded, unsecured promise of the Company to the
Participant. Unless otherwise stated in an Agreement, or unless the Committee in its discretion
honors the exercise of an SAR by issuing Stock, the holder of an SAR has no beneficial rights of
Stock ownership or to receive shares of Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.16 <U>Stock</U>. The common stock of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.17 <U>Ten Percent Shareholder</U>. An individual who owns more than 10% of the total
combined voting power of all classes of stock of the Company or an Affiliate at the time he is
granted an Incentive Option. For the purpose of determining if an individual is a Ten Percent
Shareholder, he shall be deemed to own any voting stock owned (directly or indirectly) by or for
his brothers and sisters (whether by whole or half blood), spouse, ancestors or lineal descendants
and shall be considered to own proportionately any voting stock owned (directly or indirectly) by
or for a corporation, partnership, estate or trust of which such individual is a shareholder,
partner or beneficiary.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II. PURPOSE OF PLAN</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Plan is to provide a performance incentive and to encourage stock ownership by
officers, directors, consultants and advisors of the Company and its Affiliates, and to align the
interests of such individuals with those of the Company, its Affiliates and its shareholders. It is
intended that Participants may acquire or increase their proprietary interests in the Company and
be encouraged to remain
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the employ or directorship of the Company or of its Affiliates. The proceeds received by the
Company from the sale of Stock pursuant to this Plan may be used for general corporate purposes.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III. ADMINISTRATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Administration of Plan</U>. The Plan shall be administered by the Committee. The
express grant in the Plan of any specific power to the Committee shall not be construed as limiting
any power or authority of the Committee. Any decision made or action taken by the Committee to
administer the Plan shall be final and conclusive. No member of the Committee shall be liable for
any act done in good faith with respect to this Plan or any Agreement or Option. The Company shall
bear all expenses of Plan administration. In addition to all other authority vested with the
Committee under the Plan, the Committee shall have complete authority to:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Interpret all provisions of this Plan;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prescribe the form of any Agreement and notice and manner for executing or
giving the same;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Make amendments to all Agreements;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Adopt, amend, and rescind rules for Plan administration; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Make all determinations it deems advisable for the administration of this Plan.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Authority to Grant Options</U>. The Committee shall have authority to grant Options
upon such terms the Committee deems appropriate and that are not inconsistent with the provisions
of this Plan. Such terms may include conditions on the exercise of all or any part of an Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Persons Subject to Section&nbsp;16(b)</U>. Notwithstanding anything in the Plan to the
contrary, the Committee, in its absolute discretion, may bifurcate the Plan so as to restrict,
limit or condition the use of any provision of the Plan to participants who are officers and
directors subject to Section 16(b) of the Exchange Act, without so restricting, limiting or
conditioning the Plan with respect to other Participants.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV. ELIGIBILITY AND LIMITATIONS ON GRANTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Participation</U>. The Committee may from time to time designate directors, employees,
consultants and advisors to whom Options are to be granted and who are eligible to become
Participants. Such designation shall specify the number of shares of Stock, if any, subject to each
Option. All Options granted under this Plan shall be evidenced by Agreements which shall be subject
to applicable provisions of this Plan or such other provisions as the Committee may adopt that are
not inconsistent with the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Grant of Options</U>. An Option shall be deemed to be granted to a Participant at the
time that the Committee designates in a writing that is adopted by the Committee as the grant of an
Option, and that makes reference to the name of the Participant and the number of shares of Stock
that are subject to the Option. Accordingly, an Option may be deemed to be granted prior to the
approval of this Plan by the shareholders of the Company and prior to the time that an Agreement is
executed by the Participant and the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Limitations on Grants</U>. A person who is not an employee of the Company or an
Affiliate is not eligible to receive an Incentive Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Limitation on Incentive Options</U>. To the extent that the aggregate Fair Market
Value of Stock with respect to which Incentive Options are exercisable for the first time by a
Participant during any calendar year (under all incentive stock option plans of the Company and its
Affiliates) exceeds $100,000 (or the amount specified in Section&nbsp;422 of the Code), determined as of
the date an Incentive Option is granted, such Options shall be treated as Nonqualified Options.
This provision shall be applied by taking Incentive Options into account in the order in which they
were granted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Stock Appreciation Rights</U>. The Committee may grant an SAR to a Participant either
in tandem with the grant of an Incentive Option or a Nonqualified Option, or as an award that is
separate from any other Option granted under the Plan. Subject to the terms of an Agreement, a
Participant who receives an SAR shall have the right, upon written request, to surrender any
exercisable Incentive Option or Nonqualified Option, or portion thereof, in exchange for cash,
whole shares of Stock, or a combination thereof, as determined by the Committee, with a value equal
to the excess of the Fair Market Value, as of the date of such request, of one share of Stock over
the Fair Market Value of the Stock on the Date of Grant (or such other value specified in the
Agreement), multiplied by the number of shares covered by the SAR or portion thereof to be
surrendered. In the case of any SAR which is granted in connection with an Incentive Stock Option,
such SAR shall be exercisable only when the Fair Market Value of the Stock exceeds the price
specified therefor in the SAR or portion thereof to be surrendered. In the event of the exercise of
any SAR granted hereunder, the number of shares reserved for issuance under the Plan shall be
reduced only to the extent that shares of Stock are actually issued in connection with the exercise
of such SAR. Additional terms and conditions governing any such SARs may from time to time be
prescribed by the Committee in its sole discretion.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V. STOCK SUBJECT TO PLAN</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Source of Shares</U>. Upon the exercise of an Incentive Option or Nonqualified Option,
the Company shall deliver to the Participant authorized but unissued Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Maximum Number of Shares</U>. The maximum aggregate number of shares of Stock that may
be issued under the Plan pursuant to the exercise of Incentive Options and Nonqualified Options, or
with respect to which SARs may be exercised, is 5,000,000, subject to increases and adjustments as
provided in this Article&nbsp;V and Article&nbsp;VIII hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Forfeitures</U>. If any Option granted hereunder expires or terminates for any reason
without having been exercised in full, the unpurchased shares subject thereto shall again be
available for issuance under this Plan.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI. EXERCISE OF OPTIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Exercise Price</U>. The exercise price of an Incentive Option shall be not less than
100% of the Fair Market Value of a share of Stock on the date the Incentive Option is granted. In
the case of a Ten Percent Shareholder, however, the exercise price of an Incentive Option shall not
be less than 110% of the Fair Market Value of a share of Stock on the date the Incentive Option is
granted. The exercise price of a Nonqualified Option or an SAR shall be the price determined by the
Committee at the time the Nonqualified Option or SAR is granted. If the exercise price of an Option
is changed after the date it is granted, such change shall be deemed to be a termination of the
existing Option and the issuance of a new Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Right to Exercise</U>. An Option shall be exercisable on the date of grant or any
other date established by the Committee or provided for in the agreement; provided, however, that
Options granted to officers or directors subject to Section&nbsp;16 of the Exchange Act must not be
exercisable until at least six months after the Option is granted. A Participant must exercise an
Incentive Option while he is an employee of the Company or an Affiliate or within the periods that
may be specified in the Agreement after termination of employment, death, disability, or a &#147;change
of control&#148; (as defined in any change of control agreement to which the Company and any such
Participant are parties).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Maximum Exercise Period</U>. The maximum period in which an Option may be exercised
shall be determined by the Committee on the date of grant except that no Incentive Option shall be
exercisable after the expiration of 10&nbsp;years (five years in the case of Incentive Options granted
to a Ten Percent Shareholder) from the date it was granted. The terms of any Option may provide
that it is exercisable for a shorter period. All Incentive Options shall terminate on the date that
the Participant&#146;s employment with the Company terminates, except as otherwise provided in the
Agreement with respect to termination of employment, death, disability or a &#147;change of control&#148; (as
defined in any change of control agreement to which the Company and any such Participant are
parties).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Transferability</U>. Any Option granted under this Plan shall not be transferable
except by will or by the laws of descent and distribution, and shall be exercisable during the
lifetime of the Participant only by the Participant; provided, however, that any Nonqualified
Option granted under this Plan may be transferable to the extent provided in an Agreement. No right
or interest of a Participant in any Option shall be liable for, or subject to, any lien, obligation
or liability of such Participant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Employee Status</U>. The Committee shall determine the extent to which a leave of
absence for military or government service, illness, temporary disability, or other reasons shall
be treated as a termination or interruption of employment for purposes of determining questions of
forfeiture and exercise of an Option after termination of employment; provided, however, that if
the period treated as employment with respect to an Incentive Plan exceeds 90&nbsp;days, such Option
shall be deemed a Nonqualified Option.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII. METHOD OF EXERCISE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Exercise</U>. An Option granted hereunder shall be deemed to have been exercised on
the Date of Exercise. Subject to the provisions of Articles VI, VIII and IX, an Option may be
exercised in whole or in part at such times and in compliance with such requirements as the
Committee shall determine.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Payment</U>. Unless otherwise provided by the Agreement, payment of the Option price
shall be made in cash or to the extent approved by the Committee, Stock that was acquired prior to
the exercise of the Option, other consideration acceptable to the Committee, or a combination
thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Federal Withholding Tax Requirements</U>. Upon exercise of a Nonqualified Option or an
SAR by a Participant who is an employee of the Company or an Affiliate, the Participant shall, upon
notification of the amount due and prior to or concurrently with the delivery of the certificates
representing the shares, pay to the Company amounts necessary to satisfy applicable federal, state
and local withholding tax requirements or shall otherwise make arrangements satisfactory to the
Company for such requirements. Such withholding requirements shall not apply to the exercise of an
Incentive Option, or to a disqualifying disposition of Stock that is acquired with an Incentive
Option, unless the Committee gives the Participant notice that withholding described in this
Section is required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Shareholder Rights</U>. No Participant shall have any rights as a stockholder with
respect to shares subject to his Option prior to the Date of Exercise of such Option. No
Participant shall acquire rights as a stockholder through the grant or exercise of an SAR, except
to the extent which the Committee, in its sole discretion, issues Stock to the Participant as
payment upon the exercise of the SAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <U>Issuance and Delivery of Shares</U>. Shares of Stock issued pursuant to the exercise
of Options hereunder shall be delivered to Participants by the Company as soon as administratively
feasible after a Participant exercises an Option hereunder and executes any applicable shareholder
agreement or agreement described in Section&nbsp;9.2 that the Company requires at the time of exercise.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII. ADJUSTMENT UPON CORPORATE CHANGES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Adjustments to Shares</U>. The maximum number of shares of stock with respect to which
Options hereunder may be granted and which are the subject of outstanding Options shall be adjusted
as the Committee determines (in its sole discretion) to be appropriate, in the event that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company or an Affiliate effects one or more stock dividends, stock splits,
reverse stock splits, subdivisions, consolidations, capitalization issue, rights issue
or other similar events;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company or an Affiliate engages in a transaction to which section 424 of
the Code applies; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there occurs any other event which in the judgment of the Committee
necessitates such action;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provided, however, that if an event described in paragraph (a)&nbsp;or (b)&nbsp;occurs, the Committee shall
make adjustments to the limits on Options specified in Section&nbsp;4.3 that are proportionate to the
modifications of the Stock that are on account of such corporate changes. Notwithstanding the
foregoing, the Committee may not modify the Plan or the terms of any Options then outstanding or to
be granted hereunder to provide for the issuance under the Plan of a different class of stock or
kind of securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Substitution of Options on Merger or Acquisition</U>. The Committee may grant Options in
substitution for stock awards, stock options, stock appreciation rights or similar awards held by
an individual who becomes an employee of the Company or an Affiliate in connection with a
transaction to which Section
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">424(a) of the Code applies. The terms of such substituted Options shall be determined by the
Committee in its sole discretion, subject only to the limitations of Article&nbsp;V.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <U>Effect of Certain Transactions</U>. Upon a merger, consolidation, acquisition of
property or stock, separation, reorganization or liquidation of the Company, as a result of which
the shareholders of the Company receive cash, stock or other property in exchange for their shares
of Stock (but not a public offering of Stock by the Company), and the Company is not the surviving
entity, any Option granted hereunder shall terminate, provided that the Participant may have the
right immediately prior to any such merger, consolidation, acquisition of property or stock,
separation, reorganization or liquidation to exercise his Options in whole or in part, pursuant to
the vesting Schedule set forth in the applicable Agreement unless otherwise designated by the
Committee or unless the Committee elects to convert all Options hereunder into options to purchase
stock of an acquiring corporation. Provided, however, that, notwithstanding the foregoing, a
portion of the acceleration of exercisability of Options shall not occur with respect to any holder
to the extent that such portion of acceleration would cause the grantee or holder of such Option to
be liable for the payment of taxes pursuant to Section&nbsp;4999 of the Code. If the Committee so elects
to convert the Options, the amount and price of such converted options shall be determined by
adjusting the amount and price of the Options granted hereunder in the same proportion as used for
determining the number of shares of stock of the acquiring corporation the holders of the Stock
receive in such merger, consolidation, acquisition of property or stock, separation or
reorganization, and the vesting schedule set forth in the Agreement shall continue to apply to the
converted options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <U>No Adjustment Upon Certain Issuances</U>. The issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class, for cash or
property, or for labor or services rendered, either upon direct sale or upon the exercise of rights
or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company
convertible into such shares or other securities, shall not affect, and no adjustment by reason
thereof shall be made with respect to, outstanding Options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 <U>Fractional Shares</U>. Only whole shares of Stock may be acquired through the exercise
of an Option. Any amounts tendered in the exercise of an Option remaining after the maximum number
of whole shares have been purchased will be returned to the Participant.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX. COMPLIANCE WITH LAW AND APPROVAL OF<BR>
REGULATORY BODIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>General</U>. No option shall be exercisable, no Stock shall be issued, no certificates
for shares of Stock shall be delivered, and no payment shall be made under this Plan except in
compliance with all federal or state laws and regulations (including, without limitation,
withholding tax requirements), federal and state securities laws and regulations and the rules of
all securities exchanges or self-regulatory organizations on which the Company&#146;s shares may be
listed. The Company shall have the right to rely on an opinion of its counsel as to such
compliance. Any certificate issued to evidence shares of Stock for which an Option is exercised may
bear such legends and statements as the Committee upon advice of counsel may deem advisable to
assure compliance with federal or state laws and regulations. No Options shall be exercisable, no
Stock shall be issued, no certificate for shares shall be delivered and no payment shall be made
under this Plan until the Company has obtained such consent or approval as the Committee may deem
advisable from any regulatory bodies having jurisdiction over such matters.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Representations by Participants</U>. As a condition to the exercise of an Option, the
Company may require a Participant to represent and warrant the time of any such exercise that the
shares are being purchased only for investment and without any present intention to sell or
distribute such shares, if, in the opinion of counsel for the Company, such representation is
required by any relevant provision of the laws referred to in Section&nbsp;9.1. At the option of the
Company, a stop transfer order against any shares of stock may be placed on the official stock
books and records of the Company, and a legend indicating that the stock may not be pledged, sold
or otherwise transferred unless an opinion of counsel was provided (concurred in by counsel for the
Company) and stating that such transfer is not in violation of any applicable law or regulation may
be stamped on the stock certificate in order to assure exemption from registration. The Committee
may also require such other action or agreement by the Participants as may from time to time be
necessary to comply with federal or state securities laws. This provision shall not obligate the
Company or any Affiliate to undertake registration of Options or stock hereunder.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X. GENERAL PROVISIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Effect on Employment</U>. Neither the adoption of this Plan, its operation, nor any
documents describing or referring to this Plan (or any part thereof) shall confer upon any employee
any right to continue in the employ of the Company or an Affiliate or in any way affect any right
and power of the Company or an Affiliate to terminate the employment of any employee at any time
with or without assigning a reason therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Unfunded Plan</U>. The Plan, insofar as it provides for grants, shall be unfunded,
and the Company shall not be required to segregate any assets that may at any time be represented
by grants under this Plan. Any liability of the Company to any person with respect to any grant
under this Plan shall be based solely upon contractual obligations that may be created hereunder.
No such obligation of the Company shall be deemed to be secured by any pledge of, or other
encumbrance on, any property of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <U>Rules of Construction</U>. Headings are given to the articles and sections of this
Plan solely as a convenience to facilitate reference. The masculine gender when used herein refers
to both masculine and feminine. The reference to any statute, regulation or other provision of law
shall be construed to refer to any amendment to or successor of such provision of law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 <U>Governing Law</U>. The laws of the State of Tennessee shall apply to all matters
arising under this Plan, to the extent that federal law does not apply.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 <U>Compliance With Section&nbsp;16 of the Exchange Act</U>. With respect to persons subject
to Section&nbsp;16 of the Exchange Act, transactions under this Plan are intended to comply with all
applicable conditions of Rule&nbsp;16b-3 or its successors under the Exchange Act. To the extent any
provision of this Plan or action by Committee fails to so comply, it shall be deemed null and void
to the extent permitted by law and deemed advisable by the Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6 <U>Amendment</U>. The Board may amend or terminate this Plan at any time; provided,
however, an amendment that would have a material adverse effect on the rights of a Participant
under an outstanding Option is not valid with respect to such Option without the Participant&#146;s
consent, except as necessary for Incentive Options to maintain qualification under the Code; and
provided, further, that the shareholders of the Company must approve, in general meeting prior to
the effective date of adoption, any amendment that:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes the number of shares in the aggregate which may be issued pursuant to Options
granted under the Plan or the maximum number of shares with respect to which any
individual may receive Options in any calendar year, except pursuant to Article&nbsp;VIII;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes the Participants (or class or Participants) eligible to receive Options
under the Plan;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increases the period during which Options may be granted or exercised;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reduces the exercise price of outstanding Incentive Options or reduces the
price at which future Incentive Options may be granted;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>alters the basis for determining a Participant&#146;s entitlement to and the terms
of Stock to be provided and for the adjustment thereof upon the occurrence of any event
specified in Section&nbsp;8.1 hereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>alters the Plan so that Options intended to qualify as Incentive Options under
the Code would not do so, or changes the provisions of this Section&nbsp;10.6.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, shareholder approval shall not be required for minor amendments
to the Plan pursuant to Section&nbsp;3.1 hereof intended to benefit the administration of the Plan, for
amendments necessitated by changes in legislation governing the Plan, or for amendments that the
Committee deems necessary to obtain or maintain favorable tax, exchange control or regulatory
treatment of the Plan for future Participants or for Participating Companies (as defined in
Schedule&nbsp;A hereto).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7 <U>Duration of Incentive Options.</U> No Incentive Option may be granted under this Plan
more than 10&nbsp;years after the earlier of the date that the Plan is adopted by the Board or the date
that the Plan is approved by shareholders as provided in Section&nbsp;10.8. Incentive Options granted
before such date shall remain valid in accordance with their terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8 <U>Effective Date of Plan.</U> This Plan shall be effective on the date of its adoption
by the Board, and Options may be granted hereunder at any time after such adoption; provided,
however, that the effectiveness of this Plan will be retroactively revoked if it is not approved by
the shareholders of the Company in a manner that satisfies Treasury Regulation&nbsp;Section&nbsp;1.422-5
within 12&nbsp;months of the date that the Board took action to adopt the Plan. All Options granted
under the Plan will become void immediately following the 12-month anniversary of the date the
Board adopted the Plan if such approval by shareholders has not yet been obtained.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>23
<FILENAME>g06286exv10w20.htm
<DESCRIPTION>EX-10.20 FORM OF INDEMNIFICATION AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.20 FORM OF INDEMNIFICATION AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.20</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INDEMNIFICATION AND HOLD HARMLESS AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS INDEMNIFICATION AND HOLD HARMLESS AGREEMENT </B>(this &#147;Agreement&#148;) is made as of March
<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>, 2007, by and between Cumberland Pharmaceuticals Inc., a Tennessee corporation (the
&#147;Company&#148;), and <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (&#147;Indemnitee&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, in order to incentivize Indemnitee to serve, or to continue to serve, as a director
of the Company (in any such case, the &#147;Service&#148;), the Company has agreed to indemnify Indemnitee as
set forth below;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE</B>, in consideration of the foregoing and certain other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties, intending to be legally
bound, hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Indemnification</U>. Effective as of the original date of Indemnitee&#146;s beginning
Service, the Company shall indemnify Indemnitee and hold Indemnitee harmless if Indemnitee is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative, arbitrative or investigative, and in any
appeal in such action, suit or proceeding, and in any inquiry or investigation that could lead to
such an action, suit or proceeding, against any and all liabilities, obligations (whether known or
unknown, or due or to become due or otherwise), judgments, fines, fees, penalties, interest
obligations, deficiencies, other actual losses (for example, verifiable lost income related to time
spent defending such claim or action) and reasonable expenses (including, without limitation
amounts paid in settlement, interest, court costs, costs of investigators, reasonable fees and
expenses of attorneys, accountants, financial advisors and other experts) incurred or suffered by
Indemnitee in connection with such action, suit or proceeding arising out of or pertaining to any
actual or alleged action or omission which arises out of or relates to the fact that Indemnitee is
or was serving as a director or officer of the Company or at the request of the Company as a
director, officer, trustee, employee, or agent of or in any other capacity for another corporation,
partnership, joint venture, trust or other enterprise, to the fullest extent permitted by then
applicable law and the Company&#146;s Charter and Bylaws, each as amended (but in the case of any such
amendment, only to the extent that such amendment permits the Company to provide the same or
broader indemnification rights than permitted prior thereto) (each such liability, obligation,
judgment, fine, fee, penalty, interest obligation, deficiency, other actual losses, and reasonable
expenses being referred to herein as a &#147;Loss,&#148; and collectively, as &#147;Losses&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Payment</U>. Any Loss incurred by Indemnitee shall be paid in full by the Company on
a regular, monthly basis. This indemnity applies even if Indemnitee caused the Loss through his or
her negligence, strict liability or other fault; however, if any Losses for which Indemnitee
received payment from the Company under this Agreement are determined by final judicial decision
from which there is no further right to appeal, to have been caused by Indemnitee under
circumstances with respect to which indemnification is not permitted by applicable law or this
Agreement (any such Loss, a &#147;Non-Indemnification Loss&#148;), Indemnitee shall repay to the Company such
Losses paid on behalf of Indemnitee hereunder.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Term</U>. The indemnification rights provided hereby to Indemnitee shall continue
even though he may have ceased to be a director, officer, trustee, employee, or agent of or in any
other capacity for the applicable entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Notice and Coverage Prior to Notice</U><I>. </I>Indemnitee shall give notice (the &#147;Notice&#148;)
to the Company within five days after actual receipt of service or summons related to any action
begun in respect of which indemnity may be sought hereunder or actual notice of assertion of a
claim with respect to which he seeks indemnification; provided, however, that Indemnitee&#146;s failure
to give such notice to the Company within such time shall not relieve the Company from any of its
obligations under Section&nbsp;1 of this Agreement except to the extent the Company has been materially
prejudiced by Indemnitee&#146;s failure to give such notice within such time period. Upon receipt of the
Notice, the Company shall assume the defense of such action, whereupon Indemnitee shall not be
liable for any reasonable fees or expenses of counsel for Indemnitee or any other Losses incurred
thereafter with respect to the matters set forth in the Notice and the Company shall reimburse
Indemnitee for all reasonable expenses related to the action or claim incurred by Indemnitee prior
to Indemnitee&#146;s giving of the Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Non-Exclusivity</U>. The rights of Indemnitee hereunder shall be in addition to any
rights that Indemnitee may have under the Company&#146;s governance documents (e.g. Charter, Bylaws,
etc.) (the &#147;Governance Documents&#148;), applicable law or otherwise and shall survive any termination,
resignation, death or other dismissal of Indemnitee. No amendment or alteration of the Company&#146;s
Governance Documents shall adversely affect Indemnitee&#146;s rights under the Governance Documents or
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Insurance</U>. To the extent the Company maintains, at its expense, an insurance
policy or policies providing liability insurance with respect to the acts or omissions covered by
this Agreement, Indemnitee shall be covered by such policy or policies, in accordance with its or
their terms, to the maximum extent of the coverage available thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Payment</U>. The Company shall not be liable to Indemnitee under this Agreement to
make any payment in connection with any claim against Indemnitee to the extent Indemnitee has
otherwise actually received, and is entitled to retain, payment (under any insurance policy or
otherwise) of the amounts otherwise indemnifiable hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Enforceability</U>. The indemnification contained in this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the parties hereto and their respective
successors, assigns (including any direct or indirect successor by purchase, merger, consolidation,
liquidation or otherwise to all or substantially all of the business and/or assets of the Company),
spouses, heirs and personal and legal representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Binding Obligation</U>. If this Agreement or any portion hereof shall be found to be
invalid on any ground by any court of competent jurisdiction, then the Company shall nevertheless
indemnify and hold harmless Indemnitee, as to costs, charges and expenses (including court costs
and attorneys&#146; fees), judgments, fines, penalties and amounts paid in settlement with respect to
any action, suit or proceeding, whether civil, criminal, administrative, arbitrative or
investigative, and in any appeal in such action, suit or proceeding, and in any inquiry or
investigation that could lead to such an action, suit or proceeding, to the full extent permitted
by any applicable portion of this Agreement that shall not have been invalidated and to the fullest
extent permitted by applicable law.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law; Venue</U>. This Agreement shall be construed in accordance with and
governed by the laws of the State of Tennessee, without regard to the principles of conflicts of
laws. The parties agree that any litigation directly or indirectly relating to this Agreement must
be brought before and determined by a court of competent jurisdiction within Davidson County,
Tennessee, and the parties hereby agree to waive any rights to object to, and hereby agree to
submit to, the jurisdiction of such courts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Right to Sue; Attorneys&#146; Fees and Costs</U>. If a claim by Indemnitee for payment of
Losses hereunder is not paid in full by the Company within forty-five (45)&nbsp;days after a written
claim has been delivered to the Company, Indemnitee may at any time thereafter bring suit against
the Company to recover the unpaid amount of the claim. If successful in whole or in part in any
such suit, Indemnitee shall be entitled to be paid also the reasonable costs and expenses of
prosecuting such suit. In any suit brought by Indemnitee to enforce any right hereunder (including,
without limitation, the right to indemnification), the burden of proving that Indemnitee is not
entitled to such right shall be borne by the Company. If a claim by the Company for repayment of
any Non-Indemnification Losses previously paid on behalf of Indemnitee hereunder is not repaid in
full to the Company within forty-five (45)&nbsp;days after such ruling has been delivered to Indemnitee,
the Company may at any time thereafter bring suit against Indemnitee to recover the unpaid amount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Amendment</U>. This Agreement may be amended, modified or supplemented only by a
written instrument executed by each of the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Facsimile and Counterpart Signature</U>. This Agreement may be executed by facsimile
signature and in one or more counterparts, each of which shall for all purposes be deemed an
original and all of which shall constitute the same instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the undersigned have executed this Agreement as of the date first above
written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">COMPANY</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND PHARMACEUTICALS INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">INDEMNITEE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">&#091;Insert Name&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>24
<FILENAME>g06286exv10w21.htm
<DESCRIPTION>EX-10.21 LEASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.21 LEASE AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.21</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>2525 WEST END</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OFFICE LEASE AGREEMENT</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BY AND BETWEEN</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>NASHVILLE HINES DEVELOPMENT, LLC<BR>
AS LANDLORD</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AND</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CUMBERLAND PHARMACEUTICALS INC.,<BR>
AS TENANT</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BASIC LEASE INFORMATION</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lease Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sept 10, 2005</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tenant:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address of Tenant:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue, Suite&nbsp;950</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Primary Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jean W. Marstiller</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Landlord:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville Hines Development, LLC</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address of Landlord:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Five Greenway Plaza</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Houston, Texas 77046</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: F. Russ Nicholson</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Leased Premises:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Approximately 6,341 square feet of RSF</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Located on Floor 9</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Commencement Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January&nbsp;1, 2006</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lease Term:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Five (5)&nbsp;years</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Base Rental:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Per <u>Exhibit&nbsp;G</u>. Initial monthly Base Rental is &#091;***&#093;.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Initial Allowance:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;***&#093; per square foot of RSF</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The foregoing Basic Lease Information is hereby incorporated into and made a part of the Lease
identified above. In the event of any conflict between any Basic Lease Information and the Lease,
the Lease shall control.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">PAGE</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.1. Leased Premises </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.2. Term</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.3. Use</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.4. Landlord&#146;s Relocation Right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.5. Surrender of Premises</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.6. Survival</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.1. Rental Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.2. Base Rental</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.3. Additional Rental</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.4. Operating Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.5. Security Deposit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.6. Landlord&#146;s Lien</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.1. Services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.2. Keys and Locks </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.3. Graphics, Building Directory and Name</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.4. Parking</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.1. Care of Leased Premises</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.2. Entry for Repairs and Inspection</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.3. Nuisance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.4. Laws and Regulations; Encumbrances; Rules of Building</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.5. Legal Use and Violations of Insurance Coverage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.6. Hazardous Substances </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.7. Tenant Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.1. Initial Allowance; Leasehold Improvements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.2. Repairs by Landlord</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.3. Repairs by Tenant</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.1. Condemnation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.2. Damages from Certain Causes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.3. Casualty Clause</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.4. Casualty Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.5. Liability Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.6. Hold Harmless</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.7. Waiver of Subrogation Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">PAGE</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.1. Default and Remedies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.2. Insolvency or Bankruptcy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.3. Late Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.4. Attorney&#146;s Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.5. Waiver of Homestead</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.6. No Waiver of Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.7. Holding Over</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.8. Subordination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.9. Estoppel Certificate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.1. Sublease or Assignment by Tenant</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.2. Assignment by Landlord</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.3. Peaceful Enjoyment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.4. Limitation of Landlord&#146;s Personal Liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.5. Force Majeure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.1. Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.2. Miscellaneous</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.3. Option to Renew</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SITE PLAN AND LOCATION OF THE BUILDING</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT A-1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DESCRIPTION OF LAND</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLOOR PLAN OF LEASED PREMISES</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AIR CONDITIONING AND HEATING SERVICES</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BUILDING RULES AND REGULATIONS</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT F
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;INTENTIONALLY DELETED&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT G
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BASE RENTAL</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXHIBIT H
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JANITORIAL SPECIFICATIONS</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ii
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2525 WEST END<BR>
OFFICE LEASE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS LEASE AGREEMENT <I>(</I><B><I>&#147;Lease&#148;</I></B><I>) is </I>made and entered into on this <U> 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> </U> day
of <U> Sept </U>, 2005 (the <B><I>&#147;Date of Lease&#148;</I></B><I>), </I>by and between NASHVILLE HINES DEVELOPMENT, LLC, a
limited partnership organized under the laws of the State of Delaware, whose address for purposes
hereof is Five Greenway Plaza, Houston, Texas 77046 Attention: F. Russ Nicholson (hereinafter
called <B><I>&#147;Landlord&#148;</I></B><I>), </I>and CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation, whose address for
purposes hereof is 2525 West End Avenue, Suite&nbsp;950, Nashville, TN 37203, Attention: Jean W.
Marstiller, (the address of the Leased Premises within the Building) (hereinafter called <B><I>&#147;Tenant&#148;</I></B><I>)</I>.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. <U>Leased Premises.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord has constructed or intends to construct certain improvements on a certain tract or
parcel of land located on West End Avenue in Nashville, Davidson County, Tennessee, and more
particularly described in <U>Exhibit&nbsp;A-1,</U> attached hereto and incorporated herein by this
reference (the <I>&#147;</I><B><I>Land</I></B><I>&#148;). </I>The certain improvements including an office building with a retail area
included within it currently known as 2525 West End Avenue (the
<B><I>&#147;Building&#148;</I></B><I>) </I>and the Parking
Facility (as defined herein). The Building, the Parking Facility, and the Land together with all
common areas not specifically made a part of the Building or the Parking Facility, and all other
improvements from time to time located thereon or related thereto are hereinafter collectively
referred to as the <I>&#147;</I><B><I>Project</I></B><I>.&#148; </I>Subject to and upon the terms hereinafter set forth, and in
consideration of the sum of Ten Dollars ($10.00), the premises, and the mutual covenants set
forth herein, the receipt and sufficiency of which are hereby acknowledged, Landlord does hereby
lease and demise to Tenant and Tenant does hereby lease and take from Landlord (subject to all
matters of record in Davidson County, Tennessee, that affect the Project) those certain premises
(hereinafter sometimes called the <B><I>&#147;Leased Premises&#148;</I></B>) located in the Building as shown on
<U>Exhibit&nbsp;A,</U> attached hereto and incorporated herein, such Leased Premises being more
particularly described as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Approximately 6,341 RSF on the ninth (9<SUP style="font-size: 85%; vertical-align: text-top"><I>th</I></SUP>) Floor of the Building and as
generally described or depicted on <U>Exhibit&nbsp;B,</U> attached hereto and
incorporated herein.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tenant accepts the Leased Premises &#147;AS-IS.&#148; Landlord has not undertaken to perform any alteration
or improvement to the Lease Premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms <B><I>&#147;Rentable Square Feet&#148; </I></B>and <B><I>&#147;RSF&#148;, </I></B>as used herein, shall refer to (i)&nbsp;in the case
of a floor leased to a single tenant, the total square footage of all floor area measured from
the inside surface of the exterior glass line of the Building to the inside surface of the
opposite exterior glass line, excluding only Service Areas (defined below) and General Common
Areas (defined below), plus an allocation of the square footage of the General Common Areas, and
(ii)&nbsp;in the case of a floor leased to more than one tenant, the total square footage of all floor
areas within the inside surface of the exterior glass line of the Building enclosing the Leased
Premises and measured to the mid-point of demising walls (i.e., walls separating the Leased
Premises from areas leased to or held for lease to other tenants, from On-Floor Common Areas
(defined
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">below), and from General Common Areas), excluding only Service Areas, plus an allocation of
the square footage of the General Common Areas and an allocation of the square footage of the
On-Floor Common Areas. No deductions from Rentable Square Feet shall be made for columns or
projections.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;</I><B><I>Service Areas</I></B><I>&#148; </I>shall mean the areas within (and measured from the exterior surface of the
interior walls enclosing, or from the inside surface of the exterior glass or wall enclosing, as
the case may be) Building stairs, elevator shafts, flues, vents, stacks, pipe shafts and vertical
ducts. Areas for the specific use of Tenant or other tenants of the Building or installed at the
request of Tenant such as special stairs or elevators are not included within the definition of
Service Areas.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;General Common Areas&#148; </I></B>shall mean those areas within (and measured from the midpoint of the
walls or from the inside surface of the exterior glass enclosing) the Building&#146;s elevator machine
rooms, main mechanical rooms, electrical rooms, and public lobbies, engineering and cleaning
staging areas, and other areas not leased or held for lease within the Building but which are
reasonably necessary for the proper utilization of the Building or to provide customary services
to the Building, plus an allocation of any On-Floor Common Areas to the General Common Areas on
the floor for floors that contain General Common Areas. The allocation of the square footage of
the General Common Areas shall be equal to the total square footage of the General Common Areas
multiplied by a fraction, the numerator of which is the Rentable Square Feet of the Leased
Premises (excluding the total square footage of the General Common Areas) and the denominator of
which is the total of all Rentable Square Feet contained in the Building (excluding the allocation
of the General Common Areas).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>&#147;On-Floor Common Areas&#148; </I></B>shall mean the total square footage of all areas within (and measured
from the midpoint of the walls enclosing) public corridors, elevator foyers, rest rooms,
mechanical rooms, janitor closets, telephone and equipment rooms, and other similar facilities for
the use of all tenants on the floor on which the Leased Premises are located. The allocation of
the square footage of the On-Floor Common Areas shall be equal to the total On-Floor Common Areas
on said floor multiplied by a fraction, the numerator of which is the Rentable Square Feet of the
portion of the Leased Premises (excluding the allocations of General Common Areas and On-Floor
Common Areas) located on said floor and the denominator of which is the total of all Rentable
Square Feet on said floor (excluding the allocations of General Common Areas and On-Floor Common
Areas on the floor).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;</I><B><I>Parking Facility</I></B><I>&#148; </I>shall mean the parking structure that is constructed or intended to be
constructed and located adjacent to the Building (the <I>&#147;</I><B><I>Adjacent Parking Facility&#148;), </I></B>the surface
parking area adjacent to the Building (the <B><I>&#147;Surface Parking Area&#148;), </I></B>and the existing garage
located across Kensington Place (the <B><I>&#147;Kensington Parking Facility&#148;) </I></B><B>as </B>shown and labeled on
<U>Exhibit&nbsp;A</U> (which shall only be used by Tenant as parking for Tenant&#146;s employees and the
employees of other office tenants, not customer parking), together with any connecting walkways,
covered walkways, or other means of access to said building or buildings, the grounds related
thereto and any additional improvements at any time related thereto. The Parking Facility may be
operated by a parking contractor designated from time to time by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Lease does not grant Tenant any rights to light, air or view over or about the Land
or any other real property. Landlord specifically excepts and reserves to itself all
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rights to and the use of any roofs, the exterior portions of the Leased Premises, the Land,
improvements and air and other rights below the improved floor level of the Leased Premises, the
improvements and air and other rights above the improved ceiling of Leased Premises, the
improvements and air and other rights located outside the demising walls of the Leased Premises and
such areas within the Leased Premises as are required for installation of utility lines and other
installations required to serve the Building or any occupants of the Building, and Landlord
specifically reserves to itself the right to use, maintain and repair same, and no rights with
respect thereto are conferred upon Tenant, unless otherwise specifically provided herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant has been in possession of the Leased Premises prior to the Commencement Date
pursuant to a sublease agreement, is aware of the condition of the Leased Premises and represents
and acknowledges that the Leased Premises is, as of the Commencement Date, in good order and
satisfactory condition. Tenant acknowledges that no promise by or on behalf of Landlord, any of
Landlord&#146;s beneficiaries, the managing agent of the Building, the leasing agent of the Building or
any of their respective agents, partners or employees to alter, remodel, improve, repair, decorate
or clean the Leased Premises has been made to or relied upon by Tenant, and that no representation
respecting the condition of the Leased Premises or the Building by or on behalf of Landlord, any of
Landlord&#146;s beneficiaries, the managing agent of the Building, the leasing agent of the Building or
any of their respective agents, partners or employees has been made to or relied upon by Tenant,
except to the extent expressly set forth in this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2. <U>Term.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to and upon the terms and conditions set forth herein, or in any exhibit hereto,
the term of this Lease shall commence on the Commencement Date (defined below) and shall expire at
6:00 P.M on December&nbsp;31, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As used herein, <B><I>&#147;Commencement Date&#148; </I></B>means January&nbsp;1, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3. <U>Use</U>. The Leased Premises are to be used and occupied by Tenant (and its permitted
assignees and subtenants) solely for the purpose of office space and for no other purpose. The
Leased Premises shall not be used for any purpose which would create unreasonable elevator loads or
otherwise unreasonably interfere with Building operations, and Tenant shall not engage in any
activity which is not in keeping with the first class standards of the Building. In no event shall
the Leased Premises be used for the purpose of installing, marketing, operating, or providing
electronic telecommunications, information or data processing, storage or transmissions, or other
electronic office services or equipment for tenants or other occupants of the Building on a
shared-usage basis through a central switch or a local area network.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4. <U>Landlord&#146;s Relocation Right.</U> Upon ninety (90)&nbsp;days&#146; written notice to Tenant
<I>(&#147;</I><B><I>Landlord&#146;s Relocation Notice</I></B><I>&#148;), </I>Landlord may substitute for the Leased Premises other premises
in the Building (the <I>&#147;</I><B><I>New Premises</I></B><I>&#148;), </I>in which event the New Premises shall be deemed to be the
Leased Premises for all purposes hereunder, provided:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The New Premises shall be comparable to the Leased Premises in size, configuration and
market value;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Landlord and Tenant shall cooperate in good faith in making any changes to the Tenant
Program, Space Plan, Preliminary Working Drawings, and/or Working Drawings (as defined herein and
as may be applicable depending upon which, if any, of the foregoing has then been prepared at the
time of Landlord&#146;s election to relocate the Leased Premises) so as to conform the leasehold
improvements in the New Premises as closely as practicable to those planned for the Leased
Premises;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To the extent Tenant shall have incurred any expense in the preparation of the Tenant
Program, Space Plan, Preliminary Working Drawings, Working Drawings and/or leasehold improvements
(as defined herein and as may be applicable depending upon which, if any, of the foregoing has
then been prepared, purchased or installed at the time of Landlord&#146;s election to relocate the
Leased Premises), Landlord shall, at Landlord&#146;s expense, cause each of such applicable items to be
reproduced for the New Premises so that Tenant shall not incur expenses in connection therewith by
reason of the exercise by Landlord of the relocation right contained herein. In addition, Landlord
shall reimburse Tenant within thirty (30)&nbsp;days after receipt of genuine, third-party invoices
marked &#147;paid&#148; for Tenant&#146;s moving costs and all costs of reprinting stationery, cards and other
printed material bearing tenant&#146;s address at the Lease Premises if such address changes due to the
relocation (but only the reasonable quantities existing immediately prior to the relocation); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Upon substitution of the New Premises for the Leased Premises, the Rentable Square Feet
of the New Premises shall control for purposes of this Lease, and Tenant Percentage Share
(hereinafter defined) and the Base Rental shall be recalculated and adjusted based on the Rentable
Square Feet of the New Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall not be entitled to any compensation for any inconvenience or interference with
Tenant&#146;s business, nor to any abatement or reduction in rent or other sums payable by Tenant
hereunder, nor shall Tenant&#146;s obligations under this Lease be otherwise affected, as a result of
the substitution of the New Premises, except as otherwise expressly provided in this Section.
Tenant agrees to cooperate with Landlord so as to facilitate the prompt completion by Landlord of
its obligations under this <B>Section. </B>Without limiting the generality of the preceding sentence,
Tenant agrees to promptly provide to Landlord such approvals, instructions, plans, specifications
and other information as may be reasonably requested by Landlord in connection with such
obligations. At Landlord&#146;s request, Tenant shall execute a supplement to this Lease confirming the
substitution of the New Premises for the Leased Premises. Within twenty (20)&nbsp;days after receipt of
Landlord&#146;s Relocation Notice, Tenant shall either accept such relocation or deliver written notice
to Landlord terminating this Lease effective no later than the ninetieth (90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day
after Landlord&#146;s relocation Notice. Tenant&#146;s failure to deliver such termination notice within
such twenty (20)&nbsp;day period shall be deemed conclusively Tenant&#146;s election to relocate to the New
Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5. <U>Surrender of Premises.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Upon the termination of this Lease by lapse of time or otherwise or upon the earlier
termination of Tenant&#146;s right of possession, Tenant shall quit and surrender possession of the
Leased Premises to Landlord, broom clean, in the same condition as upon delivery of possession to
Tenant hereunder, normal wear and tear excepted. Before surrendering possession of the Leased
Premises, Tenant shall, without expense to Landlord, remove all signs, furnishings, equipment
(including all communication and other cables),
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">trade fixtures, merchandise and other personal property installed or placed in the Leased
Premises and all debris and rubbish, and Tenant shall repair all damage to the Leased Premises
resulting from such removal; provided if Tenant is then in default under this Lease, Tenant shall
not remove any such item unless Tenant receives written directions from Landlord authorizing or
directing the removal thereof. If Tenant fails to remove any of the signs, furnishings, equipment,
trade fixtures, merchandise and other personal property installed or placed in the Leased Premises
by the expiration or termination of this Lease, then Landlord may, at its sole option, (i)&nbsp;treat
Tenant as a holdover, in which event the provisions of this Lease regarding holding over shall
apply, (ii)&nbsp;deem any or all of such items abandoned and the sole property of Landlord, or (iii)
remove any and all such items and dispose of same in any manner. Tenant shall pay Landlord on
demand any and all expenses incurred by Landlord in the removal of such items, including, without
limitation, the cost of repairing any damage to the Leased Premises or the Building caused by such
removal and storage charges (if Landlord elects to store such property).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All installations, additions, partitions, hardware, cables, wires, fixtures and
improvements, temporary or permanent (including, but not limited to, Tenant&#146;s Extra Work), except
for Tenant&#146;s signs, furnishings, equipment, communication cables, telephone switches, trade
fixtures, merchandise and other personal property, in or upon the Leased Premises, whether placed
there by Tenant or Landlord, shall, upon the termination of this lease by lapse of time or
otherwise or upon the earlier termination of Tenant&#146;s right of possession, become Landlord&#146;s
property and shall remain upon the Leased Premises, all without compensation, allowance or credit
to Tenant; provided, however, that if at the time Landlord consents to Tenant&#146;s installation of
any installations, additions, partitions, hardware, cables, wires, fixtures and improvements or at
any time prior to termination of this Lease, Landlord requires removal of the same upon
termination, then Tenant, at Tenant&#146;s sole cost and expense, upon termination of this Lease by
lapse of time or otherwise or upon the earlier termination of Tenant&#146;s right of possession, shall
promptly remove such designated items placed in or upon the Leased Premises by or on behalf of
Tenant and, repair any damage to the Leased Premises or the Building caused by such removal,
failing which Landlord may remove the same and repair the Leased Premises or the Building, as the
case may be, and Tenant shall pay the cost thereof to Landlord on written demand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6. <U>Survival.</U> Any claim, cause of action, liability or obligation arising under the
term of this Lease and under the provisions hereof in favor of a party hereto against or
obligating the other party hereto and all of Tenant&#146;s indemnification obligations hereunder shall
survive the expiration or any earlier termination of this Lease.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. <U>Rental Payments.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Commencing on the Commencement Date and continuing thereafter throughout the full term of
this Lease, Tenant hereby agrees to pay the Base Rental (defined below), and Tenant&#146;s Forecast
Additional Rental (defined below) and Tenant&#146;s Additional Rental Adjustment (defined below) in
accordance with this Article. The Base Rental and Tenant&#146;s Forecast Additional Rental shall be due
and payable in equal monthly installments on the first
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">day of each calendar month during the initial term of this Lease and any extensions or
renewals hereof, and Tenant hereby agrees to so pay such rent to Landlord at Landlord&#146;s address as
provided herein (or such other address as may be designated by Landlord from time to time) monthly
in advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the Commencement Date is other than the first day of a calendar month, then the
installments of Base Rental and Tenant&#146;s Forecast Additional Rental for such month shall be
prorated and the installment or installments so prorated shall be paid in advance. Said
installments for such prorated month shall be calculated by multiplying the equal monthly
installment by a fraction, the numerator of which shall be the number of days of the Lease term
occurring during said commencement or expiration month, as the case may be, and the denominator of
which shall be thirty (30). If the term of this Lease commences or expires on other than the first
day of a calendar year, Tenant&#146;s Forecast Additional Rental and Tenant&#146;s Additional Rental shall be
prorated for such commencement or expiration year, as the case may be, by multiplying Tenant&#146;s
Forecast Additional Rental and Tenant&#146;s Additional Rental by a fraction, the numerator of which
shall be the number of whole and partial months of the Lease term during the commencement or
expiration year, as the case may be, and the denominator of which shall be twelve (12). In such
event the Tenant&#146;s Additional Rental Adjustment shall be made as soon as reasonably possible after
the termination of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For purposes hereof, the term <B><I>&#147;Rental&#148; </I></B>shall mean and collectively refer to the Base
Rental, Tenant&#146;s Forecast Additional Rental, Tenant&#146;s Additional Rental Adjustment and other sums
payable by Tenant hereunder. Tenant agrees to pay all Rental at the times and in the manner
provided in this Lease, without abatement, demand, notice, set-off, deduction or counterclaim, and
all sums payable under this Lease by Tenant shall be deemed to be rent due and owing hereunder. All
Rental shall bear interest from the tenth (10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day after the date due thereof until
paid at the lesser of (i)&nbsp;a per annum rate equal to the &#147;prime rate&#148; announced by Chase Manhattan
Bank, New York, New York, or its successor, (or if the &#147;prime rate&#148; is discontinued, the rate
announced as that being charged to the most credit-worthy commercial borrowers) plus two percent
(2%) or (ii)&nbsp;the maximum interest rate per annum allowed by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. <U>Base Rental.</U> Throughout the full term of this Lease, Tenant hereby agrees to pay
a base annual rental (the <B><I>&#147;Base Rental&#148;) </I></B>in accordance with the schedule attached hereto as
<U>Exhibit&nbsp;G,</U> as such dollar amount may be adjusted from lease year to lease year pursuant to
the terms of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. <U>Additional Rental.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Commencing with the calendar year in which the Commencement Date occurs and continuing
thereafter for each calendar year during the full term of this Lease, Landlord shall present to
Tenant prior to the beginning of said calendar year (or for the calendar year in which the Lease
term commences, on the Commencement Date) a statement of Tenant&#146;s Forecast Additional Rental.
Landlord&#146;s failure to deliver such a statement of Tenant&#146;s Forecast Additional Rental shall not
operate to excuse Tenant from the payment of the monthly installment of Tenant&#146;s Forecast
Additional Rental due under <B>Section&nbsp;2.</B><B>1(a)</B><B>. </B>Rather, Tenant shall continue to pay the monthly
installment of Tenant&#146;s Forecast Additional Rental based on Landlord&#146;s most recent calculation
thereof until such a statement is delivered to Tenant, with such statement being applied
retroactively to the beginning of the calendar year and Tenant
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">making up any under payments immediately upon its receipt of such statement. Landlord may,
from time to time, recalculate Tenant&#146;s Forecast Additional Rental in order to more accurately
reflect Landlord&#146;s good faith estimate of Tenant&#146;s Additional Rental, and Tenant shall commence
paying the recalculated Tenant&#146;s Forecast Additional Rental, in accordance with Section&nbsp;2.1(a)
hereof, immediately after receiving notice thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As used herein, <I>&#147;</I><B><I>Tenant&#146;s Forecast Additional Rental&#148; </I></B>shall mean Landlord&#146;s reasonable
estimate of Tenant&#146;s Additional Rental (defined below) for the coming calendar year (or, in the
calendar year in which the lease term commences, for such calendar year).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Landlord shall absorb and be responsible for paying Operating Expenses (defined below)
during any calendar year to the extent such Operating Expenses are less than Nine and 17/100
Dollars ($9.17) per square foot of space in the Building leased to rent paying tenants (the
<B><I>&#147;Expense Stop&#148;</I></B><I>). </I>As part of Tenant&#146;s Additional Rental, Tenant shall be responsible for paying its
pro rata share of the Operating Expenses for any calendar year in excess of the Expense Stop. For
purposes hereof, <B><I>&#147;Tenant&#146;s Additional Rental&#148; </I></B>for any calendar year shall mean Tenant&#146;s Percentage
Share (defined below) of the Operating Expenses for such calendar year in excess of the Expense
Stop. As used herein, <B><I>&#147;Tenant&#146;s Percentage Share&#148; </I></B>shall mean a fraction, the numerator of which is
the total number of square feet of Rentable Square Feet within the Leased Premises and the
denominator of which is the greater of (i)&nbsp;ninety-five percent (95%) of the total square footage of
all Rentable Square Feet in the Building (exclusive of any retail space) held for lease, or (ii)
the total square footage of all Rentable Square Feet in the Building (exclusive of any retail
space) actually leased to rent paying tenants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Landlord shall use reasonable efforts to provide Tenant, within one hundred twenty (120)
days after the end of the calendar year in which the Commencement Date occurs and of each calendar
year thereafter during the term of this Lease, with a statement detailing the Operating Expenses
for each such calendar year (the <B><I>&#147;Annual Operating Expense Statement&#148;</I></B><I>) </I>and a statement prepared by
Landlord comparing Tenant&#146;s Forecast Additional Rental with Tenant&#146;s Additional Rental. In the
event that Tenant&#146;s Forecast Additional Rental exceeds Tenant&#146;s Additional Rental for said calendar
year, Landlord shall pay Tenant (in the form of a credit against rentals next due or, upon
expiration of this Lease, in the form of Landlord&#146;s check) an amount equal to such excess. In the
event that the Tenant&#146;s Additional Rental exceeds Tenant&#146;s Forecast Additional Rental for said
calendar year, Tenant hereby agrees to pay Landlord, within thirty (30)&nbsp;days of receipt of the
statement, an amount equal to such difference <I>(</I><B><I>&#147;Tenant&#146;s Additional Rental Adjustment&#148;</I></B><I>).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Tenant, at Tenant&#146;s sole cost and expense, shall have the right, to be exercised by
written notice given to Landlord within sixty (60)&nbsp;days after receipt of the Annual Operating
Expense Statement for any calendar year, to audit Landlord&#146;s books and records pertaining only to
the Operating Expenses for such calendar year, provided such audit must commence within thirty (30)
days after Tenant&#146;s notice to Landlord and thereafter proceed regularly and continuously to
conclusion and, provided, further, that such audit must be conducted by a nationally recognized
independent public accounting firm in a manner that does not unreasonably interfere with the
conduct of Landlord&#146;s business. Notwithstanding the foregoing, Tenant shall not have the right to
audit Landlord&#146;s books
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and records regarding the Operating Expenses for any calendar year if (i)&nbsp;the Annual Operating
Expense Statement for such calendar year was prepared by a nationally recognized independent public
accounting firm, or (ii)&nbsp;Tenant is in default under the terms of this Lease or any circumstance
exists which with the giving of notice, the passage of time, or both, would constituted such a
default. Landlord agrees to cooperate in good faith with Tenant in the conduct of any such audit.
Tenant (and its agents, employees and accountants) shall hold the results of such audits in strict
confidence and not disclose the same to any third party, except as is necessary during any dispute
between Landlord and Tenant related thereto or as required by law. A copy of the results of any
such audit shall be promptly provided to Landlord, and Landlord may conduct an independent review
of the same. If there is any disagreement regarding the results of any such audit, the parties
shall select a third party auditor to resolve the dispute. Tenant shall not employ any person or
entity to audit Landlord&#146;s books and records whose compensation is based, in whole or in part, on a
contingency fee or the results of the audit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. <U>Operating Expenses.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<B><I>&#147;Operating Expenses&#148;, </I></B>for each calendar year, shall consist of (i)&nbsp;all Operating Costs
(defined below) for the Building, plus (ii)&nbsp;an amount equal to the sum of the total ownership,
management, maintenance, repair, replacement and operating costs accruing during each such calendar
year for portions of the Project not within the Building that are designated or maintained from
time to time as common areas, including, but not limited to, fifty (50%) percent of the cost of
maintaining the Kensington Place roadway adjoining the Project and those areas which are for the
benefit of the occupants of the Project whether or not so designated or maintained as common areas
(net of any contribution received from time to time from the owners of the other portions of the
Project for such expenses).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;For the purposes of this Lease, <I>&#147;</I><B><I>Operating Costs</I></B><I>&#148; </I>shall mean all expenses, costs and
accruals (excluding therefrom, however, specific costs billed to or otherwise incurred for the
particular benefit of specific tenants of the Building) of every kind and nature, computed on an
accrual basis, incurred or accrued in connection with, or relating to, the ownership, operation,
management, maintenance, repair and replacement of the Building during each calendar year,
including, but not limited to, the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>wages and salaries, including taxes, insurance
and benefits, of all on and off-site employees engaged in operations,
management, maintenance, repair, replacement or access control, as
reasonably allocated by Landlord and rent for the Building&#146;s management
office exclusive of that portion of such office used for leasing;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost of all supplies, tools, equipment and
materials to the extent used in operations, management, maintenance,
repairs or replacements, as reasonably allocated by Landlord;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost of all utilities, including, but not
limited to, the cost of electricity, the cost of water and the cost of
power for heating, lighting, air conditioning and ventilating;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of trash and garbage removal, cleaning,
vermin extermination, snow, ice and debris removal, and other services;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost related to and fees payable under all
maintenance, management and service agreements, including, but not
limited to, a management fee contribution equal to three percent (3%)
of the gross revenues;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to those agreements related to
access control services, garage operations, window cleaning, elevator
maintenance, janitorial service, pest control and landscaping
maintenance;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost of inspections, repairs, maintenance and
replacements (except to the extent covered by proceeds of insurance);
provided the cost of capital repairs and replacements shall be
amortized over such reasonable period of time as Landlord shall
determine and only the portion of such costs allocable to any calendar
year (plus interest on the unpaid balance of such costs) may be
included in the Operating Costs for such calendar year;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of legal and accounting services incurred by Landlord
relating to management and maintenance of the Building but not
including any such expenses related to leasing of space in the
Building;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(ix)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>amortization of the cost (plus interest on the
unpaid balance of such costs) of any system, apparatus, device, or
equipment which is installed for the principal purpose of (i)&nbsp;reducing
Operating Expenses, (ii)&nbsp;promoting safety or (iii)&nbsp;complying with
governmental requirements;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(x)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of all insurance, including, but not
limited to, the cost of casualty, rental loss and liability insurance,
and insurance on Landlord&#146;s personal property, plus the cost of all
deductible and co-insurance payments made by Landlord in connection
therewith;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>amounts due under easements, operating agreements,
parking operating agreements, declarations, covenants or instruments
encumbering the Land;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reasonable replacement reserves;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xiii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost of maintaining, striping, repairing, replacing, repaving and
lighting grounds, streets, parking areas, sidewalks, curbs, walkways,
landscaping, drainage and lighting facilities; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xiv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all taxes, assessments and governmental charges,
whether or not directly paid by Landlord, whether federal, state, county
or municipal</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and whether they be by taxing districts or authorities presently
taxing the Building and said common areas or by others subsequently
created or otherwise, and any other taxes, assessments and
governmental charges attributable to the Building and that portion of
the common areas or their operation, excluding, however, taxes and
assessments attributable to the personal property of other tenants,
federal and state taxes on income, death taxes, franchise taxes, and
any taxes imposed or measured on or by the income of Landlord from the
operation of the Building or imposed in connection with any change of
ownership of the Building; provided, however, that if at any time
during the term of this Lease, the present method of taxation or
assessment shall be so changed that the whole or any part of the
taxes, assessments, levies, impositions or charges now levied,
assessed or imposed on real estate and the improvements thereon shall
be discontinued and as a substitute therefor, or in lieu of or in
addition thereto, taxes, assessments, levies, impositions or charges
shall be levied, assessed or imposed, wholly or partially, as a
capital levy or otherwise, on the rents received from the Building or
the rents reserved herein or any part thereof, then such substitute or
additional taxes, assessments, levies, impositions or charges, to the
extent so levied, assessed or imposed with respect to the Building,
shall be deemed to be included within the Operating Costs.
Consultation, legal fees and costs resulting from any challenge of tax
assessments as reasonably allocated by Landlord shall also be included
in Operating Costs. It is agreed that Tenant will be responsible for
ad valorem taxes on its personal property and on the value of the
leasehold improvements in the Leased Premises to the extent that the
same exceed the Tenant Improvement Allowance (and if the taxing
authorities do not separately assess Tenant&#146;s leasehold improvements,
Landlord may make a reasonable allocation of the ad valorem taxes
allocated to the Building to give effect to this sentence). In the
case of special taxes and assessments which may be payable in
installments, only the amount of each installment accruing during a
calendar year shall be included in the Operating Costs for such year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding any language contained herein to the contrary, Tenant hereby agrees that,
during any calendar year in which the entire Building is not provided with Building Standard
Services or is not completely occupied, Landlord shall compute all Variable Operating Costs
(defined below) for such calendar year as though the entire Building were provided with Building
Standard Services and were completely occupied. For purposes of this Lease the term <B><I>&#147;Variable
Operating Costs&#148; </I></B>shall mean any operating cost that is variable with the level of occupancy of the
Building (e.g. utilities and cleaning services). In the event that Landlord excludes from
<B><I>&#147;Operating Costs&#148; </I></B>any specific costs billed to or otherwise incurred for the particular benefit of
specific tenants of the Building or to other buildings or projects on the Land, Landlord shall have
the right to increase <B><I>&#147;Operating Costs&#148; </I></B>by an amount equal to the cost of providing standard
services similar to the services for which such excluded specific costs were billed or incurred. In
no event shall Landlord receive from all tenants of the Building more than one hundred percent
(100%) of any Operating Costs.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5. <U>Security Deposit.</U> &#091;Intentionally deleted.&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6. <U>Landlord&#146;s Lien.</U> &#091;Intentionally
deleted.&#093;
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. <U>Services.</U> Landlord shall furnish the following services to Tenant during the term
of this Lease (<B><I>&#147;Building Standard Services&#148;</I></B>):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Hot and cold domestic water to common use rest rooms and toilets, in such amounts as are
reasonably determined by Landlord
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Subject to curtailment as required by governmental laws, rules or mandatory regulations,
central heat and air conditioning in season, at such temperatures and in such amounts as are
reasonably determined by Landlord and on such dates and at such times as are more particularly
described on <U>Exhibit&nbsp;C</U> attached hereto and incorporated herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Electric lighting service for all public areas and special service areas of the Building
in such amounts and locations as are reasonably determined by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Janitor service in accordance with the Janitorial Specifications attached hereto and
incorporated herein as <U>Exhibit&nbsp;H;</U> however, if Tenant&#146;s floor coverings or other
improvements are other than building standard commercial grade, Tenant shall pay one hundred and
fifteen percent (115%) of the actual additional cleaning cost, if any, attributable thereto, and if
supplying such additional cleaning service requires active managerial oversight by Landlord,
Landlord shall be entitled to collect an administrative fee equal to fifteen percent (15%) of the
cost of such service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Access control for the Building shall be provided to the extent and in the manner
reasonably determined by Landlord; provided, however, Landlord shall have no responsibility to
prevent, and shall not be liable to Tenant for, any liability or loss to Tenant, its agents,
employees and visitors arising out of losses due to theft, burglary, or damage or injury to persons
or property caused by persons gaining access to the Leased Premises, and Tenant hereby releases
Landlord from all liability for such losses, damages or injury.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Electrical service to floors with plug-in type bus risers sized to provide 8.0 watts per
useable square foot of electrical connected load capacity for tenant use above and beyond the base
building electrical requirements. Of that, 6.0 watts per useable square foot of electrical
connected load capacity will be available in 480/277V panels for tenant use leaving 2.0 watts per
useable square foot available in the bus riser for future tenant electrical loads. Of the 6.0 watts
per useable square foot, 3.0 watts per useable square foot of electrical connected load capacity
will be available in 208/120V panels for tenant use leaving 3.0 watts per useable square foot of
capacity in the 480/277V panels for future tenant electrical loads. This capacity is part of the
6.0 watts per useable square foot of power for tenant&#146;s use noted above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should Tenant&#146;s total rated electrical design load exceed the Building Standard rated
electrical design load for either low or high voltage electrical consumption, or if Tenant&#146;s
electrical design requires low voltage or high voltage circuits in excess of Tenant&#146;s share of the
Base Building Shell Condition circuits, Landlord will (at Tenant&#146;s expense) install one (1)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">additional high voltage panel and/or one (1)&nbsp;additional low voltage panel with associated
transformer, space for which has been provided in the base building electrical closets based on a
maximum of two (2)&nbsp;such additional panels per floor for all tenants on the floor (which additional
panels and transformers shall be hereinafter referred to as the <B><I>&#147;additional electrical equipment&#148;</I></B>).
If the additional electrical equipment is installed because Tenant&#146;s low or high voltage rated
electrical design load exceeds the applicable Building Standard rated electrical design load, then
a meter shall also be added (at Tenant&#146;s expense) to measure the electricity used through the
additional electrical equipment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The design and installation of any additional electrical equipment (or any related meter)
required by Tenant shall be subject to the prior approval of Landlord (which approval shall not be
unreasonably withheld). All expenses incurred by Landlord in connection with the review and
approval of any additional electrical equipment shall also be reimbursed to Landlord by Tenant.
Tenant shall also pay on demand the actual metered cost of electricity consumed through the
additional electrical equipment (if applicable), plus any actual accounting expenses incurred by
Landlord in connection with the metering thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of Tenant&#146;s electrical equipment requires conditioned air in excess of Base Building
Shell Condition air conditioning, the same shall be installed by Landlord (on Tenant&#146;s behalf), and
Tenant shall pay all design, installation, metering and operating costs relating thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If Tenant requires that certain areas within Tenant&#146;s demised premises must operate in excess
of the normal Building Operating Hours (as defined in <U>Exhibit&nbsp;C</U> attached hereto), the
electrical service to such areas shall be separately circuited and metered such that Tenant shall
be billed the costs associated with electricity consumed during hours other than Building Operating
Hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;All Building Standard fluorescent bulb replacement in all areas and all incandescent bulb
replacement in General Common Areas, Service Areas and On-Floor Common Areas.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Non-exclusive multiple cab passenger service to the Leased Premises during Building
Operating Hours and at least one (1)&nbsp;cab passenger service to the Leased Premises twenty-four (24)
hours per day and non-exclusive freight elevator service during Building Operating Hours (all
subject to temporary cessation for ordinary repair and maintenance and during times when life
safety systems override normal building operating systems) with such freight elevator service
available at other times upon reasonable prior notice and the payment by Tenant to Landlord of any
additional expense actually incurred by Landlord in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent the services described in subsection (a), (b), (c), (f)&nbsp;and (h)&nbsp;above require
electricity and water supplied by public utilities, Landlord&#146;s covenants thereunder shall only
impose on Landlord the obligation to use its good faith, reasonable efforts to cause the applicable
public utilities to furnish the same. Failure by Landlord to furnish the services described in this
Section, or any cessation thereof, shall not render Landlord liable for damages to either person or
property, nor be construed as an eviction of Tenant, nor work an abatement of rent, nor relieve
Tenant from fulfillment of any covenant or agreement
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereof. In addition to the foregoing, should any of the equipment or machinery, for any cause,
fail to operate, or function properly, Tenant shall have no claim for rebate of rent or damages on
account of an interruption in service occasioned thereby or resulting therefrom; provided, however,
Landlord agrees to use reasonable efforts to repair said equipment or machinery promptly and to
restore said services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. <U>Keys and Locks.</U> Landlord shall install a card reader on the elevator servicing
the Leased Premises that restricts after hours access to the Leased Premises. Landlord shall also
supply Tenant with two (2)&nbsp;keys for each Building Standard lockset on code required doors entering
the Leased Premises from public areas. Additional keys will be furnished by Landlord upon an order
signed by Tenant and at Tenant&#146;s expense. All such keys shall remain the property of Landlord. No
additional locks shall be allowed on any door of the Leased Premises without Landlord&#146;s permission,
and Tenant shall not make or permit to be made any duplicate keys. Upon termination of this Lease,
Tenant shall surrender to Landlord all keys to any locks on doors entering or within the Leased
Premises, and give to Landlord the explanation of the combination of all locks for safes, safe
cabinets and vault doors, if any, in the Leased Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3. <U>Graphics, Building Directory and Name.</U> Landlord shall provide and install all
graphics, letters, and numerals at the entrance to the Leased Premises on multi-tenant floors, if
any (it being understood that Tenant shall be responsible for all graphics on full floors occupied
by Tenant. Landlord shall maintain an electronic directory in such main lobby which shall include
such information relating to Tenant. All such letters and numerals shall be in the Building
standard graphics (font size to be approved by Landlord). Tenant agrees that Landlord shall not be
liable for any inconvenience or damage occurring as a result of any error or omission in any
directory or graphics. No signs, numerals, letters or other graphics shall be used or permitted on
the exterior of, or may be visible from outside, the Leased Premises, unless approved in writing by
Landlord. All on-floor graphics for full-floor tenants shall be removed by Tenant upon lease
expiration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">3.4. <U>Parking.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to the other provisions hereof, Landlord hereby agrees to make available, or to
cause the lessee or operator of the Parking Facility (the <B><I>&#147;Garage Operator&#148;</I></B>)<I>, </I>to make available to
Tenant (so long as Tenant shall continue to lease at least 6,341 RSF) up to twenty-five (25)
permits to park in the Kensington Parking Facility upon the terms and conditions set forth below
(the <B><I>&#147;Parking Permits&#148;</I></B><I>). </I>Landlord shall also provide (or cause the Garage Operator to provide)
visitor parking in a portion of the Parking Facility on a &#147;first come-first served&#148; pay basis at
such rates and upon such conditions as Landlord or the Garage Operator, as applicable, shall
establish from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant shall notify Landlord within thirty (30)&nbsp;days following the execution of this Lease
of the number of Parking Permits that it intends to utilize. Neither Landlord nor the Garage
Operator shall be obligated to hold any Parking Permits that Tenant does not elect to utilize.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Tenant shall pay as rental for the Parking Permits at the rate charged from time to time
by Landlord (or the Garage Operator), in its sole and absolute discretion,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">plus any applicable taxes thereon; provided the rate charged for the Parking Permits shall be
prorated for any partial months during the term of this Lease. The current charge to Tenant for
each Parking Permit is $40.00 per month, plus any applicable taxes thereon. In the event the rate
charged for the Parking Permits is increased, Tenant may elect to relinquish all or a portion of
the Parking Permits by giving written notice to Landlord (or its designee) within thirty (30)&nbsp;days
after receiving notice of such increase, in which event Tenant shall have no further right to or
interest in such Parking Permit and neither Landlord nor the Garage Operator shall have any
obligation to provide replacement parking for Tenant. If the rate charged for the Parking Permits
is increased and Tenant fails to notify Landlord, in writing, of its election to relinquish all or
a portion of the Parking Permits within thirty (30)&nbsp;days after receiving notice of such increase,
then Tenant shall be deemed to have agreed to such increase and shall have no further right to
relinquish its Parking Permits on account thereof. Unless Landlord directs otherwise, Tenant shall
pay the monthly charges established from time to time in accordance with this Lease by the Garage
Operator for parking in the Kensington Parking Facility to Landlord and Landlord shall collect such
payments, on behalf of the Garage Operator, monthly in advance, at the same time and place as
Tenant makes payments of Base Rent under the terms of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;In the event the parking spaces covered by the Parking Permits are not available to Tenant
due to causes beyond the control of Landlord or the Garage Operator and Landlord is unable to
provide replacement parking to Tenant, neither Landlord nor Garage Operator shall be liable for any
damages that Tenant suffers on account thereof, nor shall such fact be construed as a constructive
eviction of Tenant, entitle Tenant to an abatement of any Rental or an abatement of the charges for
the Parking Permits, or relieve Tenant from fulfillment of any covenant or agreement hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Landlord or the Garage Operator may make, modify and enforce reasonable rules and
regulations relating to the parking of vehicles in the Parking Facility, and Tenant agrees to abide
by such rules and regulations. Except as expressly provided herein, this Lease does not grant
Tenant (or its agents, employees, contractors and visitors) the right to use the Parking Facilities
or any other parking areas located on the Land or serving the Building. So long as Landlord ensures
that there is sufficient parking available in the Parking Facilities to accommodate the holders of
the Parking Permits, Landlord or the Garage Operator may, from time to time, designate specific
portions of the Parking Facilities as reserved areas and Tenant shall have no right to park in such
reserved areas, except Tenant may park in reserved areas made available to tenants of the Building
to the extent Tenant has purchased Parking Permits specifically entitling Tenant to use the same.
Landlord agrees to make (or cause the Garage Operator to make) parking for Tenant&#146;s guests and
visitors available on a non-exclusive basis in the Parking Facility. Landlord or the Garage
Operator may restrict Tenant&#146;s right to utilize the Parking Permits on weekends and after 6:00 p.m.
in the evening when athletic events are scheduled in the nearby athletic facilities.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. <U>Care of Leased Premises.</U> Tenant shall not commit or allow to be committed by
Tenant&#146;s employees, agents or contractors, any waste or damage to any portion of the Leased
Premises or the Building. Upon the expiration or any earlier termination of this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lease, Landlord shall have the right to re-enter and resume possession of the Leased Premises
immediately.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. <U>Entry for Repairs and Inspection.</U> Tenant shall permit Landlord and its
contractors, agents or representatives to enter into and upon any part of the Leased Premises
during reasonable hours to inspect or clean the same, make repairs, alterations or additions
thereto, and, upon reasonable prior notice to Tenant, for the purpose of &#145;showing the same to
prospective tenants or purchasers and Tenant shall not be entitled to any abatement or reduction of
rent by reason thereof. Landlord shall use its reasonable efforts not to interfere materially with
the operation of Tenant&#146;s business during any such entry.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3. <U>Nuisance.</U> Tenant shall conduct its business and control its agents, employees,
invitees, contractors and visitors in such a manner as not to create any nuisance, or interfere
with, annoy or disturb any other tenant or Landlord in its operation of the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4. <U>Laws and Regulations; Encumbrances; Rules of Building.</U> Tenant shall comply with,
and Tenant shall cause its employees, contractors and agents to comply with, and shall use its best
efforts to cause its visitors and invitees to comply with, (i)&nbsp;all laws, ordinances, orders, rules
and regulations of all state, federal, municipal and other governmental or judicial agencies or
bodies relating to the use, condition or occupancy of the Leased Premises, (ii)&nbsp;all recorded
easements, operating agreements, parking agreements, declarations, covenants and instruments
encumbering the Leased Premises, and (iii)&nbsp;the rules of the Building reasonably adopted and altered
by Landlord from time to time for the safety, care and cleanliness of the Leased Premises and
Building and for the preservation of good order therein. The initial rules of the Building are
attached hereto and incorporated herein as <U>Exhibit&nbsp;D.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5. <U>Legal Use and Violations of Insurance Coverage.</U> Tenant shall not occupy or use
the Leased Premises, or permit any portion of the Leased Premises to be occupied or used, for any
business or purpose which is unlawful, disreputable or deemed to be hazardous in any manner, or
permit anything to be done which would in any way increase the rate of fire, liability, or any
other insurance coverage on the Building or its contents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6. <U>Hazardous Substances.</U> Tenant shall comply, at its sole expense, with all laws,
ordinances, orders, rules and regulations of all state, federal, municipal and other governmental
or judicial agencies or bodies relating to the protection of public health, safety, welfare or the
environment (collectively, <B><I>&#147;Environmental Laws&#148;) </I></B>in the use, occupancy and operation of the Leased
Premises. Tenant agrees that no Hazardous Substances (as hereinafter defined) shall be used,
located, stored or processed on the Leased Premises or be brought onto any other portion of the
Building by Tenant or any of its agents, employees, contractors, assigns, subtenants, guests or
invitees, and no Hazardous Substances will be released or discharged from the Leased Premises
(including, but not limited to, ground water contamination). The term <B><I>&#147;Hazardous Substances&#148; </I></B>shall
mean and include all hazardous and toxic substances, waste or materials, any pollutant or
contaminant, including, without limitation, PCB&#146;s, asbestos and raw materials that include
hazardous constituents or any other similar substances or materials that are now or hereafter
included under or regulated by any Environmental Laws or that would pose a health, safety or
environmental hazard. Tenant hereby agrees to indemnify, defend and hold harmless Landlord from and
against any and all losses, liabilities (including, but not limited to, strict
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">liability), damages, injuries, expenses (including, but not limited to, court costs,
litigation expenses, reasonable attorneys&#146; fees and costs of settlement or judgment), suits and
claims of any and every kind whatsoever paid, incurred or suffered by, or asserted against,
Landlord by any person, entity or governmental agency for, with respect to, or as a direct or
indirect result of, the presence in or the escape, leakage, spillage, discharge, emission or
release from the Leased Premises of any Hazardous Substances or the presence of any Hazardous
Substances placed on or discharged from the Building by Tenant or any of its agents, employees,
contractors, assigns, subtenants, guests or invitees, including, without limitation, any losses,
liabilities (including, but not limited to, strict liability), damages, injuries, expenses
(including, but not limited to, court costs, litigation expenses, reasonable attorneys&#146; fees and
costs of settlement or judgment), suits and claims asserted or arising under the Comprehensive
Environmental Response, Compensation and Liability Act <I>(&#147;</I><B><I>CERCLA</I></B><I>&#148;), </I>any so-called federal, state or
local &#147;Superfund&#148; or &#147;Superlien&#148; laws or any other Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7. <U>Tenant Taxes.</U> Tenant shall pay promptly when due all taxes directly or indirectly
imposed or assessed upon Tenant&#146;s gross sales, business operations, machinery, equipment, trade
fixtures and other personal property or assets, whether such taxes are assessed against Tenant,
Landlord or the Building. In the event that such taxes are imposed or assessed against Landlord or
the Building, Landlord shall furnish Tenant with all applicable tax bills, public charges and other
assessments or impositions and Tenant shall forthwith pay the same either directly to the taxing
authority or, at Landlord&#146;s option, to Landlord.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. <U>Initial Allowance; Leasehold Improvements.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Within ten (10)&nbsp;days of the Commencement Date, Landlord shall contribute &#091;***&#093; per RSF in
the Leased Premises (the <I>&#147;</I><B><I>Initial Allowance</I></B><I>&#148;) </I>for Tenant&#146;s use during the initial Lease Term, all
or any portion of which Tenant may apply as a credit towards Base Rental next due and payable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant shall not make or allow to be made any alterations or physical additions in or to
the Leased Premises, or place safes, vaults or other heavy furniture or equipment within the
Leased Premises, without first obtaining the written consent of Landlord which consent shall not
be unreasonably withheld so long as said alterations do not impact on Building systems or
structure and are not visible from outside the Leased Premises. Tenant shall deliver to Landlord a
copy of the &#147;as-built&#148; plans and specifications for all alterations or physical additions so made
in or to the Leased Premises. Tenant further specifically agrees that no food, soft drink or other
vending machine will be installed within the Leased Premises without the written consent of
Landlord. Any such machine(s) shall be for the use of Tenant and its employees and invitees only.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Tenant shall indemnify and hold Landlord harmless from and against all costs (including
reasonable attorneys&#146; fees and costs of suit), losses, liabilities, or causes of action arising
out of or relating to any alterations, additions or improvements made by Tenant to the Leased
Premises, including, but not limited to, any mechanics&#146; or materialmen&#146;s liens asserted in
connection therewith. No portion of Landlord&#146;s interest in the Building shall be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">subject to attachment on account of any work performed by or on account of Tenant, and Tenant
shall provide written notice of same to all of its contractors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Should any mechanic&#146;s or other liens be filed against any portion of the Building by
reason of Tenant&#146;s acts or omissions or because of a claim against Tenant, Tenant shall cause the
same to be canceled or discharged of record by bond or otherwise within thirty (30)&nbsp;days after
notice by Landlord. If Tenant shall fail to cancel or discharge said lien or liens, within said
thirty (30)&nbsp;day period, Landlord may, at its sole option, cancel or discharge the same and upon
Landlord&#146;s demand, Tenant shall promptly reimburse Landlord for all reasonable costs incurred in
canceling or discharging such liens, and if canceling or discharging such liens requires active
managerial oversight by Landlord, Landlord shall be entitled to collect an administrative fee
equal to fifteen percent (15%) of the cost thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. <U>Repairs by Landlord.</U> All repairs, alterations or additions that affect the
Building&#146;s structural components or the Building&#146;s mechanical, electrical and plumbing systems
shall be made solely by Landlord or its contractor. In the event of any damage to such components
or systems or any other portion of the Building caused by Tenant or Tenant&#146;s agents, contractors,
employees, visitors or invitees, the cost of repair or restoration of such damage shall be paid
for solely by Tenant in an amount equal to Landlord&#146;s costs plus fifteen percent (15%) for
administrative cost recovery. Landlord shall make such repairs to Base Building Shell Condition
improvements as may be deemed necessary by Landlord for normal maintenance operations and Landlord
shall not otherwise be obligated to make improvements to, or repairs of, the Leased Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3. <U>Repairs by Tenant.</U> Subject to Section&nbsp;5.2, Tenant shall at its own cost and
expense, keep the Leased Premises and all leasehold improvements in a condition similar to the
condition as of the Commencement Date, normal wear and tear excepted, and Tenant shall perform all
maintenance, repairs and replacements necessary to accomplish the same. In addition, Tenant shall
perform all maintenance, repairs, replacements and improvements required by any governmental law,
ordination, rule or regulation. If Tenant fails to commence any maintenance, repairs, replacements
or improvements which it is required to perform hereunder within ten (10)&nbsp;days after written
notice from Landlord to Tenant and thereafter diligently proceed with such work until completion,
Landlord may, at its option, perform any such maintenance, repairs, replacements or improvements
deemed necessary by Landlord, and Tenant shall pay to Landlord on demand Landlord&#146;s cost thereof
plus a charge of fifteen percent (15%) for administrative cost recovery.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. <U>Condemnation.</U> If all or substantially all of the Leased Premises, or such
portion of the Leased Premises or the Building as would render, in Landlord&#146;s reasonable judgment,
the continuance of Tenant&#146;s business from the Leased Premises impracticable, shall be permanently
taken or condemned for any public purpose, then this Lease, at the option of Tenant or Landlord
upon the giving of written notice to the other party within ten (10)&nbsp;days from the date of such
condemnation or taking, shall forthwith cease and terminate. If less than all or substantially all
of the Leased Premises or any portion of the Building shall be permanently taken or condemned for
any public purpose, then Landlord shall have the option of terminating this Lease by written
notice to Tenant within ten (10)&nbsp;days from the date of such condemnation or taking. If this Lease
is terminated as provided above, this Lease shall cease and expire as if
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the date of transfer of possession of the Leased Premises, the Building, or any portion
thereof, was the expiration date of this Lease. In the event that this Lease is not terminated by
either Landlord or Tenant as aforesaid, Tenant shall pay the Rental up to the date of transfer of
possession of such portion of the Leased Premises so taken or condemned and this Lease shall
thereupon cease and terminate with respect to such portion of the Leased Premises so taken or
condemned as if the date of transfer of possession of the Leased Premises was the expiration date
of the term of this Lease relating to such portion of the Leased Premises. Thereafter the Base
Rental, Tenant&#146;s Forecast Additional Rental and Tenant&#146;s Additional Rental shall be adjusted on a
pro rata, net rentable square foot basis. In the event of any such condemnation or taking and this
Lease is not so terminated, Landlord shall promptly repair the Leased Premises or the Building, as
the case may be, to Base Building Shell Condition so that the remaining portion of the Leased
Premises or Building, as the case may be, shall constitute an architectural unit, fit for Tenant&#146;s
occupancy and business; provided, however, that Landlord&#146;s obligation to repair hereunder shall be
limited to the extent of the net proceeds made available to Landlord for such repair from any such
condemnation or taking. In the event of any temporary taking or condemnation for any public
purpose of the Leased Premises or any portion thereof, then this Lease shall continue in full
force and effect except that Base Rental, Tenant&#146;s Forecast Additional Rental, and Tenant&#146;s
Additional Rental shall be adjusted on a pro rata net rentable square foot basis for the period of
time that the Leased Premises are so taken as of the date of transfer of possession of the Leased
Premises and Landlord shall be under no obligation to make any repairs or alterations. In the
event of any condemnation or taking of the Leased Premises, Tenant hereby assigns to Landlord the
value of all or any portion of the unexpired term of the Lease and all leasehold improvements and
Tenant may not assert a claim for a condemnation award therefor; provided, however, Tenant may
pursue a separate attempt to recover an award or compensation against or from the condemning
authority for (i)&nbsp;the value of any fixtures, furniture, furnishings, Tenant&#146;s Extra Work and other
personal property which were condemned but which under the terms of this Lease, Tenant is
permitted to remove at the end of the term of this Lease, (ii)&nbsp;relocation and moving expenses, and
(iii)&nbsp;compensation for loss to Tenant&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. <U>Damages from Certain Causes.</U> Landlord shall not be liable or responsible to
Tenant for any loss or damage to any property or person occasioned by theft, fire, act of God,
public enemy, riot, strike, insurrection, war, act or omission of any tenant or occupant of the
Building, any nuisance or interference caused or created by any tenant or occupant of the Building,
requisition or order of governmental body or authority, court order or injunction, or any cause
beyond Landlord&#146;s control or, except in the case of the gross negligence or intentional misconduct
of Landlord, for any damage or inconvenience which may arise through repair or alteration of any
part of the Building. Tenant shall notify Landlord of any damage to the Leased Premises, regardless
of the cause of such damage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. <U>Casualty Clause.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event any portion of the Leased Premises or any portion of the General Common Areas
is damaged by fire or other casualty, earthquake or flood or by any other cause of any kind or
nature (hereinafter collectively referred to as the <B><I>&#147;damaged property&#148;</I></B><I>) </I>and the damaged property
can, in the opinion of the Landlord&#146;s architect, be repaired within ninety (90)&nbsp;calendar days from
the date of notice of Landlord&#146;s architect&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">opinion, then Landlord shall proceed to rebuild or restore the damaged property to Base
Building Shell Condition, subject to subsection (e)&nbsp;hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event the damaged property can not, in the opinion of Landlord&#146;s architect, be
repaired within ninety (90)&nbsp;days from the date of notice of Landlord&#146;s architect&#146;s opinion, but can
be repaired within one hundred eighty (180)&nbsp;days from the date of notice of Landlord&#146;s architect&#146;s
opinion, Landlord, at Landlord&#146;s sole option, shall have the right (i)&nbsp;to terminate this Lease by
notifying Tenant of such termination within twenty (20)&nbsp;days of receipt of Landlord&#146;s architect&#146;s
opinion, or (ii)&nbsp;to restore or rebuild the damaged property to Base Building Shell Condition,
subject to subsection (e)&nbsp;hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If, in the opinion of Landlord&#146;s architect, damage to the damaged property cannot be
repaired within one hundred eighty (180)&nbsp;days from the date of notice of Landlord&#146;s architect&#146;s
opinion, then both Landlord and Tenant shall have the right to terminate this Lease by notifying
the other party in writing of such termination within twenty (20)&nbsp;days of receipt of Landlord&#146;s
architect&#146;s opinion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding any language herein to the contrary, if at the time of any such damage,
less than one (1)&nbsp;year remains in the term of this Lease, exclusive of any renewal options, then
Landlord, at Landlord&#146;s sole option, shall have the right to terminate this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If at anytime during the term of this Lease the Building is damaged and the cost of
repairing and restoring the same exceeds twenty-five percent (25%) of the replacement cost of the
improvements comprising the Building, then Landlord, at Landlord&#146;s sole option, shall have the
right to terminate this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notwithstanding any language contained herein to the contrary, in the event this Lease is
not terminated as provided hereunder (i)&nbsp;Landlord shall be obligated to rebuild or restore the
damaged property only to the extent of the net insurance proceeds available to Landlord for the
purpose of rebuilding and restoration, (ii)&nbsp;if the damaged property is all or any portion of the
Leased Premises Landlord shall be obligated to rebuild or restore the damaged property only to Base
Building Shell Condition, except that Tenant shall have the right to require Landlord to rebuild or
restore the damaged property substantially to the condition which existed immediately prior to such
damage, provided that Tenant shall bear all costs and expenses, including without limitation,
rentals that are lost due to extended construction time, in excess of the lesser of (A)&nbsp;any net
insurance proceeds available to Landlord for the purpose of rebuilding or restoration, or (B)&nbsp;the
cost to Landlord of rebuilding and restoring the damaged property to Building Standard condition
(with Building Standard tenant allowances); and (iii)&nbsp;to the extent Landlord has rental loss
insurance proceeds available, Tenant shall be entitled to a pro rata abatement of Base Rental,
Tenant&#146;s Forecast Additional Rental, and Tenant&#146;s Additional Rental during the period of time the
Leased Premises, or any portion thereof, are untenantable due to such damage. Landlord&#146;s
architect&#146;s opinion shall be delivered to both Landlord and Tenant within thirty (30)&nbsp;days from the
date of any such damage. In the event of any termination of this Lease under this <B>Section, </B>this
Lease shall cease and terminate as if the date of such damage was the expiration date of the term
of this Lease. Notwithstanding any contrary language in this <B>Section, </B>if the Leased Premises, the
Building, or any portion thereof shall be damaged through the negligence or willful misconduct of
Tenant and the cost of repairing the same is not covered by Landlord&#146;s insurance, such damage shall
be repaired by Landlord at the sole expense of Tenant and rent shall continue hereunder unabated.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;If any portion of Tenant&#146;s leasehold improvements (including, but not limited to, Tenant&#146;s
Extra Work), alterations, additions, improvements, fixtures, furnishing, equipment or trade
fixtures are damaged by fire or other casualty, earthquake or flood or by any other cause of any
kind or nature, Tenant shall immediately restore the same to the condition existing immediately
prior to such damage, unless such damage is so extensive as to permit termination of this Lease as
provided herein and the Lease is terminated in accordance with such provisions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4. <U>Casualty Insurance.</U> Landlord shall maintain all-risk property insurance on the
Building and on all Base Building Shell Condition improvements. Said insurance shall be maintained
with an insurance company authorized to do business in Tennessee, at full replacement cost and
payments for losses thereunder shall be made solely to Landlord. Tenant shall maintain at its
expense business interruption insurance and all-risk property insurance on the full replacement
cost of all its personal property, including removable trade fixtures, located in the Leased
Premises and on Tenant&#146;s Extra Work and all other additions and improvements (including fixtures)
made by Tenant and not required to be insured by Landlord above, regardless of whether such
improvements were made at Landlord&#146;s or Tenant&#146;s expense. If the annual premiums to be paid by
Landlord shall exceed the standard rates because of Tenant&#146;s operations within, or contents of, the
Leased Premises or because the improvements to the Leased Premises are in excess of improvements
contemplated by the Tenant Improvement Allowance, Tenant shall promptly pay the excess amount of
the premium upon request by Landlord (and if necessary, Landlord may allocate the insurance costs
of the Building to give effect to this sentence). Upon the request of Landlord, a duly executed
certificate of insurance, reflecting Tenant&#146;s maintenance of the insurance required under this
<B>Section&nbsp;6.4 </B>and <B>Section&nbsp;6.5</B>, shall be delivered to Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5. <U>Liability Insurance.</U> Landlord and Tenant shall each maintain a policy or
policies of commercial general liability insurance with the premiums thereon fully paid on or
before the due dates, issued by and binding upon a solvent insurance company authorized to
transact business in Tennessee. Such insurance shall be written on an occurrence basis and shall
afford minimum protection (which may be affected by primary and/or excess coverage) of not less
than $1,000,000.00 per occurrence for bodily injury and property damage with umbrella liability in
excess of $1,000,000 of no less than $2,000,000 per occurrence and in the aggregate provided,
however, Tenant shall carry such greater limits of coverage as Landlord may reasonably request
from time to time so long as Landlord maintains similar limits of coverage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6. <U>Hold Harmless.</U> Landlord shall not be liable to Tenant, its agents, servants,
employees, contractors, customers or invitees for any damage to person or property caused by any
act, omission or neglect of Tenant. Without limiting or being limited by any other indemnity in
this Lease, but rather in confirmation and furtherance thereof, Tenant agrees to indemnify, defend
by counsel reasonably acceptable to Landlord and hold Landlord, Landlord&#146;s beneficiaries (if
Landlord is a land trust), the managing agent of the Building, the leasing agent of the Building
and their respective agents, partners, shareholders, officers, directors and employees of the
Building harmless of, from and against any and all losses, damages, liabilities, claims, liens,
costs and expenses (including, but not limited to, court costs, reasonable attorneys&#146; fees and
litigation expenses) in connection with injury to or death of any person or damage to or theft,
loss or loss of the use of any property occurring in or about the Leased Premises or the Building
arising from Tenant&#146;s occupancy of the Leased Premises, or the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conduct of its business or from any activity, work, or thing done, permitted or suffered by
Tenant in or about the Leased Premises or the Building, or from any breach or default on the part
of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed
pursuant to the terms of this Lease, or due to any other act or omission or willful misconduct of
Tenant or any of its agents, employees, contractors, assigns, subtenants, guest or invitees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7. <U>Waiver of Subrogation Rights.</U> Anything in this Lease to the contrary
notwithstanding, Landlord and Tenant each hereby waives any and all rights of recovery, claim,
action or cause of action, against the other, its agents, servants, partners, shareholders,
officers or employees, for personal injury, loss or damage to business, and loss or damage that
may occur to the Leased Premises, the Building or any improvements thereto or thereon or any
personal property of such party therein or thereon by reason of fire, the elements, or any other
cause to the extent such loss or damage is covered by terms of the all-risk property insurance
policies referred to in <B>Section&nbsp;6.4 </B>hereof or any other insurance policy maintained by Landlord or
Tenant, as applicable, regardless of cause or origin, including negligence of the other party
hereto, its agents, officers, partners, shareholders, servants or employees, and covenants that no
insurer shall hold any right of subrogation against such other party. The foregoing waiver shall
apply regardless of the cause or origin of such claim, including but not limited to the negligence
of a party, or such party&#146;s agents, officers, employees or contractors, but shall not apply if it
would have the effect, but only to the extent of such effect, of invalidating any insurance
coverage of Landlord or Tenant. Each party shall obtain any special endorsements, if any, required
by their respective insurers to evidence compliance with the aforementioned waiver.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1. <U>Default and Remedies.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The occurrence of any of the following shall constitute a default under and breach of this
Lease by Tenant (an <B><I>&#147;Event of Default&#148;</I></B>):
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Failure by Tenant to pay any Rental within ten
(10)&nbsp;days after the same becomes due hereunder;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Premises are deserted, vacated, or not
used for a period exceeding thirty (30)&nbsp;consecutive days, even though
the Tenant continues to pay the stipulated monthly rent;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Failure by Tenant to observe or perform any of
the covenants in respect of assignment and subletting set forth in
<B>Article&nbsp;VIII;</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Failure by Tenant to cure forthwith, immediately
after receipt of notice from Landlord, any hazardous condition which
Tenant has created or permitted in violation of law or of this Lease;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Failure by Tenant to complete, execute and
deliver any instrument or document required to be completed, executed
and delivered by Tenant pursuant to <B>Section&nbsp;7.8 </B>or <B>Section&nbsp;7.9 </B>of</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Lease, within ten (10)&nbsp;days after the initial written demand
therefor to Tenant;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Failure by Tenant to observe or perform any other
covenant, agreement, condition or provision of this Lease, if such
failure shall continue for thirty (30)&nbsp;days after written notice thereof
from Landlord to Tenant; provided that such thirty (30)&nbsp;day period shall
be extended for the time reasonably required to complete such cure, if
such failure cannot reasonably be cured within said thirty (30)&nbsp;day
period and Tenant commences to cure such failure within said thirty (30)
day period and thereafter diligently and continuously proceeds to cure
such failure;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The levy upon execution or the attachment by
legal process of the leasehold interest of Tenant, or the filing or
creation of a lien in respect of such leasehold interest, which lien
shall not be released or discharged within ten (10)&nbsp;days from the date
of such filing;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any default under or breach by any guarantor of Tenant&#146;s obligations
under this Lease of such guarantor&#146;s obligations under any agreements
with Landlord;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(ix)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant or any guarantor of Tenant&#146;s obligations
under this Lease becomes insolvent or bankrupt or admits in writing its
inability to pay its debts as they mature, or makes an assignment for
the benefit of creditors, or applies for or consents to the appointment
of a trustee or receiver for all or a major part of its property;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(x)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A trustee or receiver is appointed for Tenant,
any guarantor of Tenant&#146;s obligations under this Lease or for a major
part of either party&#146;s property and is not discharged within sixty (60)
days after such appointment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any bankruptcy, reorganization, arrangement,
insolvency or liquidation proceeding, or other proceeding for relief
under any bankruptcy law or similar law for the relief of debtors, is
instituted (A)&nbsp;by Tenant or any guarantor of Tenant&#146;s obligations under
this Lease, or (B)&nbsp;against Tenant or any guarantor of Tenant&#146;s
obligations under this Lease and is allowed against it or is consented
to by it or is not dismissed within sixty (60)&nbsp;days after such
institution;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant&#146;s repeated or continued failure to
timely pay any Rental due Landlord hereunder where such failure shall
continue or be repeated for two (2)&nbsp;consecutive months, or for a total
of four (4)&nbsp;months in any period of twelve (12)&nbsp;consecutive months; or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(xiii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant&#146;s repeated failure to observe or perform any of the other
covenants, terms or conditions hereof more than six (6)&nbsp;times, in the
aggregate, in any period of twelve (12)&nbsp;consecutive months.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Upon the occurrence of an Event of Default, Landlord shall have the option to do and
perform any one or more of the following in addition to, and not in limitation of, any other
remedy or right permitted it by law or in equity or by this Lease:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Landlord, with or without terminating this
Lease, may immediately or at any time thereafter re-enter the Leased
Premises and correct or repair any condition which shall constitute a
failure on Tenant&#146;s part to keep, observe, perform, satisfy, or abide
by any term, condition, covenant, agreement, or obligation of this
Lease or of the Rules and Regulations now in effect or hereafter
adopted or of any notice given Tenant by Landlord pursuant to the terms
of this Lease, and Tenant shall fully reimburse and compensate Landlord
on demand.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Landlord, with or without terminating this
Lease, may immediately or at any time thereafter demand in writing that
Tenant vacate the Leased Premises and thereupon Tenant shall vacate the
Leased Premises and remove therefrom all property thereon belonging to
or placed on the Leased Premises by, at the direction of, or with
consent of Tenant within ten (10)&nbsp;days of receipt by Tenant of such
notice from Landlord, whereupon Landlord shall have the right to
re-enter and take possession of the Leased Premises. Any such demand,
re-entry and taking possession of the Leased Premises by Landlord shall
not of itself constitute an acceptance by Landlord of a surrender of
this Lease or of the Leased Premises by Tenant and shall not of itself
constitute a termination of this Lease by Landlord.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Landlord, with or without terminating this Lease,
may immediately or at any time thereafter, re-enter the Leased Premises
and remove therefrom Tenant and all property belonging to or placed on
the Leased Premises by, at the direction of, or with consent of Tenant.
Any such re-entry and removal by Landlord shall not of itself constitute
an acceptance by Landlord of a surrender of this Lease or of the Leased
Premises by Tenant and shall not of itself constitute a termination of
this Lease by Landlord.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Landlord, with or without terminating this Lease,
may immediately or at any time thereafter relet the Leased Premises or
any part thereof for such time or times, at such rental or rentals and
upon such other terms and conditions as Landlord in its sole discretion
may deem advisable, and Landlord may make any alterations or repairs to
the Leased Premises which it may deem necessary or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>proper to facilitate such reletting; and Tenant shall pay all costs
of such reletting including but not limited to the cost of any such
alterations and repairs to the Leased Premises, attorneys&#146; fees,
leasing inducements, and brokerage commissions; and if this Lease
shall not have been terminated, Tenant shall continue to pay all rent
and all other charges due under this lease up to and including the
date of beginning of payment of rent by any subsequent tenant of part
or all of the Leased Premises, and thereafter Tenant shall pay
monthly during the remainder of the term of this Lease the
difference, if any, between the rent and other charges collected from
any such subsequent tenant or tenants and the rent and other charges
reserved in this Lease, but Tenant shall not be entitled to receive
any excess of any such rents collected over the rents reserved
herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Landlord may immediately or at any time thereafter
terminate this Lease, and this Lease shall be deemed to have been
terminated upon receipt by Tenant of written notice of such termination;
upon such termination Landlord shall recover from Tenant all damages
Landlord may suffer by reason of such termination including, without
limitation, unamortized sums expended by Landlord for leasing commissions
and construction of tenant improvements, all arrearages in rentals,
costs, charges, additional rentals, and reimbursements, the cost
(including court costs and attorneys&#146; fees) of recovering possession of
the Leased Premises, the cost of any alteration of or repair to the
Leased Premises which is necessary or proper to prepare the same for
reletting and, in addition thereto, Landlord at its election shall have
and recover from Tenant either (A)&nbsp;an amount equal to the excess, if any,
of the total amount of all rents and other charges to be paid by Tenant
for the remainder of the term of this Lease over the then reasonable
rental value of the Leased Premises for the remainder of the term of this
Lease, or (B)&nbsp;the rents and other charges which Landlord would be
entitled to receive from Tenant pursuant to the provisions of <B>Section
7.</B><B>1(b)(iv)</B> if the Lease were not terminated. Such election shall be made
by Landlord by serving written notice upon Tenant of its choice of one of
the two said alternatives within thirty (30)&nbsp;days of the notice of
termination. All future amounts due in accordance with this <B>Section
7.</B><B>1(b)(v)</B> shall be discounted to present value at the per annum interest
rate publicly announced by a federally insured bank selected by Landlord
in the state in which the Building is located as such bank&#146;s prime or
base rate.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If Landlord re-enters the Leased Premises or terminates this Lease pursuant to any of the
provisions of this Lease, Tenant hereby waives all claims for damages which may be caused by such
re-entry or termination by Landlord. Tenant shall and does hereby indemnify and hold Landlord
harmless from any loss, cost (including court costs and
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">attorneys&#146; fees), or damages suffered by Landlord by reason of such re-entry or termination.
No such re-entry or termination shall be considered or construed to be a forcible entry.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The exercise by Landlord of any one or more of the rights and remedies provided in this
Lease shall not prevent the subsequent exercise by Landlord of any one or more of the other rights
and remedies herein provided. All remedies provided for in this Lease are cumulative and may, at
the election of Landlord, be exercised alternatively, successively, or in any other manner and are
in addition to any other rights provided for or allowed by law or in equity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No act by Landlord with respect to the Leased Premises shall terminate this Lease,
including, but not limited to, acceptance of the keys, institution of an action for detainer or
other dispossessory proceedings, it being understood that this Lease may only be terminated by
express written notice from Landlord to Tenant, and any reletting of the Leased Premises shall be
presumed to be for and on behalf of Tenant, and not Landlord, unless Landlord expressly provides
otherwise in writing to Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Upon termination of Tenant&#146;s right to possess the Leased Premises, Landlord shall, only to
the extent required by applicable law, use objectively reasonable efforts to mitigate damages by
reletting the Leased Premises. Landlord shall not be deemed to have failed to do so if Landlord
refuses to lease the Leased Premises to a prospective tenant that Landlord deems, in the exercise
of Landlord&#146;s business judgment, unacceptable for or incompatible with the other tenants of the
Building, or who (1)&nbsp;is an Affiliate (as defined below), parent or subsidiary of Tenant; (2)&nbsp;is not
acceptable to any Mortgagee of Landlord; (3)&nbsp;requires improvements to the Leased Premises to be
made at Landlord&#146;s expense; or (4)&nbsp;is unwilling to accept lease terms then proposed by Landlord,
including: (a)&nbsp;leasing for a shorter or longer term than remains under this Lease; (b)
re-configuring or combining the Leased Premises with other space, (c)&nbsp;taking all or only a part of
the Leased Premises; and/or (d)&nbsp;changing the use of the Leased Premises. Notwithstanding Landlord&#146;s
duty to mitigate its damages as provided herein, Landlord shall not be obligated (i)&nbsp;to give any
priority to reletting Tenant&#146;s space in connection with its leasing of space in the Building or any
complex of which the Building is or becomes a part, or (ii)&nbsp;to accept below market rental rates for
the Leased Premises or any rate that would negatively impact the market rates for the Building. To
the extent that Landlord is required by applicable law to mitigate damages, Tenant must plead and
prove by clear and convincing evidence that Landlord failed to so mitigate in accordance with the
provisions of this Section&nbsp;7.1(f), and that such failure resulted in an avoidable and quantifiable
detriment to Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2. <U>Insolvency or Bankruptcy.</U> The appointment of a receiver to take possession of all
or substantially all of the assets of Tenant or any guarantor of Tenant&#146;s obligations under this
Lease, or any general assignment by Tenant or any guarantor of Tenant&#146;s obligations under this
Lease for the benefit of creditors, or any action taken or suffered by Tenant or any guarantor of
Tenant&#146;s obligations under this Lease under any insolvency, bankruptcy, or reorganization act,
shall, at Landlord&#146;s option, constitute a breach of this Lease by Tenant. Upon the happening of any
such event or at any time thereafter, this Lease shall terminate five (5)&nbsp;days after written notice
of termination from Landlord to Tenant. In no event shall this Lease be assigned or assignable by
operation of law or by voluntary or involuntary bankruptcy proceedings or otherwise and in no event
shall this Lease or any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rights or privileges hereunder be an asset of Tenant under any bankruptcy, insolvency, or
reorganization proceedings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3. <U>Late Payments.</U> Tenant shall pay, as a one (1)&nbsp;time late charge on each
installment of any Rental owed by Tenant hereunder that is not paid when due, the greater of
$100.00 or an amount equal to five percent (5%) of the amount due for each and every thirty (30)
day period that said amount remains unpaid (but in no event shall the amount of such late charge
exceed an amount based upon the highest legally permissible rate chargeable at any time by Landlord
under the circumstances). Should Tenant make a partial payment of past due amounts, the amount of
such partial payment shall be applied first to reduce all accrued and unpaid late charges, in
inverse order of their maturity, and then to reduce all other past due amounts, in inverse order of
their maturity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4. <U>Attorney&#146;s Fees.</U> In any action to enforce a party&#146;s rights under this Lease or
the terms hereof, the prevailing party shall be entitled to collect from the other party all court
costs, reasonable attorneys fees and litigation expenses, including, but not limited to, costs of
depositions and expert witnesses, actually incurred by the prevailing party in connection with such
action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5. <U>Waiver of Homestead.</U> Tenant hereby waives and renounces all homestead or
exemption rights which Tenant may have under or by virtue of the Constitutions and Laws of the
United States, the State of Tennessee, and any other State as against any debt or sum Tenant may
owe Landlord under this Lease and hereby transfers, conveys, and assigns to Landlord all homestead
or exemption rights which may be allowed or set apart to Tenant, including such as may be set apart
in any bankruptcy proceeding, to pay any debt or sum owing by Tenant to Landlord hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6. <U>No Waiver of Rights.</U> No failure or delay of Landlord to exercise any right or
power given it herein or to insist upon strict compliance by Tenant of any obligation imposed on
it herein and no custom or practice of either party hereto at variance with any term hereof shall
constitute a waiver or a modification of the terms hereof by Landlord or any right it has herein
to demand strict compliance with the terms hereof by Tenant. No waiver of any right of Landlord or
any default by Tenant on one occasion shall operate as a waiver of any of Landlord&#146;s other rights
or of any subsequent default by Tenant. No express waiver shall affect any condition, covenant,
rule, or regulation other than the one specified in such waiver and then only for the time and in
the manner specified in such waiver. No person has or shall have any authority to waive any
provision of this Lease unless such waiver is expressly made in writing and signed by an
authorized officer of Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7. <U>Holding Over.</U> In the event of holding over by Tenant after expiration or
termination of this Lease without the written consent of Landlord, Tenant shall pay as liquidated
damages, solely for such holding over, double the Rental that would have been payable if this
Lease had not so terminated or expired) for the entire holdover period. No holding over by Tenant
after the term of this Lease shall be construed to extend this Lease, and Tenant shall be deemed a
tenant at will, terminable on five (5)&nbsp;days notice from Landlord. In the event of any unauthorized
holding over, Tenant shall indemnify Landlord against all claims for damages by any other tenant
to whom Landlord shall have leased all or any part of the Leased Premises effective upon the
termination of this Lease. Any holding over with the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">express written consent of Landlord shall thereafter constitute this Lease to be a lease from
month to month (terminable by either party on thirty (30)&nbsp;days notice) at a Base Rental, Tenant&#146;s
Forecast Additional Rental, and all other sums required to be paid by Tenant prior to the
expiration or termination of this Lease as may be determined by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">7.8. <U>Subordination.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Landlord may have heretofore or may hereafter encumber with a mortgage, deed of trust,
deed to secure debt, financing statement or other security interests <B>(collectively, a </B><B><I>&#147;Mortgage&#148;)</I></B>
the Land, the Project or any part thereof or any interest therein, may sell and lease back the
Land, the Project or any part thereof, and may encumber the leasehold estate under such a sale and
leaseback arrangement with a Mortgage. (The holder of any Mortgage is herein called a <B><I>&#147;Mortgagee.&#148;</I></B>
A lease creating Landlord&#146;s interest in the Land, the Project or part thereof is herein called a
<B><I>&#147;Ground Lease&#148; </I></B>and the lessor under any such Ground Lease is herein called a <B><I>&#147;Ground Lessor.&#148;</I></B><I>)</I>
This Lease and the rights of Tenant hereunder shall be and are hereby expressly made subject to
and subordinate at all times to any Mortgage and to any Ground Lease now or hereafter existing,
and to all amendments, modifications, renewals, extensions, consolidations and replacements
thereof, and to all advances made or hereafter to be made upon the security thereof; provided,
however, that the Mortgagee or Ground Lessor shall not, so long as Tenant shall not be in default
under this Lease, disturb Tenant in its possession of the Leased Premises or terminate Tenant&#146;s
rights hereunder. Tenant agrees to execute and deliver to Landlord such further instruments
consenting to or confirming the subordination of this Lease to any Mortgage and to any Ground
Lease and containing such other provisions which may be requested in writing by Landlord within
ten (10)&nbsp;days after Tenant&#146;s receipt of such written request.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant agrees that if Landlord defaults in the performance or observance of any covenant
or condition of this Lease required to be performed or observed by Landlord hereunder, Tenant will
give written notice specifying such default by certified or registered mail, postage prepaid, to
any Mortgagee or Ground Lessor of which Tenant has been notified in writing, and before Tenant
exercises any right or remedy which it may have on account of any such default of Landlord, such
Mortgagee or Ground Lessor shall have a reasonable amount of time to cure such default of Landlord,
if such default can be cured without such Mortgagee or Ground Lessor taking possession of the
mortgaged or leased estate, or to obtain possession of the mortgaged or leased estate and then to
cure such default of Landlord, if such default cannot be cured without such Mortgagee or Ground
Lessor taking possession of the mortgaged or leased estate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If any Mortgage is foreclosed, or Landlord&#146;s interest under this Lease is conveyed or
transferred in lieu of foreclosure, or if any Ground Lease is terminated:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No person or entity which as the result of any
of the foregoing has succeeded to the interest of Landlord in this
Lease (any such person or entity being hereafter called a <I>&#147;</I><B><I>Successor</I></B><I>&#148;)</I>
shall be liable for any default by Landlord or any other matter which
occurred prior to the date such Successor succeeded to Landlord&#146;s
interest in this Lease, nor shall such Successor be bound by or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>subject to any offsets or defenses which Tenant may have against
Landlord or any other predecessor in interest to such Successor.</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon request of any Successor, Tenant will
attorn to such Successor, as Landlord under this Lease, subject to the
provisions of this <B>Section&nbsp;7.</B><B>8(c)</B> and <B>Section&nbsp;7.</B><B>8(e)</B><B>, </B>and will execute
and deliver such instruments as may be necessary or appropriate to
evidence such attornment within ten (10)&nbsp;days after receipt of a
written request to do so.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No Successor shall be bound to recognize any
prepayment by more than thirty (30)&nbsp;days of any Rental payable by
Tenant hereunder.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding anything to the contrary contained herein, any Mortgagee may subordinate,
in whole or in part, its Mortgage to this Lease by sending Tenant notice in writing subordinating
all or any part of such Mortgage to this Lease, and Tenant agrees to execute and deliver to such
Mortgagee such further instruments consenting to or confirming the subordination of all or any
portion of its Mortgage to this Lease and containing such other provisions which may be requested
in writing by such Mortgagee within ten (10)&nbsp;days after Tenant&#146;s receipt of such written request.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Whether or not any Mortgage is foreclosed or any Ground Lease is terminated, or any
Mortgagee or Ground Lessor succeeds to any interest of Landlord under this Lease, no Mortgagee or
Ground Lessor shall have any liability to Tenant for any security deposit paid to Landlord by
Tenant hereunder, unless such security deposit has actually been received by such Mortgagee or
Ground Lessor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Should any prospective Mortgagee or Ground Lessor require a modification or modifications
of this Lease, which modification or modifications will not cause an increased cost or expense to
Tenant or in any other way materially and adversely change the rights and obligations of Tenant
hereunder, in the reasonable judgment of Tenant, then and in such event, Tenant agrees that this
Lease may be so modified and agrees to execute whatever documents are required therefor and deliver
the same to Landlord within ten (10)&nbsp;days following written request therefor. Should any
prospective Mortgagee or Ground Lessor require execution of a short form of this Lease for
recording (containing, among other customary provisions, the names of the parties, a description of
the Leased Premises and the term of this Lease), Tenant agrees to execute such short form of lease
and deliver the same to Landlord within ten (10)&nbsp;days following the request therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;If Tenant fails within ten (10)&nbsp;days after initial written demand therefor to execute and
deliver any instruments as may be necessary or proper to effectuate any of the covenants of Tenant
set forth above in this <B>Section, </B>Tenant hereby makes, constitutes and irrevocably appoints any one
of Landlord or any of Landlord&#146;s beneficiaries or partners in such beneficiaries as
attorney-in-fact for Tenant (such power of attorney being coupled with an interest) with full power
and authority to execute and deliver any such instruments for and in the name of Tenant.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;No Mortgagee or Ground Lessor of which Tenant has been notified, in writing, shall be
bound any amendment or modification of this Lease made without the written consent of such
Mortgagee or Ground Lessor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9. <U>Estoppel Certificate.</U> Tenant agrees that, from time to time upon not less than
ten (10)&nbsp;days&#146; prior request by Landlord, or any existing or prospective Mortgagee or Ground
Lessor, Tenant will, and Tenant will cause any subtenant, licensee, concessionaire or other
occupant of the Leased Premises claiming by, through or under Tenant, to complete, execute and
deliver to Landlord or Landlord&#146;s designee or to any existing or prospective mortgagee or ground
lessor, a written estoppel certificate certifying (i)&nbsp;that this Lease is unmodified and is in full
force and effect (or if there have been modifications, that this Lease, as modified, is in full
force and effect and setting forth the modifications); (ii)&nbsp;the amounts of the monthly installments
of Base Rental, Tenant&#146;s Forecast Additional Rental, Tenant&#146;s Additional Rental Adjustment and
other sums then required to be paid under this Lease by Tenant; (iii)&nbsp;the date to which the Base
Rental, Tenant&#146;s Forecast Additional Rental, Tenant&#146;s Additional Rental Adjustment and other sums
required to be paid under this Lease by Tenant have been paid; (iv)&nbsp;that Landlord is not in default
under any of the provisions of this Lease, or if in default, the nature thereof in detail and what
is required to cure same; and (v)&nbsp;such other information concerning the status of this Lease or the
parties&#146; performance hereunder reasonably requested by Landlord or the party to whom such estoppel
certificate is to be addressed.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">8.1. <U>Sublease or Assignment by Tenant.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Tenant shall not, without the Landlord&#146;s prior written consent, (i)&nbsp;assign, convey,
mortgage, pledge, encumber, or otherwise transfer (whether voluntarily, by operation of law, or
otherwise) this Lease or any interest hereunder; (ii)&nbsp;allow any lien to be placed upon Tenant&#146;s
interest hereunder; (iii)&nbsp;sublet the Leased Premises or any part thereof; or (iv)&nbsp;permit the use or
occupancy of the Leased Premises or any part thereof by any one other than Tenant. Any attempt to
consummate any of the foregoing without Landlord&#146;s consent shall be void and of no force or effect.
For purposes hereof, the transfer of the ownership or voting rights in a controlling interest of
the voting stock of Tenant (if Tenant is a corporation) or the transfer of a general partnership
interest or a majority of the limited partnership interest in Tenant (if Tenant is a partnership),
at any time throughout the term of this Lease, shall be deemed to be an assignment of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything herein to the contrary, if at any time or from time to time
during the term of this Lease, Tenant desires to sublet all or any portion of the Leased Premises
or assign all or any portion of Tenant&#146;s interest in this Lease, Tenant shall notify Landlord in
writing (hereinafter referred to in this <B>Section </B>as the <I>&#147;</I><B><I>Notice</I></B><I>&#148;) </I>of the terms of the proposed
subletting or assignment, the identity of the proposed sublessee or assignee, the area proposed to
be sublet or covered by the assignment (hereinafter referred to as <B><I>&#147;Sublet Space&#148;), </I></B>and such other
information as Landlord may request to evaluate Tenant&#146;s request to sublet or assign. Landlord
shall then have the option (i)&nbsp;to sublet the Sublet Space from Tenant as provided in subsection (c)
hereof at the same Base Rental and Tenant&#146;s Additional Rental as Tenant is required to pay to
Landlord under this Lease for the Sublet Space, (ii)&nbsp;to terminate this Lease as to the Sublet Space
as provided in subsection (d)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereof, or (iii)&nbsp;to allow the proposed sublease or assignment subject only to the final review
for approval as provided in subsection (e)&nbsp;hereof. Landlord s option to sublet, to terminate, or to
allow the proposed sublease or assignment subject to final review, as the case may be, shall be
exercisable by Landlord in writing within a period of thirty (30)&nbsp;calendar days after receipt of
the Notice and any failure by Landlord to exercise any of such options within said thirty (30)&nbsp;day
period shall be deemed to constitute the election of option (iii)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In the event Landlord exercises the option to sublet the Sublet Space pursuant to
Landlord&#146;s options set forth above, the term of the subletting from the Tenant to Landlord shall be
the term set forth in the Notice (which shall not be longer than the then current term of this
Lease unless Landlord expressly agrees in writing that any extension or renewal option contained in
this Lease will apply to such Sublet Space) and shall be on such terms and conditions as are
contained in this Lease to the extent applicable, except that the Landlord shall have the right to
further sublet the Sublet Space freely and without any consent or approval from Tenant and upon
such terms and for such rent as Landlord shall agree upon in its sole and absolute discretion.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If Landlord elects to terminate this Lease pursuant to Landlord&#146;s options set forth above,
then this Lease shall terminate as to the Sublet Space on the date set forth in Landlord&#146;s notice
to Tenant, which date shall be no less than thirty (30)&nbsp;days and no more than ninety (90)&nbsp;days
after the date of such notice. If the Sublet Space does not constitute the entire Leased Premises
and Landlord exercises its option to terminate this Lease with respect to the Sublet Space, as to
that portion of the Leased Premises which is not part of the Sublet Space, this Lease shall remain
in full force and effect except that Base Rental, Tenant&#146;s Forecast Additional Rental, and Tenant&#146;s
Additional Rental shall be calculated on the difference between the Rentable Square Feet prior to
such termination and the Rentable Square Feet of the Sublet Space.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If Landlord elects or is deemed to have elected to allow the proposed sublease or
assignment subject to final review, Tenant shall submit to Landlord, within twenty (20)&nbsp;calendar
days after receipt of Landlord&#146;s notice of election (or the expiration of said thirty (30)-day
period if no such election is made), a copy of the proposed sublease or assignment, which sublease
or assignment must provide for the assumption of all of Tenant&#146;s obligations under this Lease, and
such additional information concerning the business, reputation and credit-worthiness of the
proposed sublessee or assignee as shall be sufficient to allow Landlord to form a commercially
reasonable judgment with respect thereto. Landlord agrees not to unreasonably withhold its
approval of any proposed sublease or assignment and, in the event Landlord fails to approve or
disapprove any such sublease or assignment within thirty (30)&nbsp;days after Landlord&#146;s receipt of
such submission from Tenant, such sublease or assignment shall be deemed to be approved; provided,
however, that if Landlord approves any proposed sublease or assignment, Landlord shall receive
from Tenant as additional rent hereunder seventy-five percent (75%) of any rents or other sums
received by Tenant pursuant to said sublease or assignment in excess of the rentals payable to
Landlord by Tenant under this Lease with respect to the Sublet Space (after deducting all of
Tenant&#146;s reasonable costs associated therewith, including reasonable brokerage fees and the
reasonable cost of remodeling or otherwise improving the Leased Premises for said sublessee or
assignee), as such rents or other sums are received by Tenant from the approved sublessee or
assignee. Landlord may require that any rent or other sums paid by a sublessee or assignee be paid
directly to Landlord. If Landlord approves in writing the proposed sublessee or assignee and the
terms of the proposed sublease
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or assignment, but a fully executed counterpart of such sublease or assignment is not
delivered to Landlord within sixty (60)&nbsp;calendar days after the date of Landlord&#146;s written
approval, then Landlord&#146;s approval of the proposed sublease or assignment shall be deemed null and
void and Tenant shall again comply with all the conditions of this <B>Section </B>as if the Notice and
options hereinabove referred to had not been given, received or exercised. If Landlord fails to
approve the form of sublease or assignment or the sublessee or assignee, Tenant shall have the
right to submit amended forms or other sublessees or assignees to Landlord to review for approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notwithstanding the giving by Landlord of its consent to any sublease or assignment with
respect to the Leased Premises, no sublessee or assignee may exercise any expansion option, right
of first refusal option, or renewal option under this Lease except in accordance with a separate
written agreement entered into directly between such sublessee or assignee and Landlord, and
Tenant may not exercise any such right with respect to any space that Tenant has sublet or
assigned.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Notwithstanding the giving by Landlord of its consent to any subletting, assignment or
occupancy as provided hereunder or any language contained in such lease, sublease or assignment to
the contrary, unless this Lease is expressly terminated by Landlord, Tenant shall not be relieved
of any of Tenant&#146;s obligations or covenants under this Lease and Tenant shall remain fully liable
hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;If, with the consent of the Landlord, the Leased Premises or any part thereof is sublet or
occupied by other than Tenant or this Lease is assigned, Landlord may, after default by Tenant,
collect rent from the subtenant, assignee or occupant, and apply the net amount collected to the
Rental herein reserved. No such subletting, assignment, occupancy, or collection shall be deemed
(i)&nbsp;a waiver of any of Tenant&#146;s covenants contained in this Lease, (ii)&nbsp;a release of Tenant from
further performance by Tenant of its covenants under this Lease, or (iii)&nbsp;a waiver of any of
Landlord&#146;s other rights hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In no event shall Tenant assign this Lease or enter into any sublease, license, concession
or other agreement for use, occupancy or utilization of any part of the Leased Premises which
provides for a rental or other payment for such use, occupancy or utilization based in whole or in
part on the income or profits derived by any person from the Leased Premises leased, used, occupied
or utilized (other than an amount based on a fixed percentage or percentages of gross receipts of
sales), and Tenant agrees that all assignments, subleases, licenses, concessions or other
agreements for use, occupancy or utilization of any part of the Leased Premises shall provide that
the person having an interest in the possession, use, occupancy or utilization of the Leased
Premises shall not enter into any lease, sublease, license, concession or other agreement for use,
occupancy or utilization of space in the Leased Premises which provides for a rental or other
payment for such use, occupancy or utilization based in whole or in part on the income or profits
derived by any person from the Leased Premises leased, used, occupied or utilized (other than an
amount based on a fixed percentage or percentages of gross receipts of sales) and any such
purported assignment, sublease, license, concession or other agreement shall be absolutely void and
ineffective as a conveyance of any right or interest in the possession, use, occupancy or
utilization of any part of the Leased Premises.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2. <U>Assignment by Landlord.</U> Landlord shall have the right to transfer and assign, in
whole or in part, all its rights and obligations hereunder, in the Building, the Land and all other
property referred to herein, and in such event and upon such transfer (any such transferee to have
the benefit of, and be subject to, the provisions of Sections&nbsp;8.03 and 8.04 hereof) no further
liability or obligation shall thereafter accrue against Landlord hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3. <U>Peaceful Enjoyment.</U> Landlord covenants that Tenant shall and may peacefully have,
hold and enjoy the Leased Premises free from hindrance by Landlord or any person claiming by,
through or under Landlord but subject to the other terms hereof, provided that Tenant pays the
rental and other sums herein recited to be paid by Tenant and performs all of Tenant&#146;s covenants
and agreements herein contained. It is understood and agreed that this covenant and any and all
other covenants of Landlord contained in this Lease shall be binding upon Landlord and its
successors only with respect to breaches occurring during the ownership of the Landlord&#146;s interest
hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4. <U>Limitation of Landlord&#146;s Personal Liability.</U> Tenant specifically agrees to look
solely to Landlord&#146;s equity interest in the Building for the recovery of any monetary judgment
against Landlord, it being agreed that Landlord (and its partners and shareholders) shall never be
personally liable for any such judgment. The provision contained in the foregoing sentence is not
intended to, and shall not, limit any right that Tenant might otherwise have to obtain injunctive
relief against Landlord or Landlord&#146;s successors in interest or any suit or action in connection
with enforcement or collection of amounts which may become owing or payable under or on account of
insurance maintained by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5. <U>Force Majeure.</U> Landlord and Tenant (except with respect to the payment of Rental
or any other monetary obligation under this Lease shall be excused for the period of any delay and
shall not be deemed in default with respect to the performance of any of the terms, covenants and
conditions of this Lease when prevented from so doing by a cause or causes beyond the Landlord&#146;s or
Tenant&#146;s (as the case may be) control (excluding financial inability to perform), which shall
include, without limitation, all labor disputes, governmental regulations or controls, fire or
other casualty, inability to obtain any material or services, acts of God, or any other cause not
within the reasonable control of Landlord or Tenant (as the case may be).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IX.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1. <U>Notices.</U> Any notice or other communications required or permitted to be given
under this Lease must be in writing and shall be effectively given or delivered if (i)&nbsp;hand
delivered to the addresses for Landlord and Tenant stated below, (ii)&nbsp;sent by certified or
registered United States Mail, return receipt requested, to said addresses, or (iii)&nbsp;sent by
nationally recognized overnight courier (such as Federal Express, UPS Next Day Air or Airborne
Express), with all delivery charges paid by the sender and signature required for delivery, to said
address. Any notice mailed shall be deemed to have been given upon receipt or refusal thereof.
Notice effected by hand delivery shall be deemed to have been given at the time of actual delivery.
Either party shall have the right to change its address to which notices shall thereafter be sent
and the party to whose attention such notice shall be directed by giving the other party notice
thereof in accordance with the provisions of this <B>Section&nbsp;9.1. </B>The initial addresses of the parties
for purposes of this Lease are:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">To:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lionstone Cash Flow Office One, LP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Five Greenway Plaza</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Houston, Texas 77046</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Daniel R. Dubrowski</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telecopy: (713)&nbsp;285-2911</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Property Tennessee One Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">c/o Lionstone Cash Flow Office One, LP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Five Greenway Plaza</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Houston, Texas 77046</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: F. Russ Nicholson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telecopy: (713)&nbsp;285-2911</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville Hines Development, LLC</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Property Management Office</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, TN 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Project Manager</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue, Suite&nbsp;950</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, TN 37203</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Jean W. Marstiller</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telecopy: (615)&nbsp;255-0094</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">With a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Adams and Reese / Stokes Bartholomew LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">424 Church Street, Suite&nbsp;2800</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, TN 37219-2386</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Martin S. Brown</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telecopy: (615)&nbsp;259-1470</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tenant shall also send a copy of each such notice to each Mortgagee that notifies Tenant in writing
of its interest and the address to which notices are to be sent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">9.2. <U>Miscellaneous.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Lease shall be binding upon and inure to the benefit of the successors and assigns of
Landlord, and shall be binding upon and inure to the benefit of Tenant, its successors, and, to the
extent assignment may be approved by Landlord hereunder, Tenant&#146;s assigns. Where appropriate the
pronouns of any gender shall include the other gender, and either the singular or the plural shall
include the other.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All rights and remedies of Landlord and Tenant under this Lease shall be cumulative and
none shall exclude any other rights or remedies allowed by law. This Lease is declared to be a
Tennessee contract, and all of the terms hereof shall be construed according to the laws of the
State of Tennessee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;This Lease may not be altered, changed or amended, except by an instrument in writing
executed by all parties hereto. Further, the terms and provisions of this
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lease shall not be construed against or in favor of a party hereto merely because such party
is the <B><I>&#147;Landlord&#148; </I></B>or the <B><I>&#147;Tenant&#148; </I></B>hereunder or such party or its counsel is the draftsman of this
Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If Tenant is a corporation, partnership or other entity, Tenant warrants that all consents
or approvals required of third parties (including but not limited to its Board of Directors or
partners) for the execution, delivery and performance of this Lease have been obtained and that
Tenant has the right and authority to enter into and perform its covenants contained in this Lease.
Likewise, if Landlord is a corporation, partnership or other entity, Landlord warrants that all
consent or approvals required of third parties (including but not limited to its Board of Directors
or partners) for the execution, delivery and performance of this Lease have been obtained and that
Landlord has the right and authority to enter into and perform its covenants contained in this
Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE PARTIES HERETO SHALL AND THEY HEREBY DO
WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES
HERETO AGAINST THE OTHER ON ANY MATTERS WHATSOEVER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS
LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT&#146;S USE OR OCCUPANCY OF THE DEMISED PREMISES
AND/OR ANY CLAIM OF INJURY OR DAMAGE. IN THE EVENT LANDLORD COMMENCES ANY PROCEEDINGS FOR
NONPAYMENT OF RENT OR ANY OTHER AMOUNTS PAYABLE HEREUNDER, TENANT SHALL NOT INTERPOSE ANY
COUNTERCLAIM OF WHATEVER NATURE OR DESCRIPTION IN ANY SUCH PROCEEDING, UNLESS THE FAILURE TO RAISE
THE SAME WOULD CONSTITUTE A WAIVER THEREOF. THIS SHALL NOT, HOWEVER, BE CONSTRUED AS A WAIVER OF
TENANT&#146;S RIGHT TO ASSERT SUCH CLAIMS IN ANY SEPARATE ACTION BROUGHT BY TENANT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Wherever in this Lease there is imposed upon Landlord the obligation to use best or
reasonable efforts or due diligence, Landlord shall be required to do so only to the extent the
same is economically feasible and otherwise will not impose upon Landlord extreme financial or
other burdens.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;If any term or provision of this Lease, or the application thereof to any person or
circumstance, shall to any extent be invalid or unenforceable, the remainder of this Lease, or the
application of such provision to persons or circumstances other than those as to which it is
invalid or unenforceable, shall not be affected thereby, and each provision of this Lease shall be
valid and shall be enforceable to the extent permitted by law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Time is of the essence in this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;This Lease agreement shall not convey any leasehold estate from Landlord to Tenant.
Landlord and Tenant hereby agree that this Lease creates only the interest of a usufruct in Tenant
which may not be levied upon or assigned without Landlord&#146;s permission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Tenant represents and warrants to Landlord that Tenant did not deal with any broker in
connection with this Lease. Tenant shall indemnify, defend and hold Landlord, Landlord&#146;s
beneficiaries, the managing agent of the Building, the leasing agent of the Building and their
respective agents, partners and employees and the Building harmless of, from and against any and
all losses, damages, liabilities, claims, liens, costs and expenses (including, without
limitation, court costs, reasonable attorneys&#146; fees and litigation expenses) arising from any
claims or demands of any broker or brokers or finders for any commission alleged to be due such
other broker or brokers or finders claiming to have dealt with Tenant in connection with this
Lease or with whom Tenant hereafter deals or whom Tenant employs. The provisions of this
subsection shall survive the expiration or earlier termination of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;If Tenant comprises more than one person, corporation, partnership, limited liability
company or other entity, the liability hereunder of all such persons, corporations, partnerships
or other entities shall be joint and several.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Landlord&#146;s receipt of any Rental payable by Tenant hereunder with knowledge of the breach
of a covenant or agreement contained in this Lease shall not be deemed a waiver of the breach. No
acceptance by Landlord of a lesser amount than the installment of Rental which is due shall be
considered, nor shall any endorsement or statement on any check or any letter accompanying any
check or payment be deemed, an accord and satisfaction. Landlord may accept a check or payment
without prejudice to Landlord&#146;s right to recover the balance due or to pursue any other remedy
provided in this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;Wherever Landlord&#146;s consent or approval is required pursuant to the terms of this Lease,
Landlord may grant or withhold the same in Landlord&#146;s sole and absolute discretion, except as
otherwise expressly provided herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;Tenant covenants and agrees to keep strictly confidential all of the financial terms of
this Lease and not to disseminate any such information to any third parties without the prior
written consent of Landlord. Tenant further covenants and agrees that, at all times after the date
of this Lease and prior to the Commencement Date, unless consented to in writing by Landlord, no
press release or other public disclosure concerning this Lease shall be made by Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;Submission of this instrument for examination shall not constitute a reservation of or
option to lease the Leased Premises or in any manner bind Landlord, and no lease or obligation on
Landlord shall arise until this instrument is signed and delivered by Landlord and Tenant;
provided, however, the execution and delivery by Tenant of this Lease to Landlord, or the managing
agent of the Building or the leasing agent of the Building shall constitute an irrevocable offer by
Tenant to lease the Leased Premises on the terms and conditions herein contained, which offer may
not be revoked for thirty (30)&nbsp;days after such delivery.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <U>Financial Statements.</U> Tenant shall deliver to Landlord, within fifteen (15)&nbsp;days
after Landlord&#146;s request, Tenant&#146;s annual financial statement for the immediately previous fiscal
year and Tenant&#146;s quarterly financial statements, if any, prepared since such annual financial
statement, including balance sheets, income statements and cash flow statements,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">prepared in accordance with generally accepted accounting principles consistently applied.
Such financial statements shall be certified by the chief financial officer of Tenant as being
true, accurate and complete in all material respects. If Tenant&#146;s annual financial statement will
not be prepared or complete within such fifteen (15)&nbsp;day period, then Tenant&#146;s time to deliver its
annual financial statement shall be extended to the day that such statement is completed in the
normal course of Tenant&#146;s business and in keeping with reasonable business practices. However, if
Tenant&#146;s time to respond would be extended by more than thirty (30)&nbsp;days, Tenant shall so notify
Landlord in writing upon Tenant&#146;s receipt of Landlord&#146;s request for Tenant&#146;s financial statement,
and shall offer to Landlord (in the interim) a copy of Tenant&#146;s prior year&#146;s financial statement
with Tenant&#146;s chief financial officer&#146;s estimate of any material differences in Tenant&#146;s financial
condition since that statement was prepared. Landlord shall only make request for such financial
statements when Landlord determines, in the exercise of Landlord&#146;s reasonable judgment, that such
information is of immediate value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3. <U>Option to Renew.</U> Subject to the provisions hereinafter set forth and the
expansion and renewal rights of other tenants on the floor containing the Leased Premises, Landlord
hereby grants to Tenant an option to extend the Lease Term for not less than the entire initial
Leased Premises (the <B><I>&#147;Option to Renew&#148;</I></B><I>) </I>on the same terms, conditions and provisions as contained
in this Lease, as modified in this <B>Section&nbsp;9.3</B>, for one period of five (5)&nbsp;years (the <B><I>&#147;Renewal
Period&#148;</I></B><I>) </I>commencing on January&nbsp;1, 2011 (the <B><I>&#147;Renewal Period Commencement Date&#148;</I></B><I>) </I>and ending at 6:00
p.m. on December&nbsp;31, 2015.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Option to Renew shall be exercisable by written notice from Tenant to Landlord of
Tenant&#146;s election to exercise said option <B><I>(&#147;Tenant&#146;s Renewal Notice&#148;) </I></B>given not earlier than
twenty-four (24)&nbsp;months nor later than nine (9)&nbsp;months prior to the Renewal Period Commencement
Date, time being of the essence. If the Option to Renew is not so exercised, said option shall
thereupon expire.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant may only exercise the Option to Renew, and an exercise thereof shall only be
effective, if at the time of Tenant&#146;s exercise of said option and on the Renewal Period
Commencement Date this Lease is in full force and effect and there is no Event of Default under
this Lease. No sublessee shall be entitled to exercise the renewal option under this <B>Section&nbsp;9.3.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Rent per Rentable Square Foot payable during the Renewal Period with respect to all space
included in the Leased Premises as of the Renewal Period Commencement Date shall be equal to
Landlord&#146;s then-quoted Building rental rate for the Leased Premises, which may be a stepped rate,
taking into account other pecuniary concessions such as any rent abatement, tenant improvement
allowances, commissions, lese term, lease rate escalations, operating expenses, and taxes. Landlord
shall give Tenant written notice of the proposed Market Rental Rate within twenty (20)&nbsp;days
following written request by Tenant made not earlier than fourteen (14)&nbsp;months prior to the Renewal
Period Commencement Date; provided, however, Landlord shall not be required to provide its notice
of the proposed Market Rental Rate until Landlord has received Tenant&#146;s Renewal Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If Tenant has validly exercised the Option to Renew, within thirty (30)&nbsp;days after request
by either party hereto, Landlord and Tenant shall enter into a written
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amendment to this Lease confirming the terms, conditions and provisions applicable to the
Renewal Period as determined in accordance herewith, with such revisions to the rental provisions
of this Lease as may be necessary to conform such provisions to the Market Rental Rate.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;signatures appear on following page&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties hereto have executed and sealed this Lease as of the date
aforesaid.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="37%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">LANDLORD:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>NASHVILLE HINES DEVELOPMENT, LLC,</B><br>
a Delaware limited liability company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Cash Flow Asset Management, L.P.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">a Texas limited partnership, its sole manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CFAM GP, L.L.C.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">a Texas limited liability company, its sole partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ F. Russ Nicholson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
F. Russ Nicholson
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">TENANT:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>CUMBERLAND PHARMACEUTICALS INC.</B>,<br>
a Tennessee corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:<BR>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ A.J. Kazimi
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. J. Kazimi
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>SITE PLAN AND LOCATION OF THE</B></U><BR>
<U><B>BUILDING</B></U>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628604.gif" alt="(MAP)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A-1</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>DESCRIPTION OF LAND</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Tract 1 / 3.01 Acres</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Being a parcel of land in Nashville, First Civil District, Eighteenth Councilmanic District,
Davidson County, Tennessee, generally located on the southerly side of West End Avenue between
Twenty-Fifth Avenue South and Natchez Trace, being part of Lot 1, Vanderbilt University
Consolidation Plat of record in Plat Book 9700, page 522, R.O.D.C. and being more particularly
described as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Beginning at a mag nail (new)&nbsp;in the westerly right-of-way line of Twenty-Fifth Avenue South
(50-foot right-of-way) at the southerly terminus of a curve return to the southerly right-of-way
line of West End Avenue (right-of-way varies);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE,
along said westerly right-of-way line of Twenty-Fifth Avenue South, S
36&#176; 59&#039; 53&#034; E,
179.61 to an iron pipe (old)&nbsp;at the northeast corner of property conveyed to Vanderbilt University
by deed of record in Book 5157, page 991, R.O.D.C.;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE,
along the northerly line of said property, S 53&#176; 09&#039; 57&#034; W, 150.00 feet to an &#147;x&#148; in conc.
wall;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE,
along the westerly line of said property, S 36&#176; 59&#039; 53&#034; E, 179.81 feet to an iron pin
(set)&nbsp;in the northerly line of a fifty foot wide ingress and egress easement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE, along the northerly line of said ingress and egress easement the following
calls;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">S 53&#176;
08&#039; 25&#034; W, 90.85 feet to an iron pin (set)&nbsp;at the beginning of a curve to the
left;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Along said curve to the left, 136.18 feet to a railroad spike (new), said curve having a central
angle of
17&#176; 56&#039; 44&#034;, a radius of 434.80 feet, a tangent of
68.65 feet and a chord of S 44&#176; 10&#039; 03&#034; W,
135.63 feet;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">S 35&#176;
11&#039; 41&#034; W, 8.07 feet to a mag nail (new);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE, leaving the northerly line of said ingress and egress easement and along a severance line
the following calls:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">N 36&#176; 59&#039; 13&#034; W, 103.37 feet to a mag nail
(new);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">S 53&#176; 00&#039; 47&#034; W, 43.57 feet to a mag nail (new);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">N 36&#176; 59&#039; 13&#034; W, 3.57 feet to a mag nail (new);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">S 53&#176; 00&#039; 47&#034; W, 12.00 feet to a mag nail (new);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">N 36&#176; 59&#039; 13&#034; W, 285.90 feet to a mag nail (new)&nbsp;in the southerly right-of-way line of West End
Avenue;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THENCE, along said right-of-way the following calls;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">N 54&#176; 13&#039; 39&#034; E, 33.07 feet to a mag nail (new);
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A-1 &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">N 53&#176;
00&#039; 47&#034; E, 394.99 feet to an &#147;x&#148; in conc. (new)&nbsp;at the westerly terminus of a curve return to
the right to the westerly right-of-way line of Twenty-Fifth Avenue South; Along said curve to the
right 15.71 feet to the point of beginning, said curve having a
central angle of 89&#176; 59&#039; 19&#034;, a
radius of 10.00 feet, a tangent of 10.00 feet and a chord of S
81&#176; 59&#039; 33&#034; E, 14.14 feet;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Containing 3.01 acres, more or less.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;A-1 &#151; Page 2
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>FLOOR PLAN OF LEASED PREMISES</B></U>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;to be attached&#093;
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;B &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628605.gif" alt="(MAP)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT </B>C</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>AIR CONDITIONING AND HEATING SERVICES</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of <B>Section&nbsp;3.1(b), </B>Landlord will furnish Building Standard air
conditioning and heating between 8 a.m. and 6 p.m. on weekdays (from Monday through Friday,
inclusive) and between 8 a.m. and 1:00 p.m. on Saturdays, all exclusive of Holidays as defined
below (the <B><I>&#147;Building Operating Hours&#148;</I></B><I>). </I>Upon request of Tenant made in accordance with the rules
and regulations for the Building, Landlord will furnish air conditioning and heating at other
times (that is, at times other than the times specified above), in which event Tenant shall
reimburse Landlord for Landlord&#146;s actual cost of furnishing such services, plus an amount equal to
fifteen percent (15%) of such costs to cover Landlord&#146;s administrative costs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Building Standard heating, ventilation and air conditioning system shall meet the
following design conditions, at the stated outside design conditions, based on one person per 100
square feet:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Summer &#151; Outdoor conditions 92 degrees Fahrenheit dry bulb, 75 degrees
Fahrenheit wet bulb; indoor conditions 75 degrees Fahrenheit dry bulb, 50% relative
humidity at design condition.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Winter &#151; Outdoor conditions minus 16 degrees Fahrenheit dry bulb; indoor
conditions 72 degrees Fahrenheit dry bulb.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following dates shall constitute <B><I>&#147;Holidays&#148; </I></B>as said term is used in this Lease:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>New Year&#146;s Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Memorial Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Independence Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Labor Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Thanksgiving Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Friday following Thanksgiving Day</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Christmas</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any other holiday generally recognized as such by landlords of
office space in the metropolitan Nashville, Tennessee office market, as
determined by Landlord in good faith.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If in the case of any holiday described in (a)&nbsp;through (g)&nbsp;above, a different day shall be
observed than the respective day above-described, then that day which constitutes the day observed
by national banks in Nashville, Tennessee on account of such holiday shall constitute the holiday
under this Lease.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;C &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT D</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>BUILDING RULES AND REGULATIONS</B></U>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sidewalks, doorways, vestibules, halls, stairways, and other similar areas shall not be used
for the disposal of trash, be obstructed by tenants, or be used by tenants for any purpose
other than entrance to and exit from the Leased Premises and for going from one part of the
Building to another part of the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Plumbing fixtures shall be used only for the purposes for which they are designed, and no
sweepings, rubbish, rags or other unsuitable materials shall be disposed into them. Damage
resulting to any such fixtures from misuse by a tenant shall be the liability of said tenant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Signs, advertisements, or notices visible in or from public corridors or from outside the
Building shall be subject to Landlord&#146;s prior written approval.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Movement in or out of the Building of furniture, office equipment, or any other bulky or
heavy materials shall be restricted to such hours as Landlord shall reasonably designate.
Landlord will determine the method and routing of said items so as to ensure the safety of all
persons and property concerned. Advance written notice of intent to move such items must be
made to the Building management office.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All routine deliveries to a tenant&#146;s Leased Premises during 8:00 a.m. to 5:00 p.m. weekdays
shall be made through the freight elevators. Passenger elevators are to be used only for the
movement of persons, unless an exception is approved by the Building management office.
Delivery vehicles shall be permitted only in such areas as are designated by Landlord, from
time to time, for deliveries to the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Building management shall have the authority to prescribe the manner that heavy furniture and
equipment are positioned.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Corridor doors, when not in use, shall be kept closed.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant space that is visible from public areas must be kept neat and clean.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All freight elevator lobbies are to be kept neat and clean. The disposal of trash or storage
of materials in these areas is prohibited.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No animals shall be brought into or kept in, on or about the Building, except for seeing-eye
dogs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant shall not tamper with or attempt to adjust temperature control thermostats in the
Leased Premises. Landlord shall adjust thermostats as required to maintain the Building
standard temperature. Landlord requests that all window blinds remain down and tilted at a 45
degree angle toward the street to help maintain comfortable room temperatures and conserve
energy.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;D &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant will comply with all security procedures during business hours and after hours
and on weekends.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenants are requested to lock all office doors leading to corridors and to turn out all
lights at the close of their working day.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All requests for overtime air conditioning or heating must be submitted in writing to the
Building management office by 2:00 p.m. on the day desired for weekday requests, by 2:00 p.m.
Friday for weekend requests and by 2:00 p.m. on the preceding business day for holiday
requests.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">15.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No flammable or explosive fluids or materials shall be kept or used within the Building
except in areas approved by Landlord, and Tenant shall comply with all applicable building
and fire codes relating thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant may not place any items on the balconies of the Building that alter the exterior
appearance of the Building without obtaining Landlord&#146;s prior written consent.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any motor vehicle exceeding the height restrictions of the Parking Facility shall not be
parked at any location on the Land or Parking Area.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">18.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant may not make any modifications, additions or repairs to the Leased Premises and may
not install any furniture, fixtures or equipment in the Leased Premises which is in violation
of any applicable building and/or fire code governing the Leased Premises or the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">19.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except in those areas designated by Landlord. if any, smoking is prohibited in the Building
(including, but not limited to, the Leased Premises, the main building lobby, public
corridors, elevator lobbies, service elevator vestibules, stairwells, restrooms and other
common areas within the Building).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">20.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All Tenant contractors shall abide by the contractor&#146;s rules and regulations promulgated by
Landlord from time to time.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Landlord reserves the right to rescind any of these rules and regulations and to make such other
and further rules and regulations as in its reasonable judgment shall, from time to time, be
required for the safety, protection, care and cleanliness of the Building, the operation thereof,
the preservation of good order therein and the protection and comfort of the tenants and their
agents, employees and invitees. Such rules and regulations, when made and written notice thereof
is given to a tenant, shall be binding upon it in like manner as if originally herein prescribed.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;D &#151; Page 2
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT F</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>&#091;INTENTIONALLY DELETED&#093;</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;F &#151; Page 1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT G</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BASE RENTAL</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">ANNUAL BASE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">RENTABLE SQUARE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">MONTHLY</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">PERIOD</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">RENTAL RATE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">FOOTAGE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">BASE RENTAL</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/06-12/31/06</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/07-12/31/07</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/08-12/31/09</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/09-12/31/09</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/10-12/31/10</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Exhibit&nbsp;G &#151; Page 1
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>25
<FILENAME>g06286exv10w23.htm
<DESCRIPTION>EX-10.23 AMENDED AND RESTATED LEASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.23 AMENDED AND RESTATED LEASE AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.23</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>AMENDED AND RESTATED LEASE AGREEMENT</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS AMENDED AND RESTATED LEASE AGREEMENT </B>(the &#147;<U>Lease</U>&#148;) is made and entered into
effective as of the 11<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of November, 2004 (the &#147;<U>Effective Date</U>&#148;), by and
between <B>THE GATEWAY TO NASHVILLE, L.L.C., </B>a Tennessee limited liability company, with its principal
office and place of business in Nashville, Tennessee (&#147;<U>Landlord</U>&#148;), and <B>CUMBERLAND EMERGING
TECHNOLOGIES, INC., </B>A Tennessee corporation, with its principal place of business in Nashville,
Tennessee (&#147;<U>Tenant</U>&#148;).
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>WITNESSETH:</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>pursuant to that certain Lease Agreement made by and between Landlord and Tenant
dated June&nbsp;1, 2002 (the &#147;<U>Original Lease</U>&#148;), Landlord leased and demised to Tenant, and
Tenant leased from Landlord, the Premises (as such term is defined in Section&nbsp;2 of the Original
Lease, and being referred to herein as the &#147;<U>Original Premises</U>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Landlord owns certain other premises (the &#147;<U>New Premises</U>&#148;, as more
particularly described in Section 1(b) hereof) that are adjacent to the Original Premises, and
Landlord desires to lease and demise to Tenant, and Tenant desires to lease from Landlord, the New
Premises; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Landlord has agreed to construct and prepare the New Premises for the occupancy of
Tenant in accordance with the terms hereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Landlord has granted to Tenant a first right to lease the First Floor Option Space
(as such term is defined in Section&nbsp;36 hereof) and a first right to lease the Second Floor Option
Space (as such term is defined in Section&nbsp;37 hereof); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Landlord and Tenant desire to amend and restate the Original Lease in order to
reflect the foregoing agreements and otherwise, pursuant to the terms and conditions hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW</B>, <B>THEREFORE, </B>for and in consideration of the foregoing premises and the mutual covenants,
terms and conditions recited hereinafter, and for such other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby amend and
restate the Original Lease as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>PREMISES.</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Original Premises.</U> Subject to and upon the terms and conditions set forth herein,
Landlord does by these presents hereby lease unto Tenant, and Tenant does by these presents hereby
lease
from Landlord, those certain premises in The Randall G. Sender Pavilion located at 111
10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Avenue, South in Nashville, Davidson County, Tennessee, 37203 (the
&#147;<U>Building</U>&#148;), containing approximately 1,500 square feet (with no common area percentage
factor) and identified as the &#147;Original Premises&#148; in <U>Exhibit&nbsp;A,</U> attached hereto and
incorporated herein by this reference (the &#147;<U>Original Premises</U>&#148;).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>New Premises.</U> Pursuant to the provisions of Section&nbsp;4, below, Landlord has agreed
to construct and prepare those certain premises in the Building containing approximately 5,390
rentable square feet (including a common area factor of twelve percent) and identified as the &#147;New
Premises&#148; in <U>Exhibit&nbsp;A,</U> attached hereto (the &#147;<U>New Premises</U>&#148;) for the occupancy of
Tenant. Upon the Acceptance Date (as such term is defined in Section 4(d) below), Landlord shall
lease the New Premises unto Tenant, and Tenant shall lease the New Premises from Landlord, subject
to and upon the terms and conditions set forth herein. Prior to the Acceptance Date, the term
&#147;<U>Premises</U>&#148;, as used herein, shall refer solely to the Original Premises. Commencing on the
Acceptance Date, and continuing thereafter for the remainder of the Term, the term
&#147;<U>Premises</U>&#148;, as used herein, shall refer to the Original Premises and the New Premises,
collectively, which shall be deemed to have 6,890 rentable square feet, subject to the provisions
of Section&nbsp;36 and Section&nbsp;37 hereof relating to the First Floor Option Space and the Second Floor
Option Space.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;</B><U><B>TERM</B>.</U> Subject to and upon the terms and conditions set forth herein, or in any
exhibit or addendum hereto, the term of this Lease shall commence on the date hereof and shall
terminated on the date that is sixty-six (66)&nbsp;months after the Acceptance Date, unless this Lease
is sooner terminated according to the terms hereof or unless Tenant chooses to extend this Lease
for an Extension Term, as hereinafter defined (as such term may be renewed or extended, the
&#147;Term&#148;). If Tenant is not in default under this Lease at the time of such notice and extension,
Tenant may extend the Term on two (2)&nbsp;occasions for five (5)&nbsp;years (each an &#147;<U>Extension
Term</U>&#148;) by providing written notice to Landlord of Tenant&#146;s election to extend the Term no
later than one hundred eighty (180)&nbsp;days prior to the end of the current Term or Extension Term,
as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><U><B>RENT</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Tenant shall pay to Landlord as rent at the office of Landlord in Nashville, Tennessee,
or to such other address as Landlord may direct, the amounts set forth in this <U>Section</U> 3
plus any other amounts due hereunder from time to time. The Annual Rent, Monthly Rent and any
other amounts due Landlord from Tenant shall be referred to herein collectively as &#147;Rent&#148;). Any
Rent not paid when due shall incur a late charge in the amount of five percent (5%) of such amount
and shall additionally bear interest at the rate of ten percent (10%) per annum from the date
payment was due until paid. Such late charge shall not be deemed a penalty, but is paid to
reimburse Landlord for the administrative costs associated with such late payment. Tenant shall
pay to Landlord the amounts set forth herein during the Term without demand, counterclaim,
deduction, or set-off, except as may otherwise be provided herein. In the event the Term commences
on a date other than the first (1<SUP style="font-size: 85%; vertical-align: text-top"><B>St</B></SUP>) day of a calendar month, or terminates on a date
other than the last day of a calendar month, then the amount of Monthly Rent due hereunder for
such month shall be prorated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;From the Effective Date until May&nbsp;31, 2005, Tenant shall pay to Landlord Rent at a
monthly rate equal to &#091;***&#093; for the portion of the Premises described as
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Original Premises with a square footage of 1,500 square feet. On June&nbsp;1, 2005, the Rent
rate per square foot in the Original Premises shall be equal to that hereafter set forth for the
Premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;On the Acceptance Date, the amount of Annual Rent due hereunder shall be increased based
on an additional 2,800 rentable square feet of space in the New Premises at the then applicable
Rent rate and the amount of Monthly Rent due hereunder shall increase accordingly. On the earlier
to occur of (i)&nbsp;Tenant&#146;s use of the remainder of the New Space or (ii)&nbsp;the first day of the
seventh calendar month after the month in which the Acceptance Date occurs, the amount of Annual
Rent due hereunder shall be increased for the entirety of the Premises consisting of 6,890
rentable square feet calculated on the Rent rate then applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;During the first twelve (12)&nbsp;months after the Acceptance Date, Tenant shall pay to
Landlord Rent calculated at a rate of &#091;***&#093; per rentable square foot (as modified herein, the
&#147;<U>Annual Rent</U>&#148;), payable in equal monthly installments (as modified herein, the
&#147;<U>Monthly Rent</U>&#148;), each such installment being due on the first (1)&nbsp;day of each and every
calendar month, in advance. On the first day of the thirteenth calendar month of the Term, and for
the remainder of the Term, the Annual Rent due hereunder shall be calculated based on &#091;***&#093; per
rentable square foot.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;During the first Extension Term, if any, the Annual Rent shall be based on &#091;***&#093; per
rentable square foot, or &#091;***&#093;, and the Monthly Rent shall be &#091;***&#093;, and Rent shall increase by
&#091;***&#093; per year during each subsequent year of the first Extension Term. During the second Extension
Term, if any, the Annual Rent shall be based on &#091;***&#093; per rentable square foot, or &#091;***&#093;, and the
Monthly Rent shall be &#091;***&#093;, and Rent shall increase by &#091;***&#093; per year during each subsequent year
of the second Extension Term.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Tenant shall each month promptly pay, as Rent hereunder, all utility charges for the gas,
electricity and/or water used by Tenant in the Premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U><B>LANDLORD&#146;S IMPROVEMENTS TO PREMISES.</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Landlord shall construct and prepare the New Premises for the occupancy of Tenant in
accordance with the plans and specifications the &#147;<U>Plans</U>&#148;) set forth in <U>Exhibit&nbsp;B</U>
attached hereto and incorporated herein by this reference (&#147;<U>Landlord&#146;s Work</U>&#148;) on or before
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&#95;&#95;&#95;(the &#147;<U>Completion Deadline</U>&#148;), subject to <I>force majeure </I>and any delays caused by
Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Approval of Tenant&#146;s plans and specifications by Landlord is for the sole benefit of
Landlord and shall not constitute the assumption of any responsibility by Landlord for their
accuracy or sufficiency or compliance with applicable laws, ordinances or regulations, including
without limitation the Americans with Disabilities Act, and Tenant shall be solely responsible for
such Plans.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Landlord shall complete Landlord&#146;s Work in a good and workmanlike manner in accordance
with the approved plans and specifications therefor, and all applicable statutes, laws, rules,
codes, regulations, ordinances or other requirements of any federal, state, county or local
governmental or quasi-governmental entity having jurisdiction over, or in any way applicable to,
Landlord or Landlord&#146;s Work. Landlord shall obtain all licenses and permits required for Landlord
to commence and complete Landlord&#146;s Work.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Landlord&#146;s Work shall be deemed complete, and Tenant shall be deemed to have accepted the
New Premises, on such date as all applicable permits required for the use of the New Premises have
been validly issued, and copies thereof have been provided to Tenant (such date being referred to
herein as the &#147;<U>Acceptance Date</U>&#148;), subject to the provision by Tenant of any &#147;punch list&#148;
items which shall be completed by Landlord within thirty (30)&nbsp;days after the Acceptance Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Tenant shall pay to Landlord as additional Rent hereunder all expenses and costs incurred
by Landlord in completing the Work within thirty (30)&nbsp;days after presentation to Tenant of an
invoice therefor, together with any supporting documentation reasonably requested by Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;</B><U><B>RULES AND REGULATIONS.</B></U> Tenant will comply with all reasonable rules and
regulations as may be adopted by Landlord for the safety, care and cleanliness of the Premises and
the Building, and for preservation of good order therein, including, without limitation, the Rules
and Regulations set forth in <U>Exhibit&nbsp;C,</U> attached hereto and incorporated herein by this
reference, as the same may be amended from time to time upon notice to Tenant (the &#147;<U>Rules and
Regulations</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;</B><U><B>USE.</B></U> Tenant will use and occupy the Premises for general office and research
laboratories and for no other purpose. Subject to the provisions of Section&nbsp;26 of this Amendment,
Tenant shall keep the Premises in good repair and tenantable condition and shall quit and surrender
the Premises peaceably upon the expiration of the Term in as good condition as the reasonable use
thereof will permit, reasonable wear and tear excepted. Without limiting the foregoing, Tenant
shall replace at its own expense any and all broken glass in and about the Premises with glass of
the same size and quality, including all signs thereon. If Tenant fails to make proper repairs,
Landlord, at its option, may make such repairs at Tenant&#146;s expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;</B><U><B>CONDITIONS OF PREMISES.</B></U> No representations, except as are contained herein or
endorsed hereon, have been made to Tenant with respect to the condition of the Premises. The taking
of possession of any portion of the Premises, including without limitation the New Premises, by
Tenant shall be conclusive evidence against Tenant that such portion of the Premises was in good
and satisfactory condition when possession of the same was so taken, and Tenant will, at the
termination of this Lease, by lapse of time or otherwise, return the Premises to Landlord in as
good condition as when received, loss by fire, storm or other casualty and ordinary wear and tear
excepted.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;</B><U><B>SUBLETTING AND ASSIGNMENT.</B></U> Tenant will not assign this Lease nor any interest
hereunder, and will not permit any assignment hereof by operation of law, and will not sublet the
Premises or any part thereof, and will not permit the use of the Premises by any parties other than
Tenant, and the agents and servants of Tenant, without first obtaining the written consent of
Landlord, which shall not be unreasonably withheld, conditioned or delayed. Landlord may assign
this Lease or any part thereof or right thereunder. Notwithstanding the foregoing, Tenant may
license or sublet portions of the Premises to users of the office and laboratory facilities in the
Premises in conjunction with Tenant&#146;s business purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;</B><U><B>ALTERATIONS AND IMPROVEMENTS.</B></U> No alterations, additions or improvements to the
Premises, except such as may be provided for in this Lease, shall be made without first obtaining
the consent, in writing, of Landlord, and any improvements, additions or alterations made by Tenant
after such consent shall have been given, including any and all fixtures installed, excepting trade
fixtures, shall at Landlord&#146;s option remain on the Premises as the property of Landlord, without
compensation to Tenant, or shall be removed therefrom and the Premises restored to their original
condition at cost to Tenant, at the expiration or sooner termination of this Lease. Without
limiting the foregoing, Tenant shall, at the expiration or sooner termination of this Lease,
restore the Premises to their shell condition prior to the commencement of the Lease, remove all
pipes and other equipment pursuant to Section&nbsp;26 of this Lease and repair any damage or holes to
the walls associated with such ducts, pipes, wiring and other equipment. Tenant shall at its own
cost repair any damage caused by the removal of trade fixtures in order to restore the Premises to
their original condition. Tenant agrees to save Landlord harmless on account of claims for
mechanics, materialmen or other liens in connection with any alterations, additions, or
improvements to which Landlord may give its consent in connection with the Premises, and Tenant
will, if required by Landlord, furnish such waiver or waivers of lien or bond in form and with
surety satisfactory to Landlord, as Landlord may require before starting any work in connection
with alterations, additions or improvements to the Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;</B><U><B>LIMITS OF USE AND PEACEFUL ENJOYMENT.</B></U> Tenant will not use or permit upon the
Premises anything that will invalidate any policies of insurance now or hereafter carried on the
Building or that will increase the rate of insurance on the Premises or the Building beyond the
standard rates for coverage on office space. Any increase of insurance costs due as a result of
Tenant&#146;s use of the Premises for laboratory uses shall be paid to Landlord as additional Rent
hereunder. Tenant will not in any manner deface or injure the Building or any part thereof, or
overload the floors of the Premises, it being mutually agreed that in no event shall any weight be
placed upon said floors in excess of seventy-five (75)&nbsp;pounds per square foot of floor space
covered. Tenant will not permit any objectionable noise or odor to escape or be emitted from the
Premises in any way tending to create a nuisance, or tending to disturb any other tenant in the
Building or the occupants of neighboring property, or tending to injure the reputation of the
Building. Tenant will comply with all governmental, health and police requirements and regulations
respecting the Premises and its use thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;</B><U><B>PERSONAL OR PROPERTY RISKS.</B></U> Landlord shall not be held responsible for, and is hereby
expressly relieved from, all liability by reason of any injury, loss or damage to any person or
property in or about the Premises, unless caused by the negligent or willful act or omission of
Landlord, Landlord&#146;s agents, employees or invitees, whether the loss, injury, or damage be to the
person or property of Tenant or any other person. This provision shall apply especially (but not
exclusively) to damage caused by water, snow, frost, steam, sewage, illuminating gas, sewer gas, or
odors, or by the bursting or leaking of pipes or plumbing works, and shall apply equally whether
such damage be caused by the act or neglect of other tenants, occupants or janitors of the Building
or of any other persons, and whether such damage be caused or occasioned by anything above
mentioned or referred to, or by any other thing or circumstance, whether of a like nature, or of a
wholly different nature. If any such damage shall be caused by the acts of neglect of Tenant,
Landlord may, at its option, repair such damage, whether caused to the Building or tenants thereof,
and Tenant shall thereupon reimburse Landlord the total cost of such damage both to the Building
and to tenants thereof. Tenant
further agrees that all personal property upon the Premises shall be at risk of Tenant only
and that Landlord shall not be liable for any damage thereto or theft thereof. Nor shall Landlord
be liable for the stoppage or interruption of water, light, heat, air conditioning, janitor or
elevator service, caused by riot, strike, accident, or to make needful repairs, or by any other
cause over which Landlord has no control and such failure, delay or default shall not be construed
or considered as an actual or constructive eviction of Tenant nor shall it in any way operate to
release Tenant from the punctual performance of each and every one of the other covenants herein
contained by the Tenant to be performed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;</B><U><B>RIGHTS OF LANDLORD ON DEFAULT.</B></U> If default shall at any time be made by Tenant in
the payment of the rent hereby reserved, or any installment thereof; or if default shall be made in
any of the other covenants herein contained, to be kept, observed and performed by Tenant; or if
the leasehold interest shall be levied on under execution; or in the event of the insolvency or
bankruptcy of Tenant, or the filing of any petition under the bankruptcy statute, voluntarily or
involuntarily and whether or not resulting in an adjudication in bankruptcy, provided that
involuntary filings shall be a default only if not dismissed within sixty (60)&nbsp;days of the date of
its filing; or in the event of a partial or general assignment for the benefit of a creditor; then,
and in any of said cases, Landlord may, at its option, at once, without notice to Tenant, terminate
this Lease or terminate Tenant&#146;s right to occupy the Premises without termination of the Lease; and
upon the termination of said Lease or Tenant&#146;s right of occupancy at the option of Landlord as
aforesaid, or at the expiration by lapse of time of the Term, Tenant will at once surrender
possession of the Premises to Landlord, and remove all effects therefrom, and if such possession be
not immediately surrendered, Landlord may forthwith re-enter the Premises and repossess itself
thereof as of its former estate and remove all persons and effects therefrom, using such force as
may be necessary, without being deemed guilty of any manner of trespass or forcible entry and
detainer. Tenant expressly waives the service of any notice of intention to terminate this Lease or
Tenant&#146;s right to occupy the Premises or to re-enter the Premises, and waives the service of any
demand for payment of rent or for possession, and waives the service of any and every other notice
or demand prescribed by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any statute or other law, and agrees that the simple breach of any of the said covenants
shall, of itself, without the service of any notice or demand whatever, constitute a forcible
detainer by Tenant of the Premises, within the meaning of the statutes of the State of Tennessee.
No receipt of moneys by Landlord from Tenant, after the termination in any way of this Lease or
Tenant&#146;s right of possession thereunder, or after giving of any notice, shall reinstate, continue
or extend the term of this Lease or affect any notice given to Tenant prior to the receipt of such
money, it being agreed that after the service of notice of the commencement of a suit, or after
final judgment for possession of the Premises, Landlord may receive and collect any rent due, and
the payment of said rent shall not waive or affect said notice, said suit or said judgment. If
Tenant shall not remove all effects from the Premises as above agreed, Landlord may, at its option,
remove the same in any manner that Landlord shall choose and store or dispose of the same without
liability to Tenant for loss thereof, and Tenant will pay Landlord, on request, any and all expense
incurred in such removal and also storage of said effects for any length of time during which the
same shall be in Landlord&#146;s possession; or Landlord may at its option, without notice, sell the
said effects or any of the same for such price as Landlord may deem best and apply the proceeds of
such sale upon any amounts due under this Lease from Tenant to Landlord, including the expenses of
the removal and sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;</B><U><B>RIGHTS OF LANDLORD ON ABANDONMENT.</B></U> In the event that Tenant shall vacate the
Premises or abandon the same during the Term, Landlord may, at its option, without terminating this
Lease, but Landlord shall not be under any obligation to do so, enter into the Premises, remove
Tenant&#146;s signs therefrom, and relet the same for the account of Tenant for such rent and upon terms
as shall be satisfactory to Landlord, without such reentry working a forfeiture of the rents to be
paid and the covenants to be performed by Tenant during the full Term of this Lease; and for the
purpose of such re-letting Landlord is authorized to make any repairs, changes, alterations or
additions in or to the Premises that may be necessary or convenient, and if a sufficient sum shall
not be realized monthly from such re-letting, after paying all of the costs and expenses of such
re-letting the collection of the rent accruing therefrom each month to satisfy the monthly rent
above provided to be paid by Tenant, then Tenant will pay and satisfy such deficiency each month
upon demand therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;</B><U><B>LOSS OR DAMAGE TO PREMISES.</B></U> Should the Building be totally destroyed by fire or
other cause, or so damaged that rebuilding or repairs cannot be completed within one hundred eighty
(180)&nbsp;days from date of said fire or other cause of damage, this Lease shall terminate and Tenant
shall be allowed an abatement of rent from the date of such damage or destruction. However, if the
damage is such that rebuilding or repairs can be completed within one hundred eighty (180)&nbsp;days,
Landlord covenants and agrees to make such repairs with reasonable promptness and dispatch, and to
allow Tenant an abatement in the rent for such time as the Building is untenantable (in Tenant&#146;s
reasonable determination), or proportionately for such portion of the Premises as shall be
untenantable (in Tenant&#146;s reasonable determination), and Tenant covenants and agrees that the terms
of this Lease shall not otherwise be affected.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;</B><U><B>CONDEMNATION.</B></U> If the whole of the Premises shall be taken or condemned by any
competent authority for public or quasi public use or purpose, then, and in that event, the Term
shall expire when the possession of the Premises so taken shall be required for such use or
purpose. If any part, less than the whole, of the Premises shall be so taken or condemned, then,
and in that event, either Landlord or Tenant shall have the option, exercisable by notice in
writing to the other within sixty (60)&nbsp;days from the date of the notice to Landlord of the taking
or condemnation, to terminate this Lease; and in the event said option to so terminate this Lease
is exercised by either Landlord or Tenant, the Lease shall continue in effect with respect to the
portion of the Premises not taken or condemned unless the same is rendered untenantable (in
Tenant&#146;s reasonable determination) by such taking and condemnation or cannot be made tenantable (in
Tenant&#146;s reasonable determination) by repairs to be conducted by Landlord at its expense. In the
event this Lease continues with reference to the portion of the Premises not taken, the rental
specified hereunder shall be prorated and adjusted on a square footage basis. In the event that
this Lease terminates by a taking or condemnation of the whole of the Premises or by the election
on the part of Landlord as provided herein, the current rental shall in either case be apportioned
to the date of termination of the Lease. Landlord shall be entitled to any and all awards and/or
settlements that may be awarded on account of such taking or condemnation. Tenant, however, shall
not be prevented from making a claim against the condemning party (but not against Landlord ) for
any moving or relocation expenses, loss of profits, or taking of Tenant&#146;s personal property (other
than its leasehold estate) to which Tenant may be entitled; provided that any such award shall not
reduce the amount of the award otherwise payable to Landlord for the taking of the Building and
Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;</B><U><B>REDECORATION.</B></U> If Tenant shall move from the Premises at any time prior to the
termination of this Lease, Landlord shall have the right to enter upon the Premises for the
purpose of decorating the same or making alterations or changes therein, without such entry in any
manner affecting the obligation of Tenant hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;</B><U><B>MOVING TENANT.</B></U> Landlord, at its option, may substitute for the Premises other
space (hereafter called &#147;<U>Substitute Premises</U>&#148;) owned by Landlord in the Building at any
time during the Term or any extension of this Lease. Insofar as reasonably possible, the
Substitute Premises shall be of comparable quality and shall have a comparable square foot area
and a configuration substantially similar to the Premises. If the parties cannot agree on the
adequacy of the replacement space, an independent mediator with experience in the office real
estate market in the Nashville metropolitan area shall be procured, with the costs of such
mediator shared equally by the parties. Landlord shall give Tenant at least sixty (60)&nbsp;days notice
of its intention to relocate Tenant to the Substitute Premises. This notice will be accompanied by
a floor plan of the Substitute Premises. After such notice, Tenant shall have ten (10)&nbsp;days within
which to agree with Landlord on the proposed Substitute Premises and unless such agreement is
reached within such period of time, Landlord may terminate this Lease at the end of the sixty (60)
day period of time following the notice. Landlord agrees to construct or alter, at its own
expense, the Substitute Premises as expeditiously as possible so that they are in substantially
the same condition that the Premises were in immediately prior to the relocation. Landlord shall
have the right
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to reuse the fixtures, improvements and alterations used in the Premises. Tenant agrees to
occupy the Substitute Premises as soon as Landlord&#146;s work is substantially completed, Landlord
shall pay Tenant&#146;s reasonable third-party costs of moving Tenant&#146;s furnishings, telephone and
computer wiring, and other property to the Substitute Premises, and reasonable printing costs
associated with the change of address. Except as provided herein, Tenant agrees that all of the
obligations of this Lease, including the payment of rent (to be determined on a per rentable
square foot basis and applied to the Substitute Premises), will continue despite Tenant&#146;s
relocation to the Substitute Premises. Upon substantial completion of the Substitute Premises,
this Lease will apply to the Substitute Premises as if the Substitute Premises had been the space
originally described in this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>18.&nbsp;</B><U><B>RIGHTS OF LANDLORD.</B></U> The right of Landlord to terminate this Lease as herein set
forth is in addition to and not in exhaustion of such other rights that Landlord has, or causes of
action that may accrue to Landlord because of Tenant&#146;s failure to fulfill, perform or observe the
obligations, agreements or covenants of this Lease, and the exercise or pursuit by Landlord of any
of the rights or causes of action accruing hereunder shall not be an exhaustion of such other
rights or causes of action that Landlord might otherwise have.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>19.&nbsp;</B><U><B>WAIVERS.</B></U> No waiver of any condition expressed in this Lease shall be implied by
any neglect of Landlord to declare a forfeiture on account of the violation of such condition if
such violation be repeated or continued subsequently and no express waiver shall affect any
condition other than the one specified in such waiver, and that one only for the time and in the
manner specifically stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>20.&nbsp;</B><U><B>ATTORNEYS.</B></U> Either party hereto shall be entitled to recover from the other party
hereto all reasonable attorney&#146;s fees and other costs and expenses it incurs in enforcing any of
the obligations of the other party hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>21.&nbsp;</B><U><B>LIENS.</B></U> (Intentionally omitted).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>22.&nbsp;</B><U><B>HOLD OVER.</B></U> Tenant will pay to Landlord, as liquidated damages, rent in an
amount equal to one hundred fifty percent (150%) of the rent payable hereunder immediately prior
to the end of the Term, for all the time Tenant shall retain possession of the Premises or any
part thereof for the first two (2)&nbsp;months after the termination of this Lease, whether by lapse
of time or otherwise, and two hundred percent (200%) for any period beyond such time; but the
provisions of this clause shall not operate as a waiver by Landlord of any right of re-entry
hereinbefore provided; nor shall any waiver by Landlord of its right to terminate this Lease for
breach of covenant affect its right to terminate this Lease for any later breach of the same or
another covenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>23.&nbsp;</B><U><B>AIR RIGHTS.</B></U> It is understood and agreed that this Lease does not grant any
rights to light and air over property, except public streets adjoining the land on which the
Building is situated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>24.&nbsp;</B><U><B>HOLD HARMLESS.</B></U> Tenant covenants to save and hold Landlord harmless from
violations by Tenant of the laws of the United States, of the State of Tennessee, and the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ordinances and laws of the Metropolitan Government of Nashville and Davidson County,
Tennessee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>25.&nbsp;</B><U><B>EXTRA USE OF PREMISES.</B></U> Tenant shall not use the Premises for any purpose except
that which is above specified, and in particular will not expose nor offer for sale on the
Premises, any alcoholic or other liquors, tobacco, drugs, flowers, candies, confections, nor any
other thing or things whether of a like or of a wholly different nature, without the written
consent of Landlord, the right being hereby reserved to Landlord to grant to any person, firm or
corporation the exclusive right and privilege to conduct any particular business in the Building,
and such exclusive right and privilege so granted shall be binding upon Tenant hereunder the same
as though specifically incorporated in this Lease upon Landlord&#146;s notification to Tenant of the
granting of such exclusive right and privilege.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>26.&nbsp;</B><U><B>MAINTENANCE.</B></U> Landlord shall be responsible for floors (but not floor coverings),
roof and all other structural elements of the Building, and for maintaining all common area
mechanical systems, including but without limitation the heating, ventilation, air-conditioning,
electrical and plumbing systems. Except as otherwise provided in this Lease or in the Plans, and
except for customary equipment used in laboratories, Tenant shall not install or connect any air
conditioning equipment, electric-driven motor or any electrical, gas or water appliance or
equipment, without the prior written consent of Landlord. With respect to air conditioning or any
other electrical, gas or water appliance or equipment installed by or under Tenant, Landlord shall
have the right to retain all ducts, wiring, piping, and other related equipment upon the
termination of this Lease, provided, however, that in the absence of specific direction from
Landlord, Tenant shall be required to remove all such equipment, ducts, wiring, piping and other
related equipment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>27.&nbsp;</B><U><B>STORAGE.</B></U> If Tenant shall fail to remove all effects from the Premises upon
termination of this Lease for any cause whatsoever, Landlord may at its option remove the same in
any manner that Landlord shall choose and store said effects without liability to Landlord for loss
thereof, and Tenant agrees to pay Landlord on demand any and all expenses incurred in such removal,
including court costs and attorney&#146;s fees and storage charge on such effects for any length of time
the same shall be in Landlord&#146;s possession, or Landlord may at its option without notice sell said
effects or any part of the same at private sale and without legal process for such price as
Landlord may obtain and apply the proceeds of such sale upon any amounts due under this Lease from
Tenant to Landlord and upon the expense incident to the removal and sale of said effects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>28.&nbsp;</B><U><B>DEFECTS.</B></U> Tenant shall provide Landlord or its agent prompt written notice of any
accident to or defects in mechanical or other systems for which Landlord is responsible hereunder,
which defects shall be remedied by Landlord with due diligence promptly after its receipt of any
such notice from Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>29.&nbsp;</B><U><B>SUBORDINATION.</B></U> This Lease is subject and subordinate to all present mortgages
affecting the real estate and improvements thereon of which the Premises form a part, and to all
renewals and extension thereof, and to any mortgages which may hereafter be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">executed affecting the same, and Tenant shall execute a commercially reasonable form of
agreement evidencing such subordination and attornment in favor of any of Landlord&#146;s lenders from
time to time within three (3)&nbsp;business days after request therefor from Landlord, provided only
that such agreement shall provide commercially reasonable nondisturbance provisions for Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>30.&nbsp;</B><U><B>LIQUIDATED DAMAGES.</B></U> It is agreed between the parties hereto that if the rent
stipulated herein at any time shall not be paid within ten (10)&nbsp;days of the date when due, then all
subsequent installments of rent, remaining unpaid, shall forthwith become due and payable at the
option of Landlord with notice to Tenant, and in case Tenant is declared bankrupt or voluntarily
offers to creditors terms of composition, or in case a receiver is appointed to take charge of and
conduct the affairs of Tenant, such claim for further unpaid installments of rent due under this
Lease shall be considered liquidated damages and shall constitute a debt provable in bankruptcy or
receivership.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>31.&nbsp;</B><U><B>REMEDIES.</B></U> No act or thing done by Landlord or its agents during the Term shall be
deemed an acceptance of a surrender of the Premises, and no agreement to accept a surrender of the
Premises shall be valid unless the same be made in writing and subscribed by Landlord. The
provision in this Lease of any particular remedy shall not preclude Landlord from any other remedy
Landlord might have, either in law or in equity, nor shall the waiver of or redress for any
violation of any covenant or condition in this Lease contained or any of the Rules and Regulations,
prevent a subsequent act, which would have originally constituted a violation, from having all the
force and effect of an original violation. In case it should be necessary or proper for Landlord to
bring any action under this Lease or to consult or place said Lease, for any amount payable by
Tenant thereunder, with an attorney concerning or for the enforcement of any of Landlord&#146;s rights
hereunder, then Tenant agrees in each and any such case to pay to Landlord its reasonable
attorney&#146;s fees actually incurred. The receipt by Landlord of rent with knowledge of the breach of
any covenant in this Lease contained, shall not be deemed a waiver of such breach, The failure of
Landlord to enforce any of the Rules and Regulations against Tenant and/or any other tenant in the
Building shall not be deemed a waiver thereof. The receipt by Landlord of rent from any assignee,
subtenant or occupant of the Premises shall not be deemed a waiver of the covenant in this Lease
contained, against assignment, and subletting or an acceptance of the assignee, subtenant or
occupant as Tenant, or a release of Tenant from the further observance or performance by Tenant of
the covenant in this Lease contained, on the part of Tenant to be observed and performed. No
provision of this Lease shall be deemed to have been waived by Landlord unless such waiver be in
writing signed by Landlord. In case of termination of this Lease by Landlord under any option
herein provided for, Landlord may re-enter the Premises without notice or demand, and in that event
rent shall become due and be apportioned and paid up to and including the day of such entry. The
sole remedy for Landlord&#146;s failure to complete Landlord&#146;s Work by the date set forth herein shall
be a delay in the Acceptance Date, provided, however, that if the Acceptance Date is delayed more
than ninety (90)&nbsp;days from the date set forth herein and such delay is not attributable to causes
beyond the control of Landlord, Tenant shall have a one-time right to terminate this Lease upon
written notice to Landlord within ten (10)&nbsp;days of the ninetieth (90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day of delay.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>32.&nbsp;</B><U><B>ACCESS TO PREMISES.</B></U> The parties hereto agree that for the purpose of completing or
of making re<SUP style="font-size: 85%; vertical-align: text-top">p</SUP>airs or alterations in any portion of the Building, Landlord may use one or
more of the street entrances, halls, passageways and elevators of the Building, provided, however,
that there shall be no unnecessary obstruction of the right of entry to the Premises while the same
are occupied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>33.&nbsp;</B><U><B>ESCALATION.</B></U> The rent payable by Tenant during each lease year shall be adjusted in
accordance with this Article:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Definitions.</U> For the purpose of this Section&nbsp;33, the following definitions shall
apply:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The term &#147;<U>Base Year</U>&#148; shall mean the calendar year 2002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The term &#147;<U>Percentage</U>&#148; shall mean ten and ninety-five one hundreths percent
(10.95%).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The term &#147;<U>Real Estate Taxes</U>&#148; shall mean all taxes and assessments levied,
assessed or imposed at any time by any governmental authority upon or against the Building or the
land upon which the Premises are located, and also any taxes or assessments levied, assessed or
imposed at any time by any governmental authority in connection with the receipt of income or rents
from said Building and/or land to the extent that same shall be in lieu of all or a portion of any
of the aforesaid taxes or assessments upon or against said Building and/or land.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Real Estate Taxes.</U> In the event that the Real Estate Taxes payable during any
calendar year following the Base Year shall be estimated by Landlord to exceed the amount of the
Real Estate Taxes payable during the Base Year (the &#147;<U>Base Year Taxes</U>&#148;), Tenant shall pay to
Landlord as additional Rent for such calendar year an amount equal to the Percentage of such
estimated excess (the &#147;<U>Estimated Excess Taxes</U>&#148;) in equal monthly installments as determined
by Landlord. By or after April 1st of each calendar year, Landlord shall furnish to Tenant a
statement of the actual excess Real Estate Taxes payable during the preceding calendar over the
Base Year Taxes (the &#147;<U>Actual Excess Taxes</U>&#148;). Landlord shall apply any amount by which the
Percentage of Estimated Excess Taxes exceeds the Percentage of Actual Excess Taxes to the following
year&#146;s Estimated Excess Taxes payments due hereunder, and Tenant shall pay any shortfall between
the Percentage of Actual Excess Taxes and the Percentage of Estimated Excess Taxes, with such
payments made as additional Rent by Tenant to Landlord within twenty (20)&nbsp;days after receipt of the
aforesaid statement. Such payments shall be prorated for any year in which this Lease terminates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Insurance.</U> Landlord shall maintain on the Building, associated personal property,
fixtures and other improvements, such property, hazard, liability and other insurance policies as
Landlord deems reasonably appropriate or as may be required by any party whose interests are
secured by a lien, mortgage or other security interest in the Building (the &#147;<U>Insurance</U>
<U>Coverage</U>&#148;). In the event that the premiums and charges for the Insurance Coverage (the
&#147;<U>Insurance Costs</U>&#148;) payable during any calendar year following the

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Base Year shall be estimated by Landlord to exceed the amount of the Insurance Costs payable
during the Base Year (the &#147;<U>Base Year Insurance</U>&#148;), Tenant shall pay to Landlord as
additional Rent for such calendar year an amount equal to the Percentage of such estimated excess
(the &#147;<U>Estimated Excess Insurance Costs</U>&#148;) in equal monthly installments as determined by
Landlord. By or after April 1st of each calendar year, Landlord shall furnish to Tenant a
statement of the actual excess Insurance Costs payable during the preceding calendar over the Base
Year Insurance Costs (the &#147;<U>Actual Excess Insurance Costs</U>&#148;). Landlord shall apply any
amount by which the Percentage of Estimated Excess Insurance Costs exceeds the Percentage of
Actual Excess Insurance Costs to the following year&#146;s Estimated Excess Insurance Costs payments
due hereunder, and Tenant shall pay any shortfall between the Percentage of Actual Excess
Insurance Costs and the Percentage of Estimated Excess Insurance Costs, with such payments made as
additional Rent by Tenant to Landlord within twenty (20)&nbsp;days after receipt of the aforesaid
statement. Such payments shall be prorated for any year in which this Lease terminates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>34.&nbsp;</B><U><B>QUIET ENJOYMENT.</B></U> Landlord covenants that Tenant, upon paying the Rent and
complying with the terms, covenants and conditions set forth herein, shall and may peaceably and
quietly have, hold, and enjoy the Premises during the Term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>35.&nbsp;</B><U><B>TENANT&#146;S REMEDIES</B>.</U> In addition to and without limiting the other rights and
remedies available to Tenant hereunder, or that may otherwise be available to Tenant at law or in
equity, in the event Landlord fails to perform any of its obligations or duties hereunder, or
otherwise breaches any of its covenants, warranties, representations or other obligations under
this Lease, after not less than thirty (30)&nbsp;days written notice to Landlord, Tenant may, but shall
not be obligated to, remedy such failure or breach if not cured within such time frame by
Landlord. All reasonable amounts expended or obligations reasonably incurred by Tenant in
connection therewith shall be paid by Landlord to Tenant upon demand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>36.&nbsp;</B><U><B>RIGHT OF FIRST REFUSAL TO LEASE FIRST FLOOR SPACE.</B></U> During the Term, Tenant shall
have the first right to lease (the &#147;<U>Option</U>&#148;) that certain space identified as the &#147;First
Floor Option Space&#148; on <U>Exhibit&nbsp;A,</U> attached hereto (the &#147;<U>First Floor Option
Space</U>&#148;), in the event that same becomes available, upon the terms and conditions set forth in
this Lease, except as otherwise provided in this Section&nbsp;36. In the event that the First Floor
Option Space becomes available during the Term, Landlord shall promptly provide to Tenant notice
of such availability, provided, however, that the First Floor Option Space shall not be deemed to
become available if the current tenant, by negotiation, extension of its current lease or a new
lease, extends its possession of the First Floor Option Space. Upon receipt of such notice from
Landlord, Tenant shall have fifteen (15)&nbsp;days to notify Landlord in writing of its intention to
exercise the Option. Tenant&#146;s failure to exercise the Option shall not result in a termination of
this Lease. Further, if Tenant does not exercise the Option, the Option shall not terminate and,
should Landlord fail to lease the First Floor Option Space within six (6)&nbsp;months following
Tenant&#146;s notice of its election not to exercise the Option, Landlord may not thereafter lease the
First Floor Option Space without again offering it to Tenant pursuant to the terms of this Section
36. Notwithstanding anything to the contrary set
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">forth herein, Landlord and Tenant hereby acknowledge and agree that in the event Tenant
exercises the Option at any time during the Term: (i)&nbsp;the amounts of the Annual Rent and Monthly
Rent applicable to the First Floor Option Space shall be on market rate terms based on leases of
similar duration and services within the Building, and (ii)&nbsp;the First Floor Option Space shall be
deemed to be a part of the Premises for the purposes of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>37.&nbsp;</B><U><B>RIGHT OF FIRST REFUSAL TO LEASE SECOND FLOOR SPACE.</B></U> During the Term, and so long
as Tenant is not in default under this Lease, Tenant shall have the first right to lease (the
&#147;<U>Second Option</U>&#148;) that certain space identified as the &#147;Second Floor Option Space&#148; on
<U>Exhibit&nbsp;A,</U> attached hereto (the &#147;<U>Second Floor Option Space</U>&#148;), in the event that
same becomes available, upon the terms and conditions set forth in this Lease, except as otherwise
provided in this Section&nbsp;37. Notwithstanding the foregoing, Tenant acknowledges that the Second
Floor Option Space is currently available and Tenant has elected not to rent the Second Floor
Option Space at this time. Accordingly, the Second Option shall not arise until after any lease
for the Second Floor Option Space into which Landlord may subsequently enter. In the event that
the Second Floor Option Space becomes available during the Term, Landlord shall promptly provide
to Tenant notice of such availability, provided, however, that the Second Floor Option Space shall
not be deemed to become available if any future tenant, by negotiation, extension of its current
lease or a new lease, extends its possession of the Second Floor Option Space. Upon receipt of
such notice from Landlord, Tenant shall have fifteen (15)&nbsp;days to notify Landlord in writing of
its intention to exercise the Second Option. Tenant&#146;s failure to exercise the Second Option shall
not result in a termination of this Lease. Further, if Tenant does not exercise the Second Option,
the Second Option shall not terminate and, should Landlord fail to lease the Second Floor Option
Space within six (6)&nbsp;months following Tenant&#146;s notice of its election not to exercise the Second
Option, Landlord may not thereafter lease the Second Floor Option Space without again offering it
to Tenant pursuant to the terms of this Section&nbsp;37. Notwithstanding anything to the contrary set
forth herein, Landlord and Tenant hereby acknowledge and agree that in the event Tenant exercises
the Second Option at any time during the Term: (i)&nbsp;the amounts of the Annual Rent and Monthly Rent
applicable to the Second Floor Option Space shall be on market rate terms based on leases of
similar duration and services within the Building, and (ii)&nbsp;the Second Floor Option Space shall be
deemed to be a part of the Premises for the purposes of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>38.&nbsp;</B><U><B>PARKING.</B></U> Landlord will provide Tenant, its employees and invitees, twenty-five
(25)&nbsp;spaces in the parking lot known as Gateway to Nashville, throughout the terms of Lease. Such
parking entitlement shall be on a nonexclusive basis with other tenants and parking licensees and
no guarantee is made that parking spaces will be available at all times.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>39.&nbsp;</B><U><B>MISCELLANEOUS PROVISIONS</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Remedies Cumulative</U>. All rights and remedies of either party hereunder shall be
cumulative, and none shall exclude any other rights and remedies allowed by law.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Grammar</U>. The words &#147;Landlord&#148; and &#147;Tenant&#148; whenever used herein shall be
construed to mean Landlords and Tenants in all cases where there is more than one Landlord or
Tenant, and the necessary grammatical changes required to make the provisions hereof apply either
to corporations or individuals, men or women, shall in all cases be assumed as though in each case
fully expressed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Homestead Exemption.</U> Tenant hereby waives and renounces any and all homestead
exemption rights he may have now, or hereafter, under or by virtue of the constitution and laws of
the State of Tennessee, or of any other state, or of the United States, as against the payment of
said rental or any portion thereof, or any other obligation or damage that may accrue under the
terms of this agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Notices.</U> All notices herein required shall be in writing. Whenever any notice,
demand or request is required or permitted hereunder, such notice, demand or request shall be (i)
hand-delivered personally, (ii)&nbsp;sent by express mail or courier service, (iii)&nbsp;sent by United
States mail registered or certified, postage prepaid, or (iv)&nbsp;sent by confirmed facsimile
transmission, addressed as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="19%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left"><DIV style="margin-left:15px; text-indent:-15px">If to Landlord:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Gateway To Nashville, L.L.C.</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Zach Liff</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">209 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Avenue South, Suite 432</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:  (615) 259-3141</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left"><DIV style="margin-left:15px; text-indent:-15px">If to Tenant:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cumberland Emerging Technologies, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: A.J. Kazimi, Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 West End Avenue, Suite 950</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nashville, Tennessee 37203</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:  (615) 255-0094</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice or demand to be given hereunder shall be deemed sufficiently given for all purposes
hereunder (a)&nbsp;at the time such notices or demands are hand-delivered, (b)&nbsp;one (1)&nbsp;day after
depositing any such notice or demand with any express mail or other overnight courier service, (c)
three (3)&nbsp;days after depositing any such notice or demand in the United States mail with the proper
postage affixed thereto, certified, return receipt requested, or (d)&nbsp;if sent by facsimile, upon
receipt by the sender of an acknowledgment or transmission report generated by the machine from
which the facsimile was sent indicating that the facsimile was sent in its entirety to the
recipient&#146;s facsimile number; provided that if a notice, request or other communication is served
by hand or is received by facsimile on a day which is not a business day, or after 5:00 P.M. on any
business day at the addressee&#146;s location, such notice or communication shall be deemed to be duly
received by the recipient at 9:00 a.m. on the first business day thereafter. Any party hereto may
change its address by notice in writing to the other parties in the manner herein provided.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the parties hereto have, on the day and year first above written,
executed this Lease agreement in duplicate, one copy to be retained by each of the parties and
each such copy to be considered as an original for all purposes.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>LANDLORD:</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">THE GATEWAY NASHVILLE, L.L.C.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ATTEST:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/
&#091; ILLEGIBLE &#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;&nbsp;&nbsp;/s/ Tracy N. Marsh
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>TENANT:</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">CUMBERLAND EMERGING</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">TECHNOLOGIES, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ATTEST:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;&nbsp;&nbsp;/s/ &#091; ILLEGIBLE &#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; C.E.O.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT </B>A</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DESCRIPTION OF THE PREMISES</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">See attached First Level Floor Plan
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Existing space is that marked as Phase I (completed)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">New premises is that marked as Phase II, IIa, and III

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628607.gif" alt="(MAP)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PLANS AND SPECIFICATIONS<BR>
FOR LANDLORD&#146;S WORK</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>RULES AND REGULATIONS</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;1.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No sign, picture, advertisement, or notice shall be
displayed, inscribed, painted or affixed, on any part of
the outside or inside of the Building, or on or about the
Premises hereby demised, except on the glass of the doors
and windows of the Premises and on the Directory Board of
the Building, and then only of such color, size, style and
materials as shall be first specified by Landlord in
writing on this Lease, which consent shall not be
unreasonably withheld, conditioned or delayed. Landlord
shall place a sign on a prominent location on the exterior
of the Building with the name and logo of Cumberland
Emerging Technologies, Inc. or any other name as designed
by Tenant. No &#147;For Rent&#148; signs shall be displayed by
Tenant, and no showcases, or obstructions, signs, flags,
barber poles, statuary, or any advertising device of any
kind whatever shall be placed in front of the Building or
in the passageways, halls, lobbies, or corridors thereof by
Tenant; and Landlord reserves the right to remove all such
showcases, obstructions, signs, flags, barber poles,
statuary or advertising devices and all signs other than
those provided for, without notice to Tenant and at his
expense.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;2.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant shall not, without Landlord&#146;s written consent, put
up or operate any steam engine, boiler, machinery or stove
upon the Premises, or carry on any mechanical business
thereon, or do any cooking thereon, or use or allow to be
used upon the Premises oil, burning fluids, camphene,
kerosene for heating, warming or lighting, or anything
(except gas or incandescent electric lights, and those only
of such company or companies as may be supplying the
Building) for illuminating the Premises. No article deemed
extra hazardous on account of fire and no explosives shall
be brought into the Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;3.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No additional locks shall be placed upon any doors of the
Premises. Upon the Termination of the Lease Tenant shall
surrender to Landlord all keys of the Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;4.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Safes, furniture, boxes or other bulky articles shall be
carried into the Premises only with written consent of
Landlord first obtained, and then only by means of the
elevators, by the stairways or through the windows of the
Building as Landlord may in writing direct, and at such
times and in such manner and by such persons as Landlord
may direct. Safes and other heavy articles shall be placed
by Tenant in such places only as may be first specified in
writing by Landlord, and any damage done to the Building or
to Tenants or to other persons taking a safe or other heavy
article in or out of the Premises, from overloading a
floor, or in any other manner shall be paid for by Tenant
causing such damage.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;5.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elevator service and/or self-service elevator will be
furnished by Landlord daily whenever said service shall, in
Landlord&#146;s judgement, be required for the proper occupation
and use of the Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;6.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Any person employed by Tenant to do janitor work, shall,
while in the Building and outside of the Premises, be
subject to and under the control and direction of the
Superintendent of the Building (but not as agent or servant
of said Superintendent or of Landlord).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord may retain a pass key to the Premises and be allowed admittance thereto at all
times to enable its representatives to examine the Premises from time to time.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;7.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord and its agents shall have the right to enter the
Premises at all reasonable hours for the purpose of examining or
exhibiting the same upon advance notice and without interfering
with Tenant<SUP style="font-size: 85%; vertical-align: text-top">&#146;</SUP>s operations.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;8.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord, and its agents, shall have the right to enter the
Premises at all reasonable hours for the purpose of making any
repairs, alterations, or additions which it or they shall deem
necessary for the safety, preservation, or improvement of the
Premises of the Building, and Landlord shall be allowed to take
all material into and upon the Premises that may be required to
make such repairs, improvements and additions, or any alterations
for the benefit of Tenant without in any way being deemed or held
guilty of an eviction of Tenant; and the Rent reserved shall in
no wise abate while said repairs, alterations, or additions are
being made; and Tenant shall not be entitled to maintain a
set-off or counter-claim for damages against Landlord by reason
of loss or interruption to the business of Tenant because of the
prosecution of any such work except in the event that such
repairs render the Premises untenantable. All such repairs,
decorations, alterations, additions, and improvements shall be
done during ordinary business hours.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;9.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If Tenant desires telegraphic or telephonic connections, or the
installation of any other electrical wiring, Landlord will, upon
receiving a written request from Tenant, direct the electricians
as to where and how the wires are to be introduced and run, and
without such directions no boring, cutting or installations of
wires will be permitted.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;10.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant shall not allow anything to be placed against or near the
glass in the partitions, between the Premises and the halls or
corridors of the Building, which shall diminish the light in, or
prove unsightly from the halls or corridors.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;11.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No electric current, intended for light or power purposes, shall
be used by Tenants, excepting that furnished or approved by
Landlord; nor shall electric or other wires be brought into the
Premises, except upon the written consent and approval of
Landlord.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;12.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant, when closing its office for business at any time, shall
see that all windows are closed, thus avoiding possible damage
from fire, storm, rain or freezing.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;13.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant shall not allow anything to be placed on the outside
window ledges of the Premises, nor shall anything be thrown by
Tenant, or his employees, out of the windows of the Building; nor
shall they undertake to regulate the thermostats, if any, which
control the heat or air conditioning.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;14.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The water and wash closets and other plumbing fixtures shall not
be used for any purposes other than those for which they were
constructed, and no sweepings, rubbish, rags, or other substances
shall be thrown therein. All damages resulting from any misuse of
the fixtures shall be home by Tenant who, or whose servants,
employees, agents, visitors or licensees, shall have caused the
same.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;15.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No bicycle or other vehicle, and no animal shall be brought into
the offices, halls, corridors, elevators or any other parts of
the Building, by Tenant, his agents or employees, except as
required by law.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;16.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No person shall disturb the occupants of this or any adjoining
building premises by the use of any musical instruments, unseemly
noises, whistling, singing or in any other way.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;17.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Premises shall not be used for lodging or sleeping, nor for
any immoral or illegal purposes or for any purpose that will
damage the Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;18.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The entrances, corridors, passages, stairways and elevators shall
be under the exclusive control of Landlord and shall not be
obstructed, or used by Tenant for any other purpose than ingress
and egress to and from the Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;19.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Canvassing, soliciting and peddling in the Building is prohibited
and each Tenant shall co-operate to prevent the same.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;20.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">All office or other equipment of any electrical or mechanical
nature shall be placed by Tenant in Premises in approved settings
to absorb or prevent any vibration, noise or annoyance.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;21.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No water cooler, air conditioning unit or system or other
apparatus shall be installed or used by any Tenant without the
written consent of Landlord.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;22.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">There shall not be used in any space, or in the public halls of
the Building, either by any Tenant or by jobbers or others, in
the delivery or receipt of merchandise, any hand trucks, except
those equipped with rubber tires and side guards.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rule&nbsp;23.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord reserves the right to make such other and further
reasonable rules and regulations as in its judgment may from time
to time be needful for the safety, care and cleanliness of the
Premises, and for the preservation of good order therein, and any
such other or further rules and regulations shall be binding upon
the parties hereto with the same force and effect as if they had
been inserted herein at the time of the execution hereof.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628608.gif" alt="(MAP)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g06286g0628609.gif" alt="(MAP)">
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>26
<FILENAME>g06286exv10w24.htm
<DESCRIPTION>EX-10.24 FIRST AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.24 FIRST AMENDMENT TO AMENDED LEASE AGRMT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.24</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>FIRST AMENDMENT TO</B></U>
</DIV>

<DIV align="center" style="font-size: 10pt"><U><B>AMENDED AND RESTATED LEASE AGREEMENT</B></U></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS FIRST AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT </B>(the &#147;<U>Amendment</U>&#148;) is made
and entered into effective as of the <U>23rd </U>day of August, 2005 (the &#147;<U>Effective
Date</U>&#148;), by and between <B>THE GATEWAY TO NASHVILLE, L.L.C., </B>a Tennessee limited liability company,
with its principal office and place of business in Nashville, Tennessee (&#147;<U>Landlord</U>&#148;), and
<B>CUMBERLAND EMERGING TECHNOLOGIES, INC</B>., a Tennessee corporation, with its principal office and
place of business in Nashville, Tennessee (&#147;<U>Tenant</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WITNESSETH:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>pursuant to that certain Amended and Restated Lease Agreement made by and between
Landlord and Tenant dated November&nbsp;11, 2004 (the &#147;<U>Lease</U>&#148;), Landlord leased and demised to
Tenant, and Tenant leased from Landlord, the Premises, consisting of the Original Premises and the
New Premises; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, Landlord and Tenant desire to set forth the Completion Date for the New Premises; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Landlord and Tenant desire to amend the Lease to reflect the foregoing agreements and
otherwise, pursuant to the terms and conditions hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>for and in consideration of the foregoing premises and the mutual covenants,
terms and conditions recited hereinafter, and for such other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby amend the Lease
as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. <U>Section&nbsp;4(a)</U> of the Lease is amended to provide that the Completion Date shall be
January&nbsp;1, 2006, provided however, that, if in the event the Landlord&#146;s master electrical panels
have not been installed and certified by October&nbsp;15, 2005, then the Completion Date will be
redefined to be the date reflecting seventy-five (75)&nbsp;days after completion of the Landlord&#146;s
master electrical panel installation as certified by Davidson County Codes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. <U>Section&nbsp;4(d)</U> of the Lease is amended to provide that the Acceptance Date shall be the
earlier of (a)&nbsp;the date that Tenant takes beneficial occupancy of the New Premises and (b)&nbsp;the
Completion Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. Except as herein modified and amended, the terms and conditions of the Lease shall remain in
full force and effect.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;SIGNATURES APPEAR ON FOLLOWING PAGE&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the parties hereto have, on the day and year first above written,
executed this Amendment.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LANDLORD:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">THE GATEWAY TO NASHVILLE, L.L.C.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ &#091;Illegible&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>TENANT:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CUMBERLAND EMERGING<BR>
TECHNOLOGIES, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">C.E.O.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>27
<FILENAME>g06286exv21.htm
<DESCRIPTION>EX-21 SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-21 SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 21</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SUBSIDIARIES OF CUMBERLAND PHARMACEUTICALS INC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The subsidiaries of Cumberland Pharmaceuticals Inc. are listed below.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">State of Organization</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cumberland Emerging Technologies, Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tennessee</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cumberland Pharma Sales Corp.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tennessee</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>28
<FILENAME>g06286exv23w1.htm
<DESCRIPTION>EX-23.1 CONSENT OF KPMG LLP
<TEXT>
<HTML>
<HEAD>
<TITLE>Ex-23.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;23.1</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consent
    of Independent Registered Public Accounting Firm</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cumberland Pharmaceuticals,&#160;Inc.:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We consent to the use of our report included herein and to the
    reference to our firm under the heading &#147;Experts&#148; in
    the prospectus. Our report refers to a change in accounting for
stock-based compensation in 2006.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>


<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="g06286g0628610.gif" alt="KPMG" >
</DIV>



<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Nashville, Tennessee
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    May&#160;1, 2007
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g06286g0628602.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628602.gif
M1TE&.#EA6P%*`.9_`*:MU*2CI][<[,3)XX!^H,*]VSM"FW=VMN3DZIN:I&IV
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MS/CW^TM/HI&6R"$ODNSL\H6)OH6%LL'`R_3T^<W,S["ON*.AKT=-F$A.F?S\
M_:JHPJVMRX^0OZ.BP?3S^)N8J+[!W)J7K9F=R-#0UQ`CC/___R'Y!`$``'\`
M+`````!;`4H```?_@'^"@X2%AH>$`XB+C(V.CY"1DI.4E9:7F)F:FYR9`)V@
MH:*CI*6FIZBB,%"IK:ZOL+&RLY<NK+2XN;J[O+V'?%VWOL/$Q<;'CP-5/,'(
MSL_0T:X+`%5F!LS"TMO<W=Z')0XT$`<-(]?9W^KK[,1M3BPT9!7DYNC-[?GZ
M^Z8H<RH"'!201Z_<.6SX^"E<R##2"3QE3@`42+#>P70-,VK,J,2)@!@1)PZ<
M9_&>MHTH4WX3P,+!QY`!1Q:TA_"DRILXC2D96,`E2(DQ*QHTF;.HT5XKR%B@
MT?,E4(HDA]8\2K4J+"T<*BQM^E.D4)H8K8H=&PH&!`A:F?J$"77FQ81D_^/*
MI>2DR@&T6]<^E5ERZMR_@!EA"1'B;EJN;/G:L4-.#9\S7JI<H%*'Q(<@@3//
MK3*B,%ZU3E68T+(EAHI%+H#DF`'"0X87.*1$Z"-BU((ON'/KU@V@Q"$8N1\!
MP*W(T`#<8R*5R`WCT/#=T'4G_QV].G%#UJ,O0'3\RR=.S[_X3O8E!23@WA>%
MSSY@/*+GS0<QL='9<%X3$E"@B)1Z=>O7.&A`P00)=.!&;9RDX,>"##;HH!]@
MQ)<(@X]@L.`7AWRQ8(20R,!@<858^."(#"IPR``DIHAA(2F2^%TA&OJ!`2<P
M-+BB(S&:Z`B*,BXB8HL,8@#B("6((<87,F!@WO\?6AA`GV<5<.%`#);TQYIK
ML`E(X!$!'/'#!YL`.:(,QE'HB(@W$A)CCXXLT."0@_PH)H/;%<+CG!<:@B>#
M8&2XX(R;*."@A(RLJ8![W/WIXYYY$L(``#*"D8*0?WCA9'T6")")E?]E.6`"
M7!Y1!!%[M(#)G0.DJNJJJ0K*YH0+5M@HC`TNR8@8;QXBHABL]LH`@VD*@FJO
MQ!(J"(,I$*OJKPL:^T>,@&92(X0BZMC(FGZ(@6B9KQJR*['#*0!&K82(\8<?
M`S#PQ0`*3!'%I6><IHF51F`9X*>ACMH#`4L@8,F=."IJIYF-H.DGGW4B@BVZ
MN@K,"+#<^G')AXQ,RS#_K=U>@N:=SF+GH+:+\!BMMPZ_-VZS<9X;!A@+E(#!
M`>^&D/"\JLU0+X!:@MIE$1/LBT06)%0"\+4E"TLP(P9[[$<8"YJ+"`SCAB$B
MG(*(.#(B$`\<JR44/[P@U=!JPB,8OE4;L!_,9KOM("(OFO$A"YQLK;E^U`C`
M<#Q$H48;H-#K01:>;KDS$3YGX<$%*TPR-",`8(`!F5I+?.:L:EZ(JQ_!QKG@
M&%,W_+:>E!N]=25=+U+Z(&%GDO2=,Q_L'8,@<WLU(58_LN9X7R@PXZ1BP%`#
MY'W7?#,2]Q(8P."%>P""$9I&LKC01[N=^;,7NKE@ZW]`VF/G)'].2`G(1CSQ
M_]>-G"Y(ZI>,[5[MA>:IO=JRNSW[;PQ.]X<,8>0NQG8NC%*%\']#`@%R=CQ1
M$8X`2,B`\G8P`Q8X+WJ*@Z#GIA<C#,7(:40:%X>X%Z(%Y2\[EZM;Q*SC"/,5
MPF)@*QHEDB:ZBRFL4>^+'=M4J#GO&>)D:2I!JHCD/P!F08`$1!X"%0B"'?C@
M!GJ`Q/,HL41$L+!RF!/$Y8#W!V8MB8.T8U08[`>K%I60?$]SE0@Q-K\'0FA;
M['MA%`41MZ81JFU.I.$$8_&_U=3KAP3H`1&,)\0$+A`(-S#`%)(A03-*KF"A
M.U^CK'>Q,32MAE3[@YS$%`;L_>%.*?KBGOJDM#)"XO^)+8RD(M?(QI.Q;(8V
M3",B2>D*`7S@E58(0A"&P(8D1.`-;RB@O@CP`B+N`)`ZB,+:Q)>^0G:0E:B;
M58S"4((2,,T/"<-B#7FEK%0QBVP1JZ8F\41!.1+RC)[#H-*"U48(U0F.GO-D
M(2XWO5V(``%NB(`4>.E+8-9`G2T\E3&SB,Q1IDE$,O"0'Z@HS:IY<Q`GLQ4J
M#TD)V#G.<2?+EN,4\"(R7N*9#%#6FBH*Q<R5\Y3H[!X^!Y$U9TA@"'?(0!'M
MV<_([0@W'+WD/FO8359"K4',Y&<D51G'?C8Q$J<KIPS5.-+W:%&-T_OH`D)Z
MS*(Z$HS2&((=6#K&1(UN$>C_6ZBL6EK!0BBH?L?<Z4$-ZM.9>LV%I6R:)9-I
MPT8\<T\QI5Y+__!1[7F2ISWEY"(<6(PV\.$&-5@0`QCQ4XNZ=')<3:2(!AO6
M="(V<X5]A`F?:DZLCM6H$,H.;BX7!M<M0JC>Q*O2YCJ(.#2O&"6`@@FU2K2W
M19:?-<T<U#C46)$V`GR)?&WYH$J(]YWR8$4UQ#.IB`C*9JZKGXUH*@_*.0;E
ME!%R\,$3D+$`7%G+$(Q\J':WBU'L!FF[X,4`#CV+74L65)(>S(X"WJK0%H8W
MO,0]%V][B["#?5"S0WI?QX2[H6TA=Q%%"I+;P/#>$&YHK810@P]VT(0T'*,$
M@AJF_R#>BJ?V"D*Y>(KD?[<J5D;1MHMXFMUJ!>';F"X,2&EZYG495U)_.B+`
MR]U3)1^Q`A^P)@,1D,`Q*/I9"@-IQ8,8`X:!%%\71^*\DP32C",68M"AU1#O
M\P-'3]RB&ZU)E(=X)C;9VLY"!/BN(4Z!A`_1A"ME``<1&#,N2L!%N%5S56J^
MY)M7M=\_P"!5=79S>_0\YU0A6(=]7A7V5!5G5ITPT*J2T%)W&(E%[WD0=QY`
MGK\W``0[NIH(9L0*C-"I`,&!-IH)M:@E08).Y^P';D``@D;-ZE8+8@WVREF^
M\M"!""0A"/YRM:[_(H$+X`Q??32<$6Q6!2\P``.YB>NNE_^M$02\('`Z$U7/
M$"CL&1Q1!UUX@("9S>V4((``Q8OV+G_F@6%?NPL-"BXE@-SM=L_"!!H(H@&3
M!P)KWP#;Z1[%&6SB[GY?90F?TN4!R5WO<^<[%"1`@[+='6DL0YI8T$AT+DKP
MG!1,&A%*^`$?YTWM!1I\VYT```_0$.>/93IC&G*X(#B'@3C+%7:6=AS5=%=D
M0^BNRX4``(7!@',J6W9(*&HGE>>Z``QD&L(."H/*[2SS'3T9$6TD<&4KT0<X
M")S>1KPWND&N"2P<`!M5**$"4@4`,>CU$"A_.G])FTQ5`0`,G;7JU9AZ(@9=
MW$-B``#9<87EE!OZA4"?:\.-)/'_NF,YP`H80ZJ^`(:S(\)5(T71TO^`J^\L
MX+F54,(&^NC+CU_V$2JPP$6$4,(;.1++:5<YI!C0^(!5+F2G$VTAF"8H=D_H
M:B7(M(8BD?()X;QJD5>[(`3%41C$N492$_X,)]_62HB`#>/N_+T#R_5*"(`$
M4NE?Z9-9YVRQ2E`J9QH,B$\T1S%T8(**%HK2WPA(S6A<>=;0Q6G%JC'W?H:_
MEV3PL0P&<4;B5WK7?)+W"$RS<)?P?$1`3QXW?0<W"7,0`P[`!6YQ#5H@65*#
M`;1W5@_B<)!B(LA'-`\U+C4G4[ES,192(_C$-(J@(;9G4)1P8GV'5D%W)OMG
M.B,(>W%G_R$.-X!M8B%@\"@N-PD?0`<$\$<,6'V,X`]XL`4"00(6,(%,``DR
MDAMMIB?4I"K@QPBTAQL%V#Z;Y0=5Z'LH*%,FTE:0PG-(@C*(\"LO>'[M$WCY
MYSA.AWHMN"C(]@6_HDX\^`@+@#\0$H::D`8L0`55X`,Z0'TJ)`!.8`)6T(A!
M(``KD!A.Z!9A)X7Y1U)7<W_.,2)Q]T)LU%8S"'XG>"Z>Y$PCTH(*`HB6Q7M@
M2`B.%(<UB`ABT(E*1")8MH>LJ&Z8,`5NAP$U\"Y/8A^@$8E[,8GU$`(Z9HE`
ME8G*IX)9M'"[IT@6AG]VMC1^H",VI"'!,HJ_`7>$0G'VYX:+X/](C"4(`$B#
M<Z@>UU@(U+`H0_*!B3)Y`V`_CJ2+G/`%OW@I4)(7D"B)3T@.![`%DL!V+,*,
MHN1^`T.+M%(N'S8P*^(J\>$])=!XV[)^ZGB-N.&'(TAE6/8K^>.'=1@GL?AX
M2R,#N"$H#1ED:&-S4F95#5@(XZ(`2#(NTW@*^`B,]?$934&,(F&,$#!_B0"4
MS\)1Q[%?PX$]*?`%^W5GA'!G^U5T*P(#R!8G-7<;89B4C+``K`<[JFAGQ*)F
M`*`[&)!XD+``F<9&1M=^(00&"F"42FD(P*%LZ,$;821>&,``75D*-ZF/PKB3
M_E@!'%"!_C:8^K"7P:B3+L&3,>&$7)"7.(3YF.Q@F#EY&(DIB5>@!)"9F>H@
MF?LXC&QQ!8*IF:+)#9S9EY4)%"8P!Z.YFMM0FHC9CR?0!JK)FK0)#:Y)F0*@
M`B>P'[79F\YPFTMQ!5N`F;Y9G,A0FA5``@*0C,;9G,9@F!SP!";@G-1YG+^H
J!HY9G=I9#/A(>MOYG<3P!5$(GN39"^)1GNBI"Y.7GNQ)"NO9GN49"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g06286g0628610.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628610.gif
M1TE&.#EAC``=`(```````/___R'Y!```````+`````",`!T```+_C(^I!NL/
MHYRTVJM`P[S[#TJ:%I;FB28CF;;N&ZWP3'-;/-;Z'N/K+^,)7RP'\(@,Y8:[
M8@8)!7J"S)KS0'U<`UG$;;&L?E5C6[D+WG*7MS!9K8.O&5&W]XLVPG-L=9Y^
M="(W"$6&)9>FM\%GM];HF&1"J.641?)'F<9R^9@G151V2'F&]W-A9PK8%7B'
M*!G*`.'7]EE11\OXYM@*F[+7._=TF&I;R$LWO%B$Z0N+>.6VR?SV1\6YC.TJ
MZ-S+N#KVJ"E2^8W+'77Z.PH<?.PS#KX5YEF',:DW,>L:?E=<JMW.7K>!^<X!
M`P@0$#5V`2UTNM:GH"Q^%!+N6GA/X*U/*`C9$;-B\%8'8Q^1O2KI@I!()A8=
64GSELF65F?YHVKPI\Z;.G3P7%```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g06286g0628603.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628603.gif
M1TE&.#EAJ`%=`.9_`'B$OW-ZGK6[V[S"WVMSG&-LFX>1QJ2DIWV"H9R=I3Q,
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M]'-^N_?X^IF<KC=&DQXPCD-2G&9SMD]:E^3F\I67I,7*XR`RD$M:J1DMD//T
M^;"VV9*<RZ2KT\?,Y(^8R4=6IE!?JS`_DCA)H(B-J^SM\VIVMZ6LT[*WTF!L
MK;B]TZBOT)*:RYZAN"<YF*.IR\+'XI"9Q["QNX6+J@\CC/___R'Y!`$``'\`
M+`````"H`5T```?_@'^"@X2%AH>(A!*)C(V.CY"1DI.4E9:7F)F:FYR=GI^9
M(HN@I*6FIZBIJJNLK:E@HZZRL[2UMK>XN9$=L;J^O\#!PL.W9'B]Q,G*R\S-
MRS-CR,[3U-76UY=D7'C1V-[?X.'--Q9B2]S2XNKK[.V>3BT>%$`+Y]WN^/GZ
M^X4.8$\=K'"95P\=OX,($U+#<(-*F3,>-`0<2,]>.H48,VIL=6%*$30#'D:<
M2-#BQI,H4WK"@(&,E`T?0T*4*+"D094X<^I,A.&"B98O8XJD2;'@O9U(DY[$
MX*2'DY\N88(<2K+B3:58L^YSPH.!4ZA!I\ZL:O2BUK-HJYG@(8&*UZ=`_Z7*
M'%G3ZM&T>/,R<S+`1=NW8.52K5M6K^'#P9A8R.#7[=>X0L<2-HFXLN59/#P\
M8?SW<=3(=(M2ODRZ="DJ!C1S=@SWL]C0-N^:GDW;4HL.J3<W!@SY-='89FL+
M'UZ(@0K<JG=[#COWM]W@Q*/3OJ'B>.[5O%TW)VO/!PD25*9('R_<B@SKR3NW
M9DYD`!@P:#8PX'&#$(@1)8*\Z/+C2!(D=.P0!7D$ZO5`!.<AIYMZ/UT@@@@^
M07)??OO]`$4!!`2`0`U80&"$":DX`(`8$_AAXHDHGMB$&#.85808,`(@"8PP
M,C*B&#)2\F*,B=Q(XX]``DF!!8SL&.2101)IB/^/2![9HHTT%E&*`S]Z0,F-
M4DKB8R/E-"FD`0*(T(@('HA!@0=B$D*%&@BBMR`5&\00!0:63*@??Q=FN.$)
M%21PP`H?3ME$BH06:J(`B$APHAB2H,B(&"<B.HD"BR8"J:&8GICC(8IFFJD!
MAUSJ::%*AGHB=)?,@&(3:49R:1-90B)J(P:,6N@,#B!21!,S"&"!`0K$^H<,
M;"9X'1$;D*&)G17FJ6$*?/IY0`)?0"#>)P#8:J@"B58:B:.6JMCJ(QZ@R"@B
MHFJ;HK"*J$LHJ(:DZVX3X9J(:B4.O#N)J!.,V\BLC-3JKHJE#B+"!.6:&.P$
M@PB@0+'H25`?)Q/BT"S_AL]&>\"T7^B0PAT[>$*IB5X".:B)W9+<Z(F/HCA#
M)"*<K#*Z)RI0,HPIPFM(IWZL>/./!0\BZL\R^W&1J/=2HJJ))],[(XH*^%NO
M'[2>.(&7A@;M@06*2E#N'P`HJ<;#;=*@!XB>5'RQGM#VN3&U'B,0``IO<`+N
M(TASZBTD=YN*8M)+[QWOJ8\<?*+.A?!\;B8`CUFBO31#_DF^)LX@L!]!_YMB
MU'BS'/#AC3A0SJK"BN&`H@900+4$H&8P`=DJN'`%*6K#8"'&"+0M+=PIR$U`
M`4ALTK?FDB<NN"/#%R)OOX[P?#PA>3]R.>+MSLRXYXYD6[SRA'\2N`,B6/WT
M_^92#X[RYR92GX@%YD+_AZ(E$LGZ'Q2\KD8'$]..G\4P?.!L[CIP&\?B%H#?
M?>`(&\A$\J:6#L6M['R1$]6F$C&RH3$0$M-+F1\6AXG&56U[T.M>)RBW04$$
M+G/U4L#C_,"YED$0$1F$A`#^-@@`"$!1!V.4!3S@A2:\K@RHJ)W_<)>"`.ZN
M`@0TH.U<@(D%(L)'[!*$`[^%/;\9('J(2)C1GB<T$7[0#^J3(A<IX4'T&2UR
M9_1$X$9!0H;)BF2[JEGYNOC"0\00$H%[F13%H*@_L*\($W#``WPHJ5,(\7]%
M%&`"D-B[`A;@`S!X01!\<`DG5F**?*NB^0S@@)-Q"_\1,:O<'\;X!RQ^,8SO
M(^7XJ"8]+X80A)D@(0=/^,82QE%A<RRE)@UQQT<4046$&%&.`-`$(LF@"4!,
M!1OV]X+^(=*(;ZO`"5(P!$="4I)9Z(`E+$D)3#Z"FY<"E191N316C=)ZYDNC
M(U27/@UR\!)E3,3ECN;*3,R3$+\TD1L=<:ESW9*%<XQG(7KYS1,)RP,V$X,"
M)+4$2JJ"#5DH`?^&R#8=?.&()ZA!-96(339,D(IUQ(0WD;?+5\)K9'Z((L^L
M=,X2HM%R!HBI3&<:T\"E5(,3H"E-DR90.]93$*8,Q<GV24?,=<ZE?_AG"[D7
MTH&";I6H`@(K("K19OJ/``3_&`(`+QK-C&[TD9$,0A;8D(,]4(*;DQAI(\#9
MSJ36S!`C^V1+W_G*@9F(I7JS%2K3"8D5TA.6E[A<YGA&U'IQ4*E2Z^D@",K/
M$^$U$5$T!54G"@6L:K6(7)V6-#5JS;".-0=:J,,DT"H)M3*"K6!<[%,%H<58
MD%)>Z@J.\SY5RPW>;(7J9&IN,1%*/Q2VJ"ADZCL1J]M3[FNUN9BL52N;U:UB
ME+,<%2M9M<""R":"M)$P[75+2D>=&:YGN?I#)TU$`4*\UJXG"FXJ]5K;@3G-
M;[L-;'H1,4-]-A:I#8/:N!0K",82SZC)>,,.!KR"%4"`#T+H*G3!VE'0<D"N
M!6VJ_R6TBPC4(FZ*[&Q">`5QWKM*X,,@#C&(+2"S#1M/82(6L8E=:->]!M42
MO34G(E:H7J"B<Q#L.U%YBVI<J&(C!$9H@!"@"X4/=`&;('!P:C,IX4NJTA`6
M+D3@/,`SZG4XOD]$;O7P"T_WBJ'&+ZZ$?W$L/A?251`Y%J6-F]Q?+9/41"L^
MA+*6$8(5H*#(1Q9KDK7``3@SF96/@&)>N;Q6[JZ9>C%^W&^OG+0TGWF]A*Y$
M/-,,X*-B>1*]'1B8;TP(2NN1OW\8,WV!Z8@Y4*,%*$"RDOV@QS<#^KY8IO`A
MHER(^M*P$(R&A'9E[:J24GJONDV:&0?VVU<^&LTNTR6;0__M9D:PD]6/B(`&
MJD$&.@!ASWWVLZM[#5A>X]K0R@YCNG;\[4BO^=([&Z.W+9WE$[6:Q<(&9=$T
M;5@NH<@`VGNU3]OZ"$K?"P`C$*TU6D`!/KL[POJ&]Z"//6MPA_,0XP5OP\VM
M;'376MU/KFTB;/IN-,9[WQO4J<A35V:_,1S9BP(WL_G=""U2O!!EP$\2L.&"
M):`HEX/`[KDCN^Z<.YSEA$@8*G/=2DZ+T>AD!/>SH:UP3*PPSJ!$47#[V>]"
M]1BR'L#M31]!!OP$P092N(8(\OU8-*(WZDBO\,^7?`@5;I?B8=[9"A_=\_\R
M0@0H9;K',>%H202NV,H^.9E3],7_JR%IWO/=!84^$+QK"&!0@G?YP,@-9?2^
MM5[`/FW:8>NNL@]BMNXZ,ZCQGFRSN\L0*RRD+Z5N\DA0.N%.16\Q)T$""O'G
M"`VX1APM[:X)6/</-FVQ"S/_]F-S7EL:UJ!=1:_RI!:MXT4=6"'2#'@6%YOJ
MD<@W[`EQ.7?AJA(VN-/M:M"`V5%C5_<2P,C7;P&<1]RN2[7B-C=O>5@E`O3J
M8OZR!?%/O==5^H2P0L1G"+96:70D>%*F<EWR,V)@`.UW"21@,7B".TA@!-2P
M-;1`)A3`@#!R)C@'-C!28X_"(T_$@30R`P\(628()!\E"%OR"!(`)*KG@BM(
M(_CT(U"W_TXTTH(WTH+94R._T`'-=#L5A06`4@7-\'L%LH3>,`4_X$Q$!$T'
M(`00T``AP(18R(0#`(45E5F+-$T(T`<H(`=(H`1*<"U9F(:S@0(4]2P6]5Q?
M=4TX4`)LL`44$`%``#1JN(=I<0$(\$Q>N%EQZ%ELP`)A,`8YPX>*J!4W@%7-
MA5EPV%D=98C9UFRE``:+F(G.$`(%=%EOJ&"#V&!A4(E`9PIH,&V:F(K*$`)#
MX(F!Z%62*%TY,(J)F`IDT`:HJ(JZ*`PAX`;.!8JQ^%FT>&^JH`)-P$2[F(S`
M<`58`(G`&%W"2(IL5PH70`,3D'R.<#HJ!H,&(`VL$V^_XGE%DO]BD"`*$I"#
M1?!AK,`Z,Z6$GS=R(IB.4J..C*"-*4:/B2`*.7@(ZM>.DZ"-I<5).C)3,W@)
M$/")F@6+!(!G#69PQ&@*4L`%;?`Z&%0HQ%<KZH.1D4!"P@9;L]<(G5)LO24)
M`@-](*EU)/.!W=<^+2,-R[:2A,<(J/,(`H"2?D`!'_A*(LA]%G<(P>=_F!`"
M0A")"VED#2F-`V@)+D`!"S"1-%"15/9A)+9U\C2-;9:4P*=CO19BQ-23/%.0
MEP,S)18)]=4KN>(U@R*./!F5(>:.D.*2VS<(]J@H+0)B(&F5AY!CO2(F:&F`
MC&!KU<=+/3E]-\E&"@!AF6`"#?",#"G_BPYIB9FP`08@`VO0E!/@!179"^R3
M>1KI5$E).0*SC]Q#F#ZX9715(B42";7B0T"9CX.2.2)0D(+Y<;H$EXV"E3-Y
M=Z]I"$4@FS-VDR:RDVT6;V+P7H+P()]0!2OPA43V`WF6!=A6BYRP%G8``'!`
MF4TI`ZJ96S/$F7C9F8Z@*HP"*29I*L9S<HI"(KG%/NI9CH/B@-IF;P@(0X,Y
M.+;Y+;B)EX50+N7I>G"F*H')D\3I![Z9G!"@D%#@G*KVF*5H"3V`!D^0!C1@
MG=C9!BVPG;'@`)12H&W6@#0%*0-(.8M07Z+910F8>>G)G@&X17'I5.94(OW)
MD\))GS`E4SOY_Y:5=YO9I9^$H"H<^@@P*E[!V4KQ)C`3@((EJ@E1T`!N$``%
MD*#/&9T/:0E,L0%ZX"L^(*$46IEP0)*WX@@P.:6,H"IR%:2-]2,E@HWWMT&A
M%%XJNG]_$$KP$IJ-19NJ12B"AZ/?IJ.ZQJ-=9*>#%UX`2J238`&X)0;NN`DA
M(`<(H*!ZMFJ0B0@L@0$F$`-,P`,M,`!8JJ77N09KT`->6J,.V$H9Z:=RJ4\T
MDJ8Y"2DP,C(`D*3IR6R?1J#G]`A+<T,24);9XY=>RI8?EJAZ:EXM"F7YF7FJ
M\Z.-4")\))5#6C5V6@3RP#1)R@D7@`9Y8`-;(*61V@,WP`1,L`$.X/\`,7`!
M/=&MF*JI%I"E$]JIR82AE`">JD5\/QFI-M9%`QBK;0H_'#:L0HHI)<J?\D6;
MP>IS?`J#IOH'`&L)KX<B`<IL@"H(&NH'I9D*+7"*-04C0(`@<&`%N(%O!F`&
MNJ$'),``XDJN%V"NF;JIZRH#6*E:M`FO5QDZS:I:,A8NITJ5:_I)V3(#D*(D
M^P>@.D4I,1JG@Y(..5DK`NL'9=<I!=L\!TLYD56BH00`*;:;G_.P@C!#\[D*
M0.!#;0`Q`/"Q(3NR)5NNEYJRZ<JI'7`![UJ?GBF8F3>H_="@(<23B)E7$-LS
MOD6P]0A+G?*OZ;-A(G*3SGHEOM4JI+>UHU3_K&#:,P()L:HSL<Q6LV06H$@K
M"0Z#5R(0N;_0M1/PM6T2MB#+&")+LN-JMN>JL@!@!?GCI2_[G:9*.2@DMS9+
M")2"HA"T-'BU;.)),T.+L.;2-.X8ILM&>KR";VF:J.;%N(W+-*)B?_+&H_$S
M;+=V"-KC,]+:N5X+MF)+NF1[NB=[MNBJKAV`F9?TN`'IC=THDS%5/@X04Z(Y
M(H6P(SC'M'E;LVPFHBF3I`Y0)E62DPL8)(X@`@:P0KR2D\HSHTGU99#POD""
M)G]I)HD@`"S""`'\(THX.CW3@`C<"IX+NN<ANF-KNB:+LN.;!AH`JLJXP@GQ
MP=P[NBY0NF4;OJF;T*YQ@#8LG,/[X,*AV[TQ_+TE++Z^0@0XK,-&[`X\',(^
M+,/@:\(NP`!'',7XD,0J(,+>2\*HVP)4P+92W,7K0,56_,-8'+X,$'9>?,;B
M`,9+#,3EZ@1T@L9P_`UJ#,-,3*X_$<=X[`US/,(.`!=Y_,?7L,>D2P4]P,6`
M?,C4L,<#P`,=C,B.K+V?"S$:(``\,&>/?,G.X,(H:+Z8W,F9[$-K@(R>/,K-
KT+4`8,FDG,K)D+&JW,K*``2<[,JR_`N2.\NV+`O(>LNZG`I8N\N.'`@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g06286g0628601.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628601.gif
M1TE&.#EAA@`W`,0?`$-"0H*!@<'!P3,R,H&!@<#`P$)"0J"@H-_?W_#P\*&A
MH103$R,B(M'1T<_/SV)B8G%Q<2,C(V)A89*1D>#@X+&QL5)14>_O[W)R<E-2
M4I&0D!,2$K"PL`0#`________R'Y!`$``!\`+`````"&`#<```7_H">.9&F>
M:*J*7^N^<"S/=&W;I3-X2'X@EY5P.+H9C\BDS%08'`Z:$@1B(%I3RJQVZ[)`
M3AH#1-(;$0S1JYK%;;MK(\BO="%LYB+)YKN^OO^`+20Z!@=!)!(,?!X%$HLF
M.A86?6R!EELY$`,$#B8,:&8='"8$#`0')`5E1)>M62@$'1UI(@4$IR,(&ITB
M!*M`'@0%)PX<O":NR4<JFL(DIP9E&A(>!@0D"!([)0<.MQS#=*C*Y'`K%@:B
MAPX&##T''05/(AP,3M@$$&?'(@X'M]D\E!L88PB"6`;">;`PRXN<A8T**+SU
M#T\O!`PV(#A8AJ!'040.V*+%H(.$(`,&_TA0-:)`/#(C'%@@(*'#-1XE/GI4
M<Z!D.FH#(#CHL(U1S0'\)*J\AT7GP#4]2^;IL.%:$`T,3*5*M&E54Z?D^M2K
M&F8``U0&#&PB84V;'[!A^^CHP(`#@@/6TI8!DFBFPB%PXZY!L*=#(5E51J2+
M1RFPLCX%T"UD.,`"JF`&-LP\M,9QLC47Q#`:L"&H"""&;U(2Z+D5:&H2#6>-
MDC+AZB*M+U%BI\'"!0<;-@PMP/EV;MU0/X4;^O)VSN.!^N`]I&F#M<O.*T%_
MLX;#@'`<.ECHY."1\^V`UA!(X\"4PE'9M:/G0NF`!09_XY.8SQVT!L;ZG<"?
M&]+A%R`*`[8QF/\B!R*8("9JH.-5@[@]^,H5^E#HH(5*J!&-A@)RV.$5"H`8
MHHA(F)@=BDXU$$``%;R1@``"_$&!``VTT(``%+RP8X]9_"@#C0E<D@``LL@2
M08Y<""!+"P%T`,`644[Y`9(!O("E%ENV,($+LM1HR0!))KE`D5LXV0&44E+9
MYI4=9.E"ETIL>>2:+81IB0*R3)!``E%V\&6:3WX@0``*N&DEG7#*66><AA;Z
M@9Z!D/F`E@LXJL"+,;9P8P.`BKDIC85^^L&,.58`(PR;KLKFHI#.&:NA`4P`
M9`L)3/`BDXWF&F:/OR**9AN4>NI"`F0F>>D'59(9P0<9*%MHE9$"\$#_DAC@
MFJPLRU+;J):Q7IMDHA\TL$"9Y&*IIBQ9<IOD`&ZH2<,$L@P0@2P]!BH+!GQV
M$,&]T[;IY+D`G-M!D?02!7"^;R()P(LOWINEFO9V<":TLA3L;POJEMENO0!W
M2BB>,DQ@[:EZ!JI``A0XS''`4ZKYI9HUFGQI`BDW7*;'&&?0PKU?/C!`HA44
MNJ6\>7;@<P+G.JH%TC4(@$'."X#90:?]OAKIP4F+V8+4.<,:`0!D:YSEN1/0
M>.VRIU80+9Y'2RI+IXP&B>\+..+Z@,%A6RTFTM1"K6<">Y=9H[>,;KESQN6^
MG>3+$\O=@9AU9W$NN2U8^L&U$=C:=]=?P[RU_]^;^^OYY,SJ[+3B'3P`,:(?
MW`N``D7##:G@J'_;!N=HJIGHX)]_0*:<4^,9N.0U`H\ZXK-^2R:Y%0@P8Z&U
M0SXZZ+IST8"2`11_,;<"O'WXFZ4OH(`"!FN->_*MA_]YXI!.;7X%YSX@<P7)
M6J]F!3E26GD6_4)7"QQGL0XDREL?H`#?\I>ZF"$/8V8R8`.M)ZLL,:U,"^@1
MWPS6HRU1($D^\U_SN(`_663`:W>*0`5,]B4%`"!;+FC`O3`@`+*UP(79:H`-
M.0:`'*5PA0!HX0M;@('9O:"(Y&K`VS+`)!E*J0$/`$"-D,BF#F2+;$RB(HNV
3R,4N>O&+8`RC&,=(Q@,OA@``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g06286g0628600.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628600.gif
M1TE&.#EA2P%*`.8``*^OKR(B(OGY^>GIZ1H:&H>'A]K:VG-S<R<G)^'AX<+"
MPH^/C]W=W<?'QV]O;ZNKJ_'Q\2HJ*O7U];V]O=;6UHJ*BE]?7PX.#I^?GVMK
M:X*"@J>GI[>WM^7EY='1T9&1D7=W=YN;FUI:6J*BHM34U!86%I:6EC\_/[.S
MLXB(B-C8V+FYN>WM[4]/3WM[>PD)"<C(R%=75\S,S,3$Q"\O+\K*RF-C8XR,
MC#<W-P,#`Y.3DT='1ZBHJ#L[.\#`P#,S,Z"@H&5E9:RLK+2TM%Q<7'1T=)R<
MG%%146!@8'Q\?)B8F$I*2E-34Y24E!\?'X"`@$A(2*2DI$%!06AH:#`P,$-#
M0Q`0$&QL;$Q,3%A86#P\/%145!,3$RPL+#@X.$1$1#0T-!P<'-_?WW]_?[^_
MO\_/S^_O[_?W]_O[^_/S\_W]_>?GY]/3TV=G9^OKZ_S\_+N[N^/CX_;V]O[^
M_N+BXL[.SNKJZK&QL7EY>?+R\OKZ^KZ^OM[>WN[N[@```/___R'Y!```````
M+`````!+`4H```?_@'^"@X2%AH>$'`V(C(V.CY"1DI.4E9:7F)F:FYR=A@<8
MGJ*CI*6FIZBIJI$M9:NOL+&RL[2UA``$KK:[O+V^O[)G"%:ZP,;'R,G*@VP[
M?L3+T=+3U*,4%3H58R<`U=[?X.!H,AQ5"'XY)7[/Q>'N[_"T9R[;,2(!3#3K
MZ]#Q_O\`.\G0468,BCAL,"S`@6,?OW8!(TJ<6(A-!B8<TIP!T,`&DS%C$#@I
MH8\=Q9,H_U%8H&$-H0=_UF#0X"?&"R?[^J7<R7.:"Q%Q#JU9\L!)!H</>RI=
M"HS"#R>(V+C15H(``:0ZF6K=N@H-AAXZ%"!28&9,"!,9(F"%R+6MVTX+_ZK$
M(&,@S2$*9RJT$,&$"3IU?IP8>$NX\"4T%=#U,-%HS0(;-&A<P+FO12T(*$#@
MN,#OQ)@):!J1`5G@$0608\P8$H-ZS`)("5HO*E2VM6W7#\0X`G"[=VO=A5C[
M;EUAA`PUC5"[U*1MC`:[D%"/>+0!)(=#U8=K,#&D0R,T3`B(B`'"P1GH@]*X
M$%3VP0\"G/>=0/_*3)L72)%>B#('T1A^CP"P#W"$D($4!8_@X=!KP>7GH!]@
M,,"(!0]62(8A!E:8'Q<H,+(/6Y0TX%`0D3B4@B,MK./`(2EJN`\"UQU2``XZ
MG-#&"7K)A$@(';UP00!7K?,"$VV@MD$J0L3GQ_\22G`P@P(H)!&D'T>X<<A_
MSP0X((9(?>&(`5/ZP2`A8NSC@&U('#$E%T,@0J$?)0QG&X&#9.B'!ACDJ2<&
M.A300P[[W(#(AYFHH<4ZZKPP`"0.Y0`3(RVN:$B+GK4&@@5+*.D'%@(4@D$.
M"+1P`0X]-`"=&Q280(8+;60`T@84D"$K&X.8T8,S/TQ6`@XNV/!`-YY\NLX2
M'AQB1@'X^6&9(5A:H>4Z=`J2(0$XY2`A(RZ@D^R8@Y0)[2%JR.#%.@B$9LB;
M-&!B)XB#4.#,,V(90B@F`OKQ11'K;,&H0R]<B$BD+*XS!B)OS$!$LECD,<@9
M+;SP0Q4M[*`#&R948$'_!@68P`89RS5B!@T_Y(`##3WL&D,)%Q`PQL2;U!&?
M"'8P,D<!Z^3``[,`[K9E(1G2@.^=C*!Q#@Z4<2N(MWY$2P@#^\QP"+KJSLN(
M&(#Z,;"\Z[`+B1PM;@`#%^@@Z,@^`:P31K$!^R%I(2U>C4A>^XSIP#HGG*`R
MG`?,1HD9./S00P0TE,#%"S2<XU`+,5JBA@CK$*":(UU<0,-ZA33[;-)<^D%#
M&8#F8.4A"ZP#0-&K[8Q(?#>?NTZZEZS[2!CK6'"(U)5L`.@+=K6Q3@O]-;+/
M`UVL0X72?P`\J<"/!+&.$WS\<4;9?O00@!./8I+&$CN(0,`.3M!`@%\YA&##
M_P\;./-"")8TD&P46S-BN<[?\KRZ&2"L\P$B0_]!>H/Q'\*T'Q?HE.HT%[6L
M.6(`5</#[`QXB1ZL0U!_*,,^$C>H=9"!!598!Q@$2`CCL0UYCJ!#W/Z0F!,$
MX`5PX`0;?J"#%ZC#`31X0;(L8(46.'`?."C-)#ZP#^]DXGV-J!?FY*<Y,_P/
M#'TPQ`36P9C]D<ETA%##`]21`P@.D'66<!TCXD`%?NB-$+2;Q`@0Q<&Y^6$'
M9_"=!?\@AOCTX'AJ2YO;&@$](IP!90C0`7TRL888?"\`5:"!!0B0@PMPX2KZ
M6$+9#+D#$.RQ$3][P2:`R`@A*JUGJGF7$@JAAN"!P?]*3NP6#NM&RA]$((.:
M>\`;W+2."[3@E;",)2QIE3D_%&$!N,SE`L90!"B@\@*IPYH?M-8(-:@%:(-(
M`'YRP!@/K?$/<`";'XB@APZJ2(Z0.)2]4.`'`LA`%&R(`1?\R(06Q&`'%QB5
M'X#D!P30``<B<((37!"#+S;"C"689,Z""$5IS>\/,EA'%0I1AP<*(I1'<]$^
M%M.Q0KQ)H<\D(D0O$`,?.'.8EEB!V?;(.,TAIX)^\-<?3)"L"O2N>->$XQP9
M<0*ZM2$`*12%&'!```1H``$6^('52H(.)[AP!P%H:1N(E@%('*"5^LP2_(98
MH'_^H23?'`3C%'70=1B-C6;_LDUYB!"RY:'-H>O@@@/&2M:RDG4PM71G9!!0
M@JKY@0EW,-=%B8D(-`1II7\80+*`M<"0$B)TZPB%(#QH3:ME<QU2N`!:14$&
M$5B`!AG0@!-^$(,>C,0/D4T'`6P0@0@`@`8FT,`!%LL(P/H!`IJ@)"(LF3D:
M/"X$PQJ$!]:A0_U9M73],T0'#,<%#@X":JT+XP"04+,C2&!L#)Q$O7)`!5(Z
M-SZ]!:E(!5$_/[P@=80=1-L@`3W'EL(,[SE`"1"P`QJ`(`)<4`OWG("`JSCA
M`%4(P`(L4(`"B(T1$TC6!"#1`1=P0*Z#,$+-'L&#?22@M8_[@UIRL*@_S(W!
M@T`H_U9SJ]MD`>&*!<2H(8:0K#`<>*Z4.`-E(+K)OD[W#V_80BN=EMW!@M!C
M5:OM*#ZF+1PL0:=VH\%>F+"#<S"A!">HPA(X(((08&`,#36$'*"P#BQ\M!%'
M`:`<"B&B=7R8$8FQKF_]6<1!T,P/4_B#!ZZ"!$)(&&G$(\0Q2016`@8WN848
M0GQ*<*V^TM40L`4@#P#`YS[WN:-6H(.)#2&`EG;3`"U&J6$=88*P1I44:'C`
MKT;0'!"<H`<(:`-\_P:V'`1N+C]80%'_D.!#C'$==_A2?(Y`:%0FP1%+6`<3
M#H')01@`)R^`0+:L9>;;\H^IASB#-"N`X3=K&'3)ZD',[/\\"3<TQ`^40T0=
M@J2!01N"#B4A64H_N&A&>``P-EAE+8X%!WK8X`46.($IRV"#,WPSS8)00ZR?
MP3Y$&$":!/A<FW/P:#SO8P^T=JH@DK".$>!DH+T6$VZ!70@T=#0'@FXS%BNA
M14309!U$.*XP[_S7FC68$=4E`"W!&-%"R&#$VRXL7A,!/2XT[Q@4:($.-K`!
M5+'QD820PS']\`,X:%P0*LA`U4I@T4,8`'HYR``%GBR!&6A368BH]2!4(*1U
MQ"O"OGZBU<7`]:Y[@`P@D"9FG[:."'3][&CO>BV)J8:'7J&O0T@[VE$[",/9
MX!%\V$>9"[&/$Q-"!LE*N795A';_`Y0!#B"`G9"N)6-@*$(!I3%`4!HA``>X
M-0<U]:E#JE!G__$4'5Q`&5(L(&X$%T)WB#7$F2$JI&J3G?7[6+LCSL!3*PX"
M]F.Z>`Z2^`@;"&GD@NA[(ZHL>!>S'F:#P`'.?8$".`#?$65X@A8T95T$V""N
MCY##"+80`+<*B0974$#I#=$`>2Z![LR0IQ..5`C+.L$(AHB#^N<__P!XP0(?
MZ'PA#D#__ON?_.IW7XS@;/*$`/VF/_[G?_#W!VC@!?+$9H_@!B+A!+)C9O)D
M3X9@</+D>H40!`DH3Q$@!39@`B10"`!P`-$``*3U"`)0!B@P`GFR`0J09)!`
M!WO``WKR_P`-4&IOPW4=\&2",`=<EP!;]@=QP'7H-PAH('=GUP%IY`ANP(12
MJ#1GT'5%>`AVT'4?=S13>'9T]P9=QX.-<(1B$''=PG5/V`@)P'4L<`@#,(4#
M<%*&H`,'>`QGX'>&D8?Q$&W1H`-Z^(?^8`8TF`QE@(&`>(C2L`8P00$84`4H
M8(B]@`9K@XB4*`TFL`$RL`$_T0(-(("_P`&#6(FB:`QED`8&8`-CT`,`$`!!
M14&C^(J(F`9M\`>R4@%54#]58`(X``(Q@`#H`XO`J(<FT`8<H`,A4`!,@`-,
M`$/+LU`1\`,V4&0C``<:4!T%$(K!J`IJD(04(0#+-PMY`&`-I_\#8_``,5`%
MRK@##F`!@W,"AI0#"\%S`*0/.-`&3)`5JQ`$L30%P>2&+?!R@F`$?(@(>K`%
M!0"$B*"/L!0#2>!#B/`!+3`=@Z`&&M`"/T>0(D`$"(D(<E`!2T`%7Z`!8D@(
M,"!+KW21A5``]S,(`Q`$^W4($F"2+1`$6T@(;-`"-6D(=7`%6O`#(L`!XX<(
M$F"0D"`"+_D(;Z`$6/`#)U`$#FD(%;`#<&`"F;8#$=`##W,R+A0#`&1(^[`#
M+X`#8\!QE2`#R^<$)T!64/`"S70(9=(.#G`"C\`!$>!-C^`$(J`G8Q``8-`(
M%O`"4L!!=0`V(TD(/E`"+U"'AB`!71#_`"D`!PM``,I726IC5E/V+Q5X-$X@
M6$I&5A$0`&.E`6T8</#V!S7P`DL`!"MP,%<%E6%``"AY"%;`F8[0!"^0`2&0
M`E1``)=I"&=@`B*@``[0`V(I=B:4,DZ`>5RP`Q9P`65```%P`&0Y"6C0`V?)
M+0Y`!5-S;`XFEX[P`S=P`B!PE]RR1/IV+B)@!4=9`#I5F(-P`%@`!:/6"`5@
M!>C!`B_@AZOE!Y/0`IG)1IOY"!:P+*+!<(2`!A>@0.]9`N)H"%10`"?P:HXP
MFY'`!>SW!Q"0`QV""&M@#A=@`]SC/0[Q(^D$&$X0`.@4`CLPG9+@`GRE>MQ2
M`0BPG7#IG8R0_P!^X`$5$`#DF0A^<)X.-:#C*0A:4#_N^0<)$``;,`,Y<&7!
M=@%M*0@PL&R'("#]^9]B$*".,*"/8"#P9IZ$,``PL)&$@*,ZRJ,32IMTM'>"
MP`:\QPAI@!_3TR*3T0+)B`,!H`$TP%G>,RHK*@IHT$):XP0%8`9FP`(K0`5$
ML)TB4%;-Y0@WX`1J0`$$``..@)=ZD@)=L`1^:0$F\`."D``X``=^<*0?X`1H
M\`8$T)I3YP>>J#.VH:9L@Z5:ZI<$R@A>R@A*D$^4,`4G,*E^8*F-0*&0L`=<
M8'T+H)B'(`,QD`&"8SB<D2E<T`)V4UF<$99CZ0EK<``!<`'?Z`0$$/\9D=,#
M^O=$)Q!+0=4((D9L:D`$6'"I5N`$L!,`8Y"3A&`!%D`!@O$'22"=I=H(.\!F
M1'`""H,(LU6:AB`@SI66C>"?9%*K$W*K46>@@W"J(;8??V`H[SJLLLH(9>`"
M.X`R&5"PCS`"(9`#@3<XR[,#.5`%3A`!2U`%%M`&+-H("H``+X!3C8"I&/``
M3NJ6W!F7C<`!5(*O.)`#5'H(3L`@'W`!)38ALD,$;]<%*R!![MD!+W!_Z98#
M0L`('1"LA<"-)LB?DN"PW0*Q;B*QI,D(&_`"<H@&O7D(1'L$1HNT'%L):#`"
M%T!LD8`&9&`3)6$3J.D`L78!0W83V9H):$#_E0"$#BM8"$LK"6])"$++"%.`
M`[)"!OD5I3`Z""#P`G70J7\P`@C0`5:@!U9KN9B;N6`0`XT0`?,I""=P=_LY
M"3:`!2<%`R_@-%NJMEP";R3@!R4X"'O0+Y!R`IF[N7?["$(0!G*(!U)0"6S0
M$,\H)C0P-\[`7CFP%S5+"&8@`C90`39P`1'0!K.XLZP*M#7*"&#RBX)@`260
MAITK"!`@!1$@NBS@!Q90;:F+"`3`MX)P`R_@GD+`;X/P`'Z0:K4K"0_P`FU"
M725`I@[EN_)3FE3@!>AW`MII;W[`N^\;OXQ`K"'D!Q+Z!P)@4Y;@!G`P!N]1
M2*U42#V0`2/#HF9@_P`A@`(6$`$CH`,V@#TTA8T'E;ZEL[Z(4`$$X%L&X`<O
M"KG<H@!5!+6"0%S%TK^&H`"NNC1.4`1!DP$7<`17T#!C$)2WX`<+>P+$E)[^
M63(+V+M=2K')1`,!@`13@`!=<'5020#CE\1+3`A6@`#.53T9^`)4(`)9$``X
M8*^2L`9D4`$NP`0ZE6FMA(^&(`,ZV``(48QQ4``/@`(AH&[T),2"L`"0:"Q(
ME@@=*PA"()&$4`!':0BB3`ASH`,W((>W`"QUH`&KM`9C(+^$L`('60@;L,:'
M\`9"4`1(4`1W(,&"<!JW49IF,`(.@`0NH`#*?`L7.C6IX0@=\`$9$+[E2O\(
MJ6P(K,P(!6`;H_P'"C`&-M`&"S":HG")9[`$"H`#(9"YM0@2XN0">XJ!9V`#
M+^@`Z_>?V3C0`2%$.7$".T``#[`$[EL(&B`&W9PK7/"X!%W1[X`E"Z(LX@0"
MDV=T"J`#`/`#'6W1)/T.9B0D.`$X,VL!AH@&&U!^&/`#WUC2-"T-)XT.G+$7
M#K","T"#9Y`!ML($,5731.T-&%TS+A``7%``%>``%0")&Q`#0%S45&T,&(`4
M@^,`+C!6DG@("E`&&S#353W6OF!:[:1N,7`!+U!9(^T\&(`"8DW6<KT+!JTM
M(#H&!V#'?\`&&3/7?IT,=8VR0/4#;?"+IQ$">OU@UXK="W6=3DQP`$R@`600
M`DL0NXM]V8S](#G`E`Y`!G&-V:"]"@9]`0A@$,\7VJAM"U>]#F#1UJG]VK4`
F6#;PV;!=VZCP'[1KV[I-"Z.SV[X]"V/UV\+]"B"PQ\/MVX$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g06286g0628604.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628604.gif
M1TE&.#EAY`'J`N8```P,#/#P\'Y^?KR\O("`@+BXN,#`P.[N[KJZNO/S\X*"
M@NSL[(6%A9Z>GHR,C'Q\?)B8F*BHJ&YN;L;&QGIZ>I"0D+"PL(J*BIN;FZ2D
MI*&AH8Z.CJRLK+Z^OM#0T-;6UJJJJF!@8*ZNKK2TM*:FIK:VMIJ:FH:&AL[.
MSM+2TLS,S+*RLG=W=W1T=.CHZ):6EJ"@H%Y>7FAH:,/#PXB(B'%Q<>KJZG)R
M<N+BXI24E&IJ:G9V=F-C8UA86.7EY9*2DN;FYLG)R<K*RL3$Q%!04&QL;&5E
M9=K:VDY.3EI:6F9F9EQ<7.#@X%965E145`@("-W=W5)24M34U-S<W-C8V$A(
M2$I*2D9&1D1$1$Q,3$!`0$)"0CX^/CP\/#DY.3<W-S8V-C(R,B\O+S0T-"TM
M+2LK*RHJ*@0$!"<G)R8F)B0D)"(B(B`@(!T='1L;&QD9&1<7%Q45%1,3$Q(2
M$A`0$`$!`?[^_OW]_?S\_/O[^_KZ^OGY^?;V]OCX^````/___R'Y!```````
M+`````#D`>H"``?_@'^"?WQ'1X-V>8)\'CAY"0%'$P$!`S,&*QD.`QLC#C05
M'!D6'QV#@A^GJJNJ=G:J>(J"CWB#>WJ"";F"?:=\"7P'@WD+=DP'C!XI>%0!
M$Q$R0X-41U`I(YT3*B(N!1\>?3@%#085*$%!!PMY4ZSN"4<?"Z=]!@%0[CY'
M=WAX>GI[\.P9R$=/`EV#`B20M0KA*B9\_@0XX`-(JE5[?`A"L8>)G3MW"NGQ
M<*</GSLCF!P9(,6=RY<P8\J<2;.FS9LX<^J\R:>&A0P?'C`Q\&!&!P=)+.00
MD^&"C"HL;EC!TN(!!QU73$@@T$1$$1E-=(2800%"`QDWL!#I(4,`EBYE_YS0
M8,+`P"H<'U2H&#)BQ`,>;04(B-,CA@,92`B<.%&EBEH&)QP@N`!!``TK/<!`
M0")#[!(X2-1P01-&`A8D8K*(`:!FS1H`=,)$T5)E0Y8&<.*\81.F\1HZ<?QX
M$>.ERAPK8ZZT0(+E2I8L6J9J\>+E"A8O;MZDN<+]RI8T7M:@0>,E2FO7;-*;
M$=.F31<D7-*$@1,F#AP%'"`XZ,$CPP0'$\SPDPD"./'"``,T04%9+%211!5-
M]*#&%T_0@$41.E0Q7@18;($&'!+,$49[;M#1QAQ(O.%&%6J`P8417&S@P(P7
M7+`8`PPHH``!(1`@6`Q+R%"$%T[T8`08/=QP0_\-&8A0P048ZB"!#$XXL(,$
M/(1PQ`T1\##!"#R<@$$/0$"11P0!!(%'`0'PD4<?4/#QRT%T)O`!)%1\(,5"
M<O)Q"YU]Z(%#'P'XL(<=+OC`1PH?,*&"!P?,H`(30-@0A`L''!2`%`8)TH$4
M-AA@P`1W+``"$WV,$``5*4R`*1[S>+#`!Q>=<D<"+MB`D)PF_?'*'W=\Y`I(
MK^1A;$!W&*M'GW6N$M$@$=DAC#L?Y/#'!P,4X0$+%0Q`01$O)!!$`7MXL,<4
M"[B`@0@!X%#)"WQ,$0$53$`@1`84A'$%!F&D<<%^5^30114I,,`"!#0(^JLJ
M><B)3*$NN.K""W"8(4?_"TZP4,,6.[!`P2</4&!%%E9HT0477NAP`HY$B'$!
M`P2TD40189@!@Q@4<,`##V)TP<`;6:R10PPC*""`#!=(\`887F`A1L$;M.!'
M#A24,```([1QQ@4C&/$".2&,\`,%##P@@0X:8'`8!R+\P`$'"F2`@`(S(O$"
M$1>\(`,!)E1@`01R:-`"#V>\@<0:9(CQ!!A:S`<;>W+`X88;6]1Q!AQCR%&'
M&70\P<,38G`!!QI:E$$$&@``,(<??K"V5AWI/0&`$T_<((85`"1!APYA^'&&
M&F>L080?;+QQQA=?>-%$'&-P\4`/2Q#AQ5H^,D!!%1<\$$(/9!"11A5DD.%$
M_QQ$)-%#&FWHRT48%\2``A%'Q%&%&P#4<4451O!`!!A8ZD#$#3T0`Q(&:`4D
M;.$*2,@"&H@`E\0A00=-:`(1BK"S$"`A"3'HP5^\D`0E8,$)5=$"&^#PABVT
M!P,UZ($7P'"%'M0@!%Z00`MFI`4R%*$Y::``WKBP!#G(@`A(J``!>E"!)60`
M`S@8P016@0<+>``%)!`$!R90K3]8`$$",`LI%!`!$*0`!@S00!-`4`$!-*`!
M,=#!#2@`&`KH:#$"T``/4&`5#!@L`U$X`@R"L`H06.`/3/C`#NR`AR`8``=_
MV.,>>%"`%!C@&D[(@`:X<(0$'&``!EC`!#1P!0D`8?\$$1C!&;!P@18T``9=
MN`(*7H`$/<0@"*)<(DX\(($7)$$`'JC`$'+0&0;P8`\6:,`$RA@"`V1`"A30
M01(PJ(`'?,$*9'!#!,``PQ5@(09BX($.,,"!.,@@!@18@@/D$(4LY.`-)/!!
M`S+P!`N<0`G!:0`#FJ`%-!1@!6*X@A):P((!'$``*>!#"7IP(`@\(0H6&$$5
M+`"&":S@"3O@$0%>P($3C,$)%&C"%P:@3PAX008]P,`38G`!!2@A``0@@@4*
MX($P?.$%)F!`%5J@!4T\P0$X6$,=+.B%$#0A!FV080D4<`$`^'((<#A#$Y#0
M@#XTM`H/0$(8P$"#'K"!`A'_F,,#++"Y)EQN!FQX@`@ED`$"@"$.:8@!$7)P
M(@.\8`9$(*H3B."!-BC'"RPX@A>LQ]$`7"%M2?'"#1K0!2QP80X?>,(+*-"#
M-3C@"Z/T0@6<`+ZO84`)D6F`$5H0`R]8(`A4K8$<PB`#/[1@#2%XP@7:P!LW
MM,$/LAOI:IS@!@H`(`IH6((6DL"!UYS!`L4C`!9H@S$Y)"$\<A!`$L)`@1]4
MX`IC6,,30H`&,YQ!"P#@P0/\%Q-""B)8KOC#`J3PC79!(0$H\$$"(`(%($CA
M`#C02`(4U8M,_0$"1!C`!QH0!"Y^H0#8K8(`GO`#QJR"`Q=8``)X<8$@+.`*
M$GE!_P64D(<*X"`-(0@"$W1UA!H<P0<66``51M*'%!QA!#;H00A6<($)(*`/
M`W#"!-80A@HPH0H1@,$,-'*3(ZS!#!1H``Y"\`)VA>`$,5A!EGS``^Z$P05@
M<$`7,-"&)^`K`]`!0X%:8+P6J,$"+7@!'6:@!1P$*0P$\,(8')`&-ZP!#@^H
M`_?\L#X.""`""I@!`:3@!`L0P0E-`$`.=(.%UM6F!Q#H@A<H(`$KL``,:O"#
M$\S@!BT@@8U7`$`;,E@![)P!`PUXPA9,H,,YG&$,;B``$IZ@H90N@0TOX$$-
M_*`!+?1``A8```O$<((KA`$";UB##$KTA1"PH`X,B`$`>O_@ARI<H01^:``6
MPN"#UKGAMU^`0`N:0$T`/"`":#`!"]30!@'X0:Q5\`,1X(!:.L`A#6`@@P$`
M(``IH>$)2)B>52W@!3@\@051.`$:NF"`$[#S`P10`!Q84(#]/2":5C!`#I+P
MA0D,00$@"`,9N/!:`63!#PJDPPOD$$TTI"$"?HA#&-[0!BS0+ZE^2`,`\OL%
M!UC@W74X+8S\$($NM('9=%!##5IP!@ELH`QQ@`(&KM`&#"`@FST@`AT0\(,/
M=($)5F#`&::9;^[NY.N#($(9JH"AO/`!`%[P@!3\+(`N+($`JQ"!`5"``B;\
M09:$\``(#M$''1@``CZ8P%;E/@C_/KJ`"0-P`0>BP(</I``":KB!`R0PU3;D
M@`]T`$,:V&`"!>0`"?BXB1T&@`4Z6"`-':@`6P!@`2#L1P1.4``=9"""GE6!
M`2LXPA6\5($ZO,`*/.L!!<Y`-#"T@0QQ\,`67L":)YP!`2SH`FR-L&PK^$$+
M1<K!%W#<``"<`0QB:+2M`:!6-?3@#"$PP@Q$$8;;N<$/9@"``\X@@H/&0`[\
M4\,3GE"".$S@`G[P!F\@`V+P`G$``%4@!F+@`?O'`ZT3!01@`&#P!!Z`=@#P
M!O.!`580`@J0.A_@!VO@@#R@`'[0!F*@!E:P!E50`6W@!&V@!@O@!Q7@3%W0
M!2T@!ECP_P4`H`-O4`;-!@%C0`9A@%T#$`5>D&]?``=PX`=P4`%=(`-,\`5)
M(`$%D`%L@$!L4`%I0#@SD`%J)@%P<04;(`<8<`(AX`8Q,`,B<`-AP`4NH`(]
MP`%PL`,=(``YX`<[\`6O!0!=`#W6EP8MH``:T&P>8`59!``<\`5S8#U:PVP"
M\`:L4P!B0`=FX`=?T#)T``!R0`=S`(EP4`=U4%I1)W,5,`)E(`%/4`!M``<3
MT`']$0-_(`-9P`)Q(`%M\!2-4QHWD`$-@`1@]XO]9@4%L`50L`$E<`4%T",M
M,`=[$`)SX`"K0``3P`%0L`(C4(H4X`%X``$#H!(IL`(14P)*I_\"`W`+%S``
M26``8;!).!`!*E``#18$"'`&%+`#4^4`/T!=:)`##X``90`#!-`".K$`;L`"
M`O`'5M``0[`$1I`!+&`%5Z`#$^`$%>`"0-8#+4`&#"4"5A`&.@``!?``#@``
M!L`#="`V!4".?[8$'$``#3!9!@`#$<0#:;`$`'!IE+4%#:(%>5@&!T,!`G"%
MS'4"'``"=;`"8:`$;Z``2H5H3Z`$=9`!2@`!X(<%#^`%%Z`$;&`_-[4&3F`%
M9[`%<8`%UW4!G+,$[P0`$'`#(=`"$<`!O"4!3F`"2>`&1.(%'<!\1A`Y#;`&
M6J`%5.`[%8`$"#0&9_``-U`!(="2FI#_!0!06T0PEFLP`AY4!2=7!^11!?&7
M!@_`&P*`!AM@!"#"!K_S!8PS`G`@`&W@!@*`ADYP!5KP`!=``DVP!DVP!%FP
M!0W0`E[`!0T`!F%054_0!EKP!B$P!F(0!CT0!7X@`DGP<VQP`3:XA'-P4120
M!DBP>7!`!C$P73D`A'60!G(0!T^`!7&P:P104W'0`6*0!F0%`'XP!_`I`[;8
M.TT@!@,7!U?0.7&``">`!3S@!2)0!59P`CS0!2R@-TO@!V$P!W7P`6)`!E<P
M`;[XBU^G9A`@"O(2`Q10A2Q@=#6P!%T`C:J`'Q[@`7]@`ASP`"0``SA0D30@
M`0C09SX`!D/`_P-!D``8,`('H`$U@`16L@>"L``<@`,R@`(C(`9:$`02X`#9
M`P%!0`0<H`0[T`($X``04"LV80<1L`8]<`%$,`8MV0/<<0&7]@-QT`)'<*`Q
M``$FP`,.X`$RT`4\@#5\*`8ED`5$T`1A8`1RY&=$01Y68`8UP`,J1P=)<`;N
MU@*`J``%D`2\60%D$`)5\`6G)TH&`!8;\`03T`(&T`-PT`9CH`9M40=$P`-?
M4`1L(`/'I0-<``)(L&;&1AM7@`9M(&5UH`47L`9ID`(]X`!C@`)A4`!>`!@]
M$`8`(`$]\`1<H`7-Q@9D@`1PX`!94`9)<(8$P`!*2@=6H`-KT`9Q,/]*'5D'
M3B``#S0&/'`#`#@`'/!#)W`&$X"1<%`&:,`#0%H'9*`&8[`%#S!M)[`^6H`!
M1(`!(1`&-2`#':H`8;`&<=!P.6`<;;H5+.``7X$;88`$\(E^8X`!.1`",A`!
M47`&#K`%OL.L3J`B)>L$:G"`OC,&8V`%:J`#;M`%6J`$7I",WK=3'7`"1$``
M`(`!]`14`"`&<Q`"?H`&;!`'13`&$E`B^O,`;>`%GP$`9-`$5=!8&5`':R`'
M,1`#:J`$<H"Q9\`#87`"5H``56"A.V$'X2%5*M``#A`"6F!8!B`!'B!9%?`#
MJS`"31`1";`#&9`"&5``N,(!!3``.#`*4^#_`"F@+7]P!$I0`!P0!%`@3Q5@
M!P%P!T)0`K(V`C5P!A0T;2FEFEFZ!Q+@`@G``"W@`CIA`6/K`FJPJ530`Z9J
M`6C``,#I!4`0`E9@`:H1`@W@=VD@!FY0!C?0!:3#!0,@`_"V!#.D!0)`E!#0
M!-EB,G5`!ST'DAI0B6S@!5W0``20`6V0.J<A`7Z``"M;!6>``MD3`4UP`PS0
M'EL0`KZF3,,#`&5@!E?1!230`$*@!LF)!'YP!2,P)&>P!$,'`VO`!C%0`$^`
M`;N*OR0P@$_@!D^P!L11!Q=(`7E`!BQP67RH!36@`Q&P!'-`!E[0`TW@'FX`
M!R&P'UY@6AE%CT60_VY14`5RUP5.X`1RQ@83<`85\`9R<*!GT`-ST,$&8`4$
M8)*=&#,2@`1GP`)<0`)@(`)R>P,R(`05L`$_E`(M<(Y$8`+.EYUFD`1U<#L:
MP`(7<&TM[`=;0`%/0`=>H``?%P<ZM3V%Q@-DX*!>T`9T0`=G@`;"<3M/(`!U
M(`&*NFRLTP5R$`$7+`<48+1U\`9>L#HR4`</-`%78`!8H#H]T`"?<0)),+T8
MH`4YMP7#P5@94`)JJQ-Z<`8M('@C$`9HX``C`![&20-KX02'H`H9()MXH`4S
MP`<9T`>L*P@&8PH&$`%5(`,((!";8``6D`0.\`$'``&8%P0#D&,-D`,3\/\"
M:U``*``!$G``)W`$*#``*-``9B`!$5!W.L&E<S`$&!8&:A`&7E`$1#"^J0,`
M8P`'4BL`*2,&24@'"L`%5C`'="`X&$93)_<!<4`&6I`&00!1,@")76`%7,`#
M*4`&:_``8B`<59`#9I`!$%`%=*`%<J"D#>`&28`R<#``?J##(W(W.F`#*=``
M59!V(^`&&S``=7H$;E$$(.``<>`%=>`',N`%+\`%9/`%7)!,$B`&!:L"DY4!
M:N`"ZT,$BP$!R_RNZ!<Q@,P%-W`%".`&<O`%2J9"-T`&'[`%-S#+=2`'%L`Z
M/%##/-`&!J`&WF<!:^`%5@`&;%">/5#7`G`%*P#_6W'`!3^KTVC@!,2,`A%0
M!U_@!&/P!%ZP?PB`!N1J.5K0!$*';\M:`$TP&WY@!2*@:6.[<4CP`RP0`F)@
M`B#H!A(`DDCJ!P59!U[`!EYCJQG@!\>&TF?@?843;+W3.P_0KTRXR*@&B75@
M!74POF)0!]GQ6FT&!GY0!Q`@`W.0!F?0!ZOA`$\@!V?@!!+0!'!@!3BP`C/0
MRCEA!V90!PW`!`CK!1J`!6^P`#HP!C'P`AA`-JIP!W&P4L80`Q\`BWSD`1]`
M:H*0`A$@N$`P`SB@!V"P`A$P=XCV`*.2`0PP`CI`:@_0`7Y`!WTP!C70!B$`
M!RV@E@7C`2/@`T@0!`&@_Q-8D`9'8`!$4``[`&8U\`&PS(M*4`$UP`$_,`<Q
M$`*"W0!$4`.4K00,H`-RL,);P`!?P'-7(`,P\)Q.$`4S\'[-+`=:\`1P``"S
MUFPM,`)XD`8&T`(]@&<F,`,G(`.\V@*,(XMM8`%-(`$,(`"P[00W&0,;4`4`
MD`)AD`,]\`9<\`0U@`8$8`4TX`9&D-0]$`=;\`97@`<GT`*<Z,!I`(*]`0>6
M%@-;T`08\!LO4\IR(`%Q$`=BL`:1)P804`9=8+YBT`-<@`55T`5UD&Z[#A4+
ME`5.4`99``;:2FUGP`8;,+Y^0)A>$`>O16=U4&AT$(0E*`9G,`"5"@!:``/9
MC?\&PS0$`F`%[>$`TS'87@`"&#`&D0H-/A(!DRK149`!PPNK`*4[S^ZL*9<Z
MP^D'V\UL?5P&%D`#G)T&$G2':$`&3R"#*.T%87#+D'@&H/@&"*8`6]`%;.`'
M/(`&ZFL%5:`!/4`'9*4!#1#2:@`!6Y`$&""2PNS>.($'=,`%U%P`#F`T#B``
M14`':6`&6=`!#0`!`=X&,R`%,^`!,W`$+H`#B3`%(Y``%C#C!3`"`Q!B>(`"
M!2`!%)#R4Q`%_X$?00`!=WY[6I`##$!K&*`"%##%$&P&0&_K*W``%@`#QWP3
M`?#45]`%2VQ*%\`!`WP!:I`!Y-D&6P``"(0%$B`!=2#_YN,3`O"Y`F>@!-\Z
M`BO4H%40`V0`KB\0GUSP`V$0`DG`H'+V`EA0!I^3KR5X`E_0Y2&`>`8P!Z*L
M!1!P6(HJ`>3A!G50!`ZP!&\@`=^3>7,0Z!OPH3H@`+\1`G2P!5_PVV!0!`9`
MS23``(LIT19P`R9``VI``5E0&4VPFQX9`@*@!1Y3`3*@!5=!`PU``=*9`QF`
M!7-@!L:F'",0`T5@`63P`%>0!CWPCU:0!%@0`<\%"$1K,7YE9&DA9SIS`'Y:
M9WY;#UUS#FU'@E4*.0!H9((]`&IU)QQ^51)L`"=(?EAM,3UM30P$36(/`$YQ
M<F$]169I#V<".EIT16T,=&U(_PPA96MA?B%)G6YU?GX`:VHZ7@]^=!5/?EYL
M=%YO?A58;FAT%%5T,A'F9EYMWFP:VF$;.,JM:<#&00@Q!"*D^,.PH<.'$"-*
MG-CPCI\-#JHD63-CC1@&67J$Z9*A@98"#_'XB?#!0``*#3J0"!#B080$+W(8
M^(`"2H$]>8X@&#*#0P8<5UJ4F,'@2(T6`A0TD/%@@H`W9%X(R&&!B!,*?FB@
M6:,E`A\!%BBJA4!FC9(Z/(K($-/#CQLM2^`T"<.#!9TN:HAPJ`&G2!D%.[+Y
M8?#DB9L&(6H(H!/F2@X_:^*TB;-F29!(91B=R:$EC!H284Y4*>,GC!F/7S*T
M25*ARO\3,DO67(CSH$H%)%>:'$5WPD^;!@*\Q#1#I`FY%FRZP/5"!(P7`#J&
MM,API4X-%6>L-%D%($24-&TL,*=@QHJ$;F?.Q&%S!LR;&'.0T*GS0(>8<FQ4
MX8488+51!QQHU#$''`-XP8(?,A`1@@QK"+"%$FWXD<,:&)S@AAAO?/%$%12$
M$)T63:#1AA=97!&#&FWP(,`<XK0110UU6(#&!!`(8(89=!"@P1Q$`%"'')HE
MR(8V#CC00PT,S+%&$T90T`8:89311@M5@#'&'#RL\6,,8_DQAQ9F;"%''0PH
M<8$?3[RAA0`R-*!.&4H@440:3Y3A@!=>F!&%'W&`P089``C_P$,(VA`ZAC9L
M&'#%%E>DD84$"ZBEZ:::VA$C#`R,P(`!#/BA`P<WK$%`#U'(0,!#=L"QPA]V
M'('#$3;<(4$.=L`P0!M!X&"#`V+@T`$(>,@PP0)`R/A'`D#L$`0$(4#`!Q(]
M7%!"!A^8RD`;6'3A!0$/P+''"33`@0,%%@3`J40_A.$%!#*@L84$./C1P0-:
M)$%`"%KXH4`%)6P1PA(>5%#&`!@TL80?&8CP!1I=($&`'V]TT`,=?M2!!`LC
M5*&%`V<0(```9X3Q81-J<-`"&&30H04'.H2170X"$'`&&3Q8,$`(73A1`QED
MH*&!``A8P48.`\CZ@@POL&$$"V#,_^%$&$1H\44=6H#1@QA-^F$%&&+\\`($
M;Z3A0!)L-+8#"V-D```9<VK0`R1H^'%&"*UXX8<9`6NSQA-BG=(`'4&<\",1
M?A#@A`#)P6&"'TSX(0<&8A#!A1SE9/B$#!_H$$<($C!111<DY!!%$RQ(\$0!
MCD"LQA,`:'&%!P^;TP,+/7P1P@2-5>&&#"HHX`3$&$,2@QM9Y#"'#I!L`8<5
M/'A1<05^L`"'"&U8X8<&9XS`&AF.1$%$''`(P,4;8M#1A``2&,!%G`A\T0@8
M?F``P!(@/%H(!$O"`A%P$+A&-4H$-5C#(,00`@.\ZX$0_$,7!/"`+=`!#%;2
MADC(`+\90/\.(EIP(!_20((C1,`#>,#!"#30`2Q0@5M]\,`"BC``%DQ`!S<(
MP@3^8($4#$`*6*A!!9["A@ST(`E%J$`7SI"!G/"@`4]0@!C,L`,(Z,`"%OC"
M%S`008?X0`9:>,/M.`">,EP`!5NP4`-V<(;&U,$`=ID#'<@0!CC4X08YN,PZ
M@I`*-NB`%5Z@`1OF\`8NI*$'91#`#:K0@#H(H`5RB)D9XG`Q,]")`P8P@PQJ
MH(4,0&@.<YC`&*QPA2?4A0@:(``0ZJ"$!!#@"4`@$A&B>((9'"%%:EA#[>#`
M@0^H00WT"=,;9,`#.M2L"91BC!$L\`0>^*$+.>C!"'AP!@"(H0O_;:`1)$[0
M!3\\Z@)$D(,&Q>`'<E9!!QU;4QU0H``WM``)+W##$Y90!6W,P0S[BX\;:M`%
M,DC@#!5@E`"200$U<`$`SEP'6!ZC@^Y4``-M$%`Y(S.&-K2A`(T1PQK649>_
M^:$`,LA"'.9``CE4P`UR8$,$K'`#-<AA"6*`@#@$H#<T-$)OVL!"&MC0AIL"
MH`V`0\,Z9*"A.GC/"]6,`Q'J\(0ZU*$12:B#&#Q`"`,:\#+H4T(15N#`+GIU
M(F>HF`S*\(0;/,$,*TI#"YQ`AQ1\\"%PV`D?AL"0#4Q`"1N`0`!<T($9I,`%
M.?C``H+`A!)`@0D3F,H?!I`')AR`"1YX_P`$YA"!%D2@"P,`@P=X``8=P($(
M/H``#HC0!2X\(`D!N`($(O"$#]CAJWE`9P@*L+S,M6`+&-`"&]Q)``*8H9P9
M,(,"N"``-(`A`CXP$@?&`(8FG``.6J``&\80!3$@`%)/H.D2Q@`Z&4@3"6FH
MG`62H``M3"\-!,"``$*PB"JT(0,_L,+^Z`"`&?BA!E9X`1S\T(,0M.`-87A#
M%8B`ABI\8`IA>`(<,+"S*SB@#``P0PN"T`,T5("H*`-!:_P`71T4UP%@^>D/
MYD!/&4CGI@&;+GLT<($HU(%C+_`;&M*0O0&]>$G:(,(7W+`&*#@`#8P+FA?@
MD(,OG"<,;/G""__J$`$IW"`,8S"2'VC,`@`T8@EGZ,$2EBP`+322O_0U0P8P
M$(<Z["4&9*@F%N*@#0!$P`ERD,,<FA`!(A!U`'4XP^HP,#N!12`;%ZM=$\H)
M5`#`80>-L,`02/&&-;#A"G!J`.>LH(!"G<</!B5#.<!0&:M:=0"4H4,<2J"`
M`7SUU!#QPP5Z0`0'Z.`!$N""+WJP`!T@``9$$`!$O-`!"$#!`U`80@I`D`,"
M5&`*+9#`'A2`@A%L``$!*$(`H*`""WS@`PRI@`5.8(0PU``)$Q"#!233@3ID
M(`IPB,((ZO"&-S2!1(190@<JH(4*$.`%.X1M#-A``#*25@`J4`,9X'#_!1G$
M`0!;X(+)M,`"+`"J"PU0@Q]N8(7J5J#+7*B``V`0@0D1:FX2T,$(RBE3,(P@
M#%:00A;6)^%Q&8$,3J!>!F8G`RQ@(`FLUD$&L.`'(^R`"&JP9AM>4(7VL<&\
M6S"!`++QA`G<LP=5``#O'J``I?6`!VU@01<T$@8V2``#:!@`$1J0`C!T(0D-
MN((3G.!>NM'!`MFHP@K`$-T8./(N,C`#&JR@'S(@`0!><,(-S,"&%[B[``IH
MP17L;(Y&7<`),PN#&!8T@!.40>\"<@#C\$>&&-"!#6(800[24(8J<$`0?KB"
M&(0'AP(HD@ZM6'P+ZI!@`+"A`6V(#X>?D(8S_]#!"4\(0QBJ8(5R&#P#)AA(
M[P%0KR_H8/9O(.L#YF!F/X">#A!8`YPV.H!I8*$RC6##Z(A`AC?D0)R>;A0,
M$G$&-)B``*9&M?S_$`8RG-X*=,""ZW8^AZ^380`*H&L/X090X`)\4"L#H`(F
M$``QX`(",`(A$``9H`("X`!=8`)!8`%Z@`(X@`(N\`<H8``&T``:H`$YH``8
MT`-N,((&L`1T$@I8<`560`08@`)@$'(>$`$Q0`!V-2=W<&I]X`57D`10(#<\
M(`$`\`('I14Y$`$*T`-SL`(WL`5MT`$FT01PH`,'T@90\`0G(`$U$`<<4`1>
M(`!M<`)B0`8&\`!%XO][VZ!I9&`%%9`&;\`"//`#:,`&"F`!+T`!`P`G)5`#
M%/`#XV(!$>!,48`%$<`!,8``2L``]J(%:'`.1`4&8(`$;4``51`&:>`?-4``
M;$!,1&`&1]@$#_``/)`&:X``KE,#:.<`+7`.#4!>I`4';!`#8E`#K2&#.M`&
M%5,($"(G`E8..>8%20`#:)!=TN`$UF1W`"`'`>-H8Q`'<5`%(2`E6<``=A,"
ME>$$8,`%5@,&UV@(?D`!8A`';X`$$5`&7$`$5?`&(E$',W`!8M!&@P0`56!F
M;H!4U$,'/8`$X2`!<)`&^`,'84"(Y-,&10`':U`';4`'D'8&;I`A7/!4;S#_
M!W*0!D0P`C)`!V@@`$C05&VP!5:@!0``,WFR!BG3`C(0!EPP`O90!X!B96(P
M#=K``6H0!U@``2*@`"@Q?P?P6EZ%!63P`55@!&B@!>?T!1)@"'(C`U;PDPX!
M``.``@T``5@0,1F0@1!@!5"P`3.0!060`A+0`%\0!$?P!S^0`0C`!W]0!;TA
M80TP`%2P`&AA!WR@`$>@!!0`1GXP`V3F/CAP`W.1!"/B!PY0!$6@!T+I50E0
M#3T`8.@5`68@!DC01DD@`TF0`0J@`%@`/P6@!300`0+0`S.C`0\``Q)``S2B
M`VC0EUUP4VY0%V$@=78(!5B0!<XD`UXP!"[0E0[P_P1<8`8QP(WG$`=+8`9+
MX`4Z4`5<X%$4`(];0`-GL`4Q\%M<<`%5X`0]4``CT`9C,`)O``>.DP:U<PH]
MI2!:0%9^P`-U``.-T`8*H`%$$!]<T`1(P`-S`PEK8%,0H@%A@`9L%E6I%P(P
M@`4TLCYDD(_DAQEB``+9(`;RQ8DT)0"TLS1TX`9G\`)KL`%H\#%BP`8AT`A6
M)I%:X`9?()%U\02SUP,24`7U8B(2(`8P``%H4TT(@$_[Q0:@IPT,H`:D:'<G
MT`P1$"`U```7``%M\`82YP5YQC':$$EPL`5.!0=N8"9HH`95XYQ?4`$;`9ZZ
M^`;A1C$DH`,&%P=&<`5UL?\%?X`#;LH'"Z`8;.$Z8A`!%""5IV8'(J`'7X4%
M1L`%&:`#J4`Z(]`%$8`!&$!P%*`!$,$%`\`$,R`_*9`#($``$Z`"1X`'"6`#
M-2`!1%`&*O`'/;`0,K`03C@!9#`!!O`"%7``0Q`#G8`",H`$2"`M*H`'9E`'
M.+`!/=`"RA`&3*`%)4`!.7``/^`"#G`"J.8"62``G+893:!Y2I`!3_4`==`"
M3T`L<3$!9Y`%J6(!(8`];3`#9]`&)ED+">((5<`#/.`"-R``N08'G_,?$Q`&
M!%`'11`$:P!*]08'Y[@!3U`!;?``:>-48)`1:G`&^U6'94`'/!";&9`!;+`&
M:C7_`Q9E4_O8!4BF6PH0`G#``/*R!<KQ5(0A4]*P!DE@/1R9`UP@`\O@!P(@
M!A4P`#.`!4V`KT^@`0"0!3LU!VT`:5;:!2&`00)6GV:`!0#0!/B#`!S@/5C`
M`C=0`R#R!'-``3K0!3QF!6E0G#OP!"4@+V*@`&K0DB8P:![A"G+@!JV##N/P
M`MAQ=0@*`3:3!B.%:>1D#D\`"50+:=H'!C20!EL[`9P0!F?0!!8``#0"`+%0
MGZEW!F*03=H0)V%`(W!2`_2A#>NP#6T``>4J!EI`N690`%<P`A^X`XU"`1YP
M`E$@7U@P`O/G`2V0%E[EDC(0`CQPM7(P`@```5K`!910_P`&D&\.`0<(T`$X
M<`<#L`<<L+P&<`<>D!8R``(D8``X<`(JP`=\2@$X8`<%0`$H8*DP80`6(`%3
M4`4_H`(]D`5$,`7N^@$-`+.P2W0:H`*GLP8LX`0M0`%Z\"\1@&H!@*V?.`)P
MH`$2T`)[8`876`1KX`!D``%I(`-N``)$`'4X<`9U0$R^RP8.2<!<0`%Q,"+B
M-`=%X!@7^004X``"`(`\^P5E8`%*X``)<`,`\`"J,0<P,`/+Q``"T`5=0`1Q
M(X?3L`8C$`1A<`3AP0!E@`1LT`0K$@<WX`5N\%NYIKY7$`&.I@0*H#=/H`11
MQU]UP`9<T`9/@`58,"?EH05/@/\!(<`\5\)<Y7BD`;9U)F`&!)=Z<V`%<T`7
M8J`&TY#'<<`%[A`'OY4&PS<!?@`"9_`&T"$&:>`$&;`!,I`&23`!:<``+&`#
M2)`#]!4"&J`&(/`"<7`&-*)`M]<"35,'$,`"67`"3DHC+6`:$"`YY?`$6M,&
M1-`*V@#!<.`"Z?:-:4`#7:`$Y(<%EZD-9R`#9[`&2U:98T`^@<,Q0IL&";`(
M-@4!=R,'```#2)`$1+!?C7(&#C`"L]<H#U`J50!U)."Z\B<$7D`!7P4&BJ@$
M`-`%,0`'Z!,&#A`#`:H`".#.#Q&5?&``1]!;&5``$,`$.?`"&4`J*F`$.0`!
M->`##4#_`1!0&T&@`@C#!QHP`D<@`*&2`@]P!*@8`J]BR05``'`P!RP0@&0P
M!CT0"A40&$T@`1@Q!3P`!:B&!RNP7PK0!BZ@!1IPNQ8@/VX@`:B<!$T``UWP
M!"@PLV@@`5HP``8``(XQ(%70'492QF=`E.]!`770:BV`!O8S,"-`!2'``D]@
M`30&36%0ST_0!AXPA`\0!7UI!INH&%J0!G#P`F%0!*42`TZ0A@:`!L29`D5"
M`$GT!@#0`Q+W!#&`(I32CCS`!W*`!&$0`E3XCJ^,!2]@!0:P`FN`!3FP`TV@
M`..9!6CP$7^7`T;%'F*`!>!X`V.`!AW0`DV`"%W0`P_@..03_VY7D`4[8`5P
M()\L$`*R=@5=4&5Q4`98\`1B$,95TPEL8`%&8#!G4!#)[(U`TGLA.G1U0`#B
MT09B```TY@9#*P-@0$Q/``91\`1T(`$L$`'0\P9)H`3F(`-11X5Y)@,QT$9M
M=&5M``880`T[0P#@=*4]4`X]K`2,O09JFK<%Y`=D,`,CH`1O``G:4`4&0`0-
MMP%5``+S!SPL\%5J6@`G$`,2T`,O<`55``%74`!AX`$PT(@040-I&0`OP`<>
M0`44P`1'X`4BL`(9,`$G$`'%:@":.@0TZP)`T`"N9P`EX``&,%5'8$,J<`%S
MR0%V`.4.H`0LNP9#D#;C50.:)``-\/\>!N`!&Z`!$_"!J#9W#\`S2:`#31`'
M/+`\9Z`!3R"W$]D$+5``H,H%-="2XVT&+S!<#[`"GAD"5X`$V!0#5;`#2U`'
M(=```N(!81`%5]`!+!`&8*`&+4``-]`%F>,&#."D7C!\3A`!8G`O?H``:-!&
M6Q!E"D`$5G`"5C`$5J"923H!WEH#,1@#;X`!2\`%S$@'!`(5'.`,6M`"6O``
MC=@&=>($Y$,`6T`$/'`%9=`#).,$#J`%2K!W8L`#=;%14.P+!9SI6TP!:6L&
M2.`%6+!Z31`#<H`%/8`%)Q`"3:`%+@4`**`%%W`#+0``R-X#:HH&6$`'#0"R
M7&`G81"S=8#_!2/Z!%^PK]E0!T;0`$A@DJG``D#VW6T`BST=&(W2"%R0,B?U
M`TE0!H3PA&@"[*8T!)"`"U?B!D-(!'YC'&\=`HU!C1W#!O9]"K7Y!2?P!0;D
M!0OQ`VKP`-JG#4C?!1Q0!3!9`_(7``4`!R/N5;[!!_#9`P0PZ&2@!&H`70E@
M!CH`!!!!!P[P!S-`!8Z5`"J0!WR0`M@6!%*0`"T(!2@0!`>P\!H0@A]@%#U@
MY@+PR5S@`!*@!@;P<TA@`P4``E/``8:(!@0``U[@`!%P<&UP:"'@!!)``G9@
M`8DS?RIPKYZND`V2;%&P!6&PS=7APHB;`[,S!_N"!%<:QFOP`R/P_P14901&
M@#%/L`::A@80X`1N@$E.0`)$,`,S,`$LT`0$8``#H`%Y0@0KH`0-@/-)D`-H
M4`2]L08R``"0!@8Y0`$3X`!+XF.ZZP*.+4U=``,O``46(`=)20$`(%\M(,(\
M,`=+`@AI&&IP1&\Z(3UG<2TR86=P6U\.#A``<TA5=6%L9GX\:&5T6D%P<!8,
M;&Y69UMU`%T`:G5<.G,>'A1T=1%6<0US;6AS,`8$;54`(FHQ:#%.)#IB<&81
M8G(`/PI?:C0&7$X.1&==6D\<#)IO:7YN255G1FUO(V)8['Y$3QEA(4EQ?M[X
M\1*B2ID>9N`\P>+&SQPQ`-Y(4*-#3ILG?O\RNO'R1,V7%6^0*#CCIXX8-4O:
MU<F84<:>/G@00`""T<^7"'2<=`DQQL*?GT"#"AT*U,4N+$23#JV"A$<%'@,L
M\0@1A$*;+E5T1&$P%`&'/T=P2&&0A`.2#A4J"!CA)0(#%3`2:/"`!P,5%#DB
MH,&10DJ%#P$,1.``@4&7"`HL6,C"!D`3(DH&^"F#Y4V<+F+,8M#A@`F'"C:@
M_/F@M#11-6UJ9.BA`PN1-<9T5$&`ADZ0*`I"Z!"PI$H%!B>NA*CQI,63+UH`
M7-F1\0R:*F!.("'0XX67)"VT7(%R)0*$"DM"(&E19`26(1/,/(C!X<F3,G7@
M%&!3(TL./T^\R/'_XZ11DB]GM''!$D_4@04#(<0!!SQOH/'&&5JTH44=;4@@
MVR%-(/!$''/XT408U.4G!AMU&'&"&Z_$\8HX/#P!@`4`E'%"$D^$848;=6@!
M!AM^K&#!9ST(]&`=%;B7D157^+%!#T@X(T87;HRRQAH[K`&'3<ZU$88:?B!!
MDA\0M.$&&YT\T883?BCDQQK;M`'A$W"$,9D?`'#AP!@`G`%`&#.8,4</4;01
M@IQT7J+&&2ME1,<:;[2!Q15&3"!`&^GY$8<7`\A!QAQPI*'"A@C,L55#:BC!
M)4MGB)&&%FRD042B`$!Q!!H\]#"8:;C^-$<=8.!P1ZY+C;!!'"=T\442_T2`
MP`,`/G#!PP(UX#"4``1PX$,%"2QPP`PT8(!#`QR`4,4*>QCPPQ)"/!`$$"@P
M,$$0)[B`00U''*!`%1*(4$4$!>3@009_5$#`MV&T8$8#?F!P!0$Y/($$`SVT
MX``*"O`0QP1_L#``L*;Q,4,:J7HAA@Y/$&'%&B^@X847:\!3AQ=A`$!$S"CR
MIX8"#T@0AQI-G%!'%P)(`,$59Y0!!QUGK&'&%B.T`0`=`&"1`0E-/-!8'"20
M04$=9M#A!A=K>!##&USX@0:.?LB101,R6."%'S&$D08'8&#A!SD8L<$!%FN@
M0<`66L011Q0B]%#%3B2!8=X6&A"!A1I8T%&U%_]G1(&%>7#,`08=,C1!IQ-J
M#*"&%F:`T0.C#8#!1`-G@%$`%ETT444+9PC`@P(=*'&&&B2TFH\?,,K1A0R5
MYR#'!5V\IP`S620Q`0A0LR&$%XN"<<4%!1C0!AU))`*`'V;4!,<9+?H1!@C&
M>0%&<V@XH04/5\A`A#DR6,%21G&L0<;3=(2!!A)L:,,:5L(CEHBA#D\P0Q@X
M<+\G_*`F8:C)_29XORX<00T0D,`-R``"CBG%`1B90P1^Y<&?6"$[.AA",NIP
MAG2,P0,U\,(7R,""H3@!`BA(0!\"(``?8&`""W"``#*``!6H0`HJX,`04C`#
MC!7!`AYHP0>:D(`!9"#_!2=0`01TP`,B\"$!!+A""3Q`A1-4``DSR(`#RM`&
M`M"@"QQH`@0(0`0"&*``%7A=`V;0@@244"DE0$B-V#"'";CA#1Q(@]/><`4*
M^*$",VA`!MH@``PPX`P2V$`8PF`X-$2!!VRP@*J\4`4_"&`#$M```'0`LS6T
M``-A$(("`-`&)%Q``$W0`AE(\`0+.$$"`D@5&7JPLQ?(X`U;8(,,KJ`%)0@@
M(#0X0P:TT(,G="`'77!`&!Z`!!.\0`TR,`,2;I@%,IC!"'580ARXT(0M"$$`
M-=`!`![P'C$8P0]7D)`#T```,+R!!V;H`A?`0`9+S$$-=#@@`-Z&!#I\XB)<
M_P@#'-X0A@W0H`9($`X=*`>`$,B@!@AP@QNJ@`8T6,%6`)!!%13`@CB$089>
M.($,Q$`'0?3`"F78P0NJ,(8PD,$/4>"D'UCJ!DCX(03?`QL=S&"%$/@!#.H[
MPQ=6I08`PB$*)M@!$H@7AK45H555($(9`/"$+J[*"6@PTI1<M`8"D"0+,1##
MZ=[FABZ0X4L4]`,=MG`#.UY!#'2T``@Z\$>A+,"A)2&#%/#PQY-N0`M;J,%)
MH]"$+["A`@\@P@(BT(*AL.U''9`""@PP`A1,8`L5"-<'%O`!%;B`"2BH@`+^
M`($+X.`#+!A"`#@`,`6\@`(.B$`:"L"`$91@"L`$@/\)(E`#'F2`#4^H@00`
M`+I[$>`"7E!#`UIPA:;*0`8&*"Q1#,"!#I%!!DL0(`54<X4&Z.`*:)`"%[:*
MA#2XP5%MP$`:.EJ@,%3!"2FM`@\"X@3#*($+/>!`$*HP`0.`(6C)*\()&""!
M"USA!RT3T`Z>0(8G5"$,;SA@5:W`@S;X(0,RH%,,_$`&';7`!!LP`P^T<($F
M.*$'^RF#P[I+!!Z8LP):X$(:>/"""F2A`F>K$4\<HJ>562$*;(`#&;Y0!3*P
M(0)AT`)_B.`%#F'#"72P`F1[@`8CR.`!(2!"#YBT!C=T"C](*FH8M"D'-[1`
M#`\9%%(O<`;7G*`$8%`#`)+_T(0*@$$.:MB"%=HPNA:\R@\7$!X<6L"%-]C-
M4GX0%)?80(8BD*0+1'#"&9ZPB&I"ETYF&$--ZJ"@,U#@KQUY`P"J\#9:JXH.
M<E@)&<1P`0?,H2$\D$%3.C3!.JC!"`((0QNXP(4G1)D"18B`>('2@#5\CP(`
M<(,?2]@#.O#``CJ``0!:$(,@L(H'.#"#&CLKE![4X`\IX"(1F*"!&?1``Q$X
M0@58$P05;``%P,4!#EB0@!]$8`(!4$T!`M`!29X@`QIX`1,&((08>(`#-5""
M%KP`1PXLBP8"T4$.Q!`',!!A``YH`P[$$`(!6$,(=C#-!TACFCP<@``8<8`$
MGD"!_S!`@`C?<T`5]AD'^_UUQ#L0`Q'J=X8>;*DD^0-`'!2`$"P`H`YSP,(<
M,,F&+_3`"V3P@A/J,#\UE$!/='@"YVB0MA`D$@!(*(D?M/"%!Q0@`DZ80,+B
MD(0R6(`D!(A9%>@0@@H0(0<&H,$:;$`'%MS`"EMP`@:T0(<7A$`-<Y@#`,A@
MNTDF00T4N($"BH"1+KRA"E\C`A?8(($O/($+6FY!&CRGLS6AP0P8($,=DH`$
M.%%`">&SC!]>C1\ZG*`!.SC#&Z+C$!,C]09N]@,'M(`$`&1!#`HP<49B0(<K
MI:$,2/!$&,:`@1&LP0]<X%(8Y!`&(D3!'&>80PT<TGTO`/^YE&NZ4A-V)Q`>
MN2D-,2`'SG8!+)$&+5`'Q+%0:9(1CY`%KP`'[R`#&I`$$_0&%2!P+Y(!:8`$
M\O0`1[`&`#-M?Y`$,8`!=#`""A`$C%5"/Z4`,I``:_`D*+`$7L`%-4`!'2$'
M[]9N*Z`""4`&0?`!$+`#5^`"-S`$J90"4,`!"X!>08`#/:``!7`'&=`"%8`%
M4/``!I`$`)`"6V0`0^`#',`!)S`"2T`$%<`&CS,&2:!T6!`&*N`'.%`$+0``
M6L``,\4I.1!7,(`#6$!S2O$`9W`"4I`K$;`^::`&/0```L``K\`C,2`#3R$&
M+_`%$N`%('`17&(%&)$<<;!B7:/_!6I0!CG@/SIP!F=`!-CG-!30`E5@`0L@
M!Y>82&-`!BU@!350`'#`!CD0!VZ`$6K`0"<0`SP@`"12!<93!SO@!F@8`1Q2
M`F&0!3I@.&30!3L``'US!5D`!E$@`3D1!V3C!V)P7F90!=;6!HL8`KO'`$XP
M-F/``$\`3&J0!ROE)DYP$="U!7[`A6=@!F8``#1@!&XP3`9P!H^`!F&P!L$$
M!ES@!4U0!B)`!&K0&"Q!2WYP*$I0<B<0!6]0!V7P`1>@!E<P!T1``1IP!B6@
M!BKP`@"1!6L0)!@A=1WB'J,6!P5"!''`(P7@!'/0!7>3)'Z@`_9#5E[P!F\@
M!PID!B\P_P<-\`CSY04R@`:OL@1)D"ABL`4G40?V%07?TP)(<'GW(P$.8'6[
MLE`<H!`FE@%QH`$B^`<BT`=_@`0[6%A9H`0"=`!FD`,UX`'YT08N()0KL`)S
M"11+@`%'$`%=$``R$0$D4%<&D`(+8``NJ!HCP`41,`4_<`(HD`&DY0)!\`45
M$`%"4`4EP`$"8`,$$`.N10`A\`,`T`!X4`(5$`,%4%``(`$>\&%+$`5GX`4]
MP`560&%P4`--$`4_X#QY$'-$@0<7\`17P``P@"M'8`5PH`82\`;2)08:L`-$
M@`8*,`:AP!+W504;4B"M(@%I(`9NL@-P@`2,TP3/=`5P<`-I0/\"-7`^P],#
M%U`!(=``:A`&DR(`1=`#V]@%77`#3```5I`%7M`&<G`%`&`&)Y`05N`(7,"?
M(/,$$<(E<#`&'(<&3:>/T,4%-V`$.-@%4>%4?K`%B.$$QY&5?2-`?D"1`$$C
M77(&54``"H!/&>$`+1`&P@4%7B"39T``408`$(`1]?4@&%%43E!4"X`%2J`"
M6F`%*W%"1J`&PS`H9'5?Z(1/W^,$!=`A7TE=:1(%93`'6:`&-4``6%`3:#`!
M+7`_#'`W=!)_<G<W<Y`!<_`V6M`%:``"U(=K.1(&7``',:A]:M"18C"C%=`0
M?N!T9#4',O`%^I@1&/0%;Y`#,A`13Q7_$.TG0FQ`!6T)%$0@`=-&<CU`BN9#
M`2K0!5N@D!7@!!*(JD+Q!3K@`0.R!!8@`R;@`2NP`"^`!#_``2F`B3MP1Q)P
M!3'`!VNP!'Q4!@.@`4TP!5.@`2-@<S5@`CK0"!4@`3L0!2&@`&JF`#!0!5I`
M3R<@`4T0.1S0<A`0!B/0`SF@!>A%!#%``"@@+4JQ`3&)KPX0``&0%"Z``JQ@
M*4F`23>`!CT`!D/6,EAW%15@<!80,VU``6,@`6O@!*I65Q?``.$C`6+``D:`
M!4G`$1F0!$9@)DUP7@Y``%;`!3'P!'-PBUE0$'/W!D7```70>!E@!"_0AC?0
ML'"7)-^C3MN@_P$;8)1><`5-8#]A]@8GL`1G8`5LT`5K$`5$@!D'-:-1@")E
M,#,/``=%Y0>F!R5O@"9:$`:DX@5S8*A>4`8/(`PG!'Z"]@2J`A#EX$H4:`8U
MH*!SP`5)T`4\8"I<PQ1-L`0```O7B`0:0'C[:`6.H4!>H`4MD`745P=-$"</
M8&U_Q1)O8&WX(8Y7X`!K``8Q\#8F0!(F]@4A<",1@`64(XX#Y&&91A("D1$+
ME6UI\`3GMPO[P0,DL0--(`$58*<0D&9P8(/V\`)^4`24=YL#D`16X`2E^A.G
M.FUJI@0`(`99$`8ET%$[!Q%JL`9*8*M!T0,FX'(8T`(N(`!BTX@EN/\!!<`'
M:N``#X`!%!`#$]``)0`")?!#6L`",;`!`^`$N'`"!+`#/S`#$0`#7L``$+`'
M7/`!(P`!C3`>#A`"*H<$1%`%/2`#5(!\%=,#24`")Y`&.9`"1+`">J`4+D`$
M&;&V12=M2J$"/7`2G%$>U,4".F`"/>``W)`16,`"C>)0<B``#D"V)U`&%5`'
M3=$`#H`!:R"[154.$O`JH?<_:,`"TZ5N/\4#8L`%,@`&`'`!U"0'2H`F;S@&
M<=`$:]``59`.Q,L#I@>A21`%]0I=N:0&L[L^1>"3EK(2.P`Z1\42;:``;V#"
M_S@0A.($(:!C[2`!_!2IU(F`1)`&<$!+J4+_J\AP`3#``&C@!CL@`PH`8/M8
M)$U`!W&`5#N@HFF0%?NC!FZ@`_7E!6/0`S(LN^((!C50`Q!@.`SZ-6B08K\8
M`W<UHUY3$L:!9UL`!LOF4-6$?NT0#&W08O<S!UM`$D_P!G2`!AB`R&X@GQWA
MDT6P/P"Z$C+`!CV0'#V@!H47)6[0(B[B!R8+`#Q`!T1@!`5VO7:0O>)%!'/@
M!)+%!5KB!RJ@`W'``@1@!@J``>@+%#P@`3A`!1!P!"KP`RYP`'^@`3B``5Q`
M`'O0`0\@`'>``WT0`0[0!S/@`PQP`2$@`06``3L``T&``4F0`=22`29I!02@
M!(9W>3P@&"Q`!!_K_P<&<`)H8`E8T`96H`86$`):%@)NP$D90`19X-%*,0(#
M1B=1X`+*61HJ4#95D#("X`:!JP%:Q@)V:)-N(#,LT`:%Q@!<``%I4`,)0@02
M`I^D<P58(`8/T`-NH+@U``;R1`:U!``G$`=K2@$G``<+#0=_NKAG0`<T@`3C
M$P-LL$Y:,`9TL`MA4`<\\`#[>&;G/`<*J<]QH'QC(!`0<B5WDP8/PA'F4S9T
MXHJ93&Q(``:'-%1/D`;G!P9%`,))(`&H)W5FS`6?9GK?(]M^D`9Q4#H9`5=W
M70<S50.=PR4`H$BC`W9T``9(T`/LL#=DD`XML`8@@"A@5TJ7J`$$6@%<(/\&
M,N`%.)EB#&"OI70!WP.4-2`&ZP,^JS*CYR>.BH#8<V<`C;029O`V?E"*;10!
M_UD'5T`#M),H?D``554%F0,G95`2;R``5R<\%VX$8J`%$'"]/F`&13!M48`$
M*8`%`D"&M#0_9/`"(H4"/[#B0F$$%_`'>E`!?&`'=^`""_`',C`"1\`'33`!
M2Q(`4H`%"V#">HP"$2`"%D```&,"4B`"D=0"$&`!$W`"8=`!#L`!0)`!$J#`
M83"X"G`!&Y`#=2``&HX%'B`!3K#@O$0'AN8`%9`&[24>?)`4?>`!)-&]%9PK
M-F``7&+C%L`$$"`#<P`0<>``&R`':2#((,!E[0#_CYOL!V,0`W50`$40!@W@
M347@`%HV`-N]`0`P``WP>2#`<;UGPO-=LO=`!RNU(&6@`W!0&R?0`F1P:0^P
M4-CG!R;``%$@!K\X`'U3!Q!``1%2!`/=`$8)`#-`!/+$!9;J!9>V!C$P!RD@
M'IKWK5^08@20)ED0$*N]R&JY!C<0!R`N00``!S)0!S7E!YU:-S\*``20!&ZR
M?VYP`C>0)V\``@!PGW3"867=`)V"N]B`'VI0`7TSITB@94\0)2OQBWDB!@)0
MAVI'D?@4,\J=$9EL!<9[/VB0!G00#`/Q/18.5!U^/^U$!P,0!P[%`&(`'OH)
M)EP0)6QPN;H$`'Q:@W-W_Q$?Y<].H`/3-G9C!0!R<`(%T`5($`1AX`$:P`)D
M$`=*+Q0RT`,H8`$;D`(K4``D8``#,`$34`$K$!80T`!.\$4B$`%0L`<SD`-7
M\&THT``!<`1$@`)-X`%1P`%>@`0;X`(=D`[TK3@F@`8%\`-*`*35Y`80D"AL
ML`5)\`&(\@0Y$"05,`%:\,%*<`$JD!1X$`1F4`8><`5K<`%3L&VE@0,PH`;_
M)0#<^9`.@02:$P-KX%-I@`4AL"-:@)!E$`&UZ`=*0`</L`0MP`/%.RB=0CPA
M&0-*4%E/\`(\X%]H,(I9X`9:(`$LX`5C4C5-<-ZFY%($\`9-,&!L8`1VS1)@
M$/\X9Y"Z34!=K+O)#B`&H&,&:;`2%@`(?FI=,DYI#V!^9W!E%24(5D]I?FA+
M,4@`%1)(25<R?E9H'TU$+6P7-UAS=2!7+7YM`F(A.FLQ:1DM`"%T=%<4<F9<
M3Q1U801N)D2%=2];5D1/50)(-T]L;F(2;5XA9'YL?GY/6"<7<D\``&]N6^+B
M;FAN2=_C9G,`3Y3B8GYS='[2")CCIPD`/W1TF-%WY:"X+6;:U%GSA`Z%.`[K
ML$O'!D":'FC8))'0I`L`+&UJH/CRIZ7+ES!COG0A1H?,FS&=J&EAP4`--&_6
ML*GB14@;!RH,V(0IHXF%#WT*M#A2P`$!!PV84$E2(4C_@@P3J)2`\&*&@1`6
M8N#0<0&#AA95W/RP``&"CBP01A3@4*$`"`U!'%QH(4$!`@XCV+0(4N2)@A9U
M+%3AP2,*$2\`O+QXP<$`"BTX_Y0I8\/'A#5T'(1VR0>%&C9TW*@Y*PX.R#!5
M1.0+4^&*%3-7M+"H$B.#F"IFU+PY\X5!"0U&Y$1Q\H0(!")?0HAY@L]DXC5Q
M?H8)<P)@#PEPW.QH(N&*&2U:LKS1ID6#@S8QX(@A$J?-&S\A[`!`$3W(T88;
M98QA`19:6*&%&%@\`8<1:W!Q!18".,2%"&*@P8,75X3AAQ=E2)3#&4^<`4`=
M9.@@QQMMB,$&&6H\@0899JQ1_P8<1;!QA1=HY.-$#T;4$(T58<R`&P!<,&"%
M$Q*X(<<9<8B!A!MU5.'0$G``X`8<WLB01C=57%`'&V<T<8$?/%A1ASA5$/&&
M%@`0\8X?`#@!2PO_=<&&&$VL`<<GL$3Q1`@\J%C%$P:)@P4<3[SY)A$\*))&
MBF<H(DX<9*AXQ3ATB'&&#$^8L4X=-?Q0Q0A+K.9J2W8T(<.K-S7!!0!(","%
M%3J<(<(6=.1B1@LTS`J3#D[\P8$+$\Q@@0`)$/!`##3H%0`(!Z#`!P4T&`"!
M`$%,,8$%`S`!`0L&B."!!@3H@((!%BA`@`8Q$!#")CFP@,4`(V`0@149G*`&
M'!HT</]%!>7D$((:=>C`!0$*1,##%06<0`L#1]@@TPA6N-!2$$M<T4`&KO8Q
M105@/)&!$P0\49$";5C1!AH08%1!'%Z@>8859UPQ@01J8,`#!0]L<8$$5<21
M000U/&%$#`5H@$$.2DCP@@Q:9$"'&4B$\(828'@A@!]A\%#%"UPX4$$72W11
M8!ETU'!%#5S$$$$/25C!0@T2=%$%$FML,0UX2FBA`QM/D-$0`&3PD(:@8+@1
MAQ;BU)'%&7.`8<87`(@!AAKB?/$&'#EO(0<26DX2!@7J.#%`2%7X@70-#"@Q
MB8<Y).%`=6](H,451(@1Q7@QZ&#%#9W#(0>>+HL81@]@\%#_O!4A/&$%&&T`
M(`,`6K2A(A%SZ*.(&YA%<<89==#1QJ=;>$%Z''4``/H<L>-IQAE&Q!'^FV(X
M=!`9C/."']Z@#QGHP`V/.T,:(%6;-S#@#&*0P0GBX`8_$$%Y?JB#/M)``5JM
MQ@=D,)8'7]*$L(4@!$V(@1@((`(RN$$!`J"#`4`@0I=(@`AV&,`%#,`'.XR@
M`1;XP00B,((90*$E#0A"!SP@A`C\00`%D`#3I""!"F2`+RU`0`J`.($*X"`)
M$,B"!];@!0Q<@`@.R``10D`$%C1`!UI(@Q@:((,0A.$)<8`&Y12AAAB8P0%I
M2,,7G`8MF23@#JR)`!?H\(``O$H*_V/PPA-ZT(,YA*$+"%D&&#+5A$F<X01@
MD`$<2-"$R!C`"6_H00NT@`0'J$$+8,@']][@)3BP80Y9^`(/*!*7*O1`#0"(
M0=^Z8``#^J$`7/`#&;C``S,8P0L,J$$:D,"%-9R!!4]8@QNJT`5V*$$-35#1
M&P0P@P"081I*`(`9_!`%%HA)%G/HP1LH^"8&Z*,-<^B"&4Z@@RIP008W$(`$
M`-`$(X`A#"^(0PO6X`<!A(``8^"!?\:@@Q:,80Z0`L,;DB"`-6`!5&\21^36
M```TR&$&D1Q)%+``C1<``#Q-0$@3,/`$-[2`#FM(@A>$9P$=^"$%-QP?`2Z0
MA740P0TK@/_#'"H8`S\XX"`I>P?EVI`$/\!,G5-*`P!$P@]]$.2CX@!)_.PD
MABOH(PP.P"D[(241<7`A#3Q@P0\<P($1XL0%8U""75_2`RZ$(0@2=8,$OK"?
M,/B@23VP@!%B4@,D?"`#*-``'GI"!!=XP`(C6,`$2/8'*A0A`Q"8@`QJ8(,C
M'&`$#H!""A!P`!Y\@`%5^(``<.`!#@R@`0T@0@U@,((D7``)+>"#"480@2I4
M#`:@&$$5$$`$#&2`DBS(`!Q@@`$*D,`*/%B""Q00`!1$P`5\<!4?.$`'.*C&
M57N(`.C\X8<UK&&!6`!`%[100C:)H0S-K(`!VM`%'IS@!10@0A7_(*"!+K2A
M!4]H`PO@\(`Y6($"51#1'-"PJ32400!:18,0`*`#,?3@"1!0GQC(4(,YO*$%
M$Y@##PP"UAT@2@TAX$(;CD`4+=`A#01@0/#08`;P*8('='`"0-C3`B+@`'1O
M*$(=?C&C["'A/P.%PP#7P`/&+5@-8^B!'^(0A@>T`0[GVP(`8M.$/"Z!2ASP
M`P2\@-8"A$`!5RA#!>NWR";HC@UF0(D7>E`%)*D!"0:(```>`!`JG>$!\"-#
M%)#0OS-4`44'*<*=%/$&'>CC!D2X9CH`<!4_A&@'.+B`&W*P*#J<CP9>@@49
M3*"/)SA@(4]PPAJH@R<_[`!'F>HQIW^P_TXT8(&D,I`!!U"P5YD`00Q.+/8?
MS!"&(KA@"@5P`EK-$(4M5*`'<=A!%$80DQM0X`@IP,$'+A```UR@"0WP``14
MH``#0.$%1ZC!"E*0`@-,X`0@X`,3,F`'`8PL"?T:0`9N4`$BO$`$$D@X#53`
MA`_<%@4\>`$!!/"!"``Q!YE8`J.'AH8VG-L+-4C"`';0!0)$0`Q<\,(#*O."
M!8A7`UP(SQ%>M8`08-(//>C"1>4`!P*LB`OH&W,:XL`!'E21!5TK`@$,((`N
M/*$,"J@C$0#0`AA4``TJH$`;P$"$QA$A`@BV=!A6.8(MM*$'%7`"`,H@!S7T
MP`E8\`(=N$"!%O\@@0>R(4`2PB`&#,#A"C-[PT<K($F5*7#+8VB`%L;@!S&K
M$Q:?$L,J;NP%[U5A#FD`IH[Z%P8V."`.B7C`%\2AAA,@(5-JD,`9DJ`B+L-"
M0NOT0A5(W84X8.$-)#A#3L51`QX000LY:`$6C``\*W2`!O=%PA4X!R!\-B$^
M"/'`(-=P@3"$CP[BTY0;6AT.-82A#6H0```95P<X^,<,94A'%Y1J!.]5%:IL
M,,D8LK!"<:S("V1@*`!Z0(<P<*$'/S`';5`&6]`KN@<`87`#<($#R@831^`&
M$]"`%10&1+`&51`!;1`%)T``7Z`"*@`&+A`!/A`3,<`"3.`!?,``#<#_`2H@
M`QFP`P+``Q"P!%3P`BT0`RV`%DMP`A"0!R:``\[V`?HE!57@`E5P!`E`!32@
M`$6@`3@@`3WP`@F0`"0P`E00`>W4!!U``"K0`"B6.#I``%H@`2Q0`5RP`R?0
M$2W@!%;P!5F@!DG``$DP"ROC`8BT&@=P`#5S`3<Q`'WP$@%P!%&P*>A3!VW@
M!QVB(T;``_;D!UP``5T@`!'6`%5``160`R)"`3N`!4G#!4;0!6'@!4ZP/?!@
M8%[@.YF"?6C``:;R!7&R!D@`!RA0!2C7!NOS"F30!`H@!LKQ!$B@=G6P!&%0
M!@#``W#``'!@!B&`)W#`!4\6!EH0$5S0!02Q_P8]@"-:@H`2\`1FETSFHPC]
M$0)M$`8J4@?4&`9CD`:\H$P)E@;IU&?KA#YMD`.+1U`=(08Y4V6,U@1-X`56
M@!5$0`!HY`03Z!!MT`1Z4@=$0`=J@`6&^`04F#BP%`>0F#UU4`=(("*H42,)
ML01/8"!>$%+BP`%$0`$W)T`!03UIT`98\"E74$%E,`<2<(JDEP1JP`-C0P8"
M``>E%`)IT`1/T`5U@`44D`8D,`?"`3..U(`N<01M$('*U@9T,&!K0`3(@@4Z
M\``/H@-HT`!(,((PX009L`)!\`$)T`(&T`)9H`<X@`(_P`,)X'(;4`-.4`&1
M90%4\`<E8`%,D`(OT/\>7&"6$\`'`9`#%1@")``$%>`"(L`$++``+O``:Y`#
M2_`&+J@!Q@4!6$`'/:``=7`&:)`&9@`'WO=0%!8#`;EU;0(??2,"'_`J=Q``
MK^D2I74)?48`L]D2'-``F8($4M0Y&>!/?E`&<9`%"J`/1!`),N``3A`'%=`&
MPM8&`C8Z7N`";D`!F-%G`E`$=(!1;C"574`&\]4`.W`!/(!<57<%5?`%81`%
MU%``6-``_T$V9A`':'`&%>0'&H`&%>!4%U!5^*<"+@,`7X`!,H`&A'$%/)`#
M7C``?I`#,;`$0Z`/8A`#23`&%>![3P`B>.(&;N`$45!*ZZ,&A_8"V&-J$<;_
M!4F@!&B`'':2&3(PD]>P!.X`+%90&#UP!>N!!EY`!&$``%<`!R?0C^,`CC!P
M!<#4!$K`!H/H!TI`2P!P>'[P`&G@!E'Z!F``/_9#HEX02P`0!WARB'AB?7&@
M(GE6!W$@`TB@95P`*?W@!FW@,K`P:9CTF>]0!VY"`9+WD4UE.!6`!-T@`'$`
MEDSY!U+@!D/0@&WP?VF@!7&P!2D3`6GP!A#0/UY0!+GI$CR@`3;``0E0`!\0
MB!S@`"YP!!G0-NHF`Q`0`4S0!#_0`1D@!=`IFVG`JC[P`4[@%U$``A[@`@[0
M`LH2:#4@!4L0!#Z``S@P!.^B!!C@`DW@!F&0!DE@_P0(,`0F4`$FT#\\@`'5
MI09?<@1*X`7994\;P`&;4``KD``>M``G\*5>\`'P*@$XI0)YT)1&4",#*`=Q
MX(4(8T>PQ`55$P1F(`!6<`5@\`,5!``.(`%41@?H@`1;H#].,`:CLP9!@&XG
MX`9D0"=S<`)\U@)2IB=HL`82H`1Q`Q!RL`2P8#M9L"A=0!%:D`0]L`5/(`-T
MH$YSX)DA)0'[1C8#T6-@FBG<(4#]4Q%J9P4#(#Y/P`588@8RD`2E]`!^8`80
M,`<30``K0#-`U@88<!W85P49@`;$L']($%)T0`1)L")WTJ-WH@860`%/T`)G
M0`<M``&Z!P$]0)J'^"85L/]]95`]XK`#=V(,:M`&)R`&HV-@:8H)S?@?<&`2
M#0``<F`%7K`<M)@I=S2U6,`&^KI.>.(0F1(A8R,.EU0=Y_,``'`B/3`J_Z@$
M,9`"ZEJH?Y``./"'40D`@^4RSR0`+5JE9E`%'E`#,Q`3;:`!(U`!*A``$;``
M*\!<`>`!%Y`"&)`$*M`"!4`",<`$`_`!3&```:`!6G`"4``%#I`"3<`!%A`%
M'.`%%C`!2[@%]C(!8#`#+\`".E`#<3``-]``/M```U`!#5`$2/`$%6`$4BNH
M!``!;!`&+$`'7'8&;*`&WR(!$&!'VZH`0\`#5.!RK](`[Q`""-`2*I`"0O`$
M26#_NW_`!U#`!5^`'6%P/SC@4F@P`FF@`@X0'!K``&,P`&^0=N'#``H@B@!0
M`U$`1R"@'59P`DR@/9@'`'`0!PX`!BVP!1`@!R4%"F3P!".`#P@(E&&`!'&0
M`E40!8I#2RP`*&U0<%-JI55`!U@`IE7`(C7E!Z<SP.K@!UJ"!G$0!TZ@!*#0
M);84!Y>2!F$0/V[P'W0@9\_J![+:`\QF!>$Y0>2XM!1F4_PU%"&E!&N@>%6`
M!6:7!#4```0A"&(@``+D`%P`&PHY=9UR!F1`!-ZJ*0&Q*.+`!B'@H7[0-EZP
M!4FP!4Z`(I,P!F?0I"+I!U^`('[@!N^E)5K`*"CY!&,`_P=(D$$7^:-S,,U!
M.0(WH$&)50<Y0+)$8`(?R@-^)09IP``&50&RN\YLT`8Y1@2^Z04ZH`(?P01T
M4`=CT`4J$!-LT`"MT0%Z,``K\`&\`0$#X`$90``OT``*H`09B@$HD``"``$E
M``(%X`&,Z`$CP(*?,0,$8`X8X`,*P"\Y<`-2$`,0P`4UD`-8D`.4J0,2@P0-
M<``ZP'4.J@5NP&Q^@)ITT`"RI@-:%0)I504K,(!B,`$EP`-*L)2K\0%@%0('
MX`-YD`<!8`<>(`8L4*\N$0`CD"AAP`!80`1F@'UT`"0?$@&%\4>Z``%-@&`N
MU@4A4`T4Z(Y@0`9T``97YW^O</\#;G`&61`J;N!35C`',8`U:R`#6]`%YI,/
M$.DR)$4')>`&)5@%;/`%&=D"$2`#,9#(-:`!8#`!Z^0&#A!3`U0I$$`&<6<&
M;"`!XL``EK0%%.``61`%2U`&/2#'8K`U_[&A,1`[+.D%A"P&[A6W=7JS+=`"
M<S`&3E!1^H%/(;`!88`&93#8(0`''=#51)`%%)`%<VB<^2"H.L"9IE(%6@`Z
M4^FY+1!+F>(0:4"4F1('(8"FVD$Y+J,&92`.;^`%W>,R<C`'+0!Z;Y`%C@@#
M7]"=ZCD'7E!!;<`&6,I*-;%-++#@-Q4'44`#:%"&;%`!/S`"H+;.LLL&V.$;
M(=#.WN?_!UA@`FQP`T/%!/S<``;P`"8`!2-0`@4``4=P`QH0`E(Q`S^0!19`
M`D"$`E?;`!0`RAB@`QI0`0K`!1&P!1&@`&']%BV``T&`!!Y0`5"@`Q9@-2\X
MJB-PO!/P`DL@`!=P!7.0:9UD!O=3-`M.`UR`/<==E$^P`BD^)@X@`Y91`.&U
M&AZ\TW^@!2H@`3%P`GF@`F)@`##!!WA0E/#M!Q1`!CO5!4Z@*W6)'6\0`9<:
M`C-0@@Q``0T0!F_PLEZ`!6D``Q!#`0(`C;C;`%N`!+XP`FK``.\A`"\"`!Q0
M`Y4;!U>@07YS$*)I!4;`3F008)>'$J`^:$\0%)SI54&2)Z_A_P=@H-O)3F%^
ML`%@@%%@.K6C=P9:L-S9HP6W7`=S\`#H]P1"4`55`"F7!`#$U37$H0$/`(5:
M$`,0?$MA8($WBW=:T%?22@M@D`9R8'=-`#R6Z`:<PU\```8\MNUQ(&62)`9W
MI$$>P5[)#!PWU!_])R)"2\UU(`=>P`)Z0HQQ0`%^T`5H(-POL.#QY0:ZB`5*
M8`55L`5K0+ELF")D$*W]%Z?.;`$7X`4SMQHB\`,"(``$8`-,$+NT@@=]T`<>
M<Q-KH!"!0P$M@Y0'*0&8;0`I4%<PL<D?4$[^2P4@H`!_@`$G,`444`(M@((A
M<`%@80%_,`$YT`!4L`4&@`%_,`0'L/^_,,`'#:`"04`%7@`!3)`#&<`'05`#
M/:`!*C!$$.`!"!`!'!!0`F#A8N``#TH"17"<$?`"28`&!8`]2#``<`!D1!"#
M+%"_*7`%%K##.E`'8'&'-Z$!XA`#HJ$&8G`$6'!$FGT3.-``<=!J539`%'`%
MJ/4!.-"WP88":$```J$%#>`T####;V``:-`%$``'+Q`"W1.)\>$:UYX#*X<!
M7]"C!0`DM[`$R"&I"``&/7`#98`9T7T"*4`!5H#:>`T`#'`24MLC008(<3U^
M,5=^?@)$;GY$1EYG<SUL;F*'`%9=`&\>80QR;2%U+)9:,GX56VUTAV%J5P!S
ML'!Q=70\87[_.F`1&3%@.6UK.UX.,FEP,)4`9X=/$&]C``!$?G-P:FI^8EX$
M?@YM9'Y*(5=$+0!)8'%G:(?9?D](AQ)B1'%^:V&P`.UBN`!QNK1@)B,$!FHQ
MT+1HP*8%&`E(")CR\Z#,'!YM_%1)<X891S_2XL@X$>"/R9,G1S`@4@5"@`0?
M)*2)<`2ES9L9QHB`</-D&C=E0IQQP\,-FB?G-.6`467'S34-:@#Y<\<&#@L<
M[#Q@,@'#@2`I^!S!46$(DQ=\#GP(4N8`%#X&`LB0@6/"B3\;B/!(@.!!'`LO
M+EQP`24"A@08>%!@4N)#BS8GO!A@=45+&BX[9,!@4R>$%31)&@@X__<$P+8T
M*LB$B6(DB9\V,O3T_+."S:$8?UQ`:(`B!I,_1Y+,_L,G0)DW:<S,D>!-!A%I
M76;D$!)"!X`&$-0<]8*$BXX6(2XD(7(%"8`P6A"H(2/&S1`+YT+X><'%2P@B
M6I;U8.!GT2$L,M`!``0AP%'%''1XP<(.8DB#11L9^7'&$]JDP09YKQW2A1Q5
M;'$(&T[(00<<*\P1SAECT#$'!G7,\<8;:IP!@!)M,*.&%F;`D]$9=5A1Q1I^
MI&$"`/"L4EH:+3C!```B'"+&'"$`,,(:++!1QCU/A'&1!`*\048/:]32QA>#
MB/2$'+9I\<0]51P"4AT2:.!%%6/$`4`X=/]0"$`=;US!1AI>K$+4%F2X\44:
M?JP"$C-/,'-(F'Z8$`(2%[S!C!E6^`$!&`Y\2.$92FC:J1\M$'!!$PG,=L`6
M=2!B4@$?X,!$`D3,8,=P)T&A"!1=W-H3$4I4T8";6K"`J"MFJ''"'#G<I`8&
M'FQ`VP050#%#`QSP,`$/?QA`P0H]3``!!WDDD`,3-60``AY_!*`#!1JX\$$:
M!B`Q0AX%],`$`3$TL(,9.D"!P@Q'>+!%30Y4P8`%/1!00P,O5%%$#A5PD<03
M%U3@YADP^!$&&0!P008#8PBP0PMF(.%$!"Q@T(0#17#PFTT',.>'<!K,`,,6
M+1CP1PH2X/K'`A__Q-%&9V[$<$(*0LA`0`9M)#``#Q9TX44;%A!P1@,,<,%`
M%6%$J0`8?L01!QMM1,%`$ZWZ`4>H;7"0B0-Q7-&#%Z8,X*$?=30A!T@4OA%%
M+&V8(0<`%:A1B1]O?.('&=2D060;3B#>0>6'?,&%$0"8T<!%7,1QPB%U</#X
M,FVD`:01/#RA10%AO"$#`"^,,4+;3V"J01LJ^(&$"@^P`0`<=&3*.`%B(."&
M:5N\8(A_)[PS015@Z)!C$V*\\00%;]3@QPUN4T.D&II!4,T5!+@A(#,2&,(%
M'(W60886KZF1!@^'O$&D&'2S"8\AK2`;&NA0AS9DXPDQD`88VC`'!L`!_P"K
MX`(SB(`H/V1!!S]X@@=Z@H(TM$T`?Q@!:"!0`S&,8`E$X(/0!G`T'KQA`;-!
M5!6B0`0+L.$*&P#!%<A0!39X(`@":)9-K&""`OSP#WTP0!`L,`(46&``*/A`
M%CKP@0V@H`%2P$`09E"!(/S`"@'X0`0&X($4A,`!+R"#!*0`L02T8`,R",((
M,D"!!BPA!4OHP`P&0`0(]*`$.8B`"BH``0E`(5(MN($TDJ`&-FR`#4V806EZ
MD`DO^($+(@!!"T0@#0@`H`9)F],75#`5E&3@$$E8@`2P((86A`$'?\B`<$RB
M!]&T(`=4T$,>3.*"#<R!;&O@E!?JV(.+D($-!?\@`P?J,0$)]&`&16!`%(RF
M!0FT00):N$(-]K0$)41A$G,(0P^L<((8$,$*8K#"&XRG)3]@`0T$ZD$;`-"&
M+"4A#4@XPQK:D`$W>.$*3T##&K"PISITK@H`<$-`%)`&);#A#7[8@1;(\#<X
MI&$.JMC"FIP`!S>YX0EE`$`:2A.#+X3A"G5(`QC0\$"02,(/9@!#'2!``0&,
MH0MPT$(<JA"")UB@"348S!SFH`,E\"!$:*A#&!S@@"Y4P0UA"$,;P$`'.JAA
MGB9"P^N>P`(*_80'RZ@$&'J@!/^XR4VC.$0;PG`&*]"00G]C1!?F0`09R$%C
MAV!!&]P@!S)X#PQN$`+_`)#0AB8@90Y:"$,5T-"%)UCR#1*\AQHD$#M?V<0`
M$#T$!!"`!0C<X0]V,$(#`J`!))2D)RY(@!X,P(,7U&0V5PB!$BQPAB;(%@TS
MT,$5.,`2(S1A`#=Q@`;^$(14,2"U>AF`"CB``Q@PH`%'4(`-7C``')0@`8TQ
MP`!(T(<I9,``$HB`%713@0*4H`4>\(`7&!"$"LP@`@?0@0,48(0*S/<!+7C!
M"B80`P/\@`!9,`,;+@"&,X1A#&'P11RX`(8YJ.$!8'A"",90@2]<H0D0#L$&
M#K<&&70A`@#P0@O^@(=4_8$$A^B!%`X@`\^9P05_",\?#G`$)1"!``YH`!:<
M_P"!/=S*#@;PP!GLMH4U(.$*<[@""[+`A@:<X0U9J`$2+'"%)%C@!`X8`PO@
M,`8&"&`$5;@"#^B0K#8!0"(=4`48L,"2&-2A#/3STA-V<`8>6`$`:_#"'"!1
MA#`H`0U[:L$YO("%8[!!KPER`!B:X"<ZW.`,<$""%\(0AQ!@H0ECL,(8/-.#
M_!`A&TWX0AF"Q(,D9,"@5N+"4>;`A2QHC@L`T$&@B/0$+K"@!42X@`"2P()?
M^J$)(L,"!R@`,@#$8`U$RG,3".J%'8S'#R)0@QFPH`4KR.!%1+"'$[B`V#B$
MX0M^B((%B3`G/Y2A0=(HC1?>(#P7P4&>5[A'VYK0CO]%T4]X45CGD[10AR>H
MP0AA<$(8O*"&QQ!!`FJH`0:LT`0Z:"$_9]`"#Q+[AMG<01Z:#0`#C#`6)BR$
M#WBX@`4LBQ(=6"$"1;@/<&<C@RN@@0ASR,`*JL`#&?S`"P-@`0@>X(00W,0(
M!E`!%(8``@&XH`(P4$`!>""$"WC@"#.8@@\J\(,:_*$Q&1A"$/"`@SYDX`-,
M6$,%"/`'"OQ!`R\HP`X,P'$,*(@%L7Q``9CP@0E$P0%9*(`,%N"!#/`@"%WP
M`1J:T(8X^!$,8NB1%F)@AA;X%@5>H,(%&-`+<=;@"AI`@QK>D$`Z,(`$%*@`
M"HA+/S_TP"1W\``.[H"'$G3_X0,H()OI]U"!+K"A>5K(`!1,D@=7O@'"/Q!"
M%$:@A0C<0`!I0(%>*M`&$4A``C&(@!F&-\\ND,$+7G`"'<0@!RW\@!%H0,(`
M_(WC"ZP#`)W*`BB*$(<6<.$-/`#2.-WVU#!D20EUL$`-9`>![(E@>5Y0&H=0
M!7#0!ES0!K5G!&Q@`1:24W30`R!`!"J0.FD0!Y9T!6+0!-@`!S+@`(-'!EU0
M3V#P!@_$7\VP!E-03S`%!V?`!7X@!T4``'/Q!0U@!D7@!5;#`UA0#2W0`S\0
M@CV0!D3`0/2P,8?`#!UQ!A%$!FOP!'50!]I1:UT`#S]`)%S@!!)V5H]`!S2P
M!@V2_R.'P`,5A`56$#K4@`85(`%R`',OT`,7`!)+\`1DD`80$`5P8`9$$`7,
M(`<*0()=0``CH`%D,!PSX!\O0!4_I09?\`&^H@=B,`%]<!,Y9`%$P`)0H`7#
M<05N(`%<D`$*P`984`,NT`)1P!P\$"4^8Q-H\`('(!L=8`,6D``JP`<$X`,N
ML#);\`$+`!<OT2YZ$`!!\`(4<``L\#3M%0$UP`0Q(!<D(`(N(`,5<``#8`4J
M,`(/X`)\P`,),P0(8`,?$``7\`%&8`%:T`,N4`5]E2E:\`!<<``B\`78I(1)
MT`2TT'UPX`1^4@&+,&DH!VD6T"`1,`:[,`%KP`QK8!,)@/\"9S`!>B`#%.('
M(>`#9C`!"2``5Z`"<-`$EG4'']!_/*`",\`&)5``%=`#*#!P%2``$P`+;F`"
M9H`&99`!:%`Y$N``"91D9'`!6\`=;N`E%/``F`8%5=`#1.('6U`#.>`%.;`#
M88`!Q?8(+=`B;A`@$&`!$@`R$R(Y*L(&5:``54`#8Z`:"M`%:D`'+P`&7@``
MFR<`!0@26M!1`.,'%&`G@\`#'=4C(=``-0('-D,$CA42;;`#'*`%1H`%(?4%
M7Z`!!"0'<V!MR^`'8^8'I_2"3T""9/!R:A`&U`"1I2=7#K8&-9`%7A`#CQ,%
M#S,':Y`<N5"4A<<&]V!!9R4#<-#_;Z^1;B-@``ZP@_N0`R\`45^`/%.H%^<T
M57YP`E8@`&)0&LPPFUI`!V[0!@_T!&[0!5<P'"U`(700!']@`A=``R>0!;%Q
M$DQ@!E(P&R"@0390!2K4$V30!EH0!=O0`EX0!Q/@!DY``G.@!&70!GMP$\UC
M`RC@`RGP`8,T`C6``T[0`A'``0%0`@<Z``G@`W^```4P`EBQ!3"07AI`12,P
M`2D0``8P`DS`&T=0`T%```90`'U`;-V2`@W`!R<P`S&P`$=@!AK0`Q"`!0=@
M`54P(2:`!BC58BQ`)&P0!BWP`&UBEV@@`3Q:!5Q"![OU`$0"`%40`ZX``%<@
M`#\P``Q@_P9!H$(%(`)7P`4K]P=@F`,3D`1>T`,Y8`%X8`-:($0GT0<EL%A$
M,`(B4`,0D`I-4`%84`%AH`-,D#!)(`!&(``MX@0TX`!UH`QQX`:T,CP#@`%:
MP`9C,`D_8#J560=G$`*,F9=U(`,C\`29$@([U0-",!1/@%5U8`A/Z`41P)5E
M(P9K``=H$`9R$#8%5)1QD$XOX#'PT"82PC=T<`9DR#\U0`.:-P?^UCD;,%D:
MP0-ET"C>,Q<9T%AVTH*'`%4/J09RH`-I\`9FD`-H`&A(,"EKH!IQ`*2C=@-M
MT"`&E3]>$`UMD`5H$`>KA`OZ0P;%JCV'0`8OT`8[%`7@%@<=<_]6=0`_CF5)
M;K`&<6`Z98,$MF$&6>`:3T!M3^!8T0-9'F,%,Q`&8K`*(W`!7;`"6U"F-H%7
M<5">"/!`&J`"27``**$%Y=D3"=`#8[`1)H:01Y4%/1`#%",`:S`!9"E!`L`!
M,L`3-E$$$2`!,E=<2A0$I(4#"X`#,:`##3`$'!`"6*$"1\`$4.`!+9`!6F`!
M%,``.G!E.N"5?%`!'S``&E`!%X`#2^<!!B!>/J`'2A`9.;``3!`$.B`%,X`!
M7'0!2Z"-_L:";E`$3\`&0&H%%Q`"T2<';^"D#9"K<Y`%$.`&GR$&+=4%.-L%
M%6`%=V.)'&``31`#/8`$,4!RHT8J>0#_!0KG=";Q`BT@LRC!!RVP!G(``0K0
M`EIP8V!@!C\`!FN@!5#0`G.@?6]``A"`!+=P`;HU!\'*!B.B,'!P`EQ`!PH`
M`(LV!F^`!2R0'W>6!6(P%%K`!5W`N!#U!I40!SH`!V_3`Q+0!*3REDFP!@IP
M8TCPF]=@!FJD!0-Q(%6P4SR@`!/G!'4@!V!P"W.``&Q0!#)0EU_`2CV$5UF`
M"R"Q"M9D&EC0.F@@`U$@,G73`@-P`CQ0KO6`!#D@`!1@E&MP!0-G!CT@`S7@
M`#7`#%7@!?E1!9S#`KG:46-P!BR0!'$P/P)B'H?`!1NP!LNS"'S2#1)B&ZX3
M"6XR!UU0"7NE_P:S20</$`*<UP9$T#9T8`1P\`41)P"94Y`R$']8("!D,`<<
M(`"1>!.8=0ARD`*@A0,.0`0&(*<FH05ZW!-],`$*P``KL)XV,0*D.2!@H`5B
MP``@NP1P@#\]<&48<!-1H`,FP`%!X`$6X`,)$`%\0`1'D`%]H`$7D`$$,`,+
M<`(?,`+DH@<)(`1T"S&`02X!D`(9\`=1L`$M@&4,,`.VNP#3X0`YD`(0@+8E
M0`0E$``*``(ND`.]7`(SH"[P<`).4`,\8#24%@<"P`63%0=14&V-.X57<!P_
MT`,/8`4MH@9KD`%90``<8`6XX`4*<``&@`(&$*$HX0$5]`,!X`7C@?\&0V`2
M?.``''`3=I`!.3!15="J</"<6R``<<`A&(@+X>20#S1I:P`F;,`#M0<2'.`$
M9*`#3E`0(?!\7@`'%JV<KH`/I+J3:7"^6)`C7"`4':$*^),#P90$!"`!D+"Z
M(<!\;-`P:Z#&8O!06'`!!-`%)N<&OTH&`F`%9[!M,=`&6V`$9O`$0]P&8<8W
MR?(&%RT)/;4#9,`#D9$T9O`&%>`Z:6`_E>@%1'`&8N`$;/`$1'"\<Q`'J1D&
M2?`%JJ$]5S`&Y:K$]M`A97/5PFH&]',&%00`3E"09Z4:?C""[D0&3F`&'"![
M;3`&1O""`$`_1#`&E2`:8L`#AG`(%V$&1D'_)&=@0&_P2VIPG."P`9)@`ST1
M`/@#$F6*!RG@!4I[$H(\&R(0!FB`!4N@R"A1`I60!EM@!@:E%W<F!S1@&EVP
M`>QB$Q`@`S/``@]P!&L`!7'[!T2P`BJ0`6XX`Q[0`0O@`@-``QX@`1@@`UHP
M3QTI+#4P`%=``2&0<[[!!_+"`2>@``]P`D<0`#V@`BHP`!0@`AP`!!B@`EZ0
M`0+@`+O,:A)0!&WP-9QZ!5\@/Y2L`R%`.5APU#?P;F9``1?S!#4`!O*@`SWP
M!&*0!AN!`K^*!$A@;3#V<V[R`S\S`V90!;W\!WE0`P4P'.<X:CS0`PK0!DMV
M!+7F`&)0`D@0(PJ`_T-+P*PG<`9>4`)@(``"P"/Z(T`,M@8B@-=<\`!`RP,F
M8'H2,G!UM<-S4`.V06Z;^`09L`$`D+&^8P9FD):,X$)-,()I(`'(QC=D``=S
M@`:6!`OFQC=MPSCWD`8A$-+AT`9C7@=NL-).%P8?+`W+8">380%10-E5H`8.
M\`170,D9Z08[V$@6@P5RT`-^Z0=LD$!98*P,=7`$^!P]5`<"10?F<U9GQ0[4
M:^RDTRI;,`UG(+I%Z28Z0`WR)"-^@`:0$!"Q;8!/\-0!%6EH0$D*X`<*X`64
MD`0;4([]V1//>@@5\`=[\`&@Q00C@!)!T`3ROMM)P(IKT.,V80=6``;&TO\$
M9V`&T^@)`!`!6]`%`G"@-V$"#!"A+)`64B`$>'``+I`')^D"+W!W&7`$/?,!
M,U!U)2`"'W`#(C`"""`#.B`#-'`$$8`#*F``#?!$2#`#+6`!=K<&)8`"$B`"
MN2D`PLT`+T"K,R!')N`!3!``5`0`)F`%%4`'*RT`=#`[1K`$)P``H9CBIAI;
M;2`G13`!<BQN6?!W3H`&;A`%.:`!"S`"!"`$-\$'8/CN>)`'?YSO%*``0O,'
M(-`F8U`-'.`%%0``./4$7<`"9,`S+&50?EX%+=`$RW,=+/`&29`?AH(&`D`&
M;9T$#_`&`U=P94,!:R(!<^":3S`1.=`"#F`9`&#_N$?X`#72["S0AO9R"#)@
M4+@P(<LCAS@+46S`!M-G?^CS!$6P!'3]`-)I!ET`)"W_`'E68"U``=*P!2"`
M"XT"!K.@^9>]5ECP`!1`O1G!!5?`'.U)6=+N!'Y0EFXR.)WN!T2[!00``=WP
M!$[@*&PU3%70)HVB[!L#"$]^=8)^AH=/5FTH;P!^1A)K?F):0C%Q3U\U'0,[
M`"$O6GYG<&=G=%T.%3$I?ZZOK@5BAA5_!W!D%U%9+J\2'K#!'7`2!W(!P:X)
M=$@5;6UQ`#497W!M96T\$2>]P0U$!AL-'`4T'E=,-$T\(Q\V+@M'*!901Q]9
M"P0H.34-3A`U?%AI8:6`_P`Q%;;8N2.C")\"/3A$($*%2H0#&JJ,D)'#Q8@1
M3#[X&#%%"Y$13?SP>$&GS1PT`.K,`:`AA*`U;^9@R>*'S)DG9024F74&6A@Q
M;P81D2/'#QT`%'1(2#;+3P4]8=@TB3+`50\"R<(R<4#!3Y6!8NHP*%/FAI\O
M^QJ@`-/@0XX<9C+4`&&DSALR<V*$T?$&3IP'3=2L`=!&BPP!H[I46",!SI,Y
M6^+X27,FA!PT3]J$X1+&21HW<;S$B08`QIHS=<YXN=!43AE#3Y!<&61(M0A#
M88H\`:`&.)HK75IL26G(C!I!T2;!"=/$30;<5\[HP++$")U#2[K,FM-$S(TV
M,/_JQ)80YHR?$"V(/'$28\X3,WX`Q"!"H\T3.&PX$H<%651UAF)P'!+&`X<8
MTD8/?LQQ!0!L/!%'#TX@0@0<V94BR'!-Q4;'&6^D,08;=;SGA19B//%$%"&L
M$48/7CC!`PPXA/5'!)KYL<$??;R`11,#A+"'*SA8<8".KHSP8%<Z2F!($2?$
M882#<\Q!``\@>.%%6#!4L(`//P0!`P(7?*&#`D9@(,,(#PPQP`1*)##"``[X
M8($/04A0Q00%##``!$U<@($9$F``A0PX'&!``1RT8($".41``00/*)%&``ZT
M,`8?::1P00@U$'$$`PSTL$48<>0P!P]D$"&#(F]4P07_`&^$T$4#_UTA"0$/
M\"#!%V(T@`4`7+2A1A5:S-$"&GX4<<8*!/2@Q1_=9&0(`WW$!X`7*=@!0A5,
M,)E,'@:,04<(9(1PA0(5`""?%V/T$`8A%8`Q1QBWS5&!&DZH`4`770#`@A<"
MO(&?#"TP_$0.%41@AA(]$/=`&V=DD08+D]!W1@5-E%'%%TAHT847@Z1AQ1A^
MG)#@&6YX<8487IA111M^F$&'!LT^$<8:I5CQQ!):5%''%SPX0,0A4=011Q<*
M$.&%%6F`X0<<+&B10VQ(H$(&%F[X\4;``%0111IT&'$&`#+4L9@32/2P@A!@
M7!G&&'#\((83UCA`2!IJH&V&_XM>U*$&'&:<0893S;41!6Z&&&%U'?A5L40=
M;23A1VI^L>''&IFCL?@A;)P!N!]N$"<&$E^<<4,(_JTA'@!BQ"%)&5B,4$$K
MR7QPFR$_NI("&&@$CX<#$9B+@PI60#&"CBG$D-]E/8QAA@PZG(!&#Q!LD48/
M86G`PP03,+$`$QK(P$0&$V!@P004>#"##W^$T($+`1CP`0M\[*!"!A'P@!(D
M(`,>",`'/`@!!#*P!0,0@`D*T(`23#`$$=3`!5R@P0D@P(<DS&`".M""!2A0
M@08TX0@YR!0+)B"&-LA`2@!(P@"8(8,M/"`-/'""&4)`!$,Y90(`6((5XC"&
M#"3A!/^N"X$$I*(IT8B!"0Q(PP["X`$[2*!'3CC"'U#`@"YX``)IH(*Y=(0"
M(X3`#PX@0`38X(4JP"$$%ZA!&_`S!PZ@`0+2NX(,PM"%,<S!,DAH@1_4$(4J
M`,!?8<#"&]A`!*-YH0QS6((&RJ(&&<C`#VC0`A=:H`8'O$$-+G&`@#[A!D*`
MYA`QD%D/%KFL.*@L!G3@`@$`<(('`$`VJ+,"%EH@AB^@*&=HR.1P('!&-YAA
M#EPP@QC.<(4LS$%S!XG-"<2P!AZP(`1G8`$%4D,`"3"G#G"P@BA25`<ZB&(^
M;SB!&[J0ABIX`0T\`$`<!-!.+*3A"4MS1&\LTZ`YI(@(7)#_@V:\``!%A*!T
M/"A#-5AVA@R-P@\M*"<6_!`&-[SA!Q!R@@)<B`8O/*$+;E@#&;PPAQMP(0UK
MT-$"FN`>-+["#BYH00GPH`(-$&%)3((`*%V0TK#X0`8?Y0P;>M"$$.C@"91!
M@P+8((:P9*`%*G"!!U00A`1`00H,P(()"L`'%J#`!3ZP@0I\P`)%96`$$_#`
M`XBP`0X,``PM8(`#^'"%`JB`!1MH:@X$4`$HH.`/=DA`!$Q``RAPX(Q?<``$
M5-`#'M3@"4%0P0ZN0`0B**`)3Z#`">YSA0EPX3]P`,!BXM`&H:4!`$\XPQ?B
M`(8#[9$,5C@#$C`@`32<``2%+(-@_\:@@@$TX0T;6%\8YF"%5_C``R=P0@O&
MR*0$3*`*<R!"#RQ@`#J,X`<WBP,!Q)"!#+#H7PV@A!,J4`<O/<`,=4B"`;(0
MASIH`0QM(`,`W""E@<!!D'(XU@L80(<8+.$$/#@#%SC`!AXD00&B,,434L0%
M"8!A:7[X*'K/4+HS^H$(3MA!BAH4AO;$H`J@F0,8E*`&4T0!`Z/P0OH`8($3
M+`&Y;F@"LM2PA<@<4@9G6`,'E+"Z,$RD:7YH`Q8R8((GU*`'8'#+*:Z`!#0D
MR!`2L.D;()P?"8@!)C+@PHC$X#F9*,$/$K""YS!)`2^P($5PH$,:,H+:/XE!
M#?@)`^K<$/^".N@3-@`(@]4,\4<-Z$<#0%E"!*[0!`ZT(04TX`&3\"`!1S@@
M&0$8`0^6P%P45"$)!7`#DSBP!AIHP0OV$K)[T,"`-FSH!F%Y@0,^`(4M-,`&
M#BA`&IC0UPYXX`@0P$$`!-"%'+R`#R'X4@$@H`<^\&`54S!"%E9@@P50`0P@
M6`D"%"``%BC@!AS0PA=FH(,59"!1/,@`!\!0!`$8H`4&6($%,E``("3A!RR(
M@QIVH`8YC\$*5RC=!.8`.QYLH50CT``;U$"C'@Q``#4(@P!HB04UH`QF1&@!
M"7F`A81>3`$9\(`&DE,#]HCA!=U@KKFHH`4`T($`;G@"4N3@AE+_)@L`>SZD
MB*5D96M@X`46Z`$1EK""&\2A!FTC0@C$8`0L(`%U`'@C9\KPDPB/X5\I3VU^
M(MR$&+0!`&;X'1U<C81H>&%T/1`-RQ!1`2M,HNE<D)X66K`$(KB!#ICX0H2_
M$^$P6&$%3TC#',P0MC'<TG-GD,#1WU`'IEJ!!_DQ@^VN8`1!I.$]F\&"$UID
MX2=L3Y^&.`4=PH"Q)XSA#'+._"C$H,\8L.PIET19A!-T!1?X00MG)$H;ZK"%
M'A1'`0[H@02N<R(M/*$*3G`1"!Q.A`<\`0<"R$`/KF`N.QQ!SPY(P0+VQP-"
M%T$%S/6`"387!":5I04/^,`51(`""72!_PY/R,,#T&"`1R?C`1?(PQ$.8(<&
M!&&Q0PC"$!;`AP-```(-,`,8X`$)H`=H90%]$`%Y4``5\`$K\`%\``5_H`<\
MH`<D(`!#T`<FH`,(@`-3H`<J@``GT``%<`$B<`01P00=X`0!,``*P`%]T`4O
M(`X%H`%-``86\`4@`'NCT`08\!H$$`4W(`)P0QIRH'A>L@8.\`0VY`8T4$[N
MY`";X08=8`9OT`(AX`1?(P9)@!Q(0`,)0`(1\#Z\(W+,-7W1T`(<8`8.T`8%
MT`1<0`+ED01MX`02D$,DX`9!@'58,`'*Q`4]<!D%P'=[]!UKL`0C`AIH``;Q
M]`9Q0`9.]@07\/\$3U%X50`V-18&V!0&\E1X!J`%1>`'34`%?B`'F\4"#G`:
M7"`*15`&!+`T/I,$%?`&96!V9S`+:<!E3E`%+2"%EC$!/U!]9L`"$E`!SE$'
M7?`$7N`N3:!]%$(&5<``7"`)1K`&:P`&Z)<BI9,$K54'59`K`.``7<`@8.8'
M6;`TB+<;9J$&8M`%DH!:A]`8A@`':%8&%$!Z%'5(R!(''84%9S`'[B$'2/![
MBR,&;H`&+85^$2`!CU<#^V((7T``%,4&6C`0S)4"(T!=-3`!!@`%R,!<=C``
M5B4"':8C?"`&88`$5=`$DG,%<``:8#`$13`'(.`$80$"`H`!7L4"3(#_`!V@
M:T'`!!Q0`3(`!BGP`Q,@``2P`GPP`E'``1_``%_$`T'@/`-0`$<0`3)@`2'P
M`",`!#[0``\P`#)P!!5@`<:F`A<P`:Q@`C>P!`V``0]0`36`@@(P227$'PVP
M!G1`A&#V#!'F!C$@B07`!74P::*04&)`!F`@6CWQ!#_P#&5!!VN0!4XP!KHB
M`1'P`UH0=C2P`:E`!7Q@AJ3I"GB``UA0-#J@`DA5!6KP`$;@!0RP`FXH`$7@
M!43)`%FP>7)`!QD``6<`7?J$&F'P!,4!>:;0!ERP-&XW!U^0!&(0`W+`!DA0
M!TA`!C`T"@V@!E\P!EB`,V!@!AOR&C-"!H,3_V2S4`9:4!QK4`-L4$HO4`5=
M$&%UA@8"\Q1%L`66!P`#T`5O(`9FX!\IV05U<`4\(&1LX!\50@-9($]KL!I:
MX`17UP1$$'HR<`%NT```X$=SL!EO4#AID#B8,`H!Q09I\`5<H`9:<`-U0`'5
M>`A.XP<%8PAEHSIKX`5O\'9^,`9-<09Q4!44U0B'4!1G<`(3%4_FYWE;P`)F
M0`$I!P!RP$.49H8+49I`DA5O\``'L``ZT@<UX`9U8WLL\``]4`$2X`8CP(1@
M<"W)P&DXT``:P`%_X`$A4``E\!`<<`$1``%)T``$<`1',`$Y\`5>T`<<P`1\
M@`8S<`%X,``SP`0H$/\$6,`'+7`",G`"#I`#/P"5$:`$7&`'0"``-!`!&A"4
M*5`#P$8!+\`P#6`!,)`#.]`&3,`#*)`!=4!`:#`'/1`#-,8&"2)?%D`&&[`?
MD_`$T$@'9"`':]!,_TD&#""*1O`]8T`$8'`"7Y`;,>`612`!2^`&9QER5CI&
M'\`!R8@S^.0&1)"@;``!11"(5B`&$#('<J`$LX<$5U<'$=4#*=(#5?`#D!$:
M9S0'H":DI4@'(Y)G5F`!AA`;7!`AGP,;^18V?L`&[UH'%Z`%9I!T+R!C9^H'
M/2``82,"2/!O:&!EMP$`&%!B"70&C7F+:-`&7V`&)\`&9:$97:`!,Y%CVM/_
M`D?8!EE0!`!`!@X0B@"P!8Z@`R`V"%^`!6R0HH8`=V9`+W40!J+`9V(@`PYG
M!FA`!*0583G``'(F6F>0`6X`D(:@GOGQ>'+@(@\0>@O+&TX!!O(5&V<0H.QT
M((*D.6UT,U6#!$DP>07P)>%*FC!%`3(007<`/54`!AD```\@!F`@CCH0`@*P
M`US``E^@!F%1`C20(W\P%14@`$S@`3B@`2>`45TP`QV`!!K`!Q;0`5?0``J`
M`C]@`5MP!#.0``W@`'O@6ROP!SAP`2E0`2Y0`%-5:%)@``/0`0\0/W]P!UE@
MO"@P&4:P`F#0/J>:`3R0`PZ``Q7`!7'@!"G@``(0_P$&T`4<\!TIH6<\D8M,
M0`1D8)DK5`0#L#A&P`4E,`A78`6"YP4&(`.S(`:(1U$Y\$ZW4@$3,+@BUP<G
M0`'N00J),%'6N3US0`=O!P,,DR(ZH`,4T`,G2@9),`8M$`<Y>EH4ZS0RH!EK
M0`BGX`=N`0=@4&*'L$RH)0=OH#@4-J1K,`97P%IID`98H`-D4!;*VEHQL`9$
M4&.H%0(84`<-H&T7`(DP8R$O$`=6\`"`804]\!TPXP6FH!)8('=J<`,9$@=4
MVQX:@#,-4@<Q\!4*$`8Q$!O+2@=*\&E/P`%RQI<AD&AOL01^D`19T%(-\A\1
M5@<:$'IC-@=E@0AK\`0Q,/^?`E`'3?`=U%2W;;`#AH`$91$&&O`=BX/$8,8"
MGS>%]J'`5GH`D$$!.J('HF`$-ND$6N`&I(=U!"89:1`6*7`"!6``=O`!5/`!
M1W`!?\!M`=`""<`!+Y`$1Y`!(2`%QS(!%@`",@`%JXFJ<``%#G`#.]@!54`$
M0V``-V`#CAH`%C`##1``,V``'F`!!X`%4.`!/>`#2H`"@L('(N$!$3`#']`"
M$?`&0=`$89`!E)@$23=[5]`#TF((;F`*IO,@`IP=+<,%(6`9/M"P3Z`#)>``
M+]`##^"5&B4&)T`#%U",%A!Q;P`EIFPN`2`%AV`&*QP#\68X2Q0!8@,`$<`$
M.+/_K%<';8,P`5KP6!?]!24T*FYQ`13@!*7Q%GZ@!&X0`6BPT$\P`0X`*Q'0
M#!`087[``C1`R&=`!%?``&B0`!!B"/(F'RE0>`TR!C66>1<0A_#%!9-C!A#P
M!F#0!3S@7D4A=VZ@K!>0((LQ!KD1!P`)`3IS"%[0!A*@!1A`!(_W!A#PLC<3
M`ZA5H([PQ:$'&F>`!2K'$Y^F((<``%FP&T<S`"?0(&Z@!@+0!B@R>Z,S"&10
M!CKP'40P"W7P60@@`6\`(7$@`U?@!3\`-VXP!&.@`TV5TF-D!WM@`.W4`#B5
M#'HP4=-A`+&!`@;PP"!0E0&0!&%1`2?``!70`C@P`U"0_P$@TP16X`!`H`$V
M$`(\<`0&D`('[0%,4``@,`)V$`0!X`0X``%_P`0AH`6_0`(HX`9K\@$#@`,/
MH`(.L+MVP#TX8`$.H`(",`$,0``#@`0F\`<E(&X=@`%^R@%N8`0!D`4O0+5*
M$`*&I`6G(`!.$#85DQU$`#I$4`=+LTITH!JH\X^D`0!7`,<\``8HSB%AX'9-
M`0<,$`$90*$N,)K,Y3X!T`=F>`<>,`#XD1\,``9A(P$20`:"U`!)0`#*"0?T
M6@9.T`,M,#BVVP`119&*I`9$T`6&@=5:0`?@9)V$MT@8X](Y$[0H(@I")P81
M$`8M\`1NP`*7D'EH0`!OT`5KT_\%,>`$9_``9_"N3^8'7M`"[6'#%#68;_!A
M!+K5?G#HTYC):UL$8D`'!?`$&:`$DD`0@R`3I9`#0[YZ%A(B;CL*,-"P+?4[
M=C9U+@*CA]`%_C0*9S8*#"`!Q5'E[B6%#>('"D`&72!G,S$(1@,:H1AA%%`V
M!EDX2=`$"C"EQLTD>L`&I!5!&J`C.-`"`.!O:<`%2L"6E74&!;`&+UL#R7`$
M3O`%!N#>+M`$KC`#'C`$*)#.`X`!^UZ\!Q`!P%P!Y-``%$`!`P`#/U!"NCP`
M.9!N0X`!.<`!`G!7=\`'&'`'&>`1=P#,/V`'&2``+Q`!+``!42"ZZ`P$0K#2
M=`)R%:7_YFB0!DI`(I'4'D=``UY02G'0S4\``@X0G#QN!C',`-BT*F`@`&>P
M!25G`OY17BS,`Y)@G+P(`!Q@`5HT1BBG!F,@`A\`S&(T1D/0!"U`[K-7`W#&
M#N6['VGP`;EA!77@`?C+!2@PF'/07MX3-L7QZ_DARW``!PIP(`E:P>;:"%U6
M.YL1(740?!+0&8,@"GD6!QL@<U9`[V-0!PO=!60P'*:@!%5P(-_Q!6&P!$A0
MC(SA$EX`YS6P&JRR!FQP+V:<!3+0!G10P74@!@)9`3O@+K&?!DD02R.+"2;`
MWHXPM7[06@ERJV:@+H-T"&9\"%IP&Q+`5*F9PH8`7RU0!4KT_QVB@003U6&K
MKP4K'`=GX`!J!@<$@`54J_N%8P@7$`9P$`,ON0:H'^[-!P@N+A@U-SM_B(F)
M#P\L.BLU+6XA!69I%4IQ,B&*B2X`0A:(+@M0`0(705,0,0D@%18O"!(M!4($
M%B@>%@$'(T<0`BU$%'],`CD1$1@#$7\_'`8+'!H4!G]`%SHG8"X021U!&7M(
M.@HI!0('$2U9?E4R+W%57BT`:CQ66#H;870`2IZXP5+%#QDQ;]9T>9.D2ATW
M=/RT@;"%39:"`)QH$=-B3)8V,M;L$'#EBH`N50;LZ=0)2H,V?IZH43.#RP"6
MG>[H*0+`CT\U8=*$T.(GB@`Q/01XB?^X9L27&1<X)(FA!4D3-V3F]'`2$4R2
M*W.R`)@3QH,9,&FT&&G#P\T8(FO"&*D#)XP?"V.>^#FC8XT?.G/H$/&31<?0
M,&S\B.'1PXM/GVW<``@A1DX--36ZA%`3XXN8&#QBO&E#0(P0-2P4J,&B1HR:
MGG[J`'@#H`H=NVS@^'DC00D7.7%"Z(W1Y4P=,F%V].AY?(Q/)SX;PXE1YTK/
M-FK@Z!7C!DX="<?3H"$:FX>8+7/>?(DRIP81(BUB/I%#?@X6LDF>/#&C_XF#
M+#QPX<=&<<1Q!A@\M("%%C@UZ."#$"HR@!H,>>'&``^(D<,';&!A@!!?T%`%
M3A$H(<(*?]S_,8`/0?QAAP\HW($`!7<8@`,>#.R0`0<%R""``09T<((2!"@`
M000-J("`!RFDX`,&>+3A0A,*_+%!#CT``<,(+DP`0A426,#$'SJ,$&,`"D`Q
M!1`C'##!%T=D8``$;>CP`Q9^>&'%&U>P00$=0\4&01E$U!&&;@\!H(,?:Y#1
M0P6#U=%$'!3P,$`8;_@QAQ8J*!0&&"&`04$+/)S!@0`$>"!`%7O<\>`08OA4
MQP(OJ!#A'RY$@*<;%5S01ADCB+'&0&]H$=$9-0!P019Q`&#$$E7L,()V?L@0
M:QU:;&!#&U7$\1<`$H0`D1=S'/0$&6@\H<!C?EQA10PRG"&!8FW,_]9&'13$
MUD0;:;!11QUII'&;'VQT@:<1/2VAPQQF#.`'%U\\40$/3\C``QQGA)`%!#Q$
M]&\=/R2Q!!T=,*!I1#QD50<'<)R`!AA^2-!3%VY(0,85BKD31Q=[_4N`3TN(
M80429V#@1!L&L,'`8#C+RN[3:OBD5PV/B1%1&6;X`<#6S(6!1'JZ^1&&"'Z@
M8<43-/A1EQ\]]`#&&5O<*O?<.#6@P]9I#/`!!6I8H,4;;OP!0@\?Z(!3%QDD
MXJH4'GB01PTN>G!$`3?4D#@$"M3@P0<33.``#T`L\$$$"6AA109\V$"'!ADP
M8,<,:("0P00'<,%#`DP(<4<(+9Q@00@!3/\Q@0L<O#!##V'D<,<(/9@P`A%9
MS&"!#&V$X4`/<Q00!W1/Z%#`'&W4T,03$G"W5P@.[)#V&0"X,8<:(9`!0`9$
M/)'$&X-Y$<8`=#P01]\0```1"#``'+#``D3@0TT,@(<'.6PO1#@`'^:6`"G\
MY00":(`5[#`%#`3!#TU80Q4,X),88*`)!-!3!\X`AP=D:@UT^,*_MG:&)WB+
M:G-0P`#,8``!Z>`&GPJ!500@@S`\``Y7``\,O7`"-H3O!E;P@QN&$(8DQ.$-
M7N`!%A;C!B]$`0U=:(,<SN"&.O3@#`-X0AW*P+`GM*`N`]!-$KK0@`G4@6=^
MR($5EA`',`"`#FS_>,,;*O`$-%Q!/V+KR=VT=H;=P"8V`V,!SF!#A#>DH0Y^
MB(,<$*F7IWGR,>1!)`'J@(4PI"V3WA(((A]3!1[`)),_.4/4`%"@V'2A!X.B
MFRX380?.!0`'#<+`$[QPAOO`P0G_J@`9T%>'-M"!02SA@@<2880#]($/%`B!
M!V9@!P$`X0,N8@8$""`$*#@@".CT@`&T$(`9V.P7)'`!%";@`R;,8`@3D(`-
M=F`#'XS`#BUXP`@\X(,I0($/#7!`!581`A,\`0,(X(,'"J`$`X1`!E:PF!\N
M<`8"I.$"&R4F%Z[@A2<0@0L`"&,8VM`&+*0!`&L`PQIB$(,``H"F3<A+_PO$
MH!<TU$&04F.-'ZQP-R3"P0PO6&D(<L`!/33H`!)X`A<<4(8U3%-N=BA`%#0U
M!R\@06USD,,7M-"`)HBA""68GQBZ((8R^,$`#O!#"\J@!@'T0`>Q4DS4WH"@
M+%R@#DYX*?LP68<3(`$`46R#!**0@SJ`80ZQ"@'!_B&'.K2@"WJI0R.U(`"M
MQ223/:D"%,K0AC6LH084\%H/RI"".7F!EEUH@@QZXA<_\."E;HB!;:WFDQ!X
MX3Y^2$,6TA"3GSV&#GII9!K.X`4BZ(`,,+F!1,CC26^%C5UV\4D86$`RJ?E$
M#&)XI1I""`#BJDT,39!B&%SSAAA4X"]P0,,6_/_`@1'\A0[>N8`!GK#+79(@
M4P800(,LL`4OQ&`*%XB`#MJPA`[480M*6@(.6H`3+4QS"@MP`1\FF``._,$"
M$;"`"Y3``2#\@0\5^,`!/@`!#F3``RLPP`C,T(&HB&`$(N9`!#@0`@SX@``N
M;H(=E@H!,A1`"R\0`!,J4``HF&$"%F``!ZR``R-6(`)04`()?E`#`ZR`"EKC
M`@%Z\`7P2>`$`)`#'-Y0D#5HX2U7B(L:YC``+KBA!V?;0`]X0($*M$$,:!!#
M`]C`!B*84@MV\0(;KC"&+]Q4`1)H`!_3@84'2`&8.-E#%[2P!SXH8;R)DUN'
M!<`&,;`!4EKH00;,@`3_&8"A"0"B,0-*(`8BC&`-36"!3RA`@2MDX#%U;<('
MD"`&R1J*#!<@RQ;>``<M/$"R,M""%@RC%SK8IM!AZ,*FUV`%-Y3!,6+33=3\
MX-8>2`0[9FA"&,[0`"UT(2VT"<H5*E6'`2#A"F<H0QF>D`$)A`$"1&GU%033
M`PGL8`DA@.(?V3`6G]`A(EYPJT^\((,8S.$,"@"`%B0P!IF%H:9B(RX:&C`8
M4"8F#`"C0QO(\TS$^&0C7?`.`%C(-0$:H6E54,`60C`"V!``"W0@@P/@1H8!
ME*&_NB0`U8X`39;,X`EO+L`(PI*&)"3!#UW`0!4R,((B5/@$?RB``6;P!Q0D
M_V`*"@A"`$3P`2AT`0858,(%=L`"!DQN"@X00!X`D(`'\.`#11#`"#B08@6@
M``8#.`$'2$"$(F"@!"-XP0YN,+L[!*,`!2```T0``ILE@04M@,+L*B`!`8!`
M"3H`@0R=4`,'P!`)2%!#!DYP@3(D1@S!44,;0E"&&JP4"6U`0Q2Z8(4XK"$-
M;C!#%2)6!4+[(017$`/#>F`&'=!Q#E`(@08J@+,!9,`+>'#!$@[0(`U4Z0]]
MR$`2VM`"`SCU5B@H@1:>0!4XT&$"&+AK3W9@!#_,@`XKX%+U0@>?,0>-4@7Y
M\A<0T`,L$`'UP@-YD@5HD`7U$P<]P`8R@`7.(32FY?\&WS48<``'FQ`"D.4$
M73`37W`@+,4%:#`9<[!56]`&7$`&<G!U7(`4)RA31-`$50`&F5(#$"`!;``&
M8``H:D`')[`&K49Q[Y$844`5=!`'4?`$;!`1>.(39Q`'<Z`IM>436^!&C00`
M87`T8>`8I>43:_!(?F`&6_@$[5,OZ0$&;*`%E:`8EK2&4<0#QA(1='`&$>$3
M:#`'3V`U@*07&D`N1#!S8<!'2$<W$T`Q5G!5+($#11`U:5`<29`O=,`%8=`#
M#V`&<X@3+"!@=L`##F`'=X`".>`#'C``!2`&*&`'"R@!')`"4/`!!E``4L``
MUE`#2%(`"F`'-"`"<3<%)S#_`2/P!RH```30`#H4>@M`!!UP!"[P!P3@`Q!0
M`DP``EJ0`0TP!P:@`4C0`@IP!3*0`TGP-S-0`#20*3!@`K!1!SM3%W.&!KNF
M!5NS4E(3-DG@@<FW!610!1K`;7^!17X@!U$@AE_P%V*P/P#`'RS@=RT@`S+P
M`!0@`T=P*WHP`6E(`.0G-P%0!6L0`F\P`5HP`"%@!:^V9DAP*#+@!FHP'S74
M!LW"`2(P(6,@!CHPB!W@5G^#!!0@!E6P`ESP`/H16%R0&/ZRA2T02(GH$[!G
M*%?T5V[0`D4@`Z76`S)`(3$@`6O``5NH!1S@``Z@`XU4`0)0*C/G!SOP`.RS
MA4\3_X(#H@:XQBX-4`,Z@`%ST`!RX$H^\4&:0@%D\!AGT$C;$8:/\01GD"$&
M035YP@59PR<R4`9B(`%<D`%1`!UDT5P[$"MH$`(0X`=$Z!.9HBG\HALZ,`9E
M1#!H$`8W"%-/4`5OU$?K90>-""%WD`*2@P.2XP,-8@!DT$AF0`55T"UR,`-B
MH`6I,8I-IP@R0'X?H`)V(`+PL0P[T`(D<`0],`$L,``<<`(T4`!.<@5VL`4Q
M4")5\`$K,`$X,`(\H"HKD`--(``"$`$:<`<2(`57T`4&\``KX`030`0;X@.X
M:`$M@`(^(`$5X`(R4`$&H``Z4`5"-CU2<&,:X`=?L`%(X/\&)]"@5J`".C`/
M@^DH,`$''+"??C`"3N`$+P``:8-R$I`/(5`'WF@&:.``:!`!6D`&:<`??U,Q
M:.")&M``:Q`!!``&,"(%`B8W>X!F:U"-=",`7?4=85``?I`!`]``;Y`";H`$
M-[`$6A`$*%`/17`!6F`&)J`&!6$%/:`!`%`2`5`&C0%=^V(&BO4.`R(V9A!M
M:)`O7^!6%_D8;="=>T$`KIE)7^5(;!`&;"B:<1`&8:`%W@(!3P`'='0%/^4&
M82`#77`%#2![08`=`/`!!;%1==``6;,;(B0'>Z$=<4``C_0$$3%SSB0V?K`!
M44,$7:`];X`$>F$&RQ$UAI(8G_3_227'*&K02)HU<=Y!`&<0!@]I!0@Q<YKD
M%VZ05RA'!QP@`0IP!@UTFPX"`T[0`S&@`Q)`BPTR+[X%4]0CAK0Q!@KP!$;*
M!3B!!8G#!TYP!Q$P=@.0!SO@`Q,P`#QP`07``0``!29@`"(F`56@`P(P`%*@
M4!@`C`4W`S#0`D'`!RWP`6<0`05`EAE0`S^@!5Y0`Q40!WO@`EN@!`UP!Q?0
M`$-P`CY0`0Z0`R^0`&&@`0+0!`Y@`#$0!44`!75@!"W0!FQP/T0PAV%`!-)Z
M!F^@!EGS-UC@+5BD!L7'`W$1!SN@&W_&!C%@!G[A+S%``0[`!@*P`4H@``4`
M!FY03#[1_RU)8+*5^:VWD@?X:`82$`0),#<<P`!Q0'%:0`2&Y`1G4`2R*@/X
M1@?F"@!.-(?L<09K,`9;L&ZW)`;+2@?))D57P`.2DB=U$`5[-`<>6#9A@`7Q
M:A<84`>@&!UX9`;>`@!$0X"8Q)9AH!=7,*-6(`$UH`!ED`1U\%<`P`56``=J
M8#"5`3-I035L$!_C$058T`,AU`1L@`0NE5U.<`5)\0444%NRM*$^P0:W-1>S
MJUGW,%-=*)H`X@=P\0758[FW(7V02@<%4#XS6@=RD`;^\!=MD#5KP#YB\`!A
M<`-U$!*"Z!IJ4Z5/D`?@ZB#;5P$.[,`.X"HL,0(7T*</X`<Q</\"6K!H(>@`
MXSJR.-$"R0@%_Y0`$"`%#9`.75)P5X`!%L`"4!`$/Q`%>D#!1``J%#``":`!
M)V`##3`"#(`$?=`".GH#6#``((`E%6`$$M`#-+`#/"`#?,`$'/`#1(`"&2`,
M$1`$."`!(S``.E`!)4`!1GH$7-`$3A`L85`$Y$(`(3"&:O`>&S!H5Q`#21`7
M`"!]%I($`N``85`#,C`$(.`%&F`&-]`$:=`828L%:X`M2H`<\HA8%2`#<[2&
M(1`#T1(#+2`%.3`W3(<!!M`O28`"B)```1`A$"`'$H`%&A`"&9`:J/$%)<`&
M&*`&/*H%)Z`_81`';<!1(7`!,=4%]BC_-FL`!S`#`"O72.;&JIM$+@-"%E(C
MB.\`N_X0!PT`=!*A3'L6`GUD!9#;$YO!!5\B`>MG!?&1!680`D10`SR`!F:P
M;VZH&UKP!6/0!CUP`01(!%O`!87<!D@`!C6P2NKK!:Q:!M>U!6OP`&R07":5
M5X4IB(T4?-4#E]/;&G4@NEA0!P_@!FD`'6Q`!HZ1!A+P!F5P!4DY&Y@4!UN`
MCVAPA+.K%XE13`42!XG8`VH@P0O,$A\@`0ZP`2=``CMFFRQQ`F:@!30P7W'@
M4E@0!%\@`QKP!B0``?3*$B]0`:B8`9C&`#^@`O7%`ER``BC@`'F0`#N`!SPP
M`R*@"TV0?R=0_P4"`$X"L`,:4Y(\H'Y<%X0:0,%\8`![L`-!8``>8#<8,`$>
M@`(]@`,\8`$/8'DST`(I<`(HH)U=``8#T`-%4`>#`:!10P:DQ08.H%DR@$D,
M\`4\\`;H8MJ">ZV%8B&;Y@!<H``,H`%L`)<1P0(Q,!8#,`8:0`9T,+8$,%L+
MT`4?3005.@+B>2L^,`97H,!\\`!7H`9&((M=X)L0,@-.`#/<EP68)`9+<`.X
M!+4A,`%I$`57AZEM6P%'2`_..@=H0`:#>9!9(0=S8`59$-$H'0;=T4F-@M^S
M+468Q`(=;09;0P8\L$DQV068U`,YJ36S,0<"HA_@PP)G]%5FX-YQD/\#3+M1
MNZ$%XP89="`'/;@;;S"[QK&:?&P7F=))9A`?6\@%F'0&8F`"(L``>86%GO0`
M95!9,9$&;K5HONL'#-`3\Z$)%S`&.D`U+>2&8[$&`F!>C]$3%BA"<U`%;4"W
M.8T3"=`#:%`#%R#4G=#<3BM55J``<7`!L;(&3G`"^]L%.`$+#@`&4&`!=X`'
M5%``#9"+[6D"=7`$^[H'.<``$S`%+H``-<`!/#`$=F`2'W`""8`$Q<D%6H``
M<<`#I(U0+)`$%;```Z`''X".`\`"8XD$$4`"U:`,N=T!*-``'J`$3L`#%:`<
M+#`41/#>/O$>NY'&#*!;5L`%1H`$A*48<8#_2;/^#G3P+R(I$'_H$RW02`NR
M6`8H`2]P`;-1NW-@Y@-@`:86`RG@`+?B#K&8""J``0!P`@90!R\@-R>05TGP
M`H7U?'XHFNFR`P+R,`>".`,0!P*`!4\@,"U0[+4VAF0@`T5`!,7N!S20!!Q0
M0_2'<A+Q!,X*!5&`28`CS$G`0MB16G7`!NGE<*7Y66[X%WZ0`MDF!\?H1&(P
M`R9@%R'``E\@74.`!3S@$'&@`7&@P6SQ-`S@'!(1`T\013UQ28"H&"WH$X%A
M%S4T1H]Q5)X$%YJ2!$"QM18P'##AAK/J$SGP-/L!$?ON$YC*`6L0!6*@`&'0
M`2S@!5Y^Y4Y'!$Z0_P!/T`<X,0%D``<-0`(QT0/!7N0R$`1J,`#RAQ,0P``+
MT``G,`),H`/2@P!!T#A:X``M8`(+,`(4<`0IT``E4`![8`,64`%5X`,F\`$M
M4`,PH`(,P`41H`"<L@#Q!P01D`$I$`%%T`47,`*_M`)'(`(-$`,A0`4I,`$E
M@#H#<`5,D`1IH`$MH`%1(`%>H"$1L`%IF/"U\01:+C9/\#:`X5,2D1MP$`55
M8'\^D<A'R`4PXP<*L`9;6`5:<`9<((-@P`46Z!AE<`95$`(\<%$2D`-1T'H$
M0'P1@@-=!0AX?X.$+F!S?F1,A(R-?PE_$#%^1&<I%%AL(T]?46LU9WY^:O]:
M76`\``!K=7ZA:J)O9@!A9#)P::RB?EZA<F5Q:6%A?G-@;EL";FP%?F).%AQ)
M;%6B)`!^<:Q-8J(]9ST#N6M6.BU/J6IQ8G`6)%4`7C%D;&%//&1^(7YI*P(O
MK:*XD6&5I@P;/V\0K7'3!INH-FV\$8E#AT@7+Q1"C!$%((DN77$`B`%`!\"3
M.6JZU*%CAHZ?.F2>9(/SYF/`-ZR$A3@3BE(8'FQB."#BQ8ZCHTB3-G*0Q@R#
M)WV.3J"C@,BU)";.M"'Z!DN2,%ZN'/72(`(.)CF.3/@PXT0&%RX@U)C@0`>!
M"0=2!(&09P:!"@YR7($`0<.,'C2TD&G1XT29$"#_ADAH,&!,A#LR(.0X82%#
ME`9#@FAPT:2(`1=W7H2H4D)%@Q,?<(1I0&`%G0H0'J"ID:-.G#E$8)A1@O-A
M#S=IQ#S1889`#R\PYGRX<D7.'"ULO-"2XZ=('1E><':M@Z0*'1Y6+B!!(B&&
MC!X[!DRHH,*#TC\HI-EOM`"$CH;$!'`?(RZT,!(7013QA!5Q-(%&&TF<@`H%
M<TC`0Q8RR."'%EN$4$<(+9P10QE8M'$&$5A4H08==7B!11<`M/%$&EC`$0</
M840!`!IUJ,'*'&]<\007<,B`AA8^TG$&'&%P<<4U,K+A!`O7("$4`$B$8<8+
M:WR!A!E^.$&'&&/D`$<3_UE$D08`33BA1AA.;+'.&FT`\$8/'-'AA1QNG&&&
M/EUH0<0:%/C11A5$2'!&'&5D\40N=2CSBBAS/*&+&FOP$(>E?F"!AAD.?/$"
M3FA(4(<8/'VGPT=MA-3*&5>$4D,=9ZBBA182C#`''P/VJI0'T$2@@E&.3."'
M,!R$(``2%QCPP!,]9*#`!150<!01%`3@PP*#N%``?L!BH((#4OPP`@0'#"#`
M$"`ND<,%.B!QQ`X8>(!"!D1`4<(%(PQ1!`HL&,`"`P5(P`0*$K2@@@8L5,&%
M`!9<P,!<(U31Q`CGWB5$!EXP$,0+1D@@@Q-D8'"!'Q2P\$23;:2!1A99<`3&
M&?]?:'$&'5;(L,2:;OBQ@@QRI-*%&3?$(0")=<@A03TWA''&''',3(08:#01
M!ALU6/&%!FE$\8(5!MSW`@`.''4$%S81,0"OO>KA@A=N>#$'%B<4D4$.K<KQ
MP`D8:*&!%P+L\$888H11A1LGU3$&'&<LL88(`-21A55IX)H&`6FH<086;SCA
MQ\H&V--#'=\!``>N9W!Q`@!LN(&%%6U$D(H;5;30!!%-U"$!#5^4L<1S9)7"
M!2L[1%$#!')LE80$:<0!QYX-(2&&56:T448#/;01AAO<R=`%2Z(\SX,15LS1
M0A<P<"H*=U`N<8XH(:3A!P!5H$$&#SW$(0H#,NP@`P#_;AB(5A+1HSDH0'_%
M$07XTL"3+JC`4EP8`P-.L`0?T(%MOLH@(0J@`!0X(0HN0,H$GO`$)TS@"T8X
M71448+T6Q($`2+#"4<#@`P\D(0,E$((':@`%&$0A`@4H``8D4+@&0($#`X@`
M`S)0`P-40`H?*($!!H"#%>B@!T&(0P(B,`$ON*`*!9C!Q?)0@0HLP`D$.(($
M6'"'-""A`E,(@09.DX`BB($%$X"!`P(0`PD((00Z,('"!!"$`@#@"EJH0!(0
M``!!\<!F#.R"'S8`@"[,`0)N:@/CU+`%+Z2@#16H0A4$(`8);&$"&2"!&\(P
M%![<X`T/@$,=E'`&"C0`#AD0_X(`"C`Q!I@K*1X((0_DL`>DY,$"37`#0TA'
M@0-D,`$3``,<6`"&+NB`!F\@P@Y>((8W-.`&(<#"+&YP@1]400O<H`,,1'&&
M,?3$"CMS@!/PI`LM7$`+NN!"$LX0AC:H80E6T((7GC`U+HP``''P'QM,(H>O
M<:!V6FB#&:Q@DA^XH0L9",43REB')E1`#%@0@0QJ,"\)2"L-^#C6&,S`"B-<
M00$DFA\^?$,Z=FX$(*KP`QJ<QZDUH.$'=(##%;1TC3-8*@Z+@P.G9B$*,"@0
M)]?X7!V8Q*GU?"0'?EA"'<"@A:B.H0>!(4(.Q)`'#9I5"F>0&QY9@)0@I&$`
M91C!D?\"%H$:7`$,)<#`5+UPE"3TP`4!N,,"5I``#7#``UFP@`8>\((``&$"
M`5@"$_H00B=0X04MD`$54##!%GB`!Q"@$`$.D``4N(`/4#A!`@R`!SR4(`3\
MFH`%1D"!!3@`#%FPP0`>$(,)#(`'#A#``QJ@!",H($,Z>(%A@T``2PTG#'?J
MP@H<X`8Q:*%0E>+&H^K`(RP(P`\H@(,;UB"`)UR`&KI`PQS0((8E4.`)*F"#
M',0PL[L10`(Y2`+$"L"#(##``3U`R@'<@`$#A,$$][E#:^\0@IHA01`:C,!X
MFV"$-;"A"24TPW]XDH;W^6$-V.`.&`IP!C+P1!<WHT0HWL#_`U%LP`1)B((H
MJJ"AJ#ZA"&IH`7E!/#P(&.$)!HCJCNH@SE0$`PP98.X<`)"&%QC5)%IH0FZ>
M4!,O1.$*;8!`>^/0AIEU2@X9>$(7OGL&\A###7.(QX<]5($YW&`./4B#%=[P
M!3'TH#>LT.^D5L55/U2@#FMBG"YN@`0_P($;2'"#_EK0AE,!H"=2U:@"39(&
M&2@!#?R<A0`P``=(F#6#GC.`#$X@!"=`N!%!J$(#UF`!/^B`!#*8@P/>4(40
MS.$%<3N*`B!0,#T\P@5[.(`&4!"$!+#%!1Q(@0T:`((>9.$/$Z@!'_@0A``L
M8`$/P!<%"/`"'V0@B1#`0!(<(`0]_Y@`L,!600>@T`(6X``+?<#!"V*``0LH
M(`%#D*<,<*`'+NC`!U`(0`+X8`7(9;4"$=C`C$A8!#G$H`85L`)#X!`$)'AO
M#B`6PQ5V8%0EA``.5>!!%0C@"S%P@0OOX(7]JC`&(M"A!VSH00-:(!)O-I$)
M&=!`!9`2`$YLX0)E]94=[%`""&`P@R\@`B*L$($JF*'%-3C!$RA0A3-H00`7
MR`$;,!"0,3CA&G1PP!/`$+$-#,%V.B""']A``3!D(R9AJH-,4@$`DG/@PS$"
MX!HDT`8O>($#%3"#&JA@!3'H``1L<$`<U*Z$)#".`G&XP`E8,09$A"\,<EB#
M1LI`A"K4S/^?-E/#FA"R!GRNG0UGD!\1GM`&*]2A#&D(1A.")M$GN`$`Y34T
M[=)`XX,T^FJZP)%+8I`$+10A%9:ZTSOD\`14<43&#7D!'1(FIAZ$H10OJ`(%
M1L"#8G[:5T'XG0)XP,N@-T(%S=@!+T9@!2M@0))GJ$`#B&"`*AQEEW\8`!0.
M8`<?^$`&+0`Q.#<%'N``1V``+<`!)D``+?``?<`$>.`!`C`"3!`$%1`"&'`#
M6H`6"L`!$9`!#C`"(;AKR%`"3J!S`B``"J`!.;!I6#`!+?@!44!^"*`%$W`!
M!8`%2.8!$H`$UV`$9A`&$O`$:X`+:'`%,G`%/$`'=#`'1:`%:=#_`ZF@!3U0
M!B=`!DC`!F*@!D[@!@YP`C(@!MK!!D2`!MYS!6]P!DD`'MX0!F-`95CP!3O0
M`V-``0/`!!X``9[F""C`$2'``@HP`QE$+-^'`T30!G3@!E?``I6B!72P%6C@
M!T90!6P@5&I0`VS``U_`!G2@!7*0!"R@`UD0!S&PA1*`!J;3=RR@!LL3!5YP
M#T[@*3*P!C+`?670`SS@!E:P=@00`[6C)S'P!%'`!FM0!1-P!EU`96<@2FF0
M46$0`X9C!D1`!B#6!#E@*I\0`[G03Q!0!76@`Q)'-B8&`!J"!CU0$W#P$4,H
M!EN0!=;5!FMP#D,5!JP@'O/S&S/V*#9Q_Q``,`=`\B@F$0J5L';'4CBJH`1;
MT`1(PB"\$`-F2`%7P`6>P0#?5Y%*@7XAL`.+\0!>@`:,*`<U0&Y/,`)+<!0R
MH``X(`4X,`$SP`='T``I(``24`!Z,`$M4`0>D``%T`=\``(6X`,<<`$!,`,H
M0`4J0`!-,`!>X`$&P`--``/U\0(>4(!BX`(ZD`%2X`,&0`%!P`$Y,`,O@`,H
M8``U$``Z4!8<X`"%)``A(`$.<`%FP0-U4`48\#X`0`118`5DT`9=D`5RX#0[
MX@5%@"=;%097``<`<`+<H`4S$#,U$`+L907%6`=F\`:2Y(0.T`8%T`,O0`8U
M,"-GX`#MT00%L/\61$`#98,4Z"<*F1@$W&*1&G0$(P`#JD``7;`%)8![`X,$
M;9`^G&`&7T`&&5!\:G`!2U"<;[`*;\`%7Y`.;M$$).`%57`%.K`#ID`'`J`D
M5W`"<-"!&A)CR4$CW'![J^,'7_(&;<`#J(@%6Q`1[]`#YE`$D7@!FQ('V?`&
M:E`30^142)".-=!Z:,`!7(`%0B(*#^`'78`X?F`&D"8#='`27F`Z"F03?E`&
MAN8'8W`%W/`2<A`+<(`&+K,&2G)]L?8T)A$FH9`$'D$[28`$:.`ZHL"@#B!V
M/#`'39`$.L`"4T.(L-FC/O`$2(`*8(`$3M`&1B`*2-``#M`%3O`%?97_`P<0
MI1+P`=`V`/<R`52@!2X@`5AW`CL@`!O@`57`!!CP`17@`4<`#A-@%`N0`@YP
M%CX@`CD@!`.0`"ZP`G8@%W^P`@(UHRHP`Q"@`OM6!6E`2$5P!#(``FHP`W3`
M`220!!?0)V.W!%@P!V6V!:W0`T2B!@#0`U5GGL?"`VL@)&9P1P\0*VBP!F+P
M`%H0`</0!D>C"P.@!B%`!0U0"C)09F2P`Q!`!AQP!CS``1FP`Q,``BG@3$<1
M`"#`$1'0HQ8Y`%RP9$5`!EI@!IZ)B=C1C6?``B<0`J]4!2>`$TOB=E[0>:)0
M!DK%!50"!C)0(D&&?!ZF"S&0/2%Q!FQ@*>D0_PIA,`<-X`8QT`1I$`0A4A))
MH`8;T``RL`4W(`%B<@4G8YX@8"DDL!$M0`=IP`X#I0!9@`2D<SJ_>JI/$`HA
MT"HZY0!J,`:N\VA*1:'WVC/FZ52\X!!X<GOF<"PRXA+$("2*E@\\(@MG(`.2
MR1-@T%PS\`,`4`:'$P<`9@%M("#.ZJ-OX`48``85H`6U9@7IB`%KX`4^H(F.
MT`<#0)H9(`-`P`=XP`<X\`$'@`)]D`%4T`<=<`50$`1]8``S,`-W8`(=L`$=
M,`%3=&X!8`)&8!][8"\N,`$KL`<)(`@QD`,&P`!>X``)0`,$X`):P`%<B@,]
M,`(5``)$-`$0T`0Q$/\$.5`,#4"G;K`!<V`"*B!1WP`L9Z``=N("`Q`&"O`$
M*4``?B`#51`#'_H`:D`&05`#,G":!\H%;<`!98%//4`'J\`*&4`&25`&2(!4
M:]`"1(`$*G`!/+"V`@!,J^<'.W!J3_MI#Q`"7D`&$,`&$.``:P`&#K`$49`"
M(Y`!/8`$/;`&76`%[A0%,A8C2Q`")<$*:[`&:(,-Z:@%(4M37Z$C.1`&.B`!
M7A!D25`%<1":@%=F`&`&$+`%+78&3E`%,\("<8`8Y$@&7R`'8-`$59`!:Q`#
M8"!C?D`'^D,&$=`$7$``-("I9*`!76!4^R`&/,`##/0$<&`%92`#S4<#K.#_
M!/K$!EV`F'Y``C'@!),@!U<@"A70!D@@/[KP/AZ&!BTV/UX(`G-0!EXP"A@@
MJJLG!B=P!<1H5/HK`+(4!3=P`BW`!LA:OA49`'1``3*0`H2:Q#H0!`"`1G3P
M`!8@`U\+!"-P!RK`!`G`!%PP`1Y0`1.``P8`!$>@!A#``0I`!GT@`Q,0!5+P
M+2YP9S%)`2506CU`MDCP`P*0`09``!]0;7^0`K2<O0'0`!DP`Q>@`G['`!:`
M`V7!!&A``B)3`"^0A;AD`4_2!#(P!O1E*6%P`V7@`6A@!5W`!4Y@!EQ`!!=@
M7F/V!BS0`@Q;#S0``$NP3F%Q!68@;F`@2@#P!58`_P8<D&9G$`$#\`5$D`45
M,0,2\``6<PE'D!1W<!!.L,=\_&D=X(V&YGPY$`)F,`=HU@9-,`8.`&DZ\)]^
MH`1#"!%P%P>WEP%P(#L[HKY5(`8E<RNL)P!Q@`23V0QC0`=L\`8:!P"TR@8M
MX'<P\`85P`%O@!P.,`9;,`NEH@--D,>4^`1!B!!?\!)$@`J0]@0V\P15D1UF
M((5^T+MDT`,2D`IA,"D0P")J8*XZ4&8:I0;YV1!UP`8OP!W-4$H9D@Y.``%)
M8`R&1@96P"E-`0`LD`;)`P$`P`,DD`5P@#9EP)=O0+P<H,<-79$'<`[`"P?3
M"``*H`1R@(L9<`09$`:.</\`59`"`<`!$\`'`6``4V`"K84"4QD!,%"`'=``
M'6`!G`P$#H`"`1`!*/`!$"`"?/`"1Y`"7V``&6`!$_`#%$`"FZL'=U"_(W`$
M.!@!/*`!5!`!U(T!+("F)#``"I`!*7"-=0``6,"H:^`$.@`'@(0%1^H'-3`&
MSI/&)Q`&CW8%1%`#)1$'A^.)`@`&ON<%4G(%B^<$<N`%^@,'LQ9G%]8868#1
M%4`&%M")2P`!)/#=+8`!2I$`JFH#D6V1>S`!D6AI<_"(+5`#92`+1$`$`@``
M5L``U^,`,J`%Q"L!50`6^+V@7J`%2?`]7(R*BU,296`G.B"B;-`PH>`%7]`$
M$J#_!CKP`&T@`46P!5O``*_<JU6@@173`IXY!F\`QFG0.[$R/YJC!(C2`F7`
M`E$0"E7@J0\B)%C0`+."$&GL!F;P!$IB8<JP*+I@.M/D!DNP(1MZ$&M'!Y[S
M$6CP!C[X:"?1!EH@2VM'!HX2LHWF!@^P!6X0!>OP`C>0B5S0`TZ@!#"0!J_9
MX1KD`7[0`GT=!@Q```Y0`SUM!0M@4CH`!H[P`7(``2=``4S``1U@!T$@`Q5`
M`@U@`4=@`2=@+R_``D.@+0'`,1]@&$7P`"X0`2[P`2]`?D#0`CR0`Q%`!0:@
M&4`P`"%PDA$P!2QP``6@`A``!AJ@!5)PJZLN`@HP;F:0_P9<D!G$D02^N`0*
M,#]XT@8>3`-PH`-5``9KLL%.T`1TS$_F&0?TT`M;D`9>@$GPB01E``%J4"GC
M13LO\"9P$")P8@)D$`?(Q`%6,`!*X+1(00%M,`%*(0148`)E2^I'\0$*T%4?
M8B,@V08-X,\\H08[8`(2Q215^P2C]#\2#)Q^D`1C(`=:$`5JIS]TH`,"$`5@
M\`!GH`9<'`I<<`YFH#^U\@*H1P&P<WP*8`5L\`!HIH,EW@(=(`%S!@<,``&L
MQ`U10`+;PP6DL'A:X(-_(J+7(%YJH"%JH-Y@T'+9A`1TD"-$X`U?7`650BO/
M2PERD`6AL!X%:B(=-B,?X04ML/\/:X?33^!.QT(-@)T!Z9`%8-`&45`$:(X$
M7#/J--\K*7`_72^9!+`%:-!/;\0"%D``9'`M%K!:Q5SL3)`"%G`#+!D$%O`"
M%Y`U&4``.Z`!2$`"+``",?`"8;`7`_`"F,`!4.`%+\`'*0`'!<`%.$`!4$`$
M'$``3H#A##``GU4!:>``:/`".F``6@`!.``(7GYQ519>9FDR)E=^9FUL`'YP
M3PYO9UH`9$^;?FL`8Y``=5UG<V>6?JEQ8A5<9B\3F5!C1'YM$#H%'&97;3)F
M55DY6E\2`T,*8BYX?\W.SS$C`<_..`\R$@\2:556#Q/4X>+CY,T%-4]R)VA<
M/6YP;'+_C0X`7#)=6FA8,@``.FT9V*BAX\2-@SAL4OF1T\8/O2H5YH")TZG.
M&3]D(MWH<2:+A35+SF@@0Z&&%Q-^LHS18D&+GQ9(WK0A8L9+PSI78I2*8X8'
M22=16OAAXZ8"@!PZX+RI$X),+3]$W(!QZ:=,F808^RE,Y<5+&$&IZ,`1&J,+
M@#!8V#Q)Y:9%.H5IWCC9&H:'GR=H4O&HPI5%E!4=!ERP`B!$EP<XPM@HQ[BQ
MXV92U&"Q4N/+DS-MHH0@0L9!$39)O(BS4$`%GPE"/`3@0Z#`@`D-1B1ALF**
M@2,^'AA(X,7--PT??)RPL0`+!!D0$K!(@8/&CR45V&2X083+_Y$%!J002=(@
M0Q89)VHLT%(!3!NF3>98Y&("2[\Z:]#T$$"&#I<U,JRH2?6D"Q(U8C0`!Q=T
M\.`&'6?$\40<OLS!11M(0-(-'4D<%0,/$H00`@!L=&&+!&<@(8`,#"`@00Q/
MJ.`!"=.40\(X?'A`QP`>O2"#"BD<,0$3C_4X3@`X(-&&&"F8$4$23E20P1-L
MB*$%$71PI)`<:RCP1"1GL#$5!W/X(08<J32$A1]TR%$'"V5DT<8/-A'@QQDQ
M./$4&G+`\0,7=I6PEA=J5'`1,$U((`$=:5"5RAE6Y%##&E`E\44D682PGRA/
MK"'`&5QL\402=;ST!@-^>$'&1:E\X?^A>7=1Y(4"?D1BA@0*=?K&'!0TQ,4<
M,ND0A1]YE7*&)G2H(8=:9WAQ1K%-8-4#&["VH488$E00A!=C).#CM3U^,,<(
M5V@1@1$R9`#!"&1PP<<4&0P3#A!T!&!!"ECH(<8""XR`0`(Z6#""!1,\4$8#
M:600A!4#?-"$"P+@P($%)-3@`(T.:'""``^TT((4'*QP10%_J+#P!3140<4(
M*VC111@N6+'"`S7`X48$717A!P=*S)#%#G.(`8`8,0``!Q%*5,`#&F%<(,)Y
M:KBQ1@]BZ/"$&TU4\40/?DC*Q=17X.I%#P\D@0``9T30@TY>U%%'%!15V@`)
M(,B`1`,;0!#_00C68MO,$EM`P4$**0@1`L)_>'!!%0,<8?>U?'`@P3M%E'W&
M&G(0\40;8:0"AP04*='A&6*PH8,3+51W901PJ%'?($2<04>K;9Q2AQII.*'&
M?G6(D48<:0@2PPE5_.#&#68\<?6&5X3!115::"$&JP2$@,8;?GPA0*>=TM'$
M(&<`(,.A8#<1R1LC#+#ZSF?4$$8=$GC81A)^S-Z#6S4XP04<<;CQ1!U@=:&&
M`'-,@@0O20B#S[9"AW6\H`6L*D(6EA"!M=3!"@6PBQ,ZP`4`7.$-5I"#&WI0
M`S(<X'`@%(<+"$(#+\#!#!P`P!,:T`,92$T"']"".#AP@`D<00HI_^B`!S#P
MAP9`H`@UV$T"H*""$]`@"&(0PP58H`,AT*`)+=A#$J)0&AU,H`H<0(('-$`!
M'M2@"@1P0`:Z0`0#.&`#8KL"#1[0@!8(0`):.$,:=$`$-+2A#7$$0R_0$(+H
M`6`.6KB"&/A2!S*T[PD[6(,;VL>4AJ"A6VLAPAS4@(8?^,$*9W@""QK`!B)@
M(0(-V,(6JJ``-D1!"TWH`18(@`4GF,$-3K@"`6I`@25<X`0@E$`21N`"`EC@
M!CI`P0Y\\(</[``"7<A`!_00PL?8P0$UF(,5M/`$#!"!:GZ@P!JTP(87<$$,
M4U1`M]P``!Y<@0L"0$@2GI"&,,3A#$D0P_\;B``ELT4B#6"0`P8`H`4RD.$-
M;T`"&.#0!<RQ@0T]",$:LF`0`*"!#!EXPQ7BP+1^F')R1D@##P!YPOM!"P!&
MP$A"WI`&`%0!"6X0`P]X4,$G3"8N.EM=57+VA2J880YFV`I&ND"',+R!?4UZ
MP@FL,#DYB$"%6^D')PZUEHLXX$$G^$(.8A`',(1!!Q^H0K0P4+=F-G,!8%ND
M&]R`A3<<P@QN`X,),"":<+R@""XH004\D(("S"`(%,A!&))@@C_DH`\%:,$)
M3G"#(PQ`!`R80`\@L((4L"`'`6B`%W0@@"I,(`(5J``!!!"!$_2@`@W0@`Y8
M$`0#4*``#FB`$;;_D(0WP`$-!M!"&[S0!#*XTPP``(,3X)`&-=3!07@,P_WJ
ML`K^G`$-3R`4&-3`AC?\XA&;D$$6_%`$Z)V-:6+H@5F8!H8U7*$*8;!M!=;P
MA080(`<O8(`21@""'W``A,L[K!)\:(`)I,`'*KA`"6B0@1A4808VL(-7&:.'
M/$1`#:E\0!6*T*7T3G=P7H!`V;S0O0A@9`UM0(B'ND"&"W2!#5PP`A8$0`3M
M5>4,3@!`F=:PCB;\)PTY:`@;O*`%.)"A;"C5@@Z:X(8JP`,,'A)#".`0@Q`D
MU`MR4,,#,*B65MV%#F_00AJ>(%T"=,$)!)A!#\0TRS>P0:9;\,(+"'"*_S&`
MA3\F4S$68N"';S[N(FGH2!ODX0>S.=ERDP/`%VZ@!@CLP`]CH`,28,6#)7BC
M"@W0\@(&W$P\E(YJ44B#V*PP)B]@0`<8R,$8Q%&#-_!P!BJH``X4\((WSL`'
M,\@#$BRP6`%X(`D%>($#;)A9/OPA`EA0@A>8$``.',$`2.A``>H@``8@(0#(
M!$()DJ"&+B1A"3$0PNKP5(`WO$`,,A!@5\*P@RIT80O\J`(`P@B''DC``5%0
M,0_@@(03W(<((N`"&BZPA45.,VM&B`$;OD!=`+P!#0IH00X`\`(_S,&E_M:?
M`;ZP!2)(8&%DX$`(*)#7$.3!;CC0P0H&(+(KZ/\@!EX8``K"T((:W``&UK"`
M&=30`CL(F-'D.((#UO*$-U2`$57`PAK,0`2]2B`2]+N"&=[`!35H`0(7B<,<
M'!H&AK1.`F/(WF7JX$H`9`$3=68#"TY0IU:Q&P`LZ`&5.1"#%RP2"0QH0P4F
M1SDD]&=^1/C"%=)@$2)T"DQW<8.'R#`!`CSA`FM0`QBB0`--U/P,BU2(M^D`
M@-ENI0T8;DB=.Z73)R!A=4\P`Y@T0X><<L%+<BC,#^90@2%H8.E/"`,8%E)5
M-$0!#4:H@0M@#L(@U"$,8GC"!.@`1AZ80`QA&$(%T-``*XC#"_&>P`*.D(`\
M(``('O#!$?:0`FE8``K_*]@`!^S@`6:(+0<."(,!+G"!'.2@`U98``,T$`$8
M."$'66"`&`Q0`20TX0.;!$".RM`E+L1@"S=0!P4`!TEP+&W0`#E5.CF`!&2R
M!G4@!Y_G!:O3`V'P9740"4_`9GYP/1!(!Q>H$%05`1O0!E4P`A,C`_14@3H0
M!`)0-6"0$7Y@!(2A0FN`!57``#60!`?`#-C2`QL@!P-@`!$@!4,`0P;0`P/`
M!3.P`ETP`1G`!$Q``RV@!3[P<K2W+A$0"6\2!B]P`0J@!2J@`/W@7":5!0NG
M!:P$`EC'*_)@%V)2-G,@#W"0":DP!V.B!6"0!)2#`:OG!PI@3J43`A.P%&K0
M_T=QN`00```*P`U;T`8]D`1$$`+&TP1405*IP`9TER`)``98P',>0$$?8`$,
M$`=OL!9QH`8NTQ*I4#F5MSJ=$@EAP`]KH6)HT!O\(0H`(`$,T`1>L!9W`0<-
M`0`ML`5KD(%)8`5B0`8Q\`9K8`004`/C9857Z"-"\1(-```:`"(E5`<;D`$5
MD`,JP`/B8`4M('\^0``<@`,E8`$P$`*!,@4?\`<4<`4:((H5,`,Q@`)X@`,S
MD`-T\P(5\`(X8`$TX`,L4``P\`,9T#E$X&LYH`&:Y0#@%P&$H@$9D!YTH`,:
MB8?S$`>/0@%60`"]\`57(U.2``!E$"H7(`=]1`>DJ/^%8]`&<6A(_%$%<H`&
M6N!E:9`&!$`&K``$-8`(8R`!<!`"<!('+6`%%W`$)]$#,+`%07`X."`&0$`"
M,-``3(`%#8D#$*`:%:`#"(``+>`"-(`!??`',X`$0L"#T_@,=I`!+=`IG)-[
M%X@&6X`&"8%485`%>=$/O1@&1-`&5^`%7P!.;S()3R`!T.,';B`#$5`&#^`'
M/$`!:;`&$'`#:0`#`M"+`%!BQ])XJ8`$?=0#C**%J4`#*=D#&%`!:<!&+M4$
M=1`#9H`?%A0&2]`&$A!Q"84%7V``1H`!./!.5?`&8S`&S)4*#F`%J3`&^N:+
MT6,+;I`&FB!06'`%U1@&<]#_)1:!8;SR)FU`!C5``&CE""RP!"P@!G%0(6G`
M!DH0`DF`!&V)+12@%TE0`2U@84H0`)?3!(T5`TT@#A!@`1DP!P60!]CG`D>`
M``4@!1HP!470!TPP`R90`".@!`*0`R?@`2+``1&P`E7P,%&``B.0`?7E`DW`
M!3``!@T``R/``0R`!1E``6@``<]R!CT`/5PP!G*`!'(@!EM@$E60!G+0`E&P
M!F(`9U_(!D=W`4A@`)!W!1A2<P!"#V20!BSP`%?2!@]R`U=""BP0!CDI!I`#
M!U'@!DO0`P"0!DC0`]E)!B2P`400`5"P`_2H6HMF-P?0`PY@:1>P`Q8@!"S`
M`1<@_P$NL`%-<$P.$`$<X`,D4`!'0`(#X`4.(``=$)_.D`=W@`#8Y!!"H@5[
MI0,2F(O(55;?<P9J<`((L04Q(`96L`KT,P<*L#J5@P8/P`5@D#T"H`9A9@%M
M$`)(X`41`(%7D`000`8L0`I-$`(9D`0Q4%E>H)R75`9TP'CVT1O`5X%SP`87
MZ`0R,`8UX`:#`T82``,RP`$]H`17$`4'=U`M@%2-$`F"T`;HF@HEA1$*(3E^
M\`9T4&)6P(IWT0(GPQ8#=0%MX($6,0=A@`;_<:1WT0,L(`,#@`66ZB/S60<$
MA048RP)7``%AT`0.T`'U&0+AD`"650`]P`5Z<`0FD`?7!_\!,"`$&3"0+Q`$
M)0"7$J`!/#`$`^`#0V`%$Q,##=``+V`!%)"4(TH$)*`"5A`$*T``!A`"!%`$
M%R``7Z`!\$`$+9`$38!@GV`%J_H`#G`+62`&%#`79@`&(?"75C!;7H`[6F`$
M<M$"3C`&`!`'8;`&*.(&2%`%8D!.<<``3]`$3J``-=`%34`!$&`&);,%;Q`M
M;4``IL`&(R`",S`8H60&+7`X!Z``8>`!8G0`&J``$P`$>X`'`[`R8L``1P`"
M.S`"$V`""^"R`Q!MV&!K$]L,"!`"[%0!#(`&T,$!7D!23W`#76`%Q*H6+L$%
M,#@'3<`#3;>9+E6'Q7@%IQ`"<=#_!;.R*%P00+^Z/4F@'EX0`W7`!4/F!&_@
M,ZR".Y$@2:G0*6/P>4F0%Q:18G#@`5QP`2:P`0CP`BQ``3*0!"T!$0Y@!D4`
M`E1#!BWP>>VS.E@Q!I6S4@"`!+>G%E;0@@(`!W,@`5>0`QZ8"F\P=&+0*A=$
M!E604E70`SPA`"'0!ETP!F*`!C&P`V9P`C)PNX_!)=?;!$-0`R*G`0\P!B70
M0@6@(>$`!0J@;`;@!Q#P!Q4P``Q`!%!0`3"0`5'0!A>0`1^@`QO``[QT4@R0
M``Q@`P,`!0U0!#@0`@8``RL@`8U3``40`>5J!!E@D65``V<`!YY:3?V@!EX@
M`RQ`!G.`_P872!%:X9E^`*9O<H%P``?_$`>UXP1+I70EM4A0.A0ZLP5BIR=F
M(P9+L`I3L`8:T`6`-`-L8`)@L`4A0%PA4`4&T``1H`$XH+E?4`(LX``0D`0\
M@`5`0`92<!U7P``40*+B40$2D``QL``X@`5#D`&.BI5Y((UMF0`D<#Z!#`%?
M<`9-H`2I4+<)IP-D`"9>(*9A$0.I@P5D4`<'\@0%`4\4X0</$`)@`#UPT%-5
M<`(C(`@Z`"L`<`)>5L4N`0`S4`&[X@?BU@M+X`<5P`)VY(MN0"T"$#E'``$I
MH`%*H%=/$$@\$`$OD%<3H`!M,`,TL`3IL`1=L!:H9$EDD`1\L?\6<X`26=O.
MJG`&D9D*H^0'$B`#>-<%??L$7Q@!.2`&`U`!7A`%Z+,"*H`!9K$"(Q`&-NP8
M06!*$L!<\2L'90`%C?A%1G`.X6```@`!).``@6('>'``-0`%#X"&&H`"&@`!
M`<`",3`!'[`!QAL;7P`%4C`'`D`"=W`$Q'P:"@`"`]``$A`!,_``*C``2;`#
M%YJ6)\`!;5!98Z,&<\`"(6!S`]HII*@Z19D&$J`#6-`#%,(#+$`';\0&6,!)
M]$H`>.L'6,"+N"(`V`0']ID*5%5)(;`$<Q`'(?,2&E`&#K!N!>`%*3``+C``
M#R``(-0$L+T"!F#80XN@&HL#`=`R8%W_`$2@`4Q0`SBP!2FP`!_J`7_@`]XZ
M`=#<EC^@`7'``VV``>WK!ST0`0Z@`HN4!3S`!@QB!)&0GO5P`7XP`C6P!5/(
M!O/X,VVV/C?A%%=@!120#G2P!71P)4O7!CP``$J`!FZ`!B7@!6P`)F>@`Q0`
M)G'(X7)@6SU0'VIP`V+@`0W``UO@`"&@`$I@4E40!US@!!/0!*H3!@HP!\9R
M/W@).XDL"&AZ)1\.K63"!6!MW_G:".BP.L78PA%@!CZ:!%=@WU9@!B,P`BC0
M26KP!!D@<430U(TQ`W``WU9B`$`PD#4@C.9#PR)+#52P!8$3`GS`!J@%`C;@
M`7O0`@,`WQDP_PTZ``%J>0`<(`43,`"BF`(>,`$6D`<0$`3Y60`8L`$EP`%C
MO`6\$P0LQP(SH`";1!$4,`"E*`8FH`0IS0.GP+>"90154`,.H6=CH"%VZ`5H
ML$Z80`;Q_`45T`:?30%O4#E\.P9,X@9WRQ=GL`%A0`'4!!H.,"HO8085Q`4<
MY@16T``)T`)@``YVXP)QX`%0:`2"F@(0<)!0L``5P`'TY[-:,`,4<`$5(`0(
M<`$OX%X+PP$:D`*S=`<V;`<N4,5U(`-7,`([-0:7A`08H`]Q4`%^(`,9<5Q.
MT(MQX(%T1M!=0`&GD!>-NP(50$]60`9MX`%1\%-D@`%+@`1$H,59\/\!_&T%
M;;L#:3`'11`E:7`7\MPT7C`"*N#;*G`$"C"[#C`#*%""QX%M1L``#-`+:P`&
M^B'8^R$#/6`3!`V,ASQP$`)E51!2.^-:A.$'`I`L=K=S#VX%33*N@B`5&C`"
M70`#81`$)M!;81"++R".8EX..%`I&P,!U:D`#Y`#>,T#.L`!.I"YU(`#;?`'
M`7`$*N``51``.X)J.5`"8"`$#O`!4R`!Q68`+O`!*1`"(X`!46`!*"`#6/`!
M4`!,%&"_$Q`N*.`%2I`^#YG0--``9@$&R2H`,^\'=*JDJ2`/AF0&65`&<;`%
M7R`J<5`+3W`%5U`!E(B*%YVO67`E8(`&<W#_PB.F!3Q@!$1``49&!&#P`S-'
M`DG@!B.P!<!,(>PI`&"@/3)@O0K@!#``0CF0!"2V`$2P!2"0!"O2C1J0`"\`
M""1'*4$?&`T8*!<C$$M)<#)8=70=0R=6!4!_FYR=GI^@H0L@$G!(6@!P949E
M%4]E9G,9:P1A3SH`50U^8$9+;$EGPF9I;`U98EQ^3P!$<T]@/0!),71^?DYT
M70!133):/5$8IG(F<3M.6E5UUV1G3W-H'VYL+T0A3E4G`E@Z7T16!`0,T>-!
MA#1@K%#`4$%&@2JO=C28<Z5)&S]QGOAYT*9*MS1$>L0@X,5/A3=SG,AA!F`-
MG#9/Q'@A@N9-DC5T_]"@<7/%2Y472<+`J5%%`H%02),J58K#31(>-\BH:T&"
M#``D0`40D?`)AQ4?'IQ<<"&&0X$,"H)`J.)@7Y`;'Z84D"`"0H("`R"T&""`
M0X@C/DQ0,..AB0H+#QJP$2"@AQ<O$@S(^"*GAX$7&(P(V$*$C!HW,MJ`!N"G
MS6,V%-2<H)/F3`,W:73)<#+F&I:2`$Z\B1.B"@,M#^J<L56FQIDZ-+B4<4F'
M2Q4V+%`"`.#$BYDF<*HHD$&!BX4L`9:"XE,@1!`F`HR@R6``Q@H*+(ZTT$"$
MQ@`##R#4:#*BP80*9%Q1!P!&;2=!$B)4L,,-'O`AWH.AW.&"#&#XD<033?^T
M@`42?L@11AI.R**&'`3,00079GB!`1MT2-"##$HTH<`<9L1!0!%6^=%"!5$`
M\`0<"JP!P!ET1)%-'6;(@!(:,:AQQD5QH-$$!&Z(H408?J3!S!QBP&"2`3VT
M`8$6>`31PUI;:('!`P_DP,,$)_2P!0-%E!%&&424T,(7RUBXQ#-5^&'&&&CX
M09H?5VB5A`!^J."B&]/1,4<4+,SQ!0]<Q`%''1+44(<<<S2A!!MR="&'%59P
M4<$7:$#HZJM_X.!'#%JY0088;ZP`@QDZJ.$%#Q>P\`D':2RPP@(9O##"&Q-\
M,(,%8`7AP`L73`#!%`:8@<$1'""0P1=F%%$!`23_4!&%`G%<0082FN&#!0\R
M9"##$$UH<0T#,;CA01MHM%&&#*2)T8,9%I11X9-OK'%%"-?XP44SAB8A`X=B
M^'$!''[(T,0:?H31A1\:^%&H&6(,P$.A`U@WPQ!JJ*%%%A^F<($$<\3`%@-S
ML!"""4QL,`6L?]Q!Q1,0%.!!#B`0X4("'C0PQB89Y%*#!2&,404&/#A1QC5M
MZ)!#&TB@,0``82A0PQUV3`!``P<`_:H+/NAP314S*,*U$GZ0L<83='CQA0Q<
MN"%`"F:<\4855\PQA@QSK$%!#VX4\<B)-7BQAI!/=('$&A6LY%L:<,#10A1J
M'`K`'&R\40-L5UPD!P!D_Z#!!AQ-5Z%%!DZ8<$$3821`Q`A#'$$##"-00$8%
M!DVQQ`$//(&&7C)`*L$8#X>AQ1L`"'"H'W/X`0<69PBJ$1T]6./'&PU?4X$9
MI<'10QI1I(&\&B)WL44+6JSP@MO\A^)#'6@8`1&:TX4J<$`"4:"!%V*4`1Y\
MP@<M^,,$5L`!"NPA!TDX@`%JH(4-B$$"#U!`!D`0A08L00(42$(`%!`#$YP`
M`3P00P((H)4)C$`"&:@`$L0@@P:X``M!J!`9(K`&&8AA#B1H0AS4T`(_N,$/
M[#!4'!H&!S%P#`M/8(-&LA"]:UB1`:E@0PBNT`4OT.$):WB`&YZP.4,Q@&]1
M8/_#WLY@AAY(X`I^H,$RX"`'/W@!<"%(@A=R(((&2&`'.`!:`+2`A`,$``$I
MP``4%B``!SQ`#[D30`P.F($>O``+&BA"!@S5CQX(@PP#J``7&H`&.I3@``U8
M``/$\+/^/2@/)#B#%WI0@0G$H04TN$`:`$"!$)S!1T\('Q0IT`8LT`$`+B/"
M%89DQC.$```*T`@96K"V)X1`#C"(01;\<)PKL"$,:KA(&@K0R@BXH0>%\@,1
MEN"'$#SA!2"@PPC(4`\G6.$-5M@"'#80@@8`@`YE$0,8-K#+$30&7T((`QNP
M@"(S!$$C6X!``[!0P#IT3P[/O(:DT!"::P@'BD](0\/_SB"#*O2+#DW`60-P
M\`%VH,$$1BB@"*Q@RYYN`@5AX$$;K,"#)X1P!@<10!G$D($&]."!2?B##R[P
M!P^,P`)?,,("+-"?)AP!!2X`01$0,($"7,`$)@@"`F1``!<HH09&R(`*MI"#
M,'AA#%?@004D<($A1@``DV@`&-A0!S%8H09KR((7--(#,$2A"M-9;`\"E$4>
M?,8,6`"`&S(;OB%IP0MA>($;..C'+<2!#63P0Z`,50&,H*$%%:,)!0R;V@Z9
M00(;H`,,LE"#*)Q`/Q)(0R*!9@$Q7,%.,7``!PKH(C;T@``L&$$9VA`$'?`E
M!`/PPPF^,(>4Z8``9'">`G*@_P49A$`+"7!!`"J@@39<H`0^58H="B"#,ZQ!
M`%_H0@N>0`;%>&$.%5A#",PPH#KP@`@`P,!5>B`&-`S("?*\B!5*P`(&U"$)
M4XS!'+"@`.@PP(00P$`26EL!-!#A"3WP`Q+>``8B>*%06G!"#,A0!A\L8019
MZ$!0NL`%*PS``S4@`A$\0``:',$);`!#"'+P``/PH`4%H$$*UL`!&5@A#$18
M0SP@D(TVE*<+.<I2')`PMFOTJZY8F(,RX5`!,52A"V$(WS#?4(8X2"`&/4GR
M!YX:W_Z-``!M@,,3VH!5(E0A#G%8C0(`((8B?`((6'!!#`P0@0AH``4U`$`)
M],"`#/\@80<34(("?L`%"C2!/?\9``CF%*<&I*$'+'```_H"A0J,(`H9D$`3
M`!".-=3A1>\`0`L48`8WG"$&`#"#&B(0`RVP008R\`(;KJ`&,-`A#''00ALT
M6X6!/5&U5NC,$^S\A#H8X0EX/%]EZ*"&YFF1#B%8@A'2@(47$"`$25;#&^Q%
M!"V$80UAX(`.?N`V"]#@!#.=`@.:\(`;Q"`'$5C"`!1`@QIDP`%9\``&:"B!
M-52!"-=H`3T<,`DXC*$`/<!`&`:``QTD0`\>R$`23O"!/B,%"@:(01P`X`71
MB`%+`$A#&,(@!@#$`05$J,,59/)$!JCA!D^HDA\\78,D$"'_'6\@`!+B((8Z
M/,$`&-'"/P$`AC9H`0X28/096M`"-,Q!`!TPZ1HNL',GL"!&MJ8!>8E@)@%$
M8`4%:$$-*)#92@J@"3S00@LN`)$"0(`D,>C"":(-`%*]H05E7P,8'B!MFKD!
M#J&JPQC*@(0S](`+8O@"&+0PA\HGH0=QP'(5S."`%GR\PS3@0`NX8'/^N0`.
M6M!!!)IPWB9H>&UQT(`:.("%3[A@#38H@`)N`(4$2`$$7,#"'@10@0I$@``&
MR$&<`G`!!RB`!1#(@2A-,(`&Y``%:>B`"70P@PQ`V88,&P.O?O0$#+^ACF77
M!K6E#7,0!C1R!5>0!EX`!Q>@!G'`_U%CT`6O%0>B<0858X%>P`!^\`5T\$1!
M1@<Y<`U+4%1/\`110",`T`5G@"=I(`-H$`)TH`/X]C%8<`(,<`H64`$44`!`
MTP<$H``GT`4[\',?9@7-$`0I$&4R(``-X``0$`82D``WD`,[4`%=4"'2AP4_
M4"/-$`-(4E@V<`)0T``>\`,\<`($X""]!PH)``*)TP84\@5GD$X2@`1?X`82
MP$]T8#O`!P`/0S]^$`5=(`-RL`8Q`#!B4`,F<%#5=@4.0`9RX`7VL'-C``8R
M,`ED\`9.``8UL006\!F;E5I(8$A`@8"N)`9N$`'GH`,M(`%%H`8ZL`,R<`4M
MP``:T",MH/\#&C`'28`%56`!,$`"69`&!D``:B`<:^``R18"1?`&S-""W$-Z
M;A`R?J`&1J`&9N`<;Q`"AE8'6J``ND0$2L`#!R4&]8(&LKB&0&,#9M`"9A`%
M$X`%#(4!.<`Y&0`'!`",S@<`%O`!..``!5``%2`":Q0$.)`#(?`%%N`$*3`N
M'C`%1(`!@R,!1[`#)%``3:`!$-`$UD4!"Q`%)A!S)>@%*0`!X\8%2]`%<P`'
M<4!@'O5,;\`&;@`&`(`&&D&!R,-@%G`-VL8&4T0`_:8%=:`&6>``<%"3`(`]
M8*!24^0&U^0'K'$"ZB`)*=4](7`"59`$/^`&W3-M:&`=3]``:A#_`@5'!`_0
M`V.`/EA`1!Q@`$H`8`.P`!K0`G;!`PWP`0OPB`9@`M=P!G-P$4TP<:8$!R&@
M0TK@`ENP!6,@!0,0#2A`!A]P!^H("N5S#048!^&C@J=#6%?P``MS3*21+F=`
M`!L`!^SC!UL0`F+P`TH2!C"`!%U0!V5@`&*@`P`Q!PJ`!/0#!ESP`VC@!$OP
M!)W$`$%U!D=I`1/`BB"0`12@`65@?J5V`37P`"7`!2^P`0:`"&:P`A<@@T<@
M`5,P`1=P#XF3>&\@`&\``]6$!`00"WX@$V0@!A4#*=;P`!RS!6I`!N:#"ZG5
M#$[@EV&P;S@!`!50`%O0`TXPF:]B`V>`_P56H`4[9U%7(`%L<`,M8`3B(`.?
M8`-Q\`<C<`(5-`(CT`1)0$8!,`(5T`,(X`$"0``.$`,DT``?YP0/4`-'@`!<
M\'90A@!>TT.+)@<R<`%GX`9UT`%<\`9M4#H1<`,@QPUM(`8O$#;6(P)]%`=;
MP`&RL#9GX&]7L`:9E09%@`8W\`9%UWIEH`-/D`42X`07X0!A$`-.H`%5H&2!
M5D`U(`!7$'584`%GD`0`4`8/0$X*D`4S$`0RD`1.H`E`LP#+4`=.$`4#P`*P
M5@;89`1QD`%:\`,=D`48$`(<,`+-@AER(R@M<`5@0`$6TEI((`(9X`4?$``>
M8``#\`<#P`$E\/\`/A`"$*"&"LH)&,``Q_0$7L`H:\`#<B0&&K`&7D`!6B``
M&IA%S9!B-?D$+=,%;)`&PI&"<W`!^V4&;(`!XQ8'=6"$`)`%2\EK3VA7/$=.
M*B8`5:`#-P`!$P`&0D`$&\`83T`"/U`!,(`%%B`!`J`%:9``/>$&`M@$6:8%
M7*``(U`%10$!#D`!79`U:?<$;.$'/?!D(P`"?J`#:<`^5?`&7*`%<P(`]'0-
M7I`!<V`"=:``5T!J;_`&1&`&&H`&:W`#4=6K#S("?F`%!-`";_``5>`!/1`F
M,6`$#6`!`O<)"R`'*O`##R`!/E`!*W`"`]`#<$`$'S`$(T"7\:$"3C#_7B\0
M`3"P!!F0!4;P`CJ@`QDP`TAPM"Q`!*]S3>CS!JH``%_P`G]R!K4!*560!MU#
M3F)P`\>V#,)*K76"/57@!6[@!2&`!CY"&EEY#6MP!EJ217VD!6I0!EQ2,U,D
MG&'P!6H0`T?)`V[0*P+0N!*%!$30!2%`!@(PJ[!B!U.065Z@`PT@`RR0`UZ0
M!>=E`$WP!`CP`14P>QO@!AT4!EOP`"YV#3SG%'YP7SRPAW%`!F9@`$Y`!/Y*
M`CK``Q:@`3*``BW0`Q.``9*ILW>@`A3P1+GP:FU00$2@!DWP`KM6!*W1!2!1
M!0P7`UC@!BS0!H(D`V`4`F&`!@2@!=;[!I*"_P2G\Q1:D`2J!3D`L`5H(`$:
MJ`[_R@<+0`,9$`(D8`'S\08R4`$"0&02X``&P`$JH`C(X[N_H@8J8`8B0``1
MX+BM.`=%8`0AP`,$X`9$`$8B.P=S<%IQ,`8^$EX4D(*^,@=U\$X8PS=^5,'#
M001A0*!MT`(8,`$TP!4Z*QXNX`<F(``Z8(DL4``<D!PM2@0\\"M,.P=[\`$6
M$`!\@`.Q%@0/,`)JH`$Z``%Y:0%_(``AP!X?@`4.T`5'4`,\4``WUI83P`(8
M\`9AP``P`0!:X'98XD=.H`:2,B1K5,4^>0TQ`4#7@!J%\P-B@`08(\1:L`:.
M(5*>L0Q4B9DL0C9;8/\%8-`$5^",>7->9)`&:B`&$!`"7:!#U78!1L`#-!`!
M#N``T.8#0),`F5B3'(!@XP83/20!`]`$9N`#%G`!",`$\(0"#D"%L]@P3!R;
M'B<'.F<H#@`%.:`!&P`")0`$%'`#%4>&,3`$;9`"3-#%?X`'$6`&84`&!-`&
M(/@8+:8EPZ1,8G`!TD`$;F"4$'`%EFH&"%`%S!H":_!66-`&I,(&RX`!-8!E
M?J`%5_!,1-`$,G$-#S`!NBH!7B`141`#(3`2'J`S,C<""G!'10L!$/``%<`#
M&2``$C`H`;L%2#`"O=`$5IL!$2`&<G`"+U!TH'P!)ETZY#14)]`&7M<P0]+_
M,$]@!670`V\@;4C:`T^`P#F@`#SHSTIQ``ZS.2O0!*I(`A)0!UE@5GE;`9]P
M`&[P!P>0`!U0`QX@`>$6!%`P2![P`9V4U#20`)9S!1`@`C?0`##@`BG+`DXP
M`<V3UB/04KP;M"S@7"W`'1P@!T6@FD98%=\#$VO17<V4!7"@C#IP!A(0*&'@
M!`A*P/*9/?92,=>`/H9R!ES@!2)0!:SL$@H5!5AR!LK2`TI@!$Y@!$50`TI0
M!D7`K!IP`"/0`6XS-JY6TO94!5P0@@:6!8,VM!#P!3E`$QE0`AQP`$H0`G``
MP1IV!DS-!7K5L"L6`1"`!WOI`V%P!+^1`@*3`42`_P*/>@,)X-9\0`13Y)=I
MD%HZ@`2VX@3_"45L(`980``Y4`UH4`5*0"GV)`13%+UF8`7,)W;?LTL`4`/C
M!&B:E0-&0`8@5P?1IK`XP`7,;`%MD`<7T`"+%`(ZP`$.30,6L'0*T`8_@`#8
M8[5`*`;;4`$<X`4T0`!/D`,;D`%<X`''-`-)``%^24=JD`1TL`9;8U+LP)(-
M8P7:_`0@YPYK,`)MP`6R4V]80`9DZ=9)`==,,A.W-6EK\(YHH+D$W-=>\`>#
MH`$)$``9\``#D``#0--_,`-28`0C$`%1D``4\`$),`&ZAP,=(`;3$@(&D!%:
M0`05\*<.D'T<$`:50I.&D_\*(H52RS`'%M"[SB$,TP$^#Q`'#$`$8#`<,3`!
M'(BD&J'`AI)T1I4Q8=!$U\`!'-0%9K`.(M.7`"`#,1`!;T>5Y_.>'_!V_0PK
M>:`#,8"MMND%#S`<9+`$<H`%U\"2TI>B#8"P*5`$)C`#H!H`H,RXR]!':1`"
MU-W!7Z4T*H``,Q`"0C`!":``$V`'CA0!,N`!>.#/"?`%00$!;&`!8#`'ZWX1
M9U`!+$)\+8`$=:!?`F`U`"`W=0`&.]`]+V`^%K@#&N$&A>(%3>`'&_``5+T,
M6^`'`Z!P.1`$2>``:1`!-I#J9SD")2@#NR<#84`#&C`!+\`%<LMN-T$"2'!>
M.G#_!&]00'/@`2J@`F7T!AD`!3!P!34P`*OU!$<@!V3@``W3!?;2!/4B#$[!
M$%-TXGFT>A4"#4C0UGP>"@$P!U"`!![P!!2P!A_P!04\!A&0!70#`9\0```@
M`GP`!4H`!%!VD;I;Y0V0^6F``A'0!0&0`DI`!#!P!%8``\HK<-NP\DLP(`QC
MFC>`F=C3U>JB`D_D!!\#!F4`87[P`H5B!7Z)!#$QT!_K.1D(.E9`!PQ``%*2
MGT_B##S@`/``N3>Y!MQ$6%7P`-T3!F#@!F+=`V%@!6F@`SRK5%:@`V_P`34'
M*S)P'770;8$"!R5PA0^@`^X%"%@6(40K%21.4615!C<]_UU:*@!^/2=*.5EJ
M?EA^8R]*$Q5-*@];.#-!(@PQ'CP7(TD,5UHZ07^WN+FZN[R]MP=<`"U^$2=^
M:D24;@`K$!$55'-L='$>:#UK6A)D?@`C9]E>-15B:F)R%9-Q;W1^?E4Z?G5^
M8#P/#D@-,A!6%VXD#CC(V,'`#(\Y'#[TH*`D3X882"2`0!,'PP,B)A@XX01A
M38\$8'3L\')&CL`((PP0$"'&3SDD;=SY>=+$#QH>9UJ4J/.EBA$'<D*<T0*@
MQA,Q8@`4:?%EB:^G4*/R"E!G3AP)?MRX@8-B"18956*L$>!E5P``?3@8"'#"
MP<4/&7I\P#`G0(T;)"I4"+)$!?\."32:H$G2(DD9,6LX<.E1HX$8,`JPD&E3
MI<T7.%VN($GBIDL<-!6(/&$SQ@"`)W[@]!@AYLD9,&+2B$%SI0Z/+U?`U`%P
MA@Z8+FBJO$'MQ1T`,G#27%G#HXT;)T_>`*ASIDV9)SGB"+/BP`]R(CS(#/@`
M!H)47GRJK`:`DPC2+EU:"P"`Y(&$$S\NI/$1HD`."A(PX((*7+P@1AATG/&$
M`DF@P09A"7P@0@]?0/"``61@X$45%R#@@A@LS``##QQP\`P+1AQQWHJ]\,'`
M=6YXP8877C@1AQEAG`8&%E5@`<891$!PAA%FS"$#;UTL`4`5;!!@1A=KO.%'
M&&RP083_&9/4\80<`(@QAA\YR$#'%EO,`(<3/&A!60,L*``"`&FH`0`+8)1!
M00TSO&"&!&]D<<$7/U1P`P<MA!`'!3E!T$,*''C!@@`U$"$;&K-14$41;KAS
MCCN[Y9CC$UJ$4=DBMK6!!!CDL'`&$A6\``(%+,;*8@(SG7$&'&U\QA\:-R1Q
M!1T3;+%+`@#D(<4*`6`0`0\%E,>"!@Y400`!&'R@@PQ>B'`"%%<T4(,!++A6
MA`!:0##'&$AT$44=67`)0`@46*$%"2T0$1,9,:C!0Q@4M!$&"6/`*9T'5F#!
MPQ-/M(%%"#F"0=D<1J3A!Q=^Q""&%4_TX(<9:H1Q1@VJQO#$_Q5GJ/'`$VN$
MH$4<8KR!A<=A\"`!&NZ<P87*7<10A:Q_V($#$3UH`($:3Z!A104Y8*&%'UV@
MQD8:3[0P0Q)[GL#`"!`(P$8+2U@A`1)%R+!(&FBD@80`8!#0@AI!Y+!!&1@`
M,,`^;SCQ01<4=/"#!0X@(($3,RA`P0LX\!QK'Q-8T,8<1-#Q!`\]Q/``%EX`
ML,QH:92!QA-TN`&&;G-,LD8:;6#FCA-SL"!#Z'#$L081(?!`Q!I^($$%ECDX
M,(`6;A"P`0$",$`!`A``H($,2ESP@`@.6.""&DUP40,/7D0@`A<IY1`[`750
M,``/-1SA11@<N-%$#@J(0<$7`RR!Q/\(W*"Q`QQUF$%'!FF$X,8;7.C@11(.
M2%@YN,"%@W!C#16H@0S:8+@&]H)66)##&1P0)S\H0`)J2(,!()`$"Z1A6``(
M0`\&T`,>6$@`&?"!"R;``2>(`0@HB``5/."`#$S`"#*(``G(<)HM9,->&.#"
M%NAAAEIA`0!P<`,74/,&-6CI##,!@%4`X#AUF0``--N-'-2@!05,HP8.T`(;
M&-"&#$@'-4^8A#N:4",_@.,8<WA"'<3``2Q>00>VB@-T=M"&,[@!`EG90@;(
M0`<E(`$$/--#`^K@@#<LS@]6F($;`9"$I5',-7[8@0H@L``1R*`#%9#`!)B0
M@!D<P`$0R(/_!X+@`@M\``<E8(,5,D`!&D`A`$W(@!;.,+\>:,$('3!``T*@
M@S'TH`5[@$(!2E`B)'#`@2R20`MX0P`@S40+(7A"&DX`AR3XP0%NX($<VN`!
M`I0A"6G@TA.ZT`8UC8$+<,`"S<*0@]28@0U:<(P?+E"!6X5!"R.H@P1ND`8B
M[.`%<%C,`)#R!@\<!0)A($`2DD"!%J!A#0V@``'.188>*&`C+.`"$@8P`PX@
MR@IIB,`*VL`&"%2!`T2(P@;`(`<Y>.U`:F!='/S0ABST,0EKB,`7'%"!$)"!
M`A6S@@6^!<VFWH)6G,J1%Z+``@ZD0082F(,#A,`%$/[!`T-XP1%P_X"#%AS@
M`PJ`@4?8H($)X*`)8M#"!)S@`1"T`0`[R$$*YK")-%C!#V]`0QN:X!HWM,$(
M8@A!'4[PKH^]H3AU:`$9`I:&**!F)E4XP16PL`8Q-,$-L0$`!L1P!A;@2()G
MT)A,W-@&*=7A"@QXP@6JX(0WB$$'P&K#&C)PACIP`0TM&&T8KL`Q&H#A'3=P
M@PIXA@<G"(!Z5L!!&L*@@*7-@0O)"`-/Y3$#)B@.6R.H0`3`D`80Q"$)(UB#
M&H*G@0RD:01T:,`47@"!%GB@!CW:@@Q:(`(4I(`$$7B``%P`.1EP8`Y5>8(;
MCE`#IZX(!"VI@PDXX0>BP&$-<"BB&C+@FO\'G"8'6FK#;KQ&@A0`P`)-&$,#
MSC"&)VC`#R>0`<WDH84?X(``Q\F=#,(0!BN$H`9-Z`(+('`%(K"P"VIH@`E:
M\`0.9$$'O;I"&E#`AAZ,P0QUT``/<D"$'SRA#'#`)FY'X(4KT``+1%`#1<A0
M@"6XHQU=R,(5GJ"&*CS!"ZWI1AP<H(,O]"`$FV/:#*Y``#5\P,$.Y`,D7\`%
M\F'@#4P(E9T;`(`,F&%8=2`#!X+0O`BTMPELL``)9B"!#+!!!#$`0PE&T`/_
M3`=0":L`&CDQI`^<`0"XYH""0H"E&<PA#'6``P`DT(7CELMC="C"!8AF$W?(
M@!)@@(-+VK"$)[S_<P,UX\$5XO`%-QB!!U78IYC\$((L/,$,ZTH".-JP!0"\
M@0V9TI(19#*<3@!``8:;@0"0$!!-MX$.5Z@`8#OVAG(WP`\\<$$+,G`%)EP`
M!24H@05D%H,N.($#*7!"&!PP`AD0H0%+"$,-S)`U+Y"``3W(S17&(-0.6($(
M2<`!4=[<`P)T80[=#L4!"H=H7Z3GW`B#`QJTX)LV,``R=4A0$1[`M"BP81XS
M:<`7VC"&P.ZXNNZ(0QAV>HPUU.$-&.`!`3(@@Q@X(`<@^$$#PG`!"0"@"Q:(
M@31A,`(/:*%R!KA"#P2)!27$H&8\KH(-)8`".)3!1EH0`FW?W0$D?&$(_^"$
M0PYN4)4;R&0."<K""/IX`B<`0`M:(,(2';`A`%RG#!:P8<\-I^A_;D$.:$`"
M8"T`@"A8P#51P,(N^/`$)OC@`Q_PP``08("?H6$++<#""^C``]Y:H`A*^O(9
M0!"#'E0A&$C!@AOD^)BL7W:(P:9V&M-@!BTD81+(0`,<)$`$$3B!`%EPAQS)
MT)HS".`)2O!.".3`N#A<08*N(1EKX`5W%A-ND%,Z8@99X`9QP`-P`%?NL`5<
M<`9)4`<%A0Y?H`"')BM'$`,M@`(F4@4A@`01%`)E\`(/X`5O``9AX`6SQ`)-
MT`,"T`!.H`,BH!89X#]@(``%,`,ZD`8\8``C(/\`%?`&21`!1X@&#N`OEC4'
M+6![<W`#8B`!33`)5Y`F9@`'P]!-.<)Q.4`%J]<+BJ2"<<`"U=<$%6`&#D``
M)@`'7E`'1%`#;_`&K4,`IP,[`B`&=]2"250'_I(I;Q8'L+$)5U8H;[`%`F`:
M*2@!T7("/#`!5S`!A4($D9$#8B!KUS`!31!/@T4&.F`%5V`%HY,$.G`"]9`$
M&1($?L`"5((%5N`O;D0_QK%:Q0$`;5`/6:`@?N`%94`';V`%<%`%2*`!%;"!
M8<@BBG8&9E`!1G`&.C`"&J`%#^!7#D`64;`+>6`&)2`".=``C/("1E``%8!*
M+%`#0T<'2Z4"P\`%+9#_?U%@!6&0`;JU!DGP!A6@``HX`L?P`'2`31(D`&7@
M!VG0`O\F#V[@`#N%<YFB;8*U!@`@!UZ`&6K`!GX@!]TP'#70!FC@!6C@!M21
M=%,R(RW``RU0`TA`!&\0,+A&&3W`!6(`!R'@;A#@&C!P`FI`@B3P2<SE`#SP
M`AL0`6S``EH@!IXW!V<P!VM0`W[0``PP`!0P`;+5`T5``&!0!;*@`SJ@)FX0
M!EW0`P;#`T8`=QC0!"'``?=1`V"$-@]0!6!@!&S0C>9P%`!@!!(P#;="-(V3
M!CC0`1#``/AVC+JP!P?0`)5#!$AY:Q)@!EO``GZ@=8+8$H8U)6(0`=="!S&@
M_P454#9JX`199P9*(&)&8&=$(`=/0`9YQP)$X"HAP!A?(0=CL`4FT@0:0`.O
M0`$5<`4(0`!6H``90`07$`4"H``5``;*$@%@M`+E8@(5T`!=(`$AP"$MX`9G
M4`15L`29UB7N0#M1Y0?2L`16`H3RAP1R<'<"X`3+>0>`R2)]X!U-X`10]`16
MH`,LP)9W%08R``:[H`=QH`<C>0,X8`<V,`-LL`$ST`($4`1(`P9;T`#;!T\R
M('M@0#%>\"-G$`(1201E<`4R\`9GL%-TT`9_UT=/$`=GP`9=(!.M,P9U``9$
M$`>+TP5;@`%T$`8Z@`9JM"HNP0/N(`$*4#,TD`1<P/\&I`4`<4`$=:`%:3`)
M#V`&R"%Y<<`-3'8%6<`#E44#/1!F[A`":Y``/&,#==``0&`#4A`&)^`".%``
MQ)<#<E(&9A`!8K`!9``$2'`&#%`!3I"D4=`#0;`!+;"$[60`+9`&!"`!?U8"
M&=`%`UEJ9!D+5R6-9_`%'E``,_D%G``&LF>4_I(C`"``0.`#[M$'>I">NA!@
M,<%7OB%064([8D`2)C@')]`$!N`27J`!=:!$\O`E\M`.?B`!#OD.#H!@808%
M!!`&L4%:/U`#<C`#('`$%9`"32`!F?(N<=`$`H`%!^<::_`$<"`&.2`0#=`Y
M-3`',8``CL,!,8`N,E`!0N#_!U$P!M(9`9H@#\,6;VN3JW*@=0F21CS`CC(@
M!V!P1Z*Z(GO@!TD@`PP@$_%E!E!T,1F@`6*P"WUP!JUP!7L``'N0`S60`RC0
M!CS@!!TP`3,0`6O4E3G``(#D33Q!$5K0!7XX$UOY9GX0D%#43P!`D:>!&NU0
M!W_U!IGB`%S`5T07!3H@)>Z0*S'A!Z,C;&R`!@2`!;[TH9]QL&(0D!.S=?_&
M&_;71V&`%5JU,EWI!RW`!`1@!(9S!4E0`&0@!&]0`VH0!5LI!BVY!6F0`WI0
M!`:@!1G@!2;0`>"F!1%`!!U``6C@!#6P!FM`4A3P`#@P`E_P`B%``B\E=ET0
M!KCB_P54(`9W<`(@NFIS4`4ZZ@=+(`%I``:<*09+``<R@`%M<`#WA00T@`1<
M&K"X\`&$Y8QZV`9&Y0<4V08JX`>ER`'`IJLZ4`<QN%,5H%UK(`+<,!,R`'7!
M)HL`\`(*$`!=8`#:]W%B8``J\&YQ0'Y7=E=%1$@M<09"4@5K8(=U0"D<Z04-
M,`<I`)]J``(6@`5E4`5F@!BKQ0Y,1@=BD&E^0`=U$`=,!P`7L`-BH`$$8%CO
MT@/UZP&R*Q5Z@'`'VSIPP`9G@`/U*!?Z`P#86!?SI0,X<`06(`1!5@#Y5P5A
ML`9SD`1BL(QD(`%8``Y%Y`9?(`])0%B<TVYT@"]^4%O2T?\-3T`Q=)`#`%##
M:4`'%!!_<P"W8'!>-!,%64$$RUL&/"03RMC"MU:B2!06"L(N9Z``9X`"!I,#
M;R"R:D"T>>H'!:`%7``!$K!C!7,&AI,';5``!^`#>O`!"!``5K!?#]`%`/``
M#T`8(8`#7B`#YZL!;?<!<Z`$Y4(`Q:`H:D!#!1-MH&@!8!`#&&`%6W`"9]`%
M!/`$3L![&[F1,,"9[K!%;%`%F+>JT]%;35`$P>0"#L`K*2`K0&``LC(%'T`$
M7C`';E!9U-`$25<<X$":9W`"=8`!R9`&H4,"5N"1)GBB[M`%).`.:/`&6G`%
M;H`&'<H"G5,`+"`=,%D`/8`!=:#_`#W0`%5P!$U@`1:0!%C0!BVP!FU,`V,0
M9Q!P`>E[!N($!C6@`1(0?U\@`$F@'UG'=!7Y!'.`!EWP;%5`!'"`+]&\!#]P
M`T8P`V$@`!<`!U<P!UCP`;K\P%"A:&D@`4^`!710`W*C!FY@!2/P!`#M!+M@
M!P0P`PLP`@1@`!A@`2U0!3O`'430`@Q@`!M9,F$`&];A3>Y`)?XB%NKC!Z`F
M>F$`7&`@`W"`&EH0`VW0`W]4!63`17BV!FP0!E`C)G40P(U)I.E$!#E"D=YQ
MF4V`!#-*$C;Q!<G0.)?$!3]"@%9@%9@W'6+`!6]@SR'@66B6`3QS`#F@!4$@
M.SQP!`,@_P0.``5$9098$`,"<`47$`9@0P1.L`$RX`'7P@6F60`9A!T(5P44
MY--M8K(5(#M14`%*@`5-0`%LD`!'T`/+R05+P`,]=`55<&&4Q`([X`X\X,UC
M>F_2F`$:EP%`X`(K0@)SX`0Y0`(!L")VX`(>L`%4I`-Z6$0`P`5F``:O*&?5
MA")$``!18@(M809R<`+<P%<)PPD)Y0YJH#!.M`&2<0)R0``0$`,-P,P4@`'9
M),!QP`4<<@514!@JD`$U$`*K0`0;,`!(<*0EP!<84`42Z`8AT$@B"Y$Z>M+3
MYFY2DB!;!,79:@9E8`1MX`CZT@!-P`(^0-)0,0#RUX]+$`/'8?\@\+&J/+(+
M>/`$/G`%$K`$/A`&.+`!I*@"1A`!2'`%`J"ET1879T`#;@D34]*1,2$F:?2&
M/<""X(`KNG5K2SLE<>`G*^`%=```'4`'3D<&1G`SOT:Y=&`EB/H`;,!U(?`#
M8*`%91`J:30'I;@5\L!D=4`#4"0/-0#H9&`&1;`A+(-A$``#,D`#(2(K=C"2
M$S`%$]``!.```RT!)B`!&&```M`#VF,$2J`$+[`05Y`#!`!\SAD",U,G$N`%
M`C`'38!>:U!J/_`H/.``L,,%`F`"(G4#@;H$9.`>#A`&.Z`@,D`Q;K0&-%.5
M7A`'!""<%E!^TXL!8!`$0+`B??`".\7_'150`!&0!^>!`X/@!2`J>_\+>FF4
M:61@&VA0!RG#G=GY!)51!R_`PIB'M+5(K`Z`5$^``V00!FK@`'!+!*)H!EXP
M#`+Y@#UP!F9S!ABP!57@!B^`(EX0`P/`!C+-00?P*D^@/_VH!CA>UDT=$T@T
M)<O+-&T`6>80+M`A#WZ@!!XW`#;^%$=0!RSL#F6P!E@`!P10-GX``;75`+N@
M`N5A``:0VU">`3G0!&N@`B>@`$'@`V`0+77P`64PA^Y0Q7KWGAP0';DN!D'I
M!T?WQ\1@OT-I%3IO!NP0'7W"`S4A8OU[`5:`:_J^6C6SZ'!``1?@92XQ!U<`
M`@18!SM0!R,@_ZA+VXQB@`4H0`=K0`8SN?0?P"]5`(:RT@$6\`('8``6<`%Y
M(`$J$0$0U0)T,`-\D`(4H``HA@4Y8`"!+@4DH`,N=`2#UBP2,$P2``-6`$@9
M(`%)T`-S<`$7PU)+DP9Q@`*P`P-H,`<*$`5M<`'NT`.,R5/M1+"I\1%K]^%$
MH`,%<`13`!H\=QXFL%JXE@3JV0.N09')3&'UVP/%X03Q!VQ^``A$2'2$?H8`
M<'YM20!^9V<7AE>&?C4224\M3CTU26\M,3EI&Q5?$P-K6FY/$RA8,#$`,3M=
M.G%)"AXW57-61#YF=10"96YH=89H:7Z-S%]Q7DM5#&QD<0!Q8@5C9_]^<#(C
M/!42?^7FY^CIZNOLYW=^$AQJ<!18,W$A8$LQ,6%:)^D&;.$C8P*.$4@N5&#S
MHD<(+`HLC`BCH(`?)1;\K/&C1HN6)WXT..G2XY:?"AGJ3,CBYDR+#0VJ)('0
M(DR%.EV\N9GP)(2`+6TRB&G4`$Z<,V&:F!%S!DV;.G7.1(6#AA(:.4W\S&%0
M1LTU'GZ(&'H2Q\R3-VDH.*I2A<"3G&-.>-E@)DB[=7HT;($R(0,+"@<@[)`@
M8(V:#74N)(@A(`H$"UR\$"$!A4>7`AX\M.C2A<6`!1A@0/`2P8``.@5B5%#1
MX@D`-T)BO4"2@0X8,6[>A'GC!^0),B![4PK_4\6/#A9.TD@`4$"`A!@A.E1Q
M0N/N.1PY*/FY<L1ZN@]KGE@N`B:.QC,<K"RAI,,0'(:$WKP14^>)G+%U!L2@
MQ)L(F3-C8)#!&W!$$(811I3A1PMR$(&%!`0(P04'-=1`P@<#$"`&$@[P4$4#
M$Q0`01(])-%%#`UDY`8;RU3@1W%^O'$%,F-]X8<5`)SQ1`$]^('&?[(\T,83
M3F3@AA8%>*?DDNK8$18</<QQ!@]G1+#!&72\<(8$;420#A!:T`!#$G;P8$,8
M/:A`@!0]N)'$`P0T,((:^^7P5@]6J.$'+FZL$05(;C"C%1U-$&#&&0#D*%4%
M5OC10WM^%!,C&D]4_^6C'_N9(8(?<A@A!PEK"-#%%SJH<84$/1K2@X)4/5%'
M(G0@HX48VWGA!Q9.P*`G``]4$08(6FWA@19^&,`'DW_PX8`637CA11$0[)$$
MAA&TH(0`8!00``1"O)!#!@XX@`$&/:`!P`LF'*&%$@6H$$``%/!PPA,<.#&"
M#QY($,0(;"#AAQD]D$$`"Q4\T88<)1`!1Y=H;+%J%XEH9X@6=9AA@`1HW`"`
M`"V\I`822_P0!`U7,+F?(2P$D`>R?_0!A0ZOA6%>"V;@B(P39H018PX*G,R&
M'V*<T`4`/3A1%1%:G-$C`%C((@!3;50@0!5KU`!2&!IPH<`:;82@(--%N/_!
M`!9O9*'#`#1H,+0600A!A`=S>!#""1;P$8(C#>BP`:Q^+&,('=KAYH<3-9CQ
M`!EK7-!/$V"00809,K`LN75[]`8`&P`\H8;7%(1!A!<CN"'##.E,H`4?=OC`
MQP426O```Q2\8$$$%S@!QM/_I0%X'*^JL48C(5S0AA^!@@5!%W60P0/9@%]Q
M!A=KS%$&&!^II2K@/5#@QGTMP`$'&5K`\009`.C>S5@Z:M%%3W-X$0)O:<PQ
M@"%52$"&PWZ$4<<6;CCAQ15IX``6'"``#+!!"P5AF0'&0(0,Z(IC+'C!%&00
M`BB(H0$90$(`2I`#,KS@`2@X`@%:8(`YK"`"/DC_00Y8\(4TN"%0E``<`-K@
MAAAHX`,^6$(6LB`!!)!!`A?8PAI:P`,"((((+6##%9Z0!!:$80Q8H`09[K:#
M'%0``R/8P@B"$(8(N&$,#L@!`XB``0_PP`7>49L?G`4'"*"N#\C"PPBZ(0LZ
MF,$,8WF"P6J@ACI@06=AT<H38B`&&9#!"G&(@Q;HP(.-3.(-57A#^\[0!0=<
M@`!H8`,/%%"&-?3@!5:PU16:$(<96$$&3K@`$JY@A0M0I`$;4,(""O"$-1"!
M"!N(`1SF8($JP`$,<PB+&^````ETP58A,(,7L,"&,("A"FT(PQ-VX`4`<.$*
M;&B##+*`@\EY<QTIF(0._V;0!GQ0@`Y:D$,/3("`+U0A!.DP@!;D%$$)0"`$
M#.!!`R!```A(``8-B$(5O%"')/BAF4)D@1B(T`B!'F)/#WA#&[CPA@MT(0L"
M.(,"G.`1&K@**_4YJ![=P(4T$(``8CNH`""EAAH88@Y0V8A&W*`&I1&!!GX@
M5@O:<`1D>$$#,C!#3K3`!BR``0TA:,0)WB"#+AC`+R(X%K(B,`=_]F`$'H!"
M`WI0@2KH`@PQ&($)?""!/(4!#1&(0@;*$`$E."`(%,C"^21&U]Z<10$#2$`-
M&A`#,#A`"6#0@1R$&H$XY,`*%9B!SM+`!DQ0(E%M$(,9X!`")`S@`T4`@/ZX
M(/\,-GB5#Q\J@7420($Z"``[:;!""C#`LCM@0`8`0,,%F/4$.C@@ER=(@FD$
M0(`ZQ$`L(0`+',1PMR7(U!&)&IP:&D&!,IP!#"N<`1)HT#$QC``"*<*"%2IE
MA0SHH"D>8,$(FD`B!C0A#!9P@UBT$`,"&((VI]$C`*PP7#;48`MX3$((TK`%
M`#@A#'3RP@YZT`,U/*`(76``FK[)8'0,80YL>,(5B!:"-ISA9Q/.P6\BAPX#
M<,$#:QC`!#:0@P_@P`DYT(('"*<#(S!`#BSH83:7@(PV#`^G7<!I&N+0@RO,
M`0!&>$(.#%I-+B2B#F7`PGW@L`7/Q>@)#:#!1@(5A"C_":H)D^""@BIVA6^0
M86(]$`,+@B,H6T6*`L$ISAEH>&$T>"$.)DA4%0R@@@-(3@L<6(`%3#`$/@C@
M#E+XP`MX@-,>Q&`-)*@``E2`@C8(@0,>J(`'F&`6[<3!#3:V,1LBK`88:N<*
MXM+`9IQ`AB]HH0AGP`(2WLD%-52!6'[S`^#4T(:CCJ$'7K##YXI@D=+*H`QQ
MY4$/@&`%+4S##G?A`P^:@.P1$.$)#&""Y%R@@8\407WU.8L;PN"%1P2'#<&$
M0AB2@(0-?!?)6I%#HES3AIK6@0$2,(\:=%:#`D2!`=UNB1O,D(8O.,$"`B!I
M`);P@`'\@`,DT`$&!``#'<"A_P%$0$`=W%`'&&FE!V80B\1B(*LUG/5%-%A"
M`P0``DZL(+PH0':#&XR#.O!`##]`%$A6W04AK3(-6D@'#MAP!Q<8P`$TT,(*
M+O`!#AA!!!4X@`X&'8(9T($+A^H"%R(E@3/0*@Z4$L`%1N"'.-1`"8I(207,
MD-PGO.<)7V`$N>%`ARY$`"1J()\Z&Q4).E3E#1@X`QF\T(9U>T./B#*$&B10
MA3$P`'CIK4!_F2$!+8C@`3D@P!J$08!25T!R(0B##NX0!!G<004%D$()+"`#
M'NC@MR.(@`=4H%L%I%@"":#!#0AJB#34(`4!8((*3B""#QR@`2U`0`Q:<`$]
M:0<`(O^0P1@4P`8T6(`%-T!!!*JP`QH880!G6$$25J`S'25A#`80PPZD8H(/
M?$`(-FB`&=Q0!0=$(`1$,``21HZ!'UA!Y>S0PPSN4(X\D$`^$@!'K14$(/$%
M;V`?#$!(VR$PO*$#!*`#D3$4<N`&B,,#-!('<*``NO$O.8$&"J(=<!`$*8!E
M9R``8X`&/0`!$5`',H`T##`U5E`#:-`_="`'&3``/0`'*+`,X$<TAE`'`/`%
M55$?9O`%65`".B(&7_`$;-`$&C`\7O`&="!-+I$C`KAR#-8-%<`""$0!7F`%
MC?0`B1('80`%ZG`&>1`!'#`"&!`!-6`%6&`'..`!&*`%;Z#_!#SP`R$@!B3P
M95@026<P!T40`83D!!(0!FOP!F3(`+32`',@!PY06GX@`#$@`Q>@6;2R!%WP
M!E\@`1XUB3_V+RSR$;+F!UDA`3_S"`US$B^G`T'@4K3&(F/P!@"P!D-#!"Q@
M!DT`,2WP`FA`!`3P`@+`!AOP`@6`?TO2!U70`U`P`FW0`"90%56A`S[P`0M`
M`FP@!F(`!E^P`S*``8YB`$20!%S0""P@!0:P`20P`7Q@`@.0`0&``EHP`QZ`
M`@A@B(9$(VN$`R]P`P+@!R.P`CWP!"=0`3J```A``6N@`CQ``A=`"A&@`U[`
M`TY`*P;@+#H@!F_0`]'D!`"``6I1_P"0)P`GL``;8``LDP!-T'8_(%7(<@2^
M%`M0,`</(`%$\$*5T'70E`89,`8@40=%@`7(D''KQP:/(&O=0`!)<`9BT03=
M<`9P4`484`5=]01A4`,\X`!?4`,*P`)PH`(1,`'O9WOVM`5JH``JD#]R$`=7
MH`-D$`5=<)5TT`-AD`$X,`\.<`8.8`5OP`9?<`0Q@`1TV80"(`-JH"P$,`%8
MV&#=4&M.4`0OP!MF00%=D`$\(``C<(87V0#2!P$7D`,8``%8P`%-<`)A$`1@
MX`8Z@`8\$`*8Q@!:4#A%509Z]`1@\`)IT`;*I#]QT`9?$`;^D`;A008V=@51
MI```4`,QT/\H<T`K$L`"9.@:8E`#4%&4'&$&:T`'<T`$#W`&-04`W'@&.X`Y
M4C$'1_$`:R`&X4%!)]`#<0D!5%D`;0`!.5`=+.,`#V`!#2!182`'\4EV71`%
M%#``"P4!"C`'#:`!)%``(V``1Y`%=:`#(Y`"?X`!8OD`'G`$`6``&C``%L4!
M2=``0M`!%J`#5?!EAA`'LT,E35`!#*`#-KD$%1`",A!C3N`"&&$!7"4!II@%
M)K275:`&`V`%0Q0'+7`#41`&!D`&:+`#%:`%:!`',H`#=H",=U$9O1$%0B`Y
M><`!F?(&7B`&ZM0"=6`$:4`$=."343@H.6-C/7"B<*!Y:H`%>H+_)6^P!K_6
M#*&8!$Y0!3K@'UJ``5A``57P!0IP`PY@8TA3!',@`0Q@!'#2`W5@G'4P!\`Q
M),P@`,-S!G$`$C!%"=VCGDNP/#PP6UC`&!E``U>XF)/S"%:P!6*0`4D`!FK`
M`FM``6*046O``>G@`@"P`#H0`A/``R(@`$A`!!SPHA(`>1*`!1>@``K0`%T@
M`$_@*P3V(A4V!R`1`[PC!F9I34\``E60!3VP!A;`6#F@!B\0!F5P`_71!HWB
M3"-!!)6(@1*`#&40`O-@"&)0`0``%2U`BL%D!E&@!G,P`A(@!F/0.53##-;E
M!FWB*!F@!F.@!B>@`&FP!ZWE`&+0-%]`_P!>D0-%($U@<'A@,`174`,LX`!Q
MP`5MD`54@`$JD`%/P`5]L``NX`%]<`=,4`!\D`)!4`%J4`$R,``5,`$AD`0,
M60`Z``3'D`P<``%H(``,H`96D"T9L`%E@`0"`@(:8`4NT`16,)5A``!=\'+4
M)`<QD#1M``?+05E%@`.N>05A8!3F$6U2L"1,D$D1(`<7]`$!@&P6L`)6J@Z?
M=Q.U-`ET,#QT<!9WU#?ZB`5S@`0Z8AXO$DS_X0=1P`4G@$=D$'<`\`9:D`9K
ME@$>D`$8(#M&D!,\@'`&0P!O-P(.,`$<TP,7<#Y?0`9=<`,`$B.D^X.&(`?>
M!CAKL`1.P!&#%/\&8O!E:\`&7(`$'\"JWS1(61`&*-8$,L`&\=8$.S`!YI$D
MZ!``:.!L,/`$$$"/$:%ZH!8B%1`&*J!'#A`#DNH',[`-&N$%!;`&]G,&7O`$
M+P`'#T"M+0`-$D`6V0@`_Z,&8D!@_J(%/?`&8@$&YU,'8C`!\W`&.U8'Q()<
M`"`&U40&+/`:6.`:#%!Z0H4$<P`&2-`(^Y8!9T`#,+0%@!4&*:``#B`Y%I`T
M?E`'7_`!+J(%8U``6)`!(!`#9Z`"4T``K/$&)Z`%."`%0D``S[4'.-!G?6!B
M*:`".$`!VO(!)3!+$2`!*3`$-A`$.I!8!F`$5B%B<04#,X"B7J"5:-#_!"R@
M`V7@!'1P!F[@="YZ`B&0@@%431QP!"[%`R.0`5?0`>>##1/P!3V@!5]@AM[1
M!'7@`W\0`4L9NDQ`$`#@DG=Q`!P0PE]P!A4"4S\#289@!6R`#&\`('7Z!"[!
M!H#C!@`03$9)!F"0!71`!DB`:=VC4=00!01T#00U!MOH!@*@G%8`,8Z"#`HL
M`W!`<3L@%FS0`D10!VN`DS)0`TC")3T``#]0!]G8`B'@G6#@`S&0!@_``M+K
M34]`&!9P!FL0`Y6R`;ZR'&10`]V$#BC@!Q@@!1@0`AH0`V10HSJ0`G00`@WP
M$&H0=U-P`]1S`GX``6]P'U[`""\T!Q:64V[0_P5-T`A7T"8T`P:R(`99P!%7
MT`)5L09I$'`2:1X`8`9L``>VX@!DD`9U``/((`%F)A5V58N4$#%CX`?("08-
M4`=ML`;=D$A)X09><`$A8-/@RR0)4`1>T,``@`)C$`(Y(``WH03S0P<6H`!<
MV0#\:P(%$`(N,!0PL`<VD`<O\`)_X`#'<@=VD``LX`%4<`4C``)08`%'L`$]
MX`).<`/H97Q^(`,3FTQNP`(V%@9%``<<<$D]P`,&4'("X`)?X`5@\`9\T`8*
M@`.*UR8?PP)U``9W,S@70`00L!T&8!,.P,[6<0!M(`$JAP=#<`U$4S!AH+%*
M8@<&@`7'\#A/L`%`S/\#?20#`^D'7$`!#:01!9`%%I8#:[9FCN`'-.!M9S!/
MCA!%9_`!*,``?)`$NON8`+`"4<`!'9`#2"`$06`!:J`!3[!O?2,6M/(&R%`'
MO%%:S@-,6O$($G`$3'$W`""853`"2\`%,G`"#=#.DT,6W3`'QC`E:B`'98H)
M/>#)Y=`'3Q`!;5@`@Z$!$_`!?4`&$_``F^`<W)!W2"#9BE``/*H(%.,CRV$(
M'^P&9=`&2"``-^`J,4(?WI`-.M.XD=*V`?<$9@`&/4),3U`"3V"'!W@4@NB1
M"Z(&%_`$@OD$%%!KA[+##,"I<'`SSE)95U`"#V`"1*"8R#($3-1H9X$!<\#_
M`RT@!DS(`%Q@(V?0`#\P!K=*!"_G`>4C!4!P`SK0!T"`!W^``PR@!W_P`BR0
M!S;@WE?@&1)`>CZGHP[0`A80'&?`!```#AU@AT_`%(^8&UY`!QP.`"V@`V_0
M:E[@!"R@!O/A`!7``Y,0`Q$@%EYQ*Y-`:U5`!$NH`X6+#GG0!5J`1N>0``E@
M`2CJ!Q[`)'9P!U70!4/M!R$`33+P!>4!-$W!!1KI!UM`NDX0![ML8=W`NV^Q
M!EQPNS_3`GPY`1PP!BQ`G&;0!A1P!P-`HS0`!EWD`5D0EXT@!U.7!`[`!DH]
M3&U`!H$2=^=Z`UG`!O"7:J*3!CE`G5V`!FI`!%8`_P%QP,4.+CD@(0/5)`<4
M<`$-8`!6IS];(`,*H`Y/,`/7IP$CP%L>$`$_P``6X`5A\`$-D`8M$`$9(`!&
M$"_#TP42#A)I,#YG$`*5R`96`#"Z`WG9VU)XF@3$D@'8`!96T+DV+E-V]Q3_
M4K=T@-A+$,W*$$R49`13F)T4L[SN=0:P-09=@&F/;`97(&S<-@($,.QW$0):
M``-'T00H>P5D+2,1(``1``!;@"H^H%D1T`4-0`$;```.(-H4D`%XH`=,P`!'
M<'X>,`-YNP(N@`$X@`,:0`X<4`(M<`0,`(_<9GP"``$"\H8E4%I6H`/@QP(L
MD+)$T@(UD`,/T``]3@D75O\$'!`!17`<!3#`2$`VV^BN?O`#1+`#3G``_+<.
M":`!(:$.?!`!/V,(;B#)2X('=S!!P;L%@&-0I(L&W.JM?M`%(>!O("$&:(`&
M$``'6M`"7/`^!P4(9V=^1`!5'U<L;V426E5T8DA>9#P3$2\G!$4G?GXG`'Y?
M;W%>7&)M/7Y(9S)G%6YH/!1>%7!I=&`,(5MN?E5H`&)I+PTM?\?(R<K+S,W.
MR@!S76@Z3Y`A3F=M;U\:/!',`#<9`A1'3B4&(W8.)T4-)FLW!C$//F).;U9J
M3E8Z25IPL6EC!4R2,!BN\/`BAD@8+7'.J('U)$Z/$&-68:DR!D"(-&_"/'G2
MAHS_GS!UO)B1X8;(E4%7GI"IP@\.'2XWX'C!0@>.'P!NN+3!$J+'F2M.Q)@Y
MLX:#%0TSO"#Y\*P9%#))6(C),L"`&#IN>+0@XH;-BB9DGA@1H47""S42&(!U
M<4>`#SUV?"21D&#`C0%_AAC`48#(AQ$X3HCX\*'!D1<MCI!`(:&.GR8&"*S9
M`L&#&BY=O'QAT61`E:%FE+3(X66.'RQU`%P)4T5+$A$2*H"AX:432CDL4+3A
MH65X!`L3F-WYHP)`&S[,C*3I1!U,D`15F7EX4`5.S"Q.YL0(\40+'))KZKSQ
M`@"+'R,`SKQY(O$,$<O4_<#Y<F;,A0$6H#&&&G'(8,8%_QDXT8823YP@00DL
M<!&'&U%81IL8%]1!AQEM$*'%&>QA49$.9-31!1A:N"&!`Q!8P<8936BAQ@,G
M(`&#,=GEJ.,SP=3Q!`!+4`!`#3'XX44)<7R!A@7A),!!#S`XD<("-71!&`]-
M$`"'!''`0($$3G!Q!0=-/$$$%W-X(0`=9XBAVPE$@)'!&R1JD!LIG8@!1Q-8
M"`"`$F+X(88<?ICACQRV./$$`],U(5(3(;0!@&6#U,&#'T^PP84?;)C1!1DQ
MM1%"H&N`=(863JPQ1@@RR*$%%U4@<<$%.R;3PY8-^"&!#@XT<<,$9J"AIWPL
M>-`$#R40X$$;;8S0Q1E.Y*$'=O]'>/"'#`<40``5>!B``04>!)!`"'VL8($*
M'A3Q1P8WS'"'"3/\`<H3`60P$@]B0#!#&DBP4$$*.VC1P`-^A%"#`$UTPL%/
M;`C#0QT:R%#`&?#5444%2?C1AA:=U"!#"VO@`,0R+@"60QV`,0/$#[J):<9/
M2MA1ZS$!0*'%%FGV$$<##)B!@A-PR-%"'4@H`8H?:@RR`1V=/-%T)SJ\UAL;
M=9!!1`4"6)%$$$^8(`$8[Q&1Q`<6;+IAH'[,Z0<87JP1`QAKL%&&&FS'-TA1
MPE(W2!@O.*#%!4G8($(2-\QL^(X`/('?&VWXT4`68HSEQQQ/4$!R&WNXL(`"
M,)3!0Q3_-'C0`P]5C#``$#8@H$0!%H30P`F#Q$#!%5<`($$+:,@A@1=R`.,%
M#P#<9`877&"QAA].Z.`3`*`XX(`335,JQAQ-5/%$#UJ`(@9]U#4>1@8*\\"%
M&G,\((;==(Q4P!H;T`=*%T0DW,)"-)"!A^$F,%"##DOXL48+#]#`$KX@!@1`
M0"=D@(,3S%"`";`A!QR@``TN\`3"3.$`*4C!<EPP`CQXH`0-D`('_N"!#UB+
M"520V0MP((5J76`&7(B`"MRCL01T@0!O<(,7PD`#!@@`!&$X00;4```NU*`-
M7GA!)P9!!#:P@0<%^,(3AG`%+1AA#"U`@AM`P0,DZ,<+#0!`_PL@LXP1$($*
M:,B`S)X!G3\4H`=5`(`(#G<,`S#`:6^XU!F"@88+-$X&@NJ-&'KQ!M?X@0.7
M*H(7+N":,YB$#'$(%!P,4(,7N$`,&>"``#SPJ2`<H0VQ2<(;V```MHT*#'5`
M`P3"P$"@E*`\#J@`*7=`Q#?X)@[2H4-OZC`!+'"@<'0,9C-`0806=$$&$7B"
M`%2PA-,T8`1(8)(RCH`&/-!@`!'8@U\@X(8M#``',L!!#A10@"%0@`P0V``8
M-N4'!A1`#&NP@!*XL`6CB`$-3D/#VC+0@1B0`8Y$<-H0YM6$+FQQ#10(`QS:
M@!(_Q$9Q<*C#*=PP!P(,0F,_86<GYO^`O3/T@`M@B``'TJ`%?1+11!H3@Q;"
M((,>E,$%SS%<&'L8A$Z\X!1JV`$1S#`&!WB@!9!X@@=JD`4.O(`-%.A%`(0@
M,SYH@`!\,``*_G"$!$`!&05@P07VX`,+:.`.>X"``UJ`AQM4P``(&-)%<R`!
M"2@A#!=X@0C2L`(!&"`*.8C`$MZPA64ES`]66,,:"%"')M(A!G8P01K&P#T!
M".`,;.C$%=BPAC9@(``X6$;"Z-"%/LS,!RN@0!OI&`%0.@T`HY2`&]*2.#4X
MK6"84D(:$C>&-X`H)!)014HO,(@S&"0$CSV#'`CP@Q[$0&!/0`,P0D"'2?GA
M#!D(@1O:D`/_+,RA#3]J&@#"<`;5$H<'8VA<6ZN0!33L8`(QH*0PUPL-/RA!
M!@!H`!TFT($?/,$+:%@I`$@0C@#P(0(B<$`0'A0&!U@`!0*000E.$"8)W(`(
M+-C!:].7N"KP8`EL<(,`B."'B*1!)%WH`1N^0`8`Q"&B:.C)%K)0`0A@80NZ
MQ$<8="`')(R$"^6Y0A=X\-K7-.X)O9"BCP!@XSJ$P`QN6(+V`)"#EP$E!!SX
M0!:FH8$;>.!^M;(!`$``@P^P(`9PT,$$6-""$%R@`@W`P@8PX+0-0"`$.BA`
M!$:P@,8%P`,&"$`#"H`"/-SAJ@7(\P_^<)T/0"$'(N`#!R;@`@0`_^$..%A!
M!CQ`A0N4X&@#P``2+,."-@A`!QF0@-@`X+8M&(`,(KB!']Z@@3/,81!1",$5
MX$`<5YN$.@/BP09P&`(BO($(V$G&%%Y+A@O0@`HSN\,:@VD#`F#W#/1I@@GR
M43`VK_H+#H4L'-:0M#AH*`9.4\\&K%"!5[^D#1G8U!H>0@(7*(`';8!$2=@@
M`R[(:`X9<(T:8J"#C80@#&Y0`TI"$`4WO*$+]JZ?%:I0!9&((09H<$`/=,#>
MBO^!#D1HJ1B>!08`,.`,='A`!3"`AAHP@PX!8,`,%L"$(\S@!OE"P(63<(0,
M\"`##@`M%^83*"-D@0=8L,(21B``,>@`#?]GL`!GZ>`:';#@"@\81!7,<)HN
MQ"$,1+B4&Q(&@!X`@`W@_DG'+]`$.+R!39V8FQO6($GY7*$*?OB0[LY@@$U1
MH`Y8N$`9YK`&,Z2!!2E8@1,NH(4`&.X#.T/#`-3`@RTF80$&$$`.KF#O#"SA
M1QZ0``5BT``V5(N45G6!#;P`!1?PP;/,B4`)IO!3*#3@TT&@@@&"4(`'9$`%
M$D!K!"+@@<=V(@`"P$)$O6`$%FBA!V'XP0H88($6U(`%3QA#')#VA3I8X64<
M<VZ>HFN4)\`;`C(HT?G\8($C*,,#^7$#X"T^,Q,ZX*)D:`,;[B4`-SBB-V]X
M0)JJD`2V4:?L#O7_!&"P!5X@"*]V!I:!!37P:EUP>W$P!VR@!2T0!TG@`&-`
M(BQ0"%PP`4UP$$HQ(6+@!5G@!?0Q!S]02E=P`680`P6P!*OT!&G`.>RW7G3`
M`#(@`T_``FC0!G,@`"$@&CK`!5D@`2>7`EJ@`7;``"Y0&A'C`C.0:0O@`5Y@
M`3UP`'?7`R@P`\=C%(;$!1:P15OD`5I@!2+Q!@#0$2A`!%V0!!&@6E>@`$B`
M!FL@(R,H`;;E!VYP48`%9&M@6SB8'UH06?DA`0"``0"@!:?E'&MP!6OR!,"2
M`V$P/FN@"T&P;#KB`JO$8SR`,")@/%6`!5VP!`J`!2^``E[0!'/F`3"0_P(F
M$`$-$`%LYT8ID``L$`00X`,9`!T"P``Y``43D`!3``5_AF5_8`06P`=`<``K
MX`!S8`8"4!F=<`!%$'%L`#\\0`15L`--P`']D`$E\`,Q\`).8U`:,PA&T0D7
MLT<W<`7W`09$('\R<`-<`'1?``(08'[(@'Z=H`94,8.'<P%7H$,1H`7Q=P$0
MH`5+L#UJL&IOH`!^H`,!E79T@`I/$`9^X"J=\'5AH%`]4`=F\#!LLD=-P`"(
M*(CQ4P<]X`5PL',<0P0$`PLG001JX`57X`<"]@`=T@-(-@=@X&EMP`+^&$QS
MD`9"4EA>L`,JP%E)P`!^0`$/0(3+0`=%(`1'\/\!>#!$=E(`X5AT+Q`"76<!
M`_`$6)`#1T,=4>`T3[`9`5$#XI,DYW1.=%!9<:DQV7,K!!`,`K@-G1!R9\``
MH'"#9<ETMO03;8`&O?$3K[42+8`"6!`Y+?`$.C`'5U``?L(`'Y4/&#`/AH,"
M;-`"#$`!`L`#.P``<``*Q18`G#`'8L`&#?`'#B`!*I`#)Q`!>,!F9/`'$^`#
M%>"::'4'+Z`"RO8'$-``"8`"`8`'YR4S>,`$?S`"3,``$:`#5=4%.>`:;:`'
M+?`\(J`!$X``%<`#%\`!:P`!2!`!82`&$=`$(%!B7N``<-`%3S!EG=`%#<`"
M(>!%.)8&8M``#ND',0'_`%!@`RF@`LF``$Y#!%<5E'14`[U!7EZI!5K@!6NG
M3]0AE81"!U:PEZ!T454P`5X`=F>0!G$0B%;0!;C@!Q]&'7,``&EP*87@"S10
M!X,P2`M3!EG@'W%0;%'@!W/I!%6@0T0`!Q;P!#+P`.JBH(9S3SF`!&4@&P*`
M=._!`VI``&70FLLP!Q!@`A7``2'P`7VC`S,0!/=9!`JP`U4@`R18!RVP;VU@
MF1PF`PH0`3H#!\41!E\`%&^0,=/G6B<P'WX@(-XG!F"S!E^P!3^A)T^`8Y(R
M'720.S'06Q5!<&00!B:&!&"@`&OP!!B0%F'@4IV"-)-0FGY`!EH0"42P!5!9
M_RMW$`/9N09>$`4;@`K\-)%M4%MMT``K``-$D`(A,`(OY`$04``<$`9DX`(Y
MX`,EX$8N$`"X&``J8'A[P`0?D`-'(`0EP'M_8`'8L0)!``0E,`(5H(P:$&X+
MP`$7,`(<H`%%\!^:UGQ9H``H4`$LD`$]\``4(`9V2@=-<'"6,1(*L%U.4`9/
MH`09TY574`8+5`"&=PPXD`=_P`1B<`9ED`)(&DPJ,!%#1@9\A2@:DRF^80:9
M4@;4$0+Y(;&4PBEFT`(R4"0L,*D>2P=#!@<T<`7XH`9L$`)PT`ME@"C,(ZKS
MQZA@``P_X`$_L@,0@'%R@`445[$[,@)NT'%LH%RC6O\$55`\.Z`#D3)"RR`'
M.:`'?.`$!B`!$2``$;`!7H`".N`5,E`!"I!;2T`&&P%R&C`$R94&1"`!)_!V
M24"D:G`:V3-EF]8S;Y`&:X`&91`#QF4D7@0VG:!`AP5/"PD&8<`"@S!_A^A1
M9(`$P6`D<3`&3A`'UN"1>DD$$QD'#L!C<7((8D`#,N4%2;!\+-`#4F`%6N``
M$9`#$%`!(4`"(T``!4!T1[`#3E`'US42(U$&?_`")0`!?\`!,^`!#(`#3#``
M/O`'+E``.'```<`!.3``"9``!F`!!A!@1Q@$/,`$\7-1$J``1@!<NI`$%!`$
M0F`!+S`!&3`!]MNE%8`%)^#_$]FV4A<I!W4`!V9P!1DPHT@3`O]3`"FX`B5@
M?BN`';U$?DP;3'AVAW`PN4G0.&H@!H#T$R47`H2B`SOK(YB"!EQ0!TD`"A+;
M`TX`.TB@%!<E`V&0!FZ0!6W`(4G0!$10!B:!@)*B.*!X`SS0!5?0!A;@``7B
M`"2(!EEW$EIP`DM;P=EQ`7+8+UVPJ5H`!E%@!M]S`!O0`B?`#'$``A?@`6'`
M`>D$`633`U%P`@Z2!!9V!A2HN6N3#4$8`@10!0ND?E=@!A%`!WXR"`#@!3G@
M!CW0!E6@GS/P!&)@&2$0`TC``R6V#5M`$BT0#%5`QZ[A$S"[*3F0!:BE:F=@
M!M#3_X=QH+EIV0D.L$4F`@%H``)2&@%D93@TP`,2T`-$P`%:0`&,X0(H4`\C
M,`,R($04T`,N8`"(F!_4409\,`4NH`+VD`3)40%VH`),D%E_``,H``'.Z@$=
M<``RD`(9``4HH``CT`0)0``/(`(]QLS4`0$"8#YP$):=R@&BM@,U$,4-0``Z
MX`).@`5@T)%&4H$2<"-AH`8#,`0V@`-!,`4.,`042[%_\`$#%`"62,6U@@,.
M`&0L:AYUH%`.!0!E$`5FJ$_P52@]D(<`<,G,I3%(`#T:4SR,4XZ=``:EB8!=
M\`5<$`9H``<]T`5)LS&4!<MT$!%@@`5.4&)X&`,&0@<UD/\&2R`#&IT=!;`4
M,M`%7<<%I)H*!?,!.I!@9(P#(V"['V`#?+`!!^`$1&`!)R`P)>!U;O`$(@`V
M;>`".M`+:"`$:6#$=*H&-0``$/`$;1@H,4`$6)`X<X`%:>#6<=`"JX5:/^*_
M/+HV+T,'8:`!3I`*EX($2Q`"9Y`"-6``5<`)/,",`?$$J1+82L``(G(&4<"B
M5Z"FGR,#)C<S>)`#3E``<?`"N-L%$W`$`7`#-K``!?`"-9`"4_`#84``T&,&
M3=`#35`J2Z`$8!``$0`%5#`"VHH""X!L+P`"(X``&+``5N``>``%!Y"%'K``
M4D`">A`#`G!G(Y`%YX$?\-P)/C#_`4LP`0!)!%'``5Y0`QTP/>)C!`-P!&17
M!RH\`6\`!W`'!Z7L`/V8#`>`#&WT`F@05=;"#'VQ`N8"`\Q;U<B`!RC`"6?0
M`)J;V59``0.0.!VP!7J(F!9I4_G6"3+:"QGL!P(@!%:0`0"0!!5`!UA@&Q#0
M!!K0`S;,'GX0!;DB`QRP*3W@-$VP!&L0*470?&C0`EI@`S`@`4%`U23N#`%0
M'!$@!A*`@UW0!4KD!TMP!BY@!E.<#'#P`1%0`1J``$<P`$V@`#@P`".0`?S4
M!`(G`WL"2`C`UB(0`A;C!10021!0!%H0(60@`#L@LJ]F!A`@1G4`!AV7!'4@
M*9W@!%]P_SQ@0`%BV6L/XR-[!+KY@09A,`=A<`.=\@1(0`2YTP:SY0<RT`3`
M`#84DEM^T`47<`2F9CC.Q@)@3@(K\``O4%0&P`%/!``T<`)X4&9.T`(9@P,$
MP`![$`0JL``I``7@.@'BG`=3D!P)``038'@]\-W;FP)"H`0+<`(@,``L,@(K
MP`1XP`,H0``74.\C4`(K,`(%D`--<)C\%<E@,`$/T`5(@`);$`%18`4M0&87
M(`;HN<D2,`<%T`)7X``6R0*C516EYPQ'@`4M@#9X^`490(PDG@`K4&)'LW&E
M60=7<'9^`!!$L$<$0&S:``!D0`;Z5`=<P`:-JBB.1$0#T09K,/\3>"D'UE.6
MVQ6"S&-+7```&M#32H`&J-X#:L`!49`%#:`$8^X,"@`M2*`%D>(%$C``2M`)
M$C`&/P`#<XX,:X`)%L``!E`"I',!2^``#Y!6(W`\4Q8''&`&6H`!!#`"#(#O
MWC<!<!<G;\`%`R`!:,"XUR4!F<H%#S`2J_8$54!!H]X);/`&KD5$!J4%U=FQ
M/S$&^L%=)+$%MK0J!9,!/5\'IYL$;B!K.I`%*!('66``#5`%+C`S+B``=?`_
MEH`"F##5#T``2#`"EH`$"9`#&?`%*E`#?G`$++`'.!`"%B`#3/";+=``(=`!
MG1$"$[``!Z8"`T`!4)`"03`#+_`!./#_`7;`!T$`"'<N*4,I&#@@&08-+WM_
M5SPZ%3D]?GX.$!%$15\(#C1=8`U$%5H\)P\.,V$R:UU1;7%F/$U$*G^XN;J[
MN'IVN1(X!`5J:61^`A9:7%LM6!TI*2-\O-76U]="0C%UEG-6/0!57E4E:6IT
M6W,`;&A^9W!^=#5:;99N)UIL?@``(_%QKO"#0^")ES1K:CPALB\.FC)FWIRI
MT^2)!#A@W,"9HP8)&"\_P#P1,Z`(MI,H4^;R<`:``#=^(,`)0\:+I1YL'M#0
M4>T*AA<[2#3X`"$$!QE)6$2R5V7."357E'S(0,9"`1A8KKR1T<#/FB=TQ+AY
MP\:-&P!^BFRI__'&SPTU8?RTT?)&`!TX3^#$F]/%3T<_2-B(*=--#%HB;O;Y
MJ7.&38\S9YJTU9*E#8`G6$(-/.,GS),!4;@T*:!'92X03S`U`#(#`@$C`EI8
M$!!BQX41'6:T:<!E1!,_*1@!D5'!1(4E"5AD8(%CPI$8(2`(P2""P!4#*%#`
M2!#!@QT.'#(@$$)$PX`*>R(0&B#!QP`K14<8&&/)00@*,5H`B"2XQ@PQ7'BA
M01(C*!!$'"&HL=@3<<`1`AP?F);+!WU`P40`[#T!AA_@U+&&`SH4<45L;F01
MAAL<V("'A"SRL@`1]J@!!A%OA"%."V^000<;9OCA1E]>:0'`&61$8?^)'UQH
M881H6*@1`@%5`+"%!$=VT<07W<A@24MI/%'''&5440<6$(0AQR<`6,!#&!#X
M8<09.DC0XIPH.2#''"',T887`%CQAA)^O)%!&V6(`4$U;ASA`BXO$#!"!1#T
ML8`4,Q3AEP1IM."5#06@<5D+4CC``!IP=I&&%QRPX`I:6SQQ111/O/-$%WL&
MRD8\7;QA$!;\^`'&&1=X!4<X;=01!V=P<,;9&U1RH`49!##4@!,U^#$&`#8"
M,$>4_L2!`1<[?#%!B\$2T(`"`O`P@!<1B&&`$Q8X($$7*L!@P`DR@-"-'T%D
MT,0!02A0@0<+##""""C(<,`4?-B0`@Y_I*#_P!T'&*"`<W^@8(-[>A3@@@\>
M9(##$22\L((`#^#@0`PU\+`$!;_Y<4(!56R@Q!)7A-"$''28T<`5"A3(P0LN
MB-*N`E\4(,$,1]#Y1P*X0%'%&RUX=N<;`!@AKDU<!("#!3I4X<(=3L^)@Q$`
M(#&''UZJT0T/3W#F(UKPP%$'`&;(;0D<8_1`P!)^Q+'O'&$H>*1<3QA^I!6&
MC0&9!%_LS0,`<;1111P^?H-!V9SKXL0[9XS@10$[T/'`/BU\J&L&B$XQ@@L8
MZ(''!!]8\8$3?&0`&11(\!#'$P6``,8;1[Q1!QCLF4##'%OXX041=W,!P1H`
M)`$'#Q!8(,\36L01_T839\35S1:5=1&K.SV4X7P5EK310C=T6$)&6[%N2=83
M7L:*00P1=$%`$#+@00\NT`T"X$`,`6#1'N#PAC(\X056.$(06$`$,#0!`@L@
M@`\J<*\"3*`%,>B1'`YP!`(8P`M&8!T**+"'%;"`#P<(0`:H@(<5S&`&/DB`
M`H"P``]`S`!\*,`!<(`!""10!CC`PP)L(`$7%$`1#:@"&T9P!#%88@(8*``#
MGH"$#*S,"G50`!EXH`<)G*`$:H@`#[A0`S&D``XQ``(0.O>'$QP#"0;P`Q:>
MT(0UO&$=-NF"#!8P`AB$@0LM6!0=54*`$Z`%`!.80QKZ<0,QW"T):L@"V__`
M0`8B!`HM'-+"&;QT.&_([4N'2X-`#D>'!CP!#5:H`O<VU`4S0(`(3V!##)[0
M@!)P<)&<HX`?8I"$&G#D"0```UIXX`4U:$!`O+!!&_@@@-BD(`8OD$`.UI`!
M)YBA`AE(`@5T\,T!:&@``N@""^K0!1Q40`%&\@,/NM`%$:0E!F@`PRW+T(,T
MP`$`;:"#EYQ`@.;1X0TP:1\&^%$L#\WM"15X0AO2\`8UH(4-`*@!.WC@ASE@
MC0!ND,$2YJ`V!C0!"35P0QR0T`8Q0(Q%+_"#$RK0@`QPP0(L<((`FM`#*50`
M"5<HY`1.@`)^L$`-%4B``Y+@@`D@``H1&(`'_L#_A!Q@X04PP(,-0G"O'T3`
M8T?`@0M48(<5U&`$=HC`A1;0@0`,800-J``#CH`"!Z2`"!APP1%RH!@R&"`%
M8*"##G@PASEP@:E6X((+@,"!%33!#4U0@`Q&YP,\_()S`2C``+304?990C`4
M=1(%*M"#(T!!`11(@0!B8`*H<<X%)_`!2NX`A1#4(5;QBTM'97"&-3P`#K_#
M`DPDXL`T@&$--B&##M;FIBK$10X:\)T8V%`#.&S!"O6+TAG>H!`:>$$+&:F"
M1<F@!B(4[@<4>($!@%DV86:!"#5HPT?4P(&NM(`%?@A!%8;`"RBLX0@1L$$0
M2("!<08``A``@!<L`(8V_UR`#23KP16@T($R&``#%=@/#CPP`$]9;@M:8$P2
M["$`),1JEZ4L5C_0T`7Z!&H--]""'`*7!DO(@$<`J`,9TK`/8WD)"V1X`A>0
M$)8Z<"$<D./"$W0`!S84`0)<5--+3<.$.3C`"&&X@`3"4($3.,"`5T#!`Y!0
M``-80`)$F,$9B/"''/2AL1CJ0`-2,`'L;.`%/E"!`"9``1?$X`,VB``&5@`%
M$`R@IC/X@`<T<(`*!.$/%P!!!0J`@`;,0`-"J((%1+`"(-2``Q:PAR7B,`(.
M#+`"/'B!%Q3``3FL80D9B$`('@`!!CC`!#BX+!WYX("8ZI$!EJA#&FK0E\L@
M(?\):3"`"'B0A*_=P`!A8`(UG(:'$;]@"H[`QAX&L(4>?:&?Q[*$1(?5A;,<
MJ1]+6$,.O("&&,1`63V8PYJY<(4TN*$-<\#"&[C0!3I8P0]BB`,=V#D'8B?A
M"UN(0P4@188PC&$.6BA"$M;+7CHME$]G`$$,JJ`#%MA$#$'F``\XT%]N3D$%
M'1B!#[X\`@NX@0X5T`$86E&%#U!@#12(``>0<`$-""!)71C!$C`P`CW%8`1K
M\,,5T&(%,%2B"DG`GP[4X`4+6H$.;9"`0+P@`#;L&`!NZ*T]"-69P%U!!T]P
MPA.2#@`(O&$<3[""&R8'!@IP00!LDRD!BL`&!L@``M/_-DT>,U`%D?Y`!DKN
MA@528``!C*`(/+C`.,>`H#^P0`!#$(`!>$"`(8"@#PF8`0+BA8,6<"`&%LB!
M'C+P@00LH``>&`$$+H"#$>3!!WS8\`%P@0(%@(`/%;!``H2`BP=4H.4-:,L]
M5``!'^2`#EI(@@18L`0V2*`)(8B`##Q@!`GL8*H51P$7^.&&\?=L<F"7@``*
MP&,HU+?Q.FB\%71``OXZ30@0V%80;("2`!2A"FZP=NPV:B<2!6\`?4<R27$@
M7%50$.=F.5[@!$92+!O2!F%@!E9P!1*@!6E@15Y!`U8@"U;@!?^D!5^0@=L5
M`TT`!A17<2U2"6^@2F+0!1)0_P<28$4.$`96$`!<T`"\X`-P``4X@`)`8``.
M4`$RX&X`L`87($AQP`8?D`/(8`%.X`,,`@+P$0,N005#4`1B\`1;P`-=]@6J
M5`%1X`3']CN`\08%<08MH`5/T`+N,`9OH`5H4`5@8`;:DF.!TAA<4`9P(!`\
M$`(`T`4A$`:RU`2HA`0$,`<R$%!L,`8V<@8<P`8"T``^*"$)4`%P``0Q@`55
M8`]><`-)!W`04``J,`([T``/\`8>@"!!H"A',`4XL`!0H&AZD`,7(!T:``4F
M%`#\]P<@``50XP$^4`!_$'M4@`(X8`5!D$"6A0<6\`$3,`%CLP-V$`#9%P`,
M$`,/H/\`O,(O1(`%`Z`!+1`!81`&'(`U8#,"./`!8``#4.""N+!%7!`_'24&
M[E``_.8$#2``85```M`=93`#27``*&``'!`&'Q`A+.(#&\`!*?`&%]`&7?!H
M*)$")T!1]7,D="`#<W!;=P$Z"T$YH^0$G/$$/:(%:.=UX7@D<S!C;R`'L:(W
M;7`&TA,&:-`F-D($/%`%5%`%`T"/+>)(/8-<9J`%1G(,.1`71$`'&L`+`8`&
MKI<].3`!->!\9X``41`&*8`9'G`1$E``$%`!55`%$2`!%4`&,>`"9D`$1S``
MM>47:@`!.B``8/``?M`EKM`C`-`"Z8`&&=`E2?!(=(`$8A#_!A'`26WP`#7V
M!,P4$$<B!C7R;WL#4`6P(`!0!C`A`12`!2'P`F+@!3YPB2R2!TD@$][P!#FB
M$,93`6'@`'SP=R3@!1+P`740`RK`!Q<@!=3(!S<@`2_@`1P@``AP``6``T#`
M!!/`!'^@``D`!!>`"TZT`@'@`@G0`##@`@>0!W]@``5``<D`!#U``1C0`$Q`
M`!G0<@+@``]`!OLB016P`C;``+0R`&%@!#4@&PYP!ET`?D2I``!`!/$@`)5@
M"560!FW0!E?0`S.``S:0!2O``$FP8&'P!CIP!'Q2`0ED&GQ``1LA`W]P!!7@
M!F/CG2>1`#*08Y#``SQ0!QE`)0#P_P.^(P`<@05K0`.Q$G`!)0-C`!:"<P*E
MY#N^TI%$8`;U4P=$0`1:$BLCQ@!P$`5:X`5#2902`FQP4"P[-A)^H!!K$`=N
M,`!@8'^Z@`-G@`-YH`(>P`<19`!PT`4GD`6A"``X8`!QH`8V8`0$<'P1D`$U
M@`%B4`4L0`!0H0)04``5@`5M1P0A0`8;X04M(1*60`'ADP1F(('*=R1J(`%#
M@C]K(P;X:`EQ\00?$`*!8PE$$`,5H`9-,"3^8`(S1@+WPFIIX)\OT*&FL0$;
ML"'=0`%1,`=D```A0#TC``98<`0P<`(+<``)X`-M$`,'\`$^4`*9)@!`H`<Q
MY#$&4@(D5_\`,_`")>`"-"4`0N`!$V`"'>H"0,0'`U`:+B`$*B`"/1``.X`"
M)1`""/``*R(!'9`!-[`!1R(!F.,7("``XC`'%>`",!`!:]`"\VBE>""D?E`%
M<$!O;)!T:=`E-N$'%(`#`-`$L-D#AF$%$5`&!``%#F!5F8@2%@"%CJ1(?P!U
M*G`#*2$(54`'57`&#$HY*18'X7`6'F@MSK,%9^"B2I>8:V`&(0`&%ZB#!%`/
M3N`^1M!0/4`$BJ@$%P4`%:"1<F*EID$#UG(!9W`"'*`!/]"!77`$%H`%@&H"
MO(`#=<`$4$"%$>0`:,`&(?`#(7`#:,`!5&!O))`#CA4"N2$"X*3_`$J@/`50
M!$Y0`"BP`CQ@!EQP`?B2!@ZP1@`@`5R`!EK@`$XF`&(@!FAV.&J0I7[@2<$V
M;#7&&2#[)70``/&0%W6H`U;0*CQ0!BU@$QBH!N\9`0QZ`BTB0$B`)&'0!=H"
M%F5`!`"@!7B1L`K@!"%0``61!+CW``TP`!'0`;EW,!4@!1I@`5[`H2.0`UHU
M`),R`0UP`G:0>V)U!!-@!PEP=`;@`P*V`!%@`A/@`0X``R\0!7PP`1%P`A(@
M`YYE"6M`)1VU!$X0!`4P(Q_@!2?0!U[[!Q^P!G(0/@2D!EL`05=@`FL0`G)@
M!5(0`$W0`%EP`FWP`ES1`!QP:!E0`2)`_P-+@`"RA0TFH`98@XRXD`!C0`1!
MD`2FX0($@!<BD75>0@=H<)B\D@8"-09$>R15D($9\*)G@`8]L`5NL)*&008K
M^`9?<`-A\`7M,$D&@8?#$KH\H`48P``3K!+!4L66``9L0`1:L`-G8+G(0`1N
MNPLX(`<N$`0<\``?8`"Q``,[YP9S0`&&^P:35A7PQ`)7<`(C@`0Q<`0"<`4%
M4+MLP`(TD#U>\`0]@`4!-208U0U9X$"Q`@`<$"O%ZP=P@`5?`!,F(`96X!(]
MH'8`L%QSX0ZQ^3X(S`^.FG?(A"09`%``(`-6(`(4P"(H<,MXYP=-L`11``!I
M,*PZ(`-JP`9/$/\&?!``+Q`")<`':I`$'G``?6``4R$`'T`#U8$!%F`!."`!
M$W`'$<`")&<A2F``,_!H&I!9)L`'-P0!1W`$$O!5.``%>=#-%O",`Y`#F;7/
M*L`!.M!1:!`"9L`"F&,&33`!.-`#$:``%A`"4V:E$P``6+!+DX,%<L`S<Z`$
MN`0`#``!#?"]9A`!%7"$I#`#+?`"6#`&#S`",F`*47D-"7`$RW%K.^P%'S`"
M8G`+,_"^)Y$'$P!&PKI+8W`![(9X1^($+<`%65!C_"`&+&"'/0`'#]`$-0B[
M9S`'&K`85["BZQ`#3M`%PI;-:F`%#,`%6-`#/7`?*]#&*>$`OI($7RK_N17P
M%HD3.1#@`!'P@T_PKJ3E`SR`#S(@!!#$9B0@#E/P`6Y``"^``1QETP1P`2T`
M!A+0!DS``54@!T)0GC4@$`60!%@0!CNP4I8`J7[0`TS6#4]0!0]`!V/`!A@5
M`W0`QW?+,SKK!58@!TB08X$J!U(4#VCP!E;P3WZP`3(@!DW``A(P!G3`/Q"0
M;::!G^.G!G(``#W0(QYU#SW@``,0!U*@`C,@`1*P!U;\!WPP.TQP!RO"!"+`
M>!4C`,/W!WMP`(=R`T>060$0E0M@9H^F?7:0!!E@!Q[@`DHP`"%@!R7``"[`
M!]*V`Q.P`4`@,J;*`RG`UW!0`-XS!U2I`4-P_P07<`L3;`<J$`>#>"1HL`0G
M^`9K0`=><`1Y4P$3D`!7T0`M$0$3<+DAH$UXD`<I9)_]?!(!8",.<`%$D`8+
M4`%B0%!D8`95FJ(U.`=+M[SBUCQU``=-@#ER`*ISX`6OJP09H&,DI:H,8`%+
M$`=!H$<`90E)P%FG>P6C,^9^@(%7H`$@#=@H\0*Z\@3RU@9Y`@$<4`<5`$:4
M,0.\@`=JH`)*T``1\-LK1`1.H*`S4`!TL`;-'`0XT!L4X`-N#@81<`$3<)>?
M>`,W,#P#D`(V@'=NL`,(@`5P@B1Z%`>%:=+B5F.OFQ?\P+.8PP)[`KM*IV\3
MD`9S$(#MS=UL\P9>X/\!$1"*-&`&*V`%<T`$27"(+:($<S#17/`#-\`&<M``
M8>#F@?($BN`'I@<"'#`#-H#>?P`!=38#0H`#"<`')+`'A'P$=\``"5`"LS$#
M+B``5'!"BC0`>.`""<0$'O`"B]V<`9``=E`!/N`#$@`$9M`""^``>'``3K`&
MX\@VE]$&&%51#@``13``,*`!&;`B$QP`<K`"/H`#\5#LRGL>XQ(`2A`'<Y`!
M#?`%#``"9/``%M``!M`%'#`!'.`#0Z`%5E``-5`%%Z!KU1``.O`&T-LT8>`$
M#N`&7J`"1<`'"(`2!*\CP&P)/$`?2T``/R`05H0%<]`"ZV`9,O`&/6`CHF;_
M"5C@#H&2I5E@!<-+D=I5!P_P!5I`!$Q`!`P``XA^$B")J@$8!PT2)2_``^ED
M!B]0#6CP`23P`QD0!Q/@!#V0!+7L`!8`!P@T`>90`1#L!4'@!0;0`B4@`3P@
M!FL4`:O&?G$8`F?0H&OPRC")!E$G`\V-!I&#/WZ0!77@!>M$[W%A13V2%H%2
M!7LDK$'&&%<0!L5B!3;R`LB4I&\(`:?"$Q+2!U]1P*!<!VQP!L,:`C$@`5E@
MJD4`"!MI/4TD:4U_(Q%!6!9_(@80`1]'*5-\-1][*P-Y1TP>4#8X$WP^4Q,8
M`QDM#@$J!0%_L']Y0U,U)2$^%1$##PUT54AA`&IH_WXY7G!K?D]$1&XO$7_5
MUM?8V=K:`6]P;$X$?B=J?@!O%G?6&3TN6&YP43I)611/6S%X!6H"=!)0!)3D
M@<*AB[IMU0(DX%,-S1,O0?8X&"-#"T)L?0+46+/FS),G`.*<:</BS1,W?JHH
M@&,%R9PR8OQ@,>,$#!TP?ORT`9!3"P`B7)``"*.#C!HM(<2T64,&3I(W6$A<
MG$JUJK48=+CX@:,&3AH8508`D`"&R)H8+[+A6?,!`H,G9FA@H"``#(<92+I`
MB.+@A@<F.QBT8N"#0`$=$TQ`:.#EC0$'!2K``2"#!X,X=;K`"2,'`!L`<I"\
M.;,DQ).<.1_XD7-ECC,Y<O_\$`ES`TR5-6+"\/`"@`L%.6BXB'&C)0J=-E?"
M$+'2)/@6"1K0H$E@U5J$)UR(Y#PJ],&3.`"N8*'`0@(<%#!,P$APQPRB!!]&
M#*'`A,<`*$".,,CP(D^G(QK@4,('#T1`Q1X?)##`'Q4T``H3(_@@`@<*^+"'
M""X,L<``#:AQQ`L80!!9!0:88<83=9@11AU/M/%&3M^!L08$;8!0W8W7W-%#
M"Q$HP`$9#E0@@"MX6*,'##[8P0<.+81`!!(32-!`#DB(T,`9,F0@00P18)`$
M%S*H804("U25QQIA9+#`"7!LQ<<>`G!051`7M.%13L7X48<?'NT0!QMT]/"%
M%AC_-'&%&E=`\(05;4A0Q4<YM1&'/6F<P8,6YG!111=R@"$&'&+P<$4&.)9J
M%19^O-$&$5E8$,8<#@!PA@;1=*%`#MD<\,01'H@A1@H*U)##$Q3@(<$3#00@
MP``PH#""?!B,X,4`%C3@@@PN&'`"#"STP(,&+,2AA0-AU##'%S)T@2F?-7#Q
M1CD]Q&$&2CEE8`8`=+@&XQE=M%',&E%TM`8#:,PA@Q5^I`&`%E4$>@8`\+@A
M1@A-O!!%"'&\@2,?(]#Q0!@YG7""=GZ8$9L6XG7T@`H,G&`"!SZ4X<0>)6PA
MQ`P#S&"!"#.@P`(*`N10'Q,-2)&"%2FT8,`=?"CA0PHJ_U0@1!!0W/%"`4%H
M`((*/D`AP11'&*#""2OXLL`4!$3P@1FH?4?'"U7P!$`-+%CZ@!Q$,&2J50D(
M@`80&<"P`0T0F)$'-@8P<(T42*RA1&XZ]'""!`X@H40%$'3!PPVRMG$3&DUH
ML$"1"/$A@`\N2'!&#6$H\8<%<!A0#0ZR;)/1!">`YP<:H_7@!AIPE-%$J@"`
M(8(,:'@1!QA6Q."&R72\P48<:2@@AA<N!KP##V/004$-9,C1AAADM-`%!7NG
MO\T2?O#`AA]T*-%$!$`TX\2+5H2!*S8V`,`$$5C80`M:4`$ME.$(5%#7#!R`
M`CU0B`,?$``/P``&"83`"4L@@O\.*O"#-I!@#CJ(04ZJ$(8UR,`-3X"#%DZ3
M$P#$!```J,.+G+$B,/!F#D3PB3DR<(4EG"$#.0E*3M#`ACMAJ0MO\,P9TH"%
M-W3A`60H7!L$``*+W&@!NTN"!/D4ABX@PP%5J,,<GC`'KN"``!Y00`P(((,X
M1($/-X@0!`20K"1P@`D86($4!M`"3:`@`1D8``="``H/B``'.\@`#@XP``3(
M@@,XH$(*`ED"')"@`04H``>:4`+#&($/8FB!:\Y`E#7P``YS>!\`:$`#+7"D
M#DEX@/JJL@``""`$#^!`#7B`@VRTXQH)V((#K(>$`:``"`"X``:,0(0JM.!]
M42##C&C_`H`6<$$'![G('B!`!P^PX9A6$(,UYNB!J=@A`2WP3`1<)`8MT"$-
M9`">1]S`DRO$X`E1:"$`%E6$=CE$"0J8"!$$0``[7:$)9/B(!0H`A@@08980
MK882PJ`&+'CN#62@@0MHL+H>="$#-?A!-O+`AAZ$P0,5P,($X!>`&2A%!2.`
MD`>"`(D6="`%-]``!RQ@`32,8`L:L$(00*`##FA%`C+84QW$R`4RQ*"D<[@"
M/$'E!Q:H@0P`2,(3ON`,'<P!AC-TPQLRX`06".<T::A""'H0$QVD@0U5\&9L
MGD"&-+QJ6%8P0@9J5QTL]D`"[N$)&HC0!#ID8`<Z6`(CT/"!_QS$0`<HZ`,!
M4E"&*%2#"53``1,8X`$]J",!#CA`#:C3!Q\$8$IL@$);?'"%(QR@`GA@`@J"
M8,@1H(`/-.B`'?+@`1?DX0!_P$,$/#``%TS``48(0`0R-0<Y\,`8<'`#&"B`
M46<4801NB*@VK1"'"KS@!1VH0B^MP8<9%"";?T"!`XJ$`RR0#PA2J$(<<D*'
M"?"$#5X00Q6"H(8JN"$(/#`">K?!!R_0`0E\>$`5J%.-`E1!#288+T+P4)(S
MP,@<;FC``V1@01*<P(EK4(,91L(&_+YC#5C84W[;X`<Q[,D/6AW`&@"P`3^L
MH0<9**=VU2<:#A1!!!'0``6XL,\S[/^@!5G04@6R$8#3.*`%;]#"&ZP0@0EH
M00LSR$$;7H"#*D#``!'(0`8>L`$F:&D$22!"`7(0!R)`@15G0$(-N%N,,#S,
M"'5@0PSFT(*3`*`,?@"9&+22DR6@BD]<\`(;FM`&-ZR!!540PSZ)8(8N[,`C
M8S0#P\)P!0H0H`H:X,T`Z!"''J"!!T?`$19?(`8*.`$(;7A"#+10`0MOM0MT
MR,$1!D#<$+Q@DG7E0P:"D``??.`%%J@`#BZ0ARBD0\<XT+4-"G`U/*P`"@]0
M``0&4``$X``R%TA!$#X@!B@X8`()F`$.S`L"#'#`"1+@`+=ZD!,B.*$*3H!1
M#](0@C8X(%7_>Y#RCHV$#3MT800%T(($1'J-"LB`P=;@@0O(ZX$DG"$*3D!!
M&BB0!F2%H0S[;(,6EI*$$21@#5IHP("SL8=1@P$`LKN&'80B@B5,!0]Y>$`-
MS.$')/BA"S..`K[B@(0D@&$S+?*#&]*P.V?P8`YU:`(+<L(#.O#@#?1T#;[F
MD`$NC&#@Z7OA/7,#@'"2,0O?4<(5EHR-!+2Z`A)0@@?:``,$/,`-$$#""1IP
M`3MPP@`\D$$#>(2$&#1@K<LA@!-J,`8BN)`!=%A7B_V0!0[`X3AM#@,;\.:'
M+[2!"_!H4TX>IH8OL*2P.8D#*M,`AR=(X"9^\.%(JJ"3%9JAN2L,_P,<P*"#
M#`@@!3B2@!J\<(*[^;`.=-!GU+7P@`5(80=:"$P.IN"%.']`,"Y`P0H$,(,:
M8*"7?!A`!$QQ`#1VX'43_X,+CF"!(YA@`1$H0!\&8(>])\`%'%#;"BP@!1PP
M``H-0`,%(`![(#164`1MXP9M8`5J\`PQ$`9TD$\\T`-K@`;:8`$]P%=6\0%+
M<@$Z9@T<``9%8``LH(%_\`$(<`T)M@?84``24``F`P=U$`58\``AH"ILD`05
M$`T^5P<10`(8T`H58`,7<0<#0`%C$`+68`=0P`-?T`!4H`8MD'X(<0<!X`!V
M\CY:EQ-8,`=O\`*?(0=U``"XUB9>L`4*\/\$58`&`M!Z8>`&33`&6I0$(/0&
M5]`&%V`$&`!V>R,#S^`'7"`!;$`L,4"'88`%7U(%&Y`-""`&/0`&#2`#:;!7
M&_`$"#`!%H"":>`#57`!1P`'$O`".1`!%@`##K`!2*``%\`%6L``.,$G3_`&
M1&!AJ"$&)\(G#I$&8R1Y8X`3/.$55O`$WH,:WV`.[P`&;&,.#E`'5\`&;A`%
M<C`I9^`&6>`$<``!(4`&A)`$+8!J-V('(;`&=$`Q9C`&?N`%+.`$9U`'9T`'
M4(`$(\`!/)("5$``0_`!,R"++C!N+F`!(P`!ZM<`0>"/:90!J#,!.&``>N`#
M.#`%2$4%R/8`%O#_`NV0`!P@`#"0`P'```VT`!+P`2"``!W0`%6P!"HP!'/@
M`TB0`ZAQ`1!0DBM4,BSF#"U"+-DP!34!?#>B!2@`/FY`A7]@!QZ0*-1P#4R@
M`M@P`5B0#4U`*A8@`+0(`!4@:6&P`TN'``"@`'40!S*@!P2@`@V`!@K`!Z2#
M$"*@`+4@!`4@!F"0@G^0<`^0`&6B3?)8#JD2`F*D`W1`&27C!66`53V`*F:0
M!@+@#&=P!<@(`$Z0!=I!!.D4!FV0!5_@`5'"AZ:2`77@!?##`%R0!D^U`P"0
M!2?@!1'0`(M8<+HG`P'@!5JP`#60'#\`EG2``!$@!$Y@!@,@`!=0`!E`_P`^
M\`(5X`'[A@(R8`$&4&)HH`5>,(8RPDTYT01=P"<O\F+?,88MA!IG`&BHD2]+
MI2<N]F@ZL1IN4`4Z`!)B4`!AX%&41E=5L`4YT0(BL`8F.!4)0#U8<`5BH`9Q
M@%0R4)PY8``:P!@"(`0:T`$WX`62H`$>$`9:$``'$``$L`(,$7X*<`>(%`0-
MT%@)``0H$`%24`#&U@$Z\@$1,`(',`'EE``A4`!$F`';%@!X@`"F0"8P\`)!
M0`$+4`4^H``&@!H&<`6$P@,^QP9KN09)\`4"8`4F.`%AP`!Z8`<X$@8M4`4'
MT`:.@`T!P';7,);7X`(5D&KD%7\'80<N9@8U4/\'6N`:/N<'_Y8#3H"*"V`!
M0=871E""51$`,5$!?,`'#3``1^`$%T`$$E`5=Y``:,`3)1,&7-`"`H``\#`'
M:Y`&6K`%=(`&<7`%[FD$<D,$J=1">=$$#I`%!2`7+8`$EEDJFBIT/0@`M*<P
M%R`!<E`%E*,-89`$.J`97JE?=F``5:`"$*`%$:`'2&`88\`$-,``14``6"!X
MUZ$%(N`%'_$H)E$'62`#`)`!,8`Q2!`;SN`%]'8&$.``3]`#*&)17,"5J.$'
M<R`$,=`%`B`2'U`.=;`$/*`3#F!"5:`$;!`"7?`$9U`!;5`$3K`B&.`$^=4`
M..(!,C0%+I`#)P`*/?#_`YH6?=8S`RU``;84``609E^J>3X0!6I``ID$`GPP
M!2#@`4J*`H3@67^``T&P`D%0#0@@`+3S%RQ@``+P!WL`!14`!7\``B50"GR`
M!7E@`"F``&10`"40`2>0!&[``!?@HUU`!%Z@`&\0$VR@`D7P&3W@`]B@!U>`
M!A)6'78@`7'@`#@``$!Y$0EP.-6P!R^(#1PP`&5Y!V+P!`3S!%"V3T5P`G*0
M!FG@$%DP`CC``3+0`[[P`BD'7!>1!PVP!FQ``WBP`5'P!#+P`&WP61!7A2-`
M;S`R1@#0!F6@:&N01$D`0R!!`3)P!D8`!T<0B]\1'TO`!70`!_MA!C^0!:<:
M_Z4LPA,AX`Q-T`,SX`<AH`$PT`-#0JLCH`!GD`XQ4`42201&0#D[!0$\X"3'
MV0`B0$`%T``,D`9;4`+Y%FCFZ`;'0`%D\'EH0`9.D`9<T!E84`!&\+MQP``P
M\@1KI@1M8(X)XPPLMD*RHIUB!![^\E5GX`2G(08=5P%ET`:;LP45,!804)35
M@;'/*@!D4`.#)*AB\`(WD`-:T`5%Q0"NX04ZX`$S4`U(T`;5P`=Y@`,I0`,1
M8`!-0*(:(`1#^`=3D`!9<@`Q<`(58`="``4:D`<=,`%(X`)0`*)_P02&5P`3
ML`3LT0=!\`(0X'4","0^-@"H$62_UP,RP&(>P;I#@/\"V,`',I"TIM('5L`$
M*Y`&;*<'5VH5$%F6P84"$W`--((&$$`&T9<$;8"7HQ$#/R`#<X`$'&`&U7AC
M_Y<`7F`&:3$5?!`$$?`##<`'=3``7G!^?Z!W+:"3%Q$`'/`^SI`3*-$"?L`&
M)-`%8T0$5Q`';H`E5E`%-"`#-N9X^\0"/^`'/;`!89"DNWLC"K`5`^`$+7`&
M2G`#76``%U<`7K`&1'`!VO"\<<`!?,`#\?L`;.``,%``&``")'``+W`%#I`$
M86`!22"*/'"*09!P8G`&^@D!9\`%;+`$<*`#6]`/+;"76/4&:+`4+)0B<A`"
MM.<,\Z4G=%`'97`",L`&F'+_!H)8!\C@B(MB!.4P!DV2!N;+AOAD!1)`!JMQ
M!4A9'3C`5A^6!DG``PV@`!2P!&&`.TZ`9>J:KN8``#=@/F9@`PS`!P.27AX0
M`5;@?BE@`00@2QV@`A]0`0&``"_``0ZP`@IP!!-P'PPP`1-P``F``I2``@M@
M"1_P!^EVA`,0!!#P`3!U!$KPNSD1+<^U3W"@`&W`&E.P`MB@`DW@!GF<#7?@
M`V:,$'K0!@B`2VQ`!6#]!!9@U:!,MCB@`]A@0QF59T)$C(6Y!G$P`50R`.KB
M!5A0#R?``2>0`07@MA=A"%\```X0!VU@`@Y@!2.@!3WP@=MP!T#@`Y"'&F80
M`TLP_U]QP!LR"`9RP`4-,(:D%`+/W`9=B"_51P=;4`058`7!7!W1J1SY63Q%
MI+!YV`*"(<W9\+L,D``Y0`=",`)BX"4Z@`1RV@4?0`(YD`06P`,74`$ML`+'
M$P(Q<`&RPCQ=H`0`T`0AP05=($-C)(._:$UPD`6H$7)?``9L]3YUP`)=H`:V
M6`PB<8Y\PCXTC3!,A`4.\`;+PSSW8@4H$:XX,@)UP`,0(`=88``<X`%-(`9)
ML`0N8`4G$#GEH`5.T`8OEJY!C0`#(`27Q7\04$Y&BP.IM@`ED`(&<`1\``0%
ML`$!@`,F$`$!L`),T`<N,`)6R()WX`$$``,^_@=Z`%M\T/\"#8``!@#%_FC*
M*I"&3Y`%;'`%;J``WL(`4X`-7#`'"(L-+C!)V=@`.#"VUI`':B`!6S`!9$`-
M?/!S7D`&9%`J>_``>J""8I`53Z`%]Y(4S2`&%I432-``;\`"(3`&5H`!+#`"
M)Z`%1-``1H`&#J`W?OUN+5`#&R`M=*!R`R`&7<`$58$'$*`&R??I;<!O=.`%
M&S<'')!69CL',=`#[>@%1"`#83`"<1`&;Q`&5N`C5?#<5O&*Y]@%!$``&\!8
M/^0$,9T$-*`-8(`%-C`#=<#C&C`!7"`".>`!%/`!:(0!(9`!32`!!C`"7$``
MJ$X&*&"_=4`&$H`:=Q@")Z`$?B#_`&W0`UM`!D;P&2URII@R/:M4!Y]"!P*P
MIEM!`"&@!D2`!K2G!GM"+_WK!TTPBS?`!AAPX$V4D1O0`Q:PE#=2`FR@'4EP
M[6'P`C_0!190!5@0`DE@!A5@`7Z0`7UP`#F@!C#T8MF.`3P0U7]``WI`!2NP
M`!Y@G.G'`HN``$H0`=ER.$*YHCJ``PF@`4("UGD``<`'!(D001=PR6R`]#0M
M&TR0<'Y04&V`RL1[!5;@L]6`!Q50!UB>#190!W!``?)U`D<`I=M]!2@`-[K.
M!V<0!$)@`#/@ZE:1V-50`F_@`4A0!V#``TI1NG2@!ET0<A"``5RPWC>0R$B`
M`?`]`E65_P%><%)4H0='(!6O0P"DPP=?D,=O4A4OP!-K,`!&X`#A$Q(/@`5/
M<`5GP`*LJ06%R099,``CL`!6\!CI9`%@I.U5D4\YP08\@.\R8`:/P@!:0`%@
MD%'9@`)QD``-``<Q8`<X$`75]P$'``@H.'TN)Q`>#3U:74@)1VU>8R%^8EY;
M5WY>3PY/&EAO<Q4`5G5U9W4"DWY^`&=.I&]T?G4P?G%O9VM^3V)B;F%^54]Q
M;0!?9V>X+6):=$]M<WYP#CA^;3126`\<&G_>W^#A?W@1='!U:F$2$S<I-0M@
M+F8]%VDB?C]8'G@X!R@%;=X0^0/$!8(//G`0O)""P``<(_C@&?^2HL0+'%%F
MA&`BX\J$`P$*!,@PP<&?.S,XZ$GP)\@?/DD<\9`!A<>J.E>J7$'BP\J`!W[.
MQ`'09L"<'$$P#/1VI\P-.^(^M%E5A4>&.70XB/M3984#/3RTVN%0!0(?"F*V
MJOT#048X/`.`W(E0Q0\:)`4@A%'3@H29,!&.D&GSHXD3`Q.\]``A)`>,!SQ&
M'+``Y,C:<#C$H`#G94*?%CQL[+D\CH,3``">G!G@1DV!.FWHG!H:!@`6/VL`
MB/'#0$"%*M/(/*A"NKAQXY/.^`G#0!.,-@G\:#'C!P.$$^(.='Z@98`(+0:@
MI.C2A`,*)P\4%&`QHH<%"0806`!#0,O_<@)CK,@!HP,`A:!S)`$"'6F@(8,`
M;(!1AQ85!(6$'U_$L8L$#*3A1!PUS'(!&F&`L8H?7:!AAA@2GG&%%5[T%T8/
M8931`P`%/,"%"FP<AL8,230PPG'>Z$$&%P(20$(!&K1!A01.<*#%#CQX$88%
M?DR00!)Y9'`'"4$<,0`?4TA10`$)'&#9$#;X@$$!+G@@@!U4=.#-!T(88$`"
M=^1A@P0_J"!$!CRP@(,'WM"P@`<,2/%'>5.XP$`2!:RB&`H]Y""&`"-XX8<;
M2"AAA@0`L-&&$Q1PAETX*<A2PQ5.>%$'"&"HL947`F#11Y1_[!&*#&FXX`./
M?ZC@0C@%0.&-_QT&^(&%`!FX<4P4;1"000A/M!#!`!SX`883!!C!Q08WR&'&
M`R-44$&J21AW1`8U1/"F&T,48,9X$QAG1PI$^,%&"UXX@8$8$^B@A!40"!%6
M%U@,X(`,(;20ABDI/%$'`%?P*C&O.OBAAA]I:/$&$ES0`2410;"@``*C@G-$
M"#=P<40$"11P`@$IY#!"#CFX<,0)%)@@0PM"-!$%`!Z0X8`83]!`1JPQG!%#
M&SR<(4`79W31A@-QB-%&&`^^D44K3KX!A\5LT*$;`-09.T<9<=2Q1ATQL`'`
M&W6,08>"9<"!A!9AS`$'`&6D,08`5500`0%5-%&##`'PJH<9$!"@F/\3=`A0
M10]>L!###A*@<$$&U19@1P4L'#$#93X(N\"T?/R1@!YL;?#'`BWD]0\")I40
M`A46?"##'3=0P8T=4!QQP!U_I/#'!RW<004*+LQ+PPDBU-!`H_8&P0$:5#P`
M@08`^($``&LH4`</8A2```^<,2`.]2Q>`08#;_3WJ@Q/6-`&H'9(H$,(8,R0
M.(]Z(-XW\K`#('S#`W%``AS<0(<V/,$$%9C"2UY0`S@D80`5F%X:+&"%5,A@
M!02H@1!08((57&`#0T@=:0@0AS"(X0M*0`$2K."#-!3`&WSH`VEPP`(VI&$)
MJ5F0%^20!KT]H0MF$``:RE`&`C#@09EH@P+_-!"QB5F1-"NP10V0D)LMR$()
MN^#!$\Q`A!J(8SQ/*$`#?#`%!]C!!0U0`14NT(0[6.`$!@!3`2@P`0,XX``*
MP,(9>$"=-O2@!F0(P1FJ4`<LN&$6K>"!%@`@-C_4JPMP<!A@VF`&+JSB"1N8
M2AO2@`4"4*`.2(!-#RA1!QW(80>#G(,.UJ`%,,A`"V@`0!@,((=%E(`#NZDB
MCQ)P!AFH@051>%@,6D`#,%S``@-``00VP(<N`(`&>QB!2D;@`AQ<``5WP(!"
M-O"".#8@`7Q8P`(N0``+0``#$?@3'O*PAP$T(`)Z0,*Y;O`'!!!A!5K9S`=V
MD``-T&`$`;#``F#P_X$+1``#JZ``!CR@A18T``LL>(,?8K`*(CP@#@+80A@:
MD+YPC&457^@!%\;0ACHX00'Q"H<7Q!`%"E2!=7_8`0!`Q0"%7/$/*Y@!..P@
M@`=@``,-:``!1G`!<*#@"VUP0P48T`'X9(`-!O"""5J0A`EHP0U&(``<*%"$
MTEU&#Q`H`AB"T$8XS*`$?M@""3+`@@<4IP]#Z$\=TM`""YB!##U8`AC60`0)
MQ($+50!`"-*0CF"D`04OP,)/)RN.)+#""A@P@@R>YX<!G*$'%-A!"QS0`W$,
M(`U$@`(48C`&#02@"07@0`0F@(0)*($#..!##"Q`A!D,`2T-6,,:O@6`'O]4
MP0$`N(!NK*"%,SQA%<YX`@7>((=9P,$):QA#VH#A!VAIU`W-/8$,))2:#YGW
M0U:H6!TTJHM=:(`-$H#``R:EA2_,@3B\@L(9K("%!M#A`3\@`P&*P``42&$$
M4&"`!_A@`39D(`<H(((+@A`$`03/`R[8PQ$@\LL,9,``N^*`!TRR@#VX8`8'
M4)<')L``'U@@G1;(`P2@8H<%P&4!?PB``&J@@`PTH<<>T`$'&+`*->A!`C'H
M01_V@(<EK&(,:(!#&G9Q!CFHZQM=4!\X].#)Y9BWD4>0;#BZT`,'T,`D)^D"
M'7KS`!5>,05Y``<?$/`6)!CJ&PGH@A/$``<M*.#_"!P@0Q6L(`8)5*`$"3`"
M%!H*A@(0X`L"&,!E[)`'/AB`#G5HPA\*<`8(W,(&=3"><6;@`'M9X0D5<T@#
M,#`&$7A+#/1[P@`Z$8(0P$',E,VU`/R@@"YT00LM?&D+XF"%+43!"Q40@#AF
MT#\\M``*,%`"#W!``@@H@0`]Z$$0D/`&#1#N`$2HP`@>J04"M/0>K&S#&23`
M,2V@NP9::`(=8L!=,!A!#@&9@Q@`4`<S/,%A7PO**:QAGSJ0H0Z/)`,KSN"%
M.)#AWW[H01?^'8)P.PP#-R"#M"S#JR[(H0)E$$,9_C`"#/Q`#4T0``7.T#TZ
MQ$$Y`YC`$9CP!P]4``@5_S!!`!3PAR,$;S2Z^L`!$B#-$/P!"CC`00A$D(()
M1*$$%D@`"R9@`4"Y0`5'F``3CJ""!ZQ``7P``C1YX((/!``)*/C!*AJ@`3@4
MP`E`0.H!..H$-IPA##RP)@S&S'-PY*$+84@":E?!A1<(@`/"_(8!W%F_8:TX
M!2F@0!MR_8T5H"\<(]@[.'Q0A3T$0`=<D,&C0P"#)-!`>W)@0!NN<)LG6`H+
M4"A`%ZZ\ECN48`U=^%(=T.``*;#`#T+]`U1(8P<1M$+@J"&#!%:1!#9H(`P8
MB((&G!`$"61!"Y>G_$_OP-U?+`&KG+2"<`F`!@GP``*FY<(,&!"!$SC@`1EP
M@?\$3M"!#QSA`Q^(P0I:(`-8&;K4?G`"88`+T6("W=4I4V8O7]!=;&`*G5('
M<]!>G^0'#S!ES[4V6J`J3;`&=+`%7\`&8;`&(;!ZSN`'#M`&<A`"<@``C_0$
M-2`V+L0%U:4&.3`=:1!3QY$`8P0:9*`%/;`%52`#3K!>:'!>J]`!$Q``'(`'
M5'`$;#(%":!#WK``PC("0,`!"4`!/G`"'&`#`3``1^`#3``%*F``$0`%(U``
M*B`"$+``)S``!G``>,`!=A`P$5``'A``(6``%Y`##D``5M`@?L`"`\``&X`!
M`&`"%I`"%R`+=6`$?B`Y.B!`WM`';D`"X?`!&I4:O;#_"]CE!706#G<0*X`R
M+!26)C6@;-IG`BH@BB'P*S@4`0ZP&7:`5ZA1;3?@!#$``3TP`D%A#3U`!PY0
M!73`!6+``4O`<9<Q`#GP!P/@'WQ@%%V@`T>'!/+B`D3@!6R@!3&`!0&Q7\)%
M!`Y@!3T0`CT0`P90!!80?-IW179@*4\@:'$@!V&0,'4@!B/``W'@!#Q@`-F!
M/250.3S``"?0`@A``3_@"2]@`A5G`@Q0!./H!6L@`W70`TW0!'/@!!*0@0\`
M`/5U*<I!"6J`#'.@!K+P!-&`&L.P"FM0`VSP!&X``'!@!G`P%:DQDD]P!6R@
M4771/74`%-;@#&```&>C`2:"_P5$T`9MH`%FP!(\,@2#""W/M0I(H`AK$`7*
MX05_-0?:I0=38``O@'4#8`<?P`>M:`$'P%`]X`(*\"MV8`5],`$HD`(1X&+U
MU`,>``0GH`)0D(0?X`WI\@$HL(8N4``-D0(#P(Q4!P$.H`$A@`E!00=BPV\2
M\`9B(`=LD#8@)P1\L"O@,`5^X(^;UP4?<@$[H`LM<`5:(`YV0`!/(``+<`!,
M,0=S4`-=8`5QIGU.^0T!P`<X^`=#$`)W]@U<X`4AX`0.,']80$D@T@5S8`6X
MP0;+@040T`)$``&[>1DX`"8?\`!>8`-&QP"X1GP!4)!3<0(WX`5O8`9JP&<"
MX`5G0/\$1"`#/E0R[7A%75`'$K`&.L`#.^`$+#`#E,`!)U`'"!`%HOD-=E`#
M=9!C'5"'3(`7'Y`",T``+>`",@`!SR(#3<`&U3(&&J4!#>`'9C``8M`_7(`&
M"ZA+(0"=<!!H6B!RM^$%).`'3D`$9F!3F22=?I`!J]`]&;(*)_`&83`45U`'
M:3.5LK`*;-`+(I`$`M!V?K`$MRD`5C!RO+(!4>0';[">'(4:I7`"?A`!+F`#
M4)`0PG<!!L0!HND!0L42'_`E+B!B4``$3&`#=H``/E``?2`#'X`#`P`",(`!
M+6`'/``%!V`'$6`'%D`%-)`#-Z`4*3`$$_`!(?`!9#HZ;R7_`T;X(4Y0FRT0
M!EE0`:(&#BQA!Z$I#K[(I'3``A0`#*MI4JO@!$+F#7@@G7/`!6YVGSATJ>&0
M`]0(#C.`81K``6T``6P``E^@!:C&`W20DF+@#"\"!!!@!&C`!/]3'`8`!^H#
M'CWPEQ*#`6R@!G/P!;Z(`UXP`C3P!MFF`0*P8R3%JU<D(5BP!$)@D"S0!7&@
M!7-0:A1@!4F0H-_P(!,P`,H&`#H``A-`!@J`'DUP!61@`D1P`6T`?RCI!>`C
M!D+A`7[`!43@,&B@!H-U-MWSBQ_"J0YCA"A"!V*P!EO@!V1`1&IP&OK9`#&@
M!2R`!&+0!%8@!9!0`6/D`$[`!15S_RDG``83:YDA,`.2QBM/$`&JH&]7T#T-
M<`5K``?*H0(!`!%0<`+]X`,3M@$ND`="\`=Q-@`?4&EXX`(9@`,+,`%$``0)
M0`4^0``Q)0(>(`1@V)N[V@!+8"@)@`=V<`0"<$[U9``0`+85X`57H`-8@`57
M<`4/$`U?D`8I(`=N4'H:H8K@('K180`S8`+@4`VK4(Y/\`5O@`&Q&@ZE``=S
M8`;>X`%PD`$1(`-6L*OW"05-^PTXH(S>$`%IX)DO,81\]@0G()T24@8/4`9H
ML`9D,`<]\`(0,`=OX`;9>AE3@'Y_8"E&9T4(P`##@`D#\&AM0`1DX`5$H`4V
MX`3@*J\38_\?#$``7,!R8?"IMEDM7``E`NL-_G461(`!+C`%$K`%+T`!+A``
M4*``%U`%+_`"2D`&7<`&`O8"1+"!'7`;89`AS!`#7%"Q16`%1<@*$GFU8A0,
M?E`$'[(#TF$OLJ!8+<`%16H%M+D&9W`#W7,&1>0,7M`&<!`)#I<$7I`&GF(7
M%?!,<^`FO!(,NQ$,2V!9=%`!;O`$48`),I`#$/`!0)`""V```N`!09`#`A``
M%6`'0;```Y!@1<`'$3`$N\('.1``T_,'*&!`?S`!/J`!'G`$:C`%?!`$=^0-
M`1``!@$#!^`"NH("(&`!&I8!`I`%$U`$,Y`",4`M%1`-:6!A@?/_FB$@`V(@
M+.`P!&KP2$Y0%.!0+#WC!W2P!GS0/%J`!^)``7#X85"Q`6\`%7H@!SOBOEOQ
M!I0X#C]`>]Z0!V50%WZ0`PJW"LC0`V3@F,[5`7@``0-@`4G``)AX'-2!8U?$
M!P?P`[+@!"#P)4T@27XP`E5`!+VLR\>Q!:Q5`?MY!#`@1I@6`B5D`$K05.$0
M`4_0`3XP9R`0`!Y@`!4P`QE``1+P`=%P`B=0`!>S!DF@!B'`!G-``CS`!4JP
M!3:A!;`A`2N@!C<;DF5`!C7@`&M@-4^@45B0REPJ#40P!SOY!,#Q7++`<@WX
M(0&WI'.0!G`@!FS`0CQP!4_0(!G@9Y*W_[O'40<68!\?HC:[`09@4`4-<`9L
M,`8HP`%F#%-J#`0JD*@J8`<X(`$:P&"Z.P!38!DX,`-V``)2T``7P`+"H@+)
MXPT&P`=\T`%,$"]0X$=W0(?"L@$JP`2<`P4/0`\-(``@P`0%P"`,HAPU>5%H
M<`8MX`<2T`1$[0V0N5'962P?8`<-8`$;$$<HH`6Y.7P6`#0\4`99X,HQ,`?#
M-P?QBL[?,`(C,'S>P`3[FP`Z@`).9@U?T%A^D`0/@#7`T`858`49H`!\-`,C
ME9UKT0$Q(-L_A0,/\`9H$+<1",-B@`5.Z-J\@@5LT`0L(@,WRP,DH'!:"<3'
M(@XPL`90(`,/8/\")@`"/!`"1]``52``!?!];4`&6%`!:K,&:A`'F$`!"N`'
M!5`@8["1%J0%68`,9[#$^_8P+%@&;+!KQ$`)1--1DDD'.5`'LS`'!).->W,I
M@V%98-`$'<(7<W`!2H`$,2``86!(]4H$#.#)/%('EB(#PTT)1+`W.Z!P=-D`
M8C``@1S(?-`R99TX>9`'!P`%$D`#@.(!(_``3:5.=J`'99("Y:D!'V``0^`!
M3``G&;!B3&`')=`27&T'*&`'KG4'85(`&.`#(Q`!!O"H3:`"6Z`%^^('-V`+
M@4<';G`&+/`$H0@.',#AWA,.$#4`-R``!`!@`Y`"/#`:P*D0$.`'%9#_!$=0
M!T>0!T2&T"<@!L[MVB;@W'E]SB5P`G@PE2P'<;B!F=3!!BW)`S5@`)$]!F#P
M!A4P`)*^%G8@F]K'`4'0@Q'H!0%;MMK-*XV=BA^,!$0@!@[0`>/C!$40`C^@
M>>"@`'!P!QZ0`S.0`,*=`29@`";@`2=P!$,`!$$P`G5`!`!0!&50+4\P`6S`
M!CWP!$1P!8\9C">@;LB,#&DP78^T"@2P!<;@!&!C!F\0`V`0@7[P`F:0!%D@
M5630!&\@`+*`!6KP!$06!E$0`FK0`U[3/>SI!(IT!A9@93Q0BL>Q`X\+LQWC
M!D-!-OS6!CE0!6^@!CO2'1Z`Y4>P`,%G`"@`_P4>$"8(,`(>L`>+*`!'H`$)
M\`%-X``1H`((,``*D`<68``!(`0'8`-\(-]_@`'$XYE28`$^,`$J$`2/1P(/
M4`$)4`$.@`']N`--\`3-$`=#$`;`<`7]F`63[0TMK/+>``)QL`!F4`6=I`)>
M8.+-\P<-(`%'UP9JD`&5S@=*\`(DXH`[<,['[@U*L*BF:@*;$9)+O`INL`51
M@PQ@4+$CH`$ND(8,H`!:D`1$L):[OOD^X`-`@"9:L?F\H@5$H`-U\`4KD)1?
M(`%C$(DUL`8N``#`#-=/@`=P<@1@\`$J4!4<\`,XC@5_U0-M@`9SX%QPP`9P
MT`&/M`3HD$D`(`<00/\T&U!F-@$`21`&5;$<%P,!J&$&.V,3'S(&V@@(?H)Q
M3T]^375B,H)^8((/=4Y^=4\\6#4Y:WY=%@5D+!\W)G^DI::GI&\9$GX./&UE
M.C4``&9D/WY>/$I2/U![*AD8*3,:4'EX!R(Z>APE.']Z("833"X3,`EY?Q4J
M?W<"#`A,4'\30R,!=BA2?RZE07<&?4).&3@-$@E\-CY#5A1JO!#SI,L).0"(
M^#%`P4V8;:BB^&F!R@$`,EHJ7.#0(`H#`>K^8*$(!4P)(00:O&%SXDT`$R(`
M^%%0@=\*"R)\H-K)L^<I)A;PG,+`A]0901+8^+F"IHV9+W#\T*D#9X`%/S__
M!.APXB9#AQ%GB'`YXK.LV;-HTZKE6<4/@R<5ZN02(("+'PIT/&`!\`,5BCH>
M<O304.)$%2L]RCB(8&6-@1MFGLR)RF(.F@E1VSAI\Z0)%R5NPY1Y(D;+E;9B
MB'@Y$^=$ETDYY,:I4X>`&T%T)!A*(X:1GR=GSKSY;>@,`#2)_+"Q`N!)"R5S
MXI1Q0\8*ECDE1JQM(4&.H%I5J)JA0.",%@5.ZK!(,.(=DSM\?,SPD2&!!10E
M$GS@DR*##!1,#-#`"0;@D,<+[7SS@0\"V.#"`T?<T8`>%@300AX'V&%''@9X
M,((>`^B1P`$!9))!$CR<L`(+$8A10@]H^+'&%PIH_^&'#FUXD$0!/*5P!@&H
MS-"%$@T4T$4&!7#0PQA%B:1%-&NX04MK5)#AAQ!L%`!<'T^\D48/;Y`VA#=K
MI46`!Z?L@>8?4AS%R!,`!&<$<&T(HL$(:PSA115/2-``#UI@`,``55@@0YF(
M)JIHHEGX(0876:11!`!JA!&&'YFU$`,#J.100P(N&``"'SBLD,$(!LAP`01P
M&`"'&`7((`$`5[3!P1=SQ%!#<'Y$L(4?:,0!+!UK`/#&%G/(4,8:1\410@AC
MH.$%%F\@484C73@!`!L.@/&$&T2X:<(</=2AAAM*M5%#'7,\`$`=O,Y1Q1I>
M,!#%%V0HQ8!V:4TQ1@RW"?\B1A)U@-'#&CK((`,2?B`QA`84S.!!"2)`00$>
M."C@0PL(&%"``0<XH((#,FP`00D'O*-"'A]$4<(?":Q0A``%6$"%#SP>4(`/
M)7C`@0%)X(!#!19`$$$$*2AA`4TI-$!$`TQ@L,,,$8S!B`85:%%`%#4`V9,:
MT)QBP1,/5+!$&$OHX,`+"B1`RA5>D)(R%`Z<<4(.2J'`P@@`='&#FSRD,<<3
M6F1PQZ)JN>`$!J1TL(%$F'K!ADP]S+%&N%QPP$$8*;R0@PQ\W*`1%UC$0,()
M/%C10).(M^ZZH@R'`,`::3RA0P4*&.''!ISSP`,+%;W1QP0S''!'"QH0D$$G
M+5#_L,8<9V`A@1=9G/"$$[IAD88C@O#0!>$.J%&#'`W$$4<,.IS!1@MG/.&%
M&5Q<$8<;<5PA!AN.Y%;(<5>L809RCO)##V3B&T'LX`;ERL&E'%4&.$0K#%&(
M`@%TL`.UE*\`1-B5'ZP@B"_5H0=:H(/5+C`$`?S``2Z@`@H2P`$53.$(/AA!
M.?H0@`!$@`]!*$`!^G"`!00!!1-8``8^@(<`\&$!!K#A`3K@`CMX8`4#&`$)
M^&!$*!PA>2DH@`LRX(("Z(`&%?A#"`:0@@74X`)H3`,CZ)`$&8@A#0I@W4[<
M,`%4G&`-2/@`"0J0@0@T@`,Z",#;XF:'`.P!`T@X0P4B_V"$,X3!"GP*@2#:
M)Y4P\,`/6Q#*Z\K2@@CTH106\((@JL6&)IQA"U90B!_.TX,E@(`'#S"#"PAP
M!2(D`0!.$$,/FO"`$`C``IL,IC!]HI`MG($.<]!,")%0AR:$X`=-R`+P3N&!
M,/!!`#(00`/04`,FG.`",4@"$210!S*0X`K>F@,/DG`&"K0@#(XX0QM"0!XO
MA.`)<."`%KI`@`5B:@MP.,,5*,"`,,0!`&WH00%B<"DQC*$Y7)")&=H@RJ/`
MH0&&@(4;S.`'=[5%=EA@@Q$R<!0.G*$*#E!"%]:$EA/$00Q.(%@KY%(%"`C@
MI`1PPAOV<`<?3.`#*N`/%2C@@?\I["$`"!A`'JCX!PBHH`!YT((WJC"$)`R`
M"2^@P1^.4(`$8.$#.`A=`([@@181``@E^"',[)"`)5C``"XXP@4.@((:T``.
M8*U!$X[@)X[ZP0@TT`$1?G`##MC!)US0@QWI4(4&Q&`+'U#"!:IPA0.0H@I?
MV*JEAB.&EMU3!V*@PP_LXH<XZ``./0B#%^JP@IT-$Q4:`*8IJ&"!.0BB#6JX
M*1T$48<6**!A,$B"!D*@@RLL9@`M4,0#@-<"'!A!`#P`PFNG*TR%R.`,;D"#
M%KP0)PC(LP5O^,@T34$#`'S```:``!<6`(4?<``&/!@!%V:@!3?``4]G*(,`
M_#`]SA#_00P`J`%JSR"#C#8G#&+PSA/`\`8RG,$(;I"+)FAPA1"D00UJD,L9
MN.`&+!B"?3+A`!OP62?L;JM@K+DM'9[`A@4"8+<W<``;^(66"CP!-&\@R!-"
M<`:YV!8`36A#!*;`@3X((`-"Z,$4/L`!#P01!B=(0``N$(0_#,``:&#""'A$
M@6'<@`0N6$$I"L`'K"K!!1H8&1,.X`,7-(`L?X"0%SP0@`1(0`0+4$#')C``
M'E`@!U=%6EO\4`(>D)4*>2#`'GR2A\.>@@1^X,,36,"`+]AA`/&S[!\P^X<\
M'($#FM#`';C`@B:8A@5=L-(QZRN(,H!!(@^X(76;&C92(&`,_R=@@(;/D`,U
M(&$%*S#`'QR0A"]H80`%T$`>)C`!"T3A<U9P``=F(``P^``!T)F`"PXGS!*T
M0).S3E04V("L-!`A!]N"Z1,R@`(:&.`$%$#%!70P@A<8X`I:0`$'6B"$`=3!
M!#6J0)#/\P8?6`DX"7F"%;1PAC0,``M=D)T;"*"&+7"!!PV`0Q4*<,\Z">)7
M=5B#%G+PA#"<X08%](-M!]$"-\1@`S(1UAFLY(4NG$$,:V@#%VA@AN$0P38Q
MB*QBTQ*$-4Q`M36@`!S4<`@+UZ&/$[!#`2+0-A_8P04JP^%AI5!'I;J``Q'`
M@0T2L`<@0B$!5-@#"7S@`;?]`0I0L/_`!#:``A+@`081&($=9@"1&?`!"BSP
MP0T8L`"I)P`*"^A!"11P@AJLL``<]$,.($"$&/A@"BE`5!#\8)\_9N$(+XC`
M!6Q`"DC^008RD8,H)P`")_"@!U6@`05^0ZP'L($#+`!#!*XRA0&H`0'A-H4'
MD,`'/@BA`+IK`P#"2(H/2,`&'\#`$QAPA".$87!O>`,=<G`$%P@@'3>X@`&H
M<`<%0"28$Z"#!09P%@-\(/BFX,H#XA`![$5``[E\0PHN@`8C,(#YIG`!8L`$
M#>`#-?4`.E`&%W`"/<`"UR(!%^`&-Z=/:H`U=5`!'*0#"`$&;-`%%!`>;^``
M:<`%E?,$;<#_!F6@3@(0!3#7`T[`!6#P!1)0!6J0!#G&+F+@!<_S!B%G!ENP
M!CW`!6U`!P)`"TP7!F@0`EF@!:ID!%[0`QR`!7[0!C*0!D.'%@^0!!@0`^,$
M`1"@`0KP8E@P`D40!0]`!0MP`'T0`2P`1*9P!-[@`0=P!#1T!-'';`X0`!,P
M7._W!WS0`3@P`^Z0`!CC#G8@`!-@`GWD`C-`!7\0`5"``T.P`DR0`0/0!W=`
M/$-P#3G``!X0!`H0`R80>15P!`,0!A-@``"H%D)P(U!P`@T@`":@`@Q0`^_P
M!Z87!#)!!PQP!B/P`%90`]RQ`\+2!0[Q!$48!V'@!!Z`!B=@53\@_UO!UP`)
M0@H_T``'$`3G)P/\D@`:8!UL\`$]``%*\`!?(`8#0`$C@`(.4`!CY3M-\`4W
M<`2.]CH>,`=SD`0/L`!7*&]<($CP]P<]X`<7X`5A(@8>%C`60`0`\(3Q=@K\
M1P4"T`(P``)4YP47L#!T8`4?\09C$%YU(@'/4@=TP`4C>`8U$`*3PP,<!085
M$`9N\`5.$`=[$@%@0"L9<`*3$`9RT`5H```F0`$2$!G*!P9-X`=CP`-HX"U:
M\`4"Y@8RP`.Z(PA2`@<,``<"P`9$@`1;(`$*0`9-P`$OD`:?A!9Z8`5>$`Y>
MT'A=8``1($DH@`,;0`$<(``LX`$NH"(4H/\?B_8'.%`.>Z`'5,0!'X``VG$'
M0>`Q*.!^%J`""0`!-A`$,]`$?7`$P*<!0F,`$[`"+H`"I'<`+,`'(S``1A,!
M/\`$1[`"%4``"$``5.`!)K`#!X!LC;(['+`!$R`%&$`193(!9B`#;)!S%7!2
M)-`"TO4'61`&T;`#7Z`#WF,!22`&5_`13>D'#8<%=(`%<.`&83A12F(`1&`!
M%>`V#N)VX:8'&E!'IN`IMP@S%I`%7A`#<,`"#T`!7=`%.Q`!$Z``%"`#52"%
M(6`+`^`!#Q`2KK,`%B$(7J`$%-`7%>$'[1E\`SD",I`O9+`5!/4$%[`L9M`"
M`E`1`*`"1H`"/>#_`@&`$@3:`!"P!KB`3FX@?7Y0A!9P22$@!ET``'.@!3J@
M!5$@`5K`!570!&20-2\@`)77)U4C+XQ0!%@0!R=5)V'0`X8``&KD*.Q3!=11
M`T\@+-YAG5@@!R&02V?0%'"0!FF`4%T@`PC0!N9I%BK@!NF!!69P&YAA``[P
M!`D`"C3@`2UP`B_`!$7@E@=0`1Z@!U*P`%2P`HGZ`?HA:W\P,BT@!7FP`*-9
M`0=P`D)P!!@P`RE01'0H`.4`!0;P`E!@65%G!Q9``"E05`#B`!G@(?`&`0,P
M`!*0`T-0`4)X`3G@`Q5`!A/0`#F`*`Y`&WX``&)0!7,0`FYP!4.7G*4G_P9A
M<`0PH`5&<`$#D`!.T0!*\29JT`9A``!RL`(3<`16(`,'$`45=E`2H&FS5@`-
M<`HC<`+`5PIY8`6<B01P0`,"T`9%``%:\$<:P`4`!B<-X`5BT`0\0$\.<`?U
MN"AY@'*,$`8ZL!,.X`<0$)!_$)T5``<(I06X-D]]0@05(``/X``5X00*P`(T
M``0_0%*3P"IIX&%U@`9OT`#MD@9(D(0UH')KX`3`@01DT`-%%P%-,`+(00:K
MT0.!<P4;(`:C@09IT`7>`@<ZL&"_,H6,X`8.L`.[!0%J%">,P`9?@"E'40<3
M(!.V`@9+5P5A@`1>,`!@T+!E@0(`T``I$`(MH/\"PA@!(!`"*U4!2)`!4J!W
M(^`#'""8"8``$W!L,S``+T,JI8@#)``!LSF@*6`"-=``&&!+>H!U+H!YE7F-
M;G,$`;``0"`%!6`#32`%'P!,J^H!.X`'0&``3E`#*1`&+<-;P2$<$A`$2&`5
M''```B"W9S$$@J`$T@<'&-"V<0"02*"<?Q`9,'4!DHNE1S`";.`$>L(($S4<
M?H`!`^``'',"`@`GRI$&]6,"W#9="'!^I-`#'RI\6J`3?_`!`B`L#5`%%R`!
MP;&4$B`!5X!-"B``6K`$-A`#;:`"X+8H>L`*@C"Q.[$!=X&Q2W`&/(`"W=H#
MG/$"/D`+='`&<-`&+W/_"KQ3B2M@`@SP`!(@!BK0``S``%P`)X6#KV%0!5$@
M!I%AG;LE"-=7!54+!F'0!E'0!F@0%4EP!3MP4XP@!\C1!AFD!67@!Z1E!F'`
MD'5P!68@![W!PUR@!FP@G5J`!5_@)M]:0%=`!RR@!BS0`1>;%G3;!@3`!ECP
MDE&@!3P08"*P!.4J`1W0!WT@`1#P`^R!7$R@!P4`=RB0`5"#)@DP`1Q@`3=D
M`!S`!-W$!T<P`35S!*(Z`@B``1[P27R`!QY@`P%P`#,@B"ZP!SH#F04``1RP
M`@'@`"+@``-@/3$Z`1<P`S`@`%W``#'0``M@`CT`D&H!`8RP&AVU`3%P!6'S
M_[R7A5`#D`%.$`,R``=[P05;@`6JY`=F(!=B,`(A0`8$\``#B2E`B@5N<`)J
M1,RO50#]B`%$<0H]0&-_4`)QX&`$8,ME8#]PH*5$H!3(7``"\#\5,`!]N2@&
M(`A-$*4=@`IC4PX!*4D8";9J8!'H=@$OL`8M8`2D=PH5T`8XL`M6<``2H#;^
M`0$Z$"-F8`"B=`)@<`5,IP47,0=CVS=TT#_U(M-^H)1HT`!UP`4YH`5P($J6
M\@1RD6%^4`9'80@;E`1MP!QGP"R\!2_M<P9J8`B%T`1,]P0[[`!EX+,5,`<#
MP`%=P`1JL:\#0`1.,`(.\"QU"P`8X$L_\``<D`!I.?\`1]`"!3`$D\IM!&A%
M<=D"BU9'>8`#AAH$?(`"%F#6"0`$0M$'?*```8`'.:`?*G`'[O@"+B`"P`<$
M0B`$)P`%'F``4*,!KAR-#G`"<@$!%1`"<U`')_!I\"L#"W"):X$#4CAH@M!*
M6Q`&$/U?I$`$6J`&W7`!#7`!#D`$34`#80`'#L``#:!\;:`%(Y`%D)<$3F`E
M?E`%/1!0P\`":*`!&/L'.@!GI=`!'7#0?W`!#[`'2>!@Q=H%54`&$D``.PTN
M:=``:EP`8``%`J``%N`"[ELF"0`#?O!6<3`'%%!K?\`!3V#6$=T*`T`'65`$
M(=P&$]X%33`X;;`!J%`!8H#_`A'P`.2+:1*`*Y`@%S5`!'7P8F'@8`DGI<*R
M!BQ@@UJP!F&@!2&@!F-P!F;`8Q5PPRLG"$KQ4G0@+,5ZE'X@@6]P!8(04+D`
M`,+R!I\C)<)R!0/5,%+,7_H;!EC``%O0`F0`T6CA!A*`!"'P`$1P`0T)`EH*
M!000`0Z0`QG`LADP`RTP(7Y99Z;\!U-`12K`!`:@`7K0`.>PF`W0`GP0`T>P
M9H@]!6-U`E_@B%4P/&2&`"E0`2Y``G_`!'S@-@5B`$+09#>Q`C+@`%2`!4=!
M-0SF!V]@`1D@``=@`?"[P&?A`;N%!&(@%XP@!@YP`$)!!%7P!S;0&T30`P2`
M`1SP_P!(``%=4#H4T`0`(`-.4#(=P`)MX``"H`'[]AM8T"A.P`8/T`$.<`5R
M%&Z,8PI\``$03@I\0`."N`=,X"Z"P`5T\`8\<`9[@@%GL`0GN`0$$`(]4`%$
M0`(7,.!KX0):$`%WH`(OX`5:P`&E4`'?B[&7]`9730E:0!H5+`9@\(Q)L(JD
M4`%Q<P%JD&0JD`150``\,`=F``82((4[X`:VHP5U\`9$X"W!$0/9EP3]_`)F
MD"XR4#"J!GL(5<<W,!5UH`,($`08X`1K<`'WA)0TZ>0-,)"U`B/)1`M/P%%T
M`&0XRM6"8%MH0``BH`A58-YG,0<-0"@MD")SP`#&?0;TV/\$?S(%[M0`!M"Y
M(G``^W8$*6!9*_`!`H('=O!)')P.&A`$^T%^?[``ZC`!<L@$*S`.!HT"+W`"
M`[``_U@./;`"(F`#3N``4#``.I`!IT<`!%`#&(#,0^`$%%`$10`#0X`$*#`$
M=O`!+)46*;!R8:`&=%`G+A<%$[`%6T,$4%``7I`$(E"7+7#Z6'`"7\505ZD`
M-9H&#Q`5V`$&'7"C:D#GP2D#7M`$"TV\`8D'(]"F>9`!X_4'($!`4>`%5<M?
M8"`778!,$D`!"F!J`@`(94L4'U1_AXB)BHM'0XAZ,7$@>G\#`"N+F9J;FT9^
M<T]^`'5Q`%=53SP073PW`8L_%W__,4D5#DY).A!.?@)?+V=K%W)M?D]A;EQG
M?A)5```R6J%/`'Y^;6Y/.@)^;#U/8$\0:75=(0IH:G5U?F=MJ'Y6<]9N`$Y9
MUZ)ITD]G8J)R_%1A4V1-*!98ZI!1\T&'&A><%LWA0,#-'"-NNNS@`8H)!0<4
M(/`!<V%`!`$,<GQ`$6"`BB-_/##8<P1*@P$&"G!PX8"/AP`K^#SB<^1.!QLK
M[!3X4\6%!P@>>MBP8V=!'B8?"A#8X$*%!S,)E(B1@..(B5`3''2)$4&"G!,^
M+G!H\B)B)A=<K/FA(,8-$3,*%Y1!@^8,'0@MM+08@\:`EBA>L+!!\J1$F#!O
MB%CQDJ:&_^8G<-;\J)/&2Q,)<R"PT`%&C-W7L!=]B*`HQ1N8B+KX\0*#1Q8)
MQ?R8P=+"2H,K.AQHZ&(%C`L@;,*8,!2;$PX=<<!@D!+G`Z(;90:C29.&!P$!
M`AY0P-"B18T$U0_)^!0&@AD`%-(`4/+$2YLS8%"T2`YE!(%$&#C,,0`.,YCA
MAQ9A$%&'"DV<D44Q$3"0QAS%`)`#$2)T$48#2#0@1BAL_%!%&P!8J(8752B3
MAB@]L,.+-3W`H=>.8%CCA34ZGD%!%TFX(5`<,/IQ`1T-.!"&-7'PX$8(1L2Q
M0'5Q2$!$%6O`D`81'<QP1AD&X.`&!QUP,$,+2.#0@PL5&&#''_\MI:`'%!]P
M8<`+*[BP@%,^9!$$!0%,,5L(/05`@Q0?!*``$QTDD,`,!T!0PA\+C###!TXQ
MH8(,.KS0PA$9J%"!#19`T0,/?O2PQQX(M"!`#D<T4($"44Q@0GR'3*&&7O-<
M$8(?7?PAA5YM3'%!%%%0D$03(V#10PH]G%&%&V)0P,4_&#1@@!H-"!`""S.*
MT<,7['@!!QM/$,#KNYD<@<4!BM3PP9R(Q&&-/7.$\$,-?I`0AQMH/#&'#D)D
M4((81*P0`Q('"*!`!3/`NX@+2-!AQAG>'7*C-<'M:$P[?AC`ZWP/P)'$-6X,
MP,;&:BCAAWXM#%@&'R$,H>$`+HBP#!G_.8#1`QA.M+&&&UZL`<"/99Q1910`
MP-&&&`"PT00=!/@AAA<`../'%EYX\6L5RXCH!Q%GG!'&%5<\4\8679S!CC4.
M2..&&6(@\<P;&9#!!AE8/(%&'!2PT8:^=-0P2@%5X(!E!E544`,++<11A`X`
MF&&`$A90<0(*"83@`10I?"""!0OPD82G'M`00!`I"-7`!*2J@`,?!@0P!!0'
M&%#!'SB4><`#4J0@A0H1V!'$%#&%,$,`0!S@@QU[@%#$$5-0,043!?B`00<*
M]%B'#`RHQX(,&9:801"O\&J'"B)W@T0.6(6QC!E_-.$'&3$H4<`.7&B!!MS`
M@@\YP`HM>$$:_XK@A/.I(0UMP(`&KN"'MK%A#E;8P0[:`!&+>3`%24D$"+8@
M%$0X8!E/>$!`GI`&-H2F'@RH1C0BU`8:M"`&+DA"!`[0@I!0@A,I@,(/-Y&`
M#,PH!8C0WR?<0`<_A*$`,&A`NGK@A3I,@%<2\$,1S$&!Q%!``A@`0!@H$(%M
M.$(1'#!#!&Z`'`WTH`55>(,<-)"$)S#@#!6P`A98!`9].0@4:*B&%YY`-3^$
M@`X_6@(6KO`&`#Q!"U5P0AC(H)^8@2$R`%C#C];@!SAXX0I=`(`8'#1*,#R#
M#,;(W!.JP(-E^*$%;V"#%MJ0!C4`@`LLH`8%;H`OV,"A`02(P@,D`/\&,+1A
M`G$(@P:L4(4,.``)%7@``4Z0@0I$8`\&R,$!&&`!'!``!2.`0`+X\`$;>(`#
M&U`!'Z#`!Q4P`3Y'V,,$+*`5$!QA`':`P`%44``/""`!..!!"RZ0`1^8A04P
M:((3'/`'$$#``AF(00C^$;^]!$`(#T5`!N#E`S3L*`XLB$`+?G(#:[BK"62@
MP0D\8($P\(`'2_B"&*P0A@'HX`E$,($%6M"#'G"A!EIH`@KN*(9]Q.`%#*R"
M!Y>ZB#N(H6.'2$`1GN&'HKVA7VRX`!LJH*^OC4``2/A`""8@`_0MH8A3,)\/
M.!$&&+0O(@5P`A22:`UB6(,(`<```?)"!BW_Q*$+M(E/%GN@A0AH@0M)V-9\
M*&"&,*CA`0)8A`?*$($,)$$`54B!1^N0A2+X80T6>)`7%A*#,E0A#"^0PP/>
M4`,($,$/#UM&&+[`C0M4`V1:8`=PX'"?+;PA#O-XPP^<@"(9<)(==##,,:K@
M!S2$X0E8,$+@'*L75T;@!!$PP`.2`(<3<(`ZL/$!`-;HABKD(`Q@X($!Y"`#
M/EB!!PW80`,DL($)9*``7ED`!)#H`0.PP`52P($"7'``%^3A#@PXA#?_,"D:
MS.!Y=UC!'OA0`@B@X`]64($%3M`"[T#!!WL``NU,,(7IS>"^*4@!#C(0AB;X
MH*OQ(T($*+!,,#3`_V(UB($:JB"!%&3@"&.XL`78X8$_]*`,2$@#&KQ`!`08
M0`,Q0`$+4H``%J#A`_90@A=J@(43R(`+`RA`->C`A2V<(8-8N`-3UQR`"LB@
MEW@P00UF4`&!*#$+?@,`$4+AAQJ8H`E%8,,:S!`##SQ@!%+B``44$*T&%#D3
M%@"#&BS0A_CT`%ES```2@&<`/I]!!G38:'Q*V@4GS$$-;L@"$LZ`2@'(30PA
M&,$B(("&!HS@*3F(`1N(D(/5QH`.:_%"C^A`!QI$APYJ4$-_GA$&5R\##7#@
M`M=V5(4)?*$*:,N!`^)8@3'<PLP-@(`:<B#&-K"@@A:XPAH4,`\%R$`=<_]@
M;1A^9(TQI.$)E_;#"]85AQRX0=2P<8$52'`%!TA`"43(@!HFL!\-<$$%$TBX
M'0)@@00$``H><(`'\O`'*&Q@"P:X\0`JH(-*H$`"!V""!O#P!Q)DX`X7D"\$
M*'"!"F!@`Q5HPA,<\`%]"J4G'1@!!Z:`@0L$@0_SA,H$*O""`?!!`@+0`AF(
MP`,*#,L/2(@`$8Z0!"%<H(2\.H$8E,""G*C@"DM0P1^H0(`U4*('5_""#"2@
M!2UL(0L&^P<6PA""%GQIKZF)PQN8,($W^*`(,<A:"U(PIS``8<U,Q4`3>OD'
M%Z1A#W]0`HRMH8,5$*$%?(:!$-+PA@JH@`)5\('_!SJ0@@@(P0A.P,&+N%"Q
M3!3@22QXZVORO2.&?(`&<S/#:P$>FY+*P`PMJ$,,Y@`&1#VA"6GH01RNH(19
MIZ$`2_;&$]2PA1@``"Y]M"6..)0$-A0@1_10@QC.,(8XM,$*)[I/%=1@:DT_
MPZ-(@$,7^.P'9"_C5]>@!6)0#$O@2$X`![?E!V]`!M4@!RVP!=:@`'&0!E;`
M%V<C`#P@`1S`!B10'16P!A6`;330`W0@`U;@`V_0`"&0`F47`2EP!!60`T'@
M!(>0`2"`>3CP$P'``\##>`9P3DQ@`"IP=`&P`P20!R3@`3:@`BFP`Q7@2M4@
M"P80`@MP!!UP!!;P!P;`_P%2\`<P$#L0P`./T@,9@`1(H"D-,%<A8`'<$`\)
M,`0%0`03,$3NHP"FT`(GD`,-0`%7]`<F``".DP1D(`9;L`80D`,]U09/\`1K
M,`(YX`1<X``C(`8R,`YP$`.GD`$$$`09<`$YD``2``(L8`9K!7D>Q`>.@PAY
MX%V'D`<?8`U7@`7M8"0`@`8.<'IHT`0TL`9OD$L,D`!4T`2.86$+D`8+,`#S
MHPD)4`#)Y@#P\1HK4U'S$#_$!QL[8`U=L")J0`$L,`<M8`]UX`0O8`4_L`@:
MP!!8D`,TH`625@&HI0!:``%"4`*,U`NDIP!<D`5Q8%H]0`95\`\2X``GP$0`
M@/\%;B``+,`J:8`*<R``;?`&GW`&(<`&8%`%<W`&4=!$UY`$*U,'!M$$<=!5
MH.$'3>`&FM0&NM$-7:`&(>`%;Y`&5R`&`F@%65"-$3$";R`#52``1?<"`2`!
M2U`'&9`"%N`"/,`"58$#!3`"-_8'*W`$,"$!+3!/(]`'!U``?%`!'!`!97<'
M'(`"1%``23`"`U`%=G`#0,`!*K`54/<`!H4"0+`"$8`":<@'&S`%,#$"+2`"
M.<`#"8`!/R`!-M0"7S8`4#"5T9@%/B`"1Z`"`E`7%I-/7%`!3E!W$H!Y?X`!
MKO$'23`'%P`!!O!>%.`!-^``/T``.3`!&M!27J`#5?#_`&)0`1I`<ETP`@\`
M*M[6`2`PB:GX&G9P`#7Q.G1HBG]P!R<0`D/$!W#@!FE@(>=&!$G@`Y1P!)[@
M!$3P`"J@!1K``'C0`"H`!TY0!2%P!2<P`12P`A7`<9FP`-YG!4AD%SJ@`#%@
M`DJ@`!+`!><"!EJ0!5E@!$0``+57'59@#814`455``X0`CN725<@C(N0`@#0
M!`^``O40!PYP9`I``$BP!5KP!I>A@'G!!FB`!'[``SU`!,IF!4_`'&Q``7`0
M!A+0!'-02%\0`\TV!SU0-6K``&!P!9BQ(F[@2F_``VLP&&90!CHP4RQ"'GX0
M!QO#!EP@`&N@!F@#`"'``#L@_P=JT`-N@`4PT`8:4!T98![`$0H`,`(@(```
M,``0,`$ID`,_<`0Y,*8SP`=Y8%\?``0!4`!'P)A7M!1W@`$14``:D`%0,`(_
M4`!!``(WP`$*,`$3$`%7]!@/<`1?8`$3YP,SH`(?L`<K`!]Z,!5[<$U+]P<9
M\``F``42,XPO(`,J\%I^H%-DP`+(F(4>I`<6$`)Q,`(*L!2',`*BUJ%I@`0.
M``9*0``O``!JD),&@`158`$4H`4R8`1B@`4\,&X&<`1>\`5.@($ZP`$,T`!@
M81<!`)6,LP96\``L<`!WH)[$"00"\%885P4?0(])$`))T`"I@P@9H(`B0`;5
ME``CP/\"':!U)L"G.E`"'"`#3$`$%1``:J8(?!``%*`&8\``$;L)]\)R"6`'
M0&`!>7`$-G``DL)@(Y"QL0$&9U`U<V`"Q;!=!K-O;R`$`U"*B3``:K`',_`/
M<T`#RX<!;`"41``P/;`&;'`&J2`&-&223\`&8H,%9)`-_=%$95`'$UF`]E,-
MF58&6L,%;T`'#%,-<6"F*VL&<I`$2/`"YG4"/=))>D$'86`T#G`P@[0;;*`#
M6$`'/^!:??@:0<!_IM9)3Z``9.`$'I`!E\0#`E`57[4%%U`$.#`"":`")?<!
M*M`'`<`'E,`'/M`!/G`#I])-%M`H26``4-`]'-`""&`D<##_`FDP8"DP`0%0
MJ!5@`:NG!SF1`"Y`3JCX!R@`EE"0`#Z@!4=P`SH0@M80`7A0`EA0.+UYBC^H
M"`%0:7_0!F%0`4O0`@5@`ESPGUR@!0*P1XKX!`UP!HW4-6X@`1)@!!*`!43`
M`*YJ`1%`:Q$1`#[0`#LB!PHP!FR0!2U@`'M`>4QU!V"7F0]["'=@!WC``=1[
M"!UP`W`@`S=``=&P%E_``4O@!8AD!E<P`RX``Y([`#QP)9I@E'7P'L3)*P8@
M!AG@4RB0!"MK#&LP`$M`!U28"5W0J[>U`F!@!FO0!DB`2F-P:4D@!W+@`$T`
M`8*#!/]P!3JB!9P((9<F-<P0$,Q5_P9+0RPR0`;TMAM1L`%D,`:P%5I80!@A
M4`<`D)+&D%QKO"]I0#5D@+0C$`-J8Z5P=`,^T#BQ@4H`(0?Z,[8U\`8AP`$Q
MH`,!@`<D\`!\(`5$<0<+X`$)0"^'(``V<`@S<`$%4)0C@`$!\``((`(_,`$U
M<`$J``%<H$\)0"LZX@?KL`(D$`1"8*L%X`)]\`,!("EM\@<-00)8V`(/4`$D
M$"D?;*C!`0-YP`=:T`!/P`0IK`EL<`,2X`1N(`("P*=QT`/'R@0_X`([T+I.
MT``[X``68`4A\`%%\`0%4));,`-)H#,<P`EY0`!EX`0AP%ROM`8QL`0H\`!<
M@`7JU,R'@/\'4D`!BC!6O<0'+4`'&F`I,3>H1\`%56``FCE(X=,"`2``8=H!
MO[,)?.``$P@![@K0G/`KT!4.Z&IU-T72!'`%CZ<(X.L%1M(#,`P`20`&:$`&
M"A"DQB`W310&<S"C/.!1UK"L%P%Z,O`&74`!:/`/['`+V"(&/]`"/"`"?O``
M:H`&PE=7AH2C3]!%S,0&8BP*,(`D\[`&2"`!.B(&#D`-:,`EK1$&H?$%$L#,
ML!&-8H`!9\"<SE`-(5``,3`"1^`$*C`$'!`"4``");``(A8\07`$/M"'*""[
M!7`!.+``$I`#4@`^,E`"+W``>Y`"`A"\%T`!<Q`#.<`G=M"Y'?#_!T/@`0V0
M`)7\`O=[!P^PE3TP5".@`Q.P`"H``DL0`P,0!$S`!M;0`)P\`PIJ,B*="(8#
M!CIP!350!4BP!B#0!?HK!@V@!6[P!LN'!+Z!`5B`!&-@!#'0`D3`AE(P`2]0
M`S:;"0D0$,#2#0!`!T0`!U\``!%7`R(=`+*6""Y0`L_HP%5P`B/L`D4@`$%P
MC"12`Q702`70`C0P`4*@!PF`!]CUO.O9`F>`!"2\W)K`7'6@`S<P.&9@!5=`
M#0C8`PVP0XN`9\\@`P\0!Q&%9P731.Y@!1!4#6>@!7Z@!CP^(W`P!UVP!2^R
M8U=P!JBA`UH``!!R6H"E!EU@!C-"!G2P_P9C<!&@`0YM0`=MT`19``I&>Q]$
M4"-B`)%@&P:UR`,`,`=T@`00(`IB4`H6X`1?,%>OP0>'LPRE4`\`,'VP-0)-
M,`!.@`4/QP<G@``5P`)`(+`%<`!4D+DEP(22T@<X8&$<4`!`X`$E0`52X`#J
M;0$HH`(*8`<SD`!K0`14\`(-X`-,<`0H,`,14"L30`4%8`#+XP$>$(+M]`<<
MD`$ZL*E0``$7\`$U$`$SX@<<,``(8`$5D`:K[>&'L`5)4`40@`!M0`;0(@$0
M4`$$<+$74`(LD!]DD`3J"U\\(`0%T`"HP`5S<`(!$`-!$!&<1`UUX`9;S@95
MC@9*4'H94#/0'O_0';`KB'``USZWL\,%$H",$&`%31`#?68%!B`!/2`#,#H`
MZ2$#?AD1?1`!(9`&.U#`AU``65`!DIS"!%#O<*`#:.`&)%`&;_`.KH4%%V"X
MB_`"V'@#`%`:`.`&6M!I:5#>)_`%5]`"TL8%7_``#1!]<*L&&D`-R^`%6B`!
M`,``<Q`':E`#C=4/7>`&5N`@UA!'/6`!K!:U<R"(#_`D>H$&=;`!$%(8-=!$
M3R``X8`&6```9,#$21`V6L`#WTH",M#A$2'V*IKS,*;3+'`!W.VL%,`!4,<`
M(\``5/"P`2`+`6`((I``$U`">_`!#N`M(]L'!3`!.5$I.!"F>1``-</_2>QB
M1T-@`\ON`2*@`K=&&QQP!`;@`"10``L@OSA0`1`@!EU`!&C0`C`P`P1G#4+P
M%`0P`%%@Y]".!L1&!MON`!%0!13@2,B"!9=L#NG&/TJ@!O?M2DV@!NZK`QBN
M"'@0'.W1!FRP`34`-C50`Q*`?._\[WP0;B7_!TV/!2$`"!!*$ED])U`4619O
M74].+4H,)PI<(P9!'PHU?YR=GIT+,'0$`9\!(7)7'#Z?K:ZOG5UM/6X7,4]@
M94\`3TA+)2%=1ZT:?FD$;STP`GY>:#4`:&9)1'%$90!Q9VUK5E9L9T]R<'Y)
M;N0U<0!<`$1I3W%55W)/S0!K76ETXEY/=&1L_]C(02-'CA\_;NBT$?,&S,$6
M:/R0:^-GCIDN#P[ZV>8GC)HN?AKT8`+K$P0`1LA$P$(G#04_&I;XP>`"PP`.
M2U#PV6`@A8<!5%;\.<#G#PX"?SRX"#)AA`P9#AH0(:+@PX``/'"X"%!@0@`8
M.'`LK'!"@!T^!PX8M6,G@9`]=O#\:8!C2H`/*AJD6/'##!`;1"JXR#%DS$$3
M,J+H>!!B6,G'D#LAD7@%B`$>$NH!0!*'CI\U:;8D",,F3)D?$>`\J7/&3PAU
M;'@`>/$XAY\X:]0`(".'"!PQHP"<>2/CTQVYD9-WXB/ESB<U9A",:5%#"8`B
M:9B8&"##@`4Q,=PT$/]P)(,3'%46;%#!0DKD.S[@-&B%)T;K)T`XV5%>TLL9
M(R?D,,<67=3QA!M/A#`'&0Y4P<HG&:`!`1@6'-&`&64H40<1;U34!@"LD5%'
M'!EXX0<:=%SA61Q+6.%&%/7X0803!['A$!EK`*`!&WZ\(88?;708CPX:J5&%
M&&EHX9D?,KS1AA=N^%$'`'[0\<89=1B`QAA;U-."&$G,$64:;(P!@`IKI)!<
M!6W4H4:45@`PAT9^0(`""480X<`$#$QP!`160,%`$#@,P,D>*ORA`J$KA$4#
M"!^$<$`?.+#P1Q]>-,`!"`D$T8`=7!4@Q#`X!&$`!IR\L!0)0[7P!P)AV<#_
M!P=_)%#"##/\`8(*:44PP!<':3!`!!I``8!C_"7+"1D`N-&"`&P\$:.;`+"@
MD1<J:'`""VLXX(0(89QA;0T'<6!E&`F4]!$%,:0!P!M1/F'D$LR0]XD/#RBK
MKPM&:`$'#!J$48,"!AR!@@(AM*&$!6U<P,$</1PQ01(PT-"`#>5]8&ER:6S\
M"1].Q`'D&F4XX<!^^G920!)T-$""%1%X,$%&;A@@1A5;..!*!E;`88415X@!
MP!==<"&'&U7,D002;H`!0!ME".`&`!@\\<(37]#!AA=JR-#:&V0T$VX::1PT
M!QT1,0ODBAR0(T/9%`E]4!TY>D''UU:8(6T13VP1_TYK?HR0!``])-$"#R&$
M$$,`#Q20''QP$,%##P!4T0257-`1P@<QT)!#!#(LH``0)Q3@@0$-N.#"`S9P
MD*NL+O!AP0H1B&"'!@HT$$05!1SP@P8'D-```B,,88$,3YP11P,0K)`'"A'\
ML<`'TG/"1P(0\)%!$'^$4&L*!A3P@@$<%!!``A8XY$<!,U`0`A-C4)%RL@OH
MUH,#7&P0PD$'TGE&%]%801<:4(<=),$/3_#"/2``!Q*TX`$*@$))RC8G.A"A
M!B%P`Q:ZP`,B/(`B&4@7)P:0@U+,3SDD\`,)8$"^$S2@`4T0``&68(00/*!%
M6RB"U-!`@`P(8``HX$`0//^0`1Q$+S)IZ($K$C`"<LVM"2=8P`DY080G:$$,
MCJC!"-:`ACD0@``:J((3D..)%(8A3QH1PW!"<(80@`$,1/"#%<[F!G\]H09/
M^)'R0.2'*)@!``((0Q34\(8\EN%*2(#79[3`+#K`(0V70P,D%?*$*L"A0S?H
M0AG$8)`WI&$-:Z@"`+SPFRZ@H0Y,*D/9`"*!)6"A"!(0@`#4I)RRT<$!3=A"
M$^;`!A2D00$X<$`!6%"!&^@A`GD8P`&HL`<1N.`#1T@`$XZ@%#ZL0`H+:,$.
M,A"!%"S@+QG0@P$@X``$S"``$(!"`PS@ARI40`QN>.8?\B#!Z=DA"'HX0@H2
MH`'_#<S``MW[P^RX<`4D0&``,3#``RS0A,.<@`@I<(K\II@<(OS/!PW0@7\H
M0B4Q%`@`^P/#`9(`ABLH00M3(@`JO;`&K_$@`X^)R"?;((<MQ*`%@*-#')J`
M!BKDP7H"^`%%(Y.`'_BA"5C0@0SFV(`E*&``8K"``E@@@!)4801B>`$$&)"!
M')!`""]`P@Q>P($JB#"F2GR%!Z+D!P!,`&53'((6_'`S-CB!"&PH@QN6P($V
M:.$*)/D$"7;#``FH)@P(?(,6X`$&+,P5#FOP0V'+$(8J@*$-8>/"!>[Q!@#`
M`05M:$,X9##7)YCA`EVX@A\H@`$95$$`%'C69YZ`.#\<_RT$B4Q2!<@0`S^`
M(0P[0"P<ZC`'+/D!"W4`QQG"=@.1M>,)`E@"]903D2<8Y@Q:>,`'//`$)<P@
M#'/(``\*)H8C[$%C%,!!"1#`@8N5KQ,'($`")N`#%#@@`1^800CX(`&`XF`&
MMV/!"LCE`=D]P5`H0($(<$`!'TR@!'R(``2.H)8$&&`("7"!"D9@@Q24H`(;
M,($)("`$]7G@!&+@@!C(,-VA/@8*X#!"2XW!A;;Z@0>7DT&-63`"*Z1/&T\@
M`XV$XX<)9*`((WB,F=KPDBMU00Q8X&*,O->)!$A`@IS(0P34XF)/1*`.%-@"
M$X1@A!FTH`,/W6D$:@`)%[0A!/]>B`$9HKH"QC6`"2J8P@1D@"K(H*$)L+"#
M#RJB!3=P8`]#[8%$G-"%%D1`#A?HP0<`B`4K3-3+"4,"2DD0ABI6*0Y;N!(`
MW"6M.#QA#6*X`I4`-X=^J`$!=!@#'5Z0A!IP#21(BH,:EC2W(JF62FTU`PC$
MH.L0I($B!"#'B0[2(3](H`IOF,,%_$"&"@R("#Y<P0JN\(861P8-43B"!9PP
M!"900`R*KL`$(H"`"8!!`<.8%1K&B@.R#,`%,T!!'QJ``0_HX0,)X,,`.I`#
M%U@@`WJ:``F0,((BE(H$3G@!DZ!@ACH,`P$:#L!2^`"#.R0@X!3HA`MB@(<3
M?&$`"#C_P0A20(((@.`$,CA(!/CP@0KT(`O>[K(K^!`%.;A`!B=`("IY](0T
M8"E*89A!!MB0A@:`Y`F(S4#9')`$CSPF``(P$QI>8(4N**`-**@!`^;J@4[H
MH04X\,0>4I!VG7.BJ&%0@!02D($&%"`#;D#!#Y3@`Q8XH0-,4$`,1M``'YP`
M!7OHC@%"T`06%``"28:,&0`-"SSL``EZ\$$;37C"#U#D(&(``T:\L`(,W$`'
M(7#.)R)`!W23`0P]>`,,$``&!@BOT7Y``!'"T(1CA"`,$*CQDLX0AB3D@`Q=
M:,*IR=6&,4S%`7!`0QP*]P0C^,$$&CG#&HYO62QX5`T:><,8__P%N+D]84Y^
M6.Q&_*"#'4S)#61X0ANZD((PN$<Y7\B!`$0@AC%40`,8X`0``&\A,`$[P`0?
M$`$90`)-T0`A(`(>$`05P`<EX``+L`?7$P$O4``UX``[D``.``-\$`0Y4#!4
M@``'(`4&P`=]H`$\(!%/8`5VT%\S@`$?@$Y_0`4"P'D0D'9^\@$HD`!V``09
ML`+.]`<.1R1^8``$<`5&D`-6<%9NMT1$D`4Y4`5A4P?`\@2%)`9M\`0[\`%)
ML`9.``9E"`=G4`6+=09E8`82D'Y8!@M&$`-U$`9NH`(]$`=`<`6]8`4UP'D6
M``&?P`#%,86<``4'A`0#\`&Q90#R-_\#$<`!`<``1%``3I`!=+`#:E`"%\`'
M.<``?^`#'N`#%[`$&Y!SKE`RCT$!;.`>0E`%:2`#JI<R>V`!:4`.7/!EQ_4!
M7G`$(/`%<=@)OV@$+U`%2%`!<M`#;```,1`#5=`&B+5J^_,&2J`!/6`@J%0G
M;!`"%M`#`G`D50<E:G`&!I`%85`!8!`'G>0'8T!*`+`$;C`0+.$N`!`;Z\`C
M!Q%9<T`19_`1"-0#)E(.X0(`5T`&:O`$.?`457!_R:$#3<``U<8!5H`&+"`<
M`C`%#[!4(=`"4-`&?'`$,_``3/`#.>`#)7`'!X`#5#`!+M`IUJ04"&@'>I`#
M+(`'"2!$'.#_`%*0`B=0<UBP!4I057^P`@F``A.0%$P0!`F`!Q[`!'SP``C`
M!W;@<2/`!%HQ``60@!>0%`.@A!```R=@<UMP1(;H"A-0`V5`!$5P!@``?N#7
M#&[0!24P`$C``5I@`4(0`MXR!J:4!C6P+4Z@`K,("QR@$6D@2DEP!N"A`P_R
M!QI`!471"2E0`T=990_@`EV&!Q$0`S6@`2E0!"+``!#P`3G@!#HP""V@`V'`
M`1*0`2?``%/``CI0`RM``%J0`A^P`3#U"HCV!T)V=27`97G``&UP!1$PF,KR
M`2,0!V'`!67`!G`@`2W0`AI@!5+T"85)!#]``VB@6J^7!M1@&`K0_WI;$`<0
MX`<.\%?NX`3-)DIQ0`%OP`)8,`=E,`=*@`;69P9T509T8!`'<09@X"*=D8=:
M<)Y(4"T`D`6>U`7^F01P8`99L!'5]00$=1"M1P=?,`(2(`-=$`96H`$U`%#*
M8015H`,"\``$(`!KH`4],`<RP`09L`$\\`,O\``1@`(^``5,P`(2,`(^4``B
M,``&@`)0X`)3$`0'@`!)X`$@T`0V@`="T`$X8`%Y@%\(Z%-4D`-G,!QH``9_
M$#X$H!.&P@=2F@`!('!-Q`0%8`,UF`$3P`<>@`-Y`#RC4@0'\0`#X``B@`4]
M6I8EH4VBAD`SQI8($`%-@`0P0`8A4`(]$/\&4`(``-!02=`#0Y`<A7D05O`%
M;.D&XT@#D<D'(<!Y?V`'(6`HGI`#%4!&+F8`81`&!7`#6"`#):`##A`>B4$U
M7P`#;$`$#7`#,8`!7U`%]P,!5!"6.O,*PP(%3A`%?(``RG$'!E`-#]!V*>,#
M4`@&R4,G<T`$JLH)'/`$)K`U#L"6B81%T5('-+4A/?($/1`%8?`N=2`;;?4%
M1+`#T'EN4D*A-4`'GE$!9:,`D#0;6H`%,:":<>0':M`$;:`&-<8,;"`&9:`1
M:!"Q&]$A.C!J;_E(P'80:`"&:A`#0I4<"4`'7-`%'\`&&)`!%N`%%$`&43`%
M2F!##4`A"\`#*5#_`4$P$BCWI0E``4WP`"!``!:P!!;``":0`A"0!S[@3Q50
M=A[G`QR0`C^U`$X0)PS@.*/*!,51=O,4`#B@>DP`!'QP`GT0/BV0!RK@`!5@
M`3X`8DAX$`#%!PN0!#*`M7X*"RH@`"$@+6U)LF(`!P`0!FB`!5AP!5;@`0L0
M/`V0!')0!7*K'"J`!7X@"Q11!QE@E%J@!(@K`#KP"5#@!3;@"2B@`9'I=NPA
M!Q`@!F.WIPS0`$*@`Q9`!&]&!3+0`PUP!>7&!`X0`6%0H!E`!K`P!&B@!!UD
MB\HB($T06">4`!6`!0S0!'YH`>/5"B*07-'2-'[0`QN@$710D4X@!FS0_VPW
M]@5CP(>'N1%(P`)=H`4N0CCJ0P<:H!M@P`4+H6I<`$]M-0>2*P=K,`<&\:Y(
M$`;)=1`.H08:L`,;01%/H%IQ4#;-\#<6%`<7408.4`,5H!QV$`,$,`050`-)
M$`5HD`0L<`9$(`)IL`1*($0>H`)AP`?.D0(SH`%"@)DN,',MT!8_Q0DS<``V
M<`>SD@)4@`$2<`0<P`17(`.@^`$9D`)F]0<CX`$TX`(!<@07D"M\,`(B,$_B
MPP=3D"M]H!,:@&^(V`EOV`PYX"[-R[5W6Q)VD!8!<#Y_H`?GLP>]Z0IXP`=Z
MH"P>D`9O<$L]H`8_X`5B@`$\``<ZX*6>@`<8P/\JGK`$\^$)P3A%'R`#5%,`
M8``!0%`!,<`G/-`&(1P'$]`#/?`":X``1P`#`=`&&1`/(0<+`6D1U,H?%F`&
M87"L+I8'1_`!#7#!GU"]2"`++<`%9P`'OU$';G`&^ND'+/",+Z@#NO&?7>`%
M3K,1%,I!8("N0)(&7,`CS5('>A,'<$"Q=-(&`D`'C^4%<3`'6E`%B)4\`+`/
MZ&D&57`0`(`%CL@C=,`!5]`"+[`$J1$!#D``!L`?8J`%,+`$(9"0E',!VVH`
M55`%6&!X"7`'%I``*<`$*"`$.,`!!B!%*D`]2BF(-UD!\H,'WN$``7`!/D!-
M$7@``&T?<5`'#XH#=K#_`67K`PLP!4QP!WUP!'@<`5H1<!R`R5W!`R44`*[B
M`!V@!!KA!CT@!VS`!=RSQE2M+((#`%IP!"8@!KSK!#%'!#J`+`R0`V1T!Z3S
M,4F@O!1E!V+@!0B0!680`CCP!`J@`G$0!8*,J`AS``"0`S?@`'S``Q@W!)L`
M"RC0;``P/W;P`HD]A390J9]@`>5`!F:P!EF@!.UJ!F]P"V#0&FW``UR@!0"P
M`6I$?%>R!EX0!;T%SI&J;)#J!G50!T@0`W)`!U$0!6]P.9$%H&T0!4ZM`$^@
M`V?@!F53!V]0<7)@FF1P!EA@D(!C!7Y0!E\@`]$R!EA".$3@!C'0J%.='"'`
M_P#M]0!@D`-J0`$%X%L+T`%EL`(]T`0?@`,UD+(L4`,><`1&]`(^$`$F8`=0
MD)5YX`$C@!H90`,9$``&,`4^\`(9H`%)0!0]V@`Q0`1=(,I0,`*;<@$LX"=_
M\`$2,`0N4&`.8``K-P`7``4NY`)!%0)9"0,[``\:``<7$%TTT`6\7-6=8`=[
M@)PVW@DRPP,>N@(EX$(7,'Y8P`,[@`('X`"J*@)NX&UYP`(G,(MV4)GSPP1<
M0`8ML`$(X``R(`8R0`)5H`800`#%!P8FL`0!T``4D`$&)'9&@"RN0"/.=D(6
MX`:&B,NM8`%UT'L_DKTQP-1STPYETUE@\`49(`99@/^MJR%_]_`$D@0'//`&
M7%`+7Z`%Z%P")%,%9X`&#RL'!M(L+*`%YF@8\QQ:6!`'+Z`-8Q`0"%0%_DEM
M]1`'2=`S9D`1Q/T$,J`!4\$")L`?6B``"0`";.(T32"``(`".,``3E`%,W`$
M!C``'H!?I=(![[T'>7``>J`'),`'VA.GA\8$5!``.0!,)(`"`A#B`%T^03``
M"V`#"_"U0V0!!L`$":`"^U$"0C`$>W!0'^`#%@`##6#@^&8`V3("$[@_QW`#
MC.&H56#+.X[4V3.5.]X*.'"+7((F,L`#%=`"!.`%8<`#9/D'?)`I9>T".Z"J
M!K`%%&4#CM4#%P`"`^`%!1#_!0)0`0X@!M79!6;P`Q\@`$8`!;R.`"G``HD"
M"P*PI<XZ/RL`O%.8`HW9"18``"#PG]&77%N0$%A2!V4#!A+P!0!``5$``-#-
M`[MM!4$6]FJ`13+`-W+@!5;0`F;`]5*B#:%]`0#Z!@.`0'"PW.DL!C4P!W'`
M!3J`!AS@P%Y`$8[D;`.`)1)P`G]L(E5@`ZVY`FQ@`%A0`OR!03VF:E8P`##P
M`6VE`CK0`R90!5Z0`8)PM3B0`#40/B(>`$W@K`'0!W\0`!%``W=!$AE^`B`9
MI%1\!&8P!#XP`$+@%$D@`3[@`$=@*$2I`HYS!W<0``N@`@F``/4]`@,P!$JP
M`$>`_P$Z4`!B<%\\XH5MI1MBX`17D/03;RYH,`(B.O&><``/8`5MD`2*(R,?
MJP:VV05D"0@L#2Y_A7\V24R&?WUP'XN0D9*&(W5^8$!(/0P%`'1M:6]G9EX?
M3C0<#@P*!AD%$Y.%-&QLL;:+*P"WNY,SA)`K=71S3W-Q?AH.86!H%EXM!'Y/
M7G%:;&%R?GXQ79=J/`Y:%7YL:2':9VDQ?@X/55Q/($@G8%8];6]5VD]NVJ)C
M?J+X`0#`#P0M?LY(HZ#-CY<R6+0!D,-&39L;5MH(*$"DR@%>AEH(8`!A@`@$
M$$Z\B0-`Q90P!5P44)$CPY06'CST,!`!1X8*(PY$N!$$PO^?/!_V<`ARP$4"
M/$%\%+BCQP4.!RG^S)AA!(H-'WS^"#G"Q<`?#R/^\)`P@D<"+P-@F)#Q(D@"
M&0JL8*`BH<P$;14``L#2@D@;"@I`*H:$1X\=2'U>:!M3(.SBRX4*#)B4`$R5
M-0G/G%DR(H.+%EF6!)A@A0HD"H\6J;!KB,^>CYCY!)F#Y$"!$&+:P*G!RHF)
M"@,*0#`CQL@(#0T<Y(%B2P\8(I@AC="5_=:(!Y%&G*E`1XL.!%B>Q*ESYDJ;
M@0K]-)'Q1+08B4^D/7DRF$@7)P`(D-\9.T1PA@1>$(%`"SJP1T-"S,VQA31^
M<.&'!`59<H)$5ISQQA/ZP.$'&G[_6!%:#6V$X8\<59#A1P8"E!'$8BU$T8`"
M$'`1PQIQ9"$&`!#$@<059%@@1!,6>+#%`0U`L8`%,WB0P1\+Y#"%"R-,44@.
M.AR10`X3)/#!!RVX($4"%#C`0Y=J])!'#D?@\$<#(4P0P`!0!+"`'GSP\8$!
M'6R`P@P'*)`#%`3@0(4'&F#@`A#:<$$`,<2<0082&W3'"Q]DP'$%$:`B@00/
M2S1TQAQ78"&!!)K>,@$7$#P&R5NHK"%##1$004%)#C00@Q9JU``)'PWXL(@-
M)!AKB!1J.%&#!]FM($8#,CB!!!$<$+"4`!EI0X,2`(!AWAY'9+#`+6!<T.H?
MVZT[B0'*_RXB'A=S]$`&``\05$</70Q&!SH`[+<&$G0<DX86<HSA14(*M.$A
M'0$21(1":@`00@]I\)`&%V;XD84,T6@#!A+:M)"$&W/X(8`V<7C1Q1=5:+$O
M'5:,\<4V850!P(]>7(%&$3>`$<,7L"[6A``#>%8%"&@`P(8<3P110P\Q6&"!
M!ADP@4,!&O!1P!`I3."!'GUD$(`..$"10"$<<."*+QH,8(,$(B#GPA0P7$"`
M#1"T,,$%#NB!`A10Y*``+`FPL`(,5(1P``Q0&!$`!GS@T,*A,HR@11!0U/&%
M"FZ<484,`&S@11M'N!L+'WY<T0,1,3AQA0X]@-$0?P#,(<&4JO]+LH`.13!Q
MQQV&Y-"&#&*<(<<;7GAQ!I(M.)#!!BUTH0)U?TR`1&R%N"!`6H;H$0(2,R2A
MQHR860&`%S^<<`/':\BA4#97@$#'>.THX'T/M_3`P;HE>$+O>%&"=#0!"SQ@
MQ@D<4(<PB($`;C`"`,8@`S)<(0,P@$`9WE"''"3!$R8R`Q'@PQXG>($-$`/`
M&;1@A31400P0BX,<UG,,/[S!#W+XPGHTT88Z<.`,;0``',#PAC2(I@L*80,7
M`&"&-1"#!6%P0A+:P(,SK,$))`A!!(S&@"0TH0I$<``9YC"^)PR!!0Z@@05>
M5P((!`%,"DB`!0QP`@,P00\JL(,+\N#_`0HL8`@E\(`-FI*`"*B`#PZX@`7P
MZ`,H.*`%>#C"`$`P!`W8X`@>:($/.C``.26@`3K@@PKT0((1\.$('UC`"S#P
M`1P\(`($R($>B)"&%ESA"=73@!/:4`7B#1`21SC#"Q*0@#WP(0!\^($8ZO"$
M+W"@``@PP!1@\<MAF0`)%$``\3C`!BR$H`QL6(/#9*`--^B-`VGPP@N0]X(C
M7*`)>%C$`)"0!T/880)J0,,#E`"&`0@@`'M83`K\@`0KS,$`8=#"OQKB!QZ(
MX@Q&D$$1T"`%/EC@%CZ(9ZL*(,!J_D$*J8-$`=OP3C^TH0TOT,$;?L"#8VAA
M"P,8HA'>0XPT_TB##01Y`AT@```9G(`-:$##%[0@ABYXH6-9`$,4GH"P%IQ*
M`B8(@0.<D#(W<.&%P^A8'3Q!`TM8\0)U2`,<%&*%'=SG###,3QS$`(<QH*`,
M&FA""[BW"R20I``&*,`-6I`!$%3A"3.0@0[*(($*$,$'0DB%"7@P!`*0X`-4
M8($!*C"!`73``"2@PA'6\H$!E.`$(PB"#%"0@@Y$0`<.\(%)7G"4#/A@!#CH
M0!;Q$($<'"`!/D``#DR@`PTP0`0$F$$%3-``.?WA!0Z0@-5.9P8*8(`!ZI-`
M&[;H44.DH`[0@L11>7"$`%3W%D<P00TR8(<O]-0!?DA#%]Q0!Y*!X?\]?J`#
M%Q*0@1!0(`1H"`$3ZED(.\R`FH78@T)J0($3G"`.&2!`!FR@F#X`(`(8$(,#
M-J``;=2!O19Z@R@@4(<8G"$##7#-=PW!T>I.H`.1*,`9=$2!"V1@B6L884/8
MP`/]@`%%=9B#',)P!A94P02B$,,<NK`%-Z"A#A6`PWXLX8<J6.$$+```CP%0
M!PYN-3]^J%@7!H0%..S@"77@91T><($JJH\,;M`"&N:`!E(]0`QF,"<'9%#+
M((0!`XMAP1<J4``S0!<`2["B&140A@HP(`Q]:$L$J-"`('3W"'?H0-A&(((7
MI*`/UCG`F&Y0@`+(8#:.VX':7&`%!7#A"%[_<H`+9F"'`TR!#Y2]`UKX,(`^
M(-(`'_``$!:@`ARYH`=ZF$"P6V"`^5``"Q;``!G*X(<QU`'`U>V#'Z!="`9D
M9<2%>$$&^B`)/)P`"SHXPRDF%H+<#20T"4E(&)QF`"UP@09S`,&Y_C`$!T`B
M!P`PWA7$((`?0$"Z7YCW+NP`A4N((6=K8(`*[S.',:RA#J#Q`P*08(:+8CLS
M'<V.K`/`\0-X_``+J,`,4NR0!Z0A#ECHP1L<Z`=WD\$*!`#`%!IPAAIX@@P_
M4-$;W`"`&J?!`DA(7GZ4D!`&1-P/86X`S^N@,VW`-R$UT,8%K$"&*"RA#5]`
M0\C.<(2;65@+6;A!_QK,H&PQ$H%:8N`!`+*`A`JH8#$4T`$!P("`=%T!Z1LJ
M\P4X@(41)*#4'%!!`!K0`0%00<!_B"P!$``5/_V!#TPP0!]FL(!7,H$!0C!"
M<3<0)ASDP`Y[L(`O$W`!=<'Z"'K@P1_VT`019,L`;9\``\A0`Q)T00<S2,,7
M<H`#)"@D!C=@@Q8>X`<28!L%?AC"Q6.!!P<H81)VX``=GH"$@GCH#+:+[WV:
MS$PX_,L*'#!!`;8@`RS@@`\\>+LA//`0+12``2^0``LR,($%:*$(RN=%$,YP
M@P9XH`L,0`"_EP1QH!`$80%H$`$*(`!.L'Q_@`!GT!U\H#D$T09SH`9/P/\%
M6*``FP$)")`0I>8'8J`&=2`'25`'3J`%-D4O!<A0=4`&8'`&8]4Z^X`%9W`_
M3W`!$C$'9I`&.<8>7J`S;E`%;&`&%@('ZP`::V`&9(`%VZ<-:>`BPI`06W4&
M25`&0N8&3R`&;-`&,.0&/2!E#C`';"`"<"<!$$`!5V`"`D`"0J8-#,`$3H`#
M+@`%:V$!._`"!"`"/*``1P`%&/1X!Z`'=Q`$&-```1`$5``%$I!^5"`$R6$$
M*-``>I`"@[(#&M`'%G`$&-"&!Y`")X`'$*!M$Y`"%I``+X`#)Q`!#,![(/`'
M3'`$):`&%``%L5@23L!09!0")9`%"#!B/I!\#@C_?08`!B%E"'=0`$WP!`S0
M!'XP!U&H!F8@#"&0,DQ4A6O`#UN@`3X`!EQ0!&`@`P6@47^@!V3@!4_``P*`
M!>]3`AS0``/P'1+P"[?@`1PP!@[@`&>`!@^W!F@`!EU`!Z]#)'2@`1=0?F:!
M;7<``1&(&8[T!&_@!`3``#]0`#H0`1R@`?RU"!]8!WUH3FK`!2'P!G00`G2@
M865P,Z/`4`"@!F^0#7Y@`F>P#C+`!A8@!E60'E?@!0[';`7A="=5!7*0!BKB
M!&R0'W6@!43U!&1P#MJ@!F&P!EIP#E?0<%Q0`6SF!$U`!SIP!<!B`"6``F#`
M5$2@`!)@&;SP`&20`5<0_P,U(%9OH`-IP`8*$`0Z``44T``)P`$EX%MF88EZ
M4`A!L0B^H0@EH``SX`,\P`(JH`(+@`,JX`,/P`0W\`#OV`,+@!(10`$>8`$E
M<`=0L`*%``(C4`%QTTX%L`!',`5Q.`$&20&-Z0%FV`!.A7T"$`('I#-I,&(>
MX`<CIRF!B9:V<`=2$`EW@`$*@!O=`R!<$`8+PV0F=0,U4`-S<%0LL$Q(\`18
MT`]/(``6T`0QD&!<4!D'H$=LX`0W4`1B@`4-D`8%H``RH`4SD`!5\#^\X`)O
M%@9-LP\>\P!LX!E>H`4`@``7D).*<'$#T)"780`9^`(/A`/_U@!MX`$5$`EV
M,/\"?D`#/(`&="`!1&`!64`$<<!>(1`&!/`&:Z`#SXEN8<`&9R!$+?<>9]`%
M-]0$UG`##;$OSP@'9%!C7D`';/`&;-!A%7`%/XEE".$%`#`A!'$!:F!#/&8B
M"],&8+`&8C`Q+1`&;X`&M+=&8&!O(/%F%@`"31``65IH#JH`*8``+^`!%X`'
M%T`#3)`!+F8`.?`'QA(`6E,($;``$/`_-&``"X`"2:`'"7!,`?4!B0%YN`8!
M0/`!&4`#?Z`"`[``BB`K=F`'"\`'=Y`"'"!("[!%DK0`C_`!"``$$<`'#Z`#
M8E`&.,``$;$&9_`$:7",A?`!6F((:V,(=&A/$]``*&#_`F:S"'_QFX5P!R!`
M`D(P`N4R`6)#`@,0`09@`*,8`2(0`6P!!0@`.5!BG"=@GXO0:BQ@&7;P`*F!
M!/H@@@2192>@@6[@!3`0!ASPC!+!`T<9!CZP`P2`!35@!"%0``?0!EB0`RM$
M!Q6``049!-^*`P?@`:QU&2`0=0=2!]V0!2:U!A;04$40`E>P?'9@`=QQ&1^@
M/'"@!@:``B-0`&(@!C-PIXS!<&WP!!4#`#(D!PVD#6:P`G[0@F?`7G'@@RKD
M5/+C!ST0!C27'^S5`#N`=%T@8RV``WYP#CP`!V*P,/DAE<[H!SJ`E'Y`!.MV
M*FC0!A#0!OO6`W3P"2^H#5_P_S%^\`)F@`8C()$J0`(,H!@7(`92L`$I0$9:
M$`<$R@5<H!43$`)\=@=.4`$5B@4)$`!XL*L>D`(#X`,?0`(@8!9'0`5)L)`5
M``$6P``V,`(3\`@6,``S<`<!D``+0`$=P`<Q<$Q,P`<U$!8H,`$_T`=V4`9W
M(`-0T`(VH`<X0(=A\`<44`!`4``L8)$)@3`*,0=:0`(DP"J+(*B+0`"+(`"\
M\WA<0`1/(`%?8%R/D0!^H'Y_$`1OIA`4``8P1%!N\`,5(`,9@`9R0`$I,`4'
M(`$JE@%>0`$W(`%```EZH`6["@DQ(`!_8`?EA@8UL`;],!#\T`(84`%Q<#'<
MY0*2L?]]8QD?3Z`")E`%+5`1:A`'!FL`?A`&7?"?5?L&"]`"6H!^SW(9=Q`1
M+5-#5-8&32`:HL(&QG=Q*!"@V:&6-6`&`K!N5>`R%R``+@L)'X`,1/0$!K`#
M#_$`=<!L8=8T7(`A-]`$].('%6`!5BH#<V"Q!7$O6T`$(1`'.J4-`P`N`&,)
M:.`&8``0:=8"_I`&!$!\,#0'.N`I3]`$'@`'/R,'9/`$72`!.HL$+7`?<<`#
M4.D'7\`#/#`'99"0O`!T6L`"7K`&;``!8O`$3``'9F`'`^P`,O`!/R`%#&``
M*1``=S`$WF5/+N!?`3`"`^`!#7`$?``$*X``>-8"'#`"/>#_`ZQ5`)OS`EH`
M`SX`)7:``L;'!W9`77R``<0C!)#K`3Y@`$H0!*[D)Q80`SFP`G;P7FT0/6L0
MR&*`!&H0`B]0G(:`!;[T![`D+]1;"`/P!A7@``3``T_``79``S8P`'7P>&?1
M$2PP`E4@`$SPHU6`!CF@!2V@`9+D!5F0)E0P`F20`RQ@!)!:1Y$``5D@"0<0
M`CL0`G4@`U>0!$@9'Q*@!$M@,5%`#&HP`35D8?/D!W!0!P10!FTP`]ER`7*@
M`BVP!7,D`'_:!5BP0%9@O2C0`[*B&'8P!`UP.S2M`%O`!>=H.Q)``@+W77?P
M`$60'0ZP'R=`!$Z3!A'P#D@C"1TP_VU,-22\Y`9Q8`95`*0.@``%L`-C,%%;
M$`8<=I)=:P81D<D=$Q\MA`7WTK4R\`[/^)-9@`7"40W,@Q`$A<\6]@16T`4]
MI`9-<$,B(@T`\`5E``!-@`9LX`=3%`<Z$`8U1@$1$`*+X0!O(``84``5(`'Z
ML`9RK`5V4`49(`&.$@-4H`$0<``/T`='<&V%X`$H\`<!8`!;X0$E$`!ZP`!B
MDP$>L`<(4-P1,')X\`%28``N4$D>\``?4`&=6<!VH"4#8`%-(@(SP`<<0`%,
MD``#8`<-P`0(H`(?8`$5\`#_MP;G@`46`0`8H`1$(`/D:`=ML`@!$,^%``$`
M5@!T0`"CF_\#$N`X/:`%$N`'*0`[:$`$$(`%5:`Y6:H!OG4%[0:K+Z`!-Q`"
M3Y`!$5`$.S`",2`!%Y`T_;L(">`<DB`"2!<"/U`$VF`%1*4-&-`O'=X#7E##
M"\Q08?#9!6$A-A0'$J`":]``7)"E$B`#2E``%-"FQ#4`,:`3=*484I!$(W0&
M94!]HG$&/,`$R7UQ$U"2V=$'=+(S='`"7L`#1+`&5P"NT4NT;\`#H].U6B`#
M$G!#1D0-8V`&!=@":[`&94`,Z?8$,0`'7D`B+;#(IT,&"!$!;]`&45`%=6`%
M%$`$9TL*&_`$(4`$FSTB3CG:!N'6=9#7-V@)-580`'`!-^@&H\W_!3W4<WX`
M!62P&!T`!U;`!!5@T#`0`@2@`9?P`2I0!O#*`R2``A:P`CZP`!@@!2+@`0%P
M`#A0`2N`!WA@`7D0!),U`T'0`D`PK?27!Q&PW!.``1,`!0P@!99Z`@M@`AY@
M`$+Q!P;P`AU+!1`P`WT0`4*``CAP42M0`LHQ`B.`AP/@3Q5P'QGNQG#@!&L0
M`VP`O880N(;P`A2P"$H`8!%@$!P@!H_>!7B0`TP&!W&@`&YP`G0`!W,0!0_`
M`.VA</(A?-YH5/>!!"Q`,BA`!PH`N@9P!4M="`Z@`4O_!Q;P!H7>-%AF!420
M,@/1`%VP#C50!4&0!`SUE`VU`P4Q!RFS_U4AP`8CD`8Z0(`PH,`8(`%?!`!6
M(/()AF*8L0`;8@9WUP;G\"_[L0!]<`)/[U$N``(FH"DKH`'_E0)0T"<9,`,2
MP&"0``&6_@8,$%1/J@0KDR]*^I9J0`8;H@)1`/-=0''`(SH08/E^\`-$4^E5
M0`,D4"(FE6]B0`9D,*OY0;5(QP8B+1%MT`],1A`-H/-I(`9QP&SIU09<T#P'
MI``N^L%@/P!^(,+">0MXH`7I9P$$X&[:\`%!]P)40`,S,`!A<@!`D`/CN`)\
M,`-0$`0#P`<^H.Y!$`12$`9\<`,14/`$``@I`1DA!29>5E$7`T$>=FDD3'\(
M&1-\?WQ\`2-_#O^7?T,>"7]+=AX3%C@+%DTC3@41!41^1%I:5A]S5V!H.7^_
MOUMWP!]:P[\D!\`&=6Q^94HR;DEV,G[77D%JU]P``FT2#`0G-!<.#AL7Y1?F
M%7Y<'B9.(5EH'\"_>$^??QY:?F)H+`DCAUL<`'7\`/`&P(^7)F_0_.-&L0J;
M,!3]/"E1AXX2#&("D```!XR9*&VVI!D#9H`,*?ABQHR`(@`5%4$@*&331LN(
M.FT`J%B1X@>:8S*3*ET:LP#3ITOY:!D@T\"3)Q%XQ)G08$V<*@@Q2#`R`8U"
M+6:P#(C3ID86.0">]'P2Y]J/+W&PN)FSYHR?*GZ4N&&!Y4D5H-N\`KS_]B:&
MFVMP%G-[D<8"DFM$$F[K`8`!&2V\YC`.G&3&F0M0\:GYD>;:%0K7*/1XX@#/
MB1,<@BQ0P:7&@R,)&OC`0>*!G0P8@@2_PR<'@@(I*#"1L8.#BRD'@L3P(6)!
MHSXX,$"!H6(*GPEW#$#Q8>"/*B8%,I!8@..#G14&.`2P$^$/'@AZ[#'#$GZ0
M88<$$E0AQPA8G""3,/@8`TP.$RR3T!HE<>`,'@HDY,<#5V3D!QQ)B-%#$VM$
M00012"!A15`+`3!'0P,0((83$Y@Q0@M[Q.0`&W<$@(,"3_C1PP-4?.'$&WX@
M\44;,=3AQA,A..#'#7[,D=!C?M11Y#6]T(!&_PU^55'#!E9\`<,5#:CP1`YZ
MX#$#'GFX8$$""?!Q@!VI_2%#%AZ,(!8#/1CQ`!U/G&&&`D?X((,%(B2!1Y^4
M5FII4C>D4-4U=%A100%UB"&`&7!4L00<!)P11A@A/&&&0S<PH84,</DA@1-^
M^-4&'%ZLP4.6W(P00A-59%%&"%CX88$;8[3PEQALL-$#1EVJ404/8G@XA@Y=
MY'K0DM>HX=<97K@AAA]H4("&&&!8P8(*`51*QS45),0B&F^H8,8#!`@001(&
MF-#$`".X4$03-#PPJ1X>!'`$`1F@8,$?'*1`!0,'2#`%#GRHX`,$-VS00`$X
MZ!`#'T=T\((0/;R0@/\D?-A1P`A"#&'`!T'D0%0)(N31@;\(T(""!AXT4,$5
M1YSKAQ:M4;#$&3),&M,5>>#3`I^_9$'5+Z9I=$T<SH`1A#5Q_)"L7Q3!<087
M4_K!`P0[B%"&!!&84$<.T#7P009C.'#"`!%X@5I,5$A1P=I'D(K%&76,,=$U
M9B34A(E/,'"!$:UQLX8S?W&@!1L5!/6`%4_,`847?N1P0A0\;'UIGWKHR44%
M&10`!QD7U!$"%U6_[OOO2A5QA$PS7),&`6$`]D9=;90!`!I^S8%%#VTDY$7R
M89RQ1K)M7&8K#$Y$YL<6%-1!1AAO.!$#&6(TX<4;1,`QAQQ!N8&%&#&$H</_
M&4C40$8;<2A2&\[PACF(84UM\$,<Y)"0.G0!6@#0PA-X`H8SQ&$.$.C!#QR`
MM=1LX1H24,@LYE67!S"!!RTPP`@V<`<(3,`'`1@`'W`PC`UDP`,0R`X?3&"#
M&3!!!$PPG`06<((A<.`%&+"``SB``#*`8!(34$$_[H""`0#A#\IP@1V.X`$7
M[*$!0O#`!QI@`@\8(`=):`#*&-``%H2@`V;Q0P>^$`4M0$`!5WB!3*B&#R)(
M[0]D<%W71.0'#%BC"Q%HS;RXH84XE*$!59A7"`AP!0`0`0`Q:$@26,`".7P!
M"2%(PQDX`($PP``FOX""#-``@#5H1`P\J,,2.)"%_S#P@$E9*H.4JG`0/[#A
M`568PQ(2`H`$^J$-,\!"!LYPA2N\@0==6$,3HK"#)SS@EDF(%_#ZU`L>\(`#
M.*B!"&KTQVV:\W5-0`'Q_+"&-J0@`ZB+@A_H(`8)\.`!:_"2!)1`!#;(8'OS
M)`,8BJ2]7)7A"12(`3;.!0`9A"H,<=$!`'2@!B\%\!]9H(`;P@"')8G!+`T!
M`!@48(;G(<$,8B!#&<C`!3FH`0`M\,(5L,4#)\C!#33`0@0D\`(-Z(%2R7((
M9N@P!FY00`4G>``+^J!%$$Q``9V00`,Z`1\H!"$/)X!"`N)5@`FTX`A:P$`)
M%I`""$1``"N8@`$RT(,^Q/],"`%`@0UP,($*<&`&71W!\#!QAPFL`@$($)('
M9C``)BQ@#P-H@.!H$()C,L$)`'!#')(`@#!H"A]5^"DPK@:,*"``&#AHS1/H
M4--\UD$*(92`-?R0ACK$H`9BN,H9OI21S%WCG@\8W6QB(``*<"$')&#!+Q+0
M6"T8D%HC((,"QD`!"+CA5W6(+A9X``*,G*$(3WJ"%O+IABQHI`#2H$`2BN"`
M'#2!!S*00`U^<`$&M$`%:=#L.9<2`"_PP`$#J,`'..`!'8R@G/,-,%1"L%=\
M#.$:`$`"&/ZA!=1=HPR`B8.):J$&-VA!?#GE!A'F$`<,U`$`BW1(&LC0&:@E
M(0G_3N@!&EHKAQ`DH0YP\-`UYH"1Q]`!Q)H+(1<TXH8Z<*%;?BC(-=RP!#;,
M:`ZJ)4,(K"!?J&0A#8`!80_\P(($RF`0`G"`"B8V`2!4X`ZPH$(!H/"'#Z1G
M`1,(00(D0(4*X4"52)T$"UY@@R-,00A`2,$,H.""/UC`!T08P0R.X!0?*.`#
M4+A#`JC`APXH(`$>J(`=MB"*%!S!`B.`P@(X8-=_V,]Q\\*A<\M9A1X!0P#X
M8(!3?C$$O]"A#5YH0_5^8`<&^&$$A_&##.!0!E;Z(0ES0%NNGO#AY]W8#TY(
M@QK4X`0G2$D-;X!`#21@!CZX@`QFP8*7/`2&+JA!!3&`_P`6/N<``HRA`6>0
M0PS8Y`4NL($(%E!!]MH`.A8XH0(4F`/"'%"D'&@AI%5H@06>8&H!RP0'C'-!
M`PB`@QW`8`I<*+C!)YX4`?`#&-M@)P^>T..%)(1);Y`QB,]060^-0`RO0@,1
M>E!`AV"A(5<!@P">``890-8+.O##&*JPES94P0I6T`A"O0`!U,V!!7XPPQL0
MDO0/?[@-9J"!%9I@A86<H>9H0$(:!*`#)QS!`&'H`1(`O)0&!/`!<$""!@3@
M!S7,P`%AV`(&E%"$_'Q`!1J`UPSV<`+$_N($!S"`#T!P!P<P(``"L,``CD!F
M#U1!!`E0H1.P((0&R,`$`4@`$/\XP(<&2,`!E^7#!:#`"0LPP08<R-,?&G"`
M'Y"9"1,0P@AD\`,=:($.?H%#"G0@`37`P0TA8-(0,O&+!HSBU,#@``^H`(P1
MV#8,8FB``\CL)@L<X'&0\0,'KA`!#F!$`D(H0'YR\RHKD"`#&E""`')`@`/X
M(`0!4``=#-`0!19DQWZH^0>>H(8TL/(,(:`%:+`$?6`%#Z``4.`.$^``5X8C
M!:`!#!`&&!`"<F``_P9B1*`&-Y`]!:(#+4`$9(`4YK0'?8`U=]`'?\`$!]`%
M!7`!3A`$?[`(+P`&*$AQ-A@345`A,0$83J`#.2`"8L``&.`&:6`%HG%):(`1
M8!`%4>#_!<Y0!EX00=!G`&0@!T:`.FT0!=H5`M&T$&H0!G446?EW%0<!`&>@
M!F1P%5W@!@`@!FSS`#%@%D_``K&%*''Q&(XT!Q?P!6+Q!'```]MP%6D``,*2
M`3=0@U#Q*X04!S%@!A60+S-@`E?@`DQ$``/P`WR@`3[P`)_@`@'0`1GP!S2P
M!WS0`B2``320`P[``AZP``P``<"5`%U0`S@P!%/P!7H``8Y0``%P`,K``78P
M`Q^``B[@`PTP`5Q!%1&0``@@!05@5G(@`"WP`T'0`E.`)1HP)7+Q!DK0`AB1
M!F&@!5PP!E0R!C=@"V!`!&;0`V8@!\JF!FL@!ES"#6>`B'0`_P%_`'8*E$!G
MT`(7\`8RP'-+D`1<D`9M`099<`4$H``,8`TD8`4HI058\`-#D`%9X`4>X!<#
M@#9KH`1OP`)5``9.@`%3MP3-(@'.)0`"L"*H0P;!!@9TT$Q7\``?X`,HL`0Y
MD`*L@`'7@@1R$&@OP`!=T`(&1`8JI8Z@T0-.H`;MT2>)U0+A-P`A(`$+V0)L
MH`(P4``PT`(IH`P2<'$W:(-54`(R\0!`L75PX`!HL`83%`(\0')EP`9H,`9S
M0`8QD&X=`39Q8`;HPY9JP`9J,`M>0`>\P%%N4`4"``>N%!=45A=UU$\`P',.
ML`9+T`1SH`15T`9A$#EML`TD<0(\@/\%9-`#5\`N\_08)!8N:K`%`*`B&P>6
M2U$"<=%0(;`&KG0-;:`3(J`!#J`!([`#")"5,X`"$Q`!3``%4C",`>`!(,`!
M)I"<R#@(>2`$?%`#*:`'."`"/!``Q_@`HI`#E:`!JW9W!U"3`H`""(`#!H"/
M^'$$=T`#?(`'(^!6!:!?2!!&$-``MF8$'6`$9,``&O`%<&`$9V``4Y`!,;`!
M+?!<:/`B--`"AX,!6W<53W`#9*`17(`M9^`$-9A9?^`%M$5R5D`#@=D`_"(`
M$,!)O44!OE4%#P0U'B`&-4`$;A`!88`%.4`#6L"&1'`&59`&''=,;6`%%-`"
M/+`$+!`&%-#_!$X@;(1$$66XD@G3!%G'`U=0.G"0!F90`]Y4`RC@`2D@"!_@
M`C@0.\!!*2AH>2,@`#M@`0SP`A)0!SU``@7@`"50`"(P!#1P?&%Y@V,I$TTP
M3W6`!6UP20+0*D]@!6=@!8"!!L84!VX`;?8"D&O0$#)%!VF0!%XP!!(`!R$P
M!UW0!2$``6?`!@FA8&,00FS``CU05&OP!DAJ!G0@!TLP!S(@!EV0*'/P!!*`
M<V]@!EH0!6K0`[/P7')@%FOY!2&P`PK`!DZ0;U-08$]!`#LF`2T@!]KE!X=9
M+R:@`1O```Z``04@`5#@>19`'P'@`@C`>E30!T,0`2K@`AW`%0:@_P)X$`$X
M(`@O$`$/<`=F=`0@<`(I@`$P`$YV$`0IT&B7H%5<XP%_``,OH`)ZX`*U8P('
M@`$5\`)*!0,*(``8H`!&8@4->@99\`3%=`8*IP-C<`$YD`,ML`1RX`0R`#XA
M(``2,`9%F`:>H1!6T``A`!L<<`=VH`Q_$&4-D7$K1G+7H+378++7T+%.\`,-
M4`(\$`9%T`-"D*(Z$`(/X`4A4`<U$!006:,4P`8UH`1ZP9@405NYTB6R)2)U
MT`1$T"91`!)<<`(=(+<<T`,4``829TX!@@\_I0\:&P2]V0,Y4%,.VZ<WV`,Z
MB`\3<"42V7MPT!9A$`<:D`%K$#D5(`-O@/\%:-`J^'0&:5`$7"`RN4(`?@!?
M35!)B/(&$M`%,8`H-0``XN)`_U!,E-6T9V@&9HL0.K`$3I`%.A"I%X`&"C4B
M9,`#9H`$L<4#7Q`&1/@`[V`&?7$&/'`$*L"G3V$#0:<#$"4:MV8'51`&8_`'
M4V`"0>`".2!N"/`"]>$4\>(""T`"0$`#H9BP?``35[!Z?W!\(L`"$&``10`!
M#M`#>C`$0R,#1T`![?>_L&``+F``$[`"#`,%!3`,'3`#'#`"-Z``"M`#-%`A
M"4`!C84FCP$'/;`&9>`'7]``"H!"!?`$/<`#='`"/2``8:<#"O!SC,0E;'`&
M;4`%3R`'"/`)>0#_&'008L?T//OC!Q!0`#3``#JP`1%P&5C@`&;0`F\P`M:B
ME@!@!6%0!SR0!!O7MAHQ!V_``4F@!B;`.=S0$=T2`;1%)FI0`R?06,1&2"PP
M`@=@AFJ@`T@`3%<0`#2`B#<(!&<P`DD:`@,P`5(P`D709(P+/%/@C`6P`IK<
M!-S["Q>@74G0`A/D!@JP!75P+6_P!*+46&>`>UGR`#5P#2T``V%0)!3P!;I&
M*P^0!EB@!@I``6JP3&"0`V<@`44B!SD0`F1`!)7:!ER0*,Z:$%Q0!X[Z&6R;
M$4%1)`)P!H51)#TP98CR`"M0`=L%FTLQ96VG$*0Z`E$@!F=P!A4@`K<2_P59
M@*].,`,;X`#J]`MJA0$MD`<:@"<*4`!4X;`5\`='@`,!``-!``7M00(#@``E
M4`%$(0-\X`,3,``>$`E\\`(#8`$I(``?4`(YX`('((QVI00%T``I4``U8`-]
M-@!3)@8^0`#8]@9[@5]A(`!B,`+8<DDGX`5:[`42D`9O<`4RT`5IH`4$\`5*
M$(]=`@!O<`9\*LIMEQ!.^CE-NYEFJ"5%`@"W0@!/T`464`%=0`$`P`564`1$
MQQ<O4`=>(`9P,`-FHB77(&,*\,Q/2@<R-@=-NC1%E1%;8`!M$&Q^L`,`<`4M
MX*%]B@<`$`$3T,""')H.T,F5;"DX<`%:$'`2</\!(*!"G"P3]0(#2(`Z5G`!
M'?61=9`$\W(&\_,$+\`%XP8'7^(`/(`&7D`&BR,&7H`%3D`'9%`%++P%1)".
M:S`&9,"6)BL#6-`%#E8&?0%"1<(#;,`#)"$#%=#":N!M8?<JJ?-R;G`"7(`6
M?O"Y:]``U'T%6D`$H=TG!*`%'-`"6Z``*$``36`&1%`$N<(_/$`!3U`#"<``
M4F``>G`$&O`+>J`'=I``!1`$$[,"$4`%)/"E#!`$)L`$5F`G/)`!=PH"2=`#
M?)#)5``!964``X`#!\`!>)`"?>`#%<`"'ST"$CP#JW#@9&``_/D!2&``&&!K
M=;`#6E#`854"&F`!]RS_R4L0!'4:D/8E`4<`!K/7`QX@!Y5Z3&^0!APFU?;0
M.SI!$>(K64^:$6%@!"'0`I:S`0B`!350J3200!OP!)=K!@U0(D:P$%[.#5M0
M%]S`!=Y-$2$6%'`1`Q1PI=R`!BU0`@IP!FB@6A*P!G]+<4?0!@I`25.+"B=0
MV9?M.R4@$=(;!FJ@!;!F!F"@3?C0I`V@!K%4!$@`J00T!D@0&?FI!FA@`6W@
M!C#Y)4B`HEBP!+_2!*`QB&^0!>=3!FXP4VY`!UT`%'(`-E?!):ON![7D!K8I
MU2R'*Q?V:VY@!FW0&J=Z84]@QH1.!SLV`MUS`H;>`Y:]%!P``%CP`BS``!D0
M_UU&>@%KD`$-,`(T$`")_0$18`$?X`'K\4=`X`&RYP-Z<`(>4`(6D`<^T%4&
M4``H$'@>$`0&$%<,D`=',`(=0-!,D`+]00&!90=".P53D``54%@'D&DJ8`*A
MJ`0I(`,%$`-"``,KD+S):0'L?00(D/`5\`,F@`-,<`(Q4-85X`$2@`$98`0D
M,`=J(`,7U@2S57]-^\_`8`)/JE+/&AGS<`,L0`&W#5%6+`!H2P1<(`;_\`5/
M@'-:4`%JH0`AL`(-><UQ+&/=(/="5B#00MMKP`)7@`1H\P9@,$8Y$`-KQP,J
ML%\S0P(D,`$80`$1T#M080,#X`($;0"9$`1\L`<=</\&!P`!31`"(/`!-8#/
MI)[I?7('"'!C)U``7K#9(V`%"E`"\"<35O8^%S`&/>`&V*8H?M`M9?"Y&]=B
M+4`'#O`8LV&&K5$8?E`!2(`&/,"6?A`#':D#?AALE+4&FCT'9@(049`&@S$&
M9:"RC!-;XR/71'!0,>8'$!7]<K"[*.<U31('-P!+2I`&I0\5A0K9+2``(``(
M&C)$%3%$5V$;.&==+@A>(14%`RUW`0<?#AI'*`DN%7\6)!XG00-N$Q8=-GQ'
M(T$"$PD5%CQ[?R0.4AH6=@5$>P(E?TP/01,8I1X^01XH!A\8'`P"2'Y^83Q7
M.V1H7EUR84]S=#TA(6ET#3__24Y1#B%F6FMO54@4?FH`6F=N('\``081<TW+
M-3]GL#S1PN,-`#9MX&A!XP8`G3AIRH0!8,#"G&MFGIP!`,8'BS%/(*1Q4P<A
M@#(UY!S$AL4/&3<S#\H!D+/GM2<]`/"\%@;'EP=-1D3A<,-)%P,C%$0X4L"#
MG8!8LP)LU8')!`9:M)AH08/($PP6"KQ0(P0(@RH!M,J=2[>NW:P:`-3PHT6B
MF!`ZT)P1("-N5A9/A!AP`J$.@"HO#CI&Z$?!$S]8Z-#Q`Z:*'SA/KM`A>-G/
M$P!U&J!QT@:U'P(`!/A)@\9*##%TX'B1$.?*%3`-W&`1,X:+'PUD2OL!0%QF
MBS-Q_Y[4.2/CT;R<$I`\,-#C0`LJ=[%&'/%"P``Z;;94`.`$R8<`'R*`D<!A
MS(D"=AQX`,+AF``"+N#!1P(XX'&$$3@`P0<"1PB10`H/,#'##@TL8`0/.ER2
M`4`&3`%0&;T$`8$!.?S!`0I'X)!$``AXD$$$$9101!,-",'`!6OXI...?C1P
M1PYPM*'&$5B<T-,!6NG0$P,9@!&&#JDP84`)"UC``0<@1)`"""'XD00'FYUQ
MV1,XH<'`$VQ\H%P88?"HW#5N7&;&4'Z(`<89.:E111NG>:$<&"+`0`$%(?`!
MT!U7A7=7'@@DP,>C`=#A@@07L!$`!!DT<`&2BG;J*5T>>/_!``JY^6'""5V$
M@,1E8G"*50Y/@.:$&D/<0$`=!/E1AA)U3)"&&F4`0$0<)M`1!AI^M.'0-7,L
MZT82=/"@1CY^QN&%&3EZ`9$<FZU1!1U<5)%$35Z8($889`#@`)Y^5/`%&P)T
MH:U0J%F@Q1-O/$%'#A7XP<*=9+QQ1@E$J$"$!9ZNL5$5+B"1`0\*:&"%"TZ0
MH0`3!>CY@0$X(&"!"Q]0L<<(>"0`D`<?C.!!`<A,8`06$)`PPP\H'&#`$0;D
MX>@4)@200A!Y`$0`0!$4T`<'5"2P0!Y![$%%!B&DL`<4?5"@0``S3,!#!14T
M<05"%<G1!I^YK;&&&FG0AL8:+>7_U,`#5J!!A&PL%'%-'7"<04<%MP1TQ!@Y
MG0$=<P+/UD82=%Z3Q@,GS&%!&&+2```:9FQV11!())'C-<8=Y("1?M31=D\L
M]22#%W6<QH`7,2C+10]SZ/"$3-=<,`2"%!CVZ:<I^#'%#!GTX,,$0OQ1@:N[
M)Z\H'P(`$(8,,;3@A!Q(I!%"!A)80`3R`#5P6A@AP,':%TG`D>O8<?@1AQE=
MB!$'$71H888`82#1!`!I*%#&&YQ=8\@9;3"+',BP!@!X@0>B:T,/#E(%`/3@
M"G+P@A]"<`8TJ.$)3U"#/LQP#388Y!IM$(<`D,40TP!`!F.HP@&OT0`Q[,`)
M$O!4$MP@_P,-C``+%(A!&+Y```_(``,S`(,1GB"!(/#A`C@(@AZ.0(`4X$<(
M?!A!#OAP`AL4X`\X.``>.N`#/J"`"BO(P!&"4``I+$`*"1@`"!R0@B,XX`<8
M6$8+_L,!#T`!`CEPP`MFD`(<8.``2N@`'WH@A0PX0`<U8,`+%+""'#`A`T/P
MP`$\,`(5Y"`^"O*``2[P@J<(@0C7R(`!M-"%-[0!#4;@H/IB\(0"7L!0`%%!
MEV;2A'QP`0Y#*:#Z_("&T_AA"3'HPA.6<`TRW.MT!10#'VKI!SH0X$U^<`/_
MEI,X$+(+#M%,PTSJH,TJ8($'RWG!&^H0AS9X`7!^T,$'-,`$+?]P3WEV\<$^
MC)"!__#@`R#XP3OAR<^L1.`)2."!L=H`3CK,P0Q<V,<5%J`5#=2A!VLH1`]N
M$`8(H`$.;1/#&=@@AC=XH6)BJ`,_O'`%,H!!+U%(@@RR\1@_/.`-1&!#FXP0
M!_=YX2%BF,--V7`&.)RT#3&8"0\^$@<QC4X'//%"&(APAFE9;S,_>8(8S&`&
M/A$@#C5(@1$\U0(_]$`&3L#"`+#@`!8DH0IHZ,$2P`""-X0`"",PP0$XL+$/
M]*%I3!#"!V80@`#`8$-0V,`"H#"$!$#@`9GZ0`XNN8$2B.`!'=C8$68`@Q%,
M8`43(($-F,#9!*"@D$$(@@5FH($9%.#_"#G(0`<B4(4<O(`!&U`!`0Y`(P;H
M@`(YJ`(-5$"!"MC``Q"H00Q$$`$#2-`/3!B`!/RP!2[$P0A-\*D?Y'`&<9Q!
M!;`<09MFPI,6D`D);/"#`W80A_2]0`Q;P(P7U-"::T`5(1]I@@CP%`<"?,T/
MY#@(G42R(Z8*;B9NP&9.D#"2,'@F"K7+``..$`(/]?,N*&C#!`Z`@R.`P`,K
MP,`/AO#@#F<%!F<(`19:`%LEK"\-$J!`#T90`_!\&`!=V`(`LJ"K4Q+`#:#T
M)188$(8X.$:"6-""D)@3`B*P-SK8)$@5+GB9FVX&`!(X@QBL,#8L*.0GIM$'
M-LU`A@EZE0)N_YB6`YZ`!AC,@07KU6G:('<-)##`"E*M0@W6\(,!I,%DBDJ!
M&VCP!?H0X"!=X$D%4C``/7RA#";@FPNHD`IB3.`/+LB"$#P0`YQ5^`]XX``3
MCC$"0T4`!`5H``.HX(0&S&`/&S#``4H]``^4H`$\0`')[/"!08,`"G\P60LP
MD($+],$%/`!!$%#0(AQ,(`,3N`0&!N`'`VR`"DF8@1$N$(0:G&`()J!"$!;H
M!QS4H`Q;^$$;UO"1G+B!!1PQC`FNL88WA=<TUW!-3R`P@A6(@`-=*(B8VD``
M,_AJ.2-H0S3;?)`TE`8`[-IF2Q!\D&E>)"S-%</7^"&&-X'`!PU(@/\,4B"7
MN`Q(47;(@Q[ZD(<\W&(/C\+!$\;6A@IH``:;R@$./$QS/K"A"C>@`QM"\(`-
MG"$):%`A#`I`AG]DA8-FK0,#V"`#`GC!FY>9@T$DT(0RY(,-<^!"%ZHP@'L!
M0`UK,`-._$"$-GQA.74H`QU&H@8R+$$.CP-<E[V`!C3P1`+B6$Z7P>!C818A
M#FI@0;1"YP8QD2$,:=@!`)IPRA9XH2*F1$(8&G`%,U0@#@Q5E!0^(P,HJ`&7
M=;#"!];NAS6XP0#K$T$%TJ`"":1@`@5@0A_P4#(/X,$%1_C#`.(R@#\X@`EC
MZ`(3[)`"/N#`#E`(P`1L\`$.S``"!UA``0K_L(<06``*)\B!#8*``2@8P`1,
M6($&]D"`!;C`"A9X0?0M(($6],`"/LA!`XBP@1#00`,"($%6!T``]VBA!56@
M`Q:0!:7Q`N5E$4G03'[`!4[`!33F!U?P!#:P%3G`(ZES$!C$;F/W!%C0!7,P
M!Q$@`]/R!!L1!DS0.5J@!.^E.#/!!;DB&>XU393Q&9<A)D3@!$1P4A=`02"T
M-M<``B,@`QW``P^@!0*@!60@`6!``43`!0;@`8K"!#%`/SM0!49P!&+W@4O@
M!E^P`UA`!`;@``.@?33G89L7'3,P`#5P`Q(P`FA07!$0`D5``1R@%4:"!"'@
M!CQ@`7Z0'6&0!&`P_QL%@">Y<BYS4`-[\@4AP`*@Y`=O$`9J,`<70`!P,`9-
M\`5BH"V21P=F$`=L$@-O$%[A10<2<`)P8!PQ``!M4`=T4`<&8!9S@`;IPT)*
M@"]7%09-D(!>$$(R(`-M@`2H<09.L`0]$`9%<`1X%AX?P!?O%@1D(`,D(`\"
M8`5,P``Y\`9-8`$$,``?8`,Y$`0M8"(SX`,Q,`%3H`$X,#QQ\6A04#.OIP(1
M@``?0"4MP`%\P`$5(`0IH@&X)P%30`5V8`%!<`=,$`!$D@09X"A`H`LD@`!V
M8``@4`$>,`%4P``I0``G``4]@`'&50$4$`$"<`&VT0.$LAU=``08<%\_T/\`
M2,`";?``78`!'D@:!P$!L*0'3#43&4@'7W`!1\"&&R`&:D`'.C!"?*$&7E!Q
M&8`$1"`#:$`#:<`".G!?<&`$UR`'N/0"(7`9]U('6-<20D($+S@3&A!``S<3
M/34'JC@';4-UUQ`!(B`&59`&`:`'+I`"4L`$+K`'=X`HGR(@?!``'"`"=<(3
M%Z`!:D`$6Z"$'M`"+^`"9?A@"6`0:*(#6B`#%X`%"+<!97`&8_``13!S61$9
M0(56034'9/5!:2=C9-($9$8&#<138<`%7G@&6M`#6[,&<OD&9-`#:6`&54`&
M;*`&G7@&4L<#1!!T<3`Y26"6;\`%6&`F:-`%87'_`VL0!7*0!#50#?NP!6S0
M`$XP!JK(`U9@&L9)!VF00V\@<6H0`1NB*";!)]=0`5C0!F(``'/@!G%P%!70
ME'E0``L@`"[`!PO0>RX0`'F01)[`!!R0`BGP`5`8`Q#@`3-P![G6!"Z0%E8Q
M`$'@`G=P`'R@`AZB`39@`3@``U"@!U"``UF2`![`!T.0%B,`!5A``RX0`4[`
M`$X@`RC0!SS``R%0`S/#`!4P`4D0!0I``2Q0`SV0!0)@`2`P!2"`+.W2`BP0
M`RQP`4^'!',P*'C2!`H`!`%A`0?P`,Q"!&[`$A3`!3I``!)@!4UPGT1`!%&@
M!@Y@`1D``<N5`7.@!@*P_P8*$`6LA1`AH`9?(!/XB1X"1W9L8`9B``=CMQQ5
MH!QL($%M,(OQ)@;8XP07@%9F(&,`$`,YD"L1,`,\4`!AD'EE.``W)8PA$`8^
MQ09-4`5'4`<<D`$R%YD/QC\*P`-?,`)RJ4UE0`0.0!!O@`01H!56B1!41@==
MX&-D@`7L8@9E$`)@P`(\X`2\%`5/<%X*\`!T@`%S(`<9T`5@,`?9$`9UL!$G
MH`5?<`9@(#!/$`=S@$W2)`%7@"?C6@9M``'X:08U,`?E:09?@`;D(P$QD*]O
MX`!HT&5!P2^CV@8WH`50-@9<V@5P0`,Y,#0@]P$()P<ZT`#+.2W5=05;(``;
M0/\&1?`!+!`"4%"D*&`!?%``'.`",\`$()``/L`!GC!SF#4`&6H`"9``4U``
M>>``*-!K'*``'L"-O=``E""81Y`!?%`!N=<`$!!:+S`%HS4`*F`#$``!`[`!
M0YL!*!`!/'`$%K"2$X`",5`!/*`$&:`#$K`!CW@!%9`%.A!4?K`!;=`%,F`%
M<G`#D/`&P$)=<R"F`1$`>``!UP`'X&0Q!J!!"I!O,L``#*``.:`J)V4;1#`'
M3``&3;"+9V`%3`4`5^`%2!`#W*8&Y8F!W,6O'QA2H5,'9H`/.G)+_S5=9%`'
M:*!3^>8')!`$#5`#`.`#NCH"R7*)8OD$/R`!22`&#T#_!AB@`B^@`;K:3_SC
M/%CP!0BUIB_`!EQP`Q<``HBE%8Y[`RP&(V_0`A1!`#P`!V4@!AR@)U>@!5Q0
M!PZ@!!Z1!F\`=&RP7"W0)DH:![)A!B.0!$2`!+8Q`A+@!1"P!FW@!"@@!GJ[
M&0+0/&;:3%&`)V`0K:&S&9<J.&G`!BV!0;[K!49PKF[0`7`0!E>P`6`@=C4@
M`S_0!YU"!?K%`G%@!;"Q'#S0`,Z&!#T0HB>P3LBX5[B7:T<P!!&0``5P!U#@
MH@N`!R/0Q.F8`18@!2<P`'?P`7\0!!]P!$C0('PP`$B@`@<@``L`A>OP!Q0`
M`2A``2H`!`C@`Q+P``W@'87Q_P>/8@>:I'L%H`7V6+T"H@4%$`3@)P,@T`5X
MQ%\.X``\P`(&\`9A$0+HQ`($L`8&H`=8$0`54!J"\P0#@`&8ZA/:]`8(0`!T
MB`.(\+]$$`+EY@==T`8UD1-=EBQ/<*XG]4-6H*VA$P8F[`5I,,M<\"85=PTC
MX0;^2B:AI`):``-*@+R1:0&780(]H`\*$`)5`&9>4`!EP``0X`#9RT\X\08P
M`+]/(`!`@%Z[`;]*$`,JH!46@)Z3?`:4!:0M8`9GX`!F<0U;P&W\\P!EH`!A
MX`15<`)M8#$.``8W-P<5@!-G@`A5<`8Q@`8LL`1EP`%O@`47`':@A)A<8!"F
MM#9OH/\#'0T`U*4&-^`'`S!42*"M8%`')U"?%_4#1$`#2?`":`)E%#`%!Z`&
M'Q`AG7($[N4%-Z4M<!`=`E`&3O`!XAL`'T,%-J`".-`'!7``$8`#'*`'*.``
M,X`#`3`"%C`+?1``%Z`'8X`"5\`#$B`%K8<"+:`#&)``?;``%R`!'K!]'!``
M"1`7+A`@%D`#.)``'>H&#!4#!B`#9I`!+U`$*<``1I!:=30$&A```N`;'T`!
M,]`$6O`!+:`%*B``33`!78`G%T`&+Q`&+Y"4!]$&$?",4R`'R1H0(]`2`)!!
M5A"!69`$&Y4C8A!25J`&EJS,E\$G<Y!"6D"`RT&*:[C/24C_`:!)``0PNJ;B
M01P`0BOA!WOA!>CV+6<P.C,HGVT0!1O@&`Y0RZ'D`V(P`&T@FC0'!%/``'X@
M`V0@`#XV`/UI`1!0!0H@!AA``^4,3SBQ7C>0!LZ#&P"0MF6PKEB`,/YDG!+0
M`5%0`V;0`E]`!VG*!A#@IST`G2?P!!7`!7^&!5%`!MAY#?24`5L0!V[`!I<!
M``6[93'PA9114]+K0&;P&YC:$C4@`440!@X@`1!P!@WT`WY@!M@$!_<0VFXP
M!@,0`1O@!DK@!0GHF600`D+0`]%@=.%AU+/1!$.0!$M@!7!P&PK0`R`@`$\0
M`K?@`'\U1W?`4'B@!S#0`3-`#'G0_P-!4")]8$CNZ0!00`5XD$5U[C04>A]!
M0"5#$P`#(`(6P+@#$`**-0'XN,4^,,9\(.@>R@<[P`<?\"@KE@0>T``8@`<(
M"04SP``@@)%TX`0]@`9)``.S>`4L0!"NZ*S\HP0"4!%X@@2P]`<%\!'R&3IG
ML`9-$%&>\0)^&]%LH$U^$`$#H`$.<`$U4`>ZM3\3]`1D4`94M09G\"OL-0=8
M-R8)MQRE<7"\Y(@\<1E?T"^G@2?3$1VMI"^A)`2Q5@8?H*H=!B1*$`(<P`,"
M`$HM$`$G8`!Y7`-<@`$,,.#)@P?\@P:_&0(G$-P%L`1(P`&:*0`\4(=9T24>
M0``XUUU-$/\'_UL'LL$#6Z`#/-`$=%!V9-`&.N`&:"`'I5$%8:!4'K00$*@&
M86"FO5@';S`'+4`$89`"`)`$;R!C6M!C!.'S.Q$%H6H%8H`L`<8"7,83!.LG
MF_/R$&`&(4!0+=`&9H"-:/*1+]`I4[`<6J#0;>`&(<`&3O`%?H(%"?`%/)`"
M,W``V-4'K1`!*!``=S`!8BP$)[`'$2!^!A#&"N`H:@L%%H##&H`"?Y`!%1``
MJC4"(]`!*.`#>=!\!@`$1\`$*8`"=Q`!`;`'*(`"*P`%&)8""/`"$#`-R:H"
M$T`#).`#\%`5$L`$K/R$(1``0HP`DZ^EU^``%8#\%_X2IA143U#_`PB>N`$1
M`3WQ!O_T)B@,3?32!DT@`YR9`_A`!\8[)CVA-_V@(Y/A!^^6@3/Q$4CI!R"P
M`@\`C/D@'=O4G^>0!1^@`^`(""=0?T(X?X>(B8J'?"].#&0`,BUT:U<T/4\/
M;!<`8TU.$"J+I*6FIZA_4'5^<2PL96=K+'%^8$T,;5QD3(L\9TU>7%5^;G%5
M#`!5<6)U6GY-9F%D:6):8EQ.$F8]?F%?(0U)`BUF"F=H:0)93VQQ:&A^<&YG
M-T]J74Y@Q6M%?CW1E.@80Z;)EAI7>+1Y,L#)$S\2L`#P$X(.&B1UTH0!<"6$
ME@=GV-2P90#"B52($'B+H<:+'R=7VOA1_Z#@"Q(577C884*BB`4+?SZXR.!A
M`88]'_8$N%.@P`D4$S+(R!&`!(<(31:X>.$C#P0'*@Y\$##"P(<''`)0B'"@
MA)T_`PI0:<#!`XX35#[HN$""1PT$/"K\4?'BQ`LF.(4`B<`!Q8"O'CB$N#`@
MQ(L4</SX\=#`"9(:$63(>6DFCJ<X:;90X7/(B&;-9-@`Z*(&`!HO8.+4L,)%
MBQ8*-\)8D4"A2X@J5KZP.`$`#(`SK].\+@,`P)PD3Z*\U@S@H1KI?HCXH;-D
M3G?-3^`\`;/&#Y(N6K;\B*.F!H_M=%(<X:-CS1\;'T"!P@=_V/$62HCD@0,'
M'`C@1QMFF-%$$_\#$$'!!CJX$$(&10C01"\(ABCB(E!H]EX/+)PQQAR:M5!%
M"W#(`F(B(50G@Q$L:B'`$P*\$%X!84#G@!,.<`!'"%9@`(86&LC@!Q9@B(%%
M&'&8(`8`/9#!0!AI$'!?'6W0H1D:3\3@AV_==1&&3'ZT($8;`BC@1Q?MB;&&
M&JV`T84?3XA!!AQOK/%$%DFT!P%'+*A1AQP_7.''`SVD4$"(#DST#19H`""'
M`&VX@0092V@V@@UB')%`'D=X8$$&*<S`1P!ZH/"'"%`<(,(?"030!P<N2`!%
M$"AX@`$.$MC@0@X.:-``#AED$($=`?PF@P=`+/M'``:X,$`&"1@!1!#_023`
MQ(`:X&&`#RD(\0$?&F#@;!-0$.6"!Q\$X(,7%20A@Q4/-`&='RJ``4$Z-9Q0
MRQ-SN/%$&UIX002-V_DQD1\"()#"!#-X8$`..'30P0`#((!``15(``<3%```
MH1\PL!'Q=EQT\[(?K,SLQQQ?2/R0'VI@(;%F=4!'1V8`A.#$S3MG4($"6K`Q
M(DIC^"''$\^,1H<8=`"@0QH*E%&`%C,^+78J3/B11BUF.N$!`6'PF<,%-5"P
M`Q"+-!U"#R%4@$0<9ZC(S`-SL,%%`P2X9(8)+?Q`QID9-!%&>F&T\`89!,3\
MS!(>''U&%SJH(`8<'=Q'`0,\;##&%@JLD00<_V"LV4(M;Y@Q7@P<\6E!S@#0
M48<819R1AAH]:-'"$V&LP<9#+#R3AAQ85-%#'@C:T<(994`41QQ?@-E%%O%<
M($<&?[R0P`,O(#`"$1-,$``#B.R1`H$&+"!%!2WP@(,>"MR00Q(>G.`!(A%(
M@!)&8`<9%"`!'#B`L0X`E$,<80(IZ$,"^C``!?SG!7R@@`\F(``":,`$26A`
M`T(@!`\@@5DY.($.&M`'L*2!"",00`-X\Z\1)($"10`#$;8@`S:XH05G8L$3
M>K"`1$3@(6=@13O\8`4X6"(-`-!"%HA`A"@XH0EQJ(,.`)`&*V2``S)XCMEV
M]IJ'A.!E6,B,'ZIP1O^=V6P[;6!#S;@P@!DT@&8[.P,1DJB9`FRA#0Z80P+&
M9@H%=($.,<@,$2*0F4P]@14WL,,6!D'(2I8"!WX0PYNP((,S/.$-FG'8<[3@
MJT5L@1DQJ,#DZ(`$'C0`#CQ@@QK$TSHD:($(83!"SOA4!C<H0`XY>,(.Y,"!
M.0B/16_`303,$(,KM,</;WA#!%Z@LC6@H0IPV*$?S@``..S@";+CDSW.P(4R
M-($';SC#%3;@$A,MY#EK\`(/K!""2)Q!#&ZH`@?`H`-#A$AF-$-#&P8@A1P4
M80`62(!N_M"'.P1E`(YA#00TT`(^]"$#.%C`!&R0`2#(@`HKP$$(,!"$#Y3_
MP`,J&,`?)L""/$3@"!E0`0XFI=(90,`%B<A##I0`A1<<X``,Z(`!'L`#"%0`
M!Q"0`@BH0($1N,``!\#!"W9@`,0(Y08:0$$`IHD",PQA`6[0#`H:YDPBP*$%
M0S@#BZPP!S#@5!%F>@.7ZK`&)VA`#OF4#@N0@(4M^$8+64O!`(*0A".\``(8
M>$TZGS"QB;A,:F]$S[\B"P8P>&$A<XB$=,#PV&UN!PHL((('V!``2Y+"`+70
MC`2N$(<V0&`&/0#`&FSP!RQ0TK2X_0,FSQ"&*(3!'W`H`'0DP((J:($!8KCM
M(0+0AC@T@0U@8$$2SJ"#"EQ!!RZ)@@``P`('_.`&_VJP!A9:<((JR*"3/3!"
M'';$Q8=T4S=K!``!1L.!)FA*=TY8PQG:@(3:`$!V3Y##%>9@A;ZQH@9LZ`$6
M3F#6-Q!AB@N!D`!^JP8&S`$+7R`"8]W@,"^@P0HM%5$;D>`$*XP!KVH(`P]F
M$``Z4.`($K`"`ACC`1>X``8XP$$0.-``)2``!RJ@000LP`<#-$!7=TC`"B10
MV@\$R`)0L(`(CO`!"Y06IRY801".@%@H5,`$&U#`!1R@!!D<00<Y:`$$CG"$
M'!PA`#080`JF4(`(P&`(.A""!G\``094@`@0F$"/M7`%*3Q3!?GU`J'-`($?
MA"0C:GTK(AR@G?&XK`T-0/]`.U_&1SY!Z0M5F,,%KN$'%H2A!SU0PV@ZBY[4
M1G9BW'G9%\3`)Q9MQS3%*,/17G,$"X2`"57(K2("@`$6G4&N`,C!K+OPA!FH
M(`A7.(*P<=MB;U!@OUK@P`EZ0`0$3(`&2^##%Z2="#M<`0!B4`,;<T`S/ZPA
MU41@0Y>L4`4QQ($`9F##`^)0B35DI@9S\((9W'"%++1!#&R009G,(``R#``#
M7MC"&DP0@R+$(09B,`,6")"%-2CA&6Z@`!*^X`6C^LQE#WD"&=X0`BP$SDQ6
M:$&0[#W@,CR!:D2P`G-@L`$64``"(CI!&-Z`!'?O+`LZ$(`%8'`&!73@!C>(
M``/_+J`"'UB@I!XX0`+B18/_&6`">X`+$4<`@FN5@`H34,`$_I,`%T1Y`$S`
MP+52D(>\3($!98&R`8ZP@E45P`#-VL``;'"$'7@`7&E9E@\HX($!`"$)_//!
M!6:``AN<H``Y6,/%0`DP"3"@"V]H0@.^X(8W3(`+%_`"&UJ@B!J]AF]U8(,'
MVL9Y/461"V226`DY0``E2$`&,AD#!<1P;NC4Y`UDU`P=P+.GB-E:'L_8SAED
ML,N7H8%%91C#",K`IC87X0%IP$-I$2$@UHCH#CAP00!PP(0/R.0+6+```+*0
MABY@`0()H!<+R#WM2B[@(6SP.(.2`5U@!B%0`T(@`$X@_P1@P'^(0`R!\P-[
M1`9@D"EK$`9.\EA5D`YN8!M>(`%7$@4-L`9^0@%J0`=T4``"L`5A0`?<$%8%
MT`0"<`!R$`8'4%1$X`5)@"=K$$U;$'!(@`1TX!HUD`41XP8"$`5UD#!NH`5C
M<%YTD$XKUW"W$`]^X``9``!!L`8Z0`!O@`<A8@"!<05&<%X\4`4.(`-$@`$0
MT`9F`04%`"MZD'_2-@!@6`)4YE`?,`$E\#Y6`!46,`(>X!1\<`0&,$AY<``8
ML`,=P`=,P`%_0`!0P!H)H`(HL``1$`!!T`?7H@(7,`$<D`1=\``J\`5"D`($
M,`DO)@4QH`(14`%B\`,"H`(3@/\'%I`$)[`#1-`$(Y4$0U`S'1`&&5`97-`%
M%-`#5T`,9B,'=#``170(.[`=ZC8&3U!O9U`!#U$!`@`!*Q`!1'`?WH`%5O`$
M4B$#LM,&7=!+4-0F$E`S-A-6;S0&M+8=`"`!51`T:J``G#416D`/<U`%%F&%
M1X`#-5``<'`$4H`(#.`#0S$B,Z`%2$`$7!`"73`&6.`$)P@`5M``A\`#9"``
M-Y`!5-!_EN0#FI$$'7`"<%`'*><'%>``7M``QS:2BF`%KD$1US0]+'`%#]`%
M\C8!T%1712`&`W`!`O!2=0`&:<!;.6`-9Y`!;[`,*-@&X8`!GL0#<O(`&:`$
M'M8&,5#_`VJ@`X$$!CG`36^@`&U0@T/0!I(@!H_D!3?02E=0`#R@`V"@`4Z`
M`4MP`70@`1K0`[?8)V3@`&L```V0!5X@!K05(DH```MP!=I"!"@0`@9P`@XP
M`E%(!-=A!E\`!D;0`0S@`E$0,QG0`(@6`!-0`)GF`BGP!XWW`3'%!T:``DRP
M`F_6`@&@=7F0`!'`![1E!WP0`2XP+!_@`TV@!SIV*B\P`7IP"%50``L``04P
M`0&B@D'P/F!1`0&`*CF0`R.``G<0`#*@`',``C"@1E+P`4CP22@0-=23A7Z0
M2K1`DW^``ML1!F32!F&`!&W@!+"V30#`DDF4-9H1!<@U$<=V_S,3PP/-IQEB
MD`9H\#T<$%DS\UA/:0TZPP!WE`9L^08-$`8PP"94,`,3D`!D0)]_@`<'0DA[
M`#V($!=H4`!AEP=[Z`,/0`(H2I)/8Y(U\`;#$P$ZX`?794U:0`8Q$`)$0""*
M@`1H4`$]`'HR@)42$!XAX`!=H()HL`1.0``]XP85T``3D`-L4`7!<`LZ$`)_
M!P%D,`%?<$AJ\`1N``:$LTUM4'(M4`9(T`))8)<M(`Q;$`(M5P<&``!?$`5>
M,`8GX!L/``=8P`4^TR<0&@%EX``#D`88,%Y^L@-8P`!8L`9;X`4\,@$/("(N
M``8HT`9&P``+L`<^H`5M4`(`\`8QH/\%C$4'<\`%$S$T+`D';#D'5!`!$V``
M!<`$.``%#I``>X!E=@@!5;4"#X`#"K``"R``'8`"*0`$?.``'>`!/&`O*:`%
M%E0$00`!#3`"%P"'?"`$)#`"0<!B3$`#'W`"&?`"0J`!/B`"&+``+4`!#C`%
M$/`!7$`$!C`"%D`+FB$$9I"8.I`$2.`&=<`"\#@'<N6KC'`"VW$%91`'(7`#
MOM<4`\`!(A"R(1LR%K"'B:4":T`$B_,D$^$S$H.QG%<=%#JS#_($N!8Q9``=
M+.D'$?!,'S`#76`!5G``.JH(+O`&&[!Q-T`!,N`$4Q`!2EJT3^,"X4$'3Z!H
MT)$>T.$$`K#_L4@0M8@0#2W@``@@`--5`3HT`%U`!D]0!@0`!V10IUQ0`4UP
M)>2A$7\4`F&``5<0!1G@!4NP!&I@`;T4`34@`CT``2TP!O5!!%T2`S!P`3*I
M`3FPGE?"2>8X$%[@!8\#!F^@!0#@!3ZC`&<#NF]@!9$P2_UU<,3#!7/``SG@
M!2`P`F0@(@&0L#?0!!;``$T`!BW``A50`PP9`3.``$?0`""P`05@`B-0KD!@
M`#[R`05P!T&@`C/&!-))`!"@!\["44,0`-WB`PN``E00``.@`@;@`!_``7LP
M`QWP`2;PB#@0`'S@`51@`!A@`*BY9N<;!"VP`@3P`3E0`X-(O`X@_P!20&46
M4`((``$*4"0OH`4L(`16F`)50`0L0`:>)Q--(`$3H0Q/D`+-^0<+`!ZO81X+
M`P9FD(Q>$`=O,`?XA(+5T0510`P*$`,QL#AP8(570&NTYDEOY(Z1507)-UD1
M(X1`\P1H4#,?(`44D`-F`(92>P@N``<BD`$/-`,O4`!7`;93C"`)(`<O8(YN
MT$D2\PQ<<`5U```,D*2+0`0```$\D`0]8`4.)@!F:P`UP`UA\``.T"$4T`)%
MT,9(``$H\`+$QP4ZD`4@T`(@(`-)0`)58`1O@`9_6@$2:\D4*`%T$`9AD&!<
MI`.ZD`9M9!ZH&@<(L`$\L#!(8`77(!YCQO\D55!4;^!<CZP`<=`%:-"I6O`"
M:H"D;^`T(@*43<`!&3`$(G#!29`%(\`!/-`!(<`"0U``,.```9`!)2`#/3``
M#3``?O`!-V```Q`!AP`#!I`"/Y`"!\`!-,`$XCP`/H`"?1``3"`$!W`!1V`'
MY$P#(H`#-#"B*E`!-Z``(_!3&<`$-U!$9*D$!\4!"3`"&.#,-C`!0``$%<`'
M+@`$(^`$$X`$#]!=/*3%%@`>ZLE&7-`"_"10H<LZZ#9(=W`'>#`#0HP>(E!T
MC!6?80`'%W`"S34>@\@`:`:G,H$%W/>@\.@-_YE)G)=J*_M&M/H:=$`$;9`$
M+].G[5$-2]!.3@S_&LGUQ7_@`G&0`(9L`A_@`#-@`1&0D%XM(F6@;@VP$&3@
M!370-B?P`"T8`DV@UHEP-"^0!`]`!E*0!`8@!LX!!P.`!%4`!%[@`%Q`:V^@
M!F!`!G(`EQ1@!FV`!G%`!#3@!_9Q@D^P!F?T!#PP!UU0`T_01%UP`1&P$&P`
M6#(3@-W!!9HA'G306E605FGP#&@P.6V`!3H0`7'Z`VZ0!%X`!XD$'2Q0`PXP
M7F0`8V$0`R-R`"ZC!480!A;P`/\Z`37@!`9`!$BP!%2)0T>@`?RD!54P`##@
M!U(P`[\R!`BP`UV1`&'P!PWP`1?P`R-P!$7P!S'@`AU`S8=@!_E7((.P_P(O
M,`0[L0!V4`(1X`0#P`>L80<C,`(I@`-\,`$>H!9'=0$OT`(QQ6()D`%6D`(F
MX`!`%@,E0)4<4#.!?<$`60-I0$9+$`-OP!HVP`(Y\`=\`%"OH05\X"10W0I!
M7@<Q4`5CX`0GH`9NPD0PL@6RX0<N\P5)_09LT@J<1[/0%`)GT,E^P`42<-07
MW$5JHAD=H`8CX`!BX`$V@*U/]0<'X`.PDELN4`<MD`,8,`!>4`!1\`,-H-=K
MC1+5(]HSH`!TT`")ZP<#$`,W>@`2T)J*T`1^8`%>X,MBD`564`9HD`1L(`?0
M@0&V(0$?*@$\8`8S8)7/<;4/P9^13@P&,-Q7\/\"Q),%V7P&QTL'6A`&%/``
M0Z`%!G`%+>`D9U`%,:`!VT0)=&`"?N`%#T`'!B`[9T`&&&`%8%`%F/4=>",#
M!T`$WLP\6`"Z0!H%.]`%#H@2,*`%#<``-S`!21`":6`")_!U37`"+=`D!>``
MG^<%$Q`#&!X!?I`"'J`!*2```^`!*2`!^LM!0&`$]4L`1'L'T"*)4B`"7Y4%
M?_"(=H`'.""(?P`#'\`$/U`%,S#>'#`"$-#+?S"#?Z``'W`$!*L`/)`!`;`D
M'N`#"=`C?,$`3D`$.6`!#@`>*4`&8A`%`!`!`*`!$J!A0],$40`%=H`";Q`%
MAU`$.[M-7L`!2/!\?,+_DM5A'=O$`1K0:$D`!GR5['-0"UK@,V\P:YIA!OO0
MXVI0?:_Q7V54/=L1`EZ`'#J+!2'P!/Z9]3<'-"F0-QR`!4;`H`&PP#[0O!,@
M::D@52#@:X`:`TM`QS^H`A/-`24;`$,0`8[^YRBQ.-0S!TH@!IL)$<^-!0O`
M!9V/"#U`!RT@/!*@!6E@!GEY)]NT:_VHD83J!7/0!E60`HXR`590`PP0`VO0
M!"H@`\%<MR,QJTG0!'0@`[S3V`10!W!+J&B@!F?0$@!`!EG@7%?@!OGP!MUP
M!IS4`TXR`@J0`2(0!ER`A(XBJVR@!$V@`5W@+W!*!J'X=R,""`D2=``?=`4:
M_VH-&@4,(01^.E$-$#4W<$M)$%:0'A4+'Q)_?`T-"PPX?0TC`7\C'%H^?W8I
M`QY6`20?)`0^+381'$%_"7H.,S\#.Q8C?!H)5']0$09'"=0*!09$(RI#!R]_
M-B$X""E%*546"6I^?BED7&!5:%Y:(U,C4E@99@4Y&;1$^0.B2!P)#.1<47$E
MC`P_$NKX&1"!RY$/(SYTH1.A110Q4ZB,@>.GAIPR:T*<<4?G2QL_`.BX<S?'
MW9LU,\_4G,ESYI,U`L3X01.'3@\`6B3Z>2+!00\_=*!,&'%GAP<\>?YHW<JU
MJU>M'PAPX&!AQ8BS)0JHF%-D@P$31UY4*,`AQ=>[>/_SZOV:`("?,S*\>)$0
M1LW*$TJ\K+E@Q4-7/F;F#+`29L*5"V2(=%&3I@B2*'Y"9*YQ)<2))DO$E$G2
MX0F,!S*&8'&C!DD8'@2^C$C3PDV=,$_A>`G#X`P1%C+<,"BPY(R.,$^>M.@A
M1D`:-$W,O&D3)40/,VPX?.%1Q<O3-@*4C*F#I"8/,6LL.'E!`(`7&ABJW-GK
M%0\%,A5T080./3BA`AMPM*&%'S>\$`$1.5P`Q@,<-,`#!WZH,$$`4Y@0P`$C
M+*""#PLL$(0+*/J`@P<XC,(!'P9(<0<*&BS`Q#<^&)""$`KH$4$!K`10`!!Z
M9)""`T,<84$02CI@0`0,&*#_`A06%!#!$$`4,(,*$?@@@Q$\H""&!B_YT0(/
M=<#Q@!E6C"!#"UQ($($%511P@!X2$$&,!'[4`=X53GCAA`-8$.8'`6:XT487
M7L1P!ALL<%%%%4\T(4`6A\KQ!1G>_=6<'&"$4$0/;E1!1!HAK*$%$5K4<(86
M9/``1V%8"%`#!2Q4L503#!`APQBHME%3'4_XL4:";[@S@A>,EH$"?]#B=0`=
M+<1``0,06*!`!2(X%NVWX&[%1QQ^5-&$3.XX<8(?#13A1QL?,&`75W@00<8+
M&1`@PZ1<)"$'`'!4X$6R29!$1QPM/'%&#SP\`0"A/`#PA`YC?!2%'!8\T$8(
MA[Y1_X87,CBP`P0W+$%2$Q+HX`0/7I!AAGVWI0$`"5A4`08"?HA1A0QAO%&'
M%P]\$`8-1<C00Q5AL&%$#R]P\0(;2D`P@P]OB-%R2N%N54$8(81`@@)'3)"!
M`SIH\00G&300@0Y6@&`%"0TDX0<2571AMV!>?/'%&&.$$888@`,N@1<0R&"X
M#CS$<$4$(4R0Q!)A"#``"@/H84(**7C@P00P`+$`%4=0/H`!$U!DP``CF)",
M#ZN,D(,$'X"0;046H."!`3Z44<<;(0S@!@8-K&&&"@9@X`46'&B0AE8'6*&G
M'1#XX8:C7TBPDE\SF1%"&L7*D_,58,A00TQ62,09$5%HX?_&7V!(#X86520!
MP!A5S$'$$VZP\44+=#B1V=]N&(,7B&";,OQ%"VMX0QC2$`>AN",.6,!"F69B
M``X\``0"`$+6P)6`.5@@!1\(0@(L$`$(=&N#*-0+'TBB&`"$X`ESJ,(5_+`%
M+;!!#F.X@`N\$@,W(`$#7,@``*H3`@"`X0EL\`(]9."P*SRA"F<(`QJR0(<M
M".`GNDJ#$T#@!SB,(0A8T`(:Q!`'.*C$?F<X0QJP4`<RK`$+[9/#&;C0!C;X
MX7XD\8/1U*"`.%!B!CD(01O(`)$<-(`,.'A!0C@P!@/LX`7K\H,5V``!`%CA
M!TX@`A10R`<BB&$.:4"""MK@``G_B,$`6UB!!I(P@=FX00LXT$`$Y.:'ZR3A
M"72@@Q9TUH8RB`%4<7!#%(@0A^@```!GV(Y?=@(`.:2!@6`X@Q>0^:A/IL%C
M8G"C&MP``&YR4V'%\L-.9H+,G!Q38G7HP@(0L`$DG"$+2J@!&AZ`A@X0(0(4
MV-`"+'#'/_@`4W60P0XHH)2>&/2@"$VH0A?*T)XXP0]JJ,,<YK`2/U#.`A80
M@+=2N)<^N*$`*YB`""3@A!1DH'8<3:E7PN`'(TB`!5J(`012\``S]8X'#=#"
M$;S"`S]@@0X!!,`<V&!)J)S@"6GPP%^(JH4D*,T//)#!&=H@AC,0"PU&>,D;
MP(`"F*CA_PHZ($$8,B""`D`@"F>(PQO8:`4W/($#GS3#&.A`!C;8T0TUR=4,
M;J"%'Y"$`&@`P!C54(,6H,$$$GBC&[R`!"7X)08H*(,.N`D#*7#4#@UP%`"<
M\(`HL($'8I0`!B*@!0;4Z@(,2$,!PJ"`B;A@`=;@@Q[T\(<^Z"$/?<"#;6?1
M!R9``0@N^(`/[F"#*4"!"4QP02ON@`,?^``(P'4!'_X0@#UTP`,E.@`?^%"!
M'Y0"`@^X004(4`0>$($&3NA!#`Q@@!ET@`<1D*$,=!"',5B`"VBHP!,>@!-(
MGB`#1U!#%_Z0`A6(P`\Q^`,.W`&:B32A)R<0P(+>JL:ION$)?O_S2S?%J06K
M4K0+:60)!;C@CBJ@"P#7C.A?ZK"2G<B$7,1"J!S<\80DM`$.9W@!!':"@AP\
M8`*@4ZE>`D"'!936"3BP@PM@0(%G"5G(83@#'3`00#]H`0S)PD`!E,"$"!AA
M"CR5``!.\!`!`"`*2,`"`^;P!#`HH5AGD%@:NO"$"SLA#3L(01<<\`49@,$!
M"=N"`GK*@RG<X@MGH(T'TD"&.&BA"V"H0\GJH`8L?```/!A!%00M&%?1V0AH
M"(,;RA`"+,B!6FO00=HT8*@KN#4$7'`K%N+``QH(`04)$+(+@/""*)C!S$^@
M0!>2L`8K9-IJ+6!!%S9P@A'X001/5FG_`!*PW03T@0]X@-8=LOV',!0"!@"J
M`@EBX`<'W""_8:A`KO^P!V]/UP=G>!E,IO"%GL1D#LGR`@_BP`4X7*"-$EP*
M2=Q`@6*&X`I3]8(>+9D&@P*`"-QLPQD(T(6:EDDH;NW!0Y9"KIRXXPP82%9:
ME;"@##VG!VAP\F5EFX`$!.#E!SA`"B#0AA$,0`4.8,$,PA`!$X0CVBD-0Q.,
M<`8T%,`=6N#G&]!0!K\@83]=48*5^^2&-\PA"G#H`1;@H(4E[*`-,HA!"\"`
MA'FP(`1CT,$*,.`'"?,`"5S(6\U#$`=3]>`!]^M!'82"!@'P(`UP>`$1)""`
M):2!3V>H0AP>_\J&,RBL.AT(`1&(4`4&?$$#16P"!)+^A0;(``X_V'P7KH"%
M'RQ`"GB`^I/Q$(&UP>``#VA!`VX`@1?@BP(AH``%'O```1``!@`8`-"'GS7H
M<$`N/-!!"(3R!=-T;0];8<$<;L!N!9R!#`T//A'<T0;L'70E"B-"19>ROI6<
M00P2<7P7>1)8G?"DH`@50_<KRF))/F&"`%@`9=K@AB7TU`\<4`),D``RD`1$
M$$%8<`4GH`44(`,4L%%ZX0%>L`-$<`63<H%88`5F)`,I0`0-<`0-8`,$\'/$
MMT$LY07XQ@4Q``=J<`%^D`,RL`(,(P-?(77N```5@@9L$`=6,`!LD/\$7<`!
M3Y`%-6`"`J`!<V``:!`%,@``!"`W/:`$/)`%#*!U1>![/;`&E<("<?`^Y"(I
M5M`"#,!U6!`&7D`':I`$8J`&%;`&0B$#_T(L`H`&5>`=#@,3<^`%5O``<08`
M3=`&1F`%(5`%#]!RM#5\VR8"8"`QPW`7=C!=75$`9P`")5B)_#$&5H8&;;")
M8H`&:M`U&_`'.\0\;?`$)4!=750%:U`':7`$+8!TR9)0:X!,$^0';T!(Q5('
M.)%0Q=03<+!]"J4P]L9F?Y$3"O!)9_`%J>4.`Q`#%B!$&>`!F",%'G`11Q``
MVP4M?*`"'V(#)9)=![``<3`%3_`"3G`!4*#_`24``CU@B5G3/F%P`RT0!AT`
M`AB`B1S`!58``3A@!%^A`WYP1&(@`C)P10)`:6G``]X&``WP!7Z!2UD%C!^7
M`S.P!4\1*%[0;'^W!,EE`5*8`71``P_``FQ0`&IP`@50`#*`!&7@!D>P*L4F
M,>X0!E<`!VA0-1V(=7&V!6EP`PS``!1W`5S1!T`G76%3`$D`!BS54AZ@!Q^`
M`BJ@`D(@!$'P`=76<ECI`7-@`N[8E5\!!E^`!WJP![.%!ZFG`@WP`5MA!WA@
M!6<@`=/U%!?6`G4`.2364'104;IBBR'F!G30<'7@??G#$T3%$T+%BT.!+N3D
M!>O3)S3V`7Y`8I/4_PY^$`0.T`!54`.-:(E\```3$`$RP`4J@`'!]0$0X)7?
MTCYUX`#W<2IF(!05<`,E)@I>`9!7@()K,`%Q0`0`0`9U)A.-4@87H'`.0`=(
MT`6<P`4U4`%M(`=&X(=OX`2+F`82L07CT0:U,0;&P09(T`*#DP8KL"`8$`,5
M(`-UU2M@X`9U)P84X`X24`9M@`6:6`0<$'.0""XE0FW?L@=6$(L&)08_87[@
MIS!SD$NY=$Y^<9JHN:!?(`=>T0/G`@=JJ14XX%8"H`=W,`(U<05"508#4(L+
MA04>YPYK4"9:4&^.>8/)(E'_(CUQ\)#>AU#6TQ-B4'(NY`YUP`!/8$"V:/\&
M[C`!?V``):`%$%B"=C`&6@`!!X`#1S`U.%``.K"@T%)OB4=VDM0`2.!33P!'
M%*`G7B%F9@`'9%`%"DD&;E`#0]`%;P``50``89``OG(!3^"`%60&+Z`/$1!/
M%M`%8L`#:T`!=(`%6T`"#J``3M`",L`>9D`&84`$/*E6?L`&85`%$D`N#4`$
M;\`#TM0&8.!+6*``06`!AC9MW\('CN$"++``6=`#-S"*T6('#E`#1J`$?S@3
M,C`#.-!=%N``M#,"&J`$+X`K6=![00$`:B8`NF<%+$``!'`%+:"@4LH?'X`B
M(V`!IX-1HN@"9@,$K:<`::`&X10""%`*)\`&=2#_`4``!3B@!6YJ!G)B!@[0
M!3QJ4'6`!N='HC01DPDU?C=8!G/@?='14)$9HU#A%W7`!N%T!B@0!>5#!Q+`
M,7XP`1B``U6``9ODCGWP!!@P`$R0!A^0#EN``0X0K7NA<&C6``,@!VQP`B3@
M!B,P`R]P!"M`FUTA`8L:!A`P=A#P`>85`7[@/W34!$G@;6W@!(:QIO`:`@CT
M-U\`!F2`!%H@!S$@!E%X`YKV!$;P!`UP!@K@@"\AM6YP!A0``$M@!6@@>%V8
MD!-P!-%UL7>1![J5`'M@!R+T!WFP`0Z``D)Y!'[P`EI@`$09+JV@%:8J`VDP
MBRUR%X=(#%MA`#IC`!7P_Y,G0`,%,`%",`$<0++\P0$FP`!.0``T<`&%50!8
M4`-E\`0>L`96U1,.0RQ<P`,4`'U]\!!R$`<L4`1.(#]ND$?TZJ/\"A5FL!*4
M\KN/TA/2M%`-)[!GL(MG8`4S40>*1TO"HBP8L`190`2;68E4`!&E9@$O4`)O
MD0,GH+EYH7";%@8.\`9>T`1=@!1)<)PU]A6R2:E=(*O>H88"\!!JP`1B,$S_
MY@9N@`4M`)#]RP!F0`1*<"D(-SXL4`$>(#Y>0$HQ`*XQ$!TWH`"Z4@<],&4Q
MT`5KP`5$X``ID+AZD6VIEVV.%`5ML(]/T")WH`!/P`+CFP!B<`+(&0,CH%(J
MD/\`Z0$N1S>^Y#M\>Y``>+`#3_`')8`$`.Q]/!`"8-``8*85><`"N^@'$``'
M;OHJ"H=0O,L3X20'#@`'SR2P"O42=0!_/&$&R;L4WY<[`!`#O49N?L``8^<!
M)306'``"K9<!?+R<T(('8W,!-'`""#``4"``$I;`30``>[`""3``,_`!5A#$
M=^$%3R`"$;`"28`&:*`!#Y$$7L`%LCFR7G$#1N0.\FD&%R")*,,#)&181E0'
M%;`"?V-C)?`"5E`&JA@"3=`")_!GW00F,=``Q2%E`,`&7/`$9L"8;M`""N`M
M=W``X1)2!6`%&/`'U3P8%O`!@64`=C`!8DL`?W``(,#_`%T@`!,PH2K%!X/+
M%1X@S7>!,PQ`R25(`6<P"]N&!R.P`^YP!5QA!TR0`HN5?&=0`6RF`R=0`U;3
M4,.Q%$5@?KZ+!@:E`^%D4/YIT82T4&K$$QU7!PA7!75P`1(@T7YP`B<0`Q^0
M!$TP7T4@`1)P`QWP`<<@"_QQ!R(P`R8P!-;*!6P`C!7`!?D+!FVP(J%7`/3<
M%500O#;[`\/A9B/P!`7P`%J`JNO6%2U0'G-`!BQP!2R`!CJ0`WX0P3%@!'/`
M`AB`+8_C`&OP8&>`!375)V5C$2?0@M8QB&*0!B9]`1?@`$$``A.0`'#[+5#G
M`0*P%7F`!.**OH?L!#IP`5`9_\I9D`,N<`8CX,^NP`!<,`!XX+8ER`5:H`+Q
M/,='/7Q\Z!5V<`08@`30N@?XPP("8"J4!J%%P)R5[0YC0+`)M07OLA)U`)`]
M`1T],4XX2L8+)=R*R1,&P`.5)@8J]V0X<&HPL09R)`%;2@%'0`=V$`'\.=K1
MMTL$$`>O^00*$!Y/``4J0-%/X`1?D2OR^E(2`"LDT`2RC#%6<&9=D`8QH`4#
M5`$<T`(.`#PO<`4*@`9PT!W[5@,G,`$RL-?-O99?H61<42(8T`,]H`-B\0<#
M@`5;@0=5D`7J6`4J```=`&H%>0%8(":.$G(B8`<,<`(M(`;][8X&T`9O8"7W
MJ14JX/\'"K!=[2Q;>G#CW`TM5?`&TA(`=Q`#9*,$0]`$%."W`\0"+-``%,`#
M`D!+<@"BE,D2,R$3&YQ0=:`%+Z$&T^L.B>,'23,37,`S$-4G5<P3))E0)]`#
M6H")JN(.,Y`"(U`"0<`$PQ<$;-P%62``^FAE&B``9W``1U`$)#C:U?P$V-<"
M]@,?$5%*:$`'N/<5!$`&8&`%8P,',-"=1E`&-2`#2]`"74`#$#``$%`S-0`#
M,A`"82`!5J`%6/`"/78$"K`"SZ@5BZMM`L!:@^O*.`"A$?`#,I``)K`%6^$#
M+*`"<:`'7,``87``0K`$?5`,:F`''K`%@*$`2+`#;O"QO,K_E:7*!PN0SUB1
M![.U!SZ``E`IE4*P?1+#*S/`!W*[!SI^`A6@!0^@``J@!$<`!2W0SD'.'UW0
M!D(0`1A!`GRL`1K0`"'`=GV2!#2`!$D0(%A``_[^`P]``P+P4`C%K]CSNPA5
MKS4ADUM>T3.1!M_!QN_'$Q05W#/Q`\=,+K7+C`R0!#T@`45*N'SLJM^R`%!5
M$D30`US`AW&0!F<0!2VP`4\@?$%>O>(T!A3@!B?0`"\0`'6``F0#`$'``U\Q
M`&0P`>H0`F%7!4@0`Q/``%$0#!K0!`-@-FP&0P_P6SAP]WT0N"IU!^]"!PK@
M3VA@`!AN!3XP`&K``6^@!5LA`''0_UH5,`!HH/AY$`85-`5:`,\Z4`!V<-4L
M@$)W0`9DT`9YXP5*Z3=^XQLY$6(\P05)$P5V<"@'D``@``+9I17%4/!K.0(.
M@``6D`,Z<`,8)0(<X+LK1MS&SQ/$Y@<NZ`==D#-;[`<HRJ^.CE#*G%!JL(LH
M=M$S$8MU8`0SP0#RW5K"V+<;H`57(`$VL)85<`%9<#Q^8-3@X@,'1F-/P`4]
M4$=E8`1P`)`$``@,-'^$A8:'B(F*BXD-?GX`%$1426(`3G4^.G)^8!&-?C(2
M<&\W+`@.&F\-`G1N50(>%@NT![9ZC+FZ=@]V`EIV8&(U"TQJ!@QI/P5N0(02
M1!H95R846O]_=EI+5BD4"[K@AG86)R,T#CX.%0H#!BXN`A@-#1,<,H^=5V@\
M!@$=?CG""1Q(4%R[(^X6Y."A1,:]-C5:M-BQ@P*%![^T>`DAX`0/'@I"9$&#
M!D";+2;B["#R2(X9?##]/*ES)LX9/W,`0,+'QD^=-#`!P(F)[\G01W'>Q$3S
MZ`F^-C&=/KKY2"<^(DS]&'!"Q$(.%PD2`!%S]$D$`$0\A,.!HX\`JX^\O`G"
M@0&:,UW`6,"1YT#!OP)!E/%S1@8%,VGD]-CB9PB9)IT,(+*#A`T=-F%8^"$B
M!HR6$V<BO-L#N+2A`"&83%CC8(>3/W$,_/K3`8Z`/Q'F8"#$9X7_'A6\^Y@&
M+%R1CCF%,^3YPZ?0`*W#HTM')/0"&#-H8JBQ0F`-G1ABYL1YX<6,@28"#(28
M,:)*#0)<PMS,0I5HU2H]_2B%>2^F4JB/T$%4&'Z8\8)]1.T74P]EQ($/#3"A
MP8E6'#3@PAINO/'&&4#IEX07883QA%JZ8,`#`4Z<\8087OB1Q0-7`/6%&"\T
M4`4WT^58@!9^M'&&4(HM0<8U(3RPAA@X)!(&$3V((<$-6A`@0@4ZD)"#$@GD
M>$@*I.E210A_&"#!$4<\\8<;(V0`I@T_O,#<`KAH*><?.!R``1$.#(`''V$E
M@$=8!THVYZ`#:<$%'T%XL806OTB``@TR_[#00QA<8/$$&$OPH%,%8ZC!XP8"
MY(<@/F(8I091=&0%4QU^R/&$4U+AX\503\`UJA9K/'(J/@#41T<$,-7700Q$
M\%A``P00`5X5<-1A0`<[2+##0'',T48=8-R4ZTT*<+$!&V(,@(`=A`+&@!IG
M8''&'&&LL4838+2101=Q2!#")XC008(%$!#@`A%M"*!$&`PH,,(,A!(AA"XK
M/$%$`Q^$`48-3=AQ;Q_?_+%'ECG&.:</4B!!!`!FQ"###E98<445+52!Q!=^
M'%'NS+D8ZD$,.310!A%2%`"E"&)H$0-3X9;AP!/5KA%%!75(8`:`H[;DAQBY
MQKK3J'3,@>I1"/_2U%0=O38UZAE.P.4&50,DX0<&;;000QAOR)&&&9VYH08L
M1@Q4AQ-^5%$'$NNRL80?$$C0PQ5>&%`&N30/1,`<45S`QAD,6$''!DZ%T`86
M7F!P&R($^*$%&VT,```7=RC!PPP?Z#$!H5JLH(L%9,00@AT*K)%!XPN,T$`,
M2R31`P1^#9>`!SU\@<`('/3@!AM/.*$!`TM@X,`''/@Q0P)'!.!]`27LP000
M'&MY!R'+`186'W$&X/$?ADHQN%QU5,$WN%H\$,,:6%Q`@!<R*$#H`!"V,VR@
M0_8I`P^TL"M\:,%647L$$EAUE4=HS3YHN,(C0N`&-^"C"E&#0*RTL)__`81@
M#`QX0Q<JD($ZL"`$6)@#$<#@ARX<00YX$(B/_,"#.CPA!@S`CAHDP(-'O*`/
M&&!<X\(A@)O$X0F)@807).`'%:R!`1@0PN<.H8`G0$$+6D"!%K#0@@P,0`PH
M$,,@!K6%&H!#B7\(0',`TR5&'&`(3Y```I+0A@O,P`!QJ$#Y"F('#,!!`@.@
M"@`$P(`1J$$`!8``"@3`@1GX80">ZX$F-2F%$'#`!Z9)0`MHD`$)2$`',IA!
M!I00A0_D``4%L0(:D`"&*XS."C(`PQC"@(8N>&`,;PA#!:[0!B<HX`=^2(,3
M6J`&.#S!#7&X0`\><0,XB`$@S-(/U&#BE/K@_R,#HHH@3$`($P&)LRI^H`,`
MR@``R#R"#/C0`06G5L(,C,$-`&C`%R"3@0[1P)9-P``7X)@+/HR`)V80P`2>
MP(`4F>$,4IB!%'*XQ'"080M/*,,9F@"'$7P`1'Y(P!1ZD`$S/"`1"J!!!$Y0
M`3I\H`A<B,,7**``!LA@4"DX@0"@0(5"C,`+%"W('L3'A``D"1%B:,`A(.`Q
M%'1!:W6XP!J^<`8KJ$``7G`"!-)'D`G480Y`D0`$0D`&!ZR``Q``@P2X8`$/
MT,``,2N7$"8P@2'T(`JC60!8]G"P@NB!#SA@`F`7@`,4>*`!*>BE!UZ@A3&D
M80Y.@`$7Q)`%#[@!"_\22(,1D``!!6#A$7"`0[J>L`9OGO,1\R2*K=0`%3>D
MU@\A2-%I;W*&VOZ(@J;%AQGV@X`QG*`!.DA#%2[@$S!D52X#R,$90#F0(X2`
M*6J(@!GD<(0*B`$#6N#`!%0``9E5%!P,@,,*:O"#,\BA!3TH00O\\(-K]H`/
M6S2$&YZP@"5%B0Y-F,,)"!`!)NB`J].1PAO`F@3@$"((<7@?(_+`!"FD(`46
M@,$)Z-"%+S2``\4KA!8H<(@JI(`0";"43N1`@":<`0QIB``!-I`#+!1G(#C0
M`@3"T`8S:"$.6I#`!KJP0!*PH`Y3$,$$*N`'6#9N""WX+A;`H`(D($$"<TC_
M0AUZ$%4DR(`'6+B"!*K@@18(0`PYJ`,:R#*&.3`V@CII(#KM0X=MSB0F%_0#
M&5X[*C6+CBJY0@I,FO0(!`S`"QI00`FR4(-7%7,+2DA#&K+@!`#G0@]YR,,$
M=JF$*N@``%VH@BV[8``5&$`(WOUN+AB`!?D`@`X&J*T,-!#2"$2@"".(;R&:
M```0<($-7@#`'(P`!F99P0`U>/%T$M"%1XPAJ$/PPQ02P00H0`$!"*!"">Q)
MA@?@TPH"^((9O,`".F2`"8;``H<-<84PY%`"`L+R!@H@@3;H0`)E@``++&"`
M!OB`H+GPP1-0<`8BR.!::5!#%]@0@;P@P0\2F(`"_S;@!Q<L$<G?O4(S3B"'
M*F!!#4_`0!VB@`08Q*`,;;B"!HC@AA:$X01::(,6RM!$+`"EV`C2B=7\8&=>
MX>01X2QG:NG\E#7CXR94IN$C.#"',3S""KN:0@6J(`<L%(`-50#`8]W0A`DJ
MP`I'!8<0C'"#$W1AMV\`0&R;L(0&%,`'>S@"!D8@:G"<(`Z"$\,91N`4!WAP
M`CM@009Z(&M"B,$,%M"@&#0P@`0T``T-J$-7-C`G#GAP6H6P@!^27(@/D*`!
M*@(`J^K@A16PZPALX`(23D"$>UW@#&.H`1_2=P46U-$`:@@#N9KPA#DTH<U:
MB`(::C"`&5RA#!3`P03"4/]'\/K!!#Q*`P[F8`4MR."C#V#`%E`D@0-,P`\=
M6.($;A#Q,`P!#A#``!`0P`,84+8-L15`!IZ0`PLX@$-=('0%G-*$+K#J@EPX
M[2-Z\!)\D,(/.P`5N?4(8>`%<L`&K$(@"!(#8Z,4^?<(2\`%,$=CC^`!PK,#
ML'`&;2`#&"`&(0`'/=`&/G`^`F$#4O`!%G`$?#`%'*`!I^(%\R(!'9```^!Q
M0=5VQB$'1'`$95`'.'`%=8`:?L!2R(<&+)`(.J`!8G`!+T`$3"!C#!A:4.!C
M@[(#?H`%AO``."$H:502/:(&#_!\#E`%!5`!,<`&;^,&8R`!'&`%36`".L``
M+D#_`Q.`!2S@`+OQ!R0@!W7`!T>@`Q!``AIP`R91!RN`!`0P.19``00D`7,4
M#B?@!QZ@!CU`!A6@$VWP!%?@`5QP`FSP`CY`!'QP?06``@.0`3XP`RJ``#!@
M`"#P%W9@!W=P!W:`![8X`Q(`:7HP5'VP',47#CY@"[1`"\NF!V`!0@60!"Q0
M!6\`!W$`!R,#,&HP!G$P*W[@!F1P!7+'`U60!AI(!SSG(`A26Y^E(H\@=#%'
M9T3`<S'7(C`A4T0!3411`C'P`!?``QE0!5,0`$A0>!\`!+0X'5!P!B`0`B3`
M!S*@`#7B`#B8"P&X&1H8!BV0!GQ`7-QE;]60"$G``TG0_P!BP`0UH`%>0`1O
M@`%^4`%6<%**T#Y^H0=]D`![@`,98``*(``$0``4(`*%@$<D\@<80!57``5_
M`!3JE$YQ0'ML``<WT`0<<`&1L`07X`$H1@9,(C(0<'H;10'X<G!^H`$5$!]I
M``!HT`9?(`%L@`8R\!)EP`%BL`(?T'>,0%QPI0(9\@0/(`)AH`4C```7L`0<
M$`$]<`375P(:,`,S@`-!<((3$)-_<0-LP$`@<`5LL`5M0`95P`(2$`9?H`,-
M$`5I@`2_F`L64`9#4@EB\`5:T`5GD&MB0`4ML`]6``!B<`4AX``>X`0.0`9I
MT`6<``!7T`->8$L9]8DSAP\38O\?!-1_5B&."`*.]E$'7B-./Q(3<@`55O$$
M(6`3CZ`%65$"6L`#$2`#05`%5:`%6U`"@Q*)%C`#'#``*$`$$6`%7="0C$`#
M:A`'#:`%23`Z<^`!1>0"$R``1``/B1`##<`%/$`&*B`#24`!.0`&+2`#+<!=
M&F,'"<`'&,H'JC$`!``&7Z`$3Y8$(``&#(`"#M``35`.#F!DH1@0A/`#1%`!
M45``$Y``3A&;)Q`!1'0#,V9Q2*`#I:<`&"!#;U`'8G`"D7(!??`2?T-14D$&
M,O``%Z$$^(4$9M`$$D-`8D`$:2``%B"*`N$"^<1>9]!,`&`346`%[V&08,`S
MU\=V6I+_`$QP`#C`!P'@`P'`;@D@'+;P!P?@:0N`;XQP!QC:BWS0!WV``T#@
M`0?P0`:@`3)@#UY``4;@!BQ``WV0`UPP!@_P!0"@!F\@!@1@!CWP!&B@B?KW
M%"W"!5Y06X\`A%/#%.(X!\[9(]Y4`VP0`OA0<\99'ZFU7OI!`7+W"$W@CB-`
M`'"`!%A@`!L!!6H`IW)2`(1C:Q6@!PO`!QYP!?2Y"!<`!UA@!:5'"EQ`!%;8
M`VR`!$N0!FZ""#&0!3T0`B0%`DAP`7%0!3P`B"UP`AXP`1_0`E;@!$A@!%S0
M!#P0J;^U`;%V`42``!*`!#QP`3O`/%50/!@0:C:0J7'0'$V@_P->L`9MT"E=
M$%NMV@-$``>7U@;'6@-$0#=.H`T`P)!&5P<60`@SX(R3,W=5X`4G``!/P`9R
MH`8`X"I;X`1@8*7="@'4HC4AH`7T(6=)$`9H4@!A0`=5Q0?``JTS$P0Z\%U6
MD`8!8`/M1`!(T`(-<`4_$`8&$`$9P!T`P`-JP`5)<`41P`-550=D,(#'211R
MH"UJ@"T!,A4W`4'-J7]O-C4M0D!SD&>/X`1'@06?Y0<%$`(U@`$>\)9;YP18
MFR,XX`8&L`0.@!$&\#JOL:V)0%PU$`$UD`9K@*0UY`?!XP=LT``J>0C$]2]R
M4`!5$`8.4*1QP``S%`%G@`0@L`8Q,/\$2&`#!,`#3&`!0^".8C..8;`"%O!A
MAU!H6>*M9D`'-;`#<9`!/(`&$%`'-;`&6B`%3C$"72`#MDD#9,`#I,0`?Q`$
MBL<Q5_``$@$!J>FI7:``9/`&G^4>9*0%1+`$&M`#,S"S`L$&%W1-CR`&]K,&
M<T``$+`9%F`#0>`'F4LH0G!3%94%=3`!,Z`$;/`&3D`6&84%:Y`#:%!:<)`!
M9%`&TQ@!1*`#5K`$92`!4F$2XM0#-^$$5C.^<L:<^)`&VY2JR*D#IUHK,*%F
MKLH&"V`!-:`#&6`$!.`!OBL[@'%O?Y```9!V">`#$Y`!'I4!#*`*L/8'-/"(
MI%L(#N`'/;#_PGX0!UB@A=/4`3P0!@4`!Y1W"._'`"'P`EQ0!5R00CL`!V*G
M`4-0!0N*!)!"`0[@`#Q@8D:,#V\`!F$@!(R3:EGR!EN@:TC```[@!%`P`E/@
M*0+``QZ8`T>P`2VPNS%$`=X[`(3@FVJLIG\PP64@H5=`!EI3`V(@`SJ@`P/@
M`$K@`A&``:XG$%CQ"#SP@).G`VSP`4^0?P*0!PYP4%A,,RJ@!-^5!7Y@!&OP
M`VC``6?G`B%04U,P!$5@`EZ@`$M@`"V0!!@2!6H0>\V"#W/`P!&$!44:<U`C
M%46I09-L'ZY*%-LT!T-!!PYP`L,<!A]`!18P`0"0S04Q`LWQ`1B`_Q%8T`!%
MH%P_8``/@`%J4`(JP`#@N<9\#`E+L`-N0`$R0!9M[`"6@`0[`)=,][$],`$$
M<`$9H`%.H&4Q0`?-YP!-,`-VX`%6D+?^YP5MTD@L\``<`0`,2-!58`%YP`=O
M$`!G<HT.T@9$@%Y58`9D<`)PX`:5`0=FP`-O8`$/@`1<X`$WH`1?0`BYJ]6%
MD`51<,L^L058@"T48*IL4,*'<T)ML`,^$`0D"`XHX`<L@`94NP0]#(X"\`1>
M(`83D`-_Z0<6$`$HT`![8'8>,TA:=P='0`4NP`0?P"5"$`)Z,`!R%`$BT,6#
M@@1MX`%U\`584&EI\`84T`)U$`,D,P8:Z/\3-!<&6*`#7-``6:`&I5(4]F$&
M5G.WIP5/1$'==1`"7N!!09Q;5'5:/6$57@,''^``:9`#$O`'3!`##I`$""PG
M%G`&*,``#\`!!C``+K``1(#2A\!P9)!984<``F`%1J`]#1`&,Z!%B5`&;U`$
M<%>)1/`610`O(0``$]`"6R`!#8`$<?957L`#!>#:?+``4.`#<P0!?9`"`:`"
M0J`"*K`#:+#A:1`#%Z#5V@@'U08`,H`$2?`"7B<#-5`&2"``.H`$7M`#(F`I
M9E`.$4H(00Y@(N.3Z`)98P`'9;`&%.`$,:``:H"/7D``&@!K%R`0BZT$&Q#6
M9PH5;4`RG0`"'\7_`B9I`8*5`'8`!7M`+@%`!=DW$`I``#5@"BP@$0[PTE.X
M`@UP`FWU.GV`;Q"0=8<P`070`C2*Q@Y02B_0'6>@`7#@!"R0!E8`?@#@?!70
M!FI`!$1@!2`W!UPP`(>D`W'0`S(@'_A@3OC@((4;+#&A@'Z0!#A^2G[`41?T
M`).*!E\@`U7`&+!;Z['.CD31`F''@%PP&(2S!"T`S4EPS#(0`^VM)3B0!`(P
M`D@0`RZ@!#AP'OIM"$3F!EZ0?V'P`'VD%`5``UUP`#D`>8=``&?0`CD@`#*0
M`UK``B>0!CK0RF&0`3&@`4H`%V(0!NLA1WYU!`5`!%&@W3Z1!)3P!17P_P7.
MR`,50,Q8D`-J\`(,\&<2P`)SX$L;0`8>4`#T702$0`0<H,9(P'TE\`5O,`(,
MP`4L<")8@'A!H`:R^[#($@'C!@X?<)0\H)I&Z@6*9Q):,,PCD">+G>V(D-C#
M<0-@H@@-H,8DH`)OX`4(@P@^@`(7H`(.AP(5$!%[W@9P4%U!705/@@1O@'X"
M(!)8<"-H$`95\``I$GHAYP=%`!=GD%H#B'/AU$`(6%N;-RJ](NLM`>V3+`.P
M0AB!BP$J\$`M</8&X!5!,"@9,`="=@4-T+`><`?Y7>Z$4`&9OD`2P&U>$(9^
MP`5;P`5.0`9NA`@5T`,*P`,M8`MN\.#<"*4<$/\$7"-G60`"')`COAQG:V`&
M%5!=+S`!$'`B7\P$*$`!TQL!I:@"*>`!7N``'>``!_`!WW`'!C`#RX8'Y)(!
M0GG+`.`&<L0%.O`!&=`$3;`%#V!"9-X#UL;!X0`(!GYD,E=M1')$3P\?!S!!
M$ATL$WXI?Y>8F9J;G)U_*#&>FAYT`D]^9AZBG41^'&H-/'%$$#IT`#5F9FEB
M9G443T\,9WX52"%8=6+$IV0`?FI^TM/4TC+/`&Q^:Z?5WM_?3W+/=>!IWW5L
MS]5G(U=R`DTN+R$)!@FK^9T5;DX&"A]H0,$PH8N^@PA753CS9$L9%B^0S($C
MQX\1+&9X6*#`J8(,-R[_-DB0TD+$!P<&:D!X4$Z:&1A'$B)4$8#%.C]/U#19
M0^=)FY]NX,R)<X:.'P``X,"AUN;$'#$_K(0H0&#$$`<6.*#@<&)'F#08!'AA
MXZ5*#S!AM/1X,*9+@"H1+"%,X<<!@R@#AC2P4L'#BQ$:#'``$>&'GPXR$U^2
MD.1@!C\@K&2(P2%Q%#]1"M2!L\."FPQAT/C9`4=""`=UB)B))BV,#"L.M&AX
M1J/+-`G@J(D)XZ<.,0!ST&@+40:-FR<M<_=.[D;+*3#@B'EKXZ'*M&#2.&2X
M<:%,C`L6D)"IK'C3'3QX+@T@,X0(!AU8:A!IT[B\_56&TZ`Y`X`H&3\]$08`
M_PM^%,')#V)$X$`3RDFCA05RW9</#B_,T>"%%ZY31S<84F,"&40\T`=">?"0
M1A5:A-%$#C$X\`(.$I0!P!<F)-&`*Q(>=$%]^7#P!!$T5`#`!(E91\4/=%30
MP`XG=&!A)5_TL$4;!M"!1!-C^.%%"P(`L$46$JPC78=^R,&A-!CYH8$S&](A
M`09M0/.-&5I,XR69U8A1QC1=\.:'"E48T04'!L20000RD)<8#C'$H($,63RP
M11$/9-$%&'IT,,,/7<`HQ`8YAII)#M*T40$)4,A1`P44P,%!''[(X"8G.9S!
MQ1-LP%%''7/0<<:O`.RB@0JBZF.'#Q<@H2LUR?7V!/\`:9RQ!@!/I$%M,'&0
M\6P:,E(K30]=R#''&3I8$<<S7$1!AQG!G/'&31`X($$;0214A`P76)&$`D@@
M<,,#'$2`0`\>*$``70H<,<4/"FS`P0>7J**8'79@<H<=$/3PQP0N[)%''WWP
MP4?%F.R11$5/4)#')@$<<,`","^`SQ\+_.&%'P.PL,9K.L@P`Q=K^"&!&#=4
M0<0`25`@AA9F.!&%$V9$8(4$1C6XH;?3E/,%-?WY(5T/L-8!JS=KL-:;-.)(
M4U$<<6)(!AP`R.`'&N<`@`,!:*RA0QPZ9+"!#""4A\<,(G!@P0H%"'$$%1]`
M@$8`'QCP0`(:4-!#$\6*2BK_%F(\,0<9+831`A=^D.#`Z`T(0&M=9'@01`8D
M&#!`!""`,`(.4/"1^4%V+!`$"S+`$&\&%"BAA`PY\%#"$0\78,$1)8PP0@D3
M>%!``4<P,<``-4C3`@^?D6'%?D20L0,%$K1`!AAI#*!%2R\P,$`3+"34`!<0
MA'&#%SV$$`(245`!"2(P``8XP`-^>,$?I,`$/K@@`D!03WEF`*$`<*``&'@*
M'W#`@"2P@`!.<$(/7J"[2^1A!!E@`00"L(D%$*$*,*P"%KC0@QK4H`L2.(<(
ML"`-([Q@"RT`0QG*@(4WT($.<\"`%[P@!CBH8P=J>$,0CG&3W,#A"G#S1K.L
MQ:P&_XTA2](XSE':)HU;8"@.UMD0LU(@!`W<8`T":($1:A&!W5T"42D@@0MP
M(`(/&,!R=I30"_S@AC=X00-U",,:N'`#/R`@";R100M6AP,MN""0F,S$`7B@
MF$%NHPDM>(,?<N6&..R@)]'*21>>T!-I3(`*-R"!#!+"`2L8(`E@@``9"#&"
M$*`A!`Q@@QDFX8=Z[8X/3/!!`%"0``^$0`L?\\`'H&"##U`!"CA8V25*\).?
MC`$%FL`#S%P6`!RH(`4LB(`Z;1,&&'2A#BU``@\&`(80S*$*#0"#&'I9@0)0
M8`ZMJ`(`U."&,DC@3*?0!IZFL0S,2.,_X$B"MJ`Q-FG,P?]/"V6#0*?Q)#],
M)39QN($;0"`%'=31CB@P`Q0^\`(?@$`"!>``%S)9G@+X(44`,$(+SL"&&AA%
M'6>HP0$(P(D7Q($$8;@D33'Y`2UT$FT`6(,<D&"%4VRHE&WXD1=V*89IF.`"
M.DA#"&AY!B(`0`M:^,P9KH""$"P@`%U@P,,@L]1+H(`(!YE`'$X0-"HEI@=^
M&,()N@#),YAA`$6H`!QV!@$U\&")%'"#&D[!`!XX(036J48TJC@-42XE-VT@
MAA."YH9JS.$FO]K&F/P@!@TQZTS>`$`;S#`-Z;0!"DGH`A6X`(8WO.`(-2!!
M(#\0@QP\X`I,>,#\>&"%NLJ$`W[_`$,+6(+&HT#'`(40P.DX`8$V#.`+$73N
M[JC@U,1``!5PB),5SNN'S\HA#18"@`+<((;)2@,(/N"!"!JP!X2,H`IJF``<
M+,L".:`S`SH(P`0FL`$IE,ZY5,B"?VD```G,3":`)<&[NF"$-OP@"MAA@!6X
MB(TT-+(+/3BM^8QP#@Q9:+5^P&@UFK70)XC&#QW%R8W!$0<QM)A9)P#!!,2@
M@Q$X(`2AL\`?5#``(^1`5!X@R`1$$(`-9.`#'@B#>!'BX*.<P@IK.(,`SF$"
M+A3!K+/<Q'D1$`8?;#ESY%7,>;D0C2=`H!OJ&*48.-`#.KR!!P(PXQD&$`("
M>"`)4$!(_Q\J@(8M4"`"/2"#!&10!"OTH`)Q5,``'ES7%TA8'P?HGA],,(`2
M9F("#,@!!EXP`0A88``'L,$?H#,`!X"!#FRH`!%DT(7*K6$#O8(O'-(0`QH0
MH0Y6F,@6O-`%,H:C#65`J)V:X`:DM&"SL*T&$JI(K=!*@[UJ"X.,P?&$-;RK
M"JO%`0)X@(4YC$`".:C!"9)`!.?H8`T<N/`J^H""%$#!`R)#01""P`.XT2$.
M<>3`;Y$PHC>O8M-^@*\<G-`&.&0A:&)!@@X><`/NSD$';7:XJ'#0W,28X"AN
M8`,:JO"$,5C!"E=X@QK`8($G)"$$'D##:7&<@"'T``,C&$!"3/]0!!^X(`0.
MZX,'6A""#R0@`".8``S\0`$+$$`#)A"``![0@!;<@$@RH1C%SH,'/D2@"GC0
M`Q\2T(<#!,`'.#@"R?XP@',!0`YO*(`F"\`&7L'A#&IHPQJT$`4PA`EG(1``
M!&K0@@)HP0E>.,0(R'`%+YBA"42X01-V$`<KU$"R2FB"=#C[T-=L;1H\/(HR
MP'!:+-C&"]FF1AS.]*O.22-H7MN5&]QP!L#B!!P]"(.;TCV`*C@A"4JX`0M&
M$(8SG)8-!T""`RIPD`-(,@-)R$$6S'"%X\!`#FPP+!DRP`<+K$'?(M_$IG_-
MA2ZLH0I-L,(6ZD"\*D1==9O`0!.$T*G_](>*J"8G#6>@!8:4(@[P!FP0!ET0
M*-:P!5XC'2Q``AF0`2U0`190``TP`@T``1#P`B^0`Q50`1NP`0[@`#+0!F-0
M0UU``!C@!$<P`0W``@)@`1F``GZ``0I6`3\``=?3`1G0`#,@$SC0!`]P`5:&
M!$@`-0!``DXP`3U`!";P/2%T`)C@`AP@`AWP`190,YA@!-TP!F?B+7.P*Q$0
M`B"`$4O`!#T``C-`!&(`!F,``!3P!LT'!DS0`FQP`L+Q'Q?0!@#P+IWE11;2
M`N/B#4E04>!0-5WC!V.S)4E!!#S0#3FQ(3(F'7)P>CGF!S@P&V9@`&J0`6MP
M!7[`!:,CAUR`_P$]$!,)$0"M`():``-L4`9$8`068`!N,`0?<`4LY'^<<"-/
M4$AD`09GY2.$U2)$H`.<@`%E(`1C@`.\*"$:H!@W`B!7\"M<P`5($`=9X(!'
M(0TL%P;MMU#*<0;-<@N_\0R^`#'%H@<)0(67D`#X@`%=D![Y@``""`#TEPEB
M@6,AT`7/T``*$`%T``8VL0;))09OX%U6,`4[4`%'X`(IH`$<H`)'``50<``%
M``,&@`,.(``[0`!]Z`95TR'),7-V@B%^"`!<4!%GX&S9`@=:\"3\@6,``%'3
M4#6#=PK.]B=-H!%/X`Y<@!LA(`9Q\@498P1>(!.4``U#$&A^`#Y6@?\&;3`%
M4A`&<_>,F+`$?]@&?I($;:`%A`@!1"`!!*`$$-"+5S`#S8B5]G%2,G%>2*$#
M7!`&IR`'5S!1?N`$IF`%951:XOB7T^`%5YE))8",^G`$+/``6D<!4Y`)?(D3
M1$".K-4&X4<&VG`%>1``*=``!]0#52`#%)`&#O`38&`<A?0&">D$1!`%;A`&
M1'`K`M@A3[`GTE`.1D$'-X-C=*D<%8$3X_8-="`:K15[O:$%8'@SDNB$8]``
M9*``O,!*>M8""``".5``"F0_6M)C$G`%G\<&(S!#<,`$?5`%X<66EU!F1/!+
M)``'4;*/*^`#-6`$8=``G$`#<!`!6L"%YBG_$PZ@&("E!.HP!PXP#6C``.50
M+4\0`H_Y!-+!<FTP#@<G%&_0!.(A!M>`!N76!#(0`FU06@"`AW/`+G`@E;A"
M!EO0>>(E`/2I#QJ@`RYP!Q,0`B60":33(-J0$9^I!6G`!D;!$-WXEXBH'`"`
M!!'7#5V5@'8"8X!9FRV!'>'P1H3D!WT&($Q`!'$@`Q)P`B,&`%Z0!FZP!&0`
M`6>0!B.`?P>!`R$P#63``DB0!&L@!@P0!@)0`S*0`06PB_LY=5P:77]H!5F%
M"B'``P.9`9P@`$K``6.UGS+1!RLJ$W5R!DL@#;-W!=K0`'7"!1;R!$L!`#L6
M`1D0`$F`!2T0$4C0_P4RD$Z1(P<<<`5=4`$P(`):4`1>8P9%$0$GP@,8`$=&
MH``LP`9_D`!WD`D)L`#T*"H$T*BKX(5J,``;HF28\&/3$"=UP%EU,)(WR1\3
MH11G,#8*50Z?-0UF4@T^D1MK0%O4$"T-R@,[%W%U@AE!2GH*%:UB$#1),":K
ME072```,(IEMT`<QN0(/^1\_"2NEE2ULD`41L@IVD`<#<'=MX`51L)IAH`%A
MD`1J4`1A4`9S$(2A4@##*@1_0`6#B1`MP%IP0RV0-`#G0``?T(]^@*R8@`0/
M``:A4"PB8S$!D)F!1`*)*A.I!QU^T`8AD%JI10V2-@=^Z0=3``%*<&/5$O]*
M3G`4[^)C05LG6D`$*9<US5(#:6!C1S$#:V`%()`"`M`=;\`$?P"SQN("`7`>
M1_`!"U`$#G``!A`$^)`"NK-VF0`$)I!5`&``:(L)N"<-1'H.O\@U)[`4FBH`
M:#('7W`#VH@$=9";W9`,L05C:G0=U""9=O*G3$ICN2%;S,*YWH`<TT"D-XD4
M,\E1"2``:&`!)K`#=H(4%T`&7(!.<,"QHI`#I^H%83"MCZ$-XD`M7`H`-.!Y
MQ!(J6@`%&O``.!`&SBB-3S``%^``%"8`:2&`$PL=:OL',O``$E"S]U$"/^`1
M;,`&6M!^MR8&<N`%8,`##Q`!'X"G]C$"2J`8J3?_>UY#FZ/4`EWP.0X(`&<`
M!A4U!5UP+B[Q7F+0$FL0M1%06L20!KX@#:33!A<`(*4"!SVP`T30`NS(!WJ`
M!U(0,B/S!]J$$'P``B<@!#GP`@^`!`+@!@0S!!Q`5!Z`#QN4"1!`E$%+!NIX
M"0QR%&/@)V9C)5YS8]+*4`#PFZ;E#71@&\JQD]70F[)')G7@!,\B#5Z@`Z(4
M':?@!0`PDKKBAZDW#4=P!>.B!268`QUP#OQ1!;K4!6XI"B50.!90L=5Z%&#\
M!$L@!W!`&3@P!Q70GZ'R!2JP`06``DF`?@B1`4_0!&W@!#S0?/I!##W0`F@0
M!@XPQYC0`BS``SPB$S9@_P`,$`/0T@4[(``T(`,$H`!&B`$.<#SP,7MLT`,,
M,`(N4*P)@0.JHP=<Z`)*)0K6,5`0)0-;0%LT\)4`4,I/4"=F-0T(H`97(`9B
M0`?"!QVM<`C/$2=R0`P16RHX0:0[Y@<ZT`3TDZ*$G`\%``8$@($:H&_<Z`5I
MNEI-%`T5,775P'M:=$;$>2'M8ET)1091M`889:[?T,W2T%73$"V<&@:P\@8\
MA(^@&UM!8`)GL0.9<`+4L"X=,+*KX`5N\`44(`UL$`5C,`<M0`$08``C8`4,
MD)2A@@1>X`18:@+V\1A$D`8\T`!9=5%S\`8[P)<L$`-GN0DL(`8/$,H',0(F
M$/\#=*`%K#(#;?L'>]!?EQ#"?]`'>I`'HYP#)W"B3T`&!]1P".$#JK,'$O,!
MG+0*UA$"HH@V9/"&':6Z786I840":?``BIL%"3D-81`"Y>`%5[`&!*#1/<`#
MDIH;3_`&6E!R=74!,Z4/>"`O+H`!,A"]EW`9?G`!737.<U`MT]"NU+`&-CD-
M\<H.'((%.TF<ULJ(V1NTI_`&HJ@&:7!ZC.@-VSI*W5"CI>(Y8^`%0:RDTQ"D
M?O`&.,`%5U`%'8<)*%`%2'`#8K`#..#1J_!"7-`2+>8`+!`%7E``<;`$4@#3
M.4(!"I`##3#=]D$"3TD`\6`M/3`O`/`!#Q`'%W!-G,#_&!F@,?EP!WFP!SB@
M`(+'`A?@CHKARQD@`PP:`C[`R)Y@UIN`V9Y`I+QRDD+3$VO0=SQE3VK04$^0
M`4AQ"D^`V*9U`6>06TO<!G$P%%X#!Z9[%+_B?(/7`X995PZ@9?H`!'`0!]-B
MW)G08D_P/4$+!U43!P>:F[DA!^,PCASBI5W58M8QN)I;1EU<#4ERVM-A)VE*
M#6]=6Z3;(&N0M-[(!R]``&"@WYB@!Q23!\%:'M^9T&_=!ES0!&C@`W5``$>`
M5Z'"=!(@`%_``.DM#90JP+.0!$8!>QRP!@X`=IJP'5M@YIY@!TV%XCR@`3^<
M(W8`!0,@%&XP`GJ@#PM``XJ!_[I>@`8OP`88H,56H`9<(#=S,`"&XP8!P!HG
M<0$$X@=(X'O2H`9UX@3KT&,")4I+W`"M``<XP`,44`<8$`)*,--[`(\!$'#/
M?L+V03)V4.-_@`<48\*=H-%8`!T3H,LWMBM!`P<WLR%3&@<GMZ3?0`;5YC4S
MQJ!H4S5]-]%UX(?*T<\"V`UG()55D\6LY0W".`V?]09L^P-`T`:!E``Y$#1L
M<`%%L"MTP`$RX``#$`!2<`69(TY_$`/Z*1,1((`'%0<SE%D2\`"GU0/=&P$`
MP`&8(PH)8`)"T0+$&D@+BP(,``!P86J<4';.*A.M4`=I`&WNCA/(`=I$[WI&
M;FLC@/^OL-T@#16;@EP$T!(!9)`$:5`#8E`%)?`$&%`!"J`10=``'&!TBH$#
M%]``)U`!34`!7`<`8C`$5V`!5M`".A`%/Z<)N&$G5)`).T8'.K"Y,MT:`!`#
M@2D'9%0.$TT-3V#D6K`!W[`&<8`$8.031N'XU(`$;A`G3[`"T2JNI%<-30`&
MTN'C/2`#JB$-_"L--">)NSE6X#L`,\4`,J"#G!0`-*"*!Z'5:_=T`7`!M.4&
M)T"`1W'A*S4#9&!'/H`$])L0'W\4!_6F-_"87)`$23`#(?!DFZ#R;@`&#3`!
MBW,$%@`!.9`#/_`#1I`1'Z#+F&0'!3`?7<`_(4`!1S`#0:?_>#2``=V;#U$[
M!B0`"`1^@T]?@X-=6GYB`&=MAWYG3VU/@UZ5D)F:<WX`5B=$#R=>6E$"!&(\
M37]_>7BLL+&RL[(?*A\&'BH9)$-@7'Q,3"X'"4`31[('$ADB!1$IL6:$<X]^
M1(-@9X-U;MN'`&Z#9TL`9)KHATY7AW!P;`!Q`'7C:H=S3VM^3]YU])&:Y(S#
ME.Z,F#"0G@!XHJ5*&P#IVB#D5B6.GSD83@A@$.?/D1)X;"2SHR<(K9-_BH1(
M<N-*E2I<N)A9(\:+GS<M&JS@$:&!$I1`:4V@D/.$@Z!`08R+(ZD,"S&#G+2Y
M0D=!`5H[8J3IQ*:-FX?_```(@8,/_]*S:/^X0-"&S;8Z;>3)F==F1UI9/0:)
M3>?GGZ8>&S:$T=*CC1HO2$+P6&Q$"8\0(704D>'8"M1!;F34J8*02(\&32H9
MN4M:%HNC9^]XL&!!0A4/T@:M<7+(KQA,?OF&:U-'3ILS9^J8>?-F39@Q]L3`
M&12'N/(X!,^P23AQ&YA#:[;R3:A=[XDJ3RK5>3+F$`\T$>'XA3C(`HLF+,BP
M<E%:%@H7-OC86+#`10,I'G3!``489%#`&SKPX4(1]=$"00@7P)##`@W^P8$?
M;,@A@5=DT&&&31Q4,0<;1Q!`2PXR)*'%!Q`8(8,,-[0F@04O5&CC'W?@<<<$
M'1@PPPP33/\01!`I\`%":3CPH,626V"!Q14NO51%!0UH(,`+)$30PB`YB&)!
M!@0,480!.LP2`!/1_!$`#E*``,4T?E2!1!MI8/`%`"Q08$$/X=R85A<\H`6%
M-Y4PH$<LY^P#AQOV0'(&0G64\H8923BA!1I.0-8$#P*TH$(!+-R0009D%)`#
M!CU4X``/N67R32;H^=&%&&CTT`0`"%2`4".#I(%%.D^0`0`2KK;QQB->L!-)
M&3R4D4X(*UCCAQ)ZI6#`!"*,YB=2'`S@`P\LI$!!$15,\<6V?_2@A14QL-%"
MA1=J,8<`G>1@`1@M/%%%$DH4T$8/9IIA1!=1H&MP6@&$<'!0%_K_$4,&:UPA
MA@HN/!;%!&BIH,\3/;#Q!!KR`###"1)<@0,<"Y^$!Q%IH'7$(#+X88`LEU6!
M01R/='>('![,,$`(+&3`@QA$*'`%$C-\P8`,;8"APSQA])!#"UI4<$$%[&52
MQQGB:/+/)-`%-\<V9V20%W/[;.?/(5MFHA`2.3"5SJ\)Z17``V-AD3(M-2`Q
M@`,CA,!$`B_$H?"V-@RS@!E4P-N)'&%4`<$37.2UJ@Q($*$"#K/8P(,16!2\
M]^BQ)$SZ+"(,0@0$6F1@QDP"A)&#66>],(X1/<0!!Q9OI$'$&<9%$,/IL!Q0
MQQIH+5`#>`91"`L/AQ`DD%[3T+%`&G(X_\$`F`9P4(0?;>00PJQ'$.&$&F'0
ML5D9NNO+B29GT$&''W',,?]VKFJ2:#KN'!(#_)*82$$(X@=#=((/`[#``>A`
M/%98(`PCB,`?;%"`"Y!!`[!!5P(>``>,52AU3V@!'+3@A#AH84MBH(,69*`&
M#T!@%D=80PB40(0&CFX/#;`A*U+GAQ:8P`!SJ$(+(M>#$%SE+!*(WAP(L(8N
M^$$.3VA"!'B@`C=D@`)<P$)BE/"`"E!`@DCJ0P`"L(`[Y($/<5B"#SRP`#[X
M``<J*,$,9H&"*A%A#1F(A0`MXC7T`"`!.4#"&S(P/CCTX`1U"$$9DG"!'"A`
M#3=HP!+HT(84K/_@2AUH`1_1P0XVL$$+4#D,>N@``"^L80UG$`L`N(".]^&/
M$)%8#B3H\9!T]`"5A_@&'5"@@RA8@($-M``2>!D!';CA!SF80@W0=0`/K&$%
M-[)`#[]PA3.$P`LG<,,3&H!*!?@A"`*8Q0$JD`8SU%"'"\/#$-`IS1XB0`)D
M<`(1:A`[)+SP+#481QA*F9<SS(%3+".!&#PP@0UP8`A!^H`>^$`[TO`@!Q<X
M`6L>T(`XH*$$`G!`!030@!8(`&"E4P,=T!``*7`.%DH@(%_:8`#/A,$*/#!`
M!SC0`C)D0`L4L$(;),``"9S`60!`0Q?J@`84."%KN=0$`'XED37`@0+_:6`!
M`P0IABYTH0JNL@)2^T+`5`Z"E4\0PQF6(P;T[4.EAY#?)OD(@`]H0`(\`,`$
MH!"`"(A`!7C5``D&<`"T3($U`P@2"D:@@:M9P`M_P`$57H"`!V2@`4E`5PR^
ML`4H2,$D#;+`$XR`AJ=XX0UD,$,J*1`&.=#A!A2810I<TP0DH'-A"3@!.P=1
M!BG$X01%P*(*!%`%:.)S'$GPQA?*-@`KF&`"$>#"$G08AC"@!0=^R`(7?#"+
M/2```A#```8:4*4;$.&[3J`#$H00!PL,(`D3L,(6'H!5#IA!"PKH`1%>L`1C
MD;)3#QM#/B$!$1UH8B)J0*I7D^HU5^H%E6Z8_]XA9*`//WBA"7VIP76>L$E-
MP*DO[`%`!)#P`2D\X0%.L$`-ED#0"5B@``4(0/).@(,CN(`8/F!"!$I@`2O\
M`0$#8$4$(C`"O6U+`)Y4@Q9^TJ`5/(I*@VA#`\"PAB=X@1(;J,%)8V$!'20!
M,:]=&`/0N8)!W*`"#U""#'B0`12TP0%3#DH%O`"1\9`A`6>8RP<*,!T_@+2!
M87#M68``/C9L(0O)N,L=Q)"%/VR!"&9(PW@ZH8,&P,%2;NA-'2"R`320(80+
M,8$X!HS63.!C.])Z923B<#]N9.!_D;@`1,3`"2TT>&?CR%HBN3&``1`@`@"P
M80,`L`<&7+(%/)B,?/^VY8(^)*`/?RB`'8H\B#=8P0]<<,`:($('"O0`!EYP
MPSUC@0,)].#/63:8'02@ASLP%`$)F($*A+`"YZ6E#R+0P`L\,``.0$``,*!`
MEZ-[A!L```YG@$$#9$"$"OPA`14H0`=0H@<(D#(-=-!2&]8@`P6`&``UN#/Q
MPO`&M/A`+,1I00)(PV<U^$`?<.!`<T`#!A:\X0L#'P09&I"&9S^A#E?@@A?H
M\(3@Z!)_+/"OJ%_Y`'34X0W1<P.$Q2(&%M3Y$+%*(238>@<>R,`!N6[@"<P0
M``E(H`)#,$`*7-"&;35@#C,``X5>TZ`1Y/(*<&B$&IXPAQVD`01+@(`(9C'_
MA#<T00<V#O>V^%`%%5A``29@`0<H<`$0"(`#I-F#$ECP`P<X8`,2X,`&6N!V
M/UB!!%P@`P4NE?@'Q(``9+A![E+PBEGDP0%%=_!CTM"%P7B,!E*H80(2P(<#
M\"$`OQ]C`@[E)S!TY"Q]^,`'QKB'TK@@3@88`7J2@`$PD*$"(0#`&FK0!3EP
M`1M8:()R"`Z`,O0@#"&(%5]HD]8*#_T)I6Y'.LC`9@RIK@51,`)P,H&-?;S*
M#UWS!'E`(PR0=<1#``X0`$F0`4<P`32P`BUP3C<2`&$0`6?@`3:@!6E2&IT'
M.3D@!$Z0(@@1`P*0`TH@!AL("Q_P!E[@!($G>#>B_P?A='`CQPHCMP=Y4!IZ
MH",Y^`>'8@=XT'E6D`(-4`<-$`.]A`9=<P8$P`,2L`5)P`=XL&RR``61X`8Y
MP!YB4`4"$`=!,`)PP"(5$`$]D`$84``4\%@(D&9(,0(SH`%#@`$BD`$0\`%M
M,`<?(`(5L(<5T`'K1A\58A9[D``'<``VX`=I(`66H4AB<&D"0`96(&U@``!*
M@`*3R`(S<$)$T`9RD`;T]W_H`!SLMP$7]DKQEPD`@'3<``D2(#<95@D`(`91
M@(J8@53:<08^H``S@`%/8$,:0`1'``&/=0`-\`%',#Q^H@<$QP9$$`,\T'SU
M40)^L`9:(`%88`%=L`8*@/\&9Z`!5Z`$$C`#OA4+3$`#6K`#50"#R:AQQ".-
M#K,'&,``#L`"9_`Z'/`&(M`"<^`)+``',6`!@18+>E`]FT0`;X`'("`$%?`$
MA]('OP<+*E8?'#`"5^<B+^(%EX`!$M`"+;`#.\`#80`&C1,+?#`2-D`"LH`'
M#N`85L<%/$`$,A`&9!`$G:`"31,"6F`"?G`E;5!9'``TC]`%9X`&5L`&//`"
M#D`!%#`"7+!5\#,'$.8'!'`%(3`(4+$%@W`%"G$/.@,):W!;CR(';/`&RW$&
M$I!AA]`&=P@`<W`9@V`$@S!<<4`&G&!`O:@`$7`"O7AP)#ER@'@6>-!ZM%`"
M<@#_!B,P!"D`!1QP`2K0,GXR!`*0`DS@)]*H`PY@5#T0'#4P#\G2E`,W"QU`
M=RR0CNIX(QYD0^[H!%-0!0PP!>E3`DDP`CH@EF)P`A!0`S+`!J<I"SX@!TMS
M!2UP!20P`S=`!3A``7O90%\`3$B1`-I4`PL``*@!"WAP!`/@(U/`!!\@#`MP
M`"X`!U4`!99'`&P9`5X@!^]``"'4!%AY`3<1!WE!!V)0!_,3`PJ6#G+P?W3P
M!F?0-OM#!EBU#_3@,9I0:G0P!Z5X!8K@*)%#!AOS1%#Q#4]0`'&`!:P4!MOP
M!`G0`V(@`75P`3Q0!3H0DET`!F&P!4[P`6BQ`@Z0!WW`_P0.Z0(!X`)44`#`
M@`%*``0IX``R$`0[X&XV`F1$,`4-51\%$`G$404Q,`U-8!.W:81@D%JRT``1
M$`8L<`6E>2,S:$,+D)5!``$U@05M,`0)P`9FH"YA$`=L(`,G(`</L&VQ8)!)
M(`4&P`LEX``?$`8#\`+)23QLAA8!``X.`(UID0#PEP);T)\Q4`=B$`,R<%5_
M$`)AX$1VEBR_XP02L`)<X%2_4@?N)Z`J=09>$*&SY):=H!>==@;YE&CT>0AN
M8!..XA!E8`^_L1>'H`9ND#6@M`]X8``E8`!/@`,>()E0``0)$)AW8`=4>!8+
MD%,FX'4ZH`$9\`(%<`;)M@,5`/\#4*``";`#$7DC0-@`&.`%+/"MI#$`G4`'
M')%>]",03N``:*`^1Q0+$!`%2'"E61JD"T`%?%@!&W"=&P`%U'47,[`#+?``
M.W`#-?``1&`$;7,%*&`%+9`!6W(&/^`5(0`38K`#8W`$+Q`&6#H+%%`'/("I
M$@`&3=`#!?`",J`!*&-#?WH6"=`.'&"N,AL)!O"H24`!`,`J8?`$(1`#B5(7
M;,`^:D`$7A`"HM4;/#`_H-@)DP8._G>*?5&*0Y<.6A!J@[`[?<&)VC<_#88&
M5;`0@U`=>R`!)8`!UFHP>]!7L$!\U?H'4M``1``JN!FR-W('+@`$#N`%$8`#
MR%8??.#_!^MR060;`F`@`RN0!C'0!I3!A@FP!%;``7B;KZ5A`$/@`!F%`37P
M`Q%0`!HP!4!Z%@9P`8T'`9<W`!6@`1@P"%B@`DV0!`N!!`S`!?-3!EC`!DC@
M`6;0`A,``Y4+"R.[$D&``S]0`963`40Y!K4V``40!#-0`$<P`C[REVFAK'9P
M![%P":QP!W?0!WK@"H3*"GS0!3%`!!O!ADC1!W*`!B00!CR@`!#0`S<'%64@
M+8!R<],15%RP#5W`!FGP?Z`('*D$/3+@EMO09E1;-^&QP)``/5K#'G7P=%$Q
M""_I!W3S/F>@!P6@`RVPML2#`&J@%L(X`BP0!%.`C#>"!P\0_P4PD`((,`*!
M.(UBD#VVIQ`G,`)M\`5L,`474(.P`%U5(`,^9KFE,4<ZI`>#T`/GY03AT09)
M0**1T`(6<`5MX`1<0`48,)AG`"Y40`&8F@$3$`(RX*$\X"14&0,Q,`(QH`$K
M(`6D\0`;H``,0$4OD`,1T`5/@`*;MP-;R%.D"0MV<`1):0&!*PN]=P#\@0)M
M]`>%F`=R@`4<(`8MX,9D$`57(`,-<`%-8`!FX`]:,`%UX`19H`9!D`0\X`4R
M0%&T-0A)``EP``;$<3;9Q@T68;7IP`GV0\'H8*KCT&`37&&4^@!/&PEVD``V
MD`<@?#H#D&L>0'U_T`4&IP#H\@%V`/\%&+`&&U`A$T"X#K`%88`#"N``/7=8
M?H"AD>.VL'"(0E3$1OS.LI`'@T!1/5`&1```#0`!-]`&"_H$5V`I9(`"`F`7
ML]`'9``%"&`'?!`$!'`!C)0")>!<!_-[PS!&..`#/J#'??!B+Y8??#"Z?=!S
M8B'1L8`'9>`&*.T&BV(&8&`_"-$%*@!P5R`(=7`$8%`'$_``#^``1^!T?.`)
M$J``8J!-8>`/1D`/`>HJ!N8'+*`/;T`W5UL'-?`(JI@.+/!*TJ$)-T,_KCP.
M?<`&:*#,-J0"6Z!C46`'`\`"'V`!S,2R(4#-%;('S>9?;J`%<L`"._<;1UH"
M1K";?S``;D#_!6<,SZ31@S8DSQB<!QF``&A0!UB`:N"B`Y2L`63`!6+P`,'+
M"GO@3RP``7!P`UQ$`!OUP3JDQV@AUQ0P1F<POG]PS0SUVGV``RC@`<,:!E'5
M`@"``2KPRFP0`I<1`4X@`HCT!630!7,0!1#@<DR0F3KP:IK@!;Q,!CPP2=^W
M'<_6;(/P:9F@".H7E>U@`A9@!G#`%)>0-I?1!AG0!-_P#74@SYY2!W8@!`F0
M#`8``2@0`!.0`C:+$@-``AF@`0+7`":`74F0`VA`72Z@`G90*C9`T'X"/5I@
M:S9R!P[F!4RZ5`+0!@\@`VXP5"-P`=H;"P-@!F$@`%I`V->;1SFR_P=ZH`=]
M<$9%6B$!D`![8`=2,`A:<`<`[*H%9P1@300.<&E;X0500`MW,&0K@`%#T`'Z
M70$[H`%"@#PVQ`5U@!9XX`<P@"-^@,1I<0=M0`8S<`%9X%$RD`9TZQE,_3"#
M$`,Y(`9OP"=>0`194'^PM`D7D=U^L`15T"BQXD]9D`F?NAT.:L$!40-,D4K6
M,!UG2;@G\"H-]@1X\`(M@`)/,``K$#@"<&(#D`(8,`-`@!838'D<P`$-\`,6
ML`(K4`)30`<'@`(&,`4^<P4#D`/HP@<=@`:(4>0-,@5^H`98<-D/$`=Q0`-*
M9@4O4`$0T`)@%`L?,-0FCN)H80<4<`#R*_\#1E"R%*`$-7`DI6$'N<`$4)!1
M%'`$U$*X?1`*5[`5OCV69F"[I$8',;`&;'T2,?!A9'`")H`!(3`"()!G@4P\
M8_"R2'$'=0`&>Z@&DTD:XIT!<P<';2`"I`#=W(0/ZM$%']ZS`K`98(P99<L7
MV\!']URKAV`%:_`&X1$GD)`&;@D'=,#+>C$(Y5Y`@]`$$A#S[S,=3[,(^<0>
M^T@_']`$"J``8Q"8>!"^HY,!76`AO=4!!!`#37`!";\MPA`&.50?!T`OTS@'
M(4`'*@\!?G`",?`9$5";LQ`$93R:T(X6/_`''O!B*2`%'X`#;32PI<%0>9`'
M'X`'.4`*44$$%,#_`5XP`<8B`UC%<2V`/M>QW[$@`5IP``0@`!"P&@5``R3P
M!C),D@LU1@VBK-X;F"Y`X0+@`GC`?&\D!"H:"WMP`G'W!E-0'X3K`R.TTZ[1
M`M,A!AQ@`-(Z4$Z`!/3`!4)[SIR0U/@S$4:`564P#>A!!DT`!W+@KI!PTVG%
MP]MA`(>0*%`T#;!J#YR`"6J0H83@ORI`!@KP`R?>0`(0`T/P*0/@`A_`!WG`
M`*R]+1?0(`M``WIQ`7FA!A*P!)T`"`Y>-B$F!79_B8D5;$Q:`HJ1DI.4E9:7
MF),PF9R7=W]W>`9^?BU+`#)^6!)^#09:!VP`7'5>#IB/24)2$"A`'"XI_V8#
M?PI952@<,EII:9N=BD1?6EH]/5I@)WX"!##46`P2&#V(B7D,+0D!"91Z"T='
M'Q,%%NQ_01!^6@JL?CI/;\Q4`5/##P\X5^)0Z)'!P@\&,D*XL>*$`1E2&$F%
MD0/'SQDR;WJ4\?/D3$8V&0$`N$B*3!V,13)^@;!E#:DW;D@-R(@&@,DS/>B0
MZDBG(RD+3LBP%$.*2P`+*9!P@49UDK(/'OC\F(*C1XHCY:I:"BOVCP]M1-A<
M*3D'38(Z%Q10<&#CBP2R?RJ\&?"HK-^_@`-'RN?'2@LO-2"`P6#F#1LZ5^:0
M@8##!]Y)/:)X8.-!@X`0!4)X($,L00(7`?[PZ?_#AX\>L:TIU1G!*4`+-15R
M.V`BB4F$'SE0Z%``@4:+!BT4E)+`QB:2)W[0L`C!%`PI+%>PB(G#)<P3,1#8
M$-D!XV5&/P#FH%S9QLN-4G6TE%&"48P,`''0F/=3YPW&)!AI\<03`$#'GWE9
M9#2''"SX$4,3_F%T!DJD+%2'>5PTU4`$+T0PE6"9#%"!#2[L`4$;=V2@`!*7
ME95:`PU\\E<;Z,6Q!AM(D+1"'0,0@5X8+N0@HR($^#%$7R`FJ>22B8RB"AA<
M(%'!%@P(4`$18<S!`FJ=*,""$1'(($`#5+R@1`U)(,"D)740T`D#?K#!Q1M$
M''!)'J\%(`(."D10QP/_0A`0`0$M9.#'&R28(8$<?J@QAQ^YA2&G#&2LT04%
M3)E!RJ/GG5>'24BH<<8;7?AX:!@YV(11&`!8T890$9+"%!%;:'%H3GZ$T6FG
M0F%DH`=MJ-HH*5WHD,8-%[CQB3T^!!``:ZD!YD,0$V0!AAEMA)#'`'8T(,`/
M+8H510]>4*2F7S:YH0`6`+31!0=A\$A`'0`\$`8'>"D`QP=E/+#FOY1`L0#`
ME,Q`2@]K$$#1'/FU0,<2Z5"EP`,*I#!"!C-X``,$#F!1`,&2G*%`)QJTT8$-
M03`1;B5W%/#G!#TP8$832[S1Q!I&:"##'"'8Y$$8=(AQ@JY5K`'2%5>08E*G
M_P!@1(<:_/&4D1<2['>%%B%L`?5Y'74A1M/!DE*%'V,PZH<76HA1-"D40C<&
M*2U<B%$J?G1A@`8>S'"&!0+T0(`$6(000@T2A#!P)PF@@(</\>``@1QSF#$:
M!5MH0,`!-_C`P9"`83&""RXXP`/G5.G*1AA.-!!'&1)X<<8`(81!@157?#")
M`FD4X(:_((-L0QY_X.#`"%#H,0(*)8AUQ`@S@##""AB8P$\/39`BP`U=/#>'
M$Q(!A`3PG7P@@!-L]&!@#T>TH$(<%J@6B1XK_[5W)SBT6D0,58`/S05^8!H!
M2^T*`0#$D+8HB&T%#M@`'!CP!8/08``G0`$8]H.1IO^1!"->X!\;*+BK#GIP
M5SXRBA_BT(8!(F!I_*F:@8A`04YY(0)5J,`)O)``'V2E`WW8PQ[TD`<\Q$\2
M&2@"$PJPA"?PH"TQ0,,`T)`!`?#@`BS0@P%Z0+JRM$`.Y_J#%EY3EAS40@QM
MX`*[S&"$,%P@#%A80!6>`(5)P&D$6*!`[T!F``[\80$1\`!72C"!:%&%"=PH
M``-RH(('.H`#/R!%$H8@!C.8`0Y)6$,3,N`#'A"A$R,(@8'\H`0P:-(-3H`"
M%GB@`1T0@0@4<,(,#'"+P-PA+&=H02=>8`8M%*$&M*D*_YHP@4:BYP55L$_0
M,D*!L;FA!V=T@AC(<(96&6'_5RC$2!V@PR@T+"$.:6`#__P@`QJ)801:@$,8
MUA"'7)$B"F3@%!ETU0,XF$<`6*A#')ARGCG0,P1OJ(,27K))4HS`)(,@0@LP
MX(4UN4`'%A2($AR@@S:,`0M;:%,#C@"BN%TA!#&(`1?VX!<:F8$(/7C#&[1#
M@33$(0L5<(`9U)!%1<#I`U>0XQS_]<J9)F("%2H`&OR0!`"H`0#>$8,#K,#%
M2RC@#%Y0@QF>``(DG$`!21B`%S:`AA&PQC2MP0,>^%`6'-@N$1G(`P<@,(4G
M;*$`?#1``T+@/`ZT41$3(`$?3D"`&5S&`QS08P""X()$L,,!#AI!&1A1!@.L
M80VZ_^J"`)1@DC=8`*%PJ%H:X-`&,63!"TV(YJY\,BPOU`(`=:`#`';JAS2\
MA`QFH-<T/X@1+%R@5TB8PTOB`(`Q@*$)7U!#"YIYP4TZ`#J<[<)+O'`$#>Q@
M"&C``Y.8L(83&&$.8:!L!]JP`"48H0)/P,$%DE!%L4B!`*[H0`>@\$-+-.T*
M2'A`'(CP!"M4P!E5R`X/PJ""26C#`E=@@4W7=`3]S1&GVQ@!`-(6A@ZL`0U8
MX,`,`-"'3%A0#$10`Q"(\``>[(,(:=!"^T#&`1+`H+U22($-)C``"Y0@!QCH
MJR($48`S/*$-7(U$`HJ0@PS(P`DFN`(#'!`%"<3`#RS@P?\9+B!<(^2@+60@
MP!KF0``LL($!*_@"&33PA2NH)`0FH8%F.X6$-%PP7D"KPQK$+(?]O*&!8PCM
M2^CPJ`B)UE=6V!H=O.R'-K!!``((!QE0TBN#+`T,P&WL<"MP@0CX0`W*95(5
M`-`$`<BAG!I(`P%X`"$"U&`($$@T8`J@A24(H`AMF,!?A`(=+0"@:)KT0Q-,
M<(,-@`$%_DV$-GR0W_W:FDE[`'`!7`"'.&"S`BL(@!P:(`4UQ/@2G!J#">A`
M3I-DX`E12`,`-CS')TB@$Q%X`AW:8`$_"$$2>T@`1_D0@#P$H``9R$`$0@#D
MS["``&V00V5=8(`SA($'_"`"G-3_T(,JI.`,7#BU4+:<$=YFI,\2@D,TS28L
M4CS!.G5F-RE48AX`].`\5HCN!3M(`%NMP8*DF`F!.E!0)KG`"SD)`1>\X`0T
MK*$[["V!`G;04L#8P0X3"(,9BBJ6<I("#$\+`1($(.8:[.`*9P##X2)!`S\4
MH`KZO762N"0)/'07,`F8`(#@H`(F/$H.5QCG#0HI@2H<NQ(!H,\9'O``H<"%
M!D3P`@6H,(8+V-3:T)C#8CX`XZI4P`\UN`(')E""-[0A"3MX`1$R<`4:J($.
M-8A`"Z(@(%;(`:AK:$/2=D4C.GBASA("_:Y>[(<BF(2#8$"AQ(GE\Y>`_#Q?
MJ,/6\+.J_].3PN=KZ$,-`+"`..``="X`0@%\8,,)6.#LEKC#D+3A!RG'009$
M2`(;HB"&'.0@"!=H0:PEX4=.^(``;+`!8'Y@GA[$H`9MR`($GC""';2@"UG0
M@CTBP;\C5&$'4D_2"))@`0Q48``'0`0FT`4M0`!$T&!4,01$H`5(@`5-X`5B
M$(%-\P0,@`-O0`='4$1=(`=!T&]^@'R3L`$>\09JH`-_)P-N4`-L$`-A0`0%
M``8VM08ZT`DI<`$5($@5<'66D`-^``=4`!!A\`.<$ETY\`;,="A!\`0]\`-+
MT`!H1`8,Z`?TU$%80'`>Q&YLD"D*@A%LX',9`0960`I(@%@8X?]E9^`&C'4H
M2H-"21!-2V,&=P`"!3`"<B`&&.4%8R`#+*!X$``!O)$)#:`%IT0$;9`&6``'
MD_53(P`";@`'7F$&5M9]F&$`B!,#8N`#@6$46)`&6Z``6H!27*``5O`%8%``
M7)`\DL`_'&`8^0<B>[``P5``1W``'\`'!@`%?+``Y24)'O`.!\`$?3`%*(`#
M'4!G"E`$:+`%=A8"%X`&)^(#-(0)/P9:8A`&BN<3CX0$$3`#%P`&!@`!!O`"
M)S``!8`"!0`!?G%SRJ=5-K`'8"`#>N`"?+`''E"+?&`'FO8'$$`O<^!3((@)
M#5!G`_`&2%`%1>.(`W`%U6,T:7`&)9#_1%XP!W1`!`K0`FAP!>3T0?V4$71&
M"F^C-"2A*Q#G<`KB!J:R*;@2+QDA!J'5!@Q`!VZ($>NT*V"@`3="!F"P!UJ5
M!WE04SI("8HG`E%@`5CV>:G'`FNP``"`!5S@!!MS`E@P?Y/@`3V02YCP"FYP
M`C`R`#]I"0E`!"81!_96!V)0!">$`0T00_`"!),`6$K`BJT8&`L@E2"#`\Q7
M!9;#%%[P`FCP!B&0!A4`!G0Y"6'H!Z+E!%H@!`!`!UJ`!E0@`S*0`6"P`2;@
M`0S``!G0`!X`!1U0%D&`9P+``B+``D00`G.@6T2@`S)P!57@!$YP`2J6"%`0
M`Q8P``.0`GCA_P)2,(OEF`),\`%'`#I`H(08\``ZH`490`-@0`9"1P%^0`+=
M```%0`1FT`(-5`8]@`5/T$DQ64'1U#1)I(P&LE2DP"@`D"!C@Q&/`EHD<08Z
MX`?].$(4H@8<E!)PL$DBE"LH)"H]F`!(<`4%X`6[B`D0@#Y7<`?]$$P_50=8
MT`(LL`,"8'%=0`*7X`(]L`*<\`$$$`,AP`,\(``<)19Y4$YOL%-G<)]$P`)M
M,"9*(``8P`.8*`F`E0!9($MQ*2U+USL!D"/;4`<\TP9;X`?6L2`]8`7_&`D)
M8IAN(`8T8`$`(%!#]`4>P`,U`#!,@`-XD``X<`0]0`1\X`)0H#)\0/\%'_`!
MG,,"9U`&`Q"BDA`!%Y`%45`%2'!*3G!8;)`%==`"0>`'[U$'/7`&'$`@73`'
M<W`"36,"6.`%9O!W%?`",3`[<B`!((<K#A=-,G`&C?2GJ_4$%)1Y/2@'0J8*
M7[!&%7!8;3!TK)(&G"*6G3(&1E$'5D!P.P`&M-6#I-`&!M`"(@!H@PD%&8`"
M.7H)BA$";:`#84`C/N`&^-$T7<`&;<`$36,$@QD).(`&=I0)4Z`#.)`%7'4!
MT\H)72"%[TD*=%`%.1$!75`&-;`$7T!M*W8&-'H#-PH8Y693"_`V:.`!`T``
M8A`9(R`$&H`!%B`&4_!#,=`&)O$(<\!J9U#_`QD0!P+D!QI@4_?6"7J@`U;P
M<#6P?>V@0WOP`4^0!C901#4@`_+&`@\@`3FP!!?D`.,(8;*``+$Z!@2@!F$0
M33%!`1MY'@WB!UP0$QA!(W'``:_W0>:A'Z2P!,YY'B7A!W+P>;NR`_WD!=`1
M!AC`!FA@`V.0CQZ0`TX0`0#``YV``6'@``(2`Y_'HXUQ!BP0<*("!DEPI(EP
M!TD@MIE`4`8`!PTF`)((#0_0-&G@&!)`($YP!C8K`Q'@*D$0@G(P`4A0I?/J
M%SGP,7/+57H0`'SPK9R``PNP`$"`%3:@`@D2!B50!PT`&6,V9G[P<6Q`N9;`
M!Q-@("%`!QR0!$F`_U$"L'DO8%--@(Z=8`'K%QURBW:C90'T`@9AD`%JL`:-
M64(8H087``-=``8M,`<30)4L\!Q9\'K`E1&Z<AY!2J[D.B$D(0/F@7!".G$F
MX01CPUX?%`:Q\KWG$1'Y*2L>0`0@(`%FD&@?T`0&PD0B$J.7H`%T$`YT\*$"
M@!Y>``-N$`)%J@`U``<E``4<JP@'T`7/`)!=D`\68`!1T+>=0"%-8`8FP"AO
MX`)TX``W=@)$,`?$(`E_UR.0&[EBT0`YP``\\`,K@`1#(`,QH`(44%]BD0`\
M(`,*8((4(`,\0"-L``+\H0-S`%QD\`,"D`%NX*Z5X``2UP88P`#/=`5O4/\#
M5E"D82`)KY$'FNL79=!*F;``7`!=/Y`"91$T_8L?W":>!(*I2V4%X2@&9U`4
M^,0%^*8`8$D*#<E:].&S'90T0*'(%C0@$\<I'D$@1E"_'00`;T!P=4"I'D$*
M:\`$6/`&$2H#6^`%="8&7@!46="@F<`'+)`$6G(!5O``9\,%8H`!F+R\#V`#
M/,<R,1`!G,`!52`X'DH`PWL)JG(&:4`'<K!2`5<2$\0P&`K#?H`#8W!M-"P6
M3=``*(``<RF/<ZD:Q\PRK:$'?8"/.Z0!UJ,%9R`!V>D'/0`!&A`&!5``?X@)
M1V`2,;!!Y?3&2+`$5.``8L`!E\D`*)`#"C`",H#_`W\@!.,L"6`*#T=0`"GP
M`>?Y`2K@`1X0`1S``04P/)%``%V0`P-0P9FP/2/@K#$0!5>0!0(Q3SQ``FQ@
M!ISV#U_P!M_!!4U@:73`JJR%$:MW$TOC8@T$!_P#M:3@!K8B3IL4GU&3$?4Y
MR>=!9V5P!E9]JR]1!T-0!7%@/FL@`TE`('``!DWS!G`P0)2("0EP!"10`S5P
M`^[GH(NZF$(@Q)W``S.8":8QH)A`9W*@!3;2!(SI(VG@!6P@;?>L"'\'`0"`
MS=E,%5%PK7/D`P;D!PR@`@``!EJ@*7-`!%V@!ET0F3V9"3;[!2^V`O6"!%!`
MB6%`!@<`?.2V`.1F#EW)_WU>L`9JH`;-@`9H@"TD8`5:4`42X*`]H`&)W081
M(`0KHS,8$!$QH`$K@`(0,`$I,&`D``%HX`1((`8&P`*N@P410`=DD`$"QEA@
M0-:4I5MP@-0?5"`70EJ^4G&599CA*@9TX`08X84R02-S@`6>##8[VRX=M$8V
M*RO040<'@`(1T`!GD`)W8"JPVC1ND"%&@`6`@0)4P`10D(^9D`<QD`2WUI&'
ML@5/P`)F@`1P,)M>8`%O\`&QF0B)Q`!54`2/715.(-F]8P=#0`H9&P.-G1!K
M``=SF+%I8(G!.@D!,`)'`-BES`'SEP9D8%.BW`DZ0+570%&4\`,#T`$&,`,3
MT/\"#'`%*EP$`%$`-ZN)<3*N&5%.:O$2I50%6?(//YT#;(!4=--!:9`AV_#3
MNV(>IF:%'[0%I-8T;UBM2Q`%7!P"/M(T6O"2?@`!!&6WM^8#,\,)"7#D?J$I
M3E,%:>H3;^`Z_'$&,&`GD<"#4J`%>5WCG?``(+!?<%(*7(!:)F$&J12T`P`"
M:A`$(C#.LXT'/.=(-H4$/0`-,_`"5Y!A-?#01V`/^7$%49`#&T$'/Q`!7J`$
MKQX%6$`'$A`!7]`$`&`&S)NQ5]!G48P1),[G&('?I=<H`!*TY]%P%<025@``
M(KZ&'X0&,2`'7Z`I1J$&-J`#<%`!\R4`0M$%OV4>1H/_!%$`,GUP!U(P"0E`
M`Y)^"1%@!BM@`TP0L"#,"9J>6(V(!6Y@V$_`!<N+!L`L"3OA`6"0ZJJ>"5^;
M"%*`N7*\)J=1`'`C`&T`YW"`!+*`W]9196U;.`60QI80`F9@4U<`"1F*`I<[
M``9`!.)'%7%@!HP-86JP:#T@!B)A*F>0!"(``7`@!FL@9-\A9`3TU.C>*3X]
MZVH.G^<AOQWT*'/@'W#@W^A1M)ZR$0%R>BY`!%H?`W.@JC^!'LQ4N%HP!$R2
M`(BP!S-0Y2,C"0EP`FQ\"1S@>5S@H";`X=#`%&<P!W#^`@)2`S9A%RVP`5%P
M\I'P`=S4!#+0\IW0`R>?`SA@_P,5H`AO5148P(TMT`(WX-9.8`5ZS@!BD`%^
MSRX^$@-P$-YR("IJT`!/8`":SPD"X!;D]M!_`0<A4%.8("D88P`#\`%LV@EP
M8`8$%2=PF[#;_9[TT@-'-@=78`8Y40->D`-CT-QUQM[GX6M&>QYE``A.?H.$
MA8:$;(9B`'YG<8>0?@!NA1)G@RX.1%$91%LA<'Y/<WY5``)B$7^KK*VNKZ]0
M4S-6%`4\:7YI4@$'O@O`%A*PKRI7*3-[4'S$S:UB?F8R9`!>=#5@7CUA3WX-
M<JJN$7X?8#)VSNGJZ^RP$07-">VM*A\F#0T:&?LK/X-F&-Y\"1'B28<V1?Q`
M$.`GSO^9-U&>\(`RCU48-"<JA&FBQY6+BJM*8!BQ8,2+'"\`A`#!P(&#"PTJ
M+*C0D56N0D!>X3G0)\$!/GA<P7DCP<\<"$FZ$&&3BTRI&3W\5'A0YXP@/UW(
M>&D1YDTC4I+01(IDI9"8.FW<S.FF!1HA.C>3`'AD:`ZE2&'&(@$`0,V@&-W\
M3)"A0X89`%JZL'D"9U$+/W4$H`-)3(*;P(P&,7XC1\X<.G/:G"&QCH\-.SZ&
MG/!`>55>/VW0Q&E#AXP:)RTN@*G0XPF(5QX4MB'SL;7QXZR&#$`^K\(@!U.\
MUN$A"<`E0A+B`"`"@`('RB_2_#'P@<\=5PLH.XA@(<"'&3[_?,B(80.(B_L)
M`N0QP(Q5#S<-B&"!"/VU$L$;9*S!1107.%'`##K8\$8:!6Q0!!I1M#'`%0T`
MT(8?&[B0A1\.5!&!&!@4$@8`5XTUR!EU-`+)=8-TR%@(2$!&1T-^%7(#8CJ*
MU4AFD`0&"1TMN)'$(`5XY<<(#TQ0V!7=C/%$-]:I08`!S+6R1P`F9+%6(1?$
M0$<422S!@@`.,+'."E4D$`8;.EA1'$AY$9`%&V&T$44.2#1!A`-NS&`&$CZ\
M0@6)/<005)>0MA-`HI&F`T:-59P1PAMP7&D%&V,0(L,3:PP%Q@\C@"2!>)4V
MHP8-[!@@QA$3Y%!@*P<$``$3-NR!_\,1%\!@1A1GF%%#&FW4`4<#=3A!!!<.
M#+*C'V&D$8,,7OBAQ0ED5(&!;H0\$>,A8Z9QTUN&?!C)$T0:\@089A@242%7
M:.&B'R&H.\@2W9SA`@\3:'#"!T%LD48<)*3@`Q1[_/!=JWG\D4`#;H3BQQ%]
M\#'9'Q&S4X(:'M!QA!U+9-#:%W[4$`(:.5@G`QUN:/&!`%O@8(4%KZ2@4`\\
MM.IS,^[]#`L>;N7PAA%O>)%&"U7HD%A9<_3`10\4B)$!#D&`Y(4:0KO"A`15
ML$,!&0P`\`01>["#1QX)>(`&&U+4T4(78(A1`R-<6!`"#TAD2P0#891115I7
MP$`'`C5D.__(F"[2.`@1AL0Q"@4],!*OBS&>$0,A<-#1Q;B:&1D)`/'2)48W
M;_!Q11<L\"`"$6%04(4#$ISP`AXRF"ST'CY54$4(\K3FPQ421.!"#R\$#Q+D
M@X1`Q!-J")#7$T:\,`8+9&CPR@!^Y)!$$H]V+?0"!]B!1U!ZV'%''GLLD#Y(
M!RS`!Q\NV'`?#H_Y<<(;-YSQH1@:D$$:KB"&,\PA#%5@@Q52@`$!4(8!<PB`
M^%;A`PH,8QULF`,6V%"#.N``)*(9@!,RP`$%Q<L("GA``:#``[54P`%T@,`)
MNG`&-\P)"5T0TKW&`CK-B$(,:Y"#'\;@N$/TJ!!GH)$<BC@6.A3_Y"96F!8.
MR)"],D@`"VEA``:TP``G((`!VIO@'Q"@@CX8!P@C&,`(#D`%(4B0,A`@A!;6
MX`<N<`<,80B3$W@PAC"V`@I^($$,S$`I,;:J!3!P`0QDT(`E0(``#"!"/FQ0
MD2"880U5J,(:-KE)=;W`#$_8@2`*$BHUL$M=45"#&&)`!,HP:PA2.((*)H""
M(.!@"L:Q@RY7H4L\4*`!DZ$".NYP'E=HI`XR,`$`/EB1-LSA`T\X0QBBP((<
ML`$,<1S$$LL0S1]Z00!GJ`$!KE0%NNS0$'68%B$J5@BQL',0:J"C)+KA%K`8
M@@YP8"(2Q^6(.@CI+(-@@A+:L)0GC`$$_QW0P!J2Z`<L```>AD3.`+QP@"ZX
M:0WAJ$@?-@>`3A&B!71XPA*0((8E,`$+*XB%'W`0@Q!$U&<14,`J\M,3>22@
M)A7)P_SFUX<^[.&G)A@$`=C@T#,\X1$.@,,6_$`'%H0"#BS0@AQ^`Y(&M"$(
M*GB!`2:0`A7@@)D@&<(:%,``&)B`9REYPWW<AH(_8.T5?)C`"/@0`"`4LQUZ
M:`,`L*`&-SPBFF*H@ADZP`@MT.$%/4B6'[;`D,7(X`4R((1;SCF(.,"@7>>T
MCKL&@=E_T*4./11I0S)SNG!1`$L"0$#+P'"!)P@@$9FA`!@`P`4W=>D.!(@"
M$7HP!"%8P`(<X/\`"$`0@0CL0P,PP,`;TV&`'N!!"TRP`W0I`\A&/$$"#6@$
M'"Z#@B9(@@<`R)K7_,`$(KCTI97R`08B>@!*S($`2N`"!7@0AG@U00UJP``1
M2!`""(B!#3V0P:W:T8,KI*U2.%A``M(#A`^,H`T0D!@*4O`'%Q2`#Q*80"O(
M((,BP``'87-%`@:@`@$(``8_8`$34B"%%,#`#U%H0!`44`0!5.`,#(#`!$J@
M@R/<0"U>R$`7GA`"0J3!"@#H(67O!8<XE,4/:S"#7OW@!`%4X0MH<`(,=*`!
M-+2!"UKP2U4@,0:G$*(.F`V#Q9@:%4F@@`=K^*\6T%`4IKKA"EX8`P__*.#`
M+C%A#J00ESX/`8-U&.`,7'@"%]"@!HJ`!`>7H(&'9@N#$$0A"T:X0A,\\(`U
MD$8<<$#!&R*,WDAE@-1BQ,$CV'`!,E3@!VGPKA\>@`8,6*,-8OB"`JP0@0&S
MPP4``(,AC_"&!K@"#_(X@"O6$(8PQ`$+7,C9!<I$@!8\@'9-R+83GA`&!8@A
M#)^S@AC:$`<O(X$,2%C#!=*P#3\P0`=);@()O.&D'5YA$/8:!!N:(+I&7.X,
M:&`$`,H)`#I<:M5-D,,;W'`)0$-"#ITUA'>U,PB4^<$*,XA#';1`/0M$U@]9
M2,,;9,"`&NB`"S.`U`=\@``I&*`!`WC!#&8P_X&:3R`(01"""G1@;'4,(`8Y
M:,`1(@"%CE4$#UQ@*J?&8`1Q>0$`+8"=%EK`!O&V0@-/*,$:>E[J+H&`ZQ,,
M`'4`(($VR*`+:YB#$^(LAM.=@0Y?:(`"D*!LRKB`#FTPY`3B8'5G]($-9^`+
M`'K0C#[8(0_G^>E/A7`&+3R`#1`8VQ+*(&4U1/8):7"#%T:`AJYXX0,]"$$1
M:C!KL!C018$QTAG2,&AW9>LR2XX$:!HB"B(5\7)L$$((S-`$)*2!!_=^0@6N
M$(4F<($`^8Q!UU>AQ76T@`Q%:(`/-@:2!4P+#EY@PQ7XLH2U-&$+83@=EURA
M@3;8(`[K73YSF%"!//_H(0!\.$(*7"`$''R`-?-(0!`6\`'?I@"X',`]D'$#
M$K`B#;4%CN`&=3,&75`%2E`#.$495>`&AK0`;7`$ZQ``!<`!'_`!5*`\[3`!
M?I`$%H`"`Z``:\`#&_`A;I`!`#`#1X`!;B``0,`#:J`#$P`'=4``85`'LS4(
M$J!#L3<C@V9/0XA$@]9-A-`%CZ,`7N`$<3`'59`&\0(`;P!2;,`%$,`#<I`$
MRW<$S:<.=G``2/`%7T`$']`:.#`(-=`$1@`Y.=`"/0!@/3`!-'`$;("!KN""
M3-`#Z:=^QZ$"7H`%6^``20`!7Z`%2=``$4!5[=!<CA0#"A`$19`!-Z`#TF+_
M!&-#'4Z@`!I`/$OB!VZP7,;!!V+@!D(P8BI0`2G`!V34*FI0`NO07G1`!P`P
M!X44@G[P!EW0!&8@`(]1!R]00QGP!B#0`P(0!SJ@%D1``9+0!6HP%\YD"%6@
M&4=$"''P&@"@!$@X"&.0"T:U3BX2<4<8!0[%`H/@)#L0!+=8`1!P!"1P;V_P
M`TZ@`Q%``U=P`6YX'"X``0.``P^0B^F``&Q@`NQ@!R[P`%@0!6U%&0M`"G"P
M!FX`<=PF`%<29A4P`6V04:R0`7X@!'&`:H#8&N]0@<$Q"`(`!F[P!5BP)'#0
M;2=`!$.`?\C1!U[P!C9P4SK%`4R0!^%3$4/@`DS`_P=!0&(JL`)O4`$EF`$1
M(`,=``4I``52P`I\L`)A(`$2P`5(`!(JX`=-\`)5L'UB405(8`9:,&\G4`!%
M-@%.40-S4!4&X`45$`,;5`A/$(IUT&^0,6CA"!G4$GB2Y2+Z<H2%X`6D<!U8
MT#P'4`-M<`5R8`:),`B@4P<U``==X&O-(`$9`$D-P`,Z,#T%4`93R0Y\$`,B
MV0P;L`;HQP0@"!(YDA:>XP95L`1O8`5/4`,M<"AF`%&M0`)/X`-L4`$C>1Q'
MT)I=DP=)USTSP"D/X`5BT`59P`5J,`<*``$YP1Q(\`8(Q@.,.`(F(`,.T`(4
M0`<M\0(<4`$D``$8P#,-.?]3+I``"<`5KS`",L`"14`$,7`M.E`#-2`!4=$#
M-W!`2*`#1$`'80!H;&`VHI$$(@@`8B`'"1$#3A`"=``CHIAD2E8(;U"-MJAO
MA*":L$%Z0\@8A4"..]0&HE.-?B`&QW,#8(`%%?!"B6!`9+"1"H`&#Y,.&-`$
M)2`#+2`#D),&UG$)5L!L5=`!Z\`$57":Q-`''T``1!`!M&0<D$,'1("B`(`$
M8$`&<E`&#<`"#V`%59"&KD`";V`':,`"PVD</@!6$Y0`-W$!2]`%<.`$LS4'
M2,`!7@`&)D:*[3`#0M`*1``'$X0'`9`";4"FK'`'O`,45$D$6!"I5_@*'Z!C
M-R?_!#KW`A(0HP00!TW@`$H#!V7P`D_``F&@!7+S2UT@!Q1P&6@@!C(P<`X@
M`%&@!8P035^P9C,R1&W`!NDD"4D4(V,V"&9VA$88>^)2F(/`!1[0`U%U7G;`
M/5A``?D4?@00@<1P!$A```V@!40P!HQ0`2$@!D7P!53W!>]R)\U@@2_0#GP`
M`E70!2I`I4Q5!4F@=BR`!4)*.DD`!(N@J*P0`6>``VC0KFM*&1.0'H9D!SGB
M!U>P!L\3`F'@!4MP<6[0`P>`,^LP?7C0!PP@/2G'"H-J2'>`!@BP#G@0`56`
M!C)C=.W@`'4@26X``&E`!E1W$TIP!6K@`-Q8!%$``&4P_P>,<`9EL)$MH)>8
M0P2O2@=&X`?44`>+`!L]4JR$29A!6P@6XP8'H`0LX`8:M@H!X`4SRQ@3@`=W
MY0QHD`1&,#BKY@>+$0808`%I@&5IP`8P0$G$4`(9``1>\`(!,``:2PQZ(`04
ML`4U()#S8`>0(P=<<!89!!B2P`4-X)AM,)H&0@YF((L'"Q)%D`,>X`(H4$L[
ME@,5<`*8R0[R\`'M$4N9`7Y/=R5#P08-$`<9`"#J@`<J$`5=%`/0(`#P^;M.
MH)UB%`1D4&CK<`<O``-G,`-GRPX?X`=H@`4;H`$*,``\H`(]4`6!XS]50`,Z
M(`"P!FT6P`,Q$*:2RXV08`5,-/]PD-`8L#$'\@1R?G"-5>LBH4((LD4(.S`(
M,O`'%-`$M-L*ZP,%%6"<SE`&%R`%$N`%W-@%5S`":U`&]H(%;?$$,J`%(="\
MK``!0JL&(8`%2X"MKO`!<U`#'.F01J65V<)O28`&12`!B>,')9`$NM,*(.`'
M14`'?[BY[:`"%E`$!:``,<$!(C`$*'`$?CH/.6$#5X`*#V!F%?`!7=``84`$
M5;`#`#0$8U`%+DL,#["^;F"+VG$&2@`$.""43'#&/G`$1S!^75(&)\Q+`U8!
M<,`09[##["`%\UL%&N".6M`A7K`&,=`"9Z`&,<`#+]`G#C`&3V<9"^P%'!P)
M`!=[&>K_EY5,6:TW%D+T(H/0!7\P%3&@KL9!!C'P!D[P`!>@;VN06&S@`"M`
M#1Z9`V-@N:Z0!T6F&7'L"GL`!-37&@O@!T4A!T:`%E&@/W)P:JU5`%Z`QW_`
M`4_@`FF0`SQ<$27@:%T#!`G`!S[09J@P!V8"!T40CG)P!5?`FT"#`!S0`A(`
M6MKR`0/```;0`5A`!!AP`IUP`1@0`17P6"';#GWPI2'P`TN0!"'``"_S`GMC
M!%@I`S(0`DF@KEQ*`A4@`67P"@F``RC@"QYP!#B@!_#)!PLP&Y\*!HZ'`%S@
M!!(`<6.P!=TPJ$9!!FC0M'7P&1*0!+H:"1]"%PYJ"!97).LL_SIY25GT>V:0
MD(6@0Q=SH#K\E0(!X-&K8*B],`]D8`$-@!0[`K\$T`9OH`!S,`!:$'K9$0<4
M!@M\H`!RI+!BI`?YY@088`18X`5=$"]<P`%9<`9+$`9(Z@H<X`UD\`/3/`\"
M,-:&U&8,T`638!07$'AS0`8J"[#JP`<7(`.]ZL9_D`1QP$O!XWXBO`X)D`,P
MD`%"L`\9\,YK8``@L%4I<`0HX`%"L``NFV@_,`-=@`7;0Q`40`$/V`("P`,\
MP`!1@04\$`).4`5ST`4.$`-Q#;T0P!?VP@5<D&,J^A!*LT/,5@ASD&\OLLE%
MHK[M8D!FL+B$^8.&D$)6Z!77,0=YX/\!)>`%/+`$+:`F$-``1A`"!'`'MJ4.
M<+L!)%`"_T`"DJ,&+;`&+Y`$.6!B#(`&N?P'=A``3F+.8K0Y?L"2+5D%/$`"
M?N$`)U`$9C`&PJG7=5`Y"?[7L"``[?G@*'D&35`#9B`&%L`7VFL`%."F[6`#
M'-!W9F)(3"`&-)D.5)`93S`#,K[@%LT$(U`$/'`&1$`^VB$`5T`$!L`!!9`&
M3_`A$F#839`&8W`"&_`$7B`"79",D``Z.E@(04WFEW`YXX8YZE2_E.4D=.`"
M70`"#S`"\#D%!@`!&K@'[F?-Z;!S$N#>A*`2?I`-]WH!(B@!=2,"F[T*SO@$
M?&[BW5`%7E#_`K?8!5C7!"+0`N.Z`91*!WVPD2+.#C5@L(8$X:"Z/P*0!"?0
M!E70=@K`Z9`BL8;D`6NPX^DP`#H@`1IP!S_I#'M@/PQ@I1L0`E^M$5W8!"S`
M`8Z#!AG`!0"0%VJ@!68P`R=P`9$9Z&WP`)?B!C1PBH]0!UKQ`$GWL(/0!G[A
M"-YH!F7Q&J*0+=J]9&>0`_';",P#"6[A!GP0!EM@!(B+'`%0"#6P!H#'"'ZE
MKVX0`B,`=J[P[UZ(7D>.!CI@,4K0`V;`#2T0`W&P<)2]"@50!S.0!4P:ZK!0
M`PZ`;.X7/P&0Q@OPGA6!`_!Q!!XP(!R0S_D68&70!&<`<7-`!.M=_P0`<-_K
MH`(8$`2T,@1==00=(`97,`,I,``(@`(&$`$<4`(%T.ML"@`E+CXI\`9(``$[
M,`8*P`/\1@$AX(0\4`-&8"]UH(!RL`3F/K]S9@9W00A>D62<%4TT4D.78*&'
MP`8ZR,X9BK0[I%EGUGKC$F!CP`$0D/7,$01P<&]^4`9Q0`9A,`8]0`1?$"IS
MP`0.X-BM\.\Z4&K4P6V7`P>Z?E25Z04PS?C!40)1\+4B[PP/L`%\$`$,``(S
MD`%4T``KD`*?6Q%S&0%%(`--P&=.P``6QP,%,.AGX%!7P`78YP``(`+SH``Y
MCP:UR`9),[1T<!@>`FAF\P0%4``RG@X)T/\3"X`#3'`?3.`'*84'*%#^E9(2
M>Q.$Y@X&37"+21`#20`(9S5-3X0`?GYM2F``:VU:7HB23Y*5?G!M?G5G:Y26
M?F=L?FAIGY]U<Z:JEG*@=*MN;V=^.51=1!4J?[N\O;Z_P'\)&B&2;U%^6`X4
M1!IG/S,$*<%_`7XQU-G:VDJ(/)%^=')./7,P&EM8:+J^*WXU7.S;\_3UVP<^
MNRY\]M1Z>7_T^+(3`Q$#-D_@)&OQI$L:%FF(X+`W`I21,&&>T.!2A4@4+CRR
M/`G3IH@6'GZ"$"A0CX\5)TBTQ*BA)0P-/PZ$K5&1)\`!%7R8],MS8`2?&7SX
M!/D0($$+/RPBJ.G_`"!)#"]N`(1!8P54%S>:$,&Q@N0-&2]U9-195>G,*S]/
MXOAY@RA5)4_)R/@1H^I)#4MK/\VR-)AMLE=)^M3(D4%>OVP?8,(%4*>-&"44
M"/1PXJ,"#PO4$LBI\+@T+SLHJU20\`:`AAMQTIR)0V2)C#`9?KD3$L:QZ=_`
M_VAX$;Q>`D\"NKSIX0"%A"=OJEP!(*./O0M^:K(QX^?*'"\PSYRI8@1"`PD:
MEJ0LD)O>'1>_`E0$;6>`AP\X5`31,Z#?#!4#A`!1"#H0H0461?AAA0Q/;*%%
M%Q3XX40&5SSPA18,?#&>&&&$,P<`R,QR!1J&23+8)G`A$M@G7*Q1XB<R_W!G
MB8R5R/4B(FQXL`,"<A#@PPLY0*#"!@:0\,<>$]43`!Y[['&'#F?HD,P6``#P
MA)4?9!!$%A]0,X$''11G3Q^9G`'&$S)LX0<`*'0A@Q,,A&"`%Q?XXL(`=:10
MA1!B]MG/"'7ZF<T=3ABD11H]M/&&&`*XH`2'9BQ@CP66T/4)&E]TX0<;%1#P
M1``(H%#<`2GY&<`=":2`PP<I&,"!"!<X\(05%IRA@`(.`/`#&W,0\<`((\4A
MUP,5H%''"'*8\081:WAAJ6!\S0A`&V?TP$`E8EC9@R1TA/+)AS=^\M8DA75E
M2A4!"("$!1(XX,`&&U10@`<3W<$//1%HX(($:O_<H`8=='Q("1U4%``"`S.8
M`$`V>-QQAZ#S)&C&$T;4H=`H`!#!PPQ1L&%$#K[D,<$3?'S!`<0H4P/"!3CD
M$422O4SAIQY<($(`'3*T,0=?`E`PP`-MU.`!197,`98<9SPQ6!Q6E"%#&E74
M+`0!013'AQ^DI?S+<W`XT$(1$M2<1A1PJ"$'$EY\`<99`%SA!1ABL/%`$F$H
MD,8A?8$SDA]R9,*W)W54T0,E=<1Q"-YNE.$B)N'6H48E=6AA"1I@(8+W)UCP
MT8$./TS09P+P]>%"`@8LL``5!(01@@`$<(!#`PMP@(;6P$EP!AG-/B$&%F?@
MG08!,M#QA`&^\,%!'03_M%$U[<P+0(0`%<A`0045;."NUS1T64\?*T0`@0DB
M"."`!`V`(T`=%#Q^I1]-&%&#!FU8X#`])52B!AB@I,'&6W5DX8<97@A!)!H@
M`,\%YVHTX`4>F)<#`'#!`AYXP!8,X`8RM,$$-:@#`"A0@_KQ*@->T$(=G$``
M+UCA"FZ(UB3NHB*[6.IRISC#+2@CAB>DH@YX>1$,PQ6'3'B""'S@00.2``3F
M[2(/89@``030@A%<00(3L((12R,!N23A!&W8`1'"\"@T:$$-M6D#!'RQ!R&T
MP05:*$`"CG"$!3#A`Q]@PA%2X`$/0&$/?5B`"^Z``R8<P`43@((*9O!')@AA
M_P!\"$!2/%"`H$P@'U*`PE$.X($(:,\#>_`!"D8PD40>X!<LZ(($:E"#%K1@
M!RR@``4>((`V8*,>*F"`!E8P@P9H(`,9X(`$$"$``#AA"0X8@PK4X(`**&``
M>P%//K8Q!$0\X9EG"$/2+%<E9\+A#+%(0@:T-P\[,.%.4/C`$48P`@=(Z`,&
M`,$.8C4#$C!@F?:X%S`R4!4-N"$,:A!`$M8RO"=$P`%(:$(,6J`&-YCA`5CP
M0AL$(`,U7*P25K#+C>KPK+:<(5DE0H4JQ!.N,C@3%(7R@Q<.4``.-.$(4_P#
M!7`@AA!DH`P/4`(1FI#2?MS`F0!02!S"(`$(\*`'`/\PY1EFX`L]3,`/,I"I
M`;0@`QU<80<.`%((?O""$10`"UO(P!ZT4`4-5&$+K6.!"PHP`P.,`!UB8(`3
MM&F?"/PA`A@(P#]Q@`+X_`$(B83`$2)0@`E$P$B\*(`+6'`";7BAL&*ZJ1\$
M``<P-``,2^#"`70@O$0(8`4\;8HV])"$)!S``C\8@/@&$(4G)"`((D@">B*@
M`"%`X3%;=<`)CE"!##3``=BA@`\0`($/4&$&+IC!`@023R1@80)*<0%Q_U"!
M.C"@`A\`0!%B(``Q?$%1<WD"B6RD"0"8`0Q*D$!R=ABN3^00<MS]A-_.``[`
M/.!QWQJ7)`Y1!Q=5@@L-@`/_$JQ@0"/>H`5YX,$-1J`"'"1!BC6M1PL$43C>
MJ9)N3^@!$GS0@":`K!=[0&886##&E.7!`@Q(60"<$V)_T*'$Q7G*8C.1B3I@
M01:O((,%FK`!.53A!160`D"VH0=^)"`/>8#`&11(NSWX`<7!<107CD"!%J!`
M#%$@`A+$0"(BM,`)<W!>")Y`APT&K[YRL((82F&&)H!B#54`@`#:VY=DE(B\
MJR"")+(@.<,4!A%ZX2@H+K:&REDB"4-@@Q?4,(37@NX#*A""#Z20@OX&IP5$
MX``2=%`$!Q1`!55(L(+#H5&XA($(:`A!!=J0A3"X`<E_$)D?+C($VB$`U7XZ
M0A-@_]T+/+AA!7U2L0(.5(9JU8$0(=`"$G2G@"O$00!O4`#Q'L.0E.KAR#.S
M#AX``D<4H,`#N\3"$#)!`#0HX0PA`,,$UG`F+'2A@9KR`_[JH(0V@,&C*Q+,
M*\@[36=^(:-LJ(.<5V@8^78!AH<8S!?(8!<P2.`5!LA!%:04@A`\@,9%6)`#
M")`#`M0#`16P`+RN=X$+T$`++>#K!!#0`"1`6M/T8`$BY"`#E'BA"CS0MP8<
M&X(WM(<7=V""'V;0!:)J#0$*T)H>8J"`!>JA27CL0U+X(`:?`Z</"5"Y'PB@
MAC,0(0Y)\,,(8L`A)_"%!V)8PP0<+JK'L``-`QC`!Q)`2/\H>&`"&;"`78.3
M!S\$/:4%\`,9(D")*&!!`U"IPQ?XQP`EM$`4>]'$%^!P`RZ<X0J2$'0E[*LS
M2WAA6XB(0YW94@<:<9XM)*I$%?2"B#/4#"YTB,-:9I`!#4A`!AUH$A!ZDH`$
M.,P.=J@'`R3``E+>X+^G#"4.]L"!%Z0`#A<X0@M0/H\(@4(,66!#!'0``1QQ
M@0)/T`%H0N:'<#L=90.X>\H>$(88.$`,9"`#^L7`?C+4X?N/$=T$..!\`?@A
M#D_`PEKJD(8:TB$2<=`$8"`%26`!5O!:OY``JQ(,*L<"6[`@!$`$+&!^&$`#
M_5$<=2=^1O0`B5`%)H`$:<``"O#_!'70`F!`!TN`!F=``-.R%M4$`-U2,P!0
M!9,@447C-Y)00XC`%VA@7^5E"A3U@Z6`"%GP"OIV.3-@`54``@,`?UI#`1V0
M`OR@`DS``#F0-<R7#<Y7!US@!40@!C`G%RY"!%80!A;7"W8@`MW7!AF0`AR`
M`0E@!PE@`W;@`4N2#2DP`"#&`";0`!X@`''D`L:D-7=```HR!DD`!F,@!;!C
M.@O@!=M'#T'0`@*P"R/P`3S@`#5@+@2@!`70!:U$!VWP!`8R-TC`!3O@!3?@
M!1.P?,#0!QG0&\#P`'6@-;GW!PYS!U-74_9'`29@)@H0!Q!P/"`0!"@@4E'#
M`Q(0!F+0_P8<8"4,,`(XXP0/Y09^EB(?=7^6L&]UL!;I91CG55[Q5@D<@`5^
ML`65(0D%0`$Y@`,]L&P;6`$#T`0?0(`XP!I9J`T<J`E;D`1?``!+@!)G(`!/
M@`0R\`!G>!HXX`<&P`4$8``:4!Y'4$EVH`0-,`+9H`<!$`0%@``($`1YP`<J
MH`$'T`)86!H,``$6``,,T#H<<`<U$`*MT"&4008&\`0X-P<FT`]*MPL/DVIZ
M8'_7``$+(@!-P`,1@`;6M09T<`6O4`5*H``Z$`>GP0=`%@`!``4:4@4<$`"\
MT`<C"#%V(`$=4`$OP`!9T`4PL(MB8@`6H%<Y\``&8`"1Q&@R(/\A8.`&`^`B
M)3@M[15Z9M`"2HE4:V(EOK0*<.!GE7-GV9AYE0!GQB!?X/B8JM``SX0_W!4&
M%=`"7&`"\-@\&7`?0#``,*``!+`&^9@-*N8'/``68(`!5B`L+*`%<,"%@=(+
MNAAL":0U3`(<=G``!P!'3,`$'G``JB)GAT`!9```".`&I]$&GPD<0MD$`7`"
M?J`$<T`'B$<'+,`&HA`";-`"```&:7`:1,`%6B`'<C`'^`,7;8`%II0"#=`&
M*+,/B60#-N`#=L"6Q6$`65`%`F`%.A`"/)`$"64&I6`$8]`=='!,!A`"84"#
M+D('6@`P)=`$A^,'XAD'=/`7&[4*5[#_H(A0,SY8"64`!S`D!@]57EQ@@SE8
M"3&`!&UP"&M@%Q/P`CJ0`C(`,\RC!I^4!P.``E/@`7D``JE)#9X0`E:P`@P`
M!FK``G.`!!3``C>`$1?8"];``D3`$EH#!5>*,@JP*7Z`!!K3!`GY!V%0=L6!
M>0R5!#/8?1_`!EH@`5H@9V1`.<AT!0W`"P?@!%NP!::$>8G@!5WP`!N0!S21
M4A_@!T;:)TF!!U;9)#Z``SYP!#08`5VAG11P!2(@!EP0`2VE!4]0!72P!@9*
M!)$#!@+`!FVP`6TPCB^"!*0'%WKV!%R@@P"0!BBQ%QWJH3CR!*WP@VP@0TFP
M/XC@!*>G=Z1G_P=M$`(CX`2WR`0(^`=]X)7]P"1[D`=XQ`?VH@=U$``X8``;
M@`,ZX`%\(`)'&@R!(0=1T`;4P@)NT`8]0`,O4$%D$":]P`0L``<C,%*T@P,8
MF3)!T!4A]3]@(`)*IQ]^(!3TD!0!X(@+`#J?%!@OT`-O\`+@8`4$8"E/H`8C
M@`1P8`#9<8N_D`<-X`??@:Z]4`<-0`(94``-4!\DZR<B^Z7,(SD-T`,2L`1)
M\``Q`#<A<)>><"UTT`!=8!X`0`87PP8*<&\_J&Y\@058L$^(,*>_)"%F()2K
M``!(`*N&H071X0==(`I/D'6FT`?1E`-1<`0\H`,CX%-$T`,F&`,L,/^SV5`!
M$,I35Z`%7\`"9-``9S`%#O`!$'`')W,"2Y"NP+`B'-`#;!`%,5`%,K`&2E`!
M/U`!86"S4'`"3_`!=3"M*#,!'0:FW2@>;C&*=&"-S[0&:KH-#I"),=!PGV$$
M22!D>!99<4$)LZ(%&U`'8,`#"L$#1>`&&&"WO.``61`'#.L+7+@'"O``)^`"
M&G`"+9`$'!`"0].??F"SM",Y7V`"32HL7I`%<Z`#$:`%:Q`"6&`%<"`&;C!P
M5*(AU`)NS*(&6I`.9C"#56`&9(`$<\`%48`$Y-`AI?>T!KP**#(7"#"K2?`L
M]N$!#:``"Y`?.$`%`9`"+I#!M5</&:S!$8O_E0>@!V>@`A$`!QGP`"W0!P*P
M!8K["WBA@FT@`5N@!J1H-TF`!G1@LP&0`7Z0`'4P`':`!WBP7/6@!S;0P2[@
M`UXI.KV9,DX!`D"0P0<`.C8`L?(T#WH@Q+^``A\P"P#0`6:@!&6`!&[P`@"`
M`6K"!1Q("6"@!3DP=[_`!W88#$]`&GCP6@][P4SPJ(_AI0L0!!,`1]7'O5JC
M)D9`@U7``FW@`'7`!FLP`%=@@@0@!CP0`G50!ES0!"U@!FU0!:2$!5]@`3DP
M4$1``2^G`]*Q8&+0``\@!DX@`96Q5F%0)6U`!NF&"/H'7W.1!K>,!G*@!6B@
M`W-0!W)@9G.!"">:_WCZAV=@X";[]`1/4068$`<7<P#D>0%:L&-&U"!B4`(0
MH`8U,"\AT,*^$([=08,/(`%K@`$'@`4VZP)$```%L,X6H`4U$`,YD`,"\``P
M*S/9@`-*<&`]<`+:=P)9P!R^80\X0$H.``2D@P$8(`-#``%(0,A:H[L*4`9-
M<`4N$J:EV@8=0(-NP&47`,?],*H0\P,$4`/3)P%7=BT6'1P/:P?+98X5X#T2
MH`1=<`)U8`420`1MH"E=BPA%@$,\'09K00:AT`)`U0)KX"_)T`8O@`$6P(6'
M(@,<4!!M@*%G,`=AH`5GP`--$!BP^DPLU"!?@$-X@WD38R(6I31UL29P+?\)
M?$#-,D`&VLP\H[H"+.``(P!<'Z`#Y-P+E"`&-8$(:J`$<J$`$A!478L`=I(K
MGHM(.%"M`Y`"/J#$!V`=VL`'":!9V2I(">``,;T-?!`!`P`%+K``*Z``A3<!
M)R`!D%U3GE`#7J@%5\`@;]"L_8,(&\`"T0@<3T`!*'/%U3`#?C#;Q3$#$?``
MK-0#7C`"(4!*$I`)E#A38/0X7*``3D`'RT%Z;8`&]BL`=)`&6C#&?N`&7V0&
MQ>(%3T`&$P`'8U`#1"!H5I`&9E`%A>)=.5`'=&`%Z^9%-EB;2)T&LXH(85`*
MWRB#%?4B:T`$6$`&-C(!!4`$)T``1$P[`*`""P#_`PA@2H>4$X.]"Y20`1<0
M`W1`MT.4#'"0!D4P`7&@W+L0`/H7`&=@TH)R`0E-LS*^S8B0`2!P!EEP`6*P
M`R\@JG`0`EG@!0R0UZ8!`#V04LW4X[_!!R!@`8$L'P%``<5T?GZ0`6!@)F%#
M@W#!`&20!6:@!3?P!.@!!F9&!U/[!3*P+1K4!4V@E#?P4UE`!O?K!4A0!;R#
M!=8)K(B'C7#0`R^P%O8+!C:"*980KV%1"6^@0=?X"9Z'"%^@!@"@!GX3`%UP
M!53P3E/T`4]@!A;P!/U1MRIP!2.^"TB0(FU`!V+P!A%@!K,Q!PV`!4N0!ESZ
ME3,@!J1NK2D3`7NJ-1!P_P$),,4X,,4!P`1V,`%.'AQX4P!HP9K&N`8$<+0*
M``:]'AQS$+!&=%3=SCR0-R)P\&I/X%%TH`9H,`=7D@2D1QEU1@?\X@!HT`5P
M``=74`,D$F%$L`505H4W<`"'$``BI`80L"+K[@<W0.9KTN!BP9B">8W47"*S
MX,654)N(H`+9$E`6`)R?;3H/F\$=$.W!``14@`.`[`%'$`-+L`1OT"%$@`D7
MX)54X`2M_@=W^>`A```;T!!D``8!L`-/X`0"4`7C/@%O\`8#\`3+BS(6<',H
M$\Y[,`$K(`)!L`=\<$RFTP]'<`4`/@88P04`CP2SL`904`KNUXWVQ0;H..Z/
M,?_%41>)S"/N-46#`L`!#(($I;0&][8$Z`<&1=`A:\$%0]L%27`QLM",/>`_
M/U`%96!C(H#4>+,%%S`;,5<CB,*8"&P)YBP8`+<FU_F8@<$'$G`#,?D!3#@"
MZ60!06`!*SD""S0/.#``&1`#$1`#/```5E`X[BT!57`"(6`&?/`!1)#S;\$H
M;.X%:\`@9%`%6E`$#]`#)>`+$S`=!?`$!3`%M3>'HQ,`\($'QML+%`8%'3`#
M.'`$]N&E"/D;$SR<T@H%"_`P#4.)P%![XZ\-=Q`$_`\(0BHJ*"@>'@!^3V`C
M(6U/?E@Y33I;#G(E?YJ;G)V=`1DS`@(W`"*>J*FJJ!/_?IFKL+&<59%;56=1
M<%MG?GXM-6!^211A8D]/8FMU3FU@#WY=2&!HR%T6(6=U8T@$9V)H874M48IS
M?F5JO6E=:+V];3WN\KUD=?/WO0#V^6OXO6)UTLGC0^.%AA%\9"G<5"$1@2MG
MLJ%9XB6-N0(3M"S<R-&3%7=J(O9RX\>+A#1$0K[:A(*.FP!/<MP(8F#&@`X<
M&"#X`T7/J@`"7`PPL.#(@!(30AB`TG%3A"U:HD:E\&-&"!!7(C3=2J=7D3(%
MXA!APX",$2T50G!9N9%)"#A(O&0]8T%30DUY5"78&L35UHY$_$#HH:.,EBO&
MJM#Y$@/`&C$<B`"`XP?.G#I?_ZP@">$'"9H66*+4$%,CI1<:%&B%*-###1J2
M;=ZX>4-'WQDXB>3M\^<GI#PZD-R%\;*;-YLWB;KXH</+#Q\D3;94\/!7%8U>
M;\Z`X:4%&Q<&?DYDK$Y>U05W58+[T7(&388>6#AP&=')3F`^3X:45S5%2O4[
M=]C!B0]0!`%%!1#LIU`<?IPA@VMHH)%%%SH\T`8/)VA!'T<!4'"&&P)@$$8[
M5F"0`V$1:,""`#SP$,()-#B0!`0Q'#1!"@B,,$(0*,Q@`!-,0`'%$412\0$(
M@J60PB$HX-!''WP$P<>4?"0`Q0P?)&"``1\8,,``"!0@9@DZCF"!"VBZL(,?
M#021@?\%,:300!QKS%&!$0\$T$`&/"A!A!ARH-&&!$1D@(,,=(@1!0Y",)`!
M$#)L$$(+"C#```M6A##'!2\\X1(7B:#!RQMOJ,>;/-B<RJ`?^Q2'3W/R!"!!
M&!*$$(""G)#`BQ=1>+$&`!`DPD4%.]!AP1:XXGI>/O9PP8,?<X!00#!((+'A
M)BFTX<<"95R;K"8'+/`M)WT(.&XJ#((AA0](L/$$&6W,T<,5+YR0@[<*)>%'
M'#QDT,(:9T"2"`!/Y.8'`')XZH<<<]`QQQ-U9!.'/G&X.H\]Q=GS1!QQR`'M
M'`T#ITANIOISS!/9',P++W78`\!E!9L#<2_J\7`%'#&DP8;_&9:Q@4;#<T14
M,`!$-Y<P-&Q<D4,;7KQ#QP:]@/&%#/.P,4]N_9Q*F1]<G.K'"XFTT+0?$:A@
M1082[/2M$[W(T30<;@0W!Q97I+$%!>>2AP6KBIRAQB-(\$*$%DA@P`-;?U#A
M1AM-`(!OLAQHD/<?!Z2@B4^<3&GN1B[\$8`+!S#%1`I`O*'("%A8X,:.8,!A
M0!9<7'#$"AP9\(9D`+R1PAMK-.`'`1=:(,$+%3"`@@Y56&`"!#?HH`41-!*A
M@`4::,!#%S=`Y(<8<5@M011MG."`&3]HT<`33<@PAP-=Q+&='U7P<(,`++#`
M10L4J$&$##%(\`06\-&!MN"UKS)D_R%1?G!"#QHG%C+HC#/+:8.V=!`<,BR'
M"&Y(PQ/>$`>3B.E+`\A`!AIP`@,X@`,4Z(47SC"&B.0F#`WJ!<;D`8`QS(,D
M[MB;/,S0!%B)(6"G>@(,7=.+#WP@#3+0`@AH4(`C9*`"0,#`#.JRD3M4R0>)
M0`(7?@`&+5B!`[W0@AP<`(4GM&!R?SF!'QB`A3:P@0T5X$(/GB"#$7#!`6@H
MPEXX80<KH$$/`%B!'0"$A\WM)P!,F%P#R/"`%<3`!`3H0`XP$*(^<&0`62""
M#B`@@"1P(`0UH,#6EO"`+:@!#&[@PAN]@"@)/`X6#E"$`'K@!`7(@!IPX,$"
M`;`%-%3A#?]H(`<:M-`"/PA`"SQH@QNZ4`4VY%("8L!`&M:`!`E<P%(FD4P`
MVC"&)EPF"PV0P!O40(<QM"`$:R!#"R1`!BRL@0N-T6(8JD`P-[:&(FP`0!K&
M,`8U],,-,N""&L80/S`\P6/K68,3-H9#;7W(C$280PUB0#M.!.``-F`*#O8`
M@5[$00M^"`,<`)8/`-`A&/((FAP"PYLBF"H-;=A-2+J"#QR6;`$BZ$$,,'`"
M#\P@`QRH@0N,)*Z-%$`+9%".&@BF055>00TZ($(2Y""!]*%Q*R!-PS3]0`PN
M>&P-IO/"')3B"23X00H`L$`%8K"$'D1@!#.8@!#N$`LI'&$3"8#_P13^8,G]
MW,4.=EA`8/&`!R!,P`>?.X`+H)"`!/#!D`KQ@0L\P`<H]>$.?<A#'E+H!Q%0
MP`AUH),27C`H1Z@A`QR!6DC#\(47?`&&='""`)K0AAR$H8=^6,,3B,"#)0`@
M#!0@0,L`:(8,$.$-87``&P@`@"YZP0!UT((7ML`!)Q"!<6%@@Q7F*0$_F.$-
M@?-#&UA`-"^$H0MD$(,:OJLM10#D!<PA`P#BX`AWS$$.N'$#'#Q&-(3V8@X1
M@)4?9/`%(ASW`6Z@XBHPT`LSR"`V\K@"&)`0ARV0`59$DT<<S.&U#M_0'41K
MAQ]6(`,(2"`)DN,#$/[@`L@NQ$H3B(`?_[(`,3&PX0S@]$(,;E`K(D2`!U=M
MBKY\I0,_U,`-1-A;%-JAA#@@P0!E]8,&`,`$*0QA`D/`P0>@X(`/Y`460-BC
M)G"0$!K@@`9WX40>$K!FS]%5%36800DX8``$!"$$'\C`$FX59$U`C0T&```6
M`.`$!YRA!%\0DP$PT(#4BE<103@!`UH`!R*<P0APH($8D*"#&%Q!O`X(@1@,
MT`,T_.H)F8S`&QI`!#JHH08_.Y@,DK"$+6QA`!8PJR(<4`,!-*@%9ZC"&EH@
M@#:(H0D30$`$IM,#.'!`!VC0H3LV\T,90LMJ6C!#/Z(@@6+ZTM?N:$,-!-P&
M(JS!#56`H8)5X?^[7DC`U/)H`@[/`:MTB\$=&72'JR+6BX#MAL.]^,*JYM&$
M&/HA`Q,87`B_9<%>L*$898#!(V00AC+$(0T*T$B?-Q*/0FF!:+GC0AU8(($X
M(.<--O!$8!I`!Q2<*P\!2(&+!>!L!1R@#0=8Q0'$W(D9,&7C%5!$`6;9A`J(
MD0P3T)D$'<"1H`,@&Q?P@AMLPP5D9&%[C_B"1T>"!#B0@0(JB$$R6)4&B\'0
M'4#L=QV>P.$SE($R=9B#UW\;G-N\H0XBA8"(3:>&@\9#$;UHP1:RU@LE</@)
M.&Q5V\;F!3$0X`T!X,$I8`$#>92L%R_@!<'<,3,_O`$,;3C[J^?AA!;_)"(*
M,NA"&W!CJBHHQQ\V](,':J``#"!!!=]R@5?14X0JV$,+:JB\%GQ0A(UO).AG
M..X;X*F#.I3;#VXXPV\GT(D/D(0"`!B`\37Q+"Z8X5DYWWY3!A!T/W"@`T)H
M0@N0(`,4*,$()WA"`4BPD3T$O0U&:$,#G%`&@U6Z%[3P!&U@!0"@`VOP`%<0
M!DX`0VV@!6^`4#O`:'#0!<&E`1F`!$D@`540`1N@`%L@`CJ@`0[`5C&@!"8H
M`T5@31<@`0/P`"Q``3)P`AP@`QOD!#6P/:8#!VI`7[T`0>8U-C0#!V80!L?0
M"R;0%6V0!N'V:?.#!@G0`AP0"QG@#B<`<.[@_P2F$U("X5TX1`&7YV%H8#"\
MD85\(Q@<\`):T`,_ERQ,0`W]=@8]T#M<H`/G(0,*X`7B)PM;\`_!D6T"2%I0
M2`9ED&;@TC0\```X('Y%D`]P<`;AUQ$>T`"?`P1#``0!``4B@`,>T#D;@0<#
MX`$6$(H%,`0&$`%3T%UQ$(I=%P99$`4;8'17X`45$`2JD`=TY1-[@`<?0`3\
M%@<"8`9DH`6TX`1<T!RF8S-K4`8\X`0:T`:)<@7'8&%<<(,+P`,&,!Q,8`%9
M4``#D`(9H`%K<`4_P`!)(0$4$``&X`1%(``B<`)$<`$3,`$X@`58L`5$$$X]
MT`*0X#QX%VHB%E)8L/];8R`&;=!<\V`&O7%V20`)ON$'^71Z3',%2!"%L#"%
M!Y,(QP%2'@4)<&`9'C8/QB`/7F`U@/>13Y!MO=``-]`%Z#,#XP(*W:4(84`J
M8'`%&*``-^`")X`L>0@+^M(9SM<%7F`$5E`'`*``:4$6J$`.!3`'*@!8@_0'
M@(5&'T``%^``*(`!>+`50T`$()`!!=```E`"$,`##<`#N+<10/``&>``#M`"
M#J`!!E`!5@`)3Y`$/E!Q2["#ZD4`NN0$%(D*%S`$"U`#?\`",Y`'$@``+(`;
M$9`$)U`&""D&+K$;,-45=<`%CT`S;<`+/%`!OI,"!J`"/(`$7W`#.3``#7#_
M`1:``RW0`"C0!&)`!C5P`2/`!AD0/F&@!%SP!BS``"L0![P@`5F@`R'P>H0"
M`%5P3$J`0Q)P5!'%'&/4!.KQ:7"P!+U0=>LQ-N]2!F?0!35@!H0!`K$`1HI0
M,/U&0P?C!::3A0AU!N8PF_<@!P*F'AG&&[#R*\TQ`R?``B>P`C\@`APPH!&`
M`EZ2`4(P`&\&"P'P`B90`@8PH(U3,%83+ZW3!1W@`W?6D["0`_FP,?RY!C%9
M`37@*1O@8FR3`4_0``X@`@3P`"I`ED'P9;"0!WR0<PFP!RZ0!WVPE0FPH)NP
M`$TP`V]0`VO8$4"*1G<P`?HR7DE`-0PPDQ':7+Y#_YZH,`!B``)24`9_$`8-
M<`24@1N5P0%A$`?.R`O%!BWV@`3G`P!BX`4YD!WT!%)7X`87T07)$%,.,`<R
M(`5:,`,_``4`P`-B,`<L$@,*$`%*8`9@8'1)P`5'T`-<4`5$@`0"X`'2-3,]
MP``@%07M\I.TA9T@IH")<`9FZ@YDH!Z$]P8.\`1HH`$A0`1@(`-6N@HND!N,
M>6_RP`;%Y`<P58;X5F0?.:QJ<'7NH`/-D0-Z`@$C(`9$X`5<X`1-X`0/0&SF
MR&>PH`).D`0U<#])0*A<4`8H`P`]8``*8`,=D`(5(`,<N@HOT`MKL%UNT!6#
MY@<Z`![3X)*=$`-H8`-Q,/\`.7<`>)``B;65##H#1V`Y.!``(#`#'?!6$D"(
MFG`%=7`!<?`$9L!SGL`'.8``'7`@%A`$$4!+V'I5*P!296``:Q`/<:`#)\`&
M.T"`%2`'6H$*"9"&#N`&'L`%,O`!O2``YH`&+O$`:-`$(9`(="`.B;!C?A`#
MBY@R[C4'"I!_3W`$7P`P<[10,3`"17`$9.`"*;`":5`!WR<`.>`$,M``9?``
M<<$$$R`!B6HMWUH!:F`"'A,&6(!W(L8@6<`@7-"(OM4+,0`)<Y`U6.`%^M`&
M6S@2V*$`OL6J-;L*!6`/-,LW?7<P[C*L^@820'AV;B"I[@!OEB</<N`AO5`6
M7N#_!1I0`7^`!PLZE>41)0DP`%;P`3.0`]QX`1K@`TW0KJK`4E6@!/(%`$WP
M`F^PM250`\A65)Q@!"Q@`'`0N<FR!]2+"MTU!!!@`0#`B:G@`@9P!"+P`5\R
M`18P`"BP!QMG`>1P!BL@``9(`!L0!`5YN%M`!S*0`D[B">%4`S?P`%4P`B[P
M:0(P+`1`!#D35660!(2&,+U0K*P""4C&2W%0!)8ZAVTP`47``%4@G#(@`RV`
M!V*)`40@GED@!V0*``3@``#P`5R`!@08!41@!<Y*!5Y`!Q(@`4>@A(K0`D1(
M7OO"#"R3!LF7MYN'!9,*8@YY#_M0C.+%`DY@!M*;"D>0_PAF<`$M!*]HL'8+
M13.(6T'^T%Z](6U)+(`(23/J@3+S``?LT0L.,`,2T"8)<E410`2WY0`@(`-[
M<0=,Y[NH4'Y@0`1E\%I#0(1<<`)M4`9@X`74T0DA\``S`&"3@P,^X`G=!0$V
M``%R4+(;,0"8$V37T`L1P``]$`8A8`)LF4E>T`9?X`6IH;%_L`%Q_`<U``(X
M<&]-X`55<`4>\`9.(`5(8$!6T!4<Q`:Z^@1?@'@IH!EMT`5UX`"^<@4;\$9D
M@`%P\`4#V0-)`!_V$`%=<`9DX`5-\`!DBP!IX``R8`56H`(CT`-B,`%L$`<5
M(``R8`(#<XA^L`7S]3X'>0':0O^2BE`%8@``6N<_O=`X^](;&)`(6J!_=4!_
ML&`#YK`&<,#$D!"09V#/#Y=.V5$9XB6&IY)/NF$QYO5A[N``;1D#.7!75S4!
M5F`$#I`B#7`*"5``?+R4#M<#5)P$2```$M`%20!`/&"PG``?0?`&#GTN*/`!
MGA`$Z9$[J+451R`%0K`"4L`!4/`!'H`#`\`$@;D1MJ@)0$!9"1`$7>,')##"
M#Z!+3:`XP7$"?(`%2P`!&K`Y?-`$&+`)/7`"!V`Z3F!COP,`9!`&H`(R\A`^
MT.>`&I!T@K)4D;`&&8`%(^`!/4T!,1`/(=$"\#@^!/`%X10&Y^0!6]`&7<?#
MB/$#!>#_`\P`!ETP`C!0E'XPPIL9$0+V=)ZGJ_,0DU4#!BU`4TB0A;@1!!+P
MU*O0`1IC!C.SA]!'0\HAHK#R,!^9M"DEA@-W-?+@`!;0!!0@`*Q[5;NH!5UP
M!.3H`1FP`"%0TYY0?ITG3FQS#"3``&>#"NP<!'"0`9]S!Y(%)4KMNM5A.:B@
M!_3#C:ZL$*%&!(VL!"P2`.8[`Q6U$4$`WO4C-GB+!0@)`#DP`T&@:4;`!NR,
M!!9``U40.%X0`2F"OG_`!/.]"4E@!'\P.,HA!FY`@$,3!AQ0<!LL7LW!`@VS
M*^:@`VE@!FJ0!G*0`1_7`!C@`66PS!I0>FP0!09P`3'`!AR@_P0RX`(F$`89
M(`<8$`-JT`0`_085P`)IT`00H`L@]@0:5!E)`(3BI0"^*@8HA7;-T0X`<$R0
M@!STX`Y?(`8/X`7"K0IW0!)L``:EPBH6I`9B7(!B^`S#:A%^\(_S\(4TXPXT
M,``3T`2K&6098`2V>00LH`$@,`$K\`#FW0DFT`NMUNA6HVL-\``@,`=]CN)Q
M4.H9,`))L`%/Q`"X]@="L%>Q("4',`$#0`5,@`,'$`(!S@<6L`./P+VQ`"!W
MH`=V<`'CXKI]0+UWD`=[@`,<0`#B)0!"8`;V,`<O``=/H`$#"@DMXP<84`?:
MIPDA0`:6$P"]$P`A8)1U[@"TQ0'D[O\'5P`OJP<'S,$&5A@'P`$`2-`#_J($
M&=#I*0`'-R8&&G``$8"/!I!Z#0,`1'`"->``!V``&<`%#1`"%&`!)3`%%KX4
M6-``+V`.<X.Q^3"?!T-2;;,<B7"QO4!3<>"AD1Z0DP$&!/#JJ#`%B6`%'O`1
MEG=V-`-#<\`">T@$3["X'H;TI^(8PG%V)[",)U``GXL$6$`&9N`$59`$+9`&
M/!#@?@X@?&"C!W`HLJ>^UF@'3.`!`C#JG-!N1!C0!+B'P,0"82`'28`*2U`%
M'N`'*ET=0&!%4``$!E``)\`$`J#)?V`!0FQ2*.!BG%``*H`!"!("!"`#50`"
M5<"\5Z4"4"/_!R*0!6S`3!0@!CQ@"P!0!&UP`57072<@`P6@U'\`VF*P@`^`
M`U.0#SZNN#3C`!+0=P!@!@I0*G;Z(:4R!G70#FC\!LT6!AJ@F3E@#EAP!A*4
M7B"`_!=S#)9A&1LT,;/!,$0SK[DS!UN@Z/;076.SA6U@\[T0:WYPM,9]#ZO"
MP`=C!<X("!(9?X2%AH0!;WYQ$GZ.<75^9V9^6D^27$\`<6>/G'-K88ZC<)&.
M3VN.D5VCC@!GG4^F3TAN<(X*&7Y5#D,>'BDI4A\N+DQ4>W:'RX<+(RD#!01+
M!#4`*4D-5RDM#"@"S.'BX^3B1:UQKW67/`)<;RA<`<LQ:P5^..7Z_^$,S`QT
M?JZ<<4'NPP<5(VS@"(##QX$,\_9)#+>"%1T#1L2HH:-HSA(B3M(`V/*$`IPQ
M7MC`*&2CA`40-51`.?.DRA,W82I<\@,`0)@V3]+\;.,GS9,V;LZ$H$/3CQ<_
M<GB8V:+AP1<69HPXV`2A1XPN)!HX4D,)BP(_+=R`T7*"`8\K)UHL8<%&BXPT
M.AQ$D8'&3Q@D?M[<U$(D!$TN`."H2?*T%8!6/#M!]D,$P!PK:^34B%`NCQ4_
M;K:0VJGHC>119,0XVF(YB29':!Z;4>WH#8M'?G:.VO)&-=!37M;A2A&"`!<-
M$R?RX9/@SP0T'\)X$%`"RP07,I)KW_["D?\8P$H4P7D2@08:,12:[*&W9L(9
M)MOW<5ZV8H2<.7X(X(EO8?VA.X38D4=\R^0AQ6=M6,!&&QC`,<<5(>@@@Q9^
MJ-&&%B)UP,48.A2RAQ0%F`&``7I$P-,)&GAQQ1.L^%&&0*Q(\,09C_F!!19T
M?);8*''HH,47#:B@0!1E7.?$%DJT0`,$2*3BAP,%D#$'0%J,,8H;.XWQ6!BO
M\'"!%P`\L00`:'SFQX06B"!&&VS4X40/;60ABA^T$:6E(W/(8HJ+?MQP6B7(
MD=/!)7#(Z(HK;J3A!QR-.2(2):/,D89D6=`121VF8*J**37&P<9D/"G1!A:.
MF.!$`RU4P`>!$A'_<(8$)M#`@0E3K(!##*SF&HX=5?CA!`!JF):$`F[0@04;
M2_B!!@;,A-`&%0#`IVLXX"RC!QY])$#!%])J%P($$^A`0`.$+`&!`Q(@02`?
M-BRP0``^5,`#5`C4X($6#R2VE&ACT!''(EK,T04`1!`R1`]L_&0#'BXTX<H3
M:/"0U)5:=-($&2$PX(>E78@!1FYG5!"'&U^(\049&%1100U8@,$`!FW<QH8#
M8NC@2&9H`%1&%T_TYD<;O;ZAQ6,2A!#&$V',T41E`#BY<1MKQ/`S?J"28@4=
M52B23@VW.`+'#UW`DAL=9!Q1C@".:"&&*4;DUL05/)511YA,B='3:6\H_R%9
M$J#Y)8,KB@16XTX`D`$9$E](HD/74%@P1A4*0#$M.47`44`6!BP@0P\(W$'`
MY*`O`-`K<SX1P@YS.*$%"TB,N\P!7JQAP1L'@'Y(`$$P,\()-!SPP1AZQ-="
M"CBXD$!$"QQ_?'P///`##0RPX$`$BCJA@!,.^,!###UD`,`2`A`A1INV<-%#
M%S,0HO$:?+@!GP8\`8!$K\K.^;,#8`#@A29J8"&&&TA0`QIDX`0P?"$*:6A#
M#Y!PA@%@P&AFT``<8C"'#+2!`!1H`!%L%(%;>(H,83A#'=[0@,?4X`U50$!N
M%C0&4N4&4V5XS!S,<(4Z],4,:_A4U5HA,&5!YO\)25!#X=;``\LIP&SD&((C
MSM"75D`,,F9H@QPD\PK(Q,!PK:@#478(*OK%X1)GB,(HH'"Q"6A`<K9CA@`J
M8(-?2.$%%!!``F0@A33JBE1>,$,<7B`&()H!#AB@P!7P0ZY#X&`-53`1"C!P
M!"$,@`D#^$`./L"!B(1#)D$H@`=\H`(7H.`%/\"!`IB!HSF(@0P/$(<'-*`!
M&#2@`3-H``8@``$:O,".A."#?^RP'Q"H)@T1,$,5N!!%'1!E"00$@!+2X80S
M<&$)TL*#!:H0`@`@P`[P<X,.D"`7/]2!1JRXH`C'`(8N],`,<U##W!9UAO$X
M:@DB&@(*+N"#,+Q``Q;_>,$+=B`!`0A@7DM@RJ>,H),ZT`$-8%B'%M0PB1FR
M@0Q<"$SB(-.#),1A"4_P@A4`XP@VM*`,2[S$WW@"F<<`8$&?(DH3UN`&`B!Q
M'"9:!,^N\"]'8*$+)]"-'S(Q"C%.!@L7\&<($C69/8'J-$F@A&ZD@($8T*`!
M'I"""H0P`R&D(`(DR$`&/*`K.Y#@"`%H@`"*T($C'.\'^\$E@7I5AB_``0U.
M<.<8?L`&"A#A`<PR9!@LT$PH`(&2,_#!!*#0`B@,H#GBX(,>EI.`;.$!!Q.8
MP`(LP`PU>*$'`*B`)9<1!!GXDP8"Z(`#%)"##!"@0VI=Q@D4908"P$%!1*F#
M_P0BZH=STD`'2W"#(Y+0K3_@X`-P"H(%3@&`!:YA'8T!@!;^58<O"```34B#
M#)0)FC=(8`UQL`(9(,`#9\*I!F1#@QJN@)0!2(``K-"-,$U*&S](0`-+D$,/
MB"`#-[CA!&QX`M6<^*\S$.5H6<P,4/!#ORV>@@5R<(,3VB"!.LP!4P"(0A=0
M4`X3."(,/'B"&.0P"BN8[T]&9:(DSA"'&$RB!VMHP_XD(X=.??,TRAW;*-YP
M"P,?@0!%^,@$BJ`#'1A!`C7H`05"@(%;ZL,%%4AR`#X@`@<X^00]D`$*(+`!
M!\C``#QX@1-2&Y\]?(PGV`V#9;G0A0#00`M%\($)EO^!`S`4``5K0*P=[_!2
M0ZBA%2&(#Q0NP.5#:``P29@!&AI`!R\H2@MA4X-NT4"&-YA!@+TM1!Z:L`$<
M>!-3^#D!#^*@!"N,1S=/D``;^@*`B9VA"&W`%)@X$H<`$``+*G!"'%;0`0X4
M0`)$\%)?O@D;P)Q!2DU\@A;:P#='Z!8.;@C!9-)0!:(P)3=)6,,M6'%G4+4-
M``"!!#J2!2PXI*$"!"''`QP!AB=`:HD`F-<H-`$0'J&A#2,CV!L<3"9-2,T/
M8X!43]:`14G@AT9_BI\CJ(``'80@`U285@(X\``I["$`3)#"$2:N@0(@X0-7
M4)4+(@`$(_19.SX811JZ,(?_-IQA"98V@0(8(($A0&`9/GBT:NILNP6L@!DW
M"$$!@F"`EW]<5Q%(10\P\`:I"4`7<;"`&-``J34(3`J;9<(-3O`!`VBA!P/8
M<!?J@6@D-"$+4;C"&%C0M5&$B>G>C(,8]DM"BTJA9@:8@A>*,($KH(&(5.B"
MPWAQ!C#P0`QF>`(1HN"$2(B$!VT(0[''A@8W.#@2CU'#"0`043J$:0VIB,0.
M'J/3R;PA!SR!`QD`X`&U:R&B'*@=.83@B![\X,%/$,N%.J&:)S"EBJX@0@S@
MIJPR<,`"6E`"0!3!AIIBB8MS0%LKVE`C*A@!O6)(>)]WP(,_.&`&$7``")C@
M@VK]_WP?(7>*%4*]4W/]K`T#R,$;6K`,((B!!RCP@_3MZ()!O.X/>,"`&/*\
MG0-`8`%\$``HH`(?D`%3T``#,```(A$!4`$7,`(#0`$2R`([4`-I`!`]$').
MP`8Z\$]^,`$1``,:T`0:L'1J@`)U9@0U@`3PI@4.8'6.$`-AD`+B$0.WL`Z=
M,#1S<`,C4`554`<LD`9QD'AQ$`))H!B78`$IEG@1\`-D8"5V80`5<&=(((3'
M509(,#I>@`9SP$!J(`;_1!-MX`1#<`4;*`#X$3B6X@A70`9D,%&C(`!'P4,^
M878[L#%$(`O_0@=7P`$G17/,`'I%,0,4`!AL``"@9V!LP/]AI_0S.A`FDA$'
M@(%[).8`&Q,F)+5#DN('-B-L=(`!'.8'*=``$9`!&[`J?18!6%`!?P`!'M`"
M1<,$+/!]$N$"CD`'RR4*`/``;B`'1W`!8J`!,_`YA^`":!`".'`&4V`'S$@(
M=V`'`+*`XO!P?\`$1^`#?[`JJ[(`/G<(7!`&8!`&[A,?.*`&+4```L`"+/``
M+7`$%*"."S`1)7("%W`!3N8`&Y!D,D`)36!IHK`&$F`S;*(&,#`%%D`!`V``
MRT!T9K`!+@"`$?`8/+`&J&`&7D`'M#&'=5`*@L-K8J`%,20);H!.9_`4'U`%
M=!`%5'`%$4`$`M`#8K`#:M,76R#_`8(1!Q10.`!0!4EP!9B8!C4@!@0@!VJ@
M"93@$[=@!I#"!FF`!DSD!EP0"6*0(UR@!E50!DT$&EP@A*/P*6Q`/Z-`!UQP
M`2T0;N,`*6```[:W1+UB5(Y`!I9'8WY`-98W&4C0`.V%&`X3<*B1.'^2!<6F
M`JO8`UZ`1EQF`C*``"/``#G``@:0`6U$B_M@BXM"!$W0!@(@`V`@`UTP`4V@
M`W209<M@C&-0`F@P`19@`#?W`050=1.@D..0`"KP!P:@`?U@`3[0`#X`!3W`
M#)1`!SW@!,JP'4>@`VGU<0[0`W[0!"OP!&5`!!K5*P(@`73P4%@`!,Q@![CF
M`&&0#\Z!_Q]B8($YL`,[<'V/D6MA8@1G\"FZ909H<`5:4`6Z-0>200>6.!TA
M,`$%H`0LT`47,$V>50&I``=&T`9%B09/`#=SX$ZC(`964&YU0`8)LP8GP!%T
MT`9P$'@Y6&IOH#IP\`4JM@5TX`:,(`?LEE#K``9G(`I026*G$`9B$`4[,)SC
M0`&.4`;Y,@I.TPKE%H,5LT&.X`7_PF&20423H09IT"A<E`Y^T``.XP=2P`$[
M\)AUU&<L,P$)^0%)(`:JDE>220XVH`I/(`L$$S($^@12,@9>RA)F\`!)``!`
MX`(V8$<VL&7+(`-(,&VY$PX)4`'7@414<`0O\)@%0(L<D(/NL?\$6O`/`&`&
M'M`#&M"#XG``#Z("9+`!#0`%4^`(/```6B0!GOH&@@$`3@`F7;"1H'$!6#"F
M3B`#._`%&'`.H,$"6\`!,?`#7-`"BJ<%'/`&;#`'#8`%4L,&`W,%$E!38?`&
M;@`!_P*="YH$%Y`&/!`"L1$%=+`&'6!WSJD#B,$WM_`$&Y!JWH0G%A"*N:$$
M7G`"8)DH<\``D5`!2```'(`&`U`.+>`(5N`&C9J)ZU`C/+%%IJ!;H!*<7(2)
M3F0E[?9#IB`%#E`!&<`"0?`">``%`<`'!Q``"7`'.!`\^H`#*?`+*#"`4R4$
M0:!\(?,'"7`"?%``8O"EY1"FDP$`<D#_!T]P`SK0!)8`B'D0G"U@!JE5I^+`
M!"V`&7)V"'8`!!$P`!1&FP9``P4`!:CU<R#@'2G0!6$@!W5``37@`%.0!!)@
M48E%`[YZ!EU`!R^0`I#!(%D``"^04$]04WY@!A6P0FA@&EXP'B-:`6Y@)6[P
M!@80!B$@`Z(F>KZ$`679(T_@`$]0`0!@!:'88@-S!G-@`%B@)7HS-S_8!JHA
M!@.`'YL@0I)P"HY0MJB07KIE4#QTBT1`![XFB$3@DQ^`BN-P`6GS*6,`!_?Z
M"I8A"3O:"GG$`_OE!R"@!A2@G($3<`G[EE,$&5\V"BJP`B^@``\@`!"P`AZP
M&0*0`S4P`#Q`_P+[<`)A$`9C\`5?(`&*LD3Z2@)LX`0L,`))D`%:X++DL`"0
M\29^P1,+9P7=E0/+L`!DH`4>X`:RFT8+$`7,``504``\@`-[((T380/\]W,?
MP`IDD`+A:&$`,`9S@!4-,!<TR@P)P`>Y4['TBZ]6@)>*@`HR4'Q.0@1G@`4`
M>R5/H`9LX'0`0"H#T`;_RP-8@`!F<`%A5`1A0`%%D`8TL`A^8`1](088P`!/
M80;Z2@8G$+JB^P9O.B.LD"<[62$`T`5I<(.9.)>)<5*0`0E&-3>%\P0F%@7'
M*0Y8!+K%%PEQH`5DX#!C:FRMP%'K=@NOD`X`8#-^X#2QD$5\B:8T`?\03V`!
MW+L]U7<'>(`'T'@'S]B,VC$!49"[/$`#$_`"->#".5`$RY$$\CL.)7P*2_`4
MY_,$3*!E!_!MRW`'/-`%'B"*:E7`S`"J<94&%!`?=L`#!9`#`P`!%O`!'5``
M&I"/15L."4``&C`!/U`#`A!4'Q`"31`)5=``7%("T@H"Y8L%2<``;&"6^G``
MN<$B--(&:R$8;UL%/U$L6I`#:_$87;`&2J`#:3`'<1`'4=`U&*`##*"<*)8$
M2.`EPAH"1A$#XT8F;-`;>?@&(Y4&+0``-T`'-]`U.N`$17$)S68E5,P38"FY
MD8)M<^LKCD"4(2"']^H'24`!8(`"#6`$#1#_!R-0#@YP"THP`F@@$K_F%!00
M..;C!TK@!U;P%/;C"C>P,7=6+*`2O/WEKR*7!6=P>H[@`2K0S"JPII-#`*.@
M!O$Y!UH`!G#P!D9@3WP0P:/\.AT%!U9P-5/!-Q90`8*K`*QX"'W0.K;(5;@4
M``:\##P0!040`B*#C=J1`$8``0P@!`@P`$/@2*@Y`@,B$7G@`2ZP!TS@`4'@
M`D+`!PTP4G<U!FU@``XP<@60:QPP`G0P#CB@`APP@)E]`+]&!`:6;F>@!F#`
M!E;@2ZF`!3N0!#'@V7*@&*=:(R*A*!7@!95Q"E5P`V+@!0BF!9^1!8#AG")2
M!79S!J*Q*%<0!EB@_UPU$@84X@A$$$)&=;[G5@?5%K<@91ITT&ZO,*)UP%Q@
M0`10^<ZZNK3CX),_4P,S$@F=,`<@96SHU'F040>?<@*ND@0_`1EI$&)<9#B@
MZP?7Z]P9$+6@XT)RD`6W\*:'*@$M0`8#<`#Q>];,$``W\P9<0`1IX`:EM9P@
MX`47``%S;0C:J09!X`<=<+$::P-\\%A,\,',@`>M:0%!,`$4=@3[80>SN`Q@
ML`4N4`(@0`>;90AWP`1,\)`!0+'0.+$.\'U]$%-6@`!U4"QS\`5R1P$">]KB
MH`!$2!E]0.(;^01*'`9?D`11K0.K:S>=MQ9=(V)^T04MU08H(`%H\`):$/\#
M15@#(V``2N!<\];A=*``3R&S`/"2+DD`35`&$L`#%,(&!/`%1YT&&Q0F6%)3
M2Y`"`GL*8E!3.^`&7M`%BMH#M&5Y//`9D:`&1>`%<]"W$%``,J!ZX\`!KN`"
M.D0G;3`&P$YN7;#"5?,&2.$(+1!LRM8*+S#LR[=#3T"D1Q"41)`$>VH[0>T'
M,?!E9&!0.R,'()`$$[`%(C[BK;<(,7`;6(`V(8#!6K`!S%`#0]NDOZP`2>L!
M?3`"&>#KX7`'"0`$#+$'S3$$\_#2S-`"J'"W)9!8$FH&B+,&%Q`"/%P#=OIS
MP^4B&%`'`@`&\IFL)8V1XV`'DF,"3S"G;GX)8B#_N2G)`^KW8FXB-J/;`Y)Q
M[1>I.LSW!@4@`#H`!A%@.'0`!FW`?&?``6]:`$($`&\``,J&+A`@LR:`<3I%
M.F&`&.-&4J$("VZY)YT"`/D>R%CR"E>@"%@2,ONC!70P!H!X"'RP15KPI#L%
MG77P$:-P<HX`;[WK1&;7'5P4^`:6&P%P!"X0#<1H.^JF!O\M.%I0`5O0"0[@
M?>M>""3N7E;0!E;0K\JF`(UVC_<>!B/@!_:=1@%P`LP@!4'`!@TYP,O`C,HP
M#P&("+O\?1V/!"K@!T:?!'\G`1CP!">`!%L^#GH``7!0K\[!$['1"4=/!$3@
M`%W17W,``.?K3:>!!NEB_XG0Y3`JL/7IR06Z)092(P=^8A,.L'[>C04@@`95
MH*YN@`%(,`$[,,1@@+/2&@5(4QM%809D``A=6GZ$3U]H:VZ$A&HR7FB+5V%S
MBX1LD$I/-&H@+'^?H*&?=F&$-Z6$=&N$7&%OBV>5?@)^9R&5=4^Z3V=M3W65
MNK+#LF>4?D4G#2U&10T:#0X,$#H82C(Q'J+;GPU.1#I+L8NO?KP`9T^$#B;<
M[N_P\>X)BUAB5GX;+UZV<F9)8AQP:P&'E@IY"+GQ2>)NSX$^>!(JE(%G01X\
M$25J_(0`@!\T',S,@>.E"!(Z#NHX:=`%7H(>5Q:`.F#."9@F/?R\L6*$C80T
M;_^N$!*C#M:8174``'!B980$/RH00.C1Y04*#D=>4*AC)LZ-.!?J4##3HPD9
M+#S,<*FQM$J5$$UVW*C"8,X9-%B"\=HAH4Z(-2'&U''390F=2B.?=/'CD3$9
M/\`(`8A\A@L=)Q00RL!GIH''7,?:(`'CAPZ;..;0_&)#J`VA,W*(6("!0@&A
M*N7\A)'CFMBP<>-&?&!P0H*""@PJY/A!80>$YQWX(%S`0H*$+%8DI,M%Y\P]
M.C&(7"%#X\'&\^?IZ:8@QDR7)S%DU)&Q5L*6"P-K&(&*'B$>"?TAQ(<$?&A@
M0@<3?`#%$0'@P,<=&N'Q@0<'V)#"`@L,<(0(`B@BA@O_#?A1A1D1<!"%&60(
M``(;[QS!@Q]6;."``S[0\X0`9C@1@Q]I>+$$`%6X(88:83S!0A5UB%''*V)X
ML<@<=<0@1AE<^/&`"I[-8$427$C`0P18-/#&%P"X40<<3\S1!1M(M%!%$G&@
M00$(&H3P1@4$5,$"(2=H\<0;;*P!1QL`$%$.'43D0@@DL@Q:RB20F7'&CI"!
MH<0D6F"!!@-+2!>/#HH`X(,:YG"A@T=R+.*%%JC,8488@YA#"!9DR!`'`&`T
M)HL8OA$#1Y5N]!;$!2U48$`+?V#TAQUW0!@@"UVTT84$Z*1!!@!BN,%"!E->
M4$.`X+HT%`%;6+&$;FBPL8(6_VZ8`05^HO11A1,S^!%$N!EMDX`5X<*#QPZ?
M'-#"""G4D(8%#10Q@49\V*F&&F!4@05)1%1AR11%B,&#%RW$P4,<!D#@0!SO
M>"`!%BRD3`$.ZOG!1ANHI;((&%&,86@:3ST1QQFY^F&&DN:06LL+(V1!1AA8
M$"D#%AEPT`,=)9!PP0L1/.!`"%Z\P`(`260`@!E;='G&&E#NL`X1O8VC0&/G
M`+!%;Y4H<@8<P]!1!R0`W$*&&G.$0$8<=$C@@SQ.^@%&D8RI<X;0J.FRF#EM
M["<+H7ZH`<<93JQ1PQO!+A)S)4*_$3,`3^A*"`H+N,&`$R/T*XH55[0Q-F2V
M^-&"&/\QF/#$"$!`X/KOG[A`R)DU/%7'&EV9`$,9;<A`PS9\:&$'!7Y4\,$!
M/D"!@Q1,C)"#!5+`TT<'%'"@`03X!3$!#BKP&Z`>*@1PP`%VU,_L'0=4P4T`
M`>+!Q_]Y:!9$_C``,YC#`%T(0QG8T`36/($+<HB`&N"A!Q!X@0AB2,`?^+`(
M,KRA!W23G1_BL`,Q7"$-YC`$#.;P!!D\H0%8```/GH`"+$@@`A`P0`!B,(0R
M8"$"!;#`:3C`@0FL@0Q/X$`*R'`!T=#A".E0RA,,`!DG<"``&-!"!`Z#0M00
MX3&0*<0`V!2#R!#C"2%X@E">`(;(U($UKU$$H<3@E`_((P3_C;O!8=I`MX^@
MAE3NB5D:'+@(HO21%WZ0PQ/$``=T`.<W72"5XAS`*%D]X0YZB,`$J(``X'W"
M`+GRPA;FXX<AL>$*$2!$#`X@`$^Z;@*56!QD0E``,`3."4X`P?/B=87#^<$`
M4TB!`1`0A`QX(`4H"(`&WV$'9?ZO#]))P!$6<``>@"L/)OB!%IR@`1%X0`0A
MH$#^7`D/`S@P`SFZ`@0\,`0=^"$$*:,#/*H`!PI8X`5B6``'*U&&<>C""H";
M`QN>H`8GE>%N`.C"&,ZPJB?P@0PA:-<8JA`$!0Q``4G80@56((`>:.$-8J#`
M`)I0A2^$X`0.V$(-B(`"2<"!"'((_P$-Z*`%+73A5GZ(@LO\\`+2U((!;'AC
MKV!!!IVR00NY8$!C4M6$-CCA"2BZ`!DB4(1EPJ,)L;C"88JA`P2@I@YM$)H?
M%%&EH=8"%D\Y`RH*X1$OD,8U<TA4&6JQF"?\(0!ST((+1$!.**P"`$M0W!FR
M0``EE-(#?4`6.<$%!4*$86]B>,%CT-`&(H0@"VJHPPFV80<6"&`!?EC88OO0
MA'[]CQM]Z(&G%BN*#Q3"`$X@``"FTH(3A&$,8?@!$=ZAAS)H0`]_D`(<(-"'
M0NB@#@X8@Q&6L*>"$D(+#GB"!@CAA0J$@%<DW<`37.L&-EQ`!6,00`&X$`$O
ME($(,K@"$O]J((86M*`&#8#!&K"`)PC`(`LON,(96C`(`%!!-TAH`QC`D(0H
MN.$)/4!##^;P`UN8;A%KV((89.`'2JCC%7(@PXZ*L@@^IN$,;/B5&(A@!1S(
MHP<HW,(5Y+#51;@!#L`X@[6&>H:M$J`6"X9%K!JS(SK`C1AS^,)K1-"`-$"@
M`7;\!(8VB`-]]B$A/@C`'O;P`1R\0#)]+`U!V3``#D1`"ZP-D&M?HX4YW!97
M`+BQ!#A`@<V*P@XK5<$3;,#:/(0@S'K(@HG#'(HA2$8#`J@"&XC@A*,U%0P3
M`$"+*,"_#6+A!,6MQ2N"!(<L_!@R+:"#`0DQARNPQ@U;Z$$=/.#_`"^<0`D\
MX$`3(L"#&1`!!E68`1*NT`(%!!&>3KA"$;R@:BM@00LA.,,5KG"F(_@A!DZX
M[=[6,!DUM*=0L!#`&N@I&30`("^,.<8<M@"'6$$F)X/Z%0!2E:0,&`$A35@,
M'>@P&5FLH3=B[151U'$#R)P+*4(N32TH[)O!/$D==4`!+99``2(T@`4$(`(2
M"%`!9!,M(060@`QNH`0**`&%O2@EZ=8`A@=`00`?P`"?T:."73T!`LUS0PO0
M,`<KQ(`!V\B#>%8`@"<O=GIXML(1;``%'_C@`!FJ<A`:G9`[3*`$(^B>!58@
M@@_D0')BR$`8,E"')`A``RQHPA+<H(4V_[PC!6EX043,F8,]+`(`81!#E>I`
M&C;08`NX<((?>&"%.H!1`Z09`@82TX,99"$,!@!!(Q3@A3'P0`M5$(`#`(`$
M++!;)T*20!NRP(41C!`-5`P#&QZ3&\BDX3`>:<QDDA`K,-S"L2W>:HOK<!0T
M/)8Q9ZIZ&PJ`D"5T<0YSK008$"D+"O#M])5X?"4^UT'76*Q7=<#'\.!^ACM8
M(`DZ"$("$H`"/C`!"'S0`Q[VL`!G)<0%"9#.`HXPAC&\IY$06(`+2L#1`+1R
MY!M!P"+*<`4KB$$+/!A"933@!@M$`.;;0`$`L"-#8`>?X'W)(@]V`$U[$!%V
M8%5_\'XW=P468/\!6:`#7;`#&0`!&E``&)`9$G$'+^``2;`$(6!='&`"`G`!
MDL$`?I!L8A`"1R`#6\``6,`'7_`@"`@*&P``-3`!&Y`$>:`'L"`'6E`XJ3('
MI.,119$+&5<'-\8#KX`%"_`&8<`#T2(!%.`&80`%<I<&8C``"^`%:P`##!`&
M1,`#-7`%:&,`.,`N+<``7?``!N,'6-`#L0``3?`&<%,'_D8:!^8&QQ!\M7!O
M4%4%Q%8+<O<B3T`W'M$S'I$!",$%P)!A2/$&ES,\,(`+9C49Y?!@YC`.9E4X
MN.`!+8`$3K`$\`<$06`J6-`"1%``%[`]$@A_"5%RKR%%@Q$S31`':8#_!0K`
M#0\@=W[@!2$0`TG`!DG0`PI@%@H0C.^`!\^A`3"P+`X@$Q[P`;5X'@L0`CQP
M!'^P@W=0!`=@BP1$"&!@`;H1!FY0!0W@5K95`WZ0!&70$J)P!Q$P`%40!B(@
M'7GP&CH`!WSX`G&@!G%``6.P!2Q0!R_01P#P`+]0=Y!!!)"1`4>B!1=``%=G
M!#V`!"*0!C+``3(@`4K0`AG0`Q#@`UP0!5&P!9A(!(_F!FLP`RVP`Y;'`4KA
M!T3`!6[0>8D#!Z?R-6*0!L=72G/0!A@@%$E"71A`-[QP`G[0`W$`!W/U&8-P
M9_+0!8PR`*AP*TG!*V<U5-A&"#XY#%)I5L$@_PNP)0-$@`:V.`!GT``C4`%+
M(``J<`<%L(WF"`]VD`2$\``L$`;:00$.D$@:@`4Q4&O"N`8W<`8!``0K@`.2
M.0$+X`-`,#\(D0>K]0D7(0'EV!]\<`10P`<H@`*?,``YH`(>$`)[!G\#\!H$
M,!)B`#@U0`$Q4`YB(`!HDP!,X'UY<`8>X`$#$`$K$`#_F"KJT`9NH"NE8S<C
M%!ER4`1F4`<60P8W0`EU,`(/8`$I8@4A```:X``1\`8%YP89T$0<``8@X`U%
MT`5FH`%-H)M:0`=ZH@9(D`6D`9:,X1&*<#RU0`1N@`1L$'I^T`9'40=T<`QJ
M\`2#4!1K\#B2X0=E,/^59P`,:N`W<V!-\L`%)^$=87`&KS`':D`&/B4+<T`:
M6Q4EH(B6\?8DE#`.8<4#L5`'4!`!%8`!6_"6='`"`_``*/`!$;`LW[*7"&$'
ML>)Z:_`B76!_&A`$!*``&&"/HB``+0`"9^`"K&4'`M":OQ,`(\`'\G(O;SD\
M#$`&AY<#6D`!,"$!(7!=LX`&(^()!^@'<-`%AS!U=^`'@W`&7>`&69`%BY`$
M>?$$\X(*'0,,$D``3>`$=?`4$A`#;#`)&+`&+'!PCT$$7I,$+$@"3@!.,L`#
M2:!.!9`%!>!..O"/1)`#,:!\?M`%1N""I($$P&`73S`&:Z!3E!(S'$8';S#_
M"-Z&?&G``W7@'5P@0Y,8"T=T!7/`*^A0!Z2("W"G#L)0"7*`0K(08Y6PHF<0
M"\=`.B,`1U"`14:`!&])!@K0`Q&``0M'`!8`!D2*$'>0-K60-U'0JV3``0\0
M`2>@/]N`(QU0!T3G2G<@`WPF`U@ZII#1`;I9![K3B#_0`S2@`'_"IJM0!Z!P
M!T]0DQ70`0_0FV?E!?-620"@!DVP`4[`A1Z1$U;`1T11"+;3!&$0JF'@!3*`
M!!L0`DE``#DP(J#49FRI!A(0!D\%!TOP1F+1`A5&!&8@CQ%*"'!'*;7@!F[P
M2+[R-+\:1L0`4LA#.R$`9AM:#JZR")M&*V:%!I4$_SE1``=S<`QH8$`N-#RP
M,`[Z*0LM9@`JD`%5\`03L`<JX`)!X`(HH`(E@`,N<+`(\0%`\`&E"00^\`$^
MP`06H`4QX`(0<`)L!@`&(!#O*@^T,']EH`5R\`):(`%>T`55$`-Z&8%HT`%^
M$&9V$`-\I@4*())54P$.P`([T`(-X&82,0`4D#(LD``UX``ZD`0FL`@$"0`Z
M8`:'LP$"I1-H,A*Q<`9\D`>?T`$I\`<LH`%[Y@<W4`9K*P$%H`&L"@#*>F'X
M4&]B$`M0^0:-40&FYQDAT`,#P`0?4`%:T``3<`%I\%@#X`%(@``<(`)^0``_
MH%(1T`04H`,94(P7H`;VX/\;8&0&(2"0;]!YI<"2A/`>?K`G'V$)L50)-[;!
M)Z,%V1L/6@!'E4@(9D"@J;`*?K"U<]M!L22*I0%&NJ(4=+-6LE!)&M`#11`#
M(3"+#K`!&X`#*&``&7`$IY404H`!'T!$/D`$,]`G.A`'#H"3/;`%.G0"%;"Y
M\D",6*8`9R`!=*`"DDL`7F`!W$`+$!!:]2.9!@@\(<`$898$,E`B)4)$(E"!
M0\#&&H$#0S`!"<(^`U`!$2!_M3`$6@`!:U`$J60&&"`#;%`!I70!WJFG$E"-
M?U`%!/`'=1`&5H`']%!CI7$&#!`0=(`$!<H&;U`%:N`1<W`4U,,%D!`'.\(#
M0<#_J<#`!68@`S70I@(@`C&0!ESP:VO0!%Z0;$(@`4R1!&J%!4N`!(6Y4CFQ
M2$(!.:Q,`6<``'8Q&75`?,#@A[)0#NJ0AI6`5'[0!%MP&&A`!U=P91(`7/$`
M`'2SK4Z@`ZLP!UF@!7/U(BD<!EO%!L_Z!09$!X#Z7'!DHH.(EGY05G[@`%4@
M`X(PQ^3$/__S`%_P`A70`B*@`#)@!Q$@`18-QMPPPANL5CQB.\/I!PW``=R@
M`UP0`G3P`0$`!16@`%``"H5;TMN``TR@`4,P`TP0`#,0Q0I+!)^)'DV\+/=S
M!Q@A`#[M2O1\!QS@6`G`A]<V!G2@M^#&&!A0"DT`BZ)5_P<+<P8V<`8CX&<?
MS!I;$V#N%'IF@`:LW`95@@XPEBJD<00]4`+9?`0-1`!OP`):<'^3404+-FX0
ME09F8!*TT`(`H`I"$05(4PMQH#/K[&/F0"L/%@NQDJ!/T!OK!I9=#0"-\\(:
MEZ!JX`9D`-FINPU+R09JP"YWL3-N$`<+!1E^V&(+S2,.-);#\%<._202N@A,
M<`4.``&(!G]J_``$<`$.X`9E8``)0`4F#0^VL0A1P#-/`'<;O05GD'C<H`4]
MD`3FX0XK,`)3'0K_$P#N#4U>&@%S20$[J!$?,``\0`0D8!VHN`1)8`4\L-Z+
M-<)<$`!G,*XG6@-)H`A/4`IDZ/\%9@`!K#P`?X`#?@`A$;`O`D!%<I#-=G@\
M#J`$9<!A?O`8W8QV8/0>P.`"$9`$%O`42)>;%K#AWS,`.Z``/.`&)C#)A5F,
MNOT:XZ`%L`$CA#`&/S8':>!ZA)#-TPD'9,(8:.`$=`/#BY!ZP^"^LP+9\8D0
M=9`JVXH$UB8&[DL$7@`"9A1&TSK<PQ,++>;0K@'#9]`''-#(97`0(Z<`3J4%
M'/MR?XL"]7W=ITD(4[F/BG<+=)`&5E`L("@*<!<!B[Y816"XV]`Z\C`_!X"E
M`>`I"?`!`DY.V=T%)Y`%3_`8]UH'I,(&<]`!;Y`TNM`&34#A>G`&HN4!9^``
M]3*L8<3_K1#@$=TL![G`AX?A!J!'"$E`"3@0!E>@`1ZQ!0#P0770`UJH`]("
M!V;P!A#,!2A)D68&![=C*%C0!G(`!Y"P:06*ZZ6A.Z+8S83`%'23B"("#$)>
M.95@!5&0XY4`=XQ!!`QP!N<=#V>`&C)42C6``(.A""4>M'#S!<_:;V?N!7NR
M`V9$XO)&"%^PFFC0`F'0Z<"C`%F0``'@NQ[P!7;@!$J@\6#\QJGR!<!`[:3!
M`FKP8=K)#=CVZ.2T!13N#G^N$5>0+W<^%#2G!7!)!H*1!7/%!7.UCY73PC</
M`=JR`4BP!'M0+VQ``G(P5U/)"ZN@`400"UW@)/%61FEH&P-@_W\F``!!8`8Z
M<`,>(@=OP`,&,`<4\!2GAD0`&@<,4`3S6`*9Q0!/(`=K8#8ZP5-[1`APP&9F
MQ$B<%A_K##=D7#@$%3-.@')@1`C5T,VJ,0*O+0IG0)&M"AD^]@J-<2;ZIA.7
MYAOK5@EI\-4=9$9E2>7F(`43;012RF<T(*<C@`%<X`(%<`-R"NC;H(Z48*UH
MP`6D09$<$':]'PI8<%3)3TY8T$FL)0%X8`=',(0^8`=[@`,?D//PX`-2``4C
M$)PC8`$$(`0Y$<,$0+(.P%"Q0`!VEP0MY,N1@0$4?@=[T`#6(0%VS-9=``AD
M='YA9F5:<GY/<7Z-9V&-D0!^<6!D?O\!;!0F+55M7#T%6@IA)UT3/6T,9P-9
M6&DG3TYPC$]FD6=136]I?F-S<8Q)9WYS`&5UDA?)3TUM$F%SR7YJD8U65HW`
M:EYA==)^/#UD$,T4?^CIZNEG2=]B5P!O/7#6C4]S7E=B8XUK]O;23+,&H(T;
M+_:JG"$6R4V=0122H9G@@($!-P0(M*B@0$`.`1*(.+&QKF2Z.RD\>$"!0H4*
M#%0&R.#"!`H"$!`"&$@!PJ3/GT"#_N2#<)(?`&?J3*IQP4J/$"U,8C'SIH6=
MJW?NX,%S)T\>.T*#8D$0MFQ)-!$Z$!&"H@&>"A):?#";KH*,!E%D((DB@,@.
M'8V\1,!2HT[_%3%^EE0H\Z5'G0)BG(3P<V:&BS\?B(AL0D2'C2&._'29(\:-
MC&J-6FQI1(0A$35UM-1I<V6#GQ\L0HP@T*9)$P(2Q*CB)Z;'F0*6ZABI$J8'
MF`I)_(#AXH98'"YRK+2ATR(,:D9K``#P4N?,DT:]BA$C-L>:%@!LG@STTV;+
M%L1:GF!I!(!.&BPLG"/4>?29\01L#*%1CQ@/I<$!$=8P"%`D`EF3S!QMR(&&
M/6O,Y\<;TW213!U39$`"!DZ@X($&&J0@!0X?G/`!%0F4-<$5.$;!PW(R;-!"
M$E?,8($"',1@0`8Q;$#7DDRJ@\11C6C1"P5^,$#%#W%X<8-)5V#P_X`;$7#1
M1!=>:&$%#T0T,<$,3::#1!!MAM4"'G$*Q8<Z#02&`B-^B$""'PY<4049`-1!
M!A(/()$&G.@PT4(+%T@`P`!_3!#)%VAX@00<;YQ013%T`'"%#`"(,8E1C@#0
M@A\>@#&'&\$0P8456FP1@@!@E#%F%W&T4%`=;PQ0!P%72,"=&`8&U@,`#<"7
M"!UQ($.,&76DH4,;E`&@PT!IK)%()$^$X0`=/40"1B14H>I'AT]4\`4+86E1
MCQQL`$2&&]:DH0!`!$X($+[^\N<AN)$,P(.)8=!9TAUUEE2!$4(,T$`'94QQ
M``X1@-7PQB4]21D=9RCPQ"`7()3&`O"6=/_%$5CPP`<3?."`@PL)^'!G`C7&
M>2?'/NW,<U`GW$,`!A\\L05@?H1`QB+W$`+`'B5!\,9<E3;"`P\2/#'`%V`\
M<(D<<YP!QR3-T1<'')`<E4P!*M1`P0)1G*```@-$8,4#%+C`!P8Y)$%F$2`X
M(8,?`H1!@'Y:^$&>'V2T,(?=!%P"+1K)(.3+>6=@.$8R,3@@CSU/2'#%?(4V
M;6%[?M011LI!56&<X@3_B^T]!,H7\.W6H)&XNGZD@9@?5#;B`@5*1!"'SS^7
M1,,2(:@P0!\X`(&"!EP<D#S/$T!"1PR:KMK["3<HP`?KZE1A!0`27*_^^DW2
MT$@;*.R`!AU*07C_A19.7.'`&6!@XT-)1="""M)A*<JHP3Q@^$056J`%+F#!
M#<UJ`Q+JE3HZ%(`'9U":'R;@A1!$(`WWDL$8B$"!<OG!#0:8B;:H00<B4.0)
M<&B">=[@AV_UYPP`N$`(RN"'"+3A`<E@2!TV))YKX/`?]F@#$;2@A7-9XX`#
M64@QDG$%,*1``&'Y5".R4`PS>*R(C7`#!=MP+S]0$'<`J4*__$"':F#+#5Q0
MA!J0B`2&\$$##@B`&6@`-?:A@P9H<($#&M""&RR`"S/(`/+\R*3]^*%<6Z`!
M0KQ0-S84("HEJ0(#0I`^1GK2DT>PWA\NT`@P&&`-<[@!'&20BA"((0UQ_XC!
M#Q:)CB,XH0YFB$$(0C"!(*2N=W6X@A.0(($@).$+%3@7,`!@AFJ\00X`2,-Y
MRO`/,+C@!V'0@0),8`(TY``,N>)!&%!`S2<080XAJ`()4!`"'@`@!DZP0@Q>
M`($0.,$,$HB"'Y)@!AR^X0D`E<0!*8.+#UG.&E:`PVQHJ(A(L.%;1YD#&\PP
MARN<YPWD^XD6.Q2);\%A,K<C`3Z.DA[^5&%@?D`#&.IACS=488Y'<0!+4=6!
M#(B!5`'0&/OP$($Y("$'#L@!!3I0!`A<X)-M6D4;;@&&,+"'#`YP@A=T8!)/
MA("J2,UJPR(@!0-HX`=0&``7?N``"$G'`Q2@0?\.W,!%-DR@!0T(01H\X),#
MM$$,$K@`'0BP!U]*P`\L\$(/),""+[0F"5Y@Z8:*\01H1@):8O(##BS0``DD
M`0LW6,,(K!"&>6S!`C+0P@ZV8`0MS.$!5S`#!,HP!AE4P`EB@``6U)"&#&"@
M$1MZ``/0\!_8-2(,YN13'=O0!21:8PL,.<\</IH4"T7B#=T@!@/"D@V".I&'
M9L3AA-10#>32SAIO<&(C(/J--:8N&L1`C!KZX8<B1$("#-`"!`#@@R!XX`B7
M44<`EL2P=.2!#T&HK"+.X(6,W,`&%CBJ5I=$!S;PP`]$>`(Q0J4%,PC.))`Z
M@PSX@`<[9.4J=.KP@D?_;)(1K$`#$-A!!2;0@`Q00`"-&,,`Y,&039W3#`Z(
M@1YZQ@,%&``%*PB"'GQ0$#_(X%-JT.(D<LDG+YPA#MHSS!DH@`7S^.$$:&!#
M&]B0`C!XX0D&\`,$PM"%-CB`!3)H0X$)]8(?2,`!,*@6&+C!B`+7H!&`&40D
MQN"$;,$A<]]B"$$#ACHG$&$+[(6#&LZ'ACE4(0T`L$(5,*`PH%A!#&=@`PO.
MX)BTZ4<!)7ULA`D1,,>&YAHR$"]N^[6?-A`("D9)P1%B4`$_O%(..H##!8J`
M!"18H8.T-$D#,/"#`=!`K:"FA;+"0(8VX$`!FB6Q61I0+T+1P0K]D($&7J`"
M_R64!`0&J8(2&O"#"*"!!1F``1'^L(-@2_O=ZG#`;X5P!2QX0`)=F$$5")"!
M`E#!"_TMR0?&`(8O>*$+"IC`%,QK#1A0Z#QC(,8#GG"!-LA@/F80@AF*<($P
M(,$+'?`#">3QA2H4@`)<7,,/RL"%I,"!SU7@P0,N4`46K.8*LG4$'<3PX-_R
MQ]6I0RD:)_2&->`P#=(40PS@8`4PY`PH7#S*><Q[1G^]8;'80A5\SDB&,[0!
M$BR=$!@$;70H-6('YS%#$"Z@`^#X801*T`$/R/`!,SP=*`?X``3HF8':V1K2
M3Z#`^;@@`P),%]Y!04%[L,``.:#6#S.8@0X^((.2>/]@FS/P=A\6@(,#!.#S
MB`^]3V;PVP&L00M=H(,<E$*#+I3F"S\)P`WXX((>$"$#?UB`GL5CABNPL0AT
MD,$E'%D-V\V!ADA`%18@9+@&C*`,$/!#$QPP`1FL0`<M(`($N,"!,4C`#19P
MPAD<!T)H8I<-L#'*0B:1-7M\X3SU8,`34$6!\U`08,XU%XR?$-IU$2$*"$`!
M&K!C0>$QA.`&8E`O;)`,I;(N_B(';=`>@],OO-,(7+`:MP,`/;`(#.<'(><&
M`)`%8R`&-#`"&7`%1.`%59`!-8`$^[4DCM$("N`%:0`!=;`%:$`!IN`!%U`#
MHO<3>!`T<3`);E`/7(`M<%'_$E"`-5?S@TX(%'GB!US0`6]0933$#YJR!03@
M!3^!`G20`DW@!#]0&0'`)V90`6CP#V=@!F"P!+XW"6?@$`"P-)31;'4@`1OB
M`54@*3_@!"0@`%>P!&N@!F`@#V(07P;@!3$P!IR%!#VP!')P!F*P!4[0!OT`
M`$0``VBP+W4P?_AR!@P549&0#=/"4M/@"4CD3Y-`*Z-80S$`"0\A`5J`!6V`
M!7?G$QZS!BW`!G#0!K`U'W$P'Q*B9U#2!;<0,(*6!D(D:`V5%&W`C'YP!-!`
M`;?7!OW6044@`Q00!!!`!%3`)![3B0!%`2U@!7-@!45`!`90`"_PA"8Q`:W!
M`&8`_P`;4`\K101&4!)]X(AT$`+N*'I\D`=0PP=\8`=\D``<T`A)$`%N<%?&
M$06O00$>,`):H%/KX`%DD`%M0`5"4`>4<D9%T`8W``!5```A$'9^<`4]<`M;
M\&=[*`!8L%Q^8`!U``9OP"DGT`0Z<).V9@4$H``1<$Q/\&5=,`0(V`,U\`83
MP`4W(`9H```,$`?F\P]KP`,#D39'@2K)T'4<<A0M,%/-<0L[1PQUP`-B(&&0
M\`9JH`5D4`4:@`2B!!1FY04[8%9:$!VV!@E(L$86Y0=_I0C8\@:3P("H$0D=
M`BQ/$`/$``",@`:@6%)L0`R%*01=P`5:P`-9<`(S``)[^/^5&J`"\(@"3$($
MD]`#I:$#:A`'1/`L:N`&"D`U_Z@./L!L<4`';1D.5A``G:0.0K`J`F`D>1";
MTH8!6!!//*`I/:`%89`V=+`"/56$()A]2*"#:^!N?7!I-:`'5B`!!OD&Q-!8
M<0`;<'`N!M(OTA0)&'(>WN4'*&"3)A!5;/D";[`$:,`%TZ`#9#`*.?`%92`'
MO5`!5=!"7(`:;,"(:?"5E)$$8T,&\WE"B%$&D_`)UB!%/!`'Q``=<4@-SA4'
MV`()XO=+*:D%`M`%<?D39N54$X)_`+$0(4`,;;`O97`>^V(/2+$N:0`BC>"=
MK/$$;9`X/B>%D3`#<O`$;U`!1)#_!`2PFD/`!@PP`6QP`$0@`DM2`(XUB-[B
M!9CH!5[0`FM``5I0`,*Y#@JA"'(P!&]`1M57$B-0A&$0`V$J;0<P``9@`)&7
M`$%@7RO0"&(@;V=`!#R0)TC@.G?FCSTC`3+``P4P`W.1`D/D!TZ`+UO0!IK%
MF&O`4&R0AI,@89SV.XVP`$C``S\4!D!0`U8P!&.@!%XPI&K``[TVI'7P),1P
M`@+`$4NP!&H@!UZ@!EQ`!E$W:O)0+9G#C,=@#0%%!VFC!J&H.'!0+F(0-@"@
MJ022!G2`!CQW-7T$%/H4#@,#=#%`&5?@!JA3A`;`<"`U'Z[&!F=T+N>)6];`
M`&X`:630_P7T<02)B`1-``%($`)-V@!+1`-K$`!1@`-A@0=YX`,)8"G8$@)+
ML!X?D@9/F4$;]J;I@`<<,`E5\`!<>@!!0*CJD`(2]09)@`X>H#!3()H22V(%
M]`0$0!\BHA1/D`0\(``@P(4^P00]T`.SZ@=NB@?5`%R_508Z\`19H`7(8@39
MX@F/I`418`9\,@BY%`8\8`8\H`;UI(,S0``.$`8/4`8:((LAH``=L"AYD01I
MT`,\``<Q,(05P`46X'`I90UA$$TC`!`H:0T6ZB\P-`F5&I,AD(*+Z0<Z```*
M4(XOB*UXM@:#```5@!1K@"]U@'X4\`;8Y0_3,!"8MBZ")@=Q:_]<N-"!\1$J
MOU0''X`%/=`"44!)OP$!:2``)(":@;,`8=$$8="+LW,4"O5($/8%5S"@.]`&
M#7"RZ.`"7^`'</`$)R`&-P`!7G"+0=`&!=$#Z*`"0H`.'`F\(Y8"CF`"`H`A
M+C4'#M`#7B`.(6"1)F$#3>`%1_`'-M`>8:`@%#`$G>@'5N`&@\"I%F@>3_FL
M9H<%&M`#+'"!T%)#I3D"^N``C88%(<`&.Y`&8Q`"("A83P`&2M`#5M`%1$",
MX!H',M`A<-`+3C4>]#%JUL`IX((8188%**JG_6$H-!0"2^688"`&)!$4?2:%
MLPM<7*",0SD)/%0'1'!&YY$>?08`:C#_#O,'4<,[(7$P!\1(":4S(4$PE%AP
M`1%`!Y?Y`6U``1(0`C/0`",1%@?@`B[P`4@#$-P@!W`@!DU@!ESPC=9+>HO0
M3W4@:<&I#B^0!F'0`DU@O:*'O=0P`&`P?V<@)3&@(R'``F-0N.^8!3*,#GC0
M"[/Q!%P@(F9476A`ML_ZK&-`!^>Q!F80'Y21!N<H`Z3D#V:4#'$0`EC@:YL$
M`17``S'0`UO0`U?`!CH@!EW`!AQ``#P@`T7@7E@034X&#/-7#\\X!Y#P!$I@
M7EC0+W&@AI.`>I?`'V<`R8K`"T_P),*47T!1P_]@)GZ@!0]P!E_P`'20!0"0
M".C$$+U@7HTE_Q[F\03_<!X`(`,ZC,*%U0B2(AT"P!!D\'ZIXP8D<,F+,*17
MT&(0:B)"0``QH,A"`00MVES60`2!'`=&L`1O``-*8KT?()AR@`2^AP-8M`XO
M\`1H(`M\C%0)H`<W\P$VL`=\X`%A)H4#L`0`4&4QX)UQ,``3$``RX-#I8`<3
M(`9B(`5]0("(40,FQ`9S\`0FA`8A``!N@*R8-I2UVP6]``!<T!Y>QU"^%Y-^
M8`8OD"0/4!Q6(#9$\`58.2&=2`P*\"I-30=T`#!/'`F\E3FC6"]\DA"CH2XW
M`+@`)0-G`*!7U@7<_!--,*%3YPA!-'0`$0?S-X?6L`9&]P3HYQ#O,_\P<.![
MO7,$W<),=,`#-6`>#.`!&0#2&(`&%L`D+J``;&P-7;=+:8,$&H!)P'L`5ND'
M7S`).I!1?X``2K`$8+!N*>U).2D`2G`!-(`%#A`!2S"WOK`"V)(,;6`!<=`%
M\*$%:U!IZT`%:=<#<F`&<V'";%!$;!`>E"%HDFH-66P-;$":6D`'74`!5[,%
MU:":`(`&!2``(3`$6=,&2Z`%<?`"[S$("P'9D;`/]1("$F9&:`""C5`#F4P@
MU5$%J&,-)"!%N+,X]'$4]?($7T``/=`'0I'8\W<>/HL/Y?$&8G`V]0+/@W!Q
M$W+ACNW8:.`!1+`!7&`$#U`0(U``#B`..^#_`V3P`.1;%D$+4%ZP!F3R!!FP
M!$CP'A\@`#^0TAQ0.Y-``R6A`K^S;G8`,\6]/G=`XGO082R]``%`!8UP!4+0
MK%50B)-1!5OP!AE`!_]C$@C)`2)@`2OP/'^0-C<P!O5`Q(V`!6"P'SH@+XT@
M0^418US-1LSF143@!A!2`5[P2D>`2TV`!59P`2?0`AS@`<7@!FA@!G!@ZM(1
M!VP0!8-`!G$`R=7,0]HE0>TQ-AO01GSB2"1`![5K#P.!(2FU!'!]%%A0!5P`
MNT$1U6;0`,W,!=&,I9S&H47'1B!3#9$9=`O!@&P=V7(-`',@!\$0!TMP`E9P
M!4T@3QDB1C$@`!"P_P8PQ`5KD`390ZILL`(;@`9PV28`=A1HH*N%TA\`D`1!
M(`&DE=)4\%=9$`;Z!KW=#;):H`89P!E%D`$M``$75`%#<.=AKCYJ3KS4Y@<U
M$`.A(T'!H`-LX&X^8`8D4`1'X`-4^P?LA04@`YC4_"IIT,'T?`:H0:1@L"%%
M!VFI4YM10&!F8"HU4`$.8``C@`%08``<$`+O,0)J5`>4O0//JKQJ4*XO%[?I
M00<"P'#0.`V.9`WXYP1S8,V$T`*C[0=E4`4W8`(\H/$_80,?@`(G<`$C$`%X
MY``(L.<%,`$&8`(6``(C0*='``50P`2*SP0R,P`D$`$1``(<,/E^+P5,\/\!
M"[``+NUYGX<'>]`'?2"0'W"P4!"00^`$!^`\>U`#0G!%$0`^%6``+A!P88$!
M*U`!!6`!`Y`"F!-C`/``\],!!C`!#X!5?)P#<@`!63`D/K@.1^`&1G`%5I``
M3+``0)!(+LT!/A``M[CQ/',$C0`'$7`>8I`#4DL`-1`"$,`!;5#')0'^(M`"
M)H`#<#`"?S"\IFX>KI8>TPP(77Z#A'-61$]7`%9/?DEK?G-^1G-H56LU1&Y;
M?F(*$EI(44Y.@E$M`&)^9GYG@V)NK8-M/6AU=:Z#3W5^:EV2O6V$?CV-?F!J
MJGY$?D]J3VM/:'YL@V=H/0#26D0R5SA_X>+CY.7_YN?HZ>KD>>1V5.-[>GAX
M=_1V=NOE%!D.+"P6&/#0`0/+LRXA>N2PH"`(%0'Z(DJ<6"[!&P!>GO"H4J[`
MFQY$.%(<2;*D27U'"#EHX(?,@P?">/GQ0@><.3UQT+@!0X-.@S]?_$@0TZ:-
M$2\2",6QDJ85'#]!S\0)PPJ+%D*LS,0Y4\9)CV%KT'!9`P!`&S54M3T)$R;6
MLB*#!`UZTVH1G4%5AOFI\R37'#7#<K49,R@.`&"M7-&ATS<."SETFF"0(P'-
M$1TV3P;0<[*S9Y,N%G#^\Z%-!"(2'CQQ\><(Q,^P]?'@148`DG(XQ#2Y<B6V
M[]^?IPRR8D"8'SH]?NE@_\)D`IP(.R*8TP`!`X8&*_K\D1O)3QRM&P:YX8*&
M#I<8>X?-&7-K4!:92-(3:@/`#P`W;@"H@=/FB;$G:;`A1GT`W#43'`J<88QW
M]241QH)Z*:/7('7H<,5^&`VR6"Z'Q5#?<7',\009?N@@0V8F&8$&#P<`Y^*+
M4]1!1`9<5%%`!CQ$(,.+//8A#!P0B,$'.3YTD8886/"HY)+F"-=,%_[Y@8$%
M;W#Q!AMLT$%`!D>24`X7/H1C@QH8;$>(%QC4L0:4>?D10UMUH!$',\U@,<<:
M::3!A2Q5:!+)@G(,(H,?52S1`A@`D-A>)&[I50<`#ZI1S2U<`"#'8;$\M><@
M2?_$T4P:90P#1U-Z3;673*VLH8863[!QAA=^%,`%$YYY0)@8$(S&Y*X30?&$
MK"J88`$8&110`Z^^R=E"%B>T.,X49,B)!A4NV'&'/0LDX((4+GS@P;<HH*""
M$$($$<0$$V"PPA%`&-#!`0D`D<`'1[#V1P`'+)`''PG@X((>+@2<P!X^^(##
MP0F(@\^U]M"31QYZZ+''Q'OTD0`5?&2L<3E[!."QQP>$G.\""]@0L`JZ\'#"
M5FPT<,8<<(#1RA)A$'%#&!2,L$<X?!#!A0$3F$'!'7]<%<43<(3@A1QHN*)&
M&F?<(D<CO(P(&`!HL$&8?T@'2M\3JK0QM7\*H-&73%'_UN&&IX7IU485<Z2!
M2S.$T*%*%US``8"G,J42!2%RG/$A(3(`1DT8Z<TQAQA6],!82S4@X2PY'W30
M@0,8%`!#!@&D4,(((ZQ@P>@B"*!+&FB0L4,&&<R`[.OE>'!&$%5\X$(,!1A@
MP6O(VH%'9QJXX<0;,903@>!EM0'&$DDDT8,657SQ!AAMP`%''-C'(8<<BBO^
MQ'=:E*6%##U@40865[!``1=@A"'#$DL0(08/9)`1AA,QH(%&GFIDP4,((8A!
M#)KGO![TH`E-<$(4B,!`(B#A"FFP0A4F>`4K,$`!"B```02@!"YTH0M>"*$7
MP`"&,8R!+6(0`RNLX`0QJ"`)_Q70@@D&08$0M.$-G'`#!EB0!#;8ZP\+(,`:
MVL"!A-GA*F=X0Q?*\`!<\(T.3HC$$JR`AOK$00PR:T\=Z'"&E^DB#FY(Q`Z,
MT<5D%*$+,;!"'41$*`#$P!@%TE`:PH"%0>SM#&W:RW\F)+,)^3$-5^CB?-*3
M!"L`H`EL\`(;XE`#[9##`%XX3!CD$,8X*))K7.MB+@AQAJ)@P0(GV5?&V@&[
M<=C!6SX(E[C&92X%+&(,%\C`"S;`!!F4Z74?4,#D2#("+X0``;<<AP7\`X(?
M)*$*^LF3_LR`!AG4X`8MV,$.U/<2`0A`@PI@`1LD\(8ZA*$-9%C#A;2!!2M8
MP5-?0/]#2*K2@OAHX0QPZ$(4M,!%/W2A"BE$U1S,0(:B`*"+(=R*&MJ`O35\
MH9[B"4/4<A$')%1*%U%`PA;H@(8H).$-;4!!!K1P!1Z(H0<UX$$;6.4'--!B
M9^&H0M/.\-$[X,`85<!`'7N`##NJ`1%@@T!]L#"X[NA`<+R(!0:$\:!A.``,
M4=A;&X;8!KE<(R-P$)P=-VF&H-3A&4T!0!J><)?%#>,6DFB$@H8!`)EMCXT4
M\D-_G"`'`KRM!VUH`0?,<8'^7*`/H8G`#$Q`A!PLP0$2Z,$))+27&%3``GK(
M`]%(X@,7X$``:EC#&@2`4L^X@`E!X``12"`==;B@#56M1:+_XM`&*W02#2$8
MP0!"<($=\>`GKYO!&3I;$CO$(`Y!2$(Y=-`,#$1`!S6(P00.%H$)N.`"XFB`
M#<HQA<6&@`U<Z`$/*H`&)8A!``4X`APVP(`4O*$"4^#"!;+P`#]<H08?[`(/
M_A8"*PRA#5DXQ@DLD$8']``$Z7+`!B`0AA\84P83:`!9V!"``@R`!6*HPQ:"
M0`,P-&$H+-5"`2H@LR<X`0);`(,$TA`%6!W&#T@@P@#<$(:HGF`0<_B``%HP
MA'!DH#H8.,((^#"`9@``$O0)`QOJTP9)1`T`CT(/"B!1#?FPM!F\^$)>SL)3
M0BS"#Z=I&S4T-*@I#X.K=8##+@!0_X6FD"$-H[)/D>M6`_M$@D2<#-1B%O2&
M\+G!"TN82Q7.8(4"[,`<&>A"&XZ`#A>$<'VA\@,<Q."!A)T$"F'0!FW\H(`$
M#.DD>*B`#%H`B4%@@5;IP$$<!$`^,V!``1F@@18<P($C@,`2&=`#`_Y0@6#R
M*@A^,$%G!'!C+91#`Q_Z7@N&Z@4B2((%$!"'&EI,#AZ,(!QH0,(<B``"($N"
M`6^8C48$<(8>(`&P$E!#HM8@`J:P@0Q&R,`7)/`$%JR!#%OH0A*Z@(4JQ.()
M(3`#1?V0A0K4`9DBJD,%VJ`$+!`!#CJH0A=J0``M0(`&/=A!9+'`@24@8PD7
MB/9U_9`#X_]0PQ7]B?.G/*##<]QA`GM)XA-TH`!"7$1!:W2<NIN!1[H,XV]F
M]L,+TH")3@Y##-5@P'=B/HQL!*81K;)B7\Y`R>H!3B]RB$,=Q^`?5@Q"#B$>
MQJ9,IXLKS`(;`'B!"LSA`;7RN1Q'($*9!T&$DJ\A"43H005,8@$,Q`+(R_`#
M`[B0!B1LAB0!J,`+>($J3HPA!+3%C1]$P`<09$$"!AA!$,I@@@4,@`AHJ$`%
M-D`!("1!UJ_+@90ZDX<&0*\<)?<.!KS@!!YD8`U%8```L6`O-6!^'#IP0#C"
M8+8;:PUQ>@L!$0+>AAN8H01-@,`(DC`'"IA!!PB0P`5T<-L>C*#_-E8H0A)2
M6U8M?.$%(]+/&:Z@8SK$`IZ2;0$9O)`&+8"A:E&`P_[`P(8;/*$%7)7#5O>$
M@2;`(0P1F$,;!A`#-QCB!'OS!67P-F<1;.:P!T%@(&P`!SE`!-AS`ZBC'VJ0
M!`,R;W'`!EA0,U=A#</0!FKR!+`2:,_P-#PW$PPR"#UP!;"B"W=Q!FN`.&+0
M"&(@`\8Q)X-`*H/@!%?0"&K016#P!&!@!8.0$8CR!%%`0A8W!_OV!;P@A`/@
M:N*@`?91`.;@``9"!``0!202!FLP9UY`2A3!`6SC!V/0%*ZP"`TP!Q/P:!0A
M`'WA!V2A"\EP`31@!0%P#CX0!R%0!4W@_P4WD`0,(`$Y<`'.!VH1(`(1T`(M
M$`%A\CKH002+91(<T%3ED`&Z4`-H=QY:8`4.H`4,<`.&E@8&*`XXP`.Z]0<\
ML#\20`0/$`)AP$5D0`%O$`%5H`4<4`5)4`-.T`1&X`3P5@M7H`7'YP<"H#0$
M0'H0$`-8`#8`T`,>4@`_$`8M<`5P8!5?`(1?8!6(<`5<\`0:\`7Q!0`$0#T.
M<`%&P`-7,`<\<&-:)@8YT`68@P1/4`4DP`83L("JP`8\D`8]0`'E-HKE<`"0
ML%5A\`5P8`;2N"@R8P5P8'6[4!@4$'I^$$51(`=B,`=O$`)GH`5CHU9GP&YU
M(`'ZP3:/XD5(\/\&@28+CE`%N/``+?A/UK!5*CD(;+`]?J1EA.`,\%0!Q4`(
M"I`&<H`*`*`%:.`!@2<.!2!H'V`.6Q4'T%`'9/!W`.``2"`&9S``Z)`/Y\`#
M::5'/3`'(5)'<T422N!D=D0'JZ)M/;!+XP`$=(`"#%``.%`#*"`##2`"'S``
M_%<%#O`"#U`#$.`!I=043Q`$G;$``E(.%3`(O*$%7B"$5:`!#K0$"B`.HD@.
M#]`%;Q`.2@``<#`'2*!N.N`%%2`&14`$B&(%2_`782``$\`$;[05=1`#(0`'
M+0`3<U`';Z`!3W`";V`&;>8&LN0'&E``$`!_/:8%Q4@$:T``,3`$7&#_!`\@
M!SUPFTE0!Q!P`1;0!BO0!6KP/$E@!"^@!7.0`0TP`D(0`DB0"O5H!&HU4-0@
M`!@@`.H#D.3``IU@+'"P!DE!-[>`1_-H!N4%`T!6(+R`.++0`T7P%(+F'9!E
M<7#P!FE@%FI7&`1`!H'"4D5@#,I#"&X0@[J`.,;`!HTR(6%`6)&`HG[@!F8P
M!E9`%FW``KL1"1D!``I@`6PH#GP0!W"PE`K#!#/@=&G@`(?!!MZY91(`!A6`
M!ZQQ`@FP`%``!1S0!]:2!W8``D&P&1T0"]H&!WD!D]#6#"7@`A-@``-P!'SP
M,0G0!R,C&@'C`E6&.&6Q!EB`@4^G!_A@+9'H_P-^0`$`(`$D@`$R0`(54`4<
MX`0;L`,]<$TP$``<,);(H@=%!EOIL`<Y6@Y98VCBL)A^\`8O\`$ZP`49@`$O
MT`(#H#Q:B08O0`Z#`@?A(`-Q``*KT`6)Y@<A<`5D8``1,`9:``DYX`580&XL
M4`%N("F.`Q(*DID1P`9+(`8FI`!=,"!.\!=K0`$Y$`4L``=.D`9+`&2J@$PO
M`'ELL`9FP`5>D`1G0`8OT`M`5@5MP`,26@5RD`'C^I%/``!OL`890"`#\B>#
M(!GH,"@B`@`4T`"+D85"$0=STQ>0$$8`P`5?`"M.!X>!8D=:M8)GP`5N4$=*
M<:]@HPL8YQW30"C*@/\W].$I6^`%9)"4*4H';,!/@H.2O5`-Z4H(8R`)(5`$
M7D`89Y`&8]`$2.(&=.!&5=`7#]`"+*"IXH`'2R.8XC`"_M%3>R$S,5`&1:`$
M$9`19E"L9V"0_SD&,4`&;I`%:4`&=/`&_[%4PM!1]B$S.^`'<K`%=7`6`Y(3
M;S`&I+4&2C0B4B5S3Z`%)/*WF^0&,D`#1@`&'W5`;/``&J`%!I`<A^4$/Z!?
M'^```V``)"``!Q`"I40G)?5U>$:F%;``Z.`!6W"I8U<%YM,$*K4%7%``2V``
M3?!U9L`#Y""$9P`.L(H$`N`26I`#+1`'7+`#<#"T5D=Z8J`#K()/;_!X&!'_
M!V2@!2'2!4'0!AE1!5ZP!?@$`&,0!3L6`PB!`<6P!EL`=S7@!3$@`95"?F0@
M`Q9`!!`@!R'``P]@"0`0<#Z;A6[Q!"/U%!#P%>6)!HH4!Y'E!PUPA^<P*%P0
MN$TA`TXU(6/(23$019U*`8P1"W/@!),F!FCF8,,0.![H!F5V/8U`!U_`-FV@
M(%%@!GJ;3JVR-E87";GY!&6`!@/[(<)P!AC\!H8!M_S1"#+`#`6"*`"@!$U`
M%RQ%`7=6#CX0"ZLJ#K*Z%UR0!2!``&Q@6F:`!6=`![@`!V[05R20`5)J``A@
M;5MP!@\`!TU@!E5`!FWR!$D!"6?@!!\B!AC@'1!@_P!#D`$RX`8#$`07@`(Z
MD`)2@`0AP#CHV@4,0`=RT&-V%!_+P%+-=J_]4P57T`(G@`$_$`.JU0(R,`14
MD`(-``$$``52D`$10`&P,P"D\B@;<`YV<`-TX`78NUSGX`2W-@@U<!5U%P=O
M0`8]X&EL(`7A4`:R)PX(P*"JK`-OH`-DH`8RD`82$`<3B@0R$`4]$`(M46(2
M@`5@<`7@9`5;8`BTZFY.<,@Q$$GT!@`JH#PEJ1\/&P>XZ@6;6$4-1@"A`H37
MHS]BH`0M(#AP)@-SFX%#X0'NND7\^49L<`1<&"*=P`,U(P.DBPYP@;B#(``2
ML%1=X'``L`119!8NAQ5FD/\%%9L>)2TVQV!R]5$'I7<G8V`+W,$,,0`&R\AT
MG:3-6XP$:P`K(XMB,Z&W3]&WU*-M9R!O(9`W-(MF1$<(9L@%ZT@'B((!R%4.
M*$`?QR8.%N`*<5"_S^"":%"^D+)(>;,%64`$AD4&*6`&@O`$_58%XO<&U]@)
MGN(%>M/'WE$7?J`%#V``)W"::=`":N`%0=P`1G`"%)`$:WP-36!R>^&4=U$&
M<U`%`]`#-Q!8(,`!/>`$\]D&=,`"*<`!(\``,@`%)P`]`W`'?!`#4``[%7`&
M2!`'/;`%;6`.=N`":/`&8F`!.:`#\&`.5:"T?\`!?L`%;?!O_8AX"#`",NH`
MCE3_!K8K#E5V'`F@`W2@!4T```,0!6OP*&O@`!,\`3OP049`!BS0`)X&`!LP
M!DM``P[`!A18`VC@!%E0`*A3B]\%!Z-0!72`!95&*D#H!6QA!>7*-JU)*E7`
M`PX01FA@!HQP%VTPQ3V@!D80!QK@`4&P!&MP!A9`!CH\A&J09>LP`WZP`R.%
M!<\W05S``F]@!5WPF<7*A)LT![DP!GWT!&MS!D50%A%@#8A1;8.2X>YJ#;QP
M!O;736CP!1G\X:Z(.'J6!H9C'V2P"XV`'WL2)1$B9B@V5L.0KW'0!;*ZCCQ@
M!I0Z#CC0#*`D#GW``-XQ!O>A5F2P$6O``\E0!RW@!A#P_P`]<`37S05$P`->
M4`,?,`5-\`#?Q)6=^G2'$<'FY0<;P`$NNSZ$<BDU<*82T)`Z``8;.`Q6@`IY
M$8PMP``@J`(<$`$*8'H\@(6\*P9+T(\50'`XZ@!2&@1*X*,1$0!.>Q(<(`%]
M0`8_@`,S%I"Q0!5<@`(.T`+`'0Y?L-KC(-QJ,`!#@%X<X`5V\`#"ZP49(`YD
M,-5_P`<X2''H.@ON%@%(TXQ>L`-*4`-MX`9R<`4-T`*F0U"WH`!#NQ,#P#:#
M(K0R0`"K0LV(DCZ\<`%7T`4``,Y$F0,0D,*PX@`R(`53^9$/X&$H0`1E<`/V
M<1;_)`,Z#&168(EE,PR(@`5`L/\."T`WVL!R?A@^,DXA?`$`\<$&,D(B<\`%
MO*`&^=$%5E>0-G@!V3H,W;X6?E`#U^V*<1`!%B>.K-("6Q`%!9#"\?4*,K@G
M9?!A44YB3&U5"T('%,`#+J@A*20';."!8O"$2F`.(S\'MQX.POTH46`@]\KR
M_?$4658!'V"J-=``T$@!6Q`&"H`%#*`%;]L"::4*OVJQL]`&&;"(64`&\392
M1(`!)J4!3G`!9=`!>M$F7T$A;K!%F/,!!-`)04"#0:`"#Z``$$`"+*``.-``
M'<`'%R`%&O`"N8[`$0$#1N`9CR8&:_<O[N`"0VA]6+`"2V#+Y(`%LH_V@Z`"
M7P`&V97_`CM@>BJ@!7#`!)R!^W^``GD@\.V&!E>@`'3A!5DP!B^P!(*P.$7`
M%D\`EB<@`65`Y.)A%C7`"V\0TG-1!PJK*FG@!7+Q!0:`)?0!"&(M#7XR40!:
M8U977%QH#UA^8$]G<F9^3VE680`"<UI^9V)P3R\`=&!@;'ZL=6=:)"X^?[2U
M>K6U!ZQ^5F9U<)AH.@!B8[MJ-;M<<6DRH0!C3CI/=6I^(5IO;[M^<ZP`+65=
M9ZSDU$]^:CQC#TWDH65&:%YU7F<`:&W<K&AQY6&A='`1<Z8(+VAKTOA)@X25
MG#K^0NS25H=2DQD%<.7R0\>#1A?`SIBA,*!%FQ9TZ"BIXH75_P`06&100"/G
MBH9J.N8`./.DS9D,`.I4L?)@GTA63PHTX)'!2IP+%@98Z2$FPA`9%<Y<:=`#
MG1,_<7KNBE*&WY$3%31@4)"A0A`G$98@<?"%@Y$749ILT>#$P%(@&@,'ED!$
ML.'#M/BTJ6`X`!<_`$:@Y4%&"07!8CSBLN"'B`(9(>:TN:$E29<0.U@8B($G
M1@4,/09(2,)'`HL$#&Y`)L`F1*<S#!Z'@1$'"8\"?L0\X-+%CQ<K2018`?"E
MRYHS;IYPB6Q$AQ@W`&1X^7+!BQ:>6]RT$=/#CYL>6^"P<3,/#1D`820\V?`J
MRAP>9FA111ANB.'-&AG(,(8,2-2@1O\776`0`1$_R(!#`(+9H41@?#S&2AMN
M<"`!0$^D=,8:<,PAAH>8H).&&4^H44<3<IPQ1XI/O`&`'ZMP\T89<8BA0QIP
MB"&&'U@`\,838J#1Q0Y)UE%.'6VT`0`8$A@1QQP010)`&U\8R,F.?JS1RCQ(
M\9B.&PZUPD8=6P`0!V\*J!&&"5,(%@!'FN$"AC)5C/'$&DZ\(48==7P1@@4M
M.!!&"`HT,((1/P`(P`>$%=?$`W"\D<P5`-6A4!I2QG'$#@"X$<,%$J0QQP!=
M."%!%'144,568`##IACZP+%%D+M40(,:(9Q!A!("$-$`!#IH@49Y:&2P!@<<
M0&#!"`+H@`/_8H;E4!BWX-+BPWZ&\=$0&V8PX$0./4B@0Q"!B8&"1A74$8($
M%(301D(7Y,"`&!`(`$%X7"`QAQ-_\(%A#4C0TL(N1"`1!A)5Q%&'&V_,T<48
MI2W$L!E7B-H#&\.D6H,7J=S'!J]FI)'7&`!4<<$5,=310Q=RH)%#KUO,(4,7
M1'91QQ5NR`!`#&EX\0,#;:@"0!-.A.",&DY4T48/#IBQ0P]A8$``%B9TT$>Y
M9`@&!3IQK!$'`&:&T@8=/'FQQAMTE%'%$Z;!0<<7;GB#1`S:T=&`%4UD8>PN
M^`&P2@Q;//&$-Z%`'@:7$),#WA5^.-%$&FA\\\7=6=2AP7.(?L7-_QEM;,&-
M:$]4@08G2'GQ:!QFA-'#!E><,,<L@>WY!`>!(9!=<F;$<<8;G?.PHPD96'#%
M#",$\0(,;5@00A@.>!$!'6A4<"49D9!A!@%J.%[%0E6^Q$,5$2Q@1!%9L#$`
M%DMT8`0;',@P['>MB+%*17X8PQK:@`0,M&4R3G`"'V00@1LH0``98($5A-""
M$>2@!#OH`@6D$*[`.*!A'>06'LBP@<8`Q`\V6X,6M!"")!0@`1H)P[QP$0'4
ME<,-+R!#&ES'@R:$P09%844:2DB+`T@`A,E@A1.2``<'7.$^.C("`=H``300
MX0QUH(,?S@<`"D2!!U8X0X_4D`5"^$$.(?]@`(\:T(0G=,`*,`"`$JZ`)C^T
MYPL#B$(,V$`&.LC@##Q0TP^:A(XN,$`.3U`23]@P0`E\80)A(`,8TA""$-1`
M`TOXP&$@T`8["$8"4FJ#%;1#B3/$(0[;2`E'GF`Z3,1!"U_0HAEV$@,="*T<
M,=!''=X02%8TD0UL"Z,8O$`$4;W@.JP0`"BXT88R(*(5Y*B(&A*R"RF=P0ML
M.D-[GI`D,80`#&QC0PW(1(Z8K:$!<@!`D2@`AL:PP@&"J0$%,'&^)[0$$S/Z
M@+)*<X$@U.`%1!B!$]J``0AP``U#68/M:$`..F1#@Z'P0A=`H`(.O,`+-X#`
M#+R0A`<,0`<JZ$/_'F80`W!N@0\$0,<30`"0,VC152?X0`,X4`$O2&`+!8"!
M"E(0`!7D8`1UV``+(&"`"$3!#!#(0`@#P["E<@M[AKF##E@AA@90@P5A&,(*
M5!!#KN*"!6=\0@;2T`(FP&P$,7!!#CKPASVQ8@FX2($2D.@'8$CT#,EP@P`N
M@0@QU.`)/7S"`\!0!"]D80V3*,(;XI`#.KS!:&Q(@_)BP`LS7.>/F(!#%_A8
M373X(0QF.-(3K"")731/`@SHP8O&H`)>^H$%6\B!%<8`!PETH00QD,`#<#@$
MQ(2A#C/42!^2X`<&&*X-27`"$7X&F0N820!AL=@9N.`-2K#B`N7;$1:0__`$
MROKA/E_81SK6@`0YA*%J6'`"`-`!C&N<<!<G\4-X_>``Y[!""V(@[C$<(`:%
MU*%S?J"!%^Y9CB>,X1X3^`5D6H`&(BU!!SLP3`+>:9BSH/`;Z(``S<2@I$1^
M(8NLD`$UI/2$$&`A#$GX`!G<<`FCR`$%#2BF>*R`A"PH0`1"0(*^`$"#"`RB
M`2&H@Q&XX%WQ8B($<6")'Z[0!6"HP9L\4(,.E'<#+\`A!#HX@@J.X%2-:"`+
M73X,5`7#A_/YX0$2R,$L3R"#$1A@`;C00G!IL0(_0.`%&Z@".-XP@A=LH0TD
M@"<?YCL!C;3@6Q]HG!^Z4`27D@,-"E"`&ZX@AO^R8*(-->#!*R7@GCGTK`1U
M"`,<ED"/'A2/`VF(04/\8`;T6(,:2`!%S<80AR8XIP!8J$(5U.`%-M!!/G,X
M0QBTT(8Z6,$"8^!!&]Y4!PFXH`XF2)(:,-`%(SS5#XP1S`>P\(3?ON.:2K@R
MJ[%`W!4/ZK=/8``<;"21Q'4;AWY`@QC0X5(4G@$.;*K(D;JQ;S^T@0OW!!H7
MP$"#75B`KP"&`Q@(7"(`M'@?<_"LF0```SN*0`9O.`,:QG""#6CA`E1Y0@3*
M==W#X$$(*,"`!Z:`@Q0L0`5WT`,.]E`!#@C@S4Q`P0!<8`$6)`$,2"!`!8BP
M!!HPX`0C2.H->,"#`3C_H0@2*(*(3O""%EA@"\04P!*<(``"<"$#1[]``2[@
M``U$H`(5R$$.7O""#E!A``4X0@MJD($:-(``$<C[$6XP`@Y8X`,AT,`*2K``
M'QP@S+@8"B[L0`7$_V$,%S",'9)!)2S`X6%/8$$?X56+!MQ!(R-8M!9:8(8O
M;"`.75``!)C2@#_TX02L$(*A)4"+/?0`#$[(RP8>A(HZ<&$-<G!#&MPPSR<0
M`1->\`<:W!`'+O`DD6DXF0):C84(*.?#7\""`WK`@S`0P`QHV$05RO`$"YS/
M#.,40!A$H?ZX92$"=1`4AX5]AB3PP`UPF*43UE`BIF#H,`%0%C%P&#[01OZF
M_P_3L0]6L@]:=&$HE`8V`B.)A`DG,`;@00<5@0]-H".AP"9I4"5:Q!-HL&Y<
M`@#$<`;6P`KW@4+;P`HZL0MH$!006`7O@$+4,`9FH$4045<WP@K9`0!J<`6H
M<@8:\'^!H0*A,').A0>+9P=.J!%V$`!\P`=[0`M&F"%Y<!A]0(5_@`>WX'J.
M9PLV@`L!\(5A>!A.8`6U@`%HP#W)9049H`$:X``A$`,QD`0Q<`(A$!A@$'D9
M\C#U8"4MH3@UL`&<1PLC$!BA]P5PX"VA<P(MP`,G```8`$-_D`+DX%6UT`)5
M0`MV8`'!!@!8QP+$)@-B``9O0`11,`8MP`%R4#YP`/\`1!`);.``;"`H]J`&
M<;!'5B8&"H`%7D`&F@:$9'("<&-'3Q`2;B`.D+$%DX,&K98%N'<%!2``9,`E
M)\`#L:)-9T!K,:`$2]`$R=`"8X@8`T`.9)`GAJ%69M`&<O!:=(`%^F!D_F!D
MUM!B=%`%0N$!30``-5!,D<4F;>`$KL`%.5,0!E$%-6`$+4$$;E`'8M"`Z21$
M1G8ZB((&3Y`#0"):&.@4^^`JD%,%#XD).J`$$#`V[G0&2GB&+-F2+OF2AB$#
MG4@+.[`+;!!-("9>3\"'-&`8>M!*:``&+3!:65`#)Z")?S`#@5$"):8%8<`%
MOW4!:7`**_D'+A`#<\`'N`#_!!(PD[3P`K]'#V^`!'`0!DM0!>W(!1:0!AR`
M.F\``400`\='0+L@?"`"%A6`!C$07B!B#%AT;]CA!G00(^U("7-P!>%U!@]`
M#N1E9^D`@42`'Y`!`!LP"9R!!F_0!EE@!6!`!"3`!-P2``JP"PS`+0F`!`ZY
M(U:V#RWX7IBP(\,&!_.(0G6@.$O6'OO0`S%1D6Q23;S"#3I0%F_0$K/)"@TH
M7CMR!O-5D9!Q?"@T!V'``F=P!@2P+8C!!YB0$3"YG=S9G89Q>(&Q`UYY`;N0
M!@W8``:@`4A1!FZ0'8'Q!2=P&&"%%&>@!'*C$$H0!5E("TA)"R50!2.``B_0
M`!GP_P(X<*!PIA$64)5_D``WP`*!@0)(@)I=D%XWH`-8@X<Q4$D\``%*4`3,
M<@$><`$:8`!2\`(.\``"(`"1=@(G0`-DYP!H]P$&8`!!D`(H<`$!L``?L``'
M<``J``74(@(+*BDE(`,:L"I5X`0#P`96@`%)0`1>P`5:H'!OD`9.@``?\`%4
M<`"`P2TEP`UK@`#<P@=]$`!90`2JZ`"I^`2]F2OMU0T`\6K+U`K'69$[$0KB
M59PMP@V>Y3CH8()R$A0568^L8`Q/H)[<4`</TUEIX`(I4([7B4(FX)V6>JDM
M&84&``""T0)7T'E^*HIV,`(.0`6LT`34N),:X07Q:1CS^?\$Z)2152`>,]`$
M!E![`Z@1!5`#3Q@N%@`!&J$"72`#B)$'3(BI@6$'EH@8"6H'6JD'>:`'+N!Z
MT8H'>6"L>+`'>@"M>*"5(70'R,$&<C!^+>!4=V``0-``4\`$+`H#$)`#'(`!
M&#``#O!!5I`#+&`($&`"!%`#2P`#<I@!&4`">1<!($`M%D`%%F`"%K`"(_"P
M&U``$HL``U"Q'5"C!C`#,S`%4W`$$[``+H`#0>`!,H$"%*`#'"`&4@`&7-`$
M8'`$JU<F9;`%-;$&9$!CJ/E[6S``M]I!?9"$R!JT0AN:$Z``Z^65N"`#;5`+
M\XE"J84%5FD$`P!-C1,8K'H8\X3_"1$`)-M0"A(P`"R@E2.`!-.Z&9\:0BE`
MIKB``DF0;4/[MC`I!%P@`#C@!1,P!`QPA8YW!Y^G$7C`A$[8M[T*M];J`[.`
M!PE@!],:``G@`N5X!U/@I5:IN,OJ>C_J5'O`"J4)MYQKJ1TP`@2PHORW"UK`
M`CNP`RW0`C=@`6(`M;20M:Q0CQ30!XI:7/5U!E#H!9LK&%F['@#`&=5P)3\`
M!TH9`!9@G;4P,V=H`RD`!9W[O&'(!QFQ!V+06WU0A=";O9V;N<6EO=X;AE1@
M:T;V.'-0OG(0!V00!PCSND96!TZ@$+[D#V?@K;2@!VZPNX$Q3[Y7`#%@!%33
M!:SJ`2$`_T\&\$*ZZKK?F\!!:P%NH)0*_,"7F@>LH``07,%E2G8;H%\H]&8_
M&@`>S+CT^P+:X`9>P#5Q.@=KL`9JH`9)X\"UP`44;!A%40<64`0/T`,34%,1
M<`65"#P!P`/.BPOS8\%$_)(UP`4N7,1*C'@2[`<QO,10_`<?,`*G``!PQ2UV
M<*UX\'D)D`!',`50H+>"D7J'$41A<'](\`9"\02D-P8SJ0=]6PM#',5TW$%V
M\`8]6\=Z?!AWP`H$L,=*K*P)T`%K@*Q<\,>&(0#?4`$A<!',0`'$A0$@H`$I
MH$D:,0!:`,C%NI]+S`5YK,F@?`=:A,B@3,3=:LBD'!B*[`=X&/^9;L`&6?``
M/_!3#B!G?5(+'9#)1*P"#`!/(20`(7`$?%O$4Q`&G]RY4.!)?W`'?WNLT8J]
M?Y`'6YB%>C"%@9$`TNS!^WD`UDP+7>Q4RNQ4?*`!R:H/`J!M'D"_I;S.X*(%
MYVP8&X`489!Z7^`%,;!>6!:E`5!H&F$`NIS`>[`'0.`#$``':?#$X5(O_I@!
M/B#&;WL'"Z#.M%`!;G#,M,!3+ID`,I`"?T`"2L4`&/`'&M`#;=`$4,`'4IH*
M'.`"/3`&8@":?[`#:(`&3O##*^P!`0`"M>`&"L`#<``'C,$'<A`!6F`!M'`#
MFTL`L]`!*N`"$#``?S`"5Y`$'A`!+Y#_`QS400=0`.3S!8)!#N^L$4[P!%FP
M`@G*SG`+!!);`B7PL"NP`A9@`2)`+1P``@5+`B-PH$Q@`%#0UR80`05`!5LJ
M!3-@`"D`>8?Q`[O@#3V0`7/0`SI`!PK0!2]@`08@T7_@S]^+`U+`<STPG5+B
M!0=*OWPP!0NP`#;P`9#J`1Z``D'02\D!!AK+U^&,K"[``&%`!Q9]!&[`5H'Q
M`UMP`4F,>!@`!VQ%`'M8!W!U#18P>B.@!BB@`3I`PE?@`BT`0D$@*7YPC@R0
M!$MPCERV!V<@`"Z`'%M@!XJ\`%M`!$?0`)!&"^[\!P3P`$Q0!P(P!'7U:XS4
M&;6M$0'`!%(P_P$3<$]R4`!,T-]DX`<_X,VX(`(M.`,NX`+\C-9!*Q&[X%DF
MN`]DDN%2L@]2@BBM8&]G8-&U4*<H@`4<\`49T`3'FP9=D`1/0`7]G=G_G+T$
M,9WBA2AND,)L``R""AG,60YG``8.,./=R<B`XP<7D`!P?`?7J@<&4`<^T`<^
M<*T!D(5'`!E@P``B@))A%N7'7:[V'01^H)5W$P(]>P1D(``[H`<?`)ZUD`15
M4*XDX`<Q(&Q]8`!=\(5U\``?X*81`'MEL`9-`--:0,Y>]P?V_2<)P,U23`28
M70LID"0UR`IL4`6'C`58L`4K1%40`@=>L`0$$'4]XCCWT`A%3N&7JO\'&3`!
M01`$3*`"*G"@K.T!*9`"+C`"'V`#-E``$""O'=`!3'"\,W"@$OL!((``$0[-
M@:$Z=>4&6Z`#^3<PE4$'(5`&+3#C%U"NWNL#'J`!+>`$=:H&5'`!2V"'',IT
M=R$#+'`!.E`$/X`Y/-$&#Y"Q9>N='O"^*>Q9K(`%['DKJ0`&D:`%6T`&,;`$
M<F`%.G`"'8["8T`$(0`"9]U!!O!98K`&#Z#H"E#Q3*@Z6:#,=X`%+C`>!:#,
M@?8`(;`%E5KQ#J`#3A`&$Z`%!L`<9\9?"-`#`3`&(#`&2D4+:J`%10`&)*#H
M'E4''C`#)>`!:P#5AS$!$E`#-3!O'=X&+*#_`S^CHBLJ`##P`PH0B2U``DOP
M"2G($659`1Z0`4:NZFK/::&0!EH`!@\0!U?P@1WP`#2@FX*1`6']O5Z(`R_0
M$&@0`'9P!X-[&"1@/`Y@`2C`9<C*!QB@`\NV#U@PTS-M!>+`!81Q/6?LJ0M7
MG(.B!0P`TR$T`W[0`"2@6WV@!B-`^EF(!6\0`AY@!WC``6N`!T&P`6YPK"50
M`TK`!5O0>J2?!@^P``["!5.@``30YU<@`"GP!$?``G1@!F;X!5GP`TA0!';P
M!!0<`G+3`)-F!S-0N88QQ=-0!VQP!-'JT'N0K7L0A4'@`*IC2@W@`;RC]O8O
M&%-PZDA@`4D`"!@4_UQ<;P9:)R-=?XR-?PX/CI*3E)66EY1'*U@.F))B8BB>
MHZ2-=G9W=R%A5GY^'7:E?P<]KC&)1[*.0WXC?R$A6GYS.G5Z?TU%)&49"D@M
M?UH$9G>,`@8C%%@8?P9^9)%_3UX'#"]^`EY]T1$N3[Z-6`-_#"P?6!P!.",Z
M=VX21[H@(,7GB!$YT&1AX<+&0H`\NB)*G$BQHL4_0$P<BR@#@!\B(9SLN`('
M#`4'!,#`\4)I@("+,"VEBDF3E!`%`+SLD84$W8YJ%:=(L/`GPY46%*+8((#G
M3Y\`?SR8(1*$SQ\D5:`R.@'G"04K\P2H\:"!T8P13@!H(7-B0ZP,#/ZP:/_:
M*$V%/Q7>M`$`X,*:-A?^'%%31X9563@"R^*!8&?-QY`C6[1#X$V8C;H"N(DC
MYLD+`&<<H(#`($6`&"PG<7@IN;7KQS8*`"75H\&"QZ@8W:9D(X&'2GP6+$@0
MP/%A1WL2Y-FSA^X?S,B;WLF#9X&+5'=B,6*B_37UU^##1V828`8:-G[63-&C
M)T4?/O#Y.+:D)T$3"6Q.Z`"0A`&1+EVL`<`7$$DR`6OB):C@8PDLZ."#$$8H
M840^F-$"'6[4X8HK<;BQEQMOO`$''`1T9TD"?0"A@``:B)##"PID,(('&,S7
MR($3YJCCCCSVZ...'E33!Q0!!+!``"ZH<)L++D#_P4@*OU'"QQ5MM,'&$QOZ
M48412LC@I0Y%2("$C10]T*`D*'3RXYILMNGFFW!>4,-(7<#1!!%O?-'%'$:`
M`48,(<30A)J4W($''G<X$`(/9_BA@(F,..#%<14E4<`D*)``YZ:<=NKIIS`M
M@(052"#QP`U1.-%$#STDD40-(L0P0P]@R!+$#F]HY4@>6IQIT03P.")$%:!Z
M0F:QR":K+)P1I":+KHZ4X(6O%=6PPB09I*&!!CSH,($!0QS!`000O)!##C]4
MH*X)(CC@0!`.2*"`%414D00+2#2PH@`"/%!N`SM$\`(!"MQP0PT.U"!!!B=0
MT`('%610!1(#,``!$PG8_P`"`CZ0JP$$.0P`0P89$.&N`P4(T`(-&3B000,J
M!&'`S!T,8/,+!>1<P@\CC+#""A9P(`(''#@0P03B]6%'`'Q`0)P>`1QP@'#"
MV<#$!PEDK5V1[Q7)-!-0+`#%$2[8X,,'4@`A!0XIH,#'<E+`%\`1!24`A0LX
MS##S`$RD($0!3.@\@@5\9$UW'RC88<!P.##1R&%!()J*'8@>NNSEI1C`14PI
M=$$M13T,@6VC3O#@11PZ5,&#!&-X*08;:/C!PQ,]M%'%$VR<(8$5:4`0A@9T
M\-4#!2$\0($`[D81QQ,NMR!#""U(\$046T10`1QI-$'&`$M4000;`L#`11I5
M</\5`Y9H`/!$&'RYPM?$`,SQUQIFS#$'`&W0@8869U3!QAA<J`(6R*`&M81`
M?6M`@@2JD`$2B$(R>+`!`P2@!1XH00=>V)T6P."%+7#!"UHP`QEZ@`0BR$`'
M,JB"%7J0JBU<X7MM\,(:W.`%6K4A3VX(`QKB8`4))$$-5JA"#-!0!?*)P0M?
M@`-?`$`&(GBA#65XPO?D4`41[(`!(5!9%B#@A!9`H`E:,(++)*"!!EP@"4N0
M@0`@D`3G/4`*+QB`!V8``0\X!W-X+,`B8!(`+D"+(CQ0`:8`H+H1>`0,$P!#
M!G@`AC"`(`IJJ$(16M"$,[B!`D^00!B\&`(_P.$,)"C_@A;4L($BI*$,28"#
M&#2PI2<$H`E8:(,(X6`&`,0@"JX(`Q$`P`$ZG*$(39"!$^;`A0S(``M^:`#T
M7O"$.<`A"<T\0!.2\($V7($%!>""%F3P!C:DX0L5<`,9MA"%*+"!!V$(`0_/
M1X8*G*`!+*!`#Q[`A`+1A`\&:,,9ZF"%"?``"T]H@`@HD!XBT"H"?G##"[30
M@D:YX@E*>,+L_!""1CT!#@G%7P8^,I4E^"$._<O!'/S0!3J(P0\Q$(,#D+`#
MA[[!!2?@@0.>H(`J<,$-3Z@#.EVA(9ZB!PU_D8-'`&`%,LRA"W[(0AV\@!XW
ML($,=#`#%S20`IKH82?"L8,>_P[PAP0<Q@8'2,`I[+``/<1B)G^(8)$N@8-*
MY($*KH%(=AB1A^Y`9R(%`,-L*F*",/QQ(A,@BB0,``!<"D`"?G#`&C+0A!=L
M(0Y1Z,(2H(#),+1A!U5X@1M",(<&]``.9*BH*[R@R@S(P0]HR`(`S."%,\P`
M`!9H@^Q:T8,GO,$-KECD"]@0AAC40`</H(,6((!!.?3`"%X@JA^L\(8S@*$8
M3=B"&,)0@2UXA`ANV((/L7`&6H5!#CJ@`Q;HT``-8,`CCG1"%XQ@A1!XP0<U
M^8$:WJ"#+H@A"4;P`Q<()MHVN($+1'2%&<YP!BVD@0YD:`(<NJ`&++G"J!0`
M@`:XL/\&(P0,"6_P0AC$\`\92(`,7+"M'Y"PAB?HCPY^8(,&KHL&!^1@#5K0
MT!B2H`,B^($!26B`*\3`F9$&SQ5[.H-'NO"$^`$@``"HP1B:I8$!A"`(Q](%
M#@P`BOBA00UR0,,;JH"&&"!A#F'``AHR\`453R$D%0!!#"K`@Q=P0`=9,`$&
M,$"N%[R@"B%`B1*<T(,9I(`#!J"!!2S`+^-%``8/:,$-,A"!Z"&!!]LTPL0@
MC3P'**`(#F"5`,H0!3$180E1Z($#Z!6&)N!@.!,A01L^-Y$&B(&K%V&!""81
M@3.<<PPQ8,,,G.``"!0A"P)X01CJ$`?O(<`+<M"0%W2@@`;_S$$!(8``@=/`
MYV`0H0)/`,-:6+6!,9C@"D]H@Q/\\(0,#2+%1G@#`.@0AR9*`,%T`$.CG#B&
M-2S!F6I`:?T.*`(`L,$*-;!``C6P4A/$00Y$$`$+UA"&,/@A"BQ0"QV<4`4Z
M."`&$/#"!8P@@;]2R`%T4,`7>A`&)QC!"!B]0AC94(8$?G2DM(P=&S14!36(
M@0=Q4-\)U&`&-K#A@&_8Y?[$*P`ZL&$-8ZC#&0(T!BP)"`[$3$\='.Z'-CRA
MR%DJ`Q>ZD`8_J-L,_BT@`.(@7-N)H0L2\\,&Q\``,G0A"6]P0@3PYUXN,"`#
M]I3%`2@`!C24V@M=:$(,9*`&OZ,!_PQ/B(-LE<`7+YAA&'5PL!^&VM/'^R'R
M#O5#&-;WA`8_0<A&:,,8LI03]<G!#6X``!S04-N>[H\#DG]FB@40A0TKX`1+
MB(`52".C&&BA"4X@009*4`JH!&%S?_"X+`CP:I@08-:2\``=3$"`#6"A!F(`
M0`5(@`,QM*$DK>5!%,@@ACG(@0L`0$,+G+`%-Q2^#FU`&!?"4(4JC!L`,OB"
M!&ZN2B1H/^=OP`!K<`5QL`6N,`<GY0=%L`8WT!DR`%11@#MS0'(!]`1K(`9S
MAP4M0`9O0'@1T`5-1`"^I`6;H0`Y50=$903\\@9+X`49<$`MD`$"0`$QT`)<
M``$V4!%X4/\!C1(%-W`Z7=`#8X`&2``&C+(^<&!C<D`"%.`&8/`&J-5U8"`!
M#X`%)69K=%`EDS=:W%5?%S!S70`&;/`&37!U:X"`!Z<&-/``9W`^8A!+"<@%
M65(':$`#;X`E129DRA8'27`"NB0&5J`&LN4%:"`#7!`%<P!%5:`%Y<<&1#`%
M1)`&'1`1"D`$.T0`83!Z+2`&%"`!)Q`@X78&(5`+=!!^3=!3KL`&`+`&:7`&
M84`&Y#8,`,!CDT<'WX4$=,`%G3%Y^2=;&Q)N1$`&=0`':W!Y%S5V71`"8@`#
M,^<'^:8%<1`&K&5S;.`$V:<%75$%7:`%/6`&33``)P``69!WEN#_`EJP`!90
M*RY0`Y02$1/@!;MA$2C``9/@`7/`1FP@!F^P`818!1)0/&K@!C)```!``@Z0
M?E4`&NKC!TSE!TV`#GZ0;'Z0!@\P!#Z'!D(F!ZT`;I&'9Z[0`'+@!2Q0!13H
M!R>E!3J`!F:`!D7@!32`?THE15>P3P<08@\EBT9G254@8W+P!%U';HDW4J"A
M!FF0!!D0!AC`!EIP`VX``5N0!((T$7=``<O#D%J@BPK@!6)P!DD``#RP!G!`
M`E5@&730`GHA![(U!U@2B1>%!4.4!E:`!C>0EG!0!]"D!FI08&P8=UFR(3DA
M/3V%!6_P8;ZT5%S0"AOR!B(%``[G/ZJ$_UA].9$VY@=?0`%:(```0`1UH`9X
MH`,;]@)C(``@I@L24$,LD`%K``9=<`%JX`5J@`$"5`9T,`8%4`0U4`$Q8`38
MV`5C$`=^@`6JE09#4`44]5-^H`1IX&!58`9:P$1^D$8ZX`<10`#DYA%T('E^
M(&1@(#]^Z0!;,`(7X`IM0`1TD`%S$(AK<'AD``8*$`=JP#]/\`5/L`5P\&Y&
M4`8=4`#K@`E0``!V\04I``!``"FZ0`5@$(\5\6>3D`)S\`55(`8/`'-JH0-6
MX`4GZ#Y]"0:*Q09EZ)P`4`<GT`:1-WDU%T(/0`(CP(H\D)Q^0`!5T!4+YP1(
M=SM^@&)RT`4M4/\'9M`#R!0_7H<E#>!O,_`#"5@#^$=07(`$)Y`"^28&*2`#
M.8`%)A`#+]`$(\4#[$92<;`$#_`#9;`#3.`"/+`"5T`1*8`(X0@:#Q`#`/``
M'K$92Y`$`E!++=`3%O4$9:!VI^4',@`'A<>0<J`&#%<`FB<#)Z`H+9!+2("=
M78`>D^>3J9EYKN`&)N6;GY<EL914#Q9YP_90<2``3S`5;(!8_DD'46`&ZL8&
M_$@`%0`!%.`%&Q`"^SD**2"*4>"5;D``3@@``%5)(/H$<0F(:A`\(_``8?!!
MDP<`.'5Y!%8'2.!P3GAS9O!X9P`'-8!;:M>*Z%$%7H!:!X=;)V`&W'3_.RBV
M(</J4$\@5!L2!QO$D%@2`SPP!AZ0`A&@!1(00!?@.W#`!6.0"Y@`F4J'!N08
M$1%@!CEX"7<P`"7@,RLP`#@0`0\[`BZ0`1L``I,@!7'0!#SP!A=@!3(P`UR0
M!6A0!CWQ?>[C4`!06V70!%Y@!6)P`N'9`W-`!TD0`C+@"CTP.U>005XP!UII
M:]E).P#P!O=#!*Z8>CFE:A_*!EMP`W%@!%&P3R/P!G0P!UC07C@%`#G0`WXG
M!S#``"D[K"GFE6=09$3@FWYP!4@0`G#@!%DP!R%0`UW@!%S``W(@`ST``Q.1
M`-=9!S'0`V=`!&O```I%`(QB!&<0!6E`!E8`_P9<D`/PYXNYHQ=D4&1L@`1I
MP`;E2E!B(`?>1R_"X*8M<`&CAVYFT``A!D08504WRR'-Z'X;XG``<`4CUA,]
MP`)AL`0W4*-D<`:R)68;T@71:4M!ZP<Z,"('IW8I@'R>X`,>805MH$LDY0!8
M4`;U-Y%=0`,.X%]%YPH/H`-Q0'9J&09D]U`ZX`9G<)VNT`1=H`2WVC]I$`<2
MD*>[XP=@P!_Y]E!L``<#L`;=J$]HZZ:^^%$7B%MUD`8\\*@_T+.E6`-6X)\:
MI@!E```OP``3@`1?U%:7H`)0Z`H&<!$U$`(N<`E\T`JV5@.^A(=70`!8(``%
M$`$7&P<Q0`0CP1=JH/]+<-`"5;"]#!D'.R"R<9`&V9<&G[0&[(8E9)`$6O`%
M`N!0<)`A;4!`$-`&,5AN$PD#3Q`"Z#>[SA@#35P#2G1$)S!=V)8]178!2-`$
M&_@"=%`'=3`'4(AZZN,_/*`A`J``"Y:L0H8%2>!+#"`'N[,%;+!L5Q`#,ZP!
M60!KNF`!9Y`&`'`"6_`",O"&=/``-LLA70&LZ^8%3@!"!*8%G?>3Y+9+XQ`"
M1$`$5U=N;R`6ED<,#*8A[HD&W=H&*[`%:IEM5W`%S14&,J!T]MNV9="*E9M^
M7F>+<4"[&B`'9.!O5=<H8.;&6O"JJ(6G%)`#[*L%,'!\H[``+("'.D`!&.#_
M!RUP!1I@!%TP%6J@@14@!A``BV!D!F/`%QC`!5]@!"S@"C*P3PLIE)&'4Q3`
MQ`*PA1%I8LV$>%4G!D#W/UZ@`;4@E%9@2=V:MB\@6V"0G,DI!\95MFM`?NB!
M!<)&;FWF!&^0`0-``3K0CI+@`XGZ42@=$0L0-Y>@F0)0`P^`!`I`!_\4KAGP
M`AF@!#`L"1\`!W'``@I`T\_Y2<Y*!T/DC%!$<F%PG6H;`9B)!FF0!G-`!.47
MCGGI;TT%!S$0!EH0!BJ`MFW``A44`I7D!,M3!EDPT!;J?VD0!A)@LJZ`!1#P
M!>KSH6;@!DJ48DEPA0`@`'+P`&*@`-*K!;+<!EQ`_P%XP@:82`9I5`5@``-H
M``,WH`-1\,$1D01H$&);P`*^Q09S,+]7L@5/8`1+)(BJIVX-YXMDT*=.10=?
M``:.P@-(`&ZN:$+4JWGZA0&"F(1B``>^.&9MT-9C@`$[P`(BU`4RH%I5IZQ@
M(%0>X8PU6@<Z$)TI-E)O\`#.V!D0X)U*T`/2HW9')`$,H`9=P`(_T`);,`H!
MX*BBF<5IT`+LJ4I?<`4(B`6Z?`4U\%&6U0$WX+E8P`98Y@J?M&Y8\EWYZPHK
M2P9N(`99R&Y=8`%JX-AE0`8UP`(.$`9G<`42D(30--V?Y`KLEHC%Z'5>`&(\
M(%5G,-3-30*5"P$\H`8:H/\G7I`&!+`"MTD!F,`!KI`%X7$$F]=^;(`%1\2X
M8P`]"I`&.?#3CA#4&?`$=[T&7L`%()H!-'@%'F$_>*TE:(`E<%!F8]=PVO8&
MXJT&%_``2.4*1%`#%T`'(%`$1(51!ZT%B*T%5=`&9\<A?K#78F!CMNB-!DX&
MBJ=V)/YY2%!@7I`%PH0&%=5N<]`H/>!VT$0$-'`EJ.H'Z18$(*`!!?`$)O!X
M+<`#$M$5+X`%8C==.<!;W>-J]^QUC$BTU+8A0O8--T:^7\ZF55>C8B`#9"!;
M2%`'L`@`$8`$M4#8?L`"K<4%^4Q^:*`A?"$!3B61EJ4$V>E0S`FW="`'9F#5
M;1#_`V\``A.\KOJ$6Q+X!F#P`H%;!$3P``+P!6@P"C#@4&%0`,'S!"J44[.[
MYA2`B[7`F/>34*PG#"<@`1Y1!\0)`!GP!AM.;I(Z6@V8Q85\[0SI!.>W(5YP
M!49P`G,0UC^4P.06H0"`5!;7!<I#M0[W!!BPT3+%!1=`0W]Q!FCP7S'B`5@`
M7Y:``]TJ`>%1"ZYP`=3)01*@9&50C6O0!9HB"500=`XI`TA`!35``PJV(5RP
M/&=PAX71`K4P\TKG!OT-!RRP3U&@(6:+)5>P602P!.0+)4))!ED0558`/EZ`
M!7+@`!1`!W.2>J-5`UAR!CDP8&"P`[$HVP*RS(D:/YUG_P818`%8H'UIH#!=
MH#YS4$0`4`0\4'\T8`;6F"HYD`010"BR$,?8Q0$ZI"4C%0=7T@4=W,&MD'B_
M.`?8NCX/T`/$*<1S0`:%>`6.S`S())X2,&[9^065ZUZU]'D'[P8DL&"[N"$]
MH06T602-;%R75Z,04*Y\L94;`L:NX%RS>U(",`*(90*>3RR>``$;XHT+>5&Y
MY*=BP'A0.).A-9%AI@9D@%'F3MU*IP14$@=*!PAU=%X`3WXM7'Y^<(I^5XU^
M$F\Z9`!^9V<4EE589@!M?D@[!'%L8WYJ8'1Q399/8F=P3V\\?C<A2!D2;&U+
M?F%;+"@9!G=_Q\C)/0`XR<[/T/_1T`R*&(E$?FM6;U`U4PIA1QG/5&]+`#)'
M5EE$;56PC5UT?C5@/P!U68I:<AN7BF<,^7ER1DD=+4Z2F"$R!HN$.%[0L/GU
MQ,W`,!8+86(3!@D``&?6*$+S44$,16D4:'%CHPJ2+1+H>&"`A@>:*$2PM.!Q
MA0@/`&D4/8$#AH&917Z:M/#"0T&7+A'<8(A"PXNTJQEC/)%SQJ(?#"T@8&OT
M1(T?)6X$*E'#XPV;.GZP9",31Y&7*[/"7.DBIDT:.F?@WICCQPQ<&6J2!/03
M(XPB.FF0G&"C0&XC1GZTM*E31N2<-W6\U%4$@/"E%I8@*8J#I%&/+0#@O*'P
MQLF5J\C_3"@2X.:-G`<!P2C:PF6+&[,]=I`D6*5(0#I1#'$1*+0*9C8`C@)T
MX@>DHAHMM/AI`P<`D0B&W$"<GMK/O%?4%26!M*0.=1:8GM#`X`<-DBJ.A!#!
M!6=<$48.1("!A0]7):$&;A!&>`Q_?H@AAA--7-!$$$X04$8;,E0ASC-'N%&@
M!$[,`8<85W@1!@96`""<(D3,00</<XBQ!@!JJ.%$&YZT\,0\`SV1Q@/NG3%&
M%6^(@01)5P#@1@Q7J`<'$FZP444J07'01AQCJ*'!&F>$X,<7`#YQ2F%H2+"&
M%F)(`$8;:G`A069JG/(&`&(`$`<=7YSAWAI9-,$%84`!P$,8_UYPP<4+&FB!
MPH,2)F-1#@*P@0`69Y16B!AF#`E7)D^$T8-P<W!Q!B%$BO%$&X*.A\D<"J"Q
M!AT`H$%$&%_4!=@;3\W1PQM?['I&&7%P@<9T3R3AP1RCN>?%)6]0%Y`8W9TQ
M3QM8O$&:&')09Y8B7Q)&RQEOE`'`%3&($:$)KV8AAQ%QH-8(`$JTT48!3^P`
M(AMOF`7`&R&X`<>HJBG"QAQU)CR0'W754<>.9\AQ9VSX/-81<8K(H49L@L+F
M51Q>N8'$$UZ,"X``6FBQAEYF]#`&:B%("0`9'"!1`@,LS'"5!&A4*C0T%/HA
MPQ)5`+`&&@5>8485452@`8EM*!&#&?]=(#%&&&9TVD!,9@E:1V!OJ@*Q=55H
M`4`5H,2AQA-/A."8(E?PL$J34;2`1A'"\G#"%UU(`(<";22!D0!DW`!7#%FH
M(9X<A#T1ATA<J''"&7VUX<49=H*D@QDAT$%$&E_046T<9L2A21I5H&$&AF%\
M%,(3$FQA0@0U@$#&T,=@&P,;3A!!1!QOC$#&)6+$H<!$X[D!P'P)QW&&%H`I
M,>TA9'31`A)=5,&%&UZ$T,02H$"\1A4]>.$%7(NT@09;9\1A"%]P&$&C`$T^
MT80`Y?-XPWA/F%%[TD(0TK0A8QFX0@_4QH(WM($+7?!"`7H0(0RH`0M/Z`$&
M0)&$.`1E#F3_6@,.'D"&)Z#!#5;H`4#80`$V].`,,B!24%+#MO9T84A^`(-`
M"B$+/]0A#$^06'N\0`,?`@"(%MD3([A"!%?,[0W7ZX%`Y'`4R%$O#FT@``/"
M$`?C`*``Z!.``"!@C&AH0`*\2^,?&M"(V5$@#4G0PA5TD($'=&$"!)B:,Z"P
MF<95@@<]4`,:L)"&+/S(#R$XPQ:TD*`+Q&X\$_#"&*9EA!(\@0L%B`,<Q,,=
M-V!A#J5Y!Q$2B:V`!'$.@@H5``SE!VR08AY)>($?NH"%.-R`74$4@P'8,#DP
MR,$-/?A"!+A@A#V5R0=%4`,%GM"`6X%&#$700A-Z4#,P<&`+@$%"_QN,$`$3
M:"&-,GB8'[A0AUHT(0QDJ(*)`(`%1BA`(,QKQ*J><!0TM,%;?I##"``F``"T
M)AL2\X-7%($H056D%@&I`QS4`(<S`*@*/^E.>WK0M5?X4"!-$@HD7-4(3"*!
M"&>H@1OD(,4N:&%:3^B$&2+4@,",LS1U:`,8!%4&13QJ>H\HA!EX8`C3>"$*
MD,@4D?9!EBBULCVM&9<?]O0$[JCF#0[TH515$"U%A$$+WII(:MH`KN=!;`P>
M/-ZK`E.($*"A!@<L@!F:$8T]Z$&-O&/C/MX@@"]DP0HCJ$($!,`"%YP`!L_@
MXWB<R@,G<"0RA%#$V.)#!R?(H30<!0,9L/\S,`V``0T_,,0:0-$%-`3Q"1&(
M4AB4H`@=0*`H%HE%)]"PU!Q8(B0'S,X;Z$`K.O0@#@!@`;;44"`S;`$N/Q""
MPMQ`@'"=`93^>D(,>"`H-Q2`""^#P+$D^P(9N(MW)RD/$AH`AS"$86QAL`(7
M5M2%,[#A;8O@"!8L`8!$-@*$@K("9N@P`$SXH0@S,$$5YJ"!-F2P!HI(GCH;
M>P:GU`$,`&A`%^09&/:IAA"=@L2T!J:M]JQ)JK""1"4\488,5"$(;&`IW/R@
M`#DXH0;F`6%=TA`!`-"A"G+@@G:P8UXXE*%K.6Q$TH+Z!-.\80MF$,F]XK((
MUT)"4&\()QV>(%__2%RI#4UH@T56$40MU&%<.MG">N'"!5#P2(IP,$,8&O"$
M*G@A>:AD`ES7_`RY,H8(;_#LVW[0!1@<@0A):,`SF,`\-["`JTD0R!/.HX,X
ML``,#"6+\WJB`T:4TP])H"L^VE`!162)#CK```58]"4W:*X`<R`"&?9$.0>@
M$K<U2$,E%CP0D3CF>6LXR4".YP<V3$L'-NK3/N)0!BZN9@<\8,,38J,%%O2@
M!B2(PP.^P`8Q-*`$+!A#&J=%!#F`(015`$,1TF"%#O(@!60H@@EBY8>:=D8@
M/^0`89#@!5DK0@TDBP-WY%"%.,0("USHX!#;T`6XS(&YS886DOV0!0',_P&5
M(4@#/B%V"5;'YF.D852%JN#4+EPA#A6(0QC(JH+](@%>;;""52`DUS8X``1/
M`.HR='!?M6$N!#V0@2P8B8DO`2`+[,6,!+SR!06\83%":<,7("'D[LPB%'5I
M0OL4T8.8GH'6`FW9&ZP`">%LX03O1L(CLC`M,NR("&*H@QG<4(4R8``=1!C2
M#.(`!3:[?4)^.#@<TC``(S2A!"W:T1=&H()Q.(//6$##"WC0!@Q0MD==>`.O
M`:`N0SP!FR%H0^RJ91<BP($-%SB%(*R0PG`#X`;%:>73#+$%.'`!,A_T0U`&
M<MP^Q<$R-7V"#-Q`ARW(("@!U5=3`XT$-<A`"?]1D-L6!*`5@8#`"G'0P1?>
M\#T>X!P)9B#`%S+@A@I`(`W@_,4::K!9,-1AE5S0PGK;,`<RJ!`5V.*!=KKS
M@)F&@;=>T`#SSM`&"3R/-4TH0Q7\W;4ZC$8,;"`H/3(D':1-=*`%9C%WTU(@
M"A=R?K`##C<0K5`^EW`2L+(9W0$1=5$%1D`'8L`",J`L#W`"MA4#$5)I[G$%
M<+!DK%=F$H-IZ"`&56`&#S`'<J`(6%`%3T``L2(0=*!TOZ`EE7`.BE4'AJ4&
M:\!39$`&(4`$T_)(?L(%J0$7;K`C#B,41?=]C8`$EE$7V,("*!-I<5`%%4`$
M==`%WF4!$,`#?/!V;F?_/T3P`(8S#UZP`1"(`6^0!"V0#L^0`'!R`E=`!]=F
M!FI`!DR#!;17"]6"+H(@=CH`*PYF0FD!!S\0@F&P`X@P'@_D"#<@`/-`!F,P
M!FS`!2%`=:C@,&?``W#@!G`!('50=G%P`9@Q!ZSE``[P?5N`!K-7+75P`4_`
M`V3@!%L#"CW`!HUU%#VV,EC@!540:6J@`RP0`$B01JV`1&G0!B0P4EBP!0\P
M#S+061GC0XDP$&UP/@%()`"P$I#0!E(T,37`>1.V8#J`!1XA!F!`&'$@-V<0
M<W`0!S$U-XKP``*1=BZ#!C=V/MAR!?9Q04@`+CW@!DO`!C7`'3RP?#75)V=@
M_P6<\@DC@`4QE0014@MM<`5(4'NK,0=A(`.HA`H]$`8N1`AK@"TYY`1&&!\:
MY0=>P!'^)0!%]P17,$AL@`9S\`1=\!GS$(@0PWPU10>F&'?M$1_'=6260`9@
MD`AS``IP(1(4@'Q\,0=LP)-AD`0[D`%<X(9N5PL0XP9E4"UKP`9D%@4],!EF
M<`3/,`)P8P&_\`)O8!$\Y0MIT`(OP`99P`);(!Q>,%MH0`:H,3;TURGL0STL
M6!AA!PH2T$0_=`5R8``J(`9D0!A>0#H0(XME(`>`!`<$0``!!0!1\`9D8!9N
MP%$2Q051L@4RZ"UU,`?^AQ)7T`1L(')C@)IQ40=R,/\!(B`&/2`'(0`&/.``
M#T`!::0&;1`!J,0H,J`#%Y`TL5%KT&4&.=`#H%(!QO@`</!3OB$>^>1BO[14
M&S``-S8&'X&9ER`7/>`Z9[!ZQ@E#BC$/7:`&3>`\Z3%T7H!@`#`&<$,$K!A$
M8(<%5B`Q,34/FE`[!+4/`"`/$/,$%@`@8R`!39`#(`DAM5`%-=`#<Y`"[W%#
M(-(BLGE288`?93".X[$PC>!@?@"*:%!51V:31E<(D#`+='`\:W`G^\`"C7`%
MH)!2-P()`'`]L2)DYGD)^R@`FL0%#<D#6E`")V66;(:60N$)8K`D:0`%*#("
M&_(,&0`Q)-`=/;`&%=`*D##_+(8`!EXP#RYE'CEG'UO#6R1A)N5#!AIP!AR@
MED12!VXP!U'P?6W``6"`&$`$``0@4]DB"$DA))Y&`&:`EV*0!*=P!5+0`I!0
M!5;X!-*$+4[``7%`!(!1`P2`)!+E0V^`!020-"=0!1F@`3OPG'7```\Q:.+1
M71_A!A``/D72!FT1$.1C"$ZP"5L`:>6A>O/@)\=E!IPB*/]T"71`H(_`!5[`
M"!%C+WY0`4^0`Y91`;+E8@I0"TW62K(`FE;5!1<V9(TP&D@B`8*BI@R@H"'I
M!T#E+16@`@#@!!=0/#U@!!#7A.Q6!"&P!OBT!E55,XT@.H3T!/$$"0!Y?H[A
M!$+J_V)^L*`^U"F&``M*\@1EBJ05,P<7H%AC<0+3VA^*T`39:A8$D`97X'M&
M1`%9@*5K1EJLYP`]P``]L`0I@@]S,`%H$`3/0%7N(0*S!P%29`@[<*`YE!H"
M`%V"U@4&XUE.I1?3(0&QLP9E]F/VTP4NE@9EX#QT<`*JL%B.P`*6D`3_A`5T
M4`$2D`:$D`9E42>I\3IND`9JD`8R*5`H2`#8!@!;X$``,(YI>@%V,P?38@:%
M6@1'(!8,D`$MD$;7B"UO8`82$`*@40>]&1!O,`9B\`.V5A@0@UL`\1B6<"J-
MH`9AT`(EI`7>)Y%88!FA`#?V12<4@"SCT:0+=87'8E20(/^H92"VF?$1#"<(
M:/D`"T<'#N8&7@$&).`!;1`AI$5U8=!/;/`#,BNHIN&3UT-01-"D8U$DJE$:
MY2=/Z*L(8SL0$"!L[L$(L8`=K+4:Y":C0F&Y0F&*#:H%2+`&9C(Q5^!"=5('
M4OH%M!(#+B``#&*S:60_?L``-;@JO'6L[D`'"I`!'_`,'@`:39`%;`"SJG>#
M(:!OK8.3::"P;W`R8X-0[,-31X8)<$"+.00&:1`#+5`Q:2<#3;`&U.:3=:$O
M][5>;&`B8S`'>JL(_=@&65`#H%H&#.5!+-!^J/`"C@,+90`+6X(&38`!AH`!
M?V8`FP0!^Q`%;4`!T<0#!G`#E%O_(;'0"T>A!6P@`Q)@%B$@&FO)"$B0!F`0
M!SJ4,,NQ!ETP.>B3""]V@_<8-ZE1G^]4%F[`*VE0"*`4`P?D!%]0`^@%C*"0
M!A$V;)?A5'$@!S'<"*/C"4<4*S'%6G1@!&-#!TF@`(WC!-2;/6'``T6@!!<0
M`P"P#%17!U]P!2*!.:XJN`JC"$A0"MV1@6-`=2^`;1B88SOZ<Q?G:0X&``Z@
M@^;)!BR''6+P$P(P;)$!":OG0TTJ%*"K@^%1'HV\)U40`F2@M11P!!0``0R<
M1K)D-$X`!BWR$R\S`A'0D0H@!<\0`7%W`5KP!7L[E'(@MVHP!UH@/P!0!$5P
M!1?`!EHP_VQ)LP99$AAI-UQ0IU---;RBL51^P`,4\)IR\!8B-PMO$&6M1`-H
M<`5B0`3I(P=T(`,TL,YLD`$8\`*82P;L"`9P`+8WA`;)VK,`L`,G8`1GX'T\
M`M/\H(56P`9<T00QH``R\`%HQ#NL!=3V$0,`$M*U-C%(C"UE05LM$&-"T06O
M`0)JX`5:5P=4APZ7,(67X&D`D4[=D03+&BM=8+:@Q`47L'S)4@DU-2=*(#;"
MG+&6(`"RP:J0L">0$,B%L(/VQ@5,@*MIT`01(@-8)`,EI%`<>!2W634]*SU)
MP`->P<-V_2/"$11TX`9RTA]=8P;<XF+8(B,NJ@AFH#9P,+]&(/\+!_3(W/$&
M<^`&A\);J]$(-RA5P7L)%!`E(*($69`$29`%!\N4Q^H`,!`%6)`!+S#/O*,;
M^&H%%Y(%/9`$-=`$0E`!+$`$99#!SF`!C_<$&A#3:1`'<V`&V7H1JF<(&S$Y
M(]4#:/D$*%9``)`#M'51&6LC^%H(G/I];["*@C(&2:"P<0<@X>(`!&`$8(`$
M%0`&/9!X[$T&'Z(U/!`'FD1[#```'*#;1,"IH=(%JN@%7W`4@4$!8)`#;B`>
M;Y#96U`#WR<&4-`"63TTRX(&6B"0%]0&"F!Z`MX&M.8$:R!F:$`!5X95[D$$
M6U`%]L4^`("7F7$)IE@#=-`%.<`=7;#_-!DP-ORV&V3"/O.1.HUP#D\PK0)0
M!6)U!FX+`J)]!O7M!0H@%,M:%]&B!620/&-S(440C)H-(>'$%>/9:NQF%F+P
M25K``TL`!FR0<);0NXT@9/0$&^)1&IL5*`14%T<T5(T@E'10`PJI"%G`BL?B
MDZ`M570PO][A&O/`/G-S"HYQ0V4PFB]4!%%`%"V@`PJ@<5'PW>`M-.$DYND(
MJG30`!"@`X?B`!,``L_@`KM=!3/P!2\0!-,*!PV`LV(0%%A`@;FY?H+2!I&7
M&43`W6<FYD^P`507!Q.P!D5L!!10`8P0`SPIA83B!PZ`>SXT-LR-+A=%$/(#
M%T<D''Y1&""#_V#>X@5-D`;+0N*\`0=P<"=$X`"X%@+^QP80P`$RD$8U50%D
MP`!6,&KD40=BNP945!J</&R+P3Z+`0`28`:0<3P10`:W&4.*2U#DEH&S!0"X
M]F_=@09>P'(`L1>J010HL7&6$#I,MW`RB020RB=^T`-.@`9.X,']>`1+]00.
ML,T/8`"P#"$L1Z!5(`$M$`,50,`BX)W]404Z0`0:`#Y>L$6-(`8GP0-I8&6)
M'%`,92($P'`[FF$O+)L#L7SDHEA%L.I:P##9XD^78!I*U1UIP@-<\`9\TQ4]
ML(Q^4``PAP&(I@`5T.Q"DP-"J0WTAPY;8`0?(`8:8`%9\`(Y\`PVH/\N)U$#
M8Y`&<R``85`&1""%AI@#0^*!%6(1`A'H-%)(:N``LO%OCE$%S99P"WT)OG"%
MV>`&8Y$&=?4!8S``0\`!#\#>'+`"6E`!!9`!4S`!-'`!&4`>%+!@3S`!+;,#
MZ`((%V-18FAT=&=/<&]D=7,/=7Z2<G)^`!XZ/VHR?YV>GZ">>F22EFEU;P!5
M8EVE2%5-I68[1%&2:EPZ:7YL(4\`7$]L86MQ:WYT:%6_I4^E7ET`:&=G=!M^
M861P8&Z2CF-ASI)GD7YP`&=<YLYE<Y*[I7%UQ^5^<L(`6SUD86=P<V0V?(&S
MID>H@SJZ<`#CH`>6)U::M%GS)(Z?*A+6U*G_(X:>&C9L++EA00V`FQ:29&CQ
M4N=,%Q@`R%24!,`;@)JE_*C1(NG<.7.ENG2CX\<-%C_PGJQYX^?)FR=H2FWQ
MLN.,GRY58-1!`T=.#Q(`FG"90R%+E8=AFAQ<R[:MVT\<)!5(TD4!@(;A+`1L
M`.%'J`5DR@A!*H$!EUUGDE3Q0X;.+@!B^OT0L-&,'S%GO/@YLX;"&CIST(`Q
MLI4+ECD2`,00(^F-&#%DB/AQXH:UGSE)O/2(@^2*F0``PNAX@F3,"0%8%/!@
MTT6.DS42PD3"(@;.$QI>8H`Q4P?='!TYKH3Q4TR+R2Y$T$#`<D5`BR\]Q*AY
MDL'(VU`&<&YI<@%,__7J$I0R1RS">!&&:9L!,$<=5W23AAIHO#%'%754`<`.
M#CCA1Q1)A%&&`UX0P0$<9IBAPPYB`%"&%5ZPX48/486!&`!/Q'"&$5>XX\<7
MDNA82B5UP-%-*7#H$*`86BC@#0$1\E*&&5VT,8,M;J3P0!<MW%?$36>D\4,7
M9V@!!@%P(+59&P`4@494M_DQ!E&MN:%@4YN)884:9P`P3R5M!`7G&3+E!-1M
M/#K#@U5^F`%&GL@\0<HX(=%TR!,\F),%46]XX0:F;`":)F9.Q%'%`$=IH-9]
MJ*8:B@`TA0&`$G/`H48.<:CQA0037%#!7V2PD80"&L00!:SRE4%&+E?`T?\2
M%U6<T8(6992!DQLR2/+$%34!@`0\:+2@9`&[N-$&:UDP4(<7:)B`IA\KF;%&
M&F=440$7$+Q1`0\]Q-"$%6S(\$8(:_P@1AQ/P#`#D<C0P<876<AVAAMO9'.%
M%D^(@<0;5WBAQ15I0,##!@*$44$$7)311`7VJ?K'$>-(0$02=&21HA\AG-'G
MDVV$(<<;#6BA@25)/#6',VW4D`@`%)QAAIT-)$$S%P!<H0`=1)R0A`X3+M84
M&D1(L%TDK!3U0@]0X8L2&G68X847MGDSCCA$EE$*':WP<`42[C2!SCDQT/&$
M#%V0L081]]6`YL`N(?%:$@`0$4D8VT8VWAFLQ;#_!APA:;%&%VT3P52E3XPG
M"5''(--4'1#),$U-LC7%AA9,??'&&>-EG&@8K@G:YD5BU$%&[S@)2@<`:I"W
M]AD4R$"=SB$LH?+SJ-90RDUQW(!&B&\\8$6')^P*R@$I$O&%PC60H<,:>KJY
M`>18L`%'+)9\`?]FQZBQ]!-GP)"C[CCUX`<6;J#&&L3P!@R$R`^HB,-1_!`'
M-Q`!"3*X0AP,M((7A"$$+6!!",C0@A"%H0:1H(L?+(`.(R@"/233@AE"@H3?
MD6<-:M`3`%CEARL0X`QEZ$$/0J"$YTF!*><@PA5XH#'6O($.K.'1CC8`#!%0
MP!)$F,,(`%`B.'CA"2'@_X$9NA&'.=`A$EQZ6!M:4H<`MF0SNM,=_G0'AJ:<
MKVTY>4/QIN<%#IR!3;'`6AIV8`HN+$$&`6!!&U`0!P$D@7!OJ1<`UI"$,1!A
M"P\P#\%N0P$K`"`#YBD%&BB@B#G42@V7*P6BK&65,T0J4F"@`]G<,0<]604`
M<&H*4W+2/F_4(XW!NZ4D>K>I"SBA!G2(`A%6H(4T.*`;?^."`T@`O6:RA02E
MJ$`'+N`',,C`!1?``AC64(4%>.\3!7C"$UJPABO&(4QY:ITP%E224J@!)4\8
M`P"<9A[')$()5F@*1035IXV(,@).:$$;K'*I,I%'#$0@@A8DD`0H[&"39Y##
M(O_`4`&65"$.`)">C.2`!2T@Z@QCD$,+_'=&,;0A`V7(@07D((80&"%`Y%%#
M!,Z`@1&4(`3/.X(8>+"&,9P!#`#0U&(JD$\_)*$-2XO$&71@K3*1HPE?@%M.
M"J`#'5A@:1Z`0@@P8*0)%*$&`["`"/R`@#6TP0A^X$$8VK`!-?0`"370`1$J
M<`("Y*0F#V#4.<GQ!C90TQQ<D).==))&:_TB!%'`Z"\0P`$FI.$^`<H3&^8P
MAS.<TPQ1D4`:`%")"M#D`0!XPQB><`(W_+44D9"`.IIB@!OPH`I7R,D9L%"Z
M-)Y!-HX`P!@V8Y4G="&V.6EC3G9[D5)48;4)\@(,MP+_@!:<(0<H@>%FGN"&
M#%2A`S=PIG9!80%)&$%(<GM#&MZ:A20HX0PDB$`H/M`G/W#!"5<0*!QN,(8*
MU98-9$`##[:@QE)HP1C7*@48JJ`%$JGN!138P`B>R,`G:,`-OV3"4<Y0A`?8
M*[9(F$`36EJ!GX:``4100U[G@`%7<2$*L0@#&(J'A%9(P@LW:$.MD#`YR)!A
MC`)@PQ@D(*?*DB$+6'C6&IRGLA)XX290,T`5X!$#)4[7DY1#X$6J)8DEB(,H
M<Q#`&[HAA!B$0`=GR(`#P@"!.!#!"6V`@AB<4(4NU"$'`FC#$V!Q`2VP```R
MZ-@<8+"#(L1@,XMABD4DL88S_Z2B`FQH;R,L08$T-,%1/!$EO'@[/`"TP0UH
M8$$-0@"`^V3@Q9&Q`AQ"$`8ZM`$,:"C#%BI`/"*@21E&K0,7.*BUS0`U)ZAK
M@XMS<H51/@,"<M#1-+I@AHHDPA)2+L60_B<)F=#P#>U%+35"(`DTA.$*A4#3
M$)[0@2:\(`Y6<$,$"+#=<O^ANWYP`-845*8KJ$$)7LC!.#40B@",!VGD6&1^
MV\">/)$H#55@@QFJ$%6B1$(-64ZK..G0("QH,PU.FT,8Q(!J`ZVA$F?830C:
M``>#(A"H:'`&$BC`A1Z<8`WOLD(7C$#$,!C2#"%(0^A\6SQQ(L%::FB"(3<#
M-I[(8?^T,5"6%V3`@R3`(08OX$`.7N`!1*K*!S61N:C?4.Q$M6$.;Q!!S?^<
MB$,D06E/N))%WN"$FY"!`.,90!O>(+T=P+0(<O("U1DP@0*HX05(@,`9FH"&
MHVI!`&)H`A&6X80W\*0'C!M=*=JPFB?0@0M1^05.SG"%I]"A&UNP0A=;Z`<T
MU&`,,<BD']KP@_+=Q[-UP$(3MI"G+%!`"V'P@@!JX%$XT$$.6EB&%N30!2TX
M8+_);DJD$:C42/%B#BR]@D1O0$HN<!QI-@E^DW12V:9D:WICY`P\_#`[,;!!
M#6J``QGT!(<[J:$-94BFW!]`*QV8>[LKL(03'L"&-!"A!@7_D`(;!H"!"JR@
M!PX0"@DP'F*@4W`@00@4#/;P!D0@3G(`&="@)VV`!GB6!O"`!.)"!G&0?DX@
M`9KQ160@!W<V:&7P!B0`!TMP&P"`'LX``%KP!?]E!3R@`15@!@^@!AP0!"-%
M!&Y``>AW`U[`7R'1`TO0!@0@*LT@`9$T:/=0`+"#`4Z0!FB0!7K2!#WP!3S`
M`%;0!@V0`''P/!!0$X64!BT06EBA!F_P9S)R!FH@`65R=E:@"&S@.[P@3EAW
M$TA0$RL`!V@P`EP0!T7`'6W@`&G``EN@&/L@`59`!@[0-2RP`6@R!T5`#'00
M`V$0'=C0#=5!90A4B6XB`W/@:$L@_UP`$`$A`3F,00%SH`9T`#]48P4*M2@&
MD`4YP`7W<0,1E002L`.IT`5<@`07\`8-5!0Y5&K^XP42Y01C(";<YP:/T@WS
MT05=P`)$,&@;4DRIX`^5X`78HB**$%5F\%,_X8QL(`YR0(%^``T^$@<I8@5(
M,'SL8@EMP`,*T`9*0&SB<BT;TSY#YV414'[OIUTCD([QI!I$,(WCEP%8$`8?
MH`0!"`H#B$!$`'!YV!]<0`YG$`/SD%9A@`9:<`%Z4P&P@4"8(1QD8`1BL`%F
M0`9%(`EF\!$QT'=D\`!E``=(X`0<85=+$`<AD'KQE03EQ`T10`<RX`!Q8`$M
M4`:;%0$L8/\$`'`!:R`#N7$"?K`$I29.UK($0>(HFL$#?9(!<S`#,Q!;H;,+
M$J`#!N(',J`#<9`!G:8R'B`W3V`$%+`<-,%V-1$F7U`"S?`$J&,9I!0''A<U
MLC$`!),#5A`&;$`$N/,%:V4`+7`!!>`%$@"2`L!\):<`\_%.7+`!(1(#E>('
M3[(,@E(Q9@",,?`#+8`*=<`CPC59D0`PC'%:?U--YF$!7K`!57`?+:`(;R)G
MM\$#'2$&4<`%=7!I;3B'P\@&$%0%%Q`\:424L20)HN,&<A!B=8A`,V$M/=(2
M;J`%7?`/+ID3VR=5T(D3*R@@6&`1CL=I$^`'5G`%#?!3[Q60SC3_D$T!!EG`
M"ZJ`!00``%Q5`&!P`:'`!XM"G`C'%&U``6)0`HE&!+=E"=2@!3QA%9AA">(!
M1_%C5^1!!VK``N/!!5?``&6B)Z3@0FH@`I6E`">3?G%0`&1`<"W0!3U@`.GG
M`G"@!46``6D`GA)0+>EW!CR2AQ*`/YJ2"`/3$LU"!U:@(6<@`/M)`'(W1L-P
M`0GPEJK2`*307!&5!F/``S$T#HE`,9LA!V%@!'10`4L@3^90!F=0,Q2A6S5A
M`#*0`3P@*FQP`M=1!60P!R&@#!`0`09P*R;2!H880&D`&W1@17_(&GJR1DPU
M>A5#'G8C**C@DM?Y!'&Q2#DA9ZSB6SQ`_P0-0`%C8`7WP0*WP`4*H`@AEPIM
M`#`]68Y8,%J1J@4\`&U@\`"2$&W#)5RZ,P]4)PDLL$`()#TY\02M)`D0BA-L
M,&AO.EW\)6#!(PX`8`6.`)\$TR4Y@`8DX#0R8`88\`5B4`-98I_0,P)T"`<R
M=P--T`464`%9``-_J@($"@H&VH81(``*D`-D(*1RLQECX`Z[=A$M$`.5I0XT
M`(5>Y%YA\`*4XB.VU`-AFBB7(P-A$&YU\`)5H`#5DJ(60`16``8OT*X24`$2
M$(8ZZ@68Y0!PE2?4)`=J$`U'5`4Y5A,NQ@S(4P9(T`:5H"<2T"=M(`,A\`4.
M$`,FT)O/,ZP]4?\#SO`$%R`!W5$1$]`%,.H%BQ8&_>`&7%!H[N`5-$`C`50I
M%5``EM$%#P`&)E@#/P!F-[`%U2@'!B`&6,`"$F``/;`&2+!J8D`'9K`%4J`%
M/9!/CFH1`H!1"*0G;A!`/>('+Y`1:DE%?=*T%N$/KL`31'`!&>`&`J`%6'`?
MZ-H-16"!BW0#S](X?A`#9'`%1/``K9,3.I`%9[`%;U`.B**X;U!4L_$:?%(F
M;@`/MR15Y/$H"$2Y.1%+J"-5B4"\5_<$#=`%SA""(>`.6_`$#L`&49`&3C"7
M!7`"V66NS\.7L.0%%6`!8E`$+2`#9"`#7E`$#6!R!<H%;80$5B`!,\#_!E0T
M630C!BGX!CL;"<BG!F#0!38"P$31)[U+0%5P1$%B66>`B[<E#FW`!2/5!4F0
M+VD@9_.P!D/T`DJP`3M08CS0!0(@``-`!C=P`CB`,5H0`P#@"QKP*$\0!;("
MBCRPI152!%[0)SV5*#(@!A8`!RY!!I62!$W0`D6PFRH3?WZ`3TOP`D/SG^[U
M%$50!_8[!T&+;/UUG-CG!WRW!7$``4A``X<$!W%``<SI`!2J`4J@!C$P"Q"@
M!EXP-=0Q.&M0`#'``MV@A)=QN!:Q"(`K8U91&Q>$K+&@39UG$=NQ:.-0`/,8
M!EC@-S=Q'S20>EL@!F,P:&%P2'6@.(()9CW@_P180"/FL';'(`=MD"QS4#I7
M,)WV@%QHU"-R$`.5P)U0`4L4FQ-R4$9S,"3B@+ZE4#K[V7G9@@9Q<"F5LA'.
M$,MET"\A.P,]L`661@$&X+TJ4P"$AB:+\3>(1@*^=P4<\`&A8`<!8FE#:`1K
MMQELD`%@H!E^``';-%O^,$,02@H^@@8WMP42L`]/P`*L\00:(@EFY@</``$3
MP`<"4`(:P`,G[`6C*@`;@`&]N6?CU@,,``!.$`1MH`4B<"@-4!`G8`5G$`5V
MQ@(*@$'4M`4Q\%LQU`/U9QD*$P?DY`1(8#=8D`5-($=O<`%R]3Q#,!VQK`5$
M@"3+EG&XYC3VPYW"1_]9#`0QQ>P'`L`#1L#/%9`!(0`'!/`#:H4"\39$7>!P
M,C"VW.$`3Z`$<<`%J\L`E:P96?`$+/%B%2H/>D(!+1`'$2PHZ.@'15H4;9`&
MQZ`L59``/&`%:5``4276]T$"<S#3/?`R[O5;3"`#,5`$$^@`Z,$&;5:$V``&
M#6!0WI=&%M$-9\`#MS1'8>`&A58*3D"4HE*-7X=:7@!`V%`%_VH)<Q`2'"$)
M<E,'<M!&7M&:.?<*Q*I\9V`!:+`&.S``U/8$"C`#U*PJUEP':E`S3:`%:F`$
MZ+($0$8`7#`"H9`'LB&8^SD'Q58/F7%&DM`%/."7:"L)5Y`OFP&FW#=Z;(+_
M#,?&SX<0!I:Q!#"@!4A@!&Q`!QB0`A6,!!P0$D0@`U4P`5'@!0"C!7,P`&L`
M`KO@&"`@`3DP`J(S>G)B#ZU$70W0`-:7$]7A14]PD7P0<M5]!%V0`1R0`4Z7
M*G>P"VTP//\J!ULP#'#B#/"`$]3&0#@A`13`$6RXI>VL`TN`!>?2@^C3`CP`
MHER@!&EP`0*\`MS0!2W"`CI@4EC`TG(5!D\4`G1`7)+P!6[6!O[#"T$`)VV3
M>I;@8@U\P1_W!"5@!D8P0!X0`S(P`$]P'V(=!P-0$JXB`^@C#GR7;V<^#B:P
M(VF@(S(`W6Y3"O#C%)HT/S2S?;J#NV90"<(8%,<P_R2LE!,I6$:S)"ANT'%6
M46@TH@!5(&=RL"ET4`0OT-RI8LTAW49T``%U$`<8A0,P4``L,`8Y$`HX4%08
MTP1P\`)BH$&+)P<U,,L$892:8BW)2@98(!.],PSCP,WH`&9/0`!HZ`=$X`$"
MA6<=Q@-S4`';D:,*L`!F$(4AD`(MX`#E]`(@L`-+@`064-IF0%D7\`(.,`!U
M:@`((`,HH+["Y06AR'UJ4`5Y*P'%(P-%P))1H`/AMP0EFP3/PP?G/<E.8P_Q
M\<CB#>+E,$<Y88VZ\ZP*@+8$0`-*8`0*<`(0$`4"T)*/5XX]S`5>N0829P4?
MX#A/L)=R('LA@:S$.EV[FO\M.)&L1$(I=<!@/0$'(/L@::$&;B!Y3Z`%]Q%_
M%QDIP^,&/3X.+V`MLSP/"S]GTZB=Q2L)D98VYBE+E^$L=<`#Y*03;M`!\=T:
MNW"IC,'*OXIKXQ`)1&!I:!!NV&`%!"1.'$0$$1`#/<`")R#KJ((`:H\`7!!5
M;F`"!B`$$9,#1:``X`P*>\#.)8((I\`%_'5;.<Y`I]$%[K`&\'.<951J=/`O
MDK#JEZ$93R``PR,=\G`#3G`#%L`#:?`%')";+4``-6`$%1`#%8`%)Z`#+]`%
M(6`%;R"B8Z"Y38`%-!#O50`!:5`&OS)X$B`&/6!&$`N=^8912<`&6;"2!C`N
M"C#_K&J04]X0%=>:!FQP#&?``G4`"&5U;4]A8D]^?G%B:GZ-B6MS`&9KCGX9
M/&%K34A5$F1B84EA`E4A62$./"\Q:0\`2&I=<%IB;&MR`DI:?DU^9WYU68G$
M7V%DP71^`(4Q9(B)=4G!B&\W8L0R;558<04G%5A_X^3EY`W$6D1&<@!H;UYR
M5UUH9HEACDY/;VIO8FG+ZBBK`^Q,'34"YMA;)D#9&#7*F/D!<^8-&P!BE-%I
M8B61FDJ*HBDCA@A1'3;$_%2*XP>.FT9RVIPYP0)2%S=^PO3PH\3/"8I/<H1H
M8L2<T:-(DRH=-R"1&#-:`#Z!4$5+#P9$PFBI8%1/%S]/_[RL`1#,#Z$Z+4*X
M`0`L$0`LB=#0.;'L28@G<@'(8;,DT9E&7L#4F>,F!)@U=:K4<1(AA``+`D)$
M24*%08@8'`0HP+)C21(9/X@DT7*&0HXE5FIXJ9*A21,49G@8T,+B!1(_!+QT
M.?/DA"PZ=+C$:<,F1*(;`N``8,$%R9<V8K`4&.!FZ=$#B=I@K!/FR9PG72I]
M#19B^.`Y?MB<(5NG;AT`<-:,](/A!X$P%9+4B+.E!A$/(>S@1!D$\!"<!%JP
M,4<:$L2AQ1,<$(&$#&?(L`$^)8R$!CI/M%$'-G.`T4Y)5H3!@Q@@^>$&-@(1
M<YL?8KC11!5&N'&"`%Z@8=T?(/\0TX8;=.`D1AN"\;#$(WY\]X033=1!@!]F
M+"3'&G#($4(=!B[)!A'$L.7'&V>TU4@(9X0P7TI^H9D(-,GXX04Q]J"W#%P\
M>`%-'5ND!^-<<G()0!U=4,!0!2&$L..AB)K3U$1PK#?''#>8.0(42K!A@09&
MY?$5&76$T(,;&KPA@1C&/2%#%U7\,E$B;Q"!4AW7B!%!#%RTL28Q,:Q!Q!ML
M[4"$')LZ\H`98:1QQ0`\H,$#(C)D(082/7CA`@\$]"`#%R_H,$:G6JC`Q@5A
M&.!'#6)TX$D:,FI!QGIPP)$!;V?`(08:%0'SQA)TP-'#&5C448=\5<R1@1:)
MCD-%(AK_E'&$&6QTT4`8=<B1Q@!O$%,''"E!C`8Q`A`QT!DYN#$-!CQHT48$
M;ICH!!A:K'!!&B,TT$,2=8SP@`!A7"&'7':1T(466!#!0`.D]4',3G6DP48=
M6F312`D2)-*%!\$(#9>;.)V!3TIU"-'%$'7$T`,`%M#1PXX:^($&?$\`$!%9
M<[2Q;#1:\*(%L4?`@1<Q;O"`L5EC`!!"Q6KZ]7=+9\10^.)^T`$`0&BBAXTR
M*#6.DQ](S-&>66&J#<"#O901#0,\^&'!$T644%3!K"^UZ!M1J-%A3A&@T8(.
M`A#@@`%&X3%>(G,T]00<;#25HPZ)0*"J'\81XTL=)/#`)9IU_T0@P"]LT+%9
M'1^TD(@`/GP@`\Y'^#$``%[4+`$;+4001@)7*-"#`09@L443/2#A1@%N3)FV
M$PR0@16\0(<NQ&]M<7B"=XBA`QF,H0PQ0@(=&E"%,(#!#2UH`QTLL(/KU8`-
MK!.7'[2`A"ZP00=5N((A2`"'Z:')#`DT`S/DX(<O6.$&B:A!E=Z@#`.@H`)U
MP$`28E"'`SQ!`&3``AC2T`0WE"8-)\@$+[[T@#9D(`Y?4`$`9!`&7UPO&L`8
MA(K\!:/-Y>0*K$+3FYX`.2M4C#>W44,<K-"^.NQH`&?07!&(X(8*2`(?=8@6
M+]HPADJP81I/4("I9("F5/DA"V]`A/^M%D?#8/3@";X0@^C$P)LZ%&!Q%R/+
MB["1B#,EPI%E&1Q88G"!.N1`"PV00!TD``$U,*,'$[#`%Q3`!1%LH77`1,JB
M1O@7/Y!A)V=@@`"TL`4R',4.P_"##$)`@0Q<80Y$0$,1Y&`&XFB!`\KXFQ+:
MDJ0XG"$-,CF<&+RG`R(Y@0,W$1T2_D(&#O#@##D2@`QDT`0.H*$&1.-!!8)@
MA0EH80QO6(,`>M`#`A"!`FIHP5Q<(X(>.(`,&J2"5NC`@Q#4X`U3]$,9R*(&
M,@"@#4Y8QB-CH`,"%"!]$<C`&F"`J8(-DQ@7*$,2*D"'-72A`HG0P4)^\1XW
MF9`4EC,+ET#_T@%Y2:`+N[("`S(0`AV480I@28,%O)!09;P`&?"!P3X>1Q8V
MH"0'*7$A,=!C1NV8!2QH>@(80J+21.2`DTP<@B;\<$<V@$$)3A!#!HC%/):T
M"R``(4(:PA`#.GA!!3V0G6#\0DYB;(8WQ,""`KH$EAY@@P>VZA0CT4.6+@&@
M$6L!P$X2(0%3LH2<;,`",O-TCS,@XYADB"B0M`"`XH`!1\$,;CDZD(@>$$$#
M2MA7%Z`CAMXF"0I'^>(<:O$L.J!Q#&T#R^?01`1;;8P+%!##'+#1(1[P`!8M
M<5,LVL`%E#R`#@-X@AEP8)98<,$-#7Q3%>#``#%$(0Y.&,$.Y&A;_S,\X*+/
MXD$2D-"&.`A@#4#C@A7.``$NE&8::\#"&>2`!8_.009J\,(2_#L'+G3A"0.N
MF+4*Y076+0!-D3T#D9Y`AW_-80U[E4,E&[>J)P"#&RB)&UQI((,*M``-$J#!
M%62`A`AX@0=."`-<6'`%./"@8=K1U0YH4`,G5$`-;L""#OU@@-+.@24*5%M$
M:T`'0RRV8H;8&(\KQA(_&$$E)+T;&Y3@A0=`L0$[$I<7S-`#,J!!3CT`PV8U
MP09>A,5,-$9#!I`0@C3<)STU2$2"2BD7$/WB"2!!AH^XT"5@[.8+]WA"&<IP
M/>RJI'&AP)@_E)'86YV!`%J@0TI5THCVK/]A";:"BJ:WU`4RA.``PA6N",$0
M`C0(X`F+F($"KK`!.-1``!Z(+N:`QX8WA$!O'6G)%]:@!BR0H<YI:,_O8`2,
M-;"!#%7P`CZ^``POC"$X`(A#$0`0@SD(H`)PD$$-TF`%.BR4!42H00]H88`8
M3)L(+<`"!UBP!@P*8`O8(H(6N@#:"^X3!@X@@/ZV<#TM/+@!:8@,%HI`!B3`
MP0IP<%(+3HB&=5)-"Q8(`NL"D)V*Y=HL7MC"%`G!!;)@M"WL:9P"R;*U'?"8
M"!6(P0.L4H4E"!P"_&S!%230!&+QQ@VS2F"?X5"!'EQA8*+!AP;D_(3V/,IR
M1>B7'[B9!%3'^E;_*ZD$(WN+$1B$X0QWT\`7B*`#.UB'`SSQ;QJ44)(02*`-
M;FS#'!ZPIETU[MMNX,)[H#%),)4R)5]I@QG8U-L$P4%T?EBL7]8`DL&`I;)#
M)88IH3&2-^##".TQLQ]Z,(8W>2$$'4$"!5B`A@=4X0C)#NZB!`"&-FAA#HWM
MPANJ0(`,6($%.-!V$BHF@2`D`0)M"`,1_-6#CDC`"U%(J!]V9<8XI"$$:@!&
M&PKP`B+\C2YLD```-ML&!\2A8EA@`'.`!AQ0!6*P`AK`!3FR`6M@!C+``1P`
M`!#@-[(1;S/``,>$`"$``"-0!0^@!A'0!!<`#P00`5Q`!V#`$F2@.$^0_T1G
M$`=A4#$WH7]UP'SOU@-501,UX`"&ERAE!@9/(`<WL`5L\`@5PDAT\`18T`1G
M)E)O(``Y,!]S4`9Q``=SY0@CL00T0`%U``9C<&3X`0'&-09+H`4UL`,9H!Y$
ML`$"T`%>,$E<L`58H#<`0`88$W6:UA[0E@A'!@?3X`<QT%TM4`$R,$7&40!M
M(`(RA$/&]#B5`R578`10L`5W8!U`!18:T`)5@`P)]`0%0(5)8&@`\#@UL#5?
M(5'C1PP\T!ZDIB9N\"0+1!(44`28%#6KDA)G$H2<E5X\1CUU=3EQ46?$P!)T
M<`$M8(=B0#AP@"YBH`79EWS`=`&)(#J(4'1G\/\%<U`#-2`!:C`'E6@43W(!
M%5`!7F`%%/`$20``39`$I)1Z:/`F<N8$56`&7U033I`%Z(%J8@$`-(`/:$`&
M#V``80`+5R`H%N`"$C`"15`!%Q`$3Y`"`A`#:,`$$^`%4$`'!>``\&0%&V`$
M,@`&:F`$%`!86Q`&<0`!*-$&:5`%2@``<U`L$5`'-(8F,F8"MV$!CU,"8N`%
M<;`&6W!G(1`&<.``4-"#B&(!^/0+)6`<3N!V=6`/`[`$,DD'2F(6;8<F,I`&
M9`$`N^8'#8`%:(`%)]"%;Y`&&]`"3[`%;W`$8B`&RG$%J$$'9R`!!5`#+,``
M7,`%6W$"8;`08.(E;B'_9V[0'I/T+VX35VZ"#&HP28J`,4CF.'SA!?MDE$FA
M`/\W$6A49P_@+QB#*OVV!(/)*G?1!3?`2(JP`[9H!68D369P!8Q)#&EP!J94
M.(^8>BEQ`X@@`.VA!74``Q>##RT0!G>&8U^2>WR3$FL@`3H@!@/`!55`0XM0
M8@*`!]`(3)L5#7&P!#'@!O#V!!@PAPV0!)1)#M-`.&S0`V&@!F:0!C%`2FW9
M.<L0<P#Q*,"`"&C0@AG0'N/'0^AQ!E747(E`=H,@`1)@!6JP3ZRF8"*Y3@;`
M!6_@!FQ`)#G@!1)`*"[@!N\0`@5B!02`!3)`!@HR!&B@!490A^-2`%1Q$DW0
M_P8XT!Z1=%)OD`2FTHT34`89,`$%EP6L0Q=HT`;LV%G$H)9SUY3$X`6MB"9H
M<`5F)`8\@#Q^@`,/$`(7X``"``-H0`1@0`9$,`*8U(PW```?D`8]<#U%8`69
M0``_0`;&%IL$``S(8`6EE22;`S>+4%02D`9RD@BTE49J4@!(0`8YXB860##6
MH0!M\!5FY0?7^:!E,4YH$`9T8"N7TRX-46<`\`:5A`:;4S$^%@>K&:"'Q":)
M0`!F=JDI$:?!@*F)P"D\EJ?I):J*``'`8`7Z`X@-(!RA@`_```8$,`<L@`7?
M6)T%<YU^P`,QX']Y.04`P`$84`3X%*SDX`*B%GYAP/\&9I"$5A!^@Z$&?9$D
M:G(1CX@-9W!/8(`&RV@&$#!7:!`%/"`'+P$CQ$`$7:`,9G`2[4(,#Z`!6P`'
M,;`#33`&`1<&BM0&$E`%%>")52`#8I"PF6`E9Y`$',`&`$$'._`,'^%$<E:O
M7J`%44`!::`-8%`%:$`!31!U@%8PQ/4$W>@'%,`%B$"5\*D88D`!AU-*50`Y
MG_I(./0!9V`&3@``5N``#30!X(`$7]D%%T"/RGE)6P`#05D%='!]7S$,9/)J
M<*4FHQ@-;I(69S`]+BEOD$`$N>463#<8:-`()N<%XVD4!Q`"#>8'&_`#5]``
MY,8%:+`!B1`';*"D/;!K^Y#_".W*.''J!''@1-X*)P$!`&#06^W1E@KP+[;2
ME:P*JWZ@&)QF1NFF)G*@!7+`9UX0F[;4C$M"`>NA(@NU$SHGK`7#`"31!E<2
M!BWP!3(P#V*@I'I@%"Z`>L;V!.>E)$\@!G7`!7_#!F%1;SSPKBGQ`O79"%D0
M!S1C*V>P,5^`)8J3$DV@`0#0!3'I+`J0`SU:`Q7@(1%`%3+P`K1P!@I0!4[0
M`AS0!!A0=K%5/56P!LWV!%Q729,$!D&V.4ZP'COP!FT``69@`7DR``N[!A.`
M!*PS`VA2`ZT$'2'E!RU0!U>@!0UXJLV7".W@K<#+!2DU`A(0!5V0:$40!AG`
M`E$@_P,:0`1.(`L5@@1(@`(`P`4F$`5RH`$#N`9H5`.`TAZV.`>510Q;0PQ%
M\`;<\24*U`-&K%UP4&,"H0S]*Y/ND`8P4`#0>A1X4*(`P`-6`&UP0&^'<)T0
MXP=PP09(<!%$\`0PAR1JD@9C@4\?TAY#7*R\U1[K45I2D2`'(8Q#(@"-P"9S
M/,0L@7J'2PQ0ZQ:;$P>RPP5R8+``L78<M@"J2PYY,`&WJQ2L2PQK<`)O(0-)
M,`<Z@`48(`1UL`='<362AP85]Y3D-EX4<!MN11K@H04UFPBL.P<-(WMYFP;Z
M6`?P\"6KN(E1X"\O:`_-^`9SX`4TH`8$\(_R10<L,`(R8/\$(@8&#(4`9K`!
M`/D$2J`#(;`&+[@-#5`'Y9@(?"27Q-",7&(&\X(%7'`]=4!I-T`'3,`Z)I`(
M6=`6P["8E6-NE>L'#0(&7>!V,((>RIL&;586!.`+'C!'-\"YMJ(=1H`!/1L"
M74`#]&$$$5#!,N8$)T`#9R``R.('><*J"R%?<F`$4>,JDA=SA?,&X_$F`E!9
M+=0>7D`6:``!9(`!.J$`.Y+)H#9)BO&S:HPE6WP&UKP#<I<$@D(2[4%O]W"V
M*)$&4\0F;8"-$"&,B?`%9>`$2<@YQ$#4=1`'5U,6B0"AQ!`%=;4X6=L=OT`'
M66`!;5"B;X!&5>`&5<``"3#)?P#_!&#P!F1P`1F0%'3!/$D0`C1@`!8`!3L@
M!R5P`Q)@`SUPR>:`1L[Z!)\B$UA`!STY'!63CXG@FUTB:HD0`@U0FY85`XR4
M!&>P!H3;.&$@`8609A=A%G`P!'\-`0&`!@X@`S>P`$30`$NP&D^@`1)P`@6P
M&3];!D00!YS\`"]``%70`HSD!3Z`""6@!G?3L[]K!K<Q!@+0!O)2"40@`]VU
M$:PS`6ZQBK+Y;#U@`?G<A.@1@V<`O&6!6>2$2IKC!Q.P`4A@!690`TEP!1?P
M!2'P!5?0+[[<"#<`!YKZ!EE@!E$0!@[`%FG0K<0`!<#@`&TG?AXRF#)9""E"
M#$6')KS@_]*EM<1NH09B@#]7?!2KI0@_TEQYM`89W,)H%`P*L%!.H`4RL`1M
M029%E1(U\12EI0,1^@LB6P-7`(RL,KUN$A!J0@:^P#B[2`QJP`57&)]-T@5I
M4P-HT`0`0",D[1T`H)$G,`)\[0)5\`44``$<@!06X*1H,)A%1P=R4!(D$%EQ
M8,I&<04`D)^W,)3`4"OZ`AYD<09.O@RNZV-**@!Q(`>>BAY84$E_PIMR\!XA
M@`4HLDM<0`0G<`5),`0PT@4@H`!P$`8ET`1E<`'EYP(DP`07:`%C0`0#P`&M
MT@0*X`9$T`22>0(2D`)5\`-/]1YKH`,&T0/HH3=B4`#>`P%6L/\3&"`!&A`$
M<4`&-3`!!K#7!:/>OQ`#)&`&6]`8VE$`K;@<9X`$<PHY48`-7A#$0]P'!+`!
M2<`#S<L)1,`%$,``;`$'58`!)20#K5(`8,(&%<";$X$(JH4(&*T."J\F;=.7
M[3$<I03.<B*34#(&?E`B[Q$#<6H"$14'E)T4F;Q^XBT&,F`!+)`$+Y`$V!:+
M`.T/.\`>B-5VQ$L0*J((]++H*1$%P/`#O`$-\.$6+=$>9+#H,C'EN'?61_H+
MDD`,P%!N%_,+_3`''+`&,F`/P!`%'C`!'\#7X\`&?HX4.)H(:3!4:K`%=M%U
M1*!0+_X'J+0F:Z`=9:`&[1%S-Z$`;P+_"8/0!F#%6Y][4JD.%N9)!ZFB#Y_3
M!CT`$%GJ!\LU]X=:!EJ@%DTP`UV0`10`'040!B!``=^2`A7,`"<P!E9`N"O`
M!LDQ!RT`!QL`9C6Q!!7P:_3`);T&>%NP!&F0!!)`!&:P`UGP!$1P`><'!.E=
M2D^1!G`0G&5@8I=#!)\+T(U#)(EP$6J@Q%[`G3EQ`@\`#`?P`P^@TQ/``&$0
M`0D``2>@@!60!4D`<4H``3I0!!`0`S40!3G@`"G'`1`0!]6'"#@`"$]U;4]^
M;F9E<EEU?HU^:F>.DF!@?FUL=8QPEF%J42$<;&E^`!QM77^IJJNJ#@!9?F=S
M2`XW9&)G9YU6_T].;7-/<WXM2UR&46=F$6``16IF?FEU;`IJ:(TLD7YT=2%K
M=5YJ?F1K`'YAC'YLDCW0C6UU<^F%XW5T48Y8,0!-8GYU<EJ$\4-$#9LP;O;U
M<.*$0)-G<:KP0"(&BY<]K#)JW*CQR88*$3;R&=&(#)(S4="$Z5&!"X4F+U@@
ML:.QBI\D5?R)X6%%#I="`,*P<5/.C#F;9^+XX2*&40@N=.BT42,CC)@':.1X
MN2+FBI<D2'+X69/DC`6E<NBQF:-F@PP`;AI42<*CAP,S#=CD(!/FB!,Z7A@(
M(.%$3`X(%4X0J!+#"YTE+?SL@/+DC)HUF+3%\6"E:1T*6A[0Z($D#?\;"S(6
M<.0XH!$=+5U:0.@QX8P6(V"2Q#KE1T"5,XRX&//S1D<;+VV<^)D3`@RC+#&X
M+#E#1(`;+S5X8+G2H(8.&4087$"BH,,0!AA$*.!@PL2``5XH4"@4(IVCH*\+
M<6L49HLD1^+H`,XF`O@1!R0`I)$&'6>TL<8`&?"PFBH%^$&/$W,(((86`CP1
M10\J/0&``&"XP<`C@IDCR!QQF//?-MHT\H`C9P!PC1]EW.@'`V>T8-\VC0#S
M#AGIR-%&)9LT$D(D=<21QA-IB`-`19N8,P8:5Q3V@`YLF+$%$6?0`<`<1=R`
M01HH3*CF:@SH(($#&Y40F1]H(%$%!&_4$8;_#V[`Y@0`.N"A$1%^8%"&4CQ`
M8`4`+M9PQA<::)-&%"VHP4,+3TC0H5)^*`%`&TJ(&<P33\@!P*BG8F$A#VTT
ML8:)6C@9@8A85&!%#QEPP$4&`(SP@PP"A(!$"QDTT,,+0X51!!@1-8"$!&ET
MP0`(7-S@1PQ_LB%#'$C($60+8"3E&`,:2,#-"PZPX`4!,N2QYBH1Q!+)&T8`
ML(0(9PC`1ALQA/%$%4A(,M`LC;!10QO_=?%C(]XRTJ(?<+C!9!V15$9J+!;6
MX:*%IYZQQA-:N/;?-5=8Z`@=9+QH(3V?6I@&+XU@$,(3;KS``<I.8#2A#(X0
MPD8,9\"!!!%.A$?J_QO_R$$$'7$(0\!R@V"A1"(O&FG)QHV4,$8C;KS5B#D`
M_*@-&#:=@S0`;X2@`7V2R/.%)-R@?<6/F^P@2QNJGF!$&VZ`3?0%(+PK^"H&
MB.'%"!LQD4$C2U0Q95`,E"Q!#4^`,<9&%S0BA@R1K..&<DC$80;%7P!`QAD,
M7&R&&*<DL[(@T%34B`28\-+$$V9D[H<1(@)`.1@A`$"H)6U\6L&4._1`Q`16
M2!""#E;`$0.O<9#111-P6,$0$58,$(085G@!@Q](#'0J''?[(4$5$;`QAA=K
MT'%2"Q1@,$<5?TYPQ^!_"+&[%Y(P!\7\T`,-Q:$.N*"'))#F!S.@(0Z5\/\#
M,ZS@!RV@00V%8,$<%M4%-6S!`4[@PAG2I@`_1*`!)2C`$RAP!B\HH0,0TP(1
M3N"&-ZPA&4^`PX_"YH@NQ"@6P*!#(V*0!##T(`RG&D=3`(`%&2B!.D2(@04R
M$`$B\$%-%&R1`,P`!B\`0$QED(07.N"%$,QA$\WC%.,D884XK*$1=1`.&^)0
M"'$P90RM>\+'T/##1O319"I3V<<,$4$_>"$,2MF:%Y)4!U6-AP<7N%*XS!%&
M'LB`!/P;W!PL,`$!;.0`B^L!`+3P!#54T0(^T@$':G4YC3A@#5Q8@Q764`-&
M`&<.;J@"&`AUAC%4I1%J]$,5RL",&?6@577HP1K_MM`#7?BA"+!9@PP;888G
ML"$KPVA,++M0P2NPH00Q:((`0G,#+X#``R:8@`)^T((KC+,`$UA8&6+$B"8@
M[`UI`.```9"+.I0A!Q881YCB(`8TQ$`$,?A`)E5@LC0,QP]1"$,5KD`'!=+A
M!P&;`P/_X8AU.$(,;N"F(<PPHQF8HP<0(`,`0N"'#E@`#%&@0Q6>\`8&&D$+
M`W%`(^BAA35L0A`+PV`%S\""H$`,`**3@T330(8GT`$-'I4$&K+0A7_-`6T"
M4(,2Q'#%"<$"``/@YQL*X(`8_,80I.#`$,315(+0P1I?>]M]`"1".)0A#4W8
MC\;$\(0;I>$,"NSHG"3!_P.L!?*C?NC"0/R(L$:\00T(.P,99O07.;P!"=:,
M`P^ZP(,WF```F,SDNP`PA3XD03498<+3E-0".F!`B&D(`1&R\(`<`"`!&FD"
MCL[@#R0@P:!Q8(,!:@`',7`!@6XH`R'2X89TE$,`:`#`%PZ8"S?PZPEM(,09
M+F"3./1@#$JA0Q.X4`,&C`$.=#@C'+)@!3Y0@`%AN(`9OA"#8G2!"R'@BQ>V
M``<B2&"(1:B,%KSPA1K<*1<8DZP"F;&.OFH!#@-I@P800!<6<,$`"Q5F4P&`
M!(3MHPME$$,8>Y:&.(PA9'-PPBC^,TIWW,<,<R!$')+"@#H894J6.H.W)"$&
M-O^\X8OJ2-(VX&`&-G"#$/_A'#\!>]C#;H)!$(6#'-)@+@LHH`<!4--)XM"`
M!J0A#`W(A1J^6(<F$(%(#WS#&719!3%=%2`WTD*,IA0RB=')#=L(;).GX8BM
M&2@2:'""`KT@``:*@T8[?A$=8A`D+U#0$8-4`P<(301^F4$#HGT7#XA0`09T
ME14^:,!.P4`S'@`P"=9=B!``D.6,=-@-2PB#,&QD03]`*D%A>$/((%&'4<C!
M@DGJ`DC]<(7_"DTR%<&K,%EGF_AIS`D9,`,1GL#2X$F@"6.H`1.:8`4'H"$-
M5;G4$L10!0Y(0`P3`,,%>-`(&0@Q!%_`70^V@(L67<'_J2)N@S].Q2DM-`$,
M,RA$#<P0AA!L0`PUR"0*2"&!*XS2`4@+TY,*485-A.$+'=*8NUT$&@QEW!##
M28,"O"$&';BL9&IH2IB8U+,X6.$"5FA`7"A@"$&`0;%M"%J+:N1'.9!!3$E`
M@P)I)J(W"-D/(JZ@+8EC"2^0801?8$`;6KT:)`"`=BTX8F`;,"4!(`P-3?#B
M%2*"AFG/019KD(<79CR&7$CE"6%`L""`\T?TB:,.>F:Z)+#[0S?X`Y".L#I'
M):$&3IDA!`"D$5KF4@<E5.$+7L!TIM64`G]`8"-0F)$EX,"H!YRT"`KH0AL>
MP(8^:"1@?F!!#2HBAS*$X>82_XS$#\6!!0"0&@TC4&`+V-"#&C#56W'@O(7.
M4+)MJ$&(T?!#T82,(5GP_@1B"`$/(I#M#"1A!!>@@!Q,\``K"*`'2\@<`!H@
MHDK((0XOT!$:'J"%F84!#6_X#5^!\U<_>-X/-1B`$4B@@S$<@":#LW!^\`)A
MX`45\#!&\`!74$2GHA_\A$0Q0&W'L3(-\B-U(`.%,`<0<`%Y90E(@&=G4`!&
M<`;4@%:-@`7A<H)@D`9XQ@5\]")JX`1?L`-(YUB-L`:TY`AR(`>8$6,IXUCK
M@`7KL#58TFL.\@,%D`-ZH"8LX`AY1VR-D"1Q(`'S<5AUH`5HHP:V)`;F\`!N
M\`5*T/\(6E`%;H`%A>`&/"57P--DVU`@;*@RJ!>%8))S%5`"2G$%3V%(V^5=
M90`"9L``2=``DZ<FQ]$#7`"`K(`#-T`'-X0%9,`"3<`(?*,%5Z``"4`'!Z`1
MT.(%$B->.N8%GK<&/9`$86``8[();3<F21`VP>1#<)`&)&`.@&4.;\`#[-)`
M2E``S=$$E%0Q3_!]$$`'1.8%"T`&50$':M`%9-`=$9!]9,`%J'<%,R(&D2(&
M.E4C9D!//=`(`2,FXA`&-2`#<"`#(:,G,B`':D!,V=`"F3@X'M`(WP8!?N0(
M9;`&"F`&6M`#?6,&*\8(020+6,`;+_(I22`&8=`%#"12$!#_$=PT"@@#`&:@
M`V#`!B$`!RR5<G5@`%_#3Z1B8HTU8J1`>(_P'S8A"(/G!U:P#G7@!C)%!D[@
M"@.`!%;0CJMQ/&_D",+0!550`XP8`VD@-&\@`V;0`:^%9S)U5700&0HP`6VP
M!6?0`\*@.9(505U@<F'D=/\1(Q*0#D@S=!^)!D9@2#6@,AMC!7/V-3\B`95!
M;#RP!@4"4CI`!#4@B(.X&G/@`G_@!$R@$1ZPC8G%*`Z@!F`0!DV`!1T@`5@0
M/#2Y"A6`(\*##XZ0!#D`!W/4`UI@%--E#@ZP@*2P4>=0"#D$FH;#!D50!54@
MBFX0!BSP!6U06!5T#2WB!,!"0&,@_P$:0`1:D`1PT`(5D`%L4`9.<`-?0`14
M$`*X@`0`]`0MT`8_`5A/0`2?0@!K8`8*<!+I``845`:FHP1J$`(0<`8.P``6
MH`4R8`0A\`8>("CNV`@\$'V500:V-0X<@P42`#9=<&_O(`%*-@=HT`5N:`8\
M``UH@SYM$`>+Y0APX)>R1B,=,$\2@!P5T@:(D#ET<`,>$`)5P`+WI@V18%PA
MHX.2T)H1J`-S``U-Z`@P,"9N<`(RT`45>0%B(`=H@%JK\0/[A(XT>%]@(`#<
M4`=)4`9(T`5N``9DP`/T``9Q&:+I``=Z=D'_L05.Y6<W\$:+TPB0`$<A:0;Q
MYR)&NC$AX/]GCI"-;)A=CK`$$.,M:*`QNB4O)W!Y=<D1LZ`N6)`$GY8**?"A
M?7("FQ8#.:!3+8`!Q#('-+H*/T`G1&`$=0$02^`$22`B=?!88R<O6W!5/%0$
M(.D&%P`'514%8,,+7I`!TT!J6'HJY3`'44``7)@%3*-25B`%'("'=;`%.@`'
M'0`#%G`"64`&1,`K0?HT:Z`!8J`<"R$&R!<&#Z!B9X!G:^`%Z>"7`)&@@I`]
M;4`&[N,'!9!)*2`)(:`%'"`&36"F/28'70!DKO$%<[`OZH!G>C0'7^``R!>5
M5S(?Q(=\PO0U!F(,9B"#N$,$;L`&9NDB/UD51&"0:E!#I&!+8)/_!EO#,P#@
M+5T9!TZPIH%7([1(!SQX?!%!!&\``4K0`TLX(4_S!FV0!01@%9R(1Y$`!UZT
M*"Q`!''06,B'5%A0!]C4"(32!4I3!_AI!A*0%`=$,0#`5OYB"!_J",&4%OP4
M2*;"AL#Q'Q=3"&#2,0:"9(ED`&[ZIAIQ`44@`=E7`RG`"E(@9#V0`V7W!GTR
MK2]@`=`YJ*J@>3P`!PR@ED_`!54`#T@C!Q$(#'CF!=@5!_[1!IZ)LTDQKGZ@
M`S]&!S[T;]T"`(4EJB:18CV+#V=@!6#``Q\@`TY0`0@I`3J``"R0C%?P`ST`
M!P3E!>Q6!TCP!D5@(4KE"#J`AOAY#EW0_SQ3(@D.H$)(T`0Y``8LD`,VP;9K
MDJV&$`=QP`!-=0/B(`<=I@`ZX").$`):^D<A>0DL)@=5\&/DY@@/H$!KD#)B
M@C8Q4`8BHD870QP45WC"H)V/H'D<]4=G)P!AI&L`4@51>8-*`0=@X`1K$`5<
MP`,?NQI-"`!;,R9>T`0](`/VD"`RD!P$Q058H`U-<8*FF08;U4S\E`9;$#9U
MH`;GAU[\1@]&IS&6T&1T@&?PIS)BX+U!TUBN00=<N'?:@(%^0`$\P`.4PT1F
MD`6%5@$_\`)8NQ$A,`$^X`-UJ@H)H"H&4@5IH`.X$P9(4'@"@`*$8@,:44)D
M$`-7]1<0N0;^$/\):K`"!_$$&%A8QG`-"&8(25L'564A;E`!,)`$O.(?43``
M3K"<BQ)'J\@%\5*X;2`#8[`%*-`&-7`"4=`$<[`&\?7$,?J3:+`%+<`#=-26
MP,!`$BI,0#$B3\!-&+0%2O$%2(0&/_%%9=!?[1<''P`$_".\32`#7G!S9'`#
M9@`8=RL\D3`\A_4&_(J!W,`%ARP)+2`,:O:"MT-`8U((5U@(;&"2RE<#O8?(
M^Q8<_K$-B4?"3N`%D>`&6\,(3\"W#',%77`]5["F:4`!'(!;$U)"=!!6CY`$
M;1`%,N`XBV$$YD)Z6I`&-@%A*V5=Y),)]G$&&0R9<`%`1O!^<>@($1#_`@+`
M0T'R-7\GP(;TA#UC6.=PH#?(>0/4L[Q(!DN`C/L0CCP`(3[\PQE!!'+@!ER`
MEQEA`UM#*@J`!O49`Q6P>GY0`040752W"C0H1(WZ8U_J""L0,6CP8`;BL(W0
MF"+;"!<0?%#B(W/0!2PP?\5S`C/;M,!T!ERP6$)D!E>0`FI`!#K0`2@`![N"
M!@H``TO0#5!``!DPJT_``QJ0!6&"!E90`EG`,ECC'"GKA#GD15J0C&%``E[0
M`@K0`EWP`#SP`YGT`;'0G1SPH;(7#7&P`TMP?R^BS"9S!L%#O,1K(8*W#>9`
M`.CE!5Z@`$VR!B'08#+0`B0H!N60`Y$P):<K_S:%&S+IU0A0P34O.&8XPB!S
M4`;QQP;)Z(2<<@5&,`#9)5TF<-,;H5NA\@",QK<!2@K\Q'E.``>G8`6$P`6;
M$`4Q4!KR0`#1C'0/NQPMLE%([-!ZA&<&Z0B,8`9^IS((\W=M@#*C\!HO<@)F
MP,+#%PTT>`8YP`:`108&[-_G2C$O4`$BG1%YX`)'L)<:\0&;`(I/8`71\1\O
MH`-D``>+V0HK!2WGP%=FR*/\U`.F>`.5'`9.0`/5E`XVD<$YX-MH<!WPD`1.
M4,]CD0;",`=JV0(.`#Y-<`9+``N*Y3@`(`-'(`!C\`$S]I0AP`!'@`**A0$G
M$`=>(`$U+5,EPI$-,O].8HPP!"!$/Y$&28`!*@8`;Q0'Y]<&5U`$R5`!IN`!
MB;T<20`8(4`'&]L".T`SA_;:1F"F?K!Q;\`%>,9--./"CC"&/9`.-_4;\Q"@
M4"4B'+,?!#%F"_,B=)3)HQ.5]"0DA*<45&X(MEQ!SD%*\*.`+`!M:K(`7X#9
MR^$@*?J*N+F"98,CA\:<5"LC,4(&]T0<M@P7UG1H_Q#+C54!V09$C.:REE$\
M0:(-#_4BD8`WZT!*DH!G`M`"7U"&<]X"A<847P$`/0`#1A(&")[@?^`!28``
M`E`T2;#AJ?`!&_4`5T@*<X`%$*82:J`%J)P1\B@'%H!X;\`!?L"#.:`%E5#_
M!HLF#54B/;\F#/;@,GGR-7SQ!B#5!FW4IV@N`SN`F\+#8<6&#F*`60&O!5>6
MPOBS;F2`H;FC`Q%P!6>0!6WP&P!0?-A%@`XG"*8RW4XP!@)``$-S!5Q`K5Q`
M`\N:=AX0SF(``2(@6D=`$%W`I+<2/#CU!E\`!TO@!E>@4N7P#]R$A4@F1`UR
M5:PM`WT3(V_`K/\A!G14N,=5(AYD#FT@!UBP6"W2`R7Y!&6`AW/06FO`34R*
M=/1`K.H-!YO0`SR0,OQZ`3JP8ES#`%]0!`=I2`^P!/NS&GRP!'1P`;=P!3_9
M!!#PS=M%!@(@`&;(!>OPH!HU3ZOX#[T>-E<P!VUW_SJ.X`6P+`DVT:ZDXD-+
M@8X<]0(*TU&+9<MB$@N%0`EN4'__@'Q8(A5O<%59L/QDJ@;B7J4560H<0.Y_
M<`0PH`$KP`$1P``HS0JJSHV%U@9C"`.?.P:"3>\^H!'RV`8GH`1X%@./)08*
M(`?)M#9A4#QH6`@_!@A6855N9'YN+0!U:WYU9G,,<TUC:W5S7D]@9P!O3WY>
M<V1U=5I>=6(`?GY$#AXT%P-*7@\7+$97`&86.DDF+">J%3)R:V1>26MO='X`
M=!1>?F%F5IY^:4LU6FYK8FLR<1)A*&\2)RE_Z.GJZ^E\<V%TFUYB&V_,-6MG
M,6)I1#QM6**-\..DC1M5"O_\/*D0YHT3-FG`/!%S9LR<,VGDJ#E31Q6:@W3F
M/.D29@T2,Y[.K`G3(PP:,4_26/'#Y8F:=P`.N@$0A\L<+1U5`9!SPX^8,%X`
M,&!!X8N6.41ZD`%034L;+P)TH*$CIT0)/NS8M?#3)@Z<,FVJB`20)(V9,D3F
MP&G3!D`3A0H;R/$#QD^+:JK`@`$`((T?*W%4-0*LV$^7&(S/*&X&I[&JH(WG
MI`(PYQ"/+E44JP$#APX9+:6\@.EXA@B7-&>6ODE#9A,=.#T*A-W-F_<>""V<
M)-B=1)4.+87#1$%BP4&3)FX<M/$1%H*?&20=6!'C1P*7-SD.C2'3QL^9UCT4
M`CC_HT-.&CJHKHBH;-0"AQZ$NSP`$&8+F`IO3)*&&@!XP<9.?IQ`1#2$&3%`
M(S5X88(.;X3`0!5<!*%!%CS\``8;,:@"@01:^(&%&3FAD0HSCRCB1PPMN-$%
M'+B<`0=N;33@AA89T""!#A$<T=MN=KP!0#8-&*%`-5UD888?:H11Q&I^C-'&
M&/8\(,8R55X61F-NQ)&&`PJ<$4<,=4@4T"AQU/&%'&>8<=`3DIU1A!@MB"$&
M'&#00=438_SU1!R2*2:&9@'Y,8<97*JR#%5B[*7#D^4U4N=42%2Q!A9UN"'$
MD.@H4`<;:@@B0!AU`+"&`^?UT,1@#9151VB6J1(%,X7Z_YD*?6`FUM@R.G+C
M!QJ,U9&&)SQ\P5>5*_(P&7>U-L:9*G.0\(859URABAADQ%#&"6(8T0,<9_`0
M0APCT`#JNNSX4$$&8U01`&_%^4$&&T;5$`(8:'#16@MA`(!#6!@T0X`6T!J5
M0QF2U9&$!!VI@9R]+*A1AA_X^K%&&@%W%$8;GC!PQ1->($<&&OOP]&(-9X2@
M(IQQ5/$&#P!<D40%8US0Q@4,H$&#$F&H(4,!(52!$@<[U*"*LK9=#(`2<2A!
ME0)N0/"&&&C80Y8;$6P!P!).^*%#"'`$(4$3(3B@&[OI3%&'`JE4\X8%$F"<
M2A:6F3&7QFZ\D1@=4:21V!KK^?]Q:QMGV$.N'^GY@<1/A&D0@A\A[-J`&H83
MD!-5;'Q1APYE>+'!)F[LQ$9EFC7&PRBT@L&"THJ5N*)1`#RPP1/[]5!&!D<H
M$`8"0:RK`QP"2!"A'P*0$8(79WC2`QU6?%"%&LNT<9%B/0RHBAR>L.;)DY:U
MP(@?$!3!!D9/I,K=>8#5X41G9\SA1J&*89:XH[:-4K^]DL6QX!.=\4,2NN`$
M$YR@!VU`@RK.T`8!1(`!;&/;!`*"!`\4H3<A6H@9ZL"#]'RH(56`@&0&)A8L
MQ,$,+;C5$]H@AC9$H`N.4V`/M&"&$%Q`#CQ(1KA$HHH0G`%S?OC"$R10ER>8
M08%"H1W_`QJABC@8P0Q:L$T;X!"V-12@!VQHPAJJX(`*(&$#7*`+$<)0`0!R
M``N;:,$;M.`L/[P!#FZH`2[>0(0;J:)2?A!7%3BA!,S!`0(0(`(&Z-``'4`P
M@G^8`E^>X`8T9*`1A%&,$SPQ.S^800U(:`)@%("%.7!I/59P0(C`,+EP53(@
MZ9.#G_"F$%\]`3\.V(MBTF`/R7AA#6Q``F9D"24V9.R.CJJD*E#4F2(,J`T6
M0`(+.+$%,]S`!>LRPK9*!*4JG.$N)R"&$UJ`!AD@KDK(Z4(JUN`%.I@!)I+!
M@"K80!H9'$(Q5V`##-GP!D;@\6)D25@5,F48<MXQ#F$(FRJ>_S`3.J2%"#68
M0Q><)8<O.,$P2Z@"![R`AN:I8@1-```,`&``"0`F#FT@@P(0N:X#6(``8N""
M%8:SFQ#5X0G-D``#`$"!-ICA"%>H`L-(N([PK((.#W!#%&*PDSH0@3!KV,F@
MW/`$F/JJ$D!\@QIXJ1#"T<F6;"!"XFZ0P#?0L0+DG$82JN&`*%A!`2=X`A+"
M\(48G&`-#6A"&]ZPSS$D00%(B($7Y$"`0>V%#!JP0AJ\8`8G$/$-<YAK"':0
MQQ;T(`XM:$,8K.`$&(1!!S$@`@K(9@"20D$5@B`##$CY!`HLR`\7,`P:P'>9
M)]BC&F<(PTX.<C$VT"$A1I'6]Q*#A?_-E$$,08$&'*CRB2Z4`89^H`,87HM`
M-*1A#F1;0]U488AMU8J10O$$&3Q)`6NL@041F(@7Q@"'.,1A`V#IS1W"\X0:
MD,$P/;""52H7!P"H`1HA.,@2NC"1^6W7/&9@7AOHT"9FT*$.8QAHG>#`WZ,F
MMVZ)R14U%**&L5*K4H-A8K2&TIB7HD(R88"#)[\41#@LL0YH"`$1*+`%Y""'
M#3`@`$G9A0<<)&&RYPC+Y%3Q"S(D057%P\`-8N``.C`A+`WPPQ9FR!TVS(03
M;:BP5QO1A,XDH9RU2L-+Z>`)-L`4#&EPPQ?>((#T=:$)5:B`)=EPE2+$@0QO
MX`(:RM.#-3C_(00F>,WSJM`#(D@7`#'P,0&0```6:$$JEO2#ME!\+$<M"B@`
M:$$?J:`H+I0!!BP0``#`\)C!ZB`,/"#B`#RKB@@((`T`(,-&Y$`8UV[A"41`
M0B/)8H0JA,&\032#9`SZA<3(X7S4M0RQ-!W$+;B!B"7QA!O4H`;8?`()5VHB
M&GB`*G$VHE,IX4L`Z;30@0;L`A^#Y!N^5`=<^.0)+:@"'22@A#A!%@I#"@#>
MVM"$,M0`"UBH@ACBX`0S."LH1I5#9=(`ARHT-<#VX,&C"D1<#8-A(XS4@14R
M-A(H)>Y[)J@31.C71&%RCYINY$(2JT`?)P"@+LG5@B>>H@4T$.$)_Y#Q0A,Z
M$89,ED'&,^Z-!@Q@AS\<P`4<$)*.5:$&.#\RN0J(`@',@`$DO`'>[$AR`HT`
M@,H<!`ZHYG0<V`"`[V".#7,(D658.8;XQ2#,,=C/&J`+ARAV@1ADH4,55B,!
M`3`#2@!:^Q4XH`0.B*$`,-"!#!3`@P@XH`$<"($3JH"`*C1@"UN0P69"0`![
MS"$T82I`6^G0R"UT!B8!JY<?XG`!9E3``U600P=("@1/4.`*CR10H4]0`V(9
M@0MAR`(I5"Z&)@1L6PBL'[1`1JV3,\,+.>A6$=P(`#%,_`Q8:)QD"NZ7N38U
M;@"X`$B'JXHP&.8R'>F"%^S1D29HV2;V`O\`#VR"(D7Y210`O!H*5<V"40\I
M!)9(7#.TP."Z[8@NF@$'4?`"MP(`#E4`A6$&AJ$,C=%G/<!`C0%%"Y@PBN$U
M#4,_6A.!`10MT4($:&`6"E%V9&$>5%$'!*`0C]$(_+4%`V=K;[`%.=<;31`'
M#V`!>M!SO-%&;Z`!Y/$`HR<!8Z`&!C`"2]`#4Q`6&J`>:E`%`J`%IH4JG9(*
M&8,@"_0&H_`$6E`#\S,LBJ8)=``!),9$Y:(%5A`%=!`#<:`%2R`V0Z%RU@``
MV@`',I!"+.`%7.`$.1`&74`$1'`46:`%:I`%]Z(9$K`&=Q$"6:`9=.!LR<4#
M9Z`$A]8&7```RY?_%EKP,$CP!%G#'V&@!`+P`#/&""$F!!@@<*E@(\-G4$:!
M1T)1'B-3:.M'.6(`<BP813;B.!)0&9M`.7Y@`3UP$"&`"\R@!6O@"2,3!P&Q
M!6EA(LC52'#0`B.S0`K!)9W!2ZYT%Z=SBFG@40*D!*^T!A>0!.M2.05Q!6[@
M!$W0`FJ0<#6P!$1``W%$:&109#;1`$^0#+Y&%=)T".95";52.$+A2751*-4`
M!@>A6ZI`*TTU&0+%@0,E>GX`(&'D3E4B6V^@.:Y5'F20`15@!3'8&T=0`U5W
M!'JP&QZ`.:GR!&Q@`5,0`R$@`%P``4@@!A"@!GV`9/7E!!6`)QS@&"3A_P8A
MT!G)<S%JH#_32`2=0`<AIHE9H"=54`-PH`-?X``[=@6HP04^$0-,"`#ZY@98
MX"\L]`9@@!QND`9F:082$0)TP`5P1@0W4`5L$`;RTP:)&`<R-RQNT)1NP`*5
M`6LW8@5<H`G6H`9/L"]D(`9*@`4.``8_X`!K$`-1(`/J@DA`(!)<(`-N(`-K
M^%**L08G`#^6%`:K@7+<1RXQ<3YQ,&VK@`58B(6W`C^WLF0W0">*(@$!$6>J
M\`;5A26IX`1K8`:,$!>*,7"O95YG0`=LUAD@4R)GP%2$809W(5T+!`=K9$16
M``!]:`1$`"I]L"``H#D84@=D4`5>0`9E0`9NH/\_<^$%5Q`#5T`$;%`$DB$'
M84`>`U4_H^(&,6`$WW=RAH$2;D`$F-`87Q(TM*(88`=3BG$>UT55DY&;LV,&
M7>`YDM%\2E`#+$!A6A`XI$`$+/"1O<$'.-``/+`$+W"3ZY"$S!`&-O%C$]$#
MNI-[6%`&NR$!S2`T<D`(R$$5RY,^=HE$,/52`T8&68`&GN=E75`YI<`&YA4&
M;!`0<7`"%2!'#5`#L:85$'!C5/&"`%`&KY0$(K`%&<`#!!`#/'`!2(`$*&"D
M$E`$)Y`4;-">Y(&FJI`%Q?@&.J!);3`3=5!$Z]$%6B``+^`$&%!:#``P$*`%
M#>`$1@`''D!24L`,N#3_&&5!GY.1%(KB!UD``17P$T92`4`$$0CE1G/%'="`
M!(8(&`52)5C(1MC9`IV1EX<A`#N&!9+E![\%!MR1!FL`1(R@!5IC"2J'!F.P
M(G4`#4_06XCE.(T09TW%"'"P0F,@5S+``1P`*CY@&)<@!Z8P!USW!@$:`E[F
M!UCG`.+$!B'`'=JB$'5`(`L$#8<`)Y)U$4/A-ZKP.->%1!P!3S[85&\0"5S0
M7='2/!7"*YDZ&4T@!S)P'J.P"6002)3$`$+$2&1P`SL`HNJ5`!\0`3=P`.QP
M=#\DES+P!'3``U&P"4?"`UH0%GF0$&@0!"U01GGH=.:Q`A^S!1[002A9%U:P
M_T%<D`4PM`$*<1ZIX`86P`)/4!-DH",5F@1(X$.$@06W\006`&I:P%]I$`,U
MD!:)T:X,U*>6<DW$E00QDP8R($2C$D5#H6PZX"CXAP7]$BGEQ51R\`9F,`98
ML`9:,`%3(`-"%T$XD#B=HP%5@`9RQ09+H`/BQ`6)D3Y9$">IX">F&EN-4&9<
MB0:92!A`E`T8XP>,%0W,T&YH4`<<!P9(V3'FH0INP&6.,I8MX"N*@0;<4S.8
M\8\YL8&-`0TSY0:A%`)DP`78BFH:\)Z=B"*I8@8Y0!5:``;.DDE^(`=-8`AX
M]`;[F%P1T!AG(`91D!A(6;O+P)D<T771<@ER06B4\/\%UL1QEM$0F:$(S3,'
M^=`:_:(%%>"A7;!\FV"W3L`!:,`C-X"QO%$#:=`&/;`;$=`1+6``)%``:#-8
MJK`#9+`&72`!+-M=FR`&XH0*:A!&95",BM$&5\`\;)&>72`#9*`MNO8);J`5
M7M8)!!"]8[(%=.4[&G`,4Y4#S&L&C-)$"H&&]I(8E7,&4;!C:1`").,$3S$6
M?J!N:*`C%1`!2]`$:F8OW:5NQ(@)3;`$;_`#6V0&$A`#1D(H;&`&+$$%).4#
M?2J(:8`!6D`&/-!V25`>-R``J:)06-=4941T)*NZG(`$:(!<;=L(<[`7?2DB
MS_M]=)`$;%`4,K!C5E`!/)#_>E`R.]"%.:C2&<G:=I@1!SJ0!N(TP,GE!X:F
MR$F$JQ1P$&B@'(Z(!A+0`L&;50!@!58@G,UY+&<P9L6J"EZ@!'XB%./3!"?0
M/$H@-K?1&$<E`5Y0!0(KC0T5#5@``HK!!5U0*(3S4C+P7`O*&)91NXIA!M;1
M&%Q`F!-Q0%4@)IO&`6W0IVR`!C7POP`<%FE0`8"W&S@`1#7)"`X`#A>@`PTP
M6!8`O&%A=T^0`EL@!W<HB1(P0'*`!7+@0R^%!I.4!F(`#<P#%:E``!30!2S@
M&ME;@FT``ABP!E8`!\QS!E5P@B<0-JG"#?5$`73@>85B!*2["DT``0Z0"CI0
M!;D\_P=BL`/VL!Z%0;+8(@9ND`3'Z;EQL+J?`#(`@)DR9042(`&F^P0\``8=
M9<:4"<XBIP-$(`!TL`9<,%PIA@24<P70@0%]L2)/<();`C<H`5/513F80Q'[
MZEPJ0H%T(`,O$`[04,YP0`9K2%"3<6B.@R="807+MY,P!``98`7P*MA<QA/B
MYPE>@Q+1(`?5U0(S4,!#X@(O@;PL0`<4!:OV$`./0*[KEP1H,`<LT$:CHB@,
MA`:YQ`QA\H^.0H&6<0:E=QE0LC5!,0=QX`EJ4!E7L\V!@;UTPJ)OH$#4`R7C
MR4BTY`70<(?F41`=0``4_,[L@`8>D`#IQ0XN<$D*80^2-_\7T;H"2X`!&;"R
M82$#=2`'LH9J%;`)B8,25B$)J%%FJ$6&?0$'.GP&F<@#<3"R46M5R$@&)^0$
M#N`%R[0)J+(O6=0`%;`$384&+9`$K\4G1F(N8E`Y0,L%2,#)2$`'S%8#RP4H
M-(`Y6ZL$<U`&3N`$P3V>XJFW?M&>7L`#6T`[(R"H,?`!).4"[(I:.U!?72<&
M/.`&3X(42LE``-!;'5$%Y1%%JD`$=7!>VE`&"G0&<A`'`O`&7M`",L`=3P`'
M+_!#0N$%6.`$=#!NCT<'+]"EK&1)7GH^"K0>!+F%,;%VDHJ@]$$N#;$,5X`&
M!#(8&3`/;1`"`Q`#30`JGIT^14?_TD1@%G;'R631`A)0VXKBQUZJ&(_[!F4`
M`$C0#PH!Y;K\!EU@&(D#&RIA'FO7<`JADI8Q&[66"U.E/-6@&K]G&0G4#P#`
M!L#%=5]7!2T``OHFM3!%$@I0`\ET!=FMW>I`!EMP!3RP&Q,@$D^@!&7Q!=AY
M`^.Y!F#P``I`!KM!`VN`!FM0-"'0`]-VM@WP`Z``)2A!!\O0.1AA7^41`E%`
M%=).!WVX(.*D+042`SM0=FG06\T9`GZC!.E97]\G!V!076:@`U6G`!E\!F!0
MMUY&!E^`!30#`"$PS$?A6N'5/"<'``X`;5K@#S)0-TN@!AEP`0*@-$<1`6P@
M`@+@XX@$_^0WT`/C)@8Q@!\RX))>!0#BI`7*4AEPY!%*DR9Q4)3J5U[7^6HC
MT08M\`57@&(2H1GY,`;XLEIQ()(]P/%B0`%R]070$EL[$89<QUJ;$09$C3<Y
M<7U7D@D7@T\*P68JIP4$\`6)L.,"(`.,3L8RH`9HP&D0\#Q6T`8BS0QC4.74
MD@4UT`4'J09M8-H&QPR]Y2@SH0:,L)!GP`95P)]CT06/EQA]D7Y(A*#F<9#F
MD?JJL`4<1R!QTA%DP`!PP`6?`0`%L04A8-!1\@4,0`<;RJNZDP48`/C.K@YX
M\@$>&Q9`@$2&:!J#L`%-T``8H`8],`)AL!LU\&%JP`.9WZMNP/]@Y0$:W_<D
MUP#CT_*\CB`_(5`!?#)0I04`/4`!@_`\;O``O)H6]`X(<&0U`&=/?DAT?HM:
M8EYT!$1S9T:':6=?<UQO:WY/<@Q^.F%U<6=^5QE$:#%M`#TZIT]K73V><%]>
M3U441T0_25)_P\3%QL0VBP)$8EM^9V=A3EA$?G002&)^37XL9A*+?FZG85IU
M`'YUX6=H<UXZ3P`.#4E<=`!7.DYA$CMM<ES.>"D0@DT8`&V>U+EBYE`=.IT6
MG5H49A&8=0?K="E#QPT:3PR\S-'F!\"<-^@6U7&C\)"$(4@$'#MFHXP?-5>(
MA%!C;8X9-DC\D-%RPT^(<-4\=4'5@T/_D7!^JD"-\R3-(:A^WE"5<Z84FCA^
MN"PRR:@D'$7A"CU#=V61F93ATBQ2`W?E*3I1XJ0A@X;.KD)HFG@)BT9+%`DS
M$RM6?")$DPN):_JQ,J-"A3A-!,29%H=#!"=L$CL`$"+-'#]R&4B(0R=-@216
MD,!)I\X/`44GVF`]4X:,@`M009\Z$\1,ER9H'H`!4*6%PSHRLFXP9.W*&0!6
MTLEXHV1VFSAJ#JT1,X?-8#\GL@,`*Z>!2C8OQF9O,`:+'"]DV!2AT.2)`AD7
M;,!%#2"`D<)BB2W@1Q)LP(&#'UZ(4$$4GP#PA&YT8`$`.&N\P<9$;XP@@P[/
MT!%#.&UAE19<_^D@=!HT6ER!7QM16$&`-F<X\`54']6113ACM.9&6H9<A$X=
M;X2S8UI+S#$"&4O,@D0-<6AQA@Q%;"$#@G\L0,8S=7C1@QI6L*&&%A9:\5`&
M]SC#B```R'$B6-NE(8::T8U%1D70>'((#V;X$4<7NM413S@QS."'%B>Z84)0
MGHA!1$5BB*&;6HL\84H;=-!1QQQ?@N5'&+J]X40,\9`JD#H`T+"($3R\\84'
M7-::6`))O#%#9#:%50<<)*`AQQM89#`0%Q)PD5@&:ZR!0!MI).$'&`*=P$87
MZX6`A0QSI%0'%W/,P8-*7L@AIQ\ML+B@!(,1H,X<%9AY2!=82-"&(?^!>J$%
M'4L]\808:"3I!PUNV$)`%.0IH(08!9Q7!P\RK&&&&<K%@09PZ#:@FPQC/''&
M'!E8<<473C#C!Q9TG''!%45,D,2!MA*CX+8//?$%55W,@4$5(=!!`Q9EZ(+&
M$PY0\(8`BM1Q'0$U3#Q8&T?Y8<9WST!CJ+]/T$%&/`#<XY=)<5"EAGML?.1'
MMZ?=`X86BR1QVA,H9=%%.6`A@<X3V;$!SB)M.(-&"Q?T@(2XS_C!AA)&<`$!
M#USRD848#ACQ`!MF:`,`'%RX@0$#-=`QPPUSQ+$&&TXD<8,"2L<0!P!OR.$&
M0BE[_.\69NQPPAQKH'%0#!6%$T</O5=-6QW_;*@8CA%\KZ%(/1*-X888]WQ)
M!@"!+A(V`!;H)N8+'G<!QAQA/$#&&%[(%//Y?R3Q1`L?)!;$:;Z+H04:.7``
M!Q@T/-"`&8EQX$<;;*!#%=!$JB;$(0QD2(,6J-*"))$!#FY@P!:D8H4XD.X-
MAG)>%-R0AC>D80UQ((*T+N*''LBA!P)X`1E"T``M-($',6@!':[0@C94XR2+
M",%2T``':K!A#5=@`QA6YP7=L$`-.Y#`$YP0A2W<*W>>B('=P-"K15BA`F]`
MPO>T\(8)I$$&5WA"&#B@!%JA[P`E*8\?B,"%'XB##6P`0`;`$(:`!<0,9XA#
M'=J00'0X`(-MP$)7__SPA9Y)(0DZ\,`:&&"$+?0@!Q"@0`0&8``&<*`!.OR!
M`68@`$OR0`P#"`<:L/-`/PA`:>FH@B`RE1!#N<EP8A"`-LR0)#.\8`V00L(3
MJIA&-6R@!2P(`1&XE(`NQ($+<5B"%QQ`12Q,D`X2"($"6+`&.1@A#%XXBABB
M@$`P$,`)5Y#*&23P`"M400FE]`0`2.*',@"`#&TPE/6LL(4ZF"$+P3-<CP[A
M!#_(81%H"4<<2:B2-[Q%!P!8"4\6T9\S!"0L6:B"&`@`J"NX04UK>$$(T'>^
M'$@@@HD)@!C.D(86J,$)75`#&%8`AAAX@`(PZ((;$K,!U*QA%%'8SMK<`/\!
MT@C0"F8(P1SNA84'M"`-%D/#8,0`!S@4I`?WB,,H`,`#"^!M2%50@P,"68<Q
M),$!2+`"$=@PAA!(10Q2"0<9YC"&)(FA`GS[0J#"4(,U:$$!8G@#&`3FCAP6
M@FTQ>$,(9B$.O%FAK4%:P@F6@`4O8$$#BS/C^=`8ACFPC0A60`=+DC0'!N@F
MCQ)!1[B@E08X5"%E/;@?&NJP!@``APL&((,$8F""C10A!ER`@QBN(`,V-"$$
M;]B"`KP``"[L"`)9\\,.R*!%_#QAK5$X@P[@X(796`,+)<E.2<C`CGS6@4'/
M%0,ISB,U,<1A847DP3`1=("1RD!K3>!"&>+`*0#_@$$&\I.+&^@+Q#G(X`D4
M\(,12-"%HZCC##Q`QVS8L!(`C$$B$'Z&;@0IAA"<H0IQ<&<X_OF,?PJL)5@)
M:#KDT-@YN,$)94""TL1`AB&51`-\@X8;N*`%$F1*#54()D=C%@8C6"`!(1UI
M&BP:-CH(@(X.\,(+3&`O/,Q$!&%!1Q@N48889,%3XCB#$^8P&R+D("N7>L(<
MV%B2!)^C"F?(ZP,,(8$`-H&I%A#`$^#P!CK(`6YJ<(8VKH`!M/RS#G=V@AKR
M5`>>.+0:`$@#'0H@BB[0@`-/R((9.O$$-E!@(C[ZWR)Z((^NY$@&64B!#`@A
M`@\X0`DHX&@`_%"$$Z"!_P"NM<*)&$%<,]"!`0XHB4),00<OA"$]5U!$&,10
M!C@.B0,9J`$8D("$+[`!`BV@HJ"TT`(%Q*$$2WA`&A[`!2XTP!8%8(Y01.4O
M/\B`4%!ACH6QJY(+82`=D!I+$\8I@YZAIM#*11,7PG#3"B"!2R*UE&F7X`<E
M7$$+1Y%!9JDG%(3TP`E;D`,`B$"=<)"DABK90!G"<!4_0$]31.(>$6:A&^.%
MXR'6.X.(591K,Z@C"W%X0Q.^\`0)R($$\6B#6-+1!MT]!+B\B0$-RK"$'=L*
M4&)H0$CY1`3[&H$`8`!#!.`9@@#PH0?".$:XR4TO'7``32S`!P7`D00RG``=
M<?]PE42T\'64.&$,]V+4&>!P&CFTH0F@7H/'TC```5B@&C`0V")DT*A%P1L,
MY[E!&]X`AX0J)!ULV`$`E&!%"=P``%FH1AL:\#$_#"TE`%#`&D3P@&U@00<U
M2((9*C``#%!`!^Q*-?I631L(B$$"%O)#Z<-@@?^50>]GX-T<@M`B[E:&)1X_
M2@CK,(`'8`$,++@`"4+``BXT80!UZ$$2D+"$"\3!"FL@0P1J`(<6E$0*4'G"
MN*#B!AT$:B*&.,<Z'OR,?T%%_CRX",;:H("2"D4.5]`&8<`#_X8@>1`"96`3
M;U``NI-`+Z`;$H`!4]`"1-`%5]$&<W`H`%`1:D!YX6#_7834!C9F?^R'#J2A
M7$Y`!ED@`><P9V+P!&I@-BI!(:-T<D*D(A4@%VZS"(/A!$JC?EP1%5J@=P``
M`!%S'1$!!VH0!D5G=`CB`R$P`"?P!4OW!&[``1Y0$`!``!I`!"^!!!R``Q&@
M!S-!`V)``2K``6!`9P,P/V'A!]0E!EP@!DCU!F?@!EIP(956$C,7)_+7!FT!
M`.HS#MDA<4\0`ED``65`<V4C!B1"%VM@!`IP-L_0.[U2`3@B`VQC"M`@%_%0
M/(BR)%;(!5CP!##``4B@`Q$`!N<`.$2`,"8P<69"!CW``%+`!;)W/K17!AWC
M!SE0`\7C026A`$48)P5@!GMU_PH`@`7T!0!N`#Y<$`4DP@,)-@%$P`!D4`5N
M0`9DX`7BA6%A\`910`',^()Q%`9JD`&>L`QP&!=JH!/IL%*C<B2[=G(<=ATC
MI2XR8`9P4'+QX&NC8@)N8``"4`!9T#ALHP"Z-0<R)1'JP`9NX!%?<`9=@`:A
MT`5K$`8B)!9G`(H\>#6'@!VZ@`YF8!-@T`9=``=YM(4-@#1U0`2ZT0,D]",I
M]02!%0-J4`=R,1(R"!4?4D7<11IJ8(=J,93F\6!K0``W(#!5T`8"``$]X(0(
M@@)@H`)"(`:W$@9!X05QP`(/0`"9!0=C4@A$``8N,!/`,09L@`%GD`4%009O
MP!,]$/\%=/`%/=`#0[*-O>8&XL1'$"`0GJ`#6$8&WP4':5`\7<`#&\`@GL>,
M)S%`%V$=:@`_"G$&6L`VWG0V:#4;N&=0+(`$33!61%`%2%`%<U`%6X![(9`$
M9S`&;:0IT$`^8>`&WR%&[V0.8T`!T+(%!#`'0,!1"2`U@^0G(B$8^%($D^8'
M@44$6N,'1?,`0Q@#XM4%=0!78Q`#`#``;>`$;2`&6*"-R+(#,G`"OT4$2U`&
M$,```N`%$.`'7?!E=3`!9Q`")%(2(3`&9>`ZTX(&W+ARX1`%B\`#XT-<>(.!
MSX`&],0J#,`V6U!S-'`&2]`#$6`%Q%1'IZ4(J[,&=!$-/*#_`-BX`_Q(BU)C
M7WKW+VKP!7)0"GY0`!?R0TBPDG%0%`81#G3A<:V`#MP`%7010R51!W5@)6!1
M!S]0DNH2#G,@8EH`&G0I#JVS!A"@,$W0!E9`!W"0$WY``6K0!F7P!%$IE8EA
M!WB@!&(*`;>BEFG@!@+PG2U0!5B@!#)P!DF``3S0`C@P$R.@$EH@!WL%`5P`
M!B4I`Q@2![-U!JYC7RT0'W.@`.'H!H.A!FH@)JC$-Q71`UG0`P30!CS0`QH"
M%H7Q`/N5*0^1!DX0!^VQ7QSP!G5U$O&0@8_P3IP&!XCD/1)`!#?@!5Q0C%QV
M3&?`?TNP96O``FB0$#U@?18@`P20_P$-<`%B(`3`64)R0`1-T'Y;"@8[L`U1
M$`(Q@!R+@`9=\`;5`%5)<C2$E%"G46AUX`$Q$%@5``<0T`0:,(00P`)=$`4M
ML`9SL!PL0`<(I$">X`'.N%`=604B02*GP&6U8:1C$6/CL3KAX3J&(@-A<!1W
MZ')1@`&X]3<U@$+$1"U8L`00>0(2<*]6@`5C0%T#Q`9$X`8+=1!7L`92`2EE
M4`<5P3928P:W\26&XP;9H"(_L:UK(`N@E6C0$`*%X(_KPQ)S!A4$:G*S41%B
M9IETP`9DP`5(0`1DD())$@8R8%\QX`1>FAA\`"M-4`%\<);'D`!?$`8JR0%<
M<`(C-QH;V/\%52`$=$`%,\$`<W<"'/``+%@#@Z$%#:`.@(8&(<`#)R`13F`&
MNF`(5W$.?OJ>/;`!1Y%6?E`C+:`#OW(C3X`!,ML&=PD>*H$!<"4&"68-R.<'
M:_`Z'%&CBV`54&$(`L!Q]TH!,?`1V3!4/&`%I$L51-!:;O``-=`"4=`#8U`!
M5Y`&2H<^P<DV2>`%9_```G`E+1`&=)`$>OI^6O!)9Y`D=1D1_9(25=`)=1`$
M1+`%.Y`";;`&3!`"7T`!<V,%QE0$"[@&46`&49`!27MALB0H5Y`23Q`!Q99[
MQE,'1(L5<%`#GM!3:1`!%=`[Q0.L,E4&:0``06`$97`%%+!1")+_``2UJY[G
M<?WQ!*'@!0WD:0R@=W#`!EKP)6AQ5-6S"/WT!+VW"/FA=_YTL'J4*<6U*&(0
M*#&05LH8"C,6#;<:!^R4*;WSD&G4%69@"Y4;!Q@@!D@P`2U0,H.V'55B!EJ`
M`5[[M<?`!URQ<0(P`#.!!T=A)70Q-I?C(3D@!C*@7OVC12SP`G99$B%[#CT`
M2D^@`XPW!ZS2`B%@!B85EW=#!^#Q8%FC#6&`8'[0KGI7!4Y@?@@&`$X@H#VP
MN5#A(<_@#&T@`BAQ$P)0$@(X/6.E`/XC!P]0!6\@L`U!!@K``UR*+E3Q!#LP
M!II`>V2P56S@`&K0!5_@!D3P`B^P7N?#_P>>(#4_6T4*$`-:X`;FEWO_Y+X7
MT0.#=`8K(`:5[`F8507_JP7M20`QL`0&(,(LP`89$`'VTA\S,``P6;-.ZP)*
MLZM75@<XJVAWF*?&<P8$%0X5D<27,!8>^2$A:P9H1@$]P`)5T#@3F6MJH`U1
M``>CY(QUP&)S@`7650=6P`,YJ"+T]057(+-N,)NC<K!\X7F<,BJ(<!%/8+."
M6P?.,!$G9X*BTFQ044%(;&X35P9-MS4]E2D7)@M;\'5;H`56(#++J#'$[,7%
M$`!',``#<`1@^P4RRVH?H09-P``C!082H`%(T,7'$`$`\`*O4#">T`,-$Q]/
M<!%@(!5<4`$7$O]C9H".N@`."5%NBO,_&;(H2?($")`.SP`'.A`O1J&<)O:C
M64$5)N1B81`&2".(;@,`9=`#;4!WT1`'1Z&OK04`].('8R`&`-`L7J";<>`&
M"N)!52!G76`!(O`%-;`%+N"V'&7,AK,P@+TH9\`!E^`%4^(&W3JYQ=9.BB!^
M:K`&U)($`A@..4"-&A`!XN4$["`&#-`%,=`#)E`#PP4`$4`5%Y$$7?"\^*!4
M[40\=*!=OR('*DP\+;`D==`77)"^='@V394.H5`$%QP">2@6&N$#SHVZ%S`"
M"8T@=R`#;K`%`(`!6F`$)=4"<$`!=7!*9Q`!/]##PD9Y"\$#'^''#';_*%Y`
M+>:G!9-0<HO@*H:2@==ANL43I%;P!FK[NCN"!(3Y$1<Q=Z^KDOTD%]&T"&_P
M81`0!E&`)`T0`V[0"A]Q!DM(!ECPF4I]#%)@`6'0`Q:0&'W@O(()`5O0`C'@
M`$Z``A.0!>`S`D^0&`W@+R(P!G)@`D!T!F2P`DW05&I`!W9S,IK]$VTP!@"`
M<`7=!221!H%R(3FS-G3``V63F`)@#\/B!4H0*&P`R3IW!8)C!($R<;71`,P%
M!TXP8PKP!4UG'&40`E80(RJC!2%;;VV@!M=Q!L%\!A2U5R-5`+;0!#F@!0)+
M!V*``0H0`@[`40OP$66@`68``YFCC?_T!'"2_P1INM+:6`9<H"GD1K5B81I<
M8`7]E`%=L`]A0`&D4`$%4!\08`4LL`!6\`!Q,+WX\+\C=P89#-,JMP8Q&P[^
M`@:>4AIJ("K?DA)A@`49.!=SD)-MX`7$A0;B50<4\@(G,`Y;``$&5RLL\`P=
MU%KZ(@/$*+#/T`4C=P/?A`0>OD9.@`3_!`?HF+M7IA(H<P\T.D.52`=9H*?/
M0`1C8$^#-F9A("I>=08L4`=T=`8Y"C]840=-L`4ODC*+(`=%H2EX\0!,Q>\Z
M0`!9@`;Z;&L"`#@%>`P+(`$;\'HZ(``S4*>VP@06,`)[D`=0/AAGD`%50"H7
M,(2/\P`L\`14H`")4?\`PR*A:$!#,E"!5K`!NDT$9/)'S'@):`!"FG*\YEI!
M,O"CD]V1:]`#XX%F/:`$5G"8[PB@764X5`$`CH4&$L`38;"E6*`;050C$'`%
M8E`#E]#+(;!'GMO=WN.H\]-47S`T&K!:`%H#U&B9SY6F!#@M6C`#).`!!XD^
M5#`.%%`Z8B#9B7ZX=3#P6)"3(<0[B^`&%[#IZ9"F`I`%:X`%NHM=J\@!2Q`!
M%L`#^NR%)^`$110"%'"M-^#A.F`%7!#*9[`!"84./)`R=/#)SZ`%$'UR9B`7
MS\!N$`((1G1^?E4Z27YU="$\:GX$1&AA=$15`"<./1U7?YV>GYXL?F@];5'_
M9R$23U9=9V]D<8IQIEAQ"DEQ2;AA?@`AL$5H3W6)<'YI='5EHV=^8GYE9E9D
M,GYN/6<`<W-J`FUO;(1R;6<S9UAMB>%A:6ED?G-^IF1RA&-$?G0`:EAA6@!T
MQ#P)`8=(-CIGMEPY$R?,&",MLH#ZDV"$ECHY?N3(P8`!&0XX)HKTP`5,$QDB
M_^SQDDB,&B]GS)BI0Z,-&0%>))3)(W*%GSA(G)"ID@X-EA@AJM31LN;8#@"$
M_/0@=J)*"`%Q"#3SHT.`G#0,_,2D$T/-#S-;M#01VPR"$S@"_+#1D06+&SIO
MM(RA4X4(``!LUH3`TH*+'P@2VAA&DX&+,#ELLLEI_PJ@V8,S3[3H:U-G0*\S
MY&KPB$LG3!TK<4KLD.&`0LK7G;IL:&*%P)4V8K@\@7-FSD(%8N<\B7,%3@@3
M:/P\F1-'"QHO<"8]\>.DSHY>'&@G\0)&@P8P:#1D0,*C`@\35[B(X<&"A]@1
M<)Y,+[4DB>(NX<3$FW,]IN$XS;Q1QQ73:4%((U$1`U548RA@QAI5K`'!$QRT
M@`5LG=@ARADQ.*'$&1R<P`49",Q!@!=JB`%'!"P1P5(3-=2Q0AI1G='#&X2X
M,F`:3YBA'`UNJ`'`$SR<H04!/,A11QUCB,4`''7@2,@3[U0!AG)LY8@+&5!.
M5T<%1,0A#XY_;:$&$6*T`/\5`'&X$44OO6`Q1QO:$"*&@56`$D`3[S``2AY#
M\`!`2!@&\`,#'J20DAXL/:&`&F%`D(86SYPQ1ALC..%%$")!((\6<55AG!'*
M31!'&FXT4\$5<;`DE1ALU*'&"%9<X0895H#!@&`]8'-&'6U<L$,<%(P1EA\F
MB.%+'%'D5L4;3S25!!9.7)%&'-HHT847,21'S')1(90$!HY5$84.5B2A`!<%
M/'&%!CY94"1;8_"@@A])./&$%QRD4X&H'BBP!DH8BN3%%UP(0$<7)V!A11L%
M:*$%$@G[008#.;!`!QUFG"&&F'4`L(878R"A1@A$@*&$'S-H40$&(S3QP`@H
MKE#_01@"N&$!"2%PY``8:YRA0XXC%-%#%W*)446D+X0QQQEL`&#%&TJY\493
M3%5!"'Y8^G%%.(EH0(P?CKB12'*$)&'M!A=BF`<1ISW1A!=-O-'&#F!PH$4;
M6F1QS`-$N.&%!<MI($^.&9@0!@V)$,*%&7SXY0>4;H0@QA1P"(=J$U?*4\<#
M?O`"U1A<G/&"&UV@G.`(=?"88Q5D+$''%7^U(4<(3P#``QU.G'%&<F_,T80%
M:0HD1CKG1%7#!GEZTL<<8X<@TAT<T!$`AE0L-((/*>&111T*P&&,U55\H,46
M*<"HP`@SB.29'QD1L<8/8;QPY1-&%+%#SG8>T8N/4ZK#_Q<^1X9F/`%5`TE1
M&\K@!0!<0`UD\$(%`/``'FA``K;J@1>><`TD?,D,2P#9`\+@@`B800MF6`X&
M6`$!,?%`!$4RCU3JP`,(C"$;$1``9GCTAK5$10Q;\4,(ZD"&DV$A!6F80QD&
MH(&"B:0+#E!`"!10@RJPX0LR\%TS1#"<7K2@!@R(C%C&1HB_^$$.7C!0/&8@
M`!1XX05G2(,3BL`$!6"A`F3H`@&^D`0SK,`!6P@"&H)PI3,LP&P2\D,%""&<
M,A+":FH`5@S,1@@D`*`.#H@*(XU!"'`0(P[/("(%'F`"#N@.`A]H&X9`!X$7
M\"`.3Y``%[[`@C,TH`K8\H,`Q/_@`#HPX`<9($,X'F<%HPGD"6?(`I44,@0`
MD$$,U:J#!'J0`UUPP`QAN,`[Q/`&,=1!5'Z(016LY@<>*&$`,AB!-9Z1#D+4
M0084$``9Z@`'`%2@"4UX@0SJ@`8T<`$`+6B!DBA`(]_%(`T0*(/8CI6/-SB`
M$YZ``MC\P(&4V*$#6U`!;/K0AR7XP4\BP0,2"+'/$,RA!61H`@](@)0L?*`)
M3'"?'^3TA8N$@`L]&"<:4C:',-`#`EJ8)'#F`(9MC"(&9W"`&N2@A23H@`W5
MZ((5T(!2.JAA#A((0PX`H"NIF$8+<0B!9BS6!#>8;0X!68,;!O*&,+3A"\ZX
M2!V`)H/_-!A!#&3XR^R($(:!H$$):6@*&F)`@=#Q``WIR"FP*@`&-2C`#1>(
M``?(L`,G3J0+`)"!#M*AGZCU``E^$X,`X`#!.-"A"6U(QZ2PI`@`.($-6XA"
M`SC@AP&(@0@O>($`B$"$$UP!!/^HPP9H4($1H"$@:4@!&=I`H\[0`0YO^$O'
MHK(@>,!CHF$PS$^,,8E!-,4/:^!%7P$0!GS0D`A6F`,7L$"#)LSA!TS00L'L
MX-$+N(L`L!S#',1P&2M"Y1M9>(,;6O"&$!`""QN#RL"(8""W`J@'3JA`[\IP
M!CGDCDY/BX<!,=,U^=3(=W78"AG#]89!4'<Z]8@*W]+0N?2V_X!&?M`""S(`
MF!B0C086X$@#0$&!>/C!`)U(@`]Z((#K=0(#:H#-`6KP!A9\("5WT*X?FI`!
M!BB```-XU!;":X4>I,0S(8B!%\1:@S-4(`1N$(!A:.<&U\:A!5THJ.^D)KAW
M;L%K:H`#';Q0!Q;,;X-$,4,+4O:$*F1@-UJX0A)RT(8G/`--89#`')P0.I2Z
M`9?Y>)JUGC$&_H8!`+KHP0MZP(T6-,$)3>5"&Q3``S9H`!8AV((<>'"/.0@@
M#&9P@WG$VH,K5,"RH##,%M"`F2WDS@@9P,(:D/D$=BSM!'<V1H7!&V/!E.$)
ME`C!!'Y,!`A4H05FZ`$#+@`!UJ2"`O\]T$$-K]`".+#!`'1X![ZH\PPO=&$0
MTQF2'V2`3,,\@P[0@\<<FA)K`82#WV@@`R+#`94XF,$+86`#%KX`!_U(@`A=
M*-@=B("7R>F`!G&8P#ND!(`F7`L`<&A*B37YC#D@80UT8`.E66"%->`#``PX
M0Q=84`0>G,`$%7@`!F&`A6PLR`ML$!.V`6"&.+SA"DY0@]QZ8(4R<$$H8CCH
M=+BAAB2*`0ULR$(;A)2(923B!KUY1P_"@(4MDR<R7.#!$F10!%`80+M`3D##
MW#"&$"CA"'_P@01^_1H#%$$,)X"RWWKQ%S=LH05HR,(<X%"%*L@@"'IPWQO>
ML`4B2,`:.7#_P!@<<`:E.*`*-N)!I.2#0D0>+`QG<,-DFD*&)UR;TFT@@@+`
M<(8F&$0&9>`!&,R@AC/4P`%N@$$57B`0_#P!#5J8C@+^XH0T0.4$$A#`$PB@
MA1]D008\(,,:G!`'+#1@*SHXGB[;4`4MQ#$&9M@'%]SP@QC500EBJ*EG&M`!
M%"@`V)[0`6S0!CD@`VV@`5PP`&$!/A0U$V#P!250;CV@!H,0!A\"#]XB'TZP
M`A'B!QT0`PS0`!#4!C:0!C4@-1]7!QF0`0*P`D+@`$Z`!DIA8'ZP`V+0`X0`
M-G.`!0)B($@0!V3`!740!+'P26(2+C:7#R8F"DY#!KS0!E9``6,C_R:.Q2\Q
MX$3:YP99X`9A\`4P``!OD`9B4`/"X7!ET#)1P0:N<D;#\'F.L#5J$(>(0`1<
MT`0IH``/\`51PP!*<`,M``$[,``J@`1B8`(;$`)?T`0Z@`6CY02:(``T``$/
MP`)HP`,_P`).)@8R\`81@`$88`)MT`,FX``84`62T@M(8QB<1`AA@"V^0P$B
MLP8Z,!UIL`*@<`*N`F0.P@=[L`=Z0`9`U@E^\!H)D`!J(`,)\!IQX0<3$'M8
M``':9P``D0(&H`%?(`4BT0%^4%A5P`0L@`7Q<05^<`1MH`,(D%EEH`,$`@"E
M$`*@<PS60%DY@`4TX@9.P"+QU@O#@`910/])H6,%PU`)Y90&::0%;-``!``&
M;=`!N^$'7?`&$L`CBN`'7I`!F#$'`"".QA8#+"!=L:<<<J`;(!(#$@`Z9?`&
M//`$;V`%$V`85/`7'M`%&6``7U`%%06`?S``=1`!5Q`#2_`$1$"/`F$$6X`$
MG&,E%K,D=>!1B7`C&(`&T>4%WW4%@\`'$L`&C%4#1+`%7'`#_.('#A`&U2(`
M0T,$;Z`5%`D/,R`&<F!+#7`8C@!`SU`(/%`&^A`5<0@',,`+?J`$/J1)'J@<
M./*6/T$($D,$>*`"!8`&3O0F?"$#,5`'8B`!WO0&9P`%4E=&E$8(+*`USH`!
M2J"-[;052.`%7J#_-6(@!E9P!BJ``&[U`ORQ01%0EUQ``A\C`T@BC@#P`F`)
M`"SP:?\4`AG`!C)W=1)@D*D)<63@%R"@!&4`8VZ`!65@&@WP3VX`!M671_R6
MDF?@!2,0!W!0`Z``!F,#9%\8`AY0`!<0<I[P!J\A!(N$2J^!!;KT<&[P!V"0
M<@?``67P(2Y`!QX@$@;@!UP@`1'P;EQA!%6`!B'`!NX'!GD!&%5P`A^E'*T"
MF*JF!CU0!DVA`(GV"&S@%B'0`@WX2&!@!0T``$$``#M@8^&T`<`1%2%0!&_0
M!7"@`X,0!\L@!B<$1G[@?6O`!BM@`!`P8\ZP!B\PG=/A!020!&$@G&T0_P-P
M<!.5,0(\(#$DT``1L`'RA9-Z@#!LH`8/2*(UH`8L(`!C4`4,\`588"!DHTD9
MX`?X8!/AQ)=@$`*\,`$&L`$J4$(=4`,LD%5I(`!E,`0D>0+QT``860%?@#1S
M,`%K(`8$0`>%51D_9#9PT)]G4`2`20A!F!S+@08P`)AUX`5%\@3Z(A8`(`:P
MEUD"H'UV4#!Q`08-!!HLP!EI<)!_T10GT`)@8&/,-PBE\8:%*892$0Y3*B5&
M@!E%8``6X%;D00!-8`(T8@%P<`$H``$]20@:0'1)$`(Z$*Y)P`55P`(]Y2,Q
MAUYO0'2==T]T\`0Y$`,X0@*:U05/0*N&^33>.?\&`-`&1I`9/,`%7>H)34((
M`_`'=S`!%1`E-%``L=H)5?"P$W$'""`#O?(:!F(!?K`!D[9^+;`RA]4`8W"P
M$S&@(9`4,5`";H`$:4`QL+DD-D0J6Z`$&R.5/#*7%E-Z`LL(F>1^9Z`IS/4X
M4KA6E0@`"H!2S[=Y.()O32!Q2,"O?B`P:P`Z5<`%<V!@;/)=(^`&8^<&-2`&
M2+`OV+0#3Q"2<[)V2!`&9\D5'#`"$]`#9C!81!`!#2`!!!`!./D''M`,+`$&
M<<`Z<Y`#6P`'G"$7($``JFHG!("XQ&`,`DL,N#,=DV,,_=HFHJ8&'!`#)\`#
M$=`L'Y`#9=`"(=`%!<#_#X1``&+P7&6`#X2@!N[1&Q2Y'$]`K.2U#"%`0?D@
M`68@/S[F`#50"F*P`4*4#SBE%FQ034AU!P6#N%[0`F(`65%05!>!:U_@!```
M`EX0BCE0:"46!G"P`V9`!^P'#V6064T``%4P!SV@'U>0`6`B`.;R`DN@!1AP
M`DT0O5EP`T^P!%Z``;J`!K>V!"7!`T@09G!P`A;0`D$Z`-A'!#T0DA*`!:G)
M=%5``4B3D6F0!$1$4HI`!',@`PW$OTM`!&:0!CP#"O+F!P'Z!Q\``APP`!7R
ML$!P`\HK$A,P!T=@`&P`>!.!`XX`&$M`>G0@`R$`J&(@!`(@`VP04Q/Q`?34
M_P!@T@!AP&H\\$XMX`2W6P0VUC%OE`0<=%6]0`=6$%1(8$5S$AB3IP.D`EXI
MZ0S;<`;XU01KL&I@B".904_OJ@%IJP44T`:#%SIBT`5<X`58<`.(`">EH`U)
MP`+'**=ML`5CT#G@I09A>`"E&@$%8`:0J04D,`!)4`-7P`%#D+=O>75FT`7M
M!P!/VPMN\`^*5@%7,S:(:B"EL0%(``9B``%SP+4]N6?RPP9^^P0R(`,14`-H
M0!PFT`,\0`17\`(ZP`5$D`9P40]E4+Y@($8YR$%H\`578`9SX`6L"BQ/L`7?
M5@=-806,-`@2`,+X8GUT(`F7)!9O,`)O$)GE>@)6(/^QKV%@`=L%)A`%JYH(
M(S0&WIN]@J,%3):<CB,@F:L<R."])_`]+2`F(-`$/>``<3"U`D`!5:``1/``
M8*`#$M`$+."K$O!29"`"3`<!31"Z`_@&2F`"#=`%#!H!;W":%Z!$(>`$67!U
M;,`%%U"J71!>^Z4<;4">T=4#,K`%`A`%YR._-C`"H*`#1YAY?U`!H-$/8U##
M!1`">)`2*M`&!B``1I`2YM`,:9M"Y/%28,B3%F`&7ST1*!`M''`#_F1K#E<'
M/<"%"\L5?A`%22``TU<&F\E5UB<,,K`#);9!A`">?O`%A(@&:7`C:-`$W@L'
MXW(&<(`!9<"@&7`:,28"CE/_!Q0*'>54(6<@`6N@!DGP#FVP#3R2&1JDDE#1
M`'Z,1G*`-'RC`$;0!DBP!;P0`W$P!Q>@!1O0`V"P`'F+#SV0!-,T`ATA`P(`
MVF<``6M@!A3@36W`!KD=%690>\D0`Q'P#FLP!EB`;1`J`Q@@`US``2'``6QP
M!5%01&J@!0S&`C=P9V/L46S@P0"`#''@F4VQ+P"@!6?5`VM0!TZP!930#'40
MU/F0!NZQ!F0P"$M""-P,E6KP`E>`!DOE!SA`!E?P`$Y$GU;0!&I@6I_1"T]:
MS(4+`#'@`0\``"/P`P)V#)Y")U0#`*GR>!5'#%*``EQ@++W=`$J0'6&0P&ZP
M`[TJ_P%=$'_E)0!H\`)-(`!-,!UF$`$LL`3[U0!6(P-NP`:UUZ]I@'%),%7D
MZ72(Y1Q=0`.QU\TF,`=HP`$.`(8E$*2D"PK$0P@\\0=Y(`-Q8`(80.*=@(>O
M80,T\$PD.Q$+H")U@`5=,`<U$*=FD`01`'XL<)HU#`H*@&U/H`(Y<0(`H`/?
ME`IL0'I^L`0!HC4`P`4FAAD,\`1?(`=(0`29HQ2^8S%"=`([`#=+4@56\,-L
MX`;S)R9L$`7A(*QB`@=:T$*QY[-P`P9/@(.AXP<TL`3T20<]\`4=`V.](`%R
M4`,F55B@PCHUT`(3`+8\\'DK:P5+X`')B),T`B#@]4UP,/]2"I!$4:`!.!N2
MMB,*@Z`&36<%`&`$34`,:=!:`+`%?,,`SVP'56`&.8`$.C`!*`L'6*#J;H`&
M3\YG72".X98<OC/(!S83S78&W%Q&[>1.FC0(0O@$=_0!S1`#A9L/CQ1)<2`#
M3N`:!4.?74`!N&8`CF!L\%!`,G#P6Z`!?-9HFL0#;<!D39`$N[-Y39`%;V(%
MO"``&NMM,[`!'``&+?`#.C`"HU@!)(`#7!!I(2"^`T`"OG0&1^\%.D`$&=`&
M&<!N<(`J%Y!".T4%'T\$3N\&S_#S8@$!`F$&+U"F!"H`'0`3UH!-6B/5GT"?
MA&#5")L`X\KS&:`"!Y`2'J`$(IW_`?K\"3;P#%%`!'EV+5S0`,<S`/8E`%9@
M^9_`:/'@WVT@=]#B!P("<U=`!C'P`E_P3.20&#&6!`&A&2S0!>W4!A``%<06
M`\H"`%XP?5;P`F,S).'EB7-0!`U`!A+0`"F0`23`DW"3!`]03VM0'%ZP`6H#
M`!I0L"UP!I&60E7`$E<#+4V0%(!L""\`"`!I<6Q^;0Q78G0*=4L:.'^1DI.4
MD@Q^?G)G874.-2M>=%@[$5<6/&!>+&L`8I@09W!);&*I+75^33PM?A5S?F=B
M6$\H/2%7?F@012\J7&U><V03<%</=6M%F')5?F32F)AK?A=M;6X`?F]N/&=^
M:DAJ?IQ^_T28:&IS9S'N9G5I=>)@.H-$1X4(9&IPJ<00BQ\`;L#LF`/&3Q0G
M?N+4D9!%8)TZ9%@(J\-F#*8Z=,SX>>+&CY9Z+])Y\[-CAQ\3<\8(Z"%#0)PU
M%"IXB,,BB1$E:B(4$)#DRI<"7L`X".&EP1D+=2`P(+&&2XL&(;3`,>,N3I(J
M70@`F_/&SQHQ8?RX2=/&CZ@XGN34T!$"0H@1DS;@PJ2'DATH$_Y$<."#X9\/
M82APX.!&@V,79)*9N:(`CH8U6L1HH5`N`X\\#&=P<4*$`X8P3=HH:!%CB00N
M5YXD20/@BADB%]S4J1OFFQH`7K;08A$FBI4P:\[HZU$$3!PT//_$()$!H`$!
M`DZ>\$CB!DD-)&_>T'7C9@T9`T3&Q=&D)@3W,P"P,#CC90V1,T^$!D`=3\2@
MAAA/8)+%$ZEX44<7:)@A1A$W8"$!%EJT`082(BRAQAZ.A?C')0)`4`$&'/00
M1AAQB$'&,`ZLH:(89^`"0`QHG)&2&'`,=H(1?ES!!1L\5&$%%A0@6,<,;LB@
M@1@2J`&#?3-P@(4`7[10!`1T)),!2I@`@`828&BA!#"8!)B&'UVL\<03``CT
M1!QUA6-/2T@`$(8:)FDDQAIML.&&%4H`0*8,$E0AHB15`$`5&F,`D,1U5IRA
M1A-IJ$$&&'/`D<9+:(@51DEK-,$%+F'_5!$7$CV$X\X(9R!"QQ=MM+!$"&80
M4,L6#GCA110Q8*$#`0K\T`"=6\#Q0`9@M*%&JV&T<`(9#\11QAMQB">#&6R$
MP8$:3ISA1@-O8D3!'#(TT<,977@Q'@%RP.8'&W2L,,D1N6'2!T-[0.`$)([]
MH&@D)U#@V`0)^L&"&F6HPP8'$\R1```.&%#&OI5T(%<76'11!0\5"""!DQ&X
M<88`;GA1PSA8E&&&%F%8^D(549P10@@/E,$&&&@P$,,6<PP(A@!@`$"$!7.D
MD08;/60!!A;1AD7$&P7@108==5C1QA-R`*#&&:P0P848;WB!1D!G4A"'&@GV
MD(08:FRA!1IT_V#@A2%DY!!#!&?0)0`;&S0A00P"R*```#THT$,40"S*$`=T
MI&)&%0VD(4<;=)QQP4M-/`#`$V;0T4,=6ER!BQI9H/6+'Q^YDD01,:3TGQ=M
MU(&"$Q>TD(8&!$`0`P-=\.`''%J#$,(OO8V1Q#AT:.$H'.D@@<1`N&QQ!A<F
M:X!)&5C4\0#075J58!MHD.%%S&0\<<,%8YP1AP!.*$"$XH[_T0(1!2B`06A<
M<,`##VMHP`INX`0OS`(,4?"#VOS1`RS,00P<.`,:_%"%H`&J)>W!Q0AB0`0K
MH*$5)^C!`RR`!`=<00,68(`$:D`#&=#!"Q)HPAL`\`4!**$,6H@#&?_DL`(]
ML:%E/8`(!7@0!CK`P0U5&(`#)K<)X0&`>473`AG"``8PD($,/:`#&M:P!B5D
M`3#WPH([`"8)'T2@'`<0$1&TX($4I*`"$G!,`)IUAC:8X0%A:(,,W)"!*BC`
M"#V800Y04XD3^`$#71A#"-A@CR80H06%6`<1B%`%.."'``*H`DO>,)@ZG"$W
M3V@`&&I0@2HX0287``,%JE*'+.3`#7"8`!A"0(8R>.$$%>E"J\;0!C%\`0`9
M&($$X-0&FED!#ESHP1IST0,X^*$%8AA!"`#0A3P"2%)^X)L?TL"!^3P!03``
M`!C,8(8TS.`*.D##7$`@@``DH'Z4@```RI#_`R0,4RY/V,(3EB`"3L5A"UP(
MDA>>P`4!N`,.D7*`3!ZBA2?400T.J,,<).H%L2B!#3L@RQ7&\)P02(`-<4@#
M'$8@F[NU@09S,$-`*S)+/SA@)3+)D1\(`(`M/,`E<EA#"]Q!!%P4PF->2$-%
M`-"*.K:I1M)K`P#XPP(KU"\+#SG7$RPYASET`8%G`!`7WE`!;.W)#[\0HX4`
ML(3!^.$!2O@"&M[PA!>$@`Z(2$,%N-"$%$@`BPK@P@4X$(,65``-5:#!"'H0
MA!',8`MT"$%3U(`%-5`@#0K@@0DH<(4*_$`&.K!"'6H0A21T;PX\T--`,,$W
M-XR!&^F+PP;:PH`"_YA!!6WRPP(JX0,,`&`R'(B`;F.H@SW8041#$(,97$@&
M'80(+5R4@79$]H0HW(\/*P!#&/C`$!%@0@P5\$(%FJ`%"^P`.V>`0!4TD*TG
M?!0+;.A"$GH4#B]802!)6((?O,`&"3Q`#6YP0E73(`8OO($`:&A!"]JP)S5P
MP0(]^(*;<+&&",2@"P`@`P^4:@4D7/$-K/B"'*Z`!5]6H0X4:`(9'`"&Z"0!
M`FZH0`BJX`XUU$X,"FC#%;*@!!D1(0P\L,($=$`',ABA!!G`P@S@.0D:T,$)
M&E!I&9S`!;7`H4O`:$-6_>"/-HP#+NH0@(;:0`8S..!-N(B!!(8'AB<0H/^[
M*M#"+M00AA@XP0Q.P`47TH`%*X3"#V,H*T0&(X,7>*-VWFB='WI`D388H4:L
M&X,"R""0<#A4`[V,@PS.4-HXT,`*$G#F'")3AX$MJALK&5X6!D"')M$``,K%
M`@TH2"`O5$.O7ZB"`/P`AG5->2!$Q81(8V`!T80!`%78P@[",)LEK,`*/!#`
M%D(0!S-((,!(T``$X):&JSBA#%4@0PNPH$<<YP`,'SDFJ+70`S<$%`T@@#(F
MVN"I:39T#6QX0A5:X)LT-.`##+E#"BS@@`U80`,14,$=B/R'"Z0`#R%:0%PH
MV`,"R,"9<@##&\Y@!2(P@0C4I2T`).``-XS*"E+_\7@7<E`%@&RS#CO(@:_B
M\#E,@#L)"M"!#*K`A0!S@`$5N(`#&L``!MBG"@XX@PQXH+@O%$$`H=7!$IR`
MA!LX$^@;$,!4D""`"I#A"NZ0P#&HB`4GI&$-='B"8P?,`C3TH`IMT$(2*J``
M/\0@";$(`6"MX`!UK3$$#GB#(]\@`")4@``N('@D+N"/,'@!AU](0Q,B908!
M/"$69GC"&!(I5#BE(>RX&,0:7H"UCM%W#FQ.4!+,,`,67.`!$MB!#,36A2](
M(`T"J,$3KM`$6)PA!_)^P=:\5ER7XF(,;J"#0+;P$$_Z(:!A>$+RN6$111#A
M"A@FPTMX,(>[B8&[7>A4_Q0`P(,>U*\;Y>:!R2;X.;#%)PQ):-<$K<C)."`!
M'W*X[E>[IP8KG.`,9,"($1J@KCGXYP9$4`83,#))(`$#D$E7T!HDIP4-,%P4
M`#580`0:4@91(`,/<#ZOAP4AH`,U4`3.E`91,%AH8`#LHEDK$0M^X`17(`$4
M8`2>U`)?4`,K$08$4`49)W@XZ!@X,$%/4`1H)P`0I@48X'%%T`8><H.30&K,
M9@8TN`0\\`)CT"U.$!)+\`184&MKT!XQ0$1FH`9=DB=T4E7FX`93E2'LP1XZ
MU!\J>`5.T`1GL05)D$=P$"AL@`L(X@81`@=H@&U<P#9/@`0TXC#T`@S7E"8)
MDO\.O?%Z;9$,,E`#/-,"95`$%U`##U`[2F`&6<`"8,`%%/`".'@!P*``6L!-
M(2!^$<``6.`>_X%>5;`$5M8$GY-8'_0$2O`F)A<%8M`#"?($.T`((\`##B`_
M)Y`?7.``2W`]8B`#:!`'<?`##(()$X`&25,%;U!$P2=:@Y8P*9@%[A`F<_!X
M)[",5D!!%(`$625.X8!G5L"$6=`%:J`&<'`!.4`#7E`_,N`'#,!?Z:!5=[,&
M79`1;0`+/+`%+0`'[5`%7_`/;K(&+#<@5]<#7>!,6*`2`T!]:;`P1Z``*=0$
M-3`&1S`#/^`$%2`"+/!ZX"$$/>`775`#=<``82`L5FC_`F(0!TFD!5W0AC=P
M!6N0`P8@`2E`!A20#`_P!(M@)#2(86[0`F\`!DWP)QY%=#SP3CDXE94PCF"@
M`W/69&)@!!BA`SI0!&_0``A7"07@!R]081K`!3J@!2TP;5U`!EQT(&5``0G3
M!?/#`RP`B.A0!TF``U`@!!4P`D'``%0P&4-0`B,P`#DP`DSP`1C``#G``4$0
M`P]0`U:@`!F@`"C``@WP`!#``R?0`!X``2U0`!X@``*&`1IP!!K0!%5P`0UP
M!"&P!2#@F1'0`TZ0`Q9``QE0/C@`<Z%F%P]%`$A0!R9`&_]U!CW0!APP21D`
M!02`@R^E!68@9425,%KP`,X4_R1P\`1O,`<FLQ+:B"$(P!XH:`0MX0<Z("D`
M(`<]8`721GIF``9'$`%PH`->(!!<\$@`0)R8P!XW)CRLY@46$`XF$`RK01%U
MU"JL0X;AL%:OMS`+-1A.P``]T`-'T`7#809KX``2<`7U0P1+Q0%>H`-F@`:(
MQ"(#8#Q<4`)'@`7(1"<T8#V5(@!OP`,WY4)M4`8K$@X\H!(JX`09D`2+Y`'*
M:05=X`)=T`!=@`'"U`42\`,9P``#4`%'T!4Z4""T`@<HDR`"``<J(`,6$`8\
M`DMUL09CP`!DL`*&0`1AX0=B4`8&L$4\0`0W20>"4`->Z"!^D!A4^:>1`%5O
MH@9UT/\`K_=G+A$",N(8*H`))`!L;4`$-V6`+?`$,O`$3B`&E*D&`F`&%F`]
M[K,2;/,0!D`!?:<"#-`"5J!S!#`!QL`%$&``314"ST$$#)`$2!`3-1`$6#`!
M`*``,Z`%):D%$X`PH40`$L`#.X`%T;``([`#!G`%;?`!0C`!"```$P`!7<,&
MW,@#:2`#L7,UJ-.`:X(%%<`!9F`$81`!2-`$4T!T#""5!+=$&1`&F)9SH)@U
M2."@7:<`3A`"X7`%')`&8T"L`#`'^O%X#_$G8,4%OX&/7"`$"D`07I"+,,`#
M,2`&N9$$;)$!OI$F7O@$7P!3NYB.P.!)M'`2X7`#U4A?=)#_!C$``)R4CFKE
M!QC"205*@PF"!>S@.%(P!G60#C+`&6*`.>YU-D1`!D&;!1KP!%;`!DI`(VR@
M#^DH"#IP$KC0!MCB!T?`(TAP0C-@!0^P!%Y#;KH0J["J!6?``B%0`28``3A&
M`D]PK5[0!"H@`!1`.3/)!O'7)5L0!^[@`&&0!K_P!FC0(V1@27(3!>AI!EU@
M`0!@!@8``%;0`C)0`!4`J(`Z/6G0`S<P!VA``FE``0S`G!,`!%U1&)70J&U@
MCCS:!$A@!1E``',R!TD@!W1P`V$P!G0@!P.E`S&+"P[E!S10!5>0)R\``0)`
M!GVGKCOP`7TG!0"0`P+P`%4@!@3@_P!=(``&P`-P``;0Q#[C^!U(0`-)H`,1
M0`?P-@0P,`(,P`8L@`%LI07*,S<R@`07,`<54'%^@`04T`,_FG)[P@55T"BK
M```#4*H.(`9ST`)H(`-60`72R2)P0%]L`*XA\`:VY+1/RRU?(Q?3M`5A<`%H
M,`QL,ART&R9K4@-$X`9Q``9?,`).0`!'D`%CH`'5=P5T@*=TH#4%<`$ED`YA
M@`9A<$_@B6H``&CIR`(!$@,MD3DVRU:#X0KI^(]J^Y9T@`2^ZP12=@91,#,C
MD`6.DP"R%P0R4`3WQP8%7`1UT`2P5+1.8`5J<(]?``8((@5)\`(5L:XAX`:N
MP`51P+>\\_\&;.`"`A![W*@0O-0#4I`"+&``,4($)V!O1M`"-[`55K`!9-``
M-W`AB]1I;&`&+Z``)Y`$`P(!G!0"!E`!8<#"(0`G.*8GCZ=4.=!!<7P%6Y`&
M;Y!@(_8#0:"Y?XH$0.&T8>`&*Z@&7@!;O=0$0Z"ZE%"@(U!3HX@%2R`&2:"[
M<=@LZD``_N4'J?,`;]`&7]`64L8#,U`#73`"FZB\'82*#_`%(5`$#9`$!,`7
M5J`#/!`%2Y`!&0`"!M`Y!+`G72`&)S`&8A`",."!0)E^2J`!51`!5E`#9J`!
MB3($(.`!5J`%6N`$1@(]#Q`===LI<L`"2W4@(=`$AGH&/(`$E73_!%8``2_0
M`CBX`7Y0)`G)!G`0!W?CA36P(BQV?2=!/D\T>Z!6!AJF!860CD]`!,[4!G&P
M`FC@!$8@`SF@`)C%!(NF`T7<``Z0'4_0!:#SC68P4"\Q540P/37--0ER8V;U
MP?^I!640)^`9%?'&!E31-[A09F[!!CXW`DC@."L0!F_@CF.#"5YP!1;J!UO@
M,3N`=3*P!@T<!B\`;QZ4&W#0`^/0P'2)"2]P=75@!!:0`V)@!3+@5V@@`!W0
M`T9P`BU0`QE@JBV`K"K``5]@`6H\7FT0/S*0!!9@/DN0GX3,`(QP!4H`!J7F
M!AB21P``ED%B2G4@8,W2`%6P`S]0:USB_Q-=T!C`/)4]=3Y8$`\D(!`Q@``,
M$+]='0`,,0%ND34B%"T#,K$MP`)C4`$K$9'W2&`B-0=%H-$#%0)Y!0"<B04$
MP`!HD`$70`-:P`!.P"L8``$%0`$/D.`"``,QH@,*<#A1<`6JHGS,%@(8@",U
M,#(-<")<H#@*P`!DD@&"*P,(/EQ&X&IBX`%DT`2^ZQ"TA@4]4!,/$"QT$`9:
MX``9@&I5``(&B(/TO7H0,`80708A<`8U(&#1(7O9D0R80(U%P`7MDR9JW%8)
M@XADD`[3E)@XH`0Z(*=)T$%$8`;OBVE-H``@34ZQH)UG\`#I&2H)$C.80(`V
MGHYE+09>(U\M$?\'T'<#+-`ESN,'AA0&=*P`+*`%CE,`(L4&32##\S`!_C@`
M#@('<+`&$K`&:(<6=.8$040#2``'UB,'+2$'$M"%=;"[Z2#*-5`"4=``!C"%
M[[D!,0`&!9,#&N#0/$`!!J$&*;0!6F`%<T`'1$!99M!,2Y<#3N`$`B!4QXL$
M7(`$&Q`!$C",VT0$<W`#KPP'`^!(3T`!:G`%1:!B'T0$Z8+>VYV#]D`.1!`5
M>B@!`V8!39`#1L?NE(`#Z;!6+:`$/"`#8'`%*Y`!7Q",T%,%)]`$25VW$-`Q
M.O(`=,!K7+`%3C,!D47:&8`'%D`$#C`";M`&#R"/Z74$9PX!)/``'+#_`UQP
M`C0)`5RT!F'0V^`^`_GK`2+P`"&@!'#@!&#P`A2A!3)P`SB45QI@*'/0`')@
MKE[S$#);[';$`]7M!540!P.0!'7P!AA@!@U@Y&YG`B-`=]4[`D.<!E>0?&?@
M/&3P`F9@;C>0$>FY<*$*!FSFZ;IA!2(;!4\@!1(@`1\@(4^"!B>P!%P0`2O`
M`UCP!@]`4P!P`4NC$;3&7DGP!@O($E.5#H)^!FR`^0,2#@`04'[`'?U;"(J`
M"Y.BQ8-]2$VP!`7@.$>_;B$``EV`*;6R@<54`U>0`EU0*&@0`R[4`WN0#G)`
M`Q"`ST+@'F%@871``2I0%R'@`0"PT3?C<]QN_P!JT`4;$`8^(P4-``(OD`$B
M`-.Z4G4%0#XL0`&-'P5;=0+<@G2ZY@44L%Y(L`5ZGR8[:@Z>U(VL@!\1``A8
M;!EP%`X'?XF*BXR-CH^0?R%^9F,]`%M^<Q%@:SQ-`&05"8Y49W%K8@)G4D]R
M<$]^$3QQ2V1(;7%77F<`6&!59W1B!F<O#&9`<P(L5547$E5A?B@M5C4>.G!:
M%5]H%"QH*S1I2A<Y:Q]-20P*-TT%%405``)B1AIJ9!X1(VM*&9*$N5`B2@8.
M3\@0\8/A1@\R=>@`4--$C!<1ES:X(=!`BP(48=1(D'&`5"1'/WI<>:)&B0PS
M.NJ<<%,G5AT2.L+4B?\#P$^36`YZ^I%3(\T3-WY\1HE3@$[2.!ER:&'PX885
M(G,R@-DP1`R`+LM28%%SQD\<(F_\E$VJH.>:"&1ZZ%`;,6F(&%62/JGC!P"`
M.E[F^,$2TP^:-'[6./"3Q`\8/PQ>7+G@)@01`41._H$29?"+*EVRI.TBH<4:
M)VGFC'$C)VF;%A:=N%%#9$P,AG3FM)'PI(N8'D\`Q.*RI4</&5?\N-'B!2Z7
M&3\F6`'S`("6.%I"*/A198T7,%<&M*$3`4D7"K\?]"@39D?2-R\^S+D"P0R8
MM4G]V"MCA4R,FA;PT,4%2;%!'!T+:*;@@HW<(4,=<YRADQ=^$)&#&!X`X`7_
M!^S=X4@*<H@Q0`YQ^)%%'5^DD8,,_-'10AD0/"%##6_4,4`/21D!011YS-'!
M"%%`884,7""Q@A,"_&@%!![(X``:;3"000]A\%`'&D(48<05)A#0114L*+!#
M#&L8`8X$7)BAQ045@-"`"DI4D40#;50A01,]*#&"`&"404$$:2&10Q<RQ!)'
M$U&$40479X@2QAPU75!#!3/<8`8+#"[R0RAL\&`$`'!(0\<.:B0E`!M&!`$#
M&E_X4:H?:?#5`A=H]-2&%P,X418`99"Q!AM^]`#&$7-48$$3;9S1QD](P*"#
M`&B*\9(?7SX1A@PRY*>M6H8106%2=/"0%!9$Q-)"_PY'.15&&&B$T,0+)9:8
ME!EU</%$&ERP(88..HR@V1%LG*%##TGL\,0$$"QA5AUB@)%&%0Q404$8"K2A
M5HEU=.$4"S0!D$52]_G1@L5^>%$?"S.TT$(2`FB@!1T0%!!&$G/`QD)/*\(Q
M)0T\A."$&4YHX!4!(5AQ!A(<M"%&'6:0H44873S!`!<LZ`#`&D3PI<E_3\@%
M1\50%H@&%V&<D6"FCM@11!]H_W%$&P#T$$P<(SM1AP@[H!""`#PT<#8C*?CQ
M!!@QB`&''S&`X848,0B`=03D6F$X'7#H8@8EA`L`0!A$7%&%&A1@RT4(830@
M`0M"$-%``1;00<`5.AC`0?\-(7R`!`0M$&$&!SS($`++6S0A0QLL=$%`+M\Y
M81L:`C@!0!,#2*#S)UW4`88:EUNAPQEP].!&A%[4$(8`;K``AP8\O"&!`%]P
ML(8$2E!@1]LYU`'*&V@TP0,!?K`AE!]<F(,;R""&I*#!#;'`B^#B4(36C"L$
M:6D!&I[PA"9X(0ELD((,EA"!&O#@#!*@`P4NH(43Q,$,<^"!I.AP+3>((0Q_
M,4LLR!"+I$0!#7580U+.H$,_5($-3WA#LN900QDP8`Z($4,90E66*X0A#A`X
MP0,H8(4N#*$"(=`,'X@0AR\`@`/P:@,*O2(`,H0@!"SQ@Q7:`(>>6$$X-(/;
M--3_\L8V7*%$5Y#!QRZ`"Q80@0=F>`,$-,`!$50@`EH8@0><4#4"R*`!91!4
M&JS@A2!D(0968`,<)!`&([Q!!EAH`A+&\(0\ZL`+-#G>!:;Q!@I@3`L/<`(1
MPD`&"1'@#"'`@J608#(CN*!MC1C!&2S0-CQP40!!K,(7**@#`KP!!6G(P`4R
M,+]&H```#%A"#++0*AD@`0LZA``<P@&`-*!!`F#(PA;@X(4FR,$)5?ACW"I0
M!!HT00LO>(`$0E"%"G`@!+TK`!Z`$`(*[$`,&$B"!$X@@3<LH0:*LP(<=G`%
M(S@A"G2P0I6N$($N\*`%,E``!7:7`P)`(`R$*`(#6N`$_P6D00P.>`P-(```
M(C0!#35P`Q9XH`4`S(%`:&!`&V1PCAU4X2`D\`#]V`".)1!A-S=X@@-TVA<O
MJ"$#3TM*"ZH0Q.R$`!8MF,\<`-""&OKA#3[E@0/@(`<5@$$`34C<`_J#R#<8
M(0,$4(,8.*"Y$R@A"VL0F%.J6`<GT*%4:ZB)60$@AS1\80Y>(`(15ND''I2M
M#5&H@@ZN@(4`62!JWW,#&S"[`@>DP0$2B(*"(%"'.JB0`%PMBP#D<(887"<_
M0Q4#6<KFA2?LS55G:&T=>&4&7ZP!#<#*``_:D((3].`&87@`!$(@`@%<X!M:
MRMT#B'`:!\3@"CW@@AC2`-`;R/_@90(PC@2<\+(X*(`+;G!#"\Y@A#*,00)G
M0$,%NN"&"])`#&AXJA6L$(<0/:T'<.C%'`(`3$9P@`X&:-L"ON6%):BA#491
M@PXV,`"+3,`)C^"`'\IP!3-4T0IJ+$,<9$`&8,1!`B\40Q*>8(4J]``JN5!#
MK`;@@1@TX`1KF(`#5$"`'0R`#EWH0`:\8`1LW:`*;NA`&([0@O7N0`E;6`(4
M7M``#DT`!`0(P@2PL($9/3F]&]!!$K!@AA!80`TOF0,;%(`%$WSA!PMI04]"
M`*PUP.$!*^#")LG0@B[HAP%6F$`.O*`H,#2@;2\X@VUB$`8W(*$';;!"$'CP
MA"SP%`G_9]""49)0@[[H<"^N$HD3+@R&X,1!`SV1@!^BX0&-R8`'1)"`2W?`
M`P0_@)=S,%V$;C6`%IP``''P@AS<H($VM"$)2:"#2@#`ABOXI0ZT/4,-^=($
M-[R`#8CQ@P/&&T\MJ.%Y#*C!D;W`!0TXH01-T,P=9*W&,"PA%FX(PQM,4(4V
MA$$'"DB*0F!0`">$0`>T2(J&T+"!,I#,#;6-P@!Z8@`A8.$`"X!"""0`@7LR
M(008T`'"-N``'7@B!C,800_(+`,,*"`"+%A#%SS0!"M<(0M:T``68K`$`/0,
M#5:H@!7J$`83T`$)$:L!'<A`AB[LX`U/H$,!Q#"&M$3S"DCP_Z1)&IP(%-"A
M!&W[P.&LH`8LB$$.X_&#"!C0'A-DH`4>:L0'@C4#+X+!+[R1@PS`0(%98K@.
M6*@"``Q`AATL00Q:($`30@``*!RA`AYPP0T`$`01M*`!!E"#%I)@@0^<=`;(
M40$'YO""$<3`!36`@`H>,(((.`&K7.A"&N0P!RBPX`*AX($3((`&,3Q``9MU
M@`@XS@(G7,$##'``%W1(!@"\@`X5'-FY,;T%+R@`#!JH0P-D0((!3,5;>(#T
M8,30-3^PH`05>$(#;E"'-IR@`1:H@!I"<`&MQ;`O.YP#&1`#@<6X`0!G<`9I
M$0%-X`$TT``\(`9`P`-0(`)\4`.%E/\#:*`%/>`$6P``/W`&%-`$9>`'=7`&
MY)<?`!!/`)@$/Z`Y8(`4&Q`'<'`"_0,`8,![W&5MVM(&%=`_?/$$'O!),^`%
M!,`%7F`&F@$$9"`X=4`!5V`4<Q`#;O!V:=`$:H`&&E`B3/4Q9Z`&49,4__<$
M+[,6'QAU;K`0.]`&3D`P;E`$!"``4I<!*M`#`C`$.-`"-N`!9G`!+"`&N[`"
M`V`/#C`&;3`'#A`'*(`%6B!:2;`&=$`'%>`T&Q(&6"``26``<"`&:V`&_^!%
M:+`&/6`!#H![7R```N``3M`"`M```.`#7*<(`W`3;4,%:?$$09`;8C!?=?!#
M%Z`#&3`!:?#_2W+W%`^0%P3P*W'B8RS``E3&`ER&!4K3`I7S"C71!0"0`0Z@
M!2)@!5Q0`Q_@`'\0`09!`SG0`O'G`!30!9$8`R?P9"X``2R@`3/``620`0%0
M`5I`/"K`!060!!>P`]DD!#QP`F`@!"'0`B+P*#,@`!C``1-@`2%`!@(0#'[`
M8E1$!KT7!VDQ6F;@!DD@!SIT%0,`!RHD<GS0-A#@!X=3!5'@!CKP!74PCVO@
M?`2`=F)`#_BQ!C'`:>Z1!G'@``_0?ID(6540!\OE!T@``"60!FU``&8@`I$(
M`5W0'T6P4TU`!QSE!CQP`VB@<$[@!U.G+7,`!TD`!\#B!U\0!@5T_W8>B']A
M>#B5)0%J\`1(8`4UA`9S@`97(`=OD`$W('3>X06:D0>=$0=?(I0%@$EFP`-#
ML#A8\`;")`%(("`1L`1#<")CP`-2@%\%%!QU(`%F1P80\!@3P`02$`$B0`8G
MP`$]@`(3<`4A("4L,#L](`1N<`$O4`&_L%XYX`0W0`0#4`4#`#5L,`?E(@%>
M\$8B@`!B@`1@,$L4\`0Q,`=-0`1&H`5RT`5>\`;`X1</4`-ED%-L1@8\``=U
M@(JI^`<^0`<DT#8^@`5)X05#20<CT&_IY04.<"HG4$V,<`!K(%^2DP4_T`8U
MP``4,%I:8`2*X@:+<@%RD(`RT`)IT09@4/\#<I`%*K`!NO8"4D`!+[`"%6`5
M$&!Z,C`"/+`^+1`&(&`"'``!,B`!77`%6Q`"+/``!$``%8`!`E`#1!`$.=$`
M.H`!?-<#EP$,6"`"%*$$#%"!21`!CJ0%R:$`<=`#.&D&;<`&/[`$5?`&9\`&
M]P$!;\`!%L@`6%`$\+=U#`(!<R`#5H`&D58%HI8$'.`%=0`'6[`%2"`'9"`8
M7!DU8^`'_M`$\H)D75`6:,4&/3`&N#**:&`)2)";27``3)`$:$`&8Z!\")2<
M3>!#5]`&_]<+3^`$>S$1;-"!?7$%6;DM.`(`5[`05:4%^8%$`A<8%/`#FP<&
M(5I0F@$%81D"2%#_.6%0!O?R!E&@!<45!X)1F%R0!OCB,0P0!V/`!2.V1C&0
M4S^SG&>`(T%0`2Z0`R]0`YHY`BF@`BF0`32@4$*@!0[0HF%P`S'0`P0P`E:@
M`%8P!F*@`2/J`$I0!"P%!F&0!150!@Z@;T0@17-P83)P!D7"!3RP4SR0`69`
M!*W&!0U0!700`P0B!#J`!!0@GJEH`'60`>@Y#55@!LKF$%6@`%H@`W)#`6,P
M`(]P!'X@&X>U8C4`-"MJ!EL@`VX@:TN0!8]7!A@P/E?`'IKW!E50`#5P`AN0
M`P80`P1P`JR3`YK#`@;@`>BA`!7@`!D0`B6P`0+`4".P`4I`!!-`:5B0_P-R
MP0%7P`!U(`-5\&1@$`'QU`,*<`468`4$0`$8,'$]T`4*<**-@0$2<`4Q(`.6
MX@=TH`6^A03M(@83L`06P`%R(!42\`,[(*8+@@%U<`%1``!BT`8T$`4.@`%&
M($!)0`194`/[@@%KD`8=2!02P$9$(`;<Q0!.$`8]@`8<``!M$`)M4`9,P`-7
M,`)9H`,5P`#.U0(&L3=N4`$BH`4P$`-$X'-FL!)/$`?-MTR)U7,\]+PHEA1R
M=E9:`T!:T!\!EXEA(`>7B@9=<`*Q$`5+``?Z5Q->@`$QP`%(H!E34`4Y5!.`
M*4J84#)$H`6DQ!,PY`=C``9.$`='EP;G06U.X/^F?B$`5D`!AEN$!O`#%&`=
M%L"65T`#2W`$6H`&)Z`"+)`#R\L`$Y`%'%<$/``!/&`!PN(`$!`'%1`%FM@"
M#-`%#_`%#)`$;C"!=+"U8!`"$T0$4<`#7.!>7^`!CT(M[#8"HLH#`!`%`&4"
M.#">?U`"?L"Q:(,'E0H65<`#"1`&2(`$)T`&*,!K.8`!*^L'#_`2CG,!7]`-
M=(`&#S!'5TD;9E`J78`!8P-$:3`!-<4"?Y*2/B`!LWD%/,!C"&D!%N`"1R`#
M2)L"7M``:D"V;1`!/9``=-"S$)`#+-`"$#`#;R`&+M$&7(`!9H`!"!`$'1`%
M22L"JML""I`!/R%&1Z#_GA70!H<12F5@!K$`!S5@,@H@!PH`9=I*!UM0!5Z@
M`TJ%-AC@!S6`I"W@`";;`C_8:2(P9FO0!C7Y!`6P`4W02M!(/">P!`*@!;I5
M%AM3%G'P`!G@GSFP`=^&!%.B`D]#0FTZ`%_`PG*`!BQP"0;4`S00!Q3@!X_2
M!A<@;7.!6S""!/D1!@6=$$7@!LNG!&^0!5'0&1XX%V\@!ZK:!6N@!1#`C_\"
M-V-P!FZ0`ROB!FGP,PU@+05BI4X1`PK`/WZ@!1M``9G8;W50A(7C0BW0TGY@
M`3(P`"^`!1%0`DZ0>B>@`"0@`U[PU'O(!@[8`QF8`DGP!G'P`EE@!0*`!#)V
M_T898`)I`!M@(`%U(%_+4<1KD#+6L2[M.F-DT`#6>`42H+"6(0,3T`4E\%%5
M/)X#X`<:T#8X@!@+00%U8,(56"Y00`9+8`5&$)*-,`4B8P5:,`=&10=%P`4C
M0'[M-1M/T`84D!-;\`1L@$9@@``%$`=',`%%?0*<EP=%`!4<4"4]0*XJ4`0J
MD%,],`)$@`'AD@0G8`!;X`!JD`2*AP$BP`$7D`(M4`(XX`!9X`7,FP\^``$-
M(`9NT`1SA@6F]P`S,<#FYP5#<`9&]09D``-\$0<,<`8:H`0EL@$AX`!ET`$Q
M,`)3P&!HTP!N@#]>@&QG``8L$`;;K"&::S$Q\`IP$/\K/M0&(.V!&+1<`H`%
M%$`'5N-$A+LT7B`%(-!1R]$$%^`#&^`T7&!CF$H#;(`%#M`=%I,%-:0&55`&
M/>#>)*,76H`%=1`"=5`$:3$,-70U"V&E$<`36M@$#F!M8=`";K`%!K!62E"K
M9L`3!3`'7T`'`4@\A9A\%M`&G1D%+7`!X?8&)V`&'S8'2!`,$K`%9\``8R`#
M%@`>>C8#>V`!6G`#8B`&%*`!#A`$5Z`&FJ,#IR<#00``%%"S<D`$2^`$??,$
M/N`%;!`!15`&&TH$!(`&M\8&%^`%$U`!B_94)E`!;,``,)!S'[P%9?"3OO4V
M(G`%=,`P:H@$8<`$5AS8@XW_-E/0!A0T!H+A/V9PC7$`!C?@!#,P`)+-"%#@
M!T;`C&MD!F?0*@)PE/K18?&CZY;``QM0`^@!L2\`!U,P`29`!-A8`P>``A0P
M`A]0`4@@!:9'R1DP!!A0`'M8``50`ET0!0)P#"0`!EVP`4E``5%`!@Q`!%T0
M`=%Y`DIJ!1T!<!$0X(>R`LSC>]J3!*IZ!A5`.#*@N2W`#X%8IPJ@`"$`B.G`
M6&&@`57P-PP":WFK!BW0*7H5`D6KKDD0`R0PE&N@`!(Y:VP@`W'@@GZP!120
M`<*Q!%T0U$FP:H)7`1LP=;-4!&OP`UP0`U'P`O_*`U2@$W#P1'$`001FT/G!
M!8]A_ZJQ\#\`\$8``&IQL"MH\"V#<<0.T`/#E1=G8`5\M@1W%P<T\06S_->1
M``5K``9LX`9*D!020+\XY#1&``9:`-PKX=!FP0(X_WIBHI8A<-S5XZBQ<`$?
M<+!&\'(10`418`!R,'_P0P')J0$O\`,<<&MD(`%EH!LO0`!*<`(#(@48<`4G
M\,Q:H`5FE*QL@`&^D0,;]Q/"&042``!<8`*>@`9#N3DG<`)P``<7(`9-``'%
MSG4+$&QMLT6MI0T^M`964#Q2)P!":@2/<.QT@`584`8"L`5L\&/^/!(-+`98
MD`5J<`,4X`5T$`=U@'5L``AO3&Q1%D0,/1@&7TY$00(?%_\11C(,%3$Y.11:
M&1<,#S\2$!H\:2U)/5TF.0(G5PX07&]L."\O52D<%%<5(R4E&1$G!"P&`%]L
M?C$0=%A^6AP\1&-5:"$P/',N2PXM84AC/RUD3'_FY^CIYP-P:2%I<T\Q1$1;
M=%4"13U:96@5+RS`//"#YDP5+W&>M'E2)PN=)W+@<*%C1DZ:,Q&(A)!!YLJ%
M$S]87,F`HDF#"$@,G6PQ)XX7"D]"^!DCQL^3,V?:P(OC!X"?FGZ"!I53A8X;
M"5YXR'DBX(46`43\&'GB1HP7-&7\6,ER!082(ARJ&%FB3MT``&:X`*@20D$4
M`&'"O!E0K\*`*VT`@#FQI@D2`7[_X%1)TH8)G)I/>A`@!8!(G&1&`G!IX:0%
MC@@;'(2H8$5#BRX[:K3HT8,(CQ`M0$BHP4#`CBT";C1HH*4'#Q8/Z!11$D8+
MCS)>"'CQ\H+#@SDUM)SQDP2)@C9MH,JXMZ4(D3E+L,RQTJ-<V>_?@YQI`!Y\
M@"U^'.18_D(]C0%-/I2`DF'$=R9^O%3)P0:+EC=B-('%%T1((`<=-5011QQ.
MH`$!-&"H<<82+X0PQP-.F20`$AB@,,0(5QQP0P$A="%`!3IHX$00#Q20@081
M9%``'QQ`E8$%.C2!@!4T5-`#'SN0T44%!)B0`0,,+#''%RTPP$4^0MQ`!`0C
M\`!!%WX0_Z``$5VLL4$3<,C`)09J8#$`!1#@(`,6;UR@!@DY@.%#>=\-\`06
M8)@&@`X"Q/$`&UIH4049:9A!Q!5FG.%&&W4`P$8#5L3A4Q2^R;&=#-7X8485
M5BW*P05E\-`%`S\X(``-]+3@0`5)<(!&%G,@844:3SAQ1@$^\>"&#F`\41,7
M9M`AU%``U,%&%7`(X`8<-BDPQPY5`)!&%5RP0<8;LW5AA1Q98!%#%`KT$,4.
M=/X1!!A^T/I&&404(4`6/6!!0QV2<H%&'%>((4<4;21#!P,M5!&&-V.`,9P9
M7;0!014,Q'!&"'E,\`(12!@00`84,`!!&%R`\4(%#A#AQ`1E9/_@``LC?"!"
M`Z4N(<`8,>SQP!8&3.`%`#TX0(,3.H2@1@0LM"$!"RZLP8883SRA0ZQEM("&
M`%6400`11@#@1@@]6E`#%.66NT<;Y'6-3@"VDH%%&G)T@84"2"`!A@PRB(!#
M&P&4Y<,3'(P@`0"M"%&*&V%D1L`5(O"@'PA:D"$1'$VPL6@3;;@HP15$C!!#
M%S14*4$`*$3A@089[.!%`4[LH(T(30S0@P4"G"@`!F0H8,06*,$0<@0-2-!#
M'2\0L((70:2`P@LT@`!#`Z;2%D$--W#A1P-$N-%$&CJPLD05$&"1`1DZB+!$
M'CH,X``55TR``@UVB(T.#@!\0($3?HC_T(4;`L#Q!!T-"#`!`%FTT008:YB8
M$M"U!AZT800`X`(6LD``!UQ!#C_PPQ6,$`4!/($':!#!#U`P`@?LX`0*:,$6
MPD`!,1RA!Q]00166<X$8U,0+;VC#"]B@@P&-H0YQR8`$U!"4!3WA`<(90Q&N
ML`$!B($.<GC&&N!`AS7DP`MNT(($DA`'CTE@4UA``@$DT((+E&L*4;F"$MBP
M!@9L0`PUD(`8(``'`%`@!DFH`1E^.(0RS,$/9X@#=.@`AS/`Q2=JZ`(86L`!
M(HA)!T>0`'U.H($>P"`"4-@!!QR`@BJXP`@L(,$+WD`K+VS!!4W(3056$`/K
M3`$&GTB`$6"@_P4OP"$':*C@E"J@A!XPH%]?B`<=,,`#&E@!#1(0@!4@(($L
M$$%>88H!!;RCOK+L@0T9:*8Y]*``+22!#@^HP2)ZX`4K:"$+5<)!$O!0%CLT
M(2C8FX`8CI*`$!!!A/JH@PKD`(`X2*`":EA"'1J@@P(X(`9KF$(?&C``'BB@
M/BX@@@H\$!E6@*``#-5"`P@0@5QX0%1AN((",$"$!7!@!PJ80`I:((7-A,$#
M/4"!`GX`@P\8@`UQD`$2Z#`%'B3A`BIH10MXH!D_Y``&/:@`&F(0`D4(H`PS
M((,!9@`&"4RA;>EB09JB``1I_@$';_B"#L2`@2<@8`@7J`,6=-`&#?]L8`EN
M`$`4>G`1%O#`)V8X@1O.8`9&/2`A;U!&&]2PAAY@4PQIB$`.#K"#`I```DFP
MP`D^(`.3C<`(`E##`.(0`C&TH`Z8\@,=SH"T."!@"7*P0`S',`8"J.$*60A,
M%UHP!@LDC`AEJ$,+7!`".$`@*#O(00V^4`<(/"`+3QB`A!R@!!ULK%QGL4D5
M'+%$'?@A!`;00F#H0`88@&$';C`6%[[PAA%>H@<A0$,#BF"3!C0A!E;@0`MV
M(`,!G.D+$)B`!:(@`0I\H0<N*(`"<!`"'^B@`2>@2PA2H(71H,$(]NQ"%1K0
MD!?P@`!L0((9```'"0CJ4&-H``"LX``_L`#_`$B[``0`X(4P'($)1O@"&8@`
MP`=>H04A,$+ZK&J.`#`@8FXXP@&HT$P?H&$F$>!8&RXPAQ%4`0,*F$(-YO<=
M%[3A!A-@PA5>,``-A,`$$0C!6]&04"^LX;1@:,(5=""'"H`A"G-H`!L*X`,"
M\``,&``!$HK```Z<(`(*($`21J$"`PP@!#W8`00(<($3_F`(!(B!R41Q!1OT
MH`D\D``.7%`#-\3`"0S0P`S,,($&'($!)ZB`$0J0AC`XP3I-@!H`9`"`)`!@
M!P^Y"1OJR9LZO"$&,NC!&B8P`"BXX18T'H$?(+!.+AQ(!R=X`Q%^\(0T:,$*
M8I`6$KJ`1#"P80=H_P!`THHPQSKT)*]A<(,?Y@"`!-8$!!`H@P6JX$T(M,`+
M9H;`"XS@A!#H0`LX?()I!6`0#X1`C4A0`Q./]H4J/,$!<3C#&DCLTS:(NPU!
MJ4,3.`+3)V"I#D]X`07BH`.&O&$R6B#"!UY7K@S(H05-@,`5S@GB-Y@A3$](
MBP3J<(,*(.$-"!B#3<(0[2O$W`U/($,UZ'"")3LA#-QA@@0V,(,,$($%!]#`
M%<:`A<A5P`,#X(()-J$`#9"A#0B0Z`L\P($FB*`%:X`!+W^@!>'$H`4:2+<"
M"M"`#/"@#E8(`W.>0`*"%,@-SB)`#MXZ)"L,`0D<V`(0E$#C<^!!"UNH@?\<
M`(*"'J=!L_!^@QMNVP,RC``"#0#!!<#P'0[400.SJ8$5*-``)71!#$GH@%RB
M\*<P_*`-@;+"HL`+!RV<9=0E0,$)(*""%:!`!AN`P`!0T($"*!8+%GB`%U;P
M`"-L3P$H8`$%.-`&&01``AG0`0O\"0LN-&`70X!`#0A0!0KHH`4%$$(+'G""
M%T0!!UTHP@H@8($T```)/K4&56`&8%`&'(`D6&`%5Q`&,Z0%?!,!#]`"#3`#
M34!C&N!E22`#:4`794`&$G`!#R`#QY$#;N`%=,`#9T`$#N`&9"`#;80*=8`&
M;U``3_`&.G`%;W%'6T`&HY,2/$`!1S``$E`%,:#_!FH@`VV@`A7``R)@,$X`
M``KP)S]@`67``FE`!PH`!U[`!CR@!2S@!DL`![V"%-$B<6YP>57``UPP!VB@
M!K;R!`!067601$^`!%X0*T^`!G#0!@$D!ESP`W=`)QE@*+52!0_@:DD1!A(0
M!#70!&&`*PW``TV``6NP!C<#.&OP!%<0`E[0`U6P!E6'!#)P"TC`!CF@`@R`
M`P)@`A9``!50=TU``DE0!34P!B80!03P`!%0`&*@!?_S`Q10!&'P!!%@`3(0
M0E[@!`)@955``(.T:FK``%=P!19V97YP`F*@!EH0`Q!&`P[0!37P6UZ0!DFP
M`1+`!E^@!A2P!8UW#BDP_RP]($T%\`9@T``7X`Y7<!!;8`8*4%^)-0'?H0)S
MX`$AZ`!96`1O8`5=<`:O50-QD%V.\@9/`&D-T01?`'MR<`0R$`%"T``8P)$/
M<`0GD`$@D`$0H!D%,`(IX`(CH`*=)@0F(`%$T(\2@`2$5%HGP`&VX2(\10`=
M(`8%H#H/D`/UI0!.T`,_4`57@`42\`1>P``RT`5R<`9((`&H@02Z%0(/P`,8
M(`8RP`$YT"0>T`@6T``<8`$'(`,TQ@(AD&I+\``4<!`MT(L/$`,"P`83]@XS
M$`-N<`6]`@"XYP71)@=K0`5HT`)J4`?P%DB.$05((`8&8`(5(!I>$`$R`$<Y
M8/\$.L`::+!B--`2,Q0&18![I)9:6C`&<5`%65`';;`[6K`&8O4&J^83?B`#
M<9`&:Q`!&Q(4%Z1`8U!N"E`!9C`'<\``26`%-Y`#2=``*)``=#($64`D$Y`O
MRR8!O2,&[<(!1CD';Y`$#X``8*``17`&5["%:-`&<Y07;4`'UX$S"G`$97`!
M>5``,G`-2H``3H``)Z`#,O`#/2`!-P`$88"-!F`!+5`!$1`!:$``7S`"6G`!
M,%`#,F`!<;!&$D`"Q!`#:W@"#3`:&``'%!`"MZ4`(=`&62`'``)H6%`$&;`%
M#*`&1^0'39`$K40#[6@.0"`43V`"TH1`9/`436`A%(#_FB,@!@I``0,P`SQ:
M%CE:!S3``VSP!E*E`+/&!7&0'`I`=$N3:FS0I0!P!F10`5=@`&>@D6/0!%10
M`2AP!',`!%'0`#V0`D30`!?5!D9``%30!D```UU0C#6``CQ@`%5@`9-9`2;0
M!9SP!1:P!W76!944!2R``0Z@.QE0!W/',1'@!'1P`8'B:@!0(W5@!CR@!.YD
M`EJ`!2E@!3(P`A/P`!L09ECP!!.`!0W@`C06`6?@(P]@`WS0`BG0`"G`!A&`
M`0'@)E?@!!3`!CV`GC+0*/20!3R0`>O9!86T''Y@`.ER`TBS!6W0!R(@`1]P
M`VS@`RP0`Q;@!!*0`FAP`@)0_R(Q4&8W$`-SH!Q?\`(6<`5^\`6X!VE+X`=O
M<`4T\`0]809B$`-;X'\GP`,MX`89$!3#(0820`9HD`8,P(*J&09LF`8)&08X
M4`4#4"YAE8=$("@0P`(J0`;<H09SL%E>@`%F``(Y$`:YR@4,T#B1Y02^4@9:
M(&$,T(L$(`8J$`9FH`-QT``CL`)%&@80H!-)@`4OP``?D`)78`4%P`5=@`1-
M(`4?D`'\505"0`0HD#T"H"6F00?O\P0M,`)2\`)Q8@85()$#X`<_4`8]X`?&
MI@9M\`4K0`1-(`%J9`1U6P=$H`%LT`8W^@=[T&&!855!0%ER4`074$8DX`5J
M8`$2X/\`@\,`*M!D`-`$9R``<O`!6(`&7W`&%T`3$2!L?L`&*9`$0M$$`1L4
M/:!#<(``'50%2/!Y;2`",F`%+#``&!`$8:`#3*`&+W$H+ND!4"`'.M`%QP@`
M$Q">+2!O5Y`#!?`I+.``'$`&`R`")]`&(5``5\`!6Y@$(V``&1`#M>0`$U`#
M!(L:$%`!5:`&.E`&8>!*<S``)Q"7,E`"(@,21/``"I`$MWIT9H"U3N`%(4"8
M,C":;"`!R\%#:R``8-,&E.6O1N!37;"'C/,&PE($:4AN6M"9-C`')I`$)<`&
M-A`'TTLA36`!!D`&*,`!#*$&+!`'K\A6(Y`T=9@$<)`<L3K_+?F*1VO`$VYP
M1T[P!=HF+9KU!!!0`')0`+<5%"R`!*9J*!(0`<G"`EU#`A@W!P9P`K6A`5S@
M!@@W`(X#`*$2!CX1`C_@?Y+2`X9B;!&'$QQ@!J_"`P.@!2]`GQDP`"D@`$>`
M!!G``A52`C<P"4M@`$/P#Q&@A!20F0\@!FO@D5\F`D00!6&@!`P@$V90`$!P
M!4(@4T_P4KX2`7Y0`1TP/?])$"@'`V1`9&;@+@2P!E<F`Z1WN*BL*5:%RGDE
M%,6B&#/P!`UP`V;P`SKP'4=P!ED@HF^@`6C``GC\-F4@DRWP!&/P<GY`!CW!
M!6'PH5C`!D4```@``4ZPJBP0`!"P_P`.<`(3H`0#0`:9.09,X`&:H04?,`)6
ML`-*8`$\J!_U*`!H\`=5X``,L`9@(`8.P`4O(&)%T`36E#\38`,%L``YT`A4
M,`,#4`-1`,L`0`-JX,%I,&U*$`,5P`$O$`9L4`=IP`/"20)RT`"BB@!?0&,@
M4`8#D`7-"@!+P`,P<`9@,&%GP`6H[!,M0`(1,J_>!@`-,&ZY9`";W$IHY0!D
M$#1D(`=7X`,=H#OGR@%T,``9,`$CW`(R\`5EP*$`D&[,(08XH19YE`%DQ`5&
MX"!O<$>PJ7ET\'%WJ"E^D#!^,(0&@D=7\`9Q,+%Y10=4$`-:(`<S``,IW34@
M\`02T`2G>_^279!P/7`!*V`%9_"N*!"73H`K$P`!<4"K*T8$UJJ',?%R<0`%
M9W0"1+`#_)4$!4``'*`#2!`$)QP"+R`&2B`H_0BX`A"%3T`B:7`$IJC052Q>
M30``%V`3,>`"+-`%&U!<(]`%9@`88J#2,+$<F*(%E'P&&U!@/"`&'*`%;$`,
MA_L'?2!N.6!5'Z`&_^<`%T`'/C%D6"`'84`D;*"69>$!?D"$FIHG5J`#P:0`
M!A<',`"Q-?M<;L`%2Q`&59`&B(I`*A``%.4%3TH%&>`")F`<$=@#,L`%&H`%
M%V``2W`C#9"]H/,"))`!HML#04`!(#`'+-``$R`#+G#>.1`H%]#_`&VY?A$@
M!EN``34@6#R0!1+@!!M`!F&@`1C0`VB``8("`"=0H@)@!EYP`?"2`V3``"\@
M"A]P!&1@TTY@?RS`!0=7!2+``!D`-3)TO]+"`V$P`EG``MO=(#Q18FO0`G3`
M!C7(MG1PJIJUK"FI`V'\SAR@`1.Z7CJ@&&^@!34P!V3``]/V!,.X`?;]`&#0
M`^79!2&P!9P"H@J@`W6P!H4B`U[`!270#`#@!'%`!%9`!TE``\,I`#%`!F+0
M!<KV`P:0`V5P$!1`3G0"`F<@`V]PYAP0!0Q`;3+``SJP`\>ZCC]`N5?0)69`
MU8'4!D3@)@9!!F:`!6:PD:NS!C_@`56@_P04(``98`*QPP"U$0.1-@1.\`,5
M(`$-8*`,$`$?H"(,\`8J<!AAT`8Q<`%&&2]>(`,$H`5!L)EA8`%-P`((+@%9
MT@,PXP7D*;2SG`1.<`)IH`1$D`1@H+FP8ZN'BP)/\-[29`$0.V[EI@9F$+&O
MQ`M\D.Y-]@5HH``OH`3`(T57L`3.'09@(+-N@"\9EP,:&P(@5@-P\`)Q8`$1
MD.Y98(P*,*P-/0)IH"6O(P#7]71%$`&-C`*6X`40``%&X``Q?P4,8`8P(&(#
M\`(-`.I9,`8)4L4R4`!+T`8VY07;RP(Y0`0"H`1MU``?T`9A4`-*4`$X[!,M
MLJ[4>`-G(\==D/\$$6`%-$;#=$`Y,>``OYD&:5`!1,`%.D`$2P`&6K`7#S!A
M,EB_=.`%^"J`79`!7Q`4MLQB3:`$5Y")&_`!$FX%/S`#")`%&U`!-T`"3N`&
M3C``:3`$:-"W89`$%9`"0><':W`"<5`'M;P&E)X&ML:0$Z;$`)!$84`/6+$&
M=!`%+-8"4]E>3?0$7.`%>?$`N/L%#J!-Y<(!9_`"=4`!`PP(#4D=5TXM75E>
M;75@,3UJ`!)^?F\4-2\.+2<9=')^2&U-8$AE5VX,&R$U2`^G$FI$%PQ$#SP*
M!"=%'@H1.0X"+!A+.F@%53T5+&$2!$89"CH_+3H\9"U<I`4]<1-M,EK_`&Y>
M6FAN2V9&-6)@?CT:,F)<+0]@+G_W^/GZ^_A'?C_\`N(384:'EAY:9+"0`0Q,
M$@@A*@@P$I!#'3\L"/18\4;)&C%UZ#20@$6"FS5.O)31\J-"C30O!K3H(4/.
M%`%I&D#8<42!'1`<%*3`@J&"/`XM>.R(\,9!&C$[&JQ0,`++@34-5%@1DT$$
MB"P%6KSPP,3%!1`M9,1X$T*`AQ<4@FR(@R7,@Q`XS,QQ$\9*CRUL`&BQP$-,
M&S9(0FBI,(="A2$*X%`0,$>@90Y/"FPA,@?)DQ@.0H!I(:8*"A=-B(B)8$9!
M$3]/V/CAT<7S&B1QSM0Q(LE)B#57TB@($^<!_P$O5]98V3#C0@8B*$)P8?"E
MP@8.`%A80.!E394Z`-;T"#$&S!D_1```\$/F_)GS6'H@/\,@AXPN/!QH($+`
MB1\K9I"A17)^N"$&&Q*D<4(%7[A```X)6/8'9A%X4<($*X`@`Q9$9)%2'%V8
MX$0-120(``]RE+$%`!FHL84"Y%4A@Q]T^($&''X$D4,/1."00PXWA%'#!SAH
M\4`&.33`AP()8+%#&`,`$<0#"@2!`!@;H(`%&AQ,]@0&,F1`P`A!D/!#$0VX
MH`$#+&B@!`P=L($"&0+$(($.8OB!!1==8.%`&UC(``8$%U!P1@]5&"7AHO<<
MD<8'C.KC@Q=JZ-"%#/]KJ$"`&2>P$`(/15300@@!"5$'#UGXU84!;P0A`!M1
MM*'&$T7$D,1<9%3!PQQ>G.#%$V+TP,$9.#R00P4(9.(`%0PX$($57+2Q0@4&
M>(&"#D4H(8`*HQY!@04MB`!'%V\IP8$.`Z#A@0LNZ,1%!AXL0<0,'?3`A`<;
M@+%"&$1P8(,$4"!P!3QS5#!&`6+(48,$'^C0Q``FY'#"&&HT8$$#4S2P!A50
MY%!%I/J(X$<)50B`1`]S*&%`&'Z(H8,%/1CPA1@`5'&!%2T`H`(9;[SA1`\_
M<Z#%"VT`:D8;.^A`0P1M]/"$!B-00(,%9RP!!`H#%&$%#CR,T0(*(T@PA\?_
M`,PA@`4]5T#'&;#48489%_D11P42#.`%`%"X<88;3VCA01-9**%#9UVLX<<`
MQCI@6`\,Z$!&&$54@080+7S`Q`$2BO#$&S`@088)AQM10`@Y<!%&'4[,$84:
M57@PP1(QB)'$''1D\,)!<L3FQZ<L:,P5&"'HT``9KC.`A@$GP'`$"LDV4($%
M00P0P@1)$+!`!'"0@8$%,D1``1L#.+!$%1004$$8:LB@@@`-M!7&#4UP,80$
M7IS!`1;M].!&&\]ZX0083X"#&L@0@BJ\801B(((,I@`R@4`A"0W$!Q30```%
M```.9D`#&.;`E0A@``H<D`*I^'&`)\C("51`P1L6_T"!<NR@!^TY@Q<<0(`N
M2&`-!8"`!4SP`0DX00!QH`,3MJ"!T!#``B$P@!4&0``JG,`!.8B`!49@`2U(
MH`@D4`(.^B4%.T#!`!5@P`E0D((D:8``#V0""P;@!`78H`H8$`$94)"$'OPA
M!5!HPPD4DP*&A"$'7L""$$A`@CB\@0["R@(2*."',/``!#%P2P,B4(4N%,`#
MU8K@/30GCRV\X!8%B(\C:0``)0#@:`PX`ULD(`8LF*$.9WA`'<2AAA`\05"_
MZML;UH`C+?A!`C+8`@TP4(,`-&`'!-!"%"*@`AU(@0LP``,=8A`")T@```R(
MPQ-:4`,_G4$&:&"!%N!0H_\SL$$T-)J5+_W`!C>0`09[,$,%EN`$+;`!6&'@
M`@2,8(88(-`Q(YA"%QQPA$590#)JT*%BG/`"-%S!#TVX``30A8T>U"$-7%A#
M&-Z0@Q&HX3`&*,,#(%`%-B"(""10P1;.$`,5L(%]/G``!3Q0A2UP00!=0,H(
M0G"]2Q'!"EN@0`$0H`2%3.`'`R")$9;```UT``(RD(&+\EF$&O1`?W%8@P+H
MH`,D:,$!(Y`!':S``R-@H`%1H$,5RD"4-Z@A`V3@``HTN8\\!("N4%##&0#P
MACBX`0`)(``"X."&DKD@##$(2`#\X`0A7$$%18,`29:@!"54(`EG:`$6P!"&
M"^C_I%YIT((<9!`&"-`!`2;0``Q$Q0(2%``,%\,`$CC`@1)`D'HMV$$'3E"#
M'+@`!CQX0!*,,`4(&.D''"""!R@0`P9<0`5)4,$#)*"!)0Q@`"!800M:H((,
M5.`(#$(`#X@0`22XP0%EF,`#Q&"&$&B$*P@(PBSB6@,,;$`")#/`!&1`5YAI
MX70A@,`54@F',+"A`HP]`1'X\@8BA*`'=#"#'^!0`S`8H4!:``,/V."%&`"@
M#@+P@AG>``8E^*$!356")000`!TX80=FD(`"?-"%*P#Q#$4P9QPHL(4W=+C`
M3]A=&ZS0A#;XH0MZ2H("YA`#QJ+!#VN8`QO&$`<VY"`-_U4HS2.>D`4_*"$)
M#L`"$FBPA3;<=(\6,.@3Z-$%+T`@"V>40P:J<`,P@,`+$J`)*-00!1DH(`EA
MP(*,%#`&"HQA#C<``+#4\"0*$`$)'N@""K:0`2?DP`("X$$+*@!<!DS``UZ@
MP!(B@(`+\(<!7F@!'(BPA`JP@0$[<``&8M:#!@@@`B$H@`2RH(,5K"$"+LB`
M!2#0!A8T80Y:X($9NI`>,/0@!F18`W[*\00>?$$!#H@07;>MCP"`X49UJ`,#
M!'``-)2D!BEPP`,*`$%^!.`-2;@"$KS``P+86@$0L`(%)/`%+@P`U9KV0AA,
M4!.3/6$,UYRN`2QP@1,@H0(XB/_.#08@``9PH0D6&$`#1I`!`W2@MUM@0`L$
M(``8@"`"'>@"R3G``!.D@`,:\(`#;B`&#!!A"S4(`Q1H00`D$$`"(1#4&I)@
M!@=88`Q=J($3+&"&'O`@!!@X%$EE0(8<2(`/!'C+%1#`:1VLH;]@>``&&)!G
MZKZA#4[8@@/0$(&#9^$)&9A#&I+@Y=AMX0DZX$)0V;`%+TP"R8))@Y!D@X$'
M--4`$<!D`2K0``X,(14Z@,(&+*`&V0&`+AS2PAO"Y#@WQ*`-80A!$AX0!R+4
MX`2?]\,<:G"%*)1!@',X7`\N/F0NR$$#ZV&+#.(0@1B,`0"T:(,0#.J'91NP
M"0J0@0S_':`$!A"@!6`@`0,*8'3Z7:$&1#A!&(Z!`M]TX0DU^"\1JF`!-A2A
M!5IH02$P\(7->($%#!`!!##0A")$(`$8N,`#8%"`9ET`!1Z0;R405@^0`DBP
M`2;P?"DP`%'P<S_G!#3@`RC@`W_@6QD``!@0`0S3`T-0`!O@%B_03#0@`&%S
M"S/``#`P`]RV@OB0!RO@``4P@A]P!"[``09@`!"R!U!@`VGF;F<``QEP``[`
M`WC@!"LP`D:P!N$1`B;F`61@!L`A`0_P;"%0>BW0`&F``T(@`D(`!0?P`3G`
M!QX@`$>``S1@`!Y0`&JB`AR@`A[@`U]4`!_@`CZP`"EP`4/`_P$>Y`,WT`(0
MH`'/@00*<`%(,``:8`$=4``4L&\GH`4!4`(]A#@P,(,9(`-+4`!6IP1/=R)!
M]@1)8`6@1@0M(!)$4`8*4`)G!0!TM0)^X`5)(``7\`8M8`9F``?@(7#P,&=6
M4`4/0`1J$`8`D`:K=@9#9@9@L`9EP`.*``84(`9%0`9'8`%8T`41$`1(\`(=
MIP+(4P1:0`$,T`$HD`4C<`4),%`4,`(5@`0E8`0VLW@TD`,M0``"0`:R(@85
M(`-7``9O4`42P`%`E01)$`-<$`-K$`0$4%8J(`/AHT\CX@2AEP,EP`%0P`04
MIP*+,@%7$`)6L`!4$`0'T`,GP`$D</\!)E`#'B`"^U4`5,!`#X`"-I`"?_`6
M0\`#3.```3!_'^`!?)``-:D"%L`!/H`#4W``4)``+G``=\4'?*`'1LD']Y``
M.ZD'>I`/>(`'=H`']V`'4\D/=G`'7HD/=R"5>7`'']`'>*"4:(F6"9``6QE!
M1LDN0``$/E"'^V`'=I``1W`$5/`!?"D%*9`"'N`!*#"8*J`"0A`$0;``.YD`
M*C`!+F```7!=UX4`!5"9)3"`([`"*V`!:18$=>`%3V&)`!D'(7`%9*!H"E`%
M$Q8'6O`V:<<!%^`&,[!+@#8.6L`%?-)F7N`%N0,'8!`%`"`'6E`&85"<Y?$%
MNVEKX)(!2+#_$'Q0@QP``U(P!`[P`1.@!QPP`D)P`'W@`7_P`51P#R,0`&K(
M!`GP`19`!92#+B+P`0(P`SC@`3;`DR@P!7G`+CB@`B(W`>9Y!$PP!#C`!'3E
M`010`$?P`7R``P/@`GN0`!ZPE@8P!`&`!U.9`@D0`'R`!PCZAAZ0`E(PAP=P
M!W:)!SZ`.?K@E/?0!TJ9`'BP!_S0!WEPERX:`&WY!WQP5W]P!#L9`'W0HWI0
ME549HW?P!R**#W;P!UUY!WB0!WJP!WL@E6JYE@$PI0%P``>P``M@`S;`+NWB
M``.``[`I`@V`H5.0EP?Z`5+@EX`IF(:)F!,P`4,P`S=X707`G?QI_P$BP`$@
M<'(DD`$9H`$:T``-@`$F``$Y4`0YT!(\H`4'T7`GP`#.)X\"\``4T`2%(09B
ML`55\(09A`9ID`9JL`:U%`*V(@9HP`97U02:AT'C%`=A,`=R(`=S,*NT0P=T
M(`:,RJBXV06ZZ05?``9@,`;%69QP\![&JAO!J`:AN@8FU09Q,`G0&JW2*JT`
M8*MT<!'KL1[3NJV3\`=[8`(-D`(0P`,9L`$_0`,_L`$1L*<SP`0BP)DC4(8+
M<`!YT`<J<`=(F0`38`$W:`"U-0-O^J:(J0)](`5'@)1/*I9YP),XT`<B>J1(
MFJ1`F@<4*Y7Q29A"<)A!,`%2L)8>Z[%3>O\`,^`#*5"E8#,"F<F9(I"GM.4"
M./"R,,L$*J`!3``%9CH!$(``(_`!*;!QSE,!#N``'*"Q$_"G$3`#<DIR)3<`
M<$$!+,`".[`#VW4#-U`#"W-%1:`#424#FL@#7AL"I&HK=715/=`$:@`':,LA
M2(`$5M"V5?"V5W`%6(`%6J`&8'";?$(&:N`%`$0&&K0%W+0P`J(#M-BIH+JL
MS5HT;>`&C$N<;X"V:!L'DANKM%JK=*`>%_$$`.`>=:`&9O`$H!NZH'NLQAIN
MICNMA/4$L<>MK!NM>Q5DK0NMD`L'/?,&C+L_BCL)<K`&=?`&;(`&<4"+94`&
M9("I$18&8U`>8(#_G+O9!8&A'NH!*&A@JQQ4!6VK2$A`!-H;!4[0O;)@"D7#
M!@[V*5[+`T455=A2(A)@M52[72!0`FRRB`_P`$I+``2@``H`J2=P`C1P`7H8
MM#_@G5,`J"D(!3:;EWN)IFH:F%@3M`YP`1=``X_*`/BK`#.``1I`IS1``1SP
MM!"P72U0M5=[13J@M4WPJ4[WM:2Z!`!)MDW0!-T;!60@N9,KJ[/*!G$[M[F*
MMUT0!V*P!K[:!J([NL=:!FC@J8>[!F]0!VR@N&W@"9?[N'MU'M!:-K0:NI>K
MK;"QN;';Q=-JNK!TK&U`,T,LNM![QM!KK710N5J\K7H#&XL;&R:U!J+Z_ZE'
MW`;&^@1/(0;&>9R[V;Q=P`4U(`#V2P!;4&=L\+;6:P5KJ[W:V[TO3+8]`)`Q
M0$WD&P9VC`:T2$`2L+XUT+ZYM0,L(+_T*P#4P@'WF[]B=`(0[,`.4`&!V:$>
MRI?@F9=E*J@S``49@`(?X`,3$)=`P*4NT`%,@*58:J5(.:4+.`#]:J%'$+`X
M@)8]V@=.FK`4:Y<!0`5Y"04HRH+>+`!>',[BS+I</`GAP+BP*ZU@_!YT,+S%
MBZE]#*PJ@<;T+$U=\`7><;V-_,C=2UC[HPAML`9@2[X\``8EK`.=;+7;%;6+
MV`3*:T.`_%4.X`054`%*\`(O``'S=U8-`*@9T,8`V_M#$G"$(U"9!3``'7"#
M`#L!B)FQ@^D!"_`'4/"AM6S+$\D$,(L#<RG,-G#,5OH!#0`#@$A(Z\H!%M`'
M!C`"$W"6]RH0`?#2*=#-=+4'..K-5GW56)W56KW5^?`!%%#*^+N_K?S*%9`#
M&0T!)L#10NVG)!`!$4!;[VH!)%V9"(``UZ720R"P0N`#'P"`ZP*D3'`$4S`%
M3%#8.`VS<QG3BZ('5$JE'\NB+(H'?;`H>0"D20JQ7)W9FKW9G-W9GOW9H!W:
$@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g06286g0628605.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628605.gif
M1TE&.#EAT`)<`<0``._O[]_?WQ\?'U]?7R\O+Y^?GT]/3\_/SV]O;P\/#Z^O
MKX^/C[^_OW]_?S\_/P```/___P``````````````````````````````````
M`````````````````````````"'Y!```````+`````#0`EP!``7_("2.9&F>
M:*JN;.NJC2$LPS,$[U@P34\8N2"K\"`T'`F%<,E\%7H-7'-*+05XC:IVR^UZ
MO^"P>$PNF\^Y!D(YHN4`!H,4$E`@`&@1`.$XZ`-K>5X!!@T,AP8+;():``,+
M4`P(C%P'!08.F0T%E%L,`YD#AGB=50R9F0ISC`%/#0M-`%!9I;6V8FHB3P-^
M!0XO/"<!`Z1G")R^#G<0").W0@?$#`L+.'L,ST$*!@``APP`OL79+063WN#,
MM.0N"%$C@`3C["L#R[H&BWE\"H<%`MQR'(CQ;8$#??02*B0Q0$0``A`.",!1
M`&$*3@X"BC`P(%$>!WB.,<@'`0ZVA2@`_^$0=4S/+Y0HC$`H0,!!0PB/8)XX
M(&\F`0(G;^@TL6!2`%('9)T<2L+<B)-*!5T:-]*9"P(%BC%XN)2I5T:.1"PX
MF36B112;#C#0IPK(F0*<AF&#H^.KB&FZ5D$PX.>K)!$W25CUBJ`OK8ETN@Y]
M"+B-B`;S=`8;X4!*`\1G!I8XH+:P"SN)(3"09]*NZ;<G%?0EX4"Q,`4/3!Q(
ML(#3V[X$_$1S:5HHLWEK[1YR:&(=4S@X)I-PZY6![75N&ZQF:H@$Q!'5SSS`
M!DM$LP>Y6`00():3`=N@3ZO'):6:"0.N31PR#N_`8#+9^7K7P]PK>1$"5$;"
M)G:]@U,/`^H%4_\`M&A60@$*HM2/"`HHL(E;SGVU&PFQ83?=&.D9%UR'*S1P
M4S6UC0#`=>NUZ(5M`IS4%P#=K7"*`-WT!8XC\85Q@!00;C1"8%X9"-)F9Z&T
MCFL&,L6@0[34&*17<FR$RDLS^?7?"%M"@*`9"MS47YA[1%B">W1<-@Z)+K9)
MQ4/6R&,B'0,D6<(>$@E@7P$&.0`4&@IT)U2=&WTX5(9[C5/:5U>(T$<)/:+4
MFFBV,8?E<4!BY]U],'TB%@Y=9E>&=%E@N>)675YD62+]]>?FJTN$1P1D>Q&Y
MPFQ'67&I&0?A](``SC3`HEW+""`*+0PD<-J1KB[@ZE#2`2B"LC/5R)3_07A0
M"T%WO7XU%@2_K"B8H6$$8%,#"?`)@86B::O":"+\"&X;N\)JKPM[P$?*)[ZY
M4``Q\""0FR``.%#`C(!@9IHO:_6@Q`%'+ARQ#AK9!5^:GBE0+[3(W-70$Z;Q
MY(T``BS"1QX\K.4I`W[DU()^@2A```XIWFNS0*\X8*R9MR[PP`,)U!G96P^X
M(X,J+=:&629#'Y=1O,ZN%\`#S`5@$+DZ.;)K'.KY',#7(R#P;!G&OF>MC0D$
M,",XU-SL=@X/)34%@]W<$@W2;AJT<YN6U&!/F[Y@8K"+RD`Q^'HF*N#*##R+
M`3%\_A``L!,<L6Q)1DV_K3D)LF3^@H#/S'SO_]E\VQN<F]Y<[&8TK7E>AGV8
M+(`U"UB\XOKFN*>Z!``/W'[&L&[68>\!8Z\W*:R<)FW;+3M4<3#NT*]0_!L;
M=V)KFT_"2KR]A[]JYVG*V2)J$_)&;[X)[C9!7RV>P9K]J^9R'^EIWYL6/OOS
M^]OX^9JOOX3NI;B>BV1A.O\9+W]V(9WRLH$`!+*@?/P[WWBT8$!*3,Q-]QN@
M``]H+P6N)U#9&!\3IA=!S0%0"&RR!>A>Y:!7>0I6`W"@5Y;GIE>$4(8JV&`)
M-9=")O2P%/=@8?+6\Q<8XG`H];,+NYXAPB4,<8=O^R$*R8$F%S[Q-!MZ5??<
M5#WU?.D6311"%Z%HL__9:*%#WL`!9[92$@!\[8W)L=PAKO"-.MI1CG:\4FNL
M%A&IS7%_?KF+FYX'*P]V[8AC:"`5Q$7&1@;A)5/[F20G2<E?5?*2DQ0`)G\F
M@!X4P@$_2\!/`J0S`@B@)GI,92H3@(F?J/*5"?A5)D1I`%0BH9.B"(7@KM3)
M6?CRE[\L!"CX8#0$V*,98NL(1T*A3%#8Y)70)$`"$J!)6?Z2&L#,9C9=H09W
MF(@E]D"%&O38$6CRH3:BT*0R[$&-?BCN$+592S_X5)N*S-,Y^%0<7)P#B5G`
MI9^;\&6%>E`;&Y;@8?-IX!S=^$8WD@*.:3P$9^CXC37>\:(85<L(9E>"0"S_
M`9`..4H:^W(4-H(+D28(AR-7V@(&D&B2H@`/*#=)TYI6\EC)LJE.8ZG3GOIT
MDDNI02A_&DJ>$A631OTI9GAWU")LLIJ2U"0U*9G4F]K@J3^#B!^.$E6H2K*J
MER1`)<5:20$8U:MB-6M4?5HG*!QUIDV5I%`Q.5-34M-//R&K)<$#!:_&-:Z=
M5$(,%TE"EKKIBBXXP`.2$]6:4(VL4_UK36>ILU_U`&BQ%%@1\O$S(AP$*)FL
M$T]G8("_^G62L2SM5RDIU@8\`!*7^%4!DDI--4Q2M:$][5ZI>DFHDLP`02N"
M4!.0";T6HK0V46T-'/!+2B)@`;H%JTW5FHEJ$O>4_]0<`%FOQ$E4_&P`4&5N
M,Z"`6\G2%*QVO:GA?F5*DHG2O-.DJ6[C"A0+S=:\?V7N2E!J6`FFSX<.R6H?
M^D$-&QR@0G!Y!5S.8R%?'N*U_'28XJ"[!C8=`3;S'`L-;#*:L2@@:,ZT27#C
MP(<0^\DF)BXN1V29"6.*+0X#&``KE>E:\)96I,Q``KIBD%R27:8'SS1K:6.I
M2;VR&+MB'24J?D)<5#29E#I+92UM8LI^W*`(PL)$B*D97%!*<[K!Q62`0FE*
M4_XL$[(D:X!(F5=I`N40L`E035"I60&3K*?2)>IRH0H*UU+M,GSU@7"9"=>X
MQO>GCQ"J8ZGV73_]K!DSK?_E3RQ[6?SZ5"8G-04[>%`1D/8W!5.C8+P>;:I'
MF*D9%W%+E5142QP0H!]J&\"_A@@'JWP(7C0YVS:Z@0"]F`L/A+3.'!2@E9D9
M,P$,!5<NVJ:#:/3'<MX0Q170L5!%#&04;HS()I"S43JP2$&K!H#"'L`)48P#
M+B#!RE;JZ*QO[&".!X[A1=760,@<A8Y[D9VL[<`R</!"+7O`TFQTDVV'Q.$3
M@>JGXNP1@R=P$Z#`M$,#&DR#!%>\(PX#RK^,P-P8](X.S,B'X9@[Y66:B`!%
M(8(,A!GC8QF+`&*#0LRS[,D'D!P!P#(1%$S9`V#QM0;*4@MLF#M59?AIS>HL
M\YK_[^I*)^.\R7H4:P*^=+PI5)`51A"%(CS]:?ET0;&_NHE$%E`,6>L!*RDH
MRD;_%)%.@MS/DMQB^\Q%PQ*82`HR*P9TYW*)16QC-8K3PX51H+&3+$#J/"6[
M=P)#O(JMIF`77`XM'L+XDCED8/%*P%(L,0*9T=#(0G$$YD4S,`81Z1'%R-5&
M*D8"GMQD/.L8#R=HE(#5\&01T[!Y7D_X#QP00FZZZ(EB'X_R;DN^1^DJ2;?B
M-;`E$O>;V]G)QT]@$#IUQQK`/0KK]X*9?@^IUQ$""+B8$R,>P"81MKGW>5"P
M*/D(`$+_)H&YADP+"/D.U"<D&,SG$(XP=KT,82$:/Q,F_\IW-A!#;,P%#Q5%
M"``C(]RP(@VX%UD%-/0A#A`(:I.C"Q.W+OU"!R3!;7HP&DKP"E@C,JR!63]S
M)K``![9"$MO2@0-"0^:B!*/1%<03)_IP>Q'A`&>#5G,08VJD'Y3!!D[!$+;A
M"V8B"5J1@//W4.%1,/H06Y,$//%2=3(C(RND77H@;6&S/.H2(<_5>6GC$)@!
M")-@73^C1K0B&I:W$Y,S&]U!/*^&#\6`A%RR&O\R-`PH!9(C`I0T$=+D$%KS
M4-8B"BF1?"4QAWY0,%/W,U<G!(:$!G17%V+QB/^G*Z:P6#,Q@`:#:7>B,ZO@
M39L`%)O@+!IS`(>'2Y/"`%`U3?\Q<%><0#R6=P0Z,V-3YB?4`EU^(C!%\4Q^
M(BPE1B',!0`2T6?`PB`$M0E)D(`TXE>B(#CFH%T?-TYH%@=!DPE`,!ZM84RV
ME`D^<QEAZ"58H3$?)CGA)`JS@7/.D19T4$D-=B%P430:V`-35P,R-WO:%0<T
MT!$=00,*H$EP48D"$P`)4!CZ-!8$87EJ@7U.)4E7L`.],`-],18QYAPS,`T(
MX@L:`P3K6!&OY2L5(8AX(!$(P1-J4WOPL"W5I%<T^"\1\68AN!56HR=VM'Z7
MX`??H%UXH)--\2@QEA)&4`RU!@%_^#7+0)`VB"`0$X=TL"^/<F\X@0VC,1"@
ME(#K<G__DA$8-5%V272)E*$%_^%GM!@C._$3Y")N0T0(ZP-WG952?I("VW`1
MNR(%X-`[7<$&/-$+=X$%'S8?6<`@?H6,/<`)KP8VF:(.>QF*0Y0LX"=(=\$F
M5S`,.T!N:8(E<0<THL@)PO(E@OD0'1<)B7$RZQ:9WF$>)V&3R5<(<`$*3T"9
M_Z(,CT%)1M=B$L%C5B(*-<%CWJ0+;N<EA=`#I\!A3S,3G`$!U%1-=U8$T_02
M@(8#L,%:<6<`WX%V$!,@VA5EJ``AQ265FF1,,"9R&^@ER<01L_"9-G`DQI(V
M)F)5CDAN-?`?"/!=AP93ZU($V/`OA>`S]B@SDA0%E^"<P,1-_YR`!6JH34>P
M%3UP(M<40P;B#:EG!1'!,H^1>OT""5[9`@73!:X%+.%2+X6W(F?S$$DB$?%1
M:.#QB2S#"R8`"DUCB"@P&Y=0=P%'D'4W$WIR`B9Z)S#WDR9P3AF('1N4+!YT
M>X]R4`:S17Y(24M!(SUQ`G!A!Y%A3!HS#PQ2/#QA0(3`!PH2G['D94W1AG<R
M)R=0,!RA!(JRHP[%.3/PHJ*#`O$Y27/PFD.3=V,ZG(Y1$MK%&1`9+X3P`#]2
M1SAP&>N&!Q(5$6\:523521#4!O+HI-3B>_J$BC.C-L9B`X8P&C13$0X#3X.Y
MB(>`!Q0U%G<D!=.VE^!01[)0%-B`C/_S*`K'(G/N0)9WZA"(=:$E\5]+D!JA
M1`OBMCRS`16:IR*>N!FRJJ.59'NT<1>I@@DIX`XID"Q24*3>L0[+YR4\J`?C
M4%6K8)4@,R#.X*)A4SP`@(@IA1CBIBAC.!LY6$G%,*4H@"VB<1_A(3#C\$60
M\G[L]RB80!5C]12XNGA-DX#H,@_K=P3$VB,KTC3B5DG=<7?),@\:8R;*,`];
M!1`$:2C-,*XRBB,4JWQS%4J+B&S`):%A4QDQ(!]M*A\34UD?.2530!<JU!4N
MXR5=>:'YEP//<6;,,:[.6:W,@`W_N(9T<GDUZA*TH3''()V):"W$TQ?2.0Z'
M\S>$E[(S"!C_$^-2ME$#FW>C]7EF0",%J5IVS@!YPGH3+!B#CUFT+[D4,C.1
MHR<SW:$Q1$96J1%Y81-$'8$=QB&US$`D+4$'^%J62W$$EO$#F*5)\*FB=\$<
MNQ83DT,38'NMNI"!E$DAOIJR#_)J[H@37"L.89.!<_`00MMZ?2@:TEHPW<&*
MBS!;<_$;.J`G)KH=/'$21U!VF&%,`Q*LQ-%Y%T1*A<`%C&$+(.001&*OMHH"
M8^0"V0-W1&(NX&4HVO@`%L&*R9(D?;DNR\,["("2FX$JG`('V^!!6:H7KC42
M]>((,=!K=_(Q[Z!2UE&C]C$>MK('DZ`Z\*`?TCNUO@81I_`A*V('_WS!&7;P
M$!!A(@$[NN()+F?C"$J`:JU7,D@)E'H!,?%`J!`#9^O"M6<W"=47$V=#!'[`
M=FUP'?:K?%D0)DF8!0!@(8%"-7V["B[EG*QG0R((E#<`MFPGPG20K/^X"NF1
M+''A586ANV+Q)Y"K(AHC%HH[+<[@KB<8(/7'42VE0VAP.@"R/&9WO/BG!3G[
M,ZXB+#V2+`9$!"[[I61!0^.*->.Q?8(W/3PP-./ZHVL'@_$"+$]1([-A0(=G
M0#50M)Z9A$VZ&3\1(92W>;8A,$%4`ASAIDJ;4D>@0#SQM[)1=20`79@K('U"
M+GQ@0`4C0*.1Q0\B-O";#VP<?*NPPL/@-?^R<1[;A[H_`,<VL<KFLC[_T+8K
M&D,G2@*JL8/^*SF749(V\"^*\8\T8K=PQ2U<EQ*6:`8UXR6D8`Y8>8G)6PZT
MX&>9('^]$R$^LPV<HEBLJ"#C`7AXK(DH\(QG831)DLB2EP(#`1\*8B'J*QJ3
M5S8HX!%NFK<G8$P*-)4H,!)-,Q!W&;?"\JX55,(/0L[OH4@F0)!)XBQZ@6SM
M.,:Y;`+%YZ:1<LTGX%)R>6OEMD('W2/T?`(_P7[1)PP3W5'Y:W=;D00QD=(F
M`$H1`C%V2Y#]Z2BF,,UG$&/K@)]:O`+Q0P67$)M3AR7_@#70)07K!P]K6GCR
M5ZT!^9(E^`/*-P__/SD2BE%+S3H]X3P,P-$0,9`<M!#+8RJF*=42I;MVL."S
MO_>BI<R&K>!1+GD*CK!]H)!V=DLAQ+!J&\6#X^$:0MBC"D,9SI$$@P4IK3%Z
M_$%K+G@"CZ!V#W(>@4TAF"L6/!#9V'&D5,H1B\UJTT,@&<V#.#+)]CP@5^.F
MW.M^2'H7-:%Z*F)=?8'3*Y#$V?`/CJ;0/?VL5`@-.5M;WG':#R*M.'$3&K,\
MIW`2`K,(!&FAW\RFRV,N0:5X+XG%ZU`F_*%#"\"]88*'1\*D:B$=!:D#BX"Z
M<"S)?(`4<ZA\E[L:Z4`A&FQWY)R'V@;?+U@,)W,7V<LT:#&VRR>ZS)>]_^<M
M&F6GUR3P">W#M^MR)`1I%2NR),1G)XL\$U=;)80`-H]1R@_AI^^Z#/TKK/86
MCGIP2L_\-4'A0:J[+HC]C[#@!@/2W@R!V+F[TA4($DU[)^[U?CAPUS@+V[>=
M$.)6!4NTH<)2!^1*K//@"`?CT>NB>?_+.0>ZE"]JQYP#,+C;U"5QLJWW$O4]
MIK:]+NI+/.,0#5<0TG3""^C+?@9U=@UA+M/!%70R'2\$)VCAU-+!.O7J#'8X
M)!/)R1ZN?-&:@=3K*&P1'6-X`L)2(WMPA!/SCXOXX(N+!WM@0)U1#.%AR_'R
MNSF6>D7ZCVHKUR.\50^.!X&[(BLTL10Q1!*Q//_7W1<?5B-\*Z*=IQ'"TC2L
M:!M`O-</Q;6M<!G2M*;@DLS"H.,[S@X]#M1L`.2UH<XC;"8R$-/VH(<!TB/C
M<19P4-%6,`-GP1/#6@+@91'M',@Z($U%.Q92C;Q%*S9H9P7V\-^=IP:^/2"3
MO2W'=0(6`J^<<PP.O-#97A*?M#YP>.ZM)YWOK@NUIQ?'XNTE$:LU*H))[7Z<
M`@F?X+\,%MJD.]@;1.^O#BZ<HJ+`\N7-?M;$BA#$3!-UIW8\4<*XJZ4H,%NK
M,%M*0!-?W@<0"#'@E<5T'`1!'>RFT0I58*%>XHC`4D57G@(K@C5$@-`#'B!P
MW)OY[$$%P^+8,3WFT"/_8M.LN0T86"JY*<72*.#2!_6O,S'HQ9'OTYH"5BGO
M%<1**5&Y*&LF/`'<(V`#_:STU:ZV.G@"U)3V-3\U,Q,?/%'/<"_27*_46%_M
M9W$$8"H802Y"I:5#N&(",C/0CB\XCL('&.WV0N`+.+]#3^U:02,'H9:Y;*_#
MN@P2LJW+:3,2_EOV/4IK6-'71!$C!C\3TW-X<!QCC<LY-2$S(DWW@;O0Z>*S
M)KY/)C!;_VS=]B#'P:T(=L_T,::'1E>C>R=`+E]P33$]&'<6QV\H,=S/[:.R
MS<P0_*`7LB#Q.LK)8D4NTY#:$3'DNCQ]\B&/T3(@JK_B4A_[&]&F-A$@L##A
M_U0``HP#D:5YHJFZLJW[PK$\TS5\-&3S\`6Y/$P'@B\%$!11AT>`A"`('PM2
M(6$"$!0K!&+E*!8$`%,!"ED83@<!0Q4@'%2&`95N6N0@@_$];82O$#1!&/"1
M!#BT%20*C9``&$)@::4P",013-UUO<69*/BE&(2B&$PU7)H@-CET"9G]K:`%
M%#QXEN`1DDK:NL$JP2DX1$(T#!24$2O\JCHXIB",&`R6O&D):)H(4*)@4:-(
M(=R6*"2L95<GN"JQJ2PX@)(X[!#D3=O@Y^OO\_?[QQQ`9P.!GQT"'K0AL8R*
M@&^(QB`:=P(0+CN6#C"@)*P-`$8E$"3)9<3`.@B@*/\M$$-N#Q6*)`I1<?#-
M!$D`!10$,)!'S[..W(R9:$#I2))O`$Q5(Y"P"C50118(JB:3!`,#<0#,;$#`
M$%0^".Q(\EB,I0Y71W>5.)HMS%)SCPHPX+-(KH*$$`X,F/EHP%:%VS[:"3!@
M'0`%ZQA06Z.7:H)!H`PM\S075U\2MP#P58%E&(15)A(4>6/W7(EQ:R160_(R
M"00$C>]F(@.Z&AF5T,P4*#3/@8&$:/\!#RY\./$8#%C;N+4CP>PB==>45-@X
M@5TU";CADHGP##?7`:B7$@"!P<X31[!;3@"@P;,2B\9O)P.E([&/G,E+JE=,
M_)6M!T:=`$0<\'@AD6L`*!;_("5*J3$,?99],UE07300'0`(-#%'*3[PM@)2
M)B"0QVNE,3#%`9Q1L8`ZDJ0"35PF,/#`&$)=L>(1NZAVX0H,1.6>)N]IHY((
MD?Q%"(HH\'9+&8-4*)LF!);00!Y'H%9";"6@N,PW5\;(FFT'N)6"5JH80$`T
MG.E8G)IKLMFF/I#\LQR#)CC0(@H,A-G-AR@,@(U"V,6X&``+#/";)'N>P&-E
M#2)0G7N\U4?"`&`5H,E1!-6'F925-+``<FE!>4(`T53)`%]5@I+71SNAH<(`
M#H!U!4$"'8+``@M$>M2GQ6PDI@)DD0"(,0LL1@@SEE587JVW?HJ#,)'FIU>%
M?'W3_T`9"DB8E@&IYDK`D2VM%^L/6<S38%Y%=C.`HZ@HP-Y,WQ6PAJ.G#:D"
M06DUH<`#SO1VE[@UY.:FP`,37'!"J"3P0'G"&/;I=W7J54N5XZGK!A)6I/#.
MOYUEL0)0*F!K:$Z&ZG0("@@H`.T.Q1)PG1SHE2#"Q,)L?%<"Q^H`[`E<>.AR
M"G7N"D''E?2H1`+*2B9`="64[*JC)E1<21`J#%%LI]VT,0JTF4""&@$RJG`E
M"@&TTXV^+XX]-$VCJII"GT^'!1,TWV+Y`'/_B%"PWGOS#>T,R.C`PP-@R3R6
M>8R\$TG5%@>MUGC\04W'`A::*8MM*/QZ%P+$F%K8MY=ZC/^S)),?1<P0!8BF
M1K\I*&!G@&D\EN@PPDAD3+&$NB'EA8Y>2,<`#42"6="MSPS%,7?*)'=:'T,3
M]'\%#$#K?[2C4,;$7ZUP$MP%:/5I1\"[LS1CN<$\1%TIG#@QD"F446DESJ!V
M5'L3[?L,W#,P<#_?^_,/7-[ZX*<8@B/'Y=HU"#S991D).4U0$J(O]'"/8]20
MV$>RT2JJS.D'U#``W=Q#EO^HPC8+85I[\M"$$%E,$ZD[Q&SN@JZ(N"-/)_C5
M("[HER84Q@QMX`*T"N4Q;JA-:*Q*3*@"T)3X8&X`5VF%$,R".A/H)V8T@9E"
MH@*ZI%RE:&=8U,YHE1U(1.\$@\'_2JB"53,(^"D%WXD#GARB+@`H;&>N`Q'8
MYH:8P<Q0#&^8212E5K\%#*A_@APD(:DR/QL<[`$",,/BR$`'1#CJ,3[9F1(M
MH9>,Z"I`PT!$=*[V/5%QAD8J,)4:Z```'D5"&$TP1B2L10OLL<X`K.E($X90
MG=9I`1'8$8PAJ6@2L4``2`P0QQV"T8!=W&1T-<.,0(A)B,VEI4<*&$>A9N22
M1`$+$3[H"#2I<H_6[&(JQ0C:&Y)0F#S\QQ!MC$DD'."),:H@-X.XHA[D=KJ]
MD*)<DK"5&QRP%HR-YYM8L&#1`N:$ABQF95@B'(K2]XB:D.,6A5HD`<QPE&+%
M((*%W"A'_P'B17S00REA6,PP&X*^4['/&9&JBCC54-$J%<!6,+W)&6N!/@YV
M<!F3<MM@E!?"^,FRC]7HS35CPJ/[X;%Z7^@@5$+$N2P<;R3BBUX#4(.(=\!L
M`242Q&*R99DOD%)4F_M=]>`P`%]:PE&=.-%,+GHBSF'HK+)`8F>L!0%G'"YE
MU?R$*3#C"MY]889,8.L)CG:&RW5&`,!CSS3%Y,R'=L&K0Q@#I%X1ATF132N!
M"1H+B*'1CH*VHYF:F`T,TH6R`6-BWT%L:2I*T@?X$@O*@N(A2^-3(:P.!<>$
MUA,$92;>DI,(H_09"MY1K"&$+E?1H%I,J18]:"EL,0$8W"BYV/^(2)WH5N@3
M:EI2,MNO4C$G[JR$3A)J4/(V]@J_ZV!5HCK#2HFO,V$L1>&L0[T`&,*6#2$6
M\E"#%ZW4IU`$00U4RM"&!+S*4##(BB]#Z^"]O6$.KW+&02;LC`MC.,/'O+"W
M$E8G'C`'?+<I5ABF>:PP'$!+HLJ@2S]Z%"E]EPX,/$$R7%5;29W5NGH@P+8P
M)X7AQM8<*+O35T1,A@XR!%JC>(?;R@2SCKA8L5XH</6NT[9/(%D/<1FO&(^Y
MJ]^)[T3.,ZD:RQ2I=WP7G%AY&E]XVXL45%0SW*W&FXL;1_9MIYONH6M0=!PL
MUI9@`",:G`-$IT:_4>&)#U[T_H[)OM;_""[2DIXT#^J2OP,$1'"W0$QG#ENL
M@4JJ/5TZJ"$Z\DW!IKD8KF@NC'"S"^12S="ORM`N%E"7CE1'EX$@[3V:)(39
M)+4T-^X,>-Y'BYUN(IAUUH'^Y&HO+=CTU]X,WJEGF`;`[6P$H!"(870!ROMU
M9$=6>!:-NS"`90>S(,J"BBRFH,6ZWH16.8EM&4&D6*M@[FC'\"FL68=:]5IE
M8Y-K71,4"ZN,6%I_)L,T1@*0O_R-(G_84@`@&6WQ-AFC"@FC],8I[7&[=9@-
M5>'!85(1#6B=*->.B$PQ<2B3XR@$G>KQ4*RP74]JL!)<PO9$52;VJCN@*+`P
M=S8`B%L,$R;`_\6AFMP\81NEM3`C"7B!%@V%QDS`:,L3D[C#/"L[MA:.YS`C
M,HG<4!DS:B`;!]FN1GEX=JAL6(,<HP'FD1VCO/4U`&VMJ<Q\=0#HE]B!Y8\P
MK!Y*<H0TDRUHKHE#XN_P&E,U8(*+BH0!R(P"`M@!P&F!);6^)@#%2@E;Y_XX
MZ8\Y"IU$(WI\OCCKXR0E_U3GI=Q32H;GP1=DY,]/BU`8CWA`"F]D>0>?0D.,
MGD:0[[3A?#_HS0,:-^=--6HFS?T?%*=0^?LE;B(Y\#5()'5@@8`I+BM20;TK
M'X=.44-3XSED`M)`)5\,`G9^F)QUVE!O'LF#M$;?3V)G@KTC&(5ZR/\/'_#(
MINF,79U!=/@0&CF*++&(RK@.JPV3&.%&2=1"0IR<O91'%4`$7:%06`"*67!9
M<5W.=$E&T;R5(9V`W`C:_3"/J5506HR>X#2*:WR8`9">QQ%!AI%2L14,:;7>
MP!@#>P#(711<$5045OS,3@36&<R#TKS-"JZ>7P0-*D2*P\6'S>V'WRS7W'S4
M$]S6#^B.._A9H:U#,AT*$XT-K,17)NG6[77:A(2A'MA./(V@*U#<><%((GA1
MNS3AV+C7'3",$DC)"`Y5L)$='ZB(M$S.TG"2<)F'NMA:/TE+]%R9E1S`^OP)
M$:""H,!2;0S!;/T.9NC,673$\(Q=%1U'V?C_0$ZH2[V00<`]EAPYQ+UD3EKH
M@2)Y"GMXRX?=S`.TC(?Q@``XPZ1A7LO4"0<AA`\*S'&T@DX@6A"J2;+(!'@<
MP!C$QJM`0A.@`U0H1^PY'>%)A[?41RU\%)[XS:3T1=ZEQ>?YDJ^)B?X4G=*A
M55%%27EHUTO,G-L`%)*TX1^:!R2FS<1`&=>5A9O)0C^NX(T5'6G-F1/0%::-
MR_VX'9R!VQ2RR$?%@SO,EL-9@\K$E[XHG@#\QH4X727(4)0HTM+8RJRI@B?H
MDYC,D3PLDIA,&B48PQ/(B&$<1_X@P\$]7!CMHDK8`D82!P!R0QA$HS0.QS&Q
M1V<`XT'@X#"UU`P!_R0JP,I!1!X1%&%G]`L'J0%<:(8ABA'J[)0H<5-KT`JF
MJ`#S`"*/P(SUD,Z*%4M8N0<2[D%5'@KJ[.,=?%1`?!0D.=M/":142`1_45_U
M;(Z>X8)5P`PBU,P]E9DQ^->^"<$46-(HM:&M7,V&5!LN!(U2.E>\[(S#$03<
MN.45P*-Y:`7<',6=N90OI1/[\,A'A4%5R22T5`7(2(&148&U)-U=F(0Z:5&Y
M!(!A&!$$,(%1"@?9:,&%#$).+"53M@#,)6?>)40;]*0.%"()3!KT&(+#E083
M"%:?\$`>Q(@?]!PY%(4XYIKEE0(W%$HRK1`AP)W8W,DEDLD88,;.O)D`7/\9
MP8&,SI@,YCU"5?;588G11Z$1XH5);A$;#A4`,3"C#I@$@7[1753E?"E1%WF!
M+ZU1?E1'I<3!`:P#.\+G)S`F%!5!O5D46L"FZJB/C.3$."`"'$`2):T`(HI1
M(0S91.A5=%B"+XEDI#`%[B2*C(Q)@)!G;K9E$#R!)6#801S>&033#]01EDC)
MN?U.`"R!<@)A<&R*:(A$`%&G#2Q"[3G#>CF#;QA#CTV:*3B#(*15HZBI,D::
M%BAC$X3!QM5)RRC6$WB*W<2!`+0?7SA#`GS>UTR!_#3!=WP-YN5$)DA)&GQ!
M`!R3NL!8`[1?WJE(9TJ))FC6IGY!IP"88'0!'C#_`$;`0TN2RE==XR%DHA)-
MRL,-TU:<TG(]7#2L:D`H!268RE*<5:7@`786H"1`SWBM!Z4.1C0@@\/Y4U*.
M0;S`P@$D)[+>0_Y4R!B4R"O&A:>L:F%LPZYJ%<3A9HDH&O3($C*X!L4=QU8L
M12B@@3I)765<ZSYE`YAHW2O>Q2(\*BT,Q:J20Q8@QL,EYQ.,P35>&67":I2(
MC%V:!TD,0H?NA:6(S1`PWJ#PP7%NPQ5R&7\]PA-<1<[%Q#Q]0^S\P=3@(`]\
MS>#X!B4T`9[`;-W8C2)-Q7)REG"8U'JLWR.DVID&Q^\XFG)*&NH8$7X]3A6@
MIJ090D6);#=P02#>HUY*_X4/V(5IE@$@V:JDX($/9**U[M`HX`1&',*+X`78
M/APA_(YMB"<M>:.UDNU=W40A\!<.",5`(8.4B,.)E$/FP1CW"$.(=.:@P,'!
M<8^MED@:T0)^^1/QG9*76NOLF$-&"-N[G@AGVA46=!,7D`<2S$.[2`DW;HL_
M<0^,F0H\(,$D!L`DW@5L^>3#M:H8Q)0":(&)_E(TX%2G7-OJL,<P`6>A7%CD
M%5JAK>I7"&[HH=XV34X.0%ZH5DB(5`5,L$>\#`:AA,B%C0*#[(`#8`SW\A@"
M$.-!^)X3.,`#V"F&U0,8'E/,8AZ"9,(<H!EHM$L[D"(WADC2#:$-^A-)<%`.
M+/]!+U;4E/Z%,,`$3F78022`,XR*I&U8`INOIPA:+AV3896OI&$+$^A>A>CI
MIG+!IHZIE/@`Z'JPT')P@*P#W0'M<$Q*F>3/=^I%^5I(6$B:3MR$(J5D:2B-
M&YAOL:BAC^&*$>Q+(!C:450)'+%8:?0)=O68$52DJ.1PV/C2K?AFUHU$BEJ&
M`KT/U98%&0;-JWS7&W1F-^`G#H\7TJZ$+TW*,OUH0-JCYK#NSK`'M'0%5:1,
M6"!`$"1<7!R>NG@I56AK&#G<I3T"DHK1KWCM%025:1RG4H`LICX1[2J%(V<$
M7,#*'G!/*^;/5[@3XM(.\^0Q578N1JP'`Y\%1LS!(M3_\:C<BGJLK.!0JGKT
M0KO\L`A[,(PUJI0P7BU[<+FRAC#0B<*E<#_,H`$G,/=&GB;AA>%!6J1]7E0^
MP&>ZQR7\'(W)Q&!&LR\9V%A2&9]TBJ+%(F\-6Q7@6_64":UT!$/RJ`SV"<S\
M"JS4QXP5EY^II:'DQA)?`:QH1M^I`8!ZT1O`DZB,LVX%'TF>V1,'9)H1L2\@
MV3*DF5-)U2D]C59X$1;X6=$M$]@%R&]EC%M$S&L0PR>%C3S'V1](KRU@1,L*
MSFQ]'M5TG.`X`ALHY)J`!3S?59@&\S[<L2)=Q3133T4D;)V%2T_"!;;@"B+L
MB'`-@9[=DV"@1_,-ES6K,VP@_\?'#*VPR;%^[MQ_2(3,/)`J',.-30IO8:9/
MB09T',[]U->=-`3*VA9>I"3)\DGC(`4_302NX/,]H_7?_1+M_@M;?04Q/)>K
M@*@X]'3,#`-NGL!3MJ4CU!OTU&?%TI^HC*(<!$T!^A/RD)M+L5%[R,\*M,]O
MF(K4RD,:M(%!M+3@A,*TGC(TY'2D%?,P#@Q%E)'MWG1QG!MY7",!I`+<#LT_
MFX13.Z%JND)*3(R*V(6IC8'@>642,.-=DTW<!B1.6(8#OD1Y:(C.Z4`V.#3[
M5`:NN4<HK*[%3D$=Z],YY\H?GE>):(((=!/&NL<MI$2Q@*\GS.8/A%)](IL3
ML*AF$/^R*+U=H+6W2_2Q$QPQ+NQC?@<3FI`LJ%F&.5$WG#TG81D2?Q9F&0A!
M'Y`#=BQ@^+5C'DSS(P"HG(U9%K&&]<!&A*!(B433&6E%'(!O)"S7*0I!B)<&
MN%K"-L!%I4`")#C:=(D+26(J,0K8*L*VP$R6T)2NI&!4;?/#N1D&9J!%ZPS*
MTE0!ID%!=?!(-1+I_I$-AIPD%(V!01\"$L`19XFY=YX"^$'3"$&1%K`;U<!G
MB/['R:K$=3>F$YP170<:XQ5*8E0.%N3::YS("B0(#B=?5=9"$_0YAM?3%E2E
M*($E%+D?W:5".=S/&A3%99\XG?RPG4L*3C98&-\%3*S!1/#_0:EK`WJ6$#5$
M-JFM1E#LA($&VC/8L^PH"22N@3K)C7>7`.2D<VGDR5T'4]O`T*N7!K;\`)E)
M1#F`P=!@QMCU45VP+%4L^3_,`NAB87PQ>3_LP#$]+7*`24@J*C%<PA&T\1E4
M*`NU\69,M#,,A5&8@EX(1N7DISN+2:2+B3WJ"GN-@OA`SU^[RFSYU9E+@E"0
MY7)G&7%#K5<=0J6RS_,JE[^C@<"'2$#3A#?:H5JU`L,SDVB+@%-XP=(46@KV
M!\7II39%P^V@Q>+U\"%`(S%&0I"#-#M$4M+5@NGL05HOGXD.6Y^,`Q;0`5R'
M15R09*)(&:?6$G)D'[`#CYFUVA2<_^:Y08[`J*O)G_NV]P,.YJ@\S!"#8D$J
MZD'KZAV,`/>=I+N5Q#2(LZY_5VE;-MANCM*7SQ"&8A!O[02JD^\/:49PJI$X
M)FE>SPQB:;>VXY4<*)BW!$)\P:):C\.$OH05H_D*E'UQ&4KKQ!>3J='O5+86
M6X+X"`^@C;*V^QD>3'VKE?Y'T#C[0"@N?%ZF*"K.O,'7)$1,CD=?2J@-UT=5
MW''^?$W:MTG1`3/6\\,=)V&O]UFQ1,0B2(2!I=PWX(GS/&1U$P(QO`&Q.+7-
ME<F.GM%QV%`Q.=0,W?"!0HL_\<C$1DF(B$^K1R*X?04:GL`7K*B&JA;=B&H6
MG'XPA8@7#?^Z$50U"$"B"`R,H(PCXSA$H(I*<L3*`@$.'(N-TV#T(`V$H!8K
M(8:0`P(W5`P&O%@!T4BI$(>"`\`T&`I#P$_;6SP:40(Z=C`@>[IE3X&8SE6+
MP0'<\P.8)"!0E7/`8+8VXD"6XS`PJ!(P8'`XTB#P4`#`\/#@P#1*6FIZBIJJ
MNLK:"N'PL&#H@\8RJ0*0($0D.J+PH*5`H/()!5&PFZ,[BF`7(#"),D)0T$`&
M(#:"V<#&!$`@Q&`0HUG#D'!XCG:8FTQ.`+;0`'#06Y#@XPZQT#LDT-\#"`0$
M!=(M8S`@QJ='`-@]P'0,PH`$8`Y`4_$#AHD8""@R<>!QB`$M"8S_-9$68!RQ
M!X,`,>BR3"2^`PWV$&%S(.2TA&42=.OAA1X\A0_/[>ER4:2!6R,0B!)([HO/
M))R8G-,WXAN#'U;4`.AXJ\!#JSICN/B4#``8!/`2V'&@A8!'B(5&$9@72UPH
M5WS[^OT+.+"(8N`"T//8;)0"!W,`++ATC,#1`4OJO=$A!/,H`W8&2X808.H(
MBPO^3!E4#Y"E40NX^.K<0&4.83S.Q1CP*`#C,%]&%("WP''G5U`J#6\M(B4"
MIB(0H!&[B\&+$0N&0CCQ*(<?$@ZP#ER\Q7H!GLU_@E>A\NL.)KA]C;T.U[=U
M%LG&P[C2G4EL0%(&"3!V`@_8U%(`$O5X_P?!8H#H5@5;/`B#QFF^#,)5&0;T
M!@$X?/`$@`#928>&`LD$R(1NNURQA0"9.9C))3SL8<L*`AK`DVY[:"+"`008
M4P)Y[*S&!'37"1#;7H(=B6222JXR`"@`W2,/:[/8\,\`TZG@Q`!)40+.$9N9
ME)P!(/801P#4W/+-0&!NL1Z62V"!)C@6O2$"$#,P-]!PR96&@&S4D>%A#V.8
M25X/;BB4D`(JPI'H`_I@P\`S$-4I0`]3#+0;'V08,$P,_$!PH5U@FKG`+]EI
M-XY%>Y00SI8<N6IFG:<FJ%(1[C@'VF=#?'(4.L<4FJ"O`3S`42]:XDG`E@,V
MYV<],)QC3"?3F?]IDS8T\-&I$<,9X&L>>W`F@ZLJ$.!GAUH,D!\)#RQA9J4K
M^)JAN"TN$)T+1BZ);[[Z"M;D`]+D(,^5/8@SJ43=M:G"+\".MFZ)!"PL`S5!
MKEMP`G[BPJE^;#$7FKQ-2#B$%Y-JHF=3\?50257LK=F$Q=4F*,!20\21+E#N
M)N$"Q+]*0D<#%.O',AX:!M(G5B4T,+2@D%DQQ:PBC->')S&,)`<3PE2KFU-#
MM"9,`YA4,QYS2F!RP@%2I,'8H0H=_'(3"&#5V@_<4&*E1;.6@(S'V&217)A=
M7$Q$LF(<L,>GBB+X&P`%%&C8+P]TNF_DDD]>2I,$]*/##0]4^T/;#?#_A/#3
M\'Q^QTCMP1%H%(L.H1O86P\0'!U0#4'9*+^]/;,8+%N"9Y_>M.!T$PXLT(GL
MP3>A*U`ME,@I<V^7W!STH+EP/'UAL'Q=`L?K*`E$PR(PZ?)EG#R$`S*C'$N0
MY_>`!9V9.$I%0,2R!Q`N,5NM\AW`_(Y@\PPX[12Q&4!O#VL"'00P'7T,JU"&
MR=$#KC6$/(C``%#H`B@`1[D,:C!?!%A#4GZ1`R/LH0!)P00_>#"E'"TJ)Z=Z
M!@[,Y(YOZ.P9/S'44LXQ*Q9<AV?HJ9\*?C,*'2W@&3;!C)GH])NV>0%ZE<"!
M(W"V!$;<IH:XJ!D<1!$EG"G@-YBH1QRBP$.T_YG!:22L1\D*L#Y*I&X(=W$`
M]`ABQ:>-!&BCX`9R`K(8K"6/4:/0`3>\9H,^!$\*"(H#QSA5$]H5868#<%^.
M/M,`,-6#1N/+%"YBHYCN3$HLEL32XX*4%-P@`1;WVJ`I3WDD6(1*!Y<273`$
M]@T>'&L$+%E!"D.CA=^@056//-5&0%.2WQ5``6`8SQR"(@,_&:"&A,N$=08V
MG_4=8(B>08,1?K@AB="!`';`VVATY4T24#`K+9ECR)+2&M14#7F#0&-#J'@=
MR.&L-RDY5?/J-(],U+`*SYBA.>_RP_C<205-H@1&TI@5<HF``/+,'"1.9110
MMDU'-9C"(=`%AD42=/]I2;"2V-PB@C4BCPP*X.@^_@441_F@4(FK!(9RM)LX
M4F92.D(H"9RB`&',J@$TR",Y6(H&GY42E40M*BM(^86&U=`!T`#B;1(%K'SF
M0&V^J51.Z&0FM;B1(^/HT/'R=!THW,,<\DP0%#3ZKA2((XAE+:EJWL`KF!VB
M`%#XA%H`!Z01K`YA`3@!%%J9')[YL41;;4HWOO$&(X#A&2G`!A%V40_L90,]
M/*B..PJXCR?)3(:C*"P^&Y'+L.7H8A@JZ6;\%,D1A"HYNC+3(3)ED3XF[5,B
MJ$X5AD>=0B52!'DU5*4,@\:LX-8'D..EK`"1DV2@-58CL-AH3F8BZAQG#O__
M8(8AL)#$INPHF8,XSV`*]#1[^="HY"TO[=;P`,[4H%QH!._`6F"3]=@H"IQZ
MF47,B0O*4)(]W7B)+0,(%/TR!4(WN\,>Y5@)][$@<40#TE=N4U;M+`:>F3N;
M%2Y!5R9XD7UOP^\(+"$%)#A6!\-\:16!I0C)[`<.,P$<&H6!/=T`,BN4:5)V
MD*$J8=Q".G$((RX2X.,FZH":PE7`@12B"P;/K).<>0&Z,#$`-DB0$E_XADVG
M1\6SA>94CI%$1VPR1S6\0:/V42,.1#BU%&=9>V:<E`Y4(A`0J4<MOEA/'VS`
M"6S`+@'I!8UY_PSHIZT!R+2$`U7A($6,Y.`_WO#2_T<PN-#Q^J`SH4.:[0IL
M`TCGP*1<PMXO"B:^.F$$7CUP[D<0E[\D')J@"7#D#MW1CQ84;+_^.'`C!/;#
M5&/,U1<ZE35`(POO5$=G&=*97UD'$N]\@MB(C0&Q?&;KS#JRI%C@`3N(1(EB
M\O1E4A`3RL:`;8S@Y`5=1&/H!M,"1XY'>W;!1YV@H(;'P>`0BK*TH6*#X4T0
M.]#\WB`L+J=H$I2#UKYP`XKZ)@</$R-IJJ;),U4;R=TM)Q,)\YC!#N#C\)+0
M>R:^C:M9\(PAQ.9T`3`&;;?YU=8\,08E[Q-34M(V4.&)`7WJQQ>O0R.G]8@9
MDE9<))@2AQ6SG.$_7/4PC_\A@(P/1DM8JYV%8AP)1SZ&?,2P*3K$4#!-L"P`
MURR#2+$$P8%9-&2DSD0C.SZ-A]/8T6ASLV<ELHL28!HCN&X*D&'P@S[W>^]$
MA07IMM8;':2CEC0'B,^2T<S!)-I0U\#H%D`')BR,`N01F5I_+W:X8]3/(@AZ
MQ<<W]]BIC0-J''%W^;#'"V#226(Z)$:KO1$3,EW+Y:ZODSZT-`J/ZD<4!YC?
M:%YOO:R`%"@D1)`P(C7WU0!8!9&PBR*8X*$.Z<,6PU)@M&%&9_:E8)DLCUDN
MAC!\.K`;\-CPH8[//:1)Q)W@'`&'2G],P5B`Z7Z#.3:H3!\(`6S,AMPR`Y^E
MQW?_`;@O?/8P%-(<`D-1Q#4)S9<#M;0"LK$Z=#!.F4!/"O5A4%`'"=--^R>!
M$\==,C`<),0?\;,GVM!(5G,R2H`$JS4]#/%V&A5.6^.!ZN`9]6$=*?%\UV%D
MC[0JVO`O0_9<@R`Q@S$<?^`;DG8,4G5PH($;@(!)'S8'-N$:NX(A3C`(:T5<
M`L)H.<(C[*<-N`,)W56%`,$"41A064=IV=%[=H`0J*%_H\%/*Y<$/"4$7!=&
M5X,\1[$^5=`A:N=,D8(T41AN,]"%,C,'8N(8L9=I,@`L>7!78V``#[!O`DB)
M2;()_F)MHI`'F!!+BL(4\F`F92<1+\!V/8!2MV8F)>-M_T]0.J"">E[(`#AP
M0C8P#"EQ"ZGU"FWS"ZOR&`,188W$#65%1!GR52[0?8!")SH"3#:A*$0@+@^"
M:RD!`PD@+I01&]3P1T'P1T:P%=V8A$70'8N3C=IX%]D(9-RP3`RP%=Q@">"H
MC@'05\DP+#2ACDV@$K2G6N1&:.AA!]O%.N&7*RF@('RP**$Q"=4A`Z`G@[C`
M3<#D#L[R62NP/Z3"!+)P([VP&&DQ-(28%>'607@R0%6@*/,63!+9CZ[R$-TQ
M0+VS)5ZP$S]TB4A8B3,I&*"P!O.&#4K&8G(8`_\0BS81`#Z#/=_`1`APDR@S
M84S`%DH70DS)`H;PB9LH<K$!3_\Y4A:^@2[5\@UW1R:P0VSR,&!(PS+CL4[O
MX(';9#1D.3/_T`)MZ98M@"YMR5`,Q51:4@A)EP"D9).72(TM8)-_N9>`^9<"
MP&>/@T#^PE2)B7YH)'F6T@>Q@S)$AW.",(>)T$FU]391QAPG]TU&L"8E%5E)
MP"`\B1$I%%BX48K(DU-NM$_#8SYX4ATUD'U(HRA.<R=CES#H4E]!HG:Q07/P
M`$XV*9,T29Q](1>+QU1XHBBN]@.L>0N*$@H0@1W,<V4#H7#Z!&GHHAAUIPT,
M9162:#46YU1*@2!64D>0YD(E`IXA$VI4TC8LX&J3B#)J\8YU&`")T!)@T!!\
M`8]P,#+_5?DT<]<(`#A<`88GFG"@Q"*@OL,$CH(@`%4&B\<'[\$^"DD(T/`Y
M'P(!>D<['B-FS),06-%[`!HX^,,&,/<^0U6<*]H7O<=G/X$TL.F'3]-J3K!Y
M3^1XOZ<SK,0,DG`Z/N@UCO@.RCF!=-!(:,8';_-KJ%,P"4@[<N!T!+4`Z<1A
MS'$"TI,Y44.+E2"*TH$@96@U)+H*__.$0900!4,"Y(0*<_-MD81^4T`\*&<5
M:)<#QA$\-+>$/V1L)XAL<$([3E$MV;4UUZ<;1X`,^24+P>,%\OA-QY,2EW.H
MY,"5RH,@0@H`8P8,P\FBFWH*-LD&V,"*>P((_"`V2'H,YR.H_X'S(A$(G\EQ
MF5+:%)W!`F`XD!.$(0%`3(;5I$NC"54P4YAYABO03NB'*CG@&-GQ#8_@!<]Q
MBORT/S.C*\C4'!@B#H,@"WB"3`#DA:OP%0_$5*@W0<+21ZW`IC]F!^4P+H`4
MJM44)'1JG6N!:0AYJI/06UCR=<^%`QC'#A)C+GR0*;=@JMH0&5JE`'Q(+D)!
M1>T)=@":$TNP<0Q)([[Y#I/B5SE(#J&@J9RJL4Q0F//0'K*1GK2A'YPF$'%P
M&9S1$!`J3G*0K,PP'#G9,F>66R&D+(.#<WUD4J0Z/1RA!3KB#OUACVTC(78P
M@8GQ7+O@;<PGFT,H.V_@3L)S"+0W)_\_U`T;QG4<X0<92PI:<H+E>DZR-AJK
M4+!3R7(LZ!BRL:Y?H05>FC"/D!I**4\U(S+)L8^_<I`5P;1#EQUN=8$/"(U5
MD&&UE;1WT"8Y<5A1:BI5=8BY<2:LPTU.6"C'0DP;Y@,U`YDI43]C>PS"N;&=
MJPJD]#!0`!#U@'MEH+,LQP_1QA9QU!Q9:151MC4_\`@AR$TV501`"ZU88S[<
M21!L442?4ZUE@%G:!#!]`$\@1Q!D`A=YBR6VMA@<N%$9$0A9<*N8DPTTYQ?`
MH!9&^542<9_7=PJ12@XU)'WLX)NDJ29EE`1C(!V]LS!!\`HD&%;I!%BJ51`E
M229O2#>&09K_L12PCH$#,<H$ES,)2,._4L5:.`!B43@\H8$]T&(%K0:$5`:/
MLU-;64`:AG*?.8>8GNO!IG")_\`#`%$"Z2-RIKD2!0,`NJ8"$JH"22=,C0!A
MG05I7Q&!GH*$FH!JLU9#2U4]OB=^QZ,5NV(EY8F$6C)7'Z82"B"FG0H$3`50
MX]&<2"`6>0,-:$H*XBMNXQ(\*6'"`4%L#`A&[,%I>!"4#8,R;($@'5*56\'"
M">(OH/25/O0Y%S)CKA<;$"$%<>IUT`.=+&,1L!-!H5"5.[`:_=+$'^RY%^0'
MGP$0MC4&[#.CSJC"*D(C1302ZSHN4&<2F&,)C\$416"1JN9JOJB<_Y01/&90
MOR10O\K8'-@3!\T@HD]<+91+N-A*(Q$&'X!5"9M&'M7@%XL1"LC`!CY3".GS
M"8)9RJ0`O]/+'0#**E:S&,$3=,'S=R(!3U?+%BRC`W1J7&1R=%'PFEMSBN."
M0=R0=/N9%0#S?CWP25$`D`Q)!D")<:GY2*]ZJI$R+*``@(KLP:#`%:Z5';:U
M4,/1JQJ&P@PC"F92+O^R(P4L/?/%?.*4+1=S9Z#B*K1F0L0*QV=61(=2H+::
M!$0KQ-C6BY3`;EG%D!]7SNZ1`I0Q"3D!`Z&Z5BQX$W]1'R=J4+*0!]CUK*O0
MS.,KTOK!L$]TF=+H6E,#@#ZS*_(P#OBK6O]#=&Z"9Q<,BP_7:@,[0'71<QV!
MP*&44'(%LH5\\#\9-RR:QGU*"6YH0B2'AS,PRF=GZL]S+0(/Y)(GD1!F\%+U
MT`W+MU!((+V.*X^/"PFWPH8-&:MX6S*B($/6VAGUBZY$L#YH5:;O94T?$D93
MIF?H<0!95:0L)X=W%!F"B`02G2-(<+IHPQ"!;0M(T$I/,!PL()^HH!;`K`W%
MI)#Z63>L$-3BEA*1BUR1S)YS`(:T@@06-D&%HKG88''BHR/KL'+2>+2#D5/:
M(-Q`<24_D`SX""XM@DW<T7.KI2/(ZBV:UT[YH\[V*#UQ\`C5T5V!4G+X:R8X
M\1*DE,ATO:D/='+_TO=V>B4%HM@A)=?.1.$T+2!]@A($BE@G8I+0VN0([`#,
M7EM;^(`C'%',DWP.DZ"VBZ;A4_H*>B(I_+#0!P0LP45Y]G,8^K``-"""%3G@
MJ>?>%OX)/I36@'$T23`0ON<?G5='WL$-8EQ;O1#2Q%#.WO8)N9I,$Z0G^\<I
M",+4PL?8K<:'!1DZG_"I0TX=8=>`-2#AN"(115A='0*[Y=-0)BQ!2!`CYW`(
M:@`#N7#'GM3#U[+")D$O.)`+:"1BGHK?=!T*6J-7ZSDP_\`<%D&H]RH\KT<'
MZML&V*,)Q\,/.A,;KM8,[IH36OGC3"%W;SY:?"H2ZN84-`47S"$%)'K1_VG`
M.ST3;D(-&/U9(GA"KC[>T@D2Z;SI/6WT!Y,@!7GZ@-JI'RKK&8V>`U@"%V79
MG255J0G-4#K9"-5`'EK@0JQ)8?TM/%.Z,%X@%FLR'DFI.K_;)4Y#.HQ1#RO0
M+]V[Y_D="0#!O`3502PS0,3Z"ZY&+;DG[?!1(1I<1V'<F!4*H)YH%=79)\>#
MQ*PSUEF-)V>M82[,+)=V6KO`ZC=]2EB<>SY.H@I;<`6#W)8"Q%'!<S3!1I\W
M>6@<"/*+P^Y;(L'4V[+RG8#3$"`T,2S=-D;)Z(R`YZYZ0>7NS\.<'MW];5_`
M0I<D)ZDYWC&\EN!SW70;'.RWV>H#FYKH/G?VV?^"BR`,4@9P(NT$$=C=63WN
M"G+C["9?42VB32;<^31>T]+Y7E2N3@X^SKH2,:7P]+"[<F6@.F7DL#@0\QB$
MDXQ%'^S"PT4H,P6ORN]4^*6]UJ84Y+78,`X-A`MF#Y.Z5[97OP)/!!%\_3N=
M0S`P!=`V_\'[C&V,=3S#,PA%Z@*`H`/'Q';2:LM970/WB;AJ8R;6$4L59!*:
M&0;GX^73JEJ1RU+'1*<9R%LUM".5X*0M@P;I+:WYNX(O)5K$B!Y^8A)"-])=
M14(%<5/):XH/<PF)U`=Y";9UU'BX48=TV=F0-6\#1*(G[P.?\[(`]69ZZNQC
M1JR:\2MFD4^ER\K@TP3_)F$F.O<Q(,!`@!-`YY@HD%*B4&,<9P"\"&*_J.$`
M!V'Q.@@*(\=B=2(I=T>A$U((0H`FU$%5)319#F.TD$!@AT76HP`^&1*/1C0N
MG]/K]CL^K]_7`8]_`Q"<0=0"X4M`P@(``L'5"=#,@8,("D`#&<G:3@!!)0"H
M@5'6)L-`YA<#P=*`4L-`'*/#SD"E(>(`5`'9RX!+@$S<`)RE`W$#7`#LI`D)
M%`W!3(&`CA-)Y0G"@$T+HH%2@<$C!`)4RTR4MLTN$7IK`?&.P(*`8SV"P<+#
MP!]V^L(!`W_>0`BP3T`@,`H8`"!@H`&!>+30T6H`X!N*7"@"("#6XE$`!^A,
M_U5[`6#`)F2L9BV!QRH>`RU5''3Q]HB!2!H(FB@0@&Z!(Q0*8)UX%2=DCA,,
MSE29AV(IL9.;@E5I\&R'@@04@6ZDJ:,1N@/E7BRX$O/J$$\H$`AH0J_!@YI\
MYM*M:_<NWA</ZCG`&`6``!].E(TI20.>`<,GPE%ULE0QN08R31H08*#2N([#
MCC(UJ<8!+UJG0K\H@$2P-0))=[PBL`D2S5I.`N*#O(4BBG"-TKU",&Y$D0%$
MHS@87O!'`V!&-CM)@"SY10$!@`K85U3BVC\"&CT@0""!@`'@W00&O]V&`>-V
M.A9%H.KU100%'OR^QB!Q'-!.ABHC?6*S?":9L@(E<?\PLP,)/R3PF@)D#-`8
M!`S@`,$I!CK$B2>`O1:3`LK4),8!DV"7&S4[%!<A%U@<,`T`(&(%2U9=`'"%
M:;BQT)9I_/23%X\]^OBC70_0M-U&)N5BFRAR*!!7+`\<XE@"_KQPEH%?R'%B
M%`&-N`02OZ%`@'HW^"3,:@BV==0#4@KU@&T'#"")$SAX>8)#D+E98"'X(2*%
M6C!L24T`)O3@70,%!,#`%;<X4=U>";B1``';53:0`(SNI8`^-M:!)R,I6M.7
MFDV5:1(F<1A`A37AH,4*A%/JB55ZKYW0PI,[+(#E?F-X.4D^42C0@Z9>+!B'
M*IH&$,-EJ7J'J!.O1!GH1B+_6)$;"K>VQ<!`<@&Y+;?=\KB7:@H0``!.6!@3
M2U]R(#`+GKWX4,`V.Z@RYPBHSE;$NNCI58`"(Q*Q*@_^W=";KV^^RB7`!7FJ
MTZPHC;G#-)/(^FNH,"P2!P[,D9J/K!`8X%^_1S11Z&`#C3'N11J+H>@-`[GL
MALL.P.RHRWV&(0P8#04+P0*Y""Q%7\'BNH.;QM:;'FX`*.!FDDZ81B].!\P)
ME+84%J=8`)T135,4TSTX9T]^09R`;3WMK$V4&Z$C&<J&33/G2=$TQ4_'WMI]
M-]YS"+E93R[1>15N!H@3!\LYY=:G:D-H94DUV-:=A0F=$,(2!/I5#KC6M)1%
M.!1C_YEA0@,/G\"5J5(>FX(1(94T"0KT(2(=X2X4PI+GN8G3"5J"_\:`$,FB
MH%*S#3`@?,52F.HR\LDK/^X<@1#'0\*A_Z=>@P4M3E;"%-+K\0K"/6)5*JB:
M)8`<(=$[!0SQ6E)J3X9QG:7-)CH"C(W8BN":O*O,!@/LUD!4A2)L)0`&].0F
M6Y##%*YP@`>X84MY>R`$[2:D<]T(#D`P3B=F0(*#O<`H&T%`6%YU$6+<JB3:
M,,%2*C:M+Z4'19O0"`#]D34;D.!GU[%$A4;0`-3PCX;IJ09SE'&Q(>Q$;I`P
MHFD:=[U)5`,87Z$<@MB3D=#TH!CQDLJ45G"L([V@5S]J4?]$BD,`2BD/>;=#
M8'X0)39:,&\$AKC"@RSANTX8)PF0&-9?\#<Z\BWF88Q80SBJL;2GE,@:`V@C
M25@!2-3$9`W'HM&9X`>%25`$`=<CQQHD\[TF#*"03CBD#NZS.0I)1P0XJ482
M5;0$MC3!(#N*("QCR2TA/00+9(A(%,CWOBC$(#6(NF3K\D$V)S@`(6F+PF.:
M\X7.A*4LP%P"(=@BAU)!;!:U80T9$E"K"D(@@-98TF^<V`+%:`48O^G&`D;U
M`@J^H%^,V";0NJD>1C`D<Y4K'H]6)`0&%(`APZN4`PC@``<P<`4[FT-B@L++
M;5X"%AZT1-J<TLXT)4(.[2#:,(__^3LXW&=*.I,%NK"C"AL$:$ID<]$Z19"(
MG0'&'X`QP0(11!#)E`0`BCB6[!`T4$1DC2'%5((-8A)4C<(@3>20SB/\\(<P
MR;*I3MW#`HN3G$HLB:DIL"'/K)H(W^0'BB99P&2(%K^-G*IJ8JC8%"SR%ZM@
MC""\'&M&%@8QA98&,)XT@SJ5$A'(Q`=C8\A/TQ!4F3FU"T@!D-H<:L`XNO3`
M-J^86N*LD1Z`B24!BG4:4:OEG1`A"%E8TT9R\J@_?PQE:.:2*Y?$]3C182$7
M`Y1L>KRT@%=P4"AM+,TA7V66+\`5(L(QS%+&Z,"G$K>X<7C`NBP2N2@MR#"`
M69JV=A@+_\$A4!M>G=5`>;B10MJ(=%FJE`,'!9F=Q()(^;FF$SZVI13&`5X[
M"ZA1G78AXJ@/0<Z1@RI^UA"ZWJ!J-+!-'LAE%@80^+#1(O!!Z2#0.85N9VS-
M3R01M)3WMFD5!'3,`Q*&K2O!\TLJK`Q?(TRT$A7`,&#=&3CC(-TB52NSOV-M
M!Q_P7M@=ZBG9,BZ.<UPR\!!C/H'`UC@B,0*4&,FJ)X$%N:(HCB-CI2V7T%]N
MWH2Q=<5A22O`04E"LD\C*O(H"TA80!;QC7&<1`%]+<T7?K:NBB5@&SAYC6E8
M<+"4V4FBO!3SP2@)!+D,%#PUJTZE&`50^-8#4MT1P*.01[,R,O\Z>7X>2*1B
M5AD(H!8?ZC(R+F5CAH5<=\_MS0FFJ@F`+W^2"P.H#YCD@,LL80*4&*688XP8
M6`JYN(^>-DER0T.1QHJVB1TTAG:/,`RMS'9TV/K#]G2L[%@>VZB_4D");X29
M^&D#!5JK)9VB\ILXYH9RH4-E*_0ZA$,D@EV%$-VM-O+7;$#98^-P9'A4/9SP
M/()3[,Q4SV#P).!%(8<1"C<;U/>_+QDGM"<(*R(B2VDH9U`*DQ@9DY3RB)!Q
M`A0]C1`P%B*"+]2@10.$5G)N<JAU2$V#-HC<<,0#DGCLL`G%[.#`5/T,@!=$
M?7T3RFLE;MO?;:)G.D@W"@;:#**F.C__=1.#$E9HO4K(M1,WJ63_FA64!8[#
M>RSP#Z_CY`L$EDCI"\]&>+"ACS_X=]EF?R!.ZC$\3YP.-B`T7#$L0N2T.*AN
MP,CI"?332<-4Z!P5B0RYKGM6(R4#(2^J068UHHJJ30(M;#'!W*&YSS$=P()$
M228O_>/I$K8S!Q=!2R</J\?!E*,D`BT(GI#1"2-`!#=B06&PGZ+=H83BMOH6
M%%<+0B$E5!M^IF3!24Y^L,=<Y&!S?ZA.KT+/F?B#""(X\3KC]:OO8>-!)A0"
M1V[[6#I!D00:Q/9^(KZ8T=KK(@IA+1+80->J>S(K,^`(F];"B^*W,R>,N"M9
MZ$,CP4P"B@B0_W%![-!`U,W9%>#=#$]`21'OC!O<T8*=[4!Z=(B:U%"6+4:&
M0888V)`^K(%7[1!D[-`#+@'OY)ZM&`+CI9\3]$QAT<#'G-IBL$0+J`9?]5[^
MN!K$",Z6J,$"5,Q]:,NM<!F!54%'P)6;'!(/QIZ$_%`*IL>6:(8#(5T'2<U#
M&!%(J$8./D3"7(2V#`/>L6`,>,E0[!!N#)*?1`@V]85A!(0J/(D"N0;-V4IF
M@=$4R,5.#,4GY<)O[<E_=&'6B(O!Y89[I(M@_0IJ0$M<I2$7F)<9\@FO+,DK
M&2`DYHTIC%%HM!ULE$T;.!`];(.7"$?%\%OX54QR!5T[/1,6V!,/&/]*EN#1
M8/A.%)CBK(@?Q4D!C$%3;14$4,#-J1Q%G?@**@(';O13-F08X5C67_P*7U'7
M7_@"O7@'9"0"0T2APE!$-0`&"9K(=4$"^(U8U8`%QM@>S\!!G/W%&T#&DMSB
M)-C0-%3-J02+77E)`V3%N+@4NX'-/D"&/OSA$)0CX;A.>A&C)8S.(9'!?"!;
M)![DW?1,+Q;%&KQ'E4G'J"4#%@S+"2E.-AX!`=X"J>$:00H&Y43,IYE9&'`!
M])6&.%"3XE2-%OI52!#%+9R$>WQ,3:$DAMB0,P"!82R)A%PCT#`>C`E/Y8R+
M:5'(FTB9K=QB0W081@K9E,R#WY0&PGG,C<#_C6IDC:SX0BJ]#IBM8+4$HIJ\
M`Y=%B%4,U^@)UBMH"@E`Q*K0@Y+PUQ#TA:S<RI?55T8,3CJTVQ`,PRB9!!)D
MEJ#0)5DY$!"PT@*1'4(>)K<<FPN.0(=`P\Y0DK4]@Q`M@3-2)FJL2"\XD-+H
M2>05GPX8!4L`!3J0"RIUX3JA`PVR@$*I`5_&PP%4HRO:2D[T(<\0@@=U0CS`
MI"50!#!DS_L$1#OYSA1@`WO]16PN!J8PCY:1!5$$GTT\!0[999R`P8$HQ<,L
M0"EPY>LUH!SQ0D_8BI1-2%>L04F<4NRL@S&N10*HGR`A'V486:]XW>=%"&N!
M9)9\@3G*`!-`H#@L_X5_Q(!C[=+KP,(NU%2O2$;2A`,O8A4F*$-;=(<_(J:$
M\H@CI@'"2$&M%=4X`,,RL-8EE``1O`;):`(OH@5;A02<M1`.D&<Z+09@8D%9
MBB$MEH3/W<:4!,5]5(PO5&.;!8IPO*4&/:!.;H%2`H$_/(V-3M&LA"43S6B6
MV&`V\()X((+AF&=D`L=%7@2B),KBN-\-\`*+;(3UD4/LU<LF#"<;J&(V$,7J
MW4`HK9%)5F$EC&E!G,H52%%1?`([V==PF*?46,EB'),AX,9PK*.!J(_YL0((
M0<,:,./O4`2WA9/AS<J3:*D.V"=1;H4ES%=J&%RS/8#N3:BHV@5<),`N/?](
M+Q$.7F:$S,Q)(\Q:1NS0<.U&G$#$>N4#'YD(M*WJIGI).-CA?IQ:6;Y@0]!+
M3TC)?2!#:(32*D3>1HS+Q\0":F752PG6:Z9G.VW#11)E+O&.L[+!#P!,+6S?
M8'"E@I(7Q!@*<G%"/G0"N@B,4=C1#HP+$=3$O(2$'(#5;TP!8*PJ/5P"4>$.
M!*SK7P"J4)3`2I8&J.JKK9`!D!V%=+*!F>%`8RI%`#7"AI[)BLV&OV%7*'C5
M?/RI?TQ()Y@FZCT$-L#%'RSBJ+;L'F`+1+B%>"0,O-C&OWI9EA9=&+RHPA2/
MD-C&3DGKV7"G[-&+-_9;KIH):3S"`EF5CW&&K(#_PGS(!7HD+0U8(%\!!628
M@M5NURUB2Q8.ZU.L&KN*V$880L<TA`W=7!BXQY.VRN_`+9_D50#TA'S,4^A$
M6Z=VS:ET#+SD1/T8(;'P;.B(!%WV7S8&0#CP;!;\3&EU8>7U`$_6IN7,1IOQ
MS#,4)*BZ+.?J`<RB8(2PBYK@I(&L)[&(Q+>9B80PU>DA$P`*`[`IQJ]LY-8X
MV+:&J%(&1FV59`I>$J%&BF(XPW&>0"V.@!]434S`55.8`B^9*H,-U^J&"FCL
M('%DSQLVY8-Q`D!]2O:X;=<$5#:*!5R1@.FF@U7QB1I("1"$H'4Z4-;02^@(
MC"04DYTHY7X=G..%Y0<5_R\])(PY78GR`L8P62X)88/F=BX"WP',VB6_>L%5
M'-+.J%Q[H0H^@`15Y)NYD"=(&&QZP2"$[!#DU83S$0[^V9816"ELS,#C]0(5
M[H"<=,U]0>9$$L(T;$)(5`U8U4T!48A(Q4OK\D`)#]EP>>!)N-Y]/1M?5DU6
M'%T1Q$<UYHN6CAM+P>HIFMDKE$02T4]K)F/7!@P,\!=.F!D&PZ@*<>5_+`)8
M$<TN>$%-@8:=*%S2<`V=0D(3KTN0B>T1H9AJ3`&#+,@X-5DE\,Y6_$'Y)K`A
M^\I>'`*W!=T5T&3E-(%;KLD+@4$G=`'044E&\%$B^%?Z50(1P%&MH&0GF-Z=
M8O]53S2!*G1%X_2/.@#B6C!Q$ZQ0(CS#K8WR"T"9*1AKU+4HI5[!J$$9L#Q%
M$Y14(>1F/$+#C%BG$H1$X$#2)QH1/_&"P"Z!G1W,,=/)SNC#(QQ2M1A'T]!F
M1E!RSI5K$\SA,&Y%YM)5JJ+(E5S%NE5.):HS:<2#E?'BKN4J[ZKSZ];FV-K&
M%/"1-59+?#D=SE7#-><=(1^R0J?@!#'-28!$.3Q(3=#/1U19L"G#-W`E)N`$
M9E3+-\CM$^2=N7"$6N$61SP33O0'`@7;2-GQV%1>L(U%[Z%K+*;.IA9`B"Z&
M7I48:M7L-*B03QRI$&1EW&[05_P'0]1.L_@'(S1%_7#_04BHKTC$1`0#9CBT
M)%DT1(>,E4T%RO!:[&^T:"#AF@ED#B75$+K8L.JI@I14FPP3'-!$L$B=B<80
MJQ.[2U.@A2]S,#`XK%PQ`D"$K!E8D/[^CD9)#?Y<5+=QPP`7!>""AD!(1X(M
M=,O"A0!"@5O"4!0$LZ\0;5'LLPN+'\3$'S(9SCC2`$#N!^ABA6C#RC/N*01N
M#T!@09:U2140CB&J<=F9%7)A8/Q0SAS'2?3<HC)$LL(LIG`;2&J+-".0=IR4
MZ8UL+?N^H#LN)''8R$.4UM2@EZT4"I(`3$C82UIX$6L,E(U4'C:GAG?,R4,8
M)2UPMP!AS4!%*(QBK'S%!`$1_]3F4O9"ST=`401B3='5(,@I4#&9.M8MI@^\
M9$F_Q-[#;<14G"!;K`I@1RP-!+<EB"<$GH*I9I>'#U1@?'@/?+B'C[A#9->(
M9Y=W]%EQ>'AXJ#A<A$<]@$F2E48`&T-C1,5D<0ZQ!/%,*!QS?G5J)AQ\C$)?
MU!8)>'8"?5HL0/#;4J6L&(JX/";9UJ"I.,]F$R!\GR(X\DY#/(YG1XB%A@'!
MEMK99.C_S8DR6&B%\C=ECYT9+X41O%-27?!K:'8R!UU>_8=WXIVCF@V:6=17
M\\QLME`724)8+@49$E/"Z+?).`K,+$^C,9JE1+IV4'JC71>6(=.9Y#)?BH"&
MKP7R(O^WO'!BM/:".`2$C=3U#GB38YQ!(V29"X9@+JZ5^UH)3;.@#>@O,[=7
MU+'&-A0H(EQQ.^)"W6`1,G6$,IR3#TQY[:J8CW=#]MI2;9K8^8K+^6R#A:MF
M%B3!0+CY0H^=V'P"D,?Z")#W[@D%!JF/I<4.6>A)5KB+#KC).&"YQX"9<M;+
M,,>#^2P!3=H[RQ#3!`G.QUB79>Q0,16'X/C"J7026SR(<'22<T!*H%6&99Q*
M(]3#RT"*CBR5I>P%LRB%5MT7;/BRV-2.6)QIAM-+=>K,BX5%3@%H;GCR:F\:
M#Y2T8K-#;F!K9F0I%Q6QN:`#BF[J,X`"SOGD5RPKF*!<N\'_Z9<>Q>4"#=,N
M9NC<Q"YA\0!U3-6;J4D*G_^9[!?O3"J)BPD%`SV,T<J"^R'#Q9IEA`G4/(5X
M`I[X<H"`XF(0PHYB#/XQ0PM\B".@L%(\!$K=RWGCCWO30$[T-!><1$E'D1O@
M0WB`B4"IAB<0@FO@`SSTS*],PH-H1GJX%K*D643,K#;<RI&GD]T.5$=([GP,
MT)AP7FJ8F`^TG`O#PN)!(!F@MX'$9J+F86NI,%J834-\F&'(#3W\QEA<M:N`
MPK13:4T$2)-V429`R+)7^Z=AL9M-ZEHDAC*$_!D/&0%J312?]NBX0,SFI5*4
MZ0B9$!B\40<EAFY*XTF8L134U[0@_\5"F$"_?+O:@P`DCF1IGFBJKNOQ#,XQ
M.@!AH,6CH$B#H(J&(U4@`!,/QJG@^)T8#H?RY%J<`H3![N08-*Z.Q@`%D#I>
MA`#C@2`LH`:%K5`P#%P0&$+A$#02-@8""80.!(<#@U&!8@T"+P)M=@(.!@L/
M;CD/(@@+3B8!#E8F!8D\8ELE`P,W*`&M)EY#)W&?)`=-7U0/NB0!7@(X;4M!
MMK>\7`H"`:`Q`JDC`0)%"LPF"T;7!DVT`P30(]\#H\W&$`??LR4+E@D!!24(
M!CD!``"QO229V24-!O^T#@QP!X1?-`(,8$!H,`7"F@>;6$B<2+&BQ8L8,U[,
MX8,$`P&P2O^4:7A-%(]*UE3%0,$NQ8$%4IZ`O&>"`<$39<"-`+"-Y$X#WW!V
M`O!HP8(&#XX*$$#@09>FO+K`_/5O`:%#@`@,(I#`T+\$3!,`;>H/(AN(78$Z
M`/M`P*JVG`3X%($.'LX&=D'9*1C2XX"4),H8H&D"J`Q0#=)0B3$7P#C`)!SE
M5?47Y\HG!`Z;**.YA`)WDT>40G'@F2N4*+BAL(3#`.01",8$R"?"$>'`X\@0
MB$G+P6MF-E*PNQV-S;T"FAW!U<B\N?/GT#4.B+K3@4X1H:[7_K%'I#\("P00
MQ_9:1!"7-PH(Z.Q0;AU2OE.8QLDZ<XD`O`(D\/G*R9E5(!D`427_'S%P2!),
MO>#4&9AH]0@22SUBEC=K#00()4@@\4(?79B5H&L0+80`%L35H!TZ`J6F@%&D
M&,%030:50$D*#5A!@T@ZD%C"`3?,%DM?),A3VEP&[#'&CD%1H=AB!R2@4W@&
MT@9>C"1$(5\!\FP6ATG>'6E"D^4M9$DPM%F%@#D0%$DCD"-LDPAQ:1)0P'50
MD.&':`TA@%9T?/;IYY\;47>.#0$PP\`GOX29QR=BD/`/37P05@EA6L#&IGF?
M&*@9`X.-P6ER2SK6T$BN&'!8#7G5A5T"J;(FPB.)].%'0H]4V!8"E>"Z"$QB
M&0!6%)3XV@8[%Y[11U==#>(44X.LHDQ7_PAH0H`30XZ`"SGWK:3.3U-@21@=
MA"GP[0"$:5;#`N4Y=B1/J5HG0BGA5L8`0X0%@"8G"-R#A2VY.529"*0"G!(N
MPKD&00WYCC#5P?$!?!1A#?$16C0.%'!/8BDY)@,`>'DT'P3UB';C9K&)$"4)
MI3##!&&.-0#GN_;IE2\`<@#F3SV51N;EC@E@.\`4CNT)Z-!$%\TG4C-^1O`(
M7CB$$&G=1?;#*]A"4,!^$#1QFP))I2GE"(=ZE@0$A'`\RD<7]T4J47/1)5X\
M2EQ-$@`$A4(2$L0FU50"/@3Q@C=HV8'`((!@\H"O$691"2$9[H9)AF8-F%;D
MF`P4XBUR#0H8+O_ZOIVU"0B05"<$"NQ\3C"DF][`%T0EO-G3)(RM]"TQ"0%V
M8JTHE%H^->CBJLFM-$D2-DKP(5P"M^V5=0*18;T0;3H<W/45SIN'_,$)=`80
M>`\`)I9Y5,Z03^DT;>/1]5G[S!M,9/!-PD#WT#TR!#VT:0O[#CD)-\@8/G"3
MT0`,H`!5P)&_,.]ST6"%J<@0AB5PI6K8Z0.:'.,N(*`)'5FXF#H$,@Q0G"EG
M7UJ@2%9AL!T-`%<^0<*!`)&`1'A(*Q!1G``NT12L$$)935G*W@;W"*V`97*2
M:XNRQ`(6&R`E(@-SPV5\L9Z8(5`$X=D<Z=R`)B:L;C,+6(45)E8&"$+_P"U)
MNL697`>R+S"A$RD0!9P^^+4&O&(N]FK4%6YV#1\,)D@:*\#7Q@&[$,*)'768
MBQX5<,?`Q":+[`'8/.XCA-(M@#@DZ@%D/%$:,GJD8BU2ALM*H,>$T`8`[,""
M3OZ",#DX98`D@`DK?O8R5+J2.?@YA!M=`9(P.=$$G@-%4[03GJ^1[EZA@$5'
MF%9!4B#C!'*@T;T<PAL2((&';G&*(+:QEA9BZ1DMA,A2V-(6;E*"<`SRD/^B
M@(1PM@4B>I)0#Y;C$&OD0#OX(8DZ6$&$39Y`"*\!P$=FP1XL=`8P\U/%`SHS
M+Q'T(4PS=,78D+G06#Q@8B#['DYL0)P;L4&A_VTC72[7\8!6/D(^ICL(!!E0
M@#5<:@W:>2<*;))1961T#1"EW_](4`T$R,`J[!3@X)C!#,=<ZI5`M<@EQ@D5
MM%0"%P<0`G$,I!U-D68:^O%)3O(`P?<L!ELD!=CJ>/(:+!T`2S4IH39:J:E^
MC:`H#FK#;GIU.!\.`E>`:Z&$M,D@`3VH*X:(4!ODX;]M)FB;-J"$#W)Z#V5@
M04IU>(5FG!";5IZ01GB9Z3EB4(2EAA%@%UL2Z/[2,(=\(0R*%4D#KQ"'@B0$
M3O#*W"43B1U+K)%^6)H8E#KFF9\*)%T]*!W)BJ$7B+Y"3KHA)'OTV00T194T
MG462`JK(MR4E=75>$/\#7T\YP$^!#G5!S>Y%Y)"]<VA30TF`5,,X1JYHI(0)
M83J`+4;+,*"Q@C!JLI:U;NF0+;#H8*55&#G`&HU"!J`ST4I!0@`FCY3\QQ!J
M-2)>W$!2.N!E`4%@B`(40(<%T&%.=$B(/&HT")C8P!!]L(%31HPK`=G5"P^]
M3UXFYH1W`,PN7L1.(JUQ@"TP`#(6HTO5RONZ>TT59+Q1@]7:I!GU-(0DZ&BE
M&.)GC/O:BR1T$`YM;LP`*"C@QF:U&NJDP6/PA*0S3-"-+@C),DRF:7[H2`62
M^[BC93!L,D*R6M5VNA.4$>!E`&A#\;:UD.M%<2'B=$KIM(G*S@[$=ZS5K@#_
M2_K?0AV`IX<)&?T&P@![0&0Z$`F-GA?"F"K/*SZE$9?)*AU!AE19CT]C%UTX
M885WR`8`];`/+E*A3WU>^0V!>22FXN'&&Z>A4"`KZ3G0Z^EB,^`S5SZ`LBWL
MZ::X,$,@B8*L5N&/2*S.PB>4=A3L$`4AZ`DLP4K,B#&A++.<@7"':\M:7D#2
M`QS['55V]X2OO"+D,$2/>L1+`Z[LZ0*HX:MQ*,!1^*TO8T/8TSXX]KV-HN]H
ME33"+B,S%5:!G3+"`Y3WB/0"?S$9!IPJ:B80KK%/7;IB=W+D(S^*J2=\J'-J
MTRF_.`P?&O(*:\P+H#3^%^BJ`38OT?9@PPR%]NP"_\J8!NP<A5P:)_)"'D<E
M,$R-',%YZ,(;FMWYB.M^Z%<)/<"=U6`$-5)T4-O]Z"O/2>$GI(F>(L(URE4L
M-B,2T0OH%YLH],#$JX/'H3`I$'VOCB$"^<<.#C6*=^RF1EY0@\<]<8<K`GI9
M=-6VY"=/^5QU00\&@.[?_PZ#S=M!#)E?.R96%*U.4.[TJ$^]ZD^/.)>#]])9
M?USF56B6!*@5#2U$2B($0;G"K3YR2H@-6GY?5-7_IP%)#8(=6/$9>/!H%D?T
MGUF8(&U=V84/V;:[MJUQAAM$/W+FI-Q<Q?][U,\05ZNKQ6$J47E#\&0IY?VV
M5K3-!-B!Q$!^V`9>2E<Q-__<(R'!QQ7S1VYB4`G*0$B99W6[,1W:UA59D!!C
M$PI[\P\UM!545P2AYP--0`FE8`-3L`WA(7IF@1>B)P)Z<#`PD&U"('E6@`MW
M]`KM9QUU,!F)$21B=X,K4`H1`0$O-R`G<$*)=@FMQ#DK=4!70`#V=!_1DQ+?
MUQ8Q1CI_DE0K("$_4R2QT7:1LTWD5'Y<&#GJ\0B1D`68UA:``Q40,GX>0@CG
ME"!F(0A%M#>HUP5,<4(V4%Y<L0TQ9`,PA(:H!VY<,7<X,`KV0!,/(7TYY0)A
M(@>MY`D7HV[:!@.50$*R<"8080=NF'E0P6W:U(0QY&C>`#*DYA`R`!">)@,R
M\`K_.78.'@=K>9`7*:$&/9-/CN!N)B-LW%,X$$('7O`S"\%H`:```F$=_.9I
M`8`-K'0PI6@O!E!E_P4TOW`'__4&)34G;?%?UA)O?'@4.0`6[W)%`(!A\Z)O
M9^=QR$AJ\&9L+'=CRS4W`6:"./B.#+4@Q6<6Q*$FS00P],1>4A=WEA%3V+`B
MFO4NKD%Q8#<@#Y**L?`GQ[8"(\A#0%$$\%8/\U)C?P!^X"8K6H$5QK*%#<(@
MZ@$X.C0@ZH9IQ==ZVG0(6D@)6.$AD?`S:Z%[D#"-X]`)2L!]F0,1]0",Q\8.
M598F@^,/'!8;QP81CF=(,86%&J(.Z`5<M>4M(K$;-($4_V:T(D>A!CI)80(W
M&Q#!`.P@!@.@1Q#Q2.^017QP>MG@#XFV;^\5<K'!14AX,"42.CC`-W=`"@+B
M=D`7D*D44.^3>4!@!XE4`S^U,*`0'J?W,X4X0'JT(RWF2_`H=ECW=__A/_PH
M`N834=KC9A#@!JD4(TD4)@;B3F*53*Q6D)2C'?3S)RZF`A(B!(DA%BXE"3AU
MEY0#,H_VB_@U!1Y':MWW54>T!DOQ7>J6%,&I`P(7EG(6.DI08PLI9%FC(*.'
M*SW#-4C1!"3%!H8`"`GQ7UN)4YY0G5G4%*'W58]V;--B'9C&$SJ7)B%EFI%S
M0.C`4Q]S,&ZV;^L`"SSA%'3`A?_@50JBT`7KE`30-1V:@)=-=P+W]1TTY1O^
M5`)B%0OW`B9B@B2%:&X\<8\>DU%-TQ*>X1N*Z*#MR0G=A:`P\'O8%4"F4U#T
MXYB/J5TY0$]6-AB01)`SL#&ZHTBZ`"^.8A><`G5]!$KQ40>W\5B`]GI2L'R"
M@"6#,V%?265Z5'<QV'Z4(&WF9BQ_R`NKT`?>$&%,80<+X(+C]UMRN#J'`U<K
M2$B88&$2LHV%,T3!29N.H"$,ERPG%"7S%QOXX79Q@`1(@2MMP#4U\%!%,F$1
M-5!?I`/L(`CS5R-B$`EV$`1#P`I#50]_YABA,0L&0INUESH0`UR"01A&$3]=
MX`OB*0W_M4<XW)0A&C(ONU$':!H5B2$9D7.7/7-G*&!6CI$-"$,394`M^G-6
MNL`3B28WEJ(PS#-4X)4%M@",L&&KKW,V4\<)ZO!CN)`/BWDP;8!G%#<;?X"$
MCU:1.05`U$!(>F**A=2B\'@)8O`1,288NE1_7-`#)QH.E=9E'8I:,<!GG/`%
M\_@"DN89YF4/MIDQ5'8JH6@"+,J#1!DK4,`J,"!8+30M3%`Y%;."-6)3/T-A
M7]I)1V1Z6QEHPS=NZ/06.A`K#E*BT[$4UA$ZH1!#_A`#P"4@U@$)(9L$[E:N
M"GMG#,(6$*(A3'$M?X`+$"&P&/,["A,MO"""9H$V/*->YA`V_UE0&(=3EI7F
M<7X7+>SPJN'A#3W3%1!!2(C`*JB702CP<TQS`PD5#X^$/A13:?1EK),T!)X`
M#YSX`K<A#7'#ES/@$V'&$\:`MT0!0;DQ*:E1-?KA;B#!$-157:Q2#5OW4^BJ
M75+9![[412\C#959`F>@9,X*.LD5&1L5)-\@""0%5ZT$N1K1DRHP@EU0;77@
M!Z4@!]14EC$`8=3TB);8!%E4!&QP99BV!J_7>W/E:9>V><9[O!#V>+Q`E$/E
M`VKX<GMC&II`.C'T$4S1!6<@G8+E"(;`#AWR4#2!#8DF",R`?ONV(I3P,B[@
M2YGZ@T[1)+Q0!-[P#QNH<E!1!'Q%O_]?JQS^DX)NQUKD=:M<$@OK@1-NL8A+
M1%-N`79<T0<"XDLDA&?Z:"W=BQ.)`,!`X3)PTC)4`!;Y`A2+BTI,P`>6%+GO
MJ"?>(`TVHKF.&;4LT0GZ2C\5TY[&<QJ)YAB$E#77J@++Q!R/QI!$:2!$R2%O
M);,H)+,<$WZJ%TTQ%$Y<PX?!^W(:X@8BRTVUAP0<LW9$Q""&V;\D)"Q=<U--
M03K/1#^$Q#AVUQ7ZL;^`M'8[,5#5`W:R`#%FU%']V#YRU`^'\Q"<8D>H0)?=
M.[0?@12#]+56L8Q:A(5R$<.3ME+S&AB[X46.$0GW]+D*TPN#Z!!60;@(FQ0O
M4TPE\!$WK!7_;=,ZOJ0:-1$]>28T)MS*0+4&5H(%R$$3H>`Z@)%G&35I]^`%
MMX$K]W`F`);`J32B(;<29Q(&,84R?S(G0`R&\_"5QXQ.#]4):5`K7/F^<T(N
M:O!OKK9<J<>UTP$A61C%Z$1)7]J*2)A^Z"`%0A!#[.!"8,@@83%\7*$$V+`)
M#V%[9P`3#4()"'!#`E*!?A`B%"0#10!@]6FK'G=W>):V7W(G4'`;0?,S2)`0
M6H$+77H(2#A47;!<V.:1OK(@E#"&FY`8<S/!4M<SI<(,37,+KF$BJK!,C55G
MAG)1Y(,Y8[`*_[1(#G24SU`*55,:G*4V7PD$JI4UM>+*2NU*DPLP_YC`4RK-
MP*N2:*%`@VZ&!2&Q#8>Q/3-@#:O34B$!!46Y4LG,'+:(`ULI!E:4%F-"%L'Y
M$&'`@#W1%MS[FM%E3G,%`*=G"*=7*U%`E&4QMD+$@8,E1#'4>7HT'>ND)\:2
M8VW'#-5;98>P;31K4O%;"1.["3/M-N&02TVW!K9@G_P3HOI!:P8!%5JPE8JC
MANR712`!?!%""5_;!B_0,Z=G@E@C`T7=)E*W@Z"@F71W$-;0.K!!1C<&&U("
M:[(L&OR@'T[`$P;!MD/V+L!]'[]JJ0=Q*O3D-JD`;.91"0F4U$L]W@"D)[;C
MU,C!F4ST!AA*`M-0S%!@KPN!+MZP5*;B#?\_/%;R]%4KD%5^<K!/L)7RD+C,
M,CB%@`3"4BOZ=+V9!P."$!;34FT#<A2LP!9\F(6;D!GJ5;RLT+]-P-?G%`56
M&T,@/-!1,AU:46W;X`8RL'9;=RO>C&*U/1V)P#?GQ*>9UKG64P8A!10!;$@W
M-L`[`LK^`FN90>-ZG027`$8QE&[\?$YUD'F7`!:$Y`@D-&AF@8\_X!C&@*<'
MO5+K255Y<$L",09V<!NE4;XQU21&.V"5A!OD@@X^L4A!BP-LE@<RP`?L$07W
MP&9XJU&_("D^2-Z$/C0HO"TZF%%(<2(BA+`%?$]O>83)/`YPXAO%IFS^MIN8
M'AB@B'*>_NGS]NG_CS`O=/#/-1(&5L@$X]!<?75\%;,-O(N_6G!$D<`CRQ(>
M%TXY<O(,T?>58U$)19*R^I=N9A%8(M:\ES"W@_02]MG.[S`@?Z>3)+5O:T%A
M:Y$.TW"7$?H,+_,9D1X8=8Y,=?DE42`#V<O'D;@-V<X.?L`@\:1$1A8)6:1R
M`T'2V,&5VW`=6!*B5A/F`EG"><E:A$3DUB(7*EKP[ZT->FF"A-(:;:,XY9&H
M7+2!HRCH(5SH&`\=6-<0`W$F$R>47+#F=_X3J-P/L<%:)7,"CKI\\E#A7H`+
M,DAARW6[\Q>E-@^)4;!*F>8%69`&$$:3K+`;@P.!;<$U85`)Y^DKU"2%_T09
M&SD$`^0<O(W3!W#Q34VQ%G6@SY3X$9&S&X*P;DLA(+NWLZO##*51T@/"?]DI
M>3,DLS"@AW=)!H)`!KCR[=8B>,BDMU#$H'G`"VUGIX/0"%T1JU];LG'`%/;R
M#8,3[#)^.=C1\%_2TB&GXX["R'GVZ";0!^J+20=O,L<4<A?/-`D?<M4=&92_
M$PN\!`L5$DF9\:ZO\2\`"X!J-8UN-;9Z"<,3QRA#\!=(.@]*/ULTG["51DG(
M$KG,'/SN^?YS:HW`O4F@!9FW.J(7!IC0@=P[.-NV&P_1K46UL^5T!CQK;DF)
M"3`O!$4B!`G2;0_5_64Y?X30^&.K'I?3A?T;TO]"3\6^;2WN0Q]6``)*`Y'D
M02C0,I9081QMNP@!$$#.TRC/PP@&#<-`D!@X#"N#[_`H%$0/!P)!:#06!D/A
M0?`]!!#<00`U`&0#Q&F`:PW3,E(!(9<Q"`>`("5SB`@PR!0X[!TP++04],V1
M,!C2O)40`6S-(3'<S:`Y0B`I#!!L`B`%F$$@M(`Y>+J^PL;*SM+6VM[B0C3L
M#)`L.(B1B,H=.$PRQD#D)9-T*@MZ`A"HFE!#E/::`)(`("B6-!20!#@`#KXR
MG.>Z&L`J"'@!@PE\@86!)22`$709-!"4:P#)"A(O[W88`&CO@3X?1L((@-?0
MG@X8`JP@`%;$0`)X"K[_*-#A`P6!!%L8&G#00$"6<$7"+6`0P,F#``A\I,,B
M1,"6+,`(#$A`@"5`!`-\D%#@YX0U&0#"C<M2(H`!=0/$)75PAP%6"`F9G=K!
M`*<#`M,<B%K0,=RN!TX*-'"0P($X`P@N_A)"!-^88E@;9"-A=)R620J<0?!#
MIVF+,GX"#)#YR("?N'><J.-:HA`S/#!\:2V!H%,W:]T^3RH1<E/CP'3O#,'Q
M,60))U]:K<NM>S?OWNMV`=:%QEB)7P<*L6:0X$`QU@'T?.S<`I*ZR0`L#=CT
M;M!5&:<6E,E1(+6C=+Y;!',%`&>``$O)/6@'(%FZFSX0]!M@%VB2%4C,0N!#
M_P,):!&&?2(MQ!`\.^R2444*)&#%4"D9P!)'>X5DSP`#?.0#%6$D4(<21`0P
M%R`+MN>#B?3D`046=E78443E3(-48@*`=T4T5)3``&"C'!"B#`LHDL4F96CB
M#QX"=O&#1J.5DT<10C0AXP(*K*`%8'9AH4`5\RAC2`NKZ<(")35\LL`F59"`
MA2?-R?#9;(L(`D`!!*0&ER_\>/)"9XS@H%*<HY0BP"8<"M,`:YLA9@D"-JQQ
M&9'"E'448^=AFJFFFWH"7!;!H+F9%^2))E!Y$5770@!/.$)5J-X]@(!B?_P`
M@0!BOM)>IJ?`0M,4%.VB3UM3[`0&%[%V2$\=85`IAO^`0-G#1()MW;J0*/`X
M``F$66RAGPX%4!D7*X7$NL\4.FQXTP)&);/J`S?XH$``=0@R(`WS8$O/+OS8
MJ(P^KF@[W0AMS0K.&JT"]<V8`BZ`TRY'12@4/>4LF$@Z2MQT9T9W&8'%L`D\
M1^H+&SIRP`('8P*NF3*$-P<#_A"0J@N"@(S'$/J1FA0!COB'FPRC733'<X!=
MVN/.<Q@`6=%N`09)PUUQ&K744^<&7&0EO*I".YZ<K*/+^LD,P0EA7S/*CGS.
MP8@0XBGL"66:/M"K#S&E4_=!D=5=][`#-"S$76L`0Y=0%;I[\U`)3@21M#O<
M59:'GZPT%P)SQ5>2CT\@R-__7`_?)(J26SPUC5)MV7"?/TC<@".6/$%[E`X(
M8-$ON$HL&AT>BD!(=ER!J;IAV^/H(!!."34<T15#7''4$VL4X"-^/+S`@P(N
M(FB2=)0@U@(`-)!-PW2U$=<JKFF/K]H*-7F"LR..+EJVV8Y,$XU=4$_U`.]3
M:8&;`PW[3+7__P-P#KLH1PL2L)70.,(*,Y/.2M*0K245K`0`2`#9,`,!"LI@
M%WM`2_]<`95,%6T&*JK'/2;'D.*%02[VR(*!UA`1(C0@(T=IQQ>0IP-]#$4Y
M^!A-K,SR@.*EHP?92@DOUF`_R@0!)Q-!"WXF\@5^0`990U@`7`+0L'>-Y0<^
M8D`/_]Q0%D@T21X1DHM]8O"<:\S%*4F;PW&Z<#W!C"!^T[G"!.\G#;'@)!1(
M6(!9I'4%:4%")=,``DO6M3]@^$1%<7/;T1S!MX3,H10K,),<E-,^?^F.9JD:
MRZ,,Y91"N$*.D?P!ZN90A;=Y1U#K4R7\TJ$(E4PA@+*<)=6`8XT%3"(C[>M&
M=A[Q*'`X`P!TF<H#DV*-$[S1!2@`7E?`E0Q+&`HN'FM>.N"R+MAY+)O:W"8W
M/283EAA%(#/)6Y!B)4TL%."*+-&F%!AR."38"RTI&<LO@."0E4SABB-DR+FF
MD(][`*0>ZZP0[+ADE/@4P0O1FEQ)J%`6M$1+).6@3`_<DO]%BJEP+@MBR%V\
M$!$#M45L+'D$4'HTS'$PHP`U<T0,M6&-YV1C:!*45F3(D@2@S&@H'(P7%6ZE
M@$14""`Q)`+@[-&C%I32$4K2A0"8$:1OP*XUD]`$^,AV)S.B0C34*$9G,C()
M9@@SA):H3/B$00V^]4YAUY$@`;8623Y]AP#\HR5=ZWJ>7=QJ*F@"5R@9DP<<
M$$&-*=B.]NQRHTNJI3-`2,%HYF`HNG'QI]3D"@^XDK?F82EO2K%LWNIV@`!H
M@@_S$5M[$+'%BF9#!%=ZCA=R,IX"'$!Y6AE+2E9`,?RHA0M$J(=#%Q(L?(%A
MAA'9D("$D+]_L`0)10@2<61;!UC__O"C"1(0%MR#E+9@`4$.(2X\'C)"EH2A
M1`6CAPH\R=;!&C!]C-%"8C`H0;2TMT/9PHE:HH2%%<RF+?Q[`1/Z8):@P$4E
MXG*(,LCA!\.V2@EC"L98U`$`+^EL$SPI`9XZY=;$U"H';3L!#JARX53X`4>>
M.$5G/O(&;\#A&Q":E2@>H9)+ZF$JS^E"SNQJXQO'HBWCZ]*'6Y"$\@QU4:4`
M3`1M$I<:0XA^UR!"5>;`(UC,1%/IZ1.^`%..BL2#8@!9D"%6)<^`EH4GKQ."
M2%;P!7C0(''Z6)QW85</CR5$AD&XE5Q68HQ[A>$7\;F)#]LZ.K[9X67B<`+(
M5&H_61T@_QQV60,A*[3/P7GH>N38103]4DQ,V&$.9K[4":+'6N&1\E8,@-V&
MTF7")QR!;S'AXY3:NC\7&C4-5-E2C;?QLVQY+<4AD8XTHE#6GV7O&9!I`'-:
M<P)%X<&_(32P*=&P5#@HH`Q*M@L0Q!J_SBSH=SC>-K<SZ`/>X;/6(<Q!!T6H
MY&L`QQ,WJ?':'"$7LI7@TN=)`"RP6ZA&?&(*[DG,(-K9BAX()!W'<0\#VAB%
M#/U0G_>JZ#ZTVRR.4'<$^&4.5_#S60IU5$!,0,L`YYL2`Z+E*,VS(D.$^6VD
M2!$&:]`'#SOB3C",H3Q/:%\75I!`;6,-WCL8`SQJZJ0J-&FZ&O_/`]"8,#(B
MU6&2^]">*%,9P4>X1=V-=/+4_]#+.4"H2$K^H2=R-^*F4IEL1ZGQ+BX)@1B_
MH'Z/ZS;;VZX?^R&5#<%V5#04N#Z;=T<&(8&I`'\]@W)3>`^PD+=OILS2D9CE
M5D.!QQ.3H$+OWME#P*"SXIE(H`6%PY^/U@^_^,D0'<1,)%;>$A&N;'H6!=T8
M$[U5(8R0D5NM1*7A&*P/YC4WY8CB!1DEX:/_&;>IFH`?"8B@%6RGAOOI-81!
M2B<BX(&`+#)@CVH1.EG6`+OQ3!1<^LD"N,`T"$LD9&7<0&MYAN^)Z,-N42:+
ME"D!;U83=&;6F7:*/$G5:?GA7&Q'.'?_,2H125L'1PDT1-6U70':U9=D`Q"P
M`%4HAC#-BFD\FY.9R<FT@%'(00".`4"H"EN=FXO)`N'U!@%Z&ZOP&VB-!5"T
M!VA%F7VD5C=QD_)<"9<E#C[(R$/T%R/X`!'4!Q4@72%TB17@`&]1A9ZE1,<9
MQ3NP`21$1"C83P!\#,W8QQ0L2$>DQ.'TTR)ISYQ(`R598-E41][%G&K$V*F(
MPQ#J`X?@Q&@`QMS,Q'&,F@]T@5P5`14"Q33DCQ9$838\11D.0+'U2'4PP^0D
M$WNY``*YV!Y8P1T,V8X\W0*)5&?XA0NXEPFL$<(THNT,0;*IR3`T!@B.`PXA
MGP&*HBRA82O<_TDHM$L?BLU)Q9LB,&"-X8<:L,!A@-4E6$(#I`:BI`G`Q%`R
M^1B\Y086<HV*.,@0[,6YF!Y`-,0Z>4P5``86.*/'.,X#2,&"E,3B.(0^B$3X
M/0&7'4:E<(M<V0618-.`C$0A.-H1`$5*P(6(58C%/%@8)!K#^`-:1(3+482*
M=$1"":-@+$=MB-@G5!@=C.%@%`=6!$DC)N14O%F3_,(62`NX^&"!_)#GZ8!<
MA)PW7`1=+(Z)-)[QF`C%T!E:^$$/-.*=W`&XR,$+3,(6X(`E&.)/44('YH'"
M^`DW!)8O"(G8Q$P%3@47=)U[/87"/!6C$$-/FD`!R,%3.$0CCN)33O\-<54%
M<5Q:*10?SXR&M9T;T81B*,@52VF!4U*@2\("&T@9+#2)&T0!N,S$<,U'-4T/
M-E+?7#Y!$8Y$=^F#1\8*E"P>/M'E7Q+!C"3$%*PA]24`#^C;L.S#;>"EAS3$
M8RX(RY3/=:B$?MR!3?@@^2V"0)3/F'1F%IG$MUW!N@@(,*1$1@B(B>Q`M1QF
MZ:TC[$S71OF>YUG+RV0-)WS-@UV*5T7@-;`+X;W!1["&)8P'VHCA`9`)',Q6
ML*F&WR$'B?V,&!0#>2C)<T#"%/@B5&JGIK2%291`U*D&"<)/_GF%4QID)$&2
M)QBGIAU-<OVE\OSE7+I(%OQ436`):$D3;)G_C$/X8#9Y"#>)!#,*05S\@^M$
MCL<T!%?DXZWD98ATP5%@2Q@LSAJLP3-VTX8,V'T`QCU>41%XEU!5EX(F#5[!
MUGK$1XSLPQ3>PQ1DT9@,)/S%@!=X1S;$2J=DF*9-HJ@L1![\D8#8CU")A-JT
MW!$D03YP!#S9![TA5U>40>,,@<=`Z-D9W@R(X!AXI\RY'R/(S*-8D"-XA"?$
M4H*]Z)#0F\R))YU,*0E(A`*8:#]NYYMN2K#TSY1]Q,F('T^&A"&:`+XE4"AB
M$A\-9S@AW_8$1D1\5GMTEGE<C?9$F2W<`"($B`TP!Q0$$6P=R/5EQ/3,!3^,
M(SV<6I=MJ.E59A)T_\M)/(%:T$-'N-KG78O]Q`>Q4*,?S45'E`5`3%X]H(`B
MV(,/*0A#:.,OJ$D5Z%FV=,[E\`>(Y.5=/B8_'8%T@0-X(DV/B4`I>(FV:4O1
M<(_XO)RAH`5IUN7;V1/F\&I;965!=5=![$!F^8BM5@45Q44Z",%8'*9</!T%
M]DD($=VY>1CR7<4_EL>8NBASED*%M`^@]@E2LI%<2-IP*0/,P>G#QNFYP,$;
M<)A@S`H?4(-4G)<K9$0TH(PSM4!"X$!45>#4E4.-Q1LPKH.;CF!,*!H5X>`(
M:)83/D[QV*JHGAZYK*9<#->O0$M&X-4,#LO)T`B#7ME0*"./B(0W:%<>JO]$
M'_S`#N#G4<A56Q2!"LT#/FBM0#7$-03$2RKB2`D-(ZC"=S1&U-EK<2"LWC&$
M9,!F?&"70\2*Z*VHW&Y7K;*$2.P,;`V!@+'$H586F_:`]32,=.B'*_S"B/$(
MBFE/4PTA(4#KD.Q<^5G1+\T`O1DL'-QF<?@K&^%)Q59@.U1!%K$LQ)INU?Q0
M_Q#'"U3'DQ7"`^)&&72&QNI"![Z%!*U$##!%!>JA9HH-X<#"HF)*Z3ZK%R3$
M$Q&7%SA(X(C"MW4#-=)%.&"6/XQ:;.$9/BV(1(B1#DC$IM)#-_)4(?C-_E"1
MCX1#.8"'2)B$7")(0H`+GO"$"!Q4S+2%H^ECSSW_T70)A4@\!6)4K#2$T)VL
M3-[QT22<S#GPE8_%P/:('EJT%1(DP=P8P3Z*1)`8SQ7D@ZH"A')E*`E104]H
M[Q,AK3S.2Z]Q`YMH%4[FGV.`0WHEQOB@C"ZX\!A<G=?Q#`(EV3B(K3*,82J4
M%>VJ5"-"0C(D%CBT%1QEV^DJ\6XP0>)BS8--:3?P@)X*AE:8%QP(1$`*3><:
M#>YAG2KT)KG%@B?N!O&V"4X<J@D$R.32P0W4@QVLQUQX29"4Q.4]UX"=C]8J
M4M8*1:P@P?,U!)2.IL0,R!840VC@ZA-%(4X4W'.%R2_0Q0V5P>?)@Z_R!#X>
MP4)T1$,0(IU,T)UR`S3\_T$XO$^/4&,FXH$!9406!=S34!.:C>85V$>>$@WL
M&`%/5&2%4&1\4A_4/!!\M8::'.;Y42,A&)!HR8".#$%U8(<NW&@&Z6F):$(:
MJ8HG`0,IZ,B/C5B9]L@Q7P0JBXW#+O$XX\)1.+$Q`2PES)]3',4@\NF0K.V8
MF)\C/7,)',48JVPNF+$SUZU#^-%&`<-$A$/&O`1E.-[S?3#6MA48W,2"($&%
M0)Q)?$$?F^.Y`,7#\`27K$#K*0)O%5WE;`CW?AN$ZL3)P-T``<"H">:)ID3S
M+H1WU7-X(MM:,:0;H&>5E@%S\AP,@"906(H7*`^4J(0)K1/@W`F1>`FI"2O"
M(?_$B\30@&+!\<!9OW!#69R;,*&2RUPQG:ABWVE%CT%),B4PRRQAR1#/HD2?
M%@O0YI;!%3@A[\@(RI+S7-,S)*`'53F2GX[!B3C"=@"S9R;3<R33BOD=.6SN
M'^0S+NQS6S0R<LJ+K;#Q#;0'">V%3[/C]'&$4CQ?"O$1/#`!@5AA/A1$0)>#
M2?@(Z`58&,0%"MS)R7Z+/=`#-E[$=<9G2S@$"3W$;%:+/4@,4L@,$`0%J9!8
MT=P%.PRH5ELU*Q^P_02!=O$R)5]9/I2VAPQ"'2C%+[Q('8B(K%R1=]P*SL%4
MT0CG^6UUR!*035=@$N1,8_TKO'U!C14%UU2I>+6)F0S_&_K0=7X';]RX58MU
MRCKC@5E:06>(`@[4TR*,CW:0\3O@`')H#Q380**FPWR$@X1;^(5?EE+R@V6-
M'.Z.Q.-=F8=4R-%J5^R\`'Y,PQ:HS#5V`8I+!/5=XT2D:JHQ`8>,"-_\\<C0
M!3SXBO$FJT-,GBAX@Y(DFKLRQ#SR<@:/Q";K0PVL;5%"PB;<B3C$36?P43*A
M51YL`M$]V&%2ES6ZVHR4@Q=8(?71F4+-!3^:P43K8ZQ`-$_\@TE7^3CPB>_R
ML)H<,94JG]^=<"]HMX-EXH"PADJ*#[PI`63(C(*5E/:40_M8IVCPCHKH]Z1S
M[!'QG!/4AENUU(A=F$J=6"72_["H5,=`[EK7X3=/UL8.!,2PQ,Y'"9@+PGHV
MI9/'3,\/4%'Y!A*&W@<7Z0>..`$53,]=U$$>@$'L5$63C_E'0"V1Q$KTH=`]
M>5Z!!,6ON-/K30$C>)=T]X!7Z4"X3D'X>?9#<9`_U%SPH"M;%#LV1DA';A0-
M^G:-MI<Z!`G%OD\,=04GCB=`UL\WW("T6*A)"(%-7$7T]6%&(*V8?2]@G*'Q
MW`>7+>T7$%%"9,N3=!\62O,C\&D//%-.ZD)3P)9JE#?VF-1/(ILN3!U[/\)4
MY&@UQ]0RT;G"L%*)Y!\0=,:3?8)*<#.EZ_P93X$#7M`D6,9Y"E"P+581##H:
M:`%K</_57\DW>1R&%?6!EL)"DV'*JM3;W.C%_GQ)$!SFZC![L3],21Q10-U%
M2S<,@;P=OFAOY.0#MF2PI_;-K00!%P0!1@`&N9"NC]_#/2Z>@DS..^#B3]U$
M].9@9+PZ4*A4DY>$V$MH/2B#2:K%[\0!,@D@.0Q"'*3/[Z!D&XP@="W>Q'QX
M28A"X!S\0D]T8VZD0YP,'GJ)D&_(C'A#.XD-<3:&^5F^C`46*#6&'A#J(':0
M95(%_7`B8*S)"-S?^@#%97S&%DY'A.RU^(F)"<>=UX[&<NW\]0\^3JBQ"/FI
M#[Y)$+3/";C?V96RWE$Q-\Q%>QB"V9$`&><&K[P"M4!!11C_$5#_QQ1D'(,@
M1#X`!`@8A($(@Z,HS\`(Q`,_B0`3B0$G,.(\Q$!H-'`#1<(A8!P7!H>!>:`I
M8P3$H^%Z)6ZD1D%0*#@2!`+-,#CT'A`14C=8$!0]@V`6&],$D'Z`UA<8&.!0
M$#!8T-?P`R`8"."PX.B'(^DX`#-`AE:C0[7E$C.S-0I*F@,$(X!0`CKB\")6
M,(#@A<,692FHIGFP"P!08C`)L>"`8-`X"8DPJ<!@HT!L3*`KV#`F37R0D.@(
M0)LTR>!0KBT80"+N&#`@]AQC33Q/7V]_CY^OO\_?3X\)8(Z!0[X>#;!S3A"M
M>0`$)'2T"($R1^10$`.0[.*``7T8_W"\YX"!OWM\ZC6`4<#.EH,B5I6[LW%C
M#"$/C#VPTZ"$%UI!,+E3Z>,.C0<N>MQ19?1("1@-#O[`Y*,*@@%\I+S(9&4,
M40$"L+E#,.?`$P8,#!&!L"9%#*)4D1F]2G3KT$!&Y`5JX6"B(!X-YM$ZY`P,
ML9,K#!18H",!`D^>M,B0D9BQ&:*)?2"!<>P$F1F:[E0Q;.`))@$!'P:*8AH"
M`"4BB3%XD!K"@+[$`LS1*P@'[CX-"3"LQC!!ZTF$FA$K\&"XHUP07LLH.#*Z
M].G4JUO'Q*-Y@@,/`*<3J8``=`@!NNUN/N<?`0!B<6]L%,>1@H$7'="&(,2W
MO9#6T96D1__829X(I1E1L+SBW!4G'58$'04L\8(!#%C1`&*/45'##PDT0,8+
MHT7%PQ6A!2'"`L;4PDH!+T21@X0SF$'#(FL=<=4("X3B0PQ/:-&$`5@T81DL
M7'68@R("C"<(.0`8`UT`D'!DXC=HS-."<M=D4DYE36R!F0POC>#E`V]Y:,9!
M"=@DI@)3!5&%>`P\@\`L4!#&WS3;^96&>)/,H@22`7U$''#U%=`"DD94M*>@
MDQR@IT9B`1K(.XVB4\@AA!!U7G^:;LIII_O!YH`B,_#6%5T$`!:0<7T8T@=W
M@"VSD!\#O(K-(.EUI%]'VF!T'UI`@&2E=6R81-0!5JPE9@Q<^2C_PP(SG?2:
M"4V<D*5A"B#GQ5"6E1$7$GL\8`4!EVTX1$U0O4"#?0(<4T4/`:SECBKQ(-N#
M)RN0`\8MW#F6`QDY^F"'*&LA$,!KP:Z:`&!V*/-*($'D]A\$!4SDXSQ_9((N
MLFMQ]6^RR)IP1<+4=G/5NK/Y2*@**,4A1+8P",)J'^$=C)]QZ7C3AS&'J-"D
M1:T*`@G-;5@2WCG<68+-1-P]`LQI!-!<7!]E["+.N\K]H2H=/KSJ:==>?WV=
MB(!!PT#0\H5TP&S+G6IV??*(=0@KDQC67$:#=`5)`UQ[-,Q^0DL7\6`^$%:&
M#MP>TX,#5#GPK@RA4'.R`D.(4<TM=]C;_^^%7';(F`Q4U4#"$9!=`4LY:.FP
MQ@[',!;:L3D458ZW-F@[%"?KS@"DMO:N(<`?-#>EUQ=E@^O(+.S5&<@"$H%C
M5\ZKY`"]QM!OK@H>1]AK`!Q4R<B4CT*P0GA*[C3PS%!-X\<11J=>5/$CA:@V
ME2`J)!*%<BHVHD2NW[Q_UY$2^Q^(130",>=(U:K61PPZ0`<2?2L!=*+@#068
MX#Y&>!G8+HC!#.(#!W1PQ!B:%P#DG"<@L&&(8)91!E4!K72[(>$"N*:=V,EP
MAD!0P`$"@,-#-`U5>L'A:@!0,%\4C"Q/(XL1C^B1&&1%%*E[3%:<H[.:M&`%
MQQ``#JI4".G%(/\5-`!+O];5"374`#;R,H/HG*4)QD'@*A4BR@L6`R[GZ$TV
M!3@`60KF@`.$@3"8F%V&.!:7Z&T%,[^SFR!NM(IIB$N%@1"!HB!R),*X3HO5
MP)VRM+C%K6P(+I&8S=-,M(,C(F`!T(#!^6IFC$Q9!(8H:!_0YB"<<4B(-"8T
MC0)HD;!)G``+2()`">B0J?M-P@DWLA*CR@?$5R5(@\QL)C,7I$;5J*B7J[)#
M\Z*`O%<.8(1JFX<U:U,F&-("B4@,(@H"<(!T2@X`A%)>4][9LI:%80&$FDU3
MNA+/?&)#3-QQQ85@@(8[D,`Y`WF-&'Y2%&3<2`V-RQ$-!@3(K8Q!!TO_\=R\
ML."Q07)&<<P":!T4\]`'(.<*)Z",<"!QE'V*B2J?D\SK[+6)&#1)-8UHRCP8
M%3.*_,!B*Y@'6!HQ4FT]9D!:',KF1F"#%0QE75]XE@B:<`Q5\&!=)DC=)+@R
MPFH(\1L/.TYRYH$<&#Y"0O,H@RJ[X].\6&P]%^&*6/O@@]U,(7#.K*M=^\-!
M^C0G5/,P`C`40Y&3WFF%S5.$T-9IGTFL!QR]:HX5@-4IO@)(3!!P"1J.00YN
M>*%@+(``#!2`$9$V!XAELR-H";6Z,:).!C`R05*[A*X7:"4YW4&`'H&10QR*
M1'%IB($8M.BL!Z2M.]AH!CE\*0`T6<&H9,@,_V;XA:R5^(&FV;G(%1JRC"34
MZAO=N,$D%N0+`<VH,FO10UR$$BYG*06@/###Q6`@"9'H41*9V,5N+1@()"R@
ML7W()D0@!33A#':%8O`E16HRCZ3U]6F-/00TIB+6%N`,(@_(%&+6D:08W'7#
M')X.NC["J+XM"H``Z,9IZO0NG!%BPB*636$;LDWR*$HLVA#+>!"@A+<*PK_6
M28`]3I+<_=9"GRVSS_=V0"C,'$4HR7(!&#RQAE)LH8F0X9T6;H0E98%">AM)
M$!B219@EP(`!(I#!89R$@R,E\0CL"J0.LK>5DMV`CW^PQ@(`=4HU+&]8MM+&
MG2GEB[PEB7'``,?@X/\B+RUNQE^1T5:U=$([HW#%BJ"['A)N\33>F%4VD()$
M8?%C2*`)1GB[>)@86JR&WPVX>&JN`M"`V0:)0(R:^*'E-(8!P9QHPSD^[K"O
M?XV/JX2J"@'@+W+'$Q"9(=`//IM4?_7C;/],&".SLHU>`M(:JC#@T_G]6W3H
M2F%,BCL&K;E66=XDA&<@,24`G0S'/@31+O71`!7LS@B(K,]`**NIC[E*@C2&
M0RH39=NW3$,#C!5"99E@0&LPP`V)Y\L6AP<P"0`4G\GC\(G(P0\G5`T)<B9<
M0>@.!ZD3JB:0BHGKL>`%^;&)N%8A1J:$!(DG:4!91FFB4DJ6!QI756('<1__
MN9459Q(<V[*/F]\F]4YF`'1&R,D#<0CPC#<?5P2?<:BJA2:8K>19A3?2421@
MBWWL@KC!3=(A=?Z&IY?I.,&$6Q4$_J$C#NZX:2*E1)5>ML<P*.#Z/[SMCS_\
M>$;CEIZX9HCX`Y4C%1E-#!:$>I/'?"N+1-&G/7F@N-@U!2IBNA&7AE3F>S6A
M0D6(^$F`U+'S<@DS6GFHN"BJVVI@`X:I/L9$^(R1M]<,+4ABU,$S?26':,QP
MG!D"E["0"L?80$B(*X,$MRB$F,0+7#>R`RW"/"NP(&DA?Z84E``\"+H-1T4V
M;'H?WM.&:8M@2>9'QZJ?A!ZN840:)1B.DVS**%HS_XIKY4D$(8(+;F0G@';U
M&B>A.+Z0-I>@5@FT=`ET!?2P`N<!#87%*)D"`,03$LLV#SQ&'8)'+)]T`(11
M;&6@-PR0$Y'P<(6G:#L04?Z2%*\7"LI'&"HH;F"$!TD%9501"HK1"(PB`[<@
M,(ZC,2_!%9H@'$R!3JI!%#S%2"4!0=^@&IH0&XL@5J/Q(4$H`A6W`IA1?2.R
M&$U5!I<C`RI5$_%D3Z-Q#&@P!$L1$F+R5A(T,=-P=XOR2$[C,PI!!W0S"<8P
M*_/@+,$B%NO22^"P"F_H7F#E$-]U)FZB80/HB!QV!;"A!L\@6;5&,]P0&Y@H
M6I,P2CNU'&=B=U##"GD4$O]Z10]DM2FV,7B,PSA`5C`!<"-ED!YUI#*\A0V)
MEWB7A#E":`9@<A2.`5([@&_Q5``MPWFLY3B+IF62-W#G1P,14A/7@@GE8H,W
MH#MWH#(#<0@I48>JD1D3(7AMDR3>2#-\:!=6<"9#6`,]L!@3%03KZ`)@`0N+
M8W9=`1=]<6[T=#%Y-`NCY#*%X'=`@PR,%"E-L`U5<!Y_D!H.)R[G80RAECP_
MYPP!>0T$H'L=<1/GP5"UT032\!HZ\(@A:5==41-.4@3>``Z&M#?1=A=JE`X+
M,!%MXTH0@(EWL0NYY!H6@5)?L%_#Z),_^9.LX".Q(V05(@V8,'/LU%-I\W-B
M(`3_!W"!R7%#4(6+,_0ZPY<N.L`5264#[A8>JC4#>S`D:Z&&\`(667D46R"+
MSS@U"A-Y-!`%)F,'(V`'BE-Q6TD4`9.1OI0^C'`:)@8)!4$(]?,(_D%KFN`D
M3J`76<$A&V-48N($2C5I6Z(5#P(+C$8&&%4#>Q"&2-"5G@DCGI`&]2$-W2<(
MQ&8"GUA8*4%KL/`F"Q@(8!$`VG<)%!D(0*!*IT(5NK0=X;&'L%F;RO"1%R>2
MQ7E!ES%'#<%70,`U>DAJ![E`4^)Q.,,+^/-()D:3%NE3B>@'%GD,E@>4X?F3
M-Y(R*9`"XK(CD.$"4+8',K14_J8\*W!]^N0]U9`#SZ<M_V>IGN<R:1DR+R<`
M([V(!$#0`U.D+*^E!T.RGMIBFE*G..3F$DU!(R<W&;"P15,$)0L8!1_1`OA8
M:Q2'BGV@5X+F&HVB!B*F(F(R4ITP"IOI2$11C&=`+2UQ`^)B!O9A+P='2F]B
M"$B@-R_Y#)?"!Z<D*SC33:JA/-UY'[8!D[IR8ID2!05A/`'$=2?P*LZB3*6F
M8T.@0T7P*L\Y!!.16;QA1W21`.<0+0%HG&NZ*?$`&$=C4Q3QG:.Y#3$FD`T`
M"0]A&]<22XY@(A)$,RF!&R%!I__0*>U@#\=(@\@"AR)E<X7`!#S`#0[7.XB6
M.<MR!#9H`_ZR`N)";LEAE%]@'_\A1`LB1%[VN#$WL3F2T6(8D3I7U"6LU5R0
MMP6W8!\`!F/<,&TW8D-?!3.A$A"TM@@,P#6CNA'HV)B89#AQ@8Z3H51CT)6:
M\!CU9B"96@;U`IDT4@X:YB3H$*)]$#^^(FK-H*OHH)W0\%:KD9ITH59YMQ>Y
MI`G*L1'D(0?*\!"PH`S`@`TBT0N#-D#+EGOG5PUHVHAL:K"=<@MT&H+K2@QF
M0`_<0`_94!N[Z1=HM0T-N&-DYFW`:1V08`_AT00W6E15IBV)@"UA,#JSH1-1
MX%FJ@&BDL)6(YIYCD#HJX!Q?0`:SH;/OTE`U\#E!80,IAVBA\7:TH&'M=IF7
MD;(;U1W_JM!BQ!H`:I)<QW&CQT%F%RDQFWB3.8$?82)N%LDAF(`<1X)CBG$"
MFL`*D><$*UH3!.,%@8:4Z103.3$75U-UE"($%PD$VJE8\Z%C1J`&RT%OX,8$
MB!$LHS0?_P!^OK1?&!N;]BA6$F('Q69SAZ`L!XNYF^(APW&B<G=(0=`\'J%C
M`:%C7P"1K;*V"91'Q!`2CLNZ.B8=2%</^9HI%+&B2W(2\P$$)[`L9;8%Q_)E
M*[AZ<0%3KE,)1-L5L:.R_%9>DS1&/F`O*04T>BE2YF`"0K6#CG,@%40PG`L,
M$B0).*13GL@.9G`PLND7?0-D7PEE)6!&-H`#5Y&I398CVYH]_[)EH"L`3Q7%
M%N]T?8GQB;'Q!\;6=:N)8,=Q)RT&KJ[K,$^G2P'X)YFR:0T+P8JY>S)3`[6;
MN1NL#YCP#/FE'_Y5*R5F)1Q"#QBA:E!)OLQV"!*9,[;97TJ@P6@QP_X@N_W!
M#8Z9'&2P+F1A`CAFD:FP!<G*,6ZP?#W01XH!F>"R.4YP`]S!6SA0"QO"MH.T
MF4RF10\1("*E`T#6"3487`I[%P[\#4E08C`$"<6V:K66*5S;7UY+>%YR<FFY
M`BNQ'9^S;3NP)=1K<TUU#"KS28@S&P`\"'U*#*725N%A%X+'8T8`&/J#'[TF
M.%@@5MBP7ZR+M;4FK+.$&\K9AY$PQO^4Q<&C/!+PY7_2*6,XX\8T>1!T@6KV
MQ[=[L@Z,(ED>T1K,DSR&9"Q_"7B5U2DMP"GSL1;D4!/]N:W+@HRD\RUY0!E"
MP3$O(&QB,AFM@#H_<!-OH#AD"%_H>!27)(8U,!X_0FXW(@?M%J"BLV1=00/5
M=A]?@+73)+#VM[K%`'QHX7?6$*=61Y(;$S#HG#W)ZJG.?`K/F`/_QKNU8$1$
M$2<3HCSP(,JJ@9VR5%A*0#_.]B`Z%,NR@;$M1A4Z9J7(Q36I)!NRIFD*K!`P
M7`Q]<TO@6"JVX1'W4<[_4<.D3-,0T,6[58DQW`85!A'&96O=UE^TYBS7EA$E
MAB2)9012PE?_KHD/"T!KTA&XJ8AHC4D8.-)%!H*<LS5N0%@].7M\U_)&H7$F
M3G`2^T5E%G))-5$.2S$#8P`I=Z:5R6($9M<$$24D(97#?:$B^%AQ5&+($M-K
M)980;GP2>J$XBJ#`)W$J:V$&R%`8FJ!M7J`B2&`?3;5)%AHC%OI<ZW*MLD4C
M8?F@#PW*=U$`QA&N*'0.'DB3.-E?RD#)AQ1`:YP\`[88RO`%$R%T]KP+]U'8
M?I@`$]%-)5:)DR(D,E"8-8W<\Z`#I"0WNSQ6*_P(5D32*W0"@=I^Y%$(9[H,
M=S;/WBK9V0R401!]+0,^XIF&TS(5+#!SY$2L9$%/A!(&-I2/\92V_S.!`P^R
M+CC0Q2\2EJ1#>-U\.5-6/1-5$V"2$_"+!.0PD":31&NA(M`\O`WWG4DP8?N%
ME"'#(5_V4"G'V#%0'E>03@^B!(7U!^-1-B0P'Z81!V)`>Z-TP_H\"U>QNSC0
M$D8;'M+J6HLG4M=J123`$<-\0T9Y<$Q1-OM5C!>C&#>C2Z6YN#2)R'>1!H7R
M#;"!&*PD$1*4*;>$)(AA1QS+"I``G(0P#%A@80&I!GH#W8$)#D]C%,GMYA`8
MB7&H(I=`D&.,M=@@U#_-#FI:603\![YA'^O&WF'`WH5NZ&1!D^@T(=MHX1LA
M!%;4DU,A.152C/B&:-#0#2=Y#,J##`JP8O^9[68OHA6-O8L<0S+3:"QR<(*V
MA:?B78S/JP5OT-;_4@XVZ@/]<U[=@1Q?,(/+E3HZ*`=?>7`<UPQB]2XV))S#
M4@D^Q=/999L&:(+@TIZ+H#AF1+P8\CP^:VFKMU1QS162AFE50"=6LW4F[3!U
MK@8L29-3T4M%(-*"<Y'*P\#%X`(MM+OC`*ZGJP:CHDMVX--+^.8!+W)4#AAS
M'BD<F)WN3(=%0QS:?;&TAA'D.6*SN:\$DZ@SS0]E"C08_[!`*!QOA#IW/0-*
MH"ZD0U1T["\/!4>)0R&3,02Q8S`CL!&>65(S,AG9<X-L-(-",,:S06G@&_.3
MI#O<$DA]@4.5))C_PMG=?L`&9%98<E#/Y'%`$1U`8S@5I"`NF@&M/[!<$H7S
M8J*%00`[R)(B3<%16T$^;%+?U>!J@I,:C-+D^0=6(]!+K=OD1A`;P@0K3PY)
MM#8+#$$"7'-#79<>4P#)`N_F;DH>B_FM_IJ=RK$(!5%ZIH(S9?.D@"\-!Q`E
M=R,-&/'7]%#GU&%SP>PZPH&-4R&7919<W*+-P[<&EBHF710*.BHD.>$C!(H=
MBKI/=Z"9D2=<__P#*N8$!0BJL#05\F+'.7`5Y=P7FM4<';?:U%1'GY\\2S?Y
M`10JOJ,7!J@B)E,.V/`#WWX'2$R\SGHYH5'76S83NU0(-@<P9!$G"Z`6_P,7
M#!1)"P&["Z@L]:CK]R`@'(4`0.=)B,B`H@C"N&[AF#,$$`;4M/.`H/NY$"5<
MCD!$W0B(@^/`&#@<R"LVJ]URN]XO.-Q]D!L!B&*!*AANN(`(=3`H3H5$_11P
MR"`'08&+0</)W\$5P$`?1,!#GH)!X(G.8A:AF-9")2;.'!D9@T,"6\,#0A4!
MV4("@H'#0X.#P.=#0L*#RNSM[:?!P^R#@<'LPD(5"]7@@,$`PD,-K:-H[6U#
M@H/O`\,P#!^*`@%!`:QV[`(!I,#UY^[LZ\-`-03!PDU#7(YWX<#-@>+5`@%]
M=$B"$.H,FE%ZC-1"T"`<@6L[7#F(IR*!.'@."/]@4V'$%<=E')U]JC)-P`XR
MUVS)JD+&2@YA;A2T.`#`P*(#2MP<TA/E"IR>L1`:Q#>@H$&8>EQ`<>/B)@&$
M`]2L(7`(@(`&;MCD=#&`WQ4C9^8,>Z"4$]JT:M>RQ?1R$0,A/K"$VE1@0`!7
M3OW0J8$TQU$H1&?L^1O`ZIV_#A#\?7.I[8D&C]L&(%GKSH.\"<XM:#!(HI14
MGAG^^A2.5[0!NN(]G-5@@0$C,`9M'/"+BFU:<04`PY5`P#L&"FY%52"T0(RL
MI4O!2D7&N4K446^=0F#'#AY#,]@`2)0'QZK!$!P$8C/C0((#AR7_.O`PV"K>
MOUX!=R)+Y6)XOC#"*YG_(-XGPCT1@!3CP.-'`01*<8L`?IQ1161M,$&>'P)8
MAT(`F_EAU14*"/`=!/$<4@`!E7QEAR,T"`$!">)-LI,@/]SCQAX_(+#B">`$
MH@,">[THX20E038DD44:R44CVBR2EUE8H.>B0;]@,0L6HD`9TR8G,/`;B"<X
MX(./VQ790)9J,4`+#!%!L8Q)9#Y$``2V?**`@7)B0PLVOLB"TBU??L(;G0D,
M4D`!L;!0`@.]@:*`63'4@$<J)3(P*0-.J3?I,P\<X,AE=S*S)R[O</E.8VC4
M`N4"7SW080)E$O"0BQD.TH.4O@QCP*M!!&.;`<:H&FHNP`@#G&H8,?<2GA5%
M_U/2.ZMJ&>*7#KA(!X4X?!C5%6RX:,R6X\W@$(EO+`,.(K$A,8!D`KA(CP(7
MSE`B,U#>I$BO**S2Y)'YZKOO6JKDM!A>2#2%!`#G7$EB`5T6`K"+<RA\PCEE
MDE>F"P$TT!-DFA!YTR<%,%`*3;"<8LU#7U61FS8*3,$,,`S2DDI%.$7"*"B:
M)A!+1/_M<,>9QY+!D**X9+.L`F<`X',I>\#B0+LL&(`1+[_5L@,"\@C\VV3?
M"*`:$F)=(<P5?Z`3XFVM;+09-KHHD8HS1D3$3#A3A?/+L*HU*Q`#G2U@\3OJ
M;K-`PF<^0)4?)\`"U-8='HC$*A0_?<A9)PR#Q8U0'O^VQ%,PX@"`E(R<%PQ0
M#M03(L:)XLLOZJFK?L7/CQDC^5^J(;3),%>><@8=,X"#.YSO4CP<Q:*_!G@#
MA$IV//+')XR\35<^9<(9A%SEN123`A```)1JOSWW*#-`J"/#!1`$1L!8*"UT
MM$BMB_ID4+$L&<,9XW2OO-W3X*KPDW'^7?W!WT(`%-"L3P2@4G&!!!EPHHFG
M.>,=-OC9]1C1$_0P8%.$@]B'S#.#53P,`@&1EX6VE"HI;0TXUT!)-@25/K.\
M(A6[V!\,@S`TE[A0!5%0&7*.DJ#Q'$X.H$,"'-J5)9W`X1)$"4BI>M`[;[F@
M`0B`!!)(9#`<.`$+M0.(,(#_Q`2!S&H&-S&#E^"2P-61L8RH(X/'8D(%/8Q-
M2SRPUX4```,LD,@-K_F&`3#V.C=^AT!K4!>K)+.\Y%%*,I/RV*0TP0#LV80%
M7T(7,P:%O-C$0I#H2EXD?5"1Y$EF$)Q$#0,<\HQ!@:M71^F,G^"G'%^<IA:\
MB430`I0>Y!%/,C#@'`!0`P_GI$(=-W/.5Q11P(%43W_PDY,/WE,S6%P*(23H
MR98>$X0;!,,-1MC*(FX4)O1<*!2VX0/,L+$.7[2L(O\QQ?EN!IS[1+*%WK.A
M:FY4BHX4`V64U%H2&465$Z$@+@A1@E>P91",A4B+#4+!B0)0@`6`J`8FJ!I1
M+H>A_\Q%K@A@H0)/%`(!%C`E*_T`W"3N\4,SDK2D;7F.#)P(!0Q)Z!PX<.)X
MWLBX):*@`758Z0S`AA6G;.D,PR'H4XY"L1D,%2W%(Q)Z/G&`5ABSJ3`P4)PV
M8YM;1%(EN7G5"INJU7L@8`&XF,)4]@<;-C#4)D>KH"ZS2HL0]8DCOYG'X0JR
MI3X<X`#Z[($-]$"F"]VC$JZ(C+N\R(H9O((\4RV;^5@!LZ=E98"O69N'5N)$
M7@AG([A"EP@\HQ-<$*A5H4`14/OYDYI>(E&$)00`L%&Q(T`KIR^XA`EP6JB\
MYF`5)LAE8!4`V\503J9RE%8.\-#$-^K@++:YP4;<8=+E,O_7+<^H2`L$6+&O
M/*%KKPH3&@80VGD!UXN>(9,75\8A)&SC.:?8B.V<QPGP#JF\9%!H&C[&4)NF
MX2[^L"EF9KD?=/WB-\,XK,C(,`<#*:)0Q9,,NC11RTFA3`"#"$;\SG&CES0C
MAWM3#^".AD:(:8).*HM4;.ZU`",(I`R%0X,(-K$I]/[!),?XPV`JU8RYR,&'
M@8V,64B`"W6<PA5FB0XY@34XE*A&%[;@R&>HH]U(>D@RCX2'7RSD"IQH(VS/
MP,%7`@+4PXP8+$RQRC3]P$ET,<6#5M`+41,`APO"#K=A2BWF0J1=0.``!G_(
MVM$4,3$]-;?/?M:"6:;0$YI4[!;_263@%9(&%"^_P2RHRDR'HF*:EU2I2'%>
M"Q28=1<DGVP9OE+"@\N@+'K08A8.CLAS<I.W=Z"+9EHM0%(_028!>+4&*$GE
M5XKWG^(I(`U':19_V&$A%PH'%MFP$(GB:BJ"%F0/V1/<LH(':1P,Y]+S+%ZA
M+/8]CR'/&;UQ1P+[\Q_>4,TY0P,`":K`C$9!F3%G*N#%'H!=1G6P%8C0)A#_
M<P-7KQ4)LM"*P'Z2I7'<N!#S^%V*NC9MPJB`$%LZG>K&MYAC_+GB2/@$NM13
MM``&HE<$P;)U^%D$!!P,1]26UAJ_I2Y]-!%;RZKH&L94I.%$XS5&6`9P8H&2
M&U%M%PM]_P=Z-A.,'61E%U,0,!W<%T!:)XQ."5+9]U9EH-+`@#I>-88`*>R0
MV!A'NPSEMU:Y&!&NCM@:5P:`A_8]EGS$H8#+>F)>!S/B&U%[<%=`F58'I\+]
MD+LBO'&'L:YQGU*':"3I2E568L/?=@6SNS2X<A0!N;F*\+;.KNB#SSYQA2H"
M,6819$H0V#R)9EPA+J'=!S-\5,`?L`'BJ&L7F2B%9HO3?G^2D9I*U!5'G+A`
M=#4-[)>PL`?AX\@S11!H[M;PQDW50DA7@+E:LL86]W;,0=;/@7H\=X(^,<(Y
MP"F-?B9BEE\IF-)GR@5JY&.;#$6#!2";#Q_>037!J<OMQ0-F5O^<[&3YE`@>
M%[O1E\#!X3`*Q41$`&G)L@2&Y)V`,YS`/_A00<1.WLV)2I3&,-2'@Z&$^]P)
M^*V5X"G!+#`*%>@-R"3*(6P#(_2!AW00)&!7,UQ/19S6]>3.U&$<3V5(P;&1
M`A3,06&(FJ&!0*%`&U&;0`!%B;#(#^3%8I#,*0`#]!W)9VV.3-'>G_T&3'A5
M-(#(34C%%,[#)<#&#%Q,CFB1[HS7AN25$6",#N2!0R%@-#RA]*W%`T+&T:D/
M?R36!.[/'O3*9GQ*.`A#*+F/+JE&^Z@2._Q&PER=;-Q,WR032(2"$RW`4H'"
MS:2!.,#&*0B8R;!"%=B5H?7`(C'!3!#_U)DHRB6D`88`7$P\A1I$4'7E"'U0
MRD(5@W`4"BA@2``4D(+4U:K1S1_&1?/MCUU)!N`H5"G`QF+$1F9\3#])'@=]
M0W>U(1+\%1NYRPXP08E@(2W@1:]I2?`)#)TQ(#[\04%,!1,<11'T!`E0S&%D
MDUPLR\WL3P^B3GI4#(;D(!6V%_=L3\)`T]-(RM`DT,=T&R-Z4O(L1BMPTLA4
M3?$DDG$P`JQ(@8*,CVXIPJ3HXC:D01X5TK+@#:4\FRSNHW!`G2QZ3'S95&<4
MRD)]C($=V&M\SR*%5BYB#_;M(C#F8=X!0V5=`PL@!Z,`QV9-X&_H4E,QR!XB
M8M04CTUHPA,%_X`B!<@FB0+E^9@(C,3-6,;^N)A6=H2#480&LD,\;&5A=<..
MV=JM(<^7W$-9P)!I$&4>XL%K(`<;J,/+J1M-B`KL"8?@,*-H\2!0,12+],C7
MB![8U$M0#1"E4:1.B%XAP`GV=,=&)<"&=*%#Q,1?I!8`S`$[UF,1L`>#L$T.
M:,,3%LG1$,44I&(^ZHM8BF5IV<+6Z,K=.)'B71(G(=@D;81)Q,TL]!(OK),Z
M5`&#N&9_/4=I1`1''&<M#%XT@$3.X<S6K&85>(8PK&8WJ%NZI*5T?LF$]==6
M]LH45$&J'%E`XF3>1801N.;?E40TN"5YPH]:)=!=B,(3-<.7N-HV+/_#/=#G
M>_"'9ZP$><92>P:H@)+GS>0:F>`=_(##)Y!<#XS89L'&"-")0>`*&PZ/`#U$
M&DB&">B6;HF#0F;%J\@`3;2`#L#/730A/PP%`THB/7@G0\G`;#%&(5`*>1@2
M]SA-KQ'*]Y!)KRE!9R@/;'B5RP2#9YA%[TA&'M358][`3"+$YS&"T>2B'TA!
M#F`/H?23C")4:OJ9+/#5LIP>DG0A=H%!!7E!!55/9B)"'*I%T3R/6N206+*)
MBU%!GM@F5OZ"%"&'+6"A=%:@FC&*.E6!.J`$1$0$;N)F?5#!#B`8<("#6UUB
M;&Q-NZ0*,+W//=P)J!&#(Q!'`S&6$^#"</[_0K!`32ZH0$0,J@J4A9RXE53*
MPD4@6?D0:J&JADC@YF6Y`V(:DT/HWR9A$FW<ATTA#T]6DB/T2F>@FUDPJ=.-
MV#/\*,"IC&WIEDJNY%?H8@K*0")PA),)PS")0J4PQK[=V='`FD,<!9<!9H@H
MC_V0#%HZ:_)T!B#PVO$`#O5A'*;@BW$@A*\U`VY``@O(0&50!=]`)RID$XND
MXY8VE^UEWBV*05P4R3=Z@1]EP?<4R94.R<6BQ9G$P'A\3%@=RE%DA&>`J&>,
M&*%X3`'AS4P"AT%00:\=0&=\#PN`@V+1*W+X246D@B*\RJ8(!].Q@<=X)S-J
MA86@1!VH3*]86%?Q_VML)*0P,-XR3$46P4"1C>RM12I-G`*AX(5#"%"AM(OQ
MS)<0/1&A%$.OL(`Q1B(:V%1*R4(V<`30/IBVSL84>-6@"F<J^$(E#`<2[@41
M[<!@R)%D)AI-`0')"4$EK$<CA*(<6`@6#.%+36J(/(6F5,FEK<&R$$(C0$CJ
M3(H=*-@/\&7"+I=IF,0Z=2(F/"R1[-`7V)065"R1K&E:)(R9U((_K!.JY<S6
M0(0Q``ZZ9"+.P,TN.=#?L8+B>0;1;>J]/(<`*>HYU((3_:NZ1$1`O$FQ",I\
M\,8)72!#$.*.S8(P"-XKV,*1L82L.IA9_%VPB(+4^,*$W0<-=:FJD`#12?^-
M(Y'3.N3F1@2#)\7?NLV3#)$'J9FJ+]R!"?V&;=A&!(Z-Q&W%3Z16022"XQ$4
MOIW+A=P!QI!`:^:$AFB)&WP<P53+R/X18_K!5(PI#T7#UC!'X>Z+$26,3%'I
MZ)+NY:%F6L#ND/!>ZY9P/R516LBNQ@)QZ56"X"27$[Z$,Q3IIQS+.]S(H:!&
MLYP,/&2%J?'O.OR"+WU)<\Y#"Y0`>&J**^B8;T`OS(!J2]!-<O8)(?*D+J1G
MKNX`@.#M;WS?T.F"Z)A%*?A",.EQVIC&,I0/+'S@1>`N;[R",LK:[KH$"0#'
M;EHA1W1@!_;!7!7!\M'482"$:GE%'@3!O0560&S_Z,)Y$*3!`5(06CXP*%%!
M0/)%QN">21)AA1`KD5@"`P\;">EYXR1TX0R;$90MB7IU010.R1QV`612K`\;
M59&(+B?L970PRC\"9VKTYAVJB@;JR:V!GPM]G^"AD)'^F_VHAE5,`3U$!4IH
MXWIBA!)80P8*"J[,\?A.E:F=$`+S9O.!L_E.C9Q0U7#RAMV<&BO=H1U_I5NU
MS$7(R3`H@>#QRB.AD`HT!RLP-,Z=JBWHRJG]&(Q6&6&-\UZDECAW`CK(Q&!B
MF85HE(H,A\*PP7"\,CJ^"XLD7"=4YA<`26H5%AFE"D*<00T4U2Z?T0"HS)#(
M49'H,!W&LA@0=1B@X@W'_X\+,>PG&,,<X&PO\3.>Y/-7F,_<[*]R5(TP.,=0
M2LV2Y5]RCE\PG!!8IE7Y1H<SK$)P*H$XN15^%(NI^9+4H`;*8,1Y]D*DF`)O
M^I(@BAI^Z$(V?),#N0<@/\,?FMHJM)(J5(V%=`JJF8*2)(`+/F'E39Y@3F,2
M+:Z58=>9O-EX/(QD<^;FW(S&OHKKH8X1D,<C[31SP0(M3HH3\>/)FJ2"'9*\
M&A+QE&UM=IMNO:A-^,%MY:+''`(CH5V38L],'I)(4DK,+K=S[V/"+-11X!=M
M-]N6G8&39N:9!LY%.K?'())R@P\\?,4+L0?=L(PK4($M4.5O`H,2B*JHT.6K
M[/^F?.PF.F7&A3)&T=1HH7!$8PW=*ZPQJOV&,T3-;]90&8,;LF`S-?@=^PX>
M7<I)]FZ-S@2#HJS3/<3C%,3U1-\/E`6#=BX&'+C#?_W2,!P9>>BQCXDJ+A2X
M-8@"KQ1A%`5A3CWMN51$J?@>$MR5BR2*7WAT#806%)0*5HCV>=##+T>1')2%
M+J>.@1TS:Z<.//2:LW[(O`+.U^9-0R(2>$]*5SWW]L36(ET/]-S%\3RGH!9/
M9TRW("D/=NXVG'-2,6";<G,H3'+Y(BW2<%<*\3R-3;5$LZC&F+VY#Z`+H<.Y
M;IG"IN5,-GBBMVU)@$<T%91"U;""#Q"E*]R,1%2!"&;_QJN<.(GSB:"D338,
MWB/#D!.1&RLI!^[YY]2L)PS]QJGB"KFM0V_,\?[0A$B5PC@<L2G$0JGABJQU
MU0[00_'<\2NDBFV$0Y=>`TWXK#+\F#I<Q%>8:JB0!&S8Q@+J3I,[H&#V=$ZI
M02ATB3A@02@7FHB2(0Z.1^'F!0O*6^@D^>;==#88=93?NQ?`PD+)P6AV@4)9
MK+R[@,9D@7L4"3XR@1@\9%)[.KKXUY_(!PR9$-6$Y?X6*C6D@C'0)8"@D*`T
MMCHL+V37PC`4BDP(T#20$UV:1#`*^Z#6]Z":!8/\)B^,;P+QQGERM6^6#SH'
M"ZJ:QGAB,?LVWUH^-@'W@@F5_X8LL,0TN&:D%(L\&O*"$V?#9M<-&,-D3\A`
MS-X>Y`$(0PP>E3!Z1&!7:8GC0@R0.$PJ(H2$90O+A8'DW6X/X;O<IX6^+TF_
M(TDMKY=.OY1.*W-;'#Q:2.CLEH'.(SUN&K"%G`(DR4<E!7A$?!/$^X:@L((S
MX!T"`T=L0(2'_!@"_XD[+:=;2<3^D&\+63C_L03YL@/,R[H5@OC+N'H\PP-5
M?9_VGFKS]0;4T]!JW(VIQ<R:UX>T"TW1[I(]Z]*0-G0EI$K?`E$7]5X!I!:;
M_<$.CM:2%PR<P!P1;8>ZS`&;:9;IE:'%&$!>[#@9AH'X%P)S7.[<KS\7P(+@
M)X69`/\^)U2+%[`77>0])G3[[';0%X``\P@'@3@#T:#)X!B)03CG+">Q("R$
M+J2%TP/1,#P<B1%A.&LX!P@50348&!J"`D-A@!H$B`0Q9T`(3+I"\>P0P!R.
M9:_Z,"9T<4&",(@1#`M[<`Y%2PAU)@8.(RY)7VX/#0\X5R]B#P4/FHYU`G">
M<#A]!`M7DFT\23H'/P]\KCA*2Y^N"%5=7YH,$+R\*P8`O<(0+\'#`"L$P[P'
M<07+$`=]!\3+K,_+!04."]#2!@K0"@L-`1#*YKT*#KO0[M`.O<U)`^_V]_CY
M^OO\_?[_]C0]:`>!03R`O1AT0_AN`$%]#1Y""X"-(3R+[AC_I&,H(@$$`!0+
M+&!P0&2`!0"X$%!`D@&"!0C4%!"@8!VY,@O@*$@QA9LV;0L*.,1U(DX#,P',
M%"A)D^69!C4-R'2@H,$W/F4\*3)09LH4*#_T>'+1Q@U7.(!R-ABY<X:G.WRR
MQ$&@P(PM*PL6@"'T8TDI-7T0$"F5E]P)N@,*_#%U%)"8B.4*@"M':$!=RU=,
MK(@Y0$"#*K8.$32G&($[;NX`T#!V3$9%8=L<@#RH;J6[9AN'K2.0NU<IAP$$
M#),L\=^#7@'@#,'(O+GSY]"'"21H$&/RZ!"D]HMXCT$#[+2?%PAG4<21'H/:
MX""P1\`F.$L$:G([0E,<^P/DZ[]3_T?1C"23N*?<(.VY-\(G9\CAB0Y[N#*"
M*CI,T@,.L4R2`!(6^K#''>X9X9X>``IDH(@C&IA$A9,\2`N([DTA7X,8CN"#
M0(?H\8(KG@AT(2,K1&A"9U"T<!]!*0$3U#*?O4,$:\,@P(!JO<T$P`$(`/!:
M4L4QXP`U[A!04G'K`."=:L(PX*5UX4D2"79LMNFFFT>,A%QX`%F)'53]*,#E
M.P&0!]UWT5F%D7GZ%6KHH8@FJJBB\2WJZ*.01BKII)16FJ@B@AW!%5GI79A>
M>K,,@@=:%PHX1804A@A**#-\.@A[KK[*X8$N1/%'&X'UHAB3"+EDC)IKOBGL
ML,3V<V$#VO\@&P4Y3JB!;+).-"MMM-166VU0SB+[++4#',7*`@X5%``#Y)9K
MKKD*:$/N..=NH06Z(S$P'DO(DJM&NE6M%515VA@@KW?\+G!```=0,S#!()$[
M<+L,-^SP3R+)UX-[I?J`ZR1>1.$$`F4(]MDM#A000#GFCNN=2\TXS#"PESYX
MQQUQ3.P*>_EU&ZW-H#UA+;5$B$PMM-R&G$Q<;7S1'C<MQJHT#9]RFEX54%31
MH\U%6/'946T0K8,+N;3#@`&IJ9':6L.TDUPX[;S;6R^FX7/=V._D],[7S@&P
M$+C*`5KLWGSWG0!45LF[C<J$FQOON>8$D-L!"H\+DC%3IO.2=]G_9ENM&N0X
MNT6U-3E$[EKO%E[PN"9_?HZ85FHT\,'A,#ZE5,SN_`01LM?>;$VA*VP`X^'H
MJ=%'B@>O^`$*$+S+4>!&NTVW5',KF1J`-+\S2^/)RU*["Q2_5,'<%Y`2P0@'
M`$"X'.E]#P#&"(\12!CI!4$"`]^3^`'HH^\;,.XD]DX7J:&V#P/UN$<)]C2,
M`\#/'07PB#L6\`!>,20`8+,"!,X0K+Y9\()MBD1>$D*G?P@,.S')TT+F9C[G
M=)`YXX@.2J+CO_T1,!\A],=KD#1"7H`K+W[Z"-7\Q`!/Q&:$6!A$`'G!J2%&
MPQ5%$X8D*+:G$@!@(#DLG<)XH85D44,!_UYZP`%J"(%QZ0,F2FH;-*J0FACR
MXX3"`(``'*@E-A9$@="HSG-2X@1?N*>$&,RC'@$B`M!Q<%`Y=(YE^B$G>\@+
M/-@A270(D"6+:,<>9^+'>`(ED9ID3A@'^%E"$F"O!K!&B@^)B+W*5BXF,8YT
MG_P,(=H1C&A=84\GH=;(E.&`M>W#!6P$0!=R28/]<5$?:&0&"18H`%M"(`S&
MW(8;&?*``"9'$[_<HS2G>0\-\E",")D2>`+)'.^`<(;,(1MTV!&=1\;-'W2A
MI$441\U>+-,=ZWC?.^T13VCH$H]L`]MIN)F/3+X#``1P8QB4!,=L!),A,W&G
M0/#9SH:V4X,,[?]5(RVB/^AX,SI&=`[Q6/A"YERAG-&!X$0=ZJ:$^B,=N[(G
M'W+)A]2H(#JLZ"@OOF#,,,@4`C"9YS^0@AP'C92D0+7@$0;)"R^6YZ86(:=%
M(\H0IB*D8!PM)S^3BAT!_!0Y0>WF0>]1"E]Z-7](14ARW*B7FAK`F'4!80F?
MN`2G9O6MPIH.<K`)D*EB!`%AA<92NN/6?^@3.L5CX57]H=1W@!,??WU.1)PV
M#/CXJVQ!X(ZN()-#[RAOLJX41EV<``YYW.4S&TG.(')S`H=$T1;QB"979:/2
MC+ISI?8D!$/L5\!(9D,X^0NH/7,:J'J,3QX".2Q<A_NF!KP")D0PRF'_NJ61
M9Y%$?,0#95(HTB[0):MZZ@+:SLI@NXW1;@7-@QH4G`!`;3`N&F)2'?@45ZZ"
MJ8R1A!,)5"QG.\MQX0G,LMEED'4PX2E.3*($9;JT$)1_;:Z*\GI67J"5KY_9
M[B4;0ZY4[`8\_X+OE!HA">.VD%X#DXM\__B<^<3DN#2:BS4=?I*),\PK%1]C
MGH$M4TZ@Q(^CN#$!J@6H<(DQ6'M`L(`#,"8/;EH%8PY`M13=4D'"(Q`D$_?)
M?W+(`VJRX79E$B0EB>Q(`,$T.*R@*I]BS"^<(,2-V>P$U.)N[3!'.>7)*RBB
MW,)(!@`2@D4C`"XXLA6@-HBSN(HL8O!SK&IU_[7N0N4E"\YD5<;1K'>E:P$4
MT3,*;J&(./"E54M3FI^/DF=K2<]9:E`(3)"%+984STEJL%4;7H"%'Z"`$)7F
MAM*L:I$80]F@2>&'+=P!0;JZ$P5EW/$^=H?)LR)PF-"(0MQ<RQQP_;&HFOC!
MK:?-)J&(P!P]S@>DL;-7BPH;(5OE8U[_X4EU0B>QSI$LM9\CQWUT]30,!6A$
M'PL=:22SEOG#[1B=C!`HI#$=%)%1MM=-<'P0X0B+Z%-?[Z'NYX!8'_$SY,+[
M$>Y_E`2C(!RW/YB-D89G%<71V08_S)3+HZ2F#''[]C\@*&1B0\.X-P4@=IJ1
MFFXMHH(%SWF(:PF6@?^XY*[&M$@YMO/30[(0.P/0>#_0W1P$!+V+5>H'QX4N
MD=C(MA<K0,N>%/`63V@6#(X0!BBDC9P9V.(U"L`Q;TQ\O>$XP=G($>\SXHGO
M>RAS(HQ\QQ_>T4+K4$,Q-^68,8^23/Q!AV.\TH9JZ.R*;NG\\2>=\DDTL62,
M$'6<`X>`QY=QT7'>"3L%%>33`5+Q?JA1(J,7Q]Z47A#(/"3#R.)%=51NIG?$
MWI[&'=O$\T'=8.X:GE-/$G3PC,],@C$`C)@ZY)<_C)&M0"#1\+4_-A_.U`^#
M^F52^3]*WX_,ZZ.8&"TZ8:MJ?7L4LN`B5SY.@]G+V'HO?_SV!S)L.XPJN''_
M!;8,@`F0SE!I1#T3NL!\`I@/:N(17(`1+G=XK,<,>44NB`12T1%Z3?=3Y2<,
MW%=CWE<V%1A4U7$<<Z,,^1-O=<=Y.!8=#""!O<`5MJ=;RQ`<VC=]$?5[."57
M`UB#^6,?QP0,[,,+]F-GKB,^&V$_AU,NTE4X#/,2"&8O$.,N(F%9"/83K&%T
MT%$/B!,,8L(]H-0PCK8%`Y8][@00T;01U(`P"_-<YQ(Y6^1A!:,%5$8_/_$1
M!N<<B6,WH$1*Y,(D[25]TV1,N2$^81)1*;4,JI%CP!9;=H40@4!D,8ALM15_
M.Z6'$.`">G."2;"!-EAPBY`$D;@6+I$?A/"):@**_ZJD/(8F.^-1BC)18.62
M+@J!8)Y#$C6A$75A!H2B*/FA*,IQBY$0+9]("(8F7]F#+8U61>-"7B^A`TL0
M(8BR"(N@C`)Q<\_H!"/076I`$^20/591+XQC6JZ8&#W@,IJP1`"B`X>`BX:"
M`L^'##IS?='R>N25=[I2-+FQ#D@`@LRP(SL@##`@$'YR`/)A/M`(?KT`C=A4
M%2=`82_'=$5E&W%4@G%$?\R1'`HY4Y`(=RU(:RPT50&0`,5#'<J1@9<X;8OP
M46`$AP#Q@M-GB5H@/PNX#RA98]X@#$#(#_HF'J,'3DQ"6[H2'>,#DKKR$%;X
M.UB%/KFQ3#J91CJU'?%P0O]6D$L2Y`TQ<&P^J7<H\7/#(`,-@48E`(D,\5$3
M44>=UT/NT9(A26TWIPR=AXA)F9)$QU6'"&Z?MTB6F`^%Q6OC-WPNAA"[%U0K
M8$#98'C+@')=@F2L=7@!Y!E-@F1+TB5D"4,:R9!A*1"-6990YHF\(3<4Q29#
MAX$,-Y5\]X#C-)<&EU<O.5,P)9!ZZ9G2)'+H=G>"^%(JI5K-4)HP-$23Q#;!
MM`)ZQY4`T0RR20`5024)T624&9*+0`[EU7%L@I'[@'T)09MTB72@J5AAA9#\
MH'X`(2B:=6B!]"3T`QMX-2:8M#E":4/10D!T%#B8Q#BW5U01<9MEH@!NQ!KQ
M!)C_.^%&1]8_2$45PR>8-K0G^>D.16!+!@2=\@./UL"(T:!/JB$0HEF<Q.6)
M[,`2EJ>9ENB<LF>@]W"![E95V&%KWK"7U3!\S#E30;%"9?(U.50$69<;6*,3
M%O@"1""35T`7N>$2E^1.3I)",FD]KV<%5/(,U;&9!G%_["=<R2&BY^.?O'!U
M,K@,'',;?Q-2?8=)B*E9OO42`/*@$`I7NKB@%9IQ_<!.AJ2:T#"1F1F!X&&F
M]7>:7&I#CR<W'F@%M@10'->3M_%P$0F<O)(`P0`%^*F'/:2A?-)^U@"<RT`.
MTL`2T->E-6@$E"<F54$1OE-%()JAL"&3!F.$);,Z&28P__ER."EV,@K3D1G6
MHP[8''66'5W4,.GPG2165%WT.`RX%!I&,/+91>*3DUUT#_9HEYB$7D?IJHVC
M/JF:1NZT@ZQJ@HYJ#T6@>04QD6JDAZHQ59GPIO;$I%<Y=8)Q&U,64J1P&UF@
M=W_GH,TJ@!XB'/)R$D>V63(A$H!P!0X1$==H7#$A:V=1!NC(6:]6*ZQ6!+3#
M/.-E:#8C.$X02U8"$Y:1!3DA$P!;%U7T!$ZS-%SF*ET`!T1@-1+K9>259IA3
M%0,#.S*`0\V"%U!A&3$1!#3P`#F1:2[[:G`P7M\5+<DC,+)(&LGB'99!#ND2
M75OB+FOQ7580:TI3%*"REF7YK/^16)--0JT5M0Q8-)GV``A*$E&.YPTE:D*J
MI7^/Z34"@;3G.ER+D"27:G%L\I;><)-L.@R.*$,G59X%T5AW,E+BLW$PI469
MQ%\RJ2TUD:(:=@RE-%OB@E[NU%YX:"YEXZGK^1EVNH*VIUH]A+;^X)4O-X)E
MHX?^J*3G$P2\1@/&1&\?P1X>&+:0MP@]$(DHQ"9TUI;V(#9'AW'1,;KB$592
MN`\<RGM!1FH?Y$[2\D)?0B?60Z'/J0UZH@[I41$*@;'&5E0=$S)*1"WL>"^:
M-1Y$L$;9ZGM;2Q,8M6,GD$S]QY#/D1R8>Z4)ZB3#27FD6[J1<`64"Y=KV@_=
M-C=M2W'_T^D<LIMN>466MXL/9H*M\_MQGH&"V1%,5YNH!W1N\::E,I669<))
M(06ZQX":!10/8?D*Z:N^#9``A"H,V)F=4CLW&YP_TJFF*H2MR0:N)OQXNIFM
M:.IO>O6M4PB)CG>4OA!U"1K"@FBH!90`R31,0<$ER*<)*7S!>C2V2L8<..P-
M8*L/M6M"H/?$@3+$PL";*Q=D1%Q4,J5_JYMLJK4-4IR":`H(C?02\'3`X:N]
M>$=6A5DVC7K%!#>V'D'%^=#!Y*:2/]6W@?*AV'&_S;&9?'*7[`;#*1BS'[R>
M;%L8!#0>6M`;[O5<R/%<C`RW":$GY*&;0`E;R<9Q7+"VOE%N_WK5#=C&MI`(
MGW63CU#9Q:A)$>H0(6Z,B9$0#SBL!N4'<(8T,N,B,A"AMG&C'I]B(V61(ZN2
M-"_K*JN"(:([(HE2($BP(&C$Q\SQG7,CN05D@H"9H*&`S#(BNOIQ']LL*B_2
M*3KR*<DX5+%V!L4<*Z\!$^GB"[7TJ^'J#F;$M@HJ>_0H1'^F:2F0:<7L*00B
M*C`3"D@TS.GQ=/K72/IW4UA4-H!B$+%0R*V,0<?)LFX`%BA`,6<0!E,`,VR0
M'N<<LVCA`J60%/62=2_`%1US5D.0&!V9&%L$$Y*A"&!16I6V&8)1!2'SRS1B
M5>7"+*$SA"HS$M#2+43P71#38*28&/\+-E]&S88TBYR1H`?1%B&]O"JWP`7:
M0!<7>V3^$A$I2P+N4A*<T2V8@RQ[U@50$3).8T#P(2.E(LX7`C(T@+(@(QG+
M!#!OIQ!!>V;TY6"0\3/7<RV&\S/Q<AF^2&IX32WHJ!<3U54'T;BGH8=IE\4A
M8]2EV!AFH$K?]0)0`].P5MAC5MG=U1ESXY`).L;6.YX0L`U<A[X/+9(XN+P(
MI;I\2*L;X5;.N;__I'%V=J;,)%/.K)R&),T<'%+*Q\"\G0]BTD\_M<2\\*N)
MFHVABV0!FJ@0^5K%,CS'>L;BVD@&=&_>P!)GY8^:P-RMO4?0.**U)MO;,7JW
MW4TN,`,906;_ZA%-A/H`ME3-3<=7@*Q13F;<R[!5ZK@(874`^_C%S>VLIY@=
MSJU$'.>/$\4*ZZ.S5S<<.9$+.-<<^H>U6^N\>K5VG)<"YL!`0ES>MW;>>DIN
MU7:AHY?=<NM(S202)Q0<1^`9X[$'O?&_R_#;"\X<3D=/.(ZZ%N4E+C`)1]QZ
M^'!0K#`#[+%C&=Q,:^P<J_(:V^#`+'I_\8:H]B#`^Z!+T7;AO2`*3X#&<LC'
M!M1(`#55)6!,(I`VDDGB4';>N-TD;%*7!/A3_G0:Z\3#!0'A7[D,XSK<"-%,
MT,"TS8&B"$2;<?X.6P1@!ULF;G509]`+.\X,KN#0?->.PF`8ST`(_\94`OWC
M5&_3;Y%`%QS^W^8SH^%[OZQPI]K*079%N83BYF]>!YR4Z&S#)GA%2'F5W'C.
M$=C`"FBD1KV1M73L#EHTZ#R9J]&\W\WQ-77]Z/]T$,V0M?=HN:^[0$%PVIS'
M@L<`FSYFZU85#"+`3Q!T-8K00!8ENR4@@L*E&OV'8]11'[+^9,?I)9:>Q%#:
MDEYH?LMDZY1H'P=AM/##P(<0F,R4)9S,#+RY[V=$S4'GWRW>D,KA"D24'JR@
MN0UO>V[@1NT6F([8\<8Q\?8-`?4L&R+.STA@Z;X!1QLY450+S]S-P\HJ`NXQ
M[\1UG/6`P\+=#S;L;D77[^M4:>%P$&.!`O]BLL9<YUK%#@V_C:8<T1VTB?%S
M4]QN-77Z-PDHX8&PT`;(9PT['YVVMR7\A$O>\,[\:^LGL`>*L0N9B`K$L,5-
MRLDG2$4./!'F-!Q_G@W'WIZ9L`@V+[:P,!-6EQ[/F`<PPQ^;$-F@(!C#[`,]
ML)5[\0Q.YST:UA()9BX1P0Z99%FN@AZQ(@:*55#!J3>+<%AR_`XO8B!(D!-1
M("IQ\`4O0`@GH`.;`1C$&Q'PY1!B31$X1`K.`@4"CVFN#]`[$FVKYOECUP,3
M`]4GZ+M.0"]'#G&_/1"//*7/`4<&\7?44`X6B74,%1RL!_*]:1H<7K<#"<W$
M4/?-X8^IK>79,5'_?IH1]JBL3\3:?Q]48\M(S&6$C0P"C,@$$`,%*00<D%N^
MKCS3`1`0(K2PC,(4%(5A8618'$;*$6*Y=-"BTJEK\9@6'@Y'(H$`2*'4L>L!
M"YP`@.L41G:U`LF`P4F2'QJ%U*AG/Y0@V(RYO;DPB,T`,!PD-1`"))(%L$49
M/!@@<&$:=AX*S`S"(!0AT`P,M!$L>$(H2+9..1A,=34T"#P\-(#%CAT0%!CT
M1AT8*$PI)"!+%1#8@"T\NC3H5OIB9VMO<W?'.NP2'!1XPWJ[#!0:JI'IR)X?
M3D<-/`P4M%"=:)M)@<++L!JSR!>M?R;,S6`@CPJS-Y34N0!@94L#?/\"_R"4
M00H`.8T!I8B+I2`5O`?Z:%BQ]F"/01.8(+Y(`-.5`&(T%`AHT8N1C&JZ6@(-
M*G1HF)4.+'+KV%*!S7,'&D;)2%3HM1E2MQ4TN/`<HC$*:2`%>M(@QC$#QD)H
M0#(*@`$?/3'(2I1!TZ4YVR1`*P-86!DX^\XHD.L*X*F&#R.6A2G'C6X$@K)L
MQ6[,#RI7$Y^K*L/?/P!;V4+M9,H@`Y*+Z";<VG<F9D./#]0-<#9`1P2?#Q$(
MW2DN8KT&LTPQ5A>.`]\0G+%V(?AGZ^;.#8,;`,5!\DZ/@5*/M:#Z.,N^"A<3
M@62@$"1)%")8(*CA#?!23+YO2;N=4D^7L<65./\@`2<97Z.0T`@$H\F`QG!M
M@%5=-@\@D,`J,S1`@!E%0##+<`$(\%8KI2&6%2`H)-=8)X))88QQ"M2!178`
M-B08?\_!&*-!X`C#6S>W=>.9+P.X=]P8"!D@@)`*Z#$@(@X,(`".<#!8#P$(
M:"&``0<,EH`#N8&CBP$$T,.9(9JML!8\:)`QA"\$PF,C3/\E1,`6"+QBPA$/
M$""`F%),N8``3RKWP(ONN.)``]OQ9X"",D0R1@-XV#,%``(89T@!=Z)#0`*@
M+$!7<9=VD9Q:(G!QI2L)&"`3D>PHT*`#!3B0BUQE)E#,BE$LD`,6`QS8P$D,
M"!FKC+\"BPTX!#RB&S;_:,(#@+%D]`B!>PB]0@`!$C&(JY5!:G@3)D;ETFVK
M1]39P"4"("`DG9<>&)\4V7)##!@PB=A*?5Q1FIH4`Q"9CIO%5;-`JQ'!),!(
M3^TBKC6LKDHD`7-*BTFZ`%YUU@$.L+O"$=NP&D:24)1JP%'AP$>%3]8(D$`#
M_-&SL,EN\I?+I5H^'!@L=!A7:V'*I+M`0[P*&:S//Y.1I0!;M$ITT5>Z.?06
M0_-G30+T-#!+R4@.$*2X30P!Q`@%9&J;0I-F`N<>1"P@3`%Z1&VTVFL3[><6
MEQH@'2IAZ,H#!!("PF`3O5`<1;=26BDDE_7,XJ>E=D;])`D.+/L>`G4.UFNI
M_UW4.6PN$F92Q``-I(<&$+=\&M=(K(XS#A%G(X"*`7%[_/86=3[`M)"#[7NE
M+FY*R\7"7"+I)BI>+VG"9QBB0@Z4M`@ZBSX&S.L"Y%T\X*^0"URB"P*K1PCE
ME>#,2D:BEN%@7"05PV4.AK8%)*0(43H`QBU2-!VEA%P(>7+)U><%/:FX1$I#
MQAKA:PK4.]#98A8877@):`H$FM"<Y8W^M8$$)U!!6DQ@O(&\@(+;$8'G7$&,
M6T#0/Q7JQP]:X"]Z>"P*UYG!Q*S1JL&H1$((E$ZK8K>2+#3/.V'8!IE,H`\%
M(.,.4AB$"0H1J7IQ@P&"J$$*T'";L]"%`<1ZVC/&@O\L&4@'AM6P1Y;J$21,
M#,N+NRA?@58`HK1PS5%QZX:_HH"A=^T@<-*@@5JB,#(8[L*&L<N%`K20I,CI
MX2Z22L3CJ%``F4R!5[&HW@H7Z,A@1<<>K\H&$KD1`%[$H@GTT6$H8`@E9*Q.
M`#"@T@&640,\JB25JB29G\C5"GZHL"4`^`)ER"<RN]1'B8+BVF=&1D-GH:PG
MN,AA_+242OX4TT_0B]VA#I$(1!QA46DA1;8`P*4'3A)#UNAC"<P%$'+YRC^H
M7"4Y5>D%3T2M"J)L0\BB<$@#:E(Y@WDD/8$%CG3>QQ#A[$SCJ#`9*A"1+>8X
M#09?T)2`HD0ZIU&/>`2A"5W_5>0XFSN&SF(!)@@D\!R5/$0_IQ"\;(C+*[?Y
M6@DF28UEK4$+-2RG+N+GR0U=Q5`"8J&2SA%26HF`%P'YPD<,%):1J629+$TE
MI%H1IP8="``).%"<#*&`CRP`>LVJ)U6%<HFHF:D;^<2&2<D@3<K,I"P^N^(K
MIY#1;LQ'I+[8ZH:Z&H\WL%4&65CEGNCGMNVU+7I3]4_$?#`6:WY47G'M!$80
MJ"L1D$HE6T`@RUR6`%LV@V+%248"<FB"O(AF5\BL*F=;<]7I>*.CVEAB*[;3
MCD@-=BKF.,#M(F>T(IS@HHUTRD?GF,F6L$D*N:T%?OQZ27R,`XZ'Z(82QV"H
MLLW@_V+P2!5B*E$3,X;!LHIR4%(%Z<;V>8)"56AI9[M[&/J!(K7K`HJ.8K%1
MY31.O$,9J+^*L[5;$(EST=F"/?!Q7FQ<D@S(-2]N'S&"F1Y"NEBD*B).4P,E
M^J`C;7%K-B;57*+4BH"FU&U(/)&.GLS3NQH6"O=H<5]#A!"DOK@'&9@2'/4&
M!5#88$,2](2XE@`XD7N=@6A]49KX1FTLNY4"68'&JX/)#%/VA2PV.(>8L_Y#
M$WB9"8J:V1,WS/6B&Y[R-L"QI:H1B;ZWR)1"..>6(:AE`9M#``*HU);4D:(1
M26C$$LYV"]CZX+`B*``I&B"$'X`NSZ`CLYY!]Z8MXRL(ZO\IFUJL1*>CL2W1
M1K.2VJ0EPZ$&]66L'$S1NE##AD7/-@-(CR;H!,2RW7@/<ACUG`&1X"%PF0BV
M`9T0]."Q3,0MT6_>W"W200MIN$7,^"+2$7Z'"B1L[AX_\!P#Q*PH2"-0E8+3
M(^5L1]=4XBYVH5(TM0LUADP1Z3@HIL(!]D/M;R<ZBXRNX>4>/31KR%!IBLZ=
MNCTFH;,JH,(0,V`42)L6&5(YW^>@T5GD',5XK6`1;&YB$S$*&QO@X=.-R'-Y
M^@PZ(`CZJ7KPP0^4P.41Z,P.2N"%16P0&42%54`G48?&&7$>8O^7'258E,HC
M`@B$`YR)!+\DBA)P\/;TP0:@5L#_`3(EC3G_=P\:O\$]/E2"H\^A@S)`$C3`
M$(<;_#/@$=D+P5/GD$9T<!`W,`4[.$B#F+,0!1LJ(M9U.Y;D[,T8/<:8*>;P
M7P@<`>4#;U_/(:X01J3C/$J@A!],L(CVP,%`*(B#/9:`!\Z!/5`SF12]HU`9
M:NQ)ROJ>O"&@QC%O!'8&U^N$B5L16-2T)/,[Z@;/:8#(<CE9(`)VQ>K[(?DB
M(U%9$W\8@SE+B_$U/KO8+5%7`<`\1P6#"J_GMKQI4"X"6M=_TP+I25PT?,I#
M/RJ[`*U66T&/$+9E1]71%5`^O%:MOFI%?/+&V@]!9$O`LETM$(8-W+&'`2RL
M'DA7B-U<_R"H+=.@R[=P@VQ`AQ0#L%HH[$'4O(4(I$XU05>!J``)#$@DB)Z\
MX,H0I<YP^)[X',48/%\QC-_7S8U'=4]@1&`V"(%<P<Z4Z9T(S%CTW1/U<4-<
M50/VM=X\;%^(C1AV:!4LK(6;:%0[/.#231@V]%P7J9(8!,`KW$-6*!'HN`'5
MO$]J*"&$/%Q@0-1(<1\=^<;I!,80=-L)<$%6+==L647O"8RCC"$&VM@'RD`*
M"1`8^@4;>IYF,4=WX8(U5`\FD%CTD<%G850Y>%X[^5/ME4AU:)=6V&`+XF"@
MK(0W#$1!@44,GL)-!8>8$0V!Q`UL44(]\$)IO`7C=`(@4E4=%/]`[DE*"-I1
MCUD3:H50!N[%!?+8VB4)`0T#-T14G\1A55E!TT@)':02*>)A#:R@CU0?7/AA
M(GF?=M!@+*2@?=R@_R`01"@+ESG5+;34JL##53R*M&7"%KC3@!A*'4E!$_:B
M`,'8/N7?=<38H^`(`XS1&S@B'#S#%!32%`1)/KCA-M!#+=+3*_B)-:P%E+24
M+K3CE$G1]"U7*[!6"*75;QRC4?V"0K3.E72!@!6C91"AOSQ)6'3;/DZ42;47
M]I1-*+;$1L6-`5U!1YP-%I1?+_:@I*2(%*`(!>I@B;@%;A7?#%3-@6R>BHBB
M:%A#5:GC8B!0+Y##H^UC2NH;#DS?H\#_@;.PF1.@G!.L"M&D3?*L334@";@1
MC94X2-'<PV0P0R.@6M8PX/I)4("4G!*8VMUM'`VQS2V,$X-4@](,#41%SRL<
MEEIH(1`XRPWHPVGTP94H1,M`W,,=TC_NRU8:S:-MY::I6U9N`=<@S"K0&2"0
MC19Z!A@@`\^5Y0@L3"C&EPBPY:K`I0$NBM'@`R)@Q*4@16%:"9J4CA<J`EH0
MFTVHP0@40B2PRL>U!=&<Q`VPI9A(QQ4L)&6XU?>P15'IU@^^P5Z]D8I009TP
MU;:QA0O@1)/L9'/,U3WZ"5K,4@Q92CC:)$$RSMF<S4:B@L/IF9OU&:'I"A!U
M&91@6Q%PC1-,_XIM[IT0\@?FW,`9E`VP34QIY)EZ!FB`^I5XM$JQ`9T=7!\C
ML,,<.,L=-`(0(9Q[89S'V9EM((D>".@<:DE[@LX0$`DF+$'&94VK/=4#^$&!
MXH$[^`F<`((:H$$NG,'1/54><,Z;Z=E(K(1?G0T0;=D0/`"1:*4N0!'H*96;
M@5Z!<)"71%T6GLUJZH&$^L?7%(E_@(YIO4"78>D*T(82!`9O#*(VO,*!3`P%
MDAD59$)9+6=-8M$[?N-S1=9U4L%90``JK$$UR"EF6$H,H6E0U11X-L@NI()T
MHH-!#F.)6)80JD3/>$\RAD(=]N2`>)0J1@4W6,%L-5(`7,J&5(5$#/_12M1#
MQQF:1'K52V`@5=;#Q\W`H>+)Y)'"2'!#MQV(;"Q>X]B&1?4(#AQ(&\EC++JD
M)[:"("P`*V0!/=!36Q!5__CC/PYG9V5);IP#L%(GJ]8`$OD$*Z`!E-1C0LA&
M+E!,XZ5,\_20XU$J#1#JGZ:A3:Z3,-I&$:B'L9#(\6%1^^Q'NLS"),!?E3)C
M7#S)24X!M8;CML*%H0!?85S/3'3@/Y!2(BT5/*ZK.RV?PL9CL99K:VAG4+Z!
MN>&C"NH"-?(A.CTL0-6+INK"6.A"L^C*+K20R;P!KZ2+M=8#*CQ-*Q#J.LK`
M-;`LS:X4X0S'[_E>05#/"R3BI*Z#8`0?A)C_`3Z`8Q0`;"\2JJ8"5#UV#CR>
M7RQHJF7AQ('`'Y,1K$'`ZG9MK,]<(LDT$Z0&:3CJHL?D`>;E7CHY1+T@B3,H
MP27H3'4H4<@8P]"*3,3RV!1L#-'4V-(ED=ZZ@)?8K"&PUKRL[=>AZ"=<$B+9
M'Y)AU`/LE>\Y`)H8JS`U`C@\S0\\BAN,PRT<`X0`(/,HA4-21"@8C3RDP`\\
MGC#M5K&578&<H"*T;D!0QY;&@A21Z87="]\J@M5A0R51B7$(!L+:G$XN1?*B
M`W<M$+*Z4%.TP-/1`%$J)^5=8CI-I,@XF:`80@#0DL7<8\F0TS(D!T;`@C($
MCS4Q2%UX:C]4[0YM_P,#,._-KFH/*A18?$:2^(>T&='9LL7UM0+X)H*HR)6N
M",Q"@1$+H65R\254\`$*QJ8<($A?`(*&[&<2A$(29(WMLED5@*^<]EP^^&X-
MK([6QB_3MH&ONA,:AHF;NA,O:I0]$(,_2JZ,_&1+H<7$R(";V,0EJ<1*5I4N
MI).T*DKW9EYQ*<=C^(ET:&7I>LPMN$<I-8\5],\!E$LP%((Q0(2F.JK@;@.O
M[@5G4,+N.01R1@029,LUP<$EZ,4Y@43T^-.;P99G5((M@(Z[)0*K=&PG;.\"
M0<$?.PL+5^N!4,Q,>.."E$CR!4;(VB0,WX09PT,=U4>GW7",I`2=H,4A9?_%
M_#2%=EZRAOE$U%0@D4`FVJ0G>@:2C0;HAMZ"R2B!H`4(;0`"\_P7AA2')O@E
M7QH*;)W-8&9*-8".W#S.7:GR+7`!J?`2YW29+6.Q3(D=#-CF":)&"^2:>.#8
M,>=9N*`G_!'IILD-T4@'G`#!71&-DKCNFY49@U!F'ZT$'[Q9J=2:GM&#H-":
M)LC-EI"3=$@(+M)#":,`!^U5*%,5L?K"2#`5(2,*0)NK$-.`9DS,XMD;#?R>
M`(7O/VR.<FA>ESB2/T+N7A"Q/OBC)&M3[/3B0"K)E4C)0RJ:N*BR*Z/RG!W'
M+L3R!%&3=-3*JWE,H$[,Y8[SH%R"8"B:MJKTZYC_3(0$@RI?T@DHD8/L0-P>
M0@E08Y=VV\G0T/70T*:Q"IDA#JWE6=7HV?TA\\E@HEI\*&SM'U-S'P69P'%H
MPE5N@1#\LEOP"-1DC3^>#I^I!;%H<YX!P<JYP5ATQ%@LK8CIFRFDWB"++!G:
M:D!*P1J`!23/0%3-A,<LGB"_@9&Y@%R0M<#""/>H@S(0L49$KR+<XTD3,11\
M%58TDSI.50!D2S4H0V6!$`-V%,Y0P:5ZPB=UA_&9!'IX:V7Y<3?TA4(35WTH
ME9@`J&_X7EADGU94A#@K!1ID@F;[A1`HL0+:62CH`=;(S"R("<+,PD+@<[F@
M!-$8D=&,Q0^D@E&"8.]2_^!D42U:70,78\&4^"WY#&OW$0CXNH%/$+1S^(DZ
MX+*$^.[(/(U-Y(%G:UAJ[X`W!'A:9"`%,RWA[*RTT>EC,XAT8417:2<R^\FG
MU4`J764*$VH_X%9]O""$-*M[QT)A%QD3N9$T*Q`H/""5_*&C;/=C7ZXW4()_
M2/9>2"WP)L2)E^(IE`#TFO0"E:$XJ01I:6=^-@7A3MXE.IA#UYN%L0'*39P(
MO`N[=`F7I8"IA2(:<(U-2(B+-T.?L42Q`0A/:(.1TT"$PP5R;_)P/O<_P/CH
MZ=MC."+I!`>18U'C`.`Y8`@<,#*&`<8L730=N3`WI(<EK$"&'$/8`@N=)(0J
MD?^6HFI!#1\M]%TK%"A`8G]C)Z04I#W"+/GM*KF)*IT$:]E*?Q6BPI+C`T$0
MA7N"[X4>EEO%Y`4RXDJ%<7Y=K']C"K_!%31G,\"I)4C%F>[Z-U))*D2(GSC2
M/7W"MEC#$B'E[:!;\])Y55UB&SEV,NS&%@`@"%F$$M%I0KH1CK$E7]=Q@:2#
ML8\(KX^!FGL"NY]#II1)X!:(O7L4CC0IES9%5A"XEX+<><1"GL*5I):))+-0
MUPZ[*V(V%>0$0\O5HV_)G.*[A755J;""-5'"MR=&EFQ.,@'D"W!ZH=1A.-+)
MK9YXQ5^;$0]7'HH%P+\#67PQL_1(C'TOSMO1H)A>'Z__J@M9A9+@@O\@LR0@
M@ENJ0QV8U"S``A8/`9I\T7:&)UP6KL-SFUO)ABJ0#RFT1*<+D'$7KMD?![T;
M0J0GYW^[3$=#FFD`^#CE9R]&&2_4P9Q=7+%QV<])@X`R`A+@P:BA`<*-VLO)
M08`,F]^]`%/49@N<I7C$LES#UM]O&=]GL\-MQ\&5)=:ANU\UI0_``,!1\YS]
MP,6A31"0S8?V->@@O5]KC0A(Z)W9YF'IC*#961+P91!,G'J2IS1H,YEY]::E
M3K@57M5_C:`!?S>0_,`KPG#H!()HPV-L%/L%!]JS_;W(O-_ZBEZ<#,).=('`
ML4%D=(E8R7\WC2.5DDJ8K<T"_Y73!+'+Q\[PMSX=!\%3X=U38!T0E0X(+,RB
M,(72-$=1-*<R+,.Y.$XQI(R3-H.#^*6"@USO>%0L4DKFD@&-0@$!ZN%0.BP`
MC`9448!<684``VQ2!!`M9&^Q()Q+RD*T5Y+JI796X!`5('@@6,4`L&!G9B@(
M!0$``-9X5B!R<AEEMZ?)QV"F]P=U`$$:`%%E>CIJQI5"^@H;*PL[.FM[BYNK
MNTM*D(MSBV"0*FO`$'S,RQM09`M@,.`\H&`;%Z:L'..<4/N*(/`@@#U./FOP
M$/XP@,ZN?KW^</Y`0""/3EV>KS_.`-[@L"\6@H"V5A"<%>U@K"X*8S5H^"K`
M`HBD&/]2#/"0HBN*'#O.`GBK@`-B#@T`F`6`3;",$/^=-$?@I:P!`V?U8]EP
M1TU9!PA,A!7``3IQ'@\J:(<4G8%7\!XD`(>4:-&IN!@D2"`#PK6`"2D>P+E,
M%UB%)CJ"A+B&H\5;`?`ID\B1R1&9?WJ0[.*E@=M3"@`E*W6`BS-'KR!!*0/T
M4Y6(1[H!T)+B)ZG'!P!V@U4`@4R@139'=+`7%H`!EQ4NJ-FUE(&E*&?8*B"`
MI&D!?V/U3(:S08)P5`,"(-".`(_=\UXU""=`@(.G[6KW?EX171`(O@CNA'B&
MW%A9VPF.,,L1P-:&9G*5&!=@O,(4;5(0,V,7EHD"*R0_(F3_1_2`[PL9(+`!
MBP(H_%<;"P@TL``Q>.GPBA8.&"&:"0"E1@HPMKB$$@'JP:(210N81,H#L71F
M"TT%:1A7`AN2HH``;N4V%'3ZM)@4.P.D<EP[Q*%CGXS/,8#./Q!(M<^*!`E(
M3H^S=!<0?Q2=!=%U9!GY"I+8M!47D\I`Z>.3$%"(@V>O+"'F(PZ4QJ%S!"'2
M50`)?-9`F1!T*$N+LAVT`)&V$;#760$(L`!O76I78Y"X%5K<0O>5<@@778PB
MH"*E#(I+CD)2B8V49&FI#Z?YK`41EP>51Y&3+65)::JYB*I`=;,HYXR+M[C`
MT0^Q4@@+GP4]$-JHO-IRU%YE0:"`_P-0B:HJ+O8@Y04I.:;##FNQ<+/#EPD@
MD,!Q*3P01P(&T`/!1LG*YU0-#6&J#ZD4]3HJNOE(2QZ[`0G"47JHCHOO*5Q^
M**>Y&=[YB@'R[M.`9K,$0`"N3*E)RFT<*9"`O!"CV?"9M#V`[',BV3"P?%"U
MT^&S[<`+RSQ]_6.*4.R`=";"_N0;$8\C[=$##S;<C'/._YRY`P-C^$S&'7!`
ML8A?HB#(DA[[M;%?+;4<F',1.4]-]=0KE('`8G]HPH(H$D$B&J-[$#V9&#E4
MC?;4RMU,CU!7)8+``E^=``@2;6P\]`A5I&"#2''&$E3:.3]%.'#)M0,.."HB
M$+<!,ASAM_\L7]/;<.`CS5*#6SO<;-_F`K@V&=LD%U"/E`484(:<SIW$.BD#
M=9,Q!`#:(H"FWC#,%<D<VMY+=P#\.NE!N@$<[@-JTA<`B`C.4XNG"O74@"F_
MR:&+55$%G-0`<GX^U$D')#``<_C(H1L""</\"CL(0"$""BX$@8=>>7,2Q?IG
M>'*%(%28`088C!?!!,@DP@X?0D$BW("$QQF@,B8PP!%&L`,7C*T3>J#"_L;`
M`A&`Y@5>,`$<S-""KH5P"4A0@`$>9#XY@$$$(_#"$O(P05"L@"075``73J"7
M^['/9Y^@3&8.HQ<$V6$`@+*!_?C0ET_$4`J0@D`4(-&-/Z#"#B7_6(+DI-`@
M.ISG`-"P@2]$\`H=^@PH42!$848Q1L"=0G*4J],)8L$)4WR/;PZ(237L*(MG
M*(DISAL'-&S3@Q_(*P>V^)-]Y#2.5E%,#`+8D"D48+`#P.-&/NJ'<WJFB]'H
MZ!I(P>,L"I```.3(!O%`V7&BP2LAS0Y?_U$<<7C@E")U!%2Y@`I4;&@+W1V$
ME@$1R@*(L\ART$<M`T.'<(3$"X-XB'>Z.(``F(..U!`/?0YYYE!"F4=;E0AW
MS\#=/@9`,@#L*$CF\!V@.`)*W+E)/4!"E*!D9,9^Q&,R(N)%#>;9BWD,$Q<8
M\5[R'#"1/Y`B$:<HA!B"V24@@*$!S[2F_[$(UA$E;$D=BAL8,_>!D5#18S<"
M0"0YP,`10-C"*@:`BL(*XLU.7107S]#1=:9)3>,XY9F[$=,);R&P8+@K2;@2
M)W&`HRF:E,EA&J'>++ZWH0*P@SAR^T8<?'0Z4NPG%K'1QV-B2A4'`.D'*EL9
M1CV"T%@<I3FSFF4?>>$V=,2N',K$SC0=\"T;[-$9'1$7H>:1'*Q>::G&`QSH
M9H$`BQXCI4GJ3E?1X1G'W>(*'/F6G/X$L':V(PS_.(Z/-M)!A^@5.OX1W')&
MH=0#&*\G.DJ`#9(SD/D\#0PX8(,/&G`^)X).E/-)Q!)0>(W(A<N+:\L9-1!0
M'#,H;F7G``=((/\&DG/D@`"`<B!K1R%*Q*1D/PTPP('BQH#]F*(&&=D9VL+0
MHN1>9;**<P4H-922!]E@-3=X'W1QD(S_',B!;#M31:(G5?7BC"8/E1T!4+.;
M!#`78\HA@!G_P1KC,O=F,=`&!`K((B*F0&H^@*0I[*"#J)VVP$`0"3?\BY0B
M#$4`A`C';^%:#^$8`84/^6.Q'E0$2,KM!S0Q":G^<[/JTO%F7+Q!N!0'%>'4
M,5O_/<?KC'4ZT^:L)M`[AC#6]Q4!23)ZIBC80+@@L!;`]6S@VJU]W80XK@J#
M`"I`QRB(N)S>*AD(@E#.0_I@`A.PQR?-6NA(3E.$$XY$*#YH6,*H`1O_=!`'
M:N`34>"NT39C&5'/PW`B.$![6F/1@[G).2U3V)"`5&1TLS]R#"(!0)M&KN%Z
M8LAD**;XDO201'^/V%\H)I-&0J0G:\00S"-(DA0J^:XB3IP,(5XB:ZTU@B6`
MJ,4G1A'65QP6FP>A;=GH13Q6PSIXI^#F./7$4IAFTC.BU!+8#@:<=G1.-I`P
MJ'P^(1I3J&M2K+AU1:*`#=$B!=@`)=Y49]&BU?WA"H3PQ+=K\>TTCF:N+45*
M35JTR*!H>Q>RB8,_/6&&KSQ`V@5U=/9V"QO6'8+:#=*T1W'Q1EC0ZA0[?<O'
M=;%P51D/4*(D=3G639Z2RPXIWCQID\ZZ"V/1_Y0`*>>%E2""A5L(9Z.Z+$C'
MQ'1R"Y$#(]!\P$D(NUG)JI5U/+A%,PZFHEJ!*)ND0PHU&("BHPH`YRSUA&P]
M879:8&6DH)F'HL<.@9(2L><'(21GI'JG`YBO)O_!AQ9<EXH7V]<F%_WG?Q]S
M#@?\3N9%D<,#[(*&C'LA/67`B"EX"/$_A*^WZHV&K,]#K+"U^A48]H$#$8A`
M(&0786E@7'51)XQPN:!@>#&&!>46"[#=2=5M#&-;!)0$U#.T"V<"30STRX(L
MSSX&[A-E7PA#ZS7:1OJ/6.,C%W.*&.S;"SRP[C_,%ZZ^B(.(=<@+TGK@_3=H
MI04Y3<4JJ*]JGUV!,/_EL.\QC,%I73P5T/5D`_$"BU/)]E&^@P"CX"+?D2US
M@B8O,7@'(0_AM@[,I2#X=U3#8!54\!"I4$>P07<.B&Q0H%4/ABPG!%OA0F;)
M\&BR@R-;1CPM@!DYD`H[\$S:DS#9)0P=`QT70T(8T0>TX0*50`(H4`(T0!,'
M`EOL<14,%0Z#``@H(!$FP#\]M`0?XGHU9H0RAGK&@Q@YU![L,30X)$$[=#]D
MP`*1D0CNDT$'U`6>P![\4PE&R!XQ@$"$5!8]@`-M<$0XD`@C`&<"XD'!YP(D
MY#YFJ!=E:`EQEET_6`0D$(@]`#Z]-B3^<7IZ(2!TX(5&R$)E*'R!9&6O93?_
M8\,_T#`V+<)K!=,>71,%@X@@1#,)>V!`J`@%F_A`6/1@@T!&A/1UQL,'>A$8
M4<!"K@@_<.`&PEA"7\`$?I@)6N4SOP@%X'0&`.$(/&"*9=@"<M,%)#2+=X!Z
M(H"-*9`<T$!$B+!5LU<[+C0$"%)2+;`.9K`?44"";^(C^68^#R(1';4D0+`.
MBD<L6L`<I],\D<%`W($3,4)Z($ABI%!U^:)5X3`UX18.188Z0M%(;I`<5^$/
MCBB-$Z8.FUA<78@$_L`^)%`)P"%D:<:($@0'[,")2*"2D',$QC*(!W0$2A%"
M;P!!ZS"*E78S`F8W_Q`DE=`J[I,(`1:(<#"(F0$^_Q,D(,S5CD)S&.``!QYI
M7#>SD0G$(T*)72.@,H`20^$P-BR@!(8B!606#^O0`X:C7J;U%,:",1_I%%59
M`N$S7C.E%XBC!/Z!'*JG!^'VBW:P/L<!&P`%6\K!+=A2DDS5C3[I9N4#',MR
M%3#`!C5Y''(00J?H`_-PDBZP4-7%+9G`/CII`[O!'FY9E3T0!/;P.4K`!K8U
M5NW5-4&R+4CQ(?NQ0MK2!S^HA*'I119I65WB'T9@98\%!>"P/DK%(W$'#2PT
M#5.0=B(')5`A']YH+)>)@S("&K&X(#Y9(TTAD=JI%&PS#QS5%.Y$GN5I<&CV
M2H@B?$T!G(%$1"MCGO$Y3O_WH&/SB3B(<EB$B12'%9_]>3T@9)_^*:`#>I]O
MB3B$\3$$JJ`+6BA:YIT,"J$0.G:OQ9\1&I_"8:#`M:">4!T&U9N#TAXPE2-9
MHS)-50I<9364M!#7\6VOD!PJ($EP!74RDJ`$REQ"EAP+YD7JH*'S\`^ULP[F
MLUSS,)X#VE5PN"P6JJ3NI)_1`@W>N*11ZD[+00!/4:4X$Z!2&J7VB3/6I*5?
M6B@)DP(.":80FJ4Z<@0U6J91X12>Q5Y5XP-L20_)0:>PDG]WFBQFAVP<1Q`K
M\"#)Z`5-&8NH)0`:DC#UP%YCQRVGX7:"PWDV(#4Y=C82U$%+%$.%,%A/UX2`
M8'O_,N&GGF4#.Q.G_S`?7=".L+B&$_0(1&-&HQ=&C,5O^7$P<:,2B'@',>0H
MELI8%2%0!54%>XI]N^`?_B$>B6`$.-8"`/`@GD@_V(FJS+D'DR!%LK9Q-$0%
MU"<?<#`*<;-C-G,SL8BB-P!?L1@TEFJN7$`%]3,-@=5(/U`[F>,#0?!,RR%I
M5+,Q.-.%,(8S&:95E3I!)X<-Y<9J`(NG!6NP'M&!=9(O)U$%D-"B!XM.$)L+
MNSHO$CLH!-L@,26`M^`?%NNQR0(7'VL+:V6Q<2.RLK!2$)L=)PL+-F>QL)6P
M^5=/+$NS4Y$6-5L*,UNS`(6S6M&S$H6S9)=_S=*S\-BS_T>+M&AQM!N;M$WK
MM%@5LW<:M4]+M4<[M56+M5FKM5O+M5WKM9+CLA:;1C5;G0=+L32;L@>K`D>K
MCU^KM=?*MD>[LF3;LXB!LVEKL$2+L]CFMD_+2RQ+LA*KMS0KM)P&>C4;MA"+
M7SA;+7V;M>*!M($+L3F%LXQWIP1UMSW[-STKN8Y+LYO&N4>;('7;LT%7N9H[
MHP?K*I[[M#<;NII;M@9[M5BU3XBKN1A;L(7+NA`+NCC;N7D;NP5KN?DW+#4[
MO)QFMYF[NT_+19%[M'I!NI6KNWK%M'BZMM&[O$UK+W';L\U)LZDKO,&+I\>[
M65GSO-GKM%_AO)H[NS&5N`<KJR0UB[<%NSY'.[_H"[%_Q[TX^W,T2[YZ50D]
- ->[]W.K@LJW0&&P(`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g06286g0628607.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628607.gif
M1TE&.#EAT`+H`>8``"\O+Z*BHKJZNIJ:FF]O;]?7UX:&ALK*RHJ*BDI*2N_O
M[]O;VT9&1I*2DB`@(/#P\.+BXOGY^8*"@@H*"E]?7W=W=[6UM7IZ>L'!P?S\
M_*6EI;&QL:VMK9"0D*"@H)V=G;BXN*FIJ<C(R)65E<7%Q7)R<C\_/[V]O3HZ
M.IB8F/7U]<W-S3,S,^3DY&MK:S<W-XV-C6=G9X2$A(B(B-C8V("`@-34U-S<
MW.#@X-'1T>SL['U]?4]/3WAX>%M;6V)B8A`0$'!P<"HJ*E=75^GIZ1T='71T
M=%-34VQL;$!`0!H:&FAH:"<G)V!@8&1D9!86%EQ<7$-#0UA86%!04%145$Q,
M3#P\/`0$!']_?[^_OZ^OKX^/CY^?G\_/S]_?W^?GYY>7E[>WMZ>GI\?'QZNK
MJ[.SL_?W]_/S\\/#P]/3T_O[^^OKZ_;V]J:FIK*RLHZ.CI:6EIZ>GM+2TJJJ
MJM[>WGY^?K:VMKZ^OL[.SJZNKNKJZO[^_L+"POKZ^@```/___R'Y!```````
M+`````#0`N@!``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6.67Y)IJNLK:ZOL+&RL[2UMK>XKJBJN;V^O\#!PL/$Q<;'IZE8R\S-
MSL_0T=+3U-76U\T%R-O<D5Y_67_?X%GEYN?HZ>KE7%Q97"986<L4[R;W^/GZ
M^_S]_OP\[E$(&(^`"0++""#$QG`9EV7E%F4!T["BQ8L8,TH[XB+:CW\@0XH$
MV5$C,PH54OE9R;*ERY<P8\J<2;.FS9LMM73;V66=3RY;Y%G;1W`?$'P.6!X%
MX"<ISJ=071)(6A0`@)`&35!H1F'+/(=9M+@KIT5+%B_ENJC-HH!<.$-;_XQE
M81JUKMV[>//JW<M7+],D?0,+WJOSTP((@PZ@0_-'#82>/B/[%`#M(30*""EH
M)4B@Z#X'5_,Y73G:+A`@+!W<`VW"#P`'JD?NT[SZ8#PL!K=BT3U-RS*O6!ZB
M0WO6G()O;!6$\](S46%3RL5)+M>6$(%"RM-M<8=%"_!I%#0O.XBE'UT_)JPF
M2C^XO?OW\.,'_BN_OGPA^X2P,($""``@*,!TGGTM`3'!2[#%%E)1X>W&&S;>
MH;,%`3YUT58670PRCBM>5'?)<6@IT`5STDV'SGJ);`%2;$R9X%1I>&%1B!^%
M;#&3:E8=-5L^!C6S4&7R\$`C(E@,2."12":IY/]-?YDP@1+^H+:D8`X`(01I
M+JEVQ3THL*#?/1,H>`]'^D1!&SX<\:`9!3_\P`,S$@S0P#)E""`!&<$U8(Y9
M:8P1P#EI_+%`%V<((H`VPWC!12,60O;36&%!%`T!6_&0&VV=\5"(/)M>Y100
M,,:'(B)-Z4@49PUB$10T9KT3E%?E$'>.`G[(2,BBA*`2"Q9#'D+`1_LP%9IL
MQ(9T!0KZF'J/@<4V^P\+KO4#H+3*.FOMM=8Z<$0J?P!P'2*6Q0F-#S$$I:<!
M6>#Y3!GI!H``N^BD<8``[!9@0*!KE(-&OH$ND(6\:&SXR1J%RK)&H(*H$?"_
MA8!Q0"%A_"E``UQ0QM#_5OID)9*FAV1A`B)=N'>:'Z?!5JT)J&WZUB`N:N7,
MC\YPMP6LL*8E&8CO]&I(AJ3:^HH#/@L"1"%<Z-P*KXE\N[,?<;VRP!7/"?(Q
M(3P`$(L6?JQ<"`]:4SWU3HW(PZVWB1`JS@)G;.@O&H?]D:\`)L9MH@`!#`#O
M`%@$8#'>=5N#J"&J(@*!"3^XX.P$+`3HP)51#6T=KH+0JI2+2HB)+3]KNN@`
MR$H7@DHS-Y.H"=*$=%A(/+#P*C`A)O!L2*VQP$[(YH38N*O1A`0]H^ZKG#&!
M!!)@`7<6#M#-#!-6PX+UWUM'3?4+8#OBSMB=GSZE35<HT5)20+`0)K$3-&T(
M_P&0;SK!;A=$X8P/)5CSD)[307!`&M_PX/@@:!-"J_A'T[YS]8/05>J,QJG9
M\<X415N/ZW87"P#H[FN"$.`K2'<("#+P%6=(@!_PXST3'&LUR)+`U;*&"!XX
M;Q`\0$'T&E$.ZB6",GC3$Y[*0(8[!0!/?\I"#LLAC\@P1C%LRP)C".&8/X1!
M$`3[!`_X1X@Q,,\Z]W,%!:+X!P(L<'^ILV``M1A!W*TB@;GK&NI>83M$6+%G
ML6B-36ZW.I8E0G:V8($:;H&*KJ'PA((HT@H9,3U5D&V/E@``$P=!@$$*@@!4
M9`4B-W5%I@T0$1Y#A!>\:`I>.:,@+L,"T&"!"@\5HO\>:(2%K,P!`"Z4Q1P+
M/!H)*_C&`\8"")Z<!=;L*`@3(H("R0,D(KSB0EU20I!F-.0?M)#(51!@`NB@
MP`#.408_4``67/"?Y[@(#C_$<A5:"-:P\(''4M3QEK3\`Q``*`MJPL)&X30G
M'&L!RUN$+)P4Z"8!<NE+S^VB6^2L)R.`>8B9F;&8IB#`3<K'"@E.4Y*KK(57
MZ)A0E2'"`1RSA0FN&8MOLC*4MFBG+4(F`,&M89?TU&<$[_E'D3Z"G^,3YB)O
MT9U;8`V2U'PG2PDJ"XL"+IVNA(4)POD*FQ*ME;@(PQ?<Z8>.'L)2(#5IKDB:
M3Z4>`J6%*"2X)C!46[34JI3_C.0A:,535RR#H>$LH"%,$-%::(&BG&SHK1(!
MA)R^PI8;5>L@WI54IY*CEW9=!%2M(\PM7&$!+!7F!+.JSJZVPI^V\&GIT'H/
M7.P4K"5DJUM=(08S$/6(AR!#`.KJU!;ZL:EY'<1>"2E,8N(B<(FEI`*Z^0>Y
MQJ(+-*VH:_\@UM.9\Q4$0&M/9\O3==*"!ZF41<@P"Y=\;B&D(O4L/D.K5V$V
M@`R[!"@L!%!5A5*R"X5EZ60+RMLV2NVVKN""=],:SK(6HJVXX(%N71&R;DZ(
MLTI5;DF9^U1ACH&XA3#M+2H@6%T0]HV&9847QKO;<'(AN-]U;(!7H5A")L(!
MS[P%_P\(S%ZFE<-=YW#!$;)0!CDU@P'(U:=\0<O<T1ZRM%2]!1>@F]JR(73!
ME>QO*QJ<QW2:=Q:/36U8)>M8"K?B"T]XBA"098(*Y'7$]$W$$A%AAC'L\J\J
M9G$M#%HZ:DX2QJ7X:ES#:F-<@#*U38F*C%LQT6+,[`L3\`(/;FQ7)">YOHBX
M@#`1(-T)CIG!_R45EDFAY2G[00);*(M8MJ.%(4A`(8A&]`NBH&!<P%8+:HFT
M6EX@:4E_`;#I?1@Q)J2'"6BA:F]V\YL+8>(J.K?.KJC#G4V!"LO^X0P*B/49
MSH""6-O:UE?6[BW.4"50]?HT)E`"?@"PYF*O60R-)L9V)?_,VER\%PB?#G%G
MF3IJ0Y0:T(C0KRT(T`"&/L$J!UK)!(SDDBL@K!9]%@89]BR+'[![5\:`ZS#X
MP($'>!K4219UM041!258Y=__=H"_K9*4RC&A2KC8`8)C,:A*1YH%DL;T'[Y0
M770O&]WOAL4%,OX*`QA#J,48``_8<&\A["'):,'KOO^`@9D5<F8P_\$48$[S
MF;4!%Q4PZC#`JVME2UD8%SBW,,;P46+(6QAM@((X/VW-))^!VBMG!!E('-AB
M\-P6P2N&$XLA!DT/H[;!N``)BO&`."Q=2.M-KLJCOLM5TP*UPTA`,8[#=603
MPP4<=\48$$,,#O!]&%U@@3@'(`'_!\PQWVMGNR%*X/99C$'BPJ!Z8B]."P/8
M?1@"@'PP!K#P7OR@V;;(@`+<X`-QSJSIB/^LXA6QAK\+(P`:*`8E>Y&&RPMC
M#4\$1KJ#`79@$`#TLA`!`5CPGRM8;9PV2KN($[_Z02#VZXV716Q]L8!N$V,>
MQ=B][O-^6."_@@A#2,`6#M""/QS!:D\H).KI"_7F&\("-R?&`7+_"VGW(@M'
M*`;VE3W]7O3^%X&6"SI0`0Y@`!E`"`%@-9:2?*'&?.Z'!I0W"R/P`[*G?Q%8
M4Q>X*QD("^QB9MZW"BL0!0%0?H4@`%:C!.JG?/74?NY'"-Z1?=$7.Q8X@\JV
M@3W%?:P0_X"V(`)/0`.(4`96XRT,F'K+U8+YA0`P6('79X.ZP(1'XX2L@``X
MN`HZ2`LZ``0GD`@#@'XIV("J9X0NF'_$\`8N4`R"=WT1-@S[]W50N`K_YPL-
M(`*UD`$O<`&*@`8FEP#JUWDFQ8)@^(+$,`-M:`I*H']BJ(:#6`H&X''$X`45
M%PQA8'VS8``N<(!E8TU/('[KQUQ^:(1:4(;*!HK#<(9J6'K$D`:,.`Q?0'^^
MD`4BM&FO.`LO0`2+$#(*P`-1T$PJZ$N=V():$(O"H'V_,`'%``&;10P+@%^\
MEXBD@`9#-`P%\(RQ0`*FJ`BV:"FVZ(5%"(:"\(G%0(G%$`"')_\,!R!WUR>*
MPA`&R@@,"Z!YP/!>L^`"(,`(U^@"`[")H=6+[B<'%J!UL4<,0.!ZP(`&C-:(
M,0@+!P`&^C>%I@"/L9`!0L"*A'"-`(`U7L>)#MA\GU8,V$8,=D@,:_"1:GAU
M4Y:&PI`%2+AIDB<*!Z`$$4"/?K`&5=->VCA?8&@!Z!@,!2!TP4"!Q(`&)$D+
M6H6(^B>)PE`&*QD*Q\4H?H`&,^D''ZA+^MA\$/`!Q;"1Q*`$1;=S^F>2P9`%
M(GF2*3D,6K"2&=`'$:`"??``A?(`"L`&MW9K$*`%!Z``<ZD6@B9H)>"5(.,'
M(_`"1T"31&B3GLAFOC`#/CF*?'@+:Q#_E+,PE"=YB*6@!F:@!K`6EYB)F64P
M!'G9F9T9`%I`$<L@FM9``"50`160:*JYFJJIAS[@`#_@`\.7`,0'</]V<$H`
M*E<P;E?@!T%&$[OI!P<2;L+I&DS)!$R``H+)?AFY>E@)?5;'D*0`F<%P!HX9
M"9F)F9$&:5W@F7DI`9R9E[A12*RIFKCT;U5CF^KY&D_@`,0Y)1-@(!,PGP9R
M&O8);"@#!$K``E:R9JH!!,:V9E4`H&NF83S@`H7D)IV!!2Q@`%L``V^0`G$P
M,P@P,0<P!F.@%F(0!EV``6X@!CE`!(32!5_0!6%P``3Y!&P`DT$!`,N)D5_(
MC<-DF+WP!M4H_PPY)@QIP'-F$)=F8`:7F9UQR1RQ=A9HH05>X)WM4!;=,2%E
M@8+EJ9K>DA[K6:7U\9[B%IS".0&[&9_^<9_^D9_^<155$Z"A4:98\`($8``*
M,2$$<`$N\`(UYQ5;@`"F%`;O(`!=(`!DX'!=L`5J,5041W$3AS^'IP`'L`!W
M@`%R\`<H&C#:<`>NIP=50`B-B@:!H@-HLUG?L`02X"<;\`U_1P-O(`AD$!=L
MD`%>P`<D8%D0``%]D*%_X`)`H`(PB0!%\J+YV)R*]YS"X*NT<`9J,*R659D*
M8)T=DIU)RA9ET9W>^:QBH2J6$:6(%AY4:A4!`6Y5"G"_R1)/\`18&O\87,H2
M7!J??G`%NWD%I_$?]ND`3]"NQ%8UH%%L$$56`4HI"K$5Y+EF+T=SWE%(0+$%
M#D,&#F"B7<!Y)&JB&7I@6>`O:H$&7X"DPHI$R2@.1/H'SB@HF'5X&U)9XE``
MN/<P:[`&7C`Q,C*LA5`&@A`&`_!J_J)S)RH.3A8KWV`&7A`&E44&9D`&?&<&
M7S`O=%``&5`'@MH3*D`$)Q<H#S`$"\`8%C``1$`&;*`&>G"T;H`!=U``;Z`'
M(E`&\O,%#_`%`3`&;)`#(9`%62L(&8`H$C"R%H`#!="G4:"B,(D0+@J5-9F4
MU8:5:#D(>_"2@@"7"J`"LZ8`/2JDF&D#_C+_'7<``ED@`!MP!UH0!FY0%A?`
M`-"J!81W`:O)!:QI*?G:&9V!GMOZ;V$"&]_6GEL:*C$QKN$6;O;II1/PKL"F
MG_8Y$L06!3S`!`Q`5GY@;%$0!0G``&N&&<7F`A=@*3&``#S```3@`CZP!4LT
M,P:`!0XJ9]TQ`#.3!09P8-WI<%YP`!<:!A"P`$X&``L@`&SS!Y6I!HYH65Y0
M=&-P'&J@``*@`/03.05P'&NPBH^WDW]@OV0@O@NP*&:P!CW*'!DB/PK`!2X0
M`&F0!F00MV/P,`HP!FJ`H6'@OD=$=%U0`%FP3%VP616,!F+P#5\0!EY0`&(0
M`/FR+X.RDUE0`#]*_QGNVP6(<0!TJ04"$`9:4'I[N@9=8`9?BZAC(``#)@`0
M0,-MX;6OA@8*4`8+H`!KH`!'Y`)FX04-T``#H`85@`8GR@==L`%P\`$6L`>(
M$0`/,``T,#\50`96HP9E(`%T,P8[T`0%H`5N\`$(H`,-/`((H`5L$`89D`,W
MP`%X\`4<T`)H\`!_<`-R(`<K(`YE<`8V$``E,`(G(`';HGPA@Q`.<`!X.YA-
M);BV=C"V9B&WIACRHP52G`:(VJR9ZYT7(`&:^W((T:;E635'D``\X`-6$07`
MG)ZEJYY50G`#!P!"D,R_*9^^>3WB1C)=NINQ6Y_K^J7(,Z\056SV6FPH0/]L
MF3(0F#&>6\"F,Z,J6\`"+D"]8E$.7@$&?VJB7W#$)=H%8R`&&2(B:6!9)>H%
M<>$%EO51P[I:C=$8*/L':5"^9<`%9@`&&[QN%'!$7^`%3B8`9C#$$N<%:/`P
MYLL8!+`&`0,.$V<&$E![?T##@?)W$SU'7Z`&S.-D7'!$B-%M<=$%"Z`%9K!B
M:.$G@O('%9P&:X``CQ&S@H`6"-T8*:QI$E!9!9"H9]!1:=``8X`P`X``!P`!
M/"``:>`#<7(`)@`!9[`&8"``9U`&*JL%4XT&8Z`%8@!K0W4&6$#1CBC49X`H
M"&!WY`.Q?R)>F3<&_'6S#8`&-LL%A2(`6A``89#_/F+0>AGB!1``!A"0I&F@
M!D$]1V90`!!`=P=0`F&!Q$*<!D<T8/R5!17`!0E-,`9@)UJ0`P@@!S>P6@E0
M`!WP!5E`!"E`!C$``G'0`GI0`0_@!770IP6P``/0`2L0`A;`!WBP!3I``G.0
M`5R@!R20!UI@`#DP!V80!F-P!B6``0/0LA_P`6T@`7P``@E0JW6+!4H@`J/,
MG#%J"!H$S3/1FRT1G/-YW\+9I6!ZG_&9F^WZ!$(``$J``KD9!2B0B>,FO`Z`
M`KK+`U40H#RPS=[\`TNP9BQP!%L0`RY0`@;@`QL^!S.``!F.`!7085O0!`?@
M!&.0!R-@`-,=!2+0!7B0_P*/\0<TP`=:L``WX(@^O0#S)R@N_040$`:X5P!S
MY`6`I0`%D*3BY070=0!F<`%C;>0-H(X6<A8RJP`+0``0T%$&$+[B("A<L`9D
MP`5BP`40(%[L&P9I,`!FL``$\PUBD`9<X$1-]@<CT@"1#08<]@<0H"?W7$,C
M4I82H`9D\`U1P!R0*B_(U@[AX$0%8&3(\0=BT!9:L`8SFP:%,E1>4`8E:V1V
M#0$?-2?MJ!-@3@@-$#+^7+XMW`7=]@4J"P9JT-9C0$-=@&P2;>1BKD.*`M9G
M`+%A`+'NP!Q1\`X&L,%N0P9S/`9<L$Q8@`87<##(5C`-(`8&X"\0@`9IHPU"
ME?_!ZR8.$M"P!4#;9*`%%W``9=!M@'4H:^`8[5@`6(!L"E#H.^O8;N/#/B``
M:]#%F9UY3BXO`W"A68#NC['=2#["CJ@&6`!8$M`%97#78=T`:T#<SU[=!O#4
M("`&.L`'6V!V\UP`$7"A`.`&#U`!%N`&9.`"`G`"=[`#>=`!#5^YDUP`;?``
M2+A9;/``[7X`(7#1)2`&7S``7E!^)$`&)"`"2`AB3$D`YZ>K1Y:1!A#A#>[+
M)<`^6^`"/#"\6&\$,<`""6`%0C`$0P"G!E`!4W`$2&``'T$`"%`"`;`%1X``
M-?`#,'"J8D`&<P`%)8``=G`"<$,"/1`%"#`";K`%:0#_`Q=`!GSP#B6@!5^P
M`3(P=G=P`G)0`^%P1-P;``6P=U_`!4&@!CK@`SE0`Q60`POP`!$@!UX@!FYP
M`*IZ`6A0`BL@`"2@!23@!'J``7HPQ1$@`"$@`!Y0P19``($2!F9=!CQ?`6S!
M!RI@V&+0!PM`!@*@`1N0!\#3`B-0!WK3!@TP=N&[`S8@U#RL%O*`Y!`@!IJ+
MHCOY\%U@`!_E9/NKPN@/UVR#!EM0!@%P_&*!`#<+"%\+7"8Q$%E_?X.)7&(0
M#6M??P5D!0(!7UY>`6EG9#\%G7]<8P$'!VA<6PI:8@5<DVM>:`9:!@IE`@<-
M`V5H:A-B!UY98P40K&$"8V-:_P5?:L<%"F=>$&1K9V4'7%UJEP*A7UV2E6MA
M7F=99E\":6-G75E>9@H$77]:+W]E7FD':<H82(2(V(4#+O@I^&$FS!HL8<K\
M(:-&#3HS$Q'\895HC)HS82"<*]'LP*$"6;XH('/FS)<&:2J$R9=H`00M7;PL
MT$(`C!@O?QSQ\R))RZ`%"_B-&;``#)D_`;QP60,0RQHQ$<<<R**`5B(%9M"$
M"6"BQ)<#90;\V6I&IH%Q810XK39FDI8_(;N\DY1FEH0R"]"DN27FRX`T,+P0
M<9-'Q2$S1/!J@/#'0@``+0K(89-#C98S+D@,$#``1(X^A<F@D2.FE0A\?QX(
M6/#%S/\9,W6)G%GS!Z,`/KRW3#B3J+CQXEW\+*DS`8V?N\>C2Y].O;KUZ]BE
M9_&3Y`\``M4+"-YSH,8"&G]L;#G@H0V1&P7*0)`S(T2``KTUQ#E1)P493`T4
M4,,<,)!0P1L";('`#G0$(`,9#6A0@0=(D&'$#0<8T,(/.1A@`!ECU$%$!0*`
M<<`?:Y`@`!TEV$&$'*^$H<8`662QBA<KD('`%F[,4(`%'-"AQ@$+'!``!A`8
M`8$%6'%APP5YK,"!'`.\H4<;![@QA@T^S%'&#EZ$$<<"`;BA@`!KL!%"'!K(
MH`,(7<19P`,-X,%%'1S8$4,"'.1QP@!MA*!`%R#8($$7)&C_`8$8$A"PQ0!;
MK)4%&6EH@09^6@`61A<'")`:&<H8L$P%"V":1AK*?(%(.%0-$0`7"U2@11I9
M+$,&/KR(T0`::)31`&!<0+";%UV<(<89"(R!Q1?J%#,37F@,H``$970!00!=
M9'/I&0(H,`8K`K#P!P1I$(0&BEW(-&NV`I4!QC<"C!NO`)-F(<8:U,RT!01$
M@<%L(@5\LP9E:8V[QACD_+$.$YI8H@`Q&D&33K9C("``-F*,,<X%3!&+$P)>
MU/6'%P=\`0T9"AP0!A:7@#&--G\8$$:R96"1Q0%@F*#P%VNHD092$(PQC[7Q
M4O9'B0L@DH8"`9AR00#-E)&&&"`F_U7`&&M(5(`8"_#VAS80R*F&86G<=`1^
MDDP2Q@)A,&/&.5VT$D8!*&T2@`)Q%5"/`H.R<JHQ#63,%03D7B``#(((P,$!
M<]AKAP8@P`##$P.(H8$%=H!@1Q8;#``&!UJT`88'6VBAQ18SF!YZ`P004$$3
M1_A`@`]6M&Y[%#PD\,,/``"@!`#8T7'%!+]_,0%TV26O_/+,:\>==^!1UX``
MW&XA1AHQT&%!`SG4P8<17V@1@AP22(D!`@<,H*H([[AAP0%8!&`'#6]T`<8#
M1GS`XP]:C)#""F'@0AA:5(M2=:$!%AC`'#`PAP.,H`%N"`(6-I&#!L`@`#M`
MP`8HT(`#W/]!66,801!J0(-*G<`'";!##?!`(BP8P`UH>`$92/0!"4@@#A'P
M@!S&(`$LG.`.\(.###RP@1U@H0P:F$,!0N"&"]``#!=X'P<(((`;*"`'43F!
MJ,1P@3'`H`%GV`$%R"`##'P@4S;0@!8V``<$7,,+6T`##\\`'EUQHP*M&8/@
M[F(2+60A##>#WQA.A88&!"4I6>C"`B`2*S$88`!<J`9&SK"`,KQ$#&8X76^Z
M@`8(F`$W6<#"R'`1F!D5($SCHN1$_B"!FRW`"P7`QQGH!@;!3')<6E"`']X&
M!A2%@1U84(-4L*#(4!R03#190+S@T1(O;.,/YU*#&8`RB3CA)9+_Q`J#!&K"
M-0.\;1(.B$1(T)`%-"!@#68H`P$(QZAQ<1(-)SH`;YX1AK)A09D%&,#!QF"3
M-.CE+6DK#E>20BP%O'(,$!!"<1!*O7+1PUA?$X\"U*"`-+P")823(]T44$XM
M(&P,_3`=&,"@!2QP@0NJ,]T6ML`%`I3`=@0X`A-LQP,*O(`'3^@=`'+:.P<P
MH:<3\(,#'."'HOKA"49-JE*7RM2B!M6H$YC`%8`P52!8]:I8S:I5$^``'GCU
MJV#E@0M6N@6Q3L$/4P#"CLAJ@^Q$H0`5`(#PD->\NMKUKL;93G>^4YTPP($&
M84##'6I@AP_`P`X!1$,>1!"$$VRA!4:(_P$;QM"',&!`#$ZP0!Q"4(`\P/4#
M1I#"`#IP!@R4H`-<#$,.W*!!,8S@`"=H@@1$@(4C!,$.>ID#`T(@`0ODP`XH
MJ(`;72"`!TZQ`25P@0<2\($`2.``<)!`#`8P@BRP8'L!(,,<:G"?"BSA#0BP
MPPT"!`82+``&62B#(S;P`P_4J`0-0,`)L"4&*5D`"P,`DQ9,(8/T6>$"6$C#
M%Q@P!CN,(`W6ZX`17B"!^1E@`UD(01XX]@$PM"$&Q0K#`0(VD'+^T7YDD$0X
M2L`%3I`!"Q5(0PGD"098#L`4#*A`%M)P`02T[0)?",/*+J"P$FQD7XG`0@$0
M8(8"K+,O,0@#&?^\,"0M`*0OI_IC(GIV&UC*HI(.-<,K_Y`&601@#0/H`H2\
MP(*UL8(R8Q"+L``9&$H)\SB2@`U^I"8&:/+C"_XD2G&NQV4T?,%H[YAGN?[`
M`VN9H0MF.`#?N)""+E!A`?^P0!<D,`)Y;"H`:$@I%O9;@@!4H-.GTT)+?Q`%
M+"2``@3@@>V<0(`?Q)0'48@"%$Q``3^HF@>],T'O</V$">@4J4)UZE&!W=2F
M1M4/6L6J`P#@`"`,50E/X(&SG0V`L(+5463-MK:WK>TXX21.G"3#M\'=!3V0
MNP5?&,(?Z)`!O&)G"WX0#G&8QX-%"@$"QW.WOO>=';U"CSI]@``'T!?_@C!X
M``$7($`.)("&'-PA``38P!06_@$NN"$$!MB1!3[0`!FT8;\]($`5!F"!.D@@
M#T&HP@@.4H<!V"``#$!`"K3PA2W$`0YHH(`6IL`%'!C@!R3`;PE^``8-&&`*
M<,@O!5PP``G8X*0PX,$.YJ"!$D@`>V(0`K?*L(865(`-'L`""WH`APY\8`9N
MJ,`)\&!CK=#@`C4(PQ:R$`<"B*``8+"#"PQ@@Q)XX`8P>M4#<T`""+"A<BKH
M-`QH_@4,D*`#/#A<`49``CBT0,`KX$,86J#HDI9!40M0`U<J`$MWA<,?=T'*
MUNHL!JNKI!\PD0"-Q)"238T!#&/8PA$MM31O_PWJ#RVN@,;2AH@_)(!P\5#'
MUY##-V+Q`R`"Z`>]S``!8U9T:;Q"QM*R,`&\R4,>'35=%SR-4C!((`"B1JGM
MMM"Z%ZR?"UC`0JK9[]+6?8<"J.:!"?;_:YWV3J@.\`0!^%3%5H!^,`%`@(!!
MA8#)EH!#!0#[!VL`P`!?904)D`#5A@4.X"BJ1@!8P&W9IE*B)FK@E@7C1FXH
M&"<N`1O]EA#\]H+1T07``X/4`6_PI@#-`P`0@`5*(`+/08-`^(+^QE?3<0,P
MT`.[0@8SL`)?<`-Y$`=BX`%W4`$@@`9P@`4T4`%WX`8>\`,2P`$B<``=T$-C
MP`4>``<[``!#EB$9@O\`.<!=';`%%+"#^84':'!Y9;`%.&`'6M`!1N($+N`#
MEY4":&`!*-4"6C``F68`&.`$*4`'%]``;S`"<3`'&81I+#`&`E`"81`#).8!
M+W0D7C`"V;4#`D`"5],&#8`4:Z(#31<")W!2)Y`'(^`#'J<%<,`!')`&(M`'
M4'$`SD`!+9`#+3`$(Y`!':`':!`#/#``9'`'?/,`*E!1'<`&O;=HE](%`M!!
M!G`(E=``<F<C)9`%8!``T0<&62`!EV`Z36-C9-`:(Z4%)`4&GV<`%%`"IN.!
M*"5_,-6/J193!&`"!(`[N.9_.O6``>@`016`OA-5#MF`5L6`5\4$$[E_%GG_
MD1AID13(`PS```FP?PGP5;.3`#Y``=9V:SP0?V0E:BO%`B"(`844`EJ``7>P
M`EVP`G?@;2=8+'\@">,P;WJ@`QF@![:1'L9!`AGP!39``VKP-3J@!WJP`+ZH
M,T$(@UE`E57);S*8E<=A@WZ`@\R#`@*`!4)``GX`"UR9ELLSA-$C';%D!@WP
M*V)``F'`!WF`!DRP`UI@`>;V!R)P`5O#!3DP`%GB+S&0!D4P!AN'`"2P`3@@
M`>7E:;5"`K^5*'>P!`=``U@@`6^0!@'P`'%P`%+`-T_R`.B7!Q2P!BG`!7!0
M4?$U`V`0!S7P!AL0`#'@?AT`!@,@!!R0!4Q@`,T(_Q,>,`-U8#H=X(P=<`$]
MH%S(M2,$X&D(8`6R4SL^@#LLL`07^`,H```3\`(_P`,H\`+5UCM"\#M%<`4[
MQ00\U6R]`VQ`(`1'=07$9H!^4%4)B(!))54/"9%7)6T\L&Q>Q00H<))@!8+<
M)G[>5H*)E()Q0AO,TA+5H6YJJ6_B,J%XI098::%U=94:>E=;.:%>"9;+PP5?
M@`57H`1^T$L=NJ+'P9;4P1.MTU+]N`0,<`4_X`(`$`6I-E,\$#L%"0`4H&N^
MUCM1\`)*X`#0QI!/H)X[M:3$\P2]9E10BFSS>07P29]8FJ4&2(!*%559Q8!>
MZH!7%55,X&NX8P+_^0)&9?\$!JIM*L6@/I8(+8$PX$9)+1%0RV,S+-H\?K"G
MS:-0_(81QG$&'W$<A'H;TE0NS3<H7I-7&>JGV($&/@"IRG,&(;`'(!IO7]D\
M0^!D%O`'<M!NE-JA+CH="7`%^2F18_I47CH\"9AL8?JJS(8"K]I5884"5G"2
M(6EJ*"`$7G4$!N`':EH$K<,#$@`#6Q`#!K`%-;!2R[H%%>`'+H!6&6<`$P"M
M+C`',^!(3:!A;Z`!$E`!?"`">)"'5(@'`F`!87`'(7``5:AC?`@/.?`%??`!
MQP`"![`'$>`&*^`#\*%D9=!H(58&L*`%1L6"=L5CQI$`,'@!Q3>JU]&G$(L=
M$DO_'6,P0,#X@:DF!D>0:B6@3@3```.@4P<P`61@`B?R!VI``1.``!-08Q>@
M!&&@5`];'#0VL=>!3#A;'5V@!!&0J0BPJ<SS!)^ZLZ3Z/$0H'6SP!"6@D#6"
M!@KP!2T``3G0.20P!B>P`"&VC3?P`3FP*&0">!XP``6P`1J`!AQP![2B*R=0
M!FZP!#67`EA4!3I"!EVX`0B@`200`G,`4G%P1L&*!?$F"`>``1=@!#6`!0\D
M`G1@`'R``#3@!S.[!1X0`%GP!!&0`@LP?C!@`"Z0!Q^`!2X@`1Z``0&P`2Z`
M`!(`!Y>P`8<"!AUP`R1``EN08R?0`?\3`6UP!PC0!`V@_P!;$`(+X`,(@`8C
M<`1X@`4'T`4H1@(&,`)%=05TD`ARD%+-D%+8NU*B1@!A,`0JJ7L_`(-'\"Q&
M*QU`4+[4T9;3P04,(`1'H`1,8%050&M^P`("6E11P``.<`$EX`=,H'6),`!,
ML`42<(!,@*)J"E6#=AP\@+[:\:@.O&Y28*'PU@!"NSP;(`D0H`(1G)6E.AT`
M``-"\`0E>@!C8`!B0"<<`"$#<`$K(*DE,`!48`!8``-BT,*3]@-;8``2H`'G
M)08$1@$&$`,KT`!.L`%F\%)>T%P#8``7X"L7\"0(L*R09`!6YP>".\4TS`(P
M8`$7(`$W(``7P#$(<$9^(`;Q%O\_7<`#MO"QF]8`5:"Z8_`!%\`%&Y)Q>%LC
M8L`!(:`"*J-%/G19RPH#&`!(6.`$YR4!.V`C`*`C!?`#:1`"&.`%!)"9XG:P
MB5`%8Z`)G$P$4<O)S6<<)9J6!E"S':R^'?P'$V`=64``M:8$2F`"\PMM\6M5
M2K`%#$!K)@`&#M!21N4%:#P!6!`,#J`%7C!4R.P`(F,<!2"AJ3PR=-7!.H`"
M@IJ6\!:T(JH\;#P*T?S,^_;!T?$`5[`%$T@::/`T%)`#"``#94`%1'$!2"`&
M\_LG"'`&I#`"<90`!G`$%]`")X`"N7<`.X"*-$`".V`$8=``0]``1!<`"#`"
M".`#/,#_!4.PB0@``#_`!!^P!%CL!PC@`EC`!.F#`#S7`#2L`#%`!F!`!7ZP
M'8Z"!&,``&#P2&-P`6$`!4-`!LLJ`,+U`R%0%DR'`46R`B$`?P80`A00B3H`
M1QS`!3*Q!2I0FZ0Q%C_]!14W`C1`!$90!F5@!)X;`'[``'X`&R^`I_U6`6DI
M?-[\!Q7[S!!\'"@A#Q1`#/AA@B>5!5R`'YL<)LXW,IK0&WIFUFW@`#SL`&T0
M'5^@HL_,H=X,`16JEO`6K-F</-L</FMME4B+RL81`45`SDR@`E(`:F4``T<0
M`!]P`DX@!6E``;JX`UO@`S_@!4XP`F#P`Q8@!!+PG5M@`=S+_P%A\`,Q0`)'
M\`$&$)<[8+E($)<L@`8GX&10H"-<\`,&<``7L`5+4`19C`'J-``H@``5P`%)
ML`,;,`8[X,(;T-+QA@&H,``(@`4G+`!?(`944`)0D+I;``,5$#XKYKI@8`%@
MP`465",'D`!'\`<5\``64`8AH`,!H`+M77''H`-GLP%D,`+L'6$ETJ\?<(!C
MG0C.K#R,G94F8,H1/!!K30$3NP<*H`+3B*DM^M;H&^(T***?I!+3Q,DM\``/
MP,D\WN/^P`2OM`DG->1$/N0-X`)%?E(-@'],WN1-S@(>?<':?!?/9327K6_@
M?!PJ``2>W71@(``8L`/G#)W;.&E:$/^7`G%96-`"#>`#!T`!3;,"8D``*[#/
M&G`"5E`&Y50%:!``,)#7)-``84)X6B`!8L`$+6`%8>`#8,``3G<%@BL!)5!#
M2+`$4*`%)\`"F.4"3&`#%GZ6MA;H`@`$,$``9`"L(X`%4)`&DBX!"8`!L:B&
M'[`#!Z`#M)<%,$`!`Q`&(T`$.F8"8_`?)&(`$8`$6B`%BEQI5G``"-``7-#G
M`H``IJT!(2"X104;HL0\9@#C+U@8:_T$E[T/WEP`W(X=-.[CZ#X/)*@)(]@%
M0VY21"Z'0_`$K;-23G[O3<YLR;SOR.QLSZ8$"(BB1E556EKPR#944L7O_"X$
M+.``I[9T&"#_Y91]%\K0J%>.5UEN'+I$S@Q`BF$2`*Q#+!@@`!O``2=@`0@0
M$/+E!":/!!_P`22-!"&P`[W0`.:7`R32N49@!&(F!6'``T;@L#`@`4XF!16`
M!/A5WC<0`Z;8T5+@P],#7T5@=&A0!1#P`19BL-N1<6/I`-,S``P0/Z<C*VB`
M`0V002$P`A4P`#1``"<`C#N@`S9@`63"0QFPQ#]!!/B3$N1B!1^P`EK``&8P
M!#"P`VN@=B'``VI$[5>0!!W^!Q^N/-F>E14P^:G<UCA;&\5A,MN>"5[P,#UN
MS,22Y*1/Y*Y,`5B`[TQN`@K/[T#@!T<Z`4-E\+1?5+8\5$``R\A\_Z3^CFNX
MAJ9=]01!6E/X1_Q,SE)<``84P`0HEOQ;``;QAP5@X"A<@&KQA_I<@-?PMVG1
M?P31OZP-H'NZ5T-<,``F@`(ED-0VA`#IC_JJCW_,=@2G=@1"`/Q#)00`T/#)
M+/"3#0A_@H.$A#Q:?P<M*X6-CH^0D9*3E)!9?DE_``20"GY;`$\K9`@#)R%@
M86(":5M<&!!.%6%K*SMD7&`E91`-`B$&-P,P&#]A#0-<"!QH'V`&!AH!`6%&
M&!@&`UD?QPTJ7B<()WY8?@@26D8;'P@E*QPW$ET<7F4??F)^!%A@(TPY%!Z4
M.-%`S!0#82`<0"`@S(@*:TYHD,#%2Q@!"_^X('$A`(:%+@T:C."R10`'#3DD
M)-%28L,&%@4.A.@R(`"9"A#6B#&@Q8_/+H)B5&K$8*C10C$,'%U*2(&7IU"C
M/LT2M0N7JUP<:,'*M2M6+%<)4!B+9:Q9LSQXC'4`@`(/!W#CRIT[04G<"77Q
M^@3BLZ_?OX`#*P$"!*[=N(7AGEULU@0%`F*W/"D[EB08,+FP:-Z\)<M5SUJR
MB!:]M?1FL%BV;,%L&3-8,)H9CP7SQ\0?,10<`Y@KU^X$!W8!`&`2]\5<)4\"
M]S5\Q0%AWG&5]"TR%\5NOM1]N(VB??$5GT+.8I%0&6L#+!F8\A#S!\*1#4SC
MRY__Z%*F39`R"`'_!0",#PL)(#"&!0*0,,88`\10!@Q:2`!%&!B$$$`!`D38
M0`59-#!&``-(H,$L#`Q@$A4'2'`"%$OLT$`686"A`09@3"'`"%J0,0081R!`
MP@"3?2)&``B0L<$!6-`@(!@9=/'!!0W@XX<!1G(!0!I.C'&!!AL84$4#+4C`
M00@62`###BH$H$4%)GU@01@!F)'&`1A\P`$2-R#@10$%&`!&%%N@D<4))6`P
M1`0K?!""%U"<,$88''019U]`_8&"#4S95H@94D4E&E96>>4I#S%$)IML)IC@
M@&.Y0:<J7\JUZFI?$P!A%Q"_06>J7+GQ8,);B^TF&Q8$;!*9*UP0P`58_UPP
MD5EJ8+FRZ19;B49!%EMHIL5I%&P&AFK&QD`9%FV=!8"N<+W%&P""O/!'`;LY
MIX1=TKWZEQ(F`+:J3[7"M6NX%`!@JA^V!<Q$%P1G"M4E/FWAA1E_*`")%F)H
M*I4@$;3PQP,Z0!)&7PX[L@4%'4.RQ@0^34&)4NH9((826?P@`7TPQWR4?9IP
M`@D`H/"`P`@!?!#+!@T@8<$&85Q0"@=0'.#*%%ET$<('6HPP@!8\!.""#4B`
MT:@$\E01PQ%&#,""&"O8L`(&%X1(D18<D&&`C"-<0$((?FR\!0)9H*#:!1]H
MX,04".0`#`D&?.('#`U<<``3'#AQ@!@?8-&`%O]#-,!%%P*4H`$,(W0Q!!DV
M?+#%!1=XP<$.68!AAHECY$",,!P\L$(8+BSP005=5"%`!3<L,0`"-%P`Q@%<
MD+`!I((`$*E17UA*",+R1N]7OKW%Q4-;IY+*V,<F7+4:/R118,"QFXG666B;
M4OL4`4]=BX7[!JQ&TOA=I3;JJ/O"U6Y<OB(FUR>U^0,%ZK*;4J'J5*4:H$\8
MH):/B25;94$-#QC@`+7DYH*+.8VQL*(:'OA!$!^\1`RZTC1.>8$J!GN*&=XW
M,4=0P"?JDH097F""`@3,>9`8@T^>,`1*3*`H,=L"QQ[1@`0\0!(DZ`L.(5&!
M^#BN'&-P@,UD1L4J-H+_9OAYQ`.N``HFF($"8CB`!C[0A1)P80T8$$`#.@,H
M,6S!!AO`P`DD<`$)9"$&1N"!`$1$!C-2``9<0(,1#!""`XS@"X4TP`\N@((1
MH&$#/`##$T:P1@J$89%T*QP,MC""'PQ@``;@@1`\=`$;M&(*+C"<A^(&A"QH
MH0MAP-1.N"``%6S`"&00@`88<H(`H($#8BC`L<2PA@L(@"8-L=,(!%`&:F@!
M&P^0`!(:@((!2>,#7H``"2Q@/`.4PP\3^((@&+`\HRSQ#Y<0@UHV\T)D:08K
M,7!-!,\RA'WDQE^I&HZJY/(<5@E',3$X"ZKZM4.S<($LP#K6L>HUAC_$T`3*
M_]+"*Z%BE:ED80@)B\H7ON`%!8BSHWFJ`!=<:144IC`J?]BH%QR`A0"6BA),
M\,DY'6&"+,","Q_\0PC]P`68,:"EDT@.P":!!1J.H2@OE:$#?,(>27C!6S++
M1P*N($Y'#.$)1VS$`2P0@!5D@61^0($8N.:"K#9BII0P@@2$Z(470,&*<(4K
M%J?8B`@4`12MW.H.%/`#"QP`#`7P01F64`(L",`((P`D%'*0A14\2`,$:$`9
MMC"`'2QA#%`(P`YV,`#$.D$+2R#<#L)`R`T@@0LP0(`&LB```UA`!1QH``<&
M<(5R$"`<P]""$*I@M"Y0(`0^"(`1>G(),8$A`$#`@O\1&(*!)1"`!V-8P`56
M0(745J,,96@`!="0"B&!X0,'4$&U:%"&`P!SEAK0`M%V\$P:`&`#G3L``<1P
M@P9T(0"N_*8?(A6#<@[EG)>X1&+BY8?#W,4P!@8.$R@@5`>8Y6/$\I2G/.,%
M;U8U$B_T0PPE40Y!,$$028U$`80*Q$B8`4,P8T(/U0512@AUPY&H`%#G4[@"
M:`*=?K`I?6*P!4KH<+^3`,-0>QKB2%SB!0R;1`Q*3)^-\041'F-`D@L!`R8`
M(`FR\DF\BC"!)M(T/@8@@!`U(`2T4O$!8&"!`WR@N/3$M1)SC00`*@``("@`
M2`AX`-!&L($T<.$$O\0"!`;_,((,Q``=L$D`$P9P@3&4P`DHT(`+I%"**B$`
M`4CH&^40\(H12,X98KB,!'P7@AQHX0)H$```RE$!!/Q`"AB`P1`$0(`1V.`"
M-\B!`1@@@!S[(09H",D+=G``$IP'E$.8K`&&4`$.<,$`L97``7[0``2D=@Q@
M>$<%<K"%,^Q`#"3)0@D:0`8Q-$`"-S*`#4RP@3.U8`T("-VMN7`#NOTD>?ZE
MQ%.OZ.LP""(?3"7$%_S]!S-,N>`VKI<?>@@S+]1T$F#-J23JQ;`/U\;,@_C"
M;YXTB:?J>#X\%&!M)D")%TZ@J9+@P8SE$^`_M+3E](%,);9`5TL,]8-%CL3"
M*A$#_R_#3(<D:ZC'3!`R0AB`,/KX@1\<T``A7.$"1<#`(S`>B3%X08@A8`##
MXZJ#&#!!<4\I`P`88-8W&QD3-9,SG:]P`PNL(`!BH,('`G"`,-P@#"&H1@@(
MH($RA`$%%@`#`5(1@!*0(&DTWT#$=E2"$)S``B':@)].P`4)8&`9&RB`T!)P
M]5:'J`$+*$(Y=%:!*M#@`!>@M@$^L(0MP.``EJN;'TH@@!5H@`G'A<`K)D>`
M`T1M`Q>(`0L.,(4#&,`J-P"#A+!P@ZXR<P=CN,%DM1"-,MQ`3PAHP/@,\`(1
MY>``!4!`"$)0A@MH`0P]N7=M*,*5'R"``A!^X&)XP&^8%__.)R@3A`*PH-),
MM53A5`=G,6!CDF!R/A<)+Y!C?]!3M4$!E)`/Z#()68`%'R<?/_0'2M%BDU``
M#B`4)[-R\=%R.U6!\<$$].<("F`&6K!1'=-13U%TSP,P7N"`.3<(=S0&0_`Q
M73`&8B86!`"#@_`"("@?7?!K?@"$@F``3("$-/<!":`$*"``+_!></$R4P=F
MJN$'7L``;_5F!%`"*E`($0`&*%!V9N<(<78SX,(`66`!:&``"V`!$4``8;`"
MK#``8T`!53!2(0`#%!``'/`,%2!='T`%1T)):T(&^/4%8I(%`1`"6)`#<@)*
M`K`#8#``QI<X,``&+F``#1`"R?7_"1M``D:0!<1F`!*P`@5``0)P`EY@`>70
M$U)@`U,`!D`P``3``&6`"QQ0`91%`QS@2S$``1)``P(@`3E@`6NBC&A``060
M!30P`#EP#0^@`070!5DP`JM1=Q]0`@<``"<``4J"`%L0`$M@`1@P`*'F!\D1
M*=\`%3=@4B?U@O6G@"E5+U)&"`4`!&(`;EH0!A`S@8A@90P4,ZL(928&&0<'
M"3$%%$S@!1<'9Q=F8N\#,R]E&PP`!)!@$:Y4`%K@,%K@!9_Q"/$#,RW78Y=`
M&_0Q!`[H"`Q0`4P0`\!!`$PP&+52'T-%?S4H"%SP!"_P0Q10&$+D!V#@`/E7
M"$(H,T7H_Q-"UPA8X`!(B#&"L)"3P&1&@06^J`]2]&9B8`1NU@@",`5?>8;\
M=A\U5P@X`P`3$`)TP@460`86@`!IX(O'0@)=``;M(``7@"9CX`(2T`!IX`.6
MXTU)\`1;8`(2$")H8`(7``"'I3.;M6YC@`!0X`+"$P4E4`$&<`X4H'VK)HH#
MP`,-`(L[4(X&<`&2<P0'4`%/X@=(@#<=`0$N`'L%4`8&<`0CD`#/$(Q[E4U:
M``%A@``K4'DA(`:_1`(YP`&C8)DJ,`4[$`(DH%QT1&XS>'I+8B8^D#D?\`,K
MT!/M2`@W``&"H`(0T`);86-;P04M(I(D*`@ZM#$?)Y(060AH=?\9M2%3,=-6
M!$=%]6)3$;B3@V!P2T&!%FD;B-!ACX`%"\8#L2(<@[%TK>0Q0[@4.&53#F`&
MES"A1Y$4CY"1)",&,64`,>`'3+`%%L=OMH%S:!4&3,":%(0<NU%@#C"1A&`"
M9\D4$&`!?8$!7I`QA0`*2#@?6U<)$5!>.S`%2.`'!<`#)A-74^"CCU`!!$B6
M99EV-V,`:KD"G4$37:`#'&!^`N`%%P`#)3``49`%:$!\#6!\8]"*`(!:6>`#
M3J`!)#`$Z>`$7:`!%Q`%$/`#)*`%6X`A!D`&9=`"1$`C!D`$/Y`&%D`$2&`#
M8M`C6\`!-"`!9)`&6+`$6$!Y6$`Z",#_`P=`#OKP``+R!!L0`UH@!6N$!3Q@
M?G2'##Q0!@)`!`80`);J2"<@`!]@`UE0`4O&!69`<[9T$PAP`1P2``(`G`!`
M#0)`=B$P`C<0`T1`$..@?H*0!5=P`@)$`$/``\_FJU[P!`?E4/NICZ+:GHTP
MI,_#'B80*P%8"0R@DHW`!04`!@J@GA@:%A7Q""-J4V`@3@!:`$/`!15``2SU
ME/_D`.CJ<@MK3@'C<@X`"4?G$X+G!Q0@9`"0!2:0;[>AH4;1<B;P!1D*,[[Z
M"$,@!D,`%ZE100;$L3BF+BKZ"`40`U]P4,#J"G]@+$':@`&U&/8$09JQ!$9@
M`8T``=_Q%U;Y_P<?L[/Q\:Z$(&1_035.>Q0V4`*2D`4G2*6%D(:/```QP*`V
ML%6]`%]D)`%F4"PU<0$E@`#9@`1VI`4%`0.D8*8_(@!;@`)<4`1'`""K(`%8
MX`RTAPWRQ0`!4`$$<&@:<`(VH`%5(`%@```2<`5#L`$#$`8[@`!S1WW2`%K?
M%0"R=P&]-`!`0`(^4!-DL%Q(0`8CX`1;<``PL*A4D`72&``0`+<'L!"^H)G?
M)B'&UWOH2`%"<@%&(``"L`2!@P9B8"0D\``50`(?(`$%L'1`-@@DP`.]QP1B
M0``FL`5C,`$,([+=PP0?9P9600$,X"1*L$XT.@AH=9>UP00`NA1,H/^A?@"3
MNS$!/TDR@Y&T@L":-O5P[4J2^*MA(XHS2S6B1TD(!$H?%^ER$G=%0U!4$]`]
M2\<%O]%CC@`;)ND'#,!@YDL.C=`%J%&P^W"X[@,L*+P/C_`%5-DP5YL<]>(`
M$PQ7ML%14H&$1"!>(1P8$?@\)M#"\^&!0[$%0+`%5.`R?J`%3S"U1J'!D=`%
M/:RU-HAV6=2U%!`#$Z``7#4*6I`#+G,#:),`&C``&K`#TQ"(`0!M,.!L1I`&
M/S!?%^"V6-`%#!`"E#8%=GH2>#@"'V`$27`!(5`"%\`!"+`!QZ1]'%`&8"`$
M!L!#'(`-"%`&N'AJU#(".T`"B.-KZB``X,+_$@-P!']I`5,P`)Q8`9*W566`
M!O.566#P`TA0`B6`!EX0`#`@`2W`(2,`:Q)@``J``'AY`!^`!FL`!0B0QB.`
M``RP!6LK6PC`FGQ13@L!`$<`-<"2!>Q"@%C;5@:G!0SP`A3`!>F',-"R!0P`
M`$-`@FA%+?>Y<#+#``A9"'X```2,?\D!DPS8"$(D!EWP`E3Q`B=:"%K`!(4S
M'&_!!`EH@D':&1:I+`S`!1KH"&;P!2DXGQV54I$@9DYA,-@X4EX0DED`A-#C
M%^4J".RC0B[H44U!"#<Z'U_``T_`8%N@*QRE`#2=T2D4+5NQT5Q!%>I*"?(Z
M"#;@!QSB!W8D!$E+_\Y2$``_,!;)L$C-W`!+L`%F(055P`,)P``EX`,C0`53
M8`+)?%Q<L``!4!%<4:82H%H4`%E7``92P``2\"3(00%:8!93``4=S``;8`)*
M;4`F``528`(#L`2BZ19C,055P`(!(`EG(`01(,4Q:)9RMFO\"'LVH(T&$%RJ
M7"=?$@(_$(@((`5ED)D+@`!8D``!4`95,,<#X`0-``8,\`-?<%Q@``%9X+AK
M!09.``,QP`$%0`6"%#8Y@`8GX`(!H`%%#`#6ACB#=&E08*\_$`)'@`6E*7L(
M<*1B8`):4(DL\`%0PW=D$`8Q0`+X508N4`*JXXO;@@1BD'TJX8<+(!-$8_\$
MRB`!;P(%!D`"1R``3^@$`'`!$[!()9``/Y`$/X4\@V`!.R`!3G`E4^"M/S5"
M/+!K7U"B3,`$[^P3"'-A64``0,`^@F!#CS`&/:9P+4D?9L`#"\M3IJ(\A:$%
MPK$%0$P`@='3@O`%!B!,E_,'7:`%*]2P!<`/(8F-GL$I6+$IZ[O.??$$<,4`
MV2L6$M85U<)O=;9TY]N>'@L)/W508P$9,K89^X`%2;`//)`$:D$`89X$8?Y`
M$6L;6&`"L`$95\R2P`*TU:(:FE$MG"%FH!!A17ZQN/$QY3T6,!`><VT6%^`'
M5!W/&@``2L`""4`!:L866U`$83`7IH*]3.!)LK'_`P)``1RPU(%N%BWC`LU(
M`0.PMF7JEEQ`)'XP`B7@UD\"`/RL>[0D%9BB`D00%1D0`5X0AC"(,4X,"1#`
M`H[]V%;:M70V`0N`!>"&M1G```@P2`)@!4#2!2I"208`25&0F"=P`9^%+!7`
M(9TY``P0-PDP`%-``@E`!CMPR[!X;@10``PP!E)P`C#P`9'5R$?G(,[@($44
M#PWP`K0\!AL@XT(F`2/``18`!#0``TYPFFM`.5W@`J[F>%U@`4L@`6B@`V*@
M`24@`4#":#E0!D1#;ISS211P`502`"?`)NE8>.NR`F+:IPU``AK0X'U1!3_@
MHT32!2+Y&?2:KS__!08+_ZSP[&O_?*W&T5!FX&`/-.<5L!X,AB\UY`@V'!4A
M&1I`3[`-_0CS.0A,2P@`]Q=);Y+O\^0G-.3/AG(U*JX\X`7:FYY7$08<1'.0
M@95820":>1J:(1;\,*`<A2E/L3%71PXZ%#$AV=%90`$'0M9>L04X+N)NP?<T
M1UIF$2[>:@(Q$`8V>KA"2.9<D`2#D003(/I`0`%)4"PF(`8OD`0.D`2[H19S
MO?CP!QE^O^$$8!6I`>?98A5A0/=<<`%<L0$N0-8"0'<K(-0ZB@`Z``1"D"D[
ML`%C6>R#D`\8T$DZ*N],/!1=L`22<"W4?ZU4O-+)<ST3,'<K4`(;_@#>9``H
MX/_&7J>-'Q,`*!``=50!*&`$S::QY`<(25];#5H7)48-)B,:)%0(2!<;2R5;
M#"5(+P8C4BX-'Q42`"5%0P<-61H#)5T</#Q<8!)(%EQ^67X^(UL&$R,`909=
ME!4-`1=;%RY1!@AE0AI&!L%@+A1?!QLG!2T7.1\27%LPQ@@V62H&&PU/`D=4
M`D;Q738\?O?X$U]__/W^__VP,/$"\,^36WX<%#1#8,*8/V:\>.G21:(7,PK,
M^`'"4<DM@&-X4-B"A0(7`EQ2JM22I0N7+`846)PID:5++EVTJ,RBD@N6E%CL
M;:G@AX*7(0P,E*P0(P:6IU!+4IB:)`F/D@2J4H!:(<O_OWW[9'I1\.6B`BPS
M=9IY84*!"2T$7OC$`D:,@3%1H1H=::""@:F`#?P%PP,`!0>($8MQ,(2+@Q<.
M`#!)\H+'$`=@$@/PH\0C!1-^7@`P(7*J`P-@*&0!O#7E-0)8PO3<Z=)+@8HT
M97[!R._+/G\5F'QY\:>"B8+(DRM?#AQ@%S\7JOA)0N$*`(!;NC#?SCVY+2#X
M_&AA<KQ[]P@)'BAW0L.\>^6XDOP!0$`Y`"P`)D"`D6-#CA@7A(&`"A(@L$,`
M64A@`!*(7!`"`@WL8(0$/(3Q00,E2!"##UC`8($37`A@`10&["`%"UL,@`4'
M`F#(@P98H&%#&38X`<4(',!0_X0$18@D@`0'<(%`%#$D`(`6!VIA``$(A8?/
M$UE4,<`%4`0P`A8+[G#!#0-8L$4`""@XP@<8(/!""\W`X$D`!H3A0P,"<%`%
M`@$@`0$:R0B!!IQ@-$""BAL,<84#0G!6A!_:=6<&4@H@YP!"3R2W6*+(%2">
M%EC@XE5&%WV111@T6:0`%V9HP5)*83!%&&Q32355!5R,9$(20U!```$\)+&%
M55M<%9H]`!CWPAA5U3I$:6%08(`6K`%&P&I=7)57ID]QX913!$RE1;)A$`"K
M2C]]P00`(7'!`Q-9I$M1%@JDZZZ[[7I15JB^R1NJ1!'M<]%8^RSJG!]B@.$'
M+!.(`?\0%N\ES!P6`P,QQ&@*1XP<PO\\YZ0?U_VS10$2=]Q/!%Y@X,(/#8A'
MGL?(!<"#>@61`07*"<<W7WW)`3#$"T!TN\,49`PPPA(7!#"$`@S`\$,))ESP
M0P`[B%&&!%3$4(%</E#P`P4(Q+!`"6``$(40`*"`P05(4,!!$@,,@,`()>@"
MPQ(T<&'`!09440("0DAP!0]+D''!`0F8`,033R0!Q@X4#$`RP!BSP$`.$QP@
M!!`;["#`"',N`60P'"``3@,-E%%&`!`<@*<``QAP`AD2A!$`&&:,$,`1&\":
MPP-A$('!&"@(0$,67U2X"1H,6.'%$GYHD(,?&Y`^FTHNA2'_&Q=#^`'&%LJF
MQJRM3/@1PSVK*<E#8@X4%ID#8@!P_F0`,)`0`T"X#T`2`$`&!A,O,*`9`/R_
M14%JS<("`<1PDIO,)@RUR8)-))*%L4A$)F(`6`2'\(4A5.`/%L'(;V#&G$\5
MQ`1/&`,!O+`%/W!08N7Q!RZ<-`&*^>,:)U28%V#SA*>$(88*HYD_(D"!(USA
M'E<[`7:T@,.('<!+XN%!"G$(`Q.T9X<&8((-BK@=F=%'.94A`!`X$"$-%&`,
M::B`$;10`A+$@`@#T``#C/"!#0"@`0G@P`5@`($JC"`$(>!!`*A0@03`@`-9
M"(`#&F"$"@B``%/X`0(T<((`<"$!_R7P(P^JP((0@$%I6T""$"Y0!``@@`Q)
MD,`%((0$*30`!B>1``HNX`<F%4$(#&C`!+K`A"M0X`440`$`H&`"%L``"E%X
MP8E0$`6K48`%!GB"^KZ6F`84P0!)*,($E,`1CO`@`4KX@1+R\P1J.N`)`4A(
M!8IP!184R@I2\$,5_M<LP'3A?V$0(`!Z,@8PX$0EH!&8'[R@!2^,H9^XD4@,
M3&`6!X9%`=;3P@LBZ)6*&8"*W4%H9_PP@<.X$*++*<!%^\&`"81'(1CESA+Y
M48`)@.<>2I@`%PYFAI":APDN-8\.`0($(3R!B`79`DYCRAP.2*"$"AUI#`?@
M@`H<0"*9&?\"$7A:$"O.]!\'8(%)KU"W*'S@"4``@!1>H`0'%.$"$S"`$J[0
MU6\6B@%"`-L5..*`"9"U""\8V#T&-0$F(`9G55!?$8#@@*XJ(0;U$\,VF3`5
M($BU"%(H3%Z3$!XJ^,`$#Y.`'ZKGA!]$X0<%8X(0/N"$$E"!`5L00Q0JH(4M
MO&0$&RC0"$!WC!-PP`(<($,:0%4,"0@`3#^P@01@P@4+H$$`&(`"#!!P@021
M8`0".`D0LO`#/TA@!(CRAQ96((:I\.""_7!`0Y/COA4>C`<$J8`9GE"A\1#$
M'WY@``.>$->'_,,N3*T4/CARCXW&MS?VQ>`8-H*^1MWW@P7Q#6?_)@"\@N3W
MO_TP&(*1\]1^V&"M$]CI>R6\X'YL@0`E!`-;0OH``T3!`0GP1H7YX=3DZ`!L
M#+C"`"1@!`00H$2(,(`+!N`$!!B`#+)04`Q(@`0-H$`"$D@;`:0@!4-88`H#
M$,,,,<!<!8SA`PA``P4V`(8/:.$`84B#@1`0@0&X``L!B,$.1M&C'(3A`B<@
M@0N8@`4G6.$"`G!")O<;0<G09P)&<``0#+"$5"P!3".8@AC*1@(X;:$$`Q#`
M`7KV4PMT`0L(F!(8EJ`!`82@`#`XH@0T<(`TB.$`)'"`[F"0M@"`3@Q,NABE
M_M```[P@"VAX04OY45WF@$8,!SD8PL)@_X(Q['<@(WW.5$*37YZ,F!\&B`4/
M2((%]U98H\F9[$>.S0^ADKB5VD7.0ZG=CPEPNQ]&0,X7/"H>Y(#!V=3>0F,`
MIL1O,[7$->-!0P10!AJ404DI"D'H&I"&T9%``">(00/`8``-9,$")+C>"<(0
M@@!(`0$-_Y$9?G``49[YTJY#P!&44@$,!$`,",#"%G:`QQ$@8<Q;```/Q%""
M`M!I!PZH0A>F(`4P7"$$1O`"X]PZ7S^P@`,.%P`*5GR$+Y%A"Q#0P`H^P`(R
MG,`+)$A1&H90@BF,`0H*-,`I&!"")7#``%L``QG.$(`*="$I`M`"&+`T`#)D
M@2@>+>>C5ET`)?]\``T?2*$9''!>Y=S:H[K^@PDJ0($_O`"P(_W"+6P1`^1D
MX<`(ON&W\9*<)W3WV];^PPJG#1`P])W:)G1WN/\!@18\^!Y:`%D+-"9Y;JL;
M%UIHM[L_I@.0W<N!,PD`&<K`!9T\3R4'@#=R5"XH!)B-1$43^0@@GH`#4*``
M/$/`$L`1BRA<@`H\,(`/>`$&*\#@!6%(@A9^D`0J8$8`#&""\P-@A%X1``Q.
MB`(23H`$`K0="C8&0,IY((`2\6#Y!B`$?5$"8Z`!:#!&?L`P!D`"?P,$+4`"
M-Q``6.`")<`#"'``"W!;.0`%),`!6.!:8(``6Q!RY(`%%P`!`Q`%]';_962P
M`@I``EB@"CL`!@-`70$`#3!P`1\P`.\T!A2@`=N27G^@!='5#RJ``@?@``(P
M!/V0!<1A:TWR#PKP8EU`6D]0`";```/E3_VP7\#S&<A!0.[6:]^F`&"0'.2V
M7<>6>9MWA@8V>Z'W;27@#P_@`E=P!5I`;A?@/E>`!AE@810V8A<&5$H4`8[$
M$[_7$T'6`"X@`>WTB%-A`D82!2R0&$)0B2A`/HE!31X1'B?E!WM5!)J(&"8`
M&)5H`D(`&`8W'3-C'SS04>W7``5@`0AP`S^0`V30<#`@`1]``0%@`3L0`XES
M!-*``#Z`!"BP`Q90`9(@!E8P`@-P`C!P!"_@_R%E(!<E@`(-H`$!D`98$`.[
M2`;)Y8@-D#8:H'\JQP6MI@I0@`)@<([;Z`4GD`5DX`=AX`=&$`.\Z`!=4`8G
MT&H&@`$_4`;]=P0!0`.VA0!5!@,5L`L2X">D)0`_<`)/@``P4`($0`D)\`,<
M$()AT`!.\`EX@P9'D`6[L`+7LF(<X`<71(2KEAS?N!WY=`\:`P`%0`%*EC\Q
M\`)?D&S;Q@^WP#"9%T]CJ(8CEB[1!C[?5GC^,$-8\!S=0Q<C\0^0AV`9\VT7
MM1GW``0_=#&MIU/NM@4Q0(@F8'.$\AF0N!6LX2JLD2T4<`&)^'L+$`"F0P9H
MP`4+<'MBX04Z\`!_^/\>PE<0*D<`5X``)8!S:6`%8\`!7C!'$L`!7<<%)3`[
MJR5FH?`#-.`$!L``+>`SHT0[51`"+(8$@C8`5*`!!O`#;'0!'#``/N`"J'D!
M1O`#3@!D`>`$1;!_`D`!3C!'6%`%/N``42"!)?`#`X`+$?0")U`7#H`!,/`I
M'+`%G)4%92!]>+0$8]``)R`!VVD`#8`&")`&7-`"+!(&4"``,!!/"&`$P3@"
M)&``$&`!90`#6[`%0,`%#!``&A`#5J(%`S`(]P@$0UB$RV$"K>=WC!.'_&`&
M9O`%8_`2'&-X&]0/.L<3?I!YT(9Y$4IM7O"3_#!#%$"$2LEM#.`/F7$/U7/_
M$/EQ#SRP057Y7TPP:]Q&,2OPC0>!,3<J!#]T!2A`$JL'EM_6*_O5*V]QE>^!
M*6$@!D_Q>%Y01E?3`+2)!220!3&@``*P`KWQ`S=@!0M@#24``V`#IDE0`A>`
M`G,H,8$)$(-Y!5QP7+.@!:(#!9NV`Q_@`]YY`&1D!%R0.AB``J*#!6EC@INY
M`3$``0&@!%#`!0XR``U@`1D21S5&!F!'!9`&"B$P!+/``#]@,RI'`=GW9UK@
M`"50)$0"!2X0('Z``'MC@#D`!*C3`"Q@!9YC@2[@!)!V9A:`!`,``QB@IZ*3
M`'ZD!8)VC`*`!D$"!K3SF`.`!'C1(62P`$S``3&P_P%E0@2.Q`$!0X0"^APO
MB1Q0(I.W`'@JA!^OL'+59I1`"1,7^J"?IWDO&E\F@*X+9@87Q07@\8G+]6U,
MV`^@<5+TY8DRP0_O&E_#XFZ-]P<QX`!6<`)<0`8J,#@38']3MG]>`:2N!P#/
M(08\\`)=8*3F,0),(`%0$`-%)P"MQ&8E281EP`(-X#X$AU//(04```93X`7(
MM')=4`1<<`"[%`(=DZ;_\`I:!`$-0``G(``FT'^7<P!&,``'8`!BD`!(,`)7
M$P8'()L_%W9><P$L@`*6108[<+4$4`5&(`:JN05+``52<`%@L`((0$95$`,L
M@0!>BP5(P+,$T#YEP`!D`/^-2&`75``&2$`#`1``5>(')``$%NB?5U`[!-<%
M!G`$"7`$9,``EG,#(8`&JV47#3`"%T`&8H`!,:"Q1A`"6Q`"6C`&X;`!]$:!
M"$"/)9`#C\<$9$`#'\`%8A`&=_1Q];01`VH!R86(+S$;SR&O``$:60`:GR<N
M\7H6_%I6FG@+N#`!'H4^XUJ4WY:A_$`4&P$:(TIM)5H<#D`:D4&$1$$`)C`!
M+X`%#,`##_&4[B8<[C8%_+`!6/`!$=`/)[4%_=`"7)`&'&.QU'8`Z<EN)L`%
M'ML=\O87R>0``V`%3*`$`7A9&S$0$\`_3@"S18`"?F``C0<`&FMV.EL&R_<$
M+*/_,$#K#X,)!%I0"$]``@SP!0%``0S@:*AC8PW@`T:"`"20``A0!52`!BX@
M(%B`6K!2`CHP`%L@LD#F$QQP!!<0`QS0635D`$/P`S[@B'*$`0T0`Q^@<I(A
M`4<0`JL5`"R0!`R`QC^P3EQPCP+#`S0P!6"5!25P`CD@`25`!L"@.#LP`#L)
M`$[`)0*P@R10<5/@B&G0!3`@#5$`!@20#G_F!99CDE+@6RM0!!^@`;A3C@S@
M!0/`!;TKH)9R,:3\O<HQ`0YPDQW\#W+1%-@E>(;13@3@*4[R`EX@>8^'O=SF
M!103$G)1&%JP&4_@H2.VK^GWRG]`4?;X![NQ!2^P!>^[_Z'4!@32?&RC5Q!`
M\`(3X(9#Y&[@D&%L$08)S!T$@$Q`(`5R:@``H`$3(`&IV%P'``0)P`#V.C\4
MX&@`<`(3D`9E100.L`4V@,H,,`1*P`#Y&S$IW`_'0I@:,`5Q^Y%E$#02@`7E
MB'TET,7*(@%:M@/(Q`!14)L,^0,$D`/_LP3Y*`4!\`%%%G(;P`"HM@$$,`(8
M@`&H^P,;0`)WDR$-`,;+9@2>U3JC4`))@!+D@`0(Q3!4(`%)L`-74`9'T`!"
MT`"Q4#1D\!1I`P/%<P)30($K\`/>67"J@P`Y``-FD``N@`!JRZ@$#`-=L`.H
M!2%,0%QDT+D-@`1>\%/3L!&V4?\"3D`!Y5@">QH./4$4QOL/`Q,+G,</84"O
M2<JOL?R(WV-2"6$"I4AB`\M3\>INO3Q`Z$51_,MM^TH6_O4'SP$`-S4QU3QB
M7#"AQW9@.D!NR.P/`GQL'[`$$30>!CK.R4$$&?`%M2<&51`&'H@%8A``7A``
M95`M6W`#IR``7H`&.G&8`F!P8I`%&]!;61"-@83=^AD"S^,ZO^>(AS"!P<>*
M5Y0<N,(D$C!<A+%B6A!F/_`!8_L#,?`#P"H`57`!-P,DIPLK6S`%H%,%)K`$
M);(#V>@#*5@!""`%(C(%(\`"J_`"(%E:]0W%`Y"WA<$#Y-"0$C)-WS0-+"``
M":`!"<C_D@'`D5>@GS!PTP00!B\``20P!"<@!F@``PO@`ZIK`"L``2.0.%X@
M`+5+<@U``U0`!=P(9SR@`_%]`+'QN3G``$G*!=9:`F*P`H9T`@-`RN16RAN!
M;LEA`N23V@6Q=J85*UOQ$]Y+`3*A``&#RRN%>87]7Y"77LO,;0=;$#AZ8&\.
MYYJ='$"@!$_08+3&S=2V'\\1>RS0!4!``0!0B:,XBA,@37RE9YT8'D_PZ)B.
M&)>(`FGYB&7>`&_Y$XE(;SN;T/R0WG[P=0/``86V`;<+99B"!#!`0`3P`U1"
M7%OPC]=T6XH*!1A2!FF@F0%@`PU0)2QP!'+L!`]":0;PI0Y`_P&/D`4H$!3&
MR=,430!L<@((X#`-`&8G<&@'4.(`("=:``00,)`GZ'8.D`1"T*<*JP%*<-;:
M!`,27-<+6XI14.YMAZ@6X`!&<`&A@'\!H`4?[0!74`P^`!-I\`!9L`5.(`8A
M@`\20)<7W@6=Y@4Q$"JC'5_?<Z&5<MDQM04;/V)?,.=1B95)F8"H[6Z+[6[[
MBLTV)>BDK6#<EC[/X0*!\QRUT!.=]A+./1/&>GLSH0*SIT+F+?/\\`K5TXW`
M>S@*T"L?H`!H<`5/(`0)\&$.P`!38P4A0%97<`0?<`$O\`'/_@0#L%<C((H[
MT$H(X`3("$M44!1/P`$P/@(M``-@8/\<@C'/@,4#',@(R9!V0P`$8+`!2``)
M&%#B"<"H+N``).`#!U`"2P"K"4`""(``#&""2/`#3Z`#"7`+5-4U+``$J]`5
M`$#XRGGA`0#D%W#U-&`!F'H%)O`!-\"=,!`!!C#(:-`GRKP"7I"_GUUMF%<4
M&`KR+I79W*:]`,$9=4YML8U>!,!F$^/EQ4S]%99Y?W!2,B\&@5AAXOP<N&(%
M7>``:E#T$&7J?\#HWP.#!B(&#SF"6Y`#`S"S2J$$)/`!.>,`$UB8IP\(%R@\
M/`8A1CPH/Q55`TY%8@1"4Q03!@1^/$4C)48_"4<E2$@L)1<O!@`\%0,A!AH2
M.PQ).P98+EC_:5]^8'Y5-P$!`%DQ!DL''WY&`PT`6R,_A`Q()4]C#BA(!@Q`
M8C%:6PQ<`%$P4`0!/CM:0PX7%PX#0$D;'"4C,41D9#ME)0%^&/AYX0?`!C1_
M$OZAH+"APX<0(TJ,:,*/'Q,1LV"9R+&C1X<4NGP<2?+AQHA^*/CA4K+E2(PH
M@4PX^7#+%Y<X.S+(\M"+3S,^@PHUDW,B#XE`+!*(*(9ET:<.NP#HXH<`#Q94
M%4!\H,"+C@A>S'35\<5+"R(*,-@XZX7&`@4+2.2@@2&+W2QK%JPX`"'+"2T:
M[`8X<()#`!L!N)PI<^)`BQ).1A#`X`0+@B58?A"(@D!B%C])_@!8_RJ1`0],
ML"08\9*D#(PR!!C\2()D2;@R.ZX@H`"`P1,-#(8,,?V"P`]$`$8X8("`"@`N
M/R1,<?`DQA0K4:[$*!%C0`PI!@2,,3"`@RI5'PX$&W[%`0`A#L(`*`$F!"\_
M*#Z\*#,A"X(N0Z"Q`A`$<#```5!P((0!+VSPQ`A`Y,!###R`$<,0!BQ@Q0$`
M("!!%1*0,`49:#`PA0$-/(%!/$``$0("7)!1`A$C@"'`!5KX8-&.%C&P@D(P
M0045!4_P$*1#&@FI9`4%*"DD30_MR).311V%DD50-@1&DU3^8086!&"QQ198
M4&`5`4FDF286;":QQ1`5E,DFFQ3468&9!/_420&8%4S9)0-(651!1%UHT9$"
M#[#E15<^M?`'$5YDH!`1DFK`A0`J?"05559-Y8=6?^B`100);:&$$D*\,`&$
M$P"1W15"C`"`$@XD89$!%TS'A!%/O.`;`!\X\`(`!OAQQ1-,$%05#P1AH401
M/[270`50L""$$@R^`(1[#CC`Q`6>@28::1&]0(@?*ZP1Q@`!2""&$QI\,,41
MRI30`!`&&/$<`D)P`$0`0MA7`@#Z/@*#$+,5<H$0)4CP@@E(&#$!`!/`(X`!
M#PP@P``2)%9?!><EX(,37`1``00,%%!@"2?`:<4%?H21"1D4H'&%&"Y<4`4)
M)G"A!!``D'"$`U/_^(`"!5H@8`(357"P!!0,!`"R#PA$40$7"""P`PM)6&$$
M%2P8@<42+D!AP0L?#$!!&`&40-[%8%!5D443".&'$@HQU"5.1#IP9$-C9+DW
M23L-SK=$.QI@>$M_-[2CX`EAP26566P!*DF->Y1%&(-GGE!2?B@.4:$1?<'`
M!5"4($841R1Q!`I)%"&%%7]@P`*I?[0`Q!A_1$'-H!YMNJRGH.K`PP8)K7!!
M`E+`\,,')OAP00P)7/"#!5-\($&>%"B/!1A@7,`%UG7ZQ\4&`0QP0!IDC(%&
M&H1QL:@.*Y#A4Q=$J$"$#@\4\$477UA#&A[@!140L(`/^4QH1C.1(9S&_P\G
MT$`#+O`&'_QA`],[@1B"@`(F&,`**$C`#*+@A#:@80D,\,$2)L"(-USB!W#H
M@02H8`0*&``!,C!`'610`K=Y``18:`S/G-"`'WB@.TBP0PR(!8`$!&`$&I""
M#!JP`0$@@`,CV$(,!2"'T/DA"NF3P1#2X`(N7*`$`^CA!V"```@((`02P$`L
M"*`!&]A``A7@0PX:<(`'D(`$#4A#"#;0A@7DH`U<L`,-;D`$'(C!`R0X`!,0
M$((+/.,-8"#!"AJP`"WXH44-*,$*!O`"#0!I<25Q@44\5P#(H7(B6/#3*SWB
MRC_LB'.S]`CP(/*XB&#A`'O+@AA<XCF.)&EOQ?\$';G^H`=)_:$+`9#(%HXP
M`!-<H`!;J$,`SJ`"'G3E#Q`@5Q`(,"@>U$$*9="4ISJ5%84HX"9_L,,6%K`%
M<`1```T8DP;P,*8Q&:`&6[@#"'Y`@1JXH`(:J"$%:%`'`]1I!TN@0!02P`$I
M2$%/%'!"%!R0!A,\83H,8(`#E'"%&Z"`!5:X`@"`L(0B.,`/AD*2N!@HD2@\
M`1,.3<$+.D`!&R"@#"X8P1$H(`8^D``*8BB#`69@`!]HP`E(",,"P("!.A0#
M"0,8005B0`87^"`%!NC`#"PP@S@<H0-V.,(/EA"`&,``!3NX0`!^X(0$_&")
M.V`"#WPPA`:X8`Y0)0#_&.9P@2BTX01Q&(`?MG"W!@Q@"Q,@@1/$&H,[5,`$
MKV#&$&I`A@;T``L5@$$)2*`%$+@`5UMX`QH:<$/65C$.08@'`ZH@@`\<`@,-
M>,$('!H``VA!`E@`00?J((8=B>0/*C"`&A)R!D`)Z0PHBD@9L(`0B?!@E1FI
M95&Z<(`Q<!<-:+B+>,5;A@$P0`S]S$(9Q""&+#PVJ4D5KQ@@,+A:6@0($O"(
M`GJ0`P/D(`!YH,!6W\4#%W#N`C)02`XL2`(6&,`%EW.(?9/BREP$4Y8O<8E[
M.R>`-_P@!04B0`?4H$P22,$'0>A!'2I0`0L,0"(Z`(`42@"%/HB"`#;(@`]`
M_]6"I;#A`5$(`@"(P(,9O.$%N..(\'P`!>)!9#D4^!D36/!2BS@``0R@P@0"
MDH`G2($!Y#1``@!P@090(0%Q`,`16```$R2`S4.8P0Z.$`43V/D')P9R!9K@
M@QA1X1.ME`$%D$```I1@"PF0@!P2.--E/H0`H_$#&0```P@L(8<8*$,9[B``
M`GSV`EG[@!B&X($2A``%8TA!`XXP`B<`P`%Q3@!T$-`!*$`A!B"(P0<:D`,P
M..$%6AB`&!*P!2(0X0<".$(9$$`S``"@#@[@0108L`02V(0##I6`!GY0@@\@
M``1^D(`??``!&6@!"`V`P1U,X`0$6*\*=ZA!`VJ`!?\/'``&8JCD#!!`@"%8
M@`0CR,.IXT`%!`1``RVX`01^<`@P!(`&`4@`">(@!@=48`/:/L(%0C`'"[0A
MGW1SU!\48"4OL6!):-#,&1Q"A@2,00)DD$@)L`N18W9I"%K(>1<4D(4N>*$+
M65"`T(<^]`H(8.AG2+H9S'`&H:M!`2M7B`#2N;<C(,X!0-!N0Q(PAQ?`(`$0
M4$(62M"#'4Q@"\`<FT*@H(0S&`$%)5#"&B(2`P&,:0!S$H`MK^`'+`B`$*$L
M`1;$,``,"RD+#7#(`[;0@C-\X0LKR`(&QI"%`W2A"RQH0Q?(8!<2J&$!?_C"
MF([;$)M3B04<>$@;E:"4'>S_X2%@R*]$0'T"EL3@!UL`P`.H$/,_\,$9+$A`
M"?[`@S>_``42>'U':!"#%DQ@":EHYT-LH(8L?($$7[#!6Q2`!PCHX`#<MX%0
MY%"`+K2`#Y=O@>4O3P,Z=($+7QB`^=TP@#)D00,!V`(9\N^&,/13V4>``)JQ
M`W!``"+@`X0@!;+':`OD:`Y!`$"``'X0`"B`(OER`CZ`!OGG`N\2!SOP`14@
M!1P@`080#$M09E7P!",5`%4P!QOP?%0`!770!`N``)NS`VGT`_4@!@`@!C(0
M`R/``F#``!O``#T0`US@`N>Q5Q0P0UAP!&/@`D:`!A*P`5)P`$TP!WX@@9L%
M`R=P_P5=L`,>$`1VT`9-<`1]``)ML`,Q<`(D<`,E$`:4Y`-D$`:@=@$5T`5[
MD`8:8'DV0`(GX`H(,`(2<`$?@`<2\`-MH`$%T`U+('$!D`-*H#$!L`&>9!%1
M4`(\4`(3,`>$P`-Z4Q1GX`)HL`4&D`4,$'5_0`8QH`8&-@1Z!Q&J=!'9-3A6
MUQ(48'@=H09:AQ,)T$EB`%P\<`$QUTL>\0$,D"IP\`<FP#HMD`$8\0!_P"8)
M\0!/4`0&8"I,X`##!!%*T`!"EP9#YP*VA"4^L"AJD(Y_,`8H`'I=8GI_4`!^
M\`%1@'='4`3!D1)*P%A7X`)#P`1($`50``2AQP!:P`#5I?\0\*@D*`!,#K$%
M`L`"J^0"2:80%0`N$A$!?:``BV8!.8<'#Z`%=Y`0(D!T*Z<"20=U(T$'/H`#
M$T``N2=]#F$`0B`$+0($4\8"VR(!+"4'2<`$)H`=1P`$0G9\=&,13:`M5]`J
M*0`$0G`$$W)?4;!E%V$!?,<L$M<M5J`*5:`$+^``;"8$H5%SC381D#9S,\`$
M--`$.)`$&I``]X8&G=`8+L``6&`%`K`#&H`P%-``T:,$3/`/)H`%;@`#84`%
M6A!6*$!F2^`&6M0!;8``%O"4'A("12,"6'0Q]K"$6O`!%.`#4T1P%0`&?3B,
M52"/G\$#97`!\@`&'?`&![!99*#_!$N``*-T.C,P0Q_P`P@P03*@?QK@`U4`
M`@VP!DDP7&$0`RYP##VP?Q6P`BE0`C-0`G$@!#>0!@;047F``[%W`6-0`1:!
M`@I``DQ``BA``V4`!S9P<D\A`0T`D\NU!3XP)@3``DVR!CZ0G+TG85:6$`MP
M>9>W``LI).2(B[K($5[0BR[Q`FB@`&;P=%!'CCOB%!U!!%=P`1,0`LQX`G`0
M30Z@$&2`!6=``*-F!28@`4DP!D_0&1#!`VGP$%R`!H_S`P\!`1/PHN_(H@KA
M!4K00W&B!CP@`350!,SX!T+@`PF`!28P!'#&.6+"!.ZHD#'5)2_`!S6A`'.S
M!2+0!P\A_P93&A%LT`(_YI]Z0`,.T0)RT`4@\`=R\#_.-!)=\`0V<`4L$).?
M`A&R("Q'H&8)<`[T\0,O$`),<&LN\`(2%0#4%@7U]%L2()D#0`9:@`5LH`$&
M<`<?0`"%(@!GP!40H`75UP5IP$U[8`8JT`<1P`9L$`%"QZ6GFA%E*1&2@`DN
M(`$C<`$I$`4$D`(OX@&@I@T8T`3F)`!N$`$4,``]X`([@*1P1PI3T`%34$F"
MQP`&,`80(`'6J@4S``>0:04K,`1B<`1E$XGW,@6Q<!Y14`"74$-18#U#T`0K
MH`$SL``#L`'AE@D\X"%`D`5!548Z8`="P`=-@`<&(`8PT`#T2/\'AUB%.X1'
M"B`#-]`!*](&1A"B7S`"#2!52P`":?"N:.`AQ+(#%HL$>@`&`PL&.6<13_`'
M1\`5/)".DD&012$&8$`&6Q"/%R`!6N!S/!<#(JH&/E``7&42MU0!^;2H$H`+
M@Q,%#_$%_[D`9P"@``2@0Y`%8U"S"@%/CV5X$*"@+8$"$+$1K-=W(W&>";`"
M&3`!)@`$,[`"$]`&"6$$+P"4+&!%7CE1#+!<$&$"AC<`7"`$*$"',?`0:Y"+
MP11-#>$%/N``"6`"-<L#4(`"'VH"-H`?5Z"D'N8'M]<[!XF1"LFU)<$#(M`0
M[H<$$E!E"1`$;D`&-[!U7PH16D``"8#_`CW@!K-U!0\@!]+X!P0P`@G``"2P
M!'$;81[Q`'%`%2Y@I\*;$'H``FL``6D*M70@?S2@?M[%!V/@`6U0?Q"P`)UU
M`VVP,=VU!1)`"!<0@,4V2PHT+F;I`.+6`0P@`BL`MV_2!2E4`'$`?6*`AT\0
M`A5`!O#B``$P!'%@`;"!8"X0D8@Z`)Z9!VAP`210!PG@CPA@6R=P!#[P6'"$
M!"%P#PA0`WG%`^^1`GQ[0SG@`K\U`$OP!@-P9`W0=YD@`#YP`A.@`7,`($@P
M`COP`@/``B30-@BP`0GJ!0TP!E0@``NP6D0%!CU@`)SW``&``&%0!SM0!S#`
M!P70!"6``7'`_P5OH`!)@`8#P`H'<`"+,`)B<`+)\$D9$+@*,`%L\`=:P`=2
M4!04(#7I5&9XZQ!?P`,QU[];P+F18Q%*4%X/X0.>BSD/X0+=60:+(`%EX`!8
M,`0!P`,+H`:<.P9^\*)8T`45L(`)H0"'/!(OX`4)M`:]NQ*YY!$FD+QIL`!4
M&2-?.W?OF"4)Z@,"X`)D0`-`\`(5@`V9P`(C,`%%,`%7P`2FM%@.0`!,L)\)
MD06&VR5!$`<-@0'7%P$HT&1+H081H'PDN6@3T0(5,`<F+`2P\3F&ZP)ZX`0+
MX`,_T`,X`00N66@`0`=70%\/L:=^X``3@`+@:1&0!01*\`3X,0$\`/\F7CD!
MWK($_P($"=`M3-!W0E!-+_`$-8.^KQH1!'!E?G``N&(!*6!U+I`'&E"/*D`&
M30`$5!`"4M`$/T"!8F`!#=`N/C`"5$""O-D`=E`%H'4!1L!5=$"K>``&"_`&
M.]!I6U6(4$"_"!4`8_`#0@#"21`'%#<`+A`#'7,$9!`%2U`'&'``'.#"//`!
M95`!$T`$'R``'8#66I`$,<!#PA<$`A`)8H`$8,`#'M`!,5"L?I4%4%0'IMA?
M9S`'!7`!%G`$D?D!.T!Q!\`#.=`"(R!#;``B>5``(7")0-`'3?`'9P`$TM@`
M&&!!."$^9?9,B3<1Y*$&3!P#O*,06/!%E9O_O&(0RA\!VH`#1E&`!6N`!4C*
M$[$D!IJL$'P;N%C``TP0BPJQ`++M$2^@BJRMLEA"$FE@APC@VRB0OPW1!09`
MW*3(`&#PH1Q!`5&Z$`0`:LW(!&5P!%C`!1%F85UR`&#@$%[`QVLP!@NP`(5&
M`&%0`%J`!O.5<^!0`'.7LSJ7Q\V<W!W1!J'[D/E[!5=``/#D$&!`H1&Q`/3!
M!&>PSB_V!TV0!PGA`C8PDAD@!B-9$C]]!0<`!#@R`2MP!:V;$"<@``'P!DR@
M!6$0HJ)$!R'PGI"J!1R`!A`0`@)P`&4@`%\@`G<P`U[0!S8`/P4``<V;<V?`
MI:^4OC2%T2C@21T`_P=GP&U3<`<-0`9E$*(2X`,+\`+(L`48@``#@`!S\`H(
M,`4-T*A^UP$?,%@!0`4EP`5#0`8B48AS50)-H`$OT`,#0`)!X`1470<BD`!)
MD`<P#,)`<`(O@`1*90"[!0584&:7$@07\`0_X`<)X`9KXP`:$`-,(KY]NP$#
M4-0E(`!D=0%VP$EB@`%\@`$&X)$WL``)0``OWIM(@`LJX`-VD`99<-8Q70-:
M$`5UT`7_,0`>X.A<(`%IH`43P]F!^P<X6N/%Q!%D%`8OL(Z>'!&6_`=J4`)E
M$(K3B!]"@`7AG1"&G+00D0!1X`(,$<E;,'>Q5`*\S5Q#X"QG4'^(:A*#@_\`
MX5T!`;`4"Z,$AYS;!>`#!Z`T6'#']BRB%#`&>(<%+9[(":D0:=!1/J##N`02
M!_H4HJ,0$=`&_5-=.E``>O`'>S"2^DX'":$"(F=,$NXD8$#*#XD&UU45!E"1
M"=$4'A$!44<'`@"U70#&76"F.,$'0D#,:3L$6P`$*@`$&=\01)'*.#&F'4'E
M#M@0!/`$GF0RO44&;R``?74!<$`"Y,0``V#+42`%4("!%$`%%``&1Y`L3H1;
M<1`%(`!W#*T%/^`"'"``3L``1Q`"#-`!)E`!=H``4(`$!8`!8O`#<S`#9/`%
M+`#""7`'"5#!#8`$=1`$9LP*3-`"=S`"5V``T3;_2@C09T.P`/.>`'P0!7F@
M'H8L-FU`V'Q`28:/312.`1O@`CE@@%QP`V&0`A^P:P$@!FC``=HS`G!@`>BF
M!21P!C:(!@2P`%^P`0?@!Q,P`:Q53S"Y!49P:CCABA2P7#]`X!(Q'AW^X.EN
M+&301@Z9$'@W.(`,W"X`"%]D?R4Q72YG%65H:U\,6Q0!%W\Q%6`(/B5_FYQ8
MG)^@H:*A1Z!F:E@0%"Q`%*.C9U%C8`M;#@.;#@&;6%E8:P0,"*^?)6JA"PLF
M?A-:GJ%#Q\33HU[/GR1_&[58,C8,!`8%"E%9/R8=435_#!7#H[[4\J19H1AG
M/$]^41<*H&Q=4LSCQ,2/_\&#!Z\P&0BJQH0)5Z[X(8#`RHTK71ANTI/A#YT6
M?`X\V$2G2Q<:'P\,Z-("CX`N#]I<0/.RA9Q:/Q!H\)BAC8$G"6I<X('@A808
M*#2\J#&$A0D>-%YE\9/D#P`"Q`@`">`'2Y422!#4*#``"I@27`94N>!B`(HC
M1EZ4@<(#1``7;N3&Z"%APQ`!9BS`J$,AQ8<%%$JPB%&"Q)`32S[@V2$!#98Y
M!`3$0`,FC`,>/AS$P=(@C0P\,0Q4^+#%R`2$-:[PX$(&!A,/1[[XJ-`@1`(R
M8#XPB=$`2!H+;B1\*:$#R0(C!/CT&+#"``DT""Z0D".`1)8V(@ATZ1&`"Y8A
M2O\ZM.%0X@>7L1HP[,#AYPF0#7RR+'BA`0L&$D]H!$H)880QR#P^?%'&&*!@
MX0<%71V3QB=@_""@/!:&LL8:?QRCQ8=IK)%%&E@$8(8"7GC1R!\*G'&&`F:(
M<LV%KY@@(R&OS4B-&BZ>L<D7"P"9A0%:=''`D3X.=`$$H70!@1)`*$'`%J*8
M@`:-T^C(XA\!=%F&`$-@(<`&!9B00!9>^!!%"2&X0,$`28JRAI98?N($'`=T
M42077US0!P\3F'`$#09(0(8E)5Q0@`L:`4$&'TP$L,<%<L2P0A=`T"@`"RQ<
M(0,*!`1PQ0-`',!)#%3^H0<34?"@``\+`,'"!"SXP03_"T(PL,P/0(0!A`^O
M.<#$"BB@0,$1!@7`0A1\^:$%$"L8E(,3-P"A1:<Y%)&$#PF`@4(2+%"Q!@!`
MF&`%`"[((1555F'UBE87^/%&%Q=4<(`!(92PQ1MMV&#'%HJ-`-T1$O@0QP8$
M(`%&`@$@;-8;,P!1@@13[M"`#QKL,$,-%%AA0!UO%!H'`A_`X<,9.Q"A`0H[
M5*$$#P1,`%T=6]@!1@P(&,"$0@W@48`4\@K!`AL_:`$`'$ED(4$"':#!@AP#
M4.""!G<DP,818.0Q0`-:S(!!`R.08,<,#7!10@=P:'$`"2Y@P4$7;APA@`#B
MN,!%$5#D08`&;PP@@`QS_#""_P)^,`#$'6;=8,(9"_"5*99J5,`$A_,,8`*#
M#1Y$!N:?'.%NG:*X(L\"GV#AR1=_?(&ZZAE50R?H?YC0>NFQ`W'$Z_/(^H(2
M`/3N^P3U#/3#+I^<(<8:)CC@0`D#:.'BCV.0$3SL#8X2@.EKI$$`"Z2'80(%
M6:#@7@5H&$TZ,;C7><0#&2A0AA8+J,'&'SP8Q.@?#RC0H@)[L!%"HUH@@PE>
M\(<$;,$`"&C!!+"D`RU,0`$..,(!_*``XW!""BC8!`A\P*D?U.`%"(!9HB0P
M@"T4(%%W&$$?>D"&+@Q@#%OH@PC2@`<:?$@.-A@#&S;4!PSL80'\H\$7'M`'
M,SQ@#_\/8,/S5,"&")AA#VI0@0+F-XVI5.4J6;&6'XSP`1)00`)5N(,$XA""
M(;R!`EQPP0K:``4#-&`(`3!"!7SP@98MH2Q'&$`(&A"$"EQ@"Q^0@!,"\(,E
MN.$'4)"`!':P`2B4H`9K0($#G+"!'"#A#BB0P@"6P(-9<>`",B!`!.HP@A],
M``H=(``:P$4`/_P$"&.X@1B4@($V>$!P$L!4%AHP@Q%<X`([X,`0\!`&`QP@
M"V5PPP`&$(`02,`#`Q!"&4!0@C)`X`@&$L`68'`!.'!`#$[`@P]B<``)D$`&
M8>B!'3:@"@$8)%-(V,25_K```S``=@U@R`+HY$Z#Q`,4`K#_$?5`X8-1H,$`
M6T@`%]*`@B%@90NFT\(%!H"%"D``A#Q`WT!!<8$DH8YQI5C&"])'#1NU#0((
M0&D]3#`]>5"@`%QP!A>\,),_U,H/)E##%@9P`2QHH0)FV.5&:2>*`AB5$TDR
M@QFP(($6=6@3,2*&-8;*"5>-HGY^8,$HNO"Y>:!`"VAPV1JFH`,F'$`.?@`=
M$"I(`"Y0T%JBP(,6MD!7"2"`KENXP`'FND@^`$P%+B!#)GP0`:K"SHKMRLH$
MVN`''\Q@"Q*P@`&:4`,?@$$&%^`#&<(P!P]@H0@SP((&$#``$<#A`B>X0`K^
MM80C>``*'^`".!`0AK7%P0E0N$`@_P'0!A:H@`<,2$$<9%""#S2@`MT:0A0<
MX`,@X($)`PC"!<@%!`^P@0PG0$$<4M#*+9!+#%5H``#L,(`ZU$`"82"!`Q*`
M`!)PP0@-^"4!.%"'`)#@#1((@!AF$(8//,!L)\@#!$!0!0B,]F9CT,(/L@"&
M$Q@`!$+`@A?@D(,90.`-4^`!&3:0!X-,@`WWLT(;_M"%-U@!=A70")VF8I`%
M:`(4!"BH8447"E1`P`!A0('I-I&`$F#A#`9PP`NRP`,72"!+AOU#%-9@G@I@
MX0*+B)T?@$#2:=C(`0S(P@6\P`(QQ*ZE)7V%$("`4W@<B*JY.8-)3)*,+ZS9
M)#YB\P\,T/\%-Q=IKGB=$E[Q2H%W4/4#<>`!!?AA.@J`H0*OR:`HSC`)ACA`
M"QZH0`A0^@4Q[*$%"ZG36H&@RK=J011;J`]./4SF%_C!`4`A`%8-`(0B)&\Q
M2:X38K'X"BUTQ0\`JT*7""`#!U2``!4P@1R:$([^O,$(1ZB##)`Y`PG4P0`P
M$((#I)`3`60A"BY@00Z,@(`W?&`*$P.E"\HP!`/$&`$P,,`.$("!.E#!#6RY
M"A`6$`4D$"!B5>C`7:+0!B.0`0D^\,,/R)6#>@&@#$5H@`<P`(`0+@`!(\@#
M`DJ0!`.D@`-4R$1[?^`#"_C"``(XPW0Z4`,('``%/#V`"1!@`3C_5D`"62C"
M#P3``2ZX`0Q!.$`#3K""-'CX#,1#@0Y8)(,BP,[/\H#`B@^2AO=1P'2\,4,4
MDORZ!51@#.?[!3VWT+8P;$$-$_J#%E!'#!E35:!5,DB5B;$X!R!P"._;A0EP
M,9#[B4()!C$!`2A@@KY30-`N"$.2O?"APM^Y\%[H@@(`,.53(\0!?FB`_B;/
M(QC!2*FQG@96T0X*KFI$"!`!PA4@`A$A/$'16+*:K,C@:5%$P/+Z8T,&^I`_
M,\1)!&N0QA\*>\3,RX/LGYAU5T/A(`=)`0X].$(0`,"!'6!3"%-0&AO!(`$A
M^.`''V#!<;70!KX?8;P=,`$26)"%#O@`_PD-6`(6MO"#)@R@`$((@@DL,(`Y
M!,$%/Z#`RG[`ZQ)D(0A1(`1:H0`&<`$2P`0,8`!N,`(S(`078`(U,`4]X`<\
M0"ZC<0,`X`84\$U%Y@()T`!@4!@28``4D%I.P`((\`,60`(-H`%N<!X>(!0!
M4`(-`%$7@P:*$@=H,0=;(`(^T`9/$!\VP`?&\`-N(`/G)08'T04S0`</D!OW
M@@!*`#IGP`!Q0@UE\`(%$`HLY@=@Q@EV-U13)R`[)B`90E6-EG9=42<FL`8?
ML@!:4`!Q^&4,@3O+4&:^AR5*H`4(4"+M(`8"\%,RICIJ9A+`EX>OP`,.L"RC
M\`##1PU2-'GZ<_\&1Z0">P`Z`$`J!T=!0O!IHH`Z',$&-L$23J@'*!$3$(`2
M`U`&:=`&%D`26Q!+`H`'()`?.:!9+D!79%`"/,`#6%`#;D`&(F``/"`%`A`$
M=``%`!``1Q`">G`$12`'4X`""2`$+_`$.\"%[$)KH^!`'M!8.X`%4R``)1``
M42`!,/`"'7`$3.`$$C`$0V`"/\``2-`$OV8`/W`$1[`!/^`$;S`$4A`$9(`"
M5/`&%],$/-``"%4&[]@62!`#`^`!`3`%%\!K>L<"9,`"/_`90,`%Z0@`+!`$
M6+`#UM<$8S`"%2``"4"!O;,">0,`,,`"8[`8!X`#0+`#;;`"`;`$!1C_!RA@
M`''``5)``*J4!3(`!@V0!7"P`7`@`$M@`5H`!Q10`3-0`#^P,$'P@4P`!DQ@
M!`EP`2AY`VT@!@C0`!_03Q/0`@=P7E'P:R`02752A?DU$/YW.:#0A5_("TG&
M>0,Q<7_@(F3W47!FB";A/&8W5'X$,XK9BQ(`>6M((VD`!`X`!)19F9)9*@Q!
M8Z'@`!/P!'R)B`-A(S[0`#]0:*Z`!6.X)KS(!2_`.:`I"CQP!4\``*]PF*])
M#)L&`!.D`$_@B7]@`!RP"6RP7D>@``W`F:"2!`^!`E?0`"@0!5&`+$_@*Q(`
M!R6P7@@`!Q/0!#%0/PC@`%<``"5`*Q/@`DL`_P02``!*D!/HD6%;P`0R<`(3
M,`<?<`1G,`.<LBP5,`1NH(U7](B?\"RV!@<[8`!&4(`C4`)2``-W0``20`5#
M\H%;0`).@`1:4`)&@`4A,`8]$`9+P`!<\%(#4`$R8`(Y0`!&P(IE8`$8P`%+
M,`0X"0<IP!9A(`!D,`0=@``IH%!+T`0""`1TH`4[\`0M4#YQ\`(6(P<(0`!E
M$"\(0"[+!`,-YP0#D`(8(`%:(`0?P`$+T`#U9P!0Z04\Q6EEL`91@`!C<`()
M4!)UL`,*,`1<L`(:,`0&`@=M8*%D$`!XT`(L<`!;0`8A>@#210`M\`9=F`!!
M0`$Y5FD"$`#QA"4EP/\(+R8/M/D%6O4);N5/R?!F7;`%&658/H8%%,!W6*"8
M7``SJL8#3\%WH,$#O^1D%?5DIE.1P`91.[6%2?8BD@@!67``ZJD$3%`D77"%
M\J`&DGBL^J-BKZ`$#A`#GWF;T^`*/X!_/D8`&80%`C6J6/`%E@&M5V40M#D*
M:R<*="`"%U`"@V8%454G7*`&0```:$!!`.";6```'4$#'"0$*G@L5?`"/#``
M:/!K=!`"`Q!,!.!_/5``&&`!8``!&(``8/4%(E!G.?`^\),%:.`%!8`#"D![
M"N!$D^A$IT"L\B!\Q""@?K!P=D`!)``%-O`!*1`$$G`!;<(!!*`%1G`!,U#_
M`FF0'2Z``$Z``$=P`IA5`2_P`S'@!4X``Q2`0;5@"3^P7^Q737&$`![04R?`
M!S)0`>Z0`*JF%1C@`T4P`$%Y!\(4`C/@`RE0H@T@<.32!F7@&3O:!70P`T;@
MJR`8`!0P!@B0!'-`6P<P`FU`J`=`!GC@!0)0`%M0!E)0`DX`:`A0!Q[0L&0P
M`F)@`P[0!EAPJ@0``WS01GPP`@B0-6\@`LS@!URP"1$@!)\0`S1R!MWI(Q+@
MFJ\0`%L8!D-P3YS`8A.P`%^B!5F@!36*)MXZ('W7=R_@``00CPDPAL4+"F?`
M!0E@`BY``*8FF7X0)@0``'IWB/*PA3`T5[0[#Y,:_PIW^*S/:[Z$4`$T.`8-
MX+K8N@E@<`$4`*(`ZJWYX`#A*@KERQ",YK4]2SF@\P0*(`0`X$X5E"I_($67
MR`=%ABIH]`$_*P`PTYW!F;X"8K*U-@%@T!4ZR%-+,`<;,`4G0(X+L#50<``[
M<*9ZE;8QP`=<,`9E8`42(`50X`00@`0@,`0-H`+V%P,:D)(E4`%VP%UG0`-9
MP(]D8+4'4`%X,`)FJ7<P`P1B@(`P,`:"\@,EP`%DP``@(`9'8&O3)1M"``<`
M\`,L4`5,X``>(PL((``P$`,;D``D$`<8X#?AU04<5P,;``)?$(LE<+DL(``W
M@`4/T)]D0)9ST`$'X`$&`/\&#-`[,SL")I"[6B`%7*$/J;('0?`)FLD0:P`K
M0U``:^`#ID(,5OD'!9``94`\FS`5H4:R&/P))A"W6!`&8.`"`B`!:1`&K/L'
M8W`&7\`%NOB:9[`%+T`!72`-#L)X2O`.:N`%6R`$/."]Z#,&#D!7/H"K&H&^
ML2,$\3C+;+=GW].+]2M0C?`%6;`&W(S!6+6_ZDLC10`#!.`3_@`[:S6;7=!Z
MH<!UMG*-$T``3&`"NE(X3T`!A27.\Z#!W;A8?E`!M;$!`9`%`M``Z?8!'2`'
M/X`';<0%%&%O<1`!+2``M$4`7C!?$C"A%W`<9+`%%?`#&O`!8"`&-!$&=TH&
M=>#_8_FU`A]P`D[P`"0@`(Y(`$^@%6'@!P,@!URP`6F@!3T`!W>0`JF1`+:6
MGA-@`R+P1G70`0N0/3"P`FX0`7F``2<PC!N`!UN0!UE``UY``R7@@WU@`7`0
M!A$0!T90`GCP35YG!TMP!F.P`61P`&(@!NET!W"P`%[0RG30!S>0!1B`!X03
M`[C&"2!`17^08I#Y`P5``6>@!JWY"JO\!0?@`V@0AG_0A>>CT*#`4@*P?D=P
M`0X`/ED@4#R0!01@.@DP3WEX`$I``6''":P7`S%`?J"@!@3P:/,`)HOS!=X\
M#6D("EI@`J/WR:J]"35(E-9[!![MT650W:%0/T!@VK2,_R4U0`=8``48T,Y8
MDIO[')F^^0DW4``'4`9&,D5G<`/'I#]!=8G>30P,+0H.U,$Z'`4[T`)3T`82
M<`!2P%XGH$G-B`1(4`%2D`8AP(R,80!!<`<PP%1SAP5O$`-DV0,TP0-+$`-(
M(`45L`$5<`<[4!89^07=80!M\`(&H`$,X`!2,F]7T`-C`'(0*=@<,+H24`%O
MX`<N0"[E,TX!T(<&`&US\`5Y4`<;(`,-4`-;$`0#L`!Y$`-UP&`#P`$K,`8S
M\`8($`(]70./S`$!$`=C4`(V(``^4`,RX`(-T`85L`,C0`!D4`-.+0XX1C@&
M\0)`\`)R\`(MP`FE@"5C\!>N&_\Y[[T)T7L!:@`!0R`&/B#`KWP07M#?G,!2
M2H.M6A``*+``L[T)"*!0FT#=258`0)"762"9K^'*GX`&T"4/:\#!/A"_%X([
MCMG<WMT+G/ZM654C_;U6*```^[P&<!7LT^"$3N@1;F83APX/VWB_FV!K;A7(
M)&`!#=!,[+4#-0`&?%`!)%`!(/<!>=`&'1`'`D`!<!`$;\#G`Y`#LSL#+E!+
M=T$&+G`";;!+8E+@`;`"41`'2T`"$M`#']`%,&!?""!+%*"\]R$$*R!I@FT'
M6;`#0QP$8*`P?G`$*#`!=A``(\``2(GFQ>0!*!`&)8`!9O`&&R`!`A`%+^\%
M(\"WGJK_``@`<&Q@`*:U`N48`#,@C!:@DQU``R'P!B?03#O@!F^0-6C`-AOM
M!(1C:@F1B9Q@[?-P!B6@8%MHVRC``SXV!"^D!HL"!@:@>[N;57X@RPKM`\C4
M`&4POS9*3P*U>`(4W8@(!MM,[1+A!P(P"LCSW*^PS.L\.\H*O:1SOLQ.?+*^
M^/0#KJ^0Z-6]5CP`!"3`SZJ2`YO@!LZG:FG0BZ#?BU"P00F`!0DP!3_P%;D;
M`%+@`W]W#I5\!(86`U4@CV;,`!CP`PE`+E,@!90)`&+`*4$PT&'P!(4@&TWA
M!X(??-5^L@_B!S.0!PPC!A60!48``@M?`@8`!PZ6!U#,`73L_P(PD_-O`%87
M@`%.4`5X$`58@.(:R@!#/@!:_*(P$`48\),A$`-.8`$Q``@790TQ!%9'+$`$
M$P-"!P,!7#,Q-00]'$IB8%A^/$=``E`055LU!S9#6`<U=0T-40%8/74Q?#,H
M+EL\:6\06'$T!@84(ET#)%P$&&T$.Q(N"60672("(29D8T<D.UD$?$U??A-^
MY7Y7+P!T?W\][._P\?+P7T=?"05_9%D*:G]H8OZ<H9#EPKP_6<P=.,BPH<.'
M\;"@X$$1A1"*``"8>'=&C0*!$$,>'`,DW\&$YK(P_/(BC,B7\K#$XS+A"@$6
M?DQLA,FS9TR9/H/VY%$.`,.=0I/&4_]2AH<0/'X4*)'PKH(/=EL0")F@A(L1
M!T`<1+&BY(D8)P0`#)F2!`"+*A.TH'``A8`1`CQ,'$'!(0`#`A=(#/AQ`$8)
M!"4:&+F@)<^-/"(*=&D`04:!`@(6%-"RI@_#A$G^`"#04(L?,GXN?$$29\>4
M.24.5`A1ID8;!``Z&!B`QX`'`Q6,;$#P.PP9'D]N'T@CX4(%`D\$Q&@3(@R7
M(BN0D/@1XP02.%(,_)`P0DR%2$X430!C(D$)`01)Q#!L0$L,.2,Z`0!"PH(;
M`C)<0``>ENUQ`AI;D!%)#3^<4(@8`@@@!Q==>(`'&1\0(4`9`8C`@!9SC`&#
M'0,$Z(8%<WC_0`(%$`2P@@L;4D"""UG(T(01-IB#`@`)8,"$#UVP4X%2?Z3Q
M0QH48-%`/`-P\4,6/_@S#TI^0$#DE?!LIL66$@RAQ19;HH&E2&<P449#*`'@
MATHK`6'EF/,`Q8X!YM2)%)QP#B`GGF,2Y8=1!U'`9U`\M`'`$V-$Q<,`[YQ`
M@!E_W,"&`F=$H,8-*JA@A@)]F*'"1UU`H(<("]!!30%ZI"'"&2W(488-=%`X
MF19D5$!#&P'D$$`9$M2`)VBBD<:0%A.@9D`'#1C`Q1TC&``&`E0@<4(%8)10
M`14Q0$%&#1*`84`6%`1XA`1+1"%#`#]XL4,=+$C0`P$E;!'`$G#$_Z!!``<$
M8!46")#0P0([D#!#LG\IXL<3SV`1@'@I%#!$%`):,)A^0#0`!P@LB&$`$ERX
M$8,J%DAP0!<2(%%&&#.0\(88(^@9A0MBC`%A"!K8,40+#81@QP%X4`%!%A\(
M,`86&ZA`01X(@/`#&C/D48,`2XCQA0+F;,'.'BA$D`$[>PJUA@G*RJ.&!`V8
M\,5G*0TZ9BQJAR3!$0Y1N:9#`230-M?PB/%$.1.0D]/=5TK0->`]Z:'FGT<1
M[A`;91SQQ!5[`]"%'UWP$,!!/+C0@P]"`%&$$`ETS@`04<P`Q!-J(L"#`U8X
MD``Z+@BQE0,R,#`!"D\\,003&UPQ`4Y/,/_`0`MP`CM::1,$X,<678!Q@1>L
M->!"`%W$6T8,#710`PP2(!"`%F[T0`88<,@@0!X;U($$&@QPL&P,(0`@P19(
MP&#!`3N4,$`<5<1P00,$J$$<8,``"^0A!F@H`12$D`?D4$`",SC!!3#@!@.$
M0`(6"$(`)/"#"6Q@/P6PP!2&((8`H.$".8C!`7@0`BS`X00(8(#F&I"'%'R@
M`'GP0!<H`(81E``&'EC`"A!0@P+080-\2$8*N""`$D``"25H@PC"T``\2,``
M:#@`!A$@``,TH&KO@-L[!A<4+XSA(&I8P!K0E#;%!45/;IP'!$SP$30]P0%^
M``*;&O*"(+6M:U__X`(6"F""<K#@#''T"1;(F,AYM&&$)J!`%,P!J'G<J9'@
M8((!!)`%,1#@3Y-3@`.$%8\O!&$)>1B!!&)0`BRT<@`-")`</*"%"@S`#A^P
M``DVL*7ZA.%+`O""&PIP@P5LR0TZV)D7LI`%$&C!)%@R'BGG81H)^&$*`DC0
M,`;00S#,P08"F,(*L.`#$/#``@!`@AM*0('K70`&0`H``/"P@PM(P`07$(,;
MM&"`+2B@`VZ00K\,X@(!-8`,(VB`!0H0`PF$@3'(X<#K>(`&`WS!#9.!H@%B
M0`8JT.&3</`!$#"P42BT(08W<`(%+M`#`[CA!`?X00U*8(0`"&"#?'@!_]30
M$`0(S"$',,``!#[``4A<8``=:,(8%@`&#5@@`&$X@`S>$``.9.$9<K"!?;B0
M!BU020(TZ$(76"!6L?Z@D2<QAQ?0"A.VL?4/TGM(%OPV-X>$84A_/(HY)@``
M'A!`"V=[*T/$$!#!RF,.+$"!&#SSARWXP0$[2AQ;70"``2"2'4^H`"C]D`8A
M,,JPBI,F\CS@!P/,`"__`P$"/A`"+7P@`5BLP!+J@`(XS"`*/C!`CP:P`Q?8
M(0`@P(*>&+`!&`S!!`%P`AY@H`<)R``*1J````Q@`2=H(`@E@$,#[!""`#0A
M#$%0`@\,]@06]'8*<(!!`P)0@"0$H`H7F($$'/_`@T1H`02G/0(#,&#"';2!
M`6]@S&]D(($Z.(&###"!$4:0`@ITH0,'T$`#<&``,W```R$X`!P"@(`<&$`#
M")`!!>I``")((09EV,,.YF"'$@2`>QO:FUC\R@,E-.!_L`0M.ZBT1QT?!`&,
M5)P]Y`J$-CKDDG@*L@F4<`0_5$`!6N"""10!31^'H;`ZI@,#`#"&/<"#2I64
MQU4:28<A)(`-\4@`"?S`!`A,8`T\H$KAMJ:'#-#A##3X@QYH4&<YE/5+6X!`
M"]I`JRZ4P0)XV,(6;H"',5!1T8H^0AA<H#^*3)H`%.!!#"(@5S^$YGC#6L_R
ML%"'):`!#EG(G@]2T`#_!I"``R5(P`;@=1X.7\`.3KB`YE(@`0`DP0T(L``6
MC,"#'PQ!61BXP`\V<`<#,$$`.X`"8BCP`26P``LA6,`--.""*JB'"#+8@`>J
MNX0I"'<+'7`"`H:`AB-0A#]=2`828M`%`MRA`S&@@`YD@``T:,$'92"#!'QP
MAP(T``UED$,/`E`"`W)(`PR00P;TD`480&``8]CH%NI@`!>-#`H%*`$:OG``
M+HPA:6ZX@3DJ4`(&#*`"!BB!"WZ`A1W$8!X5\&L!TH`%"@13TS%(PQ_"X)(&
MH``,3/`C3*B4`#!UX;(^_G*0`7>&,*--"$-X0H^/(B:U*1D(0O##GLZP!0=8
M_RWJB_2Q'AP@!33'0P!\LSH\2H!6,[L='F[@P&/[`(0T^/4=>,``.^3`@A<`
M`0AH.#P0$@``(2CA!65PP`1>YX`D`(&O$VB`%8102-GYH02DBW78`2``(0!`
M"R_XP14<0)<K^$$(;V`S"\#@`!>,(P%,<$`=V?CI:<J#)LJK`19`,(<+?``/
M'/N`$2K0``%(80H;V`(`R#``#7`AQ',`-@JT((8$=.`"8`A"&Z#P!A<08-(*
M^H$82FV$)$!@!'E``L0D`$$L-&$&/S`"Y\8QTBD<H:$E0``Q@``P0`#0`@58
M\`Q7X'J'QP,O0``PH"\2,`4&(`5;,`!ET`:J]`+[P/\!><!2Q($`"!`&,@`'
M$F`$M90%:`!`.#``6K`$`C`$7"`!=^!:!0`')!@`7E``,T!B9=`7`I`?Y;`%
M:F`&$7!)"L`#\R`&0J`%3'`"<0$$8T4(<0`!24!W8L``/@`'D/(23Y<0329V
MS]$>$A!84;=,;^4\$)$%A_<$>@01EI-7!U%(Y3`X:<``^.!C67`FH*4'4P`&
MC!4/D_-8<O<.)J`"['`V9O@'9[,`?V`J7U!671")DM@%6X(##<$&0[`$=P</
M/,`)`*`'$[!"I%0")L!IW(`$1W`$!U`&=1`$==`#$B"`;C`#C3,`<_`N%2``
M1L!S6'`!(Q`)6%`!LC`',^C_`1.&`5B`!ZKD`1)00@/``1^``=(H`%NB!6\`
M`GSP3&_">\'2$`UP!2<@=E;0`,\0`C<0`SX@`3DW`"$P!?H3`P$P&#8`!@7`
M!2*P`2<0!VK@!$/P`P(P&!:`8\:V`1<@!QM@`<QW!$B0!0#``%$@`,X5!R!0
M!I,D!,[5`.<!!5S``Q30`EY0`5+P`S9@!ZJP!%[@'')P`G-0`!^0!0-@!>-0
M`38``UN0/MT5``TP`BUP`3:``#YD`157!WE``@O0!3O0`CI0!XMR`'&P`0&`
M(W@@`#E0!G#0`@BP`:PU`&0P+3/"!0U0`%F0`A=P!P[P`GZ@!._0=>^0A%,R
M`46@_P0D<`4ZH04F@`(,H`-EP``L@!`L$`4PL4)I.0"I,0[OH`9>0`!`P`51
MAQ!3=S=)LH;E\#A;=Q`&\)A)$62,!P9B-P]C\P10QU9G4P98<)22^`646%99
M4(F6V`60E@5;D`5<H&BN&9L0P08LX"L',8B(<Q`?4`<_X`+$2(Q'<`'#Z$K#
MA@`"`A@-``:P1`9@LB7FT1!.D`"!&`^?N%E-04J?XF5ZH`$M\`5X8$**I@4"
MT`"`M@4:0`8WM05-)`)PH'XEX`/0^0PEP`%P4`84L`*KPP!'$`0H8`"K8P4\
M<`$HP`(L8`4ND`3_YP-*H`@5\`1%D`2<YHV@=A`#``35!/\#<'`!&I``!(!!
M%!`#M#("&D`!+V!/7?`&'RH"V%,"1_`"`Z!=+T8!1A`'NA9=KR@`\%D&ND8V
M4"D!(5`!7F`-2C`!1Z`84>0!"9`S1N`!-/4N\84'*Y``%F!1`1`#*P`#>18&
M;;`$8=!L$R`$=+`%,8`!"W`!7:`#$C`&`_!.*:!F,"`'5'F33=H`(N`!`1`!
M'[``8Z`#'U`!'0`&/;`_7[``)+!$=W`Y\$<!-W`#7A`"D(`#5\`$?F`W[&`0
M\."6\I`%/(`'+"``$S`"4_`')O`!;B``/!`%LY<%1Q!)+X%'=5(.2)8&#F`V
M/B8;;^4"F(D0CQ4#?L"8<L4`LBG_5K.Y!5S`!8[($ZCY=%]`=P?19.3`2&K`
M!2@0F@=Q!@2`!9JV2.2$!1^#!8+DK9A&`>;J5WB!!5G@K8M$C!XYBXNT)150
M`5L2G5N2K->8KUNRFEF@KT,`$3%`!5ZVFY041V=U$(37B=C)"5>``7Z@!7\G
M#UV``C_@`P_Y6+>J!$/``"]P!0``!B]0>(_C`%KPD`X`'+*Z.]#!!)EW,$E@
M`E'`!%2@!%LV`T$P`$/@`BX0!`@`!E`P0DE``$/@`T=@!`K;J9[VC0S1`!/0
M!LOS!BD`!3`@`PVP`P%0!SC+!39P!&"@GO;@`PH5`%XB`P:0!`I"`!!@`<;F
MC&%@!&20_P)S8`#-!@,(X`8"TAOO$0`?L`43P`!D8``(L`55D`5QT`0)@"L-
M@`7WHD)ST`0N``,_<`0<$!TN,*,/8`!0&04)T`,88`5Z=&-M<`)C$P00^(MC
MD`*_>%T($#`-\`5&@`9Y4`%7Q05T``$_H`%B0`8$D`46(`:MV`9LT`'*"`?;
ML@)6)0+[:@Y*R`Z7U`=!@',/.`'6E(7(004F('EL,`),,`4`4`%Q(1()8`YX
MA)9(]@=J$`5/T(V"!0$(<#=A0!'PVU<4P02]JCP'XV0084VSRC<UT7,44*Y)
MLJWFVG,$W*[/P4UL*0\FX#=3%VMRU0`*H`!="!(3+!1IYW4/(?\'0J"^$FL.
M3U#!=^-[\,``E\,0V;DF#QNQ\=`"=U`!-^M085`"/0";6E`&"Y`&7Y`"8.!O
M73!R:%`,9O`%_*``91`J.0`!=+`&:Z``;/``F[('$2#!`QM-27NA\T"87Q2!
M.2!05&`!5.`!#&``3E!R#1"G<6`",/"F+%H"U8-`3N`""&``=3`#/A`&`]`L
M6X`%%N`":_`Q(V`"/A`%!3`%>1`$#3`$5U!3+.($/+`%^50"'=`*#3``Y&="
M7``&`0`V*7``4O`!44!"?2"I=W!47*`%;;`#)C`&7P!K8[`%7X`B:-!4>*##
M',`L46`',;``#5`"6M"<'+`"<;`*92#_NRG`;,E0`QJ@`6[0`67`!V/@!KBV
M`'"0`W:P`+_3"888#V9P<_(@`^!B``]@3S"@!23`3.F(!B[```6`!5M@`@L1
M$F80P\_#9G_CF5CP`E7&$-"9(%D!G9>I:(NT"5T+!OI*T%H0!@2]2(05`'43
M`!<X!E[%3+/)!<Q4T8N4:@T0N%K`85P`N%G13ULP!E&@!`1``,]Q`2A=`0[0
MJYQ@GD(P9@Z!!1K:KQ*=!6GJ!VUC`JX7K`WA!4Q`!G%3F6.2QW+($&SPL0[!
MFTRP-83#!E5P$';`!(AHPIP`!#00%RI,#R6@+#M@6A<0`E4+!JZP`T<``C'@
M!A]@`#[``SY`_P`&8`0)X`-.\`)/0%TH,`0Q\`1Q[0Z$(UJAQIE`&09+X`)@
M2P9EG`*:EM$_T%2D9@0EP&VKE0#:&Y6Q8P!Q\`,>0`%QH!M;0`BFU0`;P`5'
M`#%A#&17H%Y=T!?D1`;D)`8?D`9LG`=+TP!!X`(0L``E!P9YX`,5P`5\$`!1
MT`!)`$LAL`748@=2``1A,`(N$`8&(`;>DP%O$`<>8`?33``+$`(*(`$#8%$0
M-`!H8!T'D"\?4`8F4`%54*@P,`-V$#)?``(;L\IC``$"<`)Y8`ZD5,)MN;SQ
ML!$.L"1W60)J4`8NP+P,M04+`".<T1-44K[OL`4OP,&6Y`5/%\%G$/_!&![!
MFV(&9P#"<=.K0J$3!9!I\*L30,#2?D`!0G`%O8H`^]LW%%`"$Y#3YJ#?(^$F
M:"+46'+!@_*8`O`"4TRPDWFT@]("+X`YGT75>Z>A6?T.-/`$*%`"8&`%NS.!
M`$`"4/"``!`'5E`%,0H%+%"Q+$``(V`52$``9(`"4(#0\+)\9P0X?GT0IL$)
M,T"V45`!R$J\3;``->!-`G`$%.`*);`$)$``4L`#*6``([".8S`$*I+9=9`"
MPL<%+R`#K_@!9/`&/R`%+_4&!C`%5\``#1"</P`#02`#7J"W!3`"%``</=`$
M;U`!2,!"!Y``$GD!/-`$LCT'>K(%:1"B&E#_!C`0!VQ@!:2'`+BX`3%0`6Y0
M`Y:=!1R0/310!VA0ZG-0`WK@`@<@`C!5!P@0`P4`!ED@J62``#"D!2N0!UF0
M`Q+P!@)0`2Y05"YI#GW)#FVWJ?P-#R908R%@!=*E``P-!.SP`GG``@-0`B^`
M!$O"X.;@X.^@A0^!J8.RKG>C$UC`5_];TB7]Y@[Q!0Q0#DJ0SVB4X1:^K3YP
M!1`K\6-"AYWI$+R=XW\$XHKD$$,`!@\Q.7A4B"]!`EN`B1#AX$^PK";\`VR6
M`4PNPNSP`'\0`9YQ!BI`Y(T9-U6,]._P19S`+PE0`1+@!/L^`%20!E0`!E1`
M"#$0![/%W6$0!4Z0_P<RP`-4D`?5%V"54``N(`.Z,P%OX`0#L`2?[@([,`)@
MB04,(`06$.T[X`-OT``L0`/5)P`,D`0&<&@ET`(),`!G+B(L0`)34`6W80$:
M$`;?4!>\"N$]@`,8X``U,`,8L&[^=`.#;@)94`(_,``%T%L(0`$I``=CA0!Y
M``(4,!QV<`0"H`%:OP!20`8_(,\:^0824``$8`-M,`9O8,WE(`3O\`+$L]_S
M@`:(S@_Q0P,*``+/^P<N<`-'D$154`.[MW0-W_$3(/+Q`*T3+_,P80`K#037
MYO`0P0GU#`A_@H.$A84^6%A^BR:&CH^0?R:+?EB1@@5`9Y!9$I>?EXF@A?]<
M9*.6D&P`?9]=E`"CD$!^!)`-6[B2CFX.K)%)%XL*0%H\M;'(R<K+67Y)?P#'
MCPA7"'X_"#U#%3$(*U`-8"@S1@<_2#%U(3\7#A1'`Q4?%"D#8S)'%P,(*"$)
M'0FVP$CS9D>)!'5\4-@PQ8$&+EF6P!'0H0*".R5X:+B`QD(#.A>^?"!0`H$,
M"0:@;%F!SL@+-R,,;(@A08:<."`0I!!S1<N=#CHZQ(LS8$J%,`C09!EB8XD8
M+@)6&+`01$N<,5(T?/`0(X"8`0%2:#G`Y\R`'S<N=#@PY\>"$&<`+.(QJ!$A
M!70=J=BSAD>5!#]\E#A2H@0#'A[V*%#ABQDENY'_PD2Y!'G9IRP_+']2M`C(
M@,K*L,AUH/G/D42/(77)LDG9I$6H+C'0HAK5@B^1?``!DTP4,C%^'*3YLQKW
MH#04>/`($]M1%Q2@7/EYPB2#YC:+)@BH`$2)!T)*LK.!XBB`BT]W./B9<(:8
ML=+PXR=K]BQ:)"U7#ESS6.<"!P0-2#%$%PE$48(=6LCP1AU;&'#`$#68$`(6
M+AQ!@``!;#"&!"P$`,,%2[0Q1!8,;""$`7`DT4442V0A!!Q&F%#"!D<8<$</
M%Y`1PP5O&!`#!E,1,`8))1Q000,57&!!&0T<,``9(,2`Q3Q(S`#&"`F0L(46
M!B`0A0(QD+##&P@(D(87_S*D,<(88S!`!A@;()$#&0*,L(4>>JQPAP$DK%&`
M`6UH$00$,("`!1]I;(&##P=P0,8679P107A^Y/6'`(6PX40D:SB@`!85%.#"
M%@TTH$`%S6G6#".@O"!&)$+(QXD/FGW!!21<!+<(`J#UMEZOR%P0A2)94.#)
M'V=L00&FR#K@AQ?+$$!)JM,<`0D:E@!QQ00)$%*`<F,,<,5TP\52@'&QS.+'
M%6F,^P0$@XPQP2)C4$M(&<`:(MT+[&GF`R4UO$*(-7Z`T<(+CE!PP2<\*%*=
M>]+(*O'$@M`'3<2&:.%',PP$<`09)AAPU`\N(-"M!%F`\54)67PAP1!<=(R`
M5_]/`2$!&)"2,8:/+P@1A@$0L)"%"Q1$`4876CPQ1!@+K($`%B6DT0`"`V!Q
M@0LEX%+"``D,@864`6R!1AB8>:$%`0-T,<`0%T3CP@5A"%`&&&2(L88275P@
M!AD-I+S%#UB`<<`6:S20QA=EI+$`!%E@(4`)%00@@18Q0$`&&0O\80\6"Y0@
M@!8+&-#`&*:>6487\SI@*0N9$V+O(*[\00$%6V!A`@6U^`;?JL&!HL7K@E`P
M2A=``/](%OF"(E<6@BA`@0FT$4<;`0!P`41IBCA`FF:V*U((!9T)P@,E"BA#
M@`,:WWI9\HW_H>X6A+P&Q&L;(\.%\8XXZX<)G-4_B+3_GC*>%C+3"DI,H`!>
MR(("%9C`!3KP@9W0E00H\81$)&)<ZQD`!89@@@YV,`$O4%\DQ&"`11R@)[BC
MF`HE9C'[0$)CS2"``>!6`1<H``&E&,`3*(!#%%P`!0ZHV@5(<@$$7,``6AB5
M&`@@&!\@@``)``,7`%`!$W3#&"7@PA'0P(($E"$`B$!`&:I6`A;$@`!@@`<#
MP%"&,G"!"PEH0!<<4`8E2%$+8N`2TA(Q!A<0@`=<T$(!N'"A,W0!>A?X(@&X
M$`8Q5$`+6DB#X([`!6Y0@`MH0`#+LJ"%,&A!C&7X0>W"T`!;;>D+8AC"%PC@
MLE()P`40T)^E`-`%0JC!6I'P_X,DMM"PVPF/`/@;A1=2\PF\1`(6MKM=(118
M/O!Y"AE=P%@L<N6'ZTF"$M`:!/BXL#W+8,$!!$@>*+JGR_AU!EKTRR8RP`<;
M4""/$_"3BQ]J.0AYHN^<A6A@`QFH0%XJ$`M:R`)$LE`["QKT-288WUQNUT%*
M.```R02``TPPT0YV,3J+8"<E-LK1CGKTH^L!@O[\(`0,;E2:AGB>,-!'`)2N
M\*7(:*%+!0%#/T0!`2[@00,D0`$L=,$`2'O;`AB``%=Q$A=#1``%PH""!F!A
M`"6@R0`:$(,A[*A>+OC"U;2P!3*40`L3($`,7N"#`!0@CV3`P@^.\#:B$F`+
M)4ACP__8J+`WE0*-#1A"3V,0@P8`DW!A`$,:M#`&-,3`!5,;``1`=X`OJ$R!
M6AC``L8@@+J180"L"4,7T!"`+'RN7EKX0A@@L(4#[*QO68!`&+90`0&LH0)I
MF)<?8"$($]!3$&>`#B=TR0,3>(%_N0"F?%P!/G'&[YCN6T0W_R"MV5+3#]$3
M9G23H=%:JLM_@@CG%JSIS5D8-Q3\<\`^B^4L'JQ&6D#@`037JT`N;"&0%)@?
M+:(S/P_RSX.THY^NY`O2_OJWHP#HX$3K:]\"&_C`!9XH1K'04X/J")ALE8!!
M)YP(`I"A#&3(0@`RS-X'2A@!"A3"3`?!`W8J``#%J(52.LS_XA8[4`M3*P.%
M9^P"=K#U"`CVX!6$P`*/.@L%)NB;,RX6B6$VPP<2B,%J`P"15*Z!"Q((P!J.
M\`,#F(`+)@@`#[AV`2QL`0Q@B,$`4&```3!`#`*@0`P,L(4S4&`UC/1IJ":0
MUR,J#@518,`6?)"%,A`@"\"\T!$^)H8O-$`+`H@"AK&%O!\D*LE^%EM:!4``
M-:1!`6!@0@#"<%DTX"P`9:B`>R%IZ0*,P<]@6*T8)&#8+.CC`I,-Z`6T<#\Q
MC*$+7BC#'Q18`$B&`:*5&L0"6H-;6D%"`94P`0&>U\&>5D\^S9#+=P51SD?`
M0F.5(,1(I0/=F`KO+N5[!*X5H`!L_YM`@028A0,6")'G>8][^UMN:/CWW\[4
MVZ'*[:`6YN?._?&OPLN>\82WT&&"/W"@`:4U0?_<80O2&A<"I[`Q>KOL^R9X
MVJX0@@-Z#-()F/3>]=9X=SP8`(9EV@]I4((6+F`"N0"9HCG.L0\0P8Z(3U@`
M$L8"B%V\P`-`8`%I.,!\ANS"1PQ3$2900QD`C>$2O.`"/^6"`9YR`<CQ8`@.
MJ``!GH(%"93`PCQ8LQ<,,(8M"($!%SA"%I!&@04HX0<DQ,($`C`$`H3!!7J]
M7PQXP`+!!.`6+HB!%L@0``$8`"P(8``*P/`%!9`!965`P$\;X((`[*.R/#B#
M4BK`A$4*8/\`!(>`!,X0!EME80"?"\.3NA`J@7XY!@IP`1H<[P,QF&$,6?@*
M&L8`>S%T(9!<6$,:NB#/;_\A"JTK=B@BGH5PPX?;TY:$`Q,1T-K1SED.*)X%
M]><`VSD+"[V-N4CG)T^0FW^C_*.M-_V-/1XHX('[?/_:_T!NYFGA_5U838O?
M2X$`]YO!R<0_S!9S%,51(W5^YV=/KZ`_`29M!.A$H/`%6$`&PV)0`\`%D8=A
M#]0`'.9`:X`&:D`(:+!"/%`,?C`,TP53*CAT]3%BR!8&3T`7]V<`F.0%"O`#
M=!<#/S`&$($%!B`!-3(&9Q,#:<`%41`&0N`DVQ4`!G!9/H!V8"#_:@@P>%A0
M25Q`9U*V!0(0!@<@`9$C160P!`TC`6D@!F#```.@>A=0=E&`(120!EUQ!"AP
M!):W!6S%!:#7=4_S0U>`,@+`!3@4`&.`0&:S!@*`0*96`$R&-'TF"%[0!3^W
M`&I@.0D4=-"R&@<0``JP`&!P>@&@/YV'`DQ0`APD!//S#HEP22_D!0G4!3XU
M"@!4;]AV6Y%P71YEBQQ%8`'600"PBP3(BQ!E4`4U8^ZU0%@`0?F7!="B`-ED
M-M6V#%@`!/S&/1-5?@AX?L979,!H8`V3'`EE.\#4,(EP/Q%W/P/U0-BF7@NT
M&K2X@L@03.X8"R4X/B@8C_;8;RT8"<@V_P`3M0`28`9D@$9.=``(``8^>!8N
M0`9"P&=<<`%?9@(2L#8E$`7F&#DN\$9P53T$D$@-(``-8`)B0"D@=P5EP`-:
ME4FJ5V4'$$T%X#4$<`4B66\XQE`FH'$\UHL5)6`455(3)037^%$(,`1`@`+Y
M)F!*P`(>-(V.`'ZX$T[M"`DPEQSB*'"T\RR@,#\6!'%>9G`M]CN_XV4$18P6
MU&#]IQSA%WX'EGTF((T=)%+W)F^^HCVET3@4]EY<U4_%N%[ZMW:7J$#T5SZ_
M=8^EL07*Y7R"J0R6<IC+,(\G2`R*^9B#(%/ZZ`=;8(T_>9F8.7<3T"8`]2<<
M*#5:,!A80#;4$_\`]G64^'4[@7$[IX$U@C&6-I<(3H4%8X0%G86'98!SK+$`
M"Q1T"B0W%[9`%*!``_"5!B5C%N1_X@91?^`%\%A;TFA^ZA0)^@52#95].8E?
M)69@X01,%$9-P/4[Y`@1Y]AA\K=`]*="BJ"4D#D*[]2>L9!NP@"?L1!]]"D^
M7,4>CGF?]RB9Q^8'/E!%*,`"`_@."1!.)O`##0-D#N`#,I((PF(UIT%]B=`-
M:98(*,$`IW<_%!``/;5TM=,W9,`%#7"!`Q"14J<QE_04OS,`+I`(`P`&GD:#
M#,`"B2".+^`U%'(:">!!4>"@!%A1$P5$)C`O\^.3F+E1!ZA<TB@$X:'_/?P3
M"12@!;/SG,21E5FY7M7#/*#P?L3!I?:(;4``IOQY%PJD4O8)G^]9IKM%F6Q*
M&6]Z"25(`?J9@G&J0O[Y",B&``**E#&G<4<Y/R@`!!Y'E$N:I/]5#=<@!H"D
M``(`-V#@!5L@=L7P1'[:0:C9001P!#WZH%,)FP;58`95HGUS@<>85H'4-_+W
M?@J@!@I4+H:0II=02\TWG1(CJY#9/_#SI@K`30`PE25XIXZPIL)*"#R@?L4Z
M"&=@;,E*"!Q!C_O9K!.3IXZ`;)5Y!3`GI$?``RY@`E'``U'0K1[D`-W*J:<A
M!%^7$1;$`%+R;R7:H0C0($-0!E&`6:^$`$=0_P8ELV$=Z179IS%E8`!@!@%=
M>*(Q\&4BDW"&8%[2BEM*T+"#\(S)NF^]\Z;<A`6V*D+22JS(('_0XI?Z]Z6U
M&E`"14^N>"OC:)B&T#X0BTH0*PAB4`"34(\O"VU$YX*T```3$`.':`(R%E47
M(`'=ZEH-H!1LU0`!@`5QQ$;<I`4=\J/U4@(&\`/S6@)H\*(4<!1<4`)=X$:S
MTP!EX(4&(`00>4D_@`(3``9^8(9<P`,+,`!1$`-'L``!<`!D\`-H0#F&\&P-
MVQ[))ZT2^YA/Z0A:``"V"I^B8:=7^K+.N0Q>P`0-X`2V4Z+KE@0E```J(`2$
M^0``0*]#L`-"P`5,</\"5C8"0S`$=5!D9"JMN-J>)2@M-%NSNW.SD:`&?M!_
M0(`&@+,T"8``@(-':,`$@'@$M.-$$E"TLS8$8K`%Y:8%$(!ZI*)33P<`:30`
M0H([+T``8;L%`%)E8J``;Q665:6H$@``CC1(J%("+L!51P0&`Y"8V;6KTJH`
M$X`NK$N?TK*ZPPJ_\'D[*CL("C"XP@J^R[`%T*$`-7`%$?`'+V``O\H#(:`Z
M+\`K6=`P"S`!1E`"?Z`!T-6+4Q`)'-NL_)NLA:8(L2N[JD*[N529$\``E]0`
M*.!E-U-$6E`$$C`X0;L%>H,`\5H&0K``MND"+/`"DO%(7T<!8]"A0W`+J.+_
M9T@R!'#E:@WP%?F@0?<S/HJ0,Q`@`&!V;F%P`0&``"76`,RJ3?+;K/1KO\W:
MNA)#`<X"!(=K"''\F,M69!K;K"$,"@)0!<UC30#@!D)0!`F@`TH``$)P`^<V
M(@I0!#CV!S:`8DD`!#`0"5UPQM)J"B_+F">,PHZ1CY!@NZ(!!&`;`%F$!4(0
M!6NEN:-X`0G@A5TA`1)@#`LP!&#@`FG@`C'Z94?``GX$:!(@!C$@!@R@>B:`
M4P6``L4P!%J0M%X0`!>0M5I7`I5PNPV2:@(U!FL`:L<XFEHP!"EER<6J`$^@
MQLEZQX))487+`W`,PFQ,,15\"8T+L>6V#'L@8CR$_SMTF@+5<P7G8P<30`$H
M$%\\@`(HD`<)(%%<X`-.D`0,,,?$,6)QVLZ*J<E``,Z<#`IHL`;OI\*04`D`
M``1<T%,F$&:FIBP\_`)C($-(=!H&D`8_JG8$$&5B@*\\P`"V608,\`*>LP4F
M0`;([``),)H!P`)@T#`Y`@8>,P:I!@8D,<T2\`-0)`!'P-./=`$_,,4Q`&;$
M)@A-`K%JX`/D7*QP>9AYK"\C3-;/!,\O6]:?T`)3;`89D`<60`=GH&0&4`-4
MH`5@8`120'=;T`9L\`>4Q0=_8`$KH`(#$(*/H`42?9B-+9B,B083X+SLEK03
MF'.Q&:IJ90)`*G[VQ0)*T/]!&(2+'Z4$(V63`O9R'B1DGOP(MGNL0/`G3V4D
M)8`"""`&7R<<!@!&8("T`&``/JA4%R`$MWS5#;!:>-<%7V``+I!D81@`3"0&
M-2(&8?`#Q<!FI",Y42`RX*,(:1@`.R@C6I`X)8!A"_`#9%#&\>O53/"WS9J-
M]QA=63#6AM"K]XEBQ62E],G6EN%OS69?Q>.(`;Q`#CT(A%2SCWV/%%T,H1US
M+\I6%/:BF0VC$)&T`N!B0O<'("@KU&H(9W"[ZCRI6<"!P]E25=2C8X`-M2,!
M6Q```#`L%=`EYC4J-+$%8K"\8&``2%@,6L``539X3O61@,0`OUP[`D4`0^#`
M3NW_`V8@`;A6`!="!D'I1GJ%2_%CT<*JN,4*T2]5/)<TW^Z4X*7!V-&!Y7?*
MW\M`2STU`A20`,2[!PQ0`39P`U50!]]HN.N#X#6[X"TU"HPC`0NPX<R!!5\P
M!@BP!L`],T^E!@9@!DE;`'\`!@60+(H=LW_`<B;@:5&0`&)@`DA)`!XZ`"7U
M`XKMGAS]")3YT0,`>LV]E2-Z8:`&ZDQ2`;P4!@G@,6.*`E%E`%OW!3PP=8Y4
M24G"A%=S%`2@!5T@M#'-@3%>`&>$S]-L`*)S!,"\1%S0!5Z%!@5@MPA@"&SB
MU0X@P'<JYLFP!6;S?LC*">1N&<<."I+ZLH=$,7X0`%$P_Z6/W$%_P`18``)J
M`-!80&[3AN9ONNXKR`-,W9AGP^7!\P)8`!SE`P2H$@!"X#4&\`05P``,P#\@
MC0(N?$($X`KA-J5_P`-'`,M*X)$&P`1D<``FP`12`@!G,`'Z"\*G[@@>#01M
MDRQ:MU-'T``&L``74$D20`9$M=L&X``(P.(D<Z))#E`&V2!(9#=8T``7X+X_
M4`%B4&,AS5E>^`4Q$%=.Y07C0Y@54`$+8`)I@`40<$F=$SA/I;R&\%8O2TLO
M&[CQ"`"-,YSTO4P$GPS#\+^/H-_T2?!^H`9`;3TO]P<[@`5LH`(;8`QX'_!]
M#U.3_U(E2)BQY5[I#@E;$-HPN/\)0YD`2'0&0N<I!*`$5S`,B4#Z!,`O9)#Z
M@K`ES!4%I^<`P>O&67#VXD+F>!]3-6\(E?+1?R?,<F,`B7-X/P`&0FMY3^*B
MGYADK54!^U`&!EP8;X0&!O`"M3R:6"!#CQ<&7I"W40`I[NLC8*!)P!0#E.D'
M:`@&MO4"A)>&QRAJ.LA=_V/F;QKSXAZGFP\(?X*#A(6&AXA_!%A:?UD`B84F
MD925EEP4EH)8FIV>GUV3GY1^6::G7*8\G(1>G5FBH[*SA+&TMY\465M^"D!;
M6SR:6"]88T`5"!,^%V),0TQF0`H4!#X_$P(.#CP``2@$0"@E?UM*0"Q^?@$)
M0MY^#A/_+PH\6D`3,6J>67Y)?P`$2!$```3,E@,77/B@(.'"$1<&""Q@,80,
M&18(>&PAXR,+&&L"`@C1$B:+!`0&P+C08DS"@`8_PDC(X@+,#Q<$!K@(L*6!
M`Q\N8O#XX<,/%C\4L(`Q@.7(F!]E*!@PT("+E@H7#!'8@JMK)P!=O(JE9&ML
M)05<@&CA9RF4V5%86%7JPO6M74%>RG8UP;>O7Q-A9\&ZZ\F5(`A>3BDVM8`"
MFE,!!&0I@V5`E@!9&L3=S!E+`4M?CO!-8$:6F`*\NOP*IDE,W#%,$6R)^T7,
M@#5_`J@1\^7,%BYJ$JM!HP;"FL<+_D`PI2;-\,6F$BMV.9E+_]R0G%G&+=GO
M7\!(?K80I"O&0(D!8U!42'-$RQ$S1RZ0T0)&BX2H#@8DN."CP0(!!G2!0!9D
M-&3=$`V4H``"$G0A`1E=J&%*&3\$0$`,9F"Q@`ME:&&=47YH01\89@QP`0]K
M<`$&&00T$$!3R1&R%6%V@47C6W[<F(A&83UBR6`Z1H)%%IW4%617;MG511=>
M*`#=DXK-UMEF!)C0F9585,G#7W\YP!<`?@#`%Q#JE&GFF6BFJ>::;)II9"2\
MF`"$`_J,4@\%O:A%P1&33<G9G@D<00&7?[$@1%\.L#"!G&VVB8(#<Z)`Z*1]
MN5`"9MT!%(D:?D@PP007Q!``#SS$4/\"&"5`4%F#":C4P!9:N.``%B:@0,&>
M94@00`E"1&'"`"_X(`$6$WS!`!HU)1``!14,P04"#$C`11<"_(")&"4\]`.(
M0G'A`P(HS"8M!0(,\`,"!X3Q12$S'MF5C>[B`DF\AV`!A&&1`$DO(=U0RJ4#
M%$@')1>IF&(=K'[Z6:4)@P[J5R.5<#&F"<+,Y4"C&)<YIPE^<-PQI0!XR=>@
MBV"1E)\$$\S2%ED4K)B'T!$<UQ9EO#3`L%-:MRHQG"WR`P$)-&6""ZLD_`3$
ME'3A1PGBS9+&&GCZHL6>FE66A6509JTUE%X<\(>37J<1)#_^:)J(&4819(`8
M`H310`QC//'_@P!H*`#,#S&@X8,)UMC$,A8!7(`%4%R$D=<6%VC!`P5AC.%#
M&6!<\,,``7!A0`4>`4"&3@>X9%T)/O#""X>#AZ'%`5LHX((N"R!P`06GLYO)
MOK/`2_LH>M&[Q<7W(N(DK`!(F?"?!&Q9\B);.NRO"0Z$S#N99&I\9O1S9FR]
M.@"`*2:E0,Q."2\$-)_C7'YXP?)B'KI\"ET#_Q:7S,-G:7)<!"Q,://:E\G7
M]?SWCZ82D%+'!-0"F@D$KQ>RN%.>%/>=V^V+;-[9E!\&`@0NB&$E%Z`9&L+P
M@P*90`(^2(4#=H("`2"`;Z@Z`A8$A(`*[`0+YN%"!8X@!BV(@0!@_T#`31!0
M``1P@0<(P(PW+O"V)PA!#$/P`Q?\0*HR)&`-6A!"`+2`AEN=+P!A>-,?LN1`
MW`5F%%Y@TM>VIC4NS$8+PMO,*DZ&)<YLR5\-S)>9NI`%3HBH"P2#7?>RD(G?
MF%%GT>M?7\@TJ>WYA518JA_#./-'-,[F?+OP`A;4EP6!B:B27;AD&`7VI$NV
M;'ABN@12!C*OI/GOE&7R$CS"`P\O;0,>)C`DPP95-/KQH&1^<M_[#+88Z0R@
M3%DH"CRR((8KJ",*IA#`*&"E"2`<4`$)!,-1%!"\6W;Q@9F*HR$4$!Z"_*"&
M`2`#`QI`3C*D80#HK$H:6BB&,!!`"PPSP?\%2G`!`F2A!&G8PA#.^00$#"`,
M2X&`#V)`@`M,,08#>$8,$("%UVUA12T+`YZT$!XQ@"$!%D4C&2HP!IB!P41(
M$X3B_K"&,RQ@#0*#`&'&T)F]16%OE%*"H0!P!2&@\J8W!4(@73DF/P#A1Q/$
M4Y/JA:?<;<(/3`)+C\BX"Q'-K#,$V\7PJD15"KRQD!\C@,0">,J+I<FK7CT3
MI.02"6X"8(D5HP0U8665(;5L%XI9TBG4X8#H.`F:0ZT$/]1Q34+P0AWV4(<0
MSE`.=1AF"*7Q!#":&;PG)/83"O0"$(JGS;[>"()F0P3:L`"`"6"!#%\8`@4J
M$H`Q#`<,,HE!!2#_EP4>U+``)C/`/!-7`;?E\%1HJ,``"%"S&&!!`C$H@Q`&
M4(&8L.`^6>A"`0S``"P`M'XA\L,%3$`&`VBA`6!(0PV1.*`#=&%7I_RB5PAP
MA4FI,"XGBXL/E#"$*37@:IM9"R^SX$F#60>-G`%&_.A',4;@\DII1"_Q^+*E
M4LK1!&SQW2/P90A['<6G@51'A"6\O+Z`R:>'W&]<6*(8EU'`F0"@+R6UQC&`
M;4&GI5"$.EC1!6C6BZR)X&:8D&*)O(R"`,"DQ5_'9]DE&E9.#HB"&@X0O=D9
M-1)A2"LEG-FT!+($J17DHF6/A-G*$H*;G`4"&E`;`RZPP'$,`,@8R%##_RZ,
MP0RU+<-YMO`#Y@U!"T,HP1#$``P*3*ZZ6E"6&`3'A1@H00);.(*)]'8!":QA
M5"**PAA<H,3P5*!9V&V`"[(0A@&<;`L-N<(1,&,*$+[W:I5[2>$6(`&DFH4`
MGO53`N+Y%PI$P0!_L2E=:X736F\,Q*D\4U_>&,I*>$$="49$%GZ:"!^'+$NW
M\M.6IJ$)7LS)+!1]]B>BMPHPS>H/2@N/(++@8D-(S!(R5H>5#:&O3OB8V;-X
M,(\MR[%,G*$!"-`';*TD!D$<.1%?<,!C(\%D`WNB'CSH!0`8.&4J9[.LW01"
M"W]0$7N.`7.Z&@`:"%"`9KE@#)(VXV_0@$]@1/^!#-8ISQG(0),T#.F'6V!`
M#+10OZG`F0+O;8`$7E`&BB0`1+.1B0!*H(4%9&$J5I'X`$HP`3),@']7B!%9
MM(B(!U]!9!6>0!0F(++S6DK#[]/9*2"Y&#HF5]WGZW8B)K%C5SR8%=XK=R+V
M&NQ#J'WLEACW(0+.U[&H&W?B#H4SN?`'CSE@VPQNQ=\M`6$:5V(+<H\$!>IZ
MB[L7_`Q9P,W<:R$+!_"=$F<P(`4<Z^2`2\V:A+A``M95\+%4&>'B*3H6O."%
M(PSAX:KE0AEH5@UHL0`+0[C``,A\`>L4X`4'P"<*)HF`6P%Z"S$`0Q?*X`,Q
M'($+V,5]&D92@@(P8`S_`HC!"[:`IZ,$.@`[H<`X!6<R+P0``3X(@%K\T&4L
MN)"2Y3E%&8A=B>!98J2>N+#WW*5N&$=B$G@";'_@8Q`3"ZH!5*6P;H)P>8XP
M>)5P;X,`@800;8DW"EIP86`$!":`5ZFS;>^S;6)7"(Q7"6;B?X?@`"%%+XY7
M>G`W""^P;YJ0!=%`"5]@0-/4>:6@)_OW!2O&@F)Q>C'634)0!F0@4><W!I%S
M-3TA!H^&!4&T+!7``Q4@:01P!&``?0Z@$N('?B6`!0KA`V,P!`)0+CF4;S&`
M$2QP(1Q$``UB`#'`,13E`EM0`F'`$[)!.?8$$1G4`%>``$FW"15X!DJ@"9D%
M_R=*9@E@`@2'&"2A$":!%PE_UP47PP/0%#V#QP/X`@3B)6S`IH!]MTL2B&T2
MF"2:,#4AB`L/1G_[L(G"1B2(\$.$5R;[)VS^IH)EXH,M*`A"ED`F6`A,AD!V
M@D8YB$:V0'?`2`EDP!"KU@`$P'!A<`$IU&6U`H/T`H2^DW#4\HQ=H%VH@@(_
M8`!A4``$!3L7@`;+MP4H``9@T!!LED%B0!=:,`9$5(1#UU`&@"<R1S"-HP7@
MR`)=P%$)``2[ET04U64_XP4QL`8Q(`'OE`6J<@%!!"*!P1*48`9,8`F95XN'
M@']?(6ZT0RNN2(B^0WF#H!%ZU8F&0`%AP0-OYW826/\_?744TD88E<1OL:@.
MBYB2O7@D*XB+DL`OLR``5_"(O@@`Q$)8HZ`NO"`UK!&!ZC"#$;-J%!``YU)<
M4^,#5Q@#%%```W!-UG@(W(0`D"(M560A!T`&E4$`)9``6D"'9=!$"6``+](`
ME,$"8;``!(`"5"D?6R`&41``]4%%+N!^/,`"+G`!$'`!!L`16H``'C(L/V`O
M'(-C#8`Y!O`%`A"&$-D4%Y`&"$(L8&!J6[23$5AC**"1AM"4'<E$/FD(J,DN
MA`"+E+!72V0(#",Q+4EN$HA@,7F+-%*3.Q*2B4!7K)DO#G"*\=*3K2D(7C,(
MI$D)/'`$2P8`W3`+L(-C3!G_1P5@3,*YG)_PE=O4:`#!!1SQ`UR!!6L@6S%`
M!J/2$Y7)C$.0`%U&`&(00BY0%956`&C@C%[`4#+!!?HI(@,`!N!W$C7D`TGF
M!<J"`!D177%17-@B&TFV%@B"A`BP?H'1+F=SD960)29`>I%0/)]P83F)BZ])
M"/O'3:Q8"'O%"X:@.%J0&*'(1Y3P;;U))I>UHH,@B6JE#I.)<-VY+U@P*YY(
M.Q!0)W\`>=)Q',G!`HKA`[1P!BC`@(:0D3<8C)ZG)]KD`SY`C=X9@P<7A/Q@
M`@>@!<R716&@E33SC5L0`&EP(70V`$.``%LQ!#[`AC'@(A=0`01@``/`?&70
M`&0@_P`5@`6_80`N@``0<(42,$,#T`6N(3<$$`5#`(=^,`1400$LT@`\\!)9
M4@:*Z05@@*&"H*&^HXJ(4``.\`7640DBFG_JP'0^Z8!"4@B8,)NQZHFS)$(_
M4J)XX0`Z:HMX<EF'YZM_\&NL-(N20*6WHYPRPA(RDPHIXU0C9C#ZA74)`W*=
M@0""JG2R``$O<`1(2@A*`P";YZ65@`!5M$"@-PC2A*Y?BJMEDWC\P`\\4`9<
M``%#(`$NT`6:>@3_2(=<\`(^9P(_0`$#L`51,`!I,`8QD'*8:@)>8)Y2\0,5
M(`%1D`!K*0$*\'H#D*<E\`(&8$(50`8N\`=E4`9T:JF@0_\?-\.I:#`$#PL&
M//",ZK<%Q5*JLGIEJ'H(U?`':@`$S9D(K[J:QEIZM+HCAL`#P>H(*^:)=80)
MN?FBD6"2EG44%[-VJ.`A[Y,P/V2H5L4(ED`!`("<@F`FOFHR5XL415JJ+)@5
M8W$&/L`$87`(SN1Y3H8GJD%P@W`&L1JOHP">A<!-O&"4X?0V#``!1[!1+N`"
M$B"W-4$`.W&%)F`>"""/6D`&<2D&J@5#)7"Q,1`&0\"GD]-"%,`%@B,:9\4`
M+(<%E\(#&<1*+G`%_70!%W``B\`%"'D!`D`&$*D6?Z@(.SL(OD`)<4-ZZ(B4
M37>TK@DFS#MESVEOY*:):P=8NHK_>'1THH,PM5.[+S[6MG]PNNO#;6%DMK0P
MI$3Y!_#`359&#1NXMF"2"-%++Z'X"<X0`]Y:KCQ`)S@X;'Q;J@*D!2<2`T=R
MI,9!4A!P5VNP'*9P`&F07)<Q`%P@`9\AKQ$4A&A5!H#)!>626^T%I0#U6U'@
M`BC@0Y+V:-X@%0G`AA\G!B\@C<OR&`?@`KG%$0DP!E&P9X\V!ELP!B90`0QP
M!`?+`-$%D06P$A+P`\LU6J?C5*.J!<$[!A6<"(((G0RH!J(1"1Q)B),8"6L`
M34NB`(DQQG$U7U'+"(SD)^EE,M5P*V'K``M#`&TL/TDQ&QO9.VZ'DK;*60BF
MO8+0!>/F_P7`6G!'T7:%H*PWH@4H>`AF4ED76(')Z9OUPH+S.PIG4`$.(`0&
ML`!H<`!ALK_CV@GU@)T#9U7\H@YR\P1;<&\4L,(:V``4X`-S9@):R02WQP#Z
M%@X;XP-7L`SA``:]`@00$`4(``\\P`!#<`Y/\`(3T&;8`,F">V5^X`%`D``<
M@#-W\`&[<@0U4`4=,`<YX`)A8`$G4%!90``<$`0)PJT'T`$!,`-98`<&0`([
M4`%44#\A$`0[D`*BL@$2@`$#X`%@X`1A*`$H0`(^$`4[,``=<$+1!30I$3F:
M.P=BP`<I4`'V@0%@,`%M()H$@`"4L`=6D`ALT`3:9`8)@,B",/\`STL()(H(
MVC$E:)0R4<54T4'&3,(DYBL(#7`+7(`"]49N>DP(8>``2H`928L(7L"L0"L&
M0A"D780%QM2S@P#);W%//K!"=8(&$_!T'2,(9L`2*I>^M],`DMQ@+-C2L\!2
M)L,#10`0Q_AO+)<G\!9'8W`%5Z`!FM``1C!/Y_P#&P`&8\`%`R``T$<&!5`X
MKL$9[.D97,#62I$%7$ERSQ).`3``"W`&8X``"T#6VQNFU^@I+%`#-O`%;T`%
MLE4!`B`!(,`'%6``5-``RG("*BD#HY(&41`"=74#%M"%/U`%%&`$,0`'*<`0
M-=0!"J$!&]``BAD#1Q`"1W`#I\L``QK_!C```WA2S#U0`@<0`QNP!'BP!:M-
M`PS@`RG@`0)P8A05&#,`MS%&U4EJ!3[`!H:@`T,P!#IP")PZHDSP!"7:E:57
MOU1,,9O(=IZ(&?63!2SP(V7Q!5&``LH+O4K@!Q.0OE9M%V?`!0#`!$DA`4_P
M*7XP$OM;#R!:<&1PUH50R>XBX%TA'BZ@!!&`@Y^G36U@`8`;N*`-EGY0!DQ$
M`B%`3G6``!@@`R7@`>!H`1]``V^`%0E0!29P!!CP`@GP!"80K@#P`DF```D0
M!4!P`4_@!PS0!%`PA780``$`$`UQ`2$P!P2@SEP@!U30`SF!`45`!3O>,0^+
M3(/)CVC0!C_`_P$#X`99X`$3X`&BF0<8H%94?0!"`-*(D`%#P`(M\*)J+0@T
M59Q:P8(L+K]/H`N)9>"&$`6L5U<S&@MJL,I<$.%35FHADPA0VD4+P'($P`2\
MLQ5:4.(L:-9U-\FE)YWN(A[5*>-J<007?N-R-*^1L``).'Z1@0&M!0/?X@82
M``<)4!.#3@!"@`5+D``_8`3<*@1X4`*+@`(&8`19/0Z:0P(\L`)-``=+8`#;
M/0)'$`=!P*\HT*\_(`%X(``%0`51X`<"X`<ND`!9,`,A\`8>8`=Y@``<(`)P
M\`4#D`(#P-&BR324H`)/,.E]B\EV4`D>(`0Q0`2$D!$C>G0E.KRWL__I^`9/
M0K`(I9:`AE``Q5,`69#4@ZL`!T`!9^"O0D`!N%YP>P6^*OV1`A2OO[3KAG"R
MI9<`\2(>/^``?>!D1^`'.#`!:*1--C"ZQOX*.?ZB?O!+ZUX&6?`&LO4!'!``
M?&">%2`%%S`"P!!G3N`"0B`$**!P$^`$:>@"3[`#1U0!3X`"<?\&-?`&]XG,
M_?$Z!O`!/F`$&A``&+`(5/`&$(DG2\0L`P`%&L"2-8`$5-!"2"`!,&`$33`!
MH3F12A\)`,`'.G`'9``%25`"=*`).H``&2L!%I`%60RK$U"BQ7XD*D\)"X`)
M/&!3ALRB0A`)H3D!3Z`$*<T%/U]ZPX;TA?#_`X2,XCZY8V;[^S2B_;+@XDR0
M`;)0CKR0;VCTZDG:`\;DQUN_;5U?"&C@!\5<#PE0+501!@(0!`.``&TP`R0`
M"%]S'T,P/`,C2@X(.0)`&F5;%RP&)%H4/&5'+C<-`R@U6SMY06XN1B,K3!)4
M72`(,QL5`A=^$GY&)15=-`E\6V479%$&(@)<CEI^77]_6C[-T=+-9Q-`0%$2
M)-/<W<TM9!<\#B[>Y@!^?CS>6^;N[_#N)O'TW`-^67[N62SN6'[_YM4;2!!>
MOG3F*!1<&(\+$(0,(Q84X&>"GS/>!$K<.*T-QWI;`/@`P+!&FUH*4)#9\B.:
MGA?I^L63\8-`'@X$_WH8,%"!`($H=S0@V!+%29R/"_,E^0.`@#L%?LKX$9(%
M"@($/,B,\`$$"YHL3<+`(C!G1`D'$Q"@`$5A0@,&(CM8B\$E`1,@"!IP.8%@
MQ4X*1K8@,""EC8P$4TI4D1(EBI$0//S<>[-D!((-00XTD(#&`(A7'O!XF#!B
M63,M3M\M0"H1G3IO$EA_U"B[V;]\3R?X`^B'=FW9^1Z:*_=[(98)0O05E\W%
MCQCEW:(L9TAE.K<+`(Y,P%B0AY;(78!(\-GQ10IZ6R0P>>'`A`\>2DS$5[("
M0)(G/4P$L;[/S]*F3^'C1Q0C-%!'"J^,$<`1`B0@`A("8'%!&#7$@$`)&/]H
M$4(!7.0A00@-E)$&"79($``)7`2@@0%&$'!`&7%0@(8,1LPP1@T7@'&$60A`
M,<,/4PS0``*\0<&#!%8,0$4#1Y1100U@8$#"!S;8<<4;?FAQVCK\?80.$%QR
MHV67]?@FVVW031,#!12-`0`SW/P3$)D<-0>3.6;2&:<M:>I)T#\0=8.%G_`P
MH.</`&P!A`H+D?%%9`H`\4QJ#.EQ1A>8/A#-%\UP2J@Y2C%%:3<+",@#,A!$
MT8`%;KQ@P`L5;!$$%`3TQ$(8`4!A@`LQI#!$"$>@YH$/*90@`047Q+%%`AT,
MZP$+&OP@02$52'"5+EQPH84!)_K0Q`!2_>."!B7__$!""''`$<8/'`P`01D"
M"$#&!&"8YDR8UG''AJ8%N8:O-%IP]VDW"4R'IC<%".&"'R\,*BA`#HPY\$!D
M^,%`G](H-/$T@/JAP,;T-."'`WX4D,4:W$`#\C0"Z!E22`SY\)W'DO(PZLK\
MA0J@.1"82@(';CP!0P-:P$"`%DB4(8$6/WCP`0!8&,"`%EP`4,$;""C!019'
M$(#`$#,PP0(5%6#!@A,D,/`!!QML<40%)/3```L_&(#%"V74D$`;!0Q0`@6\
M\1!&%1MTT)<G'<0!!@@I5$!'#Y)FV0P9_WHC0&-0G$&%"UB$88(%?^"1P"3-
MQ+"$'4VX<$$=+.`@QA`+_]FG1.6GZ8%S-`$8+*`[/%PQ@#ER]G8[/%(%RDT)
MP_^S!3X+G6%&,PI$;T;TT:LQO0+3=Z&`&DDQG(X?3W#!?332#?]'GLN]_`0;
M"WD':<VCMC``'>8#YY^H[E!$T2%B".`"%2/X@0EZ\((H4&$`1&C`$J)P`0-0
MP0IYX($'`A"%$O@N``Z8PAR<\`,>H"`!0^#""ZK`@@:X8``N2`$"$L"%"XR`
M`@:HP0VBP`<+;`$),C/"POY1@@L08`EX\,$6EO""$FRA!F0@0PDT@(<KP,!>
M66C9.^@`!#ID0`(QJ,`?8F`#`*"@#PG@@0`F8(,#3(`,Z\M``HC`!`;@X`2Q
MH__`$UK2#8G=#GT?.9@[5@,\WA2L?M[(A\@2DCP_H",-!3%``HX0`"TP@`="
M0`$!3$`!(`C`!%O@00#\L`49=>][WT-D-"Y0/SS^YF5,R$#[OJ.$",`O&CFP
MR`0^5ISG_>%Y&6#?+?^0`07LH0\JT"5K=':S::#!#YODP0AX58(0;&$(5&C#
M"CHP!PE4@`DYL,("+C`%`'S@"DZP@7Z`8`(A,.`),B"`!&80!294`09"J```
M(/"$,NR@!&20``1^(`8GC,$'?*C`"0)@!`IT(`$FY$T)HD""`*#!`CZ``PQB
MX,PUP"$%$@"!@'[W!P&HS!UE($DS6,",`&RA!"_8@3S_(2`#'T@A!@8`0C/4
MN048,&`.L4O'1Z>A!4_=CI3+^4=S)!(\-##D"UM@1AFTL`6J':T!!/`"%V+E
M-RP@KWL6`5XATP&G>BR@8&=PP!\JX(4NF$`!6>@""BZ0NS]`P`%=<%A!#@($
MBUP!"[1LQA'JMU/^O&P[J^3!=E[9C.6EPX[N^(!/=$$`EAS!!S]H0!0T((9%
M<D`)&X@"%G:0@!X,821#8``0I!`"<M:&F`'2P.S@$(00#*`-94!#!;3@!@:T
M2PP\R.P,*!``%H!A`B?H@`FZ`(`=^`">$VB#$=J``@8TS`0#>,(7BO",,>S@
M`A7@P1$&@`44W`$*;&6``2Z0_P`H_,`6$T@`!J80@P$88`Q+>$,)#*`%.!@`
M!AZX@X"V$`%G[/4=9WC""OY0`"Q((`([:$,"/,"$`RAA#4.(0NH,D(0#X.`(
M<C!`!'RP@8%\00L62```P.0-Q*[LJL71(T."9TISK&&X5@5##`0P@#>!`0PL
M&(,+OC``L_Z!"PRAB'"\(==I%(``6""#%\2PA084H,!K"`,I%8"%KI8`909X
M6UOAT;&Y:DP)!V"`"\RZ!6CXX0=2_`,+.LF0?%S!#V/80IJC462<T9%,(<'"
MH@+[!#U,X#N4TH)%@.#3=]1A"E$@`!I,(.8C1"$!'TB!$7C``_#^(`!+*,$1
M=F`W*?]0P$([F(,>?K`?^_VGF-*`2@VNX(`/5($##:#!',APM09@(%J6T8$;
MP-`#%DSA!X]H@]F`X`,&R$``#-C``&J0'0J\IPA0J((+0F``!-3-"!*(0@R@
M!(8?C*%<,`C`#^8`.`E,X`5)$`,!,%"P(#0`!1XPP!MH@``WE*9B*%`")\H0
M#PY0P`5#T,$0,#D&*81!"RDX0A".@($"2.$(.KC`$>SP@2/H(0.VHT<>2):.
M*TR`=L[@UQUUAYN(W&).!>&"PY20!1Z8(!\FX$$63'"$+$3#`5CX8T%N83R.
MG8/`/B`#%B+T!R4"V3;1.$`"RI&%&`1`BPWY7D'.\`(O/*/_`%I4@Q">=\PQ
MF(!J`E`"U0[P28S1N90N`P!V&.(^L?_99M*@0Q=$#LB-H-8<4(EN`@XPA#'T
MX`Y!V$`)C!"%&8!A'E@8P`>$D(0!@*``)$C`!LGP@Q+,(`8.,((XQE,`8(#A
M5P0PP&=AX(")QH!);O@!$NP0AP$<X`T:J(`!3NZ'RW^A``=(O1,&0($*M`$!
M<'!"`2A2O._]UQMWT((61,"&H1#!#EI8`2(JH(L2:`$');B!6S5O!"RD8"<9
M\$$,DD``4+@C".DPP?=`KH6N+@0!%;B`]HY``2RHP0#(BX+-&1"#:"P@-EH`
M-1K38D2U.Q%Q#RA'$&@`.POP`EF`_P5G<`;]\`4S%P!B\`?6(QU?@#)SU7%:
MY0TR]0?24DX%,%)A<';-(`:"]@=-AP5W]@[-T7/T``%;P`5GL!)_D`9;,`9%
MUPZ=IP4TR`5=(#`#<1!FAW3F4SYX!@#CT`=\5@"$57>_<7?>`!4<<`5+]P*Y
MP!)U@`%+0`+8%05L8``-$`)&@`$G4`$+,`42<%+#@`<R(`85H`$#(`"&YP11
M(`;6M#1;D`8:,`<6,`!S(`9(0``E8`$!T`06X`0GA045(`0^P!LS)@,GY`&#
M4088,`<P(``?$``@8`<"\CT30!S>4`%.``9P$`,S(```0`(3H`=@8")50`!&
M4`<\P`304/\V6K!7R<<$8(`%&*`'`"`"?.`.:2!:#O`0KU%'[C=7$,@`8B`=
M`(`&;H(&Q($%<H4`(:@/,D&`$:%BQL$;WM@-/I$`Z_("?S`&3&!S8,`$:9``
M+A@&#$``3&!4'5@1']@-\V`&!/"`%]``S6`"9-<,%W`&[T(!6D`760`&7L`$
M]*!G,F@=XT,0%9,.''@=]5,==!(2MY!7`^$^ZQ.%4FAJ^(-WG`0`0C``'F`$
M'N`!8;`);7`"`M`%27`#;Q``4_`3<Z`%\"(`OW<`5=`$%R``&E!_+L`%#Q`$
M!!``$E``/[``#,`*"5`"(L`"*8"'#O0&[Z4!7/`>2(!_O$%`L\?_!0Y0`VZ0
M!FX@)&,0!FD0`ET@(%;``@CP'>[`-"ZR/G^@63+%5-\A`3_0`S&`!%4P!DYP
M-`RD`5IP`DE`1V]2#^>UC/8@3(TR*`&`!3Y@F<T@3W3F,&HP!!7`@P"A!-PS
MCN%8<BNF4!'1!9R"*7_P!=RQ`$3($4:8C].0!?'!`+AB*`F`*0G`;W_@!3X0
MG.'P!V)@58U5@O$@,NDPD`.Q`/\7``T`E>IV2\_S?U-%!@O@`Q705_!@!FJP
M2>E@C]Q`FF1B*!NY"![3*`OP/H`VDE-X/SM3A2>I!")@!"80!0AP`1=``@9`
M`57`!6]P`"Z0`&_@`M.B`4DP!$P@!AR0_P<E8`,ST``:L`1.\`(_H`$!8`72
M4@9#0`(-,`,H(`$\(`9BT`"=0T$:($9<4`)BH`$QX`)IP!O_.`0N<`)P@%+X
MF0(^<`<B,``#<$SW`"=T:0Y:(`$R"00/L`="P`%"X`Q-]0,78`3TXP)BP`3K
MN8M_D`=)=0-%H$KDB0+IP'XM(!$/:`8O``8H$`8OP"E9X`/C@UU45FU=,`10
MH0`,8%3D^2=^0!$%F(`$H08%@#TEF`5I()Y_L`9KL`5/]@4-T`5;5H0C<X1_
M4&<;<P_I(`"-5818L``5`&'8^`5O9519@#PF\))$5P\%`#A^P`1^`*;,.0UY
MRA]YX#+HZ9'UX/\=)4`S6N`"J.:>9`J?O0H]?O`&0@``>3`&G8``8(`34/`&
M:``!/>`"'<!4RG($'#`$-3`$!Q`#.]`#8M`&-U`%#<0%-""'%X`$-:8+/0`"
M;,`&'U"D()``"6`!1L`%+!`"4C`#%[`"_?,$$S`'?N!T<+`!')`&*+`$'T`"
M8T`!(C`&I0`5F\110]H-?;`$)D``"9`"4X``/L`&/!`#52`'4&`"20``M\<$
M&V``'N``52`$)L"RR(,`EC*B]1`%85IBDED0;\$`7.`%/.`%"-!_1\`#HB0.
M//!O$*``G80%3160NK-)?=JJL4D/_D@!8E``1R`&".`%4<6"62!T8X#_!6"0
M`&0P$&K@$Q7S$%FPE-R@,=XP!O^G!0LP!A+0``!I2P>@;@AP`&,P!"C0?WJZ
M,$^0#FX+#VC0;24``5S`!#SX!P2`2&F`6Q?P!5T0`XW[D*`T('Y@J-(0J]:A
MD7C&!$]DJ_10#$02*>WIJQOAA,U`A=V@`GX@`T#P!.I4`18``0C@EVL;!1_`
M`F4P`#!U`1BP!2$P!PQ'-`O@`@&0%1A0!B0E`6N1`R5``B7`!%XP``$@!5"`
M!!+@`'L0`!P$!ULP`R1P`'S0`':`>4HP`@YP!7'0`;%7!D!D!&E@`#X:`'"`
M``&P`IS$25MB#AF`*5U`/Q@``!*@?33`/H4V_QT+`YD\A79!!02F&8Z`,@%<
M8$OU\(!H(`!<XP)&I08.@#)9D`40('-1<`2<^PYCP'&#^QQH`00`X`720(K=
M4`99T`!;\`74)P:K@0*MZP,O@`!B@059L,#Q\`\VJXR2.C!B,+B9BR?U,V=^
ME2A/@,$#\0%RP)YP%P'`U`<1H`;1PP8J0#UD7,9EG`8'(``*@`8+D`;*]\;*
MUU3*UT/*]X\^<<=XG,<)0`!'``!^_,>`_,<.X,<(X+K<<`8GR00KX!,(B0)G
M4)DBP`!I@`07X`(6H+\N<&M@<"$'-`<Q8$U+``.#H05!P``E``,#P`.7_`<'
MD`._YP0<``=`4P-YL/\$",``6%`'=C,`%E$#[=L&Y%(),Y"_#;`&,1`&G+,`
M9``&]W`/[7`O`_$``D`_A&*S#@PP=!<1428&87""$E`&-[,98-"I#!``M`%4
M*6:`IXD%R<BJA1L/];L%97L&1P<!0.A6-,@IET(0M_!F0^``+)`.+V`1,AP-
MQ]<-`_`Z8>!1*``!?Q`&#B##E#<$!J#,+S"UR5D1?J`$=65B*_,%6$`!VF@`
MDNJYTX%B7?(RZ=D=,X.Z1_`$`*`(0.``BF`-3U`$0.!QU[#3/,W30C`.//`$
MLT-I1%W41DUI!,`#%[`%3-W43OW43$T&`CS55(TI+6#(T]`')SD!!J`J1P#_
M`UQ@!^\6`FLF%%+@7M82`)Y#O%A0`P9@P[3"JYR5`%H@KB&@>C]`!BF``E,0
M!&"P!%LP>Q?``!0@`4V`!0R0`CM0$5@R`6_``#DP`CO`!1L@!GRP`01`H@(`
M`4$@;_\@,@#I7P,!!F$@3R%`!4;P`CS0!PJ@2CR``2_0!')@!#Y0!'"P$2SP
M`APM!"R@`]/0`'+P$6>PFRZ@`&7P:<S@`@5M`BC@`&GPBUA0:"A=&^!8$,'C
M!T,`!"<(2&>@*,3F!SY`#DH0W=/P@AY6&Q6S/%[`1PRA/=1C=9@RPA)1`EC@
M!4<@=1E1/\%Z2HN@!"UP`'M`$'1]7JBKNJ<%K.Z0_P$G"00M0`$8\`;D=0(-
M<"(I(`D;$`,C<`%+T%AW,`!+<-8E,`=+AP7V-@4F$&XZ8`!.H`$R<-ER(`8C
M<,DQ$`<[T`%<8`(7D"11X*,(8`43$`)"X``"L`,,BP`>P`67;`1P(`8JP;@6
ML`,((%3V4@`I[`YU@(U)8`%-L0)TD`:`10!=(`8NL%!@SA$,,`$6D0Y*`#K1
M\,P?$04%,`0TZ`!@T`PO`"<)``8%&6:7Z[01/,'6#1!7<+1]7C]JP#U0F*NT
M^0YHH'Q8\,9<@&184.B!G@[LO1`+\`0\``#)Z`"49@(/4=`+H7Y/[`T'C3/[
M71M;H`0S,`%*X`=.@`<#$?\QD5C@!CY,".X.?H`=CV``89`#,&`$`R`"6)`#
MG(H`:!`$<N`"A3$&9-`$":`!-PE9`9`76%0`9"`C20`''1!Z/P`#$F``,9`%
M6K`!6$```W#`NIP`%$`"5N`'.R`$5^`&'D`$,'`'.W``.R$%"G`'9H$!<$`#
M7F`')^`&`B*D(.<-.T`&<BD"%``%[*,!*!#<A9$D-.#A&2<1"7`%;_8]C\I1
M'_$%KMD,ERX-1BP-OIG.7K#$7`8QT]UFJ-%8=[P%/B'J!8$`+"!H'"VIE(HG
M*$#421UZ6\`$/3\0'6-S$?&`]DU6!+``)G"!+/\.I`Y*YI#P`Y/JLJ'2WR-2
M].#_'?=MZ[?^$5@]#>K``D`0`T2OG0\.`.-\!/WI`C/``#"P8S,`!78`!^YE
M!63@F=2'$Q[P`UAA%5NP[1U@?6*0`F(P`R,`G4?0UPG@!E-P.;N>'`@``EKP
M`7E0`>WU`VBP!`$0`G?0!,(&!B/P>\I`)%)$`C3LGH\F!-8P`64@F8_*&F9<
MQNZ@<[^A9\K0IRA@TM/0%5@P%$\=PM^8#@[0'GYPD3Y'#PZ`!IL@!F!P`&C0
M$MBX$1(PTWY@\\[(%`4S!!@!D%$O#U-Q!=<@J=P),K"SD4*`)1VW`Q^YJ[H:
M]D@Q]M+0J@0P`7RPB6\P`C$`"!T#"#XU'#\C$FU(8#0V_P%+%B4E4PPP!!HU
M#0T2,5M!+UL50GY^$Z=7J4@&+3%S%@0%6@Y^)59%%&4;4A]U&$LE(R1#%VTY
M`B<2&F`2;BE^6'Y;?W]W2-38V=K;?WA:W^#A)-SDY=E'I0DM;-M:&>;PY%E`
M/!1#//@Q"#Q`6>4F\0*2BY;%SY<L9@1JBQ8-H,)R?OY$89`%H(0`?_Q`>+C0
MU`L_+*Z<(7=!H8D#)HY<&)`%@(\#6+!PW%:PE+^9V++\6"-D2!<49@9LC(B3
MVA<%7;28(LK-1]&G\`A`Y;B%"0P'?`8\X,A#2PD_"H!HF4JV[,."2?X`D&K.
M3Q0"?IH`*''B`H4!+RB($?!A2/^``!\8'-`B14L=#1*6Q-`P18N,(26X<$A0
M00*`)_3<5&BCP?"`(Q.N'.D0`\X/%R9J`9@P@@>,+D#"%+@@H>Z&*%TD-/B1
MHT6%+0MV_(#F9^P?+2R>`DB"KWES(<G-_H'KQP$Y+72D4\N"XL\1'@O`+*#`
MX,^$F]Q^:.]8\(D?)EQF,O3C<&K$(T?(4!AC0OV5+D^!`4`!*/BAA!)JD'.$
M0DID(00!0V`Q0!0FI!'35#7Y@1Y.66`!P19:?#C&&",QA5,!M+A7RC_K3<56
MB]QL`<`68.'4%8UA&0?CCACZD=9:\/C!`P$3S$&"`"9<L,82),00@@`&!&"`
M"79L,0#_!A)L0(4!2]P!81,-#*`%%%H04,(60DP`!1=51/`#!UOX4,(24[@`
M!A!`S&`'`E7X840"?AA0@@`4!%$"`:Y)4,`,&'1PQPAY!!!&!68$$$0!&OA1
MAA]H4*,%#\IU04@'6,0@111_')"`=M2!RHT67ZR7A74.1"$`%AT"I&$YJ^[8
M@!\'E&+"%28*%(U2]4'EAQ<`#"%&%&%D(94)7D"5A18!$.M'&@,IY$`6:&0!
M00'D%J!`!3)!)4`I-3Z5Q0L`Q"OO:@!<46U1+@#!KA]`),@-!>:HH49"9RA@
ML!D&)ZSPP@PK,)(Y+_*(C8PXXN2#!1>`)9;$''/HHUH1<^/'_UI7@`&#`%I8
MP$,=!@2!PA)VE0%#`PF040(6,V"QA!-D7'#"%`,LT(,!',20Q,@#..!"'%S,
M@$88&KR1@@\[!-`%D1BD1@&@KAA!10,&N*"!&TEBP(<%49!100TB-/!!`'`,
MX$0>TO@1WW&NSM2'`U?[8"H!74!QW!/:^5!*WMIHT8*L)J@A1``27)#%$*CN
M2DZRZY'A1P#\`N'`-!S-AWE18!5P@`(%9.%%%@J@L,!3P0J[(CDN*)2`$'@"
M,4'G>(8QE03L;O34&5IT8;SQ6F1A_.M/&:#OOMPV10`7)E"`!1=8$!#3)#%@
MX0.B/,2`#Z);4+#%%@108/[Y!&R1/?\"Y_=:S@@=3RP$`NUR)$(!7^58__\!
M00O(@C0D/S#@`CV`P1!<<`<3;&$*AS+!`!+P`R?`(`$RB(/VED"`%Y3!+T9P
M00!<X("2(<`%;J`"!3X`AC)4;P9BX`0"5B"!!+@G)8$*PQ$D@``*#,H-'Y"`
M!02`!"Q40&H#V$$=W""##KC!`)DJR-T^510%^$%4+D@`"P!`@A+@33M1.-QU
M`*0=[JSA&V=`@Q?*4(`S6(X;HY,.0?PPAJ#A1'1E<8X>Z_$P#BGA%,\KAQ<5
M\H58_>$,9#3+/":@A#7`R`S^>HH"$(`%%VRN6`#<1L@TF9#Z;<$!&5.`C=Y@
M2?])S`QB@!#_`<C0QTSFY&-`,@<]X(*`&>3A`AT``Q=JT(0X!$`&*2!#$YS0
M`"X,0`@B*$$/P`"V`4Q!`EFP`@4DD`H82`!H6]A$%.*`!`L$`0L(J$`(*C`"
M(VC./;BD0`<V8(`W6"$*`,A#`WJ`RP%(H`)#^((+"N"!&KX!`7?0D#2HX07Y
M<<2*7=!``R#0`CE$(#M=0!Q9J`.`,:X'#9X[!0IT!X0#`2%ZW!@DC+@@4*C@
MD2Q<",`:"A``]V&A3!!*)$?0L+LGH&!WCN1&[1ZR@#"4X7S98]Y4N``$,7`*
M*@0:`W!,4((75,`!1V#`W:S%+IFZ,AOI8M'_/HD_4<Y$#%^`BREA_Y2!`9C`
M!5LX0!E^`(``[.&JVX'E)K4!@`+JD@,^@,$.*$```;BA"5CX`0;>((,E`*8!
M#+"#`;#`BS.)X7LFH,$*3#`!#;R`!#XP00.4$`8$-$`*)]@"!^Z'A!_((``3
MB$$72#`"3Z!@!A*`@IP((`$8C``&`]A`"2[P@QA4@`12N$`#1B!0T"&G*`^X
M`A/B]81Y`<`!0V"5&%_%CA9UH9!G^$(KS9'5%LW1I,1!`%G6,(1P7H``1_@!
M%B80IJGBY`M=V-2F-I2-.)KC#!1<[``&L-VB:*X40L7)!2!0!B8,@`M'6&`)
M"M!==]''#P&&*S4:O`TRO-63Q/$J1XY0)O^-Z6@]&9#`$'2@#3WXP`D7=J4`
M8UD.`"3@*T'PK0N&\(,&E$"+0*A`"@SP@R,X(0@!V(<,+@"''B"A#$?P0`@0
M$"4&B($"0$!"4[$P`A;<868&V$$2&A#D'V@!`;.)@Q>^_(,;H$`,'H@!`,8P
M@B-0H&I+T$(#3B"`'E2@#`BX``?@X(=U@0X-0G@*#8Y'Z.-5URP\F&X[:+`C
M2:&/``2XESGHJYUHD!2\P&L`62"`!328@`=U/0(7?""`#I$E0_VEAGHXHEY%
M98'21?D57&"MD!^H00+0)8`+&""`&(P!"SFE*DEI[<H@],$<)M`PQV@4#64K
M9`M@@`ML/JR=W;S_@QMWANN*YYH-```A&CQHPP?P4%L;4*$$,,""#^70!@(8
M0`!,T(($L.6!'_B@`02X@"9^0`88>,`%)0#"XRJ@`0H@R0Y"@`-3`S"#$'``
M`248`+`;4`$H=&#+4CI"$S[3``\$X``=,``&$D`#!-AS!P)8`7%`9X.=2E@A
M4'Z"1+%1O!VYX`<_R,(`8A"0F<NQI$^)!HV<0I8+K&008##`'RB)!C&<V@\9
M"[8V?`X/,33]`FD`:8\*1.R`$)B_`_B#&,;P!P-P80S.]IA-7IZ-$D0R&P\P
MV!2.TH5C2XRK^0N(#K[Q`R2@8ZS:4=G;2PR`0P-PV_`00A1H)`8D<.$'_Q:`
M0@/$=@0XM,`%5?"!^YSP!O1-$`XS,()L73R%&5#@#@9(PAW2%(`!N"$`3?*`
M!G9@A"1DX0`E(`,/RA`&`HQ@"&2``@7>``<*6.$"(/C!";`@!`PD80A+:``'
MZE`!/,A``@1(@]T&V@TKL-UVBDZ<X;43`Q]0(`O8"XC3&UT<3#YD/N[]_J3Y
MI1%RB/3[)"U%VN6OC0P)@/\4H`+;8`':LB\E(3$-X`!=]1#`4X!7M#$M@@#4
MM@T_$'8J)E?P<`5KX0?XE`9+T`$((`,LX`,=(`-9]'I-`"5P4``IF``6\`,2
M\`:$X@$G,`(G4`93<`0R@"A7,`5DP`<B4`<[D/\;9E`&/(!],W`!(30$<=``
M37``BX4&.[8#'W`"`'`#0S`"8D(#+L`!%[`#);`E41`-OU(&GA(=_&<.`*`$
M]$`.9;`5,)(&`]![:>`[\0`&/%(0`P`L0><'EH2&:2@/IF`OW?)]"X!>[`)/
M$1:(N,8N3U`!\K<#*38Q^\(NH-,B'Q`O0Z`$,Y!W\1`->=`$,;`#$/8$EP@5
M&6!WU+`#PE,.:$!TF81X:FA7#/`%Y5,'![`#+F`'`3`&+&`#'V`!8'`!/-,$
MTW0U(M`$#+`%-4`%5M`#(T``!\`%%(`!0O`$'7```=",WT,%<'!/$@`&"#`$
M*0`&6(`$'``"<^`D`V#_`-/$!Z%5`1Y@`'>P`%N``A<@`!P@!0'P`\/F!Q:H
M`!,8B.<`!$]@4-EP`-F1AA0F'07Q*ZDF$"2%/RB0,`2I#5_`.0:B!9VR#0?(
M=AG"+E?0=6QG`O0@<TS0D*X4@-OP*VX0`D#P!ET@!!+P$'&W!P_`!A'0,&>@
M`@-0@$]0!WY``EIP1@)`E.'P#7'``01@#7Z0`C]`.4_)!$N`!0(`:5@):3Q`
M!O'4`Y!V!"Y``&P5!U7``AS`!$)@!0!@`B:Y?]G0!8#X/[+88@X`%Q<P`AY0
M!PUP7G$@(37`!3'0"6`P`DC`93N0`UR@!4UP!%L@`3OP!@0@!EX1`)6T`TV`
M_P1.,`%<1#T=``,`\`-B,``@H`%B$)@K<`>-R0#UUHLA(`%5X`)1$`!Y(`$F
M``-',`+J=`%S<`(_``5S<$F@(P`5118+P`(F$`$[0@&E$)<TQV@,.7C2L8<T
M`A5*48E\>)'4H`17H)U`<`5Q!##?5Q!QXH=$$G\=,Q)F<`8(PS!GD`:M@P)H
M@`)>X%NL8P;)(PM)^0VR\`4O]0TO!6EC`*!9.01BR0-AD``-X`,_D`!L.01L
M&04^D`!ED``)@`]48$!'`P`C``3&R0!LR98\Y`)=$!,DB@5'X`,Y<`0?4`(\
M@%8_P`/P,S82H`3LX@#*:0`IH``-D`('D`5QH`$^>O\"RI,&JO,#2F`!+I"D
M?I`'3'!^$)`%>(`!!T!H\/4`<E!HQF.E-,`&79"37?`.%2!UW&`S5S67Y%!7
M<!$"6+`!9T`$$E`&2&`'B5`"'F`#4T``6N`W!``#+64!5'`!",`$%^`&9/`#
M5/!<)D`,&/`"*9`Q;@`#%\`#FK`!;V`$=;`!B5$`%'`!=G`#8!``/7`''/`&
M&A`#`P`&4A`'8-`#;H``$N`#!5`%`M``!2"9Q44-96`=4V$&I.`'+[`>?7`!
M+J`B0```'=`.5@578<!<#K"6+4)2))6L"O%?E4B2+^<'%&`&`%$"<80J.)$@
M"9$@"O,'#E,P#%,`:>`%9L#_.EE0!F(!/&2@%//V:"3*901PB%G)5_?*`PT0
M!B9``/(":C]0`0#`!0"``BCPH2:@!+.@!,Z3._P``$EJ`IB1:#SP!$R`#V)0
M#QL[)!Y;#V/``TKE/N=3LF/`!5M0`"4+(B"R`/"U``M0/(46!(:4#30"`5W@
M!U*A@#O"!_8V`A,`/&XY$!-`!@8``P8`+'4)([D$#R[0D;&(@>;P!$)0`WXP
M`CN0!EE$`#M`!Q)@;PQPF#:`!B=3`W#``!*@$C;@`UU`!@3P`%_``"O0`#$0
M!%`)`2!@`"'0!"5#`'`@`$L@!E`@CP2P`@$@?0/`CQ:PHB$0!W,@`5%``B>`
M+IU@_P#8,@-CP``S@`<+D`)*41`<I@4:$&]:X)PXP0?L`@3K8476.7,U]WT-
MP00H0`HM`CR;`A6;T@5[J%IO5`X#0PT/`TD(HP8-HP#$FYX,XP4%8#QID)_?
MH`8`<'Y"H`5#,+V0%@"0%@81DI60UA(54`)KB0\H\`+_2@`LT`5,8`+&6:S>
MI@4N4:%[)`:1VK$\8#@$4""4Z0?PL[+G0P8"L`40@++*0VB(Y+)8V@4&_`==
M<`;]5;/E@`4F`!M>0`"P^'+&M@UHX`="P`1^T%Q`<'\P(J\0]G[6F08)P&U3
MH0<`H(K;D`$``(=1^R,H3`U,$+1^0)LCT`8E@`(Q`*A!P/\#2$`!2[`#+U:_
M*RH#%6``Q42-N`7!,4`Y8>D"!L`"%)!%17`%2V!P4L`#+V`!HE`!<%`"1Y`#
M%7"X`7`!%7`")2"Z2_!N3/`!RW`!!I`4`G`#*5@")`"0#L@N5!<0*D"C(Q,0
MHB1*&4`$+>`%B)S(B8P!IF`%IM"L,S<&TNI*25L`46)4V:``"$.NB8PPB'P4
M7J``BKPZ7,`%"L`%8.`'J5S*K!P&8;`%85#*ZC/+!)`%%&``[L@`?A!5(Y/*
M#,"5SA4O8F`"%=!!^"`$^/`"9N(`(5L]ZO-I)J"I8#/+U-PA6!#+I;P%7#`]
M7/`%#F`"F<L%/``?:,`%Y=S-/H'_I0K\!0M`P`[LD':3RA50$-8J85C`!`3P
M!$?@K-]'!3",#3D[B`9R!:<((SF;RG8H$%^0!R%@!#%@!)RBS#N2N-=689I6
MIE+;8D!`(];9T1U]!7BB+7@R`2'M.0YPTB9]TB==!#X2(1\`!6+P`3]P`&&R
M!'@V`F'`3@A01"-0`%(`<<+%0P0`!3]`*();`A(0!IO#`150!$RP!4!`7$60
M/NE#S5:]-5&@113@`\W:JRP@!"H=UF+M.9Y3!*'AT>P"!3E0'5R`!$G`!1HP
MC:4\,Q]@=MACS21:S%CP:[7</9!&`>@2`V&@%^I3U4;4%?^:>FN1!(R=!,J9
MJ`#`P7Z=_P0$L*Q8``:S7,SJ`VT4``8Q8#W:0Z*_IIP5H,JE;``@$LL%P,JL
M/79<X,I<4-I@0",Q8$5B8`:CG,CD.K0<XP`&R@!>0`%QI)*9Y`4=C8?8^0>V
MS"[.(G\_((`8:0`(,`(H,`"-V8H[DK/1(&D/@3)&10(GO",14`)24`#:T`*)
M4=$Q/$!J"`!/F@4\D`5D$"9RYCX\4**[0:*U!38Q<3Y'"S8[P,HN,`57+057
MT`!@0`9+D`!#0`7/9``5P`5Z)0'G>(Z,O1*W@`04Y``_$`4#4`^8W0#IEC&1
M$0-%`*A7$`(?W:L>S<$3H,O6^>(CX]%P,0$?89U,\!$WS@)28/\*;%*P&O""
MI8P$$M#*7-`%K*T%I)S(HIS;H:RNB-SD?X#;FTP-SJ;47L`%Z$='LB)0G100
M$%[*L5(0;/C(=I/<?Y`:].<'T;4-D/A]*,+!I:`$`##)_%<0^K)^W\<#O"T`
MZBTQ.6M4"=W=")#*(5`%,TP6`L`"$5[*;`4&?WYX&<T-'-"=<H[6F)[I<SX!
M)PW2_(+2#L`$&I``1R`$2H`"#L``2L`$5.D#1:`!CDT>.VP"20`#4I!Z#``%
M%[!;Z%(&$F``'R`%I4U./\`$$B`!$V`!+%V)GH[6N]/LS/X\FN[L>.('4D!<
M$]#6D6SG`!0-#```#*#+[_QT]*P01B3_YLK=T?4,5U\P!NRBY]H`GO*'Y^>!
MYJ_$$/S'Y^;``/\,Z`(UD!'@!1G0`B$0(UA`(Y^2Z&3Q`+Y.`0@@`"3V<F:Z
M#2H@!,WB!QNP`Q(P`!Q0!C8@!5A@!&@@`"ZP`V&2!6!P!`L@``*``!O0!0;@
M!7/F%5I0AT4.[!L@6?QC`P7@`J]=`0/P`6*@A5V0!6;W!PVP!250!A6``2/P
M;EO&6P=P`!80`%#R`V9W`#2@"VO-`0'*`C&0!>Q5!$7``%9=`BZ0EA3P`[2!
M/<+%VA*B&USP`6XSJ]089&EP`"'`!660!@T@``=P`@<@`&F@1EZ``2%P`@7`
MXGR\#<8C?UJ@_S[1JS[CWB/E;BR3,R)_H-1P\0):4,I?CIT%D6BT9E]7Y>Y5
ML>X2SRY*)W_Z_@^\K1TY6Q`#N8E+```6\`<8(`:(+(#NHQ0);^\P,O';$"]P
M$0`C$`(8,`:+Q0%6/ZL7P6,CD`9<D`P6<`!4P$(;X&YRK,22LP6S^FX?$`(E
MP`&#R4,M%5M9L%L'1@`TX`2,A0%&8``\L`,20@!PP@,:H%E&``@7/A<_.3%D
M'&A^4$!^CH]^0B-@!A]8EQ8E"`('664D6F)E70,"66DY'"4<)%@D&&(V6!!<
M66,#7%T?&%\-%1H8)%XC&&D#$&8`#HU^$R@P?]'2"EW2UM?8V=K;V_\&8PK9
M9F;17^,*7NA>"E_I[>A:6GY9\MM:66848W]:6`Q@!7_$^,'B!PRW@P@3*OPS
MKP*];"862IP8K<"C+!0S:HPVSQ'&C2"O\0"WC0')D`F[R/.C)=N+,`1@8/AC
M00J6&%[^;,$2AB4/`BB#"DTX+\D?`$"Y`7A"P$\8,%MXB!D@!HL1"3\,`*AP
M@84%"4,:C&C@I$$,&FF,-(@2($"#%5PPG+A$`(F8(PV&#-B"P``6*CS()#"0
M@(*6`Q(0))#@`@L%"6,*W$`0XL@'%PVP7*AP@`&,%@[&'"@"Q`&+!$>D7#E"
M@0(6`%A,^'!P90H+*6.PT`APP3,%#C&@.!G_,``*&0U;2HC9@*4!C`LPMG!!
M0.8"`BT!)!RP4.```L0VMF@0<\%&A2M"F&A3\",+E_?PX\N'?^G]3@(&7&]I
MO:4"`0(Q$.!::P14T!H%22#(`P/^73(@`5A44,$E,4PHH&,4`/@?`?1)]]Y*
MXV0SQ@L,P#8.%P!*(Y!#$PSE(C8=/81-4NLIH,`X[K1C!A=_<.$%?%IL48U"
M,7[THHM%'IE1#"=EDT232DJCTCPM82-$:T=<\`<$59C!P$P[J:3%3U&6&5)1
M1]&HC1!,^8'!525@4<0`+S1P``Q=Q(```ED=84`!&/@`AA,2,$&"!A=4P0,8
M6#QQ@19<[%`"!&`$_\"`%B4((,8..I!1@0":C,"5=1((L`4:+*R!P`4:&`&#
M%"L8<0$4'PCH`P>^+-&`#Q;8@`$$!]B0A090E#%"!%AH0$(78>A01!8QA#$`
M!6&$(4$``R"P`Q=@:&%$&BC0@$8.%'P10P@#9,>!!!!<B\93/]B@2AA<'##&
M!6'\8`$8%G1AQ`14`*%-!@+,!U\677B!<([NK./.'U^`\P4V(5Z#!4!*SC//
M-ER((0887`"D104Q,*`/000Y8.90%GFD343;F#`APLU,`(DC3:E$``!^\#Q0
MCT3Y`0001JZ\49)"W5@.PTQ[@087/JC`S9-&1S,E2]G8(*`+#_RA0V$,;/^@
M$Q8JQ<`##U6G';112!WD!P--58`!#P(T,(#=,$A@`!='D#&""S&,\,,*`@``
M`Q8^O(`$#UB$T(`1!%A@!18[\+#M$F(X@<8')2!!1@,&(!%``A7L*>@*0'!!
M17(E7'#!`$=@44(,)91A0@A<A+&%`4#L<(05`S@QQA`8#&#`#R,DL$-8")R`
MH@$"^!%`5C9T489B.>S`FP1.0%J`%D2@(8:V2-""``0^8+`!5F/H``$6`L!`
M00@(X!K"5QQ(NP-!0JL-$A9%0])*])$-,#"@-2;0![1X$`.`@&$E?O#?1L9P
MD9=M@R`3<$`8O%``$YC`$4]X!!,`P`-'F,$/`L'_F@EX@+%M($V"$GGA-6)0
MGTO4T#$VM"&*2&:@UF"!"Q38B<%JP846'*0*4"J32KB`-6PD00Q>J``5_C"&
M!/@``5T+DQ\JL"`8>E$::&H;-_S@``)<`0H"B,$%=L`!%`DJ`%.@`!>&8(`M
M(&$*)S!""9;@@Q%(8(X-<`$92J`!!A1K!S_800R<4`$)W"`)`7!"":PE!A((
M8`!A:%T)0N"#$H!!`C"P@@$"8(`2=.$"#:C"`32`E;ME00!@^$!_TE6"#6Q!
M3V)@@"P&P!@)D.``#0``%$K0@`_LH`$7($,`+"`&%RB``V2(@08T`($+<,`"
M8W">%QJ``!?LX`N8^8`&_]+(3%8=TP@(:`$9#*"[`US`$0+[HD0`&"6-R>@:
M7P`BM:(!AO]4P($L<80\)5(`F]W3&C%8SP3Z,[0):($!#%`"$QB0!0*8``PF
MP$D8M```C)I`#-'@`E(FI@T9!B4,%#"(4$PJC0H,%!LF2&*4ON"4)EZ#!6KX
M0P20X+4+2(`*-_@#HY;(`P"\5()A5%,V_/"$&$P``6/8@0`ND(4*:($2K+J;
M%6(0@RTPH``\.,`("#"""QQ@"@,8P^XTL*T?@.$%WJ1"`Y#@@B'\8`@@HP(2
MFO,#!.C)>`C@BA004(8=@,$%"&B`!E;P@0#`@`P66,`%5+"$-&!A`%I(P%0V
M(/^$,AC!!4`8`P&2DQTT#&"/5B#`#\K03`&$X0(CP((!(D##ZNP`#0%0P1$@
M0(`&E($O7,#"`7R0A2T,8`4:($4(0A"`(`6@!"V(`03&0(*F].^H"!E"`(=B
M3Y)B0PQ;0`<+_]"%V!!@8O-@X@N.I(`LY&0H)W19-BB@#3.0]!P3LU&(P&$C
M[X[!#%JH6#1V-`&9,@2$VP5)%VPV@1:>J8+9P`)VI3&$KE5-)0^LTC5V4!@6
MB"T"1I3&&3"@$I(Q8,)I2ZK;>#"$"5@@!`9@0A<D4`H7U'%"8BC!#A"`!038
MX`@L^`'H_G2!(_B`E1N8@J<V>18J<.&C+IA"%SAD@!#_0,$P64B`!900`@Y$
M`08T^`$$E#,<!(P'"QO8`1(,@($J/$<*M12`;`.``1I<H`PA>$(`-A`"%.@I
M"@-(P`<2H`G7MN``V=$"`923@RYT`0D"Z`)`D-"`,30@#%+0`'&P)88/;&`%
M`:!!&$@0`T17"P'BTD(#-F#=>*)8&]JMYP"U4:YH8$$?7=B"10$BD!B0\4@?
M1!MWF7I0"M>7A`D,#0],X`!F+V,90!A"&)0Q@3`\P;O6X`(39$I!IJI4*/PK
MMD;F\0)Q_T'"*!9`!-(&@9IJ^!H<X(DVPF`$,55@O:]>F8K'^),KP&`).1A#
M`(PP@"N.@'-;V&@#X#R`$>P._PDE*($/Q.,#)]3U`L?[00$((`8.H.!U64@R
M%O"RJU5:H#H&0`$)5G7:57_``"=`0_Q\@(1L56`(7=@!&9P0A@#P8%5IH*,$
M+D#**I`'#"<@PP?"$`(KY-H$93"`%@;P6Q@;X`Q=@(`67A>",VC``BLP)08D
M(P`2Y.`#%M@@!H@0AC_<``U=X`(-6L#.`RP]!E]HRA6*`$,M.&`(\R3@D>R9
M8(:\8"?J80C@*8"1>#CD"2^*AR,$CQ*+V*SPZ,9&M_W`A+<]8@M,`(,#NN``
M,?#@"5X5V@0$;(T*`(#U$/-##$(O0#(Z&!O@:)H[5N2'+6C#I2B.:=IL@$*;
M6@,#`/^(`A!F@HWDJ$0,.\NWOOW`-J5BPP\_\8,3EF"`!GA?+&$0P`>DT``!
MZ*56)B##=W:PA2U<``V&_<$'5L6%STU/#&BH@@4N$`()E,$"4%`!3@`#.^`$
MK_,!8D`%I^4$!(```#``#'`M",`]>E,&/W`$FO`"(0`#7'`!6!``"``#&O`%
M$A!O,8`"`Q`".A`&2[`!`^``6]`6%3`%);`%4O`#0I``++`I=3%_0X`$,3`$
M4P`#"2`%,,@#%!`%4E`%+(`"3,A'/X`"/-``Z:<%+E`&)R``;`9]\"1!7L)4
M[W80#21K\X!MUZ`%29`$!*0%,5!1^O!`3=$B+K(%C]!V0N'_!5MD;O2E#7Z0
M.P"P%$!`0A5@`ALC#^6V0B_0%(7W!UIQ>_/``$_@'P<RB918B91H`JVQ;(_@
M`)S8B9[X;#<#"8V@!`X`3_*%#<(V848@-1>V$F$8#5,``7^``4X0`1B0!;B(
MBP=P`AA65-)G)ONV#7Z0B%=0!120.52P!&MP!.`E!A5@`:O"`-CB!#D@!BU`
M`TA0!A=``E/P@6Z!`0R`"QAP:5(P!0W``#<0``=P`U.P`2,P`&#0<&H%`PTG
M`0QP3`+P`R;P0U4P51KP"0)`!@-@`6A0`6W!&S;@`@)P!%N`+E%`&`V@!83A
M!"?P`T`0``+@`NNR!`4C`&.P`6`0_P(E4`$<L`"8U3PED`,CX`5D0`,;X`4J
M8`-KD`7L\`<%4`8MH`;5I`+$A04?T'0H('\9TH7^8P"/`#,)P0!F.&SS<'O2
M8`:<J`0)936U$`T"01!V.&#[Y05?P`ZZ]R->$'<A<Q'PT060,D3O<2`84HED
M9&Y3F0U`\04@E6MFH`!/\042I@5?T`7N909MYP6P9PUBX``"UA',AHF86(D>
M9(D#XAI#]$/R80M@()988`^YF(NU4``*DP4%P$28]VH-P(I&HQ)T^(I_@`+I
MX`1=<`6<J(-7H&LJ80"^^(NR5GUN`U%`T`M9X`-I<`$Y@"Z5@@7/,`8HH'!8
M@"M3\'(QN/],(1`AL94&>1,&!O`WH&(`7\(#$A`G`X`!!U``8B`!&!``)$`!
MZ'0!2'`"6\`!(;`!`3`6OD4!&N`#+C`"2%`!8A`&%9`#-+@#$;`$]#8FA",!
M/O`#%#`!8B``*H`$$D``&X`Y91!F(0`I%H<!8:`!GW0!7S`$8V`!)[!G`;`"
MP(0`'T`"(6`#&T`+C^(/(P`I`D<#!Q`%!#`!0N!J:?-`CH`3^Y6CT8`.9I`P
M#*,%"8,P[I$%9XF6P?5#!;(2A9<%!F$&0["4Y^8'0^`(GJ@$I+@,-1.*6KJE
M6MJ)&?2)GT@!G>AL`/!!A?>6$C0$O@=&?L!.*,*8<(I`!^(`/.#_`!1`0LWF
M;)\X`4I0&J7(I3<S`25TIJ]&-:TH$*9I&IPH946P;M$`!-`7F[-)FX-'?6FR
M8@PP`<OU`12@CL@T33QF!$]1!6F6)0'``1>P!0E@5MH2`D3@.E'P`R*(!5"@
M!5)@`#&@!7FS)R:``5J0`P"P-[MC!0&P:$C`!0F0+M7%!6B@D!1`!A(0`@2P
M8S]P`&C0D"T``VF@"5J`!&$P!IZ$G=/C!P3@!4,@!M":!09@!+FC:F104>NS
M`1K0GE[@`P)@`0/P`6`P!>`U!1P@!M/3`&A0!E20`UAPA0GP`_ZQ``V`,`%@
M`@10!$(P`?$Q+8$41'&ZE@A$IQ10IYRH_Z>=J`2/,(J<"`17:K*<Z`@B"Z@L
M^P@&]:6?:!%.R1%V"$#Y)!\](084P`32(2".B98@<PE$>@GP$"2U<)FX:!\'
M(P9&R@7MY[0<\AX"@7FP1Q+G8`9?J0X4`97>91%*,`%^"J:=N&QQRI9"\[--
M&Q]$Z@Y,^@@\`A&O)GRM2!"FB9KH4#U^``'HH`)`@`4$4&*32JD"9)O\%J/?
M60(P`&8<L`'HB@1C,`*$M02(4@&RNHT(\!B7:P!'`#+J=P)(P"<"8`):8`-5
MI@$?,`0G(#Q(L`-AT!<?,!EC@`1!2P!&X#A3(`%:0`R3``8(,`#)-THE8`)8
M,0)&L`-?<2X:0/\%9X$&2``$,7`X"``*VL,M7S$"2X">S2D!-(!60E(">K,%
M2F8!&@!$+J@%'T`&`.N"!O!;/Y``$AD`)V`#VP0`4^H`3&`%G3A"'K2__-N_
M'K0@!X*$EG@V0Y`$0T`!,1!$.50A.61#$((%C%,A%&`@2`J91LHH!@`R8,"T
M\J$`?D!YUI`%B?D"N`@`:NF*%%`B8KO"(NL`$Y!!8?ML?TI&^<L$G,@$)@``
M+^"_/,R_0F-N5=7`?DL7$?(?KH$%.X'$[U$!:SH1_2`--.4((#5LI_A@S?!M
M,Q2W!G8D*D&WV?`$5N!!/Z`2ETL!J..W.A.X@KM2EBI&PAB$0*`#`+#_!7KC
MC"0P!E,'!:2*<0W`!0+`2N](`=*&!B7P!0,@6040`&2P`XY35F'``R.`QU&`
M`5R``@?@24R0`0=`96.@`4XP`EPP`"ZP!!*@`2Q0`@Z`!?2X-Q@I9`QP`EH0
M!D,0`A1@``8P!6%`0V'%`%(P`1?0!1P@`"7(3C^P!6#P`R6``2Q`=/Q`="?`
M`7OCFSP!&0[@@2>`+E)PGB48`)VI`3]`!9"C'`Q@``W*`R4P`0)0MI38;'=:
MIBLLMD,CLJ38I\S@""_<LEI*BAETI2&+SX\PI8&I$WMS5;B(!7N)$1`$3P`0
MMB#[IQ60#A"37]8@,8_P7D&Q>8N($NJ:$6;`_P1O&\5.X2(V"@19:<4_`[<H
M9A)I$YO&!\71`&)=\`1MM`E]^[?D&GUK/+B7.D:"#`0M(%7:HP&"$0,;@`8;
M0!D<D`-A$`55X%9@$&^7Q0_;]-0DL`5:@`**ABTF,`!68`,7,`4!D`9]A0)<
ML`)!B,P)D`,_!09(P)`2D!F[<\"J1`8"P$A;\`%6!0"^M`$4$,EU41Z?9;(D
M@*JAK(8P<#^-)``V0`4KX`4NT+Z8508'@`4M0`$M<`$6L`49$``Y!A4D@`86
M`#4GD`2X6!4)``70<0)FA01G4`07<`5`P)J=B`+,QAIE"R%`9,'OH=L'<Y:=
M1ZX^HC#HX%[!W0Y;`/]%.3(.$\-Z%&3"[><ANQT?/KL-8G"E2H"+%/`"`!`#
M%'2S7O`"_+4-7D``&2V8]CS%01%?YA8469!Y3BQL'ES%*&$&)N"\`4T1,>+>
MU@!X*(9$P^>*V;`!#A``RAO3#&`!EY(Z-ET@1I73PT:X;US?;2&P:7#7V)&$
M.4`%8+``/E"LTVH!68``2]"I,0:L5,``R<$7"=`73D`%!#@&2X`"2*!IX2@`
M%9`$H*1MCAT#Z#0`!3`"`*L64Z`%O;L#UF0".T`>.7`"`V!8GF4!#<`!6V`%
MD6`WP)(##5@!-B"K(Z"F.F8#6C`$*W`$!8`"&"`!"\`%2Z`93@`!!C`5![#_
M`0<P!)=E-S\^`B<`(6/``&(Q`&?P`T%B`%+0:DAE4">F$/0T$1$4%#=BE06=
M!0H`,HL>#2J#$'BG$%W0"$`PLQK1,NNMT?J]$&;08#8)84/A!;7&QHY@`-IP
MZ!.6`%O\(NU&)=F`!&@`!`V0`5T@!">@/FL`J0N^!0WNX.S=QM9G#1FP14-P
MD8J%1J7`S8FQ!4I@`/[1`/").5&PY@Q05N<JSA/(`=)&!2N:3`W0H3"P`@A`
MR+OC3R\@!B.P`0!`2C?0?3``&PN@`58@!D4`GF_-2[FS-X;!`2,[`?CK`*`2
M`VA0%OPG)`)Z`57Q`;(T@0,``YD27!`P`(.T`FIU_W77^Z_35*S1<@)^-`;Y
M6`4[,`7CT05VE@-.8`1$J38IY`=(B1")+A%^8-$@80;_T05,4`!9($=.&P_6
M`'D(4>D*T12A#A*>7MX@T=X;$2#D)31$L\8Q4M+6L(<3)K=&0WQ&6;<4\`04
ML`,Q_0,L,`1:``10@"?D*NS$SL80G@W);C9`4`9)``-)(``;X/!@P`-E<,SM
M;3R%A$R+,@(!@`0A<%%&\`2K%``[,`!2,,KT(P`(L`#+W'16,`0(O]V:H84(
M$`!ET``6P`(G(`5!0@6>'`9(L`(MWP!2B``+,@((`P974`)/``,;T-XF$"F9
M4#JA]P.O-01^A*^X4%:ZPO_9L322`K!U'#FO!U`<%S"28\<L%F``76`#84`#
M)>`$4D7(#5``#<<_-%HU9D`0V[80W$T1)F#UXY;!)O,%6<``Z-`%-&4-D[X-
M7S#S7V3J"]&9]PT(?X(%6(*&AXB)?UE/?U]^D&**DY25EI>"69!^8),FF*"A
ME5LJHJ:($)Q^6HH;"AE$-C9"5%0`!P`?(5U^!%L`I\'"PY6:27\`!)4J?F(`
M0`8P#08+6&4[!2Y1$E,8*"5@'#L-%Q).-S`&`3$,)6@\(1('.V`!84LQ'Q5?
M/$LC8DPX_!A7H@2+'P@$4#$28,<(%F`T2(%78@L%#EA@E,AX@8`%`3`"?+AB
MX`G_C`5$M##9\.$"#00'$(3@XD4+EP!#7!0`LR$`!P,(`EBA(>''`#,"!K@0
M$"8`"2Q2PI#AH$5!@`$7CHSX8&`'@0%0EAAA,F0+"C`7(`$A-HS+&%%8OIS"
M4HCMGS`OAC!XD>5+!0(\7G#Q<ZB1)3!#[-K=E,64F2><,-45-J&`)D@&%&N>
MI(F`G\R*/FVV:^3!Z$HZ_`RXLD71BA\D8"2`<,6+(098"/#R!>RT[]'&D"FC
MI(#3LQ\).`PPD.6$D`I(JJ39DB-&EBT\MB!H8*/$@0L+<I1HX$(,"0A52N1#
ML*0!$B])D_Q8(8'!DA,!&AA)]X-'``,\="'!!AQP8,00_R:$4<$)4HR!PA06
M8+&$`!0TL`,"(QC@!Q832/`!%F(P0$48!&A0A@5((*#!`0UP04(,)5PPA`7W
ML;?"#AM(<((5%6#``0%CA(#!`"MPT0`'&H2!HP8"&*`%#!>,08"3\WEQ@!$6
M9#&$6K_YAD5CIG0A&EM99.&%%V)D,0867/``1AB$&6)"`98`T$67H3RBA!]@
MAD+!)G16XL5DP0Q1IA^_A(&G9IH`T,PD,2QZ2@(*2&I(*@9<P4HB/VRAQ!`/
M\"(%!:06D>5NOUBJ:BC!)5-)!H@.`4T7/8T@D10^H!'%!UL<\$(($6H0`QII
MP(`%$C\8`$86#4BP`QD.7&#`!?]0E!!`"6$@T0`6,1C00`)9[/!!3A$BD`0$
M&B"1X0_D5=#>!PV4X$(`"'`!@P3467#!!3QPH(05"$P@A006"`%$%V((<,(`
M%H21!1<;7``&#!N<@`$"*G"`004!*)"%!#G<$(`-05%1P`X/-"#&%A$@L($!
M'XCQ!0D8;-$"#0HP\`%/*C20!AEB<+$#EZL2\V4P//1I-`%?,""&&0P0@`4%
M!<0I2`QR41)&;T4K\@B<2F/"`"2574*H*&9HL848,?@!Q*-=GW*9'XHJPD#<
MEFR@QJJ\8+&*(D@8Y&P$6J#!Q>%DI%'"&1/PAO?CAK0ZW"01^#$$`4"(,4:;
M`2!Q`,S_'T`0A@1(A"!``U$@H0`990AP00DK-$#!"&14)($!*[`01K)'N&#`
M36`Y`0,")%101@D(C('$$F5XO,42`P1`A@$&;($$!UN4`*\!$HP`PW)2EP'&
M%4RD!0`*#I@`P`0)),#$``R,L<(!*TC+Q0CQSN0$&3OHJP4)ZBF#`71P@2R`
MZ`)<L($7P,`%!.Q@!V-0P0;&<((-$"`,!B``&,H`A1OH:PL93`+1(!>*,53J
M%%H8TS#&$`.5=,$,?QB"3;B@B4,,X2V3\,+!2'B(353@<$`$(JFV0`!2&7$(
M#O##$XQH1![PP`%0!``%'`"`]$&1B@YXVPN`\+8]0<*+;MM$_PR>$#8><L8/
M8SR;G!SCA2[89@QG^H(9:/(%+GRAC@<PA`[R.``*7"`'BN!!UBQE@PW]+1$[
MT$`6!+`!171A"+1QG!F[)KE7^:$"6Z0=!;2S!0$P)!\:T((+2H`O!$BM`@/X
M@13248(Q@`$),8"'&+`P+19\(`T-",`(]A.`)&!A`.W9@!&X0(,=K$,*#?B!
M$T+@LBU0@0M((`,&D&"$+?Q@`R$(P`^,@)4+7$$(6O!#^;)``BWDX!8'R($&
M&``&$CS0``/@P.VJ8`,,G$P`"'#"P[[@`P-H0`4V:$$(=G*`,#0@#&#()18X
MD`4R*)(,TQ##!;"P@#($0`MBZ((&6O_@@PE$82V3O`1SA&$"-9HB"PR@``,8
MT!@FDNH0+PA4:$`S241542U7S*E.<PH`$_#`I4#E@1](Q84M&'6&7.@"$-O(
M!2V<R0M94(!3_<"#)]0MI&>$A$G_H$),F($'*PV0`W@P@9S]\`AF,`,38""(
M"%P`!0O8`!,$@()`XE!5?FC`%3J1B`-`$0@#<&1B@"!)K%JJDI6@ZC.H=P(?
M5&!G)3`"#QB2`#0$0`(NL($/)(J`"DB@(S[XP1@&``,!@.$$4VA6#)9`U@LH
M1PA9<`(2B``&`2B$#"'`PA@,<(,?!*!)6""!4J0E!AAH``8K&(%1?N"#XV7*
M"JM!@1@2L('_`PS@`Q*X:`#`D(`R)&`(#6B`%LAQ@%XA00L8RL('!.`$,&C!
M!@U80`CT,X`!W"`-62@#&KZ@!@Q<``DP((,1O%"]`R0@GQ_8@>DL*H82C-"P
MBC#`7<,T`=NL<`M9T`(69#H)OBH"##PPK.44`-4LN+$F4$WJPQX&1!87E0(O
MYD(1F>@94DTM?02H(@6P`,6?7O&)5#3!6/T`14E`.!%SVVI7Q5:!%@A!`'EE
M@!3>,`$EY)&K8-J``YP`@0I`\0>*B,()+54YO1H9$5.`P!]NP()2(*(+!-!!
MXW)\9$DAEG)HW*(&##"$"I"`!V2X``:4)0TP&(`*`P"#!/:<A<`5_X`,VY%`
M?<(P`/]H0$H\&`,%)("``827+@/`P`@X((8D;.$+,QG!=0>P@2[H8!JG^TEM
MP?`!A"+@"2GB8ABN4`006H$*8+`>$`08!A@DH0""QAWUN.>%+7#!`D9@YA*V
M,`)]":\G`Q``&K`P#2ZDJ0*&%L,2?HL%+\0N#4,X@`0:$($=#""W7/C!%;A8
M9T6$89"G`(,#+"P,+%1QJX=8LB"V\((QUW2+FTBXPA>^B2H#8:<Z51\%9KSC
M&5MDQT$$HA9FZ(<)P*W>F=B$DD]1@4*88&A7Z(`$5*`$%\BI,0J@@A`2L(4A
M,($*#H`A(GA@<#Q!P`)HG,"F$,&`"/PA`O\,</,AX(PJKH'\-'>>1"\PMX4P
MC*`"6>C6*VDP@AA4%B$7.,&Z`U"`#(Y@ETO8@!0.X`0=..$",&"`$20`!H89
MX00Q,$&)2D``,13@"%10R?<\!)8C,.`'W*X"`DZ`@!5T83S^38`!G.`')1S!
M#T+@P@VT``0LW(`:5<`"$39@[!+LP`G%_N\(PL`!L@M@!.O0@@X>(`8-D!(-
M2Z!!"9:`@IX40`L:@$`9HK>=$93A!E_Y`\<230`"""0+W.4B2)\NB*,-(PP.
MX((P&"B(D59BR5[`C<ZQN@DQ/+7GD_!;QSD\"9H28Q,>!GF2)U&!4S````Q(
M@`_\T`4`:.$+2E#_`H/P!$D`!03`!!;`!`[``BS@`ST02.BW&2T@`4P@!$SD
M`FJ6"!PP5BQ@`8ZD&Y>4*M0'=7YP#*Z26.PP;,!D`40@`39``1^``!5R``?@
M.C^0!3\@!E.`!0DA`3Z`!`X@`&2`3=DS#48@!A@@!BYP`&\R`&5``6<B`%70
M$!(F`%WP=B6@:CI@`YU4'R[#!=H#!B:`2@*$>6#@!RQ`!&O#!4!`!8LF`4^P
M!0S#!5#P!]K"4ED0`+^5!<Q#`B]``AX1`#\T!1I0`2$0=@GP>6!`%QP``52`
M`&7@/2U`!#'`!5+00!(`!$S0<50D!%&```;C-B-8?65D"CI$`!%H"2LC_PAN
M80DJ-$=*H'U'QABF,#:0@&]>`W"B0(O4-S>RF`CU9PHOX@$-H`-8D`-?<`$*
MT`,D(`AF@`1BT`-PL`!FX`+%@UY]`(&_00(,P`+@D0&8<`)EH`40@`$?:`.:
M(H*CR"@E*!R6T`O/@`7650$"@`4VL`)@8`;PPP`;L!UBD",:X`,%!0-:0`49
M=`,)X`)<4`Y(X"Q,``4!T%X2L`)?(0%0P``%4`5:L`'04P)?L#(L,3JA9P/H
MU2Q(P#TQ$`)(\!57\`1:H`1`@`%"4T<%1P!D0`+#E@4KX`,$D#:\Y`06L`-A
ML`(%P``54#A+4``2\`"O9P&>A@`3TP7;58XUF/\E8H`&:R``!Z`;U=,`)$`#
MX]A&%K`""T`"F2**HVA]Q#`H2H"*:#,$/948KB@(7_`+5%-OFW!5H,`%'O<"
MEV!`B@%_(SA_BB"7ID!B"J``,.0%'G,()-8"`N"!=Y0&2F<WJ4@,`>``8%"9
MEY``-O`'.C`%'RAG1N5TZT@F[7B"E&!30+!(22$!43!J$&!HG"8&3M$`0[`?
M/Z`!!.`#7.`$"&`-:+`=,!`&+C`"*C``"3$\1P`&73`%+N`%I&0]6Z`!+E-?
M6F``2&`!0$,#(6`3!N`"%[!=%(@%.Z`$2D`&2L`$-E`$&[`!UP$$%M!`%@`$
M6E`"(0`!+``#SU8"`Y#_!$S!!?%C`6A@`PGP`6A@!6.@`0.0!C9`@S!``5W0
M>!Q`!`A@!N=Q`#:0!0,P#BP2`SK@3P-P`#H0`!8P!EHP`"5P!1,P?=2GEFSQ
M!03@`)O4!1EV...'"',$1Q-V"%]`*@=(`3K6HX9E!B)W"C'@`$2:"%^@BZ&P
M"4,G?T>J",%H"BK!`VPR!F`58F%P)UK``##``PT``5#@`PQP`Y7``*:Q&1%@
MIFLJ"F,2*8FP1[S@+*9YFL,0=8HP5#$`!%97`%M`!@&P`F$@7#PH`*06`U`B
MB#P@!5APG$ZP>]NA%!PP+V+P`Z+E0`'``@U@`1`@>6.0+..`!+*5!@E@+P02
M_V`A0#U!0A5E4&L<.0%,P`(/EV%#X`3UB`!`0`("P`4'``2\L@!&0`480`7S
MU046L`7"A`#!63@8('8DX`0LX@52(``N\`7V=%%?`08WP*%=8`0O`4<Z$`9.
MD"1:X%\Z8`%K8`$YT&@/]G0P:A<*$`:'TS9[4HI_8&@PY)R*H`E"Y0=GDJ-U
M5AR0$']>$IA:-9B6PP1;10'!\$BQ-$L\D!AJ%2G]=P`_\`4CD`!(<`DA8'2:
M<0`L,`"<"0H24`)<4`4-H`@V(`&\<`$N<#=X:A=ZB@AG@$8,X*<G4`(D<!4"
MH`'[80!/D4M0<`+%*4\-X`11D``.U3T7\`,<<#HPB_\"/Q`#"(`"6\``X74$
MW6,$)D`!/W`#*/`_2^`#KK,OYX$6'``#+@``53``6U`&^R<$9>`VXU54&D`%
M2[``2D`"!\!U0,`!**L`0W`!P'<$(`$!-J`#S.HM6Q``"#0&'5$&#0`&*_`%
M70`%'V`!#9!6WF(!H60`:_!'!C`":.!/8%`"-'`!@$H(%I,6:#F"\;H9FE"[
MDR`&=9,F_6I(5C."Y8<G36H7CY!&"EL!3]"P#\L%OR<(5>$(6:`H2K60\B6T
M7Q`&.D`))G"9IK`&0G!FP6`!!&".+%L!Z$@]?CFSJ&F"DR-U!@``_C<$)&`%
MX2408$`&2!`&8S`&'(`$`0#_``FP!@&P!3<@!2P@!,/#!%Q@!13P`@@``&1%
M`+OW($I@`$7@`@0P`0>@!"/``R:0```00D1P`1NP!17@+4=`(!2@!4=@`+9T
M!4HP/A,0`C#P`S9P!ML1`!A@!6FP`&*@`$"P`1IP)S]@`6`0`B/`A`T@!2=@
M60=`N3H@`'\P!A"0`PFD#F7P'3JP!0+A!"00!EH`4--``9#H:5#0`%E`Q+3$
M/7Y7`4,3NR^*KS3K!X.!KV;P`D9E`@(;<GXS`:=Y21_G&X00QPSP!+\HI6YC
ML&L4#`H``GN0@6?`JS?`!H:@!W#P!PCP!QEP7)6`,9JQ`R4`CEVB`UP023%P
MI^A[_U*IN;Y[.K$30`-0$`8:@!%@>`!:0``M`5%(B`"WXP):D%`$+`WELP0`
M(`!'$#L3\`).0``/$@40```FZJ=+T`4K``2G&@5+L`1TN`0WL"]<H"3EX"1.
MX`-#XX.79`-3``->0`-9TK,([`-0(`!`$`!=<`(N8`4P`"_NX`0T@#,2D`40
M`$`%L+=2C`:N!04DL`5B^`<#$`-(<`$C8`,7@##TR`4:T%0J,%%D``%$\#N[
M-08&A03O"G(2UB5SS">44`"^D(J:X#>(#')^8`(FW26!C)J8H;`Q0!:D@HLR
M>PHVH`?G<0<4$`4^0*-3I#Y"4`4JT!I_@`)Y?`BDH!C-#/^R7<)TB**.IQP,
M-8L(:"0K"Q``%K4!6.`A7*``%Z"<]44!@\8`B$IZ*:@!(?`"$H`&23`&-T"Y
M5G`-!)`$(V"Y+P`!(P`$8P`%.:`254`$`:`$HC8`%1`#6!`Q!H`!.?`!&B`2
M`U``'54!+G`%&J0`'+!!`E`&1"`$\20`:0`-8'``'\``-A``&Q`#8Y`.7.`A
M&$`$!?!;3JD%D3D-69`#&W`#8$`#TH`$)"`&XJ@#.7`"!279)Z`"+H`&+>#/
M`K``ZD71"SD!.;N.?M<EFB`&,8W5O'N:3_`"#@#'Q)"88M#2AVE3>EEOFF`"
M'@<)3."]<GH*+1`!#Z`",4`!8EC_P@``!DF0)BP0`:70!>R7"-EK%Q%`!8VT
M*+7<=%>=IZF\#$.U/KY]Q@KP;BJ3!@10`$@0F2&0!B=``!*@!4CP!4M@D$*`
M!$6``-[(`E+``$=0!%-$!58@`#XP``Z@`56E`0EP!!K\`NUT`1]P`T6BV`/0
M`C!#`=2%`#[0`&1@`U9P!1<0Y2;P`5Y`!#C(`3F`D?5U622B!31@`EF``27Z
M!2L0`C<P!KIT`/^!``9P`F0``V)P!H]]LAP0!A%P40C02M7&/QEP!A_`!1'0
M`F$@!3;@2FD0`[]56F5P#;SFHO!*WL2@"6`#X7ZCU",X!H:$KQI&%UPP-47D
M;'0QZJ/^_^F?_B4T@;!_?&1?H`45X`>.(DY$IC15.@QTX04FD"`$P`4)\@<.
M4+*4D`3:"PIAD`2@C"=475@/CLKJ6PELX`<E\`R`B!4AT`;?D09VL`$D8`$M
MT`!R4`,!``,'8`%SL+]C@`!B,`!H\+,S$`!MP`$+('QEP`<8(`!+<,9T4.X2
M1:`KH&TC$`)U0`,]``4=T"-B(`,NH+("@`0R4`:7!@%1X`=&(`66PP<$<`!X
M<`)YH`0=@`90@`<3$``@4`!<<*U'+`-=T`5HP`$5``$2<`.KW0`R$`(Q$`80
M`)5)@:5HH`)#D`(^L+,<8`<CP*PQ@`%[9@,+<`12B1(=8`8+8_\98>!-+;J.
M"[`WOU&[W2TWAN0`ZZ@&O)@(3MHU:B'I))0&5Y!P+Q`#48#IAG`$=D$76N(`
M3=,%)?<'3"#)H"!F=G$$@24I<$8#FFW5R\XJ$9Y8/.`#0)`',A`$?I8")6`#
M'?`!'T`R$"!/%PX'-0`'8S`'$)`'W@8&;0`&=*`%)R(&9<`!2X``1_`&&E`'
MW1(`/%!01B``)#`':1`"`X`$'Z`';+P#4%`!G)L#P)('6-`K.=`&"\`&2T`2
M5'!)00`'(&`!$@``9``'4M$$8]`&-R#7/9`$'Y!A'8!L6]",4DD&)Z"5ZO`5
M8K``,M"@&D`"Q+(#-B``69#N*_`&!H#_!P75!RL`"$,!`Q8D6%D"%5E??U@3
M0T!_DI.4E9:7F)F:EA)HFY^967ZB6:"8HEA^?J:LK:Y`?@!<F%BNMJVP?K.W
MO*U<JA.J3+N6)KV36%@+%5QA!%L&C,:L"0K'?WI%:]>@701T5P0$`-SEYJ"B
M27\`!)M^/`1`80@0!B%B.1)W`UL-2"UH%J0I@:6+AQA9FG$8\J%"&"U@RK0)
M,<>"A30/1,@)<<="B$,!L@2YP$$`CA("&GPH@Z-&`319W.2`TV;%&"UC\!#!
M\B9%G0E'!H2S\(,+&BMM+)3``$!$#P5;&*0)4,#(@P("QHRA2$+`CQ,K1H!U
M@P'#@30=2/!0_W,`A!P8/R3`N*,'@8<L`<3T$5/!QI@[-L#HD-#%RQDOJ?Q$
M.L>X$I8TC2>1&M4+E1\ED3/_40)D`AE:FF^I`E(F,Z,%DLZ<Z7*FU1H33Y@\
MF1"EUJ5IQQ`\B6*BM^_>0UI5NX;&@9K0D[R=F?",'/+GMM*M:Z?)CS@@7QH(
MV#'"A)L!6F8$<*$!3M82$-K`#&'@PQ8"82I<"(,&#(@%>&2,2=!@1QX:"&RA
M00IS&+"!`5@<L,4#=4`0A@=_<"$`&E0,T$86<Z0P@`!'_'$6'S:(@48#"/C!
M0@U^0!%&`R``8,$,,=P!1!8$8."&`Q+(X,4&%PS`AQ@+Y`%!'",<@/\%`@A(
M,<`'`7PQ@PQ@V'`!&0W4P(8`7Z0QAPUIO/1''CO(T80/=F`!Q@(;]*'#"F"(
M88$+HT%7SB&:358*+Y9=(6<Y5_CAP)V6V+:G.WX*RLH80YC`11=*F,`$`P10
M8(`2SOS`0P-14/",*UV8X<430C!@*"6X]:*&`JCF0<("-JRQ@@)]M,*#-<=L
MX8*<WLCA1X#.#>KK)=*QXPX\0&C`!Q)E;)"#%P&`X,0.`D@@0``-D(%`$S\<
MP,46,=1Q@0`\8(``%`;<88`!_>#P!01(A.&$`'9H48,!(TA0P`85B`&&"2M(
M$-X'2`0`!0(85%E&`%7PL`,'6-2QPQ!DI.'_A!\N5.`'!0H(4,0=`J`0P@1H
MQ'!`#B9L(`$?#1S,!098:+'!"0;4P,$.!^S@AP$(Q/$!``C0T,,+2UB10\P%
M()"#&P2T$,U\>3010!=:D8`'&7R0$8`>-BOV*R]T9C89K;=8M@HO"S"R6A=H
MI]W%%PMPH447VVX!P2T0J'(%H(ZU=@D/\!10!@\H9>&#`6*P($D,#4P21AA_
M9"$$`1>PHHH2G[GR@QE_O("&,5H\5L`")J01W!\+8(&&%EZT8H`?)KS@QP1`
M((")#XP]\`<$:[!Q2Q1@\R*!"0-TH5T9`G01P!;(DX'V$1=0<,,M+;A!PQ7(
M][KU]<%2E\D3Q$)0_P+'&!A0P!8Y;*#%``C<($86)'BQA0AX$!"`!$W`T7P=
M*;RAE`$@_(!%!1(8`GF6\`$)Y($`'#"!`(+@`S%HX0Y$T`,89G"',&B`!V\X
MP0>L%@,:-.``)\A#%DXP`!DL(``5*(,?*C`Q`GB!`1U```FR``2X*4`"2#C`
M!D@``Q+,(0)M&,`&LI`#'13`#2L8`!K\<`(MB&$+)7C#"!"0!!ZXP`XG>$,`
MTL"&&DB$"F.00`[*8)0PV``/#<!!`5;0A2R,`0NP6,SU6M&UR-BI,GY(#"\N
M\(,*\,`+2A#'$`A"`"$4(`%P$X(0.G>`6Z@A&!/`&R64@8D4>N$(:E""&O]N
MA887(``UC0`4!5X@"6.4BE!`D(`MIG$(!P`."P`00A9,D`5!42`&1Y#D)E(!
MA%SX(7&7H(`Y5-,%+61A"V.X!1IB=8P@`."9T(2F#\0A#A;XX0E^^,'</@$'
M%@B!!RQ(P!-0<(7Y66^.OLK>)B9`K!O<H`PSR,,%^C`#,H3A"R#0SP&TD)<E
MS>$`:)``&`QP@";8(0\#($`.HO``)!RA#"[8)P>D-P<1@`$G8;A`%RPP@`&\
MX0P@P(,`;*`!$#3`!B%(`QD^,`(RT`$&&B!!``)P@`2$H00;Z`%S)."'&+Q!
M#&)(4`U=8(,`1$$#;FB`'@H0`@C,H`P(($(:)'#_@#!PH`-T0,$"J'H$"3@@
M`&`8P@AXL(8O="`+62B`=FYP`0\T0`L7(,`!5("!'1A`#VHXPQ@\(8%@R!&=
MH*AC8^Z(ISRJ@A<.D(0L'8"`H+I`E0!(PR[28`(P\*`7?;H;:&A1B@LH0`@(
MH(X/@!E*281A"%_]@P.V@()M?L(/#'C!J$#A@M9$X0#&>&,6U*`&$ZR!!6B]
M:1:T14<_87,+>=PL-PXPA!=4H`(N*,`MAF`[.9W!#V7P`64^X0#9)B,(#-C!
M!"YP@7,"5D[JU`00B$4'&Q1I`0.`E@6RL`$W#*$-'@`#$L9@`@2,0`0!P($*
M#,"%(5!A!7,0@#-D\`8$_SQ(##V80AS^$(`/,$`*'/)"#\*P3S0(``$5P,(6
M.)`'(R#@`AMH`!=6P``/E$`+/8!#!=!P`CI4P`UQ\(`?HH"B*/!!`P2P`Q#0
M$+P86"%9;A!`!N10@ZV<0`]FJ(`(U@8&#CR!"RC8@0FTD``)^$`(*(A!#O`0
M@S6,X0TE6",=OD`".F"A1@820<LD<8`4("A.YPVL+LU!V+`9-K&W`+1OA>"%
M`OP@)'^XP@+`,`D3J&$1KO@"%Z[[BSTW(G7!1$T4_F`"0TL"`:J4!!:.$R`%
M>(&4)CB#`QH)"M@Z8+:?^$("%-6%$J0.#`+X@Q=*D`4TB.,+_B*`)UA1`"VH
M0?\`JO##`#"Q:7.8(`%9N(`3+CIL5DQ!;]#1E0(NL-U-*&$"0G@"$%#`A"CX
M00LE,&^>D9/>[1'K#UL00!,,P$6[&B`D$N``"8I@`0',(`05J`,'/,">``Q!
M`P+`0Q*@(``S9:$"6R"!%<P0`C>000R%:4`>L$!3'EA@!&"8]`H"0(8DO&$`
M!R@F`A0@@R]H@0L>X`&#*5"&*N0@#F=`$1(ZP`07G/P+3#C`'$;@!B>H@<L-
M4,T"X@D!I;T$!!0(P@;`@(`.M`%U#0@`04'0`2-DH`!]L`$$#O`%/M``#S_X
M@#?:0(0PS$$#'$A#$,;P@0Z4`,_KUL2&]-8%QO0Y.A?_4P4/*M>*$G"!"PE0
M=6M2^P4_%"`&6\""!%CP'EAGPA%^$()UNNV83+"#!V70`@N\((%:H*`"DE!`
M!<11@N!X@0!8*,$%+'V)9%M^W0+80AAV/`'25D*8YO@6"@#`!%W3'A,"B,">
M6N`'/JA"!Z#@014@IP4*'.$-?MA">?.^IW9C8KT$N,(`OB`#!,2@#6<`@P80
M(`<-'(``9'#!"DYP8A$T8`$QN$`(1C`"FV#@BA@0`&-0!A.5!PV`!RN0!64P
M`',A`C@P!S<F!@=P!%\0`B0``35`!B7P`UX``U:P`073(V(``PW0`!<0`+RF
M%S40!WU@!,VW0AT0!2N`'6"@_P`AX`,<8`!:<`"14P`I("\VT`$9,&-M0`9E
M0``TT`424`$J\`9KD`99\`$G$`86P`<I$`(K8`%E<P`%=0//@`404`8J4`(&
M8`-%`1!8<`7B]@!Z4`YGL`4\($S<L@5_@``%X`4^4`(Q@`4\$`,OP`(!H`3P
M``$,P`(L4`%",`"GY@4N0``\(`:/<P35=@U_YPIBPQF7U0J/I@5?L`9:L`U:
M(%T%T`4%<'1=L`9>@"J88PI+Y`"ODVR6!H:8L(J#\@1#(`0E$"G290IZI2V?
M@25T2`D71P')-`!OQ`H0D(9^T"<N\&J8<"OF\`5[(`4/``8A$`?'MS>]@QRZ
M$@"JL/^-F,`#6I`</=`%?G`\ZL9]=N0'ZB`LU<$#1^`'!G$!;K`%7$`"$M`O
M90``$T!""Q`"%$`!7$!$+E`&%/!C)5@")0`%3I!V8C!R%U`#%R`&/Q!M"V``
M8=`!!D`&).1&-9`'%8:/!-`!%"`!=/`!&C`"`R`%9!`'&``#`F``#6`$;7`!
M,#`%2S(`NN`'1T`"<"<%$H``9S0%)%`#'^0!(!`"72`#<4`&QN0$;6`'%U`"
M:=0#!)8%`3@?8E``N.8!!;`R:4!C?#"`6R`&!"`&-]``*R`#!K`"/9`#=3`&
M.H4"KS,!6,`'UQ`#`:``9F(`9I!_+A!=CH8%9U`&9A(`O:7_:D8R`&0`.D/P
M1KN'!EZ`6UV``,=1#I78"I8A!*XX`9EQ!E_`"*3S!Z()"FJ@7;!UCN=&"YAV
M"1#0:UZ0!6?0``-%"1#`!0.0%[M6!C%P"TQ@`@[0)Z\#&:"P!EA`!@RP*!?`
M!+4@`)B6`&80!<;D`M+)"MZ8;*_H>Y0`?.>@?'F5`9?)"K.R)^:8&.!X"0ZP
M#9+@#>9X`5N0CNKH=^PX'<-"`/*8!V4@`CEP`3FP!7E`,D#@`$L@``K``003
M`(6P`$8"`0C``1]P!QJ0!0B0=08P!U]0`FDP!A<@E`B`!HC9!CO0`%NP`U1@
M5S-0`0<@`#8U!R]``A80`"O``19@_P<:8`$'@`=A``8B(`$302TB4$L[604E
ML`(U,`%;$`!R8`15H``^D`([$`-S0`,6D`<7%019$`8"<`)RL`*$$P!4<`1Q
MP`76,@8-L*5<$`0]\`9R$`9E0`)WL`(XL$]GV208L`#N5P,P,``Q`"?823'7
M,#:EA0"S%@8,8$HND`Q1\$<F<`2]&7L\@%MJP`+^PP#JN65;4)J4.`I_@D>)
M\0[81@T\("JJA0:&4S:2(%!'P`40X`-*P`":J`5:8`:*\4NT0)R7H`98,`!9
M0`8#<`%#,#=#D#J]M08^L``(0`9;<)ZOU:=,`$J?<`9!P0`00``54`*2\`*C
MPP*%4VP\$/]JIG!TV,0$MH<)IW1>XXDKAN4'RDH)>B`$S/0'75`!YJ@%[QF?
MS^%]M><`]MEW%_`&&,`"$.`!'H!:'R``3^!949``9-`58[`#>AH`'<`%']"6
M]#$'8?`!2\`Q7(`%1H`%#9!CK2$&)1``)+`$%B`#;<`%$J``1W`&;B`!51`'
M8%`!/5`!YU(&$I`%+;``6E0"'3`"1C`"7&`'':":">`!`K`!?I`"/B!9HP<!
M8B``(J`%,O`!-)";"F@'!C``5XL&%J`!"I`%("`&;L`V!K``9Y"K84`"%S`"
M-"``ZD<P`P`Q.<`%Q#@'`\`%(R`'4/0"59!L"9`#U\``N<8%8G#_*XUE#+]S
M!IMF!KE:F;0$7#$0/`C``E]0!IT6!0E1.'`C.YBIFMFH"6*SKIM@#(P6AS%P
M'"8`3"6P``#@!8!#.ZV0!A0@`-RF"L3@&+0'`3^0=0(P2F)02J4``0DP!!?@
MB2BPB[8PJR5@`@203-^:!F>@`.&9>GIS!F:@-[38"F:0,:-A>9'#?><*'>7Y
MC9\0`+(K"0$0!.:HD/!IKY_;CMJ#"0[P.'X0!'R0BW;@`2)0`IQY`@E0`AH`
M!#;``#A``5[``6$`!QSP'B<@`6*0`@^1!QR0!5M9`_.3!1K`/)K#`)A"!AR@
M`7=1`0C@`@:``4N@!08@`0VP.",P!")4_Q<\L`1:M,(F,`<7H`$7\%S(9@!/
M4`5V``-?0``C``/WE@"&X`,U<`<49#J#``)=L`-V,`A#()$5L`!2HP4YT+0E
M(`9E<`,CT`!B$`%D``<(<&]V40(HT`5[<`(0@`9IL`8UT`81$`<_X0`3`*O5
M=0P7:@*UP`4$P`4*P&MJ0'(E8`VK1P`*&09I\&;B<(2,`QDBRXFP^HGFX`7*
MQGF6F*Z]8'A8@"H$0)QH,&S4$@!_H`9E@*GHL(Q]\DP(L@6?V@CK^H0%L(M@
MLXIJD+W5RPNP>`UQ@SS`S`/(DVN9J@J6UVQY-[[/\0!^@`'!0+K7RFB3D`CF
M2``(\+[PFZGRN_\)`!`%]GD!)U``8H`'02``4N``=K!4*[`"0Y`$`1`#!00>
M*N`#/4`!`U`"=M!8;^`!;T`#8$`"95`#'P`&%C`$%LP%4*`%4""`(2`!;^`$
M$*"1!Y`'!T`"#'0!;7``,+K/99F#6;`#)/`#`E`"]7$^/-57";"U(C`!(<`!
ML,H`8M```Z`!Z8$'(*8%1+`!$3``"]`!;!``=^`!"/`FHSP&+L`%;(`#WS$`
M/G$#.:`\2]``4&"<,+`#(@5P*2``<J"%2XAWR`&:`?&:J!&VM((:O98EE=``
MH5M8#1!)G'I8V=PXKX--?3H!P8L,??<):0#,?(T\]EP.L*,$I7$,UF'_`/!`
M`3X0``B@!0+$#:)P!<YX"="8S(,-'7K@!W%@OIIP`$R@.\EA!.59KW&]CMNL
M"0"``O;9!C;P!0@:D`[0!@@PL2F@8@Y`=53P`0/@`W"+LESF+CY@!#9`!=G5
M<F)`!2?@`7UW`&XP`OSS7#H<`RM``EQ`+U%0`#2P`%,0,&!P!`A@!#)0!Q7P
M`=J!`#"0`"/``!HP(B.0!GX@`T`@0%/@OQ^``&.P``RE`5.#!B-``F+042.K
M`&_0`GA0,&'1`BADH+BI!C*P!2@L`<_`!BM0`'AP`S80!V*@!H$L!AK0`&@@
M!SD@``7`-CW@U9I1`)/'95V56`N0`,=1''\`_T"2<M>28$R:L09Y1$MX1`9P
M?0S(RH=\\^-\`[V\<```8)`3X(IT_00RW@BQS&P20$;TK3Q&$0#E*AK&?`V)
MQ7''@R.JA`7<V0L',*[!I(Z/2IZ_I-F9\`*,0PDT(*]^(`&B/=KR6=J>!P_G
MB$3'R@,`T``/0!9\,$,EG+$D1$9.<`$D,`1QT+LS*WD40`0!D`,ET0!48$5=
M@`4[$`>'V@-E8`</4"1=,`(:\`=XD`(?\!UX@`2-50-VP`(6-)8?$`);$`3<
MH5(74`<X8%@_D&`X,`%C8*5KD`3]``-&@'`P<`9#W05\\`!E@0$^6P>ZB@8O
MEC1P\`=ID#/XLK\$`O\&$$`")$"'8!#()X`$4-0"`J`'!_``#;`$))X96,`%
MQM"\1R"[T[`O8>#E%6DH9+#6RG3C^GX)-BX*@-H+)E!Z8"!B$!$@0Y"[M_`%
M6R!Z1PZ<G::[H&`"9;`%OP,&/I!0CU;ERSL!=OFG?Q`%)U@`%?`%F($%/U`.
M8FX)7YYG-=#DFL%\YJEW4+`'E:`'Q6,=<2[G?#:?[NAY3Z"3P3H&&\L$&"`!
M.%""A2`#+M`&0A`%!F`!-9`%1.$")F`#.X`$,'`"<1``#'!U+A``,&"G(@"5
M8)`%#(`!`W!1:O`!'[`!)G`#)*`':["`%%`"82`"7-`&`P4"&`;4Y&T!6C#_
MAG<@/W:@0F_P36WP`S3`!%E@`!T@`%6@P2,`SP4P!CXI`"1@!UJ+`ENPW5AZ
M`0'(`??A`0?@!>=3!F5`!@)`!R%P`'"0=2EP!P5``%I@!T0P`%A``B$04R40
MQ>L>&7F+`EH``"ZP!4(P!FFP6GQ3!D?P`RX0`PM("6I=)WFD6;QP7:(`:,=`
M2PQP`08PRD-`#K5Q#!!`UXK!G+LL:FOMQUF@Y_"F*&?/\:Z@&%=P>Z:P"OHJ
M!B\`""X4,7]D"7^(B8J+C(I^+TI8C7]87I.7F)F:?W`TFY^:?EA^?@J7?$`'
MC%T$77X$6P"@L[2UH&=IBUE^27\`!)D`0%I^5'`6_V1,)R0-=P9H/R$K/P9`
M!C086@(;;@(E<UP"(TX:&EA@,W(N=5W:`AQT$@9D*0T:7!\C;=H[-&(N%TX,
M,"!BC`L,;O@TD+%%P``P>(QT\1&`@IL0!_S`8`(@2P`!3RXTF+,A!HP+`0+$
M63&&&Y8*(XC,"6&$#Q0R91`,""`!#ADQ"PI$T#(GS08!#^STX$+BP``:<4IP
M*0"G0P4N71!HZ7%@E!\@MFBM&?!%2YH"!;X46*-%BX(S:LZ<4:!&P@)%`K2$
MU;1`E)(L>W?M\K,WD8DL1Q+\R)(%@HL_%R3MS>CGB1\'$R0SP@)8DPLL`Q#$
MX#)$#`$R64P43N0'A0/-8?_]9&D[6PL8,%LDP-[KAPF0W8DHH%E-7!$/O<4W
MB2)EJM&"*@,:M7AZ!9:LY-B39UA09HVB7;U^94(QA820"7PN/-'0E(.%+21@
M.*FS!0$`+R8$9!%7H4&9-!XX04`)&\R`00&<B3%$`"E(($$71\@01@T5;-`#
M!S(@(,,`2#AP!PH]^+"%%0.`D((=>=C0@`$I(($`%EJHT08,8+010!L6Q.$'
M`@[P<,`'!P@1`QHD',$`'1;\(``875C0``<G'`!""RLT<,$`#32P1@P6:$`&
M&>*`<8`"%7`P@)-GB)"3'%UPD<<.`Y#QQP#,E-$%&0'4@(`+I("5W9^)9,$%
MH*S_86%"&8'Y$8`?41!W&!`^-/`E`SYT@05PM!#@!P5*(.!'=(WHMPD6,6QA
MZA8$P+*%#ZH11XHHJV&1ZJ6I$@"C%@44]^H/DT2A!J%AT<`&L(TL5THC#0!A
MQR1T[$#'%3_$0NRTGQ0PABZ\^`(,)F@04`0'`$S`!!%C:'%&'`ADD,8/!_@@
MQ@Q6\'&'!E:2`0,<6'31A00#=#%#"Q>(((<'%\@QPPH=D'&`"E\T@$83`8R!
M``);?&'!"DO(T<(7)Y3!AP`VL%%2%P84T,899)1[QA]=!.!!&0TOX4<L/)"A
M!0A`<'`$`A8(<<,`+2P0QQ<!A%"!&QCD@0-)6,BAP1AE_\@1APT>-(%!##F(
M$;$6&A0@01@6?#%&&F?4T(4<0520QA=?M+&`#'%H``$9)4SP%;5_(##&%@;D
MO04/8B@R0!@\`%,!`D`,A\@"UQ)ZAB@F8/K)+A>TYN@`6:#1SFSM#"'Y+`J8
M`00I#4S"V"9AU*HZC%ODXBH3D>#M*@4.7#")"XK+[ID%NM/A!P>C-Y<(&P8P
M(<`EK'PQ@8C7Z>X\(E_\P'N@V8J'20@;8';$IV1@8``<*H*AVP=E*$#%%4;4
MD=<84/S`!0<Q'&$`&#+DP<4&>4B1QP]S@('`$1P(0QPLD!X7-``)(:!`"7Q`
M`@MTP``.HL`@"F"`-'1A"A(PPO\17+"`-"#`!Q?PP$-(@`88("`CL6!!`SR0
M`R`L8"EV8,$!;"``#WQA"V1P@04&X(4&X"$+>&"/&XQR@Q*$00L^Z`,&.(`!
M-J3@"PO0P@5`8$*0V4$"6LA!&PQPA!<P@`D^H$`17!"%(33A"4.8@!ZH90(S
M`&`,"T#`$+0PAA(0`C((X$$#+'4!+7@'$6'(W9]V8:A!A:4O@UE987X`@$8Z
MT@0F^$48DN.`(\2N$67HS/,FX0<&O&8U=T%$%U8&12AV05>DD!QG-HF)X^CN
M<6VP&QZ&5P86)``"F&"%*ZS#2N>AH005^$[UMG6)?IU!"DH`&@Y"D`40*&`&
M$/R`^,C_\(,G;$$$(`@`!.`PA@#8P8`"<>(V2%`!`?!@!.`H`PE(4`)F9($`
M<=C!&20PA!$8``$-4$`*X%`!`S``#3$0`1P&,`(V(.$"[XG4GLRP@QP8(`LC
M^,+,`."`-P2``T*``1GP<`83B(`#,-A!"\J`!C+$H`!SF((&Z"2`-^R@`0LH
M00<ZL`,P$$$`"^``'\:@@PZXK`\@&`,($&"'CY3A*1Q8P-S^``$2Y(`.9_#*
M%4))+`"$80A_*`$"^E:(.Q)@`3]@2P5LIPBM`$L-HOC-7M`@&S^XX(^]G(4?
M?*#61JP2%&>!FABV@,ODO.ISFT!#%+B``C'\0`(,8`$**H`"_UZMAJVD(.8B
ML$#5N!H'.7@KP\Q(L84LQ.$'#$B`&/:0"5V^0EJ6)90>:/`%,1RA!"409G@D
MVP@MG'(/$?A#`;J@@7N600,G2$,9<D"&$Y0``/N"0`76D`4.<&$,,=C!%BXP
MACJ4@0,",`((EK`B).BA!@+H00`N0((YY*`#0Q5`!;*0I#@TX`=B.,`%2H`!
M"2``H3ZH`P("8,0+S$`"+8C#;TE0``SX00(3X,$&QI"'"02@"7;(00+6$(*`
MA&$`+ZA``'8H``B@P`T26$,'VA*.&^!@!!H(0PCN.0`%+(!H7&!F!41@@QXL
M0`QR(`$=1``!`GQ$#'G0@@<H,`$K^/_AE-,*G1DP\04D3\(+C2,4Y`QIBXPL
MZ@I]W0L"4#`&,:`@"@F(`@`@R01+N,H!L`J5)C>1`"RX@`M>J,"O_)K*PD@B
M#0!H``.PP`07F(`+F",.6IF0YLVDEA$$P.RTWG`%*_E!""XXS0+FK`E6/&`"
M!-!`\PZ-G0=\008&J$()=B!;;67"MHI8@P(.@`0RW.$$#;A!'=RP`3Y(```^
M2,$<1A"&DLF@`5]C0!`:@(4VF.`"8)##.#I@A"F0@010F$,)#&"$#_R@`3MP
M`@@14`,#Q"`%*`!!#!X8ABV2``<7"$&1.#`$`U9!!"&0``D,T!>:T>$X1K"`
M$1Y`@B@0FS/_?#"`&-P@!@-LP`!N:$`)+(`!(N2$`"HX`1\&H((`F&$./3C<
M!?`@!A4(@`P-&(`&X(`09)OA2E@X0`#F4`,LY"$(CY[`%YSG`"7X1@DFP#D3
MT"Q(70"V,%Z`W,\Q\;@HD**RM?#"!=*0*@JP"@'6A,#0/]$GR4E@S9H80!0(
M<`8('"$[2JCS7E(W@5@((`IR9H"IL!X;NZG2=9S^@RNI-8`K!,$'$Y``:6O!
MBC\`@0`-V'3<B0.!GE``VK&EWFQ/[61$X$`.7$@#&DX@@`#`8(D$D,$0D/`&
M$1@@#'.0``JD:(<=I&0$1Q5`$[A`@`/\P`-!:<,&:%""!E0`!C/H_T`>8L"'
M#VQA!!LX"@G`,$<$-"$%>N#"`K8@!@1T0`%:^$@&$K"!:P^`K3-0@H)U"X`#
MG&`-:&"`%]#@!8=LH00GZ,(`V@""+G```C^@`PD)0`(W7"@,'A!#&E(2AC!@
M`09<L!\"$`)I,!MYT`);@`8A@`$WP`5J0(!G,`8&X!5'YCQ^<`9#,`0"$`9G
M$`8'8`8HP':!,G6Q44B)X@.D0!P$,`:10P%#X`!9P!D*0(*A(':,@!JSL`"B
ME0`ZF!TL8(-AD06F`!=GL&1"J`:45AB/4&B3)3R<-G?$4CDUL`,3L"QAT7=_
MAUJ#5QQMT``RQ`JP`1ZFA@EWX`F*L`<X`/\"3B$'<*`U^P4#+!`#!)`$8G`!
M6[`#`H``83`"5,`%!L`"'X`!'B`!#9`&)6`"^Q4#$@`%=7`X.5`'8'`!>0`#
M,1`$54`"%\`4%F`').`!!<"!#=`!0>`&',`B)U`'#0`U>M`![X$%3N`&?F``
M3X!K"9``0#`%2E`',=`+:K`&#R!?!#`"$A!\%&`!2(`!75`?8<`5"R`':"`"
M!T`"5?(!9_`]85`&!Q`&(I`%,/`!&X`!/H`!`E``(^`#Q5<>`S``%-AXT_(X
M?V`"#*`%6!!5@`$$(H@(,0@H9`!)D`,J5;8CI)!E84%\_=<`7R`)84`!V4AG
M3*@(5T<+2X8($9G_'&'7D%OH"&XW"92UA5!(*';@!QWP`7Y@A6'Q!17`!IBF
MA1<Y"VQ``[+'!B=@2Q<0`6!8:M9S"3>P1HSP*PB"!&IP`UDPB$]P`EK08F`@
M!D%```A0!A+`!?=E03"`!Q:@!5(G`E6P`A<@`3F`!ENP!!L@`@,@`0=0`G>`
M!A9P`#&`!04``Q4@#SH0!`(0`P,3!'9@`P%``%DP!760!;8W`#_`1`*@$4P0
M!7/P`$1@!5WP!1R0!2T``QS0`"-``IB3!S10!@NP`A"0!A)@8RUP;889)V-2
M`#K@<3W0!8V1!2CA!6:R`'Q`!']``)@#!QV3`TN'!700`>NH.VAU!@X0_P-M
MY@4_$$R'<0GYF!U&]U<F(`%*&`,!N9*34)&2<SJ6M0#Z@@57\!5,8"I:,'/.
M^0=_I9$]EUH=^2=UX`=S@'>(4A@9<`>7!D^"UYV7@`<WD`%LL`9=(`,C8`5T
M($JV8I.TQ0C1=PD-LX=O$(A%``8&T`8[(`<[D`5(``4((`%B()\;$`<W``[X
MA`-B4`4/\!`@,`=SH`%1T`45@`020(`#L`820`%.(`$7X`0AQP)_H`48,``F
M$0-&``>`%P8WP``P4`4U@%UH,`8%$(M/P&4DT`,LP`424`!!N@,_\`$-$`Y9
MP`<%$`(Y`"1<=P,&(`!?T`)<,`<?(`8>@`!1T/]:7``!\GA4$*`#;:(%*M`!
M$A`Q75``6H``#A@&-E``*Z"+K\*.T^(';)$%9K`6:#`<PVDZ-/@)=8.<B\HV
M"T"=KA`&I)"$\/F.7Q&=]T@M9\`%`,`1!%"1I'`$!,`##@``7*!(6Z@$$S`!
MC6)7F\I*8<"=@/(&?K`$">`'Z5D87W`(?W<"[WFI`(H<79"6*"``(L"?7Z=X
M8RB@.G`)QT,&<<`%-I``#F`#6D`%%9`""8`#""``-9`%NI>.,U`!8@`&8P`Q
M05`&$)`"6V0!+1,`.``&Z8@'6+`#2TD`96`!)Q``ZO0"9_`&81`%6H`$,1`'
M(H``8`D!'-!.'T`$$MK_`0TP45&P`F(``4(P.&%0!QX@<!G`#4C``6!@`TL@
M!1R@!5EP`Q80!7(2`%]R`&!0`1F`4UP@"5ZP9#34!IE9`'G@!0&P`5F0`!8`
M!@I10VMP5"*0F[(3=$#0M$[KM%>@"HH**`U@`EL`.4\`=Y@`!D#0JE=PG:3`
M!:2@JL)J`IDZ"9FT29W*!'@Y9R8`!"\@!+(AD5E``2\PCUMX!5'@`(]A5T@G
MGHE'GGZ0`!PP`66P=ZOA`WYW&,$JK(H0`7V`"'58!0%@*?S9M_@X3)D0`?MY
M"33`!WDS`$`0`@*P!`?04`9P`CLPE1)0`1B0``9@`#F"!GC0`"N0!QH0I34`
M_P)\(`:"X@5R<`!!H`4NT`8=X`(D@`<XD0<A`&P#D`(W@`9FH`5&(`9PX`%6
MD@9(@!8IH``#P`%QD`-^D'T,@`<C$`!/T+IQ<`$RX`8-HPU>$*%GX%,DD`9B
M4``?`+Z1V@7^HP\/D`=K<``;$`!BT`9.X07D<P`%<!9W`@)E$``',`(%\+]-
M,0((4`)_ZCQ9T`YNH0`>_,&84)Q2A@43&ZN)@`7QV!8JG`5H):B.BP@F,`27
M=(,F_"<"(`0\H+60T1NC@W5HP`)*D"MQ]RJ!.UEF%G?@!2A\,+B%VP;)(3)^
M!P`N<`4)P`-6?,56'`4H<,4LD`+.F0MV\`-#@"AHH/\%=-`"7?`#4:`'>I`!
M?R"&-SD)VJ`)=C`",_,&96"[\`H&)R`#%K`!)1``08`$"=``)$``0:"!'5`#
M9"`%)+`%)E`""50!)0`#))`%0N4%!`$!%)`#,!*[.;`!(6<`L%`!1(`%%'`"
M%@`';S`"IB$06-`!XLLC1[`!)&`#+!`&#0`')1!%,$``>*!5`3`#"V#)-1`&
M134';<`!4:`!--``2Y`"6"`&6'!$;6`$`X`!9%``!_``7D`">J`%%D!O6?`"
M2>`#3C`$8/`#OT8!Q)O!LC,``#``!&``D'0$%'`$?!9,D["0P"(*`S"WFF"=
M3]NT?@`&?G`$`GFI)I"1C2#_G?&LT';E!ZTJT(N`!D(0.)SF!T,@!*VR&34L
MH&R#9#-W!OK2!33`)HEYTBQ]TK9%,F!0!EMP`&B0`\1A!Q,0!#N@*-@Q?7\@
M!E)``&#PP41=U`I0!B\`5W$7`'C0`O<U`4J0`%(`!5GP``N`!@G@`A$P9W#\
MGXN`:IG``==9!''@/5J@&CT0`080!%N0`R]0!B`;>B7@`C$@`/)0!QC`E6=Y
M`0@`!E3@!@.P!14@!1)0!UH0`WC`!1A@AT[R'P6J30<`(!PP!S%P`BF`)SN0
M`D%@`':<?3Q0`3[P`0Z0AQU``06:!CLP!A$P0W?0)B-`/N&*%EMP`E"P`7C@
M>F1`_P,HT`5>T`%.;``'0&\;0`:IBLEVT@4,H`;"^`9_$`!HL`8"``)\P@`5
M*#L4T`4N<+<HC`!]1@:`E09@`"@FX`":8B@N/-`EH,)N00Q>$=*<9@)/D!FF
MX][$009"8*DG[`<_\(/W.`9OM-%,<`68NPAU"$D4P`44<"GR:"@21`&V<BD0
M7@$2_N`5@`47``NP:0$2`'CJW>'J?00]H,)OX(]A40=4O-,=@+C%(0E1]@D\
MX(1Q)P!R0`4^(*I^D'BL4,1=?6JEDPE#X%8.<`4\(0`[$`8(8`9DL`)W@``A
MX`9;$`+Y,,`]2@,:T`(@8`!U,`,Q0`1-3@8@D`!-4``5,/\'`W`'!:(&`6!K
M\1$#54H")Q`W)T`$!'`""`"^<*`!!!`"*K`$5A!TLA@%=V`$Y@0'1H`#%N`"
MK3.G>2"!6'`#"!`'([`#>+`!'%`!70`'$O!R`L`'=F`'1[`&1'4#<I`"<C``
M#R``9=`]>*`%)U``=C`$[9`&4B``)P`&^^%2%%W=>$,`:6!++T!/)5!Y$,`$
M(;RHGR"WJ62V"ZV1;`>0+_"WW6D"8/!)C>`%_>+26^`.9'`JW-[ME]+BDV#?
M0CS1K[*I8?`$R[Y)K[*LCIOMB;`OA5&>-6#'-:#BQ4$!?S!)L_`$9!MW<W!M
M#@!SKT(!.,`R!##@.XX);:$);"#_!4"P`59P!1+@`MW&`"2`!0+0)00P!`;@
M!#6J`"40!S)@7&W@`1R0`EFY<!60`RX0[!O0!A=0`%1P!"F``!H0!VZ@UA=Z
M`21S`E*@5"5`:S&@CG#0`_KA`3GO!V\@!`Y0`PP0!T]@``'P!1`U`%VA`6!0
M`D8@`VW`%#%`!YD(#@LQ`"N@F&20;VII`WC@!C00!A@0!G>0`BEB`%L0!Z@.
M`[%54C1P!M%@H2XP`Y6AZ]32`(6L!B:P`)1U`"A0JIBP!M"^&FB6['Z`WXUP
M!,V^*%G[PIAJD8B@!AW.P6B0!FF@`/KRP5V@`%YP^A]<Q(U0`"A`J^1."K&Z
M!2AP:*\R_^"7>@28U7=AT09^,(6*8N_%\74^\`"@(`<.,'ALD`%?$,9&8#>O
M\BJJT04\P.YOK+E$!^Z3L`?G#A`3\`9>(&V.+KP:<!1&8/,CX`$%^JU+V0!>
M$,L2D`9DX(UB(*498#!<<``',`99`0A9#0('?!]Q)&X-<P$%"U\".Q8G9!H?
M?#`-9WY;`#PG>`%'"`8:+A=M(!LT6QQS8G(5!WEU*UH272!?&%L-<!L-`1PD
M!@(=>&!Q'PL"`B<G&'8;-UQB!V)F`PL?&&!<%F]^+WY=?^;GZ.GJZ^SM[NE9
M`^_SZUQ=!7Y8)G[T$`YJZOQP\>,G"[V#"!.>VY=/H<($[QP4>/^'A2!!@^ZP
M0'3(D9U%'AU#=N1!X%R7"QS9N)CP(<$$.R+='7$8HT+,F^<*K`AQP8$?)A:?
M$"#`8LZ?+BQ,H,OB)\D?`"7=03B`,("?!#_\+#G!14"*&C\$U/&`($B`#P7&
M'-CQY\6&$0)("/@RX$<%#@@&P'"3@`&'(PP,8##`8P<$"G<&V,@R`HZ#-#(0
M''%#IHZ8`2$LD,"C)8T?"1-XK`"1PH$-&7$N8)&Q`TT%$@@P8,#198V`!UO*
MW,ARH8``"31JC"E`ID^D.`L>N($RX(.1+M(.?!``0@R,.3+PD,&1)LL9+P*<
M6"R'LSR[+!C-_RE`P:<^?O/*N%B7[Z+_^OOH&&+!CVY_NS!@S%.1'SZEUXX2
M:/!WD$4E*)A2"^Q<0(9)6SC$ADL-N`23@DKY\,!!;`!!E8,)D3""!%&481%!
M5P@@!Q@9'`6`4N<PY114[PA`'CU[E#$!!5+X4<>)G,UQPA!W2,!#`P/@T(`%
M+F1A``$4&*&!'0B$\(,((2``AP19!(#!!74(8$`#/>35A@4L&$##`5J((`4>
M!S!9@P1?N%&"!%XL8(`66G#B"1X&[.`'&#N(40866)S@Q1B,=@&%!&/$0949
M`=Q!!A=E="'`'Q`4$$`(8T!0Q@%@!-#$'5]$<$,!#?SA01DM#%`!`1$T@($+
M;&0A`!H,9.'!_W@DEB<(?B58]!X]481!WX`&%BO2/D#XIZ"UZ_RPP#QDK!CM
M.F(,(6T[%M$X[CQ"3!"C.EL$L.U1L2KDPF<5O$2B4A^P<5`%">QQ[CQS(#'O
M!"L2-`'!\W4!P$;FV/A45.WLL2Y"=CQQ@7@2G+'#`C+8@$`*1LQP`0%P1''`
M$B0T4$`9!I2PP@!D5'`##1=L`,<-)!!1@04'W,$!!"N\,0`"E;C0@RINY*!&
M&!8@D$4,:)!10@%(>'!`MYWP@``'#0BAY`@+Q/``'V6P#,,&'RAR0!D/$'U'
M&;Z*L8$+#ZA$!A8(!-!`&&IH<48!]X00P!@+2'#`!@/D]H<-&K"Q!?\=&83A
M`QC$_MM1%MB65X&R^T#P3@$.>`2MY2'IY]`977Q!SP_N7$%/`WX`$?NWZJP!
M$D<\F-L1P7[H3GHZ"!!T1`9M.)#`"G^L-,$5/1P%\4$#^%'!!7[$ZZ`$?^@Q
ML3MT.$#'[^C0@<8-"_#Q@P-@\%ZP12@<P`$`/XR!0<--/?R.!7(XA,8$*+CD
MPQ@K,(`;>%"&'8`!`4[``1BRX`(Y;&`,8Q"!`L+PA38,P``W@(,`!M"'&F#!
M.VF(0!@*<($5N"`&+M""S;S``3"0(0P@:,,&+B`",*0!!@.0P`K(@(^LQ:$+
M6@#`'5*PBQ,@@`L&6`$"XJ`##GAA!0)8P`'_.I`%WPC`"QKHP@SR\(4`H"$`
M6S##`D*@APV(@`M3T<(72%"`#<AA9248``E@((`&T$``+H@B]0BR(_`=!'/X
M48,8$""$(U"@(.Y0@`/&(#K[J,<+C+J/Z122+!8HX`]:V((7S,$H+%3H#Q1H
M1P-B0(^!6(1VZG!!'P]B`(*(*R1``((#?.?'/_B$(`?@'0O^D`:".4!U"VC0
M0<[@`B!X(`H3X("_2&23(UP279^J)01$,(<Q;,$`#%D?091`D"W@0`$HX($9
M]/4'A^'('6LX`T<*\`0AM-(!:``#&"2P``KXJET"0``8#!`&IW6G#`L80!@$
MH``>G`(,!!`##[;`_P4R;`$,8[#'`0)0@C)(`%8-X$(.+_`%,4"`H!7(@@0R
MN@9!\2`-0E`8%\*PA01D]!I'^$(8Q'"$,A``4&M8@!@*4`("?,$`7>""!`*0
M!3%PP2!94(`6_E"G,1C`5UD@PQBZ,`8$N,`+G")`,"'0!044H)5\_)T64,F.
M+F1./4"@``$0V8Z%DFMTZMG"/LC*$88\CQY=N"47MD"0T/U!=GZXW5G/P0,N
MT"-0)BA0*0VKD%O"IR,$H@`M_3B`*_@A"@H0`D%`0@;+3B!678C*&=!S@#0<
MX`P+0`-ZT.,#Z;U@`@F2EE*P,0\",!9\8S"#.1;`!7X=\C/:Y!T3$'```/]@
MRYQWK9TZ.0*!"?B`KR@(0P``A40#;$$,#5B`"[.`AA*@P0=!S4(%L%"!`8@A
M!@HP@.&P5S8N<,$+6W`!&&>:!3#H=*Q'I<`8<HB`"PA@#&0(5-;,0`@`<$%;
M-PV0%OZD!2Y,5P(0V.4!;UH`,,3`"V#`<!H64($T'!6K6*VBWGHA!D]](6\&
MH``9LO"%`G04#0W8G.Q6.2Z"+/4@9G60"4S``[:NPPL`<$<^%*L>`&Q6/3QV
M0'+?P12"Z..6Y@B4'S;YA\&:PP1T/<=`=MR0>0!2(6OU0Y`3HH#5-MD!`%AM
M)]?,YC9G@<KEZ(*9YTSG+&P!/1+`PHH19H(K+$__"99='V"UJ4TN(`"VYUKJ
M%I[9#@(PH9;I*(`/]DB0<5ADT"L:``M"6:/ZG;,=6J`Q0O9'`+[&P`QBH,!*
ML\"`,*`A2EF('QF^@%Y-0F`,MXBJ&AJPJ3!0``T%&"D:T+"``OS@`EDH@U$#
M`*<&(*``:PA`&`8PA@H0%1\&>((#!M"`+`"@"Q((<'TMG`4(3+`""S##%@C@
M@@5H00UI^(,7RD"&VFAA(@AX5&X#P-18C2$`7)TN%]0P``)TH0MFX`(%TA`&
M+WA.RN0@'4.`@)`O\V>6:V5T.K@`!+HZ``L?USA.+#+F\O"X6@I1@.R`$%J"
M4/PIL>/T[?Z@`"]X8;4`_Q`Y.P9D8WID@<<[ENR=S;R%!C-T"T7?1YO7O..F
M4Z#'ZP.`8PE-]8(-V@&Q!,#58V<"('`Y`2QPP!..8`(E$`"L*#`!HTI`@1<,
M`0L_(,#2ESX`+F`A#%I`]+F4LNAVG"$!45@#I%-KCB$$(-!]K3I!2H""YR'W
M':$6R1B8$!@_E*2C:Y#T/"L@@2U@@:H!N$<QP#V&(P33YMQ][QD"'`8)</X`
M#5\``B00QP;@(@9W-D`:&K#AB$:O$P`X`])90.\&`-L`%Y3`&M;`>PB4N`M>
M0,`7T@`FV2^P`6J8-1K*@`8(N)?F@/*"P3W'!0(<``T(`/!1UJ"%,@B`46``
M0O]K14VB2R-$J0Y*ZUS5H0`*4(#*;R4[6W!PYB%7$=<.959G6:`%N=-T.P98
ML^2`:M=F/,`#G=1C/$8`LA.!L>,`$>AU#[@^668./-!Q!*!V/@>"%KAR"T4!
M^N<)!,`#4E>!O>,`[<$#AR1UI7:")^<`<Y9)>V5W<V=W%(`%!)`%0H@%/89F
M4M>!79=8?058)C`C^Z`$6L<$+R`[*,`"2@""#G@$"2"!8CB&37<%UC,N2G$!
MRZ4.9(`^`/$[+?8':T`XU<8`F+8^OQ5U/[!)F_1X[A!Y(K$_2\(),08&!W`$
M`B`$U:911L4#X*8%WM``/N!^6[`&7=``6E`!TS=O%S#_75X0`)PW`"UF`#>W
M`&G`*`%@``>0!6%`BA%E4B<A`(HB`%J06@'@!6M0`:%(`%X`;P>P!F'P0O+V
M!V(0!NXE10R@!0(0!MSG?0O0)U0E!JC3!6?045L0`QZE7?.1!::(`%>``@?X
M+WP56`@!23'A!9>4@.C!!5W'*#YF#D#&:>^0#W=($&I'AF((`#.":1X8A2LR
M:+'4=4U8@_8HAD!D=U3BCEZ'@U2R!44(`&IE`I+58_['*$A7=.[%@`9W2)]W
M5$PQ@G]```[`4"CH94KF?YT@9@1B9"Y7,#+X$6*&=3XA2['D`#S0CXJ7DP5C
MDUA@=PHG=W:V9N$EA.Z%!0,0_P",,C1E,`!9`"EL!A1^L#PZ*3UK%B!B@`5F
M$`8-8`",4@!B$`4F(`8_L&-:8`(7$`4)``9?<`1C(``H@`4N`!!:H`04,!/Y
M\0<(L(;F<`8-P``(4DMG('A_,`9K@(V(MR)AY@=Y6##&M12>MF3XP11#<`17
MD#@K`P$"=812DFP*P'VX]GY>4``00`!G(`$"$``"D%!=@`!1\WYI``9G4`8`
M<F((8(QAX"O:`'UP`P9=X`?95G(O4%0$0`;GQV)H@%II4`!FL(`-(`9?L`!=
MT!UFD%LC%`!?X`6AI@!G((WIA(Z9=V<YU6):<%4#T$G.-@I8,`06$0-8<(MU
M=G-(N/^.GH>$8Q64#,4H6C!WG62//,ACDB61N1.!.R:@7*9U!9--*FD1CB5U
M4T@@)E"6759.&@B2?Y`/"N=)C,*.O0,`ZU9T:G53QE6!:\6A'!=87#!66$`!
M]_E;0Y&B""F1@&)Y4N<`^>EF:X:#,^D3)1A87>>$(IE80,"2,JAV^QB3`WE*
M]/!;._9)[]`%_]ET[Z4%\)E41Z&.<0:/Z'&EZ@!]F=1)##%TZ%&?;S9G7B!G
M-Z=S)#(`;B>$",!K=Q8`3(D>`1`#)8<.8R`$@N0%!.0%80`$"N`"#0`!+]!1
M2I$`9^"G/&`0^^$?75`"9Q!-"P%*VIEG)9!8/D`&;PAIYL#_!2Y0607S!#$P
ME1#IF#<"F>=P6CBQ!5<0!D?@!R[@`RY0`JPX!@<4!K>Y@&/0?0=@6`O`#%N0
M!F(@3S(%-P)06-R%`$M7A!)P`1ER!"ZP#UQ($`C@6'YV!26@$5-(`5%``1?0
M=`2``D=P!/UIJ0Q*A0X@!``0=D*0%%VG68XU2TK`38KW!'C3A7[@9P[*333I
M"8GE$S9H>;GC=1O*A%B75E`A=1S:KXJ9HK>$=5"G=++C">UA>>WA=3,2@X&U
M5EC`DI8WA4`0@R>HF';&D7:FCUR`INP@2U/H@4WG@2RYF%(72T%JL3/ZDE/8
M=;)4@6KE?[E#$B5HDQ/+8U#G6"OG_W6S-$N)BA[P6:8W1W,'!WVHIP!2RV3Q
M"7T)87<`J*GN<$N3I;7J@`4W-@]<4*?H4&K8PP,5,`0*<`$`P&\*XSQ_H`0F
ML$L`,!&.&!5=@`(Q<%M7]@<#4(U8`)97\`((()BU9`_F0`!@\`0$\010.94$
M\6GE])@YHI<AH09@<`454`(.,`$.P$U,T(4HX`,^P`!#8+J6^@*,>[I8$`,6
MF`!`D```<`0^\%2M&@4&D`#OQV9%B`6,ZZKH@:P\M&*K=4L5X'^G&V-1L`4,
MX`,Q,`$)X*XL0':)-99E=P0LP`316@$,<`3'2SD4X`-'D*)"X`*'Q`07\`-S
M1P`#P`!C\/\#XP`$FI44\7H%6,=U=PB%LZ2/LG1+*]>!0'"37>>R$)F/$#E+
MLB.!#8B#.X:#G21W0>A)->IY&!IT,<@H64!_?WBBZV9WJR6U&4RE6?M(2M9@
M1R6$8'IG^F!/7CL/G=#"B50N,)P15J8."#!SZ2"H!E!EW;8W$"`$1_$/3AJW
M9V!@B4I,7V`39-``)>$">MFU:5`&9,=ON'4!"E`!M/NX/\$[$Z#%5`<`)9"I
M?M@.Q&8>:\6>C`(4?M:/MP0`^$IHCL6X4W<%\OJ/'@B._QBY"AIU\IL4*."!
M/F`"GBM+ZVH"8"@$LQ0%8/"%S[ICUPJ7.Z:^C.("X\LH@8R/.X;_`E>@#R90
M#%MPE`J8P>50<^4PPORA2`(QP^W@29#F`*:\<Z^LRN9P9[*\#N-(H9JZ;@=1
M`DS*AIZ#`BY`7D/P='Z;`-.6`-I*`16@!@7``PD`8.RV9@B0J7_`=RA;`"\P
MJ.!C#U&B/MN$>-ZL34>0!6])JO9C.6S7=%%`5/%)!G`#IN@16W^P`-PE9YX#
M`>F44YZ3$,^X6CDTI>C!`AH\PPJ09K6<#E#W6`?-234\+@9-#Q^TT.G@D!*-
M#IY0T>>@R_1@`BC[+UV;#I45ML5"!LLUGF0`@2LR==HT:%K%`L=%N1@-:6>@
M!#%-<UB&T7D8TY%42RIZ$$=8TT98TYXG_]2FB@X"\`+4W`_)QI0-P&9BX!!+
ME5LYLDB6<P8Q0`9,@*"71FA'H%DK\@)F8`)AW&FE6M.UI`:[%-,J%\LS[`5$
M5M$[[4=!=!")RF2,PL(AJ06J)G=-5X$[QM8AT9.`#</H4=-D0,7O0`%G2-=#
M,)8^4`)8899TZA`5TG>?8P*,1")G@`9?@`8_X`(`X,6!%97U&%@^\+&"#`0,
M8`9,0`&ZA50P;=:_HW(U[041*M%94-0S'-=^!`2#38)9QG,&H05!.L!EF=!B
MI@!C^]OEB+@8_7TQK='ND`5/H#H*L5!;P'AA@`(6%FIDFZ1_8-GOP`5/H%LD
ML@404`(G36@54/^)PPB/YR#2Y\`$-D'6YPQJ`RW;'4';,>T%$[#/%9UC,0W=
MM<3*\V"U[J!PWE:$0>H31O9S`^$3:[5H(,>W(H$YS)T."D`E1UA^1T@E)F!6
M..A>)A"#.%@.%LC12F8"@,W;$GW8[S#3N(P./)!)0_`"9^`#:A`#7_"V"A$`
M:B#5]&"!Q3(&MN7&*^*Y%O%,MP4QMP6`2L`#:SC&[`"(^FT>K%W37?`$3XW1
M31O3<J:I;OW;$;W!(8F2-/=>40HHD42`,J+;?U3F";&`F"17;XXY'X0%M*T4
M6.8%0'"B?\`%.%C-=%78,;W$[U"!(Z$/-[X%C0T`#>#C"<$":D#+]/#_!4!@
MN3A1!F](`!>`I]T!$/BL#H3'229Q#M;"`@G`:%2^#F5\Y5B^PS$-`9OK(#?'
MM.909ILD9_E]#E@%U`V=:#A\'K_MYAJ^25-;#@9ACC2G#[W.9):>$#/W98&E
MA')6@8;%#S=M7$BE=B=($<$.P]*M#L3$`-;M$#SP=HPBR8PRV92D!LZ=I.'N
M$!!T!@/@NE\0FV%P2::USP50`&B0G&=P6GM%07&Y2;F1!EX@!%&`!F_8ZJ2N
MZ;`>$C-=VR7ITR<(MA_JUD^G,`009!8H63%84`JGHD_7R^Z`\@O]Y9KJXE^;
M96[M<@ZY(C._5WZ@`/#AVS4"`!F^<W*.$-]W_^WE1!*YG71R5=`*@&5CBSDD
M_W\FH/+],>]>.^[H``$H,`1)G1!AT$E')`@"0%H.`=9CA1"@XR!EJ04'X`(\
M$`,$4`$ND!?,2P$&X`-#$`42P`7:JU]J8"T[X@.89=^2NPY6/O$Q@?//KK5F
M``92+V^<E@5^:DM9\']!9G!*D>?[$?(T5Q`5*-^@)M2+3R(%#?6H'MSVI&HV
M22TLFTE&AG4VQ_/HD%<SOG%8T//]\?38J:(;OA^>%TI)F*$-`[95EE06G@XN
M?]!;,.Q_<`85X`#"5!Y=``%9H`:JQ8T*D7,GFQ#!=Q\0`!!R%6HE;E!H0`$_
M`"<(\`-;``383`$QP/\"8!`%`V`&UL*DL\3JL5WEAT_X\Y"7,7T&0@`(6'^#
MA(6&7`2$?H,F60``7G\\)EM_6%E8@EA;%(-`628`"H:D@UXFI:FJJZRMAX*N
ML;*I%":CI5A<K%B=@HT4NE@`?GXFOWX.0#RD7D"1LX19%%G0U=:XL-?:UEV)
MA!`&0$,%VX-#+PTF/!3L`$-8)F'0MM4\U.6&8U]_6Y1:$E$85!C2C4L,"B\(
M_#"!@D&6+4P`$#B3+1L`"K?^9/&3Y(]$5@7VX1M)LMH9(")+JBRD8$(#60KL
M:7G(Q9$""EH<..H"@!,G"EAXW$24J9$]5]E6*L6D=!L!$UJ>%;K$RDNB+G__
MO"C0^D?!5E.#L&I)Q464M2Q<I(Y\:LQ$K;:4M&U)VI1D@2%/,ATQEH#<VC\4
MA@SA0<#%CW%T70E=4&86`5TE(WF!((#"CRY9,&=AO"9-*C(&%A#RTN7`FF4U
M+W9YMK'CQU5KSM2=K?1%2MKX%'R"EN49YJZ]O63),BH2UGM@K27&K8W+<N:K
M%&!Q`*S0%N30^0$X2[4D@,Q8NF@11"W+LFM,LV_;0LQ/F36U8P@QH-.6EB%C
M8IB!YD-!%@E9-)#)@`0NU)8#YY6DSQ]=8#%1%(T-\H5?AJ2AQB#WG)%`&ILU
MT)LD6&34FD?>J!*;>BC.@H)L*5JCVW/0:#;<C#5]_XA/@BU",U>.K2C`A0G%
M$"",`S#6!0!6O*6E4B-:<,%#%Q1LL1THVJ3'HRSL^?'$?DH5,,`!9VRAA@1F
MG"'!&!:V@L:,`9A0!@H\$/,.@<X-,.-P95!(TA?[.,F%%GY,`,$67/Q0`0,)
M8`$$`C_XD4`4+S`1PP0$$$"8$%@\T8@D0D7#$8FLH"':E:02@DJIL>A&$EP\
M3$)8JZ>6@R.JJUA)*RG^F4=,K-E1R5N(2PZW!0$*$$"!,[YR=VLI%&420S%^
M"&&,"US2VD5[V/I!01D3C)7C&?!!"<83Q%`@0`P#E/`#&(66@44,+G`1`!A'
MA`8&&&.`(<$/8NQ'F(B?OO^V[,"$L#`JP;A>0<9(J#BHA:5!>=$/PPBGDD6)
M%1."Q:XM;EK5G=)@5A.2VS`)U(]>"'+*+%LXX$"V[0$Q,*`H&'/$!"Q(^W)&
MI5+F!Q@^>$C!H3Q(X`=DV4$`WQE>A,M##%$8\\,@"GPA#X-_C%&F&N^!5<D@
M9:AQQ@'K`.P:QJ6$E+%ZMJW-$A`DEVP)4%99HA&OVN"]]L6C$:S%@280X(`)
M@Q>I4A<.M$*!'\,P3J0#``R.CS&3P&4,`'JO$LIXSDWS)P&+E.,5(5_ENMIP
M$"P`<HUHS>O'``[@C+,02I3QA'/.$:C[@"4$GL`//AA3"P478%&""\?#`Y</
M4</_0X$+E@IY_+-`3D"X$$!<<C2*9+`X(8,.#B(`&F%Y:PAR_29G"`_`8A@P
MVJ2D<;#;M!U)/]5P4\P..T^2E[DK(`-`3;0PDX&!#F;M2=RR%$4Y=EQ,&/]K
MBLQ880PM`(4"_9O+,A2`I,P`9T;""<Z=1,8.`@UK6(_9W8#6P0MCU2).,-O8
ML&K10G70<!U",E8#&T2!2K%/A;G(Q``D,``NE$$+8C``%\C0`#(@X`D&\,,0
MF/`$A/B!/648SAH@T`7X\.@+E&+<>+JQ"3^8CS9C,\3W&N2-,XQJ`>1C!B$D
M<"&-]&T0[#,;J%:AA;C=KRD4\..ROI")"PS-#P9(@,UN_S,+F6&&@]3H@@+^
M9@TN(!!;@KS2=`;THYE((X+9&=UJG,06`+`O<$_1S"7&0Z@MN#(3N:/3PXPE
MI$RPT$&\B%)/,.@6PIB`%ZU27C&`M#$_!"66NHME%[BP!0(.AYF844M7#.$?
M+Y"&*ZEXRN)JP@-`&3-TM[I6,6-F1C_PK%376MP$*"*-$`'AC$VAUQ64P`(3
MI$D\X/-&%[XV3?49#CEY]-396-%'DJP!B%BX0`Q8A*HS3`!;0,@6TE`%J'H"
M0`G:&IP0S'@-'D0N%)8+W%G\``HNE(50SO&#<+J`&9821T8@BZE,1PC"F6!!
M"]>IT5P<]$MD0)07#6H2[N@41/]>9.)D#B+`3Z+T$%JR<*=`>6`FYH*[I_BA
M53H!0N!L@1:0L90TA9#F'7?1"<T9XZI`LJ0Q0=DB>(#N.HT@!GL&)DX_H""B
M0F#!-\])JKHZ8`LN"`,#"*"%[,T&`B7P`1DN!`$N5*`$?X!C/ILV"`B<83,0
MN)#YI$(<<$UF'U+A`1#T*+!4%'0D`I"B"AG@ATSFR`Q/0($!8M"`(TB@#`,8
M0T^TH0;/1':F:,!,&@X`,@$T8`"Y:(``N'"%OUW4F"Y#@#%W5RE:[N^"&`QD
M;]#"3.ZF[(<#`HJEV&$,;;[PFWX`@GK+1=(!H66GF[@3ZV2ZFER1QK6K$,;&
MWM*X'PW_3)@UR856X:$>!6S'K(0S043+LM:2($)P+A.KXLZ:"U3(%9S6VFL"
MS.A00/'U2NG44@%NBD$$7`%^=F&!`/)!#@!XBXT*6(/5!G$&L6E60GH::VC;
MIY'WL0*_U0!4.D**@`E(``$J!$HF#/.\*+C`!%%X'CN.X():'&')QK+E!7Z0
M@!)@H<M8J/+Q+D`?C_IAGNWQZ`M\4`+V!>\([/!R+L/\`TXB-)D-0+*\LB"`
M`,B4"T"P)/,<P-QO9D$V0.[5-TV`.,!HBZ0+)!("";S`6I`4$5Y(+Z69LQ6X
MH9@1QO#%(C:VZ1L)R0OCL<8D2-U)8FR,KAHV8X@_?*7LB1@+_U[@@0/`0"DC
M8<<0!0`"HGM(X_F5`FD?)EE`W3?0582!D=I(+18F<%,`E>&;=KI3'+,BX;HH
M0%L`N,(!*@4HC_*3HA.(8GN*N;%$JX)]?6P5K'SH;E*0NAA_6`20@/1K4L$C
M?/P&E##^.PEC2B/?1#HP<_X&!`?@MRV=`%*#&DR2'G9S1]6@X='ZL9%OPGIC
M%7@9`Q3%'EKGJ*Y^$$,%QF."`%"[*5E@01T+\3W`1'(=$JK`6,FBL9[CD<<C
M*FTI1$62C6#A"@<SPS?K#9UO$P``,B-`&-C#`Q:<NU2%!10"CH!(,"S]+&AA
M'S!:%=6)RL*2&S-!IO\`I,5U.T?_%O\U)HZ&850!>$>%4V!VWCX("F#N.Q%>
M7*G+\3FHF#T6H3;F*3INR8\CL.2#G,"S_("&"^RSY=T"Y-4-@88TD.-O%"C`
M&!;0`,^,@1QG6)CY[O&>-%SM#UY:@QC&P+[?]+C9T#'Z!%+R[7;?ZML>G8`8
M"""&<EM]60)O+>BP4``_@([IAMBG,,3.`ZL,QW`66[1NN@`DT/$]19NDP"F.
M9DE`_=?2UT?<+R=XJ\IA:W$4OU4M0$>-N-+=\1S<SJR7Y5#X8VO7$_`#6]`@
M0A0``X(&6)`O*A0&!A`>F?`#+I`)3&!RI!-945`BAD,R_<8/A+!LM[='JG!:
M^!`&7T<U)8C_*DXW#"=D2>:&?$OW5LVW$=!G",TT(TWR!\XQ'".5=M?"=LX'
M:;=R;S#3,O]U5M<1'@.F=[0"<<-A#\O'5BDR?PC4>*S@'[D24_[A4C$5%<3!
M.F6``%D0`%\@!E@0!IG@=8MC``,0!2509!%5`;QS`4/@`P^3"5'3%EQ`),%S
M((RC#G37'BAP!<3@`_/T,C`S`2]CB-B"!0PP`2^`!0<`1&E0AF!`!A*`!0C@
M+@(`1]L%,C[@;H+P!8/E<SBX<SI&BK4G4""8"B<R$D;76J1S@J7R;7ZW>P10
M`5%4=9MW)<G'`ACU`R\#*#.(&Z]H8=SW@QO((Z2&(((3%/>W0&?5_RHN5@R*
M0BI>84T<I"@7D04/,Q[@%E,AY!_CH3N8@`G4Y22,MCO&T`]!$5*$XU.7%">0
M@T!:!14N0SA/5T&!\R-M\13)$%&7!%$!.9`(E$5;X`7RDP5K(`'!E0:>!Q^1
M4"9<\%`$20S#8#TY,S@FD``9>5-`\&GEX$JE8'M_@D=E93>K0#(&P"52D0V$
MH8$^M@IB4W0GV'NP>"NF-`P/$P#2Q0,OL(L\DGSM$04/Y7NW\HK?T5K#L#')
MF",MDPE9@0H;D05*V`HS4DTAY%7"D2LF=2=9F)54)4R&N#$-]Y$-8@_L4SEI
M*3A_`Q?$X`""$SCM\5')\#+^ERTP!)`Q5/^1V=)#SG&0-W4)M806,\%2!*2(
M?!DS>LDXZT60RC`C6?$PO2%)EQ!3^Z8.;1$\B7($!)`H%)`\)A5+1((%`T`H
M#T$&!AB!""`!3,0$U@,7.0,7#G!7*,`"$P"0%9`2D;`5;J0`9\!2!Z``:F`C
MF?4'`1`&2%8!5S`K>X(",T<(`G`&ER4&+R&*`#`&@T`>8*$T85``B!`&1Q``
M7E``8O`'8%``:#`&K`D!:9``XA<V'RATI(!/KEB3LE@J/0$D6[<%)7!5/^F"
MT[8/C?!MEC2,HI,5AB`9&Y$E\/AHA;F5KI0[A'()\:4[3\$#G50YEH-";.&.
M&?5_NY)>E]1PWP'_1`U2$ZZ$4S7B4E<X(W>9F..4F#HA"]CH!13@,AK9%H3Q
M%K>DCCBU4T/U)R95@P]Q53^T/QX54CE:#-94HU@A35+A%5[1(!KX!S?H(ZN1
MI?F&#)%#(,,`!)%C+!L1.?AFI<X1!EE:F&X4%EZ`!FJ@"V@P/FH`B6)0`$UZ
M!@+P#-U)!A'U2\:C!$)P!4(PFR:@5PSP!-;3*(M2!DUD`&008^)Q!F``+E^0
M!ER0B6201.?I`Q>`BQX)DB'Y`\\969Y!!D+`)3$P!(1@/B23:$A#1S]'6J":
M%4!9#:](,F=P11Q%*[`E)3#S`D]P=5Z@!ID%`8.@.EV@.A!`7.`8AJH3_U,)
MF97#00:9D`8(,`2/%@-8H`0-4`%7Y0<5\"@)!1=;0!C\:`SJ-0QQ`@^3%E$'
M!#-`D@P#V3C9LEZ("5&4,"#PY4QJUY774:2)&;"3IA0;4RF[4XZ9@1GE"C*>
M-!Q]9#K9R#B14PN)6)?RF@R8XVJC(1F#T$=1@6L<Q+$,4AX=BZ!66AY?L1$N
M8TG]X!:6DH=!H0RNM&\,PE(^P@_7Y$'VD!G8B!DW10@UTK%;0;*.,)?S6"[O
M>$GW,!SRD`5H4`9FL`_4`$?6]`<0H``#H`9`4``&4`#RX`5YRIYE(`";J`LF
M@(CM\5!*@%?UF&#&H%=$5`:H*0!@$`;<-:UE@/],080``9``0W`00]!K==%-
M:E0`$``$!W`U,?`"T5`.^A&KJBB?A:`&`4`&U`H&:X``8A!+'D(&-8(&:U!<
M6``&&P$ZVCH@V1H&9+@[`>`"1#2N<+%E+F$Y@WH%%V`"1^`#F&,,&O4"#$`=
M:$NOT/*65T"1%OF6,,,"O^,``1`\@YI@LI4`0M`F?`$S]TI."`0D`MM5F8&B
MJX%K++4:/1NC`:M5L((@@[.[.6HY;T$X`O1>?X(6011@ND,=UX%3=S(3PK&5
M6X$56]$)5<L27[&*)#$=0#M6&2&DPR%)!3038U%-&@.F#@*S#\,))A440&$"
M/P*$JRH<-6L<'X(5UY'_,@V,)*L7%M3PKM]ZO-!"KPWW,K'2&V.1%@F;%:O!
M;3;,$S=LI1KQI%FIO\[70\D$2YN0.SCU='^9.V1P!%K``L5#(%3&F2X0!3Z0
M`%>PAWPQQ;$9F]*2`*\W"V-@O`(+,X%Z0-BG#05@`@;@15D3``!`/MYR/*2X
MBXGFDN(7N:"J!A4@!00@`5M`!EO@!H#L2H1\'8LYQ@&[!`AP`@V0`EM@!Q;P
M!F*P!7.`!F!``0:P`7:0!7R@`0@T`6+\4$`@RNHURK=YHVM;RJILRNJU:T2@
M`"IP!E(ZRSC0!OVK`#C`!5&0!*UB*:UR!%O@`SP@@(2,`"5`R&3&K1(@`6#@
M_\A;8`"N-`<;X$H&,"_'LI&*-`2*)!'9'`51\"A0IE<+0+:WT`5ID*P,50A=
MI`8+L`9E,#5_@`9?L`9K8`9:(0!?T'E_H`;8N6)@@(^]TT-M*`%#<&6[I@5T
M*%W&E#42`A\(H``!P-`+,!EJH!5V>P$,;0D'$`D3[07RH&`&"AO1HA6C8*?8
M26,*,`8>78[&&L]A``9_<`8M/0;I.0AI<`%*P``U\P*$DP`8ZS(\X`*PP@-A
MX``2X`7V?(T*(`'BP0`$I`4-\-12C1_-5"C5M0E4=4($4`)"X`4#4`99-!QB
M`$(QU04(T+9M\0BRV:"(G"TZ5PVGT,JK#`1"\,WR=O_7>*T,>(W76X<`KE0"
M(F`-8Z"0:S(C!P`!7@`F63"J]J8%#V`';'Q8!B`$#!`#NI8%*S`(Y6D&J?H'
M*J`&=?`'^R$/>O`'+_$'$5`&78`#7^`%-R`'?W`'$;`/@?0'7\`$6!`A\3FK
M"E"KU!0M,>#'A`S-KN37`7``S[P%<BL`6A``96``>;`"73`^6G``#=`%).`"
M?L`$//T"+``$+&`%+/`"TF(,*.``2C`!&*5S%V(&?O$`>-#26/$%<D`$@]`'
M(L`%.3`(9I`&;*`"<8`!"^,E!Z`!?5``.@"L22#,1W`$3G`H3"`!`(`"55`"
M*$``#("M#N`%<Z`"GK$'.%#_!GIP`_=-!"3P``N`V#']!CEP!SJ``3G0`YBM
M!C2@$420`?OP!0A`$5=@``1@V;E`Q0C@`Q3`!"7P*#E-E'X``<::.F%`!@NP
M'V/0!>30SJ5QTN,3`$\@!E^P,+IP`!,=TQ"`G1&]SVN@W4!2`F0:$.[`.(=*
M1;6YMLPG$E\@&G5NG#26-?!AJ0O0",[:>2HM`!<2``6@5TU9"&/PQ:K0<9&E
M!E]PTMPV!A`P`%ECFP.0`$_``H_@,H.J5PE$+O93#;`SUZ4L6F6IRNK0*BE'
M=IR0EG=M<99RVM`P=5VE!0O`!>$[@.$K'KO.4A"`T7_$=L%N"5K`!AJ@'N!"
M"'J0_P%GT``88-M'L`P%P`8[$-,F&WU_0`<MD&.:W8$N<`!X7(6^70@X\`0\
M4`8YP`%C,``!,`9:(``'<`)GD)M[$`(+$``#4``(C@1A(`)Z\`4DD`%B<`!R
MT`)8T`.!@@(RD``?4`0\T`9^*P&%,05.8`)!P'5^T.X(4``?``$6``<WL`8Y
ML(EL(``BT`(5D`8"$`%W``8!()QAX`4GD.\'4`:><0`@X`8;L"W#H`2A``!)
MP```P`)/D`1^\`-*``7)X(N!\@41X`8KY@%V``%]U`5C0`-X('JBLAH9$`9W
M```#T`)GP`9_<`->0`>#H`?$00V#/1U@>MZ1PP1"P`018?\"2O`"ZB4$0A`G
MZZX`9@`!AJL`8:``G2=):'"U$+!R]Z$%$.`'HL>-!.3R4JT%DT0H$A``K<)2
M:%#U7]#K7<`G^R`:$"&-FPX`3P`Y"/((C_`$P_`$"*`$7<$%82`;@Y_L.,AO
M2''&C;\(60`!(K$`SXD5"4!%U,D#@]Q,`D`H/ZH%G;],"V,2Y5`!(=TBR7(_
M4+A`8\'MT/$`T'8!"4`(,+T*2`-ML->!3!SNT3'N&N-\:'``"%!$'V`!>3`"
M*F`!&$`''Q`!>'`!&0`(:UH@;F->:5EB)WEC$#ET%C]^?E=`3$``#D!`$YM`
M14Q/`)=^)&,J:PM$>3<D&GP*!3K_!7@%71`0"@I+8&AA65ID%2L695L+'@-A
M:&`"`$(\/!(7T247/UM;"%L7!-A;%1-O6P,$)<$E'A5<+T<)1P3Q\2;F#@8H
M%```/%$)^O\`&13X\X7@GX,("W9!B+#$DTE/)DR:-$'B1(L3KDC,Z&=3)8^=
M/(GT)(3+0@@,4ZK\DT4>EFP\"&2;.1,+ERU<6&`!H`O"`059P&1)E*6+&"%^
MLJQ4F<#%'S5JS!R,^D<JPB=,O,GC<20*#WTFHBG9@L4,@J5HTZI=JQ:+&K9P
MX\I%F,7$W+MXT=K-RY<O%BU_L/3ER^8!0C`'C^S]$Z8M0C((!QX4?+#$7[I^
MDOP!0$!M_X80'-AB\<,CCYD6$-;`T<.A`A@0=G+(H>?CB+XH!$SX`!#%Q1$4
M^D0]2]'E0(:##]C\R:!GI1<%$B1R@NCGX<3KV/U@[,BI8DA.W5]8D+P4I<H@
MGD3Q<!"MO?OW/'X`2$&!ZP4)VDK0?)F-@/FY"W0A8!=?#$A@@0,B>,8"!7ZQ
M``L'+8`0@X-5B)`!!_&0@';7F>"`=B*]@$47"B"D@!9%<:$B%EB88((6`?CB
M119IC)%%&#9UH08*,<!'``]8\$`3`65<4`9E%B:Y4A<)**7DDRFAL1B45/ZA
MQ!E55GG9&%FJE,$>!T5@AG)O%:0&%$(T,$``1VA!`!DER",G`__R_$!`%#ZP
M`(4++$3Q`PHF""$#8`=ED=EFG:45`32B^8'%`H1T04(."QR0@P"UX*'!!-EH
ML44<*=@A1A8:Q"&&!G-D$<=00Z7Q1W)QG9&%")(::.NM!OJ`@8!?R(&<'BTT
MMUQS>CS0A;!S8=D7"@MU^:00SE8H064/(FBKL@=]P8*3:D4!P%MJ*3"E6K\0
MD`:2T0[F7[I)CLMN7E^@\*Z%&`PDQKMGJ&#&'A"@P<4?"K20QQ]K\("$A@1,
MD0`/5C`0314.:[AP>U&PP$][`%3Q4@D_D("99IRIM0<2+ISQ@`)G**""JR:C
M?$80F@`DQ!-(*>'`0P\!<=`!\_)%0+/_/><%`(9!Y^5`T7(-<!`7:[B[E`G<
MHJ4&!0E`IE;3<961Q04%H(LT7"Y(^+5<7IPUMEP9#-#'V7))`)C719_A180"
M,-=%#LW1<<)!;+1PD!XYJ$7H'VF`6^BA(:=%`PL`6!#`%@)`+L`?(."QQ2U.
MO*`?3=G<Q[D=!RG-]EK,C@X7`(B9OI;3JO_Q[Q\&B`L7U&L-T,`!0ZPE95Q#
M_:`%W*TCI$8#40>?T@(_&(]6%TI$H/Q2!EA`0PE(9R`9&S0<1(8'6G2/``+>
MRTE`'2R6'T0=/%QC@@M8_.`B^U70\3&B:K'!`A"&J57!%G"Q@<%DSTL)`(`6
M0(0,L(`I89WJ_V)P$#"DP0>S*YY*U,`$-)P!"%Q*BQH4J)(L>"$,1T+@0=!`
M`0D^SPL<#!X=:B!"A@A`#FS8`=+D,`*$7.`@0QA!^7;(0RQT@`Q:B-/X:B"^
M(L(A=2Q!7*+00@9NF"TM,H&+`AH`0!$>L(6+JD,+EX9`0@F&@6RA75IBX)0_
M#$`(AEO)[N`RE".@`7C*NT``MK@&T2G)*E5:8K0>@`88%1%\:P!36BX#QRQ]
M(7]84L`:)O<'`@AA)@;80AG$X`%5;8!56>B`'3`Y%*$,!00D$)`1+G,XD.EQ
M)3[8`@:L<!PH\H\M9G#5'Z8E0C`49(MO^,`6_^`'!+Y.,"E$B!B74O^&)V`+
M!2847C#I`H$QD(&6(@S#*]-B!ETHP`QX[!D$EID6"+CI3B9@@HM,8"<N9"&;
M\'I!M'30`'_P8!L"$)`6NG"3+;R`!2X(`[92<ID;(HV1?[A78!8#-+&E1`^M
MQ&,&_P`'O_UA"Q08G*%,J18E3"L*"UU*%-EB@U>6$8%7;"$`/BK"HQ60:((A
M8%J&J9("3*`Q"#D#`]#)$!3R[@`.M","L;"&E9RH129X@8MX$`-QLH``62C1
MN[BI$@A@`04H^$L7#!HA>F+A!030PC[G\@5U5BD"8HC!"\#@4+7HH0$_*`(2
M#K`VAESF"#V;VT&P1<6!(@1)2)JF6Q$2`4'_,H0L$E7B6B875K5L="UT\&(+
M?Z#2`FK@#;O4J_)HB84#<).E*:&32B[`A%NJ)`U,'4IE"QD\+-1UKEJP3431
MLH"6`"`&6_A/EY@Z5W:@0*N\(P`*&)L7VL(E`Q5@P05LD!<^_"D,?KU,,I7T
M`-!-124/J&N+[@HN@:J!/`N%P1DRT(<`J.`MY/$!*9-(4<>H@0&Z1$L0)(L6
M!8@-B04,`'E$.`06INL+6N""G(8P!`)(=2U70&`9L7`&,*Y%"";\PA&LII(!
M..!U*=DF[[+`@RR0MG6740,7CF`D6<+E"VA`P/YHFB0)?YB,9?#L70J```H@
M0#ERN9*2(F"$&*"A_Y5]T0,7EC`&,%U&KEWRGUP+D-$_G`$-!^F`"70PAC,8
M8`VR.M4<N("'/Y!`#4#[0@;8H(.#E`C(+`IL>=,B4"(\P6-+><E=8(I``A09
M(7U8``((X(,74"&H]"!``]+@O'>%E$I8W@(#&/"2>1HH"S")R3F?AL#D_6&.
MW-Q62K"<E;040`EN44EH+7R&"ZO.!4!!P1:V>A<M,&`+)![,!MFBABVP8'"#
M.4,#K,"SN`!!J17Z```\`"4Z#$$*$*@!8.;[-:N4P`IZ```2UK0#%PCA#57P
MP09N"5_#CG>B]%,+MT#@@!6DF;U+V4.?#5Q``H@@)0H@`Q6B<`1)$DA^A_\L
MSA9<P``7:($(Z?JSDB#`A028@`LJ3DL7L$"GQBIAIP<1P*K#J-,N1$$)L%[*
M&<*)A?]8=L)8"`-)"\@C'A"[+ULP06,'8^*TI"&JI!X,':8@@[8>N,]]R8`!
M$M#E*O$!!0D`#-'.1IGI_HP`1Q#"&1R@@")(00`U)X\(7(Z0PAV$+*$I9;;C
M\H$G9$\E^Y/B*W4:0#<?9`]C@((5#"`_N(@``0F@0!F<I>\*?>$'"<!"P',[
MA*CULH`0_`,82JX6$V#AIQ1P`&[A<@`"*"$F6PC`QM,B6@E$081J,+4_G_2%
MF*2Q0AR,?&>[A``6U+KO%2)"$BJ`XRJQ@0HC8'K_NKZT$LJXP`08@*H07."#
M#RC!`D48@A*0'-"IN,`,$5"65##PDSU<``M(Q';BTL+F@W#`"CW@/4*RSI8S
M$`K"Y>["&70X`S3C)0<(P,(`:@ZEMO/E"]WX?%^^8``7-.ON`80K2_[`31\,
M`4@&&#D;R8(%<FO;PFM``0@T!A0P`)[&%V3P`P)E(0KT!11@`"GW)'(`!0,#
M>GW!`0P@?<ZR!4<@!=1#)7AP`VE@,@DG`,1U$%LF-X!A`U%@`GSP`&N``(:!
M!G*P70CQ`'(0!E*1!@AU`%R@`F#W!Q>0!P.0`99A1\IW2BOQ9AD`!BAP!&'0
M2D$`!W!1`%;C:&UV#VV0_R09(`8)``:E9R$`P'5YH08$QV!)XH`_\`7P]SQ6
M$P:RTT))Q2("&$!HP`!8@GS.0@'-UQ>L$R\?UR5.8`1^I1*+TQ<G,`5AV"5P
M8`%\,`"R124+X&%J00&+\41SE!9(5`;@P@<W\'37)EAJL8`ID0%A(`2W\0+I
MM18*\$IH^#QG4`5.`&-*(G-3@&]*`@"9V!<0(%Y=<@`,H#,%]$I8X`70(H=>
M@`4!@(7&@P8QH"Q8L'-94@$1EQ>/IQ)K(`3JQRYU(`&%R!!L$`)\L0(T5S1Q
MD`#?^#73=1!EU`)W$`%I``$J<`;P.#`#P68&8!41T%:`-3_+MQ1]$`1J\0`'
M$/\`%;"%L"0V!S@V`L``(I<EJR2.26)^<I$&#A"(4)(4!50!!T%%`+!%0^$"
M3O4\=X@M8E!M5?(B;H>-#/"*[U(''_@D.8`"5Q<T9!``-9".?0%D*3%RB>("
M3"`5&0!7-```0>`#">``5E`%%0``VU(!:H`!PM)7SN,&;!4!;X`%-21U_[@2
MP$4E"B`Z"UDT>R`#0<`&7I<E&2`!);"(>/$"9"@77!`#&`DE5W`!)7!YJD-+
MDV-2(I0%$%`&!S"6\Q(`SY@2<Y='4$EY%/!F\U('V%<A&)``5-4S6,`&%R`#
M2E(8"`$!>OD`GF4>)6`"7_(%8A`!7S`#`4`%02`$)0#_`!60`(Y$!3P(`MIC
M!FY@AG%P`PL``^+GCTJH$H3Y6\(RG.^R!Q*@18VD?TJR`D[@EG/Q`OXG%W$R
M+SSP4#^@EZ-31@V@G<_C)!9F/&60=S6UC5U"!J18(2C0AT63!)7)%SH@!#59
M-)1!!7%9(0N@@7-E1UZT&(VQ`);0`W9R!"%P'R\0`8C!B0?A=+,D-OW(E<&9
M$M*8)&>@`:&C/,BIG'_0`[X2+1_@!#"7%ZV5%P:)-%PPH:9#-$.Q2T["(L&C
M!C^0<B[9)5&0F'@Q!AS)-G20`+38%P8@D5\C4'J0`#8*%S>`+&KQ!1Y&-#RP
M&$AD1V'0-_,7)H(T!E81@J`H_V93AQ;L62&M>!#3R39]D)Q(LP%4`)UQ$9D?
MQ@(1F"[V9CRBDU0L^A0-8)S.$@...4OS4@`)X)URL2-MVC,#T`,5H@.+-S9S
M\$1X\1-P00=1%QCLN!A(PF`8P(\/`"9;H%29>A`88!Y0!YQKD:=]\:6N8SP[
MD*,F6C)]89P+X'%GXP-=.C8"M:(@^0<0D`81BC1HD#L2US-@H*9SH08Q,*-?
MXYXQ!P4`56P,$:-\,0;)VE(VT`>*Q!#WT@7N,Q1G(`$@\`4>``=$X`86`(DD
M$`<5\"8XP`$V``(7X`.QM`:Y`(K))XI!0ZK09#HXQ38?@)!Y,9P;%(E((Q`8
M5BC+9?\\2A$5P(HT7Q`%;>JG6?(#=<D69'"H8T,'5M`788"J8X,N(A"F[](B
M75`!+5@%*4`%4,`Q/$`!(V``*LL"+=`%$Y``*$`$/+`&82`'F_I0OPFA2$.J
M=IHE;,``/?HU0S"?<S&<%9">7P,!"1"P?X``_AI`2I$&8G"?13,$L7H0BLHN
MO=@7"?"T9U,"@:H6,3LZ*L8&`%!V5/(%),9(/F`">N``'<`"3-``9&!:/V(`
M,N!<=M$%/A`%+T`'!,`!"[`&!V`5#TI>6SHO$5!E?R"J1=,#6?LU*]"6>>&X
M$W2-IE,!ECLOE%$&[PFU")&K/;,&7H46#]NPG\L68\",JB/_!Q@K%QC`L4'3
MAP$0N=$B.BY"`U/P!0Y`MU4@!",P`ZB8!%+P`QY0!`4`!DQP`&VP!"Y`!C4@
M`G(0.`^%LJ!:-'WPB7]PNO.R`%/0.@B`DG`A!_G#%B7`O?-R!I/'-BHZL,'C
M)`O0LU`"!E=[$#T5-,Z4%WCZ/%:@>G#!`[8Y.GVH!PR@DVQ1$,""3AF@`%#Q
M'#V5!5]P2RW(!@5Q2TJ1!6=P`'+@4!!P''D0`F<@!F&``6S`)1I05Q"%)$FX
M%JG6%]%516**`DC*-AF0!$0+%RT0M*S%`,93`?4[+T2S`#R)0`P<&.Z[5+6#
M-.0I%Z0;0&!P6G&A`[[5)31U!*D;_Q><F1)L@*9_\'H(L8M##,-6^EQ/IZGL
M<[V#1"5]D%X'B[^O.SII$)-9@@!K%SP0("\"?!`2$,8!!!1_4*>CLP8H*IQ(
M8P`_O!+H&4!L8`4&C!9O`,5G@[0E>A>L]P<WX+]KT8*/<1#S^`=L,(_<]0<[
M<`9?0`=`>!`IH"QNH`)/=P3ZNL*.`25J($N'S"Y6@+:J$P$L>Q=(BQ9"ISP^
M/#J40:LME`8E8H"C`P9A"ZE%L[5%BT!67+2XF,PJH0=5@!=WP,I_@`<A"A=M
MBQ!6\0()X`4$P``LD`>`D0!48,X5H%0(I3VR-&\S@,9HT<9\H0)4J'=DRZO&
M(P;.)1>0S/^E]=HZ#R3,(Z2?"(1D@,PVRV3/SL(#N`8V"%2[<R&Q2+.+#`$%
MC+L4H?P'!W#)"`$XY>%32[<`+K(&:7`#,O@'4X``)@``*"`D6E`&)A"QT@`"
M7#(&&?0``C`&7X``4:#"\HH6\BLUA%*-17,!'6H\$<"Z$`L7*+#,7Q/-/+<S
MYEE`/..B9[,`\J<6@\PN/_"L:L'5"#2!<M$"10TE)!8`Q,HWY?O.#/$`F*P6
MHXD0CB961(``-<`"O4D`U^`$/T`#;47"*I'"])QF5&(&*,4V>W#-`>0$Y0L7
M`[T4:X"YRM,`MMLSF8@&1ZPZ*!T82-TS"!#0*]'+[++0</%,5C3_UX@,6:H#
M/'Q;A2NQQ<B1F#3EQ0?!QTN!`.[<2AK0H5L@`?:%N%U9VE7">Z8]+VL`(0$D
M`>*;%E3+$`:`T<VXQ$AC-8>P2YX9&`Z=+CX@U5^=+EE@T:W7V6?#`A&M%F^J
M.HG9!1_)%AC0R'_0!4B-)!GD(@CQ41#65TMC%7"@S3=P2\13*-MPV"MAWG*Q
M![A8R\Z"`')L/!!PG7)Q`9&]%"C@M:KCE^IHO_>[14@V!FE=(>]=0&=PC&"#
MX:KS`U>=9J&--%U*!\S-$%F@`D"8`2\H!Q*@S?D)?&Y@!FL0P39`4V'P``7`
M!F6D&'^@`G=@`"M092/0!@\P!CNP`@JP_P)S$`8>((\"0`)]L)L!8`8!``)A
M(`,$,`)'8!6P'#2SS$5G\P)%.CJ+,A<],,,KH>'/$P4=CC1U1<PM)"''Q]"R
M_37".#LMM`4MKA(0_20C0`!B(-]H8:-.0P=TL&4Y_`#Y>!`:<`8%0`<YH`;*
M0L&E2!ZWY")Z8`(74`51T`0/(`1D0&@4X`-6,`!VT;<60+(AD`>RA`9?<`,,
ML`044+YI;KI4$@%W<!#)S2YLX``Z'#Q#*Q<60.<JT=4!A`4(7B5D,#?NNDOS
M=RY;[=1+P>#5!"6T=7!*L@8_$MUW8>AQD>A)<@,3``!^\-QX<8@I`=+HAA`B
M`&,!GA8V``.:9O\7/\<"/%8Q<N``2G`!`\`#$.1(8I!X=+`";;4!(L`#;5".
M!JX2AUZ&M'3LZ:(`/(Q`8"#O>=$UT53M5.)!VZO;WSG?(=X7X:DD8*`$0,#@
MA!X7_&PA!.``3.`';SX7ZOZ_S+EF?G``$R"ZR[,D(WZ#BT@#K00&2@5E:@%D
M,(7?0I``#3`$"8`$$L"N0_`!`F``$%"Q)9```V```I"`^?,%0W`!1$I^Q&WT
M7=(LZULT!2"[JN,I9]W-'43S7W,C5:WM"#$W9'$V+[\6G?T$+C(!3V("+:P2
MI6LA,4`!8,#S2K(%(I\2[&XA$"`13T#=<#%R.H#'!]$"1-!*#_")$9#_`2?0
M9P*@MK:J,@RA5)&-&E:!WQ#@!21P2&:@`UXPQ+CV`*4'!F:@7Q2@`SJ@?L'^
M[8F=*!D?+7B/0%_PQFG1`GHOH2:O%A!%`(T_%X6/-!GD!9O;.DHQ^&/3_6F\
M%ID`!!+>+@C.!$^2C)+_)-VS[CUOF2L1^C7E!=K[`-X&"!$977^%#PIF?P=C
M&86.$381CG\/&5J%)B:%$22.A).%7XZ1A0)H$"9+4`^@A5E^27\`!*VM!;6X
MN:T9#858NL#!PEH4PL81%0Y#+<;""CS-?[?`6%G1P*\42M#7N6._W>&X8H5F
MUN+HZ%Y_W^GN?UG@P?*Z7EQ:"N^3)HG&FOH`_W$9N&2L`L&`Z>AYBM$J7RL!
MC4`]4-$J`L566S`!D/1'GCR'?_K]^<#J#XTQ4@1$L8'K5:Q9P:8A5!/`%\)N
M6C("#.-G!Q"=^KIP,[:!I2XQY_1Q\;/E"8.`!13>#*9E79:D4Z=:BT$NJ[%V
MPJ1ZK?7/&`.18]WQD!E,S(>TU\2.H65#@*.#(CEP%(.VD`X(P!R:V%CHX+I"
M7&H=_M,%RA8*"R(N0#/)I2Q:NB)PF)H!<$>XP'(&Y(D$")B`"C`;,_`IUU6$
M)AP`:/T.+&A<X,8DOJW/6I<PO',-I1:\5;%F!KH6O\8`9+`N8I<[$KOE=`08
MCBH5"O-@!3)*"BJL@/^@(\>-?"=J@M(10<$)'93_9&JQ`<V9DKO7;X!@03N)
M!@T8P4$#+9R!!AB+P0/+9<!DD,-4$5A@DW1W`?5.!@)P(2%JPP4S'C9841C3
M:2+^84`A8X18HC#6&)`@A6411^$73S43SXK!Z,`$1\)$(`&.DXCUPC0.*0!!
M1']$\(`777B1@PU:J*""D1GD@\$*%5&4SSF9.,+05V:T$$4`0[!B`PTM+0@3
M,"\"Y-"))88Q!)#`A`&G,5K05DL!=])92Q@J%G>.`FSYZ=H?,>0G8@RBS".B
M&'W&]*6AH'0QJ3$6XJAG(1@@.4D$:7!1A0M8_&`"%A0@04$)6RP0QD6XU-7_
M2I>%*(>+=G^,L`8#8*Q4""FU6+9F+AA"B$0AG93X#*6UB-9,GHXR"THU*[HH
MS4'2MG*.HA2&06)@(E80J"YS9EL(&+8*4P(1?@('"@=V@=*"!$,@,,(`)5#`
M@@/\HG!!`QQ($(4!:'+PX!]_U>)0!66Y^P>VCBR@1B$M_/#!#SE,PUZ:+ZF&
MBPKJ(91:(26LJ((0YCI2@</#;-I*C2DSNF(8MQ10:,I_K/-%=,'1B+,)C3;#
M,YT,H!G-")F66.XD,5P2@1D91.!"`@&,L"\*`XS`Q0%>H+$%%T,``,`.&A@A
MP0`J?&'D"@KD4X`7$7SQ`98QF$!$"U^HYAS"?\"`_Z86%<10A0Y_A#'&%UW<
M[(J:'N.RMSXJ7%`K*!%(D<GEF&=N0@(,)$%%`A1TGL3H%%11!C`_$)XR"D89
M0UXP,6;[`HZOF=$7SH2,\6V)E^;B,FAFS'Z-%F.8"X$5W>B`@J=`?G%)%PE0
M=,8&6(`A00)3<&`#10^P^\EB!WP@!0/_2H$//%XHH,,!"D0`P0'L\F`"!"J8
MH1S$DI#30@((+`%8"R7Q0M!`(:S&U6)HXHC`L?XP`%!D```K\(($)TA!"MZ-
M?CR:!`.2!@ITI>P!`,C*%L9%IP+T3CJOP5FP_J``B%$H"XH#Q>UNPP4.`F,,
MQY$6%KAEC!@4SU`;JP""_O]P`0J(@0%#P,#C_@"!B2GB(H*XP1!8D(42G"`D
M?RH$PU26(QZ`@0>J"\%%.%`2;3$N&$MTAP(+$8)6S`8@&P1&`2J0,A->0P?Q
MTL47EB8M#ZXH"S^<8;;,\3`$\L:`&*$0#P0)#!X,T%`OR&`S5E`R')6G,%F(
MP`O&H((&?``!`(B7"_\0-#$BQB$"`(`$"$"&:2R@%Y/K2%G2U8H!^&`+0WA5
ME@I!O\J<43HJ^$$A;D"Y(NR``C]`0`/.1@%44>"9T(PF!1+@``J@X`@4$,+N
M:A&!(Z3,`"P3A@"P!+N4.1)'B$","AWQA75PP9"W&<(C6P'/F^Q,'%JH9W%.
M0,O_9E#!:")ZVH8@H`$;E``"8!@`%930`B+`RA$+Z\<8)O(',2`B`@6`0!(D
M\(,&K"$+-UC`'QSJ!`A8"@!?V$`+EL">$VR@$(00@Q94L@4PVB`+&%!#!?IQ
MI<3EP%,%#,8V]6$&$N6Q$!D@P54LL(&K.#4+2'FJ5)]:``S`+1@$\(RTI'"&
M:T"@=;H`PU#I9"D@I;!-*;.&&/HI'2_0,:S2H4`,A2'/GI6#$DAZFOHHH`,S
MJ*![Z:,(!"3(24.<`@(+B$`.$D""+KPT#3;@@@:TH(83?+4!SOL#EB#0@"5T
M<F)E($,`T!``+(1A`5`5P`9*.X`&8*$`^3C#&13`BC3<_T`*7W`!`BCP@8]:
M5@>10.P9R%`(D#S@`3?(0!K40(0ST``"9Y````+0@`/<@`L9<"@:UJ``?:G`
M!@\X@2"(<,6<_2H!!D``,P10@$8(XE=']67'HG43./%0.F%@JR41T(T-D+.<
MTHK!7(.30OU*2ZUCI=`0!)F/;2[1=E](A$."9@8%"#!]$7X1H)Y!""UP00R-
M4M06"O`-+F2AAAY^`1>Z\,Y?6+@+6<A3%[9`B*_=@PLKOL<6O("/+$!G'="Y
ML;M(K!>8ZJ``!P"#"73P!0B0X`0K9H4&<#P&SSP@``_00!H:@84!**`3M/5"
M"_)AD9+D`U9$8%XX=%`2&V`-"O]EH$(EHX&!BXRA'U]H5`RL8``,Z"!D.J'5
M'Y:6GRY$@`$#`,!%@%7G35PD88X(*C!^EXX,2.X//\)1!F+G)S"0,!=K(*XP
MMC#*%?D,2#8KS#HC_0<N&*``>.["X3XAZ\.%@H5C($07NJ"%`F3A1??X=6)B
MW.H9$X`07L@"!4R,A6;/&`N7^$558*H`9/,8$5^@&6-0Q$Y>AX$+7KCSB]26
MRWQ8.,(*LQU$'3&$3Q<G`BP`:`*7H&:XX`H"Y*2!`=#0`"K0&Z;`$,!%)%:*
M1WLF`DXPP!#0T$978*(LW_JA27Q`AABPJ^"Z@/3BY@L,&Z8C`B-0-9!\\%\_
M92`*JHO_1@2(*8P],NO8P1!%/AHU806H+7U%8B$+NZ`V!63!7;]&#!8^H4^S
MPL/F_:APA(MDNZ27PSF,;`8#*%WT=\CI':<&TA8B)8X!>#P=N&*A&;1S`G;=
M;4DZ`,`8D("!(AS7!@=8`08(&MX#D"`,:X``&L2P!AQO@`89>JD&NCP"#83@
M`&D?0`PNP(42W``,9!"#"5!P`@)<P`EED``7"N!I'A@`"TA@;Y):<*1;.P0"
M:VA!DN7+(&`DV!TZ*?5R;)``U$Q"!1;1>=ORX5<BY+D0ZU`!0D<`-POD_0\D
MN/ASL["`)L%=LCO8P!@"L(X#B*&K#_M#!0;"`Z14PQ[0.;H[_[-@82:UVJ(I
MVO6*O\V%,.#C"S?.@AFT$(9O@X'%$DQ<`8:0.!@WB4GGUB0^]C;6D&UF$&Z[
MYFOM5%RDE#,75G[`YQ#I,QVKYG"O1R%><!8"$1QF`#2ZX'0,*&%FT$[HPB3I
MHVXAL1LP)D/;QACXP&N>X`5;@#A>(`#UAP82$&[P%P8?@`(6L`-0544W$!58
ML`!<P`$ED"(9=0`558-8``,6P`%4PV)<0`898`'$AU,TX`5$<`!IT$XA0`00
MP'PY@`&_9@/-MP)E<`:(10,:D`4D0`-Y=@ME<`!C:`08L`4E```8P$1QEP$T
ML`9IL`8TL#XM4(@'<`"*90-I8(==(/]2$$`$:1`!#74#N^8``X``3M)5;:,O
MLP5R$O$#._`#<I@(E'@&3A1NO+09%,5ZPY(+\Z0/X*`%WO%5#W``1\@%)^!8
M`0!E`D`#)"``8Z`;J@4&PQ@&6,`!2P`I!1``"(`&D?<-7S`&$B``6-!.]K,$
M/[`&#9`&]U<\Z+(S)R(&!4`&:'".!2`!9Y`%8G4`Q),%:-`%"*`#EM@`:E`&
M`G`Z7Y`#)S`&IZ-S#T`&+,!9-T`"M/4'#35,%K9[#Z`#7G``(X`W6O5((Q@2
M59<6,>!N&%B!\/`9X=!TNQ<22B=!-A=A%=:`\Y=LN78X7E!_8H`%R18&"L`%
MHK!60X=_T&'_#1)D#3H1(CS6:EDP0@KP"XOQ:UG0;CQF#T.7?83@:Z:5,S$&
M0XR1;5PP!B9@8DR"@@=87'LC8<6U#H^#""`1DH_``D81=<9``PE01J`!7I.`
MA%Y``0AP@<!`B:W0BCI'``0@!<PC:&_%&/#V`4EP,`0W$B4!!J>7+&;$<;J`
M2.\`#BIP`V76D%P(-PI`>@Z99F5D!FSF')T1#A&0`))4(A5P7\*P`$S8###7
M/)Q&(>F$15_'+%\08R;6)#DC@1/48<"G@P7@?^S03M_V:X93`&J#DA.D-NB6
M9V8P=0WH!8F`E@@A!G^I#U[@@>'2<`&Q`6O)&PN(,%R``A&`!1K`_P*2`!0N
M<V<`MQTB<1@<\%(.UP),4`($L1L$4!8'00$QL`5'L!GJA"+]0!*%L`)&\P5L
M(6G2<9&@@6-T@@%1,)K&H`!?AX*A\`)M,PE-QX`056$.H73YX)S.>7,I8G,7
M5@!<8&Y=8',K`TA!-P9B\!LL)I,YZ7`4<!55,4'LUR:[)D%:<!4E&F.]MF+D
M@%8X8YHKT@4O,$]$BA`%\`+0>0U9L$@4L@.M^0X:P`/U!A`"@'W^M0D[H`41
M@#6PM!BMD11HX$2FQ$1@Y1>IV9%_0`!+\"-%%0$ZD`DG20X6\0$^0`$W,`(0
M(`D"]P`M@`3'%0(6(``6$`&>5@AG(%*1]O]+!QH,&="0XX4PM*4"%C1F$-`"
M$A0!J'D&78`&`D1;#LF%"+,&:#"<5I`%=C<`3Z8(2'8#6A``1D((YK$`)\`!
M!2`&AV%HX\$!A$->$``!6\.$-%``&B`&8=`":5`%`=`%+O4>-M`"!2``:9`#
M$/``:D"M;Y,#7H"&#5`&E2``*6<#AL,DLTD.6K!)HF`--M,H6,%SYD=*+IHS
M!V@&8\!CLREKX?:`+&1SO#)_Q4E*R&EA$E:ACG`84,>1"JL.%$I`H/&D$H<0
M1]FD`1$!%U`";(D0(T``&8L.K4,#:_H%@ZA9!W`(7!``*(`&7'`&C8)ZH&!N
M?]!5G;*H[T4YS!#_"6*@`SK`!4)@`">PI]E&`2:P:Q5%2CZ0`*5)"21`.$=B
M`QMPHA#`K1IP)#`8+(Z:"[!T$R30`UMP!A<``W'0`_47!QA0!QK@!@>``7=P
M1<U*`L**8[KXM%,[`#70'A#09$;(-=W#!6G`+CJ@`&3P!3K0?"R@!Q:F`NSB
M$%6B59]R:Q;:#1?@!NG0!RP7#:55(B4PG0LK+0.V(E[`!&M0'&D0!10;#EZ0
M`$YT&SZ`H-%@!PD0B]$03G[1!X6P!0J@`0Z0`WOP!TO0`$LC$J4["1C`!A0C
M![7P`C.@!3K@G@E0%G-"`0$`!1N""V2`?0?``3SFCH8P0`:ZN5X!`R$C_QUV
M4`7$BPX*D+71X`(1&QQHH+G>2RGK"[]#D+KQBQ`0P`"=^P[?";LW`0,2<*4(
M80<,$%_Z``<E@0<:<`0Z0`?"1P$ND&F@4+^3D!^VI@NI>P0$T`-_H!-84!8E
M@`$78`38>7N[^P<+X!E;X`<3X`=56`ALP);=^[Y3$0=O(1T+(`1TX`X94+[7
M<`;G5!P%P`2,*\.&(KN40@8HT"C\Y15H\`)#[!4%\$9CH0,,(`7!(0=0$`8E
M?!,T4`(A`!BO1`(<(`3_^`>IBY8.TT2Z<`:+00*FHGV%T+R.,`-"@`4AT$]Y
M$!'0\@=HX`=5,`%D@+ZNZ)B38,1$G"-4@`4`G/\5=_`#.>P.?9!RUU``%&#(
M68%#0GK(*_+$S%(`':4&<X807Q`XV'<;!:!;P6L,:O`8<[#(4\$&6"`%)[#%
MS<`7CL"RR*<%$$``!G!Q@#$'7,`$./``??``<>`($]4'AZ'&3,2F)4L$&]"2
MB:`'OM<%B`5\:,@`57`&.4`'9N`#)E``'%`&/'`!.K$`"K"F)C$'%-,&)$`&
M3.`'\GP/'--Z1Z')W9`!)5`"KAP0`C`%//QQ>(`.9^`#LH<07.`"I8S/?I(&
MJX9+!RT.71`%HK8<`LD%J:P+76`"&"LB=!`#"<#)NK!<O[('724`/X`=D_!*
M<T`"+/`';+##GA+3P7#_!B,4"IT[`"9P!`L`#EUR,3#P!MS6"F#@&0%@`W.J
MPF#`!2M0:C%<"_S+T+E0`T[0S^\PO@&-(P00OE.QRCDDU>U2@0=`!EBPT.E@
M!EC``V9='#9M`AH9#'&Y%D!"`BA@``/=#15P`PV``D5P$05B"+EJ``1`EW09
M!A*E.`<A`"PPEW"2"2OP`@A``$XD#QN`?3'@$"0@!SS@!U?0<'0@`O7\BKC`
MU6`=#!]`!1>7%6?0`U20U4`R`$<@TNZ`!@D0FZ6]'!*<+?+)!%R0NA\)T73R
M!3PP!%N0T?-'`0"0I,O!!@$P!5,P``=`RX[0%RK`;_B)`SG0!H5@CC!%!@B@
M_X<(1-I_D`$E?`=^;;PF3,`FP@/0!DLFP`0HL`4?4`$7L30_X!!C@'T!``-7
MX`<PT"C9EB1F0+N-RIBYT$"WW0PY\`-NX*#IL`=H4`7LC!!LT(?O<``QH(D!
ML0`2(&`)_N%P41-GP`4^T`!AL-:Z``$"8``^H-S2L3,^T#0PY-N3H`8^1PQ#
M0``172)T8`!5\`,NT*5ND`4BL`>GHP9I(-\\X`,!\`41T`=8X!!Z$!$XA@5;
M@``-)`I>$--IP*A_0`9Z8,*40*!;@`;H;`'3$`"*.08TLP!,E@-G\$70QA!6
M*00C(#D([@AI\`%\X`5_,0<TT`6?YP=`4`%?<`,$^O\`=U``>)#7@QP,X@WB
MN*!DN=T-!<`#4)`5]AH09V`"E^T."G`!*.#0DE[J4X$M/2T$0U`-Y*<8\0``
M/-``*&XH9R`&0LL"`!`%S;;K`,`")D``!I8M<B`&&-!L9H!L-R``Y7MG"U``
M=%!O#5!#!%!/7<4&+,O,-(VA9Q"ZK1``[*T%HF8"(;`$A<!5M>0(MOL'1M#?
M%0U33GVUN&'J+><#1Y"_P*`&/X"_7J$&LHU/OY[)NM!=`+#C\E[PH!Z40CL8
ME^,`OUX-::1",/94#[^Y$P\*DW$703GMS0(,U8LBTU"UT]@*7P`&``!MF*$$
M,>!$/H!]BX$`V&?8%R#/1S#_,2YKPO&QF/:<"P!O\(50`)[>[Z`F`0Y@R?H`
MH5FA;#P`;L(P8X-!\#P/%ZQ+(83\])+.S+@PC6(`!@20%(LA#X:AYS3^Y:1^
M\:"0;8L=E$)'@22C!@7``BPP`6F0!@$0`/UMZ(J:FMN.TX^.#51_0PYL`%=!
MZK6@!E<Q`"YP!'1)5/8N#A!*`#PP[:SN5%N`!01``010HGV/3AQ9\9E?VAW_
MFXK*J,19!EJ0]'?!1&I`"#4_"?E`!A!P>J&[79Y!TNL@B&OP`R@0Y:WQ"ZA7
MUFK@!3_PN7G"!11P`0!P!1/@`%C@`UT@`,*U`-G61'E?X#F/"RZ>^5Z``%C`
M`"QP_P2[C@47D`D\<`0-0&F''/%.M?.=+RCKW_X;"0QD?PE9;\NN``9"8!<C
MGP5?<`!K``A;$&5K?X:'$&ID!6N)?PI_8P=>AHY_7FH0:ULF1VIH:H9:AQ2'
M6']D#@U=6&!/?F518FEG"UVC?PL0A[Q_67Y)?P`$O<7&Q\C)RLO,S<[*7@M9
MT]-HS]?*9P/8W-W>W^#AXN/DY7]=YNGJZ^S(68>0Q0)GAEO&7V.&8V$'6P!<
MAR@9BH<,H*$%UOYLB?>EP*%WAB@,&?+GE"&#%0V=0>&`218`#"KX\>-)R0`S
M6;;<.KCK#SY>OX(-6X:QG<V;.'/JW,FSIS&!/K$1"TJT:/\YH,N0'N*"SF6%
M/Q2V#/V#$6C50V3H1?I2+]Z",@$/`0`SJM3%0R74G!$"D``!"@&8C*1$P8&6
M(6D:&EKYY\P!F,"$345FT:AAG6K2?#.3[[#CQSJ;0D9F=K)EQV<*):MY*$VH
M7K4.@BTQALEGR4!!#3QT0>L8AU2[>(G6X(R7,F#.9!D#!`&:!6F[:(.@H$N"
M,D...)A&8(L#/PY\E,FRQ@2*`+G0:/I#`!*:-6N^<(TI>%GAR^B_:>'Q38&]
M],IL<3W8A>N9+ET6\+*5_X\`S@7`1H9P"@D"WS>-'6B(&`HVF`X;#QR"!P;G
MU!%!"FKLP,8=$21H"!9G<'&&-1#_G/"!'!^P@8$<ACP@QQDZ?"%""3P@<,$/
M`>33`A]_A(%!`32$T<88*1SP60IL&`)#`7-$$(87700`@1>3_(&&!"7\D-\&
M2?[!`P2UN#`#$&1((004&TS@QP5J2,`$"&PD\9<A)1STWAF?&4+>3,K8H(>#
M@":S0!3?J`';'S=LH2@<`R!@QP"*&C1`"3Z@@44,/&"ZBQ<\U/F(#SY@P4`8
M)22PX`\&^&`""P:4``0NH@!!@0E"2/`J:S%@`<`V!/RPW@`+*/'##R8<`H8?
M7#!P`1A"]/(#H9%,\%0%`>09*#/G'<C@M=QRTP*+AD209`9G[$&/-1'L@<`A
M7*FPQWQ__[2A@B%\S/N''A'N98@+`["7BS%X1&`(#EWR4F\E<W:QC2%<R:'$
M!6$<=(@`ANCAP`(T,"&%$P.H:85^(GS!``IOS/G'MBTL7,R>@QVC4K<P*^!'
M&]XHX,(A=TQ`7`T:H)"!"S%X(008?UR16!8\F('"?W/Z`=$?)D1<P!AK`&`(
M#VM@8:JAOQ3CAR%I9(%"9P"$PEL8S;IT!00F9'&&'TT=\'49)@10["%CQ`#$
M+EE<L#<63\.<#-$.PBOXX>/D2?@?;@C\A[OA[F%(#N#JY5\%0]"`C`9])).&
M9CC,]ZTI;#`1`!6=_W'SAW^HB`(D*P#1L1]"&!!%#@T@((0=?/_1X8$A;.QP
M#,O+!)`!XH'*_!XW;&CP$!!_$.'&>A6=PL*Z$X"H6=N\.'V("1=TX:\+%T!0
MBJA2^?)U+WY@@84!6=S]1P,^'.)'%/+[X84)+B0P51H.V$(4`H`%^?VA!&LH
M00Q\@84T"*$$@4.>X+0BP0HF@PTX.,2VD+&&>!0@7P$#7KY.9H@,),`##/C#
M!8RQP?T<SR5FT,=\Y`""0Q2@#$+80!-,P9H_Q``%53#`%EQ5!#]8X0QZF,*N
M7."&/Y!``S3X0@;R@(<'H($,]VI!&@Y%/&4<RH*7T8$+E"`7(;R@#`5SAGL0
M,0$"2&$+U"O@$Q;H$@)<H3'<L]_3?$#_EA<8(@PL^(%#L(""+MBC:^PK@P+"
M8+=#(.!N$/!##"#IAP.8H`PO:"$0%!`*++"`'E_82'.^EH525.`*$01CH&*H
M2L1Q10\Z^`,='J"'&]PA`[74PQ=2\`<\W"`&K`1((<:0!A$48`-YH$I?QF`&
M%?7H`!KP@AER4``7#"$*`DA#`MC`%0BD(0U<N,``F-(0#-S!"V.X`;AR<0`%
MK$`3.A``<CX`A3G\J`!!@$`!M$``$I@A8Q^(`0!&,H`;#$`!;(A=&23W``BP
MP0QZ$)X:TO6'"/0A8@\)#)]:>2T=/($':-"!'_"`MJ=<8XUZ@MX>(A!'+,3E
M#!#8!0$-D4=#_U3R#VFPW2G,@,4_3&!L?WBD(2Z`2`2@PPL3T(]_[H8``>SM
M#V!@P`(<D`\P'`%J62@`537B`*UP@0("Z,(1T`"0,_QC`#'`$P-2:4$*<O2M
MCXGA`Q:PAI`]0$9]F$$?(K"`9%KT&$M@0Q_,($V&*>8/HT/L'0Q!!P[,P0)"
M",$?8LA*G'XF3P8X!(2*(0<+'*(!,K""/M'"0T-8``@!4%,"DN`#`=S`$"<Q
MA!URL!>5;7`.V-&31EL&5_AD@`(E.)[,&M`Z`-3AI,M+$QT,\88D?$&!?QB9
MV+K`KURP0&4+:-\6?!``!S!@"P4<ZKK^X(,`$@`%/O`##R@`O:`"8?^%?T@`
M"Y@``.AQP00)B`)7T.``'@Q!#5Q@@:DDX$?R$F"%7JB`6PA0@@H030!2<8M^
MOJ`9CLX#/V?X@E(O`Y;>!HJ9P'LA:!ZBC,H>8P&.ZY%&+O``*H0``*]E1@GR
M-5=ZV8L&B_W#'!C`A8@5YF[0_5`8GF.".B0@`T2X00,B$$)$I:YW&V`L`S*K
M6YGPMA@8^).'BX*&"=@`/WAP@`08-H'E.J,/,?[#&PCP@<FZI0(E((`7OL"%
M`ZP'"X4(`!>F$@`M^%D+$/BS%@Y+85'\V0P*2'07#GL&!6@%$HC6BEIX@6AK
MA4,\Y[`/?C;-:4YS00OXT4(6N/!I19GZU*C_3C46>,`#++R%U;".M0D`$.OZ
M`N'6M[8UKAW@`#7Y80(3<$!Z++UE!VG!K8>@H(F5(096\J$%AJ`!!9OR@&2N
M8`D=8,'Q/'0(-]C`$#5H"0E.8`@O$"2S=IC`!CRUN.`N@`6G8$,+*A"%7U=@
M"4=@P``L8`(('-00G=T+<<^!'39,X0Z%Z6(R8%5LGY1@)!#W@TFYLSQF1*#-
M?\C`;#;.\=EPH>->H`:I14WJDIO\Y.[;0LD5A04*N/SE,']Y`F:.ZYK;W.9J
MF@`0?GV%B/O\YR-Y#M!'(A?H1'SG(V'!T",N]*4/O>@[?S@37N`')>P<"$\`
M`*^9P`1>]Y?70%`"_Z]-X`"KH8<@#7>0`.P%@L4JH`54C@"T*\O*"+R6(!A(
M4@0*`(-'M/T<9HBA#L*)AAR`P01B4,(*M$`"(OAG$ED(@P!HL($=[.``&X"#
M#%8P@!!8X!U9",`45)&`&QB```9H11<NX`(7,"`!-(`#$]0DX"2T^0-`.((`
MW!""`ZP!(C3@P!1U$%,-?.`'`)!"PG>[#,FDG2<\^#D+7IX$)KA\-@_0P0-:
MP/$%4"CCDGV$T\=/_O*;__Q`WWFPO<Y^7@-`Z^UG__MY4'8`O)S5)HBY_J6B
M<E>?_/__IP4AQQ0?QW$*8&ZS<8"(9FX*8#C%H`#+EA[9\GR7\044`P:5I?\%
M8``&AZ(#DN40HS`?.O!:SA<N"T!;"J`#Q-6`Z!`!7J`!"O``*A`"/K`%0!`"
M#W`\)%`(B:8`<K<`**8"6:`%$:`"')`O$0`$):`%":`R5,8=(\`"*``$#E`"
M5>`'3+`#8@`07V`^+P0!(H8(Y/8'!U`&+6<CRV=ER\!6%-@.#8!TXW<%+_`$
M7`<$/;=^95<,#]!^9.=ULY9_^A>(@JA_;K%G*N=RI!8I*U=RHU9R79`%(!>)
M".B`;8@X$UB)CK%VSC`?$1!+Y<9LN"!W>',($X<%-S`$8B`$`'`\*^`X-N`X
M6P`;8H`+"Q$!8%`$4Z`!2_``E3$51F!W3%`!&Q#_?7[P`SRP!1*0`580`0I@
M`'^Q$(9``E%V#ML2!@!0`B%@`R4P7NJCALHP`-^&B3>A`U,P>P!`=7Y0!12`
M!26`!``@3H\C@QOG>*"A,MH'`0$0`0?`!2TQ!CUF!EK08X]P#ES@$*,6B^+(
M+=P&'PR7D#RA%'L1#Q"P`LW0B8?0D,5@`W-2A*1X""ED"!31`DY@`&`0!6`P
M`+`8#]`(5;@@!AR0!"B``01`.$"Q0!C@`A40(6,02%57!`D@`$_@!`)P"F(`
M`!3Q`=\W!ML"`7W78A?@!.?P`D^H<,C0`BGFD.O`!=#1<\_Q'AD```N9#!'0
M=PLB!`OP`@-@`"H```[A_P=:8`!,4`!>8`!?\`0`85)8$`9;P(98>1D1F!X8
MU9?E0!!L%0#VP@L0$&,<65$C,)`P\0<R&`8Y^`<V\`"5!0D/H``J$`%K,`89
M1@(Y\'9=$`,GL`$/L`-?$`%$H`$KT`)H0`-#T``?\`0H@`"+H`'2@``Z8`3X
MJ)<_4`0H,`)(4`5@L`-;L`$:H!@$(`;]D@53\`++HG0.,`04$`8\X`-(4#Y:
MPP,<\`4<`#$2T`(J@`8CL`$"\`$4L`16L`8V$`(OP(U4>0P<T!*"F0X1``#;
M)TU"\!X'\`17N0P1@`07V0!1L`05@`Y&P""<$`;RHY=^9!$M9T#UF1X82:$3
M*O\.K_B$+70(1)`!0(@&`>`0S)0%$)`#`K`+Q/<'`;"/8>`0!F`&KO4%KS@&
M9;``\$()`O`%*J`#7]$0:8`&78`!.6``K?D`1F`&&<`!"""*71`!8D`!`R``
M)<`"LH(`7#`$);`#/,``_04#7-!@.?`%2Y`!,2AB%\`#4/``9,`"+>8'5X`$
M`?8$&<!C3G0$"3`G-.!9?^!G>Q$"%R`%54`QY]`<&>6-"U>"%RH.&,`"+0$`
M]F`#3^`\UU`8H!8"3Q`&89`!+#`*KV$"3`"!84`!7,`#6?`4I2H&7E!QB3H9
M?&D9%;JJSI"#E166O/`!-&8OB]D+L%*A)_"?_G%8$2#_J1"@ISHPC1EA")<9
M+DA``52``!^0!>-$`*06I0/@!%"`!$NIIWMJ"`W`!%U`!5#0``(U$E8@!3JP
M`D)`!0DZ!B4P>8=@`2UA.5XP!13@!&L@/(.Z//%I#*`&J^4PI08@-#OPABKS
M#(6Q!$8`51E0!2;P`X;P`B\`!EU``5/&'E*1*P00`V_QJOY:%*H*'Y?8L<D@
M&;NJ#)AJ"`+@B1-I""E:#`DB&33P0EEA"#9`CWPA:N$BJ<>ZK:QC"-U!!%="
M`4:`!3^0!$E`!2Z@F^>`"TQY")G%`>K)`FG@!$QP`7[0&P0F`0:0`T>X!%?@
M!`_0J_J`"Q9`,0>``NMU/*>`_P\Q\!XHP7S*0`-F)K+AL``IX`)`D`1Q<%C8
M$+)T^[?F0)^`BPP90)]/J`.2TPLI$D,YL&&?44L9MYAFD)@:UP"P@04/T`<J
ML`01\``WP`$6X&C4U(5W8`$XH`8'0%QK0`(A8)P#\!0-$3%I,&$DX`9\<`*E
M"@8],`+.>@%E8`9;<`0[D`=PT`%U0`,YQ04N0`,)4&?0:0!%@`!*]P(H4`(#
M0`94<$9=$`5%0`$DH`<+X`%D8`,!4`9G$`(88`$&,`1+(`5WP`<BP`4KX`9S
MP`+O\07[.KCKL`?[^0U?I+\5M*'/T&CT`(&-AJP,HP5H@`9^]@YK\&?_JPS<
MF`Q>4/\"%Y`&9&``72!G?U``&(4",1`&`Y``$$,5\!8%1.NW,#,U!>`&)-`+
MZ$`'WY89'<Q*84``<:`#:V``(#`G`B$`*<8@"Z`':1!%%7,&.!``&<0&`0.^
M"S`"$!`A&;`'=&!(`M`'M5``5?P`@?F_>M`""_!"86`&=$`#B68(9>!0#T`#
M<W`(@5D"#D`M"?`%V>8'G>`%/T`%5"P%`*D`,>"K7%(/)^`")K`$J;3!^@JW
MR?`%(P3`W*``$X`'WR#`CGPXM,H,/^`##"`&+S`&!B!L:_`$H<`$SB$&0[!G
M??$#:%4`9H!LO5!9@4ELO%`"9I4%I]!>H&(($H`&8C`-"M#_$L42S*U$B<P`
M.;V@!R\TQ<JP.(+:"QS0)0EQ#LTL`>_@(H=066-6#!7&"W"0+V/@%4U!`YZR
MIU]@`"P``"N@!'[```<0`PFP`E(@M2YP6CZ0(I7P&2L9!E$P!"D2?KR`R(5:
M'LIP`UI6R=@0`6GC#;*,/`T@K0)``%D`!E368793`ECP`B;P%%[``%@P!*OC
M8<NVS<H`.$-Y`0I`-W]0`0A`-"A``8_(`!IH"$>0!1)P``G``(O3"ZF;;*5U
M#-^5`/&#!4I@",/"%5N*O^\'$<TBS'VY9/K`2B"6"X[#RIEKF0JP4F&0:&:`
M!CW8!3WH!D30@PRL!0(``W\V`#!`_P9M,`)^%@"^TM9_%@`7(`$7T&<+MF!S
M70)Y4`:X\`4)L<%_()/9_`<P0'4L0`4#L`):MP$4V0,9G0%E\!D5M@7ZL0(,
M@`#V\`#']0<TL#!=X`.#G;\2U&CNHIF-=CRL-`@Y$&A:4`89T`>M'88\T5/>
M``<<9;TQ0`;0@P5@(0`L4`A1``'\X+`&L4*`TUNLA`4"P05D@'8CO05BP#99
M0#=JD``_H`2H*P`F<`8\0*,Q!#C30`$5$+)GH`7@P1V&,+/(P`#H8,M_(&QB
M$-\NT`5J0$#3<`86P0)0L]]@%!I_$`)0L`444(-TO04_<`$&,`/OXSY8H+4,
MC@4I@``I0/\&%\#@;*T%$N`!$@`&6,`!`\#@'(X%(["-;[`#%]".=YWB!&`"
M4G#7+Y``HS=))F`"&$UV*##C#C#C.C[C3]`#4C``:U`!6X`&"!`&:)`&,^`#
M#1`'52"%/M`!OA8%%(`$8Y4J!O`"`-`!7H"/JED`)QJ-*?`#R_H#874+:Q``
M7X`!LT$&1S`#`;U1R'`&FG,M+B`$"6`$+/`H0,`&;```FM,$$H`")"`$6G`!
M=)`!/C`%!:T@?0`!*99F>A#!,-/@%*!5!?0.!/"6'?P":)`%0D``%E$LQPU7
M8=!)GSBI&%4*!8`"9"`!78`J*"`T:T#H)2`!:C`$$K#A42`!'WG_#&:8$1B<
M#%7S#A(0!0O`!%S@1UZ@!&5P!#\0!D=P!/A%%0E``2BP!0F@PM=R5^GD`4<@
M`U'@/T<``.=\CC=.X]1K!2]@!2A0XR\P=?0UXR\@!+>&`D+`:@)VSOA%:['6
M[T#S`L8H`0AP!`3``Q>P!3.``!)@:F0@L0&P!0:@!8HR`%V`!@/``0=P"Z`F
M`BU]!-^V(GWA&?3`!QMPU=/7`"R@)C=^`%!`!`!070)`!E8P`O1`!L2&`6A0
M`:#]0KYSS7M!J%4FT,F@``6[T),A\6O@`'6@`#C0+&3@`G7B`Q5P`VR0`&L@
M`S[[L?`1`2[@U"[!,!<PY\B#!2[`%<52_P8(H`8F(%!]<09`@`;%@@MU,NIP
M%0!>H.W)(`;UXP4^P`5BL`5C@$4(<+W2"@&F!E.F=@!?@!_*D"/V8-+)D&')
M=@:NO`Y_.5F3I0:5U6ASUFB<%'B<9`AKD">6T\'F_0>=60`'0`-:4(9?$0H%
MP`8;T`:^30`2H`5BT`5E<`!57!\1X@6Z]`#R!B%?D-6],`8YVAGZ<.H,\P4Z
MX`4RD+A9<0,%@``Q-`;TB6-T,`!!@%$/`%_<$8%-U@$*P`!!\`-SW@"X@`84
M\P`Q(`1%4`,5T`,%(!=`8`'$0`$8,`(2``A3*T!I6"9A?UA_BXQ_9`Q1/Q%]
MBQD0BU]@BUTN6_^,67Y)?P`$C::,"IY_=%PRIZ^PL;*SLEH.478$3D-`?S\!
M#CH/!DDM$P@^BP2JM,W.S[(>`XL-?UX&76S0V]S=C4,2?P5*!09#)0A_+&)"
M$@D!0E@OBS\$#"7>^?KY60$+"MW4_!%HAI&9,VK,"%QT4`&$+W\4%#BCP,N:
M16O,%&A4H,PB"6`DCO'X)XN76"<;<>'2)8LU+26SP.QB"J8U+UZXJ&24$M$?
MFG^T:/$RYD\8"$47"=BR)0P9IF?&A-%R9M&9JI@@+BK0I>J9+U_.Z.E"-L."
M1GHL..%Q`6NS"'L6A4FY``TC,HL>:/UC@%&7A7`7N8FP2(.<4P^T_=3_DB;%
MG0YQV>Q@I'.1W44RL):`881*"<5=5!W`^\.!%CH3LO"8X@=(#1)"($A`<"F$
M@Q!U'##@X,OMHA5"=L"(D&/#(CG&_]#`]Y,%,U"B2-$*_>=+9L7[LM,*H.@/
M@2X*@"QPDJ4$%D4$R)CX$T"#=V;:X]/ZBLC(F@LDL,O?OZU+T2]=>+$`66>!
M]<=99S7B6WP`Q=+@3;'0Y-(?6X26TB8_Y73A(CJ95%D79)QADX![8639&A<M
M`M!)7@BDAA<'*!`6(U^DD<4"$'7QQ0('9('55QON&)$"TSR4(']()JD/&3Y,
M,4`&%#!BTT\T:K7%A1N>4M<K%S`R1D&FB`&F_P9X_`%!&N&<D48'4`B`PP\+
M8:$`&FI41B%"7B"`!@19R#"$#V@@4``7`31P@0!9N"`!4T)0D(42`B1Q16LL
ME`"%$@"`LX4#1Y1P1!1E5"`!6&88@$46$OS@0@P"^-!%&F-HLL`-<IQ1`E=8
M+'-@2:&,4LHL7FQAA@27*<D?&11\888/%P10P@7I@&%`"29<@,9Y/$ST`Q8E
M&HND3EP<`9226:+"XKA>9)%%@#@%:(I,`9[GQ8AD8:$%%YZTY)<6"HRK8KD4
M=H%%2CB9PE(C0_$$L(H\/>CMPTAVH1-`$T)L\<4-+$#&$"Z<&A1%:"28Q@%B
MM`1&&5\0>@"=7ZXQ1O\)%32P!EX08`$&&`2(@8`:ZWK!;0!H-*!&&&:<5``$
M"(2!`$Z%:)%%&&A($`86$@>H!1AA$##&`&1X489`7GPA0``#-`!!`D>XH$4#
M/DA`J`$2J.M"`%GTZ(<#%3SA!PL)./H#&EK(N8`)1ZB1@`$#+-0(&@I4X`,`
M/N!#0&698.)3%[HN`IVOM*P;Z\6@-Z+&@A@R,KHUBWA!N@)J7*)`%B]>LLCI
MXBR`%<]8C3&&%DFYE)(`6J"11@$'/%3"%^FBH/5YW"[B3QJ->-'%E(V8Y#$7
M]U:D;A8>4VD->/JJ2-;X/SF\R<*AI\^?2Y[(!,U)`.%+$Q9;*(`%%^<1\!W_
M!5L$GL@?.CG/+%H"D"C]I&+J2^`^O!`&COT@7=:@R!D.L(@TA"A=8,"*TZR2
M(BX@<!%;2MTGI,0(H2U"3HNHWR9@4@`"@"DHK[#)`ICS!QYX)VTV(0!`D-:`
MNO5O$5J@0`Q\X(<)A`$,+WC"$:XPN2\`00(#J``9RE""A4QI#$+$`@44P"P7
M:$59(*S&3S+'J^C\2A9F&,#?["(@"V9!`&:CR1H&\`7<J<L,8RC```R0QY.H
MH4)8\<DIU@`]A3%B`6D(P$`,``8(F.$\$"F`)@J0E*/DR`SJTH09S+:&UU7%
M)*WSGNQ,P3K7M<@AKTC1(;%B.VZ808I"*Z0"9TG+_UKVRQ3H.\467`(`^VV!
M:B;P`@%X(!1[\<`$"IB<`_#W!Q/@[X,&"U]W#EC+:C[C!VD;PD8XQ`@#EH01
M*DQ$2A#"H09]89M"`2<C;'B*`"S$A$8!T\&JDZ/P+4"1W*R.)A9Q@7!5X`>,
MJ$`6AJ`$!_C!#P```@,$\!-W'#0*)SF#$&*P$28@``%D0`$%"G+&!IV!`5MX
M5A2.X(-UJ>(+25E`.'YB@FEN3CJS4`,:OH`&NR@`D=;,:4X+L`4Q_&&2:""=
M3H=*5&]0KQ'F@\5ZN-#24S%E/5C@0;KDQ`,>V,]I!+A?%EJ:A8K``H$.2VI1
MK1D&'I2@!!#8YQ\JL,\MZ/]$#!08@`(DD+,RR$-&8.B"!!K@P0%(0*5<(,,%
MFH4/!+C`A2ZH@`(H$-4&B&$(M&'`!7R0@"A0X`**,@$%2@&`"OPS5Q48`@O&
MT"5EJ$@57J#`$'Y0AJF=APE_>D$2@<`+`S"``08`@A^><%$'^,"P1T##`93P
MA#5$(0&(6D.4MJ"&'PQ@##P@0-NP\(0$$``,..U"`<S@U3)<I`L.H,!"7GI&
M6I!AFV-5R1?.@S0)O&Q'S"-#`OZ`!L*Y0+,E2,`08A`%,*`!+^DUG0&T4A0S
ME,%.`4ZP@O=#`2\`X`\.,$%5PT,!+0!@>E3C01<HP#]%<,\[AJ"`OV(QS077
M$J7_XDC`!0"*NHBH9A$(<``$>,`%`)C`$THH01>`H``#"(&O,?`"`]Y(`!-H
M@04+0`$`N)98%PQT"%P@P!F.8``NO(`,8C@"&0Z++12`@0)X*X`#`)"`$C0`
M`110@A`L?(`+C"$`'A1H`0J`@HDVP!QW.Z@?AL`$/>_Y!7XHPP3\H`0TC($,
M/.!8%-+@@A<X0,A8T'&,%'$`GYW!!P9(0!BR4`$M4-`49.&03;3P@KYHKE<P
ME84%_W`&ABHX--H,0PRR,(9-,64+)N@"#SS!13),#7,#2(,60@.&(2PX``!V
M!",*($@3._O9S]"0^G();8B=I`R8'L(:LI`&5W./!V!A_P(#RCJ$)VAX`4"@
M5N'$'84U6%6J6B````"@$Z:<$(I8*+<`I'P!INPZWA32@K_3P(4&`-R9`1#O
MKH]@@B\4[H24N:&387P%W1XT`9/2\P0<D``]*_(+CGL=%A"`@B@@((E09,09
M`\``%PSA!9ZX``4*23007N;#`/Q!.DYM1EK@<78"2$IZO[,>[V@7"P;0[!8J
M5>N(H``?+"'``,HP;.P5_=G0K+;6B2I69[CD5%F@``\X3``M1+<+N2Y%NLS.
MV#'_L!G4WKJ2)$(!1;G:%%B(@@MX<(0R7``%?)9O#`@PA`!H]`)9>,("HG#H
M!/#@`!,@@WA>P(2"2.<*"D"!X?]+OF()2X`!:4!!`ZAE`A.4P`<L@$D,>(<&
M'KC#`$XQ@4#N:94!(*`")3#`0KA01#_[WO>A#<HO7S`&(5P`#&;X`0H\X<U?
M%<`$,0##$0(0`X"X`"OAQ&E);()KEZ*ZO+#(@!Z>388`N$$&#7"#!);@@00@
M8`<78/P"?F``!`PA"&Z0.EOA9H`+Z(#%SM8',R!W!$A4.\<-8S`$9[`>!;`&
MZT$`!I!:?^4"/N`1):"`']8HS>0,"%:`$!,"0P`M7^!3?\`&#\`(%\`!6E``
M)/``0E$!=/`'-S``<T9)'B`'-T`"P",'$"`"<O``>-!LK[`!E/`'>9`!'*(5
M:;`08R#_.Q(#1#;Q`+]R`FZ0%UT"%A7P`E!P!XI`!P\P!7PS:!>G`7<0!A+@
M9R;P`D)0?F]0!@?0`WZ@>5(@!'G0!32`!70`!SD`!0<``SS@`U4P=D=P`25`
M!DA@`&3P`1:$`0#2!6Y`!%UP`F+`!1?04C+8!^1%"ZGP;'O@"F=`&";8!R?8
M!Q'`!I,0`6>`A`I0BH1A"@6P`AX8B[(8.AWX#!3P#NM1%>M!!MH%@353`#R0
M@(5'16<@8A"0#,U08K.8)'Q`!09`!24(`WF!7IZ@`QD@!@N0&$00%VD1@PNP
M!6D@!UU@`WG`!C1P``7@!FD@`VB`!R1@`02@!QKP!0;@!F6P_P50\`=N@`!(
MX`8Q(`9&8`9=HBI;X`)5$`>8)0:\@P50@`!<\`-S8`0(<`$-T`-E\`,'(`&S
MP0!58`2(\`(2L`-+8`7*=U`.P`-%M`$`<%`E8)+;P@0BP`!18P)6X`51\`0&
ML`):<`=<<`(68"L*D``_T`3[%04^$`(JH`!U@`-G``%P0`0"<0!?H`)[T`5E
M8`9F8`=(\`:?\'V:"!_+&)9A(I9D^3"*`PUIP`-D$`/;HC91\`<O8`(!@&0^
M,`\%4`$+(`!8DS%G)0:E10O*6);9@0<)X`YLL`8@<`<_P4@0L!$9U`!X`&<+
MD`,0X04Y2!AHL`5?8`%:8`$>D`%\,/\&9]`":Z`%>!`!#]`"+9`!34D"*L!=
M%!0!$*"`6$D"K/8'`Z`"?U"*C!`",?@'=H`!4`A"))$R?W"+1H!/<$`81\`#
M5D`!!W4%-3!H*#!H/""&0*`!##`!"Q`"<B$!+(`"-&";_(2"4V`$)<`$!&`'
M3U`!BF%5BX`!BG$`-C$]F^`#`\ASG#,+FRB891F8_AF@Z9,0\4$GS@"@`KH-
M9V`$G?&;WU0==C)*7[,(HU0_)JB9=M@_;-`%(?`%8Q$T9+$"!T`6$!``6Q`!
M<A`#78!L0F`!?#``'7`<2(``3/$#'1``.-``5=4D!M"<28!-%V`!7'E"<^`$
M1B`!<?$'3L#_!FS`!!1P!9.24+]W4`UP4!/P!"9PCWEA6W2P'(S@`HO`!E.P
M`Q*`#D*P!`%@`+K)%V`"!R>X&,/)'B;@`5W9<_P)E@GJ@0B:IWRZC.C5I^\S
M!`1`!7LP3:8F&RY0=TP0B"C@`"@P&6?Z!V/@``%@!7\7!57@`T8``3.P!$60
M!=:%`E0``'7`!$T@6Q1``@Z@`5;P`I52!1?``U3`!2B@!GC@`$/@64L0!W_(
M!!C0!&"0`#T@`8J%#BA0`=/'"'7``!2```Y*``_0!06E9P2P`D7P>Q<`!W[&
M6W4`%G2P`R18"E\@!PS0`E^P`U(@!<)Q!#5P`1`0`W@@`B30``<P_P8M@`4'
MP`%>(`8-D`9V,``D<``84&1P4*?[*0MJL%*`6H![NK`.^[!D28(%D``-,`5Q
M\4(3HG-_$`)OX`-BP`%LH&&7H"B+\`2+=0!3@`!OD``6T`5O\`(A$`=(\`4M
M(`=1T`5/%P0`\`,5X'CQ-@9(0`%1D&E+=@`E0``[T`8<(`1#8`)04`,L\`)9
M$`,#``,^8`(.0`)`4`0!T`,!``8\```ED`<(H`5U``)@X`05T`5[UF=^(%U1
MX'L.@`-8H&>`Q@=3D'`Q8`0%=P8L<`!IT`!2L`)2``-)L`,-P`0=8``*(`<]
M8`)^(`0)<*T2(``@,#P28`=0X`?S90,]YO],!IMJL7`&T@BQ6_=IIINZJBN+
MDP0`%\``=-``86`<-!$&(TA,ET`&5E`!?*!K4AD#]2<&8\!C`"`!/K`%(R`!
M`<`&+2`&3"`#6L,&:/`"72`%8O`!"7`&*,`$/A``/M`"""`#8!``*Q``3_``
M8``J:W`'+K`"`I`"O@"F/-!(BE!^2S`$,'`8<Y`$1_H'#T`"&1`7.D$#$V!Q
M?O`#=*`$O_<#*Z!QHF<37_!I73`-_FL`4.`.4+"53L``C'"\?M!C.@``3``#
M#;(%*X`&$^`#)Y!"/C`EF0B8JPMM9QG#-%S#"U:,Z2L0*K``?[H(8%`'&=`&
M)^`J,1H%LB,!=1#_!@TP`07P`BW`!FHK`4*@`RX@``"0`W^[!"7@`$9@`@B0
M!#Z``3C`LG@S!3S`!#R``B_0!"CP!RU@!0G``&A#`4R0!!J`.5^0`"P`#VGX
M`CZ0`U.``6V0`#M@!'&!!T3`"-WQ`ATP`8/F`&+X>RBY6RB0!#2Z""U0`9O`
M'&Q0!3`0&QW0!D>I>_2P!1]L59#;`&"R!9<`!$U@)146NN`'"R-FP[9\R[B,
MRW8"!C$0`PP@=-4Q0F82`\WZ913P`5\P!=+X!4O`80$@`3#P`QI``@;@5B$`
M(UPP`%ZP`E@P`!^0!2OA5EPPH@!A`UR0`Q#@!16P`LBC`041`5Z@`P!Q_P`M
M$`$JH"X<`@&ZJ0/>>2!?;``&()QNW(K_`Y=)P`)4<%!/-&A)H%L;=U!%@`PL
MH`$V00(KU06:_`<N@`!"D,A@<``_\`!V8@:FO%A?@`)^$-!>H`+]<P83\`,"
M``$*@`05H$@Y<,]>F<LZO=,\W=-FL&O&]B`Z,$HVH0-_63%J10*M:`.)_%-:
M89\'(CL/L*9?((3*`"8C$`%$D`%.\!`ZL`$J4#P#P`5CL``^&2-:$,$'8`$'
M8`,;L`6\=0%I4`(K,,YF<`)DH`$$H`$70%=6L))^,`4,X`=6L`(^,`%7\`,*
MS0+ZHP4_4`(\,`(#$&DZ&BE,P`0VL`4&4`$%</\>83`UA6C*M48%$U`")(`!
M$F`$#9`#&,!$B:0%2Q`#WJG/+]S3MGW;N`VHBE``0R#"[J,`.H`&%,T(!J`#
M$1`!)P`!PNT")5H=$*`&.<D!6:#9'(`%8B`!&H`%4Q$&NE-_AK8$,!`X2!!T
M9J`%;.42!%``:-#9$"``)\`!L$($%Y`!.F`!"'`"8=`%#3`":-V3:YT##T`&
M#H``6+"F1.`%:+`!1/`%.J`%Z:P`+["SD5P"99`&7F`$?L8#280!7``&-VT#
M$J";*,5(#F`!POP',<`(,6#*5B"YQA%.'Y`#-G`%(9Y"]B++N9WC.K[C!5@Q
M6&`&U\4$7L!=\Q(!*%7_NM41`6;1`!%@!BW`$'_P0J@@`&L:(CY<R_ZQ0CRA
M3II#W(PP'/RTIASPIKOCPP6P`2Q@!$N`A`\*`3>@R(P`!D```!G7&G7N>PR0
MXO1HJ6/@`AP,`4*``$QP`BF^"-XD2-7\P6"]"+F90OWB!\1DXRZ<TSQ>Z99^
MZ4/U(`2P60R@5@]R3G!>'4(W)7MQ(3;0BEH`)E^R"#0`BV[LA%,R+OL4`480
M`4\N`4\.`1]``U[0`MKL!1EP`&].(=MD`S]@`A+@!!\0ZA#@Z@4=`0;@R!NG
M!)(2AU`:!0#``KKU!*4`!MD.!BS@`&#P`!(P!%)@`SI`P05-(0RAV1\\WQ&Q
M_UT0`7MH<`52,`8.`0-8(#,74=N8_N\`'_`/0S`O(`8Q@$DDY!=;WN5_``,;
M``&\L0,10`,4X`,"@#A(L`1:$`*=X0,PL`(E$`X8L,$W$`&V&0$LP`2RY:J1
MQ@$O8`48$`-GS`,"(`11,`)"4`0QD`0.L`100`4%(+P08-0%@-\V```(H`$!
M(``W@`8M(!4+H`$8T.R&@@!E&@!%```<!P`[(`20WAIYMP0K20K1+KO97@(T
MP`(&4`0G\#=B$/1B(`9EP%@;\4;EX0=A\$N[DP5.H`0!<`2-XP=<8`-H$``$
M'@)3748'*_",W_B.SPU3PU(Q``!>($EIW3]?<`(Q#?\3)S`&-@`!-O`%U;``
M!N``9+`!%O`"1QH%$H`!#?`!$`@S%J`$.[#Q'^`#3V$%:#\&>;(!%T`%86`I
MF@8`AA"V)6!A/Q`&2=``#2`$P)\$+V"X"?"N!?``*T`"_O<!>=XEI[[@"F`$
M_T$3MGX!O2Z#DU,"+V![23`!!J`$5;!7/(``WAP"*/!X5M#I+Y.XY(EWKP`(
M2R@F)CY_AQA&#F9@#2A""4EI?UM86H=_67Y)?P`$F*"AHJ.DI::GJ*FJJZRM
MKJ^PL;*SM+6VM[BYNKNZ7UA>%%@O7W]F"@K&Q3I$*H=$7BMF#VL0AUL-#!8$
M2`E$(R8C#$@_"SXQ)"];6F7_#5A_!@@;?SH#F#P*6TAD'R$N4CP8)FA!04.#
M&"@C(#!HA&9*`PL:MF0Y-$:+!1-82F3X<Z+!H2]@1EW8^,?=H0UB`#``X,>!
M%10#UI0,P62(`"4.-GR9LB,*#0J'="#`9/)/%TP;FOWA@FD,$1U_Q%SZHX&&
M-4N8-''RQ*NKUZ]@PXH=2[:LV;-H=74Y4B'!&4S53A7`-+6"`0,?`*!!D6`$
M$S((P%3I(X.=`PI5?+QX\0.`E1A6EH@XU$)(D"$`*`#HH"<(BC0#IBAY,032
M&Q9'##@Q\8("@Q5CXFZQ$&5$E0=$#W79<NC!W$,7'O2)BBG,(3H'T!3H(H#-
MH0H2_Z+8D"!D0P8G"%A`-<E&1NY#GPY-/#24O()#:*9VF8H`J_A-G<*GG4^_
MOOW[^//KWQ]*32OC?T#@P`47_!$%)A6,\H49=!TB0!F'R&&5'@^,\0<;7="0
M@7_I'4*"<W]\,<DA#!Z`DAEF]!$!,F%D<<87$)#1@`)]D"#''RKPD8%S=*Q`
M(14XZ$""`5+8<4`%+!`0`@E&C#&&&QW\@<86(_`Q0!X/&(#!'&74<4`60Y1Q
M@047!.##`@=HH447301`P1!1_`#"$3E)D(01*&@1@Q@@O!-&&%YLH88!7Z@Q
M@`MX'"``5'<@<,`!96C@Q@T!Z`%%&F2,X8,.;>CP`Q9MM/]`1P9:Q<??J:BF
MJNJJK(+B7ZNX>,2*&'\$P(`!#$!0@#MA='$&;UXT2)$9%H(!P0)_"`"&A6>0
M`8&N`@A`P@!8(&"!%V,$H&T6:N@JAAD2_$&'&#&$,<8*%FPAQA9C"$`&!BYD
ML<4-;V#P!Q\VZ&'#'R/D@`,;&M#!AAP"G*$#&"@$P04;ON5VQ@)TM(#;<1E@
M<08)?TS%!@(1'.("@W_$8,8"2+PP0ATQ-+``!3T(8=4?-+CQW0,RFT+K(;]%
M!?('>QSB@P]390(?5[`6;?312(L%X%GEG;7TJEU\0<`1!+SU10`AEO*%A8<$
M#0K(?]1#XBA\3/;'#<,=\E8H>G#_,,K:&1>'"0%*P3&Q!F<$\,,.<_1&#,PE
M1!B$WY@$WC4F3!TB]A\4J"!&$#DX@L,!+/SPPP:_[89)2!?N(+<HR!X"U',=
M_T'W(3S\$'2I1"?M^NNNO`I[*VO(=%;.9OU]ENZKHO&##Q1P'B`F1XG2L"G"
M8_W1*!K$!4<.E-WX1P9Z1/_Y'R.6]%W8US>0P@\N&!!7%V+3X?;T=!S7I^*8
MY/S#YI@XX5P&0V!AA@X)&%'@%N<9Y?4?;\'"BA0P!@5$8`]E>,`QT'`,!8"A
M@6)H8`#2T(4L7,`%E_`/Z^0SNP[RH@`80XOPRG(,M)P!;AY,(7W2,(08U&-I
MQ8O;X0[!_[`,]`P3-+C#'R+0AS$H4`%S^&$:)(B#8QB@B`JX`Q$44(8V;$!-
M^%)3&SJ@)BT,H8I@J.(5*]$``A```3'PHAB]Z(,$_(`(<B#!"@+PA06(H`!\
M((,'T""U/RR@!7M`0P7$X`X-O&$-8"C!&,K@"S.0@0P!"$,!TM`#G'`@!56(
M`0^BP(-*6O*2F+2D#TI@R1X@(`@7,,`6:L`#+)CRE%@(ABD14(("W*$%0ML*
M!\D"MK*<P0-H2=!9%$`&%?KRE\"DA7+*P(`2.(``%-`,`);)3`(P$P`L,,$R
M4?`"*[Q@$*P!@`F$H$T@>!,`W@PG$,")`@=X,P&5?($),IG)3?_R``I'8$`3
ML/"#(U#`!:C,)RJ_F(7+_<$"<H``#=B0`3Q\`0-HH$/HIB>1%VF/#2V8"VYN
M]H><G6`/)7@#+&/0@R.LTP<$B`(A3)"`5);`!Z8\J3Y-68$2M,4)6#@"#PC`
M`Q?\``$7V`(%ML!3GI8NEJ8Z2U'*HH+1F86B98D`'H+)U*8ZE10\^$("`D``
M`Q#`E.N\*@4P8H*KEM(%(35!$\@XUC&:=8P(^$`,6`"`!!P!`"[@P1'T&82Y
MKO241TA!#"C``P1L00)]W8(7>]H$O_84D5L((?]$,8#^@0(//T4J)FSW!Z[]
MP0T18!AE<R`]#(#H8:-XVB@2]X<1IF+_@V@AK5G&\]36NO:U3`U6%F9+6R[0
ME@)>F*UMLY!;;@%0=H>`@`(HRXHQU!)TV?N?*@C@6$PL%GNOTD*P*-'<86%B
MNJ$(&F\.@=T!K(T,*`0=&CZBRR]0='6CP"XH#%!+U,+VO?"-KWR-MMU2Q)`4
MQOV(:551`)`]%Q0+&"\`B3L*UK+VOHC#!'M%D=]DC0B\Z1V%=A/,8)`53&VV
M.\.KO@"@+^#N%&D`+BG<.]\2F_C$*!Y+=74CK/E`@,`IY@6)8TSC&MOXQCBV
M\8QSS.,>^_C'0#;:CH-,Y"(;^<A(QL60D\SD)COYR456@P+>TCHH6_G*6,ZR
MB:NLY2Y[^<M@)W8=E\-,YC*;^<QG&3.:U\SF-KNY%6I^LYSG3&<TQ[G.>,ZS
&GIL<"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g06286g0628608.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628608.gif
M1TE&.#EA3@*>`^8``,O+RUI:6D='1]/3T[>WMT]/3^/CXU]?7S\_/X>'AS(R
M,L/#PQ`0$#<W-V]O;SL[._GY^9>7E[.SLQ\?'RHJ*JNKJ_7U]1H:&B<G)_'Q
M\>WM[:>GIY.3DXN+BW-S<^#@X+N[N^3DY*.CH]W=W<C(R"\O+]75U5=75X.#
M@^GIZ9N;FPD)"=G9V2`@(&=G9PT-#4M+2\W-S<#`P+"PL'=W=ZBHJ,7%Q6-C
M8Q<7%VMK:U-34]#0T*VMK;BXN+2TM*2DI$-#0Y24E'M[>Z"@H)"0D$!`0)B8
MF+V]O7!P<(2$A)V=G6!@8%!04&AH:(B(B'U]?6QL;(R,C$A(2$Q,3%145",C
M(W1T=%Q<7'AX>`0$!("`@&1D9"PL+#P\/']_?[^_OY^?G^_O[\_/S]_?W^?G
MYZ^OKX^/C_?W]_/S\]?7U\?'Q]O;V_O[^^OKZ_[^_OS\_/W]_?;V]OKZ^O+R
M\M[>WNKJZL;&QL[.SN[N[N;FYMK:VHZ.CIZ>GM;6U@```/___R'Y!```````
M+`````!.`IX#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH94J#@Y:B0-EJA^BK:ZOL+&RL[2UMK>XN84%?GXMB0Z]?F"ZQ<;'R,G*R\S-
MN;R^P,+$SM76U]C9VMO<C="_B,&]U-WEYN?HZ>KKAM_2X^SQ\O/T]?::[N'3
M]_S]_O\`M^4[)&Y8P(,($RI<V&F@H8+D&$J<2+'B08>%(%K<R+&CQVX8"6G\
M2+*DR9.S0@X:B;*ERY<P'ZD4Q#*FS9LX3<[\4S.GSY]`$>[L&;2HT:/JANY#
MRK2ITVM*X3V=2K7JK:@&K6K=RK5A+W`$EW8=2[8L(ZP1S:I=.]:AE[=>_\80
M94NW+LPQ81"!@3O&H3`_8>;:'4S88I@O9KP<2#L(@;`O?A\++DRY,D#$$Q@4
M^/(%`2(OCR/W^C+9LNG3Z@XC8#`A+B$$8PZ!'BW:#T^QJ'/K+J>8-1@QA\`4
MD!WZ*Z$)PFY+W<V\.;,Q9A!,<.`ZT9@2AQS3-CZHA#`QI9V+'^]J3!D$"!;'
M;C0A;Z$#Q:,-8B`9-_G[^#UA]E/`BR0SC,WF!V3<":+=@.'E=U`)7RB8T!A>
M9%;=)&$P8(B`!,HG"'*C)>@@(PV>,\8$8H3X(4`3%+">(A!*ET@)*PJ"H4,<
M(FC?B9!\X=\Y>YG(&XZ/@,&?(H@50)\?,1;BA?\92L8'UA_>=7@CD(U\<0!G
M6&:IY99<8ED&&%YZ4<878);A!1A[>8$87'"!V:5[@PCG!9RNA`$<(3Y.8AN5
MBU3H1PET"J+C@;U@1\B.@HSAV:%.$G*DC<OQ^0A_Z#F`7GIO'7#IIIQVBH"E
MEF*:*769;@I7?Y[V(IUTPOA'YAA^M(9>K&^U-D%ZK8%V@*:W_N7KK[TP\*BP
M-0+[:ZY^(.#%HI+J)4P9@^A8[%\1B0'8<3X*Z(5#CY(V9;.)['G.`8,`5^*=
M8MCY1Y><X95D*R:&,0&XB-08U[2_#D<(?#XZP.0@T/A11FW>1DJO(N*6,R("
M>6[#[,&""&GLQ-"6VPO_HG^,0>X@`O95X!]_R?4MQ(0D;(X##6MC,KUA$#KQ
M7PYD)`R=)'+<Z"!_%9P5R8G,F\X7[ZK,\[HO&^NC&(]6+$@!Y,SX<;<>'HQQ
M62N#.V+1PDSW\!_P";.Q(&;$+./-!M9G\-#E3DU6U>`&;.P$8,16@-(9^_KP
M%Q:.O9V&?QRH,V-HR\@6V\U*;#?*<(Z1=W>^,D#W9GH/Z-"!(I\=^!]JCT6X
MI+`*4\(!=`/\+]@%3"NVC&([S;??4=.;>5>;2_KGZ8>4X;,@\HKA\NWK^JSZ
MDZR///3B9L7.9\H91>2%A0(F5W+D9DQN]LZ7+XM`"9Q.<*NGW*-7`@/2:?]G
M_Z'(3?!]]^A7>BF;;4*XXA@143-&@^QSMFZ;0+.O__[\P_4'F&DQU.42H3M"
MP"HV5\O9H>A'MKZUJG5\<L"5DH4<!!1@-18L093`=ZE882]*YGO4ITJ@/2,=
M($7H80WVTI="K$TL,[[BT/=<2,,:OFQ[ET*.=V2X0DZ%[D.E,Y&F5N(K`:YK
M.`(2SL>"9SF>]2<,`\)2&.;WARG.[PMW$A1>JBA%-=GO#^=25Q;/Y8@29>E+
M:=J?I0[`I@-0)U348:/^S$0J-B'&#.S:4F+ZIS\_3$U'A\%2"<S(F0F4(3I\
MXM!FQ,"@09CA5XEC0!BT)3TI-9%D_;$6(XPG"$XBX_]KA@#E*_P8L1A]<1!T
MZPR5NO87?0G"6K[RSV$BI"-A1&^)TP,<S]X"LDTZPI/'V-IK9D%*,!8"?J\$
M&YZ$J:!'%2I0OV+`\GJ!Q&=5$E+4"YRRN.;+1@#3&*(<IBS\(,J]&)!WO50E
MCEAYHS*\+"^4Q*4ELXDVT*"'$>$\!*P$$JA!Y%,4R:))%M>5IXH!1YT?@N5?
MT(DS8RTJGJO+Y0#']@7C,=,081A.&8*VC$8>X@`<!84?Q`8&.I&I$!%!J(/<
M-IIZ`6L"ZX$H\"0ZT655E!&O*X08XA(W;#`,$2`=Y]3,>9Q"P$:E^:EH$1/1
M/*_9[&(.*<C?)HHY!MQT$7/_8@08$#!0:_Q4-L046[JJB$#WW&D]![TH>:89
MK*X20J$*C-RV/B8@-PI/:@/Z)[8:(8;17>.KAE"K2!?5TVA-#6-(=9#N`JJ(
M:8%2IB(1QJ?NZKH!Y700#*U=4+,!6*/.XE8HG9HK!9?8#ZEB$?`!'QY-VJIK
M3O:2$'NDCG#:"$O]T!F;#>PL[@G&O(BA8NO)$Y-*2S*;(L*=4)5GLB!(I8J:
MB;9:I8XV<BK83_#6`0,EZDJ6J99``@UHA<"B(<;0U2QQ`K)/'09S@00:$D(7
M1)=5!G5WN[6^AE>GZZKN3QX9*QOZ%UCZ=01RR>D6R:X71T*ZJB+41(^0YO85
MH/T#_QG.D+&*N>=?[HD;<8NBU%_1KA,;CD1="ZRJ`Y](!0,R'H,9$8&0*B-L
MNHRO)ZJP*!4,H!`1*$0"N/N4#L<R%"&&A`1:2U<#4Q9<'$@Q3I&G)#1D8PT<
M0)Z,.\';0:Q!!()P,D\*L0`V?($"4_'Q7Z9,B2`_HL-SY9N`7DO/H55@0!A8
M<B-HH(T%"&$#GYD%!1:%!C;\80#_HO`?;E`(`I!!P4T1<ZN`'.`J$5G-1H;M
MP5`PH!7(N9O8$$$$")!G62A@40+PD78%0>AH?=,FBKX8HS6!9A(O]\C-JN@7
M+(U5`WAS&VA8`R("H.M8\!8-3CX#&00Q[(P)HM<3_D(5PO]L+`>,X=G0CK:T
M8Q,&,DB[`X@PLR-:7>02PUI2>`/"!7#JYT*P(0SHMI.9T&V>C:I[HU]0!;K%
M@!<VJ.)=JA"#H#MQAC!HV1`ZN+&O%\4&/P\`VW\0M"@#L(`OC/LI!BB`Q"=.
M\8I3/$4P.%()<+`"861A`N$\0QDH(`169\W5;-8ER52@`TUB%0#C?4L!#N`"
MB;O1`Q+W@!=J7@`%/$`SVSJ!!T#:BV7;NPQM`-D$&I!C3PRLZ1>BKR!0`'-"
M>*`0'"`V&A!=ES0$IN/`<D"OWWJ#!]RVS,*H>;=?+6G7^4?%3$;Z)?SP`$(/
M0.+`25$6R"P)#.0`$3E(^L`%8>C_/[!!T/_2LE^YSI8P!,!8*^@`8\Z0@!5@
MF1,=%@'*3?PA7AHO`DQ6`)-_V0%!"\``7?;S`_@."3!X`.I&';TGJBR(!9R@
M$#`HQ`T`P'BSG.'-P,+!`8I]S`8T@/B;Z'"*UMX`SCO(\XQ0@QH2`0!;5V(-
M?L``#@1Q@1(<O`H"*.8G7("(SKJ"MRC`L]6Q?NRMG_HI9,"`L1@`N#-TX`)^
MQ?RCGR2@+#A?0="G"&FP;X;`!D+@`>4V"08@,-/W!QO``6Q@`%]@`"7`>I$P
M=K$G"[P%`&E@>%I6`;@C"`CG9&CP?DQ!!@X`=KZR`EZ`?()P!F"P*RZH?[V`
M`ZZF`/^7_Q\!F`@;4`8+@`@0X@$NMDE`4`"<Y@$G,`85H$$L"`I]5GZR1V5;
M(Q>>10@NH&LF:!1G\`5``"Q9@`"WI3$3\`7_]@D^YFH/D(/XL8.)\`42H`AQ
M9@E^0`._@3DY1@9H@@$6^`CFUQA1R`F\Y8.%4(9_]DIDP`99&!0#T(7`H@.<
M5H`1@`-TY@H=)@"N-E+?QB<[!S(S2`@`L`*CU0F(&`!H(AQ,`P8H@`)-:%W(
MTX>BP%M?4'6#L&/[0@@+D(@^P082H()_L0(20(C'5@4PT(EFV$IKAXEM!R[+
M`C+`2`AH0`:E9@AG0(654%$"8`;8:`;7F(U5L(>.X(I]\X>;0/][@@![@X9U
M:X!]8P$`C+B")]"`A7`&$4`!XFARPN`0G=,+:G@?R\@`"8@(&X"!A&``V&@)
M)7@"JJ`*")F0%^"-C0".X`@*O-4&'2AAK^1GO5:1(&``^[059Y""OY(%)0""
M!5@&,-""LW"&'Q,!,).)5+*,"""+B$`#778(;5`&'R8)V4=Q&&`DX"--H'`#
M)&D(-U"/F<!;`Z!^@R``,8(Q'6D5`P,L*V`&G3@&-X``(%`+*@EIO>!_+LE>
MGA&1&R($`E<(>`B!<D@#Z18&I0=L8;!ZH.`%62<;1HD)"$`!@B<(;4"+@^`!
M27<G:3!L?I"73T%Y7CA(AR"/EG<+6\G_?\*0AE^)(R@0EE&X>XEP`#]8";WP
M`@SP`G[``%7``!>P`EE`?I^P8A=2EY>```K@9`7W!VA`BX(F!&68`"H`,A7Y
M%&N@`+XB?R5P>8.H!@K@`5Z';F=`@(-P!@F(G)?0827@$!O0DLD8:Y3)"&O0
MC)J0?3#@`#I``PZ0:Q+V`(TF":BI)*II"0AP`;JV`',Y"+='"&#R/%/A,L$"
M!C.X!@>P`B\@`#67(B5P`B?@*1B@`'#A`I:B"6C`FWZ$$=+99CRS5>&X"&1`
MF.@X=UX``A(TCT)`*N`3E\B3`^=9"8[1(,\H"'/9:PN0=&0P;`0P?;C8$@Z%
M"`2)1\6F:V0`_VQBD*,ZJJ/.N&R:H!TG``,?`S+"L(_DH4H48'U,Q62A9J$<
M<P!)I@(CIP,>"H4:.""&-YLO*`AD20@;D)6#.16-HRJAD`;;]Z.]L`)5,*0-
MJG(0\P4/$`8ED)F)`'J'@`9A8``&@&[`Q@9XFFXDN):""D6(XDX%(`9"<`!9
MD'NGF979$:*4``0XT($+,#48,%`1`'M^@)U%442]``2A`$7C2$T,6J21>2(=
M!B(I<P(MT*JM2@$4``04T*HKT`(4<$$O`Y2.I*0(<'46R0G29Z6QX`7J26P)
MYX+%MJ)51&%^()-,82R36(RC2DUL:JK3"6[.0R31J@AK`(]_,'8NX/\'89.-
M9G``,V<&WFI4%X`>ZXH`#Y";A;`&`>H]#^`!&%H*^)JO8D>4D#H)H.$C`\"H
M@R`$,9(`68>E3Q&C3OBBKW&/U:J/I_HA2I4%%&H(VC9;AT`#6<B:(-!&^1<M
M5\(9%WH!$D"NY.H")V`&2LHQMSFL6$I%WTIXA<9IRHJP3F$L<2JHOX47['9O
MZ3*HZ49>AY$N3VF7#LLW1`JQU\HGMX@!8IE?C0`"[6E4&\LPFC%Q`G=N<#(`
MPB(L6?`%&$",O"0;#DD)_SJ(R61X?I:C)=.O*-&U<!NW<CNW=%NWPC*M=/>P
MR.B@/.,'*_"TVE:>#4L)Z%%:>`,#*^N':C7_MA>"`K)PMH[R'CZ2J2!#IU25
M'<)P)$^2M'OKIA#C!Y\F>X';BE7;`<QTFS'YJ+Y*MI_AMB*&I6?PB,56!A0&
M;%64%S4KD)?;L+V@H)O;II?K!^LJN@$FN(V!)).`'A+`3+J#`67Y&E;"46H`
MKPOTN%AJ`.HWF\^[`4H),JXK*0=2JDK+MR2C*L3;"!%@N0W;3P_),,S+&?_H
MAR>@N^N"`@,H&XX*"Y#KGH6@`AB8!IQFL[M+M=2*M'_Q>$O+)^:["&:6!@OP
MAIA[GH7+3!&``"^@O@:"-\A#`&70O1Q3MI"P``E0!B>`I6R`+H(P`'ZFK,<)
M1L"Q`M_+)^&KMU%"_[Z?ZP?TR,#Z108T,+4-RZF*,,&'@`)DP`%N%8[@R`;_
MQ+BBT#P-D@8-@'N6FP!\B3DQ3"4S;,">$[$?4@6Z(WL&$&!B8(Z#$)W.^HWN
M>Z=KL*^!U1G(PV1,'`I>X,5BT`$(MUV$D(Z$$`;08KP#[$"]0`$TS,4*T@;S
M@I6,$&#3FVT"S(=8>5$8<`#LZ[[(<P*+P;JN0*R"8``=>,*"4#%/J*=9^@=J
M@&U/.U$'HKF%\!<U[+GTHDH(X+ELH%]L4`&.>PBREKRQ?%$`\&"*BSQ@L`%!
M$\=Q:3)C(`"%X`(R60&PY\<#?"`X,,@)#"2P?+Z+<'=#&5Z-C,;:%GL1F?\`
M'BPC(/P(H"$(:4"]!C5L;:"B=W)CSKR[CG$!FC&D"CH^TXPCU:S#W]B)N2P)
M0AP)E$R>X^P(Y?P'*E#%W&2+ZIM[[WRYCE$%H#BD!]+*5)7/1-)HUXG+V]R^
MW?P:*@".$1#.,I+-<KPR1O0''H"!'%R]?UP(.2`,%R#16WS/J%J=%]T(%,G(
MYZD##/,`DK`!QH7)%S+0C;`\Q%:1=^(>&6T`29<&(-C"#4U5J2S3A4+(2>49
M0$#2AK```8:Q%KO1BH!N+D`!"\``^HJO8*"O"5D&-\`!X"@")2?43>S3?\`!
M""U**&"Y7W!U48W*F4O5]FS#K[Q]Q&P(=,W`K]/_SXZ`?1/@`@(0!AM@LMC(
M`:6H`A%P`Q0'!&3P`,@S`'%M"$#]"@5-"*%SSH30!@+':7T]0#H@#`T`V!0]
M43=5V*M<)8D-UN&R`G0+=BN@0250!3C@VTRX<1T@W,8-`R[0LH30`42-4WMR
M>(*P,>56!C*Y`(]UQ4`BI+V@W9L[T5:-'[/=?*7PB(;`25ZMS49Y!B.U16:Y
MH^[]W@6P`._MWKI+VXJ`D\Y&SGO"`5-SQX(``.;(U]B-(S?PUTCKW30ML;;A
M!1B``0[P``'PI^EV;F;@;XBMTY`P`,(@L)-P)0+MS[>2!6?\&7M2HG]0,<66
MHK"ISA6I:ZM=/;TPH(`=_S"N#"ZS30,!4`(HH#6;$BJ?<LTB330HD)#^\B4.
M``;8>.2E`""2A9ZJ:=^),"LZ((X%#=U_\"_EY@(_^)HBS-(M_50-\`"P_=WW
MH>&8TPLH%H=;O0@)L"MNWN8JX`%MGFJ0)[<!X.0?#M!5D`,X0.5[$@%3$P&$
M>4I_8-HO'C@"HLJ\&]@U#BX+[@(Z2HRTE@AKH*,1<`!"X-YAH`;S/=_(EZZ3
M``1!OF![*`)N3KV)(`1[HJQ5I'4)YV>F/0ADT,<#?B*)/N8)_B$++F,O:@#>
MR+!>H-6,(`+;&@H%;@B;JP-3"P!_QS&U_B$(_)FX+MCTLNN81@EL\.N8`.79
M-O^>D=`&7N``"KDG:P#!@T``*^QD;<!I)OZ#7E#L+5W@P3+MC=XLUKX(+PHA
M>K+MMYPCT0ABOT)A`T"+6B;,A)"4A5!RR_CEZ:7HQ]L+7$#F]W'O"+/M^WX)
M)Z":Y\T)\7>*8$`#4W,!A'E:@Y`&RHTYWCXTMW[@'B?QY.$':P#RUSX)`."-
MDUX)'J#QIND)G^@%KUFB5I[1ROD'```MT`V>'(/,#!\Y#E\V59WK#M(+B3'S
MDK#QCI"3Y*F:<0X*%>4%P3H(:O#O5^ZM:C`UA"8F2\_T0]K:3T_MX-)Q*L#K
MEU"I%V\)ASX($M#<6[UW@S`&/OQA!""[WWIY+I[RNV3_X)L;[=$,]0H2KGE/
M]9$P275?"7<O*'H_B`3Z\R#HI]&]I:0\?=!M`-F\\$LO(&#7W<!2[Y+RKS*6
M!7.O[9<0[%7_GM:E)B>_`!S^!PF`@5U."#M&^@QO^H!-+9>K&(^_"(==":'X
M2]N^AQT="?'G!;9+!N0M",/X5BO+^3&[O&E_YO/.\IOI\N,Q&S)&/)1@@L#N
M_(;O"`NP=Z\I^BBULE\O\)\-M6G??VLO#!'/^#H(""LK7G^%AH>%#XB+C(L"
MC9"%?I&4AEXBE8M?")F=B&@*7F)EAV-@B"!KI1&(''^;GK&RL[2UMK>XN8Q>
M?GXK#+TMB+R]Q7ZGNLG*R\S-_\I>)QN$E).X);35MUZLLK#.:Q?3?VP+B`ML
M?V1D?V=GA6*%:(4$KYS.]_CY^OO$)57!P_P`,X9LG\&#"!/^X?5%'*1LMB!Z
MDDAKVRQOSA"(2P,#$8QRAA(D\'@(H\*3*%,R(^;G!<!#+`FJG$FSYBX&.APV
MHHC(@:M()[!1.C/&'20O/V-]\7#O3`,O:^@96M,!$0%5AQRT6F/2IM>O-5D.
M%`;36+&"8-.J=>9%@ID<E7@>BE"!6J,O)8PNDFL(@)<QD;R`N"CDGH$J7@RH
M&5?.@-8_Y_ZH,<#.J)E"(#L8Z+JVL^>5Q<8&''CVL^G3L1J4NU&)09M(!`+8
M;53@R_].2@T!'ZW:K>,]!'`+C?%M"(;N0F70_B%>#[7SY['$OK1DMI=RZ-A-
M^WD=E)(+VY`2@(>$`1*9Q8RR4%J3(TTD:1?M9;S1QKTA-@,0D7E]"-XA=YQE
M)^!S'%1'%G7573?@@EZM8-L#:H`AX80PN#`A`C1,J"$8ZXSR!P$;@N%""62L
M$"(8[M"0CH8N6(@!&#"<R.$?:8#`1H1AY)@C&&%(H%,F`2:#``)ID&)(&B,=
M4H9]AC2`""E!,BAE6AL8&%""4V89EFT*E&'&EV!^`0:8`:@@QIAFE*&F&90Y
M`!@(8)HAII=H4/!%G&9PR(%/!GSIY1=BB+&"EWB"25DA`WS_V<*BC)Y0P(^5
M1)D+<(?(5X@'`!Q"@%2&/%:(I%J&BE("H4U72$REB:HJ0E[89FDC"!S*2!K`
MC<>(7&MXR,@%E!"04R0-Q8?/D#06<@H;_H%`V1GHJ(&>?\B@P0:HJU:;SQ<M
M"63J0M4=8^VW][3ZQZN,4!")&F:HL`XDET'B0B,'4+)!!TPRLD"22I&K#+$;
ME/*(DOX94EY68GQA+K@([X.M`WY<L"VJUB4L<2[BZHL(`^A$XJE"`^"K#+6V
M$&N(D4?R5T@:*IA3TL`3M_RQE65AZ?+,GE1<"0*V)@QR+2(7$J^2]2*)"%.&
M[$SST8R``#."9BF(]-,+N7ISS@@;_SW+D&L4@`AOAFR0Z2'7',(!5[Q";78E
MQ%!0S(&G=NOTV3/;O)X\+0^@P[`(H&%DS@.\E@9E;-#M7QB%K('&`'S!?7:!
M?F21Q<-N*VZVW)"`,$88&4\,J9"6EFV("R"]L_&XA["AGN2H?]K+!"M`+G/J
M-%/>"!D%%+#NQ#]GQ(G'?_!>)"*Y8]:&P;"CCJU9;'/[>O$MR\[NS,$S0ZQN
MNJT;ACMGW%X(-X:0<0:VS"N.[0HXN.1'\A![&W[S4I^K!LD3J_B;I44@<H*M
M0A_"-OCKFXUM"Q@03<R:UC_-M0\2[8A>PC:GBR&1(6#;*\3UTL$I8PEG'N=)
M7`%U5HS'G?_O2@3<(,*<QPCM2>P,\G.&"Q!`!OCU#A'Y,T38/J>&,VA0A-\Z
MGC&21ZKEX7!5)%P$`B"8,#7,L!E>H!\BP%!!,?"N?H80PPU_N"H=K@T15DP5
M%8%("(LIB6H(\V(N!,`)POVA>A(D7/;.B(QU'><54]QBJ++XP4/T,(1R%)47
M+B/&3X$17'V\!0TXP01$:*T_H\,!(LR@!C+$,8]3HF/R"!`Y2(8JB%A\F[4"
M:8L"6`H99HQ`T+BQ+E"ZXY&67)`DL5C)5$[)"P(P0R"_4$&)=<<9@X0)(D1Y
MB/RM*WJH=&5V5EF25@IS0640R+\B488_?NM=X2J/<GPWNE<Q\0__P3SF<XA9
M-&-J<YA^2``#+>',3>+#"Q/X@QG?^`K[K&.-Z;B@.@F7S6^>AINJ\Z$]M^F'
M"(RS$`XH9[4X68LD9F6):!'#Z$97SWUZ!I]PU*=#[RF0%$(BH#,C:$4X,4T8
M\@Z:([--0R>J%C4L+9]X)"EJOL``!AP26`)=E49GX84&C.$OI@"#KKI72ZF8
M,5#85.F4QK"Z*Q93HD)="UX:`%)(T#*CYS10"]JEIEY:]`]FJ-=(DVH3B-)1
M?5S]S!<$\5*G_C,E>FG&3+OAA;:ZU0LKB-X90&FLM$YPJV&=B5>]F=>T'(][
M3FT7E8:%CR\)L:SI6*CVP-`OO/85)=@B_TT=NXG4Q];D>#2H%R.^$-.3.,"$
MRUAK='XTB$(8]DC++`1B'6O9A!`5>:RL;&M5\@4<E$``[-1$9Q42`<$V([4K
M^9$?Y`?4>+:P$-Y[11J#.MN5GE0RK4MI<VM"`$[@;!'::V8DO*<],NB&*-E+
M*SO6D5RB7*X2:2C!!-ER3N$"]P^W+,0)T&/:R[!VNOI(PW/')5O\)@0,G!"`
M`%K0`$:U@`%%2#`&6E""(A1X41@H0@DBC($'+VK"+4AP@1N``0HOF,`,MNVB
M6OIA`S,*`R6X3!J^,(8O&-@%!6"46UOPUK<^JL9M=0$#<%SC`KB`QT!^:P0<
M(-QIW,DJ6$3$??_]>P^3PA81".@ODPT"BP-LH"ACR/(8;D>&IYIWR^J\W9?-
MN`C"J2/+[,@14<B@9BV[.<ML)IQ[V/SF.F>Y#&<JPQCTC&=`@4'/9Q+#&!P@
MH2\T$\\3:N:$SB2C0FOH"T1>!`;D%P;_K$LJ!'#'X$ZIV2E[1;]/[AX&I.SI
M:W$"H\#BG4W,<`!5)^.LMFBK$-^+V!-`4*?8W&VI$R(0TB3OJYK<M:G')=!@
MI44,<@H7$95152@_IKB&H.\[TNH'70O;(,]50W1E<FV%P.*ZYX+U2=#,%C(;
M!`$_"P-X2HG%-_I!VMV>R7ZC+-UXZ^/;`DV#N"^ID)X98@7VDW:>L&G_;GNG
M9-ZD-K@NOMTO8.U;2^_51\_0@T;)=$C3\'"0PN4=:D/0F]L;'[9&<//P+(D6
M%ST;G7+T?(@&6#ODRWBN&"0;,9CCX]LNU$3)IS2Z??C;@@3K#SPP\'*;Y\*&
M'3_C!!)N=&'1X``M\D*G);-S78!A&P4W2-7=6LM,],R,.DENT6PS@:(WW180
MY6^]SYX+6)P`@`DH`2'4_04SAD'/N95X+ZJ.BZK[`0<86`&\;R8?X,87J](&
M-]OOC?"U+Q[M#%B(`\AGQ`,\W?('\,+3'=!SO?NAJ0?Q0M8K,0$,'.!^LNC9
MNHR$'@*L8X)`=?GC]8'T'0J1Z;/'C9.\P(`)_QP`!S0PMYES;I"X^_@D>Y0%
M44M0@@D,GA(__P/H72#M,?U!X[F_QVMMWTL<X#[[=^&$%P[`619OEN\+\@+Q
M*<'J5E]-/KQ3.01Q8';P5\*125<[R.U/"U@(H.N(<%-QTV_RX4;(=8#JA#V$
MHWC\EPRU9U25\GT-6#36Y6K#,(`)$7U0U"GU(@8JPH`3F`N-MW\AV`E?D$XC
M1PGH-R`K2`L(X"F\`UBOT'"%`((E&!'Y]W%:=(-`XB0I&!@8B!`(L$RD%$$)
M.(.54G\\>`@CN(-+""P5B#9QLVSY@`"1APB*=`BUT1\C88-/&`N]X&NWYWA?
M>`AJT`!GX(47$S<MF/]Z3H*`ZQ*'[C!!:Z2&94@)KR6&4":!)?AWV*<Q;)B!
M\K%02P1!=GB'3M6$-8>(.^$'AUB#<>-;/I>%AQ`]VG4DK/"(C(@(#[@M^N>$
MFV@(O4!^E=!YX")Z&<@RZ/$8JV<;8$8&]*")H2B*.<B'(;AW,=6&V*&+L=`S
MA^<"\`,&B0>`LW@KM4B&C(B+4N@RO.@)"/"&<_%&9D"#9Q2+P5:,DN`'4@"!
M'F>+$]@+J!8)"C1"Z_<;+&,(,Q)%$`2+Q(:-<2%9R?.)B^B.O?"'#Q&(0B@?
M.A&.DI%X2OB$CK1MD]6-R(B(ON`'Q,B$^'@0S]@]R%$(:D`X@I8.[[0.""#_
M@^X(0XH(5O080!BY%S-3!LWH=11Q1%CE6VH0%#^8D<;(?1%8D'?H!P>@B::8
M0R-Y,]`X.LEF".16@S?9@!MYC67H!V)0`.4H0S,C3H)H"+4$;119*3_)?T')
MDD$E:Y2`6`L4E>X"<#WQ1G]6"J>PDE3)A.>S=`-9@]X(E`MQ5DOF'%89>BSS
M!>Z07&)`.#E2&>,U+EH)?E/)DI/PEO?(C'NY"_)!)$H"/VE`C6(YEMGHD@1)
M@L7XEVRYD`9!`UQY""=P'!]Y&5?'F'O1"QX4CSHXC]@HF7%!F?O@`BRC&YEV
M1G\`!@5@!F\$&(O)F"T0AIYX`FDIE6MYFBX#'PA!_P-7^`<%((UAZ0`MT&)0
MZ9D@Y(D'L)OV9YJST3+^E!`',`%FE%RN-T\;T`#-1D%ZR9P#Y(DN`)U\V9M7
MB9KZ`%<NE`!,\CYE0&9I\"Z/(IY,XXFCR9&EB9Y`*)@)@4Z?DU9R(@!>X`*X
MA1;&9I^H$H\"8)[9)YT7]0='R47_F4[(05X8-S`'P([J]`J#F7L+N@@TX*"Y
M!Z&-<`J2B#`;,([G9(]_X``!4P);%E^$D*#BR3".V38P.93\V0B$1H4Y!'KK
MF0W;R9-B`"($$`'J4!(?.GLED'\CNJ-?:**,4`81(%Y5<W*QE@UN<@@;8`8$
M@`$X@%-,:I\ZRHV%4)Y2^O^$?UF3A7`&HP<NDM)B<5H1?N!"\V4(.-`.P'@R
M(X$79JH\`C2>I!F9"R&DBY!W<HJHU%$`C-9HUX0V?F!&-?0A'2(&,GH&!Y`&
M],".D!:H(=J<A3J+5,H(T#@QP-D(O(``97``KOJJKQH!!&J!`6$(LGF8"1`!
M8G`",>2AH)I_$".44]JCL**>I0`H4%@S1-D3`3,A&_.G;IJ1!0"L)#I[I;H(
M%MHR!,"BGF`T#"%!Q@(8<.H'G.<`@D4/+!6H^Q6L5/F7$8<(YR@Q$7!5PM()
MO&`(O&I'7H`!;Q5?7\"M+#FM.?H'$5"MC^<'9Z!Y-S,SU7D+WKJL'6JI\Y0`
M@8+_9^1U"H!JIJ,9CW0DK$\XIO4)?3/S!8S:K1K%"RY$`_2U`4DJ6&2@%5^`
ME8P9JH=@!@:[>/1V5H;9,E:S6?$:&%P*06=")"YP`+M:3+\ZL.S*DCF[L"[3
MLYKP2/<Z#^+J#BV&`&-@>6;`#83#/PI*K3C@?:,:BF4P83H[LEIJ"&>P@9(J
MB>$(!D6PK8?P"%XKGKRGM#?+=@4@`&/JM"W3J[-`%'C6"<D42N[1#G\0*!L0
M`=4I%>M0M\Q)L_<YMIO("PYP-Y2@`#.3*[?0)S20D(A`*NLR-G^`!O*@!@10
M!080`%:6%*]`B79+K6NZA"/J!<S1")XC,0/0`#(;"X$"_UJJZ@<Z\05)<0%E
MT`$>P#V%0;))BZ9_4"6SRX/8(G=^*S%I@`G6@`)`N@A*,PV&,P[H``!E0``P
M0`8I@Q6JT[R>B`)Y>W;'H[/`:RUM8(6Z`+K%-`TJ4"\+X$(I<Q]M.8&26P@=
MT+Y-EP`3<`)$$PFRJ"5C(`2X9@OQVP@VJQ,#T'4#0(,-][\-2`RAR;T$;'0T
M4`4P``13TS)LP`$W@+ZT(!X`>PC=6SCR4!^E2P8`8`9BT`&B,`^2D+0='%N0
M.8NU02T+'"H#H,*S0`"<UPFD8D8W\#6%```YL">7ZP4FJ<'\%\`1]<.AB#-"
M_(]/\Y&,4"6^DW,`P#UEL`Y6;/]_6-RQ5,G%@33$67(#9)`?!U$@.O$[R'4#
ML0DTS/6U`\O&3,M9V0H)6.LR<V7$LF``'CO`T[`!$G`(`R`$WS$<:K!:ZGN6
M?R`!'VQS7*P(T!<Z$U,!BMH);7`ZE/!`I#(-:;`.!N`>;;``]E`!ZH=<:'S)
M\;BT&8D`$C!6E1``7GPTN7L4Q:`398RO(D`&!\`I.L`*:0Q^6`R]6KR)"-`!
MD+L+OXP=A8$+I@RT/6(4"="_F+&A+J`#BU$%;[K#9LH+#N.)@)S+G'5#.G#-
MT.%84S2U1S)GZQ`X2::09BH"^=?.[LC%-P3'67(PMU#/U1`]``#.%0`F].4%
MI]#,V:?_`O^\R3"',^`0)[)R"`&`O0J1*XA\;K.`!CHE!O+@!W0,M.?<C^/@
M#@90`?LK`!Z0?'@IT;G'.,X+T-B(`%T(!"A``?3'"`20T@G1.I>9@92P4ZJC
M`Q>@-2N`I8M@S_-006OP$P+0$`QERU$;O3<X<@@0!C()2P?``#``JU704A/:
M#*-FT\4:";V0*Q%P`!*P`"7P`.(D!@L0*'03O#[C48@``,5<""+1Q['[QQ8=
M<M6)`"_@!56P`B*@(Y#]!6FP7D+8"R<!R]3@!RJ@)@E0!AZ``">``7;]JE-'
M'0]9.O6BQQ:5!N[!UH]7L(;-U248+`@`!ISG!28#$_(L"P.@_R81?`]LH+F1
MH-1_L`8ED`-`P!KV*A')@4@+(`)CX`$)<*J$S9S8,@&#:@AM<-@;IY2!=`DS
MX0$;;1#;[`DZLM>5,,"F)0]LX`YZ,PYH\!T>2L>-5-V>F47QZ&31S(@B23HJ
MV*21``#1V@R.U2>14@T%H,)98P@@T`%D@,.&P+CVS9C8\G'Q"`#<K7!?4!7?
M#>!NK1!XM2<*4-K=%+H>DP;F+`$,T`%G4`5:%:CXW9*@.(M?$``1,,BJZN&0
M\`!$O0]X10XZD#F-X,\021FL#5#C\`5VXP%"P%G-LA@H;:;8`@/.BTVR'8+8
M0@.>'!AU,1,YX-'8E@L+\,B4,,"4<?\5/5$T@V$5]%!M4NX':XW)5K[?B&A#
M!J6"NUT+8:#<!X%7)Y`#9!X)FJS"%9#`?V``#P#%0)6GHICG#7@\YA./<S[C
MH;@`POO=@:X2`8#>^H!7$O``*""I"&@`7Y//CRP!$L*I0N[F]AGCGTGG=X@M
M=QX8.@X)0D"-^G!XM9#62I,?4($(T+@`O5<`-+@IN?;F`SOIE,N(VWT#'5X3
M:=#"H740V)(I1D$`#6<4!<`&8>`3:=#EC8[LT27I&:YP?A``@:1O-B'MST#M
M?H`.ZX*ZPX`&8L`!:E#52N;H_+?=R5[N!B>\M\L(9E#KD-`!*1HNZ[&]2O%N
M"P%O!V+<!=#_`'S>T,=NI@U3Y?YN;[YPU#G>58:>#_\497@6*"1?\B3_V]AB
M&\Q"(U_S4]'NJ@F`%6<P=/IN?_KE07*>\?'V>5M^%`3?"&WPLPBOP,+KV;!Z
M]*YZE-@BY"J@$S@@!A60(UB3A,B.\5=^B[..0#_?"+`+\I30VR3^!T+`Z9L5
MY73<WJH5#\$"RW0S`%61!34/?JZN9%?_C5G?"&JP]8R``N-]#T*?>J!\%WZ0
M`UM+RZ>]!FO@*#H@`M^[!IA@)U7OB<JNGZ7I!;+QWUXAX`8QX"5,"1C>V/:P
M`<'1)&K@`1'Y!TU,]:WN!PU@];!^AP60`V<%F#2!`63?##CN@IV%_SG1=P!T
MPP9F,`$/X-'7VXZKW^]USW\#X&,Y'`D)^Q4Y@.ML$?BSP(_01RX>D-L/P-/:
M70X$C8ALD']_@`,M1>F;&/X*,-.GK/>SPN?GY,6<Y8SVL`"7;PA:<P!@,``5
MX)2Z#`A_@H.$A8:'B(F*BXR-CH^0D9*3BP9^$WZ9+8<T65F9?F"4HZ2EIJ>H
MJ8<X'@5>BPFOJJ4':+.&7E^E+KJ."`J";0N"%;9A?VIB:%5L;'\&('\(9K?5
MUM?8V88`?BN@F[B@F:+:Y>;GZ(-J`G]>:8MALNF),+W77FNE"/:,""N&-_()
M*E%"P#]!`&Y(XS>OH<.'IL3Y`5?(BT1R$/\S:MPHZ(N?=O(2A=38`46V@Z3V
M/4*`0%":!(4:O!.$8,&P0=,XZMRY42)%0A;%8>1)M.BL+R=`,AJ9,4V`;!_U
M,52$`$.PFX/$&`##M4*;-H00;#!*MFPUGX>"@AIJMJU;15]<*%T$A.<!,MA.
M8*5$8&HB?X8<B`D6`4$)K`OD(E#QMK'C1FC#"7U,N3&`?UZ8&H+!4X40;%[`
MDOK"8>4#008J"$+CS($!!!X"J!A@X$^;`=)$5-Y=.7+%B[R#&_V8F=&QG6M.
MWU-3Z@MC7U4$G2E3*,$9!W_./%@C4%``S<+#[_0-%+CX\QF)@Q^$!DUWCNM/
MY6HNX1&,J(0N8"W_(4CYGP6<%8?>@!SY@<$W:9E'X(+FJ+>(!#`\IU,$>\TR
MWVBJ.>)"5&00L)HS@Z'`D@IDX,6&+0(RJ&(ZF3"@28*3K2CC67,I$@%U.P'P
ME#47CK*!7XC<)\@:'A02P1@!'"!`!P!(^(<.\<THY2GD#:+6.%-F&5&-B'S1
M'D]L9'$/D(\<0*8A0N!WAB!"U+;F%VJ<(`(;:Z;V1PY1:JDG)%42H^">@$+&
MI6,-U%9-CY2<L:8C%AG"07<@Z(#;EV>4EF*@F/(ISD]6_IGIIX0X6!D!$?!X
M9B,'5%&A2/C!1$@"8BA0!0;UF#2(!WF""FJ?[7BJZZ>B*L(946Q850T(_Z<:
M%X8SC30JG2`$X+6HHJPMZB$"N?Z**:\=^*IMH,0IM$A-10G@X2U?)+N(`QN,
MU:P?@Q'R*"%KE)&A(*4)D>VW>WJ#H"$@>,NOGGX,X$5+B\``0%$2T%`-::6@
M<:DB'OCAC`$=%++!``Z<0(,(`[@KB!?B#OSM`YL>XE&,)H/[!0$(*[+O/,,>
ME7$I81S'2`!132<(&;80L$8.&'C`W;F#'=SRMU6D;,C*:RT=Z`-A?!&S2&2=
M,),JZ9:2!H[OQCM(!`L/,H8'#!""V=529\HKU%BVK><^7^2P%%E"B)Q*UZ/M
MZ^P?GQ&R,0QFHA'R:NT$+K?;3A<"=RB+:[D8GO]W&Z7"S([P/<H7;,F,WTU`
M_Y%&&P2X`.4:YXZ,>>0#7M`X(8]WSCJ#"+Q00IZKGP-`7;-PH"Y<-[^+&R$N
MZ";("2J`4-\@GTT\>Y8(^/')1"H+_#QZ-/C!0)&+Y'X.#'BITA=]CUBT)AHX
MAK$FT&$T`!L:X>/E_/4S-NTOIQU93W]X0/AQ`]N'T!I9-I`4KOTN$5_PFQ]L
M08::"4(,)2I(M$IE)>_MKS(8.$`)7O0T_5V0-SDPT(ZH<L!YL"%M7+/5*(I5
M/C\P)&^#X(`9$C`4:J2!=Q^<4?3^Y3@/YI`R0<F32K)F*%0D<$N.J(`+AR2(
M!6P-!D)P0)'"AR,`_I#_0/[@(>Q\>,7&>($"#!!B">>A`KV9XHBD0`-V'"&"
M)?[!@7]0@1J`,0AC"4(-5NSB>1"0)@X6@@Q<U&-;O)`%#.`P$2X(GU'(0$<C
MFE$2:'Q7+Q95AH4UXR#2>N`?Q)!'00IGAWXDQ``"Z4FR6*0$G1Q$(LV"GU-H
MCA)IV%<;&5(&L#'``0Z0RR`.0)-28O%U@XB=+WEC$0^DDB9CG,<#AN?*TI1"
M@;W090P7T`!"V+&7P]PC,//'LFPZQ@LX0&4_DIF."#C3E184Q!B@*8CAJ8$Y
M9&B#&109KW@=TYMO`27U.MA-?+K%`P1HPSV'2)8SL,.(Z?P#&J2Y%#>.360W
M_U"!!QY0Q`)@TY^\T2?^_B!,C.8S7??D15L>L+7F)!20+>P%+PFQ`&.&P0$2
M^(*K<.+1C&[3-J2L*43H%E)RIB,'CZ1$)$?1RD4$K!?,#,9K'B`$':2A0O?4
M:5$T>@@QY%2J#=G'&`;J4W2D@7MGC`\:Q/">53S"(RL=!%?84X:O$>(`8Y`&
M5A^3/2T.@@U7G2LZ`B`!`'#5+19%IR(6P(`)B$$,8*CE%VIY6$X>MA$>F0ES
MLE.G>PF"&MEQ1E3URI$-V740>>5L.6[@A66,\Y^V""M<,H'+UKJVM0>(JD=Z
MD3KIG/.BN!4M61"`B5"&JI^ZU8@0D.6?1`BAJ^AP`?\%3:H(-DA@>:[TPQH'
M48:T_@>.U91K<,M"U4.$=KL\,L,)ER([HI0AH8)@PP30X1%R3/(]82CK3#8+
MWJS>]`_?K:^%=.$'+QS@`."97S;"8(97%F(,7S"#%UQQ@,":8G5C`+`7P)8Y
M-X*!(6QQ<&[URY'H36^C^`4NA]-Q`%'X`0$%8$FZ5CP8SETX'6)PD1^.@V`%
M(\`!__5"@06A85*LSB,'XP\DT%H(,(1$#-/M2%SI.V)S7`G$^6VR*0",WS*@
M,K8LR;*6$2"V<H1A@RY,,0(`3"8F*\*ZF8N>%U!X5C?&M2.:)$27_S"!-TM9
M(]TU1)3O/(KB9*($F$#$&'3_=HXP['#.5$'%>B/A$3.(<\@6'@J2"\&V$B"7
MSZC(<R'VC&E)^+EJ8[!S1=!K#C-C+1)52Q>B%P%DQX5D#&SYPI(OW6E]W)?3
MM2[?*XJ:%EJ7&A6D;C-;QH"CP82!PAR==:X=HNG?1FW9VO#S4I"]VTRSUXV(
M&L.B!Y'D/S#`U]".1+-!*^)PJT+:W0NV-L!MZM%`CA"A)D08YCSHA9@;'>,6
M!*[OC0ATRTS=U8@9H4F!YFQXA&UK'02!#WP,2_/;''"#<KD?_LQ=+P7@L]CQ
M'\Q0-9!X0=1\NC8Y$J[.;CM`U`ZG>#;R'>)GJSP5_A8)QE4!:S`0.+'!).JU
MURB&_U[H(@RBF/<#CS&&P1#TY0&7GF_)[7*D/W@"!^`U+F:N"BX#W0$M^8(#
MNBKUAV7FQ(&!]TC*0(T)@-OIX?@P(O;M=##XX;^,&"I1OG#8JL7+P)"@.HS<
MS)!M"\+F83D[VK?X67U/?/!\*H#?^ZWW4VQU,)Q<HW]U7@ZER1OD##%#EX^.
M^.C*6.)-[_PDI+OXM#3>%&6@^R;'#.=1M'L2EN=\CT>R8\Z+WMV%;WG<;C_Z
M`[!9YF2)L$5O_@<C<]W)9M^D.M_\9G(T_Q@YLS?OSWCKPT\_$9FXIX`W@N!>
MB"&N"01YR"NO/3FSY?RBMOWU&5W]T*^?$=EGA)&#?PF.0O].UJ3H^BV"T@X,
M%P+9\:9^[U=AGX<(,K9[`PA_F1!WKU<.L,9+9#<!\8!<^F<A"R@&`S=G<Q9]
M`IB`K'9?^E1>'E@($\!ZK-9M.Q$&!T`-N3!H8U``(@A_3K:`:C42154`_-"!
M(]@E]]5;"+B#AU""%=@1IU<*8J!X?U!C')43E#"$,'>!`S<4QZ9.1'<,.@B$
M/91[(8B%B5""I6<(YT46J<91DZ=@U/8(3@AL"ZAY%:%)Z_1_U'"%7,A-2T<3
MUC>"$:9=_T86G)1U#59\I9"&\D&#JE,(OR<-Z2=XG1=QB+"%<U@1%N6$<F<4
M]48E,_@1T2=G!U8('*B(B,>(A^#_B(]80?@5=P57%%YP.Z=PB/>P@/%&".=W
M8,HVB@@$@G?H@9,GB2A8%&/@`&<H"0T8"?Q'72-1C)OGB8,'BH8@BK2H-)(8
MC.?0B^(W"=#80JV$8'$6:XE(BXDP!K;H?G/H!=CQC&[Q!0>P:L!XB9LT9X85
M%H[3$G(XAU:EA;>8@%\0B7%7A*APA+X6CP_F!QH&:VT(.]O(C=5#C^#(A4IS
M3Y/(BQ-V"E]X*`[U!T('%$5&84QHD%E8A])0CP.8A_=4D5K"BCSR=BP1=IHH
M9]2`@QK)3QS)C*/HC(O`%8@B)219#6#`$A.P:&&`>86`@4D85S79DLI(:1[Y
M?DIC)O"`_XXK4HV1`':;U&ULPY*#0)4M&4S?^(.CV!)#61&I-S=,>1:\QA;=
M)@;40&57B94(J96/R)732`B*-3<#!Q4HU)/JU'KQ4F]"AP`Q.(I%&19'^7Y<
MF2QV*3EO:0V7(`IB,!(]5F)OI8\4]Y<X$9CK-YB+()!S<YAB651E0&C()G3;
M1XMAD)7O9I"6"1=.Z1BI62:$.'2$@%D*AQVAZ9?W!3=].8)6TW^LMIKYE`[1
MTQ*3YHZ$8)5_4`"_R(V2^7>4.7U;I9MP`9D[@0!SB0UJ1I%OUIEP2844.1@.
M`)MIF9P=F9!<:&E="3L])B7^F&GU1PB"89%RAAUHF9:;1)JW.?^".Z29FW2>
M.H2,K,)+F&DEHO9*V"*?3+=/R[B<T[=#C;"+,I*>@Q@5&BB+PPF=_#:/'&F;
M+8E+:<B@3<F?_=::TL=C!\:5%'IO%FJ@&UF:W'AHBW"$>^*@#^8B26AR`<H/
ML_F(X(FA&AD]Q*DRO.D6,/I,"RB2KLE\HG:C<^B-N:>CIOEVIY*;#4&DY\!E
MDU"8P@BB[6DE;$&B!&IX%XJ@O!<]2MD]C3!I9P>EJH!8XR)4N<-_P<EMA/:*
MA=BEM0FFMQ=;!Y,9>KJG>HH`ZY0N'R</Z_1QRU<<1N8%HI!`+:BGG!-7ZQ17
M8(!@,3,4]8D(\^:G?T%.:)IW\)*$YQ?_IT=:HO=6I^*)A0V6B@K&IWPZ`:K:
MJK!6`J'6JK(ZJWUZJ/Z%90=S8^*X95J6JV.&+8-Z81*6&5DV`:C$J\BZ96;0
M;A8Q9U[09<-F44@ZATJ'HH3'EG/(6R5PFYO5?7OSHP^D8(DPIHS&K#,69_4&
ME';V9KHPK5Q(JMC*A7!ECOTP9-]J#7**"^3DHIX&H=U&KL4W%.Z*A?"JHK3H
MA_7:$)MZ#CWJ""\%>^<*%X:0-*)J;@5;J0GX"IR3L/.PL*6FJ9O%6R<V9H"V
M90P`:`R@DS<&BX-RE1?;DA"8)QQJ<."**B#K"RG[7\G*JUBVL:1(ITMJIZ)7
M`O%PFS.+#1Y;_PY!NH2^8&I*$U>@6;'AICU?6JI`Z$+E^58.P4D-D;6HV;2>
M%C.]V+(MZ0<*4+7QBH5$Z[6"<+34V;4WVPAE<),RPY<"*[701K76JI9I>[6+
M-5`/4;-+X5/[\F*04())"!1XNVQZ"V),RHT%4#7<&KAP2PG[LE73B7U7(ZVG
MJ)'=@+8&.XIUEK241KGST+",`@E\R2<,D*\+UJ7XI78'V;<[Z$)6TW-E]A`8
M6W4^=9R-F+G>9;N*"[LOZ[GI<@D;Q*!N6PU]Z*&9"HR7P`!A60BN\`B!1E/B
M"+L'Z+A"VWEF9S6\!0:LVJH`AJGGL#(5"["^@$H:9XITBPNM^V:#`?\&RSN'
M/LB]5KN#WS8&)WL`QKIB`+QB''=M_34/0<H2!:"^:9'`#\DH^T"IBYMKQ6N:
MZ3*^B(H(]3L+@^J\B("ZBZ!X43>]TN"T5[->RTJ\09N_]@E2')LE.I8-*=:O
MB:M\I&N0U8J_M#N"WU;#-*4G%PP:3FMV(<'#M'C#@M:]B/>]]]2Y*\*VIG"2
MPG@UKP`&^NFY*9S#'LA3C%#%3<S!4)QW4DRV5@RZNRN8++P(3*PB'IP*7UP^
M+6%=V4NG!3B[H?N(.PRX/NS%3OL1`2JX:`=F>TN'=3R'EM:0I3LW>BS#V.O'
M3@=*.#S(7!@]R;<N>_+"U+G'8)C!6'B_/*C_PAX8=28H,Y5<A%@'%U]9'F#(
MR$AGQ(<P2IZ<@/[0QHAP2%,RL).@`ZF4&2HT,JVT7AR@RB]W7[I7QNL'!#@`
M`R$URMD@!*DT`!50(8TRQ,"L<L*,Q(-G$62`QUIBR\"82BI0!D7$RW_P'D0\
MBDW#D7CUR@-H$334PK6\R]5@3$\#`KH1`#0`7>)<E4S;I1<@N]M@S6AG$2!0
M0(GFP\0<Q89`!BJ@&]_<;8TR$_E0SG:<>ZZ,Q1D[`0K@G8C`4+5L/-<0``!T
M!@G@+F%06W_``1^A-Q(]AQ20>\/<DJG8,96SS47(S&!8`J5"``=@1AY!"`JQ
MTER(`RX-T$X'3C'<_SW`RR#<+&X`!`(Y@!>J,5E829%,!-18Z,C8I\[OEP,J
M4,Y>,%-3$@O94,J%4`$=H`MH@(U;]`=@;=5`B-5KI]65><8RHTA38LBI<-2$
M0``TX"%@,%%EW4K4X=8["-?!:]$#N`\#H'W*#,2X\``*(08<$#R"L`&M]-/3
M3'&&K6=R?7U;E\TS[<)%:'ER)@MC1<L]/12$;9]#W=D)2M>)8`927<NC#4`B
MX`"EL0!J8$8$X`?=P0%G\`791:";O6FN'::P?0C5HB=B#1H48`@>``"X40$(
M`-9_T$9%5`$&8`#1T:7%[6R0?-5?\!K=`P(.HR5D,-J\Y@4$\!D20]GVU_\&
M_-`&7+RBK8W89OP'SVU4(DP@ZCUUC/$9UCU;[,$&7[#?Q'W?X?W6_+4(`)"R
ME9P-?T-=`&`+8)`#F.=0"9`&/>W="G[0K[T&0P@_@/+?B1`&%`!6^;-8BZ)0
MC22?WUV@(([<`_"^F6+BB+`!"<`0L[4&ML`:>BB?4<>1+[VCNG`!BW`&F9@E
M9X#C;68/[4G+5WD?1$[42`<$I3*$$5`"];T@2\VID.1""R`:XWQ0"5[EQWU[
MQ2%DB:#DJ94E9<#1^R>(6R13)979#U<Q:([?Z^<%NC&$:F`&EC4EJMQ&86X/
M\X+G_,8S>[[@.R@$JI&&!)TE<'0+*F`Q[.<ESJ#_W4&>E@[@TN?LZ"-(96GH
MNVB0,ZB>ZJJ^ZJG.6#E3!H/V?:P^ZZFNY*A^(K2.@:P.`+3>Z[?.""C@!_C9
M08TJG`1*Y8%LAWQ^?3&'"'2B"`%PLCO)`"=;``<H$=B>[=J^[=@.9I@@`$+-
M[>(N/=1>[N9^[N4^0HF@1(<^"$_5Z5>I`RX-2C-^>]7KA!V0)QU":2N@`F(@
M`?\E`4+P7P1_`$(P\`5?\!(03@3?`+Y'./]5!3```PY?\'X@``F?\1I_`&V4
M00?@`@C`!EPQ\B1?\LSAA!)`YUBIZ0J%%XI^;VH!8N$IZKAH<8N``GFRL`@@
M`*L"C+GC!R;-"&SP7SIP_P,8?C!?4`5FL/1,W_1,'QV2J/(K'@![\?+F%O-_
MD>:BAP(-,.&((`$YSS;1\^:NI^YH..F-L`$8@`;TFP8(X#X2W1)17U:,8`E?
M$#I.!.\P/>]:OXA*QPB7PX!&R2PI43)\8F:4<P+1,$K[$%4(T-MQ-Y&-@%?V
M(`)C8?7AAO6-V/>?F`4K\.)=$O9&.15G0/B-L`)UH2B''PD>\!D3KP9XU?B-
M(/>1W_.K%1=E0Q/]K9!\O^S3]P7>,-P()/J`R1`$``1KT.*,4`4!<`8-,.B+
M`)6/D`#51`9CX0`I*]$"4`"^_8'*#UDN%#I*+@UV?96:'XJ<GXPM$G=FW\IP
M%/\]#*$&!Q``OF/Z?X$`!N`%+F"X\`<("'^#A(6&@P8E9AT(!P5>"%^"A6!>
M&X9I9F9HAX9??@.=HH-A?B"$`Y<(::.MKJ^PL;*SM+6VM[B'7GZ\+:,(O'Y@
MN<3%QL?(R;B?$Y.MDK``;(7`7X<1+@I`EZ\(@ALT54"Q?LZR9`<Z`@YH7@\@
MYG\.8BJWGVNT`'YF:6W4"<H""AQ(L."K7;U^!1MFL*'#AQ"?\:+P"IHK$0Q"
M$:K6B0"(,3DTMO)&B("8`R)'E2NV"Y(A'67PV?ID;=8"/Q7$D/G#YLP?!#XC
M"AU*M"!"/[Y$`5E8M*G3I[$^X?!3,5XG,6"F;5Q1\U#_&@IF3FC]Y8S#@0IE
M#+A:2<P+C@CQ#HCA---/5UE^O!!:`!"!7JB``PL>=#1I)P=,!RM>W/#3!:JN
MOMQX1<8+W4$(,-PU!*:"B`.N2!+RX(%,@Y2'V.;R<D%%O`X.RMBS2VM-7@(I
M_3+>S9M@X5%2$O<>3IS6IQ(3*L)XQ0;%78ZCQ@A)4&'L(=&%'GPI($&EU5I>
M)H")IX"#"NNR:-)"XT>$&C6%;OPM3K\^K-]*A=O?;_\+@P#)1?:=(0!X8`@"
M`FS620`H9"4*=H20P<$-!:!'B&JXM!2/$&!P$$9="KZ"4R$$_)'#?/REN!]^
MA^FGXHN,0;.*@*\,,($_&P$1_^(A$Y10P8,#FA&`#A;^@>$M&F*"`#>U?`("
M&F%$*>645$:9UQE:B?&'#BC"Z.5N+!Z"&"\,?6DF8%^,$XDK"PQ8"`!D7/83
M;:^(H08-45[GIG826'BD+4D6@D8!91J7!08K!*,H+PI0X$<!#V`0P`%E>)'`
M`H5XT>69G#X5IB%C"M/IJ$1]H=>:KJSP"AH`3$;(!E7L:`@9FIA1A9ZC>%#&
M(C)=Z*8LNTCP*R%K.-!!12L(T,*R'@B`P[++`G$!M"T`40(0/Y;T1P";DNKM
M0Y\6$FJAWY8KT!?+H3I*&PK`8@``A7S!E2Q@"'%!B=1<T,H"!R@0@2%_@F<7
M1:^``/]$%?"V8@!M09&A%AMTP?<'75K^@>4@\'G0K;D<*Q,N(>-V+#(R7X"F
MKB@6N2);O'3"0@:Z8&"Z$62BH&$&#0?(/$C`M.SR"2P=P'"R*+2I@.\@8C@`
MJB$J,/F'IB-'G<S'@X0L]=6UP/.3K(.DW`H#GK0<"QDGN%`($%F\L@$"0A3B
M;#%BV$5S*Y`,W0EM9&B9!BN%Z#P(WWG__?3&6!=^4#"&B>FBX8Q?(XC=G@P[
MR`.>,'!*;7(*@4$TAJR`0S$1R`T+"@B`P?7.=Y6Q,B$`\33(ZH3(!G7CM+M"
MM3R+U]ZXC*<;T``L<_^1#>&R``.HY(=_XL#RS#?/O`X>0`[_L#41_$M(JX:<
M8$CUF1*O>^-I(#Z*U=_7SKN(L,1#PPT<%+,4H*H2DX`?$GQA!AB5:JJ__@F8
ML8;TA1A1&N!S!E:@029\0^`TR+"3/WQH=N6+X.W(%T'&04,`'C##\G#$(UA\
MCAIBHT4:5)>#X,5B%\4@@Q]*X(T6NM"%.J`!#"YP.B.UCQ!?<-H?=)B`,1@"
M-!"LH.XFF#LA1@T:$7C``V#P``Z(0750_,(8H.B*`AC"!04PPX<.`:4I3;$,
M8Y`2#7B1A154Z1!LJ-(8'5@E.0WB#%624@@?=`('T*"&&/A1&?@VB#88J!`)
MX.`?VL#'P1GQ>T0DTR$-!XT-@$$'_R>0@``.0,E*6A(THI#`&F(2!@F`(0P@
M",!CK%<(!BSJE(K"0`D7E3`<GO("%R@!*N.7*50&HX8_R<(+ZG<0O92A@8-`
M0]LL-H@$<"(H:`#FTX:YR,8E4E3-O-H7].68!LQQ$"5P1:VVR8]:*7,0(."F
M_;BYR@=P4Q-J$108SLE.39#K#[1J)QC<*`H!7$`'UP15ET@YB.5D"C56=$DT
M&:?"A(B"@@/MV,^^T`$Q.)2>@[A5+0#`SUJ@P:%0X1YEQ&`&%=10`'K9VR`:
MN#*9R*R!;="(E@2:T,*)[Z!%;"FI_/.'+]0C-#/Q'GU0H--XW70D>MF`#JU8
M"&8.8@"M(_\,\F0ZJD\8M$6*9"K'H.&`&XXDIV8RU2RT:KLNP>X/27U=(<'Z
M!]))]6HOA2HTS_JM1EZN%;3<:D^)P]58M*.7%FL8*08A@F`ND!,00]H.E\I6
M,Z55<5$M+*G4((":ZM2$L*@KC-`U"P#H%&H5<!4A$O>'$T@,8]IC'6$5"Z/#
M@BJFI(41#!P15J+9XJX%$0,-OAH0KU6D2VVH&"&"^(>QBJ"0!!#D'S!5LM1R
MS+3B0JUQ4P2,.Z*O%FN8*R[0X`($%(EDFB5$&+P`AK'^80PH.@-C.:.7P/Y!
M8G3IP&=WF$Y"_(BRR_T6<D&FW/C:!Q@.T&$GP#:*`93!;UV3+B[_U,"!;RI#
MLH!L)0Y1M`$7?!5J:3*$O@K!@5[]80U6K>EH[5N?^5:MOAPNS@G\H#0TG`&.
M$PL#'+'$A@>PH2=P_!`:IK$&->"#+FA`@ZDN1I<S'',:,9YQG@:1QD,$)78,
M,'`R)!L4">S1*UTZ0VLM.[$&)DPF8CBRQ=#S(=N&^$M9>"IBU_IE%<'`#QP`
MPPD:T(`6%(`"+6AS`X``!`;0F<W+*L`%QA$&#."&`@5X,P74@`$S`.'-@6X`
MH.=<@#:W@`)`6%8#!%"`2#<@T)B^=`$08"`"K`$-&VA`"4:=Z5&7@,V8;G2J
M$RT`;X@:`8%^P`0*((`2%&`"DPGM!FJ-_X!+@U0(@6X;`3XDZA)X(`%=^B,A
M-%&("JSW#Y3S<IE?!`RDC`_$T][-#4I0AKZZXG>':*`:OJ!D`1/K,A8N1)S8
M,`8/^&,-#M4MO!VZ!@NG^\+))`.\&PB-BUX8'T((@#4NJF_'QNL`9KCP0RN@
MES54-.&%B("],RSM;/,G4=:&:6(M;I]@U3"NLS!;0<9P@I@51-I?R,&]!]`E
M,I!+JP:X7%`J=N(_@.!ATS!`MCA1<8YW6,RGW;C/B[,+%*#@(+P10QH`K`PR
M',T09D#-(/2K6\)T*;M@#>L"`+R<G@^=.![&G="_WANWY#-3O4GF8&!@ZE&C
M``8N,'6#W.X",/_8W>XE\&$A=%((\W9MPV0/S%3\$""UOC/PC&$-`GXZ"B]4
M/9HL#+0W;LT`!@2Z1P^X0(\J7WE@M(X,K%`#SB<F$YX#'O%/F0`O^*M6+:!^
M.%Y@@`@N"]%#?CJ8G)CW(-;`0#'P/MYSH9,(PHI1<8W!ZZ]73+4YFUQ>G#[Y
MX/*#?)#^=3]4-`W?+"09G@]]H53[@VKE?O>-8I?+GA4`,%!#[;UCB`0P_@^P
M`X#XQ^^0:K_@VLZGOV)\9GZI?D$`9C!)8Z!EK<`6&K5[Z59AR*=_3F%_^,<S
M#$@4[L!PU,=47Q``@P`&!S![7W!=OC)2.W$Q!I!.0?%I!C!_$3@0C^'_!^`W
M9BB8@L;@!3<P>P=Q;]$T'H)B!C#@`&;P>`$4#V#P>#1P(#"H&%5`1@_X@D6X
M&C0P`.!&-[@400-@5(70`260`[^4&I.0!EK6!NE4,0O@#Y2SA(%1;9#U8?E'
MAD7A>`MP65'8.&=@/0C@`,.@8AAS-,+T`-SQ@Z\#.P=D"+=WAFKH?<&0A(-(
M%#2P$T_8>&_(.#20`X-``#61``H`+QJ$&FO@`0UP`!MP!@QP`4X3`0KV!QEF
M)(?X%-4V8>%WBMZW,P?1B(4S!C0P3#G`$#1@&7]@!@<0(O#F`BK`&HV5)W%B
M,0TD$W8HB*S8$-66-AH'@<D8$*"1!D35"OP0_TUAD`!#^`?#-@@1X``/Q`#/
M5@A1X@4KX$N%DC2<X4/(^(P$88:&R(X-H3T(%FXM50#<$`';"!`^I`FGTQ*4
M0"Y*$T#P*!1%4(C-J(0#V7A@<`8!.3[@-5!F(#&:P0IC4`"L(`81L$6-YP>L
MQT:S`C`)"1$"8)"K&)(#X07J^`IG0%L5I$$,D0`'0$!CD'`%P`3A:`B[8$5J
M('*@U7[6L#DFV1!3P`L@UWQ^$%I!Z3%ZL8X.Y5T5E$,,80;<]@<T8"?P)U2V
MDR@6\R$8=08-]'2FF)0%,9)^D`5.*7;.*):`LI2NX%`L&4%A@4FF\R&.)!MA
MX'*VTP)S\T3;`Y)J.?\09K@CH=):?[D:;&E<8S`&:D!L!^!+$>!#8%`"V=AX
M$0`V8D!\#9F!);*.A7D+9JB10><'_M29;7&8K?`>T60&"1`!U.,%UI,`EP!&
M2E9+5.&5>W4&#!$4>8*0I(D9).F"O5F:8=D*"0"+6`,&"=!`&\")?Z!TUD`&
M-'"3F>("<U,IAJ!#'1F<Q!`<O/".VKF6PSD*K!E-X]9`&L0*)1`!\'$`8""=
MN\4`@N!T>T56>Z<EG/F=L%``OQF:O*F64,.97V"<5^.2&=@`)5(":0`0.>2#
M.+E"\-0Z6P26&'6?^%E%^VF4_2F64)--D?&6$61W/J03.S%D95``[DD8?J#_
M=Z_3)?@CD!6:"_K9G0?YHCUS*E4Q4,>G-&N&E+,0'H,P!@RQ14':-:Q`H33:
M"4,IHVI5E$?:>+O8@B@#<<TTA_`!DQ55!@=``V=)&!\DG^)B"!/:I+;@CLU8
M>&+:"AO`D=,X"@$Z4#`Y#`Z0`%]%!A%`@+H0//9C"%]EI&<Z"&29HLW(IS3Z
M"1B`2<\@H!$A6T^Q3@FW`<=G"&$`EIV`0O!4(F%0,0VD6Q\BJ&<:HX"J5AS:
MIVS*D2Y@IYZ`J!"Q`5+:%'(*5B?P>!N0G+8#&6G`HYUU"`EGJ*+Z"IXJF,&P
MB+L:-G[@7(<Z'&I0`IDI%&1PETB3!J!I,0,XJX>P_QEMNEO!FI^\@`.FBI:<
M6J%?@`$8(`"SB4.H^A`1D(A-00!,@$D.T``GNI&'\'C%-PC9>:V=<&9^L`)G
M&2I0:J\UM0(34%&=L!W#$:F'5Q1V*##+9@A%P!G#X`?CZJ\..*/^RC(X4`8E
M8TDX8TG.<DF4Y`!>X+&4M+$B6TETZ`5T:$D:Z+%VQX/LJ2G,8PT5@[+W<W<M
M"[.4M++L:;,V2X=VM[/<9;-!RX,N>7?<Y;-V%[*-:;0_NP&[P#=!@2]Z)P8?
MDB<%4*X5RIV"&"H25;%=,Q5E,&X!&J!A,+8!2@!W9+9JN[9?4+9L^[9P&[=J
MFYAV5U-R"[>Z:`9W*[="Q?^)::N+E+0!`;JQ9B"X8RL&3SM2Q01UL.,%6(N?
MGOJ`R>JO7S!J4D0CO;%=*OHBE"H&(`>4$?<TC_N=GBJ=H1*J7NM4"/"N"YA1
MFZLBE/I=@@5//TH(/N&X7ML)O1JHN=LU#3`&#7`ZK>L488`-7U(&)G2E=X&[
MO5L(I<N[O7L^SY"A`D&8_#$_(Y6LD_LOS-N\@^"IVQHJW8J?TCL*V_=UV.M`
MD]DU\]F<3_.LO1NC_4I?O-"UJ?LXPDN]1@0&)I2LW)4I[WJMGOJZ]*ND][LU
MKI`&^BM$L9NLF+1%?-F]WEN0O!"^BA*Q?5J^HJ#`7Y>F(+,T6]F<LC.ZVLF=
MS*C_5GZPI:*JP9W`P4-'`'[P>%^U3IE"PL&Y%'Z@BF,VOM])536TP!6T"SYT
M!J\+EF4KNMY+"!2\M8K2O-"010'*H)CQ=68`&630L"0"IM8@P<W[I_O:Q-$K
M"+'G#2V@!EYIAU6;D4.!`<NRJKUA!@C0`@<;63$,PH10M[MEP[UIAK,IODZ\
M.;<X:C=S`"SD`)04LD5P`"X@18G9R(FI3&'@R)+\39$LR8T<!M9T)9;\R&1`
M@&,`3`Q$Q%JVR0,81H5@FR>VK-#ZK&-$8B'<":I,Q)_\76<`PT'!$%])"E6[
M4GI,FF2*PMNZJRK468KR+`5`R`A:NRY`+<S,H^-Q`,R\_RRH^P=%$,TM@`,,
MX`(TT,9JL`(K$,VC]EEIP`0M4`),4`35W`+DG`!'9LWJW`(\>5XX4`0-P`0E
M@,[DS*-E@`'9:L\M@,Y2P$=I4`+J3,XK4`)+H,[61`BZ2I^Q,\))[)M^<'^!
MVLM)^06_XP5F,$5>L*U,2A`H-BL8/)^5;,K:B`%S;+ZS7+L.9`BR#$>.;&`F
MK4R?\&QNK`:KRL6]FXH/>'8KG$TZ?0CS6QS620@5B0#P&QCJ45,L71,AS<L1
M_0=)FL(5';V;$]1^F2)1]@4GX`5)_11+#9"'`!!87;$QR@`6?$MAW%DUQ,-/
ML5VP'+(!+!1+'3NS4G5E[:\QNO\"?:PH%AV4-.4`DGH('TT<O%4(:G``)S#2
M$+'4>B<Q#13)>U6<4;V[*/S7)HG13Y/24ZS5WJ,&#."A=$TGG(4!CP<:IE/9
M:GW9T?LY7B#:G<T?AQUN7D`H4%'7&6@(:@`[@JO:O."KP3#734H&$S`&(-L-
M*E+4KY`&+C`/3K'46V0]4ULQ78;9:KG77QP,!&RO2+$DKS#8]"%=N'D"`MO8
M=-*VSGL(PU"M2>RI;ES`^MJ\#-!FIT,`1:#"95<+""#%C1%"Y.*E4V?=8FG9
M8[8"PMVD(7NU";S=X5T+!\#@_4VMAC`&3Y?:$4W@H>G3HIJE+7`ZIOW5A@T>
M3;'46$S_""<P5@!!V1>^VCLLX`G)"\'K"F%0N+!;"^L[VC6Q17K7R<2(,7\0
M`>^=NV<MQ>+KX@/I!Q@`0'\SK_:!N+706$6!VS\.J57W!9,KY&1DNG[=O`>`
M`0YP.F.`W[SQD+00SSB>@<KD`-\$$)+HV_E4Y,WK!24@`."-0YR=W[1@JQ&Q
MU%^@93RN;G]0"6X.W+\=YVP6Y)B`Z"&>'I?;TF=>""Y02#A]<(->U;TKYR6@
M7^'&W["W577;@S?>$&I`)WP7H2$(P35UY5Z+X4:IX7V:=\?M"G5.''K^#%[`
M"D%H;L4P!GZ`+Z5>3-]D#02[XH7.VKU+%;-M"/5:'[7.INC=_UVP'1#ATR61
M7@AID)GL[;TQ^@)]S>)>B^R/]2(-[0IDOM)"T>NDX.=Z1;O9WKRL7L"N?J;@
M_EPILJ8JJ7=FL`1BK@RE4!,F00F/IS3C2>QOKBB:?JWSOA:<.PMJH!<47BHA
ME`"%!*3Q8N_Q&]S-^`+6B_"&Y`J@*]L,'Y"5$NT'%D($L!,\;ILM/;RB>M9?
MS:]&#H\)?U4JTNRB`$<K<P8'3Q!+G86$$)U0IV&5;NRY._._(.ZS,`8,H'<A
M#1&\3BX$0("%PO)]^NYHR`LD+Z9&_R#[SABC10!8Z05,T/7($#YN?/*&\'14
MWZG!\);B6]X<+P:E,^LV7Q`N!P80#O\+=1^O@2,&GF4<>(\+X5,3@6_4KXN2
M:R^FG@KW<'[L.U,.=\^S=I<`8##K`E%0&W]"MU`&"7#@].H'F0\\^&*'*>\3
MM3Q29Y#X36KUW!KS[`@9#+`"JX!PNV@_X)!#7W#G`<$+NHYVMG!\>7\W>9$+
MPP](A52K\0+$2>FI!]_X1>]`7L!`-#\4B0GBL!#J!5$IY8KN-;6YG;\TJG^D
MGGJPSO_M'3_]_*'\N\\-=J@&.X%]/<[NZF^2\@O>Y5^Q6]\)\P^8^P$(?EY_
MA(1F:85_8PZ)7PB)D)&2DY25EI>8F9J;G)V>G`5^?CB#D@ZBHFJ?JZRMKJ^P
ML91^?UZEE8__LKJ6N;N^A'X1A&)DB03%QF1DO;_-SL_0LJ&BMY"GJ(C1VMO<
MW7^TMI?,WJV,Y*M^!(1A9XEB8Y`$9X[G]?;WGM.DD]?4^/\``8*K-FE<0$P&
M#TH2!,F,JD)I3C1*J+"BQ5_35A`LU"_=Q8\@80T4%[*2Q)*)//YAM[(=&7A_
MD)&91Q&ES9N2IC'82*BC,)Q`@WZKQ1,2@G9":0#ULX'0%YB$TJA+!&8,/:%8
M@4Y[4;1CT:Q@=X6!JLD/F`)?"YW(%K3F1894Q4`ZZ=1MV+OXIF7IBLI/&;R`
M=WE!T,"%FC"9KB6P=&8,XJ1`-4)*@[00V:N!,^<5U8(OJI^:0W^R_\4F3!DA
M$SH@HU1!5--*$@XLP.IB-4H$I=:L220$#*0%;3"+'KY-+VAKJ'!\(<X\4SC+
MIV^8D2OIRX0J:?\\Q!I@]TT&`B!M&/"'#1M"*B8V7^],[V)3?26PGQ_I.20#
M8!RX\`(`TA<@!V27Q@)3!95=10^<A`8:?Z31QA]H(+-<(<+19R$K.N7`3U\=
M7&BA?9*$L<$)+9@QX1<YP%7)&.0)=0-0N!$"@`>)`'#<'T(,4*&'/&JR%5O(
MH3)AC\V!2$D8$L!00@(15!'`@2!D)02,!)'!H#N)D)$%D5QF,HV*0;K6)7-E
M`'D)&@-X\<(7!RK@`G=`[01)&?(E<D`B"__0,N:>.8GR@H;PH7(@G_1YX8<(
M!WHQFU"#'O1`*0N@D,@`KQ62P`!LZ$GHIAG=R!&'FVK&IA>/.7=``H,V6I&J
M`,7X1QL&Q%1,&]EX-T`;8V@:ZIY;]1>H*$/N"E@%G'BA@P.L&D@E)!'<V``D
MN@K+I4[O1=*1I-+>5<8!OFKBPA=D')B`F3<!L:A-^S0(9!K=$E+F4-EVJ1>-
MOP83;UAGA/'@)GZ,*DZP."$`<$A^8$!(&_M&=2XA9YP7[;T79D111V1!#!2;
M`UMRPA=G`"%.NP%G_!$%./@'\)TI6=RCQ!NB(H+*67FGB1?+V?4'`A7?)'#`
M2OUA0*R%&/`04FK_J/(PS.OI!4/+HKR)-$X;',!!L36+(S.,(E^$@-.Z)7)&
M@800H,[13Q.G$[W6]E5RV3==T`G--XMS95M96X1`M`E42P@#T+(]GSX!,%VP
MWS;-/7/5O-0-TLXZGZ3,'V>X1-UCQ,!+.'-?`IJV*"78?/D]:ESMW'*!)XX5
MXS8AL`(A:VC^QQI@_T%`E&1_#EA&'O^:1>VVXZ.&$&90_0<&:!50P"01*/Z+
M&,RSDH/RLBS(RMV%,%BT-8;SWCM8>BE@^*>H/+M]16H`0=WA?S3@@!DZ7/`%
M\_`S7W3EW*#""MS:M(`##NE]0GTB82@5(<90&<N-+S!?ZE>]2G!`A9`!_PR^
MV03<JE`"%-Q``6!P`03!H*0*EJ`$==J&_5:!OV@(:15W8]XRW,$WJOC&#PMK
M8%@2F+&.:$^&)8';W:8QB0&TJ!L'.``#5Z$#Z,&B!*+HGR?N)HH5^&$`9)C<
M,*"5,!QRKXD/.,_F1.$I*Y(##<02W@$"&,!)?,&(OBA@)U`'C7R%08N>0$,9
MYFB`?L&.$,@@`%ENZ,62?"D+,>Q)7[#5QWJ,P0,11)_-SG@Z-"HD3T,:0W@2
M(8&F\+&0'_D2`VK8%X-A\AQA,,,/1Q<W2WR+.XX\R!?Z];B5X)%!^3+@)W%"
MPU]1(%FSC,4#)JG(2WPAA$#9&%8`T"\)W"@"[?]:`;ER&9+NV09\HG@9,[E!
M!AKDKI>68!-6GI<5!1:B9X6@U/"6.<V+Z&4%@?Q#/\!3SFVP80$"Q(0.?1E&
M`Z7R(/V*D+L@0:L_7&"4[<QD7S@IBBS0):#/8`!`+U&!02Q2FD$YP#T#TJ\%
MZ.T/3TD$&Q%JD5INT0\MY*@S'*!&7R*N$E_H$*,F*A".40X2C]NH2`_R)0P0
M5!3'FVDSA/`]7PK@`#9KI3V[&:RE45(8,M7I/[ZT@IN"2:FR*$,!>HI2/Q1@
M2I8P0_"$(E&B6@42$AAE4J%JCR_A`&2"1(73R"J+`90A9U7U@PXN409<`J2$
M0>D7&Y!"'3(\2)]C92O_.712`KC:4+"RD(``@):)5?K!+D5;`U5SR-)_>+,G
MC/V#C6Y66<1*8Z#UXJEG7R$$E&GB"P_(@5W8L`RTHL0+7;1)14WK+B`%=K3:
M8*I3_5!%W'9B`##XRR:^0`$*>&ZA-@&!75O:!H#Z5:.=]6TK_GC3XDIW%6P0
M[B8`H``%N&X2HL,)"E0JE,O^(9$#],UMK]N,C&SR5]UEKSNSD`7:3N*J6/&"
M=O/Z!0/4DQ!JR.QZY;L+O61AMP36AA^0A9#,WL0+2N3O&J8VJ:L-.,&Q\&B8
M_(!.##]#$&BK!`">:1/8$C41,%C8`I9V80^[0L.)Z`@&R.EB5PP`!P1``(D#
M_V,DG+!R*F@XS^/8P*`6UW@5,(9F`RYY9$[08[UCN.A-5+!<RWZA#2*0P'18
M=S4"0+3)!>X+A</4`B:#N;&/6"\;JGP/;6+%#Q0F`PH40(-Z^A>C;#XS);Y4
M`IX<5L^P>++R\EP/-Y?W%B@2@@>D=X9BH`K0NM#++>LE&TB[0M"7(/0Y#)U7
M+XC!`6`X@1K.`P!>_L$,E;+TBYN8!?+&N"_F574G,%V)<&&%TT"9-"%T<`(!
M1(E!`YB2B63]"KW`^5<8>"^Q/4%K2K1!T^1`5%80T"$T1$`,;##`#:3'!O(8
M>=GW[8N?^^(^<,_Z$=RT!+2]T="L,,`W9>A`E,B@`_\Q;)40$1BSN3N1P'&C
MHJG['NXC\#J)=7<#USBY0&Z>%8%$WAGA`<=$O^L5ZXA3@AY>^"F-_S`!<I#A
M`+%MK,$M@0;F3;83>RF$$!IP`.V201T0MW@E)K[%*E1<YI'X`M\,Y0<7B,%X
MQML@!"-P`U='@^>I=O+(*]$&41R4%?M(P`)R,!9SN2[F..^3H'XU`65GW8S@
MJ`*.TS#'LIN][-V(@#\^\8400T,4]D7A(.;Q&@00&4*[P?K7$T'S#=]\[YI=
MG1<D((;>0B+NT3A#&0ZQBB_D5!OY^?+T<H,!`PR`EV,8A-X!_X>^OQH5PN1\
M)!10"^69695+WP9N#+!H`A3_;0!WIE#JS^QY:`)+])$`Q[WW?.O91P,W;```
M"L"``1HT@`U@VSS@$YCTM**B^:('A_(\&13E?\157AB`P-:ZAA=9_^M;.?86
M,>"'_^)^*%VUQ.D#TO9I#V(#$9CP&CQ@`*RVX_M9G\8%&.!:&T97U7Y@!@U@
M>L/T>&TQ"/)P`&-0!K>R,/B'<QEQ`>&E3GTA`)*'>Q=P>^J'%6C@=@%3"@:P
M/CK`#$WQ@#)W3N;G?!3@!PZ&>SAP`W^7"*LC%#NB,X.P!E^P`31#(U=C@A97
M>\XG=NG$>3BP`A2@/)YC$368.H.@`FQP`X:A%"\B>^>G=4VC.Q>@;^>'``AP
M8&=R_VM):#>WH(!F\%\=XH,1ET!21H&HT&=56`@(P``Q2`BV\'_DL(2W\29D
M,``W(`(>\`C>,1MH&'`)!$Z?MW5O>#.CH#AR<7(@`0!&)12$\0?/HP(G(`$*
M,``AI5EKE8B=%SX)84.^YV)W<TJ54`)DT(DWT8'3UG'E@0*&\297LAAIL'YI
MF!RAV!>/XHE,I#QI$'(@@8<EX2J4,!N9XHF%D$"Y*`H8H`"CZ&$(<`$40$B4
ML`%PA!-L@%62:##HI0SC8(N$B`H3L(P@%2"\&(?9,09/AQ//Z`S4TP[,LP9Y
M\Q@/`8[[QE3DN'9OJ#HZD!UA\`7;`13MV`PTH"DE<``-X/^,A:`.`V"/YO8E
M`1")AZB/54@8'I`J^945J_0'>H,"$;"):."0X'9.'LB&(-4``TE@=X.2F%!2
M)985+D`+Q6`&7D`#3?$84;(&(KEL&>%=NN,`P/AU=R,!!Y*"#Y85)Z`G:%`"
M82`&`;`=PM"0R$@("32%&R8``;F%?M`!!Q*&JZ*1M.`!5R$"$?``B=!T4_F)
M'/98O_)!T,=Y"$`#--"50YA#62$`M!!D52`&$F`P`D0&.TEL7_(`YA`F.%!!
MO.@OO'"-[#AMFF(`97`IB3"%@2EK&9$%Y)@%_9B8/18)"-""-F&504$`M)"5
M7@,,:?DE#5`Z8<(`"IF(FT1E_X+_%1=X$QM)``:@55IEFI6I:C4U5UN$1"DI
M7Q/P!6#0E7;H#5]U:YIRG#1S"Q'4FY:60`9H>T^%>R5P1L@I%'4%5RBQD6,`
M$UY`DP`CG9"60+MGG</)7GY@%7W6F83P;0$!!EZI$!N940,T!NEIGH#V)>;X
M4=<I>A/PC^,H1`4@!F>4H%_0E/&D#4A4G9M@!HBW/%R(`.?#"AM)E0?@``4`
M%=&9FFV8C_`)>!.`H$%46"50`!5:H<A2A]TP0LR&7L^0*QK8"N#Y!T-$DV*`
M&##!GWJF2?D8H)S7GJM4`@[`A9/@&.2`1/8X&/53HQA*"Q#40FSB`'L$HJ+`
M`.28;!,*_WC9^056>D;>27`V,19@60@!`E0>BII3^243X&\%\Z:)J7SR"1!F
MX)W?J2F9%R!#,B$^2GNHH*44MY[7)3!TFIS=8`9UQ9RGAJ,)N@A7VJ9]D8]R
MFHB&NIU!816(>G"T``_,0!WA*4MOJ(SU4JEON$DT.9M"L9S5IRD($"#5`$&B
M6H6D"J"$*EV7JJK,M)&#\(^*P%DI(ZFB,`$0:I(4N87:J:M`49BM6@BV<``5
MUY["R@#$^BM:RJQ;J%4'X@";R@WUJ4K2ZB[I1PBR^J=@]B4(4*SKY`!=NG=>
M4`"F>G%X&A+8BA.KY*MG409/417!BHP9`50+U*Y?1S/$.`G_./^O(%&OMDD+
MR^&<-".CX>J)"81XHIB80EH(_WBA`7.F>\.%;DBN+X2EHI"/'[N/JY0=WWH0
M*0L0]UE*;,*OA6"N399`FVB="@N7)WL)LBJ)62$&#&L=9P1J,,NF_HH*041Q
M*[ML$A6OE("PUY<5N5((-*E?[O!"#7I^.B&HMNJ)9U2P!7>UK\6QZE0`_%I&
MA5"<PFI5^2@GB0@&CN"/[X,5-YNG]N908E`"9N``%^IUB5BK&X:DB6@+7AL)
M8Z&`7`66,`$&$W``8'`^8N!0W?JCHH`#;`F@24ML7W``$S"WB?!6A\N<B0L3
M>HL830FL1<MA#*"N?5&MB>@(9G"YPPC_ED]AG&Y;!EP8+'4:CEFJNJ@@H;Q(
ML)?`K:<CN^3ZK+WP5;E[C["&M+RHKS:3O'E!O.YP;V8*O2.YO)8[IS9#IB_)
MG+1[I%R8'Q=JO3R)O7\KL%F'`&Z[O9&K#>@+$OTR%F%@"XQ01J5+OH)IOA.Y
M8)ZH7\)(A^EY$^][$;ER(OHZGH7PN*8KL?IKG;"K:F[[O[4@HT?IO5:1"V,@
M,&2!OY;9P,XWLMJ;:>U[=+);N'\!!M,A0!SLFQYLK*\:PNH6P-U+@]ZDN'Y@
MN$X!N6GK!T.T80PPP!;G!55AJ)7`O="`H!I;+`>WH*\0!OVBJ8M7`E6Q'-4[
MPC,KCJZX8?3)_[4.)0K_J*`*>@`FDL3/P$33PPV.E9P*M!R.L!RA"H=6?&0)
M=#0=D:)<K(C]PKC:&;X2E;DR[(ZB<#]H#*6LX$V@%B")I$TK/)TMW!$_S,5C
M4`",1`D[VPU(+,C;,+]F`+:=\,0+^JAO')]Q7&.:5+,?_*Z>>)P2/*(A<:NR
MX,D)_`ZX.\HN-L<4!\01AQNK[,JOP,NOX+,3\K@.`&H)K,.G"Z/[^\"6AC';
MZ\NMX,RM`,QC809D"P]E-`;J1<L>1K/,FXA\VLP9251N]G-ZBUZ+?)Y]T</)
M_+NKO%^->6+G%2">FUX+W+?B&*3*#&EL\G.9!LTD!!;QBZ!>,,P+"O\/"UC/
MH]H7IFRLE?N&;#(&Z"O$X?QF[S.>TZ&O8K!?Y]R?(=K-#HT`KRO"^>6T'W%9
M!JI=V(S0M-K(L);/@.;$#2T:7D#2;S$D')JW&,L(&RVY64J..`"PG@C"E2`&
MK\K)(,'*!/,^#C"_,(&@T+7#=*PV$EF%0DT)$2(]!N+/Z#`A1_I!5HD&V0S5
MI5JLG!>2,2T)V&P&M4E9\(P`9#0W8_`B.PVH?5&JWX5[.GG6_#"!.124\-M?
M:L`,0O/4QQS(V1O4.##5DI!B$UU>X$+4+$H&`N;7X,?2DXJ,@G`@0'`#9&R7
M;2T)"Q`X@XNUEHT*+@UHF7T)S1)A%4S1!@#_`C>P&@:`"'>'`$:)>[9\V(GH
M!R=0DI"`!BB@S8+QEBAA1Q&0!AQ``"Z@`FL0):]S,UJXTG6MVU6(!C_M.2R1
MU?"<`&U'`#/X!]IW,UHM6'-LFC9TVF>FR)BP8Z\UWIZ03VNP``*@`VHP8[Y2
M9.Y-5G.\$>=]QS;S:(R2WYS0+VVP&%\P`&F`X!I-V?D':_R-"N2'WF"FWNHF
MX#-CX641+`E0,5,RU^?:A@Q`+OW=N@[5S_FU<4F-!K9R'OKT![.!`&LM>KF]
M81<@X4U&X46,X?+TQ\7]!0`@FIIU'$^RPPQ`8AV!F?YMX@$.SY.`!HL!!#HN
M4FZZ`IXRXF_X;*54_PEG$.45SN22T`8O[MP,7%!9D,167H4+4.*7`.0W<9S=
M)!\R.@:IE@/4F-#B1MWGI\BZ:0:@F>5`P97=)"E78B7E@0@J_@?_.>:(.)%_
MZ-]5X``D(S+NK`T>T`(M@.(H-9PDT@*^W<G5L`'M\N-$`=6QP]`V?F2*'`8O
M$"`PP``_W.H,T.I5``.*7<;'N@DH,)Q,I(V=L"U!!*V#4`63H3=(O7=S+&4R
M=NHU]@7/@@!_(G:D0D9D=$9AX(B^P$0,+@G%'@M,=$V=4(M(=``X0![QQ`9`
MLNT-WA>3?N9Y[E!"1\:+Z@TO`0;L+4^3W@QI`$&FR2]Z]`>&J$X7^FFC7O_8
M%<?NN(?C19Q?G7T1/OL3+O$>,Q$3<M%H`Z_H#-`"`U/'RNYB"$\)7)[C[&@O
M&'M1II$(Z`Z!#H[G!Y]FF&!J[/CQD&`H$]("<Y&5SW+R)YCR?K?Q'@:F?DX)
M/-\,!+".(.&S4P$34Q'Q?T`=?X'S/ZCSZTSB/U\0MZ:*(>'$Z2EE^^7TMQBH
MZ][27'L\GA/TOS"(YV`H4U$$D)``&LL(7*^[J$#!'=$`$T#3$:=S4R\)N(QZ
M]@H7/Y%'%>,;;Z^\J"``#_YO&%#O7W>W&^`Y%&P39G\.3[4VB4#SS@KS[;3?
M`(H#F(YS5=VT8[#PP8CY*?$:$!\VR``3Q3#X#PG_]0Z,V7I='P1P[R41^>3@
M3>_Q&,<]&15OSW>^\YC-`.*#4A1??:0?L^DY_(6@]I</U8?O=&2?8()P0PV@
M!D1?^_]>$G`!$S"1W=U?"]E/VK\_D5J[V[W&'!*L$'#!_-^4=$Q0"V0MXZ[_
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MA^"FI*K4CY!!%0S\$3-(#=<%;*P1`\NV<$.R.8R6RI+6L&.#;N4.NBN5KE`_
M0!HQ<`1CP"'"CT.;(YH%)\E2!QJ+7MTMLKQ)H('2O,R(P+!!8O@>4A:;M>]F
M1%>8-EM*]>_COR)SE70C[$.KC/(>\MNHS*#>R+.S(MO\='&UVL.KBEQ)2."E
M7_\H6TW\V5&!BG\(8!=/_Q)9@,6-U]^_[BVR20?`)]0","B517=H!*8;&>_L
M9<P?:LS'WX3NE<(`?M]1J*$D5;PEF60?L2%A1PH%L,`A$2302`G7;>@B)/<I
MEN&+-/X1&0ULG`>)>96-"!$"PPT2Y"`$Z/B'CS6*1Y9+WI4"7I(3*K"&"'Y4
MT8$DTG4#0`D(9,6)`1=PXP$"5Z:"`&'6-9)EBU"^V`\#*P0@HY-M;HC`%U_X
M,X87"#BPB`,'."#$(B<("$V>^FFB`#<(5*D*`HF`H1MNRA`"!D%(UGE<2`G-
M"4JEFNYW9P4K,%`"&KFEFIL97X@`0AEH<+,`8T]BDFG_*T#(\NA/9,2:1AM_
MH#&,%X'U>F2H&I(%VE&)(AO>G8M0<J<Y!(!QVR:WLB(&&`3LVL@&GAUR0[AL
M.KN?LIXB96Y]T$HVK539[G/F(!$`<(@$KQ$2`2KQKEL8NDV"TJV_X3'01K2P
MU5I3O_G,^X>Q,3T\#!G(J!$KPP2'!3!QI8B0L7;M2JNP3!BKXS`A"1AJ8GL?
M:[<Q(<R.W+)C(2<<5LGF."Q"5L.TT:"QOQX[,W(O#\(L"$/_A@`("$OR[E(4
M*.6P&>3^,<`&WWJ&0X-)LU:T-?F!V/52"."`P[60>"!S2FX)=3*]]HH;]R#-
MCFU8/P+`@$&Z?H!JMV%>%#6)_Q=KH]1V4&__,4;$A(C!^)&%_ZU4/Q,P<#C,
M^9DA^6.!,U"XI&%-('55DRK.C!BX%%#ZYFP193G?8K.N4N`'2!:&H8A++?HA
MBU<G8("RWXW-[AR#$GOP'P4^@5P.@.'`S5)O=L@7AGI1^M/(:YP?[-F+%7C3
M,X7Q^&6C#^*%YHTS2<@7AF#?_>3;!_R)W^\#%;A"D90AQO$-X>S-`809@Z&^
M<+W(U:\C9+F<T<)V0*4HSW9I6@K_]E$`%O'.4&"((.0:"+_B<(^#]FN49%8G
ME`GJ`P&[`]];&L$0]X$P)0GT%%I,^$)O!*XL,RG#!.A7$QKBPP$65)Q%(I81
MC?#%A?\U]`A1&B7#"R5Q=H*+Q!?,,+Z@^%`=GJ"(W\"'Q"<>IA034"#80"%"
M+Z(D<"4`T17SL49OD&(JX/';&(K113,6)(;R\\/S[-B1&[8Q)?[K1N`P`AX-
M*HZ.!N1C-_!8/,L%4I&P\.-"2`B41VYCD-,C#!<3"4EM$"6,?+-D)UD1N`+L
M41(JM*(#Q2BR41Z$+-(K7A1=R48_3&!$J;0?[E*"R3^`AQETJ2,MN>&Z6&*N
M.*<<ICJ\<(L1@>&/YO!"%7FI0#$DDQ@:%*8R01(_63)`?=NT(>%P"4T;<G(?
MO32&;HKXF7.&$Q8)7!VSROE.3"S",JBD)S<(5\+#@5,PAQ#_0S:T6<]?)!`\
MS!)E02MQ3W*&A9]6[-LAPK`Z`7[&D`N%1@+'E]",7M(+;7"H5"!J/S]P[0]I
M4-$ATJ#!07ET&PFLVABQ\=)H1(L!9L@I#__0`7U>TIVU)(1Z)N,(0^2RIKI(
MH)%F2D:D/B-:H:!`F!Z1AH%U8U`.T`LG2`J-"N04:5OU`];^<*)#E/5A@[#.
M49WZ"D8>$Q0G8`];?1&M!FS`#Q'PP@D\T(*^^M6OZ-M&H^IFB0X`E1,P^(2<
MPBH9N7IHKL`!Q0,LMYP%%D>AD#6?("[P@C7H8`4&^(+X1DO:6!&"#&)`;5;6
M@(K57@)MG_F$!%)!AJ4Z(W`KR(PF_\2`AN\-PF.'\-(A5+36S*KBH'G$;&;+
M\``P8,`/</+#"_Q0`4>04`=^6`$.LL"`+)2*N]QE@'C'2U[REJJ\XV5,=M'+
MWO:Z][WPA>\*_)"%\+IW`C*M@'3G6P`P@*&__O4O!P(<8`S\UZ?&16XC=67<
M7)2!`F5`@00@7(8<4(`&$5S`"@X!@A($H`,/N,!\LXN6*F@7!]I=015`4061
MK'C%)5B!#A!0`B`ZH`"!NH`7',#C'ONXQ\[[,8^9>8,+]-@,#1"!%\K0`"$[
MF<<`/,&3P7`""O"X3T]VP`62`H("[-`!3OGQ#8K<`"Q#N<8\KFR#I>$/6R;J
M*"LHT)IAD?\-%U#%,P`8PQ<>4``SD"%/42E#`1!0AC1L``9B>``*4/"`,/AA
M#`$0000>D.@Q,.#!$A`!!<;P:`J$X0%?0$-,8G*&P""`<4-5#ZH&,0`OH$&X
M9R##`M*@U32,(1M6?81%\<2&WD((K(2H@!=>@X;J#J``6B4$`SCPAS4`T7J$
ML&JO!#@+6K!AFG/>SB=&/`%@R;(*#<CV*P;ZA1O$K;5E@&X!@$"!!]1X8`9H
MSITD@``#N`5:O<C&O;^0`'VC85$K4!@")+`&E_#V#P:H`!E8ZTL_J*$"6UI#
M":I+"#2`0;A_J,``T`!L1X0[H(-0P4]:4%T`$$!8@V"VLQ.0[#__Z.`$'&#`
M`3R#@@&``!5F\)@.V$,&`>1:W+Y(8,N9"ET=`+T5Y$;Y'R*0V@`@``PPV)(8
M$O&'`P!@,[81`P#8@$C"]=M&D..3&-+BEH!#`@<;$(004ONPYF0A,PY``6H;
MMX$TH2X"7A+6&,A``UPPN0JW.0!OJU!6/]BFUUE909G^`(`&@(&ET;Y6!'!P
M@U@9@@9"B(`\SB!X`XB"H$=/A8+?VM30JR(Q=TI#!')M`*UJ+D]E+<,`C%FM
MZZ#C"U\!.P)0P"<RI.4!&WP$J*W6-JN&(58J;8003',"%)!U$!N0DQC6$)@T
MB($&&`C7702@FC"4(4W92)`CVA!!)EUM__/_B<<"<'!:V`IAK*;/14C0@M#\
M*#>S`S#ZM#B0!;PTNP%1L0!E$`9>0`'A`@`;!B$&@`(Y@"H*@`XN$"&ZMPAW
MDA:;T47[%QG=\2UC]1,PP&P0PA5KL`;UL@;5,@%1`0(J4`"!X07OH'IL<$U_
MH%N.@`$*L`$=4`P#\'HWD`84L%A_X`+(H#_--H+-)BG/4P`(9GK]D`4B47^7
M%7^<\`6+<@*XP%)",`8'@"HH,#`-,`9GT`"X(`0$8$$HT`%`X`!3MSPJ,`$1
MH&]'X@4BMP9^T`91@X$>0P`%4`&E1E7=<@`1$RX;H`-,8DICL`"BXVSOX`(`
M$"NNQ@9JL``E\/\%9T4(:C!6"T<(^D,`$D``0M`&S],&)_(%!)!W]((`8_`4
M?U`"U!<K?B*%\O<)TV4V4$A3L)@)=O@'&S!;//,''K`&.#`D%H$,9``&"<@!
M`/`?D","`S6!7^<'!M`A&*@"A'`#9(`"Z(,*9&`&6K5'%!<?9Z4&`Y`#9_`\
M`["!CE"*#?`)Z+,&*F`&,$$DGF-:A'".@_``:N`2:@``O<$XAD4(^'.+VN8'
M+>`'`N`YR260F("`?W`"*Y`&!7)P?P`"_#8(!`(&"?!]+;(&:/!J#@(MS7AO
M%&@C;`!\&/@%$,D7!2`"8I`&![`""Q`X;.`QJ,!;`!`!L5(`IK$!0F#_6F4`
M`**`<AR9%4(@$G[PB_40`/!A'6-@=HZP`"C@`''#%_2(&S^)&X,@5RZED`-9
MD.HB2]#%E9>0#5_@`&V`#*K1!N2'"FQP(F>0!BEU+'="%_O&)\?B!P-0;?HV
M>\'G"`C``1<`*5X1&&Q0!A[0!G]&`-0(DVKE#F^A4F<0`6"5!E\0`'Q!D9F1
M`'%9!B?P"26P`)SX#YKX!Q.0('G)`,G'!@DP6P[B/&2`6GSA`7"95@&@`_!1
M7&)9"=/@E6^6'ZR4FW[I2W)B`&`0!N>A!@:P,PHH!`;P:L@P4&!`EY"C`A.A
M;R&E@G+B!VL0)A@(`@X`7,%""`40+@&@%W?"_Y%G\!\","T;D`!JT"LN4`9>
MT"T;H`*+,@ADX`4`D!NR1P@B$``JH`*F%0;%T`9B,`#$.`@<25:"P`8N0`%F
MH`)>8#&-(`(%D!46UP#4")R<L)LFD4>_R:$`J8N]L`9`4`QS5(I"T`$'H`8F
MT@8=\#QI4`4'4`4!D`-58`;!8*,!``,.P`"DX`4\V@`Z:@95X`!5P)I^B7ME
MH%4Q>3%>HI]_@`-E63HH<"D-*0!CP`$+,`#>]@=L,``QT2O%<`"Z!4YMP`$(
ML$[]9PW>]@58(P`Q<9.#``(.!P`TX`4H$&IK,``$`0`L!0,*``9?*J*8L)LE
M,`%54(N?<`$?9ZB/D/\-)R`*UT0&`.`2%P``9`""7J`##1"C#G`"):`#629D
M3<9C.L``0W<=*B*&#V`&(@%.K!4K%X%Q8'`!,1&=%*.,?;$"6.,%B=$`\2A$
M^*F-C>,9>=D.*#!JA.`!FG,&%5$!%]$!3MD!%U``L`6IG?`)7DFE":FMP?D0
M/"$&O9">IR4`C+`X-+`"?F4Y./!7\!JO#.!73QBI@O`%[W%#IQ:/$V`&$1`3
M]``J$5`&W;((AJ8B8S"`IC,5Q8!M.94`^3(!X)$`>],(7S='^*D(!?`%$=``
M#?!SX&H?W/JA8!E$(=LB#R$*>5J154<`8:`&">!H8-`G&^``'3L&&&!-![#_
M`5\H>`Y0LS_[:#DKA@T0`;P*D(S`(C>T`EZ0`+U@'6'P&AJ9!CI!.*A0!FI@
M!F#`?E]0`ACU!PF`"P(4!@C`%2J2&L:0!LIX.T?"E-23L63P<R=``!N``$5`
M22>KFR.+`Y,(HGD[HE_``&*0GL/P3*A%,0CPA62@!@1@!K>V"(2S&6Z!KG3!
M`&I`./?$?O?6EXV@$("R)]N2&XP#>7,'(5A3`$5`$!'`N(]'`"FJ+PY`/03@
M!P(E!FK0`E'1M&]!$+;;`GL4!@RQ+W\@:&50C#&A9_7P#CW7`@7PM7^KMP3Y
M"1/P3\P2HH9*EB50`L70"TO')">@!L#K$G%['2U9_VB"8`@N,$Y_L`)J,(D-
MI7N<>PBU0P@58:Z:Z``$D`8.P%+B4P8$X07T8`U%L`$M(`88H")[=&NW`0;0
MZA5@.+RG*SYB,$>,X&=\0:!GL"T/XX:#H")9>P`M@7O/VZ$CZP<80!C5.\)D
MZ05@H`9IP'Z'E`PQ`7EQ&08GP!=E,*P>$DPV@@[JN[D($%B=*PK%BU('0`81
M@P$"X`)I8$$Y108G<`8T4`QQRRI[@9J-4#H.4%FHD`";$08%\$]_$,"$,,7*
M4&BX08`M('@C?%PES&"D!PHCS!'/,0P$#$?&P#CV(`A%6P+DNL,A^04K"X<#
MY;P*86FJ>\*`N'2/@R<-E_^U>R/%L>L5HS4(9A#%AY!N\!')"LLM@\`3C4"9
M#^)+N!"9%X)M;2RRT?L)*)P?"?BW]RH*%/,P!!`!UJ<;9D``Z1D339,R>N@%
M&[L9[)L6LT"79#!0Z;">&U`"8Z`;UK$_.&`&-#!6Q9#+!=#`T?DP99"1&`$&
M5'0&+F"%:?4\14P,PY`;:<64"8`*#O`?7V!(!Q`!#D"DAY7*A^"AK)Q'QG2R
MO5"6$6,&?$$&FDD&^=("+6S%3:/+L>8%?1=N6Y,6Z4N7P90.-&!G#F<;@Y`&
M`I`&#9``YAJ/!Z"_C1/0+>G):NN2Y!H!O>!]UK&_W^<`PW`&`Y,;BX@*ONLX
MC7#_!F#`$A-JSVRVRG!L6=(EQ\_K`,![``70+6)@&ZX)MKJQ`O^*L8L`$V3`
ME&<P;'1Q"FGA!7:F;U0QL^F@5TV<4N@C/GNA(CFL!L+8"$NP!%PRI2B%/FK0
M"_3`%^Q+`!JD!@UP&S&A069PP(U#`PRP`:CLTYF`ST$]4]CU"2-\3]+$E,>@
MA!7Q%`?0+5F[PX3C%FEQ`&'KU5M]"Z)#S%01UK1@5;TS"`"8TV'@`O#G(<(+
M6[$V%61`$$*<T15Q.TW;"R?@#A@9'RU0M(5MV(==PIT"EM8KHHZM/V7PD([`
M%>A\!G7GV&%H(U*\`70AAAN["+[7P]E@#Y"P8[IQ:LHF_PA%$#&FL3B\4(R\
M0P![E%-9?$IWHF8N$"0"(`8,D`;:6`;WK8=4&MS"/=S1"R>M_`D/0-2PC+D$
M49:WD<.-<!'?!P8-L)XN@`&IX641O@(O>9`8D*B>D!H"``X;?@`B/N(BGD8#
M8P91H6=?*"DN`-!6>`($J\.6DL%IM<21L*M;S,L"<,+#T"W)9SH'(`#E_-]M
MQ:TB<4M-LMC'S:'W9+*S_`=?6+.6DEH7W+CR.4?/)!'^Y:\$YE_-T^7^Q<(!
M]M?60@9'[!6$L`+QB%I7O7IH98F18`8JLCK?U[1B4+RBU<($@+N[\1]3=P+%
M2>1)Q:V#->!#O0*OG+>+X&@0,O\(`@"/9$`/*$;)?7&O#``34(L,K/(\*)X,
M'9Q6H!+;Z$P&!G8&\CFF_Q'2Q/`?8.`"!($#DZ**QA!K2YT,UM<MJ=AG&8G?
M>#W+L9WF:ET$)4#8@AYTA)[/'),:B#['7G`&:6%!P#O7JE/+>]RB;[$!G.<%
MUDT`U+/:7S#;QL!I%N%+&E$I<PT3!-&4_EL"$]&0:A8!X4P(.O'D8Y!K8/P%
M*^#)?^!E!-`M4'TM.NWN8%L5WA?ASEOL/]T"A=XDJ8$!%?NW*UL`XM/">Q$3
M.'T&9=G"&\!2Y=KCYG,`R!#`>E4"<[T7CQ>$IJ&9.+"Q%`6^7M$`M].XCX`V
M+DD0?O#_XU0&Q>B.$?^!"G%9[[4=!J@0!F;``$4@P@AO4,>>V`&A[(E^LDM6
MEAB!Q&$,M@U2L2R5!BX$EVJ(SGM1RFPG!IJW`?5N/EF;!BZ8`)T^!ONR/X)P
MYSBQLTNWU"Y9MRV0!A.0!A$3$_E"#D+2%_(POJRRS3VQ%U[0$@>?]*ZPFPN?
M[`:NZ&40N-,SGV`[#`+RZT2R.`SR/%Y_YQHTA!C0[E4'[X3PEO^Q=WO1+::>
M#9Y,L.LL*=LX!BV`O,`[O(R`,(Q`BEXO]`0@K)CN!25P"T>K^(-.D(W_5JGQ
M":T=LHNP`&UC6M>V%Q5A`,,```NP`/28`#J@$SGB""K0IF0`_]//$^@805'K
MPP##$`%ED@B<_3#%P`'`9UU[!--_(`$=<@9J8'?(<#L:"0AH?PD+96$`+1@%
M87^-CH^0D9*3E)66EYB9FIN<G9Z?H)X%?GXM"*0(D`ZD?@>L9Z&QLK.TM;:Q
M7EY_?HT)C0M9$;N-7E_")XVI?V0&7R5H7U5L*A$W?P-B`W\`:4)H(G\N8HX`
M8@8286QH*VD$9&E5C0!_!.-_P`9H0HUH;+K+:P@,$O2'$89'!!*`^</@SYD*
M`ARM0<'`!9E;&#-JW,BQHZU1I4[Y4>9H%2E7I-1X7,FRI<M)N8:%&0/K#PB5
M9AJ107-1Y9\U'`@84&/`@P<:9ARH(?\#)@)/''\$1-C0R(,?'0O6_/'`H8(?
M"E^6_9%@X)&'/P42<-"ZYJ"C$P:T<FBDM='<B)!6S'-T`X=*``56H+CXLK#A
MPXA9@C2%2A4KE+P22YY,&:8N7AO,>*D+J4V9,G]4B/@R1L<_B6?:I/F3!0$9
M;'\VG/`I00R8`V7_[!.C1L*?+U[,"!#CX(N8'`O0J"6P9@"9->#^I$$0@0V8
M,V@$B2FSFFHC=3=.$&PTAH.7$S#`<*[,OKU[R8L13!CI^.2K]_CS;XP9>9N!
MFJ#]XD<\W>SD10.1X$;`&6"4(0(RO3CB"R0$_#-7``LL4$("8NSTQ3X52'#"
M`BB@84`'C63_IL88#H`1$QH2$!!66!P`X$4%/DE'AH@(@#&>?D`&*20H\37V
MB$E^),#*A$,VZ60E_/W$@2`E+/#'#1Y8^0<8A!W0B`0.-+(0)!NT$4D:!X!6
MAIF/"%%`(P+I-H`(%$"R1H"-P$`7DP6)5<@?$4S01EDR0L+&"0I,,.:3C#;Z
M9)'T'<F*"J0TY.BE3D:9YQ\'W#!.%B[`>1$;*#3B`@X[\1E)37^(T<!%?H3E
MR!FJQMFJH6D`X)N=Y/@!@"\J("`(&FUP.(@C$H!1!0RR8NKLL^S%ET6D)3W&
MBC#09ML>?V4L@$!-%5BS1ET(A*6&GEN980`"VA0P#QC6_%$"`3!$_X!B`&4(
MI.Z5``QP@S;]-I)3!!$0`,!>9WS1PE*-E."`0!>%<<8:9A#DP!HJA($`#.^0
M`4L8'91P@CW:EFRR8J28L@*UC2`)V6DGQ^P2?VN0(4!98^1$#%T$!<3F3R)0
MK%!68JJAP@9B$!#!T;ULEH,OQ*E``#6-Y+`4#6&M(<%9J_W1A@0=='"&$")@
M\$4`I^F\00<5!,`0!PX`X0`(,M=M=RV0/E!?*ZS`?/??MVB*K0@$#4!W9V"`
M((:L'6C3P0HBJ`9G740Y$@$X:WAP41O:2!>6`14T(L1J!FRP0AM4F2&&"&4T
M$-8##%@YQA>PQ,G</6.44,(!70/N^^^70/^ZPMZ0>0?\\:#$M`)A<$H9`$F,
M_+1!H&^FT3O=9-C3H2-IJ-"(&#F1$6\"$Y(!1!D!\,X(2<$T4@!AMC:RYA\!
MI&'/!@.<00$#.I",_/_(@U1_6L8*#EP+@`C4A!=H$(;SC`,`WF-*(TX@@1*H
M0`>-&-X?V`"+,C")8(VX`6%@L(8P?($DCB#(@DR%JC^XSDN<^0*>($$&GY`A
M#&#8CB/4X(()A"J!0/P=I$JP-S#T+8A(E(0$2'$:Y4R-`HQ(@QK*L((3:,,/
M6E'#/PHP%UT]IPP5,(#$6-$!NH%@`V>`140\(`!T@0$%UMA)(\)`F#`YQ&/1
M^X,:(/0;!N2&#`7_4(`9F)?$0IZL2"O;6PY883Q#(O$+I(`*Z\(@A`BD@0Q\
M6IU6'#"`,*"!!@[1U5B@`0*WA6,!K`!#&L8@`!RHP!<",$/-@$(`-:A!*Y=D
MCA<PR*E&#$`(`]B`&GZVP2\DX"(+<``&O/`C1SH36HO1@1\>0$1)V8<!L7HF
M$@>P`@:LP`,76('N=.>`<CK``UX`YPEHX`$$E``!-W!``0Y0``>LH)Q`P$$Y
M3W`#5@"A`0Z0I@`PX``8P,"<%VB`0LO9`!V<0`<++:<9P&!.!S2TH@?`P07*
MB0`'[$6;('768KS@!QQHL%JDL`HI>A=2`(XC:3D$@TQE2@,,3"4,F=D`_PU"
M-=.9/L`,0`4J!XS8TZ+V]`8T2&H!C*K4&X"!!@6(JE2C"H8.1+4#4.T`O&3J
MOY9Z]5$I6R0I]D8I4JCJJTD$CA=V=P`&N#5`!%!/(]KJ5K<.;X!HS2M:!;@W
M%[`B?GH-HEK]YH@<*F`2?C@#7@/+V&<N1J5X19(1F=C8;>(@)I%@@PO*@*U(
M^`&5E0TM$M/HB)&RHHA^P"9A17L\/V`6$@#0`2<1BX;%LO:V@/M"LQ8CULBF
M\HBX_9]K5]LJXR!V&,%-[O$6`Q+?D@))Q%6NS,(P7$E\X0#&E00O;"O=[IK,
MM&.UIFO]H+OH>K=DD'SM(\(P#B]I%[GGC6_)P/_K7#^88203,*]\GR6&ZDJB
M#`[0F6?AN]\"7XJ^J*6L@4\V!O]&PD5C."YW%TQA_2!8O)-U;871FU_S1E@2
ME]FPB(-T893Z(</Z'?&0OI!?[.KVQ3#6[4QD/%<"J_C&E"DQ`4F!8AQC"I)A
MT$PNADSD(M?3"P<(L8^7G!@=_P%)]U4PDY\4!@8@X,H.N+*6$5``(A\@R46>
M\)3'K!'3NG5O1&X6F5<\Y-\XHLAP+O*:Y]R1Q0!'ID6DLY[W?-O%4$*R?`ZT
MH//JYTD`>M"(3K0C"RV)0ROZT9#^'Z,CX>A(6_K2=9MTGC'-Z4YG2],8]K2H
M1\TH4)MX4:1.M:K=8^K_'9]XU;".-7Q2]N=4ROK6N$99*6K-XUS[^M>W:/63
M;0WL8AM;%+0V-+&/S>QF4T+8E7:VM)T-[65/^]K'KG:OL<WM8FO[U=T.=ZZ_
MC6IQFUO5Y#ZWNM&=[$9;>]WPQG2ZXTWO2\^[WOA6]+WSS>]`[[O?`)_SOP-.
M<"8/O.`(5_'!$\YP"B\\WS,HP0PJ@X4?--QW#\<W42O#`/=>_&X9K_?&*=/Q
MC_\MY/0>^61*;G*[H3S>*I<,RULNLY?#.^:)F3G-#]EN2K\;X#A'C,YW/M^>
M;[K@03_,T(G^::.'&N%)-\S2F?XLFZ\[ZH69.M4Q975U8_TE6M^ZH[I^[J^[
M_R3L8B^UTT^=<+.W!.UI=Q+9S>UVEL`][D.:N[CKOI*[XYW$:W=UN8$.;DIL
MX<MI2@$1=&,!1Q#A"E]NPB/8$"8L8,+O?[=PX(>];:07?A(3R.,8O(2`/![@
MPY#00P#D8(7+>SSSC=*[1\"PY3"ARQ($V/(^-A&42(@G$R#H0@L"T/A:D&'W
M8BKW!X#0`BO,X25F#[TC1O^'TCOB])'@``8HH``*+.!-E<!\M@!@A@,(0080
M<-3L7BP#EEJB&?SX0A[7^P6"B.&C2)1]1])0!A10H%L,@0E@<`*?408DP`DM
M$@E*D'Z7,`,-``(3`02V,`;@1PPPPP(XX`-KD`-7`/]]GR<)$\`%NO,'U&=]
M<T4!NA,OC>`$!A`$^$<)XN<L`U`%?I`%+;`R5=`#F``!3H!\DD%2K$`*%]`'
MF'!?WY--D0!)]N!.AJ1_'G%"CL``%>`!=M`()$`#'?`C+O((;A`!%B`'U1$;
M5L`#5B@$3M!X"<@#2,`'C;>`?]`#'F`$<?"&1R`$#/@'"G`$C>`&)Z`!=5`#
M6@``;[`U8/`&8]$(890!-1`%*$`'DD"!CZ!>0J`%C8`'9^$2T2=ZI&=ZJ.<(
M!/``7L`%5N!^DA"#E]('#*``/M!X;P`"7#`!&G`)8S`!=C09)+4`8S`&+%`&
M+=`"AF@))C`F_:5FCJ"$<#+_<87DA!T!A8V0!5NP!P*0`1K0`&8`!3GP"&`@
M#F*P/2?P`SX0$3P``QS`!2&0`@+0`1X@>2WR`1B@`@*@!'\0>@#`!2H@CIQ2
M!$CPBVSP`JP"!ZV"`S>@!C-0!$8@`&0(?N4R!@Q``TW0@9$`B6\&,P4P`H[@
MCYCX@9$@?>1!>A\0!F$``0>P`QX9!A;Y`4V0.V-@`8X8?J\G,VX0&"P`"514
M*HX0!W?P!7UPASLP`4TP?R.P`$38"'"0`<7W!Q:0`8X``6'@!HWP!BSP!0#P
M?(TP!S\B!R09"235B?>5!XUPE.O%@$IYA,WB!B9@!QI@C'^`!E()`4B9`@LP
M`!;I_P@68`-B<`9L67.;%VWMP8RLP09_``-B4`$+`0<8$)=@P``3D)@YH3$(
M0)$"8"5'L`/!T0@38`$M8@<-D`<?$&&AAP7PR`8"8`$'8`/KU0+RDPMC(`9N
M$0!DJ`%$A)"D,0$;!`-^"0D0:8&/@$*%8792()5_$`)/<"7C-`-/,$XE$`*^
ME``6L`2-@`268(J-P@)^('F&LD)_X`8U\`*L0`$?%H2-D`&0\0`I\`<04`1X
M\08PL`*_F`26`@`*P`H,4`.-0`55@)R]L`)W^&9^T(E1D`4$<0"RZ0CV)3"1
M,8S?*0"5H@5^L(35=)BF0PH-,!X+H)U^T`!68"D\MVO*UO]Y[\&7EE(`X/,"
M=8648D)84."0)8!Z!]!-;O4!+0('5)`%#1`#\1@&V(<6H]>);+`"_K@`8&`V
M8J`,(-H(#0&;8Z`,-_H(M_D'ZE4`'S`K'CAX2M>2,5,#?D"CE5`!6=`$C2<!
M#,`$OW`!2Q!A;B`%*_`%;+`&7'`!?ND%+\"4`X!-VO`&`H!!<)!0R!D""F":
M>N0'1M`(9]`%8(J5?N`#VP@`3I`%3G!]`=H(`_H'1M@J2$@%>L$&/3`M#"HF
M67`!)L`&5NJ<?[`#65``&1`&4)!:>*FA[L:A[N&A[B,&1D"&?T"1A>4W:-`%
M#U`6#Z`-)"`#30"/)/AD8``!;5#_!T*`#*$'!;(R!1J0I`U#FLE@',K`!&'!
M!K()?JXS!@CR!SI0E--7@4P*,Y/(#P)0FRS!=QX!G8Q"!/O)/42&+5^0!(\0
M`(=%@K38"#+@!_+9"!_@!SIX!'Z@#4:``1<`2B2P`O()G!_5`5G@"`HP!8W`
M`UD@`R`6A$+8.9S2J+N@,Y%JH";@!]Y#H)FZ)7YP@(W`?8U``PP@!XT``1B`
MH=^5ES_''JZ*%F+``@@0`QM036*R5#(E$%?0(%+P!TF`!#L@!6)``@)``F50
MF"VR`%W``DD@>:%7`46@!PD`!9S2B7_@`PA0`0`0!1-@`D':"%$0`"R`!:6R
M!4:P``Q`_QHK<`0B\"8XI*0*,%-HX`4^&SI]T`(;0`(W0)TM@:X=H:Y/8@1^
MT#L]D)@3($Z.(`<`(`()L`074$VS:$?LBDY#E@51\`=QP`!G\64><!`=@`.U
MZ09T4`%$X``4T!]:\`*QN`4\"PDD9:CW-P,"L`*=`Z"/\*@=FTU>\:16N*#)
MT*!^$(O%VPA3@!>-0!&IRJ>KBI'L\4N.8$H)X(@)``-8\0A',%5"<`9;@`80
MT`1$V00"@`5,&04P4``'J`)'(`<%=0#:L`46,#93$``4203C"0D_4`!=<`)A
M00>[IP$T``-7$(L+``1+X`$#,`;#IP,4FP*\U`@I,%4IL`%2M?\%C?"-7>``
MN3&XTJL)&1"3)J1;.<()ANLD/>`'T6&4N<A*U;0&5_`"./``+J``EGNO?Z"@
M6W9E8^(`\4`!9C`#69`!3,!+<"`$C2LR"$H.#.`$<#`!H%2QG=A@$\*[`LJQ
M!9I-0^`'>30"Q%M]QIM'3/@'10"N>P"S1:>J/L>J*I8[CV`!9Z4?A`L)<+`%
M88(F!X"KGY#"33('#%`%O_@(!5!-5X"PU9O#=A0$QSMYC@`"`;L"-D`&?@`"
M.!`$C:`$?N`"M=D!`T2OI@.MA-J);S"=<]6H$."[6QP6!)"XCD`"85S&1D3&
MU10`V]H(4*#&VJ*,P07'LS*'35+'N1G_`+4X!SHP?YO@QTWR`WZ`!"SK"#%0
M!=6D`%W@"",P`8HL#QKF2WX0.@XAHP^0?A/0`#C0-4OP`ECZ!U,P0!O@!W7*
ME%3\"#/@!WQ0%2]@D:BDQ6+I-5F@M8V@H",[RXY0QD:0!75!!UF@RTW'QD>'
M8W#@FXTBS$D)8([@!"D&@U0:,VY`4BVP!%Z`!`V0T,AX`UF0!&/PHRO`IV%0
M`A.0`^FW"C=``!QP`3A0E$#@!Y=XJB<`SU9:``,@`[GK!Q\\!RLS!)1`4@(@
M5>]9F?+C!U3@`PEP`2^@SY(J*Q'@!SG@`_84RV,\T-5D`;F[!)3[LL_+:R&,
M0#T@S5S`OI"`_\TET`#[^@A&0*K_(]&.0-'S2:N>H,Q.<@0NT``30`%3L`?"
M^YL>4`)5(`4UP`,Z`,P;\``-8"80L`<((,U-L+^-``(%<#@#4`#(V`A$T`7C
MC`(+\-2/8`4K4`>4@,%3=0!$D$=OX`0-L"P]L`6[(@'@1P<^W901\`!5P`0\
M4``K*02@VKU%2=R.,`<=<`)+4`--`!4QP\LF4P9%<'\T((&]NXTBH+&-(`4/
M`%B^8]?R8T<&P)R@P-=/8@%C@-F0@`<&,,B/``'Y"0$&@`>>$`<T(0EE^D.A
M8"+/G`EQ$`+FN@D+8#QNH`#UFJ'0V\9G#4!E`'YP,`7^$QERT+"/\/\&$Z`"
MM0@\XOT'>,T!<ZP)Z(U;9Z`'(A#&3C($60`";V`!E!*R"F[64II`#^X(6,`G
M)P8&5Z""O_`$@%37#7X)&6"?9("\?9S1*C8M5-`H$'`%K-#/F2:S;@Q$-8Z;
M`IH+4S"TC["]4"#*O]/AMC#BN`4`.X`I;@D`]AWE#/UTA53E5_+9R/4&#:#7
M$,``(E@%?/3E0?YV2`Y[0B+=)5/E?1"AO=N4#1"3\M``N7@'$Q"7X;WG=M?G
M?@XD@*XM39M.$T"3%[,+6.X6#H`&3F#4\[D#QZ?G,YYUDC[I^5'IV?(!,B4"
MJ$<`L3A3(,"`!``!,T"B?\`",8`&>OCHIP[_=JD>4C7`!5GP`DS`E9W``)WU
M"#[``"%N"P,P`='N3*S.;&!>"V)^//VY!2!0`8'-M9CPJ#*YS1PA!@QPT4ET
M[<>6[;2P[<!S`2[PB]S4N9Q`[H]0!N:^$>BN[ODGY9!^<P&?KL/^3&QP!3KH
M"!=PB6!``';0!$Q@!2;P"&K@`4Q``R&`[W>][X\@!S5P`Q=OLG\0!;LB/YC\
M!ZV8`P4`!3(`S_U.:``?["(W\(5;\%XU`%DP%]6'`1-P`"[``!B0&P#P`A0`
M!5.``1K?U*O%!D@PJE"@`"N0\('D"'5``>ZE!5E0!'&3!7OP/>D.\VO.=K3P
M`XB'>&V0`5@@ZM?I_P2=90+T.B*.5_9?U@LS))1!T`4*<-F.D"5):01=8*&8
MW0-EWP0^`,^/H`)R?P"-IP*+Z@@]P"1N<`1,4`)3@"=HT@AIL`6(_@<?X%YD
M+_>K\?EE;R5Z_&4WP`,,N`"7J`(P'AH6YP@54,A3H"67X.ZS`.__X[(*P"8(
M\`):LD3U[$+"$D))[^$<WP@UD/--"047("9A#`99L!HAD`67^`=/\`+I]_)[
M%?.UX`!<$%1`A90UL`*YH0(X0!`)L`)1T'\,$)QH@0#@KS,(0%@"T`!#4`'V
MU#DM,";L"`@*/S5+*S)_?V838(Q1.%>(D7\'#6:6EA"3?DJ19@B(:`$X0?]E
M'%4!B%]^J7XPD6*K?PY<EY8&LK2U)G^JC&!!$P%L?V`MB`=^()$'#H@0"EP1
M940O*)+7DF!^8-C=WM_@X`P'X>7FY^CIZNN@7%D[D0@"<(AP?F9_9UE$D6U9
M^-C*^/'2;<D$23+\K/G3A@ND/U2Z(/+`X$ZD'0PB_!'#@""[CR!#BI14P(\?
M8]X<F-PV,I*#`MW>-*&`!D25(XAF7``0J<**,'\*-,.&P&.D%'YN(9*2`%$+
M;FRN2!GVQPT'!AH2E9!$(,N9:P?(83LP`4<*1)X0H:`0(M*`%1]XQ?J"8P('
M1+`0O>RV%YLJ23M>\"QVC(*"N).&YNC2)I*-"0/_RFGCUG+DN,J8,VON!H#+
M3DD(8$:Z]\>`GPJ2<`"\)M"H)"!9&,AF\,+/`D1/<+S)P*`#(BI97LQ^D<7#
MQHZ;DRM75_+D-Y4F*;?LBZW.A00-:$1J(AI1'`)?A78K>BU#E@AH$(U!_/3/
M#ASP(IUA,$,KURR9)(7M=L"%`"IN)/+)'PHT)8D$&<B52@EFX%#'1K%0)XF$
MD?SUR@LQ$(/2`1$H,!0S?T"P`@'7])!5.),MI\YE*K;H(C@$8("!&->$)@EI
M2&V0VFJ2M-:-`!B4(>20C?UAAQ\D-!C9'R=<`,:00D;&D6LO5IE<<RCQM9)T
M(SF`@1=@>J%1)`!D4<!7_X@(@(4W!300IA<Z_D'>-2JL\`(3?!3Y1WLUX(!-
M`TXDLD@C#"`Q5@EO4L:,`2M(("`B(WICX1<EA#'%$F[D)<N788[IY9L1?-4+
M(QQ<T`0]A$T"!@@,V)#8'RSX008[*5HICEBVYJH<1@B@"5IW?Y#VQPM"1#*&
ML*P-U`T4#%@0B0D<)(@(%U0TL$4D6JR@#"(CF+'+E+J&VQ*6SVV)V:>=2C)#
M%AB,$0D03[#I9IAQSGF-!00L@4,6).[)S1`'7=.%-6:L@``"#)2PRZ&)'M/,
M$"N$D-8?6>#TAQ<K$31II1JL4(&FZ(+I*:<BB^K'P3C@8$>`&A[#31(3L`'B
M#O]^G&C&2CQZ4ZNXDK#(\\\@P3&!`CN,8?08)]HX&D`WX'`(&UT@VZ,?#AQM
M]%<RK##5'QH(H%LD/ZR0A:.(G(%#`^FQH<,*68$+]-OGD)N2N951^(HA`LR#
MB`LG2/*&%K>(1Q25(Z!63Q`,9-*>&@P@5@\..IJQ56E`2/'&6+CJ-]045*`P
M(`9W_1&&T3IH/%>EQ%2AC5[`NM0Z*XA8($47)Z9Z`#<6`!$`B.;=]D<&1E<B
M&4MP^PSW\>4DM-)*0RF-B+`0'/`"!86^D#,B`BUOTA>(^(#!"R6\H`!/D62P
MP@2^\M+`"B4P0$%]QU&)_/R(R*UE=.>^SK4".?Q!P@3_>T#$#R[@.!ED801!
M&4J-J-0#!@`%$7?PBK_R<2FN1,P^B"@3EXZ1N64,90P3H,"`H("V2+B!":9;
MT`-A0($(Z<]N"D($&1A@(-M1YBT4&`H,F."L2`@/1<1[F_'H1\1(D.$+2$SB
M%Q:RD26E0BE_B`,(B#`#.2P`BI)H@Q*3^,`_A.`'9JA`'K"AAH5)H@X5,(,(
M'(>&!;BKB$2T'S:@$\0N-0!*96C#&[Q$CS\,(0MT^`,;EM""&8CA!U402P&F
M@,?&(.`$0_)!!MA0A2[XX`X2F$"\)GB<&]B`!%'(@@K0,CE$=&`%#])/$?"8
M(!`A(@A9&%`('L`%'MR!`%?P_U@,*?7`'5P@0G>$4AID$<PA#=-"B"`"`VYC
MPT@D@6J(T,`%I&!('PB`/L/;X#7"0(5*^NX'0%``%*1U!`7TL91_Z$()UMFW
M6\'QG?",ISS+(<=KT%&;(.G`.O=9`@#,0`$(1(0;D`"#`,F!"!APWR@1@01^
MKI,G-^!G%UB0CQRT@`$8(`++J!D)/%SA`C@H0H8$V$Y$0"U0DGB"0TM`T2?X
M!A%OL,(-(@&!(%"O!4M0"@`F!X`3S"$2-9B</AVJD:'R4R,[!0L4_C`#*>`&
M?E4IP$OS\82$5@$)>@+'SKH1@-MHP!A#R($<_E"!I4)D"[YC@"2R5(XASO.M
M<(TKT/_J.2&ZR?6N>$7'5K&!@ALL)"M`((%`@<*"!GP`%7]0:R38.@GN=<.M
M>8VL9">[#KJZQ*Z4S2Q>]WH-.:A`*EAP@P("*8D.)"`,&*"H8IT2E@,L]!N0
MU:QL9RM9R^H%L[3-+1PY*XDA("(/.O@`#'P'!R-8@`E6\((`HI#8M:(CMKJ-
MKG3C:!+&UA5_T\TNW'@;"0%L``)M8$(*:G`%#<"!`TB8`6+/((`Y.#`,86!#
M"^`;A@1](#V/[:!V]\M?7=E6%KCMKX!;Q%WO'*`*"H#?$!I0`BO((0EEB`02
M>L!/`$AAGQ)Y`OFP`=T!>_C#(OGO/4%,XLT4.%<=+K&*5]S_#1$'F,4P/L>)
M;97B&-L8Q"[&[HUWK-4Z_JS&/`YR=G/L8[@%-`4\@<,`$!.#L_P6$6V)8GI"
M`($WS,J(8DA#)L0@!CT,PPT`8`'+/G`Y-(AA`#WDU@(@8&8NQV$-9TZ/";C\
M@3AP60QVYO*5(Y$&-4```A1%0PC00`<-W'DC>C:64M+@K#<,X'(O.G$,HMR&
M8?Y!#GA,LP$V4($N/E>_0@[U?HF,SY^%8"L&6((1?*`")R#A#`D8@A4BH8-=
M#`4/32G"%_00X4AX(0@HB-<#P."!)#!)UBBE@F"_H`4.4($J%;A``ZK0&?"Q
M``$RXL(?)L"%$CQ!##A8)PM*L`(,_XP)$14(]Q+&L)4O..`+!9A!^+:2A76.
M*0@MF(`,C(`!)LC!`Q0P5*2+K!\N9.(+'H$`(Q@0!##@UP9W%$$54OEI45N\
MOZ2F7Q#ZM@$-X$$#&JBI!JXE@C<F8`FRB$0`SK"$",P@RHCP0AC@P%QRQ*$#
M(QA3H.:P`=]^@48RX,<?DD"%,U1`#F$0#0+$``>U3N"!8G#-TJ^1A!.PX0AZ
M:/>[12.:U2+"#B&(0$--``0`O(`-9Q]XJ8]1`&,C_!I/ET0$M(`("3CN'$"^
MN-YK6]URZ1AYY(B`%U#`/1)000/-*(-CS2`!$BC0!34@`!&,<`TOT,`%\2J!
M$`+0`QF,-/^`(@B!"N+P\S^,X8,'N$`.W)!T1""@!%R8]01@4(`-B`$#!4#L
MU"4Q!AU,@`ATT#J\ZX<(,Q7`8K`JP@XF,`8$E$&M#E0[.`X0`QWTX.V2B'LD
M0N""*7B@!RRK^-['G]N,TR_P,]^#!MBP`QXTX0\;6)(9(!``!:H@`!H@`MTE
M(7,+6",`;4`#`S``\.,;4N`%5+``I0<`*$4`,0``%Y`"K2<G2@`$/[!M'Q`&
M9R`&-%!?KD<C7$$',E!V%/`'!.`!PQ<4B/!>^0$!4V!L&*`'17`$*_`'*Q`'
MTO<-!R`&1\`$($`EVN<,<0``$=``VR)^Y)>$F65^\T,.:A`!`"#_`D[@`WP0
M`TT@!L:&%B8H`'^`0'K@"D;0#&@6<PM@`]I!#@,0+P)P!S/@!1I@#3NP!U]0
M`X[W0!SP`!'0+!.X=&5P`1`P`0G`>&(@`+8@)S12!HAQAWL@`'AP`7M0!$&0
M@J*Q`I9P"'\@!`PB`S?P!`*@`45`!$!0)2>V@W_0`6X"=YX&!7$R`UF(A$KX
MBGG%A,CC.PM@!&\0!S^@#,6U80O#/;N0*7_P`11%`O@E!F!0`6?A.S124SP`
M`2&`!U4Q`&0`!AL`<V_0`TEP"Q!@,02@`6[P`R%0`8QP!!K@"[/2C7_``TOR
M!F70`6?1!@E0`59F,1;C"X+U!SW`""0`_P%[0%$:D``GXB*C2"-RH``$@00_
MM6T/)`5S```8L`1(T`)IP`(SA7>@!HL8*4^RF)'J``"0-EDG5F>(@`>S0@>0
M9@(G>3EQ0`(V@(-OYHH<&9/OM)$R*6`S9B5Y5Y,ZF2LT"5=BL`L`D`:5]@=D
M4)1(%!EC@$1B$`9(!`])B41_H`9(-$P#(`&W()4VD`EP(`-',`QB\`4+D$HD
M0`#X%0E2^04#T`:1L09[!@!Q,6=BD`EKT!@:(`-?,0+Q03\W624YN9-^Z2(]
M^58(4`2)=0!E0`Z^<`$(<P=>4`4(\&Z*>0$DT)@'LVT/@``)0`83(``E(#2T
M!`DN4`(-H`-RHO\`#/8'08`!16!.DM`D&"`$98`#$.``E)$`T)`!4D`!+T`&
M%E`"98`'+2``2V`')4`!=D!$>_DB??F7S'DE?3<W?R=7!5`"9'`!AHF8C-`,
M1#`$7@`0[O8'-8`"W1D)VK<`.J`!)'`&3Y<&#:"><N`&#5`'2P<'?A*!LK!A
M>L$-99`%/T";B-`'<W`%-#($+O`'#Q`D&?`%;L``6A`%`!"*>DEPX;*<S5FA
ME1&8\U0`0$`$.7"=Q,`(+S`!&)`"7K`"R_0%(5H%)&JBVC8!LI$`4;$"I.FB
M*X`$8R`67B`&"'`!%]`,*,$(]J2?.8`#MQ,)*%`%7Z$#QQD]O88%-`#_!@@0
MFL@IH;I"H19ZI2"!H1J)!!<@`0?@`WW#`2(`!DO``5T``5YP6FSP!2U7`FBZ
M&MIG!R0@7#$P`1^P!A>0`0;W!@(0`@A0`3!`>1?P(%9@B2ZAGUZP!`Q`&28P
M!QX0!1;P;,<082J``!F`!Q&`!0,R/\GI(E:*I:":#EH:3P5@!%G0!P?``@K@
M!%Q``F#@`''0I>/)"[!:`BJ@7&"BGC0`)V*@`$G0`)I)`PZP%4#@`DC0`&[`
MAQ<0!SE`!55E`41@:;*`J&.PJ(B0`U``!%\@`P(W"8CX`EO@!2`0`%O@6Q&Z
M=BAVD:&ZKB'VG/=#I?*T`=T2!A$6`TA0`QM!_R)J``9?H`;J02(#8`8(EZMF
M`"8Z4@8><`@%FYF"U`$H\!5@,"L)@$`J@`6S\@2N@@@$0"-IP#VV9U))P`,;
MX5A_4`9ID`9A`@=@$#KG>CR?RJXPVV+N.D<OQI%'QU^=VB(O&[,\6S\S:T\U
MV[-WE;,JLK-""[.C&ED+4`8$``$?$!EI,$8C,`0\D0>W\0$?,`)#,E8F)`;W
M^`'#-`)?``!4,0($\"`Q(`-PX`9E&`G7&!ESX`-QD0=GRRW2^E9$NQQ&>[3K
MFK1Y!00%H``1\*H74P8#@``!0`$D$)OE"`9F@'L%D&8F&$YY<`:EPR0*<`-I
M4P(P``4C4`(*(`'E5/\"%L%4G*D'23"=<;`$4C`%^7`"\A-/>:L<>\NWH.JW
M>`439%`$A.L%92`$3<$"D)0%3<`(!1L)*C!2-Q`%1W`&3<`%!$$!01!0O;D#
M5S`$*C``2\`"!D`#^+H1:"`%/1`#:-`"*1`#!G`!?_`#R!%7LYL<M6N[5XJ[
M=P4$"%`%9J`-)G&8O=8"90`#+T`$CFNB![$`B%$`%$!`;G"\)6"*5X8P0O`%
M#9`#,(&BI/4'*F"?7L`%PW`"5,`DR257[[L9\2N_%4J_<@4#8ZNRS>"[2,`/
M(2``AVD$.."XL1L`/*`"OG6\CL0](3`%>>`*%<`'`<!F99"%9\`&+A`$Z='_
M``N`!F^``T-0!5R@`"(,KS2FKAC9!E21`=+B#?'5#6PP*UR\9]T``583%T[F
M17V4D2@<5]W1NV5@!PV`!270`X>)!HMJ!@W@``Z0?_<8`5,@`+M0L&]0!2@@
M`!^P!1:``0Z@`WW0!7A2`T4@`#RP`1(0!%O`!2"0`UAP`08P!4A0!710!C?P
M$'`UPII1PC9V`(AE">#@!6]T#2E0+`?0?.`0`H]<!0ZP)@S@`XB`.ASYQG!%
M-G]@`H>@!@AD!UI0`6XP`CW`5"9P!Y>0`3T04!F@`I1Q!_X:`UH0`Q#`"3V0
M`#OP!A$0`180!T80!!"@!G<P!QWP`V_P`4E`(@"0_P#WR,U7C*Y9_)<'H`.W
M`<M?P`$UD`'L2`0DX`9>(`$<L&:&LP`I0"*W_`DIH`(B(+D5TAT44`"9(,QN
M_+/7A<4F_$X[4P="H``GT`?$P$0+T!0'<S#-<`(O[0`$\-*/Z46!(@$"H`!F
M\`8RP`<<IL6P>``AT`)H8`D+``-KD`,H(`%-L`94,`!>H`-IT`4V``/U%0"X
M/-'P*0%\P`3=D(*38`:&XM$82<PCO5U!A`241P8%$`<YBCWDP%@%X&D;L:DN
M8`%GP`1SX`96X,P>0!61P,HQ1@X5X`&P/`(\H`,.8`<7X`4(!-FR4`82L`$U
MX`%;W7PL(`6,4()^T1T'P/\&"#!N=OV*:'U7,F`)%E&.B,`#=18!X1<B0V`Q
M((!`/``&OD-6>0(!*D``;A`"C'`B9,`!AZ`'09`@(``&)"(!,Y`?>;4S"7``
M((`&9,`&7E`#7+8'Y'`!1Y,>4E`T8R`M.HH(>@`39\#9C)8@-=`40H!?A`UC
M8J$#76`&/Y`#7T`$#F``+,`#4E`#LCS99U"L:I#9"#`"5,!E01#6H!V,%#!?
M,7G:<O7(#G`(%?`"Z8$"-"`"9F6D5%`$$$`"_OL'1+I0+/``G;,!)]!//T`!
M!X`8.@!P>A``5_!^0$`%"9`""H``QKQ9080'0:`#4F`$<N`%4Q`614`.+]!:
MMZ'_`+MS`-%\UZT]:[R0`S!P`@@T`&!M`2SSWBPF%@8P`69@!$)``%30!#[@
M`D=P!1+PWPX084QP`')`X&^``#_`!T[%`3#'"PN.FGY0VDH(X7'E`!LP!IG0
M!!Z`&G@@`.CS!UN@%%R@`CQ!"65@`2\PL8BP`S=@!AZP!",@!!V0!##`!RRS
M"T`P!$50G7_0`$G``A*0``FP)I&U,W:`)E)P!'%=LG-]#75]#>/M1P3!`A3U
M!S&`"KC<,T+]BKD-`"8`!T,0!`9P"#80UV*0'G/Z!VD0&6A`(D],(FQ@!)SP
M!U;@1$2)?+G]70\.TI<5G='E`'5A`B/`!`8P.5;`A7]`_P?Y,0$1U4IE$`('
M4`-30`]AT`)5H`)*(`!5\&LUH`!'*&\`@`!AP`!HX`%\0`&.:P8*Q./2<0`)
M;@$%``"W?IA[HNMVW>L]L%0[,`4/PJU_<`=]DP)]Q.582@!MC*6`#E?OA@@1
M$!M^D`=V``0PD)?3L@8W;YAAX"H(D!X_8`0@P`1GX`,Y0`3^FN&(H`8.(H-Y
M<`%A(`9M@`,^X.K%$NM!E`=/H``"P#U@P-(N_=)](],OC0A"CP@9\``Y,04*
M0`,)HL.7Z-['GM8]6_-O=?-_@,-AX`0B$``U,``E(`=($&4)(`5`\!6&F0*X
M)P0`@`1ZT`!`X`05(`4*D`8=`/\#+4`'2$`"7+#18K`$!8`%:(``4W`#;5`"
M77"$&*\B23#+D6`!-"#8*[CW?!^S?C]/:?EUZ8$'?2`#..@#9T`"/00!MH0(
M,3!&,?`#8=`&@G4$,S`'$+`!&8(&-7`;)$`&1&(`/X"#=[`!0"$#7_"1L[\<
M=2"RUV`"_6+LO=_[OS__HBC2?,G[]A^J]0\(?X*#A(6&AXB)BHN,C8Z/D)&2
MDF!^8)(:9(008X4CD@P'DZ.DI::GJ*FJJZRMB`5^?BV)#K&6KKBYNKN\CI67
MD'0-P'\64UZ$4**1H;W.S]#1TM.EL+*TML34V]S=K;^16R?`%D)6R())'<N0
MS=[O\/'_\O'6LXBUL=KS^_SOX)!HS`![@^8+NC\:PK![Y*Z?PX<0(RJJARV?
MQ(L86?V#))"004(*02W,2+*D25X4[V4[R;(EHHV/.@[Z."@DLY$N<^K<>2CE
M(7RW>`K%"-.13$$T!=ELAW.HTZ<7?1H"J@^J57]!(1G05+/3(#9I1%X=2W:>
MU$)4RZJE5G1;P[5PX^XZ2RBMW+NYVE)[B[>OWTET!]G]2[B4WFE\"RM>/"BP
MH,&,(R\Z+"VQY,MW'?^!C+FS(,K1+'L>?54S9]*204,3C;HU3],K75]6_8RU
M[-LG85O$S9BV,]N\@TO4G57X7]^]@!M?OH]X5>9QD?-2#KUZ)C?GUO%*WT4]
@NW=HV+_#W:ZKN_CSN<*C)TL^E_GU\%,=`0.F`J%``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g06286g0628609.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286g0628609.gif
M1TE&.#EA3`*@`^8``+^_OS\_/W]_?^_O[U]?7\_/SY^?GR\O+T!`0&]O;Z^O
MK]_?WT]/3X^/CQ\?'P\/#Q`0$.?GY_/S\_?W]_O[^]O;V]?7UR`@(,?'QZ>G
MI[>WMU=75]/3T^/CX\/#PV=G9Y.3DW=W=Y>7E\O+R^OKZR,C(Q<7%WM[>X>'
MAW-S<[.SLV-C8S,S,TM+2X.#@SL[.ZNKJS<W-XN+BT='1PL+"P0$!`@(")N;
MFQL;&R<G)[N[NT-#0Z.CHU-34VMK:UM;6RLK*Q,3$PP,#!@8&#`P,.SL[-K:
MVN#@X,[.SMG9V='1T:RLK/7U]?3T]-W=W?W]_9*2DCP\/-34U,7%Q?;V]@H*
M"L3$Q(*"@CX^/BXN+@```/___P``````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````"'Y!```````
M+`````!,`J`#``?_@%N"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^"
M``*CI*,$!`(,"0D!I:X"!`&R!*P$#+*XN;J[O+(/`5H.`0\.Q%H&H,G*R\S-
MSL_0T=+3U),"6MC9VMO<W=[?X.'<#@O5YN?HZ>KK[.WNDM?B\O/T]5H/!8\&
MH^7O_O\``PH<2##3M5^^[ODZD(UAL`.]$/::2%$7+0:C]F4#\`@!-HX%0XH<
M2;*DR9.?XFD!V<CC2I0P8\J<2;.F.94L&;G,:;.GSY]`@]94B<S13J%(DRI=
MRK0:SHX?FTJ=2K6JU40J&T!]>;5KS0X#+'@=2_6IT:ADTYIL<&`&3[5P_WN:
M;8DVKE<"6D-&>,$AI(:^=@,SFJNSKN"J`12(K/#A0\@&B@]+-D1TZ]O)2V4Y
MX!;`P>9MJ%Z)+M4``(`&!O:97LVZM6L7.BIL*="B`@I7,[:9$)##7K<8,S`&
M"#&ZE`X`(`1DL``9L_,M62T_EQK@\B$``PIPU.ZZN_=<&S*TFC$Q!(`$&_H&
M$,3!-84*"RAL\2!_D^SVWE?/T,"Z1>3IAQ&VR%$`9F;=/QC8X$)("?Q7H%T"
M*D+@@TA5)U('`!`P04$-"$!A8-&=Q=6'0050E$@_2,!A`B3&I9*'(A[8HDRB
MS*A(`RS:R-0"!O1#638PTC6BCC4!X""1@^"(I/]0`Q#`T`$'(/*B=$O25&.5
M2>:()4T&)(`-`2!IX2,AE<6XI4P6GJGDF2@-H``##AR0P(F"&'"D("$**2.;
M!`FP9XNH\5F2`DX^T.``UZWW(S9!%C:DH"/Y&5@!&&"R)J0#&4"`%G+^J06B
MA30`))68CF0D-`L0L$)!$33@0P267%JJ.P,8`,P!!N3C"`-W`C"JF;.*=*4S
M=RYS`F"5G+!@K%H&JXX`##GPYR&P&.(KHZ0Z.]"PS2@@P*K.\'K)">8QJRTZ
M!<@R)ZB*](@(`^R&\JN>YQ*4H6G[9(2OM_GUNYJN`"PPP```1+D`!Q-(0,(6
M8PXB6P<C2.":"C*8QH/_`/PE-TH&+[B@L2LP7%R<`")L@<$,$7BK0&G^4G#P
M"(+(6F\T`\#)",&LX//ND==JT>B`ALWL#P`!T&(T*[BLDO0M%5'48\!;M!"$
M%C3D0,,+-G!3`@T'T-`9"U[S\@-N(#"PP<BB%9#!*"6G4(ZWHZS00MQ-!U!"
MLT(_HP`VBA"J#=YDXMWSSQ(&G7<[W#*3``.RA5OL(QK$"7,E,A_.#`-!\_C9
M-O&FN04`#Q0R>+:6LY/X,K*$\(RXE43@@@N34U)YZ<EDH^@"`CSP#9U;/)"7
M("82,CJPM)M.^#(*3*L)Z[$V',GLQ7>".38.I*+[-Z$3LBD!A#3`_2##TQO]
M_SJG+S/PZH]#TL&&E`,^_B8+7$_/[UL,H'OVH3@@_+R.*O\^,^6;"?.J88`4
M_"\EOBF$E_A&"&F!SW:D.^`T`BB3`5*C``R08">`48^?:6-,@9(7MHBGP0D>
M;R8R2-\STE7"3?0L'`(HP/>2I`U%"6(!6G@@-FS8OQ9>\(0R68$*G8%!'V9B
M`-A+0&GP-,/Z;8Z!@WA`/WK&0Z`]RHC-P!U).-"X15AP&@4`(A8?\42%Q+`0
M!\B)2K*A*SSEJ``0).$8`>@_=F1``XT(P1";$<9G).$)>=O4/3`BI28JP`'3
MVP@A<"@()'XI@G-L1)=&P8!8.(T54`J`0^XA#,TT3?\`%3G%*!(0&K2)9@6R
M8`$.<L&"'.3"!"70PBI-\`U!:F$#X8B!`""PC1P$`0A!B$'36`"1NC5M:MR@
M@8H$08!XG2L5,L)AO"KY0FR,R0'("%\/(QF)!90F`:?Q5ZI.HX52OB).FX*(
M_+1Q`%A()"+!D$4L@:"%6&+#EU1K92\^L(,3C.(#P:B!%EC0`Q8\P`8T"(()
MB+.!7/S@!#T8&RE2,#=7]"``+4B!#T9!G@WTP)*LU,(+6%F#'OCKI*R!F07J
M\X(N-O-PSBO$/H3W`.QP@TZT^%PVFFC%.G*3$%5$Q`#6@\-BYH(!M]#=9M39
MC4X::F2Z:X4`<D-/>VJ!`;W_H0$+,/(*5(8T&PG=Q@&<.0@=E*P1&&CC(B16
M'T$4``+N(P0&Q#*)#9SHI1(<@`/B=8"\)/*1X%M/SWA:N"O^M!%!O4X.B78+
MD.8"%8XU)J<ZDPW/:&$8G!*H2#5;V8(2@+/8"-L/5,5/?[Y"!"L8*R(*Z(@0
M3N*M<<W$!>Y*UNAYB1QUPJU..==`T\11?(>%1&*MM5@Q/B([CLC'"G+B`0"0
M``")W*1)9;`"("Q3DJH]!`L;X5I)&*`&L<7$;`>!U_\-8),,2-?O'*D-^B7`
M3[_=9G`?,5S1%3<31'-$`$1@IRTT8`,L$``,,(`-Q<!`%C4P5`]ZH(,2M)41
M(<BN_R&VRXCN1@(`0L#;!MB'B`J`BQ$IH*T$1;4-_1%BD]A:P`(-T+/P%F)"
M\T6L?B=YQ/H68@`N"``#3C`""RQ,$!(00@QXH``3%(`%,,!!"DB@`!L;@@$2
M+D01N:N"2L"V$/11A`1BMPC7EO=]Z[1F(=88#%L&@&#Q[6F,Z=O:JZK5$BXV
MA`1"P`$+`*`^099!"5A0SQG,H"C00T2$:SN;.,>,T(VX,BCL2EY$'X[$VLA@
M(7#X#<50$9)K/H23!Q$_^$VB`D`PP(8-@`,6F$!%*<"&";2T"DB$0`N/HW"7
MJTP)12>B`?2#!*.9Z>B\E3&'A_AK#6^8YL+Z-+B;%D2K-?^1@`.\F;LC:*L*
MOI<>(=!`TEM@0$P3D5I"R_I&792$K1$A@6TSX@4B?I\!N'%",F<#5.Q-MB!@
MG.E$)+L`4>)$`9[="!'L@'T$B(P.:K"`#[2@!Q,H0`YZ+5-8(^+;M^8=),;=
M"2\SO%[CX/<6]L:90<0;T_4&:B.6K8D"Y!H2`MB`6%K`$0S@0#$$(,$)@+`"
ME<O@QXQ8=ZSE;>&)P[40('CP(3+0VG2K.Y%B%+:8"%'L1-`[Y(;8]`*<S0GD
M5B(#!+B!$`8`@Q(4Y<Q;T$`.`NYP299]PCR7^",HWH+K(H+HW#7Z^]R$.8W'
M3!L/P+8@FHZ(IT-=Y(MH]L63*XS_DT,B`BFH@0I8`)@(@$D%'^!:1#W@")T_
M/.U6_CDH+-Y"M2_R'F`Z!-\/X?>_`X\02A^VIS'!2QS8TP13\UJ57]`"?9Q=
MRIBOM>83T8%P0X+S,<:?Z+,!\K\'U32$:#(G<"<`<S\"`AM(P0\RP$^)"F!#
M^+;]SHN>>1<K0'63:(!C>#TCYIM2%*8L!4:<#PEM%!_JQV<)P1C@>2OOT1$1
M0($%!.P"4G!8^Y?G"`I0?XP0`7*2#`VP+%OP99+Q0O+33J!D3$G#"K`P&H8U
M":-G"*5G>GH7"B=R'@;0@?[@`2"`1Y1@>=HE;P5`@(R@"E@F=(:`+%U6>^3G
M'"^$=+5S_VR(D($O9CBFAR?6$B0+<&8!P'X7]@FW88*3L&Z>YWC)Q8)>A#<$
MX':&X&&ME6\+.'AC44W\TPD7*`D\2`@;^'>$PRT&,``-((*6`&R=``*V`&<L
M\']DDEPT2`E0AH!RUX#;P$'&M88Z>`B;]'XA1P`-,P"-PA%(9(2/P(:<<``B
M<%:4(`$$`'>%X(2)-GYVB(6>P!:-]AP+\&L^DPQII`D<9&+`]8.$D`#.9(8;
MQRF$U0@"$RJ?H`$H@'.44`$.((>SL7")!H6*<(>*4`%]N%I8R("'\8G=,(R4
MX$"9L#F"6&]E2#BPX"N,D"ZM@%1%0TJR(`!(DPJQP#3;J&-W<O]P/(`($2`;
M$6!WC;`!M$8("G=Q*V@)P/@)V5>#F,&%V`"!(\,RJY$OE%0L2*2.D.",<H2*
MT!&$E.$AC/AP.^0-L:`-F[$Y`N`9J$`($L`#-M!DM84"-J",P8@#<@AQB-!S
MD#"/GE"/6>B):(-4D:5C[I8-#U`LA_2*RTA\!8F*Z25ETJB0C7``-/D(#!$D
M,A`$.*`!);`#5"@(&A``&N![D]`",(![E>>+B6"2"[@GUI5HQ:B%'V(`8;93
MAS!4.K,)[G>3/W@\SC,*6V!4)Z=)''0)P+`>*1`$.U`I$6`#<=4#'\"4EH`!
M*6`"/"4!AC8;=3@)5JEO6\DF!H!B?\/_;]!B>'!IDZ=HD-GV9IIR)&II*+3@
M``2@5I4D"Y!)7Z>@"C#0.!50`PR@BUO``3?P`Y8``3%0,;8H"#\`*XQ@A95P
MF)N`DL:H(S+D#0^@=K:2``))"1RTD,9&F4#%$VJGEFPH0YP9&=BFAL+53@D0
M`4BY?SJ088D@`<6I"+OW9$88`4J8B8L@C+5F`@#'E<YAB%_Y)<\V``G@`/=G
MG)(I7\KI.<##C(/@G)01G38D;_;F`.]5`0'@`DMY`GB9#.%9"-IVFR6``8KX
M+IIX"!'PA[S)GI.!0=YP`#+Y`#])BMDPH6,(?SRQ@KSCG]KE.U$$EVG4'=R)
M"#@P+1(#H^E3_YN-P$7M*`F<"`H9BB3'>5-A"243:@G'294E&G+Z.1O/IJ*,
M@)R1T!FP0`#`@0T,L*"(`'855FF)\`$7YR<R0#D5B@*4IPC?.1N):2,)\)X.
MT`"U=0WUB0G'^8R9MJ2FX4Q.N@A06IT+```24`++%&11!E07YROFT1I"D#X/
MR@AI%:>&T``.1@@^M@B#]Z,M`ET.R6]-1HC/P$'!:9:FMZ3K-V8\V0A[2E]7
MY0`K4`,SX$^)-ZB#H*6+X"L2!P&AN:B+8`%G.I+JZ:-I2B%H^)XL:@AHB"O1
MX*G*F*3UMJ30@9FER@C"-PFQ,`@.`@&P*@@0<'\"T`//!@'UAZLW$O\"L_E[
M%7H=D7AJ]E@@Z>*0B#"$U(DZ]ZEFR@D\E]$P>:H(LFH-P="AA$:?U<AX#2`?
M,,!G`]"@A'`#MKD(&.*4C]"CBE"D4O:K`$(`[YD`VY8['KE!V8"D/GB6;_$6
M]VIO?P@\Y00`*`!K"+.6UYIM>Y2&$O`"L!8!$SD!!BL(RP$)@WD(#GN2O9J2
M`-(`[ZD%D.F5JN@47>AT'6MZDE((IMB?S[H(S%J26L`*+<``,T``*1``-9"O
MJ!<"CA8!,:`8/8`"6R`Q=%:S&Y<#(/`(#-M:RB2IXUIKGY*N&VI+[*1VHG``
MG)E^H@&Q[3*BH$J&;X&<U7*JA1"UC[`I(&'_`#/P`CAP`@'0`X3V13)%`!00
M`3>[!7;5`6A;`/M1>;'2LX+``V6*"7<)*KTI&$%J.QKW``?`57Q+&@P0FE$:
MK\DYKU=I"(3K(5*$6".[!<``$J\V`P*P`T$@81C0`.SS`S+RLEJ!FR9S?6AK
M`3FF7[$RMY]PNG0K&:N[0\E`2)EPG"2:M,8WN`D)O-."N/J576;%/M:**!$`
M!":`5(+P`>JX*6=S?8:`MC:KE=?;:W\89*BKH5?1O9>5#&J)7T?;=^0+=>"D
MNY3!(ER;I;\K"X@``27`,3@@`"10`)&:N8G@`2X`4)@X"`>(".O3""_[OXN0
M`02LO3[K''8;AI7P_UZ:H$VW.Z]+RW2&H`"_$*TB:Z1C60B\!`0(:D`1``$9
M``,-A0OE>`@#JP6'RAHO$%L-,*$YH)IM1L`JO'7;>Q@&G+&1`+Z8@,-(^X5D
M*''(V3/Z5<&&Q1"*40"1<0':@`.T%%<-L$J\P`(?]J@3"@%<[%_8"V1Q2P@=
M`(,7/,#3L4#<\+N*D,"8,"63:9"0/`AK;+N(\,"5$+R+$'""D)6"T`$RB\<F
MU1TC4%^!1L2!+"KQTD>*``/E"9Z*_!P&'$\3<5FRH+=1-1'1,@QBG`AL'+A0
M5\E[1UQ0U,F_ZR5[TIDG``+.Q@V02;VBD0.@=&N#"<B4,\B>``$@D;J!T?^G
MJP'.`H-2Y,P:`[``?@O,BC3)J"@`)P+.TF(:D$%.Q/"=ZML(U[`G)3!M>Y,A
ME\``^362U[S*VMP)$*`KWEQO/<.Q:#S,OT,HHQ0`JV`*EQ5ZC'#/@]'0$/`!
M*L?-W'-'`"`R39P+3VP(TH+*@XD#2=FP!6T()Y"PD8#-,8R*/:,\RIII[DP9
MQ-4*Z?N[^;P(@"P``W`!_KPW-'`"(H`!UX<A=^:"@&@KMS:A+(#(6\R@LVR0
M9LS`#1UR`G!RE_P`.XRO/JW1+[`#0^W/HO*V21("(!"")]0*J!RFC2#3X=?2
MF\#-7PQU64UZ#<S5A)-8KMC3EO#3BC#5!C`!1`W_2U13`_'"`04@RAZ*".V$
MTHY`USRJS16PMC="E7@]TS^XUQK8U]#XUSSA*[\P+39<"82="+%0`S1@`P3@
M%C\0`U%F`"\00Y:->M4LT)5-T.PI`3`-GI&1T)E6T\+LUU''$SCT)MKZRV32
MT`D``[!-U`1@*S+P9;9-=`?]+KNMLX/9`K[-H,,=R%ADW.Q\EJ0M.OHS)_A,
MNSF'QC)+I0E`U#.P`TY2`FH%`#M0:O3'W?6E`(-)W#=BUX2@`5PLTP(>8SWS
MKCVXU:,==6^67P'@WGCBJ*(G(S=@`C\@`Z_M*UWMDPXR`C<P`#W@U$_6W1,6
MX(',A(N0LD_9S>1M1`M^_]P/?K@-(^&^2,R1L&Y[T@(S,`);%=L4P!:>/`@7
M&@,%(`/7*AS6[`@)SI!MFPG9FM<A!]H-[LACI.-VNAX3[KN7`-\'$`(`U@`Y
MT`(D$()%+@@1X`,^H`$%``0QQ>2(<!Y.'LA[PSOLEXZ5/=[*:=I@3>,X_=<W
MSN6^B-%/2H`88%<8D`,SX,$MT``ID.:#`-QKJ788P8N'T"5U;F7'(#J+H.>-
M4`)\3IDM!NAKIN/$*3KKH>/!9N&Z*T;$(0`H(`1:P`-MD0WI0W*Z75\%$."[
M.F&=#@K^0>4*3<-;<--KYBV&@,[VM06IO0BLWGYBM&41``.\E`,U@!U#\(4[
M._\(&!&'#Q>BVN/J@P!'5#D)4^[9IO=QYVUZB0,`J:'JP#N,%.0(H9@([#@;
MO%2PQ4H(*+"7]O0#R4%6O`*N[BCNY$7N;A7LB8`!L9RXHX[5QH[L"LY3Z'RB
M45*1^&P)'FZF518!(#`$_.X]&K`");`;I=D(*Y`*VS9EC"#ID6#NR5#D3QY<
M[(Z?I/XS*J;&T%$TLY`(,[6&8-(=(``#&8`"10\`(K_1,9`#.R`+%:7%A2`#
MB]/R@TFFC#H*=%7N#.]65`UD7*8(-!_C1I0-#"Z&HEW<QP,X.01*O**WUA'M
M9,0`09L-)>```K68^?@YDD`<!F]G"Z`#9[\%*M`:/)#_`=YQLE,K95WO["OM
M,'TL]A%OD&9OZ@JNC&U_"IHTBM3BW-JS"QL``'NY`3=0`@TP'"Q@`+Q43Z:Q
MEQ,1'K*P`2B0AB&(^*Y?`K(@`CH09S>@`(TK"P`>`':%"^;A`]B`-S(/"F,_
MKPUA^?-U.LS:]@VY=)W_SXM0`&'C`W_&`2V0#2"@`@)0,2$]"C`P_@*@`RP&
M`"]P-CF0`(@/`%SF\IU<G$H]NXQ_[I(0ML1>;Q,/"%I:`%N%AH>(B8J+C(V.
MCY"1DI.4E9,``8D!A(A:6P("A0,#C`NAEH:9C1(."2@[+(('-5HY`;>XN0RW
M)B4XN!L]03(`%(D%!Y$$"JA;_P5:!HXP(*@MS%L$I,W;W-W>W^"3@EJJCPB"
MG.'JZ^SM[H68B0GIAIZ@D`"GS>6,!"8\%`"$R)"BAY80`!(F!`$#@(@>)6*`
M`E#A$`87*UCTB(`(F;)KEIY%:]2AHB4"-PIE>\>RI<N7G00YB'1N$,R;.'-Z
MBX=(`+U"]O@U2L"-P2.4!PPH#4```S1$#`2].*%A2P@,C"24X("H0HR/S9Y]
M<$>`@$IM.M.J71M3$$UT;./*U<GST+U.A80RTDLI`=I%*@B,R'$#QP\*SY))
M`/!"RXL`$0[<\H#!V*(6*1))F`$6E4A$Q1P1A;3L[-S3J-N-XZNHYL_4L&,W
MTV?H[O\A3UM8:^*VR5$!LQ8@F)BP18$6$S-J),A@65($&PN.)8-4`&0E"4/&
M'EK0G%M9T[+#BX>T^JW-\>C3)QHPVB[M0JT$M'>D6UGT1L\&P+!!(P.(#UHP
MH`,)A?RP0@,1\!"`"RQ$T(('BK@00'>%>-49*A>X0%9*V/REWH>RC?.`>:^!
M:")J==4VDEU:.%"B(O-9XI=O!ZA00@@WF!!#"%IH5X@`'(2@30<$HD`<(A'@
M<!^2]1VB`H>61`"!CXM$4)4E(IC5X8E<HE8>)*YU*>9<*>;UF@"#O+>(*;P]
M\DR`#1B`#)H^'J"`!@8DH*!26QB)B`4^&*6(1Y"H@$(S%=C_,!TC5GJFY4IC
M1JK3.+B9`Y>DF.)4YB=G#A+CFFI2$H"'QPA"0PF.I2"$+#7@4$(`#N3"`BW'
M!4&I($LB(L$(D9P`I247++K.;^!E:NP[XPC;2)C'-NO.ICXE@J9\D0C:#`&Y
M+H)"0S<@]-\X)@!XZT'B:D&``Z"D.P`$XU*J)7[O`JLL`$<RXN<C61;K[+[>
M)$LBOP"#0UL#3!'`@``/!'!P`%H($&\C31XU":%;G+"%#"9D4(D.U'!#;#/!
M@E:OMB,S$IB^`:<\R0,LSP3FI2K'W-<A`P!@@``%;)%0S@($8!M]O.4<"<4[
M&,.!21,_')+2DX3<3KY;RBPU?8)$_UP(LU-GO9>T:DX;JB)60_SBH--A1ZHD
MFU;R,8;*AO,QI%K'G9=,_\IM=R&?_OQCPU_OMDUO0T]'L24-6!L6TY(XS<C@
M2:-\M\P,N_7R>8_'K;3>GYC[Z2)A[S6V=(5$T+DB#2#>.,AM@_/VV94'[,`X
M=;>>]:?Y2,O4YF#S]GE'@J<N20.XG\ZV.ZO++G7DE3J"M?$R=]TU(89#K+LD
MA#)."?#=5+>-XH4P8)TB$+#>T:/B,W\L\K&;K[*:-TM+2-\]31^X(=%3DF?V
MID/"O3K%JQ\P^I/;G?\R5;]/),(F@',$_""10#<M*@8EFUCPG$.E2NS/;>0;
M(,``:"G*:?^07WII'R)ZTT!&+/`1)<3/HBY0/M_D3Q+A0YTC(N`#1SGN@YB*
MG.\2L3P<-JM^?.H)(5((HQ;21X"&H!@+PU)`2DB@!Q1J&@TDX`BNA.0`Q(&;
M#S,5.9=U$(E;/-$)?S1$)#Y`:*@@XB(H!L&P[)!Z+W3$!;1@1%14H`:DT&(8
M(Q6YL/5PCY*JWRW02,;<('&,8IM$.8!`1<^\<6AQ;$0*Z'@(&*C`$2EHY"-B
MJ$=`=BER#ZCC'STI)J$L("'9BM:,4"@_ZBRJB4.;("2WT0!*&J(DCKA!!!?!
MR3J24CS(0^(H?WDBH13```3XB2KK&,E$1B("0+`,(P^'O^T]<AO_S\FC+XD9
M&QUF:Q'#Y.:'^-(`0G+*D)!`I.<F$<,M+-&1W9#`)67H"(V%A)*=%&=Z(D<`
M<X(39OHL9B(`\,UHJ1$1V-I&,MFIC7=>L1M&X@XJ&M-">UJBEP$UD0[3E]$/
MJ8DI[CLG"L&X"`$T(!$6B&(AVNG01)#``)K4S`M4.@D#A&`',9U$+;=9"8QV
M5#T<5!Y`?YH>-=E,F:&(UDA-N$`!K,@0(Q#`#'*:&QT(0`,;$%\(8N#/0[1Q
M&PDPP/=T:LM"8.!*C+)`)'Q*U/$@KZL\'&I;Q:/40RC@J9_(1%T+L0!_'E0!
M`OBF7?#J"!Q(H`(&:$#Y8&"Q-5[S$17P_P%64+'32O+`$0I0*R38.E?9!#.`
MG4U/`@1K.VPH``!HC-5]4(L-@C:"$-FJ&7M\DI`!>&!D&%`(15A``0N,8`,J
MT*UNC5&`!2Q&N#:[P6,=(0$2D#01E6T'9T.;FL]^D;KC(8!1$Z&`3"BLC[D1
M:\\"D+`''.``[4I((0H0JX3%"A<.($`N`@`"#P!@!!1(P7QS0(`-6.`"(5C!
M?&\A`09,H``1V,$)>I"+%IQ@=(Q`&N'*NH[I8G<NUA6J!R^<&LS5KV=;8,!K
MBCO"%]7L`"<UX6OL>X,H0L`"+TB!8AEQ@AJ8SGJ6V`!-(1%==EB8PVQ)@$R$
M*5<@RP5S>@'Q7O_7R8C:F3#%B>AD^`K`@`;LTBZ,$H$WVCEAGE+BQT9.2U2*
M'-<-ASDN2!ZH=Y&X@!;"-5-<KD2/*ZS-,Q]Y'*1%1#CMG!,/JQF=,N/`E1_A
M`"\?P@!:(.0T',$#"&TV.OGD\TW01&8]5UK2D^[:0`\``$XWKP0<L00##&T(
MXSSWR\R(-*9=0FDMY/D0>UXUJPE+.T$\X-1<DL`!U`D^4A=BSNJ`0*I]+6MN
MM)JCQ9XT8?4"@''@VD0Z^,>.&4CL9K=P`U1=Z["3C9-6OQG6E^:V.Y:<FX&2
MXZ"2LL`/>M"!;AR`V,_8'0P&[0@11TW<K'8V:/$]Z3.5BBG/3H\.6)#_`GI+
MXMUA2;0[#I`S5?,['*TFLID?/NXEF2)=&`>%(.;AK,WL0+-;AC>%(["["(#<
M$0[8-L7?$?%]KYPE/TO(:0%0,X5L/.#A&4$0&C#M2A0ZX;E"+',)!`GOW?OE
MZVCY=9'.<C79>SOZ-A8#7F#%<(PZX6,%A]$=SO39V/K5AHAUU[<APD.DL$4N
MRI0&=H`"HJO#Z)[10M8KV6Y1JWSL`L.SR_$>#B>;_35:V/7<020!$<3`T>R`
M^ST'7X@4\,KN1^>[L;^^=\E[`\F`WS6O8X.!%M3P'0'X-F;E[HZM$]OR+`J0
M*,.-^DM\]"?/$.EX/.#V0_#``?-\Q\_CSOBB_]R]]:AH=23%#GP>OQXT]MB\
M3@P"9;/B(`&U+[W(O[>[M=7[]\6GA-(UC//L%Z+LADCH(3K]">6[I-&%4$`.
M7-#8+5@@!`>00<^UCO-G]'X;IO>^)5H]1N+K?Q%^EPH_$0^8PQ85D`*ET0$!
M,`(%L`/$P0$SD`(2UA**IS:DUP[Y]W^3T&J$U1JLIX&*$(`J,8!Z97XL\0(Y
MH``2H##=LP`:@'LY48&4\`R_0CH=6'38!X*-P(&5IX./``#UTV:@,2(%R!82
MP`(HD``.F'Y:X`+SEWCWMSA:<"@8F(,^J`C\UX-7V&1"<3/O$7M%R!;/8`)H
M)"6GAW]1N$87"(61M_^%TC(._?>!;E@F"K``WY1\L>$",^`#&U`O+743,C@)
MSV$=$7"#AE`!5/@(&>B&BX!H@A"'$\>(H!$]WC-6>)@:=V06"=`#]T4!?P@3
M@<A.A&B(E;"(DH@("R`3PR>'6RB"SO`IEY@:*C`#&8`J@N`JN8<3H1@)=Y2&
MEK`"T<!U6TAI:;=TIPB`L(07`J!Y3H4:["(1'M`8PR%F]Q<!H'!RSK"&52)Z
MC'`_PGB%V[<LK'B%9;(`">!/]B`(B%:,<B$"*"`(_Q`":=$!`,`0R"5<%?`F
M,?(<B;B-J!`"1/&-/IB%QGB,?W8(!'``L/@)92$9Y+86M11X:Z%?`U:1/R#_
M+I\"`9G1#@#9AL?8;%6CA0:I,WJQ`$KC"<8Q"./8$C!P"RL0%P6`C8I0`;?0
M,8<``?TH`:(G`3*Y""L0D&?8>JD8D@4YDH8P`'Q!6(G6,P;@,S0'&^VW%F(%
M"1%0@RL5+Q+0?(J0E9'PDQYYBD-)#B)ID&FC"'1D`,D(D\O%$@P@2Z$3E88`
M`<UD"1TID#XH$U;C?ZV89("75^*!8SFQ`FD8*G+)7*'&"!P0?=\'E$9Y&X*P
MBI%(EGJQ4,H(83@!F#@A`VE(`!%4F/A!BEN0`3WIC4'9>E''?8T)&GQY0'X9
M'IAY$R&0AJ.2")[)#J29FD!!E*B)F^NUFI7YEVOY_P[WDT[@,Y>5<)NX^26[
MR9M;X$6U`7BF8)PY(3IR,9R*2%6U"0^/L`(&MYA?>8J/"9I7LY(^V#;-B`CH
MQ0!I&1?3Q!;621^DDIU;8$0>\(3(F9K**8Z1:9!)]E$M8H(P431Q\9Z-P`#8
M*9TUQ9C)*0A:^4_[>8S]J0D(`Z`NL1G5Z98JT9DO%`&YJ`BBJ0CWV9AP.);\
M&5(CQ#?`>:&1D``N]D(58)6(0"0@JJ#X&2OBN05ZN85APS"W(![4.:`W:D"T
MB:"2$*)&F9^,D*,^B)2'<##R)1],`0JODP"6J8O5B4@&.J2(D`$MQ)V08*0C
MB9<D"I8A-%8\NIYL@:8M0?^@>Q&?#\.ECE"?7TJC(JJ;^ME]^N></_)1\M6@
MJ?%54HFAN>&F[F``[V:7.B@+>4F>.M@VKK@)8BD>GY@3;+H(5X<(\JD9C\<(
M,IH(R$0!B`J"2.J@>.I](](3'\4`WR&II>DQ\EATA-H($:!EC7`G($H`H-JJ
MEO<ZD;J<O)D\>ZH)VG6JW]``3PD.D\H-/V`HW5D(&K"1*!2KMDFG1LFKB_J@
MIZBGY:<)">$`IW2/X!JN-&>2=BA<!F`S`L`QQ"`"(@`"&9=Q-S`$&?"N]%JO
M]>H!;:8"$S"OH`!8`D`,#&$`*B``*;`#7@@*ZXIQ.L`8TBH)'&"?U#J2O*JM
M'HC_K9(8H24&``_07179L169+K_AK4"H70F@7?9ZLJ```2&`LBS[K@H@`T#`
MF?R*L@RP`2TK`#%`*B7P,.+'""V0;9Z*JZ&J@:`TIJ?(;*]7EIXQ`&!'"6HJ
M:D4JJ+.)4$0:"6LG`4/[?PS#,D8KB<1:&TE;I;X1#LG:#75'E7#9IE%6M=31
MAUFK?UO[6$KJ@]IZ2MRJM.9#H?X`M(8@J,>0LV_K?>BE!5^;I(P*@FI2`*[U
M=WC+/!3:`E@TMFDT`(&;?2+2M8P80DNV">P11E-K"3%`8>HP*I5;?*_S`!1;
M9J6:?4K3@9M`?EN4I:BPJK=D<(D9":2KJY+'3YCKAL"J_S-/)X`#$)S<1``4
MA@$M=+O45KK`MU%%F9H[2E"I:SX]4`$3.`G&J[LC1+G:BW==U+LZF@A"6&+E
MYD,>(`-^J@RBFPARRJF*F1?<RYO@];PB:J)F%PUBFS4@H`"O>A+KBP@_VPB+
M!C;QBYM!9;@6RXB_N[AFQPSY.S7'Q+;9ZPZY*[\M\KL5N[K%QQ=^=5(//#4Z
M>0@-$`,I85_%8,+"-0$3+(COJPC9P+RM=\"DRIP_4D<^4[X^9``C4TLF(``[
M<`LG\,.X$`2/$0$K7`@<XPBQ&0D]8)+=.W;&*SF^BIM+M@"$I5TXC$-:A`$"
M0*N6J@U'O`[>`\.HM[48K+HT+/^DXX>T6?Q!ERH)3Q?&ZH`#`$#&EE>T]&N4
M.*.:FH"_GNMEWJH2_WL(AH4?7U/!!DPW>3R21B5(?KQ%G[M68#S(2=0,.^#$
MO$D`#R#%=YK&`N`A=:P)#OS'7S;)3UP(=F+'DC=F9VQI">R&2[8IF*``TVL^
MD5QT]V&\N6(!:+5&/:D(*:?*?(<\33NW.KAD5&9NG/Q!/W!J<'<"KG8((V"3
M5=+"B3#&I\QT#).0X`N._@8:!M/*YK.+C`!W^5%Z"B#,WJMW4YR:Y*8FJ8BZ
M8?3)E%`!$B4""E>K]%:(EIK.V8QTR&-$QHRXKY%U+?+!4I,"37L($?`#!,`5
M]L=H?+O_!?RL"-B<R;"SR`995R#9+F@2*V'4S%B'SNH\=JU6S(>K@>16(EJ0
M`!0Z-?0L"3SP"Q`2T2Q<+?[,F\>FT<=(;D%(N,1K-R+=%U1DT]33RP6:TU2<
MT>W<F.]LELNL0>2\"&AAU&*LU.[,U)U,P^3&-(1;R\PSU8E0`2J@`,1AU6^'
MU4X]#@*=TO]WKO)@END2N[Y(T2&@T-G8>Z4184UTT4O->@.M@3;C-X<`A@M=
M.6)MT<R`UE:GUGI\F@BLP<`WV"-4*KGQTC*3V.)+7-J8UB7==2F)K8']?^I5
MV>"\!2Y-UY2@O,_0?!7PDHV@`=2<U)_-=(XHVFZM?\9*V(:P_P`S$89A7=<A
M=@W/,!\2`)H1H`,X7=M(%XXSS-6O05BAC,4^I-E-2MPM3=+__'(I29E;S9R4
M33/9$GL'H]J3()@54@.]AP)G.Y-][=@C&=H"--KZ%][P<)ZWP9!;E`#"G5BA
M8P.]9P'6S%>66K+;O7(=/=^Y[7TBV`""90]/>S<-T-^CT8MD8>"\F>`\?8IT
MV$^LZ3!;U`#IVXWM`0%:V6*.<-C`P]POI^%-;91IHY2?@"Z@,.)I80$WX`*'
MJ183_@A6)0`04G80$"->^EK5@DP'3G$N_MT9KA=GXPD:&TH'P+;M$)%^RPX"
MKKR)^2;1P0'%H"`!$`,2D`$-P2M#/O]N&(Z;S79>"O[*>XD(YVJ)6T`P#F,P
MJ6'E:^&O&2<N*YLN\(5Q6G;F59[FJ;GDD9W&(E@`'(<7("D`KY,:.A``5!$7
M,(!XA0`#\E?8/4``L[T%@FXOEJX()[#CAK#B2?YPAO[<X!TJ"]EINB4;'PJ1
M%/KIZV#J&3YD&RZ)C5L/)(D>!@"M:8$]JTUTM*X.MJ[FMG9"],W@)7F'BHO0
M+2$!5\X.PBX)-R`"&UGL,##1J,WMOT;HC=G1-CZ>;DZ.&'L;IP3M+;$<$#GM
MBLL)Q=X!/5<`3WCLA3X.XXZC"YY]T*(F#U"R$:X6`##MQN[N!J!9Q1X.]A[N
M(_KB(UD`YU[_:@\06.D!\1"9[XC@`2Z`\++THHX@`Z3^[2R.X`W/Y+C)I*AZ
MD.H!J#E1[9'`C@F/)+_\"`O?F%NK[/M>?-#R&B@&(@HP63KA\I$@[#%?K.`.
MXR5_Z#2\\WP,(A40\`I/\!@P6?'><SK,8V5QZOS6T>),[I+=>BAO5^^QUR!R
M`-X^Z-O0"HB``09W]8^@`#$P\A17`)O\`'&T[(([4+2Q``]PV*AQ`L(-#OR+
M?P0O"7`O]Q3',+N6ZY+XNTQ[:!/O]W-A?3=1`.\Q1V"D]MP@`;L$\8C_<%M;
MN!F<QEN0/%WT.L8;7PTC^7*1`V=?ZS$R1P<P`^VR&G34EC-408D0_P%GX_E:
MSV]X;/+)*;[T0/>?Q(WL,/B'T`$B$/*'D`"-I)[-&A),\?OXIO@1@_?9)_HB
MB&[A$0)!6O"5,+4,@'"WI%*X-#'5SYSS*_RIJ:UZ8_$G4@!]F!.67PGZ4/Y_
M`0-(#0A;6Q@O#"(4@HF*BP4!!`.+D9*3E)66EYB9FIN<G9Z2`5I:`9<(H@"?
MJ:JKK*VNKX):D0`"D0<*L+F5*0NZEP8IG0P2@@P'D)@%(2O'R8[(OM'2T]2?
MH:*EI]7;W-W>LHL`#+/CWJX"#>9;`">=`<C&T)41A3J(SH_J^OO\F-?@E4QI
M0=6OH$&#`!/1DD2`X$%-`'ZH*U!NT[MBS?\J@=@B080``1@6Z=@8J5&^ARA3
M2@OE(.$D@0Y5RIS9RN6ZBHD:!`A0B^8D"2TBF&OD#EY&2A4$S<B0H44'11*2
MEGSFLZI5?UH>V(P$\ZK7KY(<S"*UB`&J`V!S9AA*UJ)1>90:)"B&ZQ*`%R?3
MZJ492FNV@7L#^[0)H&TB!K6V6BW,MBA&>2,T2"K`(D($!D_MXH4KN#._4`<4
M*^KJN33"67,7\=PBVJ>$`Q.\%4CM5E"(HULL%)B$P3*)3"8YFQY>[=_?F,23
M;[.Y`/F6`.E:^WPAE1O%3@1B;V$F/)*$`"<^N-!NB?*&[LK3NV(I?0MI]?!]
MV31@N)@!UH$-W.__1I33Q2WQ6.(!!040((@/,5D@64DY,(!>?!#ZIP4!6O02
MD#819LA*`!8*,L!ND2206&`1`''/-A70IHD`R-SVX!8M2'#=%@G4)<A(DU&E
MX8X29G4<CT#ZM\@`!@"`'&+X!=9"AS3]0)`!N%72@&0-G%B)>2\&&>0U#SBW
MR'M:ACE)?5L4B=Q'2>ZE`@K=9%#`6ILP4%>`ET2PPDX!\)`,!`AD*::&%(K"
MI"1@_FGH<Y(,`!>:6O@IDP0^=-.!!BYP(J<@4,JCPX*,L#!""@WT9,EW?1YJ
MJ`"B`':AJJ8:2N86BB["Z*!@S4#,-B`8,`,G3F)*@Y<E)5"``@WL=PD#_Z6V
M&B8#J8)(2:'*;LG(`P$X*PBCG5VZ#08"B,`)`-H9H(6-\V@0@04PZ(D)LHY&
MFQRSV%@"K;L[OFJDK",*II\W'&P2P0<DB4NN)`YN\<(`/FR0F2`%H$5PLO3N
MB.J$/T:\I7.Q*H*M8!&TLTT$QF82`0!2&6""M4C%<)D/Z:P+L<413MS>O##'
M%P"P^#Z'\U4;H!Q-!#.TNP5%!`AE0`FT2A(!"P+<0("HEK!;<X8R[^P>AE-G
M>',D!N8L@-55A<K-!T)OX8$/O0BL2`3>2@*#`!&`(-2Z1)2==5I5RXOUW38[
M9Q.:7W>FP`;<,$!K!"Y80`D&D*B="-N3I$!`"/\G9\*LW7Q[E?>J8&?>V=:+
M_%U+X)W],#<U*9`G"``X##@)![^5.:[E6\2@@L?'ONSY<!/_]^S>NR=W;^B1
M`-ZY3PW`28WABKB0@Y61:.LX)2=XL`40":S00,N"5!#,PY@'3]/FO[,J/G&@
M*R*6U\?3!$#7U)@NB`4;?`!]]'5-/TD&0G4```D=B)T@)#""23#@`N$[GTHF
MUB6]F4^!I4E?(L@$@`,8H"&>:=@V4K<%#FQ`75'+W^RB<3D(EF9B#DC::(!G
M0L%(4!"O$D4*2W.P:IA.`RSHU[I$.#"?+0(#G+)$`QK5PLZ0[R4L+*)>7I@F
M162%=)TQ@`JJX8(,/&#_89<@``\540$63&)*`/"!BBI!@+HI,3!')%02S_B5
M(D5B*UIP`!/U0@_5^2(!.[B?E&P$@8$MSD@WP)T0=<?&J\@,:FI\8"&_,CQ%
MP,^):TQ+"WSX"@&80(5Q$54?.0&R1>@P>D1<Y%=D%K)$MD^4#P%`R#Y"@`"(
MZ&D"@%)+3DD3$?C1%1((SPDP^47:0(![DZA>;E8@``)\4A`QL*,@$A!*5%KE
MD`ZDI3/[L1!)T,)8H<%@:0KD"PFPX`,3:``O)2$V04!@C)1(0>-(<@EF)G":
MW(`FY^#I%0#X<2LM.8`T9Y*#6[VB`":8XA8(,$[\)>*<F4#@T!`9EV;24R;B
M_Q(%0[\4R8>F$IBQ`,5`]BF3:L$"!@'X)/,VT0`^CA$'_FS>"F`P@UN2TZ$6
M14E$M5!*KE0TI@51Y1LE$9I&>D8&&%6%#@@0DL,4=!'%.N@87><=CV!`CR]]
M)TY]`8!4372%BISJ0:JI,4EHX0`'N.I>LM.*$>1P$03EA%R4*HTA2E6KL*BJ
M1*,)5Y44@*$3W>BKE,1118R@!K1J@/5(ZDMT+D(#4]P`GBJEB`VD-"<PK>L^
MJAJ*H%(TJY+E!UYII5?BE#,5.@#"Z12Q5L*R=1Y)Z4`$`J""2"FB`WIT:V9S
MFBK+8K6OLX7%`O#J-R/M=2\IZL0)6@`)&/R@.DA=*O\`H%JF[VT!H9IP@`4>
M*:7(YI8_5J7K=:G)4`/XK+/$(=LD(J`\CJA@!S78P016>\SD+@("6E"!D>9;
M`0P`LB$%/,!2H2H!$(S`I9%0@'6W6XT%B.(!8A4$S0B\#:Y:`KS#28`*H;2%
MM\V`!BS00JB\24E!E%80$;"!%H"`IQ*;>`7/&2,*E)F;(/@@!K:-A&P9[`VY
M:B'!5\,LC:GAX#(=@+JL\6UR#&#8@8IB!E\C@0-@4(`5^*!M<5$N<Q?A@"++
M>(HSNL2,=]Q@41"@II?%+9<_@>-$0-@T&IS,`210`AY@``@PX$@`O/59&5L9
M$_K-1`,@$0%$8H#%57WKF#'_86,@AWG0WD!D+->GB)LQ1C`<```/!+"#'_3`
M`2S6(`=FX(`>(*(",^P`<MV;B@/@1!(:V,@(6B"`%8!0$#!XK"`$+&A$5\+&
M.%ZPK7.!2%0\(!(W6P""\51K5T2@TLKS``!0(`!+_T``&2#9%M2IY@I#YP!3
MC,`!!EL)&+`3*2T(`(K?:^C(!>#)F0CTKJ4A5P?$6,$W77<K&.JEK7U5`0R8
M(S\*((I;C/C<`J#DGB?3`TOV*P(Q2``%"'!G'7SDX1"'N`,$,(-4P06ZB;"`
M'@'P@4$H+AD#EC<KO'QJF^I8Y*VX<Z-1,:$#.*+#^N#W5S4Q\$7<(,,YZ$`'
M,A``_PT`P<DJMY`$YCL!"5A``LHNX!!%`9<J+Z($7DKJ)L15;)2;>:[SM+HO
MZG-7AMK[JRV!N3HZHH,"ZIDSS(Q!"H*@A0U\!%X%_3`ED`X`LRN"`2I_G,O%
M#9R0:[T3,I^X=O\.BU>A,P#W:4]::KZ("MA@!MP>(`]8O`@%Y+T2#"BW(GKA
M/P"H0`=]K[K6LYMUPK_B53ZSMW+.PYLI"_'RE#!&%B=@@8^LX-N#\"&_16_U
M`VL>WB<WO3LBD;&5;^'7R8D`Y5<A=V$X+!,6U,3NA;\*F=]X\-1?!06=L[7?
MIL4!R*@`FX:>`"RF@LBJD#TF*K`!`&1``,M7Q/2SGPK2E_]/S/1'5#B`O#7D
M>P:E!B`!&N``03-T_],*LY%^SS=K'[<(!D@+\9<(\Y=_G9`5+H=]%#A\X4`F
MJE<:?182&*`#,N`!?290K)!EGJ!^B3`"#2A_B"$`,7!4$YB!FB!#OY=C^$=_
M%.1U+&<:(Z`#)R`!&+`!*4""`M`"KI!FGZ""Y;$?`B"#?D>#7B4*WH>#4IB"
ML\!]-U:%7L$#+"`"X?01$U``,3`#+9@*"9@*3#@)!C`!%4``HB9>.5%4C!"%
M5PA)CH"!=W@)].8<,F,:QZ8G%;`]U@,`%B!`JI"&2[B`DU``%-!?XB9KC6B'
M>\@:HO!N5EB)F;!]Q:,%:Q@8H#?_0`G``A.``2GP`JX''%Q8"0+`B',7`@$P
M'J&GB0_F97I(BZ`P%ITH`(S6&15P`M["+8?0`3XP;B=X@Y:0`(QXB)30`S.P
MBD-#B7<X`*E2A;J&BS`4"<W1B0%P`,TQ7Q$7C@*0``'```R`B=T@`3>`"'V&
M"PN``3>0A+`W":VX""@0>8D@`3)P`"A`A^4AC5=H?=88;[CX2/"2*G$T"O]`
M'SLA(N&8-`N`C-P``#G0`!/0`2T0&[TP+`@XCPSABI2P'XP#<KR'<O:'1,&'
MC63"D;+2;Y\P`!XY#16@`+VP9P:@`!%``'97?2!)<SWI'4:2`4#`)!*@1S.(
MC9`T"K>(_Y2'@3*/IC'7\)(Q*0TGX`/@M`@7@([`\9.8T``T,%J@,``/Z`,R
ML#;E)8$`>86I<@`P=XW8F%:*\)2)P(L!X'^=4&;<T&<AL%X"\`$>8`$I<`(1
MN)6JT``E,)@_U%Z3X'@E*7)<LC-NB8LCI1!D(@`/T`!<>24EMP]Q(QD2H`+P
M-Y*N4`$QH`JH<E0PL@+/YB@*Q92A(T.\%)FT"&1R>2T?,4.=4)LY56$G`'^Y
ML%JJ0"%,H@!GN(("$`!G60FMZ9I7%T>Q29"T2&^560OZ9@D#H)7F4`$!<`/%
MR9.%62%0@8CY>``D(`'R@PG+R9R6F!5M"9V:R`!..9TZDQP58/\"C`4+2N@)
M0R2#^R%."=68\D:%#]">*8F++Z2;:%*=E;!;3Y@2`P`"<),+^=D)F/D+$G`9
M,,`!/2`/%1!$BI">S!DH47)HZED6\5D\U(E;`.H)Z7*`L$":A?F5EK``CR@#
M0?`">PD58#E`0["BN\8E!)J#V0>7C58\<Z&@K.@[#Q$#0"")JY!'J;"?F-!G
M%'<`.SH9:2F%*/2<!4J+"8`<"U"9I("DE5!\!U$!M^,+($I2X/DXW;E,/)"*
MB;"F3-D[7"JDU$>F6R``XZ"GDF``L902%SIJKI!,4=JF`R2>B7`";L<B_UFB
MUW)@00JIQJ<(]#$H"9I`"P!F\.&A:H7_J)9@`43WJ)!:3!4EF^\9$P.P`#Z3
MH/M4`/0A=L21.K+:4./DB)5`0)-`ITB91B1*J302$[/AARGZ"3T&(1S``/C(
MIN/4`,3@`1_@`"\P6A40CY+`J]A83`?@`)#IGI6H39M7/&.*6YR:'JQ:KEH&
MJI6@C&"H"=B*B[W3K5V:JIAPG/-IK+5J&AJ@F,P*%6_:02W@`%=ZK3YJ:_\@
MKW@J?$Q4<N-XKYTP`$2:-5+Z."ZE`&2I`XBY!>\:G:F"L,`*0\[1B[;IL)SP
M-07[$,O:KYB@`#OP`C"0L1>`KAP["A[[L4Q$)@W0IQS5'"=[$!M[)1"`FI.$
M=*JCJ]=J@NK)_T"3^K%?"FRZZ*>'PIAH"`%E60D?L!L2@!=*JHZ[VK-CIK2E
M1ZE0-$%/RU&T@)JFT:13B[8!\`$^P)K^R)P,5+/`VK2J4;;&FA<98JB?H``V
M@)H*@`(C(*<P1*AUVK%A"ZDW.POZI$^?4`#^N2,_VU#X6&0Q\`([,;"1$+-B
MB[CW]['!NE/AX+FY*2P\,KEL6`-C9+C/53:<6ZJD:TJ@"ZYF-@NQNPGCF*^F
M@;J3$;29L&*<\+HE.E-T*[;.89<3%$<[F[!6P;LE@7&3,((#U9L]@'L;P&('
M$+>NB2I:4;REZAR&%0JTB[L:=KH)5`#0*PD!U+J-.`E?UKFGZJU["/]%#"J.
M@3*^FH"VP^&\C``!R3D)U\L)[PN[\3NOE8@F$C@H(!(*`("=Q*>D$<*_\N>[
MBL!4BZ`"@2FPF3#`)8I"[X:J!UQ36\'`RPM@Z2'!$DBU]LAB+$`!`F!Y&RRS
MFLB]T?>Y'_O"HKMY#N``^`L<WL4C-?2XZ4L)KO8!,`!['*R>`E;`S$MX".Q$
MMLNM#EQY#:"[I<%X@#?$GO0;%N`"&,`!HV;!CB3#E0@`6G%R(#R_#"6RZ_!5
M4!L."B"1PX'%G("^*B>]E1#`7$/&>VACWMO!7N>4:'&LF:``X,<C4N<)=BP-
M2<R<<M5`-@RL@`ILR%%5ZX"7DV"F$=(`K+O_)U.I"8WLFNUVIZ#[Q&0[+9><
M.9R<?F/T`TX*8JZ517Q\AU75O8D+R$[KM(1L,0V`M)SP'6/$`80KRY1:5:'Q
MP?)[AZ:<44,RR)AL*@V@O=*GQ:X0RDP)`#M\?9$LMEYGN^L@Q]#<R9<`S*]G
M"24@'-:,E+AVRTGK=;1""KH),]',RHS<<9!J8^B:QG>H`-WUSJG,-XG<"=JV
MF=6<F9K(;RV18/I\A9.L"`,``/[,30`]RY&@;6-T`OSJ"01@T)5(C:*0S\G,
MT(C4"(?'S'<3T,+PR1O,T7TL0PH=TE+88[C`@;&@2CW<#P8HSMR`TI(@`>=8
MG'C'R"Q-RZ*`)-M\_\^(M%O<%PL:%B\H(7/0&`T88`%_5@"*$P$%P&PM*'-`
MEF^6,-66H``L1@#V7*(&AG4HV<1_5V>)4%-D05,3\L;5('-#[0OO)X[B*`*V
M6!8$G0A@70EBS1!(>,\G:7)JK77+/#2YR!KZ]0"0_!#'%@#.Q0^;<@G<L@%L
M4A9U+<";38/\%@""=]0ERM;Z=[>LD0`O.#6PJH!;_-5RNM'`2H4O;<!]',B4
MO*>94P"#O8B+P#]"A)BP3:DNS<Z.S('<API1?2@%<)\I",[8T=D96,O:G-:@
MJYN+VT2J3='14X42H+^.!-T4Z-$4(]KJ:=W<UPN*URJKK8:960$R>X\?2?^I
MU`A6?9V)P`H`A\=]^7(W.L7>0BW?!S;;AVUU[W/;JE$+SFTH/!TGX(T)P0VI
M<634U/VQYAT]X_C,A[(O_JT(PI3'K_S=`.X`ID;<HER9Q(I@N5W6*<B(L./:
M#EX"PRR%!M82O[?0,<V)+;G+$:/;K!T-!&`"&7N'7Z4%=V;C-*B;/A6I*&Y1
M%9JKXP3?7-/@^>=EWF?DT4U!-84J8<4W%?`#._#A49.9,A*JBCI04DY_5%CE
M,$V#$6FI?`IQ/#&.<83A?R(!"A#C,G;F9*3GU.=[),Z4;2Z!\Z5*@TXAK90Y
M&_`"8"XEC!@!9:X(?^;@?"Y\_:;FM#V_Q>.'`X'_O-.DC(>5LI`.W)-N>IZH
ME.2=M%RCZ3L14TWN"P0`X\(M"D6^YE<^"W@U$&SL3*VN"Q3BM5R6*C5.Z^&-
M3L?*BPF0ZQ:S`AN0T5W9WBI7`2G;Z[%NZA/^L257[-3I.><2I4#NXUE*@RU!
M[;(+NCN(HL_AZW^R9;D@[8H;1Y8^X%;W*GA%G58,0>*2`\N.*3C6RP[^[1G(
M$N\.NJ4M@?,^\*JMYY\)!&7IZ-7L[Q1X#0%/[B61Y<5Z-Q/Z":0I>NQ>HBR!
M[,`'[RAGPAI3\5ES\?IIC)$@L]7*$`Z??Z%0EW\NWSQ\)B2?-<E-"3C0Q!NO
MGN(;\<"Z=PX-"7#!SR0[_S4W+PF]Z>HMKX,3PNFW)?"#4A@]MA!R_2<Y$.23
M0,&9@`&UNO/,R1)<:>442`M^9+H:<Z0@3QP0D$#TH^(,7PFZT>_>38/7X/'V
M3:D+D`!C5``^0Q]%7S,HE0H")LVM0"$BKXD`'_/8:"0U-9FK,ZZ9<_3R%X4=
M$(&&2P!!</B5^/)V+_;YMP`P>;>5#/E\(_EHZ<N1<`*:*PBX)PB8K_E[:!RG
M[LB2,+;K0/IWH^*`IP6$SPH$\`+U3O>IHOBXR,\,!?H;^/>;4`"0P*H@\M"#
M'OW2/_U&X@(Z(&EXG?U-PP,RD`$W`)HZX`(R`*C=K_W9?P,0&G$;X`,]4&(_
M</\G._$#&[`!,^!D$8<>%^K@\$FI%`((!P];A(6&"%I:`(:,C8Z/D)&2DY25
MEI>8F9J."P`)C0N-``%;`8N;6P\'`0X/#P$!!XFSM+,/M;BYNKN\O;Z)-"<"
MPSH@.@#(``W'`EI`)3$FM"\L-:&/%1J4!`P*J-_@X>+CY)L`6@D.D8B*Y>[O
M\/'RD5J-]8RCI:>;#P[#_P`#`F2@98/`@`4BH!`@@E`!+1@*6-C20(`%#/\L
M&)B`<5A#""@(11`PH9`"`!HP3(#@31($`#9Z,7@XX%$!"->^<6LYKZ?/GT`;
M-=/"8%VB?4&3*EW:\X`H4J:^%<AIR8`6GI9H:F))B2O_(0T!-I0T!*'!)T@%
M#CS$:N@FU4T[F<J=2S=2`"T'!!AM5[>OW[^,2.$;%%6I5;:4M&**8`.Q(Z];
M0``@\+;L69MJM11XU$!+SA,17-9D%!>PZ=/P[FH9!(D=4M2P8X,;9D^4NL))
M#V\9$2!#Z$E:9:`P4$F"$,>-(%Q>J(V1Y4AI'[XVZ6#TE@YC,966S;W[)-7W
M'KGV3KX\)`'3PQ<:X,_!=)^Z?3`@P(.2`BTU%[BX,:(2Y$C*%7("`!4D9Q9T
MF;U52`,T_*93-^9%2!YX>[TGX86HZ56;/5H(T$`Y`"C82`1"G'6""S9D,,E]
MH[G@PU5=(>?<90Z$T)!S!Z*5_QERG8DHTHV2;(?AD'^=DTB%1"9Y&GH;,I((
M`1;"19PD5DVY18@5:(@61(1T`,`(/T@PR7^0!$@(#PLT1U:.CT0`@2S(N07=
M-A`J::=<%+9VU)U\SD4;(T[9D\"?F\"24P)60J)!#9=M<<(-.XA`P988&/*!
M`PU,!&!(AF"P@8ID75;!!R!,0``!I6[QG$,^H'#")7*"0P`*,O9I*XBS('GK
MKCX16DBCA2@2@)::L))3`:,9H``!6W@PC*:J-FK!!F`ERHAB9S*@P0;6/<:L
M(1W(\&JHAGBPP@!0&C`1!!:,NT4!*KC07U8X%8(!!Y+XU@@WG/+J+SE&JM?(
M>/\6#/^BE@L$1(`_!,"BP+#?P-+69J5TL@BP9AH200P%Z&`3?HTDD$`#V27W
MK;TKS%M(QH2@@"X0*XCY4@B&W-`""+!"`.H6&*CY2`;0%@+ER087G<DY#@C,
M",%&-ZT)`,0ZY,@L46,2P`,4;T%``\0M<(`W%1S0`KZ$L%R(!B4D@',C#UE+
MB`$BDVTR(Q4X\!8#EYT@0G\&3%JV!2^,IH$'F<2J$P]$.ZTX)$8*X.,63"\N
M>20&5!V`@HGXF@D!!XRF3"=;)+#`9A%\(.;;Z#RBP`DH=,"V%FX3DL$'`/1+
M5N(\`TD(WH5$```/Z(90J:H#!&!=`C/(D+/RD,2^+PJX3S[_^3FR1!FY]-@7
MHGG%'":LDV"$#+-(`09L)L$!/?QF%;#V&J`!`V^U_<@`*.A`@,HK)QY!"Q_X
MO?ME!4B`B@P`M+(5SSH5@,':*G&3G3E"+),@@`^BESVG&>D!52O$]2HHO8HT
M`C?!LEL&+2&QMQD`&80``'%&8CJ1E`@2%NC!`6Z`%?D]0@,""$`*%E@VW(7`
M@5O@'2$XT(`;E$0$(B@)!`YHKQ#P$#@0()RL$,=!Z2V`:GKB2Q6Q![4/IH<!
M_HA8YPJ!K%``8#Z1&<[IHA6D!C"@0`Z!G21Z@`*.&:(%B>,`"'P6Q,MD@"%;
MJ$`+1C"I&"S`>(7(``S@R,!ZR6HR_UN<7"(@)IX]15)ZGO#BAL"G"08<8!\$
M4("U$B"WLK&/$1+(`!`$,"\;0H(#.M`,M""0.`.XH!'S\5\`SA(!0FKM8=WB
M`",3`P'F;0%NDCB!%`TQM$LN+A$8S&*4G%DP2`8F/:'@9"::L8\&-&":92O*
MBH``@S@ZCQ$8^(''>D@)3R;K/:%$)"1>P``;C/`FI]2.-:EIM-5T2)K\7-P9
M->FDS6@3$P0!I2C'%*A)W,!O$AC".1GANI4=H&2/8``#QC(2$NP+F)&XP`#,
M1D:2;FZ?`2W8:O("T)0V+1^,2``V2_&-!&CQA%UIZ"4N<,M,M&`&_H,$`P*P
MQE-]5)Z/$/^I2=^U5$)`,$@H=2FO$A'&2FI1JM4\:(CLL8B#7D(`[LG$`<2)
MB0OHU!($`)DDW/DC(/X2J8Y0*G+JEL]+-!.K_GK2""%G2;S^"Z:&"`#\G%03
MKUJ"FYEPP%DK<8&)MH69:J7<&+>P`@YD36@@A812\TG7<-S5K[?2@@,8L-<-
M@K9/7;Q6MPBA&9HB-%!@!:<C/*F)"[1@$JJD05$C*]08:(H#0<4L7!NQ69MD
MK`(ID,3@]F6!#YPVM*LQ+%^O^ES4:A-1CF,$DZ0+"@,P3"_-<.QLR;K3Q19B
M!)?Z5"B%QMN,_F`'+-!"XCKP@@0T)A:PR*]^`U`""2P5GX60`/[_'!&!X&IM
M!"S`:'6))-I!M73!UFW$0J_I6DDL(`'#VHP"P,O2U];6O!TX00!\@(%)J2`D
M$A!D>\%5$@:8(`0,N2@A).`"%C"@!S9P0;P$D`$7!*08-P#`"QW165E9(`8*
MAO"%L&A5V2HY0@>]'%>WD)>#!,0!HBL$`-K3,('@8@:UB`&8$\$6(VT@!V'&
M@2YLMP7&0%,+'YB%"3#:F41,=HD24,$!7F#97]2BKD)479))`P`9/YG!F7OP
MH97D505M-VG]2(`L<''9=_5B%4E+A`GRRX)-YS<'Q.)`"W`0@!H``Q9!B,%^
M\_M40_A@U;`P`546%I8O^2T`S\!!3C8`_^L`A.!%6B#U!H2@@F$R(M".0,$:
M(4&`#@AAM8LVSRS.:=IH2TAI`C#`6YB$'M&RHM+P.8L"7A"#YD``&&(:K&>]
M$8$-F$`#!FYS"9Q,B,X$88Q+C`2RX3)2:%O;.]-6]+^7W`@#&&"UVY7O73ZD
ME`@<0`8'^``,_#=I+5!C!^-0P0]"T`(9Q'L3*9`&#5X0`"3K^S("ED0$/$J:
M?@\\0J(=J\!?+NV09=D0VVW`?1C@;Y^4W*U>2@:!QB$!'*S`0>2P@-"1/MN3
M56`%REVFT%Q.<_)`4[K5KCIWO$H9[2Y"$01XP.-ZTK/)T5965-<Z=V91UZRK
M'36`E023$L"BM_]GE()V3;O=47/UF>\=-MS%>5=3]_=CFQ>S$=1[X?_2]R8O
M?NU"<5NV2Q%XM6O4LXI_?%V@6=J^:OXTZF`$,AFA``?$HE9O/[M.,O]YN5`5
MZYYO_5^X[HC*R3Y\#8U`#@;M$#YJC?6W3THK5N'WX+O>$1G\Y.T9$`).EA*M
MP#?^3ZXF@+;'7OK'%WW5#'#XPKO8K9N+/O;GX8!6P)ZZXU^*TFQOB.*!^_'[
M;L0(@O8(`@S@`&-/?VI8<7YZZS\UHA`UI?=R^6<(%D`!:!0)"D!_CF!_`8!Z
M_U<.JM%_$<@45>,K`\``XH4*`Z`,XE,15C8,OA:"5O8!PR(+,`8!(1#_$^CP
M#W%63P9Q;K.P`3AP9GYV@[GP`J8V"S&P`>)@?U]3@=/G"IV'?D+8$QE$%07@
M#\CP?N"0:3>(`_&E!260"#A@:CA0`B2W@[G0"B60`_D5!";P`D$`!+T&"RR`
M`R1WAFS8AOHE`CYP`"Z``B$P`V'Q?!WP<86@(/97)T<H#ZK!&H[@=G_H#L1B
M`!AD>K.@&L.P@9=@4W65"0W0?>&`+?)P'ZC'+7*W+QD(@86("G=Q"\7WB8:H
M($BQ`*0%#VFU5YKP`I0(#G77$PH0A._0AYY(BIE@4Z+H>+@X#TQR;/A0>;E(
M%.ZP`:\H%2OV#@VP7K78B;WH#GDRB-?WC.20_T'L(V7D\!!XAPHI<(RH8(GQ
MT!E840$,%PE/U(#.2(WC,!2".##3J([A\(N!57#;J`E*(PYF)0_@"`^8J(KI
M"(^S(5K4]HX`B0H9%#T,X'_`48^;,(GZF(SNL!;^Z(<%N0D$T0\^0H@5^57@
MUF@,B5:WB`D.&0_2X1,2&0DIL&RUAU&VN)&HD%8/,)!&Z)+;-!T9-$D*"0F>
M`0\-,&>5$`$ND#P,!)&/L`$C$))QA)301Y$TB5;>9B$:V91R9Y..0`H"X(V.
M``">@Y626`)ZZ`C"-)1(V0&M@PDGZ0Y]R(I2B7RW`)%1N9:/@$+`>"WJ8!4?
M>6R)\"&3QY-$V0CEYO^#B0$CE@`$$:"49]EFCE4!;(:.#%".<#D)S;!+/?>6
MCXD/TX$8!3`(RUA5E(`N\G5AK"`/G=%S8,D!NA,)%6`-EX`!'7".DG"8$@"!
MQH:.!E>9E-`,Y3>*MLD9KU$Y;S$`]3`,"H`UE=`,`.28[C":EB`"*1"29"()
M#1`"AJD%R#D.]F<`U;F;VO4`0Z6;VFF9X(D/P:D7=U&`]R&,XZ"<E?`!3O@(
MSQD)&Q`!L_F:A`<)$4$E+#D`(9"=W_DVW."6!-F?AB"7A6`*OQF<@K$*I,E:
MD\5LH1=(-X`*ZED);#(FAFF8.!")U\%TH!!<UZFANVD5MP"5`2J@]?8:4Y'_
M'EM0?83`"N"D!>AI"#QG#GT)#N\9D?59#A]JHD(Q"Y-9HB:*4]HU-2OZ+5?S
MHN3U"`9``!2C+JC@`C5J"""0`!Q:)D@9`1MEECF07(;``;SW-E_Y>Z/'HUJ&
M%^VX-$`JH`3J$`T`;@C:HF%%#Y57.3.!3@/`<I0``S80`&%J"`:@$I9PHX\@
M`4EDECY`,X;@,I*``E_Z>R$`HK9I)!1(IG'Y&MW@-F]:"C,9+"":HB$"`.>R
M!1NP`+>(`4"P>_,``8Z(C)`:?F-*J<TPHKQ(J:*0.*-3G?4`4PSP`"]:>06P
M2Y\*`!0@`<B`IY$``$&``U4:"1PP=/[1JET"`#.@_Y+T":UY]ZID>D6K0**;
M2J9K2@@#X*;')!BQ)0D=-@D+D*X?X`+#.E3/1V`VL`/+RJQ?8@DQ8*T=,&")
M\6+A```JN:.T2@C]L)/2V*T\FEJ34`_+@GN.-5J38`!1`0`J($7%,)\&"`0L
MP("5<`)<2@EI<PD6<`.KNC+6"GW82J8#^Z,&:Z)Q1P@)X*8=2*X!P)^%$$V2
M,``"4$8I@&(+(77R=ZKM:6$8X`/V:JTEYGN3D`.(>@G`%20#<+(\F@@R-:L!
MJV4'E0#0YAXPA5CTD*2.X!3:M@`R4"H2X`%,&1COA@H<P`/@5W_6.BC.A0DX
MD`)!=7.0T*#U][0ENY:[Q/^K5%NU5Q)ETV$*`/`*K&"P!X"UDJ``"?`M$%(!
M(%!1&25':JL"QA1!>]NTES"W?<H('A"F`!NPKB!??UNU"%N@@XL,'0)6=B,)
M@K6@;Z-SR*`!*D`).F`#-%L<^LILF=NY9$%4S0BU)BI?\HBF*RN@AQ0R@]NF
M=PFG09M""I"N)^`#[_H(`O`*)U!B/D$`>[L5!/"562(),."SUPF\`8L7<>J.
MQRN@!R4`B'$7`="\E)=_Y+,9R`("MTBH-R`"++`!-S"O/]B]F?`F"YIRD=`!
MQOI[$1`X53L+W)J3N]F^;G,.W'`)L0!.0@H.&9`"I?:\+RG`F$#`S5@*L+N;
ML^#_A)3YG6>J#Z*`%UYK%S$Z#A;07_'`O8U@P.1@=-V"'>(+NH55PK8)3?F4
MPMKYH$(S'><@`/)K+$E1`NNDBL""`2^POOZ!MQ@`NQG0J/9'P@TL6@\,N(%A
M""=Q0AL&$&GE1A8\HT#Q`28`P+)R%C2V`S_``2H@OY,0`WAKG3_<Q<19L!!L
MFSH5@MZD6#$L6`5(#E!J$,.0`0```@$!`RK`R$(WR4+G`B+@R`+P`B\@##NP
M`9JR,0>A`3Y&@O^P`SZP`RV0`BVP`VL8`#^P`C^P`:>`PX^`P"W'Q>>;",Y#
MQ+MIQ.$SP:NPQ%"2%"*0`";(AEJ8A;QP"SE0`T`P`R?P_T,[,`/#LS(N$G1"
M0`L-(`0;4!`Q80)*_`$$`&HVT'P"$0,"\`%P*Q)Q"PD*=,O#Q:.A2$&\;)LK
M[+ZB(&E+G+Y`P0''#`L&H5^RG`$R1<F3G`&R;-#!U:PMH`4J8-!"YU$80,F3
M$G1"YS^TM'JX3*M2^\5@'"Q"4363L6$63,5V$BZU&P\9_3-:O,?GFS0>_=%;
MX,LK*M+#HI:!D<>5H`$/=2$1X`"-B@HK[0@%%`E;',\FZ@!I1<]I*J#8AA@$
MH!<:^`_@=!<0#`,'L`&G61X2I])V#,]`7)G^9%CU7)DTC<_:19ZST#"N:]);
MH`,Y,`/=S`.^"Q@5P`)NO`E#K?\)1QW6C]D/YVJ\?UR9[2O2Y%FS:FG5E[`H
M+.`Z<=8W$K("(QNH7\U,+LW1HI613=V?9VW8%298DG`._G<?,\!RJ60#E4T7
MS4>MX;#7X;?1E`JC,UG6C[E8'H0/ATT(#AL)UTMO5N&5C'`"0;`#DBL;,!``
M/2``\"82LYF'D;``!A8#J4T(?5VUF1;3'WU0`^!HN3W3+SR@I%7&)-@`_;"[
MS<`"_S`#3X1#!R''*]`"`K`#([8"JW8"/1``\/T#U4P(,@`+!(#*Q>TH_.4"
M#"#?GT9J^Z6%;.@`K?QI1&L3&FO9L$VF#ERZ57M0%9I"W6UZH9U6?K;"AJ`#
M7$B%_N/_`4`@9T&`"S0@#0XPXKO0*!F0`S3``B-7`B:@`_[#`&;HACP.:SXP
M#++0<P70TA,>M?Z@LH/]F(T6@!4&HZ&=BF0T#BU0$S=@8YK"C+(R`1&0`C4`
M`AZ5%C5A`2Y0`CY0$_G6$T;UDC6QQ;G<=7XLTRVJ?1-,GM?@Y,=*`)-="03P
M`2P0`BJC`QE:UY`P`PP0`SP`+6!>"'IDA]^;"2(`2'I^,I\;";YSRSUPR&(M
M7_Q)VW#IR^F*.UV4#H-BYXSCM^^@`C-@;!>PV9"0`"N`42>0QQ(P`S[K'UI@
M`F&=YI'QE94NX6<[O+=`UJQ>Q)40Z@O0,*0>E_S<$ZONUEFA_].HD&F8KNM\
M71/LV<4<_N9PKE6FJ`X8]DW)GI6"^1,;4`,FP-KB4``TD.2-P`%_%-34#9'R
MZ;1!I)12N1JO8.$!&P"5!C76XCTY-`SAWL)Y_@V"6HGCOA1IU7/S;M0U\>L"
MV@H#3PB<SK?3P7YDI`Y_LCWB"<$2X,'NV;&6X`$`D,".H.X0K$=^S6Q`I>;U
M7K4'D#0C5/%2"4+@^A8`KR$'4(\E"2LIL+0A'*%6X\G`40*8;@@JT``K7W]J
M->F1L%I;#/']&7.:[>RV:?.@$XQ!I"'4S@F4:PD1(`,S`.]S@PDJD``F_SKV
MG@+O+"MJ10#HOH>WC.64FFG";O6$_?\:+;L%.%O3`OO=6A;5F*`!(+#T^9,)
MPY'7!6#TF7`#*2TK+<]O*VKO37D7Q*?M,FWS414^?E\*:KEE..T(AL].A1/4
M*)\)&_&#AE;M+[_ON*GOM*KYN).\8/4*%7RL-FL)&H`"*9#7WH()-&81P)'P
M.^T#1\]L$+E<#M_ZL;\:WTWSE:_W6F65-[TUH<V9EZ"H`US9R@\=Q$\)$B`#
ME$\:4<IL#S_^+FGYNSSL$2S]59E#JUJXH=\()^":8S+=PT_Y5^Q9Y0\(6X*#
M@@0#6PP*A(N,C8Z/D)&2DY25EI>8F80!#PX'C@A:6@":I::GJ*FJJXP&I(0#
M"8U:`5J6`UK_`JR2$`28$@`4D@5:BI<<(ZD$6H=;AI`5NH3/#<:[U]C9VMBU
M#P&@HJ_;X^3EYI(`XH/2BUH.`>J2N9<%+/&5O9@E.I/$UI49>D1`M:Q9)FK_
MSBE<R-!4MP;@1C6<2+&BI72,V!%R]^#>HP4/-)(KX2N;!"$)%:I@]LB@HV<$
M4EJ<2=,<IP#?&H626+.G3X4$[KTJL&#0`2T,#%0"X$#D.`(SA%GRP*&"I),R
M(W$`X5)3P4<0(3U+D/6GV;.8;N9DM-,CVK=P+<$;5`"GW;NU'#1P^G&>I1,!
M5FB*<6#")109-$B*8*,L)`Q=,Q&+7.E9HKB8,SNJI>63SG":0XM>_^1JT8`"
MLQ[LM>2WDH$.(BA+(GE)0H4&+B9!<.R(PX>!IR:7@JETM'&TG#VS!7V\.5P!
M\6+-"D"`[Z.F]'3(.LCRT@G>@G9C6J!#!BKA6Q18B(3");7MSN-;K'5@[:*V
M\O/W!."4KX-WUCGR0$F5:*###\E@0D!AEX0@@PI202+>)1V<0&`IZ%E`@E:&
M#?*>?B`NQ)E]A.`7XHD,`5`<(7Q1MUHE#\!'200NP*"8@B9(<!@'"70H(7B,
M8)"!<AAV=]`A#<B(XI*[<.9`1&XQ*>4J_&74B"?5L18@)`8H20D!%UJRHH1>
M3E*!8,$9R4B4A2!9YI1PIO5`?5#&:2>53O^1*(@M3.7U9"2ME0/F-A",N1`Q
M418EEIMW-GH)`Z(062)SCE9Z"4:+A+GG%@`$((``#$AZY9;7?)4-!*1N0PQJ
M7B$)I*6-"B!*6,OQ!.NMD6#*XBR<,B"(`']"$L";V9B*#:H4K2J(AAQ.PRBN
MT`H"J5YU1FLM(;JNPVNGOSY@*",.^'J.L==,V)`_@O#@0209N/?LM;`F@-,#
MU<)K;;:">,1G3@0X\(JBC-`YKIJ[F,L0NJUND:2]L`I0BYZ"F,@PM/@J#/`@
M^PH2P)\"A'3QGA!K0V[!Q)*#\)$*ESSQDJ`"6^_*L`)`*UT?;Y'Q%@G8LD4`
M"BC```,7'R"N.2O_R98*!"JK6LPC">CXR(<PWREK)R]'[6B5+"[`ZD:<YB1K
M40X<,D`##A#`:@))1])!.A%XD,[;<*<SPC(JQ&WWW7B_K8(K`.2P@=TJB`#"
MISID\.GAB"?^Z0T`B*#XXQ^4L+6"AQB0@M5VREIVU9C;B35=!NAI2P$.R"O`
M@K(2LH`!#."4)%[#!O"S76#BY0-.)8B20PTT/""**+Z+8H(,91,00.[`TU"#
M%C0X\'OPP"^/`Q"\LZ#%"PX\@(,)*:!0@O6_T]#"[^1KL0/ST-/P0@DM0*I%
M#-MKX3L+,4!/OCW#':)`")W#*2LMG.O?E#Y'B&^QY'?U\8:F%.`\;\#N_X$0
MC&``6M"#N_A``!\0Q0P0UX,+?BH%U3G<"D*0@F&%\'$H3*$*$Z<`"+Q/`#XB
MC-$$$0'>).!B4!,@RWX70!TNB8!;T%HC#E``7(ABAA,I``V"\"J:N%!)"T(B
MRA;F0Q3)"@`ZJQ6;JJ@?("[`9XP(0`&8\JF:S008`-A0?*)8JD,`H`5</-'_
MLG@?2L5Q20,0"0`6H"EX<.N.EP!3A`31`!\YP@"&9,0S"I`J0&:F8[[KH2/E
MPY=O^3%DDVP$`;R$@4$V0@&)S-0A"J"I3(JF`;^;W"`D9DK]-')GZ<!D*SW$
M@%`29)2RG.5;L&C'5?92E\WI3R,N"<RG'4"*DO]HE[.V4)=BBH:7MII4-)UI
MG#P-,Y;49,0):+#%&D9"`^YB9BZS61->/D.+Y#R.4TI)S'0*H@#';*,XW0D7
M:$J2GF8!XA9:A$UZJB">NUCD./$Y$::(XIX$W8\PP]A/=[*1$`U0021BLJAY
M)O0GO!15Q'YY48PN=!$!.("\\"D"@+)"H!WU"30]PLJ4_B2/5@ICZP9J2G@B
M4VV&1*E+:;+2STQSIS59P$<WH8"1TE,$-/@6(VX$E@PLLYE`M0@6/<%2CD;5
M(D/UT,9HFLF3K4*G5RWH[V;FRY^&M2*:4M087]$QG.!3B5M$&53/FB):F+6E
M=*4('5484H>]U:2"@$'_@AYQ@G4]#9=YK>M!?1K7Q)*#CH)0ZJ=:]]>N=``X
MC^B`&E_2C%<Z5A4`\,8#S(C7SRHD6.NHF0`.X%=Z%L`$JE1&9TUK#H-J@;16
MI2TY^M,?+32`JY,DAE))X\E%1(`#RT2$&77+BDYQM+3,'0=J?]6?ID`VF\0@
M:R-\X#1'V":Y0(NN-C*JW2U`5[S9N.ZG&,&`!F#QK4L+:#/"B]YK0),RYZWO
M+J:[SSPIY;K4].H6)%#<16BVHLK5[S6ZH=3\*E@5_%TO2/\+WX148+".@(%A
M.2NMY3Y8$^ZKJED_O`H]&8"W-G,.!PILE@K4H(F5F:^'27R);N`WMS0^A:A>
M_\0B70!8,RMHK!-A_"49YQ@5G!&QD(_,&D8,0+4^CDL&;#D:"``!LYJ8JS.,
MS.12T$>C#N[R)2`[@(JM5PNQ]4E2\H.#)<>XPV+6!"=\R]@X0W@10D7QCQFQ
M@)ON@@%IBXO!5'%.^MI9+IV!6)@/+0D2`8`H&='%DU(E@.&.HP`B"$T',#R(
M01?@`Y&P@%4."V=&5X(S?%FTJ1]!HB=K:KV:<][0,J+17Q1@;7;[@,/N(KT-
MQ\5]71FT;*5EGE5/(@'.2S6.C2VLCRT``%V!-5,<P$`4YBP7GW)@]G#B#N?]
M+GLO.%[YM!""Q?'@<(Q[6P5<&"BX`'L1PKZE(&[([/]&=Z;!RZ[W-4VCVJ"4
MCCJAXH_B3MP``_"-,K'U``DZ0.5(M""D(-`,8`+0W?"D:LJ0B$"F/=2,!LQ8
MW_]3]HCUS6IU"+6(BQ"`+$['`.-Y]APRL/19(,,(",S:$3IH^(#'=$X"?+S>
M4U-TODF^B9HIX&.AVZ>;&7*9T'B\YH&VQ#D;X%2B-V)J]$*GU2<AQE:H<@&^
M@HZ[B6R1I\-;21+@-"-N@V`"^'KKO]+"H+0.=V$U%E1*=W>:WV+V3:#]!I&0
MP-[;5.JZQ[T6=3;\T^+!2#Y_0^QO8<#2R_[V+91.GBE3_+QY2'?-+R(!\?BC
MZAX_>86$@.P5*6K`DL:!S3;_(NW)W:3GE]&9Q'L>I*'7DU\ACQ8#H#Y97CH`
M#K#<B`94GA`1F$%WIQYU4\OJ`/PU[]"W/A=L08ST<#&X:+K$WN87F9#>/_3_
MPM;YVVLL'@NX?M[?POW0%,!+@,8\%16ON0/<0]56K_X@TM\(;Y2&_>7U%N\'
M=8R0`SH7#0@V?X;W/X"U42.G>/J7+Q`3#J5W#KZW?5Z"-(PP>((@`3/&?)[W
M?`"&?T07@4$T@:-0@>9@``'8>_`7?I(`@IJG`)$26R1(<KPW"!!S`/:G@N70
M?IHQ@(O``#1`?(RP`KRQ`<O7<3`89S0X)S8X?5;'>\\&`*`7-P,`)D$!%Q%P
M`J*A_V72DC01X'HQR(2>9T[W)X5$QWNA`T'(!GT^6`XO-Q-"2`CQ)U_@=X;R
M8VAE%8>,)@`IT2+UX8>#,`!/YF?#P#_7L`,L%ASP=W-;('/YDH!-*&:A=11I
M^(`+Z!0`5@MSEPJ&J'VK,(>5@`(5IPIU.`BALH&2\('-``"U1G18!'U1J(EU
M)V&$$'VUT"DGMD*'`R8MHW(XD0!*,8`^4T(2E(PXD0,X8!<X$`2B$&YX$00T
M$``U((T0U!&"M041T(P!P`(U@`,U``3@.&Y:L`$Y0#XX,0.BL`$?`'^QF#^"
MH`#QJ&]8-">V9WZ_8DG#)%)B!``*`!UPTP#5P#=YDPZH\?\I>W20Z;`>`Y8.
M"Q<W%*`!EW,-'5``BL@*J2@M]<B-_``),.`CYP2+>I@+M4B(=H:+@Z"+FP1<
MD[!'JP"$U\"!6:8G#&`"2(1ID5!('/=.'<EL]\@SY6=^*KDI#"5ZO9<?#?"3
M@=0,\%220F>+<%>4SG!-2$E.JXB'S,24JQ9:!H`==2256R=4,85[5YE-JZ5(
M-#E13LF5IA9:(9&)*)F2871-8)A-1&B$IW!.3ZEYQ*`%H#>4MZ=/'C$7+@E(
MR_!S/Y=<?:EYD5(S-XB#B\`?EM10Z81*Q?8(&K`#I[@(,+"$/GE[[F`V@NEY
M)T8)[>1.J+284M>6GO>743F78E;_E$H!B?`P`%FGFK>EE4K4F5OW.W*IC]CB
M%,3(4)8G``U@B&GV;#,3D.E`&3!Y"HSQ`A&G&9`"1Q"UFX1@BM]D-.<4`2S0
MB"1'"PD0&9&I;Y!H`+$U%V.U`.55A80P1JQI"BY42F@!*9*RFHM@`>*Y!3/T
MG>'I>?)#;:7I>7JR.F'D8Z(@B1/Q`P%0D9EA.!LW"/IY4@9Q`8C(:+G`6@6J
M>23R?NNI"V[I2*AT?(M`DS;2DX*`H0)Z%.:IAB78?PF:8O2D`#90=9"`1)>E
MHH@@FLX3G,*I@XUP#V>&3S8ZG]_'C0'JF++S+>=9;VEU=5%&3Q4Z".K!+M[9
M#!5@`QEZ_VA(87\="H$90:13JIL?$P$.^0@TQV$KVJ5V)C]"&9:R*6:Z1Z2*
ML&?`5*6$=J%N&F?RXPUA:GAUNH$;TX)YJ@4X^@@`H',:QZ,LZICNH"=/RFP^
MEW(>00`,.DL`(`0GT)\9D*:-T*B$UZ:>YSP$`(F3:FQ.X5X;.*+!!0%(.@GG
MM`6/"H&TX*3,T:>F5JG8<@_%25`%`*N+(`%DR`@,1VJD"JF`J75KF7^AAWX!
MH*MQ%*R9^4Z\`0/5J4E\.GNY@*HP*IF6FBFD^*J).FS):JNM)4USVF7?H@"3
M4P#><E'!&JME.`BU*JB1&JBW"#`!^8N(XW_`"@'5Z@@B@%Q)2O^KTLIDJP6H
M<AJD'O(QA@A1\9I0P5J);(JP(2AWDOJMZ*E*5XF<\JJ!%CH(*9"P1P8L`J.N
M#GM^DZDG1$2Q(DL(V9IA,RM*%&JR.28KLM>P*UN>D]D?]AE@,3L(H_8(WW6Q
M%W`%5J!Y_8*I79&JJV:"`)!6!T"O@%2Q6KD%[OA[748?`?`Q4+NK'Z-/"C.N
M=Q2L03L(&`"JC;`BL]H`/<"U"OL?3A&V?[@F3I%^,?)6^:`VQ7JB//H"U:!Y
MP.(I6F>UJ\8`'JLIL+@`#2BT%JNM%(H`<GNRM$":*KNR4JLGW&*"D#NL$@4)
ML'>Q#4"YA%LZ`@"VS(&XIF:""-JRL.3_6D/+C0/+"*(JN81DNHIG`)>KKW`7
MF+VZ)M_@N<XD`<.2M:5;N3DK=]IEM^(7#V4$N\3K3)05"6O[9KFKO#1V.L:C
M2B;2K&L8#P:P`&/[#5NX#6B4#CP@`X[S*1J0`!K``\I$"!B7'S\C"1C`5/6:
MO3-("QW!L^NZO8QWOH,06KUR.)FZ@64&D)\2%AJ0`2#0`HFC`^I6`&/(`8G$
M`(ZCOW!A.(!(",8;N8ID$,FK>:C42R82P"26@X)`OK`+BSQS%).@`*0P@*!'
ME:C@/B)L#NZ#`L@G4K]0M",\N=J[PK[3=9FKPA_&P@H0&08<2[>E,XPT7.";
M"NYSF!-!>Q"Z_P45\`Z,4+-K%P/(JC"ZNX"BH"DI'*0LG(4>^PU317N1^&Q5
MK`TZ\"GE^A:X1H99^54D7,9UU[GQD,;"";+8,D8O+)`5HTM[O*=$K'GW6+4\
MR[I_Z!0%8"@DJ2+X1(1JYYE@O)]2\;9^#'>H]!^!S!Q*_&`XO"9/0K;4F[8H
MP[^*-U7^`L!J3)QK\@FL7$R+;*X*$V^R"#RES!.GK&!4R;E\8K9<M,M;T`*^
M20A>2+JAO'58Y#!D)<CZ6&EU:1JXC,Q5I,PK)H^P;'A3-4W63)0IH5%NS,T^
MI,Q[:1`&$,U6%UK.8RCE?'M4V8G,F<DEH)?(MT4*`!RSJ@#P_,N=$?_,KS#,
M^G7/PY0S"'TM1/AQ'L@>'3"JD3C0)(=%#]6'A!2D`<D(^$QG])0`KLJ6=.'+
M%RUW3<RSZFQG^M2)PH5/#6`"B=1ZULMBLRI@THP4AINY*QUG+7U-[99-2ZE-
M!@L65';3\27.ERL2)M+38M;1G\<I>U0`100/8IE)(IVU.!W/','4S.'478:+
M6/0PL-,1(*V:(XU@S)34=4<,/)@03<W1G#A,"Q#4U(1*H?L(C0<)*&!82%W$
M)"8*LYRYA@IW^I2;17?5DX1*.,NC6VUU[@"F21RD/":D842#A3U+#5`"_=F4
M=,'6<%?7#N.]S)'`%]U'D9$4.ZV:,CV$O/'_`K+QUX[\.U[-$X#-9&?IN=0,
MUIC#V"/[3J"]=;C0%#<7U\*9VS4C>>]%I033SI]]VPK&2PQ0VVP5I`!@F_?P
M#0.`Q7'DVQDGB2A@L+(=R[0PW2IMW7D2&6X<?<[DW4;+&\RR9<^M>74M/]3]
M*^B=S2!EE+K9V!3]V$3W._3\U=:M)RBWWS3J3N@Q".H2"3"P7..M>,!YWL?M
M:-@LK@F>3C2(`8M`TY"PH[B[UM"M8()-VCS!VT=VE?+)7F5ZF5H@Q*@@`$TP
M"(PQXOJEL=5,X!6^"!"A9S"M!3"03#,4WTP`;S9>7S5(X?IXEJ_;8S83O9J`
MR=@P`P$PH9AQ`7)W_Z)GK:B1T."-8-+C*0KWO4\%W@@U8[B_(WF5=CIW41==
MEQ2R`)#^R2H54P$;L`,>T``P`'B-Y4)IW1!8'B8+?BQ'CEZ1.N`G7N:J<QHS
MFN9G\3"A$3H^3`@TV!46;+W@"^;Z]J=*8MQ+3B(*\%N-G@Z2K`UK`^/&4>F+
MH`$FJK:97NCB]:6=KN.??B6-#E_^O8'!_9MBSK.0&(*4D``M3DZ#O@M8(:#N
M8.+5K<:48-YXJDO$`&H[&0D%D!6:7F^TS;.N/)6*E-W#CEW-S0K7SFR1,N;<
MO6I.\7^;\.T!%NZK,.[&UAGM9B+GSFAGJ>X>PN[.]-(%I#*BR`NP'EURM_^L
MF5OOAY;;]^#L\&4H8_CN`<]<P4,B]*[HFQ`9\L*["T\H#Z];ICKF*)YC?!1&
ML<6[V0-?/]"?[0$-DUYS&T];[G"_F?OK3#NF:\)Y"JX%#`K1;-MI+6]:1QPF
M$Q^DG"L4-I]._'XJ/?]9(\*S!G]H!AY;L+A8-V\HK.[@'/P(\!ZURR#QS-'T
M=B8CPGBJ>'$`#Q!)KH7SQO6WA`#B`&^@HC#K/.'U<39K8]0S<3-&G<'>Q40,
MJ"[N2>]8ON/%!>^PZ4GT;G7V5MX;C&JB6=^ZX5+<7>^P>4+T_P%?T@X)\^L(
MWO3E?Y]8G`'Y/+'#<]\*1"_U1H_VVM#XC-8-</__"G(O9I`H,ZH,+*4N0$?_
M3E=O7(F/]9V?5Q'/]`[+N4X!R&=O*`60^R"\R8T0`[U/5_\!0(,O]'C+"&`T
MV*=OV@?1_&?E)\`O_9.I7:>S!9)]_=M`41[:&3D>]\&_)F1J,PT=+<20`\VL
MBA_W)JKO]/4!64$OG)P+"`U;@X0"`EM:`(2+C(V.CY"1DI.4E9:5!5H&EYQ;
M$`J=H:*CI*6FIY<!6EH.C`BKBEL!J+2UMK>XI;.4`@2RL;G!PK<1$)O!):##
MR\S-SH.JK*ZPT,_6U]BUNXL!`0N,"K,!P-GESA4V'XP%(I(5AY0MRN;T]>6J
M#P?3B=7V_O_8M@T:,&!+_\%%`,21`\BPU`5]C!:22M:PHD5=K`1N><5/UL6/
M($5I3`B@`+A#`1(0Z":1G@<``"*$'+2A6P=&%UH((S!OID^?JE3MBQ7@V,^C
M1^$Q.O!MD0!QW0P0:,5I@0$!``PQZ,8U``LM)DJX*/%5RXX,'TX$\-`@@`-@
M!U;IG'EA5<\M%UA,D`0#A"2_CG@B'7PQJ$:.1)427ER10:5PLMH>`*`%TU,!
M!0`T6*``U`(`!TLQ6.7"9UTM=R^4H""IP]Y(%1X)9DR[GJH#$`DAAJ:XMF]S
M&F4):$HHX18"^0@<"$Y/QDH-/F$8LH"S=+#9O[,[$Z#E`57=U&01UT[>67`'
M"O_&;S&>P$!6K.7_7;"^2+TCHY*PQ]]?B[(6QXOLML5P_!68"W,!F(200@;Z
M\U`C^#U"0B7Z-6@A)Y0Y4%F`X3%WX8>I5&+<.""6\^!U=Y6H8B.4"<5A1T6M
M*.,DS$DT8H0S#J/:A)%T$%LD(KS&2(4YK@B``P]L"!Z,]A69(P$X?E><.+TY
MF<L%-'`@B0Z`0?*#!(&E:.6'_BDYB(`QCNDD@(R8.8AQ#%2I9BT;Y(8+D7,V
M6.90T+24YX=R5FF<(7_B<F(N>!:ZGW]V;M2AG(HV6.4"@LY"@""1TG(H(00(
M^8@,%(J9*7EECB=@G*."F$`CE++JP%-^ILK)IH,T*4K_HK+Z5J9B:,::JW:^
M-"+G*AW]*DH#JP63@*C&,L8HKX\V6Z``.`ZKH:_20M*`%J$]4D&7CS#04@*K
M9ON;?P^8&JVYY1'*R+"KX,AN),BREHL!Y<[K+"L/D(,FI/H2YJY3CF@1E[P!
M-U)O,/@FO%B&Q3H*(\`._S0PI89DK+$#VS);\1;;=CL@F)&@X"DD#7]\%&4/
M/`#MQ"HS=K'&&!N2E18$4%QQ!`>(#,#)C2@`]'WYQAS2KB\F9K3`54I)R"H#
M7Q2!!3A@>U'(#!>]]$7^O9HT;ULC%?4@;I*-FD\N2"`R+M`Q@H'&&KRML2$:
M9#!WQAI0MC8C$;0-20%#IQPV_]=:N/6RTH/[-#8B!2="P$HIJ90`;@(PD/-6
M":1D".0I$9`Y5RET)?H)/8A.P`ZB=Y6"!$!L`D--`7">.E<^E)YZ"P*D@/L/
M<Z>P`^X]\'[W\!J+`(`*&G^@A8*01-!.)(`3G?A'W7F])%'!3@_2XF4C@K,B
M,(5&T!8%?)-9.1$(((*]@V6R-RI2L:\]0*M,]K4L6L_?T.(/%#Q@_A8Q`,D&
M$P$;B&P!\G.$!1+X"`,P8&CZ,P>Q#@<-#T70'I!A1/\:L2$+?JP"-1#9"3P@
M"10,,!*"NZ`])GB_;JBP(L9ID_\\DK@"ON\4#H3@"ZU!+#9)C"@`W*$Y8KB(
M#<J0AO^#`^$-39%"(69C%0[(W@^A$40G8@,`^6-.!Z>7B>>1(@(\8D03K<A#
MJ+70@V1T1E8JL<7$9<)6.*QB&H<!Q:*A"8US7$8#>N,6B6Q(CA5[8];R>(U5
MN/!Z%21D.=:X"(3Q`X\)R\1"8$#"DIT090]4I#.()<4[:A(;;6%$`A8@1;(I
M@B<-6&(V(H`"`6#@)RL!@?Q`R+Q!="",CU@@)0S0LT\R8Q4,P(\G??D,`)1R
M$/GC!P'"TZW/-,``Z;&9QMXS-P6`P!`#D(#=,A:"QQDB+2Z8VP16D`$(&*P`
M`KC!"$`2`X.)[!,,ZR4QA:&APMUO)?-48W"&I0CN:(%:[5'_2LW<`R$`$,<`
M"TCH%MY6D`+XS1(%,.=J6ND#D)A3GH2`IR0PP,!%%."5$,)H/F^AH0=TLD,^
M'&DPB$@(!U1+$5L)@,?*<8,0`*"C%;$``'Y$B$RD8!()P.D@-``N0O!2E2H5
M19(>(!`TI32IMV`I^0KPTN-P\6SW$BE43\%"1,H"DEL5A50)<DSX`-)AF9BI
M(T9`G4D<-:RT6&I3.P16N&*(.;4<!'R.:;2T=D(!;97$6^UJBFB<%$9U):R(
M@E.`M<'GJ7W%*BX&J]A1Q,4!=J1K96DAU2V(2UC]%,4`SJHF$*IU%)3=;">@
M:,0IRL)IJAU%:_4J$4-(1128^14(_X%P284M<8Q;2&UL+1&-N2)VN*:8[7%J
MFR0&P)%>S\U3)EP@U%((%[DTBHMQB9)8[#8"M@FHK8;@TXGQY:J`IQ7%=;T+
M"54@J86P92\;00LA#1D@KTO3*"$4$`))B."TZY5O(Z)A)C1U3\"2*!MY$0(U
M_!I-OX.00'0M88`23%C`W''1F32+X$O`=L'%P5D"D)HP"*"`89+ML".XXYT6
M'EC%CFC4+UB$LU1.#P(_Y<LZ(]$2`Z08QDXAEHN!3`D%X]<_(-X:CB?1`9GP
M^#X_)O*`"B<E`TLYP4XAG@"V%9[!F1C%Z66O/ULKH`3$]\I/JP]H#+IFF!A@
MO%8K<2DC@/^M"``XRD0>\SU?C&;87H5%E(MSP"`P9VQ)0`6[Q#.0_5GE\(P&
MS9`0U*2@AC"5E8"O\%,TC!D]9$BO&$*3_J?.'-;.$,B`IXV(P$TB@4`(:5K%
M_BQPA_A\94PW8@"K:("@`T;G&W#+6P]U1*O%>(`P>]>?VX4&K:7L)@`<`$H<
MU$)X]:<`R%I7IIX>$,<.2Y3E99L1P;%*BE8Q;>U)8"V70#7*L.WI6+MXUQTF
M4$06@NL`'*#2,5/`"X2$;[WN,@"CQK"0O:H*>",8)HL80),&%7"'X8H4!F`W
MI+GC@`"$!DUO^;93R)$9`=S%.`IH.*]?0.).1)RT\LTP`9B')OO_:9RVC7#Y
ME$`F<GVMH-\5"#:$>GOR;,>:Y1W*^,L'9*.%,'QZRXRN!)P,B6$W,B7?7L7*
M"2[TER?Y$<X>$,4&T-@+9VJ9)3<YU+-=/^(8V.`8MD_^CJ1M2C."4EIH@$NO
MP0&8!!8DZ1-`!H;TZT6XQK\Z-.K8/9T/+9A]UFA/N42"0YD!3<79%N>4RWR\
MQW^&W11<-D%O*Y()@_%=9'^/A`\V+\;!0_H__D+\T+>@@,736.NQD\HW$J")
MICC@&P.0.Z;T*'6?B$#JZ6LKV.]E>C07KEAG7[U"P=&(-V[K5=U!SH@)UM.G
M=,.;&;-<`$Y@B!5\P':S"S]72D"L%XC___SBKP&QUD^#'*S__?"/__IQ0/[W
M?T``*^B&#^:6_Z[\`'6C(P`S(#HY8#V>EA'`D'P:)SOB!SD1=P`5)SJ[%PFQ
MEB3$PE1+I7[RAP/HUX&B\P,#V!6?$WX$T`(I\`$`V`T;L`+[IV5S<P/AI#%]
M(0!YPP-:9@#AE`'A)`,V*``ZT(/IA#PRL$UZ=SPN``-0L`2X9'Q(DH#AL4S]
MMGJU$`YN$3LY<P"9DS,.$`(0$`(,,`,?8`("8`,&T%]2F#`&0P!."",X<X;/
ML"KP<0A8H0$L,``7,``W5P#ZD`,N@')NF"G=@7RS5G-_2`JS$'$>D0A'=8?!
MI(=;,`,OX&"%^/\K&7%X;!B%DX@+;]$PC*@`CL@`,9!XF6@E$%AU"CB*PX`5
M!8$9G#@`#.")CN$`&+`"EX>*5H(DFN!5#'!OMB@,5Y%0EP&*%M")"C!_3!<2
M$@`3.]:+UA`4^6)@F,B,)I<`)D%6`!!Q$L"([B%C/@%"GB>-SX`/S]@A^`2.
MM2`R6(&-=Q@"U&@"04!Z'U%`WVB.S&!O]K1A;$B(]`@)U%@`J\(`Z'2-`9"-
MKF@`%1`$.U!=%A$!J+,"^\@,%K@-I_B0HS`.QO$`!>`-&O!3ZR@(%Q"-%#DC
M<7&/KA4`28(`(5E>,'%OQJ&&:NAL*C`$*A`"*0``0U"+*0DBUR>1'1+_%RB9
MDY90)O(G?S0`CY:@`4%``PX)E+]A;YE#<*OPDTRIDJ"Q##XVCU/)&/;(DXBE
M!5*9E15QE=P(EC_A`-I%<,OTE60)$!&0@VNY&/C`E=WFE6]9ERI37%!)EW:Y
MEP'C7G*I;'K)EX*9+7B)CW.IEH.9F*D2EWF)F(KYF(7B%I[3F)!9F9'B%B1I
M8(%IF9PY)ERA))KIF)TYFBHR&K1'F:29FC)">]Q!<+0GFJH9F_PQ&N58DE$I
MF[AI(<B&FKG9F_'!F(8)F+#IF\0I,%!$<">Y-))8G!-G2%2WF1_CA\P9;ZQ@
M%*$YG=BY&.X6G+)PF]GYG19#;KP)GN1Y$;O)_YW1,)SEN9[FP&GHZ9WL&9_^
ML)VV"9WR>9_80'&@.6OVB9_^V0P"4$]-<9W_6:#;44^Q0*`&NJ#"$*#=H2`*
MRJ`2:@NQ=A`1.J$8:@H"\&P=<:$9^J&A4(RJ,*#\J9Z3&''0M@RPHR4@6DR%
M!Z$ENH_GJ2/=(8HM*E8&TZ$Q2H\SRB(+4!"@40#+F1DP4:0`T%:GX74W>@H_
M]Y[]:8L8$T0`P%2B8X!.$8%=P0+!T@$PL81+&@Q-6I\FNH\)@2\Y\Q16:E18
MV@TK4`"V]J6^B#,ZRH9/FI()`7":4:1-<1D#8:0P,006H`YP:@V4$1<)NJ-@
M:4PDX@C/Q"QW&`"!-_^H405%ATJG8TJ/,+&H+)*BCG`!@2JIQ40LE7J8:WFG
MHM)8D7"'$("3H(JC[^6DEVJ.IOH(&PHP=RB=K4H*>P*KI;H2?I)0CCI:N<H,
M&9*B'@J467$I36>KPCJLPU``%J@,QYJ3"<&IC-``,M<(M^JLP[``492+8EJJ
M`8`JCY"1D*"JK,JM(I*CTHJH69D0BU,)Z*JNN5`FQS"M=BI3.3."N.&!+3`!
M.6"4]#H*&<(4O$J61U*D(6<`#=`9T+1'1AIR<R.H`VL+T)HDHRJ<:SD`$5@Y
MO8!]^QH[FJ,Q,Q`"%%NQM#``!]`RXSF5\*J/@T!RN(JRDU`F[6JIXAJOE'#_
MAP%+LYS55?@:DAFILY,PKSY["O9ZL&"Y```'LUNP`0.PJD>+M**JM._:M*)@
MM%.KJ\2"*4%+D2\K"AN0`WJQM:7@K?^4L=U9IR$9MF9;#BJK"E[KKBY[``.C
M<`,`##]*"`.P3AZ@;F\K"FC[3U;KLBZC%%L&K<:TDI2B:RL0`1_@18%KB+E6
MN$SIMNNA#]OP%)[E#020`>@VN1B!55_[D)B[1H>`<$XA`;YF;*+K"$$!#Z5+
MIEC[NLW("K)+MTPY``#WII$@-Y%JNP-F1N%*EIG0`+ZK+08@M<)+7,0[N_2(
M:\9D`.X1<3!A"%'AIQ\0`"'``BK`O,U+"?B0NSA+_Y8+T#-[9`C/Y!X-ZZ?N
M>U/@&[Z2X%[D2Q0:$JOF2*7BAUE=00`U\0#F!P0S$+SRVYW]8KE,2:3O6Z1Y
MJZ<Z-0*LX0%>6L"PFR0W2ZH4')^JH(8(G,'9&0WWJKL>_,%VT<$CS)P,H"$7
MK+$G3)XK0;HBW,+%&0WUR\(R_,'=`"#0>\.IN4S!9,(\C)N]`*X[/(KE%L0#
M(:1OM\!%ZAX1VZ@I+&U.&@4$4<56?,58G,5:O,5<W,5>_,5@',9B/,9D7,9F
MG,4->\9JO,9LW,9N_,9PS,5(<`15C`1,?,=&"@(Z`!,B(`-[W``@P+!`Z(*$
M?#>ZEKZ$+)FO4G'>%(%#.?^4(_G(DBQ_(4RGDWS)F)S)FKS)G-S)GOS)H!S*
MHCS*I%S*IGS*J)S*JKS*K)S)%5<X'L@5$9<Q>LIBNZ"9K9S+NKS+O-S+OOS+
MP!S,PCS,Q-(#>+S`3FRDS+.<^<D*.LR?A1/)Q#S-FQP75+JRTBS-.5H]+:/)
M:SH[#A#.DKP<F-D=L2PZ(QD#7+&RY\P5"6!]7=$"_><#*X`[<[,#I!,"`O`!
M-J`%^ES(PS.#6G8#*"`#`,`#!AV#>>-FQ[S`4J`$=#P`4P``'3`"1E`$3F"D
M16`$,%$$?>O1<1S2(CW264P%DD*E3GH!!M'0[IO,[]NH1:IK[BO3>7J-M,S0
M'@?_`!)+R`U[R*UGI#*M`"[-TD::MPK"=0T</G[:P.4CI$1M4)*04)]QQP<Q
MU<P,"?Y!'%R7#0K0S^F:JRKGI!!`IJN@I,(047TGN@X:+$4LA5EM#USVU:W*
M'4]9O+):UG"]"G(-JN>)RV1M>!CDU;:;8>7BUYB*U_40UX-=/=^@F2I]V("=
MV'J]V(<D(,O$MIGXUO70U6D]N=RQ'-SI3T3PUV:]4D+0V8'K8Q47V@-WUY%-
M#VB]UY+:(K?G6@ZZ;(6HV;!M3K(]J)1!>XH@(/0)CKIM#K%MN\5(#<+=VL2-
MV(_0%:WG&`E""".H$2W@`3]02=##VXNMW.$QW-*(ML\E_VI8P78!L'OG?;V$
MP*5"(`)"H`!-MMVH_;:J?<#+O0K["*VO73"*8!)9!W"$,`Z9P3PP8)(]4`,"
M\`+X=MRO>Y6U?=^X_8?B'0D6F`CF;13V9H&+$`$Q$`$GL%"!Q^"B6R;!_=W,
M;0YY>Q`*=]6LPN+-U^(4U@VE'0G35ROJ084V6@HJN]\Q!PS_#0R:2@A<1GYC
MZ5'<?2%<"@`3[!/)Z*=+W@@GL`$WT0)!U0@5$`!^<>4GIBA=4^(=`=[EX&.7
MC3-!#@FPO$SPM@!E<R03QK3GK7NH4"R<*^3B<B2NBPH[/MX^7AF:6N8TP4LJ
M4`$8P,PB7B`8T$[$0@,_0,#I`_\J]M!Y[X<#/#`)HP$*1^Y14IP)FL?EE&K;
MJ_#8_]`1_:*ZZU$21]13N/<-XM84FJ$`!%$9"]``F[$%G#$(>W0,MB7DW]$`
M##``AA!-U,)UL8!0U^OJ'`0,<SX(<P<R,XL*(TKAP&``_4-@$;<*WN$W&S`"
M+0`F'X!O:-O;']$`2:G/-M@#-L`"QUBN;?CH6C`#1NH#-8!'$0#!GG``0%-`
MY>(!"IDC_D$B]SW6]!,+9HD;CA&@)DD.RS/@6Z`2D7&^W7!["L!4K])XN`&!
M`X*1$3\5JR)BA,``^:)P:AY0=GNX`#(.N`O@;8+L`A$QV##A?R,^)J'`Y`,3
MY0,)2Q?_"19@`O--'A*``SF`:(O@`EJPY9%00,G;#)EP`Z)$`S+!`?0^"'6W
M%W4W(1"PZ5M@`>&D`10``>6"`J`@`2B@`FTI`#)PC%BO=Q+0`'?''UWNZ?@=
M\-"`*97!#VJ^"/Q2UN<;\0.R"]2(\I/!Y\,AAXG`#YG`.-QP"&X^"Y6ALF]2
M%+LP#H22=>`V#\F."#GN[#R>#84>'[\G+TLV"%C?S_ZL)9!K,`+05AHP`ZNP
M`3)10'LW"`00`FV3"9DT`F,(%C(P(<L$4N0CQ>N@!4J_"*/Q#97>\8!=_,.'
M`:*O"4)0+A!@[\50`BM`+";05LF]^NMN("UBWR:^"BZ^2;%P_\"(@&OKQSPL
M3QG]5#0$AI'<L@"C\0"^WC/\@&N&W_&[8%#ZL/@&*PL9!`@!`@(`6P!:6XF*
M!P**`@&*6P\-B@$%D9B9FIN<D0%:"YVBHZ2*!1!:`Z6KK*VNB1`S%*(5-5JW
MN`,%.+9:C1^X+S4TE"VIB<8)B05:RLQ:0`$L6@1;(S8'B@:^F<P$'`#A#4&0
M6PQ:"HKGH>?I!*D20UH@`!FVRENHJA=:+A6&U+;$HZ&A`H<3`5\I7,@0X*U"
M"!XF$H"K4,.+D;18Y+9%HX-0"P*$2J0QTH(#!"`]2L2@00"+"0X-L#2```&*
M`&P"[(A)@18#B0YM"Q6@&@!!#@PY&/_42$`V3`?232P'-&4B`@=486SU:>36
MA1%R'/M*=BN$:J*VH=VR3>K91!%LF+#(X46.`2)*YM-BXM([H`VTW%`4X]@%
M$Q,2O=!R*1,J7+BDME,':HL,=%O>Z=+R=(N*9K`,C]V[N;.WLJ@Q'M+R`*+$
M+12U0/":VI7>UB0+$'`0@+?6C@<""%>0`)(#!@48\'Y@0,&#W@D6($KPX(`#
M`-L`%*CN(#JBGEJ$.ZC&V-`!+0X,G`POR&G*<`\\'7B`WD"`\QH7G.MML7:G
MK@LUH,PCP@4@P2L#G/>;?PR.\I8B&@A7P@M!J"(!`"0DTL$-F.6#%C-260#`
M91Y((`0#$S#_`P`$Z91@0@=;=("A0`!,HXI/Z40``0T'.L8(4Q\$D0,'YG2X
M10*5A8"99H&IH(B)!N8CRQ:')1;:9D#!9<-:#7;9R2'TN:97;!=XR8H`(ZDW
MT18+&""``0LVP!0A!A0"0",#*""`5.$`H$HC6RB@P$A^;E$``",!BDF?C?4W
M`**)/,KF`H0LH,H`WRW#:*3A:!4.;6964MDK`CB0S2.!I3"+*PF.%NJK#R:R
MC18XV)B(!"`(T$,)M[@UI4_1!&`">J`)>V@J$`A0RUH6^"!-+@()D0`%/KFP
M2:R)P&"",DI*5:0,EBV92F`+0I!5/B8<>$%G6Q@SP#881(+MJZ\>_Q(`;A&-
MB0N]_/9+RG6>^+L0@*X`$%Q2B300GT*M+BBP?X4YG$A>JL1U"PX!?&"#6\<P
M\T*!!8+`EA8-D'O``8>$:(,6'[>@X%6@(!FO)O.:P\#(WB*909'NC*O%/XJ8
MJXH^5+(;L4]9&IK0PUVN=D`H^5H46Z9,5TVOI58//"JIY228-*LO9YW:9U\K
MHMG((YC2(=',E*U(!$(0T,"I)5RFU6+]\:I5VPRPBTD,*]`V`@[9M.5(99?U
MO%D+:I_K;M&1N%N!#0&LZL+28J-VR'EB6C0KU9F'+GK5!).Z<`,(,QSVZ%L=
M@`,/F&"`PS&!]=<#:*1M$=>0HNZ\Q2?];/\1F!8EK,I/8SK8\MMY#W")R5F_
M%6#=SMM`$L$'MNS<;6;'I*#%!A;(SMG0AK%[-@C0G###+<ZSWM!J`5`2]405
MN6]F`8=*K,L"A6(BJ?W^*9TKBL.2<JC.50!42`'$@H,/"&`%O-)"#Q)SB&"Q
M(`<U$,`L>/6!G0&#!C\0@%CN(BM;`.44P4L$^H#P@QC08%C]49(6/+`)BT'F
M%CNP$GYN<0X:GD,9[TB'!6;'PQR<BVCKBL0["B$!%PP+!R!@0?L26#`'.(`;
M\X--_:A8F^W0YP"4B(13SG.`QFB#9%PLBP!;X91$)$!1"%I=&EW1@1!$$!HM
MR,"J)!`"L6@A!B/_$,Z!>!`$S@C$CK<PP0]FIKL#Q$`#NOM!"9QTJQ\4D@9U
MRN#;A,`"*VFB!2`+P`9ND*%$:"`%`6B!"#3``$CRP`>05$`/B+0%"^1*`!W0
M@0@2<P,1S`(&(HB$GB(@@;2!XQ\02,$<%2*=!SR@$5F<6G^6N95#)$(ZT[Q3
M(@2!"0*<0V+4=`5%0.6OAH7SG*,H@`WPD4!F_&!5.$(G*V[!B"U$$UKR?%^F
MVJ@(`.`#C)CPR#3SN8IQ6LV<!"5H!RBP`AH,U'Z+,<&SMI903MQB*?9\S><J
MNA!KTB\2JWG-1*JA``-R=!3O(&>_$'K2<&Z`AYY,H`6`<8L$,+*EF<`%_S1?
MXY-;J!2GG/`H;%)GB$8LP"6>X,U\?@I4^C'U52QM*A<#Z0,+4#,",Y)J3EFC
MC'OZ5*NC$*I.^@DHH2Y@$N$`(];`>KBGABJJ;(VK7)EVB^9E5%\BG2M(-6(`
M`CP@%`8`"@"6\@Y*W(0B9A/$%)MJT*K!5:^0C2R#KHC%UTA3LHJ8B7`(,!(!
M;6$`@WA)PIJC*-#Z<ZZ-9=IC,<O:UBZ$(ACUJEY<2ULVEL>Q<JRM;G>[B=A4
M(XLA?2AOAWLX.<UI3B4[KG*7J]P4'+8')R``*@-P@D%L(`7#`B=Q1R&B52ED
M!`*(0)=:L(&8;E<4N(`$</%YWO-.[8;PC:]\Y_]+7US88&7:;>\F(C8*"6R`
MAIE`B+?\\SC]HI<U-UOO+<)H8(ZNE5-F+`5.W,3<"C.E/_S31`:8,H$(``4%
M(LIL;AN<"0E<!H&:`%&*C>2?LY&XM^C9J5Z"R[`^/4(`U7@C2+D46$AQJD]]
M8E/_,'$H`O3O4=%[DX^#`F3A'B64D"A``-@)FYM=$W@`2Y@#5-$;,59#RJ%T
MP"4>0%EBA:(ZO>$,G$A"B4,P6$57QD6628&3@X[XQ8G0`1!HH+QTLEAM`[Z(
M!#P``/&:#<5XW@)E$_P:&BLDO@`I*^YZNAN.A!0R6GSH.>1\B4-8I*>X0(MT
M;OA7\,#7(5Y!;*"H$=K_\-"/RQS1XC;;\XZ/;"$XQRV$<)AR14!Q8S7]+,E9
M`Z"`<'S";3`6+K]6BV<'F,`#_%6'+6A0U2VD8!I`6$$W_JP(#*SO%C-P$C/@
MB(I0_*`7?*&EBQ.=$6HP>L:164BL#<42QIQDRVPZ3F,"TV9?%&`!_RY$G2/A
M#544H#L`.6%X5'%4+5C9U<MXYJ+FW>FZ:@6Q"0K`;RAR"8[_CC52^TY1-"'Q
M3`3`RK,F22-6PP"&<^,=$3ZYA&?[L%;=E-U;`(%5B9:(%4!#.#5@00=<4H-L
M;YO!D8@`#FB0L1T$@0;I.$!?X"($2%PN!M5-00ZBM&Z<?_P`[[9(2.'8"IIG
M_Y8W%)'*4#([Y4AGPLT3]Y8`E)&RH2X(29>`>,KW2G:`W`L?B/7)-$-R"<'_
MCA'X5K5P-,%-DYMT\1U9.<DFP29NV-4D$>[$Y91-+YM[/1-ZJT0)1M(#(-"P
M%H%>!NXP(0-B=!L(+*"`DK)T&4J8R]"Z,T%5$(UGBCSGKF+7J;Q1IH#`>NNL
M#C_T)@Z1@$-]RNV8Z$VQ?W.(1D`^(\IP-:*0-G$&W$E0@O6%QQ&K:DUX^DB6
M0*/BE\+K;8Y'SN[G]0/P`1I/*R<4:/Q)/T%2BLMP'JKG<7.?MV[GD0(`X%U*
M@VS,0&7J,$E`Y@.IH$Y6%@`.E0\_PA0Y4`U=AW.QH?]>C29\CW9JE7!YOV-2
M>W5#D"`=?2<\E/4T;G=]BA`0\)5ZAV!%F'8(-^,`#U``B/4)E'$+DJ=KD/`)
M>B)R[,<4VQ053!%&!;)%MV84^6%%'5$(:.00MS!S__=6YX%L.+=N$0`$P0`"
MB=$V*\:`]19?3D*!X@4!*/(,\)4-&\AN'0A\00&"KX`Y9O0.NS$2U($)6%-]
M`[`_C:%_F/=9`*``P?$HW,``)M@1Y($R=S)GP=9WS,<FU;$-F98(>F(`&'5^
MBY<@!X`D>Q=]9O@[*#<>6F%7YU=]:$2"X<!/HS!PJK6%G]=-KM(!*#!1SL!M
M2E.*Y^`"/#`(.@``/``C!E#_`PF0%Y10"S'19&D3AXE6*JZF8/-6=BNX'=$1
M'+)"B$D(?0%%=O>R5^'`#:4R<90`<3.!;WO5/O9"/U=D*..!"1+GB>4``/0A
M<HUHBHQG0(%!?Y!P?D5"CK?U4:3@?YW@)FOV66[B*$FC``"F.W,"(YS0*ES(
M;BFE"#"@1P+A`D:D-*G7BYK@<U^3`3<P"Q%P`"RP/HT!`>GR-BX03-#8>Y_@
M@;-EA[;1B#-1'MQG#NK(#/]8C2J'"=M@1M1Q+(W`#`PV`%>$?P8T;A.G<7NC
M"[_G1E<H/"1C8[]6$M<W/-N4"D!V"2>G``U`8>D`@^O0$3]I$0O0:XEP'@1@
M`'*2_WRD4#N<\`A8L64#P``,D`#QB#-7L18%8`(G@$II,Y&T6(N'YBT.,'IY
M1CE*@W1J0V7%-#(Y-#$YP"-4N32WLP+#"`!"8%<Q^6)SF$4=`83R!E^#4(7<
MHPI.@Q^L24^001ZFXDQH=`[/45/0%QLG\QIZ5R39%%^4<'V8LD\WA!;T&`FB
M^'$HJ)R0,80FY1.0\'L`Z8U8<0L!D)"C0)>;0&S;Q(,H]W"GE1F`R24:L`,]
MXC^'B9C<XRT\@&ZF:2(T\`*XEPBU$%^JL&F0<0)J(QB1<#N0L0,PLD2(.9JO
M,6I`N0JD)9:#@!UPQ(,6`5J#H":?95QS$@H4.@A\R#YK9O]:IE`J#3!D;Q()
M'$IPX5`GSX<_)C%-CQ(.B\)P$?8__*,+B*)2E@(2H*(+7J*=YO<<G/4[9'<4
MO^,7@,D9)F0H""ABW(B8>F)5$$)3X*,(&;`RY/08,;`R?&$E&$!3+L"DMX("
MX84)'G!+#RDBI?1Y!`IOIJF>D148*VB(_&,`#Z``8\46,_$<$C>GS-`!A#:?
MF4"1:OH*'6!>?QHJPY,4662@;3JH3148BW56Z9`@`H`Z)]0:&H$='X&GQT!+
M/^6GBMJI]K-1I&F3GBI5.IH)P\,:H8`D>K@2+$$`>7$+-.`!-Y0!+`!.G#JJ
MN"HV4T.'5IBHN9I0@9&/)N&'D++_`%X!<%M0`3)2F(F``6FSJ>GYJ]+J+[M*
MC;XZK>@4K':6I-C:K5X24KPZG`?JK=G:FP)SJ^2:KK4!G?%QJ**JKN>DK;C%
MK?!:KQ>Q#?3!JZ4YKO;*1?+:"06@``PG`%JA)Q'J+3*"`CI0IJ*`KOWZL*\`
MKJ&:IA"[3/_*"8P*$!;A$M;1=BS!=";0DJ/0*GY3L28;5IP!"A/+K_J535GR
MIFBR@FW"9#2+)B9*"/T1HI02"MI$+Q>[?%94`)@R3:RJ#MD0`0+`I9U`LB?;
MM*004@NPLM?:-(!2',5W<N\R<BQ1"`R0JO@C6EU[93)7',(1#E;T3ROW3)>G
M'UA14CHH_P@'$Q+!$1.\P0!N&XJ1P(BML1)W\I9C=!-OE"4VL9>^X``EE0`H
M9R8_:W[IH7$TYX.1(`.%]`(@<*2;P+1.F[G+E[+ZB@NE^"J)N);^]);7T1($
M(!6+!S"1ZA,W,Y`:P0!]%1,W`48`T!)**1(&HQ1VDA0].G>P00@O$3_:D1,L
M:@X#!;O%QK=(.`BP46QJUR9]<R0.<(X^:Z[FAP@DXRJ0JPC@$(PVD(610D::
M.[X3QQJ=:YVD`Q\8Q6_*@%2F:!^%H(*ELI8942JAI8,>=11W\A+VN$V`(HU_
MTA2FDA3W`7:#!7FB91)^%5C_>&._`Q1.T7B!`KNG@AF@TR6+F_\)B(4DB("B
M'Q<4,D`!#M`#`*`"&Y,!P;2TXDN^+"RQ(I5>5;.#0&ID?A<H:*%QSF019*8`
MQS%@B"``C+@GV4`[?7,RWE<.(B$\-R-:S,L`A/```Q`306%4VQ2_08%6A%`X
M#AP_L!$.C8$C*C)EUWG!#9+!$_=9G',?JO`.KW8#A00-'1"]*FQ(+$R^-4B3
M_7$+1""LK[*#`]`\#)`2!]!7UC$2/VD`RJ#&V=&C:-D\W"0(G%C(7DFI5V1E
M!X<>H7`3F=$(?04\H"!\3/QIMW`)@7&IA:#)O`98$4HI!*LGF8?!UMNGC1&C
M^1,4D5*8%X++0&.8=%S'F@LF/S&Q1+#_6*\BM(8")WF2#OQC1ON&'6QR":`U
M``U`*"PZ`*$0L(8`*8W1:0_V%1(ZD=>47UECQIVWPKZ<N6X8M2^,ON<<.N0,
M@+W<SDV+'LRQLGPLS_WRSEH8S_A<L3I%FE<$`??<SZ\2&`LSBUJ`F00-L6-'
MFG.XT$S#E?-:LA"MKN(J`*3Y#K',.H*2,`6P9@KPT1@*H3&+H:P<LV_4%-=Y
M)&]$"=*,N*"U:X%8'"VG""$A'-ZG#&[")KT!Q,*A#,BQ`"FQ)\+A5@(CT0A-
MT16=KA=E`*0)/`.=.>$8>:(E",\A')S(B(,%Q-?Q3&A2%)&J:*52`(AK'SQX
MG=>)N#SL3R^1_P!45KL$<"P\:!3-80D&LR>5^A*\43+$'-%5F=1+_;#_+%(4
M(=!IA"3%)GZZ5BII=7"(8C#C&!*=PA1`,<@")P@:D<"%.]::C0G,6Q2'M0Q=
M5KM5?$U65#)1[2_#TV2LW=I`IB=]T@`B8&$6%@+#HM2!W:V#/5L:G=I90[93
MMJ!'0A&?0+#/42>W69;"(67!,2B1>!-&9F2BE1,X-C>_\ZB@X\2_4[L852<=
MD1R`,MU;=A3N*SJG6E_HG=[JS<^Y3:Z[W1^]G4:I*7XXMI:8F`!&MC!`RHGT
MNTV'M=6[Q@AMS0B,X,28(I9*Y2;>\L@-`*EL$ARID&6MP0PH<9?@J__:#]$<
M#;")%M;:S>':(!X.I60!(W`>B-'>\/K>A[;1H_,F<A-842P(,\$2!F#)^)#3
M6$T@D"`G#=XF8LF:>Q(HE^#=AW().A84G58(A[(,:M(_B+*B?G+A1_W7->>:
M**ZN*DX2[*R>VC%72%WEMR#.5SZJ6:Z<OCWF&/'EYVKE:*[;0.C06][F#*+F
MY<3F<BZM9?[0%<6B,\OGA,`F@O6*S`M2"4`)>H)^!N3`C%AL1>U&@G#3Q<:(
MU_RY`$3G*V7G=YZK90[5'-4=)P>DCW!PQ9$`0\$4-V$`!1!&=^U]VD@R#(8R
M&O%&;XF(2@Z\J1ZA?54(\Q%.EKYLF)[I9$[_'Q@M4O%=41_A$I!-`('[6<&;
MTCBV)R4U$<^!'"N!9CJ,)'>"5-2QX%DA/8<L)XF;1KU>SF$.[+_JN7#.XM3$
M&=-KCT7Q1A;Q$J7BQ,_^-;Y['4`J<$U1#2*!%4Q\,SAZG?@GL/!C=E3TY<YW
M*=X")_S#H``W)W<R)TYB`3?01`(@`U:%`O/9*KQG[FK*&L&1[F>>0*.RW\3V
M-%AQ%&L)W6^B&U=\+_QC'/<"Q.X^'B?3`'<Y=\'J?:9B$U:4)2,O-DCMDX8$
MI"2QOTRQ`&N]H"(``R_0`R@03(S0`"4P(C:0`2IP`)[$\6+N\9^''J$(YX9=
M48Q,UH'2OI$*<,I0_WP1;V0HQX.7,+/.)SS&VN4H^BA`,2B'PK,6X<'T1DW#
MXRE/@;,&I!&#SK.-N)?+$`384?4DP`'(E!,`_^M>_Z?,,^RS11$7$/25GYU?
M]>!3)EA7W16E(AZ',OH6@;=;$`($0`$1L`,Y``0?D!C7"?EH7.Z=KZC`@_DY
M&^>YWQ!(C35\";PQV+<@U8@0<./*@`&&E@`[H_CAB_N=&@)A%->=0`"">B0M
M@0$A\)'T66:#?.(-$.ZZ3PT!(/*_OQ6!/Q%6-@C;,8@1?_R.H?S65CD2H/C0
M?_L=7XL,``@T`%L$"EN'B(D!`XF('14-!@P)C95;$(P%6BY;#0>6H*&BH_^D
MI::GJ*4'6EH)"*R#AP*L`:FVM[B-"P($!H<,"UL"@\"Z`0'!`KX,QX<%#@&1
M#PX`#K!;"]8)FEH%#*Q;#@\"N>7FC0W7V%H'JX,'C%M:``(/QP$&#?;'E%L'
M_0;@65BE9<4$?PHF;1E`,-ZYAQ`CEF.PX0,A!15:'..@PX26$Y>LM9`T0<&!
M!@DB39)A0XL)"94T93K0HH`GB3ASZA1%,,"K>8AF74"VLVBI:LH6MMH24%(!
M`HD(3#(0D)R#I%L`,!`0@(&"A`X4%'#6`$```0H:2&U00("``0^,RCV4KANB
M`0``!-MBZ!"``0ORYEV`5_#>#B001:ND8@:%#@?_&;+:.[>RY5);$YPHI.,$
MO10-=JA0<4FLE@$Q"J1P@5)E`@8Q!.3HVPC3E@('`+`0,>.R[]^@K&GQJ4X8
M+>"5`1PP,"CE`T:S`$-5?""`@EV4CCD(IL!!NZT"#K@-$$M8`@*,N@9PD,"7
M%N02ZU+6&;H2@?(+"8Z%SW_N)`LY[*``!C/$P`(!%FP0P`840&#:``D(<`$&
M#3#@VB1N66");;AMT<."_84H%RM:$/!3>;-``)2(."%EP``E.N!+`'8U<I99
MPM0RUC#"D#,/+P20XQ9=E%##E2$TOO4>B[G4A1]\DIW&Y)0/*?2!%FD1T`$O
M#*0`@!`#."B3`C:8,$&%_ZXE((,*-BC0P0BUS72(=U36:0Z)Q*UHG!8//&GG
M+5S)`H]RKVEB0"U!>2=D+0\<X,``,GI7G:.2P-*-%@Y8R(H"`:P23J9_HN*D
MB%$Z%.JIHJQ`B00.$#`"#NP0`$,0-*Q0FDQ;*-3:`2L((`$S"5`04",E,%*!
MK5O<P`FJS(J"YXE!L=)GL[;0XU<L#0@0#%N^W)77(0N,%5@P@^#%B%[@DEO8
M6'@MY">UH8R:RK>)T'L(!B*<4BJ\_(Y2`2C[04;*L/T63$I/T,I"XKL&-^QP
M)Y.E@ANBSCS0K00:`/&)*?L^['$Y$OS[L<<TEI@P4PN/K'*_=>UG2@'34)Q5
M7/^'&/``"QN7$J7+*_?L\\];E)PGBBD#;?24\IJR@`&!(G(H(A$`8)*^!,UW
M]-58,ROTR;/PR7/68%N6]"E-'Y)`/XC<Q#%!M(7M]MO\#0<-UZPX\#7<>$<T
MMBG,*$).(@W0`)/.;.=M^.%%;5U<UWHB[O@M>Y?2#")8HB,EX9L^KOGFM@0P
MC2N+%\WYZ*)$3HH"W<IB=0<`4+!VYJ3'+OLA)3-`=W&SSV[Z;U&VG?OOB)=L
M8NBX`S_Z[K[U;OSRAM-X%=TJ,LS\X<A?IOSTV(--(P/#Z\FX]-G#7;UEUX=O
M_L_'$#!TM,6?CW==J?-7OOOT6U+```4(!NY?@O7O____@C$`ZJCBE@(:D"MG
M.<8D")"``*CO'IX3Q_H4UK[ZA6U\E=D9W"3@LD<@@@.).80'\D*!"(R``AQ(
MQ-W,(8$0BI"$41,,ZP!(0QX(0`8@.*`.=?B!`^3`!`7,`8F&2,0B&O&(2$RB
M$HWX@"4ZD41-9,4!;M<X"[H-@Z+8#V!:",(9^@\%(A`,&)GQ`AJP`@09F`$$
MU\C&-KKQC7!<T`?BN,8@()$&'B&1'8D8Q202H`8XV",K@""M)QH2B0ZH01$)
M<LA&D@A6CN1C)"=)R4-&\1NW@P?G_L8<`#!G%SL,I2A'&4H"/)".J(2@-:#A
MG3Y6\I6PC"4K6B!+6=)`D5JX_V4M222<24)RE\",90]H2,QB&K-_^3NF,I?Y
M/RI"@XZO2:4TI[G&`^P#CM-@QP-<&<QN>O.;X.RF"7`9SG*:\YQ#Q",K<!``
M%F@!"*@\I0]6<(P3%'`%]BS@!GPP2@W@C8KHC"0WASA0=#J@EXXL:$`7ZLU$
MLJ(*63@`%B#(`GB^,0$[H.,&Z$G-8P2!FN<9908RX!8-B$`'+A#`#0#@`AC8
M4``PR(L*8-H_$.B`ABIP@098&E/_O50&"C#@#4`P4Z9I(*5N62DS\S(""^3E
M7Q(`@`NM*(J$E8RA6,VJ5K?*U:YZ]:M@A>7?WM;``.SGJF%-JUK7RM:VNO6M
861WKX1'0"M>ZVO6N>,VK7K<JU[`%`@`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
